Human	B
embryonic	O
stem	O
cells	O
(	O
hESCs	O
)	O
and	O
neural	O
progenitor	O
(	O
NP	O
)	O
cells	O
are	O
excellent	O
models	O
for	O
recapitulating	O
early	O
neuronal	O
development	O
in	O
vitro	O
,	O
and	O
are	O
key	O
to	O
establishing	O
strategies	O
for	O
the	O
treatment	O
of	O
degenerative	O
disorders	O
.	O

While	O
much	O
effort	O
had	O
been	O
undertaken	O
to	O
analyze	O
transcriptional	O
and	O
epigenetic	O
differences	O
during	O
the	O
transition	O
of	O
hESC	O
to	O
NP	O
,	O
very	O
little	O
work	O
has	O
been	O
performed	O
to	O
understand	O
post	O
-	O
transcriptional	O
changes	O
during	O
neuronal	O
differentiation	O
.	O

Alternative	O
RNA	O
splicing	O
(	O
AS	O
)	O
,	O
a	O
major	O
form	O
of	O
post	O
-	O
transcriptional	O
gene	O
regulation	O
,	O
is	O
important	O
in	O
mammalian	O
development	O
and	O
neuronal	O
function	O
.	O

Human	B
ESC	O
,	O
hESC	O
-	O
derived	O
NP	O
,	O
and	O
human	B
central	O
nervous	O
system	O
stem	O
cells	O
were	O
compared	O
using	O
Affymetrix	O
exon	O
arrays	O
.	O

We	O
introduced	O
an	O
outlier	O
detection	O
approach	O
,	O
REAP	O
(	O
Regression	O
-	O
based	O
Exon	O
Array	O
Protocol	O
)	O
,	O
to	O
identify	O
1,737	O
internal	O
exons	O
that	O
are	O
predicted	O
to	O
undergo	O
AS	O
in	O
NP	O
compared	O
to	O
hESC	O
.	O

Experimental	O
validation	O
of	O
REAP	O
-	O
predicted	O
AS	O
events	O
indicated	O
a	O
threshold	O
-	O
dependent	O
sensitivity	O
ranging	O
from	O
56	O
%	O
to	O
69	O
%	O
,	O
at	O
a	O
specificity	O
of	O
77	O
%	O
to	O
96	O
%	O
.	O

REAP	O
predictions	O
significantly	O
overlapped	O
sets	O
of	O
alternative	O
events	O
identified	O
using	O
expressed	O
sequence	O
tags	O
and	O
evolutionarily	O
conserved	O
AS	O
events	O
.	O

Our	O
results	O
also	O
reveal	O
that	O
focusing	O
on	O
differentially	O
expressed	O
genes	O
between	O
hESC	O
and	O
NP	O
will	O
overlook	O
14	O
%	O
of	O
potential	O
AS	O
genes	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
REAP	O
predictions	O
are	O
enriched	O
in	O
genes	O
encoding	O
serine	O
/	O
threonine	O
kinase	O
and	O
helicase	O
activities	O
.	O

An	O
example	O
is	O
a	O
REAP	O
-	O
predicted	O
alternative	O
exon	O
in	O
the	O
SLK	O
(	O
serine	O
/	O
threonine	O
kinase	O
2	O
)	O
gene	O
that	O
is	O
differentially	O
included	O
in	O
hESC	O
,	O
but	O
skipped	O
in	O
NP	O
as	O
well	O
as	O
in	O
other	O
differentiated	O
tissues	O
.	O

Lastly	O
,	O
comparative	O
sequence	O
analysis	O
revealed	O
conserved	O
intronic	O
cis	O
-	O
regulatory	O
elements	O
such	O
as	O
the	O
FOX1	O
/	O
2	O
binding	O
site	O
GCAUG	O
as	O
being	O
proximal	O
to	O
candidate	O
AS	O
exons	O
,	O
suggesting	O
that	O
FOX1	O
/	O
2	O
may	O
participate	O
in	O
the	O
regulation	O
of	O
AS	O
in	O
NP	O
and	O
hESC	O
.	O

In	O
summary	O
,	O
a	O
new	O
methodology	O
for	O
exon	O
array	O
analysis	O
was	O
introduced	O
,	O
leading	O
to	O
new	O
insights	O
into	O
the	O
complexity	O
of	O
AS	O
in	O
human	B
embryonic	O
stem	O
cells	O
and	O
their	O
transition	O
to	O
neural	O
stem	O
cells	O
.	O

Author	O
SummaryDeriving	O
neural	O
progenitors	O
(	O
NP	O
)	O
from	O
human	B
embryonic	O
stem	O
cells	O
(	O
hESC	O
)	O
is	O
the	O
first	O
step	O
in	O
creating	O
homogeneous	O
populations	O
of	O
cells	O
that	O
will	O
differentiate	O
into	O
myriad	O
neuronal	O
subtypes	O
necessary	O
to	O
form	O
a	O
human	B
brain	O
.	O

During	O
alternative	O
RNA	O
splicing	O
(	O
AS	O
)	O
,	O
noncoding	O
sequences	O
(	O
introns	O
)	O
in	O
a	O
pre	O
-	O
mRNA	O
are	O
differentially	O
removed	O
in	O
different	O
cell	O
types	O
and	O
tissues	O
,	O
and	O
the	O
remaining	O
sequences	O
(	O
exons	O
)	O
are	O
joined	O
to	O
form	O
multiple	O
forms	O
of	O
mature	O
RNA	O
,	O
playing	O
an	O
important	O
role	O
in	O
cellular	O
diversity	O
.	O

The	O
authors	O
utilized	O
Affymetrix	O
exon	O
arrays	O
with	O
probes	O
targeting	O
hundreds	O
of	O
thousands	O
of	O
exons	O
to	O
study	O
AS	O
comparing	O
human	B
ES	O
to	O
NP	O
.	O

To	O
accomplish	O
this	O
,	O
a	O
novel	O
computational	O
method	O
,	O
REAP	O
(	O
Regression	O
-	O
based	O
Exon	O
Array	O
Protocol	O
)	O
,	O
is	O
introduced	O
to	O
analyze	O
the	O
exon	O
array	O
data	O
.	O

The	O
authors	O
showed	O
that	O
REAP	O
candidates	O
are	O
consistent	O
with	O
other	O
types	O
of	O
methods	O
for	O
discovering	O
alternative	O
exons	O
.	O

In	O
addition	O
,	O
REAP	O
candidate	O
alternative	O
exons	O
are	O
enriched	O
in	O
genes	O
encoding	O
serine	O
/	O
theronine	O
kinases	O
and	O
helicase	O
activities	O
.	O

An	O
example	O
is	O
the	O
alternative	O
exon	O
in	O
the	O
SLK	O
(	O
serine	O
/	O
threonine	O
kinase	O
2	O
)	O
gene	O
that	O
is	O
included	O
in	O
hESC	O
,	O
but	O
excluded	O
in	O
NP	O
as	O
well	O
as	O
in	O
other	O
differentiated	O
tissues	O
.	O

Finally	O
,	O
by	O
comparing	O
genomic	O
sequences	O
across	O
multiple	O
mammals	O
,	O
the	O
authors	O
identified	O
dozens	O
of	O
conserved	O
candidate	O
binding	O
sites	O
that	O
were	O
enriched	O
proximal	O
to	O
REAP	O
candidate	O
exons	O
.	O

The	O
human	B
central	O
nervous	O
system	O
is	O
composed	O
of	O
thousands	O
of	O
neuronal	O
subtypes	O
originating	O
from	O
neural	O
stem	O
cells	O
(	O
NSCs	O
)	O
that	O
migrate	O
from	O
the	O
developing	O
neural	O
tube	O
.	O

Such	O
neuronal	O
complexity	O
is	O
generated	O
by	O
a	O
vast	O
repertoire	O
of	O
molecular	O
,	O
genetic	O
,	O
and	O
epigenetic	O
mechanisms	O
,	O
such	O
as	O
the	O
active	O
retrotransposition	O
of	O
transposable	O
elements	O
[	O
1	O
]	O
,	O
alternative	O
promoter	O
usage	O
,	O
alternative	O
RNA	O
splicing	O
(	O
AS	O
)	O
,	O
alternative	O
polyadenylation	O
,	O
RNA	O
editing	O
,	O
post	O
-	O
translational	O
modifications	O
,	O
and	O
epigenetic	O
modulation	O
[	O
2	O
]	O
.	O

Understanding	O
the	O
processes	O
that	O
generate	O
neuronal	O
diversity	O
is	O
key	O
to	O
gaining	O
insights	O
into	O
neuronal	O
development	O
and	O
paving	O
new	O
avenues	O
for	O
biomedical	O
research	O
.	O

Human	B
embryonic	O
stem	O
cells	O
(	O
hESCs	O
)	O
are	O
pluripotent	O
cells	O
that	O
propagate	O
perpetually	O
in	O
culture	O
as	O
undifferentiated	O
cells	O
and	O
can	O
be	O
induced	O
to	O
differentiate	O
into	O
a	O
multitude	O
of	O
cell	O
types	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
[	O
3	O
]	O
.	O

As	O
hESCs	O
can	O
theoretically	O
generate	O
all	O
cell	O
types	O
that	O
make	O
up	O
an	O
organism	O
,	O
they	O
serve	O
as	O
an	O
important	O
model	O
for	O
understanding	O
early	O
human	B
embryonic	O
development	O
.	O

In	O
addition	O
,	O
the	O
hESCs	O
are	O
a	O
nearly	O
infinite	O
source	O
for	O
generating	O
specialized	O
cells	O
such	O
as	O
neurons	O
and	O
glia	O
for	O
potential	O
therapeutic	O
purposes	O
[	O
4,5	O
]	O
.	O

In	O
recent	O
years	O
,	O
methods	O
have	O
been	O
introduced	O
to	O
induce	O
hESCs	O
to	O
differentiate	O
into	O
neural	O
progenitors	O
(	O
NPs	O
)	O
[	O
6,7	O
]	O
and	O
neuronal	O
and	O
glial	O
subtypes	O
[	O
8–12	O
]	O
.	O

The	O
therapeutic	O
interest	O
in	O
understanding	O
the	O
molecular	O
basis	O
of	O
pluripotency	O
and	O
differentiation	O
has	O
led	O
to	O
many	O
studies	O
comparing	O
transcriptional	O
profiles	O
in	O
different	O
hESC	O
lines	O
and	O
the	O
study	O
of	O
expression	O
changes	O
during	O
the	O
differentiation	O
of	O
hESCs	O
to	O
various	O
lineages	O
[	O
13–17	O
]	O
.	O

NSCs	O
and	O
progenitor	O
cells	O
(	O
NPs	O
)	O
are	O
present	O
throughout	O
development	O
and	O
persist	O
into	O
adulthood	O
[	O
18–20	O
]	O
.	O

They	O
are	O
critical	O
for	O
both	O
basic	O
research	O
and	O
developing	O
approaches	O
to	O
treat	O
neurological	O
disorders	O
,	O
such	O
as	O
Parkinson	O
disease	O
and	O
amyotrophic	O
lateral	O
sclerosis	O
(	O
ALS	O
)	O
,	O
and	O
stroke	O
or	O
head	O
injuries	O
[	O
21,22	O
]	O
.	O

NSCs	O
and	O
NPCs	O
can	O
be	O
isolated	O
from	O
human	B
fetal	O
brain	O
tissue	O
[	O
23–26	O
]	O
,	O
as	O
well	O
as	O
from	O
several	O
regions	O
of	O
the	O
adult	O
human	B
brain	O
,	O
such	O
as	O
the	O
cortex	O
,	O
hippocampus	O
,	O
and	O
the	O
subventricular	O
zone	O
(	O
SVZ	O
)	O
of	O
the	O
lateral	O
ventricles	O
[	O
26–35	O
]	O
.	O

Several	O
studies	O
have	O
explored	O
expression	O
patterns	O
of	O
NPCs	O
.	O

For	O
example	O
,	O
Wright	O
et	O
al.	O
identified	O
"	O
expressed	O
"	O
and	O
"	O
not	O
expressed	O
"	O
genes	O
in	O
NPCs	O
isolated	O
from	O
the	O
human	B
embryonic	O
cortex	O
[	O
24	O
]	O
;	O
Cai	O
et	O
al.	O
used	O
the	O
massively	O
parallel	O
signature	O
sequencing	O
profiling	O
(	O
MPSS	O
)	O
technique	O
to	O
analyze	O
expression	O
of	O
fetal	O
NPCs	O
in	O
comparison	O
to	O
hESCs	O
and	O
astrocyte	O
precursors	O
[	O
27	O
]	O
;	O
Maisel	O
et	O
al.	O
used	O
Affymetrix	O
Gene	O
Chip	O
arrays	O
to	O
compare	O
adult	O
and	O
fetal	O
NPCs	O
propagated	O
in	O
neurospheres	O
[	O
35	O
]	O
.	O

However	O
,	O
as	O
with	O
hESCs	O
,	O
the	O
focus	O
thus	O
far	O
has	O
been	O
primarily	O
on	O
transcriptional	O
differences	O
,	O
which	O
ignores	O
differential	O
RNA	O
processing	O
such	O
as	O
AS	O
,	O
polyadenylation	O
,	O
degradation	O
,	O
or	O
promoter	O
usage	O
.	O

AS	O
is	O
frequently	O
used	O
to	O
regulate	O
gene	O
expression	O
and	O
to	O
generate	O
tissue	O
-	O
specific	O
mRNA	O
and	O
protein	O
isoforms	O
[	O
36–39	O
]	O
.	O

Recent	O
studies	O
using	O
splicing	O
-	O
sensitive	O
microarrays	O
suggested	O
that	O
up	O
to	O
75	O
%	O
of	O
human	B
genes	O
undergo	O
AS	O
,	O
where	O
multiple	O
isoforms	O
are	O
derived	O
from	O
the	O
same	O
genetic	O
loci	O
[	O
40	O
]	O
.	O

This	O
functional	O
complexity	O
underscores	O
the	O
challenge	O
and	O
importance	O
of	O
elucidating	O
AS	O
regulation	O
.	O

AS	O
appears	O
to	O
play	O
a	O
dominant	O
role	O
in	O
regulating	O
neuronal	O
gene	O
expression	O
and	O
function	O
[	O
41,42	O
]	O
.	O

Examples	O
of	O
splicing	O
regulators	O
that	O
are	O
enriched	O
and	O
function	O
specifically	O
in	O
neuronal	O
cells	O
include	O
the	O
brain	O
-	O
specific	O
splicing	O
factor	O
Nova	O
[	O
43,44	O
]	O
and	O
neural	O
-	O
specific	O
polypyrimidine	O
tract	O
binding	O
protein	O
(	O
nPTB	O
)	O
,	O
which	O
antagonizes	O
its	O
paralogous	O
PTB	O
to	O
regulate	O
exon	O
exclusion	O
in	O
neuronal	O
cells	O
[	O
45–47	O
]	O
.	O

Finally	O
,	O
an	O
early	O
report	O
estimating	O
that	O
15	O
%	O
of	O
point	O
mutations	O
disrupt	O
splicing	O
underscores	O
the	O
importance	O
of	O
splicing	O
in	O
human	B
disease	O
[	O
48	O
]	O
.	O

Indeed	O
,	O
the	O
disruption	O
of	O
specific	O
AS	O
events	O
has	O
been	O
implicated	O
in	O
several	O
human	B
genetic	O
diseases	O
,	O
such	O
as	O
frontotemporal	O
dementia	O
and	O
parkinsonism	O
,	O
Frasier	O
syndrome	O
,	O
and	O
atypical	O
cystic	O
fibrosis	O
[	O
49	O
]	O
.	O

While	O
insights	O
into	O
the	O
regulation	O
of	O
AS	O
have	O
come	O
predominantly	O
from	O
the	O
molecular	O
dissection	O
of	O
individual	O
genes	O
[	O
36,49	O
]	O
,	O
it	O
is	O
becoming	O
clear	O
that	O
molecular	O
rules	O
can	O
be	O
identified	O
from	O
large	O
-	O
scale	O
studies	O
of	O
both	O
constitutive	O
splicing	O
and	O
AS	O
[	O
40	O
]	O
.	O

Most	O
systematic	O
global	O
analyses	O
on	O
AS	O
have	O
focused	O
on	O
comparisons	O
across	O
differentiated	O
human	B
tissues	O
[	O
50–52	O
]	O
.	O

Only	O
one	O
study	O
,	O
utilizing	O
expressed	O
sequence	O
tag	O
(	O
EST	O
)	O
collections	O
from	O
stem	O
cells	O
,	O
has	O
attempted	O
to	O
find	O
AS	O
differences	O
between	O
embryonic	O
and	O
hematopoietic	O
stem	O
cells	O
[	O
53	O
]	O
.	O

However	O
,	O
utilizing	O
ESTs	O
to	O
identify	O
AS	O
has	O
intrinsic	O
problems	O
,	O
as	O
ESTs	O
tend	O
to	O
be	O
biased	O
for	O
the	O
3′	O
ends	O
of	O
genes	O
,	O
and	O
full	O
coverage	O
of	O
the	O
genome	O
by	O
ESTs	O
is	O
severely	O
limited	O
by	O
sequencing	O
costs	O
.	O

The	O
commercial	O
availability	O
of	O
Affymetrix	O
exon	O
arrays	O
provides	O
an	O
alternative	O
approach	O
to	O
interrogate	O
the	O
expression	O
of	O
every	O
known	O
and	O
predicted	O
exon	O
in	O
the	O
human	B
genome	O
.	O

The	O
Affymetrix	O
GeneChip	O
Human	O
Exon	O
1.0	O
ST	O
array	O
contains	O
∼5.4	O
million	O
features	O
used	O
to	O
interrogate	O
∼1	O
million	O
exon	O
clusters	O
(	O
collections	O
of	O
overlapping	O
)	O
of	O
known	O
and	O
predicted	O
exons	O
with	O
more	O
than	O
1.4	O
million	O
probesets	O
,	O
with	O
an	O
average	O
of	O
four	O
probes	O
per	O
exon	O
.	O

Our	O
goal	O
was	O
to	O
identify	O
and	O
characterize	O
AS	O
events	O
that	O
distinguish	O
pluripotent	O
hESCs	O
from	O
multipotent	O
NPs	O
,	O
paving	O
the	O
way	O
for	O
future	O
candidate	O
gene	O
approaches	O
to	O
study	O
the	O
impact	O
of	O
AS	O
in	O
hESCs	O
and	O
NPs	O
.	O

However	O
,	O
as	O
different	O
hESC	O
lines	O
were	O
established	O
under	O
different	O
culture	O
conditions	O
from	O
embryos	O
with	O
unique	O
genetic	O
backgrounds	O
,	O
we	O
expected	O
that	O
hESCs	O
and	O
their	O
derived	O
NPs	O
might	O
have	O
distinct	O
epigenetic	O
and	O
molecular	O
signatures	O
[	O
54	O
]	O
.	O

As	O
both	O
common	O
and	O
cell	O
-	O
line	O
specific	O
alternatively	O
spliced	O
exons	O
are	O
likely	O
to	O
be	O
important	O
in	O
regenerative	O
research	O
,	O
in	O
our	O
study	O
two	O
separate	O
hESC	O
lines	O
were	O
used	O
,	O
with	O
independent	O
protocols	O
for	O
differentiating	O
the	O
hESCs	O
into	O
NPs	O
positive	O
for	O
Sox1	O
,	O
an	O
early	O
neuroectodermal	O
marker	O
.	O

As	O
an	O
endogenously	O
occurring	O
population	O
of	O
NPs	O
,	O
human	B
central	O
nervous	O
system	O
stem	O
cells	O
grown	O
as	O
neurospheres	O
(	O
hCNS	O
-	O
SCns	O
)	O
were	O
utilized	O
as	O
a	O
natural	O
benchmark	O
for	O
derived	O
NPs	O
.	O

We	O
developed	O
an	O
approach	O
called	O
REAP	O
(	O
Regression	O
-	O
based	O
Exon	O
Array	O
Protocol	O
)	O
,	O
which	O
is	O
based	O
on	O
robust	O
regression	O
that	O
analyzed	O
signal	O
estimates	O
from	O
Affymetrix	O
exon	O
array	O
data	O
to	O
identify	O
AS	O
exons	O
.	O

Experimental	O
validation	O
revealed	O
alternative	O
exons	O
that	O
distinguish	O
hESCs	O
from	O
NPs	O
;	O
some	O
of	O
them	O
also	O
distinguish	O
hESCs	O
from	O
a	O
variety	O
of	O
differentiated	O
tissues	O
.	O

A	O
comparison	O
of	O
REAP	O
-	O
predicted	O
alternative	O
events	O
with	O
independent	O
methods	O
,	O
such	O
as	O
using	O
publicly	O
available	O
transcripts	O
(	O
ESTs	O
and	O
mRNAs	O
)	O
and	O
computational	O
predictions	O
based	O
on	O
genomic	O
sequence	O
information	O
alone	O
[	O
55	O
]	O
,	O
showed	O
a	O
strong	O
concordance	O
of	O
REAP	O
-	O
identified	O
AS	O
exons	O
with	O
AS	O
events	O
identified	O
from	O
these	O
orthogonal	O
methods	O
.	O

Finally	O
,	O
using	O
analysis	O
of	O
the	O
sequences	O
flanking	O
REAP	O
-	O
identified	O
alternative	O
exons	O
,	O
we	O
were	O
able	O
to	O
discover	O
known	O
and	O
novel	O
cis	O
-	O
regulatory	O
elements	O
that	O
potentially	O
regulate	O
these	O
AS	O
events	O
.	O

Derivation	O
of	O
Neural	O
Progenitors	O
from	O
Embryonic	O
Stem	O
CellsNPs	O
were	O
independently	O
derived	O
from	O
two	O
hESC	O
lines	O
,	O
and	O
RNA	O
extracted	O
from	O
the	O
cell	O
lines	O
was	O
processed	O
and	O
hybridized	O
onto	O
Affymetrix	O
Human	B
1.0	O
ST	O
exon	O
arrays	O
.	O

Immunohistochemical	O
and	O
reverse	O
-	O
transcriptase	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
analyses	O
demonstrated	O
that	O
the	O
hESCs	O
expressed	O
pluripotent	O
marker	O
genes	O
,	O
and	O
the	O
derived	O
NPs	O
expressed	O
multipotent	O
and	O
neurogenic	O
markers	O
similar	O
to	O
hCNS	O
-	O
SCns	O
.	O

Undifferentiated	O
Cythera	O
(	O
Cyt	O
-	O
ES	O
)	O
and	O
HUES6	O
(	O
HUES6-ES	O
)	O
hESC	O
lines	O
were	O
maintained	O
in	O
culture	O
as	O
previously	O
described	O
[	O
12,23,56	O
]	O
.	O

Utilizing	O
specific	O
antibodies	O
,	O
we	O
observed	O
that	O
undifferentiated	O
Cyt	O
-	O
ES	O
and	O
HUES6-ES	O
cells	O
were	O
positive	O
for	O
the	O
pluripotent	O
markers	O
Oct4	O
,	O
SSEA-4	O
,	O
and	O
Tra-1–80	O
(	O
unpublished	O
data	O
)	O
.	O

NPs	O
were	O
derived	O
from	O
the	O
hESC	O
cell	O
lines	O
using	O
protocols	O
optimized	O
for	O
each	O
line	O
(	O
see	O
Materials	O
and	O
Methods	O
)	O
.	O

Greater	O
than	O
90	O
%	O
of	O
derived	O
NP	O
cells	O
(	O
Cyt	O
-	O
NP	O
from	O
Cyt	O
-	O
ES	O
and	O
HUES6-NP	O
from	O
HUES6-ES	O
)	O
were	O
positive	O
for	O
Sox1	O
,	O
an	O
early	O
neuroectodermal	O
marker	O
,	O
and	O
Nestin	O
(	O
Figure	O
1A	O
)	O
,	O
and	O
negative	O
for	O
Oct4	O
(	O
unpublished	O
data	O
)	O
.	O

As	O
a	O
natural	O
benchmark	O
for	O
the	O
derived	O
NPs	O
,	O
we	O
utilized	O
hCNS	O
-	O
SCns	O
,	O
which	O
were	O
previously	O
isolated	O
from	O
fresh	O
human	B
fetal	O
brain	O
tissues	O
using	O
antibodies	O
to	O
cell	O
-	O
surface	O
markers	O
and	O
fluorescence	O
-	O
activated	O
cell	O
sorting	O
[	O
12,23	O
]	O
.	O

The	O
hCNS	O
-	O
SCns	O
form	O
neurospheres	O
in	O
culture	O
which	O
are	O
greater	O
than	O
90	O
%	O
Nestin	O
and	O
Sox1	O
positive	O
,	O
and	O
differentiate	O
into	O
both	O
neurons	O
and	O
glial	O
cells	O
in	O
vitro	O
[	O
12,23	O
]	O
.	O

Immunohistochemical	O
analysis	O
confirmed	O
that	O
hCNS	O
-	O
SCns	O
were	O
negative	O
for	O
Oct4	O
(	O
unpublished	O
data	O
)	O
and	O
positive	O
for	O
Sox1	O
and	O
Nestin	O
(	O
Figure	O
1A	O
)	O
.Figure	O
1Molecular	O
Characterization	O
of	O
Human	B
Embryonic	O
Stem	O
Cell	O
Lines	O
and	O
Neuronal	O
Progenitors	O
(	O
A	O
)	O
Immunohistochemical	O
analysis	O
of	O
markers	O
in	O
NPs	O
derived	O
from	O
the	O
hESC	O
lines	O
(	O
Cyt	O
-	O
NP	O
from	O
Cyt	O
-	O
ES	O
;	O
and	O
HUES6-NP	O
from	O
HUES6-ES	O
)	O
and	O
in	O
hCNS	O
-	O
SCns	O
.	O

Cyt	O
-	O
NP	O
,	O
HUES6-NP	O
,	O
and	O
hCNS	O
-	O
SCns	O
cells	O
were	O
Nestin	O
and	O
Sox1	O
positive	O
.	O

Nuclei	O
stained	O
positive	O
for	O
Dapi	O
.	O

White	O
horizontal	O
bar	O
indicated	O
15	O
μm.	O
(	O
B	O
)	O
Gene	O
-	O
level	O
signal	O
estimates	O
of	O
marker	O
genes	O
(	O
GAPDH	O
,	O
Oct4	O
,	O
Nanog	O
,	O
Nestin	O
,	O
Notch1	O
,	O
DNER	O
,	O
and	O
Sox1	O
)	O
from	O
Affymetrix	O
exon	O
array	O
analysis	O
.	O

Vertical	O
bars	O
indicated	O
average	O
log2	O
normalized	O
signal	O
estimates	O
,	O
and	O
error	O
bars	O
represented	O
standard	O
deviations	O
from	O
three	O
independent	O
replicate	O
experiments	O
per	O
cell	O
type.	O
(	O
C	O
)	O
RT	O
-	O
PCR	O
of	O
marker	O
genes	O
(	O
GAPDH	O
,	O
Oct4	O
,	O
Nanog	O
,	O
Nestin	O
,	O
Notch1	O
,	O
DNER	O
,	O
and	O
Sox1	O
)	O
.Here	O
,	O
known	O
molecular	O
markers	O
were	O
subjected	O
to	O
RT	O
-	O
PCR	O
measurements	O
,	O
which	O
were	O
compared	O
to	O
gene	O
-	O
level	O
signal	O
estimates	O
generated	O
from	O
the	O
exon	O
array	O
data	O
.	O

Total	O
RNA	O
was	O
extracted	O
,	O
and	O
labeled	O
cDNA	O
targets	O
were	O
generated	O
from	O
three	O
independent	O
preparations	O
of	O
each	O
cell	O
type	O
,	O
namely	O
Cyt	O
-	O
ES	O
,	O
HUES6-ES	O
,	O
Cyt	O
-	O
NP	O
,	O
HUES6-NP	O
,	O
and	O
hCNS	O
-	O
SCns	O
.	O

To	O
facilitate	O
downstream	O
analyses	O
,	O
instead	O
of	O
utilizing	O
the	O
meta	O
-	O
gene	O
sets	O
available	O
from	O
the	O
manufacturers	O
,	O
we	O
generated	O
our	O
own	O
gene	O
models	O
by	O
clustering	O
alignments	O
of	O
ESTs	O
and	O
mRNAs	O
to	O
annotated	O
known	O
genes	O
from	O
the	O
University	O
of	O
California	O
Santa	O
Cruz	O
(	O
UCSC	O
)	O
Genome	O
Browser	O
Database	O
.	O

After	O
hybridization	O
,	O
scanning	O
,	O
and	O
extraction	O
of	O
signal	O
estimates	O
for	O
each	O
probeset	O
on	O
the	O
exon	O
arrays	O
,	O
gene	O
-	O
level	O
estimates	O
were	O
computed	O
based	O
on	O
our	O
gene	O
models	O
using	O
available	O
normalization	O
and	O
signal	O
estimation	O
software	O
from	O
Affymetrix	O
.	O

For	O
every	O
gene	O
,	O
a	O
t	O
-	O
statistic	O
and	O
corresponding	O
p	O
-	O
value	O
were	O
computed	O
representing	O
the	O
relative	O
enrichment	O
of	O
the	O
expression	O
of	O
the	O
gene	O
in	O
hESC	O
versus	O
NP	O
,	O
such	O
as	O
in	O
Cyt	O
-	O
ES	O
versus	O
Cyt	O
-	O
NP	O
.	O

After	O
correcting	O
for	O
multiple	O
hypothesis	O
testing	O
using	O
the	O
Benjamini	O
-	O
Hochberg	O
method	O
,	O
a	O
p	O
-	O
value	O
cutoff	O
of	O
0.01	O
was	O
used	O
to	O
identify	O
enriched	O
genes	O
.	O

Close	O
inspection	O
of	O
all	O
pairs	O
of	O
hESC	O
-	O
NP	O
comparisons	O
revealed	O
a	O
generally	O
significant	O
overlap	O
from	O
31	O
%	O
to	O
85	O
%	O
of	O
the	O
smaller	O
of	O
two	O
compared	O
sets	O
of	O
enriched	O
genes	O
(	O
see	O
Figure	O
S1	O
)	O
.	O

Thus	O
for	O
the	O
purpose	O
of	O
identifying	O
overall	O
pluripotent	O
and	O
neural	O
lineage	O
-	O
specific	O
genes	O
,	O
the	O
collective	O
set	O
of	O
NPs	O
(	O
Cyt	O
-	O
NP	O
,	O
HUES6-NP	O
,	O
and	O
hCNS	O
-	O
SCns	O
)	O
was	O
compared	O
to	O
the	O
collective	O
set	O
of	O
hESCs	O
(	O
Cyt	O
-	O
ES	O
and	O
HUES6-ES	O
)	O
.Oct4	O
and	O
Nanog	O
,	O
which	O
are	O
important	O
in	O
maintaining	O
the	O
pluripotent	O
state	O
of	O
embryonic	O
stem	O
cells	O
(	O
ESCs	O
)	O
,	O
were	O
highly	O
expressed	O
in	O
hESCs	O
but	O
were	O
significantly	O
lower	O
in	O
NPs	O
(	O
Figure	O
1B	O
)	O
.	O

RT	O
-	O
PCR	O
of	O
Oct4	O
and	O
Nanog	O
mRNA	O
levels	O
accurately	O
reflected	O
the	O
signal	O
estimates	O
from	O
the	O
array	O
(	O
Figure	O
1C	O
)	O
.	O

Interestingly	O
,	O
Nestin	O
was	O
not	O
significantly	O
higher	O
in	O
NPs	O
as	O
compared	O
to	O
the	O
hESC	O
from	O
the	O
gene	O
-	O
level	O
estimates	O
(	O
p	O
-	O
value	O
0.065	O
)	O
,	O
which	O
was	O
further	O
confirmed	O
by	O
RT	O
-	O
PCR	O
(	O
Figure	O
1C	O
)	O
.	O

Notch	O
was	O
recently	O
identified	O
to	O
be	O
important	O
in	O
promoting	O
the	O
neural	O
lineage	O
entry	O
in	O
mouse	B
ESCs	O
[	O
57	O
]	O
and	O
was	O
shown	O
to	O
regulate	O
stem	O
cell	O
proliferation	O
in	O
somatic	O
mouse	B
and	O
hESC	O
[	O
58	O
]	O
.	O

Gene	O
-	O
level	O
signal	O
estimates	O
suggested	O
that	O
Notch	O
was	O
significantly	O
higher	O
in	O
hCNS	O
-	O
SCns	O
relative	O
to	O
hESCs	O
,	O
but	O
levels	O
of	O
Notch	O
were	O
not	O
significantly	O
different	O
in	O
the	O
derived	O
NPs	O
compared	O
to	O
hESCs	O
.	O

Delta	O
/	O
Notch	O
-	O
like	O
EGF	O
-	O
related	O
receptor	O
(	O
DNER	O
)	O
,	O
a	O
neuron	O
-	O
specific	O
transmembrane	O
protein	O
,	O
was	O
recently	O
shown	O
to	O
bind	O
to	O
Notch	O
at	O
cell	O
–	O
cell	O
contacts	O
and	O
activates	O
Notch	O
signaling	O
in	O
vitro	O
[	O
59	O
]	O
.	O

RT	O
-	O
PCR	O
validation	O
of	O
DNER	O
confirmed	O
array	O
-	O
derived	O
signal	O
estimates	O
,	O
indicating	O
an	O
enrichment	O
of	O
DNER	O
in	O
NPs	O
relative	O
to	O
hESCs	O
(	O
Figure	O
1C	O
)	O
.	O

Finally	O
,	O
Sox1	O
,	O
a	O
HMG	O
-	O
box	O
protein	O
related	O
to	O
SRY	O
,	O
was	O
shown	O
to	O
be	O
one	O
of	O
the	O
earliest	O
transcription	O
factors	O
expressed	O
in	O
cells	O
committed	O
to	O
the	O
neural	O
fate	O
[	O
60	O
]	O
.	O

Here	O
the	O
gene	O
-	O
level	O
estimates	O
indicated	O
that	O
Sox1	O
was	O
expressed	O
significantly	O
higher	O
in	O
NPs	O
relative	O
to	O
hESCs	O
(	O
p	O
-	O
value	O
0.00013	O
,	O
Figure	O
1B	O
)	O
,	O
a	O
finding	O
that	O
was	O
confirmed	O
by	O
RT	O
-	O
PCR	O
(	O
Figure	O
1C	O
)	O
.From	O
these	O
examples	O
,	O
we	O
concluded	O
that	O
RT	O
-	O
PCR	O
validation	O
correlated	O
well	O
with	O
gene	O
-	O
level	O
estimates	O
from	O
the	O
exon	O
array	O
.	O

In	O
addition	O
,	O
the	O
derived	O
NPs	O
had	O
decreased	O
levels	O
of	O
pluripotent	O
markers	O
Oct4	O
and	O
Nanog	O
but	O
had	O
levels	O
of	O
Sox1	O
that	O
were	O
comparable	O
to	O
hCNS	O
-	O
SCns	O
.	O

This	O
finding	O
confirmed	O
that	O
the	O
derived	O
NPs	O
were	O
committed	O
to	O
a	O
neural	O
fate	O
and	O
validated	O
the	O
use	O
of	O
hCNS	O
-	O
SCns	O
as	O
a	O
benchmark	O
for	O
NPs	O
.	O

Next	O
we	O
asked	O
whether	O
the	O
highest	O
enriched	O
genes	O
in	O
hESCs	O
relative	O
to	O
NPs	O
reflected	O
our	O
existing	O
knowledge	O
in	O
the	O
literature	O
.	O

Using	O
the	O
above	O
-	O
mentioned	O
groupings	O
of	O
hESCs	O
(	O
Cyt	O
-	O
ES	O
,	O
HUES6-ES	O
)	O
and	O
NPs	O
(	O
Cyt	O
-	O
NP	O
,	O
HUES6-NP	O
,	O
and	O
hCNS	O
-	O
SCns	O
)	O
,	O
2,945	O
genes	O
were	O
enriched	O
in	O
hESCs	O
relative	O
to	O
NPs	O
;	O
and	O
552	O
genes	O
were	O
enriched	O
in	O
the	O
NPs	O
relative	O
to	O
hESCs	O
,	O
at	O
a	O
p	O
-	O
value	O
significance	O
cutoff	O
of	O
0.01	O
(	O
correcting	O
for	O
multiple	O
hypothesis	O
testing	O
using	O
the	O
Benjamini	O
-	O
Hochberg	O
method	O
)	O
.	O

The	O
15	O
most	O
enriched	O
genes	O
in	O
hESCs	O
included	O
genes	O
such	O
as	O
teratocarcinoma	O
-	O
derived	O
growth	O
factor	O
1	O
(	O
TDGF1	O
/	O
cripto	O
;	O
p	O
-	O
value	O
<	O
10−12	O
)	O
,	O
zinc	O
finger	O
protein	O
42	O
(	O
Zfp42	O
/	O
Rex1	O
;	O
p	O
-	O
value	O
<	O
10−12	O
)	O
,	O
Oct4	O
(	O
p	O
-	O
value	O
<	O
10−12	O
)	O
,	O
Nanog	O
(	O
p	O
-	O
value	O
<	O
10−10	O
)	O
,	O
lin-28	O
homolog	O
(	O
p	O
-	O
value	O
<	O
10−10	O
)	O
,	O
cadherin	O
1	O
preprotein	O
(	O
p	O
-	O
value	O
<	O
10−10	O
)	O
,	O
claudin	O
6	O
(	O
p	O
-	O
value	O
<	O
10−9	O
)	O
,	O
ephrin	O
receptor	O
EphA1	O
(	O
p	O
-	O
value	O
<	O
10−9	O
)	O
,	O
and	O
erbB3	O
(	O
p	O
-	O
value	O
<	O
10−9	O
)	O
.	O

TDGF1	O
/	O
cripto	O
was	O
first	O
shown	O
to	O
stimulate	O
DNA	O
synthesis	O
and	O
cell	O
proliferation	O
of	O
both	O
undifferentiated	O
and	O
differentiated	O
embryonic	O
carcinoma	O
cells	O
[	O
61	O
]	O
and	O
was	O
later	O
shown	O
to	O
be	O
important	O
for	O
cardiomyocyte	O
formation	O
from	O
mouse	B
ESC	O
[	O
62	O
]	O
.	O

Oct4	O
,	O
reviewed	O
in	O
[	O
63	O
]	O
,	O
and	O
Nanog	O
[	O
64	O
]	O
are	O
crucial	O
for	O
the	O
pluripotency	O
of	O
hESCs	O
.	O

Recently	O
,	O
knockdown	O
of	O
Zfp42	O
/	O
Rex-1	O
in	O
mouse	B
ESC	O
caused	O
the	O
cells	O
to	O
differentiate	O
[	O
65	O
]	O
.	O

Our	O
gene	O
-	O
level	O
exon	O
array	O
analysis	O
confirmed	O
that	O
the	O
hESCs	O
and	O
NPs	O
were	O
molecularly	O
distinct	O
.	O

To	O
reveal	O
global	O
functional	O
differences	O
between	O
the	O
enriched	O
genes	O
in	O
hESCs	O
or	O
NPs	O
,	O
the	O
enriched	O
genes	O
were	O
subjected	O
to	O
a	O
Gene	O
Ontology	O
(	O
GO	O
,	O
http://www.geneontology.org	O
)	O
analysis	O
as	O
described	O
previously	O
[	O
55	O
]	O
.	O

Enriched	O
genes	O
in	O
hESCs	O
were	O
more	O
likely	O
to	O
be	O
in	O
molecular	O
function	O
categories	O
,	O
such	O
as	O
"	O
RNA	O
binding	O
"	O
(	O
p	O
-	O
value	O
<	O
10−12	O
)	O
,	O
"	O
structural	O
constituent	O
of	O
ribosome	O
"	O
(	O
p	O
-	O
value	O
<	O
10−51	O
)	O
,	O
"	O
exonuclease	O
activity	O
"	O
(	O
p	O
-	O
value	O
<	O
10−6	O
)	O
,	O
"	O
cytochrome	O
-	O
c	O
oxidase	O
activity	O
"	O
(	O
p	O
-	O
value	O
<	O
10−5	O
)	O
,	O
and	O
"	O
ATP	O
binding	O
"	O
(	O
p	O
-	O
value	O
<	O
10−6	O
)	O
,	O
and	O
in	O
biological	O
processes	O
involved	O
with	O
"	O
tRNA	O
processing	O
"	O
(	O
p	O
-	O
value	O
<	O
10−6	O
)	O
and	O
"	O
protein	O
biosynthesis	O
"	O
(	O
p	O
-	O
value	O
<	O
10−48	O
)	O
,	O
consistent	O
with	O
our	O
knowledge	O
of	O
hESCs	O
as	O
a	O
rapidly	O
proliferating	O
population	O
of	O
cells	O
(	O
Figure	O
2A	O
)	O
.	O

Similar	O
analysis	O
of	O
the	O
enriched	O
genes	O
in	O
NPs	O
revealed	O
an	O
overrepresentation	O
in	O
molecular	O
functional	O
categories	O
,	O
such	O
as	O
"	O
calcium	O
ion	O
binding	O
"	O
(	O
p	O
-	O
value	O
<	O
10−8	O
)	O
and	O
"	O
structural	O
molecule	O
activity	O
"	O
(	O
p	O
-	O
value	O
<	O
10−5	O
)	O
,	O
and	O
in	O
biological	O
processes	O
involved	O
with	O
"	O
neurogenesis	O
"	O
(	O
p	O
-	O
value	O
<	O
10−38	O
)	O
,	O
"	O
cell	O
adhesion	O
"	O
(	O
p	O
-	O
value	O
<	O
10−13	O
)	O
,	O
"	O
cell	O
motility	O
"	O
(	O
p	O
-	O
value	O
<	O
10−4	O
)	O
,	O
"	O
development	O
"	O
(	O
p	O
-	O
value	O
<	O
10−6	O
)	O
,	O
"	O
neuropeptide	O
signaling	O
pathway	O
"	O
(	O
p	O
-	O
value	O
<	O
10−4	O
)	O
,	O
and	O
"	O
endocytosis	O
"	O
(	O
p	O
-	O
value	O
<	O
10−4	O
)	O
(	O
Figure	O
2B	O
)	O
.	O

Considering	O
that	O
these	O
were	O
the	O
only	O
categories	O
that	O
were	O
significantly	O
enriched	O
out	O
of	O
more	O
than	O
18,000	O
GO	O
terms	O
,	O
and	O
that	O
randomly	O
selected	O
sets	O
of	O
similar	O
numbers	O
of	O
genes	O
did	O
not	O
reveal	O
statistical	O
differences	O
in	O
GO	O
categories	O
,	O
our	O
results	O
confirmed	O
that	O
the	O
global	O
molecular	O
profiles	O
derived	O
from	O
exon	O
array	O
analysis	O
were	O
consistent	O
with	O
known	O
differences	O
between	O
hESCs	O
and	O
NPs	O
.	O

Figure	O
2Gene	O
Ontology	O
AnalysisDifferential	O
gene	O
expression	O
of	O
hESCs	O
(	O
Cyt	O
-	O
ES	O
and	O
HUES6-ES	O
)	O
and	O
NPs	O
(	O
Cyt	O
-	O
NP	O
,	O
HUES6-NP	O
,	O
and	O
hCNS	O
-	O
SCns	O
)	O
was	O
computed	O
from	O
gene	O
-	O
level	O
signal	O
estimates	O
.	O

Statistical	O
significance	O
for	O
differential	O
gene	O
expression	O
was	O
determined	O
by	O
using	O
t	O
-	O
statistics	O
with	O
Benjamini	O
-	O
Hochberg	O
correction	O
for	O
false	O
discovery	O
rate	O
(	O
p	O
<	O
0.01	O
)	O
.	O

Gene	O
Ontology	O
"	O
molecular	O
function	O
,	O
"	O
"	O
cellular	O
component	O
,	O
"	O
and	O
"	O
biological	O
process	O
"	O
categories	O
,	O
which	O
differed	O
significantly	O
(	O
p	O
<	O
0.05	O
)	O
in	O
the	O
representation	O
between	O
significantly	O
enriched	O
genes	O
(	O
black	O
bars	O
)	O
and	O
all	O
other	O
genes	O
(	O
white	O
bars	O
)	O
,	O
were	O
shown	O
.	O

Statistical	O
significance	O
for	O
GO	O
analysis	O
was	O
assessed	O
by	O
using	O
χ2	O
statistics	O
with	O
Bonferroni	O
correction	O
for	O
multiple	O
hypothesis	O
testing	O
.	O

GO	O
categories	O
are	O
ordered	O
from	O
top	O
to	O
bottom	O
in	O
order	O
of	O
decreasingly	O
significant	O
bias	O
toward	O
enriched	O
genes.	O
(	O
A	O
)	O
GO	O
analysis	O
of	O
enriched	O
genes	O
in	O
hESCs.	O
(	O
B	O
)	O
GO	O
analysis	O
of	O
enriched	O
genes	O
in	O
NPs	O
.	O

To	O
summarize	O
,	O
firstly	O
immunohistochemical	O
and	O
RT	O
-	O
PCR	O
evidence	O
validated	O
that	O
the	O
cells	O
exhibited	O
expected	O
characteristics	O
;	O
secondly	O
,	O
stage	O
-	O
specific	O
marker	O
gene	O
differences	O
by	O
RT	O
-	O
PCR	O
were	O
reflected	O
accurately	O
by	O
gene	O
-	O
level	O
estimates	O
from	O
the	O
exon	O
arrays	O
;	O
thirdly	O
,	O
the	O
hESC	O
-	O
enriched	O
genes	O
were	O
coherent	O
with	O
known	O
genes	O
that	O
controlled	O
pluripotency	O
and	O
self	O
-	O
renewal	O
;	O
and	O
lastly	O
,	O
the	O
global	O
functional	O
profiles	O
exemplified	O
expected	O
biological	O
differences	O
between	O
hESC	O
and	O
NP	O
cells	O
.	O

Description	O
of	O
the	O
Regression	O
-	O
Based	O
Exon	O
Array	O
ProtocolConvinced	O
that	O
the	O
signal	O
estimates	O
from	O
the	O
exon	O
arrays	O
reflected	O
expected	O
molecular	O
and	O
biological	O
differences	O
between	O
hESCs	O
and	O
NPs	O
,	O
we	O
sought	O
to	O
identify	O
AS	O
events	O
.	O

We	O
compared	O
Cyt	O
-	O
ES	O
to	O
hCNS	O
-	O
SCns	O
to	O
illustrate	O
our	O
approach	O
.	O

First	O
we	O
normalized	O
the	O
data	O
and	O
generated	O
signal	O
estimates	O
with	O
Robust	O
Multichip	O
Analysis	O
(	O
RMA	O
)	O
and	O
estimated	O
the	O
probability	O
that	O
each	O
probeset	O
was	O
detected	O
above	O
background	O
(	O
DABG	O
)	O
using	O
publicly	O
available	O
Affymetrix	O
Power	O
Tools	O
(	O
APT	O
)	O
.	O

We	O
analyzed	O
probesets	O
that	O
(	O
i	O
)	O
comprised	O
three	O
or	O
more	O
individual	O
probes	O
;	O
(	O
ii	O
)	O
were	O
localized	O
within	O
the	O
exons	O
of	O
our	O
gene	O
models	O
with	O
evidence	O
from	O
at	O
least	O
three	O
sources	O
(	O
mRNA	O
,	O
EST	O
,	O
or	O
full	O
-	O
length	O
cDNA	O
)	O
;	O
and	O
(	O
iii	O
)	O
were	O
detected	O
above	O
background	O
in	O
at	O
least	O
one	O
of	O
the	O
cell	O
lines	O
.	O

In	O
total	O
,	O
17,430	O
gene	O
models	O
were	O
represented	O
by	O
probesets	O
that	O
satisfied	O
these	O
criteria	O
.	O

Next	O
we	O
asked	O
whether	O
the	O
probeset	O
expression	O
within	O
each	O
gene	O
model	O
was	O
positively	O
correlated	O
for	O
any	O
two	O
cell	O
lines	O
.	O

To	O
do	O
this	O
we	O
calculated	O
the	O
Pearson	O
correlation	O
coefficient	O
between	O
the	O
vectors	O
of	O
median	O
signal	O
estimates	O
across	O
replicates	O
in	O
Cyt	O
-	O
ES	O
versus	O
hCNS	O
-	O
SCns	O
.	O

The	O
vast	O
majority	O
of	O
genes	O
(	O
>	O
80	O
%	O
)	O
was	O
found	O
to	O
have	O
probeset	O
-	O
level	O
Pearson	O
correlation	O
coefficients	O
of	O
greater	O
than	O
0.8	O
(	O
Figure	O
3A	O
)	O
.	O

Next	O
we	O
randomly	O
permuted	O
the	O
association	O
between	O
the	O
median	O
signal	O
estimates	O
and	O
the	O
probesets	O
for	O
each	O
gene	O
in	O
hESCs	O
(	O
or	O
hCNS	O
-	O
SCns	O
)	O
and	O
observed	O
that	O
the	O
distribution	O
of	O
Pearson	O
correlation	O
coefficients	O
for	O
the	O
permuted	O
sets	O
was	O
centered	O
at	O
zero	O
,	O
as	O
expected	O
(	O
Figure	O
3A	O
)	O
.	O

This	O
indicated	O
that	O
the	O
signal	O
estimates	O
for	O
probesets	O
between	O
hESCs	O
and	O
hCNS	O
-	O
SCns	O
were	O
highly	O
correlated	O
and	O
suggested	O
that	O
a	O
scatter	O
plot	O
of	O
probeset	O
signal	O
estimates	O
between	O
hESCs	O
and	O
hCNS	O
-	O
SCns	O
would	O
reveal	O
a	O
linear	O
relationship	O
for	O
the	O
majority	O
of	O
genes	O
.	O

We	O
hypothesized	O
that	O
a	O
linear	O
regression	O
to	O
determine	O
if	O
some	O
probesets	O
behaved	O
unexpectedly	O
in	O
one	O
cell	O
type	O
compared	O
to	O
the	O
other	O
might	O
be	O
a	O
reasonable	O
approach	O
to	O
identify	O
AS	O
exons	O
.	O

Figure	O
3Description	O
of	O
the	O
REAP	O
Algorithm	O
Comparing	O
Exon	O
Array	O
Signal	O
Estimates	O
from	O
hCNS	O
-	O
SCns	O
and	O
Cyt	O
-	O
ES	O
(	O
A	O
)	O
Histogram	O
of	O
Pearson	O
correlation	O
coefficients	O
computed	O
from	O
median	O
signal	O
estimates	O
for	O
probesets	O
between	O
Cyt	O
-	O
ES	O
versus	O
hCNS	O
-	O
SCns	O
for	O
genes	O
(	O
blue	O
bars	O
)	O
.	O

Genes	O
were	O
required	O
to	O
have	O
more	O
than	O
five	O
probesets	O
localized	O
within	O
the	O
exons	O
in	O
the	O
gene	O
.	O

Red	O
bars	O
represented	O
Pearson	O
correlation	O
coefficients	O
computed	O
from	O
exons	O
with	O
shuffled	O
signal	O
estimates.	O
(	O
B	O
)	O

Each	O
probeset	O
contained	O
probeset	O
-	O
level	O
estimates	O
from	O
three	O
replicates	O
each	O
,	O
(	O
a	O
,	O
b	O
,	O
c	O
)	O
in	O
Cyt	O
-	O
ES	O
and	O
(	O
d	O
,	O
e	O
,	O
f	O
)	O
in	O
hCNS	O
-	O
SCns	O
.	O

The	O
five	O
points	O
summarizing	O
the	O
log2	O
probeset	O
-	O
level	O
estimates	O
are	O
indicated	O
by	O
black	O
filled	O
circles.	O
(	O
C	O
)	O

Each	O
probeset	O
was	O
summarized	O
by	O
five	O
points	O
.	O

Scatter	O
plots	O
of	O
signal	O
estimates	O
for	O
probesets	O
that	O
were	O
present	O
in	O
at	O
least	O
one	O
cell	O
type	O
(	O
Cyt	O
-	O
ES	O
or	O
hCNS	O
-	O
SCns	O
)	O
for	O
the	O
EHBP1	O
gene	O
.	O

Probesets	O
were	O
considered	O
present	O
if	O
the	O
DABG	O
p	O
-	O
value	O
was	O
<	O
0.05	O
for	O
all	O
three	O
replicates	O
in	O
the	O
cell	O
type	O
.	O

A	O
regression	O
line	O
derived	O
from	O
robust	O
linear	O
regression	O
with	O
MM	O
estimation	O
is	O
indicated	O
.	O

Points	O
above	O
the	O
line	O
represent	O
probesets	O
within	O
exons	O
that	O
were	O
enriched	O
in	O
Cyt	O
-	O
ES	O
and	O
points	O
below	O
represent	O
exons	O
that	O
were	O
enriched	O
in	O
hCNS	O
-	O
SCns	O
.	O

Points	O
close	O
to	O
the	O
regression	O
line	O
are	O
not	O
significantly	O
different	O
in	O
Cyt	O
-	O
ES	O
versus	O
hCNS	O
-	O
SCns	O
.	O

Boxed	O
points	O
represented	O
the	O
five	O
-	O
point	O
summary	O
of	O
a	O
probeset	O
that	O
was	O
significantly	O
enriched	O
in	O
Cyt	O
-	O
ES	O
but	O
was	O
skipped	O
in	O
hCNS	O
-	O
SCns.	O
(	O
D	O
)	O
Histogram	O
of	O
studentized	O
residuals	O
for	O
points	O
from	O
the	O
scatter	O
plot	O
in	O
(	O
C	O
)	O
in	O
EHBP1.	O
(	O
E	O
)	O
The	O
histogram	O
of	O
studentized	O
residuals	O
for	O
all	O
points	O
for	O
all	O
analyzed	O
probesets	O
(	O
100	O
bins	O
)	O
.	O
(	O
F	O
)	O

The	O
scatter	O
plot	O
of	O
studentized	O
residuals	O
generated	O
from	O
comparing	O
Cyt	O
-	O
ES	O
versus	O
hCNS	O
-	O
SCns	O
and	O
hCNS	O
-	O
SCns	O
versus	O
Cyt	O
-	O
ES	O
of	O
5,000	O
randomly	O
chosen	O
probesets	O
.	O

Here	O
,	O
a	O
possible	O
representation	O
of	O
the	O
data	O
was	O
explored	O
.	O

If	O
we	O
had	O
N	O
replicates	O
in	O
one	O
condition	O
and	O
M	O
replicates	O
in	O
the	O
other	O
,	O
we	O
could	O
consider	O
N*M	O
points	O
if	O
we	O
analyzed	O
every	O
possible	O
pairing	O
.	O

For	O
instance	O
,	O
three	O
replicate	O
signal	O
estimates	O
for	O
every	O
probeset	O
per	O
cell	O
line	O
,	O
such	O
as	O
signal	O
estimates	O
a	O
,	O
b	O
,	O
and	O
c	O
in	O
hESCs	O
and	O
d	O
,	O
e	O
,	O
and	O
f	O
in	O
hCNS	O
-	O
SCns	O
,	O
would	O
translate	O
to	O
pairing	O
every	O
signal	O
(	O
d	O
,	O
a	O
)	O
,	O
(	O
d	O
,	O
b	O
)	O
,	O
(	O
d	O
,	O
c	O
)	O
…	O
(	O
f	O
,	O
a	O
)	O
,	O
(	O
f	O
,	O
b	O
)	O
,	O
(	O
f	O
,	O
c	O
)	O
for	O
linear	O
regression	O
(	O
Figure	O
3B	O
)	O
.	O

Instead	O
,	O
pairing	O
the	O
signal	O
estimates	O
of	O
all	O
replicates	O
in	O
one	O
condition	O
to	O
the	O
median	O
of	O
the	O
other	O
would	O
only	O
require	O
N	O
+	O
M	O
−	O
1	O
points	O
and	O
would	O
capture	O
the	O
variation	O
of	O
the	O
signal	O
estimates	O
of	O
each	O
probeset	O
.	O

For	O
example	O
,	O
we	O
considered	O
(	O
d	O
,	O
b	O
)	O
,	O
(	O
e	O
,	O
a	O
)	O
,	O
(	O
e	O
,	O
b	O
)	O
,	O
(	O
e	O
,	O
c	O
)	O
,	O
and	O
(	O
f	O
,	O
b	O
)	O
points	O
where	O
b	O
and	O
d	O
were	O
the	O
median	O
intensities	O
for	O
the	O
replicates	O
in	O
Cyt	O
-	O
ES	O
and	O
hCNS	O
-	O
SCns	O
,	O
respectively	O
(	O
Figure	O
3B	O
)	O
.	O

A	O
scatter	O
plot	O
of	O
all	O
probesets	O
of	O
the	O
EHBP1	O
(	O
EH	O
domain	O
binding	O
protein	O
,	O
RefSeq	O
identifier	O
NM_015252	O
)	O
is	O
shown	O
in	O
Figure	O
3C	O
in	O
the	O
format	O
described	O
.	O

Each	O
probeset	O
was	O
represented	O
by	O
5	O
points	O
of	O
log	O
-	O
transformed	O
(	O
base	O
2	O
)	O
values	O
;	O
and	O
each	O
point	O
on	O
the	O
scatter	O
plot	O
reflected	O
the	O
extent	O
of	O
inclusion	O
of	O
an	O
exon	O
in	O
hESCs	O
and	O
in	O
hCNS	O
-	O
SCns	O
(	O
Figure	O
3C	O
)	O
.A	O
classical	O
linear	O
regression	O
model	O
could	O
be	O
proposed	O
to	O
fit	O
the	O
response	O
variable	O
yij	O
,	O
the	O
log2	O
expression	O
of	O
probeset	O
i	O
in	O
cell	O
-	O
type	O
j	O
(	O
for	O
example	O
,	O
j	O
is	O
Cyt	O
-	O
ESC	O
)	O
to	O
explanatory	O
variables	O
xik	O
,	O
and	O
the	O
log2	O
expression	O
of	O
probeset	O
i	O
in	O
cell	O
type	O
k	O
(	O
for	O
example	O
,	O
k	O
is	O
hCNS	O
-	O
SCns	O
)	O
.	O

However	O
,	O
classical	O
linear	O
regression	O
by	O
least	O
-	O
squares	O
estimation	O
is	O
biased	O
because	O
the	O
least	O
squares	O
predictions	O
are	O
strongly	O
influenced	O
by	O
the	O
outliers	O
,	O
leading	O
to	O
completely	O
incorrect	O
regression	O
line	O
estimates	O
,	O
masking	O
of	O
the	O
outliers	O
,	O
and	O
incorrect	O
predictions	O
of	O
outliers	O
.	O

Therefore	O
,	O
we	O
applied	O
M	O
-	O
estimation	O
robust	O
regression	O
to	O
estimate	O
the	O
line	O
,	O
which	O
is	O
less	O
sensitive	O
to	O
outliers	O
.	O

Fitting	O
was	O
performed	O
using	O
an	O
iterated	O
,	O
re	O
-	O
weighted	O
least	O
squares	O
analysis	O
.	O

Our	O
assumption	O
was	O
that	O
most	O
of	O
the	O
points	O
were	O
"	O
correct	O
,	O
"	O
i.e.	O
,	O
that	O
most	O
of	O
the	O
exons	O
were	O
constitutively	O
spliced	O
.	O

Thus	O
,	O
robust	O
regression	O
would	O
find	O
the	O
line	O
that	O
was	O
least	O
dependent	O
on	O
outliers	O
,	O
which	O
would	O
be	O
potential	O
AS	O
exons	O
.	O

This	O
assumption	O
was	O
substantiated	O
by	O
our	O
observation	O
that	O
,	O
using	O
publicly	O
available	O
ESTs	O
and	O
mRNAs	O
,	O
a	O
minority	O
of	O
human	B
exons	O
(	O
7	O
%	O
)	O
have	O
evidence	O
for	O
exon	O
-	O
skipping	O
,	O
the	O
most	O
common	O
form	O
of	O
AS	O
.	O

Using	O
robust	O
regression	O
,	O
the	O
regression	O
line	O
for	O
Cyt	O
-	O
ESC	O
versus	O
hCNS	O
-	O
SCns	O
in	O
the	O
EHBP1	O
gene	O
is	O
illustrated	O
in	O
Figure	O
3C	O
.	O

The	O
boxed	O
points	O
belonged	O
to	O
a	O
probeset	O
that	O
was	O
enriched	O
in	O
hESCs	O
but	O
depleted	O
in	O
hCNS	O
-	O
SCns	O
,	O
which	O
was	O
suspected	O
to	O
be	O
due	O
to	O
AS	O
.	O

The	O
difference	O
between	O
the	O
actual	O
and	O
regression	O
-	O
based	O
predicted	O
value	O
,	O
normalized	O
by	O
the	O
estimate	O
of	O
its	O
standard	O
deviation	O
,	O
is	O
called	O
the	O
studentized	O
residuals	O
.	O

Studentized	O
residuals	O
were	O
computed	O
for	O
all	O
probeset	O
pairs	O
in	O
EHBP1	O
,	O
and	O
the	O
histogram	O
depicting	O
their	O
distribution	O
is	O
illustrated	O
in	O
Figure	O
3D	O
.	O

As	O
expected	O
,	O
the	O
mean	O
of	O
the	O
distribution	O
was	O
close	O
to	O
zero	O
,	O
and	O
the	O
distribution	O
was	O
approximated	O
by	O
a	O
t	O
-	O
distribution	O
with	O
n	O
-	O
p-1	O
degrees	O
of	O
freedom	O
,	O
where	O
n	O
was	O
the	O
number	O
of	O
points	O
on	O
the	O
scatter	O
plot	O
,	O
and	O
the	O
number	O
of	O
parameters	O
p	O
was	O
2	O
.	O

The	O
boxed	O
points	O
had	O
studentized	O
residuals	O
of	O
1.829	O
,	O
3.104	O
,	O
2.634	O
,	O
3.012	O
,	O
and	O
2.125	O
with	O
p	O
-	O
values	O
of	O
0.034	O
,	O
0.00119	O
,	O
0.00477	O
,	O
0.00158	O
,	O
and	O
0.01780	O
,	O
respectively	O
,	O
computed	O
based	O
on	O
the	O
t	O
-	O
distribution	O
(	O
Figure	O
3C	O
)	O
.	O

At	O
a	O
stringent	O
p	O
-	O
value	O
cutoff	O
of	O
0.01	O
,	O
four	O
of	O
the	O
five	O
studentized	O
residuals	O
were	O
designated	O
as	O
significant	O
"	O
outliers	O
,	O
"	O
indicating	O
that	O
the	O
probeset	O
was	O
"	O
unusual	O
.	O
"	O
RT	O
-	O
PCR	O
confirmed	O
that	O
the	O
exon	O
,	O
represented	O
by	O
the	O
probeset	O
,	O
was	O
indeed	O
differentially	O
included	O
in	O
hESCs	O
and	O
skipped	O
in	O
hCNS	O
-	O
SCns	O
(	O
Figure	O
7B	O
)	O
.	O

Applying	O
this	O
approach	O
to	O
all	O
gene	O
models	O
revealed	O
that	O
,	O
as	O
expected	O
,	O
the	O
majority	O
of	O
studentized	O
residuals	O
are	O
centered	O
at	O
zero	O
(	O
Figure	O
3E	O
)	O
.	O

Thus	O
far	O
in	O
the	O
example	O
,	O
our	O
analysis	O
was	O
based	O
on	O
regression	O
of	O
hESCs	O
(	O
y	O
-	O
axis	O
)	O
versus	O
hCNS	O
-	O
SCns	O
(	O
x	O
-	O
axis	O
)	O
(	O
Figure	O
3B–3D	O
)	O
.	O

However	O
,	O
robust	O
regression	O
as	O
described	O
was	O
not	O
symmetrical	O
,	O
i.e.	O
,	O
parameter	O
estimation	O
of	O
y	O
as	O
a	O
function	O
of	O
x	O
was	O
not	O
the	O
same	O
as	O
that	O
of	O
x	O
as	O
a	O
function	O
of	O
y.	O
The	O
negative	O
slope	O
revealed	O
that	O
probesets	O
enriched	O
in	O
hESCs	O
versus	O
hCNS	O
-	O
SCns	O
(	O
positive	O
valued	O
)	O
,	O
were	O
expectedly	O
depleted	O
when	O
hCNS	O
-	O
SCns	O
was	O
compared	O
to	O
hESCs	O
(	O
negative	O
valued	O
;	O
Figure	O
3F	O
)	O
.	O

As	O
our	O
method	O
for	O
predicting	O
candidate	O
alternative	O
exons	O
was	O
based	O
on	O
identification	O
of	O
outliers	O
using	O
robust	O
regression	O
,	O
we	O
named	O
the	O
method	O
REAP	O
.	O

Identification	O
and	O
Removal	O
of	O
False	O
PositivesIn	O
the	O
process	O
of	O
experimentally	O
validating	O
our	O
predictions	O
,	O
we	O
encountered	O
three	O
main	O
sources	O
of	O
false	O
positives	O
(	O
FP	O
)	O
from	O
robust	O
regression	O
.	O

First	O
,	O
we	O
identified	O
genes	O
with	O
probeset	O
signal	O
estimates	O
that	O
were	O
poorly	O
correlated	O
and	O
were	O
not	O
amenable	O
to	O
our	O
method	O
.	O

As	O
an	O
example	O
,	O
the	O
median	O
probeset	O
signal	O
estimates	O
in	O
hESCs	O
and	O
hCNS	O
-	O
SCns	O
of	O
the	O
FIP1L1	O
gene	O
(	O
gene	O
identifiers	O
BC011543	O
,	O
AL136910	O
)	O
had	O
a	O
Pearson	O
correlation	O
coefficient	O
of	O
0.38	O
,	O
and	O
the	O
distribution	O
of	O
points	O
was	O
not	O
amenable	O
to	O
robust	O
regression	O
(	O
Figure	O
4A	O
)	O
.	O

To	O
avoid	O
inappropriate	O
application	O
of	O
REAP	O
and	O
generating	O
false	O
predictions	O
,	O
we	O
empirically	O
determined	O
that	O
a	O
gene	O
had	O
to	O
have	O
a	O
Pearson	O
correlation	O
coefficient	O
cutoff	O
of	O
0.6	O
before	O
being	O
amenable	O
to	O
REAP	O
analysis	O
.	O

Next	O
,	O
we	O
managed	O
two	O
additional	O
sources	O
of	O
FPs	O
,	O
namely	O
"	O
high	O
-	O
leverage	O
"	O
and	O
"	O
high	O
-	O
influence	O
"	O
points	O
,	O
which	O
we	O
were	O
able	O
to	O
identify	O
by	O
computing	O
the	O
following	O
metrics	O
.	O

For	O
every	O
point	O
,	O
we	O
computed	O
(	O
i	O
)	O
the	O
studentized	O
residual	O
(	O
as	O
described	O
above	O
)	O
,	O
(	O
ii	O
)	O
the	O
influence	O
,	O
and	O
(	O
iii	O
)	O
the	O
leverage	O
(	O
see	O
Materials	O
and	O
Methods	O
for	O
more	O
details	O
)	O
.	O

Leverage	O
assessed	O
how	O
far	O
away	O
a	O
value	O
of	O
the	O
independent	O
variable	O
was	O
from	O
the	O
mean	O
value	O
;	O
the	O
farther	O
away	O
the	O
observation	O
the	O
more	O
leverage	O
it	O
had	O
.	O

The	O
influence	O
of	O
a	O
point	O
was	O
related	O
to	O
its	O
covariance	O
ratio	O
:	O
a	O
covariance	O
ratio	O
larger	O
(	O
or	O
smaller	O
)	O
than	O
1	O
implied	O
that	O
the	O
point	O
was	O
closer	O
(	O
or	O
farther	O
)	O
than	O
was	O
typical	O
to	O
the	O
regression	O
line	O
,	O
so	O
removing	O
it	O
would	O
hurt	O
(	O
or	O
help	O
)	O
the	O
accuracy	O
of	O
the	O
line	O
and	O
would	O
increase	O
(	O
or	O
decrease	O
)	O
the	O
error	O
term	O
variance	O
.	O

Influence	O
was	O
computed	O
as	O
the	O
absolute	O
difference	O
between	O
the	O
covariance	O
ratio	O
and	O
unity	O
.	O

To	O
illustrate	O
further	O
,	O
a	O
point	O
was	O
classified	O
as	O
an	O
"	O
outlier	O
"	O
if	O
it	O
had	O
a	O
large	O
studentized	O
residual	O
(	O
p	O
<	O
0.01	O
)	O
and	O
low	O
leverage	O
(	O
boxed	O
point	O
"	O
a	O
"	O
)	O
;	O
as	O
a	O
"	O
high	O
-	O
leverage	O
"	O
point	O
if	O
it	O
had	O
a	O
low	O
studentized	O
residual	O
and	O
high	O
leverage	O
(	O
boxed	O
point	O
"	O
b	O
"	O
)	O
;	O
and	O
as	O
a	O
"	O
high	O
-	O
influence	O
"	O
point	O
if	O
it	O
had	O
a	O
high	O
studentized	O
residual	O
,	O
high	O
leverage	O
,	O
and	O
high	O
influence	O
(	O
boxed	O
point	O
"	O
c	O
"	O
;	O
Figure	O
4B	O
)	O
.	O

Points	O
that	O
resembled	O
boxed	O
point	O
"	O
a	O
"	O
were	O
designated	O
as	O
potential	O
AS	O
events	O
.	O

For	O
example	O
,	O
four	O
of	O
the	O
five	O
boxed	O
points	O
in	O
Figure	O
3C	O
were	O
"	O
outliers	O
,	O
"	O
and	O
RT	O
-	O
PCR	O
validation	O
indicated	O
that	O
the	O
exon	O
represented	O
by	O
the	O
probeset	O
was	O
indeed	O
skipped	O
in	O
hCNS	O
-	O
SCns	O
(	O
EHBP1	O
,	O
Figure	O
7B	O
)	O
.	O

Points	O
that	O
were	O
"	O
high	O
-	O
leverage	O
,	O
"	O
such	O
as	O
the	O
five	O
points	O
in	O
the	O
CLCN2	O
gene	O
,	O
were	O
experimentally	O
verified	O
to	O
be	O
a	O
FP	O
(	O
Figure	O
4C	O
;	O
unpublished	O
data	O
)	O
.	O

Points	O
that	O
were	O
"	O
high	O
-	O
influence	O
,	O
"	O
such	O
as	O
the	O
four	O
of	O
five	O
boxed	O
points	O
in	O
the	O
ABCA3	O
gene	O
were	O
also	O
experimentally	O
verified	O
to	O
be	O
a	O
FP	O
(	O
Figure	O
4D	O
;	O
unpublished	O
data	O
)	O
.	O

In	O
conclusion	O
,	O
in	O
order	O
to	O
reduce	O
the	O
FP	O
rate	O
,	O
all	O
points	O
were	O
evaluated	O
according	O
to	O
the	O
metrics	O
described	O
,	O
and	O
points	O
that	O
were	O
significant	O
"	O
outliers	O
"	O
were	O
considered	O
putative	O
AS	O
events	O
.	O

Figure	O
4Sources	O
of	O
False	O
Positives	O
(	O
A	O
)	O
Scatter	O
plot	O
of	O
points	O
for	O
the	O
FIP1L1	O
gene	O
and	O
the	O
line	O
representing	O
the	O
robust	O
regression	O
estimate.	O
(	O
B	O
)	O

Boxed	O
point	O
"	O
a	O
"	O
represents	O
a	O
significant	O
"	O
outlier	O
"	O
(	O
with	O
a	O
significantly	O
different	O
studentized	O
residual	O
and	O
low	O
leverage	O
)	O
.	O

Boxed	O
point	O
"	O
b	O
"	O
represents	O
a	O
"	O
high	O
leverage	O
"	O
point	O
(	O
low	O
studentized	O
residual	O
and	O
a	O
high	O
leverage	O
)	O
.	O

Boxed	O
point	O
"	O
c	O
"	O
represents	O
a	O
"	O
high	O
influence	O
"	O
point	O
(	O
high	O
studentized	O
residual	O
,	O
high	O
leverage	O
,	O
and	O
high	O
influence	O
)	O
.	O
(	O
C	O
)	O
Scatter	O
plot	O
of	O
points	O
for	O
the	O
CLCN2	O
gene	O
.	O

Boxed	O
points	O
represent	O
"	O
high	O
leverage	O
"	O
points.	O
(	O
D	O
)	O
Scatter	O
plot	O
of	O
points	O
for	O
the	O
ABCA3	O
gene	O
.	O

Boxed	O
points	O
represent	O
"	O
high	O
influence	O
"	O
points	O
.	O

Global	O
Identification	O
and	O
Characterization	O
of	O
REAP	O
[	O
+	O
]	O
ExonsREAP	O
was	O
applied	O
to	O
identify	O
AS	O
events	O
in	O
NPs	O
compared	O
to	O
hESCs	O
:	O
Cyt	O
-	O
NP	O
versus	O
Cyt	O
-	O
ES	O
;	O
HUES6-NP	O
versus	O
HUES6-ES	O
;	O
hCNS	O
-	O
SCns	O
versus	O
Cyt	O
-	O
ES	O
,	O
and	O
hCNS	O
-	O
SCns	O
versus	O
HUES6-ES	O
.	O

After	O
removing	O
potential	O
FPs	O
,	O
11,348	O
genes	O
containing	O
158,657	O
probesets	O
were	O
scored	O
by	O
REAP.As	O
described	O
above	O
,	O
for	O
each	O
pair	O
of	O
cell	O
lines	O
compared	O
,	O
each	O
probset	O
was	O
represented	O
by	O
five	O
points	O
,	O
where	O
each	O
point	O
was	O
defined	O
a	O
significant	O
outlier	O
if	O
it	O
had	O
a	O
high	O
residual	O
(	O
p	O
<	O
0.01	O
)	O
,	O
low	O
influence	O
,	O
and	O
high	O
leverage	O
.	O

Points	O
per	O
probeset	O
should	O
be	O
correlated	O
;	O
in	O
other	O
words	O
,	O
if	O
one	O
point	O
was	O
a	O
significant	O
outlier	O
,	O
the	O
other	O
points	O
were	O
expected	O
to	O
be	O
outliers	O
as	O
well	O
.	O

To	O
ensure	O
that	O
this	O
was	O
the	O
case	O
,	O
we	O
counted	O
the	O
number	O
of	O
probesets	O
with	O
N	O
significant	O
outliers	O
,	O
where	O
N	O
was	O
varied	O
from	O
0	O
to	O
5	O
.	O

Next	O
,	O
the	O
identity	O
of	O
the	O
probesets	O
and	O
points	O
derived	O
from	O
them	O
were	O
exchanged	O
with	O
other	O
probesets	O
,	O
keeping	O
constant	O
the	O
total	O
number	O
of	O
points	O
that	O
were	O
considered	O
significant	O
outliers	O
.	O

At	O
N	O
=	O
0	O
,	O
we	O
observed	O
approximately	O
equal	O
numbers	O
of	O
probesets	O
in	O
the	O
actual	O
versus	O
shuffled	O
controls	O
.	O

In	O
contrast	O
,	O
we	O
observed	O
that	O
there	O
were	O
1.5	O
times	O
more	O
probesets	O
with	O
N	O
=	O
2	O
significant	O
outliers	O
relative	O
to	O
shuffled	O
controls	O
;	O
12–31	O
times	O
more	O
probesets	O
with	O
N	O
=	O
3	O
;	O
and	O
17–612	O
times	O
more	O
probesets	O
that	O
had	O
N	O
=	O
4	O
significant	O
outliers	O
(	O
Figure	O
5A	O
;	O
see	O
Table	O
S1	O
)	O
.	O

For	O
example	O
,	O
in	O
hCNS	O
-	O
SCns	O
compared	O
to	O
Cyt	O
-	O
ES	O
,	O
approximately	O
0.39	O
%	O
(	O
490	O
of	O
124,604	O
)	O
of	O
probesets	O
had	O
three	O
significant	O
outliers	O
and	O
0.25	O
%	O
(	O
308	O
probesets	O
)	O
had	O
four	O
significant	O
outliers	O
,	O
relative	O
to	O
0.02	O
%	O
and	O
0	O
%	O
of	O
shuffled	O
controls	O
,	O
respectively	O
.	O

Figure	O
5Correlation	O
between	O
"	O
Outliers"	O
(	O
A	O
)	O
The	O
number	O
of	O
probesets	O
with	O
N	O
significant	O
"	O
outliers	O
"	O
was	O
determined	O
for	O
hCNS	O
-	O
SCns	O
versus	O
Cyt	O
-	O
ES	O
,	O
hCNS	O
-	O
SCns	O
versus	O
HUES6-ES	O
,	O
Cyt	O
-	O
NPs	O
versus	O
Cyt	O
-	O
ES	O
,	O
and	O
HUES6-NPs	O
versus	O
HUES6-ES	O
(	O
N	O
=	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
)	O
.	O

For	O
comparison	O
,	O
points	O
to	O
probeset	O
relationships	O
were	O
randomly	O
permuted	O
,	O
retaining	O
the	O
same	O
number	O
of	O
"	O
outliers	O
.	O
"	O

Vertical	O
bars	O
represent	O
the	O
ratio	O
between	O
the	O
number	O
of	O
actual	O
points	O
and	O
the	O
randomly	O
permutated	O
sets.	O
(	O
B	O
)	O
Similar	O
to	O
(	O
A	O
)	O
,	O
except	O
points	O
were	O
counted	O
as	O
"	O
outliers	O
"	O
only	O
if	O
they	O
were	O
"	O
outliers	O
"	O
in	O
both	O
hCNS	O
-	O
SCns	O
versus	O
Cyt	O
-	O
ES	O
and	O
hCNS	O
-	O
SCns	O
versus	O
HUES6-ES	O
(	O
combined	O
hCNS	O
-	O
SCns	O
versus	O
hESC	O
;	O
blue	O
bars	O
)	O
;	O
in	O
both	O
HUES6-NP	O
versus	O
HUES6-ES	O
and	O
Cyt	O
-	O
NP	O
versus	O
Cyt	O
-	O
ES	O
(	O
combined	O
derived	O
NP	O
versus	O
hESC	O
;	O
red	O
bars	O
)	O
;	O
and	O
in	O
all	O
four	O
comparisons	O
(	O
combined	O
NP	O
versus	O
hESC	O
;	O
yellow	O
bar	O
)	O
.Next	O
we	O
asked	O
whether	O
the	O
overlap	O
between	O
related	O
comparisons	O
was	O
higher	O
than	O
expected	O
.	O

Comparing	O
the	O
significant	O
probesets	O
between	O
hCNS	O
-	O
SCns	O
versus	O
Cyt	O
-	O
ES	O
and	O
hCNS	O
-	O
SCns	O
versus	O
HUES6-ES	O
revealed	O
672	O
significant	O
probesets	O
(	O
N	O
≥	O
2	O
)	O
,	O
whereas	O
if	O
we	O
shuffled	O
the	O
associations	O
between	O
probeset	O
identity	O
and	O
significant	O
outliers	O
,	O
only	O
four	O
significant	O
probesets	O
(	O
N	O
≥	O
2	O
)	O
were	O
identified	O
—	O
a	O
168-fold	O
enrichment	O
(	O
Figure	O
5B	O
,	O
Table	O
S1	O
)	O
.	O

A	O
total	O
of	O
236	O
significant	O
probesets	O
overlapped	O
when	O
we	O
compared	O
the	O
derived	O
NPs	O
to	O
hESCs	O
(	O
Cyt	O
-	O
NP	O
versus	O
Cyt	O
-	O
ES	O
and	O
HUES6-NP	O
versus	O
HUES6-ES	O
)	O
,	O
relative	O
to	O
seven	O
significant	O
probesets	O
(	O
34-fold	O
enrichment	O
)	O
.At	O
a	O
cutoff	O
of	O
two	O
significant	O
outliers	O
,	O
1,737	O
probesets	O
contained	O
in	O
internal	O
exons	O
were	O
defined	O
as	O
positive	O
REAP	O
predictions	O
(	O
hereafter	O
called	O
REAP	O
[	O
+	O
]	O
)	O
exons	O
—	O
candidate	O
AS	O
events	O
that	O
distinguished	O
NP	O
from	O
hESC	O
.	O

Surprisingly	O
,	O
we	O
observed	O
that	O
the	O
majority	O
of	O
REAP	O
[	O
+	O
]	O
exons	O
were	O
specific	O
to	O
the	O
pair	O
of	O
hESC	O
and	O
NP	O
that	O
was	O
compared	O
,	O
likely	O
reflecting	O
differences	O
in	O
genetic	O
origins	O
and/or	O
culturing	O
and	O
differentiation	O
conditions	O
of	O
the	O
cell	O
lines	O
:	O
614	O
REAP	O
[	O
+	O
]	O
events	O
were	O
unique	O
to	O
hCNS	O
-	O
SCns	O
versus	O
HUE6-ES	O
;	O
220	O
were	O
unique	O
to	O
hCNS	O
-	O
SCns	O
versus	O
Cyt	O
-	O
ES	O
;	O
439	O
were	O
unique	O
to	O
HUES6-NP	O
versus	O
HUES6-ES	O
;	O
and	O
250	O
were	O
unique	O
to	O
Cyt	O
-	O
NP	O
versus	O
Cyt	O
-	O
ES	O
.	O

The	O
shared	O
events	O
between	O
pairs	O
of	O
comparisons	O
made	O
up	O
a	O
minority	O
of	O
the	O
total	O
number	O
identified	O
:	O
102	O
REAP	O
[	O
+	O
]	O
events	O
were	O
found	O
to	O
be	O
in	O
common	O
between	O
hCNS	O
-	O
SCns	O
versus	O
Cyt	O
-	O
ES	O
and	O
hCNS	O
-	O
SCns	O
versus	O
HUES6-ES	O
;	O
48	O
between	O
hCNS	O
-	O
SCns	O
versus	O
HUES6-ES	O
and	O
HUES6-NP	O
versus	O
HUES6-ES	O
;	O
and	O
only	O
17	O
between	O
hCNS	O
-	O
SCns	O
versus	O
Cyt	O
-	O
ES	O
and	O
Cyt	O
-	O
NP	O
versus	O
Cyt	O
-	O
ES	O
(	O
Table	O
S2	O
)	O
.	O

Comparison	O
of	O
REAP	O
to	O
EST	O
-	O
Based	O
Method	O
and	O
ACEScanTraditionally	O
,	O
AS	O
exons	O
were	O
discovered	O
by	O
using	O
EST	O
alignments	O
to	O
genomic	O
loci	O
,	O
and	O
also	O
more	O
recently	O
by	O
computational	O
algorithms	O
that	O
used	O
sequence	O
information	O
extracted	O
from	O
multiple	O
genomes	O
.	O

Here	O
,	O
we	O
compared	O
REAP	O
predictions	O
to	O
both	O
approaches	O
.	O

In	O
the	O
first	O
comparison	O
,	O
publicly	O
available	O
ESTs	O
and	O
mRNA	O
transcripts	O
were	O
aligned	O
to	O
the	O
human	B
genome	O
sequence	O
.	O

13,934	O
exons	O
with	O
evidence	O
for	O
exon	O
-	O
skipping	O
and/or	O
inclusion	O
(	O
EST	O
-	O
SE	O
for	O
EST	O
-	O
verified	O
skipped	O
exons	O
)	O
were	O
generated	O
,	O
comprising	O
∼7	O
%	O
of	O
all	O
internal	O
exons	O
.	O

First	O
we	O
analyzed	O
Cyt	O
-	O
ES	O
versus	O
hCNS	O
-	O
SCns	O
.	O

If	O
we	O
required	O
that	O
none	O
of	O
the	O
points	O
per	O
probeset	O
(	O
exon	O
)	O
was	O
significant	O
,	O
6	O
%	O
(	O
4,402	O
of	O
71,731	O
)	O
of	O
exons	O
(	O
after	O
probeset	O
mapping	O
)	O
had	O
evidence	O
for	O
EST	O
-	O
SE	O
(	O
Figure	O
6A	O
)	O
.	O

Shuffling	O
the	O
mapping	O
between	O
these	O
probesets	O
and	O
exons	O
resulted	O
in	O
8	O
%	O
(	O
5,777	O
of	O
71,731	O
)	O
of	O
exons	O
with	O
evidence	O
for	O
EST	O
-	O
SE	O
(	O
Figure	O
6A	O
)	O
.	O

These	O
percentages	O
were	O
not	O
significantly	O
different	O
from	O
the	O
7	O
%	O
of	O
exons	O
with	O
EST	O
evidence	O
for	O
AS	O
observed	O
from	O
using	O
all	O
exons	O
.	O

By	O
raising	O
the	O
requirement	O
that	O
probesets	O
had	O
to	O
contain	O
at	O
least	O
one	O
significant	O
point	O
to	O
five	O
significant	O
points	O
,	O
the	O
percentage	O
of	O
EST	O
-	O
SE	O
increased	O
dramatically	O
from	O
11	O
%	O
(	O
531	O
of	O
4,898	O
exons	O
)	O
to	O
26	O
%	O
(	O
33	O
of	O
126	O
)	O
.	O

In	O
comparison	O
,	O
the	O
shuffled	O
probesets	O
at	O
the	O
same	O
requirements	O
remained	O
at	O
∼8	O
%	O
,	O
rising	O
slightly	O
to	O
11	O
%	O
at	O
five	O
points	O
,	O
due	O
to	O
small	O
sample	O
sizes	O
.	O

Similar	O
trends	O
were	O
observed	O
with	O
hCNS	O
-	O
SCns	O
versus	O
HUES6-ES	O
and	O
the	O
derived	O
NPs	O
versus	O
hESCs	O
(	O
Figure	O
6A	O
)	O
.	O

Therefore	O
,	O
we	O
concluded	O
that	O
REAP	O
[	O
+	O
]	O
exons	O
were	O
enriched	O
for	O
AS	O
events	O
independently	O
identified	O
by	O
a	O
transcript	O
-	O
based	O
approach	O
.	O

Figure	O
6Comparison	O
of	O
REAP	O
Predictions	O
for	O
hCNS	O
-	O
SCns	O
versus	O
Cyt	O
-	O
hES	O
,	O
hCNS	O
-	O
SCns	O
versus	O
HUES6-ES	O
,	O
Cyt	O
-	O
NP	O
versus	O
Cyt	O
-	O
ES	O
,	O
and	O
HUES6-NPs	O
versus	O
HUES6-ES	O
with	O
Alternative	O
Exons	O
Identified	O
by	O
an	O
EST	O
-	O
Based	O
Method	O
and	O
ACEScan	O
(	O
A	O
)	O
Black	O
-	O
filled	O
squares	O
represented	O
the	O
fraction	O
of	O
exons	O
containing	O
probesets	O
with	O
N	O
significant	O
points	O
that	O
had	O
EST	O
evidence	O
for	O
exon	O
inclusion	O
or	O
exclusion	O
(	O
N	O
=	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
and	O
5	O
)	O
.	O

White	O
-	O
filled	O
triangles	O
represented	O
similarly	O
computed	O
fractions	O
with	O
permuted	O
probeset	O
to	O
exon	O
mappings.	O
(	O
B	O
)	O
Black	O
-	O
filled	O
squares	O
represented	O
the	O
fraction	O
of	O
exons	O
containing	O
probesets	O
with	O
N	O
significant	O
points	O
that	O
had	O
ACEScan	O
positive	O
scores	O
,	O
indicative	O
of	O
evolutionarily	O
conserved	O
alternative	O
exons	O
.	O

White	O
-	O
filled	O
triangles	O
represented	O
similarly	O
computed	O
fractions	O
with	O
permuted	O
probeset	O
to	O
exon	O
mappings	O
.	O

Next	O
,	O
we	O
compared	O
REAP	O
predictions	O
to	O
a	O
computational	O
approach	O
of	O
identifying	O
exons	O
with	O
AS	O
conserved	O
in	O
human	B
and	O
mouse	B
,	O
ACEScan	O
[	O
55	O
]	O
.	O

ACEScan	O
receives	O
as	O
input	O
orthologous	O
human	B
–	O
mouse	B
exon	O
pairs	O
and	O
flanking	O
intronic	O
regions	O
and	O
computes	O
sequence	O
features	O
and	O
integrates	O
the	O
features	O
into	O
a	O
machine	O
-	O
learning	O
algorithm	O
to	O
assign	O
a	O
real	O
-	O
valued	O
score	O
to	O
the	O
exon	O
.	O

A	O
positive	O
score	O
indicated	O
a	O
higher	O
likelihood	O
of	O
being	O
AS	O
in	O
both	O
human	B
and	O
mouse	B
.	O

ACEScan	O
was	O
updated	O
in	O
the	O
following	O
ways	O
.	O

Firstly	O
,	O
instead	O
of	O
relying	O
on	O
orthology	O
information	O
by	O
Ensembl	O
,	O
and	O
then	O
aligning	O
flanking	O
introns	O
in	O
"	O
orthologous	O
"	O
exons	O
,	O
conserved	O
exonic	O
and	O
intronic	O
regions	O
in	O
human	B
and	O
mouse	B
from	O
genome	O
-	O
wide	O
multiple	O
alignments	O
were	O
extracted	O
.	O

Secondly	O
,	O
whereas	O
in	O
our	O
previous	O
analysis	O
exons	O
from	O
the	O
longest	O
transcript	O
in	O
Ensembl	O
were	O
utilized	O
,	O
now	O
we	O
collapsed	O
all	O
the	O
transcripts	O
available	O
at	O
the	O
UCSC	O
genome	O
browser	O
and	O
analyzed	O
all	O
exons	O
in	O
the	O
entire	O
gene	O
loci	O
.	O

ACEScan	O
was	O
utilized	O
to	O
assign	O
ACEScan	O
scores	O
to	O
all	O
∼162,000	O
internal	O
exons	O
in	O
our	O
genes	O
.	O

Exons	O
annotated	O
as	O
first	O
or	O
last	O
exons	O
in	O
Refseq	O
mRNAs	O
were	O
excluded	O
from	O
our	O
analysis	O
,	O
resulting	O
in	O
4,487	O
positive	O
-	O
scoring	O
exons	O
,	O
2-fold	O
more	O
exons	O
than	O
originally	O
published	O
.	O

Here	O
we	O
repeated	O
our	O
analysis	O
with	O
exons	O
with	O
positive	O
ACEScan	O
scores	O
(	O
ACE	O
[	O
+	O
]	O
)	O
instead	O
of	O
EST	O
-	O
SEs	O
.	O

If	O
we	O
required	O
that	O
none	O
of	O
the	O
points	O
per	O
probeset	O
(	O
exon	O
)	O
was	O
significant	O
,	O
2	O
%	O
(	O
1,645	O
of	O
71,731	O
)	O
of	O
exons	O
(	O
after	O
probeset	O
mapping	O
)	O
were	O
ACE	O
[	O
+	O
]	O
(	O
Figure	O
6B	O
)	O
.	O

Shuffling	O
the	O
mapping	O
between	O
these	O
probesets	O
and	O
exons	O
resulted	O
in	O
3	O
%	O
(	O
2,044	O
of	O
71,731	O
)	O
of	O
exons	O
being	O
ACE	O
[	O
+	O
]	O
(	O
Figure	O
6B	O
)	O
.	O

These	O
percentages	O
were	O
not	O
significantly	O
different	O
from	O
the	O
2.7	O
%	O
observed	O
from	O
all	O
exons	O
(	O
4,487	O
of	O
the	O
162,000	O
exons	O
that	O
were	O
scored	O
by	O
ACEScan	O
)	O
.	O

By	O
raising	O
the	O
requirement	O
that	O
probesets	O
had	O
to	O
contain	O
five	O
significant	O
points	O
,	O
the	O
percentage	O
of	O
ACE	O
[	O
+	O
]	O
exons	O
increased	O
from	O
4	O
%	O
to	O
11	O
%	O
.	O

However	O
,	O
the	O
sample	O
sizes	O
were	O
small	O
.	O

In	O
comparison	O
,	O
the	O
shuffled	O
probesets	O
at	O
the	O
same	O
requirements	O
remained	O
at	O
∼4	O
%	O
.	O

Similar	O
overall	O
trends	O
were	O
observed	O
with	O
hCNS	O
-	O
SCns	O
versus	O
HUES6-ES	O
and	O
the	O
derived	O
NPs	O
versus	O
hESCs	O
(	O
Figure	O
6B	O
)	O
.	O

In	O
total	O
,	O
7.5	O
%	O
(	O
131	O
of	O
1,737	O
)	O
of	O
REAP	O
[	O
+	O
]	O
exons	O
were	O
designated	O
as	O
ACEScan	O
[	O
+	O
]	O
compared	O
to	O
2.4	O
%	O
(	O
2,328	O
of	O
97,437	O
)	O
of	O
REAP	O
[	O
−	O
]	O
exons	O
.	O

This	O
result	O
suggested	O
that	O
a	O
small	O
but	O
significantly	O
enriched	O
fraction	O
of	O
AS	O
events	O
in	O
hESCs	O
versus	O
NPs	O
was	O
likely	O
to	O
be	O
evolutionarily	O
conserved	O
in	O
human	B
and	O
mouse	B
.	O

In	O
conclusion	O
,	O
our	O
results	O
suggested	O
that	O
REAP	O
predictions	O
were	O
congruent	O
with	O
predictions	O
from	O
two	O
independent	O
,	O
orthogonal	O
methods	O
.	O

Experimental	O
Validation	O
of	O
Alternative	O
ExonsThe	O
sensitivity	O
and	O
specificity	O
of	O
REAP	O
in	O
the	O
identification	O
of	O
REAP	O
[	O
+	O
]	O
exons	O
was	O
tested	O
by	O
RT	O
-	O
PCR	O
.	O

To	O
validate	O
REAP	O
[	O
+	O
]	O
alternative	O
exons	O
,	O
RT	O
-	O
PCR	O
primers	O
were	O
designed	O
in	O
the	O
flanking	O
exons	O
to	O
amplify	O
both	O
isoforms	O
.	O

To	O
be	O
a	O
positively	O
validated	O
candidate	O
,	O
the	O
PCR	O
products	O
on	O
a	O
gel	O
had	O
to	O
satisfy	O
all	O
of	O
the	O
following	O
criteria	O
:	O
(	O
i	O
)	O
at	O
least	O
one	O
isoform	O
with	O
the	O
expected	O
size	O
must	O
be	O
visible	O
in	O
each	O
cell	O
type	O
;	O
(	O
ii	O
)	O
the	O
relative	O
abundance	O
of	O
the	O
two	O
isoforms	O
must	O
be	O
altered	O
between	O
two	O
cell	O
types	O
and	O
the	O
direction	O
of	O
change	O
have	O
to	O
be	O
consistent	O
with	O
the	O
REAP	O
studentized	O
residuals	O
:	O
in	O
our	O
study	O
positive	O
residuals	O
implied	O
inclusion	O
in	O
hESCs	O
and	O
skipping	O
in	O
NPs	O
,	O
and	O
negative	O
residuals	O
implied	O
inclusion	O
in	O
NP	O
and	O
skipping	O
in	O
hESCs	O
;	O
and	O
(	O
iii	O
)	O
the	O
results	O
were	O
replicable	O
in	O
at	O
least	O
two	O
experiments	O
.	O

For	O
simplicity	O
of	O
design	O
,	O
we	O
tested	O
candidates	O
predicted	O
from	O
Cyt	O
-	O
ES	O
versus	O
hCNS	O
-	O
SCns	O
.	O

Fifteen	O
REAP	O
[	O
+	O
]	O
exons	O
with	O
at	O
least	O
two	O
significant	O
outliers	O
(	O
out	O
of	O
five	O
)	O
were	O
randomly	O
chosen	O
as	O
predicted	O
alternative	O
events	O
and	O
thirty	O
-	O
five	O
exons	O
with	O
less	O
than	O
two	O
significant	O
outliers	O
were	O
randomly	O
chosen	O
as	O
constitutive	O
events	O
(	O
Table	O
S3	O
)	O
.	O

Nine	O
of	O
the	O
fifteen	O
exons	O
(	O
60	O
%	O
)	O
were	O
validated	O
as	O
AS	O
events	O
by	O
our	O
criteria	O
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
the	O
algorithm	O
at	O
the	O
cutoff	O
of	O
two	O
is	O
69	O
%	O
and	O
77	O
%	O
.	O

Increasing	O
the	O
cutoff	O
to	O
three	O
increased	O
the	O
specificity	O
to	O
85	O
%	O
,	O
with	O
a	O
slight	O
decrease	O
in	O
sensitivity	O
to	O
67	O
%	O
(	O
Figure	O
7A	O
)	O
.	O

The	O
patterns	O
of	O
AS	O
in	O
hESCs	O
were	O
similar	O
in	O
both	O
Cyt	O
-	O
ES	O
and	O
HUES6-ES	O
for	O
all	O
AS	O
events	O
validated	O
,	O
but	O
the	O
NPs	O
(	O
Cyt	O
-	O
NP	O
,	O
HUES6-NP	O
,	O
and	O
hCNS	O
-	O
SCns	O
)	O
had	O
more	O
varied	O
AS	O
.	O

The	O
pattern	O
of	O
AS	O
in	O
the	O
REAP	O
[	O
+	O
]	O
exons	O
in	O
the	O
SLK	O
(	O
serine	O
/	O
threonine	O
kinase	O
2	O
)	O
and	O
POT1	O
(	O
protection	O
of	O
telomeres	O
1	O
)	O
genes	O
showed	O
remarkable	O
agreement	O
within	O
derived	O
NPs	O
and	O
hCNS	O
-	O
SCns	O
(	O
Figure	O
7B	O
)	O
.	O

The	O
AS	O
exon	O
in	O
SLK	O
was	O
observed	O
to	O
be	O
included	O
in	O
hESCs	O
and	O
completely	O
excluded	O
in	O
NPs	O
;	O
the	O
AS	O
exon	O
in	O
the	O
POT1	O
gene	O
was	O
included	O
more	O
in	O
hESCs	O
and	O
a	O
smaller	O
isoform	O
persisted	O
in	O
NPs	O
.	O

The	O
AS	O
patterns	O
of	O
the	O
other	O
verified	O
REAP	O
[	O
+	O
]	O
exons	O
were	O
consistently	O
similar	O
in	O
hESCs	O
but	O
were	O
more	O
varied	O
in	O
the	O
NP	O
.	O

Interestingly	O
,	O
the	O
patterns	O
of	O
AS	O
in	O
the	O
derived	O
NPs	O
(	O
Cyt	O
-	O
NP	O
and	O
HUES6-NP	O
)	O
were	O
not	O
always	O
identical	O
to	O
those	O
of	O
hCNS	O
-	O
SCns	O
.	O

For	O
example	O
,	O
the	O
AS	O
exon	O
in	O
the	O
EHBP1	O
(	O
EH	O
domain	O
binding	O
protein	O
1	O
)	O
gene	O
was	O
included	O
in	O
hESCs	O
but	O
skipped	O
in	O
hCNS	O
-	O
SCns	O
,	O
and	O
both	O
isoforms	O
were	O
present	O
in	O
the	O
derived	O
NPs	O
(	O
Figure	O
7B	O
)	O
.	O

As	O
another	O
example	O
,	O
the	O
AS	O
exon	O
in	O
the	O
SORBS1	O
(	O
sorbin	O
and	O
SH3	O
domain	O
containing	O
1	O
)	O
gene	O
was	O
skipped	O
in	O
hESCs	O
and	O
included	O
in	O
hCNS	O
-	O
SCns	O
,	O
but	O
exhibited	O
an	O
intermediate	O
pattern	O
in	O
the	O
derived	O
NPs	O
.	O

However	O
,	O
in	O
some	O
cases	O
,	O
the	O
AS	O
patterns	O
in	O
the	O
derived	O
NPs	O
were	O
different	O
from	O
both	O
hESCs	O
and	O
hCNS	O
-	O
SCns	O
(	O
such	O
as	O
in	O
the	O
AS	O
exon	O
in	O
UNC84A	O
,	O
SIRT1	O
,	O
and	O
MLLT10	O
)	O
.Figure	O
7RT	O
-	O
PCR	O
Validation	O
of	O
REAP	O
-	O
Predicted	O
Alternative	O
Exons	O
(	O
A	O
)	O
Probesets	O
(	O
exons	O
)	O
were	O
considered	O
REAP	O
[	O
+	O
]	O
candidates	O
if	O
they	O
contained	O
at	O
least	O
N	O
=	O
2	O
(	O
white	O
bars	O
)	O
,	O
3	O
(	O
gray	O
bars	O
)	O
,	O
or	O
4	O
(	O
black	O
bars	O
)	O
significant	O
outliers	O
.	O

True	O
positive	O
(	O
TP	O
)	O
,	O
true	O
negative	O
(	O
TN	O
)	O
,	O
false	O
positive	O
(	O
FP	O
)	O
,	O
and	O
false	O
negative	O
(	O
FN	O
)	O
rates	O
were	O
calculated	O
from	O
RT	O
-	O
PCR	O
-	O
validated	O
REAP	O
[	O
+	O
]	O
exons	O
at	O
the	O
different	O
cutoffs	O
(	O
N	O
=	O
2	O
,	O
3	O
,	O
4	O
)	O
.	O
(	O
B	O
)	O
Nine	O
RT	O
-	O
PCR	O
validated	O
REAP	O
[	O
+	O
]	O
AS	O
events	O
in	O
hESCs	O
(	O
Cyt	O
-	O
ES	O
and	O
HUES6-ES	O
)	O
,	O
derived	O
NPs	O
(	O
Cyt	O
-	O
NP	O
and	O
HUES6-NP	O
)	O
,	O
and	O
hCNS	O
-	O
SCns	O
.	O

Arrows	O
indicate	O
the	O
larger	O
(	O
exon	O
-	O
included	O
)	O
isoforms	O
and	O
smaller	O
(	O
exon	O
-	O
skipped	O
)	O
isoforms.	O
(	O
C	O
)	O
RT	O
-	O
PCR	O
of	O
REAP	O
[	O
+	O
]	O
alternative	O
exons	O
from	O
EHBP1	O
,	O
SLK	O
,	O
and	O
RAI14	O
across	O
a	O
panel	O
of	O
human	B
tissues	O
.	O

Arrows	O
indicate	O
the	O
larger	O
(	O
exon	O
-	O
included	O
)	O
isoforms	O
and	O
smaller	O
(	O
exon	O
-	O
skipped	O
)	O
isoforms	O
.	O

First	O
,	O
given	O
three	O
independent	O
samples	O
each	O
from	O
two	O
conditions	O
,	O
we	O
concluded	O
that	O
REAP	O
was	O
able	O
to	O
identify	O
AS	O
events	O
with	O
high	O
specificity	O
but	O
with	O
moderate	O
sensitivity	O
.	O

Second	O
,	O
AS	O
events	O
in	O
hESCs	O
were	O
more	O
similar	O
,	O
whereas	O
the	O
AS	O
events	O
in	O
derived	O
NPs	O
were	O
consistent	O
with	O
or	O
intermediate	O
to	O
the	O
benchmark	O
hCNS	O
-	O
SCns	O
,	O
likely	O
reflecting	O
differences	O
in	O
the	O
cell	O
lines	O
and/or	O
differentiation	O
protocols	O
.	O

In	O
addition	O
,	O
we	O
tested	O
the	O
AS	O
patterns	O
of	O
REAP	O
[	O
+	O
]	O
exons	O
from	O
EHBP1	O
,	O
SLK	O
,	O
and	O
RAI14	O
in	O
a	O
panel	O
of	O
differentiated	O
human	B
tissues	O
(	O
Figure	O
7C	O
)	O
.	O

The	O
REAP	O
[	O
+	O
]	O
alternative	O
exon	O
in	O
the	O
RAI14	O
(	O
retinoic	O
acid	O
induced	O
14	O
)	O
gene	O
was	O
observed	O
to	O
have	O
the	O
same	O
AS	O
pattern	O
in	O
NPs	O
as	O
in	O
frontal	O
and	O
temporal	O
cortex	O
and	O
in	O
several	O
other	O
,	O
non	O
-	O
brain	O
adult	O
tissues	O
,	O
such	O
as	O
heart	O
and	O
spleen	O
.	O

The	O
AS	O
pattern	O
of	O
the	O
REAP	O
[	O
+	O
]	O
exon	O
in	O
the	O
SLK	O
gene	O
in	O
NPs	O
was	O
similar	O
to	O
most	O
differentiated	O
tissues	O
;	O
however	O
,	O
the	O
relatively	O
strong	O
inclusion	O
of	O
the	O
exon	O
in	O
hESCs	O
was	O
unique	O
.	O

Even	O
in	O
esophagus	O
,	O
kidney	O
,	O
liver	O
,	O
and	O
prostate	O
,	O
both	O
isoforms	O
were	O
present	O
.	O

The	O
relative	O
ratio	O
of	O
the	O
exon	O
-	O
included	O
to	O
exon	O
-	O
skipped	O
isoforms	O
in	O
SLK	O
likely	O
represents	O
an	O
ESC	O
-	O
specific	O
AS	O
signature	O
.	O

The	O
alternative	O
exon	O
in	O
the	O
EHBP1	O
gene	O
was	O
unusual	O
.	O

The	O
exon	O
was	O
included	O
in	O
hESCs	O
but	O
also	O
in	O
frontal	O
cortex	O
and	O
temporal	O
cortex	O
,	O
a	O
finding	O
that	O
was	O
unexpected	O
given	O
the	O
exclusion	O
of	O
the	O
exon	O
in	O
hCNS	O
-	O
SCns	O
(	O
Figure	O
7C	O
)	O
.	O

The	O
AS	O
pattern	O
in	O
hCNS	O
-	O
SCns	O
may	O
represent	O
a	O
transient	O
,	O
early	O
neuronal	O
molecular	O
change	O
.	O

Functional	O
and	O
Expression	O
Characteristics	O
of	O
REAP	O
[	O
+	O
]	O
GenesIn	O
total	O
,	O
1,500	O
genes	O
were	O
identified	O
that	O
contained	O
1,737	O
REAP	O
[	O
+	O
]	O
exons	O
,	O
68	O
%	O
of	O
which	O
lacked	O
prior	O
transcript	O
(	O
EST	O
/	O
cDNA	O
)	O
evidence	O
for	O
AS	O
.	O

To	O
determine	O
whether	O
genes	O
that	O
contained	O
REAP	O
[	O
+	O
]	O
exons	O
,	O
which	O
we	O
refer	O
to	O
as	O
REAP	O
[	O
+	O
]	O
genes	O
,	O
are	O
biased	O
toward	O
particular	O
biological	O
activities	O
,	O
REAP	O
[	O
+	O
]	O
genes	O
were	O
compared	O
to	O
a	O
set	O
of	O
REAP	O
analyzed	O
genes	O
not	O
found	O
to	O
have	O
REAP	O
[	O
+	O
]	O
exons	O
(	O
REAP	O
[	O
−	O
]	O
genes	O
)	O
.	O

A	O
Gene	O
Ontology	O
analysis	O
revealed	O
that	O
REAP	O
[	O
+	O
]	O
genes	O
are	O
enriched	O
for	O
GO	O
molecular	O
function	O
categories	O
"	O
ATP	O
binding	O
,	O
"	O
"	O
helicase	O
activity	O
,	O
"	O
"	O
protein	O
serine	O
/	O
theronine	O
kinase	O
activity	O
,	O
"	O
"	O
small	O
GTPase	O
regulatory	O
/	O
interacting	O
protein	O
activity	O
,	O
"	O
and	O
"	O
thyroid	O
hormone	O
receptor	O
binding	O
"	O
(	O
Table	O
1	O
)	O
.	O

In	O
terms	O
of	O
GO	O
biological	O
process	O
categories	O
,	O
REAP	O
[	O
+	O
]	O
genes	O
were	O
more	O
frequently	O
involved	O
in	O
"	O
ubiquitin	O
cycle	O
.	O
"	O

Similar	O
results	O
were	O
obtained	O
when	O
we	O
compared	O
REAP	O
[	O
+	O
]	O
genes	O
to	O
all	O
human	B
genes	O
that	O
did	O
not	O
contain	O
REAP	O
[	O
+	O
]	O
exons	O
(	O
Table	O
1	O
)	O
[	O
55	O
]	O
.Table	O
1Significantly	O
Enriched	O
Gene	O
Ontology	O
Terms	O
in	O
REAP	O
[	O
+	O
]	O
Genes	O
(	O
Cutoff	O
of	O
Two	O
Significant	O
"	O
Outliers	O
"	O
per	O
Probeset	O
)	O
Next	O
we	O
asked	O
if	O
REAP	O
[	O
+	O
]	O
genes	O
are	O
differentially	O
expressed	O
in	O
hESCs	O
compared	O
to	O
NPs	O
and	O
vice	O
versa	O
.	O

For	O
this	O
analysis	O
,	O
the	O
t	O
-	O
statistics	O
computed	O
above	O
measuring	O
the	O
enrichment	O
of	O
a	O
gene	O
in	O
hESCs	O
relative	O
to	O
NPs	O
was	O
utilized	O
for	O
only	O
REAP	O
-	O
analyzed	O
genes	O
.	O

At	O
a	O
defined	O
absolute	O
-	O
valued	O
cutoff	O
,	O
genes	O
were	O
divided	O
into	O
three	O
categories	O
:	O
"	O
enriched	O
in	O
hESCs	O
,	O
"	O
"	O
enriched	O
in	O
NP	O
,	O
"	O
or	O
"	O
unchanged	O
"	O
(	O
Figure	O
8A	O
)	O
.	O

Increasing	O
the	O
t	O
-	O
statistic	O
cutoff	O
from	O
one	O
to	O
five	O
,	O
the	O
fraction	O
of	O
REAP	O
[	O
+	O
]	O
genes	O
relative	O
to	O
REAP	O
-	O
analyzed	O
genes	O
remained	O
constant	O
in	O
the	O
"	O
unchanged	O
"	O
categories	O
(	O
Figure	O
8B	O
)	O
.	O

However	O
,	O
the	O
fraction	O
of	O
REAP	O
[	O
+	O
]	O
exons	O
decreased	O
significantly	O
in	O
"	O
enriched	O
in	O
hESCs	O
"	O
and	O
"	O
enriched	O
in	O
NPs	O
"	O
categories	O
.	O

If	O
we	O
increased	O
the	O
cutoffs	O
on	O
genes	O
that	O
were	O
randomly	O
assigned	O
as	O
REAP	O
[	O
+	O
]	O
and	O
REAP	O
[	O
−	O
]	O
,	O
controlling	O
for	O
the	O
same	O
number	O
of	O
genes	O
in	O
each	O
category	O
,	O
we	O
observed	O
that	O
the	O
fraction	O
of	O
REAP	O
[	O
+	O
]	O
exons	O
remained	O
unchanged	O
for	O
all	O
three	O
categories	O
(	O
Figure	O
8C	O
)	O
.	O

To	O
illustrate	O
,	O
at	O
a	O
cutoff	O
of	O
five	O
,	O
10	O
%	O
(	O
29	O
of	O
267	O
)	O
of	O
enriched	O
NP	O
genes	O
were	O
REAP	O
[	O
+	O
]	O
genes	O
and	O
8.8	O
%	O
(	O
102	O
of	O
1,162	O
)	O
of	O
enriched	O
hESC	O
genes	O
were	O
REAP	O
[	O
+	O
]	O
,	O
significantly	O
different	O
(	O
p	O
<	O
0.000005	O
)	O
from	O
the	O
random	O
control	O
where	O
∼14	O
%	O
of	O
enriched	O
NP	O
and	O
enriched	O
hESC	O
genes	O
were	O
REAP	O
[	O
+	O
]	O
.	O

At	O
a	O
cutoff	O
of	O
five	O
,	O
14	O
%	O
(	O
1,368	O
of	O
9,636	O
)	O
of	O
genes	O
that	O
were	O
expressed	O
at	O
similar	O
levels	O
between	O
hESCs	O
and	O
NPs	O
were	O
REAP	O
[	O
+	O
]	O
.	O

Our	O
results	O
suggested	O
that	O
a	O
strategy	O
of	O
focusing	O
on	O
differentially	O
expressed	O
genes	O
would	O
miss	O
at	O
least	O
14	O
%	O
of	O
transcriptionally	O
unchanged	O
genes	O
that	O
may	O
nevertheless	O
have	O
functional	O
AS	O
differences	O
between	O
hESCs	O
and	O
NPs	O
.	O

Figure	O
8Analysis	O
of	O
REAP	O
[	O
+	O
]	O
Genes	O
Relative	O
to	O
Transcriptional	O
Differences	O
(	O
A	O
)	O
Histogam	O
of	O
t	O
-	O
statistics	O
computed	O
from	O
gene	O
-	O
level	O
signal	O
estimates	O
measuring	O
the	O
enrichment	O
of	O
genes	O
in	O
hESC	O
and	O
in	O
NP	O
.	O

Genes	O
on	O
the	O
right	O
of	O
the	O
vertical	O
line	O
at	O
5	O
were	O
designated	O
enriched	O
in	O
hESC	O
and	O
genes	O
on	O
the	O
left	O
of	O
the	O
vertical	O
line	O
at	O
−5	O
were	O
designated	O
enriched	O
in	O
NP	O
;	O
genes	O
in	O
between	O
−5	O
and	O
5	O
were	O
designated	O
as	O
"	O
unchanged	O
"	O
or	O
expressed	O
similarly	O
in	O
hESC	O
and	O
NP.	O
(	O
B	O
)	O
Vertical	O
bars	O
representing	O
the	O
percentage	O
of	O
REAP	O
[	O
+	O
]	O
genes	O
out	O
of	O
all	O
genes	O
in	O
the	O
different	O
classifications	O
(	O
dashed	O
bar	O
:	O
"	O
enriched	O
in	O
hESC	O
"	O
;	O
black	O
filled	O
bar	O
:	O
"	O
unchanged	O
"	O
;	O
white	O
filled	O
bar	O
:	O
"	O
enriched	O
in	O
NP	O
"	O
)	O
,	O
at	O
different	O
cutoffs	O
of	O
1	O
to	O
5.	O
(	O
C	O
)	O
Set	O
of	O
genes	O
where	O
REAP	O
[	O
+	O
]	O
designation	O
was	O
randomly	O
chosen	O
.	O

Similar	O
representation	O
as	O
in	O
(	O
B	O
)	O
.	O

Conserved	O
Intronic	O
Splicing	O
Regulatory	O
Elements	O
Proximal	O
to	O
REAP	O
[	O
+	O
]	O
hESC	O
and	O
NP	O
ExonsMany	O
,	O
if	O
not	O
most	O
,	O
alternative	O
exons	O
undergo	O
cell	O
type	O
–	O
specific	O
regulation	O
by	O
the	O
binding	O
of	O
trans	O
-	O
factors	O
to	O
splicing	O
regulatory	O
cis	O
-	O
elements	O
located	O
proximal	O
to	O
or	O
within	O
the	O
exons	O
.	O

As	O
many	O
tissue	O
-	O
specific	O
splicing	O
cis	O
-	O
regulatory	O
elements	O
were	O
localized	O
in	O
intronic	O
regions	O
of	O
AS	O
exons	O
,	O
we	O
focused	O
on	O
the	O
identification	O
of	O
intronic	O
splicing	O
regulatory	O
elements	O
(	O
ISREs	O
)	O
proximal	O
to	O
REAP	O
[	O
+	O
]	O
exons	O
.	O

In	O
addition	O
,	O
we	O
wanted	O
to	O
identify	O
both	O
common	O
and	O
cell	O
type	O
–	O
specific	O
ISREs	O
.	O

Three	O
sets	O
of	O
exons	O
were	O
generated	O
:	O
(	O
i	O
)	O
REAP	O
[	O
+	O
]	O
exons	O
that	O
were	O
predicted	O
to	O
be	O
included	O
in	O
NPs	O
and	O
skipped	O
in	O
hESCs	O
(	O
REAP	O
[	O
+	O
]	O
NP	O
)	O
;	O
(	O
ii	O
)	O
REAP	O
[	O
+	O
]	O
exons	O
that	O
were	O
predicted	O
to	O
be	O
included	O
in	O
hESCs	O
and	O
skipped	O
in	O
NPs	O
(	O
REAP	O
[	O
+	O
]	O
hESC	O
)	O
;	O
and	O
(	O
iii	O
)	O
all	O
REAP	O
[	O
−	O
]	O
exons	O
.	O

Regions	O
of	O
400	O
base	O
pairs	O
flanking	O
the	O
exons	O
were	O
targeted	O
for	O
search	O
.	O

Initially	O
,	O
5-mers	O
that	O
were	O
significantly	O
enriched	O
between	O
the	O
upstream	O
and	O
downstream	O
intronic	O
regions	O
of	O
REAP	O
[	O
+	O
]	O
NP	O
and	O
REAP	O
[	O
+	O
]	O
ES	O
relative	O
to	O
REAP	O
[	O
−	O
]	O
exons	O
were	O
enumerated	O
.	O

We	O
were	O
not	O
able	O
to	O
identify	O
5-mers	O
that	O
were	O
statistically	O
significantly	O
different	O
.	O

Next	O
,	O
we	O
focused	O
on	O
splicing	O
signals	O
that	O
were	O
conserved	O
across	O
mammalian	O
genomes	O
as	O
a	O
way	O
of	O
enhancing	O
the	O
signal	O
of	O
detecting	O
functional	O
splicing	O
regulatory	O
sequences	O
[	O
66	O
]	O
.	O

Exons	O
that	O
were	O
orthologous	O
across	O
human	B
,	O
dog	B
,	O
rat	B
,	O
and	O
mouse	B
were	O
obtained	O
and	O
the	O
flanking	O
intronic	O
regions	O
were	O
aligned	O
(	O
400	O
bases	O
upstream	O
and	O
downstream	O
separately	O
;	O
Figure	O
9A	O
)	O
.	O

We	O
enumerated	O
k	O
-	O
mers	O
that	O
were	O
perfectly	O
conserved	O
across	O
all	O
four	O
genomes	O
in	O
the	O
upstream	O
(	O
and	O
downstream	O
)	O
intronic	O
regions	O
.	O

Each	O
conserved	O
k	O
-	O
mer	O
was	O
attributed	O
a	O
χ	O
score	O
representing	O
its	O
enrichment	O
in	O
a	O
set	O
of	O
exons	O
relative	O
to	O
another	O
set	O
of	O
exons	O
.	O

The	O
higher	O
the	O
score	O
,	O
the	O
more	O
frequent	O
the	O
conserved	O
k	O
-	O
mer	O
was	O
in	O
the	O
first	O
set	O
relative	O
to	O
the	O
second	O
set	O
.	O

As	O
a	O
negative	O
control	O
,	O
the	O
associations	O
between	O
REAP	O
scores	O
and	O
exons	O
were	O
shuffled	O
.	O

The	O
enrichment	O
scores	O
for	O
all	O
downstream	O
intronic	O
5-mers	O
for	O
shuffled	O
REAP	O
[	O
+	O
]	O
NP	O
versus	O
set	O
REAP	O
[	O
−	O
]	O
exons	O
(	O
x	O
-	O
axis	O
)	O
,	O
and	O
for	O
shuffled	O
REAP	O
[	O
+	O
]	O
ES	O
exons	O
versus	O
REAP	O
[	O
−	O
]	O
exons	O
(	O
y	O
-	O
axis	O
)	O
were	O
displayed	O
(	O
Figure	O
9B	O
)	O
.	O

At	O
a	O
χ	O
cutoff	O
of	O
three	O
,	O
which	O
corresponded	O
to	O
a	O
p	O
-	O
value	O
of	O
0.0015	O
,	O
the	O
majority	O
of	O
5-mers	O
were	O
not	O
significantly	O
enriched	O
in	O
either	O
shuffled	O
set	O
.	O

Confident	O
that	O
no	O
association	O
of	O
k	O
-	O
mers	O
with	O
shuffled	O
REAP	O
exons	O
were	O
found	O
;	O
we	O
repeated	O
the	O
analyses	O
for	O
upstream	O
and	O
downstream	O
intronic	O
5-mers	O
for	O
the	O
original	O
unshuffled	O
sets	O
.	O

We	O
identified	O
68	O
conserved	O
5-mers	O
enriched	O
upstream	O
of	O
REAP	O
[	O
+	O
]	O
NP	O
exons	O
;	O
and	O
34	O
5-mers	O
enriched	O
upstream	O
of	O
REAP	O
[	O
+	O
]	O
ES	O
exons	O
(	O
Figure	O
9C	O
;	O
Table	O
S4	O
)	O
.	O

Of	O
the	O
5-mers	O
that	O
were	O
significantly	O
enriched	O
upstream	O
of	O
REAP	O
[	O
+	O
]	O
NP	O
exons	O
,	O
we	O
identified	O
a	O
U	O
-	O
rich	O
motif	O
(	O
UUUUU	O
)	O
,	O
a	O
GU	O
-	O
rich	O
motif	O
(	O
GUGUG	O
)	O
,	O
and	O
a	O
CU	O
-	O
rich	O
motif	O
(	O
CCUCU	O
,	O
CUCUC	O
,	O
UCUCU	O
,	O
GCUCU	O
)	O
.	O

It	O
is	O
known	O
that	O
the	O
heterogeneous	O
ribonucleoprotein	O
C	O
(	O
hnRNP	O
C	O
)	O
binding	O
site	O
obtained	O
by	O
SELEX	O
is	O
five	O
"	O
U"s	O
[	O
67	O
]	O
.	O

GU	O
-	O
rich	O
sequences	O
in	O
flanking	O
intronic	O
regions	O
were	O
shown	O
to	O
bind	O
to	O
splicing	O
factor	O
ETR-3	O
to	O
regulate	O
AS	O
[	O
68	O
]	O
.	O

CU	O
-	O
rich	O
sequences	O
were	O
shown	O
to	O
bind	O
the	O
splicing	O
factor	O
PTB	O
[	O
69	O
]	O
.	O

Of	O
the	O
5-mers	O
enriched	O
upstream	O
of	O
REAP	O
[	O
+	O
]	O
ES	O
exons	O
,	O
we	O
observed	O
CUAAC	O
,	O
which	O
resembled	O
the	O
splicing	O
branch	O
-	O
signal	O
.	O

Of	O
the	O
six	O
5-mers	O
that	O
were	O
enriched	O
upstream	O
of	O
both	O
REAP	O
[	O
+	O
]	O
NP	O
and	O
REAP	O
[	O
+	O
]	O
ES	O
exons	O
,	O
we	O
identified	O
GCAUG	O
,	O
which	O
was	O
previously	O
shown	O
to	O
be	O
an	O
intronic	O
splicing	O
cis	O
-	O
element	O
for	O
the	O
mammalian	O
fibronectin	O
and	O
calcitonin	O
/	O
CGRP	O
genes	O
[	O
70–72	O
]	O
.	O

More	O
recently	O
,	O
both	O
mammalian	O
Fox1	O
and	O
2	O
have	O
been	O
demonstrated	O
to	O
regulate	O
alternatively	O
spliced	O
exons	O
via	O
UGCAUG	O
binding	O
sites	O
in	O
neighboring	O
introns	O
in	O
neuronal	O
cell	O
cultures	O
[	O
73	O
]	O
.Figure	O
9Conserved	O
Intronic	O
cis	O
-	O
Elements	O
Enriched	O
Proximal	O
to	O
REAP	O
[	O
+	O
]	O
Alternative	O
Exons	O
(	O
A	O
)	O
Schematic	O
describing	O
the	O
enumeration	O
of	O
intronic	O
elements	O
across	O
400	O
bases	O
of	O
flanking	O
mammalian	O
introns	O
(	O
human	B
,	O
dog	B
,	O
rat	B
,	O
and	O
mouse	B
)	O
.	O

Red	O
and	O
green	O
horizontal	O
bars	O
represent	O
conserved	O
intronic	O
elements	O
and	O
nonconserved	O
elements	O
,	O
respectively	O
.	O

Internal	O
exons	O
were	O
divided	O
into	O
REAP	O
[	O
+	O
]	O
NP	O
,	O
REAP	O
[	O
+	O
]	O
ES	O
,	O
and	O
REAP	O
[	O
−	O
]	O
exons	O
.	O

The	O
χ	O
statistic	O
was	O
computed	O
to	O
represent	O
the	O
enrichment	O
of	O
conserved	O
elements	O
in	O
intronic	O
regions	O
flanking	O
REAP	O
[	O
+	O
]	O
NP	O
versus	O
REAP	O
[	O
−	O
]	O
exons	O
(	O
x	O
-	O
axis	O
)	O
,	O
and	O
REAP	O
[	O
+	O
]	O
ES	O
versus	O
REAP	O
[	O
−	O
]	O
exons	O
(	O
y	O
-	O
axis	O
)	O
.	O

The	O
sign	O
represented	O
the	O
direction	O
of	O
change	O
,	O
i.e.	O
,	O
positive	O
if	O
enriched	O
in	O
introns	O
flanking	O
REAP	O
[	O
+	O
]	O
versus	O
REAP	O
[	O
−	O
]	O
exon	O
.	O

Each	O
conserved	O
5-mer	O
was	O
associated	O
with	O
two	O
numbers	O
:	O
the	O
enrichment	O
in	O
introns	O
proximal	O
to	O
REAP	O
[	O
+	O
]	O
NP	O
versus	O
REAP	O
[	O
−	O
]	O
exons	O
(	O
x	O
-	O
axis	O
)	O
,	O
and	O
REAP	O
[	O
+	O
]	O
ES	O
versus	O
REAP	O
[	O
−	O
]	O
exons	O
(	O
y	O
-	O
axis	O
)	O
.	O
(	O
B	O
)	O
Downstream	O
intronic	O
regions	O
,	O
where	O
the	O
association	O
between	O
REAP	O
[	O
+	O
]	O
designation	O
and	O
the	O
exons	O
was	O
shuffled.	O
(	O
C	O
)	O
Upstream	O
intronic	O
regions	O
.	O

Circled	O
5-mers	O
in	O
the	O
upper	O
right	O
quadrant	O
represent	O
conserved	O
5-mers	O
enriched	O
in	O
the	O
upstream	O
intronic	O
regions	O
of	O
REAP	O
[	O
+	O
]	O
NP	O
and	O
REAP	O
[	O
+	O
]	O
ES	O
exons.	O
(	O
D	O
)	O

Downstream	O
intronic	O
regions	O
.	O

Circled	O
5-mers	O
in	O
the	O
upper	O
right	O
quadrant	O
represent	O
conserved	O
5-mers	O
enriched	O
in	O
the	O
downstream	O
intronic	O
regions	O
of	O
REAP	O
[	O
+	O
]	O
NP	O
and	O
REAP	O
[	O
+	O
]	O
ES	O
exons	O
.	O

Eighteen	O
conserved	O
5-mers	O
were	O
significantly	O
enriched	O
in	O
the	O
downstream	O
introns	O
of	O
REAP	O
[	O
+	O
]	O
ES	O
exons	O
;	O
and	O
76	O
5-mers	O
were	O
enriched	O
downstream	O
of	O
REAP	O
[	O
+	O
]	O
NP	O
exons	O
(	O
Table	O
S4	O
,	O
Figure	O
9D	O
)	O
.	O

We	O
identified	O
a	O
motif	O
CUCAU	O
resembling	O
the	O
Nova	O
binding	O
site	O
YCAY	O
[	O
74	O
]	O
,	O
and	O
a	O
G	O
-	O
rich	O
motif	O
(	O
AGGGG	O
,	O
GGGGA	O
,	O
GGGGC	O
,	O
GGGGG	O
,	O
GGGGU	O
)	O
enriched	O
in	O
the	O
introns	O
downstream	O
of	O
REAP	O
[	O
+	O
]	O
ES	O
exons	O
.	O

G	O
-	O
rich	O
motifs	O
had	O
previously	O
been	O
shown	O
to	O
be	O
part	O
of	O
a	O
bipartite	O
signal	O
that	O
silences	O
AS	O
exons	O
[	O
75	O
]	O
.	O

Of	O
the	O
five	O
5-mers	O
that	O
were	O
enriched	O
downstream	O
of	O
both	O
REAP	O
[	O
+	O
]	O
NP	O
and	O
REAP	O
[	O
+	O
]	O
ES	O
exons	O
,	O
GCAUG	O
and	O
a	O
U	O
-	O
rich	O
motif	O
(	O
UUUUU	O
)	O
were	O
identified	O
.	O

We	O
concluded	O
that	O
potential	O
ISREs	O
were	O
enriched	O
proximal	O
to	O
a	O
subset	O
of	O
REAP	O
[	O
+	O
]	O
exons	O
;	O
in	O
particular	O
,	O
the	O
Fox1	O
/	O
2	O
binding	O
site	O
GCUAG	O
may	O
play	O
a	O
regulatory	O
role	O
in	O
controlling	O
AS	O
events	O
in	O
hESCs	O
and	O
NPs	O
.	O

The	O
ability	O
of	O
ESCs	O
to	O
generate	O
all	O
three	O
embryonic	O
germ	O
layers	O
has	O
raised	O
the	O
exciting	O
possibility	O
that	O
hESCs	O
may	O
become	O
an	O
unlimited	O
source	O
of	O
cells	O
for	O
transplantation	O
therapies	O
involving	O
organs	O
or	O
tissues	O
such	O
as	O
the	O
liver	O
,	O
pancreas	O
,	O
blood	O
,	O
and	O
nervous	O
system	O
,	O
and	O
become	O
tools	O
to	O
explore	O
the	O
molecular	O
mechanisms	O
of	O
human	B
development	O
.	O

Despite	O
such	O
interests	O
,	O
relatively	O
little	O
is	O
understood	O
about	O
the	O
molecular	O
mechanisms	O
defining	O
their	O
pluripotency	O
and	O
the	O
molecular	O
changes	O
important	O
for	O
hESCs	O
to	O
differentiate	O
into	O
specific	O
cell	O
types	O
.	O

To	O
understand	O
these	O
events	O
,	O
protocols	O
are	O
still	O
being	O
developed	O
to	O
differentiate	O
ESCs	O
into	O
a	O
variety	O
of	O
lineages	O
.	O

Of	O
particular	O
biomedical	O
interest	O
is	O
in	O
the	O
capacity	O
of	O
hESCs	O
to	O
be	O
differentiated	O
into	O
a	O
self	O
-	O
renewing	O
population	O
of	O
NPs	O
that	O
can	O
be	O
then	O
further	O
coaxed	O
into	O
a	O
variety	O
of	O
neuronal	O
subtypes	O
,	O
such	O
as	O
dopaminergic	O
neurons	O
that	O
are	O
important	O
in	O
the	O
treatment	O
of	O
Parkinson	O
disease	O
or	O
cholinergic	O
neurons	O
for	O
ALS	O
(	O
amyotrophic	O
lateral	O
sclerosis	O
)	O
.	O

While	O
many	O
microarray	O
studies	O
have	O
explored	O
molecular	O
differences	O
between	O
hESCs	O
and	O
derived	O
NPs	O
,	O
most	O
,	O
if	O
not	O
all	O
,	O
have	O
focused	O
on	O
transcriptional	O
changes	O
.	O

These	O
studies	O
have	O
largely	O
ignored	O
intermediate	O
RNA	O
processing	O
events	O
prior	O
to	O
and	O
during	O
translation	O
.	O

In	O
recent	O
years	O
,	O
AS	O
has	O
gained	O
momentum	O
as	O
being	O
important	O
in	O
development	O
,	O
apoptosis	O
,	O
and	O
cancer	O
.	O

REAP	O
,	O
a	O
regression	O
-	O
based	O
method	O
for	O
analyzing	O
exon	O
array	O
data	O
was	O
introduced	O
,	O
and	O
was	O
applied	O
to	O
discover	O
AS	O
events	O
in	O
hESCs	O
,	O
their	O
derived	O
NPs	O
,	O
and	O
in	O
hCNS	O
-	O
SCns	O
.	O

REAP	O
was	O
based	O
on	O
the	O
assumptions	O
that	O
most	O
exons	O
in	O
the	O
gene	O
of	O
interest	O
and	O
in	O
the	O
genome	O
are	O
constitutively	O
spliced	O
and	O
that	O
outliers	O
in	O
a	O
linear	O
pairwise	O
comparison	O
of	O
the	O
signal	O
estimates	O
for	O
probesets	O
in	O
a	O
gene	O
could	O
be	O
detected	O
using	O
a	O
robust	O
regression	O
-	O
based	O
approach	O
.	O

REAP	O
predictions	O
were	O
found	O
to	O
correlate	O
well	O
with	O
transcript	O
-	O
based	O
methods	O
for	O
identifying	O
alternative	O
exons	O
,	O
which	O
interestingly	O
suggested	O
that	O
current	O
databases	O
of	O
transcript	O
information	O
,	O
albeit	O
not	O
specifically	O
enriched	O
for	O
hESC	O
or	O
NPs	O
,	O
in	O
aggregate	O
are	O
nevertheless	O
predictive	O
of	O
AS	O
events	O
in	O
hESC	O
and	O
NP	O
.	O

In	O
addition	O
,	O
REAP	O
[	O
+	O
]	O
exons	O
were	O
also	O
enriched	O
for	O
ACEScan	O
-	O
predicted	O
evolutionarily	O
conserved	O
exons	O
[	O
55	O
]	O
.	O

As	O
ACEScan	O
utilized	O
a	O
different	O
set	O
of	O
information	O
from	O
REAP	O
,	O
the	O
agreement	O
between	O
both	O
algorithms	O
served	O
to	O
further	O
validate	O
the	O
predicted	O
alternative	O
exons	O
.	O

Additional	O
studies	O
in	O
mouse	B
ESCs	O
and	O
neural	O
derivatives	O
will	O
be	O
necessary	O
to	O
determine	O
if	O
these	O
AS	O
events	O
are	O
indeed	O
preserved	O
in	O
these	O
analogous	O
and	O
orthologous	O
cell	O
types	O
.	O

Our	O
finding	O
that	O
only	O
a	O
minority	O
of	O
AS	O
events	O
was	O
common	O
between	O
various	O
hESC	O
to	O
NP	O
comparisons	O
is	O
intriguing	O
.	O

A	O
possible	O
explanation	O
is	O
that	O
the	O
cell	O
lines	O
were	O
not	O
only	O
genetically	O
different	O
,	O
but	O
were	O
also	O
exposed	O
to	O
different	O
isolation	O
and	O
culture	O
conditions	O
.	O

In	O
addition	O
,	O
the	O
different	O
differentiation	O
protocols	O
established	O
as	O
optimal	O
for	O
generating	O
Nestin	O
and	O
Sox1	O
positive	O
neural	O
precursors	O
may	O
lead	O
to	O
vastly	O
different	O
molecular	O
changes	O
.	O

It	O
is	O
likely	O
that	O
post	O
-	O
transcriptional	O
changes	O
such	O
as	O
AS	O
may	O
be	O
more	O
variable	O
despite	O
the	O
cells	O
being	O
at	O
acknowledged	O
"	O
end	O
-	O
points	O
"	O
defined	O
by	O
a	O
limited	O
set	O
of	O
immunohistochemical	O
markers	O
.	O

Our	O
results	O
are	O
consistent	O
with	O
a	O
recent	O
study	O
that	O
showed	O
that	O
while	O
two	O
well	O
-	O
established	O
hESC	O
lines	O
differentiate	O
into	O
functional	O
neurons	O
,	O
the	O
two	O
lines	O
exhibited	O
distinct	O
differentiation	O
potentials	O
,	O
suggesting	O
that	O
some	O
preprogramming	O
had	O
occurred	O
[	O
76	O
]	O
.	O

In	O
particular	O
,	O
microRNA	O
profiling	O
revealed	O
significant	O
expression	O
differences	O
between	O
the	O
two	O
hESC	O
lines	O
,	O
suggesting	O
that	O
microRNAs	O
,	O
known	O
post	O
-	O
transcriptional	O
regulators	O
,	O
may	O
sway	O
the	O
differentiation	O
properties	O
of	O
the	O
cell	O
lines	O
[	O
76	O
]	O
.	O

We	O
postulated	O
that	O
AS	O
events	O
may	O
serve	O
also	O
to	O
bias	O
the	O
differentiation	O
spectrum	O
of	O
the	O
cells	O
,	O
an	O
important	O
avenue	O
for	O
future	O
work	O
.	O

Experimental	O
validation	O
of	O
REAP	O
[	O
+	O
]	O
exons	O
suggested	O
a	O
high	O
specificity	O
at	O
the	O
expense	O
of	O
relatively	O
moderate	O
sensitivity	O
.	O

We	O
believe	O
that	O
the	O
high	O
FP	O
rates	O
may	O
arise	O
from	O
cross	O
-	O
hybridization	O
effects	O
that	O
remained	O
unaccounted	O
for	O
.	O

However	O
,	O
our	O
specificity	O
of	O
77	O
%	O
at	O
the	O
cutoff	O
of	O
two	O
significant	O
outliers	O
per	O
probeset	O
allowed	O
us	O
to	O
estimate	O
that	O
at	O
least	O
1,336	O
of	O
1,737	O
REAP	O
[	O
+	O
]	O
exons	O
were	O
true	O
AS	O
events	O
that	O
changed	O
during	O
neuronal	O
differentiation	O
of	O
hESC	O
cells	O
,	O
and/or	O
were	O
different	O
between	O
endogeneous	O
NPs	O
and	O
hESC	O
.	O

On	O
average	O
,	O
7	O
%	O
of	O
all	O
human	B
exons	O
have	O
been	O
estimated	O
by	O
transcript	O
data	O
to	O
undergo	O
AS	O
;	O
thus	O
REAP	O
's	O
validation	O
rate	O
of	O
60	O
%	O
at	O
the	O
cutoff	O
of	O
two	O
is	O
73-fold	O
(	O
60	O
/	O
7	O
)	O
higher	O
than	O
expected	O
.	O

In	O
addition	O
,	O
we	O
validated	O
nine	O
novel	O
AS	O
events	O
that	O
distinguish	O
hESCs	O
and	O
NPs	O
.	O

Consistent	O
with	O
our	O
computational	O
results	O
,	O
we	O
observed	O
that	O
the	O
AS	O
patterns	O
in	O
hCNS	O
-	O
SCns	O
were	O
not	O
always	O
similar	O
to	O
those	O
of	O
the	O
derived	O
NPs	O
.	O

It	O
was	O
important	O
to	O
point	O
out	O
that	O
while	O
transcriptional	O
expression	O
of	O
these	O
genes	O
did	O
not	O
distinguish	O
these	O
cells	O
from	O
one	O
another	O
,	O
in	O
several	O
instances	O
the	O
REAP	O
-	O
predicted	O
AS	O
event	O
was	O
able	O
to	O
separate	O
derived	O
NPs	O
and	O
hCNS	O
-	O
SCns	O
.	O

A	O
notable	O
exception	O
was	O
the	O
alternative	O
exon	O
in	O
the	O
SLK	O
gene	O
,	O
encoding	O
a	O
serine	O
/	O
threonine	O
kinase	O
protein	O
,	O
which	O
was	O
commonly	O
included	O
in	O
both	O
hESCs	O
,	O
i.e.	O
,	O
the	O
exon	O
-	O
excluded	O
isoform	O
was	O
not	O
present	O
in	O
hESCs	O
compared	O
to	O
NPs	O
,	O
as	O
well	O
as	O
in	O
a	O
variety	O
of	O
differentiated	O
tissues	O
.	O

Closer	O
inspection	O
of	O
the	O
REAP	O
[	O
+	O
]	O
-validated	O
AS	O
exon	O
in	O
the	O
SLK	O
gene	O
revealed	O
strong	O
conservation	O
in	O
the	O
intronic	O
region	O
flanking	O
the	O
exon	O
,	O
a	O
hallmark	O
feature	O
of	O
evolutionarily	O
conserved	O
AS	O
exons	O
[	O
55,77,78	O
]	O
.	O

A	O
study	O
analyzing	O
the	O
expression	O
patterns	O
of	O
the	O
SLK	O
gene	O
suggested	O
a	O
potential	O
functional	O
role	O
during	O
embryonic	O
development	O
and	O
in	O
the	O
adult	O
central	O
nervous	O
system	O
[	O
79	O
]	O
;	O
however	O
,	O
to	O
our	O
knowledge	O
,	O
our	O
identification	O
of	O
the	O
SLK	O
alternative	O
exon	O
is	O
the	O
first	O
report	O
of	O
a	O
hESC	O
-	O
biased	O
AS	O
pattern	O
during	O
neuronal	O
differentiation	O
and	O
across	O
a	O
myriad	O
of	O
differentiated	O
tissues	O
.	O

In	O
agreement	O
,	O
GO	O
analysis	O
suggested	O
that	O
genes	O
containing	O
REAP	O
[	O
+	O
]	O
exons	O
were	O
enriched	O
in	O
serine	O
/	O
threonine	O
kinase	O
activity	O
,	O
of	O
which	O
SLK	O
is	O
a	O
family	O
member	O
.	O

Future	O
work	O
will	O
be	O
required	O
to	O
study	O
the	O
impact	O
of	O
AS	O
in	O
these	O
genes	O
in	O
hESCs	O
and	O
NPs	O
.	O

We	O
predict	O
it	O
is	O
unlikely	O
that	O
the	O
alternative	O
exon	O
in	O
the	O
SLK	O
gene	O
is	O
the	O
only	O
case	O
common	O
across	O
hESC	O
and	O
different	O
from	O
differentiated	O
tissues	O
,	O
but	O
further	O
studies	O
will	O
be	O
necessary	O
to	O
identify	O
other	O
hESC	O
-	O
specific	O
exons	O
.	O

REAP	O
[	O
+	O
]	O
exons	O
were	O
underrepresented	O
in	O
genes	O
that	O
were	O
differentially	O
transcriptionally	O
regulated	O
in	O
hESCs	O
and	O
NPs	O
.	O

Our	O
results	O
act	O
as	O
a	O
reminder	O
that	O
focusing	O
only	O
on	O
genes	O
that	O
are	O
differentially	O
expressed	O
will	O
overlook	O
RNA	O
processing	O
events	O
that	O
may	O
be	O
biologically	O
relevant	O
to	O
the	O
system	O
of	O
interest	O
.	O

Finally	O
,	O
we	O
identified	O
potential	O
cis	O
-	O
regulatory	O
intronic	O
elements	O
conserved	O
and	O
enriched	O
proximal	O
to	O
the	O
REAP	O
[	O
+	O
]	O
exons	O
.	O

In	O
particular	O
,	O
the	O
FOX1	O
/	O
2	O
binding	O
site	O
,	O
GCUAG	O
,	O
was	O
conserved	O
and	O
enriched	O
in	O
the	O
flanking	O
introns	O
of	O
a	O
subset	O
of	O
REAP	O
[	O
+	O
]	O
exons	O
.	O

Further	O
studies	O
will	O
be	O
required	O
to	O
explore	O
the	O
importance	O
of	O
FOX1	O
family	O
members	O
in	O
early	O
neuronal	O
differentiation	O
.	O

In	O
conclusion	O
,	O
our	O
introduction	O
of	O
REAP	O
and	O
its	O
application	O
to	O
identifying	O
AS	O
events	O
has	O
revealed	O
new	O
and	O
unanticipated	O
insights	O
into	O
hESC	O
biology	O
and	O
their	O
transition	O
to	O
NP	O
cells	O
.	O

Collectively	O
,	O
these	O
exons	O
represent	O
a	O
set	O
of	O
molecular	O
changes	O
that	O
are	O
likely	O
to	O
be	O
important	O
for	O
studying	O
human	B
neural	O
differentiation	O
with	O
applications	O
in	O
neuronal	O
regenerative	O
medicine	O
.	O

Maintenance	O
and	O
differentiation	O
of	O
hESCs	O
and	O
hCNS	O
-	O
SCns.hESC	O
line	O
Cy203	O
(	O
Cythera	O
)	O
was	O
cultured	O
as	O
previously	O
described	O
[	O
12	O
]	O
.	O

To	O
differentiate	O
into	O
neuroepithelial	O
precursor	O
cells	O
,	O
colonies	O
were	O
manually	O
isolated	O
from	O
mouse	B
embryonic	O
fibroblasts	O
(	O
MEFs	O
)	O
and	O
cut	O
in	O
small	O
pieces	O
.	O

These	O
pieces	O
were	O
transferred	O
to	O
a	O
T75	O
flask	O
with	O
hESCs	O
differentiation	O
media	O
(	O
same	O
hESC	O
medium	O
but	O
10	O
%	O
KSR	O
and	O
no	O
FGF-2	O
)	O
.	O

Medium	O
was	O
changed	O
the	O
next	O
day	O
by	O
transferring	O
the	O
floating	O
hESC	O
aggregates	O
to	O
a	O
new	O
flask	O
.	O

After	O
culturing	O
for	O
a	O
week	O
,	O
the	O
hESC	O
cell	O
aggregates	O
formed	O
mature	O
embroid	O
bodies	O
(	O
EBs	O
;	O
∼10	O
um	O
round	O
clusters	O
with	O
dark	O
centers	O
)	O
.	O

EBs	O
were	O
plated	O
on	O
a	O
coated	O
10-cm	O
dish	O
in	O
hESC	O
differentiation	O
media	O
.	O

The	O
next	O
day	O
,	O
the	O
medium	O
was	O
changed	O
to	O
DMEM	O
/	O
F12	O
supplemented	O
with	O
ITS	O
and	O
fibronectin	O
.	O

Medium	O
was	O
changed	O
every	O
other	O
day	O
for	O
a	O
week	O
or	O
until	O
the	O
cells	O
formed	O
rosette	O
-	O
like	O
columnar	O
structures	O
that	O
were	O
isolated	O
manually	O
.	O

These	O
structures	O
were	O
then	O
transferred	O
to	O
coated	O
dishes	O
in	O
neural	O
induction	O
medium	O
(	O
DMEM	O
/	O
F12	O
supplemented	O
with	O
N2	O
and	O
FGF-2	O
)	O
for	O
a	O
week	O
.	O

Elongated	O
single	O
cells	O
were	O
separated	O
from	O
leftover	O
aggregates	O
using	O
non	O
-	O
enzymatic	O
dissociation	O
.	O

After	O
one	O
to	O
two	O
passages	O
,	O
the	O
cells	O
formed	O
a	O
monolayer	O
of	O
homogeneous	O
NPs	O
(	O
negative	O
for	O
Sox1	O
immunostaining	O
)	O
.	O

Upon	O
confluence	O
,	O
cells	O
will	O
form	O
neurospheres	O
that	O
can	O
also	O
be	O
isolated	O
from	O
the	O
neuroepithelial	O
precursor	O
cells	O
(	O
positive	O
for	O
Sox1	O
immunostaining	O
)	O
.	O

At	O
any	O
of	O
these	O
two	O
stages	O
,	O
pan	O
-	O
neuronal	O
differentiation	O
can	O
be	O
achieved	O
after	O
three	O
to	O
four	O
weeks	O
.	O

hESC	O
line	O
HUES6	O
was	O
cultured	O
on	O
MEF	O
feeders	O
as	O
previously	O
described	O
(	O
http://www.mcb.harvard.edu/melton/hues/	O
)	O
or	O
on	O
GFR	O
matrigel	O
coated	O
plates	O
.	O

Cells	O
grown	O
on	O
matrigel	O
were	O
grown	O
in	O
MEF	O
-	O
conditioned	O
medium	O
and	O
FGF-2	O
was	O
used	O
at	O
20	O
ng	O
/	O
mL	O
instead	O
of	O
10	O
ng	O
/	O
mL	O
for	O
cells	O
grown	O
on	O
MEFs	O
.	O

To	O
differentiate	O
neuroepithelial	O
precursors	O
,	O
colonies	O
were	O
removed	O
by	O
treatment	O
with	O
collagenase	O
IV	O
(	O
Sigma	O
)	O
and	O
washed	O
three	O
times	O
in	O
growth	O
media	O
.	O

The	O
pieces	O
of	O
colonies	O
were	O
resuspended	O
in	O
HUES	O
growth	O
media	O
without	O
FGF2	O
in	O
an	O
uncoated	O
bacterial	O
Petri	O
dish	O
to	O
form	O
EBs	O
.	O

After	O
one	O
week	O
,	O
EBs	O
were	O
plated	O
on	O
polyornathine	O
/	O
laminin	O
coated	O
plates	O
in	O
DMEM	O
/	O
F12	O
supplemented	O
with	O
N2	O
and	O
FGF2	O
.	O

Rosette	O
structures	O
were	O
manually	O
collected	O
and	O
enzymatically	O
dissociated	O
with	O
TryPLE	O
(	O
Invitrogen	O
)	O
,	O
plated	O
on	O
polyornathine	O
/	O
laminin	O
coated	O
plates	O
,	O
and	O
grown	O
in	O
DMEM	O
/	O
F12	O
supplemented	O
with	O
N2	O
and	O
B27-RA	O
and	O
20	O
ng	O
/	O
mL	O
FGF-2	O
.	O

Cells	O
could	O
be	O
grown	O
as	O
a	O
monolayer	O
for	O
up	O
to	O
at	O
least	O
ten	O
passages	O
.	O

Cells	O
were	O
Sox1	O
and	O
nestin	O
positive	O
and	O
readily	O
differentiated	O
into	O
neurons	O
upon	O
withdrawal	O
of	O
FGF-2	O
.	O

Human	B
central	O
nervous	O
system	O
stem	O
cell	O
line	O
FBR1664	O
(	O
StemCells	O
)	O
which	O
is	O
referred	O
to	O
as	O
hCNS	O
-	O
SCns	O
in	O
the	O
main	O
text	O
was	O
cultured	O
as	O
previously	O
described	O
[	O
23	O
]	O
.	O

The	O
cells	O
were	O
cultured	O
in	O
medium	O
consisting	O
of	O
Ex	O
Vivo	O
15	O
(	O
BioWhittaker	O
)	O
medium	O
with	O
N2	O
supplement	O
(	O
GIBCO	O
)	O
,	O
FGF2	O
(	O
20	O
ng	O
/	O
mL	O
)	O
,	O
epidermal	O
growth	O
factor	O
(	O
20	O
ng	O
/	O
mL	O
)	O
,	O
lymphocyte	O
inhibitory	O
factor	O
(	O
10	O
ng	O
/	O
mL	O
)	O
,	O
0.2	O
mg	O
/	O
ml	O
heparin	O
,	O
and	O
60	O
ug	O
/	O
mL	O
N	O
-	O
acetylcysteine	O
.	O

Cultures	O
were	O
fed	O
weekly	O
and	O
passaged	O
at	O
∼two	O
to	O
three	O
weeks	O
using	O
collagenases	O
(	O
Roche	O
)	O
.	O

The	O
following	O
antibodies	O
and	O
corresponding	O
dilutions	O
were	O
utilized	O
for	O
the	O
immunohistochemical	O
analysis	O
of	O
marker	O
genes	O
in	O
Cyt	O
-	O
ES	O
and	O
HUES6-ES	O
:	O
Sox2	O
(	O
Chemicon	O
,	O
1:500	O
)	O
,	O
Oct4	O
(	O
Santa	O
Cruz	O
,	O
1:500	O
)	O
,	O
Sox1	O
(	O
Chemicon	O
,	O
1:500	O
)	O
,	O
Nestin	O
(	O
Pharmingen	O
,	O
1:250	O
)	O
;	O
hCNS	O
-	O
SCns	O
:	O
Sox2	O
(	O
Chemicon	O
,	O
1:200	O
)	O
,	O
Nestin	O
(	O
Chemicon	O
,	O
1:200	O
)	O
.	O

RNA	O
preparation	O
and	O
array	O
hybridization	O
.	O

Total	O
RNA	O
from	O
cells	O
was	O
processed	O
as	O
follows	O
.	O

Cells	O
were	O
lysed	O
in	O
1	O
mL	O
of	O
RNA	O
-	O
bee	O
(	O
Teltest	O
)	O
.	O

The	O
RNA	O
was	O
isolated	O
by	O
chloroform	O
extraction	O
of	O
the	O
aqueous	O
phase	O
,	O
followed	O
by	O
isopropanol	O
precipitation	O
as	O
per	O
the	O
manufacturer	O
's	O
instructions	O
.	O

The	O
precipitated	O
RNA	O
was	O
washed	O
in	O
75	O
%	O
ethanol	O
and	O
eluted	O
with	O
DEPC	O
-	O
treated	O
water	O
.	O

Five	O
ug	O
of	O
RNA	O
was	O
treated	O
with	O
RQ1	O
DNAase	O
(	O
Promega	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

One	O
ug	O
of	O
total	O
RNA	O
for	O
each	O
sample	O
was	O
processed	O
using	O
the	O
Affymetrix	O
GeneChip	O
Whole	O
Transcript	O
Sense	O
Target	O
Labeling	O
Assay	O
(	O
Affymetrix	O
)	O
.	O

Ribosomal	O
RNA	O
was	O
reduced	O
with	O
the	O
RiboMinus	O
Kit	O
(	O
Invitrogen	O
)	O
.	O

Target	O
material	O
was	O
prepared	O
using	O
commercially	O
available	O
Affymetrix	O
GeneChip	O
WT	O
cDNA	O
Synthesis	O
Kit	O
,	O
WT	O
cDNA	O
Amplification	O
Kit	O
,	O
and	O
WT	O
Terminal	O
Labeling	O
Kit	O
(	O
Affymetrix	O
)	O
as	O
per	O
manufacturer	O
's	O
instructions	O
.	O

Hybridization	O
cocktails	O
containing	O
∼5	O
ug	O
of	O
fragmented	O
and	O
labeled	O
DNA	O
target	O
were	O
prepared	O
and	O
applied	O
to	O
GeneChip	O
Human	B
Exon	O
1.0	O
ST	O
arrays	O
.	O

Hybridization	O
was	O
performed	O
for	O
16	O
hours	O
using	O
the	O
Fluidics	O
450	O
station	O
.	O

Arrays	O
were	O
scanned	O
using	O
the	O
Affymetrix	O
3000	O
7	O
G	O
scanner	O
and	O
GeneChip	O
Operating	O
Software	O
version	O
1.4	O
to	O
produce	O
.CEL	O
intensity	O
files	O
.	O

Detection	O
of	O
AS	O
by	O
RT	O
-	O
PCR.cDNAs	O
were	O
generated	O
from	O
total	O
RNA	O
with	O
Superscript	O
III	O
reverse	O
transcriptase	O
(	O
Invitrogen	O
)	O
.	O

PCR	O
reactions	O
were	O
performed	O
with	O
primer	O
pairs	O
designed	O
for	O
AS	O
targets	O
(	O
annealing	O
at	O
58	O
°	O
C	O
and	O
amplification	O
for	O
30	O
or	O
35	O
cycles	O
)	O
.	O

PCR	O
products	O
were	O
resolved	O
on	O
either	O
1.5	O
%	O
or	O
3	O
%	O
agarose	O
gel	O
in	O
TBE	O
.	O

The	O
Ethidium	O
Bromide	O
-	O
stained	O
gels	O
were	O
scanned	O
with	O
Typhoon	O
8600	O
scanner	O
(	O
Molecular	O
Dynamics	O
)	O
for	O
quantification	O
.	O

The	O
number	O
of	O
true	O
positives	O
(	O
TP	O
;	O
false	O
negatives	O
,	O
FN	O
)	O
was	O
computed	O
as	O
the	O
number	O
of	O
REAP	O
[	O
+	O
]	O
(	O
REAP	O
[	O
−	O
]	O
)	O
exons	O
that	O
were	O
validated	O
by	O
RT	O
-	O
PCR	O
as	O
AS	O
.	O

The	O
number	O
of	O
true	O
negatives	O
(	O
TN	O
;	O
or	O
FPs	O
)	O
was	O
computed	O
as	O
the	O
number	O
of	O
REAP	O
[	O
−	O
]	O
(	O
REAP	O
[	O
+	O
]	O
)	O
exons	O
that	O
were	O
validated	O
by	O
RT	O
-	O
PCR	O
as	O
constitutively	O
spliced	O
.	O

The	O
true	O
(	O
false	O
)	O
positive	O
rate	O
was	O
computed	O
as	O
TP	O
(	O
FP	O
)	O
divided	O
by	O
the	O
total	O
number	O
of	O
REAP	O
[	O
+	O
]	O
exons	O
in	O
the	O
experimentally	O
validated	O
set	O
.	O

The	O
true	O
(	O
false	O
)	O
negative	O
rate	O
was	O
computed	O
as	O
the	O
TN	O
(	O
FN	O
)	O
divided	O
by	O
the	O
total	O
number	O
of	O
REAP	O
[	O
−	O
]	O
exons	O
in	O
the	O
experimentally	O
validated	O
set	O
.	O

Sensitivity	O
was	O
computed	O
as	O
TP	O
/	O
(	O
TP+FN	O
)	O
and	O
specificity	O
was	O
computed	O
as	O
TN	O
/	O
(	O
FP+TN	O
)	O
.	O

Sequence	O
databases	O
.	O

Genome	O
sequences	O
of	O
human	B
(	O
hg17	O
)	O
,	O
dog	B
(	O
canFam1	O
)	O
,	O
rat	B
(	O
rn3	O
)	O
,	O
and	O
mouse	B
(	O
mm5	O
)	O
were	O
obtained	O
from	O
UCSC	O
,	O
as	O
were	O
the	O
whole	O
-	O
genome	O
MULTIZ	O
alignments	O
[	O
80	O
]	O
.	O

The	O
lists	O
of	O
known	O
human	B
genes	O
(	O
knownGene	O
containing	O
43,401	O
entries	O
)	O
and	O
known	O
isoforms	O
(	O
knownIsoforms	O
containing	O
43,286	O
entries	O
in	O
21,397	O
unique	O
isoform	O
clusters	O
)	O
with	O
annotated	O
exon	O
alignments	O
to	O
human	B
hg17	O
genomic	O
sequence	O
were	O
processed	O
as	O
follows	O
.	O

Known	O
genes	O
that	O
were	O
mapped	O
to	O
different	O
isoform	O
clusters	O
were	O
discarded	O
.	O

All	O
mRNAs	O
aligned	O
to	O
hg17	O
that	O
were	O
greater	O
than	O
300	O
bases	O
long	O
were	O
clustered	O
together	O
with	O
the	O
known	O
isoforms	O
.	O

Genes	O
containing	O
less	O
than	O
three	O
exons	O
were	O
removed	O
from	O
further	O
consideration	O
.	O

A	O
total	O
of	O
2.7	O
million	O
spliced	O
ESTs	O
were	O
mapped	O
onto	O
the	O
17,478	O
high	O
-	O
quality	O
genes	O
to	O
infer	O
AS	O
.	O

Exons	O
with	O
canonical	O
splice	O
signals	O
(	O
GT	O
-	O
AG	O
,	O
AT	O
-	O
AC	O
,	O
GC	O
-	O
AG	O
)	O
were	O
retained	O
,	O
resulting	O
in	O
a	O
total	O
of	O
213,736	O
exons	O
.	O

Of	O
these	O
,	O
197,262	O
(	O
92	O
%	O
of	O
all	O
exons	O
)	O
were	O
constitutive	O
exons	O
,	O
13,934	O
exons	O
(	O
7	O
%	O
)	O
had	O
evidence	O
of	O
exon	O
-	O
skipping	O
,	O
1,615	O
(	O
1	O
%	O
)	O
exons	O
were	O
mutually	O
exclusive	O
alternative	O
events	O
,	O
5,930	O
(	O
3	O
%	O
)	O
exons	O
had	O
alternative	O
3′	O
splice	O
sites	O
,	O
5,181	O
(	O
2	O
%	O
)	O
exons	O
had	O
alternative	O
5′	O
splice	O
sites	O
,	O
and	O
175	O
(	O
<	O
1	O
%	O
)	O
exons	O
overlapped	O
another	O
exon	O
,	O
but	O
did	O
not	O
fall	O
into	O
the	O
above	O
classifications	O
.	O

A	O
total	O
of	O
324,139	O
probesets	O
from	O
the	O
Affymetrix	O
Human	B
Exon	O
1.0	O
ST	O
array	O
were	O
mapped	O
to	O
208,422	O
human	B
exons	O
,	O
representing	O
17,431	O
genes	O
.	O

These	O
probesets	O
were	O
used	O
to	O
derive	O
gene	O
and	O
exon	O
-	O
level	O
signal	O
estimates	O
from	O
the	O
CEL	O
files	O
.	O

The	O
four	O
-	O
way	O
mammalian	O
(	O
four	O
-	O
mammal	O
)	O
whole	O
-	O
genome	O
alignment	O
(	O
hg17	O
,	O
canFam1	O
,	O
mm5	O
,	O
rn3	O
)	O
was	O
extracted	O
from	O
the	O
eight	O
-	O
way	O
vertebrate	O
MULTIZ	O
alignments	O
(	O
hg17	O
,	O
panTrol1	O
,	O
mm5	O
,	O
rn3	O
,	O
canFam1	O
,	O
galGal2	O
,	O
fr1	O
,	O
danRer1	O
)	O
obtained	O
from	O
the	O
UCSC	O
Genome	O
Browser	O
.	O

Four	O
-	O
way	O
mammal	O
alignments	O
were	O
extracted	O
for	O
all	O
internal	O
exons	O
,	O
and	O
400	O
bases	O
of	O
flanking	O
intronic	O
sequence	O
,	O
resulting	O
in	O
a	O
total	O
of	O
161,731	O
conserved	O
internal	O
exons	O
.	O

A	O
total	O
of	O
145,613	O
(	O
90	O
%	O
of	O
total	O
)	O
conserved	O
internal	O
exons	O
were	O
constitutive	O
exons	O
,	O
13,653	O
exons	O
(	O
8	O
%	O
)	O
had	O
evidence	O
of	O
exon	O
-	O
skipping	O
,	O
1,576	O
exons	O
were	O
mutually	O
exclusive	O
alternative	O
events	O
,	O
5,818	O
exons	O
had	O
alternative	O
3′	O
splice	O
sites	O
,	O
5,046	O
exons	O
had	O
alternative	O
5′	O
splice	O
sites	O
,	O
and	O
168	O
exons	O
overlapped	O
another	O
exon	O
.	O

Exon	O
array	O
analysis	O
.	O

The	O
Affymetrix	O
Power	O
Tools	O
(	O
APT	O
)	O
suite	O
of	O
programs	O
was	O
obtained	O
from	O
http://www.affymetrix.com/support/developer/powertools/index.affx	O
.	O

Exon	O
(	O
probeset	O
)	O
and	O
gene	O
-	O
level	O
signal	O
estimates	O
were	O
derived	O
from	O
the	O
CEL	O
files	O
by	O
RMA	O
–	O
sketch	O
normalization	O
as	O
a	O
method	O
in	O
the	O
apt	O
-	O
probeset	O
-	O
summarize	O
program	O
.	O

To	O
determine	O
if	O
the	O
signal	O
intensity	O
for	O
a	O
given	O
probeset	O
is	O
above	O
the	O
expected	O
level	O
of	O
background	O
noise	O
,	O
we	O
utilized	O
the	O
DABG	O
(	O
detection	O
above	O
background	O
)	O
quantification	O
method	O
available	O
in	O
the	O
apt	O
-	O
probeset	O
-	O
summarize	O
program	O
as	O
part	O
of	O
Affymetrix	O
Power	O
Tools	O
(	O
APT	O
)	O
.	O

Briefly	O
,	O
DABG	O
compared	O
the	O
signal	O
for	O
each	O
probe	O
to	O
a	O
background	O
distribution	O
of	O
signals	O
from	O
anti	O
-	O
genomic	O
probes	O
with	O
the	O
same	O
GC	O
content	O
.	O

The	O
DABG	O
algorithm	O
generated	O
a	O
p	O
-	O
value	O
representing	O
the	O
probability	O
that	O
the	O
signal	O
intensity	O
of	O
a	O
given	O
probe	O
was	O
part	O
of	O
the	O
background	O
distribution	O
.	O

We	O
considered	O
a	O
probeset	O
with	O
a	O
DABG	O
p	O
-	O
value	O
lower	O
than	O
0.05	O
as	O
detected	O
above	O
background	O
.	O

The	O
statistic	O
thCNS	O
-	O
SCns	O
,	O
ESC	O
=	O
(	O
μhCNS	O
-	O
SCns	O
−	O
μESC	O
)	O
/	O
sqrt	O
(	O
(	O
(	O
nhCNS	O
-	O
SCns	O
−	O
1	O
)	O
σ2hCNS	O
-	O
SCns	O
+	O
(	O
nESC	O
−	O
1	O
)	O
σ2ESC	O
)	O
(	O
nhCNS	O
-	O
SCns	O
+	O
nESC	O
)	O
)	O
/	O
(	O
(	O
nhCNS	O
-	O
SCnsnESC	O
)	O
(	O
nhCNS	O
-	O
SCns	O
+	O
nESC	O
−	O
2	O
)	O
)	O
)	O
,	O
where	O
nhCNS	O
-	O
SCns	O
and	O
nESC	O
were	O
the	O
number	O
of	O
replicates	O
,	O
μhCNS	O
-	O
SCns	O
and	O
μESC	O
were	O
the	O
mean	O
,	O
and	O
σ2hCNS	O
-	O
SCns	O
and	O
σ2ESC	O
were	O
the	O
variances	O
of	O
the	O
expression	O
values	O
for	O
the	O
two	O
datasets	O
used	O
to	O
represent	O
the	O
differential	O
enrichment	O
of	O
a	O
gene	O
using	O
gene	O
-	O
level	O
estimates	O
in	O
hCNS	O
-	O
SCns	O
relative	O
to	O
hESCs	O
.	O

Multiple	O
hypothesis	O
testing	O
was	O
corrected	O
by	O
controlling	O
for	O
the	O
false	O
discovery	O
rate	O
(	O
Benjamini	O
-	O
Hochberg	O
)	O
.	O

AS	O
detection	O
by	O
REAP.The	O
log2	O
signal	O
estimate	O
xij	O
for	O
probeset	O
i	O
in	O
cell	O
-	O
type	O
j	O
had	O
to	O
satisfy	O
two	O
conditions	O
,	O
otherwise	O
the	O
probeset	O
was	O
discarded	O
:	O
(	O
i	O
)	O
2	O
<	O
xij	O
<	O
10,000	O
for	O
all	O
conditions	O
/	O
cell	O
-	O
types	O
j	O
;	O
and	O
(	O
ii	O
)	O
DABG	O
p	O
-	O
value	O
<	O
0.05	O
for	O
all	O
replicates	O
in	O
at	O
least	O
one	O
condition	O
/	O
cell	O
-	O
type	O
j.	O
A	O
gene	O
had	O
to	O
have	O
five	O
probesets	O
that	O
satisfied	O
the	O
two	O
conditions	O
above	O
in	O
order	O
to	O
be	O
considered	O
for	O
robust	O
regression	O
analysis	O
.	O

After	O
generating	O
the	O
points	O
(	O
as	O
described	O
in	O
the	O
Results	O
section	O
)	O
,	O
we	O
utilized	O
the	O
robust	O
regression	O
method	O
rlm	O
in	O
R	O
-	O
package	O
"	O
MASS	O
"	O
(	O
version	O
6.1–2	O
)	O
with	O
M	O
-	O
estimation	O
and	O
a	O
maximum	O
iteration	O
setting	O
of	O
30	O
to	O
estimate	O
the	O
linear	O
function	O
yi	O
=	O
αxi	O
+	O
β	O
.	O

For	O
each	O
probeset	O
,	O
we	O
computed	O
the	O
error	O
term	O
ei	O
,	O
,	O
which	O
was	O
the	O
difference	O
between	O
the	O
actual	O
value	O
yi	O
and	O
the	O
estimated	O
value	O
ξi	O
,	O
from	O
the	O
estimated	O
function	O
ξi	O
=	O
Axi	O
+	O
B	O
,	O
where	O
A	O
and	O
B	O
were	O
estimates	O
of	O
α	O
and	O
β	O
.	O

The	O
error	O
term	O
variance	O
was	O
estimated	O
by	O
se2	O
=	O
Σei2	O
/	O
(	O
n	O
−	O
p	O
)	O
,	O
which	O
was	O
used	O
to	O
estimate	O
the	O
variance	O
of	O
the	O
predicted	O
value	O
,	O
sξi2	O
=	O
se2	O
(	O
n−1	O
+	O
(	O
xi	O
−	O
μx	O
)	O
2	O
/	O
sx2	O
(	O
n	O
−	O
1	O
)	O
)	O
.	O

Here	O
,	O
n	O
referred	O
to	O
the	O
number	O
of	O
points	O
(	O
generated	O
for	O
each	O
gene	O
)	O
,	O
and	O
p	O
referred	O
to	O
the	O
number	O
of	O
independent	O
variables	O
(	O
p	O
=	O
2	O
in	O
our	O
method	O
)	O
;	O
and	O
μx	O
=	O
Σxi2	O
/	O
n	O
;	O
sx2	O
=	O
n−1	O
Σ	O
(	O
xi	O
−	O
μx	O
)	O
2	O
.	O

Following	O
Belsley	O
et	O
al.	O
[	O
81	O
]	O
,	O
we	O
defined	O
the	O
leverage	O
hi	O
of	O
the	O
ith	O
point	O
as	O
hi	O
=	O
n−1	O
+	O
(	O
xi	O
−	O
μx	O
)	O
2	O
/	O
sx2	O
(	O
n	O
−	O
1	O
)	O
.	O

Here	O
we	O
considered	O
a	O
point	O
to	O
have	O
high	O
leverage	O
if	O
hi	O
>	O
3p	O
/	O
n	O
.	O

Next	O
,	O
we	O
calculated	O
the	O
covariance	O
ratio	O
,	O
covi	O
=	O
(	O
si2	O
/	O
sr2	O
)	O
p	O
/	O
(	O
1	O
−	O
hi	O
)	O
,	O
which	O
is	O
the	O
ratio	O
of	O
the	O
determinant	O
of	O
the	O
covariance	O
matrix	O
after	O
deleting	O
the	O
ith	O
observation	O
to	O
the	O
determinant	O
of	O
the	O
covariance	O
matrix	O
with	O
the	O
entire	O
sample	O
.	O

We	O
considered	O
a	O
point	O
to	O
have	O
high	O
influence	O
if	O
|covi	O
−	O
1|	O
>	O
3p	O
/	O
n	O
.	O

Lastly	O
,	O
we	O
computed	O
the	O
studentized	O
residuals	O
,	O
rstudenti	O
=	O
ei	O
/	O
(	O
s	O
(	O
i	O
)	O
2	O
(	O
1	O
−	O
hi	O
)	O
0.5	O
)	O
,	O
where	O
s	O
(	O
i	O
)	O
2	O
=	O
(	O
n	O
-	O
p	O
)	O
se2	O
/	O
(	O
n	O
-	O
p-1	O
)	O
–	O
ei2	O
/	O
(	O
n	O
-	O
p-1	O
)	O
(	O
1	O
−	O
hi	O
)	O
,	O
the	O
error	O
term	O
variance	O
after	O
deleting	O
the	O
ith	O
point	O
.	O

As	O
rstudenti	O
was	O
distributed	O
as	O
Student	O
's	O
t	O
-	O
distribution	O
with	O
n	O
-	O
p-1	O
degrees	O
of	O
freedom	O
,	O
each	O
rstudenti	O
value	O
was	O
associated	O
with	O
a	O
p	O
-	O
value	O
.	O

We	O
considered	O
a	O
point	O
to	O
be	O
an	O
"	O
outlier	O
"	O
if	O
p	O
<	O
0.01	O
.	O

Identification	O
of	O
motifs	O
.	O

The	O
enrichment	O
score	O
of	O
a	O
sequence	O
element	O
of	O
length	O
k	O
(	O
k	O
-	O
mer	O
)	O
in	O
one	O
set	O
of	O
sequences	O
(	O
set	O
1	O
)	O
versus	O
another	O
set	O
of	O
sequences	O
(	O
set	O
2	O
)	O
was	O
represented	O
by	O
the	O
nonparametric	O
χ2	O
statistic	O
with	O
Yates	O
correction	O
,	O
computed	O
from	O
the	O
two	O
by	O
two	O
contingency	O
table	O
,	O
T	O
(	O
T11	O
:	O
number	O
of	O
occurrences	O
of	O
the	O
element	O
in	O
set	O
1	O
;	O
T12	O
:	O
number	O
of	O
occurrences	O
of	O
all	O
other	O
elements	O
of	O
similar	O
length	O
in	O
set	O
1	O
;	O
T21	O
:	O
number	O
of	O
occurrences	O
of	O
element	O
in	O
set	O
2	O
;	O
T22	O
:	O
number	O
of	O
occurrences	O
of	O
all	O
other	O
elements	O
of	O
similar	O
length	O
in	O
set	O
2	O
.	O

All	O
elements	O
had	O
to	O
be	O
greater	O
than	O
5	O
.	O

To	O
correct	O
for	O
multiple	O
hypothesis	O
testing	O
,	O
p	O
-	O
values	O
were	O
multiplied	O
by	O
the	O
total	O
number	O
of	O
comparisons	O
.	O

Extracts	O
of	O
the	O
creosote	B
bush	I
(	O
Larrea	B
tridentata	I
,	O
family	O
Zygophyllaceae	B
)	O
have	O
long	O
been	O
used	O
as	O
a	O
folk	O
remedy	O
for	O
Type	O
II	O
(	O
non	O
-	O
insulin	O
-	O
dependent	O
)	O
diabetes	O
by	O
native	B
Americans	I
in	O
southwestern	O
North	O
America	O
.	O

In	O
this	O
study	O
we	O
have	O
evaluated	O
the	O
metabolic	O
effects	O
of	O
masoprocol	O
,	O
a	O
pure	O
compound	O
isolated	O
from	O
the	O
creosote	B
bush	I
,	O
in	O
a	O
rat	B
model	O
of	O
Type	O
II	O
diabetes	O
.	O

Animals	O
were	O
fed	O
a	O
20	O
%	O
fat	O
(	O
by	O
weight	O
)	O
diet	O
for	O
2	O
weeks	O
prior	O
to	O
intravenous	O
injection	O
with	O
streptozotocin	O
(	O
STZ	O
,	O
0.19	O
mmol	O
/	O
kg	O
)	O
.	O

Diabetic	O
animals	O
(	O
glucose	O
16	O
-	O
33	O
mmol	O
/	O
l	O
)	O
were	O
treated	O
with	O
vehicle	O
,	O
metformin	O
(	O
0.83	O
mmol	O
/	O
kg	O
body	O
weight	O
)	O
or	O
masoprocol	O
(	O
0.83	O
mmol	O
/	O
kg	O
body	O
weight	O
)	O
twice	O
a	O
day	O
for	O
4	O
days	O
.	O

Masoprocol	O
treatment	O
lowered	O
glucose	O
concentrations	O
an	O
average	O
of	O
35	O
%	O
compared	O
with	O
vehicle	O
(	O
14.2+	O
/	O
-1.1	O
vs	O
21.7+	O
/	O
-1.0	O
mmol	O
/	O
l	O
,	O
p	O
<	O
0.001	O
)	O
,	O
a	O
reduction	O
similar	O
to	O
metformin	O
treatment	O
(	O
12.8+	O
/	O
-0.9	O
mmol	O
/	O
l	O
)	O
,	O
without	O
any	O
change	O
in	O
insulin	O
concentration	O
.	O

Masoprocol	O
treatment	O
also	O
lowered	O
triglyceride	O
concentrations	O
80	O
%	O
compared	O
with	O
vehicle	O
(	O
1.0+	O
/	O
-0.1	O
vs	O
4.8+	O
/	O
-0.3	O
mmol	O
/	O
l	O
,	O
p	O
<	O
0.001	O
)	O
,	O
a	O
reduction	O
far	O
greater	O
than	O
following	O
metformin	O
treatment	O
(	O
3.6+	O
/	O
-0.3	O
mmol	O
/	O
l	O
)	O
.	O

Non	O
-	O
esterified	O
fatty	O
acid	O
and	O
glycerol	O
concentration	O
were	O
decreased	O
by	O
approximately	O
65	O
%	O
by	O
masoprocol	O
compared	O
with	O
vehicle	O
,	O
a	O
reduction	O
approximately	O
twice	O
as	O
great	O
as	O
seen	O
with	O
metformin	O
(	O
p	O
<	O
0.001	O
)	O
.	O

The	O
effect	O
of	O
masoprocol	O
on	O
in	O
vivo	O
insulin	O
-	O
mediated	O
glucose	O
disposal	O
was	O
evaluated	O
by	O
infusing	O
fat	O
-	O
fed	O
/	O
STZ	O
rats	B
with	O
glucose	O
(	O
0.22	O
mmol	O
kg	O
x	O
min	O
(	O
-1	O
)	O
)	O
and	O
insulin	O
(	O
30	O
pmol	O
x	O
kg	O
x	O
min	O
(	O
-1	O
)	O
)	O
for	O
5	O
h.	O
In	O
response	O
to	O
the	O
infusion	O
,	O
steady	O
-	O
state	O
plasma	O
glucose	O
concentrations	O
were	O
reduced	O
30	O
%	O
in	O
masoprocol	O
-	O
treated	O
animals	O
compared	O
with	O
vehicle	O
controls	O
(	O
p	O
<	O
0.05	O
)	O
with	O
no	O
change	O
noted	O
in	O
rats	B
treated	O
with	O
metformin	O
.	O

The	O
effect	O
of	O
masoprocol	O
treatment	O
was	O
also	O
tested	O
in	O
primary	O
adipocytes	O
isolated	O
from	O
normal	O
animals	O
.	O

Adipocytes	O
treated	O
with	O
masoprocol	O
(	O
30	O
micromol	O
/	O
l	O
)	O
had	O
higher	O
basal	O
and	O
insulin	O
-	O
stimulated	O
glucose	O
clearance	O
than	O
did	O
adipocytes	O
treated	O
with	O
vehicle	O
(	O
p	O
<	O
0.05	O
)	O
.	O

These	O
data	O
show	O
that	O
masoprocol	O
decreases	O
both	O
plasma	O
glucose	O
and	O
triglyceride	O
concentrations	O
in	O
fat	O
-	O
fed	O
/	O
STZ	O
rats	B
,	O
presumably	O
as	O
a	O
result	O
of	O
its	O
ability	O
to	O
both	O
increase	O
glucose	O
disposal	O
and	O
decrease	O
lipolysis	O
.	O

The	O
induction	O
of	O
micronucleated	O
erythrocytes	O
by	O
diisopropylcarbodiimide	O
(	O
DIC	O
)	O
and	O
dicyclohexylcarbodiimide	O
(	O
DCC	O
)	O
was	O
investigated	O
as	O
part	O
of	O
a	O
U.S.	O
National	O
Toxicology	O
Program	O
(	O
NTP	O
)	O
evaluation	O
of	O
the	O
subchronic	O
toxicity	O
of	O
these	O
chemicals	O
.	O

Analysis	O
of	O
peripheral	O
blood	O
smears	O
from	O
male	O
and	O
female	O
B6C3F1	B
mice	I
exposed	O
to	O
17.5	O
-	O
140.0	O
mg	O
DIC	O
/	O
kg	O
/	O
day	O
by	O
skin	O
painting	O
for	O
13	O
weeks	O
revealed	O
dose	O
-	O
related	O
increases	O
in	O
the	O
frequency	O
of	O
micronucleated	O
normochromatic	O
erythrocytes	O
(	O
MN	O
-	O
NCE	O
)	O
in	O
both	O
sexes	O
.	O

Results	O
of	O
a	O
similar	O
13-week	O
peripheral	O
blood	O
micronucleus	O
(	O
MN	O
)	O
test	O
with	O
DCC	O
(	O
1.5	O
-	O
12.0	O
mg	O
/	O
kg	O
/	O
day	O
)	O
were	O
also	O
positive	O
,	O
although	O
the	O
increases	O
in	O
MN	O
-	O
NCE	O
were	O
not	O
as	O
great	O
as	O
those	O
observed	O
with	O
DIC	O
.	O

In	O
contrast	O
to	O
the	O
positive	O
results	O
of	O
the	O
subchronic	O
skin	O
-	O
painting	O
studies	O
in	O
mice	B
,	O
acute	O
bone	O
marrow	O
MN	O
studies	O
with	O
DIC	O
and	O
DCC	O
in	O
male	O
F344	B
rats	I
,	I
using	O
intraperitoneal	O
(	O
i.p	O
.	O
)	O
injection	O
,	O
yielded	O
negative	O
results	O
.	O

Both	O
the	O
acute	O
and	O
the	O
subchronic	O
exposures	O
included	O
doses	O
that	O
produced	O
clinical	O
signs	O
of	O
toxicity	O
.	O

Acute	O
mouse	B
bone	O
marrow	O
MN	O
tests	O
with	O
DIC	O
administered	O
in	O
single	O
or	O
triple	O
i.p	O
.	O

injection	O
protocols	O
were	O
subsequently	O
conducted	O
to	O
determine	O
if	O
the	O
differing	O
responses	O
between	O
mice	B
and	O
rats	B
were	O
due	O
to	O
species	O
or	O
protocol	O
differences	O
.	O

The	O
results	O
of	O
these	O
acute	O
tests	O
were	O
negative	O
or	O
equivocal	O
.	O

Because	O
the	O
subchronic	O
studies	O
produced	O
positive	O
results	O
,	O
it	O
was	O
hypothesized	O
that	O
these	O
carbodiimides	O
required	O
multiple	O
treatments	O
over	O
an	O
extended	O
period	O
of	O
time	O
to	O
produce	O
an	O
increase	O
in	O
MN	O
-	O
erythrocytes	O
.	O

To	O
confirm	O
the	O
original	O
response	O
,	O
a	O
second	O
dermal	O
subchronic	O
study	O
was	O
conducted	O
with	O
DIC	O
;	O
the	O
protocol	O
was	O
modified	O
to	O
include	O
sequential	O
blood	O
samplings	O
to	O
permit	O
monitoring	O
MN	O
frequencies	O
over	O
time	O
.	O

The	O
data	O
demonstrated	O
a	O
small	O
but	O
consistent	O
induction	O
of	O
micronucleated	O
erythrocytes	O
in	O
mice	B
treated	O
with	O
DIC	O
by	O
skin	O
painting	O
.	O

Antibacterial	O
antibiotics	O
,	O
diperamycin	O
(	O
1	O
)	O
was	O
produced	O
in	O
the	O
culture	O
broth	O
of	O
Streptomyces	B
griseoaurantiacus	I
MK393-AF2	O
.	O

Various	O
spectroscopic	O
analyses	O
of	O
1	O
suggested	O
that	O
1	O
belonged	O
to	O
a	O
member	O
of	O
cyclic	O
hexadepsipeptide	O
antibiotic	O
.	O

Antibiotic	O
1	O
had	O
potent	O
inhibitory	O
activity	O
against	O
various	O
Gram	B
-	I
positive	I
bacteria	I
including	O
Enterococcus	B
seriolicida	I
and	O
methicillin	O
-	O
resistant	O
Staphylococcus	B
aureus	I
.	O

Subcutaneous	O
tumor	O
induction	O
with	O
three	O
dose	O
levels	O
of	O
3-methylcholanthrene	O
(	O
MCA	O
)	O
,	O
benzo	O
[	O
a	O
]	O
pyrene	O
(	O
BP	O
)	O
,	O
and	O
7,12-dimethylbenz	O
[	O
a	O
]	O
anthracene	O
(	O
DMBA	O
)	O
in	O
two	O
vehicles	O
was	O
studied	O
in	O
C3H	O
/	O
Anf	O
Cum	O
,	O
C57BL	O
/	O
6	O
Cum	O
,	O
DBA	O
/	O
2J	O
,	O
and	O
(	O
C57BLXC3H	O
/	O
Anf	O
)	O
F1	O
(	O
BC3F1	O
/	O
Cum	O
)	O
mice	B
.	O

Median	O
tumor	O
dose	O
levels	O
were	O
significantly	O
lower	O
when	O
the	O
three	O
carcinogens	O
were	O
suspended	O
in	O
trioctanoin	O
.	O

When	O
beeswax	O
:	O
trioctanoin	O
(	O
B	O
:	O
T	O
)	O
was	O
used	O
as	O
a	O
vehicle	O
,	O
the	O
three	O
carcinogens	O
differed	O
in	O
their	O
abilities	O
to	O
be	O
absorbed	O
or	O
solubilized	O
from	O
the	O
vehicle	O
by	O
the	O
three	O
strains	O
of	O
mice	B
and	O
the	O
hybrid	O
.	O

In	O
C3H	O
/	O
Anf	O
mice	B
,	O
BP	O
in	O
B	O
:	O
T	O
failed	O
to	O
produce	O
tumors	O
.	O

In	O
BC3F1	O
mice	B
,	O
no	O
tumors	O
were	O
produced	O
by	O
MCA	O
,	O
BP	O
,	O
or	O
DMBA	O
in	O
B	O
:	O
T.	O
In	O
C57BL	O
/	O
6	O
mice	B
,	O
no	O
tumors	O
were	O
produced	O
with	O
DMBA	O
or	O
MCA	O
in	O
B	O
:	O
T.	O
In	O
DBA	O
/	O
2	O
mice	B
,	O
no	O
tumors	O
were	O
produced	O
by	O
BP	O
or	O
MCA	O
in	O
B	O
:	O
T.	O
These	O
results	O
indicated	O
that	O
the	O
interpretation	O
of	O
tumor	O
induction	O
results	O
obtained	O
with	O
B	O
:	O
T	O
vehicle	O
may	O
be	O
related	O
to	O
the	O
conditions	O
of	O
bioassay	O
rather	O
than	O
to	O
the	O
carcinogenic	O
potential	O
of	O
a	O
compound	O
.	O

DNA	O
-	O
dependent	O
protein	O
kinase	O
(	O
DNA	O
-	O
PK	O
)	O
and	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
(	O
PARP	O
)	O
are	O
activated	O
by	O
DNA	O
strand	O
breaks	O
and	O
participate	O
in	O
DNA	O
repair	O
.	O

We	O
investigated	O
the	O
interactive	O
effects	O
of	O
inhibitors	O
of	O
these	O
enzymes	O
[	O
wortmannin	O
(	O
WM	O
)	O
,	O
which	O
inhibits	O
DNA	O
-	O
PK	O
,	O
and	O
8-hydroxy-2-methylquinazolin-4-one	O
(	O
NU1025	O
)	O
,	O
a	O
PARP	O
inhibitor	O
]	O
on	O
cell	O
survival	O
and	O
DNA	O
double	O
-	O
strand	O
break	O
(	O
DSB	O
)	O
and	O
single	O
-	O
strand	O
break	O
(	O
SSB	O
)	O
rejoining	O
in	O
Chinese	B
hamster	I
ovary	O
-	O
K1	O
cells	O
following	O
exposure	O
to	O
ionizing	O
radiation	O
(	O
IR	O
)	O
or	O
temozolomide	O
.	O

WM	O
(	O
20	O
microM	O
)	O
or	O
NU1025	O
(	O
300	O
microM	O
)	O
potentiated	O
the	O
cytotoxicity	O
of	O
IR	O
with	O
dose	O
enhancement	O
factors	O
at	O
10	O
%	O
survival	O
(	O
DEF10	O
)	O
values	O
of	O
4.5	O
+	O
/-	O

0.6	O
and	O
1.7	O
+	O
/-	O

0.2	O
,	O
respectively	O
.	O

When	O
used	O
in	O
combination	O
,	O
a	O
DEF10	O
of	O
7.8	O
+	O
/-	O

1.5	O
was	O
obtained	O
.	O

WM	O
or	O
NU1025	O
potentiated	O
the	O
cytotoxicity	O
of	O
temozolomide	O
,	O
and	O
an	O
additive	O
effect	O
on	O
the	O
DEF10	O
value	O
was	O
obtained	O
with	O
the	O
combined	O
inhibitors	O
.	O

Using	O
the	O
same	O
inhibitor	O
concentrations	O
,	O
their	O
single	O
and	O
combined	O
effects	O
on	O
DSB	O
and	O
SSB	O
levels	O
following	O
IR	O
were	O
assessed	O
by	O
neutral	O
and	O
alkaline	O
elution	O
.	O

Cells	O
exposed	O
to	O
IR	O
were	O
post	O
-	O
incubated	O
for	O
30	O
min	O
to	O
allow	O
repair	O
to	O
occur	O
.	O

WM	O
or	O
NU1025	O
increased	O
net	O
DSB	O
levels	O
relative	O
to	O
IR	O
alone	O
(	O
DSB	O
levels	O
of	O
1.29	O
+	O
/-	O

0.04	O
and	O
1.20	O
+	O
/-	O

0.05	O
,	O
respectively	O
,	O
compared	O
with	O
1.01	O
+	O
/-	O

0.03	O
for	O
IR	O
alone	O
)	O
and	O
the	O
combination	O
had	O
an	O
additive	O
effect	O
.	O

WM	O
had	O
no	O
effect	O
on	O
SSB	O
levels	O
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
NU1025	O
.	O

SSB	O
levels	O
were	O
increased	O
to	O
1.27	O
+	O
/-	O

0.05	O
with	O
NU1025	O
compared	O
with	O
IR	O
alone	O
,	O
1.02	O
+	O
/-	O

0.04	O
.	O

The	O
dose	O
-	O
dependent	O
effects	O
of	O
the	O
inhibitors	O
on	O
DSB	O
levels	O
showed	O
that	O
they	O
were	O
near	O
maximal	O
by	O
20	O
microM	O
WM	O
and	O
300	O
microM	O
NU1025	O
.	O

DSB	O
repair	O
kinetics	O
were	O
studied	O
.	O

Both	O
inhibitors	O
increased	O
net	O
DSB	O
levels	O
over	O
a	O
3	O
h	O
time	O
period	O
;	O
when	O
they	O
were	O
combined	O
,	O
net	O
DSB	O
levels	O
at	O
3	O
h	O
were	O
identical	O
to	O
DSB	O
levels	O
immediately	O
post	O
-	O
IR	O
.	O

The	O
combined	O
use	O
of	O
DNA	O
repair	O
inhibitors	O
may	O
have	O
therapeutic	O
potential	O
.	O

Chemical	O
investigation	O
of	O
the	O
sponge	O
Spongia	B
matamata	I
collected	O
in	O
Yap	O
,	O
Micronesia	O
,	O
has	O
resulted	O
in	O
the	O
isolation	O
of	O
six	O
new	O
spongian	O
diterpenoids	O
,	O
2	O
-	O
7	O
,	O
along	O
with	O
the	O
known	O
compound	O
,	O
spongia-13	O
(	O
16	O
)	O
,	O
14-dien-19-oic	O
acid	O
(	O
1	O
)	O
.	O

The	O
structures	O
were	O
determined	O
by	O
spectroscopic	O
methods	O
.	O

Meloxicam	O
[	O
4-hydroxy-2-methyl	O
-	O
N-	O
(	O
5-methyl-2-thiazolyl	O
)	O
-2H-1,2-benzothiazine	O
-3-carboxamide-1	O
,	O
1-dioxide	O
]	O
is	O
a	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
(	O
NSAID	O
)	O
of	O
the	O
oxicam	O
class	O
which	O
shows	O
preferential	O
inhibition	O
of	O
cyclo	O
-	O
oxygenase-2	O
.	O

Meloxicam	O
has	O
a	O
plasma	O
half	O
-	O
life	O
of	O
approximately	O
20	O
hours	O
,	O
making	O
it	O
convenient	O
for	O
once	O
-	O
daily	O
administration	O
.	O

Meloxicam	O
is	O
eliminated	O
after	O
biotransformation	O
to	O
4	O
pharmacologically	O
inactive	O
metabolites	O
,	O
which	O
are	O
excreted	O
in	O
urine	O
and	O
faeces	O
.	O

Meloxicam	O
and	O
its	O
metabolites	O
bind	O
extensively	O
to	O
plasma	O
albumin	O
.	O

Substantial	O
concentrations	O
of	O
meloxicam	O
are	O
attained	O
in	O
synovial	O
fluid	O
,	O
the	O
proposed	O
site	O
of	O
action	O
in	O
chronic	O
inflammatory	O
arthropathies	O
.	O

Neither	O
moderate	O
renal	O
nor	O
hepatic	O
insufficiency	O
significantly	O
alter	O
the	O
pharmacokinetics	O
of	O
meloxicam	O
.	O

Dosage	O
adjustment	O
is	O
not	O
required	O
in	O
the	O
elderly	O
.	O

Drug	O
-	O
drug	O
interaction	O
studies	O
are	O
available	O
for	O
some	O
commonly	O
co	O
-	O
prescribed	O
medications	O
.	O

Concentration	O
-	O
dependent	O
therapeutic	O
and	O
toxicological	O
effects	O
have	O
yet	O
to	O
be	O
extensively	O
elucidated	O
for	O
this	O
NSAID	O
.	O

Recent	O
work	O
within	O
our	O
laboratory	O
has	O
focused	O
on	O
the	O
enzymes	O
we	O
hypothesize	O
are	O
involved	O
in	O
the	O
biosynthesis	O
of	O
bis	O
(	O
monoacylglycerol	O
)	O
phosphate	O
from	O
phosphatidylglycerol	O
.	O

Here	O
we	O
describe	O
a	O
transacylase	O
,	O
active	O
at	O
acidic	O
pH	O
values	O
,	O
isolated	O
from	O
a	O
macrophage	O
-	O
like	O
cell	O
line	O
,	O
RAW	O
264.7	O
.	O

This	O
enzyme	O
acylates	O
the	O
head	O
group	O
glycerol	O
of	O
sn-3	O
:	O
sn-1	O
'	O
lysophosphatidylglycerol	O
to	O
form	O
sn-3	O
:	O
sn-1	O
'	O
bis	O
(	O
monoacylglycerol	O
)	O
phosphate	O
.	O

Here	O
we	O
demonstrate	O
that	O
this	O
enzyme	O
uses	O
two	O
lysophosphatidylglycerol	O
molecules	O
,	O
one	O
as	O
an	O
acyl	O
donor	O
and	O
another	O
as	O
an	O
acyl	O
acceptor	O
,	O
and	O
that	O
the	O
acyl	O
contributions	O
from	O
all	O
other	O
lipids	O
tested	O
are	O
comparatively	O
minor	O
.	O

This	O
enzyme	O
prefers	O
saturated	O
acyl	O
chains	O
to	O
monounsaturates	O
,	O
16	O
and	O
18	O
carbon	O
fatty	O
acids	O
over	O
14	O
carbon	O
fatty	O
acids	O
,	O
and	O
saturated	O
acyl	O
chains	O
at	O
the	O
sn-1	O
position	O
to	O
monounsaturated	O
acyl	O
chains	O
on	O
the	O
sn-2	O
carbon	O
of	O
lysophosphatidylglycerol	O
.	O

We	O
present	O
data	O
which	O
show	O
the	O
transacylase	O
activity	O
depends	O
on	O
the	O
presence	O
of	O
a	O
lipid	O
-	O
water	O
interface	O
and	O
the	O
lipid	O
polymorphic	O
state	O
.	O

INTRODUCTION	O
We	O
have	O
recently	O
shown	O
that	O
rabbit	B
antibodies	O
to	O
the	O
p	O
-	O
azophenylphosphorylcholine	O
(	O
APPC	O
)	O
determinant	O
,	O
which	O
bears	O
2	O
charges	O
of	O
opposite	O
sign	O
,	O
have	O
both	O
positively	O
and	O
negatively	O
charged	O
groups	O
in	O
their	O
binding	O
sites	O
(	O
Krausz	O
et	O
al.	O
,	O
1976	O
)	O
.	O

The	O
positive	O
charge	O
is	O
contributed	O
by	O
the	O
guanidinium	O
group	O
of	O
arginine	O
and	O
the	O
negative	O
charge	O
is	O
contributed	O
by	O
the	O
carboxylate	O
group	O
of	O
either	O
a	O
glutamyl	O
or	O
aspartyl	O
residue	O
.	O

We	O
have	O
also	O
previously	O
shown	O
(	O
Grossberg	O
et	O
al.	O
,	O
1974	O
)	O
that	O
the	O
phosphorylcholine	O
-	O
binding	O
mouse	B
myeloma	O
protein	O
,	O
HOPC-8	O
,	O
similarly	O
contains	O
gaunidinium	O
and	O
carboxylate	O
groups	O
in	O
its	O
binding	O
site	O
.	O

In	O
an	O
attempt	O
to	O
gain	O
further	O
insight	O
into	O
the	O
nature	O
of	O
these	O
binding	O
sites	O
we	O
have	O
measured	O
the	O
relative	O
binding	O
constants	O
of	O
several	O
structurally	O
related	O
small	O
molecules	O
with	O
anti	O
-	O
APPC	O
antibodies	O
and	O
with	O
HOPC-8	O
.	O

The	O
Krel	O
values	O
for	O
hapten	O
binding	O
to	O
the	O
rabbit	B
anti	O
-	O
APPC	O
antibodies	O
and	O
to	O
the	O
myeloma	O
protein	O
,	O
together	O
with	O
our	O
evidence	O
for	O
specific	O
functional	O
groups	O
in	O
the	O
binding	O
sites	O
,	O
have	O
allowed	O
us	O
to	O
draw	O
inferences	O
regarding	O
the	O
topography	O
of	O
the	O
binding	O
sites	O
of	O
anti	O
-	O
APPC	O
antibodies	O
and	O
HOPC-8	O
.	O

*	O
This	O
work	O
was	O
supported	O
in	O
part	O
by	O
U.S.	O
Public	O
Health	O
Service	O
Research	O
Grants	O
CA-11656	O
and	O
AI-03962	O
from	O
the	O
National	O
Cancer	O
Institute	O
.	O

t	O
A	O
unit	O
of	O
the	O
New	O
York	O
State	O
Department	O
of	O
Health	O
.	O

$	O
Abbreviations	O
used	O
:	O
APPC	O
,	O
p	O
-	O
azophenylphosphorylcholine	O
;	O
NPPC	O
,	O
p	O
-	O
nitrophenylphosphorylcholine	O
;	O
PC	O
,	O
phosphorylcholine	O
;	O
GPC	O
,	O
L	O
-	O
a	O
-	O
glycerophosphorylcholine	O
;	O
AcC	O
,	O
acetylcholine	O
;	O
I	O
-	O
Ap	O
,	O
p	O
-	O
iodophenyltrimethylammonium	O
;	O
PO3	O
,	O
phenylphosphate	O
;	O
03	O
,	O
phenylphosphonate	O
;	O
BBS	O
,	O
borate	O
buffered	O
saline	O
.	O

901	O
MATERIALS	O
AND	O
METHODS	O
p	O
-	O
Diazonium	O
phenylphosphorylcholine	O
chloride	O
(	O
DPPC	O
)	O
This	O
was	O
prepared	O
according	O
to	O
Chesebro	O
&	O
Metzger	O
(	O
1972	O
)	O
with	O
the	O
exception	O
that	O
in	O
the	O
diazotization	O
step	O
1.0	O
N	O
HCl	O
rather	O
than	O
0.1	O
N	O
HCl	O
was	O
used	O
(	O
Grossberg	O
et	O
al.	O
,	O
1974	O
)	O
.	O

Haptens	O
Haptens	O
tested	O
were	O
reagent	O
grade	O
commercial	O
products	O
,	O
used	O
without	O
further	O
purification	O
.	O

Goat	B
anti	O
-	O
rabbit	B
IgG	O
This	O
serum	O
was	O
a	O
preparation	O
previously	O
described	O
(	O
Hoffman	O
et	O
al.	O
,	O
1971	O
)	O
.	O

Rabbit	B
anti	O
-	O
mouse	B
IgA	O
This	O
serum	O
was	O
obtained	O
from	O
Dr.	O
Oliver	O
A.	O
Roholt	O
of	O
our	O
Department	O
.	O

It	O
was	O
prepared	O
by	O
hyperimmunization	O
of	O
rabbits	B
with	O
MOPC-315	O
myeloma	O
protein	O
.	O

Anti	O
-	O
APPC	O
antibodies	O
The	O
preparation	O
of	O
rabbit	B
antisera	O
to	O
the	O
APPC	O
determinant	O
and	O
the	O
subsequent	O
isolation	O
and	O
purification	O
of	O
the	O
antibodies	O
from	O
individual	O
rabbits	B
by	O
specific	O
immunoadsorption	O
has	O
been	O
described	O
previously	O
(	O
Krausz	O
et	O
al.	O
,	O
1976	O
)	O
.	O

In	O
the	O
present	O
work	O
preparations	O
from	O
rabbits	B
6055	B
and	O
6057	B
were	O
specifically	O
purified	O
anti	O
-	O
APPC	O
antibodies	O
and	O
the	O
preparation	O
from	O
rabbit	B
5920	I
was	O
a	O
gamma	O
globulin	O
fraction	O
of	O
anti	O
-	O
APPC	O
serum	O
.	O

HOPC-8	O
myeloma	O
protein	O
This	O
was	O
obtained	O
from	O
the	O
serum	O
of	O
tumor	O
-	O
bearing	O
mice	B
as	O
previously	O
described	O
(	O
Grossberg	O
et	O
al.	O
,	O
1974	O
)	O
.	O

The	O
myeloma	O
tumor	O
was	O
obtained	O
through	O
the	O
courtesy	O
of	O
Dr.	O
Michael	O
Potter	O
,	O
National	O
Cancer	O
Institute	O
,	O
Bethesda	O
,	O
MD	O
.	O

L.	O
M.	O
KRAUSZ	O
,	O
A.	O
L.	O
GROSSBERG	O
and	O
D.	O
PRESSMAN	O
Rabbit	B
serum	O
albumin	O
(	O
RSA	O
)	O
This	O
was	O
Fraction	O
V	O
obtained	O
from	O
Pentex	O
,	O
Inc.	O
,	O
Kankakee	O
,	O
IL	O
.	O

RSA	O
-	O
APPC	O
This	O
was	O
prepared	O
by	O
reacting	O
160	O
mg	O
of	O
RSA	O
in	O
about	O
10	O
ml	O
of	O
pH	O
9.5	O
borate	O
buffer	O
with	O
90	O
umoles	O
of	O
DPPC	O
for	O
18	O
hr	O
.	O

The	O
solution	O
was	O
then	O
dialyzed	O
against	O
pH	O
8	O
z	O
BBS	O
,	O
stored	O
frozen	O
and	O
used	O
as	O
needed	O
.	O

The	O
entire	O
prep-	O
ae	O
aration	O
was	O
carried	O
out	O
at	O
4	O
.	O

Radioiodination	O
of	O
RSA	O
-	O
APPC	O
RSA	O
-	O
APPC	O
was	O
trace	O
labeled	O
with	O
'	O
251	O
by	O
a	O
modification	O
of	O
the	O
method	O
of	O
Greenwood	O
et	O
al.	O
(	O
1963	O
)	O
.	O

Iodination	O
was	O
carried	O
out	O
in	O
0.45	O
ml	O
of	O
pH	O
8	O
BBS	O
containing	O
200	O
Ug	O
(	O
ca	O
.	O

3	O
n	O
-	O
mole	O
)	O
RSA	O
-	O
APPC	O
,	O
1	O
n	O
-	O
mole	O
of	O
KI	O
,	O
0.4	O
mCi	O
of	O
'	O
ZSI	O
and	O
300	O
n	O
-	O
mole	O
of	O
chloromine	O
T.	O
The	O
reaction	O
was	O
allowed	O
to	O
proceed	O
for	O
30	O
min	O
,	O
stopped	O
with	O
300	O
n	O
-	O
mole	O
of	O
bisulfite	O
and	O
the	O
product	O
dialyzed	O
to	O
remove	O
free	O
"	O
'	O
I	O
and	O
reagents	O
.	O

Measurement	O
of	O
K	O
,	O
e	O
,	O
The	O
method	O
used	O
to	O
obtain	O
the	O
relative	O
binding	O
constants	O
for	O
the	O
various	O
haptens	O
is	O
based	O
on	O
the	O
technique	O
originally	O
developed	O
by	O
Skom	O
&	O
Talmadge	O
(	O
1958	O
)	O
for	O
precipitating	O
antigen	O
-	O
antibody	O
complexes	O
with	O
antiglobulin	O
.	O

In	O
our	O
assay	O
the	O
primary	O
haptenic	O
determinant	O
,	O
p	O
-	O
azophenylphosphory1choline	O
,	O
was	O
coupled	O
to	O
rabbit	B
serum	O
albumin	O
which	O
was	O
then	O
trace	O
labeled	O
with	O
1251	O
.	O

Labeled	O
antigen	O
was	O
mixed	O
with	O
varying	O
amounts	O
of	O
antibody	O
and	O
the	O
amount	O
of	O
antigen	O
bound	O
was	O
determined	O
by	O
precipitating	O
all	O
the	O
gamma	O
globulin	O
(	O
i.e.	O
bound	O
and	O
unbound	O
antibody	O
as	O
well	O
as	O
non	O
-	O
specific	O
y	O
globulin	O
)	O
with	O
goat	B
antiglobulin	O
antibody	O
and	O
measuring	O
the	O
radioactivity	O
associated	O
with	O
the	O
precipitate	O
.	O

Relative	O
binding	O
constants	O
(	O
K	O
,	O
e	O
,	O
)	O
for	O
the	O
different	O
haptens	O
were	O
determined	O
by	O
measuring	O
their	O
ability	O
to	O
inhibit	O
the	O
reaction	O
of	O
labeled	O
antigen	O
with	O
antibody	O
.	O

The	O
amount	O
of	O
antibody	O
was	O
chosen	O
so	O
that	O
about	O
60	O
%	O
of	O
the	O
labeled	O
antigen	O
was	O
bound	O
by	O
antibody	O
in	O
the	O
absence	O
of	O
hapten	O
.	O

In	O
a	O
typical	O
determination	O
the	O
antigen	O
solution	O
was	O
made	O
to	O
contain	O
100	O
ng	O
per	O
ml	O
of	O
1251-RSA	O
-	O
APPC	O
and	O
1	O
mg	O
/	O
ml	O
of	O
RSA	O
in	O
pH	O
8	O
BBS	O
.	O

The	O
required	O
concentration	O
of	O
antibody	O
was	O
made	O
up	O
in	O
normal	O
rabbit	B
serum	O
diluted	O
1:5	O
with	O
pH	O
8	O
BBS	O
.	O

HOPC-8	O
myeloma	O
protein	O
was	O
made	O
up	O
in	O
normal	O
mouse	B
serum	O
diluted	O
1:5	O
.	O

To	O
0.1	O
ml	O
of	O
antibody	O
(	O
or	O
HOPC-8	O
)	O
solution	O
were	O
added	O
,	O
0.1	O
ml	O
'	O
251-RSA	O
-	O
APPC	O
solution	O
and	O
0.1	O
ml	O
hapten	O
solution	O
in	O
pH	O
8	O
BBS	O
.	O

Hapten	O
concentrations	O
ranged	O
from	O
10	O
'	O
to	O
10-'M.	O
In	O
one	O
sample	O
(	O
uninhibited	O
)	O
,	O
hapten	O
solution	O
was	O
replaced	O
by	O
buffer	O
to	O
determine	O
the	O
amount	O
of	O
antigen	O
precipitated	O
in	O
the	O
absence	O
of	O
hapten	O
.	O

Another	O
mixture	O
(	O
non	O
-	O
specific	O
control	O
)	O
contained	O
0.1	O
ml	O
1:5	O
diluted	O
normal	O
rabbit	B
(	O
or	O
mouse	B
)	O
serum	O
in	O
place	O
of	O
antibody	O
,	O
0.1	O
ml	O
of	O
antigen	O
and	O
0.1	O
ml	O
of	O
buffer	O
.	O

All	O
tubes	O
were	O
incubated	O
at	O
37	O
for	O
30	O
min	O
.	O

Then	O
0.2	O
ml	O
of	O
anti	O
-	O
globulin	O
antiserum	O
was	O
added	O
to	O
all	O
tubes	O
.	O

The	O
amount	O
added	O
was	O
that	O
determined	O
to	O
be	O
sufficient	O
to	O
precipitate	O
all	O
the	O
globulin	O
in	O
the	O
mixture	O
.	O

Goat	B
anti	O
-	O
rabbit	B
y	O
-	O
globulin	O
was	O
used	O
to	O
precipitate	O
the	O
rabbit	B
antibodies	O
and	O
rabbit	B
anti	O
-	O
mouse	B
IgA	O
was	O
used	O
to	O
precipitate	O
the	O
HOPC-8	O
myeloma	O
protein	O
.	O

The	O
reaction	O
mixtures	O
were	O
allowed	O
to	O
stand	O
at	O
room	O
temperature	O
for	O
1	O
hr	O
,	O
and	O
then	O
stored	O
at	O
5	O
overnight	O
.	O

The	O
tubes	O
were	O
centrifuged	O
,	O
the	O
supernatants	O
discarded	O
and	O
the	O
precipitates	O
washed	O
twice	O
with	O
saline	O
.	O

Radioactivity	O
in	O
the	O
precipitates	O
was	O
determined	O
.	O

All	O
determinations	O
were	O
done	O
in	O
duplicate	O
.	O

Per	O
cent	O
inhibition	O
is	O
given	O
by	O
:	O
Inhibition	O
=	O
f	O
1	O
ANTI	O
-	O
APPC	O
#	O
6055	O
loo	O
50	O
01	O
10	O
-	O
6	O
10	O
-	O
5	O
NPPC	O
GPC	O
,	O
Pc	O
P03	O
I_AD	O
CHOLINE	O
10	O
4	O
10	O
-	O
3	O
10-z	O
10	O
I	O
INHIBITOR	O
CONC	O
.	O

(	O
M	O
)	O
Fig.	O
1	O
.	O

Plots	O
of	O
the	O
inhibition	O
by	O
haptens	O
of	O
the	O
binding	O
of	O
RSA	O
-	O
APPC	O
antigen	O
to	O
anti	O
-	O
APPC	O
antibody	O
from	O
rabbit	B
6055	I
.	O

Values	O
determined	O
in	O
this	O
manner	O
were	O
reproducible	O
to	O
within	O
%	O
.	O

RESULTS	O
Plots	O
of	O
effect	O
of	O
hapten	O
on	O
antigen	O
binding	O
are	O
given	O
in	O
Fig.	O
1	O
for	O
anti	O
-	O
APPC	O
from	O
rabbit	B
6055	I
and	O
in	O
Fig.	O
2	O
for	O
anti	O
-	O
APPC	O
from	O
rabbit	B
5920	I
.	O

The	O
plots	O
for	O
anti	O
-	O
APPC	O
from	O
rabbit	B
6057	I
,	O
were	O
essentially	O
identical	O
to	O
those	O
in	O
Fig.	O
1	O
.	O

From	O
these	O
data	O
,	O
K	O
,	O
el	O
values	O
were	O
calculated	O
relative	O
to	O
the	O
most	O
inhibitory	O
hapten	O
,	O
NPPC	O
,	O
according	O
to	O
the	O
formula	O
:	O
_	O
(	O
NPPC	O
)	O
at	O
50	O
%	O
inhibition	O
K	O
"	O
'	O
(	O
HAPTEN	O
)	O
at	O
50	O
%	O
inhibition	O
The	O
values	O
of	O
K	O
,	O
e	O
,	O
are	O
given	O
in	O
Table	O
1	O
.	O

The	O
only	O
effective	O
inhibitors	O
observed	O
are	O
those	O
listed	O
in	O
Table	O
1	O
,	O
having	O
K	O
,	O
e	O
,	O
values	O
>	O
0.0001	O
.	O

It	O
is	O
interesting	O
that	O
the	O
p	O
-	O
iodophenyltrimethylammonium	O
ion	O
gave	O
detectable	O
inhibition	O
in	O
2	O
instances	O
.	O

Twentyfive	O
other	O
haptens	O
were	O
tested	O
.	O

None	O
showed	O
appreciable	O
binding	O
to	O
anti	O
-	O
APPC	O
antibodies	O
.	O

Among	O
those	O
tested	O
were	O
negatively	O
and	O
positively	O
chargen	O
haptens	O
,	O
including	O
other	O
phenyltrimethylammonium	O
ions	O
and	O
ANTI	O
-	O
APPC	O
#	O
5920	O
loo	O
50	O
z	O
x	O
NPPC	O
,	O
GPC	O
I	O
-	O
AP	O
PC	O
CHOLINE	O
0	O
10	O
-	O
6	O
10	O
-	O
5	O
10	O
4	O
10	O
-	O
3	O
10-z	O
10-I	O
INHIBITOR	O
CONC.	O
(	O
M	O
)	O
Fig.	O
2	O
.	O

Plots	O
of	O
the	O
inhibition	O
by	O
haptens	O
of	O
the	O
binding	O
of	O
RSA	O
-	O
APPC	O
antigen	O
to	O
anti	O
-	O
APPC	O
antibody	O
from	O
rabbit	B
5920	B
.	O

inhibited	O
sample	O
counts	O
/	O
min	O
-	O
non	O
-	O
specific	O
control	O
counts	O
/	O
min	O
uninhibited	O
sample	O
counts	O
/	O
min	O
-	O
non	O
-	O
specific	O
control	O
counts	O
/	O
min	O
x	O
100	O
.	O

Specificity	O
of	O
Anti	O
-	O
p	O
-	O
Azophenylphosphorylcholine	O
Antibodies	O
Table	O
1	O
.	O

Relative	O
binding	O
constants	O
of	O
haptens	O
for	O
anti	O
APPC	O
antibodies	O
Hapten	O
NPPC	O
t	O
.-	O
a	O
-	O
glycerophosphorylcholine	O
Phosphorylcholine	O
I	O
-	O
Ap	O
Choline	O
Phenylphosphonate	O
Phenylphosphate	O
Rabbit	B
No.	O
5920	O
6055	O
6057	O
K	O
1.0	O
0.015	O
0.0003	O
0.004	O
0.0007	O
0.0001	O
0.0001	O
1.0	O
1.0	O
0.019	O
0.016	O
0.0004	O
0.0005	O
0.0001	O
<	O
0.0001	O
0.00006	O
0.00006	O
0.0002	O
<	O
0.0001	O
0.0001	O
<	O
0.0001	O
several	O
phenylarsonates	O
and	O
sulfonates	O
.	O

A	O
representative	O
list	O
of	O
some	O
of	O
these	O
non	O
-	O
inhibitory	O
haptens	O
is	O
given	O
in	O
Table	O
2	O
.	O

The	O
results	O
of	O
inhibition	O
studies	O
with	O
the	O
mouse	B
myeloma	O
protein	O
HOPC-8	O
are	O
given	O
in	O
Fig.	O
3	O
where	O
the	O
inhibition	O
curves	O
are	O
drawn	O
only	O
for	O
those	O
haptens	O
showing	O
significant	O
ability	O
to	O
inhibit	O
.	O

K	O
,	O
e	O
,	O
values	O
were	O
calculated	O
as	O
described	O
above	O
and	O
are	O
listed	O
in	O
Table	O
3	O
.	O

For	O
comparison	O
,	O
Table	O
3	O
also	O
lists	O
values	O
of	O
K	O
,	O
el	O
calculated	O
from	O
the	O
data	O
of	O
Leon	O
&	O
Young	O
(	O
1971	O
)	O
for	O
TEPC-15	O
in	O
a	O
system	O
using	O
the	O
C	O
-	O
polysaccharide	O
of	O
pneumococcus	B
as	O
an	O
antigen	O
.	O

There	O
is	O
adequate	O
serological	O
and	O
chemical	O
evidence	O
showing	O
that	O
HOPC-8	O
and	O
TEPC-15	O
are	O
nearly	O
identical	O
proteins	O
(	O
Potter	O
&	O
Lieberman	O
,	O
1970	O
;	O
Hood	O
et	O
al.	O
,	O
1970	O
)	O
.	O

The	O
values	O
in	O
Table	O
3	O
show	O
the	O
close	O
correspondence	O
between	O
our	O
values	O
of	O
K	O
,	O
e	O
,	O
for	O
HOPC-8	O
and	O
those	O
calculated	O
from	O
the	O
data	O
of	O
Leon	O
&	O
Young	O
for	O
TECP-15	O
.	O

The	O
K	O
,	O
e	O
,	O
values	O
for	O
anti	O
-	O
APPC	O
from	O
rabbit	B
6055	B
are	O
also	O
listed	O
in	O
Table	O
3	O
to	O
facilitate	O
comparisons	O
with	O
HOPC-8	O
.	O

In	O
order	O
to	O
assess	O
further	O
the	O
validity	O
of	O
the	O
inhibition	O
method	O
as	O
used	O
here	O
for	O
obtaining	O
Kre	O
,	O
values	O
,	O
we	O
have	O
compared	O
the	O
value	O
of	O
K	O
,	O
e	O
,	O
calculated	O
from	O
the	O
individual	O
binding	O
constants	O
of	O
HOPC-8	O
for	O
phosphory1choline	O
(	O
PC	O
)	O
and	O
p	O
-	O
nitrophenylphosphorylcholine	O
(	O
NPPC	O
)	O
as	O
determined	O
by	O
equilibrium	O
dialysis	O
,	O
to	O
the	O
Kre	O
,	O
values	O
calculated	O
from	O
the	O
inhibition	O
data	O
.	O

As	O
measured	O
by	O
equilibrium	O
dialysis	O
with	O
HOPC-8	O
the	O
binding	O
constant	O
for	O
PC	O
(	O
KPc	O
)	O
was	O
found	O
to	O
be	O
1.2	O
x	O
106	O
M-1	O
and	O
for	O
NPPC	O
the	O
KNPPC	O
was	O
0.43	O
x	O
106	O
M-1	O
(	O
Krausz	O
et	O
al.	O
,	O
1976	O
)	O
.	O

The	O
ratio	O
of	O
the	O
two	O
is	O
:	O
1.20	O
x	O
106	O
_	O
KPCIKNPPC	O
-	O
0.43	O
x	O
106	O
-	O
2.8	O
.	O

Table	O
2	O
.	O

Haptens	O
unable	O
to	O
inhibit	O
binding	O
of	O
RSA	O
-	O
APPC	O
to	O
anti	O
-	O
APPC	O
antibodies	O
"	O
Acetylcholine	O
Phenyltrimethylammonium	O
p	O
-	O
Aminophenyltrimethylammonium	O
chloride	O
Phenylarsonate	O
p	O
-	O
Nitrophenylarsonate	O
p	O
-	O
lodophenylarsonate	O
Hydroxyphenylazo	O
)	O
phenylarsonate	O
p	O
-	O
lodobenzenesulfonate	O
Naphthalene	O
-	O
l	O
-	O
sulfonate	O
5-Nitro-3-iodo-4-hydroxyphenylacetate	O
5-Nitro-4-hydroxyphenylacetate	O
Kre	O
,	O
<	O
0.0001	O
,	O
relative	O
to	O
NPPC	O
,	O
which	O
is	O
equivalent	O
to	O
<	O
50	O
%	O
inhibition	O
at	O
0.1	O
M	O
hapten	O
concentration	O
.	O

903	O
HOPC-8	O
100	O
PC	O
WPC	O
I	O
-	O
Ap	O
GPC	O
AcC	O
m	O
50	O
z	O
_	O
<	O
60P	O
Y	O
,	O
OOPO=3	O
~	O
OP	O
03	O
0	O
ITS	O
I	O
I	O
INHIBITOR	O
CONC	O
.	O

(	O
M	O
)	O
IT	O
2	O
IT	O
l	O
Fig.	O
3	O
.	O

Plots	O
of	O
the	O
inhibition	O
by	O
haptens	O
of	O
the	O
binding	O
of	O
RSA	O
-	O
APPC	O
antigen	O
to	O
mouse	B
myeloma	O
protein	O
HOPC-8	O
.	O

The	O
ratio	O
obtained	O
using	O
K	O
,	O
e	O
,	O
values	O
obtained	O
by	O
hapten	O
inhibition	O
(	O
Table	O
3	O
)	O
is	O
2.9	O
,	O
a	O
satisfactory	O
agreement	O
.	O

DISCUSSION	O
The	O
relative	O
binding	O
constants	O
(	O
K	O
,	O
,	O
,	O
)	O
for	O
haptens	O
to	O
anti	O
-	O
APPC	O
antibodies	O
were	O
determined	O
by	O
hapten	O
inhibition	O
.	O

About	O
30	O
potential	O
ligands	O
were	O
tested	O
and	O
only	O
5	O
of	O
these	O
were	O
shown	O
to	O
bind	O
significantly	O
(	O
NPPC	O
,	O
glycerophosphorylcholine	O
,	O
I	O
-	O
Ap	O
,	O
choline	O
and	O
phosphorylcholine	O
)	O
.	O

The	O
values	O
of	O
K	O
,	O
,	O
,	O
obtained	O
with	O
the	O
several	O
haptens	O
allow	O
inferences	O
as	O
to	O
the	O
relative	O
importance	O
of	O
the	O
particular	O
structural	O
features	O
of	O
each	O
hapten	O
in	O
contributing	O
to	O
the	O
binding	O
energy	O
.	O

The	O
rabbit	B
anti	O
-	O
APPC	O
antibodies	O
studied	O
here	O
were	O
raised	O
against	O
a	O
hapten	O
having	O
3	O
distinct	O
structural	O
features	O
-	O
a	O
p	O
-	O
azophenyl	O
group	O
,	O
a	O
negatively	O
charged	O
phosphoryl	O
ester	O
group	O
,	O
and	O
a	O
positively	O
charged	O
quarternary	O
ammonium	O
group	O
.	O

Of	O
these	O
,	O
the	O
one	O
apparently	O
very	O
important	O
for	O
binding	O
is	O
the	O
positively	O
charged	O
group	O
,	O
since	O
haptens	O
which	O
were	O
most	O
effective	O
in	O
inhibiting	O
the	O
binding	O
of	O
the	O
APPC	O
-	O
containing	O
antigen	O
to	O
antibody	O
contained	O
this	O
group	O
(	O
Table	O
1	O
)	O
and	O
those	O
least	O
effective	O
did	O
not	O
.	O

Thus	O
,	O
removal	O
of	O
the	O
choline	O
group	O
from	O
phenylphosphorylcholine	O
decreases	O
its	O
binding	O
strength	O
by	O
a	O
factor	O
of	O
about	O
Table	O
3	O
.	O

Comparison	O
of	O
K	O
,	O
e	O
,	O
values	O
for	O
HOPC-8	O
,	O
TEPC-15	O
and	O
a	O
rabbit	B
anti	O
-	O
APPC	O
antibody	O
Hapten	O
HOPC-8	O
2.9	O
1.0	O
0.5	O
0.033	O
0.015	O
0.01	O
"	O
0.001	O
<	O
0.0001	O
Rabbit	B
anti	O
APPC	O
-	O
No	O
.	O

6055	O
K	O
,	O
TEPC-15	O
Phosphorylcholine	O
NPPC	O
-a	O
-	O
glycerophosphorylchole	O
I	O
-	O
Ap	O
Acetylcholine	O
Choline	O
Phenylphosphate	O
Phenylphosphonate	O
2.9	O
0.0004	O
1.0	O
0.019	O
0.0001	O
0.0001	O
0.008	O
0.00006	O
0.005	O
0.0001	O
-	O
0.0002	O
-	O
0.27	O
Calculated	O
from	O
the	O
data	O
of	O
Leon	O
&	O
Young	O
(	O
1971	O
)	O
for	O
the	O
inhibition	O
of	O
binding	O
of	O
c	O
-	O
polysaccharide	O
of	O
Pneumococcus	B
.	O

The	O
values	O
were	O
obtained	O
by	O
setting	O
the	O
Kre	O
,	O
value	O
for	O
phosphorylchole	O
at	O
2.9	O
and	O
calculating	O
the	O
other	O
values	O
relative	O
to	O
this	O
.	O

"	O
Estimated	O
from	O
the	O
value	O
of	O
Kre	O
,	O
for	O
choline	O
with	O
TEPC-15	O
.	O

904	O
L.	O
M.	O
KRAUSZ	O
,	O
A.	O
L.	O
GROSSBERG	O
and	O
D.	O
PRESSMAN	O
10,000	O
since	O
K	O
,	O
e	O
,	O
for	O
phenylphosphate	O
was	O
at	O
least	O
this	O
much	O
smaller	O
than	O
the	O
K	O
,	O
e	O
,	O
for	O
NPPC	O
(	O
Table	O
1	O
)	O
.	O

Moreover	O
,	O
p	O
-	O
iodophenyltrimethylammonium	O
gave	O
detectable	O
inhibition	O
with	O
one	O
anti	O
-	O
APPC	O
preparation	O
,	O
although	O
its	O
structure	O
is	O
otherwise	O
rather	O
different	O
from	O
the	O
choline	O
inhibitors	O
.	O

The	O
p	O
-	O
nitrophenyl	O
group	O
of	O
NPPC	O
contributes	O
very	O
effectively	O
to	O
the	O
specific	O
interaction	O
,	O
since	O
replacing	O
it	O
by	O
the	O
glycerol	O
group	O
decreases	O
the	O
binding	O
by	O
a	O
factor	O
of	O
50	O
(	O
Table	O
1	O
)	O
.	O

Similarly	O
,	O
removing	O
the	O
p	O
-	O
nitrophenyl	O
group	O
,	O
to	O
give	O
phosphorylcholine	O
,	O
decreases	O
the	O
binding	O
by	O
another	O
factor	O
of	O
50	O
(	O
Table	O
1	O
)	O
so	O
that	O
phosphorylcholine	O
binds	O
2500	O
times	O
more	O
weakly	O
than	O
NPPC	O
.	O

The	O
negatively	O
charged	O
phosphoryl	O
group	O
apparently	O
interacts	O
only	O
to	O
a	O
small	O
extent	O
with	O
the	O
antibody	O
site	O
.	O

This	O
is	O
evident	O
from	O
the	O
fact	O
that	O
K	O
,	O
,	O
,	O
for	O
phosphorylcholine	O
is	O
only	O
6	O
-	O
8	O
times	O
greater	O
than	O
Kre	O
,	O
for	O
choline	O
for	O
2	O
antibody	O
preparations	O
studied	O
and	O
is	O
actually	O
smaller	O
than	O
that	O
for	O
choline	O
for	O
the	O
third	O
antibody	O
preparation	O
(	O
Table	O
1	O
)	O
.	O

In	O
addition	O
,	O
phenylphosphate	O
(	O
Table	O
2	O
)	O
and	O
phenylphosphonate	O
(	O
Table	O
1	O
)	O
show	O
only	O
weak	O
binding	O
to	O
the	O
antibodies	O
.	O

Thus	O
the	O
contribution	O
of	O
the	O
negative	O
charge	O
to	O
binding	O
is	O
not	O
great	O
,	O
in	O
spite	O
of	O
the	O
fact	O
that	O
we	O
have	O
previously	O
shown	O
(	O
Krausz	O
et	O
al.	O
,	O
1976	O
)	O
that	O
a	O
positively	O
charged	O
arginyl	O
residue	O
is	O
present	O
in	O
the	O
anti	O
-	O
APPC	O
antibody	O
site	O
,	O
providing	O
a	O
basis	O
for	O
electrostatic	O
interaction	O
with	O
the	O
phosphoryl	O
group	O
.	O

When	O
the	O
rabbit	B
anti	O
-	O
APPC	O
antibodies	O
are	O
compared	O
to	O
the	O
mouse	B
myeloma	O
protein	O
,	O
HOPC-8	O
,	O
some	O
very	O
obvious	O
differences	O
in	O
specificity	O
are	O
apparent	O
.	O

In	O
general	O
HOPC-8	O
shows	O
broader	O
cross	O
-	O
reactivity	O
than	O
the	O
induced	O
rabbit	B
antibody	O
.	O

The	O
representative	O
comparison	O
of	O
K	O
,	O
e	O
,	O
values	O
(	O
relative	O
to	O
NPPC	O
)	O
given	O
in	O
Table	O
3	O
,	O
indicates	O
that	O
many	O
more	O
of	O
the	O
compounds	O
listed	O
show	O
appreciable	O
binding	O
(	O
K	O
,	O
e	O
,	O
>	O
0.005	O
)	O
to	O
HOPC-8	O
than	O
to	O
rabbit	B
anti	O
-	O
APPC	O
.	O

In	O
addition	O
,	O
the	O
fine	O
specificity	O
of	O
HOPC-8	O
is	O
quite	O
different	O
from	O
that	O
of	O
the	O
rabbit	B
antibody	O
,	O
since	O
the	O
relative	O
binding	O
constant	O
for	O
phosphorylcholine	O
is	O
10	O
'	O
greater	O
with	O
HOPC-8	O
than	O
with	O
rabbit	B
anti	O
-	O
APPC	O
.	O

The	O
binding	O
to	O
the	O
2	O
proteins	O
differs	O
for	O
glycerophosphorylcholine	O
by	O
a	O
factor	O
of	O
25	O
,	O
for	O
chohne	O
by	O
a	O
factor	O
of	O
100	O
and	O
for	O
acetylcholine	O
by	O
a	O
factor	O
greater	O
than	O
100	O
.	O

The	O
negatively	O
charged	O
phosphoryl	O
group	O
appears	O
to	O
be	O
much	O
more	O
important	O
for	O
binding	O
to	O
HOPC-8	O
than	O
to	O
the	O
rabbit	B
antibody	O
,	O
since	O
the	O
K-	O
,	O
value	O
for	O
phosphorylcholine	O
is	O
greater	O
than	O
that	O
for	O
choline	O
by	O
a	O
factor	O
of	O
about	O
300	O
in	O
the	O
case	O
of	O
HOPC-8	O
.	O

For	O
rabbit	B
antibody	O
this	O
factor	O
is	O
only	O
about	O
10	O
(	O
Table	O
3	O
)	O
.	O

Moreover	O
,	O
phenylphosphate	O
binds	O
more	O
than	O
10	O
times	O
more	O
strongly	O
to	O
HOPC-8	O
than	O
to	O
anti	O
-	O
APPC	O
antibody	O
.	O

This	O
is	O
in	O
spite	O
of	O
the	O
fact	O
that	O
the	O
addition	O
of	O
the	O
p	O
-	O
nitrophenyl	O
group	O
to	O
phosphorylcholine	O
neither	O
adds	O
to	O
nor	O
subtracts	O
from	O
the	O
binding	O
energy	O
with	O
HOPC-8	O
,	O
whereas	O
it	O
adds	O
a	O
great	O
deal	O
to	O
the	O
binding	O
energy	O
with	O
anti	O
-	O
APPC	O
antibody	O
.	O

The	O
fact	O
that	O
the	O
HOPC-8	O
site	O
is	O
large	O
enough	O
to	O
accommodate	O
the	O
p	O
-	O
nitrophenyl	O
group	O
of	O
NPPC	O
with	O
little	O
steric	O
hindrance	O
is	O
of	O
interest	O
,	O
since	O
the	O
site	O
of	O
McPC-603	O
protein	O
,	O
which	O
also	O
binds	O
phosphorylcholine	O
analogues	O
with	O
similar	O
although	O
not	O
identical	O
specificity	O
(	O
Leon	O
&	O
Young	O
,	O
1971	O
)	O
also	O
can	O
accommodate	O
a	O
large	O
substituent	O
on	O
phosphorylcholine	O
.	O

Thus	O
,	O
the	O
X	O
-	O
ray	O
crystallographic	O
structure	O
studies	O
of	O
the	O
Fab	O
fragment	O
of	O
McPC-603	O
as	O
summarized	O
by	O
Segal	O
et	O
al.	O
(	O
1974	O
)	O
indicate	O
that	O
there	O
is	O
a	O
large	O
region	O
of	O
the	O
cleft	O
in	O
which	O
phosphorylcholine	O
is	O
bound	O
which	O
is	O
available	O
for	O
binding	O
additional	O
structure	O
.	O

Indeed	O
,	O
one	O
of	O
the	O
compounds	O
used	O
in	O
defining	O
the	O
site	O
region	O
was	O
2-	O
(	O
5'-acetoxy	O
-	O
mercury-2'-thiemyl	O
)	O
-ethylphosphory1choline	O
(	O
Padlan	O
et	O
al.	O
,	O
1973	O
)	O
.	O

Our	O
studies	O
suggest	O
that	O
this	O
large	O
compound	O
might	O
bind	O
equally	O
as	O
well	O
to	O
the	O
HOPC-8	O
site	O
as	O
to	O
the	O
McPC-603	O
site	O
.	O

The	O
differences	O
between	O
HOPC-8	O
sites	O
and	O
rabbit	B
anti	O
-	O
APPC	O
sites	O
are	O
interesting	O
in	O
view	O
of	O
the	O
fact	O
that	O
when	O
APPC	O
conjugated	O
to	O
protein	O
is	O
used	O
as	O
an	O
immunogen	O
in	O
the	O
BALB	B
/	I
c	I
mouse	I
,	O
the	O
IgM	O
antibodies	O
elicited	O
are	O
largely	O
of	O
the	O
HOPC-8-TEPC-15	O
idiotype	O
and	O
show	O
the	O
same	O
binding	O
characteristics	O
as	O
the	O
myeloma	O
proteins	O
(	O
Lee	O
it	O
al.	O
,	O
1974	O
)	O
.	O

Thus	O
it	O
appears	O
that	O
the	O
receptor	O
sites	O
on	O
cells	O
responding	O
to	O
APPC	O
in	O
the	O
rabbits	B
we	O
used	O
are	O
quite	O
different	O
in	O
structure	O
from	O
sites	O
on	O
cells	O
which	O
respond	O
in	O
the	O
mouse	B
.	O

Furthermore	O
,	O
we	O
have	O
previously	O
observed	O
that	O
the	O
rabbit	B
antibodies	O
are	O
rather	O
heterogeneous	O
,	O
as	O
evidenced	O
by	O
their	O
non	O
-	O
linear	O
binding	O
curves	O
(	O
Krausz	O
et	O
al.	O
,	O
1976	O
)	O
,	O
and	O
their	O
complex	O
isoelectric	O
focusing	O
patterns	O
(	O
Nutt	O
et	O
al.	O
,	O
1976	O
)	O
.	O

Populations	O
of	O
anti	O
-	O
APPC	O
antibodies	O
produced	O
also	O
differ	O
from	O
rabbit	B
to	O
rabbit	B
as	O
evidenced	O
by	O
the	O
differences	O
in	O
binding	O
strength	O
for	O
p	O
-	O
iodophenyltrimethylammonium	O
and	O
for	O
choline	O
shown	O
by	O
antibodies	O
from	O
rabbits	B
6055	B
and	O
5920	B
(	O
Table	O
1	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
induced	O
mouse	B
antibodies	O
appear	O
to	O
be	O
essentially	O
monoclonal	O
products	O
(	O
Lee	O
et	O
al.	O
,	O
1974	O
)	O
.	O

There	O
are	O
,	O
of	O
course	O
,	O
some	O
similarities	O
between	O
the	O
rabbit	B
antibodies	O
and	O
HOPC-8	O
.	O

The	O
major	O
of	O
these	O
is	O
that	O
for	O
both	O
binding	O
sites	O
the	O
positively	O
charged	O
quarternary	O
ammonium	O
group	O
appears	O
to	O
be	O
the	O
immunodominant	O
group	O
,	O
since	O
those	O
haptens	O
not	O
containing	O
this	O
group	O
are	O
bound	O
very	O
poorly	O
in	O
both	O
cases	O
(	O
Table	O
3	O
)	O
.	O

Thus	O
a	O
negatively	O
charged	O
carboxylate	O
group	O
which	O
would	O
interact	O
with	O
this	O
group	O
,	O
and	O
which	O
we	O
have	O
shown	O
to	O
be	O
present	O
in	O
the	O
combining	O
site	O
of	O
both	O
HOPC-8	O
and	O
anti	O
-	O
APPC	O
antibodies	O
,	O
is	O
probably	O
the	O
most	O
important	O
common	O
feature	O
of	O
both	O
sites	O
.	O

The	O
above	O
considerations	O
allow	O
us	O
to	O
make	O
the	O
following	O
inferences	O
about	O
the	O
topography	O
of	O
the	O
antiAPPC	O
and	O
HOPC-8	O
binding	O
sites	O
:	O
(	O
1	O
)	O
The	O
anti	O
-	O
APPC	O
site	O
contains	O
a	O
region	O
closely	O
complementary	O
to	O
the	O
phenyl	O
group	O
of	O
APPC	O
,	O
so	O
that	O
an	O
appreciable	O
part	O
ofAhe	O
binding	O
interaction	O
occurs	O
in	O
this	O
region	O
.	O

The	O
HOPC-8	O
site	O
accommodates	O
the	O
phenyl	O
group	O
with	O
little	O
interaction	O
energy	O
.	O

(	O
2	O
)	O
An	O
arginyl	O
residue	O
in	O
the	O
HOPC-8	O
site	O
contributes	O
a	O
positive	O
charge	O
which	O
interacts	O
strongly	O
with	O
the	O
negative	O
charge	O
on	O
the	O
phosphoryl	O
group	O
.	O

In	O
the	O
anti	O
-	O
APPC	O
site	O
,	O
which	O
also	O
contains	O
an	O
arginyl	O
residue	O
,	O
the	O
interaction	O
with	O
the	O
phosphoryl	O
group	O
is	O
much	O
weaker	O
,	O
and	O
therefore	O
the	O
2	O
groups	O
are	O
probably	O
farther	O
apart	O
than	O
in	O
the	O
HOPC-8	O
site	O
.	O

(	O
3	O
)	O
Both	O
sites	O
interact	O
strongly	O
with	O
the	O
quaternary	O
ammonium	O
group	O
of	O
choline	O
and	O
thus	O
this	O
group	O
probably	O
closely	O
approaches	O
a	O
carboxylate	O
group	O
present	O
in	O
both	O
sites	O
.	O

Acknowledgements	O
-	O
We	O
thank	O
Messrs.	O
Robert	O
Hewson	O
,	O
Leonard	O
Rendina	O
and	O
Arthur	O
Trott	O
for	O
expert	O
technical	O
assistance	O
.	O

Specificity	O
of	O
Anti	O
-	O
p	O
-	O
Azophenylphosphorylcholine	O
Antibodies	O

Manganous	O
chloride	O
and	O
Congo	O
red	O
incorporated	O
into	O
blotting	O
paper	O
discs	O
have	O
been	O
used	O
to	O
differentiate	O
gonococci	B
from	O
meningococci	B
.	O

The	O
new	O
technique	O
is	O
simple	O
and	O
reliable	O
;	O
the	O
materials	O
for	O
the	O
test	O
are	O
inexpensive	O
.	O

The	O
method	O
will	O
increase	O
the	O
efficiency	O
of	O
distinguishing	O
between	O
the	O
pathogenic	O
Neisseria	B
in	O
any	O
clinical	O
bacteriology	O
laboratory	O
and	O
especially	O
in	O
those	O
in	O
the	O
tropical	O
areas	O
.	O

A	O
methodology	O
to	O
determine	O
the	O
intrinsic	O
capacities	O
of	O
a	O
microflora	B
to	O
degrade	O
gasoline	O
was	O
developed	O
,	O
in	O
particular	O
for	O
assessing	O
the	O
potential	O
of	O
autochtonous	O
populations	O
of	O
polluted	O
and	O
non	O
polluted	O
soils	O
for	O
natural	O
attenuation	O
and	O
engineered	O
bioremediation	O
.	O

A	O
model	O
mixture	O
(	O
GM23	O
)	O
constituted	O
of	O
the	O
23	O
most	O
representative	O
hydrocarbons	O
of	O
a	O
commercial	O
gasoline	O
was	O
used	O
.	O

The	O
capacities	O
of	O
the	O
microflorae	B
(	O
kinetics	O
and	O
extent	O
of	O
biodegradation	O
)	O
were	O
assessed	O
by	O
chromatographic	O
analysis	O
of	O
hydrocarbon	O
consumption	O
and	O
of	O
CO2	O
production	O
.	O

The	O
degradation	O
of	O
the	O
components	O
of	O
GM23	O
was	O
assayed	O
in	O
separate	O
incubations	O
of	O
each	O
component	O
and	O
in	O
the	O
complete	O
mixture	O
.	O

For	O
the	O
microflora	B
of	O
an	O
unpolluted	O
spruce	B
forest	O
soil	O
,	O
all	O
hydrocarbons	O
of	O
GM23	O
except	O
cyclohexane	O
,	O
2,2,4-	O
and	O
2,3,4-trimethylpentane	O
isomers	O
were	O
degraded	O
to	O
below	O
detection	O
limit	O
in	O
28	O
days	O
.	O

This	O
microflora	B
was	O
reinforced	O
with	O
two	O
mixed	O
microbial	O
communities	O
selected	O
from	O
gasoline	O
-	O
polluted	O
sites	O
and	O
shown	O
to	O
degrade	O
cyclohexane	O
and	O
2,2,4-trimethylpentane	O
.	O

With	O
the	O
reinforced	O
microflora	B
,	O
complete	O
degradation	O
of	O
GM23	O
was	O
observed	O
.	O

The	O
degradation	O
patterns	O
of	O
individual	O
components	O
of	O
GM23	O
were	O
similar	O
when	O
the	O
compounds	O
were	O
present	O
individually	O
or	O
in	O
the	O
GM23	O
mixture	O
,	O
as	O
long	O
as	O
the	O
concentrations	O
of	O
2-ethyltoluene	O
and	O
trimethylbenzene	O
isomers	O
were	O
kept	O
sufficiently	O
low	O
(	O
<	O
or	O
=	O
35	O
mg.l-1	O
)	O
to	O
remain	O
below	O
their	O
inhibitory	O
level	O
.	O

The	O
first	O
acyclonucleosides	O
based	O
on	O
the	O
benzothiadiazine	O
dioxide	O
system	O
were	O
synthesized	O
following	O
the	O
silylation	O
procedure	O
.	O

Several	O
acyclic	O
moieties	O
,	O
including	O
acetoxyethoxymethyl	O
,	O
benzyloxymethyl	O
,	O
and	O
propargyloxymethyl	O
groups	O
,	O
were	O
introduced	O
.	O

Two	O
synthetic	O
strategies	O
were	O
designed	O
to	O
selectively	O
obtain	O
the	O
N-1	O
or	O
N-3	O
derivatives	O
.	O

Lipase	O
-	O
mediated	O
deacylation	O
was	O
used	O
for	O
the	O
deprotection	O
of	O
the	O
acyclonucleosides	O
.	O

Some	O
of	O
the	O
benzothiadiazine	O
dioxide	O
acyclonucleosides	O
,	O
in	O
particular	O
16	O
,	O
proved	O
active	O
against	O
human	O
cytomegalovirus	O
(	O
CMV	O
)	O
at	O
concentrations	O
slightly	O
higher	O
than	O
that	O
found	O
for	O
ganciclovir	O
[	O
50	O
%	O
inhibitory	O
concentration	O
(	O
IC50	O
)	O
=	O
3	O
.	O
5	O
-	O
3.7	O
micrograms	O
/	O
mL	O
,	O
cytotoxicity	O
(	O
CC50	O
)	O
>	O
/=	O
40	O
micrograms	O
/	O
mL	O
,	O
MCC	O
=	O
20	O
micrograms	O
/	O
mL	O
]	O
.	O

Additionally	O
,	O
compound	O
16	O
inhibited	O
the	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
and	O
HIV-2	O
in	O
CEM	O
cells	O
at	O
concentrations	O
that	O
were	O
5-fold	O
lower	O
than	O
its	O
cytotoxic	O
concentration	O
.	O

To	O
examine	O
the	O
stereospecific	O
effects	O
of	O
lipoic	O
compounds	O
on	O
pyruvate	O
metabolism	O
,	O
the	O
effects	O
of	O
R	O
-	O
lipoic	O
acid	O
(	O
R	O
-	O
LA	O
)	O
,	O
S	O
-	O
lipoic	O
acid	O
(	O
S	O
-	O
LA	O
)	O
and	O
1,2-diselenolane-3-pentanoic	O
acid	O
(	O
Se	O
-	O
LA	O
)	O
on	O
the	O
activities	O
of	O
the	O
mammalian	B
pyruvate	O
dehydrogenase	O
complex	O
(	O
PDC	O
)	O
and	O
its	O
catalytic	O
components	O
were	O
investigated	O
.	O

Both	O
S	O
-	O
LA	O
and	O
R	O
-	O
LA	O
markedly	O
inhibited	O
PDC	O
activity	O
;	O
whereas	O
Se	O
-	O
LA	O
displayed	O
inhibition	O
only	O
at	O
higher	O
concentrations	O
.	O

Examination	O
of	O
the	O
effects	O
on	O
the	O
individual	O
catalytic	O
components	O
indicated	O
that	O
Se	O
-	O
LA	O
inhibited	O
the	O
pyruvate	O
dehydrogenase	O
component	O
;	O
whereas	O
R	O
-	O
LA	O
and	O
S	O
-	O
LA	O
inhibited	O
the	O
dihydrolipoamide	O
acetyltransferase	O
component	O
.	O

The	O
three	O
lipoic	O
compounds	O
lowered	O
dihydrolipoamide	O
dehydrogrenase	O
(	O
E3	O
)	O
activity	O
in	O
the	O
forward	O
reaction	O
by	O
about	O
30	O
to	O
45	O
%	O
.	O

The	O
kinetic	O
data	O
of	O
E3	O
showed	O
that	O
both	O
R	O
-	O
LA	O
and	O
Se	O
-	O
LA	O
are	O
used	O
as	O
substrates	O
by	O
E3	O
for	O
the	O
reverse	O
reaction	O
.	O

Decarboxylation	O
of	O
[	O
1	O
-	O
14C	O
]	O
pyruvate	O
via	O
PDC	O
by	O
cultured	O
HepG2	O
cells	O
was	O
not	O
affected	O
by	O
R	O
-	O
LA	O
,	O
but	O
moderately	O
decreased	O
with	O
S	O
-	O
LA	O
and	O
Se	O
-	O
LA	O
.	O

These	O
findings	O
indicate	O
that	O
(	O
i	O
)	O
purified	O
PDC	O
and	O
its	O
catalytic	O
components	O
are	O
affected	O
by	O
lipoic	O
compounds	O
based	O
on	O
their	O
stereoselectivity	O
;	O
and	O
(	O
ii	O
)	O
the	O
oxidation	O
of	O
pyruvate	O
by	O
intact	O
HepG2	O
cells	O
is	O
not	O
inhibited	O
by	O
R	O
-	O
LA	O
.	O

The	O
later	O
finding	O
with	O
the	O
intact	O
cells	O
is	O
in	O
support	O
of	O
therapeutic	O
role	O
of	O
R	O
-	O
LA	O
as	O
an	O
antioxidant	O
.	O

A	O
highly	O
sensitive	O
pre	O
-	O
column	O
HPLC	O
method	O
for	O
simultaneous	O
determination	O
of	O
prolyl	O
dipeptides	O
,	O
Pro	O
and	O
Hyp	O
in	O
urine	O
was	O
developed	O
.	O

The	O
analytes	O
were	O
labelled	O
with	O
4-	O
(	O
5,6-dimethoxy-2-phthalimidinyl	O
)	O
-2-methoxyphenylsulfonyl	O
chloride	O
at	O
70	O
degrees	O
C	O
for	O
20	O
min	O
.	O

The	O
derivatives	O
separated	O
on	O
tandem	O
reversed	O
-	O
phase	O
columns	O
by	O
a	O
gradient	O
elution	O
and	O
were	O
monitored	O
with	O
fluorescence	O
detection	O
at	O
318	O
nm	O
(	O
excitation	O
)	O
and	O
392	O
nm	O
(	O
emission	O
)	O
.	O

The	O
detection	O
limits	O
for	O
prolyl	O
dipeptides	O
,	O
Pro	O
and	O
Hyp	O
were	O
1	O
-	O
5	O
fmol	O
/	O
injection	O
(	O
S	O
/	O
N	O
=	O
3	O
)	O
.	O

Urine	O
samples	O
were	O
treated	O
with	O
o	O
-	O
phthalaldehyde	O
,	O
followed	O
by	O
purification	O
on	O
a	O
Bond	O
Elut	O
C18	O
column	O
before	O
conducting	O
the	O
labelling	O
reaction	O
.	O

Pro	O
-	O
Hyp	O
,	O
Pro	O
-	O
Gly	O
and	O
Pro	O
-	O
Pro	O
were	O
identified	O
as	O
prolyl	O
dipeptides	O
in	O
urine	O
.	O

The	O
within	O
-	O
day	O
and	O
between	O
-	O
day	O
relative	O
standard	O
deviations	O
were	O
1.5	O
-	O
4.8	O
and	O
1.7	O
-	O
5.8	O
%	O
,	O
respectively	O
.	O

The	O
concentrations	O
of	O
Pro	O
-	O
Hyp	O
,	O
Pro	O
-	O
Gly	O
,	O
Pro	O
-	O
Pro	O
,	O
Pro	O
and	O
Hyp	O
in	O
normal	O
human	B
urine	O
were	O
97.6	O
+	O
/-	O

28.2	O
,	O
2.74	O
+	O
/-	O

1.48	O
,	O
2.08	O
+	O
/-	O

1.13	O
,	O
6.71	O
+	O
/-	O

3.34	O
and	O
2.30	O
+	O
/-	O

1.59	O
nmol	O
/	O
mg	O
creatinine	O
,	O
respectively	O
.	O

An	O
enzyme	O
with	O
lipase	O
and	O
esterase	O
activity	O
was	O
purified	O
from	O
bovine	B
pancreas	O
.	O

Furthermore	O
,	O
a	O
non	O
-	O
radioactive	O
lipase	O
assay	O
was	O
developed	O
which	O
is	O
100	O
times	O
more	O
sensitive	O
than	O
the	O
conventional	O
methods	O
and	O
allowed	O
the	O
characterization	O
of	O
the	O
lipase	O
activity	O
of	O
the	O
enzyme	O
.	O

The	O
lipase	O
activity	O
increased	O
42	O
times	O
in	O
the	O
presence	O
of	O
10	O
mM	O
sodium	O
taurocholate	O
,	O
which	O
for	O
the	O
first	O
time	O
provides	O
direct	O
evidence	O
that	O
a	O
bile	O
salt	O
-	O
activated	O
lipase	O
(	O
bp	O
-	O
BAL	O
)	O
was	O
isolated	O
from	O
bovine	B
pancreas	O
.	O

This	O
conclusion	O
is	O
further	O
supported	O
by	O
the	O
fact	O
that	O
the	O
N	O
-	O
terminal	O
amino	O
acid	O
sequence	O
of	O
this	O
lipase	O
/	O
esterase	O
is	O
88	O
%	O
homologous	O
to	O
human	B
milk	O
BAL	O
and	O
human	B
pancreatic	O
BAL	O
.	O

Staining	O
with	O
various	O
lectins	O
showed	O
that	O
bp	O
-	O
BAL	O
is	O
a	O
glycoprotein	O
which	O
contains	O
fucose	O
residues	O
.	O

Previously	O
from	O
bovine	B
pancreas	O
a	O
lysophospholipase	O
has	O
been	O
purified	O
and	O
a	O
gene	O
was	O
cloned	O
and	O
sequenced	O
encoding	O
an	O
enzyme	O
with	O
cholesterol	O
esterase	O
/	O
lysophospholipase	O
activity	O
.	O

Comparison	O
of	O
the	O
N	O
-	O
terminal	O
amino	O
acid	O
sequence	O
of	O
bp	O
-	O
BAL	O
with	O
the	O
deduced	O
amino	O
acid	O
sequence	O
of	O
the	O
latter	O
revealed	O
that	O
they	O
are	O
identical	O
.	O

Furthermore	O
,	O
the	O
molecular	O
weight	O
of	O
the	O
purified	O
bp	O
-	O
BAL	O
of	O
63,000	O
,	O
as	O
estimated	O
by	O
SDS	O
-	O
PAGE	O
,	O
is	O
very	O
similar	O
to	O
that	O
of	O
the	O
purified	O
lysophospholipase	O
(	O
65,000	O
)	O
and	O
to	O
the	O
theoretical	O
molecular	O
weight	O
of	O
65,147	O
of	O
the	O
cholesterol	O
esterase	O
/	O
lysophospholipase	O
.	O

These	O
data	O
suggest	O
that	O
these	O
three	O
enzymes	O
are	O
one	O
and	O
the	O
same	O
.	O

The	O
antioxidant	O
activity	O
of	O
Eriobotrya	B
japonica	I
was	O
determined	O
by	O
measuring	O
the	O
radical	O
scavenging	O
effect	O
on	O
DPPH	O
(	O
1,1-diphenyl-2-picrylhydrazyl	O
)	O
radical	O
and	O
lipid	O
peroxidation	O
produced	O
when	O
mouse	B
liver	O
homogenate	O
was	O
exposed	O
to	O
the	O
air	O
at	O
37	O
degrees	O
C	O
,	O
using	O
2-thiobarbituric	O
acid	O
(	O
TBA	O
)	O
.	O

The	O
methanol	O
extract	O
and	O
its	O
fractions	O
of	O
Eriobotrya	B
japonica	I
leaves	O
showed	O
strong	O
antioxidant	O
activity	O
.	O

The	O
antioxidant	O
activity	O
of	O
EtOAc	O
and	O
n	O
-	O
BuOH	O
soluble	O
fractions	O
were	O
stronger	O
than	O
the	O
others	O
,	O
and	O
were	O
further	O
purified	O
by	O
repeated	O
silica	O
gel	O
,	O
MCl	O
gel	O
CHP-20P	O
,	O
and	O
Sephadex	O
LH-20	O
column	O
chromatography	O
.	O

Antioxidant	O
chlorogenic	O
acid	O
,	O
quercetin-3-sambubioside	O
from	O
n	O
-	O
BuOH	O
fraction	O
,	O
and	O
methyl	O
chlorogenate	O
,	O
kaempferol-	O
and	O
quercetin-3-rhamnosides	O
,	O
together	O
with	O
the	O
inactive	O
ursolic	O
acid	O
and	O
2	O
alpha	O
-	O
hydroxyursolic	O
acid	O
from	O
EtOAc	O
fraction	O
were	O
isolated	O
.	O

Antioxidant	O
flavonoids	O
and	O
chlorogenic	O
acid	O
also	O
showed	O
prominent	O
inhibitory	O
activity	O
against	O
free	O
radical	O
generation	O
in	O
dichlorofluorescein	O
(	O
DCF	O
)	O
method	O
.	O

The	O
synthesis	O
and	O
the	O
antimicrobial	O
properties	O
of	O
a	O
new	O
series	O
of	O
cephalosporinic	O
beta	O
-	O
lactam	O
antibiotics	O
is	O
described	O
.	O

The	O
data	O
reported	O
in	O
the	O
present	O
paper	O
show	O
the	O
potential	O
of	O
this	O
type	O
of	O
substituted	O
cephalosporins	O
as	O
new	O
anti	O
Gram	O
-	O
positive	O
antibiotic	O
drugs	O
.	O

In	O
fact	O
,	O
all	O
compounds	O
tested	O
showed	O
a	O
good	O
in	O
vitro	O
antibacterial	O
activity	O
against	O
the	O
most	O
relevant	O
Gram	B
-	I
positive	I
pathogens	I
including	O
resistant	O
species	O
that	O
currently	O
represent	O
unmet	O
medical	O
need	O
.	O

On	O
the	O
contrary	O
,	O
the	O
new	O
synthesized	O
compounds	O
were	O
found	O
to	O
be	O
completely	O
devoid	O
of	O
any	O
activity	O
on	O
Gram	B
-	I
negative	I
bacteria	I
up	O
to	O
a	O
concentration	O
of	O
the	O
single	O
agent	O
of	O
128	O
microg	O
/	O
ml	O
.	O

The	O
hydroxylation	O
at	O
C-2	O
of	O
testosterone	O
and	O
5alpha	O
-	O
dihydrotestosterone	O
is	O
measured	O
by	O
isolation	O
of	O
HTO	O
after	O
incubating	O
"	O
metabolically	O
labile	O
"	O
tritium	O
labeled	O
steroids	O
with	O
the	O
enzymes	O
.	O

After	O
hydroxylation	O
of	O
testosterone	O
in	O
rat	B
liver	O
2alpha	O
-	O
hydroxytestosterone	O
was	O
isolated	O
and	O
identified	O
by	O
gaschromatography	O
and	O
mass	O
spectra	O
.	O

Oxamniquine	O
(	O
1,2,3,4-tetrahydro-2-	O
[	O
(	O
isopropylamino	O
)	O
methyl	O
]	O
-7-nitro-6-quinoline	O
methanol	O
)	O
is	O
an	O
antischistosomal	O
agent	O
that	O
is	O
indicated	O
for	O
the	O
treatment	O
of	O
S.	B
mansoni	I
(	O
intestinal	O
schistosomiasis	O
)	O
infection	O
.	O

It	O
has	O
been	O
shown	O
to	O
inhibit	O
DNA	O
,	O
RNA	O
and	O
protein	O
synthesis	O
in	O
schistosomes	O
.	O

The	O
oral	O
bioavailability	O
of	O
oxamniquine	O
is	O
good	O
,	O
effective	O
plasma	O
levels	O
are	O
achieved	O
in	O
1–1.5	O
h	O
[	O
1	O
]	O
.	O

Oxamniquine	O
is	O
the	O
subject	O
of	O
a	O
monograph	O
in	O
the	O
US	O
Pharmacopoeia	O
(	O
USP	O
XXIII	O
)	O
[	O
2	O
]	O
whereby	O
a	O
spectrophotometric	O
method	O
is	O
recommended	O
for	O
its	O
determination	O
,	O
whether	O
in	O
its	O
pure	O
form	O
or	O
in	O
capsules	O
.	O

Other	O
reported	O
methods	O
include	O
spectrophotometry	O
[	O
3,4	O
]	O
,	O
non	O
-	O
aqueous	O
titration	O
[	O
5	O
]	O
,	O
gas	O
chromatography	O
[	O
6	O
]	O
,	O
high	O
-	O
performance	O
liquid	O
chromatography	O
[	O
7–11	O
]	O
,	O
polarography	O
[	O
12	O
]	O
,	O
capillary	O
electrophoresis	O
[	O
9	O
]	O
,	O
flow	O
-	O
injection	O
analysis	O
[	O
13	O
]	O
and	O
cyclic	O
voltammetry	O
[	O
14	O
]	O
.	O

The	O
above	O
-	O
mentioned	O
methods	O
are	O
either	O
not	O
sufficiently	O
sensitive	O
or	O
are	O
tedious	O
and	O
require	O
highly	O
sophisticated	O
instrumentation	O
.	O

Therefore	O
,	O
there	O
is	O
still	O
a	O
need	O
for	O
a	O
much	O
more	O
sensitive	O
and	O
simple	O
method	O
for	O
the	O
determination	O
of	O
oxamniquine	O
,	O
especially	O
in	O
biological	O
fluids	O
.	O

Fluorimetry	O
,	O
by	O
virtue	O
of	O
its	O
high	O
sensitivity	O
,	O
meets	O
this	O
requirement	O
.	O

Reviewing	O
the	O
literature	O
revealed	O
that	O
no	O
fluorimetric	O
methods	O
were	O
reported	O
for	O
oxamniquine	O
.	O

As	O
for	O
2-cyanoacetamide	O
,	O
it	O
has	O
been	O
recently	O
used	O
for	O
the	O
determination	O
of	O
aminoglycosides	O
[	O
15	O
]	O
,	O
reducing	O
carbohydrates	O
[	O
16–18	O
]	O
,	O
enzymatic	O
degradation	O
products	O
of	O
reducing	O
polysaccharides	O
[	O
19	O
]	O
and	O
catecholamines	O
[	O
20,21	O
]	O
.	O

The	O
aim	O
of	O
the	O
present	O
work	O
is	O
to	O
study	O
the	O
reaction	O
of	O
the	O
reduced	O
derivative	O
(	O
nitroso	O
)	O
of	O
oxamniquine	O
with	O
2-cyanoacetamide	O
in	O
an	O
attempt	O
to	O
develop	O
a	O
sensitive	O
fluorimetric	O
method	O
to	O
be	O
used	O
for	O
its	O
determination	O
in	O
biological	O
fluids	O
.	O

2	O
Experimental	O
2.1	O
Apparatus	O
An	O
Aminco	O
-	O
Bowman	O
Model	O
J4	O
-9860	O
spectrofluorometer	O
was	O
used	O
with	O
the	O
excitation	O
and	O
emission	O
slits	O
set	O
at	O
5	O
mm	O
.	O

A	O
1-cm	O
quartz	O
cell	O
was	O
used	O
for	O
all	O
measurements	O
.	O

2.2	O
Materials	O
and	O
reagents	O
All	O
the	O
chemicals	O
used	O
were	O
of	O
analytical	O
reagent	O
grade	O
,	O
while	O
the	O
solvents	O
were	O
of	O
the	O
spectroscopic	O
grade	O
.	O

A	O
pure	O
drug	O
sample	O
of	O
oxamniquine	O
was	O
kindly	O
supplied	O
by	O
Pfizer	O
(	O
Sandwich	O
,	O
UK	O
)	O
and	O
was	O
used	O
as	O
received	O
.	O

2-Cyanoacetamide	O
was	O
purchased	O
from	O
Aldrich	O
Chemical	O
Co.	O
Plasma	O
was	O
obtained	O
from	O
Mansoura	O
University	O
Hospital	O
,	O
Mansoura	O
(	O
Egypt	O
)	O
and	O
urine	O
was	O
obtained	O
from	O
healthy	O
volunteers	B
.	O

Freshly	O
prepared	O
10	O
%	O
aqueous	O
solution	O
of	O
calcium	O
chloride	O
and	O
4	O
%	O
aqueous	O
solution	O
of	O
2-cyanoacetamide	O
were	O
prepared	O
and	O
used	O
throughout	O
the	O
study	O
.	O

2.2.1	O
Stock	O
solution	O
Dissolve	O
20	O
mg	O
of	O
oxamniquine	O
in	O
100	O
of	O
methanol	O
.	O

Make	O
serial	O
dilutions	O
with	O
water	O
to	O
obtain	O
a	O
final	O
concentration	O
of	O
20	O
μg	O
/	O
ml	O
.	O

2.3	O
Procedure	O
2.3.1	O
Preparation	O
of	O
the	O
calibration	O
curve	O
Transfer	O
aliquots	O
of	O
oxamniquine	O
final	O
stock	O
solution	O
into	O
a	O
series	O
of	O
25	O
ml	O
standard	O
flasks	O
so	O
that	O
the	O
final	O
drug	O
concentration	O
is	O
in	O
the	O
range	O
0.08–0.88	O
μg	O
/	O
ml	O
.	O

Add	O
to	O
each	O
flask	O
120±5	O
mg	O
of	O
zinc	O
dust	O
and	O
12	O
ml	O
of	O
calcium	O
chloride	O
solution	O
.	O

Shake	O
well	O
and	O
leave	O
to	O
stand	O
for	O
20	O
min	O
.	O

Filter	O
the	O
excess	O
zinc	O
powder	O
.	O

Add	O
1	O
ml	O
of	O
2-cyanoacetamide	O
solution	O
to	O
the	O
filtrate	O
,	O
then	O
heat	O
on	O
a	O
boiling	O
water	O
bath	O
for	O
1	O
h.	O
Cool	O
and	O
fill	O
to	O
the	O
mark	O
in	O
25	O
ml	O
standard	O
flask	O
with	O
water	O
.	O

Measure	O
the	O
fluorescence	O
of	O
the	O
filtrate	O
using	O
370	O
nm	O
as	O
the	O
excitation	O
wavelength	O
and	O
450	O
nm	O
as	O
the	O
emission	O
wavelength	O
.	O

A	O
blank	O
reagent	O
is	O
prepared	O
simultaneously	O
.	O

Plot	O
the	O
values	O
of	O
the	O
%	O
relative	O
intensity	O
against	O
the	O
final	O
concentration	O
in	O
μg	O
/	O
ml	O
to	O
get	O
the	O
calibration	O
graph	O
.	O

Alternatively	O
,	O
the	O
regression	O
equation	O
is	O
derived	O
.	O

2.3.2	O
Determination	O
of	O
oxamniquine	O
in	O
spiked	O
human	B
plasma	O
and	O
urine	O
A	O
standard	O
calibration	O
curve	O
was	O
prepared	O
daily	O
by	O
spiking	O
blank	O
plasma	O
or	O
urine	O
with	O
varying	O
amounts	O
of	O
oxamniquine	O
.	O

A	O
stock	O
solution	O
containing	O
10	O
μg	O
/	O
ml	O
of	O
oxamniquine	O
was	O
freshly	O
prepared	O
.	O

Control	O
samples	O
of	O
plasma	O
or	O
urine	O
were	O
spiked	O
with	O
different	O
quantities	O
of	O
oxamniquine	O
to	O
give	O
a	O
final	O
drug	O
concentration	O
of	O
0.2–0.8	O
μg	O
/	O
ml	O
.	O

Add	O
0.8	O
ml	O
of	O
1	O
M	O
NaOH	O
with	O
gentle	O
shaking	O
to	O
1.0	O
ml	O
of	O
the	O
spiked	O
urine	O
or	O
plasma	O
.	O

The	O
solution	O
was	O
then	O
vortexed	O
with	O
3	O
×	O
5	O
ml	O
of	O
ether	O
for	O
2	O
min	O
then	O
centrifuged	O
at	O
2500	O
rpm	O
for	O
5	O
min	O
.	O

The	O
resulting	O
supernatant	O
was	O
then	O
evaporated	O
to	O
dryness	O
under	O
nitrogen	O
at	O
ambient	O
temperature	O
.	O

The	O
resulting	O
residue	O
was	O
dissolved	O
in	O
5	O
ml	O
of	O
methanol	O
and	O
then	O
made	O
up	O
to	O
10	O
ml	O
with	O
water	O
in	O
a	O
volumetric	O
flask	O
.	O

The	O
procedure	O
described	O
in	O
Section	O
2.3.1	O
was	O
then	O
applied	O
.	O

A	O
blank	O
experiment	O
using	O
plasma	O
or	O
urine	O
without	O
the	O
drug	O
was	O
carried	O
out	O
simultaneously	O
.	O

The	O
content	O
of	O
oxamniquine	O
was	O
then	O
determined	O
from	O
the	O
previously	O
plotted	O
calibration	O
graphs	O
.	O

3	O
Results	O
and	O
discussion	O
The	O
nitro	O
group	O
is	O
reported	O
to	O
be	O
reduced	O
into	O
the	O
corresponding	O
nitroso	O
group	O
upon	O
reduction	O
with	O
Zn	O
/	O
CaCl2	O
[	O
22	O
]	O
.	O

This	O
process	O
was	O
confirmed	O
by	O
testing	O
for	O
the	O
nitroso	O
group	O
using	O
sodium	O
nitroprusside	O
[	O
23	O
]	O
.	O

The	O
nitroso	O
compounds	O
were	O
reported	O
to	O
react	O
with	O
active	O
methylene	O
containing	O
compounds	O
with	O
the	O
production	O
of	O
the	O
corresponding	O
imines	O
[	O
24	O
]	O
.	O

The	O
latter	O
is	O
proposed	O
to	O
undergo	O
a	O
ring	O
-	O
closing	O
reaction	O
with	O
the	O
elimination	O
of	O
one	O
molecule	O
of	O
ammonia	O
and	O
the	O
production	O
of	O
the	O
3-cyanooxazazepin-2-one	O
derivative	O
,	O
which	O
is	O
the	O
fluorescent	O
product	O
.	O

A	O
proposal	O
of	O
reaction	O
pathway	O
is	O
suggested	O
in	O
Scheme	O
1	O
.	O

A	O
highly	O
fluorescent	O
product	O
with	O
λmax	O
excitation	O
at	O
370	O
nm	O
and	O
λmax	O
emission	O
of	O
450	O
nm	O
was	O
obtained	O
(	O
Fig.	O
1	O
)	O
.	O

3.1	O
Study	O
of	O
the	O
experimental	O
conditions	O
The	O
factors	O
affecting	O
the	O
production	O
of	O
nitroso	O
derivative	O
were	O
first	O
studied	O
.	O

All	O
factors	O
were	O
kept	O
constant	O
except	O
one	O
,	O
which	O
was	O
changed	O
in	O
turn	O
to	O
study	O
its	O
effect	O
.	O

Any	O
amount	O
of	O
zinc	O
powder	O
in	O
the	O
range	O
100–300	O
mg	O
was	O
found	O
to	O
give	O
the	O
same	O
results	O
;	O
therefore	O
120±5	O
mg	O
were	O
used	O
throughout	O
the	O
work	O
.	O

As	O
for	O
calcium	O
chloride	O
solution	O
12±1	O
ml	O
of	O
10	O
%	O
(	O
wt.	O
/	O
vol	O
.	O
)	O

aqueous	O
solution	O
was	O
found	O
to	O
give	O
maximum	O
fluorescence	O
.	O

Larger	O
volumes	O
caused	O
slight	O
decrease	O
in	O
fluorescence	O
.	O

Increasing	O
the	O
reduction	O
time	O
(	O
at	O
room	O
temperature	O
)	O
was	O
found	O
to	O
increase	O
the	O
fluorescence	O
up	O
to	O
20	O
min	O
,	O
after	O
which	O
time	O
the	O
fluorescence	O
intensity	O
remained	O
unchanged	O
.	O

3.2	O
Factors	O
affecting	O
the	O
development	O
of	O
the	O
fluorophore	O
The	O
effect	O
of	O
the	O
concentration	O
of	O
2-cyanoacetamide	O
was	O
studied	O
by	O
using	O
increasing	O
volumes	O
of	O
4	O
%	O
aqueous	O
solution	O
.	O

It	O
was	O
found	O
that	O
1.0±0.1	O
ml	O
is	O
appropriate	O
for	O
maximum	O
fluorescence	O
intensity	O
;	O
larger	O
volumes	O
caused	O
no	O
further	O
increase	O
in	O
fluorescence	O
.	O

The	O
temperature	O
and	O
time	O
of	O
heating	O
were	O
also	O
studied	O
.	O

It	O
was	O
concluded	O
that	O
heating	O
in	O
a	O
boiling	O
water	O
-	O
bath	O
for	O
1	O
h	O
gave	O
the	O
highest	O
fluorescence	O
readings	O
.	O

Longer	O
heating	O
time	O
caused	O
a	O
decrease	O
in	O
fluorescence	O
as	O
shown	O
in	O
Fig.	O
2	O
.	O

After	O
optimizing	O
the	O
conditions	O
,	O
it	O
was	O
found	O
that	O
the	O
relation	O
between	O
the	O
%	O
relative	O
intensity	O
(	O
%	O
RI	O
)	O
and	O
final	O
concentration	O
of	O
oxamniquine	O
was	O
rectilinear	O
over	O
the	O
range	O
0.08–0.88	O
μg	O
/	O
ml	O
with	O
a	O
minimum	O
detectability	O
(	O
S	O
/N	O
=	O
2	O
)	O
of	O
8	O
ng	O
/	O
ml	O
(	O
Fig.	O
3	O
)	O
.	O

The	O
linear	O
regression	O
analysis	O
of	O
the	O
results	O
gave	O
the	O
following	O
equation:%	O
RI	O
=	O
0.0358	O
+	O
107.4C	O
(	O
r=0.9999	O
)	O
where	O
C	O
=	O
final	O
concentration	O
in	O
μg	O
/	O
ml	O
,	O
%	O
RI	O
=	O
relative	O
fluorescence	O
intensity	O
and	O
r	O
=	O
correlation	O
coefficient	O
.	O

Statistical	O
analysis	O
of	O
the	O
results	O
of	O
analysis	O
of	O
authentic	O
sample	O
of	O
oxamniquine	O
obtained	O
by	O
both	O
the	O
proposed	O
method	O
and	O
the	O
official	O
method	O
[	O
2	O
]	O
revealed	O
no	O
significant	O
difference	O
between	O
the	O
two	O
methods	O
regarding	O
the	O
accuracy	O
and	O
precision	O
,	O
as	O
indicated	O
by	O
the	O
F	O
-test	O
and	O
Student	O
's	O
t	O
-test	O
,	O
respectively	O
[	O
25	O
]	O
.	O

Oxamniquine	O
is	O
readily	O
absorbed	O
following	O
oral	O
ingestion	O
,	O
and	O
a	O
peak	O
concentration	O
in	O
plasma	O
occurs	O
within	O
about	O
3	O
h.	O
The	O
presence	O
of	O
food	O
significantly	O
delays	O
absorption	O
and	O
limits	O
the	O
concentration	O
achieved	O
in	O
plasma	O
during	O
the	O
first	O
several	O
hours	O
after	O
administration	O
.	O

Urinary	O
excretion	O
is	O
the	O
major	O
route	O
of	O
elimination	O
in	O
humans	B
[	O
26	O
]	O
.	O

Oxamniquine	O
is	O
given	O
orally	O
in	O
a	O
dose	O
of	O
250	O
mg	O
three	O
times	O
daily	O
;	O
this	O
leads	O
to	O
a	O
final	O
blood	O
level	O
concentration	O
of	O
about	O
5	O
μg	O
/	O
ml	O
,	O
i.e.	O
higher	O
than	O
the	O
upper	O
limit	O
of	O
the	O
working	O
range	O
of	O
the	O
proposed	O
method	O
.	O

Thus	O
,	O
the	O
high	O
sensitivity	O
of	O
the	O
proposed	O
method	O
allowed	O
the	O
determination	O
of	O
oxamniquine	O
in	O
biological	O
fluids	O
.	O

Table	O
1	O
shows	O
the	O
results	O
for	O
the	O
fluorimetric	O
determination	O
of	O
a	O
pure	O
sample	O
of	O
oxamniquine	O
,	O
while	O
Table	O
2	O
shows	O
the	O
results	O
of	O
the	O
fluorometric	O
determination	O
of	O
oxamniquine	O
in	O
spiked	O
urine	O
and	O
plasma	O
samples	O
,	O
respectively	O
.	O

The	O
extraction	O
procedure	O
described	O
by	O
Woolhouse	O
and	O
Wood	O
[	O
6	O
]	O
was	O
adopted	O
here	O
.	O

The	O
results	O
are	O
satisfactorily	O
accurate	O
and	O
precise	O
.	O

In	O
conclusion	O
,	O
a	O
highly	O
sensitive	O
and	O
accurate	O
method	O
was	O
developed	O
for	O
the	O
determination	O
of	O
oxamniquine	O
in	O
urine	O
and	O
plasma	O
.	O

Although	O
the	O
previously	O
reported	O
methods	O
[	O
6,7	O
]	O
for	O
its	O
determination	O
in	O
biological	O
fluids	O
may	O
be	O
less	O
time	O
-	O
consuming	O
,	O
the	O
proposed	O
method	O
is	O
,	O
however	O
,	O
more	O
sensitive	O
and	O
does	O
not	O
need	O
complicated	O
instrumentation	O
.	O

The	O
relationship	O
between	O
taurine	O
and	O
aging	O
of	O
brain	O
neural	O
cells	O
was	O
studied	O
by	O
using	O
primary	O
human	B
fetal	O
brain	O
neural	O
cells	O
cultured	O
in	O
serum	O
-	O
free	O
medium	O
.	O

The	O
results	O
indicated	O
that	O
the	O
activity	O
of	O
superoxide	O
dismutase	O
(	O
SOD	O
)	O
was	O
significantly	O
higher	O
in	O
taurine	O
added	O
group	O
than	O
the	O
control	O
group	O
cultured	O
for	O
6	O
,	O
9	O
and	O
15	O
days	O
(	O
P	O
<	O
0.05	O
)	O
.	O

With	O
different	O
taurine	O
levels	O
,	O
the	O
SOD	O
activities	O
of	O
50	O
mg	O
/	O
L	O
and	O
200	O
mg	O
/	O
L	O
taurine	O
groups	O
were	O
significantly	O
higher	O
than	O
the	O
control	O
group	O
cultured	O
for	O
6	O
days	O
(	O
P	O
<	O
0.05	O
)	O
.	O

After	O
3-day	O
culture	O
,	O
the	O
activity	O
of	O
glutathione	O
peroxidase	O
(	O
GSH	O
-	O
Px	O
)	O
in	O
the	O
taurine	O
added	O
group	O
was	O
significantly	O
higher	O
than	O
the	O
control	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
membrane	O
lipid	O
fluidity	O
of	O
neural	O
cells	O
decreased	O
with	O
time	O
in	O
control	O
group	O
,	O
but	O
was	O
stable	O
in	O
the	O
group	O
treated	O
with	O
taurine	O
.	O

The	O
fluidity	O
was	O
more	O
stable	O
in	O
the	O
groups	O
treated	O
with	O
50	O
,	O
200	O
and	O
400	O
mg	O
/	O
L	O
groups	O
cultured	O
for	O
6	O
days	O
,	O
compared	O
with	O
the	O
control	O
group	O
(	O
P	O
<	O
0.05	O
or	O
0.01	O
)	O
.	O

The	O
present	O
study	O
showed	O
that	O
taurine	O
is	O
necessary	O
for	O
maintaining	O
membrane	O
lipid	O
fluidity	O
of	O
neural	O
cells	O
in	O
proper	O
levels	O
,	O
and	O
plays	O
an	O
important	O
role	O
in	O
postponing	O
the	O
aging	O
process	O
of	O
brain	O
neural	O
cells	O
.	O

A	O
combination	O
of	O
atovaquone	O
and	O
proguanil	O
has	O
been	O
found	O
to	O
be	O
quite	O
effective	O
in	O
treating	O
malaria	O
,	O
with	O
little	O
evidence	O
of	O
the	O
emergence	O
of	O
resistance	O
when	O
atovaquone	O
was	O
used	O
as	O
a	O
single	O
agent	O
.	O

We	O
have	O
examined	O
possible	O
mechanisms	O
for	O
the	O
synergy	O
between	O
these	O
two	O
drugs	O
.	O

While	O
proguanil	O
by	O
itself	O
had	O
no	O
effect	O
on	O
electron	O
transport	O
or	O
mitochondrial	O
membrane	O
potential	O
(	O
DeltaPsim	O
)	O
,	O
it	O
significantly	O
enhanced	O
the	O
ability	O
of	O
atovaquone	O
to	O
collapse	O
DeltaPsim	O
when	O
used	O
in	O
combination	O
.	O

This	O
enhancement	O
was	O
observed	O
at	O
pharmacologically	O
achievable	O
doses	O
.	O

Proguanil	O
acted	O
as	O
a	O
biguanide	O
rather	O
than	O
as	O
its	O
metabolite	O
cycloguanil	O
(	O
a	O
parasite	B
dihydrofolate	O
reductase	O
[	O
DHFR	O
]	O
inhibitor	O
)	O
to	O
enhance	O
the	O
atovaquone	O
effect	O
;	O
another	O
DHFR	O
inhibitor	O
,	O
pyrimethamine	O
,	O
also	O
had	O
no	O
enhancing	O
effect	O
.	O

Proguanil	O
-	O
mediated	O
enhancement	O
was	O
specific	O
for	O
atovaquone	O
,	O
since	O
the	O
effects	O
of	O
other	O
mitochondrial	O
electron	O
transport	O
inhibitors	O
,	O
such	O
as	O
myxothiazole	O
and	O
antimycin	O
,	O
were	O
not	O
altered	O
by	O
inclusion	O
of	O
proguanil	O
.	O

Surprisingly	O
,	O
proguanil	O
did	O
not	O
enhance	O
the	O
ability	O
of	O
atovaquone	O
to	O
inhibit	O
mitochondrial	O
electron	O
transport	O
in	O
malaria	O
parasites	O
.	O

These	O
results	O
suggest	O
that	O
proguanil	O
in	O
its	O
prodrug	O
form	O
acts	O
in	O
synergy	O
with	O
atovaquone	O
by	O
lowering	O
the	O
effective	O
concentration	O
at	O
which	O
atovaquone	O
collapses	O
DeltaPsim	O
in	O
malaria	O
parasites	O
.	O

This	O
could	O
explain	O
the	O
paradoxical	O
success	O
of	O
the	O
atovaquone	O
-	O
proguanil	O
combination	O
even	O
in	O
regions	O
where	O
proguanil	O
alone	O
is	O
ineffective	O
due	O
to	O
resistance	O
.	O

The	O
results	O
also	O
suggest	O
that	O
the	O
atovaquone	O
-	O
proguanil	O
combination	O
may	O
act	O
as	O
a	O
site	O
-	O
specific	O
uncoupler	O
of	O
parasite	B
mitochondria	O
in	O
a	O
selective	O
manner	O
.	O

To	O
develop	O
positron	O
-	O
emitting	O
tracers	O
for	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
studies	O
,	O
ex	O
vivo	O
autoradiography	O
(	O
ARG	O
)	O
is	O
a	O
useful	O
technique	O
to	O
demonstrate	O
the	O
distribution	O
of	O
the	O
tracer	O
in	O
the	O
brain	O
as	O
well	O
as	O
in	O
the	O
whole	O
body	O
.	O

A	O
recent	O
advent	O
of	O
radioluminography	O
using	O
phosphor	O
-	O
imaging	O
plates	O
(	O
12	O
,	O
14	O
)	O
has	O
enabled	O
the	O
ex	O
vivo	O
ARG	O
to	O
be	O
applied	O
to	O
ultrashort	O
-	O
lived	O
11	O
C	O
-	O
labeled	O
tracers	O
.	O

Yanai	O
et	O
al.	O
reported	O
a	O
potential	O
of	O
the	O
imaging	O
plates	O
for	O
receptor	O
ARG	O
with	O
11	O
C	O
-	O
labeled	O
ligands	O
compared	O
with	O
tritiated	O
ligands	O
(	O
25	O
)	O
.	O

Planas	O
et	O
al.	O
(	O
18	O
)	O
characterized	O
a	O
cholinesterase	O
inhibitor	O
[	O
11	O
C	O
]	O
physostigmine	O
using	O
a	O
similar	O
type	O
storage	O
phosphor	O
plates	O
.	O

We	O
also	O
used	O
imaging	O
plates	O
to	O
characterize	O
newly	O
developed	O
11	O
C	O
-	O
labeled	O
receptor	O
ligands	O
(	O
3	O
,	O
10	O
,	O
16	O
)	O
.	O

Because	O
the	O
intensity	O
of	O
photo	O
-	O
stimulated	O
-	O
luminescence	O
(	O
PSL	O
)	O
is	O
linearly	O
proportional	O
to	O
the	O
radioactivity	O
in	O
a	O
wide	O
range	O
,	O
ARG	O
images	O
expressed	O
as	O
PSL	O
is	O
considered	O
to	O
reflect	O
the	O
quantitative	O
distribution	O
of	O
radioactivity	O
.	O

Recently	O
,	O
Sihver	O
et	O
al.	O
(	O
21	O
)	O
have	O
quantitatively	O
evaluated	O
in	O
vitro	O
ARG	O
with	O
storage	O
phosphor	O
plates	O
and	O
11	O
C	O
-	O
flumazenil	O
.	O

In	O
the	O
present	O
paper	O
,	O
we	O
describe	O
quantitative	O
evaluation	O
of	O
ex	O
vivo	O
and	O
in	O
vitro	O
ARG	O
using	O
an	O
imaging	O
plate	O
and	O
a	O
11	O
C	O
-	O
labeled	O
dopamine	O
D2	O
-like	O
receptor	O
ligand	O
,	O
[	O
11	O
C	O
]	O
nemonapride	O
(	O
[	O
11	O
C	O
]	O
YM-09151	O
-	O
2	O
)	O
(	O
5	O
,	O
6	O
,	O
8	O
,	O
9	O
,	O
11	O
)	O
.	O

Its	O
tritiated	O
compound	O
has	O
been	O
used	O
widely	O
for	O
pharmacological	O
studies	O
as	O
one	O
of	O
representative	O
dopamine	O
D2	O
-like	O
receptor	O
ligands	O
.	O

We	O
report	O
the	O
presence	O
of	O
saturable	O
binding	O
sites	O
for	O
[	O
11	O
C	O
]	O
nemonapride	O
in	O
the	O
cortex	O
beside	O
the	O
dopamine	O
D2	O
-like	O
receptors	O
in	O
the	O
striatum	O
both	O
ex	O
vivo	O
and	O
in	O
vitro	O
.	O

Materials	O
and	O
methods	O
[	O
11	O
C	O
]	O
Nemonapride	O
(	O
9	O
)	O
and	O
[	O
11	O
C	O
]	O
SCH	O
23390	O
(	O
4	O
)	O
were	O
synthesized	O
by	O
11	O
C	O
-	O
methylation	O
of	O
the	O
corresponding	O
desmethyl	O
compound	O
with	O
[	O
11	O
C	O
]	O
methyl	O
iodide	O
by	O
the	O
method	O
previously	O
described	O
.	O

The	O
specific	O
activity	O
of	O
the	O
compounds	O
was	O
measured	O
as	O
follows	O
.	O

The	O
radioactivity	O
(	O
MBq	O
)	O
of	O
an	O
appropriate	O
volume	O
of	O
tracer	O
solution	O
was	O
measured	O
by	O
a	O
radioisotope	O
calibrator	O
(	O
type	O
CRC-712	O
,	O
Capintec	O
Inc.	O
,	O
Ramsey	O
,	O
NJ	O
)	O
,	O
and	O
a	O
part	O
of	O
the	O
solution	O
was	O
applied	O
to	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
to	O
determine	O
the	O
mass	O
(	O
nmol	O
)	O
of	O
the	O
compounds	O
based	O
on	O
the	O
ultraviolet	O
(	O
UV	O
)	O
response	O
to	O
the	O
authentic	O
sample	O
.	O

Male	B
Wistar	I
rats	I
(	O
8–10	O
weeks	O
old	O
)	O
were	O
obtained	O
from	O
Tokyo	O
Laboratory	O
Animals	O
Company	O
(	O
Tokyo	O
,	O
Japan	O
)	O
.	O

The	O
animal	B
studies	O
were	O
approved	O
by	O
the	O
Animal	B
Care	O
and	O
Use	O
Committee	O
of	O
Tokyo	O
Metropolitan	O
Institute	O
of	O
Gerontology	O
.	O

Calibration	O
of	O
PSL	O
Relationship	O
between	O
PSL	O
and	O
radioactivity	O
on	O
filter	O
paper	O
A	O
solution	O
of	O
11	O
C	O
-	O
tracer	O
was	O
prepared	O
at	O
the	O
concentration	O
of	O
100	O
MBq	O
/	O
mL	O
measured	O
with	O
a	O
radioisotope	O
calibrator	O
(	O
t	O
=	O
0	O
min	O
,	O
26	O
min	O
after	O
end	O
of	O
bombardment	O
[	O
EOB	O
]	O
)	O
.	O

The	O
solution	O
was	O
diluted	O
to	O
0.03–10	O
MBq	O
/	O
mL	O
,	O
and	O
10	O
μL	O
of	O
each	O
diluted	O
solution	O
(	O
0.3–100	O
kBq	O
)	O
was	O
loaded	O
on	O
six	O
pieces	O
of	O
filter	O
paper	O
(	O
5	O
mm	O
×	O
5	O
mm	O
,	O
0.23	O
±	O
0.05	O
mm	O
thickness	O
,	O
Toyo	O
Roshi	O
Kaisha	O
,	O
Tokyo	O
,	O
Japan	O
)	O
.	O

Three	O
pieces	O
of	O
the	O
filter	O
paper	O
were	O
exposed	O
on	O
an	O
imaging	O
plate	O
of	O
type	O
IP	O
BAS	O
SR	O
(	O
FUJIX	O
Fuji	O
Photo	O
Film	O
Co.	O
,	O
Tokyo	O
,	O
Japan	O
)	O
until	O
the	O
decay	O
-	O
out	O
of	O
11	O
C	O
(	O
t	O
=	O
20	O
h	O
)	O
.	O

The	O
activity	O
at	O
the	O
start	O
of	O
contact	O
ranged	O
from	O
1.05	O
to	O
2990	O
Bq	O
(	O
t	O
=	O
35.5	O
min	O
)	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
radioactivity	O
(	O
cpm	O
)	O
of	O
the	O
other	O
three	O
pieces	O
of	O
the	O
filter	O
paper	O
was	O
measured	O
with	O
a	O
well	O
-	O
type	O
auto	O
-	O
gamma	O
counter	O
(	O
type	O
1282	O
Compugamma	O
CS	O
,	O
Wallac	O
Oy	O
,	O
Turku	O
,	O
Finland	O
)	O
for	O
15	O
s	O
,	O
and	O
the	O
cpm	O
/	O
Bq	O
was	O
computed	O
with	O
decay	O
correction	O
.	O

The	O
PSL	O
values	O
over	O
the	O
entire	O
piece	O
of	O
filter	O
paper	O
(	O
25	O
mm2	O
)	O
were	O
measured	O
with	O
a	O
bioimaging	O
analyzer	O
of	O
type	O
BAS	O
2500	O
(	O
FUJIX	O
Fuji	O
Photo	O
Film	O
Co.	O
,	O
Tokyo	O
,	O
Japan	O
)	O
,	O
to	O
compute	O
the	O
PSL	O
per	O
Bq	O
at	O
the	O
start	O
of	O
contact	O
.	O

Reproducibility	O
between	O
imaging	O
plates	O
The	O
filter	O
paper	O
provided	O
with	O
the	O
11	O
C	O
-	O
radioactivity	O
as	O
described	O
above	O
and	O
the	O
autoradiographic	O
[	O
14	O
C	O
]	O
micro	O
-	O
scales	O
(	O
1.11–31.73	O
kBq	O
/	O
g	O
)	O
(	O
Amersham	O
International	O
plc	O
.	O
,	O
Buckinghamshire	O
,	O
England	O
)	O
were	O
exposed	O
to	O
five	O
imaging	O
plates	O
of	O
the	O
same	O
type	O
for	O
4	O
h	O
to	O
examine	O
the	O
reproducibility	O
between	O
imaging	O
plates	O
;	O
the	O
PSL	O
of	O
the	O
micro	O
-	O
scales	O
were	O
measured	O
as	O
PSL	O
/	O
mm2	O
.	O

Ex	O
vivo	O
autoradiography	O
Effect	O
of	O
section	O
thickness	O
[	O
11	O
C	O
]	O
Nemonapride	O
(	O
143	O
MBq	O
/	O
4.3	O
nmol	O
)	O
was	O
injected	O
intravenously	O
into	O
a	O
rat	O
(	O
235	O
g	O
)	O
(	O
t	O
=	O
0	O
min	O
,	O
29	O
min	O
after	O
EOB	O
)	O
.	O

Fifteen	O
minutes	O
later	O
,	O
the	O
rat	B
was	O
killed	O
and	O
the	O
brain	O
was	O
removed	O
.	O

The	O
brain	O
at	O
the	O
bregma	O
(	O
17	O
)	O
was	O
cut	O
into	O
10-	O
,	O
15-	O
,	O
20-	O
,	O
30-	O
,	O
75-	O
,	O
100-	O
,	O
and	O
150-μm	O
thick	O
coronal	O
sections	O
using	O
a	O
cryotome	O
(	O
Bright	O
Instruments	O
Co.	O
Ltd.	O
,	O
UK	O
)	O
at	O
−15	O
°	O
C	O
.	O

The	O
brain	O
sections	O
were	O
thaw	O
-	O
mounted	O
on	O
glass	O
plates	O
(	O
20	O
×	O
32	O
mm2	O
)	O
that	O
were	O
precoated	O
with	O
3	O
%	O
3-aminopropyltriethoxysilane	O
in	O
acetone	O
.	O

The	O
sections	O
were	O
dried	O
on	O
a	O
hot	O
plate	O
at	O
60	O
°	O
C	O
and	O
apposed	O
placed	O
on	O
an	O
imaging	O
plate	O
(	O
t	O
=	O
110	O
min	O
)	O
.	O

The	O
tracer	O
uptake	O
was	O
visualized	O
as	O
described	O
above	O
.	O

Regions	O
of	O
interest	O
(	O
ROIs	O
)	O
were	O
placed	O
on	O
the	O
striatum	O
(	O
6–8	O
mm2	O
)	O
and	O
on	O
the	O
cerebral	O
cortex	O
(	O
6–8	O
mm2	O
)	O
,	O
and	O
the	O
PSL	O
/	O
mm2	O
values	O
were	O
measured	O
.	O

From	O
the	O
other	O
rat	B
(	O
230	O
g	O
)	O
given	O
[	O
11	O
C	O
]	O
nemonapride	O
(	O
136	O
MBq	O
/	O
4.4	O
nmol	O
)	O
,	O
the	O
coronal	O
brain	O
sections	O
with	O
10-	O
,	O
15-	O
,	O
20-	O
,	O
30-	O
,	O
75-	O
,	O
100-	O
,	O
and	O
150-μm	O
thickness	O
were	O
also	O
obtained	O
as	O
described	O
above	O
.	O

The	O
whole	O
section	O
was	O
measured	O
for	O
the	O
radioactivity	O
(	O
cpm	O
)	O
with	O
an	O
auto	O
-	O
gamma	O
counter	O
for	O
15	O
s.	O

The	O
effect	O
of	O
section	O
thickness	O
was	O
evaluated	O
,	O
assuming	O
equal	O
radioactivity	O
concentration	O
between	O
corresponding	O
regions	O
or	O
whole	O
brains	O
in	O
neighboring	O
sections	O
at	O
the	O
bregma	O
.	O

Relationship	O
between	O
PSL	O
and	O
radioactivity	O
on	O
the	O
brain	O
section	O
To	O
obtain	O
coronal	O
brain	O
sections	O
having	O
a	O
wider	O
range	O
of	O
radioactivity	O
,	O
ex	O
vivo	O
ARG	O
was	O
performed	O
with	O
[	O
11	O
C	O
]	O
SCH	O
23390	O
,	O
which	O
is	O
more	O
concentrated	O
in	O
the	O
striatum	O
than	O
[	O
11	O
C	O
]	O
nemonapride	O
.	O

[	O
11	O
C	O
]	O
SCH	O
23390	O
(	O
236	O
MBq	O
/	O
11.1	O
nmol	O
and	O
47	O
MBq	O
/	O
2.2	O
nmol	O
)	O
was	O
injected	O
intravenously	O
into	O
two	O
rats	B
(	O
t	O
=	O
0	O
min	O
,	O
30	O
min	O
after	O
EOB	O
)	O
.	O

The	O
rats	B
were	O
killed	O
15	O
min	O
later	O
,	O
and	O
25	O
pairs	O
of	O
the	O
adjacent	O
coronal	O
brain	O
sections	O
with	O
20-μm	O
thickness	O
were	O
prepared	O
throughout	O
the	O
brain	O
as	O
described	O
above	O
.	O

One	O
set	O
of	O
the	O
brain	O
sections	O
was	O
applied	O
to	O
an	O
imaging	O
plate	O
until	O
decay	O
-	O
out	O
to	O
measure	O
the	O
PSL	O
for	O
the	O
whole	O
section	O
,	O
and	O
the	O
other	O
set	O
was	O
measured	O
for	O
the	O
radioactivity	O
(	O
cpm	O
)	O
with	O
an	O
auto	O
-	O
gamma	O
counter	O
(	O
t	O
=	O
102	O
min	O
)	O
.	O

Then	O
the	O
PSL	O
/	O
cpm	O
was	O
calculated	O
for	O
each	O
brain	O
section	O
.	O

Regional	O
brain	O
uptake	O
of	O
[	O
11	O
C	O
]	O
nemonapride	O
measured	O
by	O
ex	O
vivo	O
ARG	O
and	O
tissue	O
sampling	O
method	O
[	O
11	O
C	O
]	O
Nemonapride	O
(	O
82.6–96.7	O
MBq	O
/	O
2.1–5.7	O
nmol	O
)	O
was	O
injected	O
intravenously	O
into	O
four	O
rats	B
(	O
260–290	O
g	O
)	O
.	O

They	O
were	O
killed	O
30	O
min	O
later	O
and	O
the	O
brains	O
were	O
removed	O
.	O

From	O
a	O
half	O
brain	O
hemisphere	O
,	O
three	O
pairs	O
of	O
adjacent	O
coronal	O
brain	O
sections	O
with	O
20-μm	O
thickness	O
were	O
cut	O
near	O
bregma	O
.	O

The	O
radioactivity	O
(	O
cpm	O
)	O
of	O
one	O
set	O
of	O
section	O
was	O
measured	O
with	O
an	O
auto	O
-	O
gamma	O
counter	O
and	O
converted	O
to	O
Bq	O
.	O

The	O
other	O
section	O
was	O
exposed	O
to	O
an	O
imaging	O
plate	O
to	O
measure	O
the	O
PSL	O
for	O
the	O
whole	O
section	O
as	O
described	O
above	O
,	O
and	O
the	O
PSL	O
/	O
Bq	O
was	O
calculated	O
assuming	O
that	O
the	O
pair	O
of	O
adjacent	O
brain	O
sections	O
had	O
the	O
same	O
radioactivity	O
.	O

ROIs	O
were	O
placed	O
on	O
the	O
striatum	O
and	O
on	O
the	O
cortex	O
to	O
measure	O
the	O
PSL	O
for	O
the	O
regional	O
brain	O
section	O
volume	O
(	O
mm2	O
×	O
0.02	O
mm	O
)	O
,	O
which	O
was	O
converted	O
to	O
Bq	O
/	O
mL.	O
Then	O
,	O
the	O
uptake	O
of	O
[	O
11	O
C	O
]	O
nemonapride	O
by	O
the	O
striatum	O
or	O
cortex	O
was	O
assessed	O
as	O
the	O
percent	O
of	O
the	O
injected	O
dose	O
per	O
milliliter	O
of	O
tissue	O
(	O
%	O
ID	O
/	O
mL	O
)	O
.	O

From	O
the	O
other	O
hemisphere	O
the	O
striatum	O
and	O
cortex	O
were	O
dissected	O
and	O
weighed	O
,	O
and	O
the	O
radioactivity	O
of	O
the	O
tissues	O
was	O
measured	O
with	O
an	O
auto	O
-	O
gamma	O
counter	O
.	O

The	O
uptake	O
was	O
expressed	O
as	O
the	O
percent	O
of	O
the	O
injected	O
dose	O
per	O
gram	O
of	O
tissue	O
(	O
%	O
ID	O
/	O
g	O
)	O
.	O

Effect	O
of	O
carrier	O
dose	O
To	O
measure	O
the	O
receptor	O
binding	O
capacity	O
quantitatively	O
in	O
ex	O
vivo	O
ARG	O
,	O
the	O
amount	O
of	O
injected	O
carrier	O
ligand	O
must	O
be	O
sufficiently	O
small	O
to	O
avoid	O
saturation	O
effect	O
.	O

To	O
determine	O
if	O
the	O
carrier	O
amount	O
of	O
nemonapride	O
meets	O
this	O
requirement	O
under	O
the	O
specific	O
activity	O
of	O
current	O
experimental	O
condition	O
,	O
the	O
effect	O
of	O
carrier	O
dose	O
on	O
the	O
regional	O
uptake	O
of	O
[	O
11	O
C	O
]	O
nemonapride	O
was	O
evaluated	O
by	O
tissue	O
sampling	O
.	O

[	O
11	O
C	O
]	O
Nemonapride	O
with	O
various	O
amount	O
of	O
carrier	O
(	O
10	O
MBq	O
/	O
0.027–500	O
nmol	O
)	O
was	O
injected	O
into	O
rats	B
(	O
227	O
±	O
12	O
g	O
)	O
,	O
and	O
the	O
uptake	O
(	O
%	O
ID	O
/	O
g	O
)	O
by	O
the	O
striatum	O
,	O
cortex	O
,	O
and	O
cerebellum	O
was	O
measured	O
at	O
30	O
min	O
after	O
the	O
injection	O
by	O
the	O
tissue	O
sampling	O
method	O
as	O
described	O
above	O
.	O

In	O
vitro	O
autoradiography	O
Effect	O
of	O
section	O
thickness	O
In	O
vitro	O
ARG	O
with	O
[	O
11	O
C	O
]	O
nemonapride	O
was	O
performed	O
according	O
to	O
the	O
method	O
of	O
Przedborski	O
et	O
al.	O
(	O
19	O
)	O
with	O
a	O
slight	O
modification	O
.	O

Coronal	O
rat	B
brain	O
sections	O
with	O
10-	O
,	O
20-	O
,	O
30-	O
,	O
75-	O
,	O
100-	O
,	O
and	O
150-μm	O
thickness	O
near	O
the	O
bregma	O
(	O
17	O
)	O
were	O
prepared	O
.	O

The	O
brain	O
sections	O
were	O
pre	O
-	O
incubated	O
in	O
100	O
mL	O
50	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH	O
7.4	O
,	O
containing	O
120	O
mM	O
NaCl	O
for	O
30	O
min	O
at	O
room	O
temperature	O
.	O

Then	O
,	O
the	O
same	O
buffer	O
containing	O
100	O
kBq	O
/	O
mL	O
(	O
25	O
TBq	O
/	O
mmol	O
)	O
[	O
11	O
C	O
]	O
nemonapride	O
was	O
prepared	O
(	O
t	O
=	O
0	O
min	O
,	O
29	O
min	O
after	O
EOB	O
)	O
,	O
in	O
which	O
all	O
the	O
sections	O
were	O
incubated	O
for	O
30	O
min	O
at	O
37	O
°	O
C	O
.	O

After	O
being	O
washed	O
with	O
ice	O
-	O
cold	O
50	O
mM	O
Tris	O
-	O
HCl	O
(	O
pH	O
7.4	O
)	O
containing	O
120	O
mM	O
NaCl	O
,	O
the	O
brain	O
sections	O
were	O
dried	O
on	O
a	O
hot	O
plate	O
at	O
60	O
°	O
C	O
,	O
and	O
then	O
contacted	O
on	O
an	O
imaging	O
plate	O
(	O
t	O
=	O
58	O
min	O
)	O
until	O
the	O
activity	O
decayed	O
out	O
(	O
t	O
=	O
20	O
h	O
)	O
.	O

The	O
binding	O
of	O
11	O
C	O
was	O
measured	O
as	O
the	O
PSL	O
/	O
mm2	O
over	O
the	O
ROIs	O
placed	O
in	O
the	O
same	O
manner	O
as	O
in	O
the	O
ex	O
vivo	O
ARG	O
,	O
and	O
the	O
effect	O
of	O
section	O
thickness	O
was	O
evaluated	O
.	O

The	O
other	O
set	O
of	O
the	O
brain	O
section	O
was	O
also	O
assayed	O
as	O
described	O
above	O
and	O
the	O
radioactivity	O
(	O
cpm	O
)	O
of	O
the	O
whole	O
section	O
was	O
measured	O
with	O
a	O
gamma	O
counter	O
.	O

Saturation	O
of	O
[	O
11	O
C	O
]	O
nemonapride	O
binding	O
The	O
buffer	O
containing	O
various	O
concentrations	O
(	O
0.156	O
,	O
0.313	O
,	O
0.625	O
,	O
1.25	O
,	O
and	O
2.50	O
nM	O
)	O
of	O
[	O
11	O
C	O
]	O
nemonapride	O
(	O
21	O
TBq	O
/	O
mmol	O
)	O
was	O
prepared	O
(	O
t	O
=	O
0	O
min	O
,	O
40	O
min	O
after	O
EOB	O
)	O
,	O
and	O
six	O
brain	O
sections	O
with	O
20-μm	O
thickness	O
were	O
incubated	O
for	O
30	O
min	O
at	O
37	O
°	O
C	O
in	O
each	O
buffer	O
as	O
described	O
above	O
.	O

Nonspecific	O
binding	O
was	O
determined	O
by	O
incubating	O
adjacent	O
six	O
sections	O
in	O
the	O
medium	O
to	O
which	O
haloperidol	O
was	O
added	O
to	O
a	O
final	O
concentration	O
of	O
20	O
μM.	O
Three	O
brain	O
sections	O
in	O
each	O
assay	O
were	O
exposed	O
on	O
an	O
imaging	O
plate	O
(	O
t	O
=	O
85	O
min	O
)	O
to	O
measure	O
the	O
PSL	O
values	O
,	O
and	O
the	O
adjacent	O
three	O
sections	O
were	O
measured	O
for	O
radioactivity	O
(	O
cpm	O
)	O
.	O

Then	O
,	O
the	O
PSL	O
/	O
Bq	O
calculated	O
as	O
described	O
above	O
was	O
converted	O
to	O
concentration	O
of	O
receptor	O
-	O
bound	O
ligand	O
(	O
nmol	O
/	O
mL	O
tissue	O
)	O
using	O
the	O
specific	O
activity	O
of	O
the	O
ligand	O
.	O

Scatchard	O
plot	O
,	O
bound	O
ligand	O
(	O
nmol	O
/	O
mL	O
tissue	O
)	O
versus	O
bound	O
ligand	O
/	O
free	O
ligand	O
(	O
nmol	O
/	O
mL	O
tissue	O
/	O
nM	O
)	O
,	O
was	O
carried	O
out	O
.	O

Results	O
and	O
discussion	O
Relationship	O
between	O
PSL	O
and	O
radioactivity	O
on	O
filter	O
paper	O
Figure	O
1	O
shows	O
the	O
PSL	O
values	O
of	O
the	O
standard	O
sample	O
on	O
filter	O
paper	O
.	O

The	O
PSL	O
values	O
were	O
linearly	O
proportional	O
to	O
the	O
11	O
C	O
radioactivity	O
(	O
Bq	O
)	O
measured	O
with	O
a	O
radioisotope	O
calibrator	O
(	O
Fig.	O
1A	O
)	O
,	O
and	O
the	O
ratio	O
was	O
10.7	O
PSL	O
/	O
Bq	O
at	O
the	O
start	O
of	O
contact	O
.	O

Because	O
each	O
sample	O
presented	O
uniform	O
activity	O
distribution	O
within	O
the	O
piece	O
of	O
filter	O
paper	O
,	O
the	O
PSL	O
of	O
the	O
standard	O
sample	O
on	O
the	O
filter	O
paper	O
was	O
expressed	O
as	O
a	O
linear	O
function	O
of	O
radioactivity	O
in	O
the	O
range	O
from	O
0.4	O
to	O
1110	O
PSL	O
/	O
mm2	O
(	O
0.04–104	O
Bq	O
/	O
mm2	O
)	O
in	O
the	O
present	O
study	O
.	O

The	O
linearity	O
between	O
the	O
radioisotope	O
calibrator	O
and	O
the	O
well	O
-	O
type	O
gamma	O
counter	O
was	O
also	O
confirmed	O
,	O
the	O
ratio	O
being	O
40.1	O
cpm	O
/	O
Bq	O
.	O

Reproducibility	O
between	O
imaging	O
plates	O
When	O
the	O
11	O
C	O
-	O
samples	O
on	O
filter	O
paper	O
and	O
standard	O
[	O
14	O
C	O
]	O
micro	O
-	O
scales	O
were	O
exposed	O
to	O
five	O
imaging	O
plates	O
,	O
the	O
coefficient	O
variation	O
(	O
SD	O
/	O
mean	O
)	O
of	O
the	O
five	O
plates	O
for	O
11	O
C	O
-	O
sensitivity	O
and	O
14	O
C	O
-	O
sensitivity	O
was	O
2.4–3.2	O
%	O
at	O
17.4–164	O
PSL	O
/	O
mm2	O
and	O
2.6–6.9	O
%	O
at	O
5.2–36.6	O
PSL	O
/	O
mm2	O
,	O
respectively	O
.	O

The	O
variation	O
for	O
11	O
C	O
was	O
comparable	O
to	O
that	O
for	O
14	O
C	O
,	O
which	O
confirmed	O
the	O
reliability	O
of	O
our	O
homemade	O
standard	O
source	O
on	O
filter	O
paper	O
.	O

Effect	O
of	O
section	O
thickness	O
Figure	O
2	O
shows	O
representative	O
autoradiograms	O
of	O
[	O
11	O
C	O
]	O
nemonapride	O
by	O
ex	O
vivo	O
and	O
in	O
vitro	O
ARG	O
.	O

High	O
11	O
C	O
density	O
was	O
observed	O
in	O
the	O
caudate	O
putamen	O
,	O
nucleus	O
accumbens	O
,	O
and	O
olfactory	O
tubercle	O
,	O
consistent	O
with	O
the	O
well	O
-	O
known	O
distribution	O
of	O
dopamine	O
D2	O
receptors	O
.	O

Figure	O
3	O
illustrates	O
the	O
relationship	O
between	O
brain	O
section	O
thickness	O
and	O
PSL	O
values	O
measured	O
by	O
ex	O
vivo	O
and	O
in	O
vitro	O
ARG	O
.	O

The	O
PSL	O
/	O
mm2	O
value	O
for	O
ex	O
vivo	O
ARG	O
was	O
not	O
linearly	O
proportional	O
to	O
the	O
slice	O
thickness	O
(	O
Fig.	O
3A	O
)	O
,	O
suggesting	O
that	O
the	O
absorption	O
of	O
radiation	O
increases	O
as	O
the	O
section	O
thickness	O
increases	O
,	O
because	O
it	O
is	O
reasonably	O
assumed	O
that	O
the	O
radioactivity	O
of	O
[	O
11	O
C	O
]	O
nemonapride	O
was	O
uniformly	O
distributed	O
throughout	O
the	O
thickness	O
in	O
the	O
striatum	O
and	O
cortex	O
near	O
the	O
bregma	O
.	O

On	O
the	O
other	O
hand	O
,	O
a	O
deviation	O
from	O
the	O
linear	O
function	O
was	O
much	O
larger	O
for	O
the	O
in	O
vitro	O
ARG	O
than	O
for	O
the	O
ex	O
vivo	O
ARG	O
,	O
and	O
the	O
PSL	O
/	O
mm2	O
values	O
reached	O
a	O
plateau	O
both	O
in	O
the	O
striatum	O
and	O
cortex	O
for	O
over	O
100-μm	O
thick	O
sections	O
.	O

This	O
finding	O
is	O
probably	O
because	O
diffusion	O
of	O
the	O
11	O
C	O
-	O
tracer	O
into	O
the	O
brain	O
tissue	O
was	O
not	O
completed	O
in	O
thick	O
brain	O
sections	O
during	O
the	O
incubation	O
period	O
,	O
and	O
the	O
binding	O
did	O
not	O
reach	O
an	O
equilibrium	O
state	O
.	O

The	O
explanation	O
was	O
approved	O
by	O
measurement	O
of	O
radioactivity	O
of	O
the	O
whole	O
brain	O
sections	O
with	O
a	O
gamma	O
counter	O
(	O
Fig.	O
3C	O
)	O
.	O

The	O
radioactivity	O
was	O
linearly	O
proportional	O
to	O
the	O
slice	O
thickness	O
in	O
ex	O
vivo	O
ARG	O
,	O
but	O
not	O
in	O
in	O
vitro	O
ARG	O
.	O

Relationship	O
between	O
PSL	O
and	O
radioactivity	O
on	O
the	O
brain	O
section	O
Figure	O
4	O
shows	O
relationship	O
between	O
the	O
PSL	O
value	O
and	O
the	O
radioactivity	O
of	O
11	O
C	O
on	O
the	O
whole	O
section	O
with	O
20-μm	O
thickness	O
and	O
for	O
the	O
entire	O
piece	O
of	O
25-mm2	O
filter	O
paper	O
with	O
230-μm	O
thickness	O
.	O

The	O
PSL	O
was	O
found	O
to	O
be	O
linearly	O
proportional	O
to	O
the	O
radioactivity	O
within	O
the	O
brain	O
sections	O
or	O
filter	O
paper	O
,	O
although	O
the	O
coefficient	O
was	O
different	O
between	O
the	O
two	O
materials	O
because	O
of	O
different	O
thickness	O
as	O
suggested	O
from	O
Figure	O
2	O
.	O

Therefore	O
,	O
the	O
PSL	O
value	O
can	O
be	O
converted	O
to	O
the	O
radioactivity	O
expressed	O
as	O
Bq	O
unit	O
,	O
if	O
the	O
radioactivity	O
of	O
the	O
adjacent	O
brain	O
sections	O
with	O
the	O
same	O
thickness	O
is	O
measured	O
with	O
a	O
gamma	O
-	O
counter	O
.	O

Table	O
1	O
summarizes	O
the	O
uptake	O
of	O
[	O
11	O
C	O
]	O
nemonapride	O
by	O
the	O
striatum	O
and	O
cortex	O
measured	O
by	O
ex	O
vivo	O
ARG	O
and	O
by	O
the	O
tissue	O
sampling	O
.	O

Comparable	O
values	O
of	O
the	O
striatal	O
and	O
cortical	O
uptake	O
were	O
obtained	O
by	O
the	O
two	O
methods	O
,	O
nevertheless	O
the	O
technical	O
problem	O
that	O
the	O
nonstriatal	O
region	O
might	O
be	O
contaminated	O
with	O
the	O
striatal	O
sample	O
in	O
the	O
tissue	O
sampling	O
,	O
and	O
the	O
fact	O
that	O
the	O
uptake	O
of	O
[	O
11	O
C	O
]	O
nemonapride	O
is	O
less	O
homogeneous	O
in	O
the	O
striatum	O
than	O
in	O
the	O
cortex	O
.	O

Therefore	O
,	O
ex	O
vivo	O
ARG	O
may	O
be	O
a	O
suitable	O
method	O
to	O
quantitatively	O
evaluate	O
small	O
regions	O
such	O
as	O
nucleus	O
accumbens	O
and	O
olfactory	O
tubercles	O
.	O

Effect	O
of	O
carrier	O
dose	O
To	O
evaluate	O
the	O
carrier	O
dose	O
on	O
the	O
regional	O
brain	O
uptake	O
of	O
[	O
11	O
C	O
]	O
nemonapride	O
,	O
the	O
uptake	O
was	O
measured	O
by	O
tissue	O
sampling	O
method	O
.	O

As	O
shown	O
in	O
Figure	O
5	O
,	O
at	O
the	O
dose	O
of	O
22	O
nmol	O
/	O
kg	O
the	O
uptake	O
was	O
slightly	O
decreased	O
,	O
though	O
not	O
statistically	O
significant	O
.	O

In	O
the	O
regional	O
brain	O
distribution	O
study	O
with	O
ex	O
vivo	O
ARG	O
and	O
tissue	O
sampling	O
(	O
Table	O
1	O
)	O
,	O
the	O
injected	O
doses	O
were	O
320–330	O
MBq	O
/	O
kg	O
as	O
radioactivity	O
and	O
8.1–20	O
nmol	O
/	O
kg	O
as	O
carrier	O
amounts	O
.	O

Therefore	O
,	O
the	O
injected	O
carrier	O
dose	O
of	O
[	O
11	O
C	O
]	O
nemonapride	O
slightly	O
exceeded	O
to	O
the	O
optimum	O
condition	O
.	O

However	O
,	O
because	O
the	O
PSL	O
/	O
mm2	O
values	O
measured	O
in	O
the	O
cortex	O
were	O
12–14	O
at	O
65–70	O
min	O
after	O
the	O
tracer	O
injection	O
(	O
at	O
35–40	O
min	O
after	O
the	O
exposing	O
time	O
)	O
in	O
the	O
study	O
described	O
in	O
Table	O
1	O
,	O
the	O
injected	O
dose	O
for	O
the	O
[	O
11	O
C	O
]	O
nemonapride	O
can	O
be	O
reasonably	O
reduced	O
to	O
approximately	O
one	O
-	O
tenth	O
within	O
the	O
linearity	O
range	O
for	O
the	O
PSL	O
/	O
mm2	O
(	O
>	O
0.4	O
in	O
Fig.	O
1	O
)	O
,	O
although	O
statistical	O
noise	O
is	O
increased	O
.	O

Therefore	O
,	O
the	O
quantitative	O
ex	O
vivo	O
ARG	O
method	O
using	O
imaging	O
plates	O
presented	O
in	O
this	O
study	O
is	O
applicable	O
to	O
quantitative	O
measurement	O
of	O
the	O
receptor	O
binding	O
capacity	O
with	O
[	O
11	O
C	O
]	O
nemonapride	O
.	O

It	O
can	O
also	O
be	O
applied	O
to	O
other	O
dopamine	O
receptor	O
ligands	O
such	O
as	O
[	O
11	O
C	O
]	O
raclopride	O
,	O
[	O
11	O
C	O
]	O
N	O
-methylspiperone	O
,	O
and	O
[	O
11	O
C	O
]	O
SCH	O
23390	O
(	O
data	O
not	O
shown	O
)	O
,	O
although	O
the	O
uptake	O
depends	O
in	O
the	O
ligand	O
.	O

Figure	O
5	O
also	O
showed	O
that	O
a	O
saturable	O
uptake	O
of	O
[	O
11	O
C	O
]	O
nemonapride	O
was	O
observed	O
in	O
the	O
cortex	O
and	O
cerebellum	O
besides	O
in	O
the	O
striatum	O
,	O
which	O
was	O
preliminarily	O
suggested	O
by	O
a	O
previous	O
report	O
(	O
5	O
)	O
.	O

In	O
vitro	O
[	O
11	O
C	O
]	O
Nemonapride	O
binding	O
to	O
the	O
striatum	O
and	O
cortex	O
In	O
previous	O
studies	O
on	O
in	O
vitro	O
binding	O
of	O
radiolabeled	O
nemonapride	O
(	O
[	O
3	O
H	O
]	O
YM-09151	O
-	O
2	O
)	O
at	O
room	O
temperature	O
,	O
the	O
tracer	O
binding	O
reached	O
equilibrium	O
after	O
90	O
min	O
(	O
2	O
,	O
15	O
,	O
24	O
)	O
.	O

In	O
our	O
preliminary	O
experiment	O
,	O
when	O
the	O
incubation	O
was	O
carried	O
out	O
at	O
37	O
°	O
C	O
to	O
accelerate	O
the	O
equilibration	O
,	O
the	O
[	O
11	O
C	O
]	O
nemonapride	O
binding	O
reached	O
a	O
maximal	O
level	O
at	O
30	O
min	O
(	O
data	O
not	O
shown	O
)	O
,	O
which	O
enabled	O
the	O
use	O
of	O
the	O
short	O
-	O
lived	O
11	O
C	O
-	O
ligand	O
.	O

The	O
specific	O
activity	O
of	O
[	O
11	O
C	O
]	O
nemonapride	O
was	O
reasonably	O
high	O
(	O
25	O
TBq	O
/	O
mmol	O
at	O
the	O
start	O
of	O
assay	O
in	O
the	O
present	O
study	O
)	O
compared	O
with	O
conventional	O
in	O
vitro	O
ARG	O
using	O
3	O
H	O
-	O
labeled	O
compounds	O
.	O

Thus	O
the	O
in	O
vitro	O
ARG	O
with	O
[	O
11	O
C	O
]	O
nemonapride	O
is	O
a	O
practicable	O
technique	O
.	O

The	O
period	O
required	O
from	O
the	O
end	O
of	O
radiosynthesis	O
to	O
the	O
exposing	O
the	O
brain	O
slice	O
to	O
imaging	O
plate	O
was	O
approximately	O
90	O
min	O
.	O

A	O
saturation	O
binding	O
experiment	O
showed	O
a	O
specific	O
binding	O
of	O
[	O
11	O
C	O
]	O
nemonapride	O
to	O
the	O
striatum	O
and	O
cortex	O
(	O
Fig.	O
6A	O
)	O
.	O

Scatchard	O
analysis	O
indicated	O
a	O
Kd	O
of	O
730	O
pM	O
and	O
an	O
apparent	O
Bmax	O
of	O
160	O
nmol	O
/	O
mL	O
tissue	O
in	O
the	O
striatum	O
and	O
a	O
Kd	O
of	O
1.5	O
nM	O
and	O
a	O
Bmax	O
of	O
29	O
nmol	O
/	O
mL	O
tissue	O
in	O
the	O
cortex	O
.	O

The	O
Kd	O
value	O
of	O
730	O
pM	O
for	O
the	O
striatum	O
is	O
in	O
the	O
same	O
order	O
as	O
those	O
obtained	O
with	O
in	O
vitro	O
ARG	O
by	O
Unis	O
et	O
al.	O
(	O
626	O
pM	O
)	O
(	O
24	O
)	O
and	O
Yokoyama	O
et	O
al.	O
(	O
315	O
pM	O
)	O
(	O
26	O
)	O
,	O
but	O
is	O
larger	O
than	O
those	O
(	O
21–82	O
pM	O
)	O
measured	O
by	O
the	O
membrane	O
binding	O
assay	O
(	O
1	O
,	O
13	O
,	O
15	O
,	O
23	O
)	O
or	O
with	O
in	O
vitro	O
ARG	O
(	O
2	O
)	O
.	O

These	O
differences	O
may	O
be	O
caused	O
by	O
the	O
assay	O
conditions	O
such	O
as	O
incubation	O
time	O
,	O
temperature	O
,	O
blockers	O
used	O
to	O
evaluate	O
the	O
nonspecific	O
binding	O
,	O
other	O
medium	O
components	O
,	O
and	O
slice	O
thickness	O
in	O
ARG	O
.	O

The	O
saturation	O
kinetics	O
may	O
also	O
be	O
different	O
between	O
the	O
membrane	O
homogenate	O
and	O
the	O
brain	O
slice	O
.	O

An	O
in	O
vivo	O
saturation	O
binding	O
experiment	O
in	O
Figure	O
6	O
revealed	O
the	O
presence	O
of	O
saturable	O
binding	O
sites	O
for	O
[	O
11	O
C	O
]	O
nemonapride	O
in	O
the	O
cortex	O
and	O
striatum	O
.	O

This	O
finding	O
was	O
also	O
revealed	O
by	O
an	O
ex	O
vivo	O
study	O
(	O
Fig.	O
5	O
)	O
,	O
which	O
also	O
suggested	O
the	O
presence	O
of	O
saturable	O
binding	O
sites	O
in	O
the	O
cerebellum	O
.	O

The	O
specific	O
binding	O
evaluated	O
with	O
a	O
haloperidol	O
-	O
blockade	O
was	O
lower	O
than	O
the	O
nonspecific	O
binding	O
in	O
the	O
cortex	O
(	O
Fig.	O
6A	O
-2	O
)	O
.	O

Kazawa	O
et	O
al.	O
(	O
13	O
)	O
demonstrated	O
that	O
[	O
3	O
H	O
]	O
nemonapride	O
binding	O
in	O
the	O
cortical	O
membrane	O
was	O
displaced	O
by	O
sulpiride	O
or	O
by	O
haloperidol	O
.	O

They	O
also	O
showed	O
that	O
these	O
binding	O
sites	O
were	O
apparently	O
different	O
from	O
serotonin-2	O
receptors	O
.	O

The	O
unknown	O
binding	O
sites	O
may	O
be	O
dopamine	O
D4	O
receptors	O
,	O
because	O
haloperidol	O
,	O
but	O
not	O
raclopride	O
,	O
displaced	O
the	O
uptake	O
(	O
20	O
)	O
.	O

Sigma	O
receptors	O
may	O
be	O
another	O
candidate	O
for	O
the	O
unknown	O
binding	O
sites	O
.	O

Helmeste	O
et	O
al.	O
(	O
7	O
)	O
suggested	O
that	O
nemonapride	O
also	O
has	O
an	O
affinity	O
for	O
sigma	O
receptors	O
,	O
which	O
was	O
evaluated	O
by	O
a	O
blocking	O
study	O
with	O
a	O
selective	O
sigma	O
receptor	O
ligand	O
,	O
R	O
(	O
−	O
)	O
-N	O
-	O
(	O
3-phenyl	O
-	O
n	O
-propyl	O
)	O
-1-phenyl-2-aminopropane	O
(	O
PPAP	O
)	O
.	O

Preliminary	O
findings	O
indicated	O
that	O
the	O
[	O
11	O
C	O
]	O
nemonapride	O
uptake	O
was	O
reduced	O
by	O
carrier	O
nemonapride	O
or	O
by	O
haloperidol	O
in	O
the	O
striatum	O
,	O
cortex	O
,	O
and	O
cerebellum	O
of	O
the	O
mouse	B
brain	O
,	O
but	O
that	O
other	O
sigma	O
receptor	O
ligands	O
such	O
as	O
PPAP	O
,	O
(	O
+	O
)	O
-SKF10047	O
,	O
R	O
(	O
+	O
)	O
-3-	O
(	O
3-hydroxyphenyl	O
)	O
-N	O
-propylpiperidine	O
hydrochloride	O
(	O
R	O
[	O
+	O
]	O
-3-PPP	O
)	O
and	O
NE-100	O
(	O
22	O
)	O
did	O
not	O
reduce	O
the	O
[	O
11	O
C	O
]	O
nemonapride	O
uptake	O
by	O
the	O
striatum	O
(	O
unpublished	O
data	O
)	O
.	O

The	O
in	O
vivo	O
affinity	O
of	O
the	O
[	O
11	O
C	O
]	O
nemonapride	O
for	O
sigma	O
receptors	O
is	O
under	O
investigation	O
.	O

So	O
far	O
,	O
we	O
confirmed	O
in	O
ex	O
vivo	O
and	O
in	O
vitro	O
experiments	O
that	O
the	O
saturable	O
binding	O
sites	O
of	O
[	O
11	O
C	O
]	O
nemonapride	O
are	O
present	O
in	O
the	O
cortex	O
(	O
and	O
probably	O
in	O
the	O
cerebellum	O
)	O
although	O
their	O
characteristics	O
remain	O
unknown	O
.	O

Acknowledgements	O
This	O
work	O
was	O
supported	O
by	O
a	O
Grant	O
-	O
in	O
-	O
Aid	O
for	O
Scientific	O
Research	O
(	O
B	O
)	O
No.	O
10558115	O
from	O
the	O
Ministry	O
of	O
Education	O
,	O
Science	O
,	O
Sports	O
and	O
Culture	O
,	O
Japan	O
.	O

Perillyl	O
alcohol	O
is	O
a	O
hydroxylated	O
metabolite	O
of	O
d	O
-limonene	O
[	O
1–3	O
]	O
,	O
which	O
is	O
the	O
major	O
,	O
naturally	O
occurring	O
monoterpene	O
present	O
in	O
orange	B
peel	O
oil	O
.	O

Perillyl	O
alcohol	O
is	O
also	O
found	O
in	O
lavender	B
,	O
mints	B
,	O
and	O
celery	B
seeds	O
.	O

It	O
has	O
been	O
shown	O
that	O
d	O
-limonene	O
and	O
metabolites	O
possess	O
chemopreventative	O
and	O
chemotherapeutic	O
activity	O
against	O
human	B
malignancies	O
with	O
low	O
toxicity	O
[	O
4–8	O
]	O
.	O

d	O
-Limonene	O
is	O
extensively	O
metabolized	O
(	O
Scheme	O
1	O
)	O
in	O
animals	B
[	O
1–5	O
]	O
and	O
in	O
humans	B
[	O
9,10	O
]	O
and	O
perillic	O
acid	O
and	O
dihydroperillic	O
acid	O
were	O
found	O
to	O
be	O
the	O
major	O
circulating	O
metabolites	O
[	O
1–3,5,6	O
]	O
and	O
for	O
perillyl	O
alcohol	O
[	O
11	O
]	O
.	O

Metabolites	O
of	O
limonene	O
with	O
intermediate	O
polarity	O
such	O
as	O
perillyl	O
alcohol	O
,	O
perillic	O
acid	O
methyl	O
ester	O
and	O
perillaldehyde	O
were	O
found	O
to	O
be	O
more	O
potent	O
inhibitors	O
of	O
isoprenylation	O
of	O
the	O
p21–26	O
kDa	O
protein	O
,	O
which	O
is	O
involved	O
in	O
cell	O
growth	O
and	O
proliferation	O
[	O
7	O
]	O
,	O
than	O
limonene	O
itself	O
.	O

In	O
vivo	O
,	O
perillyl	O
alcohol	O
was	O
also	O
found	O
to	O
be	O
more	O
active	O
than	O
d	O
-limonene	O
[	O
4–7,12–14	O
]	O
.	O

Phillips	O
et	O
al.	O
[	O
11	O
]	O
conducted	O
a	O
pharmacokinetic	O
study	O
of	O
perillyl	O
alcohol	O
in	O
dogs	B
using	O
a	O
GC	O
–	O
MS	O
method	O
with	O
a	O
sensitivity	O
limit	O
of	O
0.25	O
μg	O
/	O
ml	O
,	O
but	O
were	O
unable	O
to	O
detect	O
the	O
parent	O
drug	O
in	O
circulation	O
.	O

In	O
order	O
to	O
understand	O
the	O
pharmacokinetic	O
and	O
disposition	O
characteristics	O
of	O
perillyl	O
alcohol	O
,	O
the	O
development	O
of	O
a	O
more	O
sensitive	O
quantitation	O
assay	O
method	O
is	O
necessary	O
.	O

The	O
present	O
report	O
describes	O
a	O
sensitive	O
GC	O
–	O
MS	O
method	O
for	O
the	O
measurement	O
of	O
perillyl	O
alcohol	O
and	O
its	O
metabolites	O
in	O
plasma	O
using	O
the	O
stable	O
isotope	O
-	O
labelled	O
analogs	O
as	O
the	O
internal	O
standards	O
.	O

A	O
derivatization	O
procedure	O
is	O
also	O
used	O
to	O
facilitate	O
the	O
GC	O
separation	O
and	O
mass	O
spectrometric	O
detection	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Chemicals	O
and	O
reagents	O
(	O
S	O
)	O
-	O
(	O
−	O
)	O
-Perillyl	O
alcohol	O
(	O
POH	O
)	O
was	O
purchased	O
from	O
Aldrich	O
(	O
Milwaukee	O
,	O
WI	O
,	O
USA	O
)	O
.	O

Perillic	O
acid	O
(	O
PA	O
)	O
,	O
cis-	O
/trans-	O
dihydroperillic	O
acid	O
(	O
cis-	O
/trans-	O
DHPA	O
,	O
cis-	O
/trans-	O
4	O
(	O
1′-methylethenyl	O
)	O
cyclohexane-1-carboxylic	O
acid	O
)	O
,	O
perillyl	O
alcohol	O
-	O
d3	O
(	O
POH	O
-	O
d3	O
)	O
and	O
perillic	O
acid	O
-	O
d2	O
-13	O
C	O
(	O
13	O
C	O
-	O
PA	O
-	O
d2	O
)	O
(	O
Fig.	O
1	O
)	O
were	O
synthesized	O
according	O
to	O
the	O
literature	O
method	O
[	O
15	O
]	O
.	O

POH	O
-	O
d3	O
was	O
used	O
as	O
the	O
internal	O
standard	O
for	O
POH	O
,	O
whereas	O
13	O
C	O
-	O
PA	O
-	O
d2	O
was	O
used	O
as	O
the	O
internal	O
standard	O
for	O
PA	O
and	O
cis-	O
/	O
trans	O
-DHPA	O
.	O

Cis-	O
and	O
trans-	O
1-carboxy-4-methylcyclohexane	O
were	O
purchased	O
from	O
Aldrich	O
.	O

The	O
chemical	O
purity	O
of	O
all	O
these	O
synthetic	O
compounds	O
as	O
well	O
as	O
the	O
isotope	O
purity	O
of	O
labeled	O
compounds	O
was	O
99	O
%	O
.	O

N	O
,-	O
O	O
-Bis-	O
(	O
trimethylsilyl	O
)	O
silyltrifluoroacetamide	O
(	O
BSTFA	O
)	O
was	O
obtained	O
from	O
Pierce	O
(	O
Rockford	O
,	O
IL	O
,	O
USA	O
)	O
.	O

Acetonitrile	O
(	O
HPLC	O
grade	O
)	O
was	O
purchased	O
from	O
Fisher	O
Scientific	O
(	O
Pittsburgh	O
,	O
PA	O
,	O
USA	O
)	O
.	O

All	O
other	O
organic	O
solvents	O
and	O
reagents	O
purchased	O
from	O
Fisher	O
Scientific	O
were	O
of	O
reagent	O
grade	O
.	O

2.2	O
Sample	O
extraction	O
To	O
each	O
of	O
a	O
set	O
of	O
16	O
×	O
125-mm	O
disposable	O
tubes	O
was	O
added	O
appropriate	O
amounts	O
of	O
the	O
internal	O
standards	O
in	O
acetonitrile	O
followed	O
by	O
gentle	O
evaporation	O
of	O
the	O
solvent	O
with	O
a	O
stream	O
of	O
nitrogen	O
.	O

A	O
plasma	O
sample	O
(	O
0.5	O
ml	O
or	O
less	O
)	O
was	O
then	O
added	O
and	O
the	O
content	O
mixed	O
.	O

The	O
sample	O
volume	O
of	O
less	O
than	O
0.5	O
ml	O
was	O
made	O
up	O
to	O
0.5	O
ml	O
by	O
addition	O
of	O
blank	O
mouse	B
or	O
human	B
plasma	O
.	O

Acetonitrile	O
(	O
1.0	O
ml	O
)	O
was	O
added	O
to	O
precipitate	O
the	O
protein	O
.	O

The	O
mixture	O
was	O
centrifuged	O
at	O
500	O
g	O
for	O
3	O
min	O
.	O

The	O
supernatant	O
was	O
transferred	O
to	O
a	O
new	O
set	O
of	O
disposable	O
tubes	O
and	O
was	O
acidified	O
by	O
addition	O
of	O
10	O
μl	O
of	O
3	O
M	O
HCl	O
.	O

The	O
extraction	O
was	O
accomplished	O
with	O
3	O
×	O
2	O
ml	O
methylene	O
chloride	O
by	O
vigorously	O
mixing	O
on	O
a	O
vortex	O
-	O
mixer	O
for	O
10	O
s	O
,	O
followed	O
by	O
centrifugation	O
at	O
500	O
g	O
for	O
3	O
min	O
.	O

The	O
methylene	O
chloride	O
extracts	O
were	O
combined	O
and	O
evaporated	O
to	O
dryness	O
by	O
a	O
stream	O
of	O
N2	O
.	O

Forty	O
μl	O
of	O
60	O
%	O
BSTFA	O
in	O
acetonitrile	O
was	O
then	O
added	O
.	O

The	O
content	O
was	O
allowed	O
to	O
stand	O
at	O
room	O
temperature	O
for	O
5	O
min	O
before	O
analysis	O
by	O
GC	O
–	O
MS	O
.	O

2.3	O
GC	O
–	O
MS	O
analysis	O
GC	O
–	O
MS	O
analysis	O
of	O
the	O
analytes	O
was	O
performed	O
on	O
a	O
Finnigan	O
MAT	O
ITS40	O
(	O
Finnigan	O
MAT	O
,	O
San	O
Jose	O
,	O
CA	O
,	O
USA	O
)	O
coupled	O
to	O
a	O
3300	O
/	O
3400	O
Model	O
Varian	O
gas	O
chromatograph	O
(	O
Walnut	O
Creek	O
,	O
CA	O
,	O
USA	O
)	O
.	O

The	O
gas	O
chromatograph	O
was	O
equipped	O
with	O
a	O
DB-5	O
fused	O
-	O
silica	O
capillary	O
column	O
(	O
30	O
m	O
×	O
0.25	O
mm	O
)	O
wall	O
-	O
coated	O
with	O
0.25	O
mm	O
of	O
cross	O
-	O
linked	O
95	O
%	O
methyl-	O
and	O
5	O
%	O
phenyl	O
-	O
polysiloxane	O
(	O
J&W	O
Scientific	O
,	O
Folsom	O
,	O
CA	O
,	O
USA	O
)	O
and	O
an	O
autosampler	O
(	O
Finnigan	O
MAT	O
)	O
.	O

Ultra	O
-	O
high	O
purity	O
helium	O
was	O
used	O
as	O
the	O
carrier	O
gas	O
with	O
a	O
head	O
pressure	O
of	O
15	O
psi	O
(	O
ca	O
.	O

105	O
Pa	O
)	O
.	O

The	O
injection	O
port	O
and	O
the	O
transfer	O
line	O
were	O
set	O
at	O
270	O
°	O
C	O
.	O

The	O
oven	O
temperature	O
was	O
initiated	O
at	O
100	O
°	O
C	O
for	O
1	O
min	O
,	O
and	O
was	O
ramped	O
to	O
250	O
°	O
C	O
at	O
15	O
°	O
C	O
/	O
min	O
,	O
then	O
increased	O
to	O
280	O
°	O
C	O
at	O
30	O
°	O
C	O
/	O
min	O
.	O

The	O
column	O
was	O
held	O
at	O
250	O
°	O
C	O
for	O
1	O
min	O
.	O

Analysis	O
was	O
performed	O
using	O
chemical	O
ionization	O
mode	O
and	O
ammonia	O
was	O
used	O
as	O
the	O
reagent	O
gas	O
.	O

Quantitation	O
was	O
performed	O
in	O
the	O
selected	O
ion	O
monitor	O
mode	O
by	O
measuring	O
the	O
base	O
peak	O
of	O
either	O
MH+	O
or	O
the	O
fragment	O
ions	O
characteristic	O
of	O
the	O
trimethylsilylated	O
derivatives	O
of	O
the	O
analytes	O
and	O
their	O
respective	O
internal	O
standards	O
.	O

The	O
peak	O
area	O
ratio	O
method	O
was	O
used	O
in	O
construction	O
of	O
the	O
calibration	O
curves	O
.	O

2.4	O
13	O
C	O
-	O
NMR	O
analysis	O
13	O
C	O
-	O
NMR	O
spectra	O
were	O
recorded	O
on	O
either	O
a	O
Brucker	O
NR-250	O
spectrometer	O
at	O
a	O
radio	O
frequency	O
of	O
62.89	O
MHz	O
or	O
a	O
Brucker	O
AM-500	O
spectrometer	O
at	O
a	O
radio	O
frequency	O
of	O
125.77	O
MHz	O
with	O
tetramethylsilane	O
as	O
the	O
internal	O
standard	O
and	O
CDCl3	O
as	O
the	O
solvent	O
.	O

2.5	O
Separation	O
of	O
cis-	O
and	O
trans-	O
dihydroperillic	O
acid	O
A	O
mixture	O
of	O
synthetic	O
cis-	O
and	O
trans-	O
dihydroperillic	O
acids	O
was	O
separated	O
by	O
thin	O
-	O
layer	O
chromatography	O
.	O

The	O
mixture	O
(	O
10	O
mg	O
)	O
was	O
dissolved	O
in	O
a	O
small	O
volume	O
of	O
CH2	O
Cl2	O
and	O
the	O
solution	O
was	O
applied	O
onto	O
a	O
precoated	O
silica	O
gel	O
G	O
60	O
thin	O
-	O
layer	O
plate	O
(	O
EM	O
Merck	O
,	O
thickness	O
0.2	O
mm	O
,	O
20	O
×	O
20	O
cm	O
)	O
.	O

This	O
plate	O
was	O
developed	O
ascendingly	O
with	O
50:1	O
CH2	O
Cl2	O
–MeOH	O
on	O
a	O
lined	O
tank	O
for	O
one	O
full	O
-	O
length	O
.	O

Under	O
UV	O
light	O
visualization	O
,	O
two	O
overlapping	O
spots	O
(	O
ca	O
.	O
50	O
%	O
)	O
(	O
R	O
f	O
0.55–0.76	O
)	O
were	O
seen	O
and	O
the	O
upper	O
portion	O
of	O
the	O
faster	O
-	O
running	O
spot	O
(	O
R	O
f	O
0.72–0.76	O
)	O
was	O
scrapped	O
off	O
and	O
eluted	O
with	O
CH2	O
Cl2	O
.	O

The	O
collected	O
compound	O
(	O
ca	O
.	O

2	O
mg	O
)	O
was	O
found	O
to	O
be	O
the	O
pure	O
component	O
corresponding	O
to	O
a	O
retention	O
time	O
of	O
6.3	O
min	O
on	O
GC	O
–	O
MS	O
using	O
the	O
condition	O
as	O
described	O
above	O
.	O

The	O
lower	O
portion	O
of	O
the	O
spot	O
was	O
also	O
collected	O
and	O
GC	O
–	O
MS	O
still	O
showed	O
a	O
mixture	O
of	O
cis	O
/	O
trans	O
-DHPA	O
with	O
retention	O
times	O
of	O
6.3	O
and	O
6.7	O
min	O
.	O

Attempts	O
to	O
further	O
resolve	O
these	O
components	O
were	O
unsuccessful	O
.	O

2.6	O
Assay	O
characterization	O
and	O
validation	O
Detection	O
limit	O
was	O
measured	O
by	O
reducing	O
the	O
amount	O
of	O
each	O
analyte	O
until	O
the	O
signal	O
-	O
to	O
-	O
noise	O
equaled	O
to	O
four	O
,	O
which	O
is	O
defined	O
as	O
the	O
detection	O
limit	O
.	O

The	O
recovery	O
was	O
estimated	O
by	O
comparing	O
the	O
ratio	O
of	O
the	O
extracted	O
analytes	O
to	O
the	O
unextracted	O
internal	O
standard	O
with	O
that	O
of	O
the	O
unextracted	O
pairs	O
.	O

Within	O
-	O
run	O
precision	O
for	O
POH	O
,	O
PA	O
,	O
cis-	O
and	O
trans-	O
DHPA	O
was	O
determined	O
by	O
analyzing	O
six	O
replicates	O
at	O
each	O
concentration	O
on	O
the	O
same	O
day	O
.	O

The	O
concentrations	O
used	O
were	O
:	O
for	O
POH	O
at	O
2	O
,	O
4	O
,	O
20	O
,	O
200	O
and	O
2000	O
ng	O
/	O
ml	O
,	O
for	O
PA	O
at	O
40	O
,	O
200	O
,	O
and	O
2000	O
ng	O
/	O
ml	O
,	O
and	O
for	O
cis-	O
and	O
trans-	O
DHPA	O
each	O
at	O
20	O
,	O
100	O
,	O
and	O
1000	O
ng	O
/	O
ml	O
.	O

Between	O
-	O
run	O
precision	O
was	O
evaluated	O
by	O
analyzing	O
the	O
variation	O
of	O
the	O
slopes	O
of	O
six	O
standard	O
curves	O
for	O
each	O
analyte	O
obtained	O
on	O
six	O
different	O
days	O
.	O

2.7	O
Pilot	O
animal	B
study	O
The	O
femoral	O
and	O
jugular	O
veins	O
of	O
a	O
Sprague	B
-	I
Dawley	I
rat	I
weighing	O
350	O
g	O
were	O
cannulated	O
under	O
ether	O
anesthesia	O
.	O

Three	O
hours	O
after	O
recovery	O
,	O
the	O
animal	B
was	O
given	O
neat	O
perillyl	O
alcohol	O
(	O
ca	O
.	O

22	O
μl	O
)	O
at	O
23	O
mg	O
/	O
kg	O
i.v	O
.	O

via	O
the	O
femoral	O
cannula	O
over	O
30	O
s	O
followed	O
by	O
a	O
rinse	O
of	O
0.5	O
ml	O
normal	O
saline	O
.	O

At	O
the	O
time	O
schedule	O
of	O
0	O
,	O
3	O
,	O
5	O
,	O
10	O
,	O
30	O
,	O
60	O
,	O
120	O
,	O
180	O
,	O
240	O
,	O
300	O
,	O
360	O
,	O
480	O
,	O
720	O
,	O
960	O
,	O
1200	O
,	O
and	O
1440	O
min	O
following	O
dosing	O
,	O
approximately	O
0.2	O
ml	O
of	O
heparinized	O
blood	O
each	O
was	O
withdrawn	O
from	O
the	O
jugular	O
vein	O
cannula	O
.	O

Plasma	O
was	O
separated	O
by	O
centrifugation	O
.	O

An	O
aliquot	O
of	O
each	O
plasma	O
sample	O
was	O
appropriately	O
diluted	O
with	O
blank	O
rat	B
plasma	O
to	O
make	O
up	O
to	O
0.5	O
ml	O
.	O

Under	O
this	O
condition	O
,	O
the	O
measured	O
concentrations	O
were	O
in	O
the	O
range	O
of	O
the	O
calibration	O
-	O
curve	O
.	O

To	O
each	O
plasma	O
sample	O
was	O
added	O
200	O
ng	O
of	O
the	O
internal	O
standard	O
followed	O
by	O
an	O
addition	O
of	O
1.0	O
ml	O
acetonitrile	O
to	O
precipitate	O
the	O
protein	O
.	O

The	O
mixture	O
was	O
centrifuged	O
at	O
2000	O
g	O
for	O
5	O
m.	O
The	O
supernatant	O
was	O
removed	O
and	O
frozen	O
at	O
−20	O
°	O
C	O
until	O
analysis	O
.	O

2.8	O
Preliminary	O
clinical	O
study	O
The	O
clinical	O
study	O
is	O
a	O
part	O
of	O
an	O
ongoing	O
Phase	O
I	O
evaluation	O
of	O
POH	O
as	O
a	O
chemopreventative	O
agent	O
at	O
the	O
Cleveland	O
Clinic	O
Foundation	O
.	O

The	O
Phase	O
I	O
protocol	O
was	O
approved	O
by	O
the	O
Institution	O
Review	O
Board	O
(	O
IRB	O
)	O
at	O
the	O
Cleveland	O
Clinic	O
Foundation	O
.	O

Subjects	B
with	O
a	O
personal	O
history	O
of	O
AJCC	O
Stage	O
I	O
–	O
IIIa	O
breast	O
cancer	O
who	O
have	O
undergone	O
definitive	O
resection	O
with	O
curative	O
intent	O
and	O
who	O
have	O
completed	O
all	O
adjuvant	O
radiation	O
therapy	O
,	O
chemotherapy	O
,	O
and	O
reversible	O
hormone	O
therapy	O
are	O
eligible	O
to	O
enroll	O
in	O
this	O
study	O
.	O

All	O
subjects	B
were	O
in	O
good	O
general	O
health	O
with	O
adequate	O
major	O
organ	O
functions	O
and	O
ECOG	O
Performance	O
Status	O
of	O
0–1	O
.	O

Patients	B
were	O
treated	O
at	O
the	O
Cleveland	O
Clinic	O
Foundation	O
,	O
Cleveland	O
,	O
Ohio	O
.	O

The	O
current	O
study	O
was	O
limited	O
to	O
patients	B
at	O
the	O
first	O
of	O
the	O
five	O
dose	O
levels	O
.	O

Dose	O
at	O
0.5	O
g	O
/	O
m2	O
was	O
given	O
as	O
capsules	O
,	O
which	O
were	O
supplied	O
by	O
the	O
National	O
Cancer	O
Institute	O
.	O

Following	O
dosing	O
,	O
blood	O
samples	O
were	O
drawn	O
at	O
0	O
(	O
predose	O
)	O
,	O
0.25	O
,	O
0.5	O
,	O
0.75	O
,	O
1.0	O
,	O
1.5	O
,	O
2.0	O
,	O
3.0	O
,	O
4.0	O
,	O
6.0	O
,	O
8.0	O
,	O
10.0	O
,	O
and	O
24	O
h.	O
Plasma	O
was	O
separated	O
from	O
red	O
blood	O
cells	O
by	O
centrifugation	O
and	O
kept	O
frozen	O
at	O
−20	O
°	O
C	O
until	O
shipment	O
.	O

All	O
frozen	O
specimens	O
were	O
then	O
shipped	O
in	O
a	O
dry	O
-	O
ice	O
container	O
(	O
overnight	O
)	O
to	O
Dr.	O
Chan	O
's	O
Laboratory	O
at	O
the	O
Ohio	O
State	O
University	O
.	O

Plasma	O
samples	O
were	O
analyzed	O
in	O
the	O
same	O
manner	O
as	O
the	O
rat	B
plasma	O
samples	O
.	O

2.9	O
Quality	O
control	O
and	O
stability	O
Two	O
sets	O
of	O
spiked	O
plasma	O
samples	O
consisting	O
of	O
three	O
concentration	O
levels	O
,	O
20	O
,	O
50	O
,	O
and	O
100	O
ng	O
/	O
ml	O
of	O
POH	O
,	O
PA	O
,	O
cis-	O
/trans-	O
DHPA	O
were	O
prepared	O
and	O
frozen	O
at	O
−20	O
°	O
C	O
.	O

One	O
frozen	O
set	O
was	O
sent	O
to	O
the	O
Laboratory	O
at	O
the	O
Cleveland	O
Clinic	O
Foundation	O
by	O
overnight	O
courier	O
service	O
in	O
dry	O
-	O
ice	O
.	O

After	O
storage	O
for	O
approximately	O
one	O
week	O
at	O
−20	O
°	O
C	O
,	O
the	O
same	O
samples	O
were	O
returned	O
by	O
courier	O
service	O
to	O
the	O
Ohio	O
State	O
University	O
Laboratory	O
.	O

Another	O
set	O
of	O
samples	O
were	O
maintained	O
frozen	O
at	O
the	O
Ohio	O
State	O
University	O
Laboratory	O
for	O
the	O
same	O
duration	O
until	O
analysis	O
.	O

Drug	O
and	O
metabolite	O
levels	O
were	O
analyzed	O
in	O
these	O
two	O
sets	O
of	O
samples	O
at	O
the	O
same	O
time	O
and	O
the	O
results	O
were	O
compared	O
.	O

3	O
Results	O
3.1	O
Analysis	O
of	O
perillyl	O
alcohol	O
and	O
its	O
metabolites	O
The	O
GC	O
–	O
MS	O
mass	O
spectra	O
of	O
POH	O
,	O
PA	O
and	O
cis-	O
/trans-	O
DHPA	O
and	O
their	O
internal	O
standards	O
,	O
POH	O
-	O
d3	O
and	O
13	O
C	O
-	O
PA	O
-	O
d2	O
are	O
shown	O
in	O
Fig.	O
1	O
.	O

As	O
shown	O
,	O
silylated	O
POH	O
and	O
its	O
internal	O
standard	O
each	O
showed	O
the	O
base	O
peak	O
at	O
m	O
/	O
z	O
135	O
and	O
138	O
corresponding	O
to	O
their	O
C	O
–	O
O	O
cleavages	O
.	O

MH+	O
ions	O
as	O
their	O
TMS	O
derivatives	O
at	O
m	O
/	O
z	O
239	O
and	O
m	O
/	O
z	O
242	O
,	O
respectively	O
,	O
were	O
detected	O
for	O
PA	O
and	O
13	O
C	O
-	O
PA	O
-	O
d2	O
as	O
the	O
base	O
peak	O
,	O
and	O
also	O
for	O
cis-	O
/trans-	O
DHPA	O
at	O
m	O
/	O
z	O
241	O
at	O
55	O
%	O
relative	O
abundance	O
.	O

These	O
ions	O
were	O
used	O
for	O
subsequent	O
quantitation	O
.	O

On	O
this	O
basis	O
,	O
a	O
typical	O
set	O
of	O
GC	O
mass	O
chromatograms	O
of	O
human	B
and	O
rat	B
plasma	O
extracts	O
is	O
shown	O
in	O
Fig.	O
2	O
.	O

As	O
shown	O
,	O
all	O
analytes	O
were	O
detected	O
as	O
symmetrical	O
peaks	O
and	O
cis-	O
and	O
trans-	O
DHPA	O
were	O
well	O
resolved	O
.	O

The	O
retention	O
times	O
of	O
the	O
analytes	O
were	O
:	O
POH	O
/	O
POH	O
-	O
d3	O
at	O
6.2	O
min	O
,	O
PA	O
/	O
13	O
C	O
-	O
PA	O
-	O
d2	O
at	O
7.3	O
min	O
,	O
cis-	O
DHPA	O
at	O
6.3	O
min	O
,	O
and	O
trans-	O
DHPA	O
at	O
6.7	O
min	O
.	O

The	O
assignments	O
of	O
cis-	O
and	O
trans-	O
DHPA	O
are	O
described	O
below	O
and	O
coincided	O
with	O
those	O
of	O
Phillips	O
et	O
al.	O
[	O
11	O
]	O
.	O

No	O
interference	O
peaks	O
at	O
the	O
selected	O
ion	O
regions	O
were	O
found	O
in	O
the	O
human	B
or	O
rat	B
plasma	O
blank	O
,	O
except	O
for	O
low	O
levels	O
of	O
signal	O
contributed	O
by	O
the	O
internal	O
standards	O
.	O

These	O
interference	O
contributions	O
were	O
due	O
to	O
incomplete	O
isotope	O
labeling	O
and	O
were	O
all	O
<	O
2	O
%	O
.	O

Thus	O
,	O
the	O
ions	O
monitored	O
at	O
m	O
/	O
z	O
135	O
,	O
138	O
,	O
239	O
,	O
242	O
and	O
241	O
were	O
considered	O
to	O
be	O
highly	O
specific	O
and	O
sensitive	O
for	O
detecting	O
POH	O
and	O
its	O
metabolites	O
.	O

3.2	O
Assignments	O
of	O
cis-	O
and	O
trans-	O
DHPA	O
Phillips	O
et	O
al.	O
[	O
11	O
]	O
using	O
GC	O
–	O
MS	O
method	O
with	O
electron	O
-	O
impact	O
ionization	O
partially	O
resolved	O
the	O
underivatized	O
cis-	O
and	O
trans-	O
DHPA	O
.	O

On	O
the	O
basis	O
of	O
the	O
different	O
mass	O
spectral	O
fragmentation	O
patterns	O
of	O
these	O
two	O
isomers	O
augmented	O
by	O
a	O
quantum	O
mechanical	O
calculation	O
to	O
correlate	O
the	O
configuration	O
and	O
mass	O
fragmentation	O
preference	O
,	O
they	O
assigned	O
the	O
smaller	O
component	O
with	O
a	O
shorter	O
retention	O
time	O
as	O
the	O
cis-	O
isomer	O
and	O
the	O
larger	O
slower	O
-	O
eluting	O
component	O
as	O
the	O
trans-	O
isomer	O
.	O

Since	O
we	O
employed	O
derivatization	O
in	O
our	O
GC	O
–	O
MS	O
assay	O
,	O
direct	O
correlation	O
of	O
our	O
system	O
with	O
those	O
of	O
Philips	O
et	O
al.	O
was	O
difficult	O
.	O

Therefore	O
,	O
we	O
resorted	O
to	O
use	O
an	O
alternative	O
method	O
for	O
the	O
assignment	O
of	O
these	O
isomers	O
.	O

Using	O
thin	O
layer	O
chromatographic	O
separation	O
,	O
we	O
were	O
able	O
to	O
partially	O
resolve	O
the	O
two	O
isomers	O
.	O

The	O
faster	O
running	O
spot	O
was	O
enriched	O
and	O
accumulated	O
.	O

The	O
GC	O
–	O
MS	O
showed	O
that	O
the	O
enriched	O
component	O
had	O
a	O
retention	O
time	O
of	O
6.3	O
min	O
.	O

The	O
H	O
-	O
decoupled	O
13	O
C	O
-	O
NMR	O
spectrum	O
of	O
the	O
synthetic	O
mixture	O
of	O
cis-	O
and	O
trans-	O
DHPA	O
showed	O
sets	O
of	O
doublets	O
at	O
180.97	O
and	O
181.65	O
ppm	O
corresponding	O
to	O
the	O
-COOH	O
signals	O
,	O
at	O
149.76	O
and	O
149.96	O
ppm	O
corresponding	O
to	O
C-1′	O
,	O
at	O
108.54	O
and	O
108.75	O
ppm	O
corresponding	O
to	O
C-2′	O
,	O
at	O
44.15	O
and	O
44.55	O
ppm	O
corresponding	O
to	O
C-4	O
,	O
at	O
39.37	O
and	O
42.98	O
ppm	O
corresponding	O
to	O
C-1	O
,	O
and	O
at	O
above	O
40	O
ppm	O
for	O
the	O
remaining	O
carbons	O
and	O
the	O
side	O
chain	O
methyl	O
.	O

The	O
carbon	O
chemical	O
shift	O
assignments	O
were	O
based	O
on	O
the	O
H	O
-	O
coupling	O
,	O
H	O
-	O
decoupling	O
data	O
,	O
and	O
comparison	O
with	O
known	O
assignments	O
of	O
several	O
monoterpenes	O
and	O
cyclohexane	O
systems	O
[	O
16–18	O
]	O
.	O

However	O
,	O
the	O
H	O
-	O
decoupled	O
13	O
C	O
-	O
NMR	O
spectrum	O
of	O
the	O
above	O
described	O
enriched	O
component	O
failed	O
to	O
show	O
signals	O
with	O
adequate	O
intensity	O
at	O
the	O
downfield	O
region	O
(	O
180	O
ppm	O
)	O
but	O
signals	O
above	O
120	O
ppm	O
were	O
clearly	O
discernible	O
with	O
unequal	O
intensity	O
,	O
consistent	O
with	O
the	O
enrichment	O
.	O

Based	O
on	O
the	O
cyclohexanol	O
system	O
,	O
chemical	O
shift	O
of	O
C-1	O
appears	O
to	O
be	O
most	O
sensitive	O
to	O
cis-	O
/trans-	O
isomerism	O
[	O
18	O
]	O
.	O

Thus	O
,	O
13	O
C	O
-	O
NMR	O
spectra	O
of	O
cis-	O
and	O
trans-	O
1,4-methyl	O
cyclohexanol	O
show	O
C-1	O
at	O
66.2	O
and	O
70.0	O
ppm	O
,	O
respectively	O
,	O
and	O
cis-	O
and	O
trans-	O
1,4-t	O
-	O
butylcyclohexanol	O
show	O
C-1	O
at	O
65.0	O
and	O
70.4	O
ppm	O
,	O
respectively	O
.	O

In	O
both	O
cases	O
C-1s	O
for	O
the	O
cis-	O
isomer	O
are	O
several	O
ppm	O
upfield	O
from	O
the	O
trans-	O
isomer	O
.	O

The	O
enriched	O
DHPA	O
isomer	O
showed	O
only	O
a	O
singlet	O
at	O
39.36	O
ppm	O
of	O
C-1	O
with	O
the	O
more	O
downfield	O
signal	O
missing	O
.	O

This	O
suggests	O
that	O
the	O
enriched	O
DHPA	O
isomer	O
may	O
be	O
the	O
cis-	O
isomer	O
.	O

This	O
possibility	O
was	O
further	O
supported	O
by	O
examination	O
of	O
the	O
13	O
C	O
-	O
NMR	O
spectra	O
of	O
synthetic	O
cis-	O
and	O
trans-	O
1-carboxyl-4-methylcyclohexanes	O
which	O
showed	O
C-1	O
chemical	O
shifts	O
at	O
31.32	O
and	O
34.21	O
ppm	O
,	O
respectively	O
.	O

Again	O
,	O
the	O
C-1	O
of	O
cis-	O
isomer	O
shows	O
nearly	O
3	O
ppm	O
upfield	O
from	O
that	O
of	O
the	O
trans-	O
isomer	O
.	O

In	O
order	O
to	O
correlate	O
the	O
GC	O
–	O
MS	O
retention	O
times	O
of	O
the	O
silyl	O
derivatives	O
of	O
these	O
cyclohexane	O
isomers	O
with	O
their	O
stereochemistry	O
,	O
cis-	O
and	O
trans-	O
1-carboxyl-4-methylcyclohexane	O
were	O
silylated	O
with	O
BSTFA	O
.	O

The	O
GC	O
–	O
MS	O
showed	O
that	O
the	O
cis-	O
isomer	O
gave	O
a	O
retention	O
time	O
of	O
4.12	O
min	O
while	O
the	O
trans-	O
isomer	O
gave	O
a	O
retention	O
time	O
of	O
4.28	O
min	O
using	O
the	O
similar	O
temperature	O
programming	O
and	O
column	O
as	O
those	O
of	O
DHPA	O
.	O

On	O
this	O
basis	O
,	O
it	O
was	O
concluded	O
that	O
the	O
DHPA	O
isomer	O
with	O
the	O
shorter	O
retention	O
time	O
was	O
the	O
cis-	O
isomer	O
and	O
that	O
with	O
the	O
longer	O
retention	O
time	O
was	O
the	O
isomer	O
with	O
trans-	O
configuration	O
.	O

Interestingly	O
,	O
the	O
assignment	O
appeared	O
to	O
be	O
the	O
same	O
as	O
those	O
of	O
Philips	O
et	O
al.	O
[	O
11	O
]	O
,	O
based	O
on	O
the	O
relative	O
retention	O
times	O
of	O
the	O
underivatized	O
compounds	O
and	O
the	O
relative	O
amount	O
of	O
the	O
DHPA	O
found	O
as	O
metabolite	O
in	O
vivo	O
.	O

3.3	O
Within	O
-	O
run	O
validation	O
When	O
plotting	O
the	O
peak	O
area	O
ratios	O
between	O
the	O
analyte	O
and	O
the	O
internal	O
standard	O
against	O
the	O
added	O
concentrations	O
of	O
the	O
analytes	O
a	O
linear	O
relationship	O
was	O
obtained	O
within	O
the	O
concentration	O
ranges	O
monitored	O
for	O
all	O
analytes	O
.	O

In	O
both	O
human	B
and	O
rat	B
plasma	O
,	O
for	O
POH	O
linearity	O
was	O
demonstrated	O
from	O
2	O
to	O
2000	O
ng	O
/	O
ml	O
,	O
for	O
PA	O
and	O
trans-	O
DHPA	O
from	O
10	O
to	O
1000	O
ng	O
/	O
ml	O
,	O
and	O
for	O
cis-	O
DHPA	O
20	O
to1000	O
ng	O
/	O
ml	O
.	O

The	O
routine	O
sensitivity	O
limit	O
was	O
found	O
to	O
be	O
2	O
ng	O
/	O
ml	O
for	O
POH	O
,	O
10	O
ng	O
/	O
ml	O
for	O
PA	O
and	O
trans-	O
DHPA	O
,	O
and	O
20	O
ng	O
/	O
ml	O
for	O
cis-	O
DHPA	O
.	O

The	O
within	O
-	O
run	O
validation	O
data	O
for	O
POH	O
and	O
metabolites	O
in	O
rat	B
and	O
human	B
plasma	O
are	O
shown	O
in	O
Table	O
1	O
.	O

Also	O
shown	O
in	O
the	O
same	O
table	O
are	O
the	O
accuracy	O
data	O
.	O

As	O
shown	O
,	O
the	O
%	O
C.V.	O
values	O
ranged	O
from	O
0.5	O
to	O
8	O
%	O
with	O
the	O
majority	O
falling	O
below	O
5	O
%	O
and	O
a	O
mean	O
accuracy	O
value	O
of	O
98.6	O
%	O
.	O

3.4	O
Between	O
-	O
run	O
validation	O
The	O
between	O
-	O
run	O
variation	O
for	O
POH	O
in	O
human	B
plasma	O
was	O
5.5	O
%	O
and	O
6.3	O
%	O
in	O
rat	B
plasma	O
as	O
measured	O
by	O
the	O
slopes	O
of	O
six	O
calibration	O
curves	O
in	O
each	O
medium	O
at	O
six	O
different	O
occasions	O
(	O
Table	O
2	O
)	O
.	O

At	O
each	O
case	O
,	O
the	O
mean	O
intercept	O
is	O
less	O
than	O
2	O
ng	O
/	O
ml	O
equivalent	O
.	O

The	O
between	O
-	O
run	O
C.V.s	O
for	O
PA	O
by	O
similar	O
measurements	O
were	O
5.5	O
%	O
in	O
human	B
plasma	O
and	O
3.4	O
%	O
in	O
rat	B
plasma	O
,	O
all	O
n	O
=	O
6	O
.	O

The	O
between	O
-	O
run	O
C.V.s	O
for	O
cis-	O
DHPA	O
in	O
human	B
and	O
rat	B
plasma	O
were	O
6.9	O
%	O
and	O
5.1	O
%	O
,	O
respectively	O
(	O
n	O
=	O
6	O
)	O
.	O

The	O
between	O
-	O
run	O
C.V.s	O
for	O
trans-	O
DHPA	O
were	O
5.0	O
and	O
6.3	O
%	O
,	O
respectively	O
(	O
n	O
=	O
6	O
)	O
(	O
Table	O
2	O
)	O
.	O

In	O
these	O
cases	O
,	O
the	O
mean	O
intercepts	O
for	O
the	O
calibration	O
curves	O
of	O
the	O
metabolites	O
were	O
less	O
than	O
5	O
ng	O
/	O
ml	O
analyte	O
equivalent	O
.	O

3.5	O
Recovery	O
and	O
quality	O
control	O
The	O
recovery	O
values	O
of	O
POH	O
,	O
PA	O
,	O
cis-	O
and	O
trans-	O
DHPA	O
from	O
the	O
entire	O
procedure	O
were	O
:	O
98	O
%	O
,	O
59	O
%	O
,	O
64	O
%	O
and	O
72	O
%	O
in	O
human	B
plasma	O
and	O
90	O
%	O
,	O
77	O
%	O
,	O
69	O
%	O
and	O
76	O
%	O
in	O
rat	B
plasma	O
,	O
respectively	O
.	O

There	O
was	O
less	O
than	O
3	O
%	O
variation	O
for	O
POH	O
and	O
metabolite	O
levels	O
in	O
plasma	O
samples	O
kept	O
at	O
−20	O
°	O
C	O
over	O
the	O
course	O
of	O
four	O
weeks	O
and	O
there	O
was	O
no	O
appreciable	O
difference	O
in	O
the	O
samples	O
tested	O
through	O
mailing	O
via	O
the	O
courier	O
service	O
.	O

3.6	O
Preliminary	O
pharmacokinetics	O
of	O
perillyl	O
alcohol	O
and	O
its	O
metabolites	O
in	O
a	O
rat	B
Fig.	O
3	O
shows	O
a	O
plasma	O
concentration	O
–	O
time	O
profile	O
of	O
POH	O
and	O
metabolites	O
in	O
the	O
rat	B
given	O
POH	O
at	O
23	O
mg	O
/	O
kg	O
i.v	O
.	O

As	O
shown	O
,	O
POH	O
was	O
detected	O
in	O
circulation	O
up	O
to	O
360	O
min	O
with	O
the	O
initial	O
concentration	O
at	O
2089	O
ng	O
/	O
ml	O
.	O

The	O
concentrations	O
declined	O
biexponentially	O
with	O
a	O
terminal	O
half	O
-	O
life	O
of	O
approximately	O
135	O
min	O
.	O

PA	O
appeared	O
in	O
plasma	O
in	O
the	O
first	O
sample	O
at	O
3	O
min	O
and	O
peaked	O
at	O
10	O
at	O
8893	O
ng	O
/	O
ml	O
and	O
declined	O
approximately	O
monoexponentially	O
to	O
about	O
35	O
ng	O
/	O
ml	O
at	O
720	O
min	O
.	O

Cis	O
-	O
and	O
trans-	O
DHPA	O
appeared	O
in	O
plasma	O
at	O
about	O
10	O
min	O
and	O
peaked	O
at	O
about	O
60	O
min	O
and	O
also	O
declined	O
monoexponentially	O
.	O

The	O
plasma	O
levels	O
of	O
the	O
trans-	O
metabolite	O
were	O
significantly	O
higher	O
than	O
those	O
of	O
the	O
cis-	O
isomer	O
.	O

An	O
unknown	O
metabolite	O
,	O
labeled	O
as	O
M2	O
,	O
was	O
also	O
detected	O
in	O
plasma	O
at	O
high	O
levels	O
and	O
this	O
metabolite	O
has	O
the	O
same	O
m	O
/	O
z	O
value	O
as	O
PA	O
but	O
with	O
a	O
retention	O
time	O
of	O
8.3	O
min	O
.	O

M2	O
appeared	O
in	O
plasma	O
at	O
3	O
min	O
at	O
2070	O
ng	O
/	O
ml	O
PA	O
equivalent	O
and	O
peaked	O
at	O
10	O
min	O
at	O
levels	O
over	O
6000	O
ng	O
/	O
ml	O
.	O

Although	O
the	O
initial	O
levels	O
of	O
this	O
metabolite	O
were	O
slightly	O
lower	O
than	O
those	O
of	O
PA	O
,	O
the	O
levels	O
after	O
2	O
h	O
exceeded	O
those	O
of	O
PA	O
after	O
and	O
were	O
detectable	O
even	O
at	O
1440	O
min	O
.	O

The	O
plasma	O
half	O
-	O
life	O
was	O
approximately	O
3	O
h.	O
3.7	O
Preliminary	O
pharmacokinetics	O
of	O
perillyl	O
alcohol	O
and	O
its	O
metabolites	O
in	O
a	O
patient	B
The	O
plasma	O
concentration	O
–	O
time	O
profiles	O
of	O
POH	O
and	O
its	O
metabolites	O
were	O
measured	O
in	O
a	O
patient	B
who	O
received	O
a	O
p.o	O
.	O

dose	O
at	O
500	O
mg	O
/	O
m2	O
and	O
the	O
results	O
are	O
shown	O
in	O
Fig.	O
4	O
.	O

As	O
shown	O
,	O
POH	O
,	O
PA	O
,	O
cis-	O
and	O
trans-	O
DHPA	O
were	O
all	O
detectable	O
in	O
plasma	O
.	O

POH	O
was	O
detectable	O
at	O
3.5	O
ng	O
/	O
ml	O
at	O
0.75	O
h	O
and	O
peaked	O
at	O
5.0	O
ng	O
/	O
ml	O
at	O
1.5	O
h.	O
The	O
levels	O
then	O
declined	O
monoexponentially	O
with	O
a	O
half	O
-	O
life	O
of	O
approximately	O
2.3	O
h.	O
The	O
AUC	O
value	O
was	O
22	O
ng	O
/	O
ml	O
h.	O
The	O
most	O
abundant	O
metabolite	O
in	O
circulation	O
was	O
PA	O
which	O
peaked	O
slowly	O
at	O
11400	O
ng	O
/	O
ml	O
at	O
about	O
1.5	O
h.	O
PA	O
was	O
formed	O
rapidly	O
following	O
the	O
POH	O
administration	O
,	O
and	O
remained	O
at	O
a	O
steady	O
-	O
state	O
for	O
1–2	O
h	O
before	O
declining	O
.	O

The	O
level	O
then	O
declined	O
monoexponentially	O
to	O
about	O
40	O
ng	O
/	O
ml	O
at	O
8	O
h	O
and	O
became	O
undetectable	O
thereafter	O
.	O

Similar	O
to	O
the	O
case	O
in	O
the	O
rat	B
,	O
cis-	O
DHPA	O
levels	O
were	O
lower	O
than	O
those	O
of	O
trans	O
.	O

Two	O
previously	O
undescribed	O
metabolites	O
were	O
detected	O
in	O
circulation	O
.	O

M1	O
gave	O
a	O
retention	O
time	O
of	O
7.7	O
min	O
and	O
M2	O
gave	O
a	O
retention	O
of	O
8.3	O
min	O
,	O
which	O
appears	O
identical	O
to	O
the	O
one	O
described	O
in	O
the	O
rat	B
.	O

Both	O
of	O
these	O
metabolites	O
gave	O
the	O
MH+	O
ion	O
identical	O
to	O
that	O
of	O
PA	O
.	O

Levels	O
of	O
M2	O
were	O
lower	O
than	O
those	O
of	O
PA	O
but	O
higher	O
than	O
those	O
of	O
M1	O
.	O

M2	O
peaked	O
at	O
over	O
1000	O
ng	O
/	O
ml	O
at	O
3	O
h	O
,	O
and	O
M1	O
peaked	O
at	O
76	O
ng	O
/	O
ml	O
at	O
1	O
h.	O
4	O
Discussion	O
Previous	O
GC	O
and	O
GC	O
–	O
MS	O
methods	O
failed	O
to	O
detect	O
POH	O
in	O
plasma	O
presumably	O
because	O
of	O
inadequate	O
sensitivity	O
[	O
11	O
]	O
.	O

The	O
reason	O
for	O
the	O
low	O
sensitivity	O
may	O
be	O
due	O
to	O
the	O
use	O
of	O
electron	O
impact	O
mass	O
spectrometry	O
for	O
detection	O
.	O

Excess	O
fragmentation	O
under	O
the	O
EI	O
condition	O
significantly	O
reduced	O
the	O
assay	O
sensitivity	O
.	O

Moreover	O
,	O
POH	O
and	O
its	O
metabolites	O
such	O
as	O
PA	O
are	O
still	O
rather	O
polar	O
.	O

Tailing	O
of	O
their	O
GC	O
peaks	O
may	O
also	O
reduce	O
the	O
assay	O
sensitivity	O
.	O

The	O
present	O
method	O
used	O
a	O
soft	O
ammonia	O
chemical	O
ionization	O
,	O
which	O
could	O
reduce	O
fragmentation	O
and	O
increase	O
the	O
relative	O
abundance	O
of	O
the	O
ion	O
.	O

Additionally	O
,	O
we	O
also	O
found	O
that	O
BSTFA	O
derivatization	O
of	O
POH	O
and	O
its	O
metabolites	O
reduced	O
tailing	O
and	O
further	O
reduced	O
fragmentation	O
and	O
enhanced	O
sensitivity	O
.	O

Another	O
improvement	O
of	O
our	O
analytical	O
method	O
was	O
to	O
use	O
the	O
stable	O
isotopically	O
labeled	O
POH	O
and	O
PA	O
as	O
the	O
internal	O
standard	O
that	O
provided	O
the	O
excellent	O
C.V.s	O
obtained	O
.	O

Thus	O
,	O
the	O
current	O
assay	O
provided	O
more	O
than	O
a	O
hundred	O
-	O
fold	O
improvement	O
in	O
sensitivity	O
over	O
the	O
previous	O
GC	O
–	O
MS	O
method	O
,	O
and	O
made	O
it	O
possible	O
to	O
detect	O
circulating	O
POH	O
following	O
POH	O
administration	O
.	O

The	O
use	O
of	O
derivatization	O
and	O
a	O
capillary	O
column	O
in	O
this	O
method	O
also	O
permitted	O
the	O
complete	O
separation	O
of	O
cis-	O
and	O
trans-	O
DHPA	O
(	O
Fig.	O
3	O
)	O
.	O

The	O
earlier	O
eluting	O
peak	O
(	O
6.3	O
min	O
)	O
was	O
assigned	O
to	O
be	O
the	O
cis-	O
isomer	O
,	O
based	O
on	O
the	O
NMR	O
method	O
and	O
this	O
assignment	O
is	O
identical	O
to	O
those	O
of	O
Philip	O
et	O
al.	O
[	O
11	O
]	O
who	O
assigned	O
their	O
earlier	O
eluting	O
component	O
in	O
the	O
partially	O
resolved	O
pair	O
as	O
the	O
cis-	O
isomer	O
.	O

Both	O
the	O
preliminary	O
rat	B
and	O
human	B
pharmacokinetic	O
data	O
show	O
that	O
POH	O
was	O
detectable	O
in	O
circulation	O
for	O
the	O
first	O
time	O
following	O
POH	O
administration	O
.	O

Metabolites	O
of	O
POH	O
were	O
detected	O
in	O
high	O
levels	O
in	O
both	O
rat	B
and	O
human	B
plasma	O
.	O

PA	O
appeared	O
very	O
rapidly	O
in	O
circulation	O
and	O
rose	O
to	O
high	O
concentrations	O
,	O
suggesting	O
that	O
POH	O
underwent	O
rapid	O
metabolism	O
.	O

Both	O
cis-	O
and	O
trans-	O
DHPA	O
were	O
unequivocally	O
detected	O
in	O
the	O
human	B
and	O
in	O
the	O
rat	B
and	O
their	O
formation	O
as	O
a	O
mixture	O
was	O
previously	O
under	O
debate	O
[	O
11	O
]	O
.	O

Two	O
previously	O
undescribed	O
metabolites	O
were	O
detected	O
in	O
significant	O
levels	O
in	O
human	B
plasma	O
and	O
one	O
also	O
in	O
the	O
rat	B
.	O

These	O
two	O
metabolites	O
as	O
their	O
silylated	O
derivatives	O
gave	O
the	O
parent	O
ion	O
(	O
MH+	O
)	O
at	O
m	O
/	O
z	O
239	O
identical	O
to	O
that	O
of	O
silylated	O
PA	O
but	O
with	O
different	O
retention	O
times	O
.	O

Characterization	O
of	O
these	O
metabolites	O
is	O
currently	O
underway	O
.	O

Thus	O
,	O
the	O
current	O
method	O
is	O
useful	O
to	O
support	O
preclinical	O
and	O
clinical	O
investigations	O
of	O
disposition	O
of	O
perillyl	O
alcohol	O
.	O

5	O
Conclusion	O
A	O
GC	O
–	O
MS	O
stable	O
isotope	O
-	O
dilution	O
method	O
has	O
been	O
developed	O
for	O
the	O
analysis	O
of	O
perillyl	O
alcohol	O
and	O
its	O
metabolites	O
in	O
human	B
and	O
animal	B
plasma	O
and	O
the	O
method	O
has	O
been	O
validated	O
.	O

Unchanged	O
perillyl	O
alcohol	O
in	O
plasma	O
was	O
detected	O
in	O
human	B
and	O
animal	B
circulation	O
for	O
the	O
first	O
time	O
.	O

Isomers	O
of	O
a	O
reduced	O
metabolite	O
DHPA	O
have	O
been	O
total	O
resolved	O
and	O
detected	O
and	O
their	O
previous	O
cis-	O
and	O
trans-	O
assignments	O
verified	O
by	O
alternate	O
techniques	O
.	O

Two	O
new	O
metabolites	O
were	O
also	O
detected	O
.	O

This	O
GC	O
–	O
MS	O
can	O
be	O
applied	O
to	O
investigate	O
preclinical	O
and	O
clinical	O
pharmacokinetics	O
of	O
perillyl	O
alcohol	O
both	O
as	O
a	O
chemopreventative	O
and	O
chemotherapeutical	O
agent	O
.	O

Acknowledgments	O
This	O
study	O
was	O
in	O
part	O
supported	O
by	O
PHS	O
Contract	O
NCI	O
-	O
CN-55083070	O
,	O
Task	O
22	O
,	O
awarded	O
to	O
the	O
Cleveland	O
Clinic	O
Foundation	O
subcontracted	O
to	O
the	O
Ohio	O
State	O
University	O
and	O
by	O
P30	O
CA16058	O
by	O
the	O
National	O
Cancer	O
Institute	O
.	O

Eosinophils	O
may	O
play	O
important	O
roles	O
in	O
allergic	O
diseases	O
such	O
as	O
asthma	O
and	O
atopic	O
dermatitis	O
)	O
'	O
2	O
In	O
such	O
diseases	O
,	O
eosinophiis	O
migrate	O
to	O
inflammatory	O
sites	O
and	O
degranulate	O
eytotoxic	O
proteins	O
such	O
as	O
major	O
basic	O
protein	O
and	O
eosinophil	O
-	O
derived	O
neurotoxin	O
(	O
EDN	O
)	O
.	O

The	O
cytotoxic	O
proteins	O
damage	O
tissues	O
and	O
cause	O
physiologic	O
abnormalities	O
in	O
patients	B
with	O
allergic	O
diseases	O
.	O

Therefore	O
,	O
cosinophil	O
degranulation	O
inhibitors	O
may	O
be	O
anti	O
-	O
allergic	O
drugs	O
.	O

Recently	O
,	O
we	O
found	O
that	O
sulochrin	O
(	O
6	O
)	O
,	O
a	O
metabolite	O
of	O
fungi	B
,	O
was	O
a	O
specific	O
inhibitor	O
of	O
eosinophil	O
degranulation3	O
and	O
also	O
inhibited	O
eosinophll	O
activation	O
and	O
chemotaxis	O
.	O

*	O
We	O
report	O
here	O
the	O
effects	O
of	O
ortho-	O
substituent	O
groups	O
on	O
inhibitory	O
activity	O
to	O
eosinophil	O
degranulation	O
.	O

Chemistry	O
Sulochrin	O
(	O
6	O
)	O
was	O
synthesized	O
as	O
shown	O
in	O
scheme	O
1	O
.	O

Benzoic	O
acid	O
benzyl	O
ester	O
(	O
5	O
)	O
was	O
obtained	O
by	O
the	O
condensation	O
of	O
2-bromo	O
benzyl	O
alcohol	O
(	O
2	O
)	O
and	O
benzoic	O
acid	O
(	O
4	O
)	O
.	O

Anion	O
induced	O
rearrangement	O
of	O
(	O
5	O
)	O
gave	O
1-	O
benzoyl	O
benzyl	O
alcohol	O
,	O
which	O
was	O
oxidized	O
to	O
benzoyl	O
benzoic	O
acid	O
without	O
isolation.5	O
'	O
6	O
Esterification	O
of	O
the	O
benzoyl	O
benzoic	O
acid	O
followed	O
by	O
debenzylatinn	O
afforded	O
sulochrin	O
(	O
6	O
)	O
.7	O
All	O
other	O
sulochrin	O
derivatives	O
except	O
for	O
(	O
9	O
)	O
were	O
obtained	O
through	O
a	O
modified	O
methodology	O
.	O

Compound	O
9	O
was	O
prepared	O
as	O
shown	O
in	O
scheme	O
2	O
.	O

Results	O
and	O
Discussion	O
The	O
derivatives	O
of	O
sulochrin	O
(	O
6	O
)	O
were	O
examined	O
for	O
their	O
inba"oitory	O
activity	O
against	O
eosinophil	O
degranulation	O
as	O
descn'bed	O
previously.3	O
At	O
first	O
,	O
ester	O
derivatives	O
were	O
synthesized	O
to	O
examine	O
the	O
structure	O
-	O
activity	O
relationship	O
.	O

As	O
shown	O
in	O
Table	O
la	O
,	O
alkyl	O
esters	O
(	O
11	O
-	O
15	O
)	O
retained	O
activity	O
,	O
and	O
in	O
particular	O
,	O
n	O
-	O
butyl	O
and	O
see	O
-	O
butyl	O
esters	O
0960	O
-	O
894X	O
/	O
99	O
/	O
$	O
-	O
see	O
front	O
matter	O
1999	O
Elsevier	O
Science	O
Ltd.	O
All	O
rights	O
reserved	O
.	O

Pll	O
:	O
S0960	O
-	O
894X	O
(	O
99	O
)	O
00305	O
-	O
4	O
1946	O
H.	O
Ohashi	O
et	O
al.	O
/	O
Bioorg	O
.	O

Med	O
.	O

Chem	O
.	O

Lett	O
.	O

9	O
(	O
1999	O
)	O
1945	O
-	O
1948	O

Scheme	O
I	O
OH	O
OBn	O
a	O
,	O
b	O
,	O
c	O
,	O
d	O
Br	O
Me	O
"	O
<	O
~	O
OH	O
Me	O
"	O
"	O
~	O
OBn	O
COOMe	O
"	O
~OH	O
e	O
,	O
f	O
1	O
2	O
3	O
4	O
O	O
OBn	O
7	O
~	O
-~	O
OMe	O
QH13	O
!	O

r	O
2	O
+	O
4	O
P	O
5~	O
15	O
T	O
"	O
Br	O
BnO	O
"	O
-	O
..	O

:	O
I	O
"	O
Me	O
h	O
,	O
i	O
,	O
j	O
,	O
k	O
,	O
I	O
I	O
"	O
~1	O
-	O
1	O
"	O
g	O
OMe	O
MeOOC	O
O	O
OH	O
9	O
8	O
5	O
6	O
(	O
Sulochrln	O
)	O
(	O
a	O
)	O
BnBr	O
,	O
K	O
~	O
O~	O
/	O
CH3CN	O
/	O
reflux,33	O
%	O
;	O
(	O
b	O
)	O
Me	O
zSO4,K	O
~	O
CO3	O
/	O
CHaCN	O
/	O
reflux,96	O
%	O
;	O
(	O
c	O
)	O
UAIH4	O
/	O
I'HF,96	O
%	O
;	O
(	O
d	O
)	O
NBS	O
/	O
CCI4,43	O
%	O
;	O
(	O
e	O
)	O
BnBr	O
,	O
l	O
~	O
COa	O
/	O
DMF	O
/	O
reflux,74	O
%	O
;	O
(	O
f	O
)	O
t	O
-	O
BuOWiPr	O
=	O
O	O
/	O
reflux,93	O
%	O
;	O
(	O
g	O
)	O
DEAD	O
/	O
PPh	O
.	O

VrHF,82	O
%	O
;	O
(	O
h	O
)	O
n	O
-	O
BuLi	O
/	O
1"HF,-78"C,45	O
%	O
;	O
(	O
i	O
)	O
PDC	O
/	O
DMF,54	O
%	O
;	O
(	O
j	O
)	O
BudNH4	O
)	O
KMnO,~=yddlne,81	O
%	O
;	O
(	O
k	O
)	O
Mel	O
K2CO	O
~	O
JDMF	O
;	O
(	O
I	O
)	O
Pd	O
(	O
OH	O
)	O
rCarbon	O
/	O
EtOH	O
/	O
Cyclohexene	O
/	O
refiux	O
81	O
%	O
Scheme	O
2	O
Me	O
~	O
OMe	O
o~	O
OMe	O
OH	O
MeO	O
~	O
OMe	O
~	O
MeO'~OMe	O
.	O

HO	O
~	O
Me	O
"	O
COOH	O
m	O
"	O
~	O
"	O
COCI	O
n	O
,	O
p	O
7	O
8	O
O	O
OH	O
(	O
m	O
)	O
SOCle	O
;	O
(	O
n	O
)	O
n	O
-	O
BuLi	O
/	O
THF	O
,	O
-4YC,15	O
%	O
;	O
(	O
P	O
)	O
BBrdCH	O
=	O
Cle,64	O
%	O
(	O
13	O
and	O
14	O
)	O
showed	O
more	O
potent	O
activity	O
than	O
sulochrin	O
(	O
6	O
)	O
.	O

On	O
thc	O
other	O
hand	O
,	O
decarboxyl	O
and	O
flee	O
carboxylic	O
acid	O
derivatives	O
(	O
9	O
and	O
10	O
)	O
did	O
not	O
show	O
any	O
activity	O
even	O
at	O
10	O
pM.	O
These	O
results	O
suggest	O
that	O
the	O
existence	O
of	O
H.	O
Ohashi	O
et	O
al.	O
/	O
Bioorg	O
.	O

Med	O
.	O

Chem	O
.	O

Lett	O
.	O

9	O
(	O
1999	O
)	O
1945	O
-	O
1948	O
1947	O
Table	O
la	O
Effects	O
of	O
alkylester	O
on	O
eoslnophll	O
degranulation	O
OMe	O
OH	O
R1	O
O	O
OH	O
Compound	O
R	O
,	O
ICso	O
(	O
mlcroM	O
)	O
Sulochrin	O
(	O
6	O
)	O
9	O
10	O
11	O
12	O
13	O
14	O
15	O
COOCHa	O
H	O
COOH	O
COOCH2CHa	O
COOCH	O
=	O
CH	O
=	O
CHa	O
COOCH	O
=	O
CH2CH	O
=	O
CHa	O
COO	O
(	O
CH	O
)	O
CHaCH	O
=	O
CHa	O
COO	O
(	O
CH=	O
)	O
sCH.~	O
0.1	O
>	O
10	O
>	O
10	O
0.1	O
0.1	O
0.04	O
0.03	O
0.3	O
Table	O
lb	O
Effects	O
of	O
phenolic	O
hydroxyl	O
groups	O
on	O
eoslnophil	O
degranulation	O
Sulochdn	O
(	O
6	O
)	O
HO-,~zFtz	O
12~	O
16	O
17	O
MeOOC	O
O	O
OR	O
,	O
19	O
2O	O
Compound	O
R2	O
FL~	O
P~	O
ICs0	O
(	O
microM	O
)	O
H	O
Me	O
H	O
Me	O
H	O
H	O
Me	O
H	O
Me	O
Me	O
Me	O
H	O
(	O
CH2	O
)	O
2OH	O
H	O
H	O
Me	O
H	O
(	O
CH=	O
)	O
=OH	O
0.1	O
0.4	O
0.3	O
>	O
10	O
>	O
10	O
>	O
10	O
alkyl	O
ester	O
at	O
C-6	O
position	O
is	O
essential	O
and	O
see	O
-	O
butyl	O
ester	O
is	O
most	O
suitable	O
for	O
activity	O
.	O

Next	O
,	O
we	O
examined	O
the	O
importance	O
of	O
methoxy	O
and	O
hydroxyl	O
groups	O
at	O
C-2	O
,	O
C-12	O
and	O
C-16	O
positions	O
(	O
Table	O
lb	O
)	O
.	O

Compared	O
to	O
sulochrin	O
(	O
6	O
)	O
,	O
19	O
showed	O
much	O
less	O
activity	O
.	O

Activity	O
of	O
16	O
approached	O
that	O
of	O
sulochrin	O
(	O
6	O
)	O
after	O
methylation	O
of	O
hydroxyl	O
group	O
at	O
C-12	O
position	O
in	O
19	O
.	O

Furthermore	O
,	O
compound	O
17	O
also	O
showed	O
activity	O
.	O

These	O
results	O
indicate	O
that	O
at	O
least	O
one	O
methoxy	O
group	O
at	O
C-2	O
or	O
(	O
2	O
-	O
12	O
position	O
is	O
required	O
for	O
activity	O
.	O

Compound	O
18	O
,	O
in	O
which	O
two	O
methoxy	O
groups	O
at	O
C-12	O
and	O
(	O
2	O
-	O
16	O
positions	O
on	O
the	O
ring	O
B	O
were	O
introduced	O
,	O
showed	O
much	O
less	O
activity	O
than	O
16	O
or	O
17	O
.	O

Furthermore	O
,	O
compound	O
20	O
also	O
lost	O
activity	O
.	O

These	O
results	O
indicate	O
that	O
at	O
least	O
one	O
free	O
hydroxyl	O
group	O
at	O
ortho	O
-	O
position	O
on	O
the	O
ring	O
B	O
is	O
required	O
for	O
activity	O
,	O
suggesting	O
that	O
hydrogen	O
bond	O
between	O
16-OH	O
and	O
carbunyl	O
at	O
(	O
2	O
-	O
10	O
might	O
contn'bute	O
to	O
activity	O
.	O

We	O
have	O
recently	O
shown	O
that	O
substituents	O
at	O
ortho	O
-	O
positions	O
showed	O
effect	O
on	O
the	O
conformation	O
from	O
the	O
analysis	O
of	O
crystal	O
structures	O
of	O
suiochrin	O
derivatives	O
,	O
a	O
The	O
hydrogen	O
bond	O
between	O
16-OH	O
and	O
earbonyl	O
at	O
C-10	O
may	O
contribute	O
to	O
the	O
conformation	O
where	O
the	O
ring	O
B	O
and	O
the	O
central	O
carbunyl	O
planes	O
are	O
co	O
-	O
planner	O
and	O
cross	O
at	O
a	O
right	O
angle	O
to	O
the	O
1948	O
1	O
t	O
.	O

Ohashi	O
et	O
al.	O
/	O
Bioorg	O
.	O

Med	O
.	O

Chem	O
.	O

Lett	O
.	O

9	O
(	O
1999	O
)	O
1945	O
-	O
1948	O
ring	O
A.	O
This	O
conformation	O
would	O
be	O
inaccess	O
~	O
le	O
to	O
the	O
less	O
active	O
compounds	O
that	O
lack	O
the	O
hydrogen	O
bond	O
,	O
supporting	O
the	O
speculation	O
.	O

Compounds	O
10	O
and	O
19	O
,	O
which	O
have	O
more	O
hydrophilic	O
substitution	O
at	O
ortho	O
-	O
positions	O
,	O
lost	O
activity	O
.	O

Therefore	O
,	O
hydrophobicity	O
is	O
also	O
important	O
for	O
activity	O
.	O

In	O
conclusion	O
,	O
we	O
found	O
that	O
i	O
)	O
alkylester	O
at	O
C-6	O
position	O
is	O
required	O
;	O
ii	O
)	O
see	O
-	O
butyl	O
ester	O
at	O
C-6	O
position	O
is	O
optimal	O
for	O
activity	O
;	O
ill	O
)	O
optimal	O
hydrophobicity	O
of	O
the	O
ortho	O
-	O
substituents	O
may	O
exist	O
;	O
and	O
iv	O
)	O
the	O
conformation	O
of	O
sulochrin	O
may	O
influence	O
to	O
the	O
inlu'bitory	O
activity	O
against	O
eosinophil	O
degranulation	O
.	O

Acknowledgements	O

We	O
thank	O
to	O
Dr.	O
Masakazu	O
Sakalo'bara	O
for	O
critical	O
reading	O
of	O
this	O
manuscript	O
.	O

An	O
accurate	O
estimation	O
of	O
the	O
onset	O
of	O
oestrus	O
in	O
cows	B
is	O
vital	O
to	O
the	O
cost	O
-	O
efficient	O
application	O
of	O
artificial	O
insemination	O
(	O
AI	O
)	O
procedures	O
(	O
Ball	O
,	O
1982	O
)	O
.	O

The	O
steroid	O
hormone	O
progesterone	O
,	O
which	O
is	O
secreted	O
by	O
the	O
corpus	O
luteum	O
,	O
functions	O
to	O
prepare	O
the	O
uterus	O
for	O
pregnancy	O
and	O
to	O
maintain	O
pregnancy	O
following	O
conception	O
.	O

Fluctuations	O
in	O
the	O
level	O
of	O
secreted	O
progesterone	O
are	O
reflected	O
throughout	O
the	O
oestrus	O
cycle	O
by	O
the	O
concentration	O
of	O
the	O
hormone	O
present	O
in	O
cows	B
'	O
milk	O
.	O

It	O
follows	O
that	O
by	O
monitoring	O
milk	O
progesterone	O
concentration	O
it	O
has	O
been	O
possible	O
accurately	O
to	O
predict	O
the	O
onset	O
of	O
oestrus	O
;	O
using	O
enzyme	O
immunoassay	O
methodology	O
(	O
Foulkes	O
et	O
al.	O
,	O
1982a	O
)	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
optimum	O
fertility	O
rates	O
can	O
be	O
achieved	O
when	O
AI	O
is	O
performed	O
on	O
the	O
third	O
day	O
of	O
sustained	O
low	O
milk	O
progesterone	O
concentration	O
(	O
Foulkes	O
et	O
al.	O
,	O
1982b	O
;	O
Foulkes	O
and	O
Goodey	O
,	O
1988	O
)	O
.	O

The	O
search	O
for	O
a	O
rapid	O
,	O
convenient	O
and	O
inexpensive	O
means	O
of	O
frequently	O
monitoring	O
milk	O
progesterone	O
levels	O
in	O
a	O
herd	O
of	O
animals	B
has	O
led	O
into	O
research	O
toward	O
a	O
user	O
-	O
friendly	O
on	O
-	O
the	O
-	O
farm	O
device	O
.	O

One	O
such	O
approach	O
is	O
a	O
disposable	O
screen	O
-	O
printed	O
amperometric	O
biosensor	O
.	O

Previously	O
,	O
we	O
described	O
the	O
development	O
of	O
a	O
prototype	O
progesterone	O
biosensor	O
comprising	O
mAb	O
immobilised	O
on	O
the	O
working	O
surface	O
of	O
a	O
screen	O
-	O
printed	O
carbon	O
electrode	O
(	O
SPCE	O
)	O
.	O

It	O
operated	O
in	O
a	O
competitive	O
immunoassay	O
format	O
,	O
relying	O
upon	O
a	O
reduction	O
in	O
the	O
binding	O
of	O
enzyme	O
-	O
labelled	O
progesterone	O
in	O
the	O
presence	O
of	O
endogenous	O
milk	O
progesterone	O
.	O

Initial	O
proof	O
-	O
of	O
-	O
principle	O
was	O
provided	O
from	O
experiments	O
conducted	O
in	O
aqueous	O
buffer	O
solution	O
using	O
phenyl	O
phosphate	O
as	O
substrate	O
for	O
the	O
enzyme	O
alkaline	O
phosphatase	O
,	O
with	O
a	O
chronoamperometric	O
readout	O
dependent	O
on	O
the	O
oxidation	O
of	O
phenol	O
at	O
a	O
potential	O
of	O
+	O
700	O
mV	O
versus	O
SCE	O
(	O
Hart	O
et	O
al.	O
,	O
1997	O
)	O
.	O

Operating	O
at	O
this	O
relatively	O
high	O
electrode	O
potential	O
,	O
however	O
,	O
it	O
was	O
not	O
possible	O
to	O
obtain	O
a	O
calibration	O
in	O
milk	O
,	O
due	O
to	O
variable	O
adsorption	O
,	O
at	O
the	O
electrode	O
surface	O
,	O
of	O
electroactive	O
species	O
present	O
within	O
this	O
complex	O
matrix	O
(	O
Pemberton	O
et	O
al.	O
,	O
1998	O
)	O
;	O
even	O
washing	O
with	O
solvents	O
of	O
varying	O
polarity	O
did	O
not	O
remove	O
the	O
interferent	O
.	O

For	O
this	O
reason	O
,	O
it	O
is	O
desirable	O
to	O
reduce	O
the	O
operating	O
potential	O
to	O
below	O
that	O
required	O
to	O
oxidise	O
the	O
interferent	O
.	O

In	O
order	O
to	O
achieve	O
this	O
objective	O
,	O
two	O
potentially	O
useful	O
enzyme	O
substrates	O
,	O
1-naphthyl	O
phosphate	O
(	O
1-NP	O
)	O
and	O
4-aminophenyl	O
phosphate	O
(	O
4-APP	O
)	O
,	O
may	O
be	O
considered	O
.	O

These	O
are	O
hydrolysed	O
to	O
their	O
corresponding	O
phenols	O
,	O
1-naphthol	O
and	O
4-aminophenol	O
,	O
on	O
reaction	O
with	O
alkaline	O
phosphatase	O
.	O

Both	O
4-APP	O
(	O
Tang	O
et	O
al.	O
,	O
1988	O
;	O
Pemberton	O
et	O
al.	O
,	O
1998	O
;	O
Schreiber	O
et	O
al.	O
,	O
1997	O
)	O
and	O
1-NP	O
(	O
Athey	O
et	O
al.	O
,	O
1993	O
;	O
Fernandez	O
-	O
Sanchez	O
and	O
Costa	O
-	O
Garcia	O
,	O
1997	O
)	O
have	O
been	O
investigated	O
previously	O
in	O
immunoassay	O
systems	O
,	O
but	O
no	O
detailed	O
comparative	O
studies	O
of	O
their	O
performance	O
have	O
been	O
reported	O
at	O
SPCEs	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
compare	O
the	O
electrochemical	O
behaviour	O
of	O
1-naphthol	O
and	O
4-aminophenol	O
at	O
bare	O
and	O
antibody	O
-	O
coated	O
SPCEs	O
and	O
to	O
determine	O
which	O
phenol	O
would	O
be	O
the	O
more	O
compatible	O
with	O
biosensor	O
operation	O
.	O

Their	O
phosphorylated	O
derivatives	O
were	O
then	O
evaluated	O
as	O
substrates	O
for	O
use	O
with	O
a	O
milk	O
progesterone	O
immunosensor	O
.	O

This	O
paper	O
describes	O
the	O
results	O
of	O
these	O
studies	O
.	O

2	O
Experimental	O
2.1	O
Chemicals	O
and	O
reagents	O
Chemicals	O
used	O
were	O
of	O
AR	O
-	O
grade	O
and	O
were	O
purchased	O
from	O
Merck	O
(	O
Poole	O
,	O
Dorset	O
,	O
UK	O
)	O
.	O

Water	O
for	O
the	O
preparation	O
of	O
buffer	O
solutions	O
was	O
drawn	O
from	O
a	O
Milli	O
-	O
Q	O
Water	O
Purification	O
System	O
(	O
Millipore	O
UK	O
,	O
Watford	O
,	O
UK	O
)	O
.	O

Carbonate	O
coating	O
buffer	O
(	O
CB	O
)	O
comprised	O
0.015	O
mol	O
/	O
dm	O
Na2	O
CO3	O
and	O
0.035	O
mol	O
/	O
dm3	O
NaHCO3	O
at	O
a	O
pH	O
of	O
9.6	O
.	O

Diethanolamine	O
-	O
HCl	O
buffer	O
(	O
DB	O
;	O
0.1	O
mol	O
/	O
dm3	O
)	O
was	O
adjusted	O
to	O
a	O
final	O
pH	O
of	O
7.2	O
or	O
9.8	O
.	O

MgCl2	O
at	O
a	O
concentration	O
of	O
0.01	O
mol	O
/	O
dm3	O
was	O
included	O
in	O
pH9.8	O
DB	O
as	O
a	O
cofactor	O
for	O
alkaline	O
phosphatase	O
.	O

Before	O
final	O
dilution	O
in	O
DB	O
,	O
4-aminophenol	O
(	O
Sigma	O
-	O
Aldrich	O
Company	O
,	O
Poole	O
,	O
Dorset	O
,	O
UK	O
)	O
was	O
dissolved	O
in	O
0.1	O
mol	O
/	O
dm3	O
NaOH	O
;	O
1-naphthol	O
(	O
Acros	O
Organics	O
,	O
Loughborough	O
,	O
Leics	O
,	O
UK	O
)	O
was	O
dissolved	O
directly	O
in	O
DB	O
.	O

A	O
polyclonal	O
rabbit	B
antibody	O
(	O
IgG	O
fraction	O
)	O
against	O
sheep	B
IgG	O
was	O
purchased	O
from	O
Sigma	O
-	O
Aldrich	O
(	O
rIg	O
)	O
.	O

Sheep	B
monoclonal	O
antibody	O
(	O
mAb	O
)	O
against	O
progesterone	O
(	O
Groves	O
et	O
al.	O
,	O
1990	O
)	O
was	O
kindly	O
provided	O
by	O
Ridgeway	O
Science	O
Ltd.	O
in	O
the	O
form	O
of	O
culture	O
supernatant	O
.	O

A	O
solution	O
containing	O
alkaline	O
-	O
phosphatase	O
-	O
labelled	O
progesterone	O
(	O
AP	O
-	O
prog	O
)	O
was	O
obtained	O
from	O
the	O
same	O
source	O
.	O

Unlabelled	O
progesterone	O
(	O
f.wt.=314.5	O
)	O
was	O
purchased	O
from	O
Sigma	O
-	O
Aldrich	O
.	O

4-APP	O
(	O
monosodium	O
salt	O
)	O
and	O
1-NP	O
were	O
purchased	O
from	O
ICN	O
Biomedicals	O
Ltd.	O
,	O
Thame	O
,	O
Oxon	O
,	O
UK	O
and	O
Acros	O
Organics	O
,	O
respectively	O
.	O

Whole	O
milk	O
test	O
samples	O
from	O
six	O
different	O
Fresian	B
Holstein	I
dairy	I
cows	I
at	O
various	O
stages	O
of	O
their	O
oestrus	O
cycles	O
were	O
obtained	O
from	O
Ridgeway	O
Science	O
Ltd.	O
These	O
samples	O
were	O
collected	O
following	O
agitation	O
of	O
the	O
complete	O
milking	O
jar	O
after	O
morning	O
milking	O
of	O
cows	B
.	O

One	O
Lactab	O
MkIII	O
tablet	O
(	O
Thompson	O
and	O
Capper	O
Ltd.	O
,	O
Runcorn	O
,	O
Cheshire	O
,	O
UK	O
)	O
containing	O
30	O
mg	O
potassium	O
dichromate	O
was	O
added	O
to	O
every	O
25	O
ml	O
milk	O
as	O
a	O
preservative	O
.	O

Samples	O
were	O
then	O
stored	O
at	O
4	O
°	O
C	O
where	O
they	O
were	O
stable	O
for	O
up	O
to	O
3	O
months	O
.	O

In	O
the	O
present	O
study	O
,	O
assays	O
were	O
performed	O
after	O
21	O
days	O
of	O
storage	O
.	O

Standards	O
containing	O
known	O
concentrations	O
of	O
progesterone	O
were	O
prepared	O
by	O
dissolving	O
progesterone	O
in	O
methanol	O
at	O
1	O
mg	O
/	O
ml	O
,	O
aliquoting	O
a	O
known	O
volume	O
into	O
a	O
glass	O
tube	O
and	O
evaporating	O
the	O
methanol	O
under	O
N2	O
before	O
adding	O
to	O
whole	O
milk	O
(	O
sampled	O
and	O
preserved	O
as	O
above	O
)	O
from	O
an	O
oestrus	O
cow	B
(	O
containing	O
<	O
1	O
ng	O
/	O
ml	O
progesterone	O
)	O
.	O

Serial	O
dilutions	O
were	O
then	O
performed	O
in	O
the	O
same	O
milk	O
over	O
the	O
desired	O
concentration	O
range	O
.	O

2.2	O
Biosensor	O
preparation	O
Carbon	O
electrodes	O
(	O
3	O
×	O
3	O
mm	O
working	O
area	O
)	O
were	O
screen	O
-	O
printed	O
using	O
code	O
D14	O
ink	O
formulation	O
onto	O
PVC	O
backing	O
card	O
at	O
Gwent	O
Electronic	O
Materials	O
Ltd.	O
(	O
Mamhilad	O
,	O
Gwent	O
,	O
UK	O
)	O
as	O
described	O
elsewhere	O
(	O
Sprules	O
et	O
al.	O
,	O
1996	O
)	O
.	O

Individual	O
screen	O
-	O
printed	O
electrodes	O
(	O
SPCEs	O
)	O
were	O
coated	O
with	O
rIg	O
(	O
to	O
capture	O
and	O
orientate	O
the	O
mAb	O
)	O
and	O
mAb	O
as	O
described	O
previously	O
(	O
Hart	O
et	O
al.	O
,	O
1997	O
)	O
.	O

For	O
these	O
studies	O
,	O
a	O
1	O
/	O
20	O
dilution	O
of	O
mAb	O
was	O
applied	O
to	O
the	O
electrodes	O
,	O
being	O
chosen	O
empirically	O
as	O
the	O
highest	O
dilution	O
giving	O
an	O
optimum	O
sigmoidal	O
calibration	O
plot	O
for	O
progesterone	O
measured	O
colorimetrically	O
(	O
see	O
Pemberton	O
et	O
al.	O
,	O
1998	O
)	O
.	O

These	O
are	O
referred	O
to	O
as	O
mAb	O
-	O
SPCEs	O
.	O

2.3	O
Instrumentation	O
Electrochemical	O
procedures	O
were	O
carried	O
out	O
using	O
an	O
E612	O
VA	O
Scanner	O
and	O
an	O
E611	O
VA	O
Detector	O
(	O
Metrohm	O
,	O
Herisau	O
,	O
Switzerland	O
)	O
attached	O
to	O
a	O
Linseis	O
LY18100	O
x	O
–y	O
plotter	O
(	O
Recorder	O
Laboratory	O
Services	O
,	O
Sutton	O
,	O
Surrey	O
,	O
UK	O
)	O
.	O

A	O
Viglen	O
486	O
Sx	O
computer	O
was	O
used	O
for	O
simulation	O
of	O
cyclic	O
voltammograms	O
using	O
the	O
simulation	O
program	O
CVSIM	O
(	O
Gosser	O
,	O
1993	O
)	O
.	O

The	O
simple	O
'	O
E	O
r	O
'	O
,	O
mechanism	O
for	O
a	O
one	O
-	O
electron	O
oxidation	O
of	O
a	O
solution	O
species	O
at	O
the	O
working	O
electrode	O
was	O
used	O
to	O
estimate	O
values	O
for	O
k	O
het	O
from	O
simulations	O
of	O
the	O
oxidation	O
of	O
4-aminophenol	O
at	O
bare	O
and	O
mAb	O
-	O
coated	O
SPCEs	O
.	O

Common	O
electroactive	O
species	O
parameters	O
were	O
:	O
C	O
red	O
=	O
1	O
mM	O
,	O
C	O
ox	O
=	O
0.0	O
mM	O
,	O
D	O
=	O
5	O
×	O
10−6	O
cm2	O
/s	O
;	O
and	O
common	O
experimental	O
settings	O
were	O
:	O
number	O
of	O
half	O
cycles=2	O
,	O
A	O
=	O
0.09	O
cm2	O
,	O
E	O
i	O
=	O
−0.3	O
V	O
,	O
E	O
s	O
=	O
+	O
1.0	O
V	O
,	O
E	O
f	O
=	O
−0.3	O
V	O
,	O
v	O
=	O
0.05	O
vs−1	O
.	O

Parameters	O
specific	O
for	O
reaction	O
at	O
a	O
bare	O
SPCE	O
were	O
:	O
E	O
0	O
/	O
=	O
−0.050	O
V	O
,	O
α	O
=	O
0.533	O
and	O
for	O
reaction	O
at	O
a	O
mAb	O
-	O
coated	O
SPCE	O
were	O
:	O
E	O
0	O
/	O
=	O
−0.037	O
V	O
,	O
α	O
=	O
0.400	O
.	O

2.4	O
Cyclic	O
voltammetry	O
and	O
chronoamperometry	O
Cyclic	O
voltammetric	O
studies	O
were	O
conducted	O
using	O
10	O
ml	O
analyte	O
volumes	O
in	O
a	O
glass	O
voltammetric	O
cell	O
.	O

Individual	O
working	O
SPCEs	O
or	O
mAb	O
-	O
SPCEs	O
were	O
used	O
in	O
a	O
3-electrode	O
configuration	O
in	O
conjunction	O
with	O
a	O
saturated	O
calomel	O
reference	O
and	O
platinum	O
counter	O
electrode	O
.	O

Chronoamperometric	O
measurements	O
were	O
made	O
by	O
using	O
individual	O
working	O
mAb	O
-	O
SPCEs	O
,	O
together	O
with	O
a	O
saturated	O
calomel	O
electrode	O
functioning	O
as	O
a	O
combined	O
counter	O
/	O
reference	O
electrode	O
in	O
a	O
two	O
electrode	O
configuration	O
.	O

In	O
this	O
way	O
it	O
was	O
possible	O
to	O
perform	O
measurements	O
using	O
a	O
small	O
(	O
0.5	O
ml	O
)	O
volume	O
of	O
enzyme	O
substrate	O
solution	O
in	O
a	O
conical	O
polypropylene	O
cell	O
.	O

2.5	O
Electrochemical	O
immunoassay	O
procedure	O
Milk	O
samples	O
were	O
mixed	O
with	O
AP	O
-	O
prog	O
solution	O
in	O
the	O
ratio	O
3:5	O
(	O
this	O
combination	O
gave	O
a	O
maximum	O
signal	O
:	O
noise	O
ratio	O
)	O
.	O

Eight	O
microlitre	O
volumes	O
of	O
these	O
mixtures	O
were	O
added	O
to	O
the	O
surface	O
of	O
individual	O
mAb	O
-	O
SPCEs	O
.	O

After	O
30	O
min	O
at	O
room	O
temperature	O
(	O
18–25	O
°	O
C	O
;	O
RT	O
)	O
,	O
the	O
electrodes	O
were	O
washed	O
three	O
times	O
in	O
DB	O
,	O
pH	O
9.8	O
,	O
then	O
placed	O
in	O
0.5	O
ml	O
DB	O
,	O
pH	O
9.8	O
or	O
the	O
same	O
buffer	O
containing	O
5	O
mmol	O
/	O
dm3	O
4-APP	O
or	O
1-NP	O
.	O

After	O
5	O
min	O
(	O
a	O
compromise	O
between	O
maximum	O
enzyme	O
activity	O
and	O
speed	O
of	O
assay	O
for	O
multiple	O
samples	O
)	O
,	O
the	O
working	O
electrode	O
potential	O
was	O
stepped	O
from	O
open	O
circuit	O
to	O
+	O
200	O
or	O
+	O
300	O
mV	O
versus	O
SCE	O
,	O
respectively	O
and	O
the	O
peak	O
current	O
(	O
i	O
p	O
)	O
response	O
was	O
recorded	O
.	O

Calibration	O
graphs	O
were	O
obtained	O
by	O
plotting	O
i	O
p	O
values	O
in	O
the	O
presence	O
of	O
an	O
enzyme	O
substrate	O
minus	O
background	O
i	O
p	O
values	O
in	O
buffer	O
only	O
for	O
each	O
known	O
standard	O
progesterone	O
concentration	O
(	O
y	O
-axis	O
)	O
against	O
progesterone	O
concentration	O
(	O
x	O
-axis	O
)	O
.	O

For	O
each	O
unknown	O
cow	B
sample	O
,	O
a	O
similar	O
subtraction	O
of	O
the	O
buffer	O
blank	O
i	O
p	O
value	O
was	O
performed	O
before	O
using	O
the	O
calibration	O
plot	O
by	O
interpolation	O
to	O
obtain	O
an	O
estimate	O
of	O
progesterone	O
concentration	O
.	O

The	O
relationship	O
between	O
readings	O
obtained	O
by	O
EIA	O
and	O
electrochemical	O
assays	O
was	O
investigated	O
using	O
linear	O
regression	O
analysis	O
.	O

3	O
Results	O
and	O
discussion	O
3.1	O
Electrochemistry	O
of	O
4-aminophenol	O
,	O
1-naphthol	O
and	O
corresponding	O
monophosphates	O
The	O
electrochemical	O
behaviour	O
of	O
the	O
enzyme	O
substrates	O
4-APP	O
and	O
1-NP	O
,	O
and	O
their	O
hydrolysis	O
products	O
,	O
4-aminophenol	O
and	O
1-naphthol	O
,	O
was	O
examined	O
by	O
cyclic	O
voltammetry	O
at	O
unmodified	O
SPCEs	O
(	O
Fig.	O
1	O
)	O
.	O

4-Aminophenol	O
showed	O
well	O
-	O
defined	O
oxidation	O
and	O
reduction	O
peaks	O
and	O
the	O
ΔE	O
p	O
value	O
indicated	O
that	O
the	O
electrode	O
reaction	O
was	O
quasi	O
-	O
reversible	O
(	O
Fig.	O
1	O
(	O
a	O
)	O
)	O
.	O

The	O
anodic	O
potential	O
(	O
E	O
pa	O
)	O
was	O
well	O
below	O
that	O
required	O
for	O
the	O
oxidation	O
of	O
the	O
corresponding	O
monophosphate	O
,	O
4-APP	O
(	O
Fig.	O
1	O
(	O
b	O
)	O
)	O
.	O

In	O
contrast	O
,	O
1-naphthol	O
gave	O
only	O
an	O
oxidation	O
peak	O
at	O
+	O
230	O
mV	O
(	O
Fig.	O
1	O
(	O
c	O
)	O
)	O
,	O
which	O
could	O
be	O
due	O
to	O
the	O
electrode	O
reaction	O
itself	O
giving	O
an	O
electro	O
-	O
inactive	O
product	O
,	O
or	O
to	O
the	O
oxidised	O
naphthol	O
product	O
undergoing	O
an	O
irreversible	O
chemical	O
reaction	O
.	O

1-NP	O
(	O
Fig.	O
1	O
(	O
d	O
)	O
)	O
was	O
not	O
electrochemically	O
active	O
over	O
the	O
potential	O
range	O
studied	O
.	O

At	O
this	O
stage	O
,	O
it	O
appeared	O
that	O
the	O
anodic	O
signals	O
for	O
either	O
4-aminophenol	O
or	O
1-naphthol	O
could	O
be	O
used	O
as	O
the	O
basis	O
for	O
an	O
immunoassay	O
for	O
progesterone	O
.	O

Further	O
studies	O
were	O
therefore	O
performed	O
to	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
voltammetric	O
behaviour	O
of	O
these	O
two	O
phenols	O
.	O

The	O
cyclic	O
voltammetric	O
behaviour	O
of	O
4-aminophenol	O
and	O
1-naphthol	O
was	O
next	O
compared	O
at	O
naked	O
and	O
mAb	O
-	O
SPCEs	O
(	O
Fig.	O
2	O
)	O
.	O

For	O
both	O
analytes	O
,	O
the	O
presence	O
of	O
the	O
antibodies	O
increased	O
the	O
background	O
oxidation	O
signal	O
at	O
potentials	O
above	O
+	O
0.5	O
V	O
(	O
Fig.	O
2	O
(	O
b	O
,	O
d	O
)	O
)	O
,	O
but	O
the	O
magnitude	O
of	O
the	O
overall	O
peak	O
currents	O
were	O
the	O
same	O
as	O
obtained	O
at	O
naked	O
SPCEs	O
(	O
Fig.	O
2	O
(	O
a	O
,	O
c	O
)	O
)	O
.	O

However	O
,	O
in	O
the	O
case	O
of	O
4aminophenol	O
,	O
the	O
oxidation	O
peak	O
became	O
broader	O
in	O
the	O
presence	O
of	O
the	O
antibodies	O
and	O
showed	O
a	O
small	O
positive	O
E	O
p	O
shift	O
(	O
∼30	O
mV	O
,	O
Fig.	O
2	O
(	O
a	O
,	O
b	O
)	O
)	O
.	O

In	O
the	O
case	O
of	O
1-naphthol	O
,	O
there	O
was	O
also	O
a	O
small	O
positive	O
E	O
p	O
shift	O
(	O
∼10	O
mV	O
)	O
in	O
the	O
presence	O
of	O
the	O
antibodies	O
(	O
Fig.	O
2	O
(	O
c	O
,	O
d	O
)	O
)	O
.	O

Further	O
comparison	O
of	O
the	O
electrochemistry	O
of	O
4-aminophenol	O
and	O
1-naphthol	O
,	O
at	O
naked	O
and	O
mAb	O
-	O
coated	O
SPCEs	O
,	O
was	O
obtained	O
by	O
performing	O
cyclic	O
voltammetry	O
at	O
various	O
scan	O
rates	O
.	O

The	O
relationship	O
produced	O
during	O
cyclic	O
voltammetry	O
between	O
peak	O
current	O
(	O
i	O
p	O
)	O
and	O
v	O
1	O
/	O
2	O
is	O
described	O
by	O
the	O
Randles	O
-	O
Sevcik	O
equation	O
,	O
modified	O
for	O
irreversible	O
systems	O
:	O

Cv	O
1	O
/	O
2	O
ip	O
=	O
(	O
2.99	O
×	O
10	O
5	O
)	O
·	O
n	O
(	O
αna	O
)	O
1	O
/	O
2	O
AD1	O
/	O
2	O
(	O
Heineman	O
and	O
Kissinger	O
,	O
1984	O
)	O
where	O
i	O
p	O
=	O
peak	O
current	O
(	O
μA	O
)	O
,	O
n	O
=	O
number	O
of	O
electrons	O
,	O
αn	O
a	O
=	O
electron	O
transfer	O
coefficient	O
,	O
A	O
=	O
working	O
electrode	O
area	O
(	O
cm2	O
)	O
,	O
D	O
=	O
diffusion	O
coefficient	O
(	O
cm2	O
/s	O
)	O
,	O
C=	O
bulk	O
concentration	O
of	O
analyte	O
(	O
mmoles	O
/	O
ml	O
)	O
and	O
v	O
=	O
scan	O
rate	O
(	O
mV	O
/	O
s	O
)	O
.	O

Plots	O
of	O
i	O
p	O
versus	O
v	O
1	O
/	O
2	O
for	O
both	O
analytes	O
at	O
naked	O
and	O
mAb	O
-	O
SPCEs	O
are	O
shown	O
in	O
Fig.	O
3	O
.	O

In	O
the	O
case	O
of	O
4-aminophenol	O
,	O
there	O
is	O
evidence	O
that	O
the	O
presence	O
of	O
the	O
mAb	O
results	O
in	O
lower	O
i	O
p	O
values	O
at	O
all	O
scan	O
rates	O
compared	O
with	O
naked	O
SPCEs	O
(	O
Fig.	O
3	O
(	O
a	O
)	O
)	O
.	O

These	O
observations	O
suggest	O
that	O
the	O
mAb	O
may	O
slow	O
the	O
diffusion	O
of	O
4-AP	O
towards	O
the	O
electrode	O
surface	O
,	O
and	O
may	O
combine	O
with	O
polyphenols	O
to	O
reduce	O
the	O
working	O
area	O
available	O
for	O
the	O
oxidation	O
of	O
4-AP	O
.	O

In	O
contrast	O
,	O
ip	O
values	O
obtained	O
for	O
1-naphthol	O
at	O
naked	O
and	O
mAb	O
-	O
SPCEs	O
are	O
almost	O
superimposed	O
for	O
scan	O
rates	O
up	O
to	O
200	O
mVs−1	O
(	O
Fig.	O
3	O
(	O
b	O
)	O
)	O
.	O

This	O
suggests	O
that	O
the	O
antibody	O
coating	O
has	O
little	O
effect	O
on	O
the	O
diffusional	O
characteristics	O
of	O
1-naphthol	O
.	O

Electron	O
transfer	O
coefficients	O
(	O
αn	O
a	O
)	O
were	O
calculated	O
for	O
naked	O
and	O
mAb	O
-	O
SPCEs	O
as	O
described	O
previously	O
(	O
Galus	O
,	O
1976	O
)	O
.	O

For	O
4-aminophenol	O
,	O
these	O
values	O
were	O
0.533	O
and	O
0.400	O
,	O
respectively	O
;	O
this	O
decrease	O
indicates	O
that	O
the	O
antibody	O
layer	O
partially	O
inhibits	O
the	O
electron	O
transfer	O
step	O
,	O
possibly	O
due	O
to	O
steric	O
hindrance	O
.	O

A	O
computer	O
simulation	O
program	O
(	O
CVSIM	O
,	O
Gosser	O
,	O
1993	O
)	O
was	O
used	O
to	O
simulate	O
cyclic	O
voltammograms	O
for	O
4-aminophenol	O
in	O
order	O
to	O
obtain	O
values	O
for	O
the	O
electrochemical	O
rate	O
constant	O
.	O

Using	O
the	O
above	O
αn	O
a	O
values	O
,	O
it	O
was	O
found	O
that	O
the	O
heterogeneous	O
rate	O
constant	O
(	O
k	O
het	O
)	O
for	O
the	O
mAb	O
-	O
SPCEs	O
was	O
3.0	O
×	O
10−4	O
/cm	O
s−1	O
,	O
whereas	O
k	O
het	O
for	O
a	O
naked	O
SPCE	O
was	O
calculated	O
to	O
be	O
6.5	O
×	O
10−4	O
cm	O
s−1	O
.	O

The	O
slower	O
rate	O
constant	O
obtained	O
with	O
the	O
mAb	O
-	O
SPCEs	O
supports	O
the	O
suggestion	O
of	O
partial	O
inhibition	O
discussed	O
above	O
.	O

Finally	O
,	O
the	O
αn	O
a	O
values	O
were	O
calculated	O
for	O
1-naphthol	O
at	O
naked-	O
and	O
mAb	O
-	O
SPCEs	O
,	O
to	O
be	O
0.53	O
and	O
0.60	O
,	O
respectively	O
.	O

These	O
values	O
suggest	O
that	O
the	O
antibody	O
coating	O
does	O
not	O
inhibit	O
the	O
rate	O
of	O
electron	O
transfer	O
during	O
the	O
oxidation	O
of	O
this	O
phenol	O
.	O

Fig.	O
4	O
(	O
a	O
)	O
shows	O
the	O
effect	O
of	O
scan	O
rate	O
on	O
the	O
anodic	O
peak	O
potential	O
for	O
4-aminophenol	O
,	O
at	O
naked	O
and	O
antibody	O
-	O
coated	O
SPCEs	O
.	O

True	O
reversible	O
reactions	O
do	O
not	O
show	O
shifts	O
of	O
E	O
p	O
with	O
scan	O
rate	O
,	O
inferring	O
that	O
the	O
oxidation	O
reactions	O
at	O
both	O
types	O
of	O
SPCE	O
appear	O
to	O
be	O
quasi	O
-	O
reversible	O
over	O
the	O
range	O
studied	O
.	O

In	O
contrast	O
,	O
at	O
scan	O
rates	O
above	O
100	O
mVs−1	O
,	O
1-naphthol	O
appears	O
to	O
show	O
more	O
reversible	O
behaviour	O
at	O
both	O
SPCEs	O
than	O
4-aminophenol	O
.	O

This	O
may	O
be	O
explained	O
by	O
a	O
slow	O
chemical	O
follow	O
-	O
up	O
reaction	O
(	O
possibly	O
polymerisation	O
)	O
for	O
1-naphthol	O
after	O
the	O
initial	O
electron	O
transfer	O
step	O
.	O

It	O
should	O
also	O
be	O
noted	O
that	O
the	O
peak	O
potential	O
for	O
the	O
oxidation	O
of	O
1-naphthol	O
obtained	O
at	O
the	O
mAb	O
-	O
SPCE	O
at	O
200	O
mVs−1	O
is	O
+	O
0.38	O
V	O
;	O
for	O
4-aminophenol	O
at	O
this	O
electrode	O
the	O
E	O
p	O
value	O
was	O
+	O
0.28	O
V.	O
All	O
of	O
the	O
above	O
observations	O
using	O
cyclic	O
voltammetry	O
suggested	O
that	O
1-NP	O
would	O
be	O
a	O
suitable	O
candidate	O
for	O
the	O
chronoamperometric	O
immunoassay	O
.	O

Although	O
the	O
magnitude	O
of	O
the	O
anodic	O
response	O
was	O
lower	O
than	O
that	O
seen	O
for	O
4-aminophenol	O
at	O
equivalent	O
concentration	O
,	O
the	O
hydrolysis	O
product	O
,	O
1-naphthol	O
,	O
appeared	O
capable	O
of	O
producing	O
a	O
significant	O
and	O
unimpeded	O
oxidation	O
signal	O
at	O
mAb	O
-	O
SPCEs	O
.	O

3.2	O
Establishing	O
the	O
operating	O
potential	O
for	O
chronoamperometric	O
detection	O
of	O
l	O
-	O
naphthol	O
Previous	O
cyclic	O
voltammograms	O
with	O
SPCEs	O
(	O
Pemberton	O
et	O
al.	O
,	O
1998	O
)	O
have	O
demonstrated	O
the	O
presence	O
,	O
in	O
milk	O
,	O
of	O
electroactive	O
species	O
capable	O
of	O
adsorbing	O
onto	O
the	O
electrode	O
surface	O
and	O
being	O
oxidised	O
to	O
produce	O
anodic	O
signals	O
capable	O
of	O
interfering	O
with	O
the	O
operation	O
of	O
the	O
immunosensor	O
by	O
chronoamperometry	O
.	O

Using	O
4-APP	O
as	O
enzyme	O
substrate	O
it	O
was	O
possible	O
to	O
select	O
an	O
operating	O
potential	O
of	O
+	O
200	O
mV	O
,	O
well	O
below	O
the	O
potential	O
required	O
to	O
oxidise	O
adsorbed	O
milk	O
species	O
(	O
Pemberton	O
et	O
al.	O
,	O
1998	O
)	O
.	O

In	O
order	O
to	O
confirm	O
that	O
1-naphthol	O
could	O
be	O
detected	O
amperometrically	O
and	O
to	O
establish	O
an	O
operating	O
potential	O
for	O
use	O
in	O
the	O
assay	O
,	O
chronoamperometric	O
measurement	O
of	O
a	O
1	O
mM	O
1-naphthol	O
solution	O
was	O
performed	O
over	O
a	O
range	O
of	O
operating	O
potentials	O
at	O
mAb	O
-	O
SPCEs	O
which	O
had	O
been	O
incubated	O
with	O
enzyme	O
-	O
labelled	O
progesterone	O
either	O
in	O
buffer	O
solution	O
or	O
in	O
milk	O
.	O

Fig.	O
5	O
shows	O
that	O
in	O
order	O
to	O
avoid	O
signals	O
due	O
to	O
the	O
oxidation	O
of	O
electroactive	O
species	O
within	O
milk	O
,	O
it	O
would	O
be	O
necessary	O
to	O
operate	O
below	O
+	O
400	O
mV.	O
It	O
was	O
necessary	O
to	O
operate	O
at	O
+	O
600	O
mV	O
to	O
achieve	O
the	O
maximum	O
current	O
signal	O
from	O
chronoamperometry	O
of	O
1-naphthol	O
.	O

However	O
,	O
it	O
was	O
still	O
possible	O
to	O
obtain	O
over	O
50	O
%	O
of	O
this	O
response	O
at	O
+	O
300	O
mV	O
which	O
was	O
therefore	O
chosen	O
as	O
the	O
operating	O
potential	O
for	O
the	O
biosensor	O
.	O

3.3	O
Analysis	O
of	O
cows	B
'	O
milk	O
-	O
comparison	O
of	O
enzyme	O
substrates	O
4-APP	O
and	O
1-NP	O
In	O
order	O
to	O
compare	O
the	O
performance	O
of	O
the	O
immunosensor	O
using	O
1-NP	O
as	O
an	O
enzyme	O
substrate	O
with	O
its	O
performance	O
using	O
4-APP	O
,	O
milk	O
samples	O
obtained	O
from	O
a	O
number	O
of	O
different	O
cows	B
were	O
analysed	O
for	O
progesterone	O
content	O
using	O
both	O
approaches	O
.	O

The	O
results	O
were	O
then	O
compared	O
with	O
those	O
obtained	O
using	O
a	O
commercial	O
EIA	O
(	O
Ridgeway	O
Science	O
Ltd.	O
;	O
accuracy=±8	O
%	O
inter	O
-	O
assay	O
C.V.	O
,	O
sensitivity=0.6	O
ng	O
/	O
ml	O
)	O
by	O
reference	O
to	O
a	O
standard	O
curve	O
of	O
absorbance	O
reading	O
versus	O
progesterone	O
concentration	O
(	O
Sauer	O
et	O
al.	O
,	O
1986	O
)	O
.	O

Fig.	O
6	O
(	O
a	O
)	O
shows	O
the	O
calibration	O
curve	O
obtained	O
using	O
4-APP	O
as	O
substrate	O
to	O
measure	O
progesterone	O
milk	O
standards	O
over	O
the	O
concentration	O
range	O
,	O
0–50	O
ng	O
/	O
ml	O
,	O
before	O
and	O
after	O
background	O
subtraction	O
.	O

Precision	O
for	O
triplicate	O
sensors	O
at	O
each	O
concentration	O
ranged	O
from	O
5.3	O
to	O
18.3	O
%	O
.	O

The	O
readings	O
obtained	O
for	O
six	O
cows	B
'	O
milk	O
samples	O
,	O
together	O
with	O
those	O
obtained	O
using	O
the	O
standard	O
EIA	O
are	O
shown	O
on	O
a	O
correlation	O
plot	O
for	O
the	O
two	O
sets	O
of	O
values	O
(	O
Fig.	O
6	O
(	O
b	O
)	O
)	O
.	O

Reasonable	O
agreement	O
(	O
r	O
=	O
0.840	O
)	O
was	O
obtained	O
between	O
the	O
two	O
methods	O
.	O

One	O
calibration	O
curve	O
obtained	O
using	O
1-NP	O
is	O
shown	O
in	O
Fig.	O
7	O
(	O
a	O
)	O
,	O
before	O
and	O
after	O
adjustment	O
for	O
background	O
current	O
.	O

Precision	O
for	O
triplicate	O
sensors	O
at	O
each	O
concentration	O
was	O
improved	O
compared	O
with	O
the	O
4-APP	O
assay	O
and	O
ranged	O
from	O
4.1	O
to	O
12.4	O
%	O
;	O
this	O
may	O
have	O
been	O
due	O
to	O
the	O
improved	O
solubility	O
of	O
the	O
1-naphthyl	O
phosphate	O
over	O
the	O
4-APP	O
.	O

Readings	O
obtained	O
for	O
the	O
same	O
six	O
cows	B
'	O
milk	O
samples	O
tested	O
above	O
are	O
shown	O
on	O
a	O
correlation	O
plot	O
comparing	O
these	O
values	O
with	O
those	O
obtained	O
by	O
EIA	O
(	O
Fig.	O
7	O
(	O
b	O
)	O
)	O
.	O

The	O
result	O
was	O
a	O
close	O
agreement	O
between	O
the	O
two	O
sets	O
of	O
readings	O
and	O
an	O
improved	O
correlation	O
(	O
r	O
=	O
0.946	O
)	O
over	O
the	O
4-APP	O
assay	O
.	O

4	O
Conclusion	O
In	O
summary	O
,	O
the	O
above	O
results	O
have	O
demonstrated	O
that	O
by	O
using	O
1-naphthyl	O
phosphate	O
(	O
1-NP	O
)	O
as	O
enzyme	O
substrate	O
,	O
it	O
is	O
possible	O
to	O
develop	O
an	O
amperometric	O
screen	O
-	O
printed	O
immunosensor	O
for	O
milk	O
progesterone	O
based	O
on	O
the	O
detection	O
of	O
the	O
product	O
,	O
1-naphthol	O
at	O
an	O
operating	O
potential	O
of	O
+	O
300	O
mV.	O
The	O
required	O
detection	O
limit	O
of	O
2–5	O
ng	O
/	O
ml	O
(	O
Bulman	O
,	O
1979	O
;	O
Sauer	O
et	O
al.	O
,	O
1986	O
)	O
was	O
achieved	O
using	O
this	O
approach	O
.	O

Examination	O
of	O
the	O
electrochemistry	O
of	O
1-naphthol	O
itself	O
indicated	O
that	O
it	O
was	O
readily	O
oxidisable	O
at	O
the	O
surface	O
of	O
an	O
SPCE	O
in	O
the	O
presence	O
or	O
absence	O
of	O
immobilised	O
antibody	O
.	O

This	O
was	O
a	O
potential	O
advantage	O
over	O
4-aminophenol	O
which	O
appeared	O
to	O
suffer	O
from	O
a	O
diffusional	O
barrier	O
,	O
most	O
probably	O
as	O
a	O
result	O
of	O
the	O
formation	O
of	O
polyphenols	O
at	O
the	O
electrode	O
surface	O
.	O

Although	O
the	O
operating	O
potential	O
required	O
for	O
oxidation	O
of	O
1-naphthol	O
was	O
100	O
mV	O
higher	O
than	O
that	O
used	O
for	O
the	O
detection	O
of	O
4-aminophenol	O
,	O
the	O
1-naphthol	O
assay	O
operated	O
below	O
the	O
oxidation	O
potential	O
of	O
milkborne	O
interferents	O
and	O
did	O
not	O
suffer	O
from	O
a	O
loss	O
of	O
sensitivity	O
.	O

Indeed	O
,	O
a	O
closer	O
agreement	O
than	O
that	O
achieved	O
using	O
4-APP	O
was	O
obtained	O
with	O
an	O
established	O
EIA	O
method	O
for	O
milk	O
samples	O
taken	O
from	O
different	O
cows	B
having	O
varying	O
background	O
responses	O
.	O

Furthermore	O
,	O
this	O
correlation	O
was	O
also	O
better	O
than	O
that	O
obtained	O
using	O
4-APP	O
in	O
a	O
previous	O
study	O
on	O
milk	O
samples	O
taken	O
from	O
a	O
single	O
animal	B
(	O
Pemberton	O
et	O
al.	O
,	O
1998	O
)	O
.	O

Since	O
1-NP	O
is	O
inexpensive	O
,	O
readily	O
soluble	O
and	O
easy	O
to	O
obtain	O
,	O
the	O
screenprinted	O
immunosensor	O
when	O
used	O
in	O
combination	O
with	O
this	O
substrate	O
may	O
hold	O
promise	O
for	O
future	O
development	O
into	O
a	O
device	O
for	O
large	O
-	O
scale	O
milk	O
monitoring	O
.	O

Acknowledgements	O
The	O
authors	O
wish	O
to	O
thank	O
R.	O
Pittson	O
and	O
his	O
staff	O
at	O
Gwent	O
Electronic	O
Materials	O
Ltd.	O
(	O
GEM	O
)	O
,	O
Mamhilad	O
,	O
Gwent	O
for	O
supplying	O
the	O
SPCEs	O
.	O

Drs	O
D.J.	O
Groves	O
and	O
B.A.	O
Morris	O
from	O
the	O
Heterohybridoma	O
Antibody	O
Group	O
,	O
Department	O
of	O
Biochemistry	O
,	O
University	O
of	O
Surrey	O
are	O
gratefully	O
acknowledged	O
as	O
the	O
originators	O
of	O
the	O
mAb	O
.	O

Financial	O
support	O
for	O
this	O
project	O
was	O
provided	O
by	O
the	O
HEFCE	O
.	O

Ferbam	O
[	O
iron	O
(	O
III	O
)	O
dimethyldithiocarbamate	O
]	O
is	O
a	O
well	O
known	O
dithiocarbamate	O
effective	O
fungicide	O
widely	O
used	O
against	O
a	O
variety	O
of	O
plant	B
pathogenic	O
fungi	B
.	O

Ferbam	O
is	O
generally	O
determined	O
by	O
the	O
carbon	O
disulphide	O
evolution	O
method	O
based	O
on	O
its	O
decomposition	O
by	O
hot	O
mineral	O
acids	O
to	O
amine	O
and	O
carbon	O
disulfide	O
using	O
different	O
approaches	O
[	O
1	O
]	O
.	O

Ferbam	O
is	O
also	O
determined	O
by	O
converting	O
it	O
into	O
moybdenum	O
[	O
2	O
]	O
,	O
copper	O
[	O
3	O
]	O
and	O
1,10-phenanthroline	O
[	O
4	O
]	O
complexes	O
.	O

McLeod	O
and	O
McCulley	O
[	O
5	O
]	O
determined	O
dithiocarbamate	O
fungicides	O
by	O
headspace	O
gas	O
chromatography	O
of	O
the	O
carbon	O
disulphide	O
evolved	O
in	O
controlled	O
conditions	O
from	O
foodstuffs	O
and	O
similar	O
methods	O
were	O
also	O
given	O
by	O
the	O
Committee	O
for	O
Analytical	O
Methods	O
[	O
6	O
]	O
.	O

However	O
,	O
all	O
these	O
methods	O
suffer	O
from	O
the	O
following	O
disadvantages	O
:	O
(	O
a	O
)	O
Methods	O
other	O
than	O
gas	O
chromatography	O
are	O
indirect	O
,	O
time	O
consuming	O
and	O
sensitivity	O
is	O
low	O
.	O

(	O
b	O
)	O
Gas	O
chromatographic	O
methods	O
are	O
sensitive	O
but	O
suffer	O
from	O
lack	O
of	O
the	O
selectivity	O
since	O
all	O
dithiocarbamate	O
fungicides	O
evolve	O
carbon	O
disulphide	O
on	O
acid	O
hydrolysis	O
.	O

(	O
c	O
)	O
Spectrophotometric	O
methods	O
suffer	O
the	O
interference	O
of	O
various	O
ions	O
.	O

Capillary	O
electrophoresis	O
[	O
7,8	O
]	O
,	O
is	O
a	O
microvolume	O
separation	O
technique	O
increasingly	O
achieving	O
recognition	O
for	O
its	O
use	O
in	O
the	O
separation	O
of	O
inorganic	O
and	O
organic	O
compounds	O
.	O

The	O
key	O
features	O
of	O
this	O
technique	O
are	O
its	O
very	O
short	O
analysis	O
time	O
and	O
small	O
sample	O
volumes	O
in	O
the	O
nanoliter	O
and	O
picoliter	O
range	O
.	O

Capillary	O
electrophoresis	O
has	O
been	O
used	O
for	O
the	O
determination	O
of	O
sodium	O
dimethyldithiocarbamate	O
using	O
sulphonic	O
acid	O
polymer	O
coated	O
capillary	O
columns	O
at	O
pH	O
6.5	O
using	O
sodium	O
phosphate	O
buffer	O
[	O
9	O
]	O
.	O

Liang	O
et	O
al.	O
used	O
diode	O
array	O
detection	O
and	O
factor	O
analysis	O
for	O
the	O
determination	O
of	O
dithiocarbamates	O
[	O
10	O
]	O
.	O

In	O
another	O
approach	O
,	O
solid	O
-	O
phase	O
extraction	O
was	O
used	O
to	O
separate	O
dithiocarbamates	O
with	O
other	O
pesticides	O
[	O
11	O
]	O
.	O

The	O
extensive	O
studies	O
of	O
metal	O
–	O
aminopolycarboxylate	O
complexes	O
are	O
reviewed	O
by	O
Timerbaev	O
[	O
12	O
]	O
.	O

This	O
report	O
is	O
concerned	O
with	O
the	O
investigation	O
of	O
the	O
potential	O
of	O
capillary	O
electrophoresis	O
in	O
the	O
determination	O
of	O
Ferbam	O
.	O

As	O
will	O
be	O
demonstrated	O
in	O
this	O
report	O
,	O
capillary	O
electrophoresis	O
with	O
its	O
precision	O
instrumentation	O
and	O
small	O
sample	O
requirements	O
is	O
well	O
suited	O
for	O
the	O
determination	O
of	O
Ferbam	O
.	O

Here	O
,	O
we	O
present	O
a	O
relatively	O
simple	O
and	O
selective	O
capillary	O
electrophoretic	O
method	O
by	O
converting	O
Fe	O
(	O
III	O
)	O
present	O
in	O
Ferbam	O
into	O
Fe	O
(	O
III	O
)	O
–EDTA−	O
complex	O
.	O

The	O
chemical	O
structure	O
of	O
Ferbam	O
is	O
as	O
follows	O
:	O
[	O
(	O
CH3	O
)	O
2	O
–NC	O
(	O
S	O
)	O
2	O
]	O
3	O
Fe	O
.	O

2	O
Experimental	O
2.1	O
Instrumentation	O
Separations	O
were	O
performed	O
on	O
a	O
Thermo	O
Separation	O
Products	O
100	O
CE	O
-	O
system	O
equipped	O
with	O
an	O
UV	O
absorbance	O
detector	O
.	O

Fused	O
silica	O
capillaries	O
of	O
75	O
cm	O
long	O
(	O
45	O
cm	O
to	O
the	O
detector	O
)	O
×	O
100	O
μm	O
I.D.	O
were	O
used	O
.	O

The	O
solutes	O
were	O
injected	O
in	O
the	O
hydrodynamic	O
mode	O
by	O
vacuum	O
injection	O
for	O
2	O
s.	O
TSP	O
1000	O
software	O
was	O
used	O
for	O
the	O
data	O
acquisition	O
.	O

Detection	O
was	O
performed	O
by	O
direct	O
UV	O
absorbance	O
at	O
254	O
nm	O
.	O

All	O
experiments	O
were	O
conducted	O
at	O
25±1	O
°	O
C	O
.	O

2.2	O
Reagents	O
and	O
solutions	O
All	O
chemicals	O
used	O
were	O
of	O
analytical	O
-	O
reagent	O
grade	O
and	O
doubly	O
distilled	O
water	O
was	O
used	O
for	O
the	O
preparation	O
of	O
solutions	O
and	O
all	O
dilutions	O
.	O

2.2.1	O
Ferbam	O
solution	O
Ferbam	O
was	O
obtained	O
from	O
Riedel	O
-	O
de	O
Haën	O
(	O
Germany	O
)	O
and	O
used	O
as	O
received	O
.	O

Ferbam	O
solution	O
was	O
prepared	O
by	O
decomposing	O
its	O
20	O
mg	O
with	O
concentrated	O
nitric	O
acid	O
(	O
5–10	O
ml	O
)	O
and	O
heated	O
till	O
all	O
the	O
fumes	O
were	O
ceased	O
(	O
almost	O
to	O
dryness	O
)	O
and	O
dissolved	O
the	O
residue	O
in	O
1–2	O
ml	O
of	O
concentrated	O
HCl	O
and	O
diluted	O
upto	O
30–40	O
ml	O
and	O
pH	O
adjusted	O
in	O
the	O
range	O
2–3	O
using	O
dilute	O
NaOH	O
and	O
finally	O
diluted	O
to	O
100	O
ml	O
in	O
a	O
calibrated	O
flask	O
.	O

The	O
recovery	O
of	O
iron	O
(	O
III	O
)	O
from	O
Ferbam	O
was	O
checked	O
by	O
titrating	O
it	O
using	O
Variamine	O
Blue	O
B	O
as	O
indicator	O
[	O
13	O
]	O
.	O

Working	O
solutions	O
of	O
lower	O
concentrations	O
were	O
prepared	O
by	O
appropriate	O
dilutions	O
with	O
distilled	O
water	O
.	O

2.2.2	O
EDTA	O
solution	O
Stock	O
solution	O
of	O
EDTA	O
(	O
0.5	O
mM	O
)	O
as	O
disodium	O
salt	O
was	O
prepared	O
in	O
distilled	O
water	O
.	O

2.2.3	O
Buffer	O
solution	O
Electrophoretic	O
buffer	O
solution	O
was	O
prepared	O
from	O
boric	O
acid	O
50	O
mM	O
and	O
adjusting	O
the	O
desired	O
pH	O
by	O
adding	O
0.1	O
M	O
NaOH	O
solution	O
.	O

2.3	O
Procedures	O
2.3.1	O
Basic	O
procedure	O
The	O
capillary	O
was	O
rinsed	O
with	O
1	O
M	O
NaOH	O
,	O
0.1	O
M	O
NaOH	O
and	O
water	O
for	O
2	O
min	O
,	O
respectively	O
,	O
then	O
equilibrated	O
with	O
the	O
carrier	O
electrolyte	O
for	O
2	O
min	O
.	O

Between	O
all	O
electrophoretic	O
separations	O
the	O
capillary	O
was	O
rinsed	O
for	O
2	O
min	O
with	O
carrier	O
electrolyte	O
.	O

All	O
electrolyte	O
solutions	O
were	O
filtered	O
through	O
a	O
0.45	O
μm	O
membrane	O
filter	O
.	O

2.3.2	O
Preparation	O
of	O
standard	O
calibration	O
graph	O
A	O
series	O
of	O
standard	O
solutions	O
of	O
Ferbam	O
were	O
mixed	O
with	O
EDTA	O
(	O
1	O
ml	O
)	O
and	O
diluted	O
to	O
2	O
ml	O
with	O
distilled	O
water	O
and	O
injected	O
into	O
the	O
capillary	O
under	O
the	O
optimised	O
conditions	O
to	O
test	O
the	O
linearity	O
of	O
the	O
calibration	O
graph	O
.	O

2.3.3	O
Determination	O
of	O
Ferbam	O
in	O
grains	O
The	O
method	O
was	O
applied	O
for	O
the	O
determination	O
of	O
Ferbam	O
from	O
wheat	B
grains	O
.	O

A	O
known	O
amount	O
of	O
Ferbam	O
in	O
acetonitrile	O
was	O
crushed	O
with	O
10	O
g	O
of	O
wheat	O
grains	O
and	O
shaken	O
mechanically	O
with	O
chloroform	O
(	O
100	O
ml	O
)	O
for	O
1	O
h.	O
The	O
mixture	O
was	O
filtered	O
and	O
the	O
residue	O
in	O
the	O
funnel	O
was	O
washed	O
with	O
chloroform	O
(	O
3	O
×	O
10	O
ml	O
)	O
.	O

The	O
extracts	O
were	O
evaporated	O
to	O
dryness	O
and	O
solution	O
was	O
prepared	O
as	O
discussed	O
above	O
and	O
determined	O
by	O
the	O
general	O
procedure	O
.	O

Untreated	O
samples	O
were	O
taken	O
as	O
reference	O
and	O
the	O
results	O
indicated	O
good	O
recoveries	O
in	O
all	O
cases	O
.	O

The	O
results	O
of	O
the	O
determinations	O
are	O
given	O
in	O
Table	O
1	O
.	O

3	O
Results	O
and	O
discussion	O
A	O
typical	O
capillary	O
electropherogram	O
of	O
Ferbam	O
at	O
pH	O
9.0	O
is	O
shown	O
in	O
Fig.	O
1	O
.	O

It	O
shows	O
a	O
sharp	O
peak	O
with	O
baseline	O
resolution	O
.	O

In	O
order	O
to	O
determine	O
the	O
best	O
experimental	O
conditions	O
(	O
peak	O
efficiency	O
,	O
analysis	O
time	O
)	O
borate	O
,	O
phosphate	O
and	O
acetate	O
buffer	O
of	O
pH	O
9.0	O
,	O
7.0	O
and	O
4.5	O
,	O
respectively	O
of	O
1.25–50	O
mM	O
were	O
investigated	O
and	O
compared	O
.	O

It	O
was	O
observed	O
that	O
below	O
pH	O
7.0	O
in	O
phosphate	O
and	O
acetate	O
buffer	O
good	O
peak	O
were	O
not	O
observed	O
.	O

A	O
well	O
defined	O
peak	O
was	O
obtained	O
in	O
between	O
25	O
and	O
50	O
mM	O
borate	O
buffer	O
of	O
pH	O
9.0	O
.	O

It	O
was	O
observed	O
that	O
the	O
migration	O
time	O
was	O
more	O
at	O
the	O
higher	O
concentrations	O
of	O
the	O
borate	O
buffer	O
.	O

Above	O
25	O
mM	O
concentration	O
of	O
borate	O
buffer	O
there	O
was	O
a	O
considerable	O
increase	O
in	O
the	O
migration	O
time	O
of	O
the	O
both	O
analytes	O
,	O
resulting	O
in	O
an	O
increase	O
in	O
the	O
analysis	O
time	O
.	O

Therefore	O
,	O
25	O
mM	O
of	O
borate	O
buffer	O
concentration	O
was	O
preferred	O
.	O

The	O
influence	O
of	O
the	O
applied	O
voltage	O
was	O
also	O
studied	O
by	O
increasing	O
the	O
applied	O
voltage	O
.	O

The	O
retention	O
time	O
decreases	O
with	O
increasing	O
voltage	O
.	O

Therefore	O
,	O
+	O
30	O
kV	O
was	O
applied	O
to	O
get	O
the	O
shortest	O
time	O
.	O

A	O
linear	O
relationship	O
between	O
peak	O
height	O
and	O
concentrations	O
were	O
obtained	O
in	O
the	O
range	O
3.5–500	O
μg	O
/	O
ml	O
with	O
an	O
correlation	O
coefficient	O
of	O
0.9994	O
.	O

The	O
linear	O
regression	O
equation	O
for	O
the	O
calibration	O
curve	O
is	O
y	O
=	O
0.0001x	O
+	O
0.0003	O
.	O

Aliquots	O
containing	O
50	O
μg	O
/	O
ml	O
of	O
give	O
a	O
relative	O
standard	O
deviation	O
of	O
2.9	O
%	O
in	O
analysis	O
.	O

Ferbam	O
,	O
if	O
present	O
with	O
other	O
water	O
soluble	O
dithiocarbamates	O
such	O
as	O
nabam	O
,	O
metham	O
,	O
sodium	O
diethyldithiocarbamate	O
,	O
etc	O
.	O
,	O
can	O
easily	O
be	O
separated	O
by	O
extraction	O
with	O
chloroform	O
;	O
Nabam	O
and	O
others	O
will	O
remain	O
in	O
the	O
aqueous	O
phase	O
which	O
can	O
then	O
be	O
analysed	O
by	O
the	O
basic	O
procedure	O
[	O
14	O
]	O
.	O

Furthermore	O
,	O
our	O
experiments	O
have	O
shown	O
that	O
Ferbam	O
can	O
be	O
determined	O
directly	O
in	O
the	O
presence	O
of	O
metal	O
ions	O
like	O
Co	O
(	O
II	O
)	O
,	O
Zn	O
(	O
II	O
)	O
,	O
Cu	O
(	O
II	O
)	O
and	O
Ni	O
(	O
II	O
)	O
without	O
any	O
interference	O
,	O
whereas	O
,	O
these	O
metal	O
ions	O
strongly	O
interfere	O
in	O
the	O
spectrophotometric	O
methods	O
[	O
2,3	O
]	O
.	O

These	O
results	O
are	O
similar	O
to	O
as	O
reported	O
by	O
earlier	O
workers	O
[	O
12,15	O
]	O
.	O

4	O
Conclusions	O
Capillary	O
electrophoresis	O
provides	O
an	O
important	O
tool	O
in	O
the	O
hands	O
of	O
the	O
analytical	O
chemists	O
for	O
the	O
determination	O
of	O
Ferbam	O
.	O

The	O
detection	O
limit	O
(	O
S	O
/N	O
=3	O
)	O
using	O
this	O
method	O
is	O
0.7	O
μg	O
/	O
ml	O
(	O
0.7	O
mg	O
/	O
kg	O
)	O
of	O
Ferbam	O
which	O
is	O
better	O
than	O
1	O
μg	O
/	O
ml	O
of	O
Nitowski	O
et	O
al.	O
's	O
[	O
9	O
]	O
method	O
reported	O
for	O
dimethyldithiocarbamate	O
using	O
sulphonic	O
acid	O
polymer	O
-	O
coated	O
capillary	O
columns	O
.	O

As	O
most	O
of	O
the	O
cations	O
and	O
anions	O
do	O
not	O
interfere	O
in	O
the	O
determination	O
of	O
Ferbam	O
,	O
moreover	O
,	O
the	O
simplicity	O
and	O
small	O
sample	O
volume	O
requirements	O
makes	O
it	O
advantageous	O
to	O
other	O
chromatographic	O
techniques	O
.	O

Thus	O
,	O
the	O
usefulness	O
of	O
capillary	O
electrophoresis	O
as	O
a	O
tool	O
for	O
checking	O
the	O
amount	O
of	O
Ferbam	O
is	O
successfully	O
demonstrated	O
.	O

Acknowledgements	O
One	O
of	O
the	O
authors	O
(	O
A.K.M.	O
)	O
thanks	O
the	O
AvH	O
Foundation	O
,	O
Bonn	O
,	O
Germany	O
for	O
financial	O
assistance	O
.	O

l	O
-cis	O
Diltiazem	O
,	O
the	O
enantiomer	O
of	O
diltiazem	O
(	O
d	O
-cis	O
diltiazem	O
)	O
,	O
has	O
100	O
times	O
less	O
Ca2	O
+	O
channel	O
blocking	O
activity	O
than	O
diltiazem	O
(	O
Ikeda	O
et	O
al.	O
,	O
1991	O
)	O
.	O

l	O
-cis	O
Diltiazem	O
is	O
not	O
a	O
simple	O
inactive	O
stereoisomer	O
but	O
has	O
been	O
established	O
as	O
a	O
unique	O
pharmacological	O
tool	O
(	O
Caretta	O
et	O
al.	O
,	O
1979	O
)	O
.	O

For	O
example	O
,	O
l	O
-cis	O
diltiazem	O
,	O
but	O
not	O
diltiazem	O
,	O
inhibits	O
the	O
cGMP	O
-	O
gated	O
cation	O
channel	O
in	O
rod	O
cells	O
(	O
Stern	O
et	O
al.	O
,	O
1986	O
;	O
Quandt	O
et	O
al.	O
,	O
1991	O
)	O
.	O

Interestingly	O
,	O
there	O
have	O
been	O
several	O
reports	O
indicating	O
that	O
l	O
-cis	O
diltiazem	O
protects	O
against	O
ischemic	O
cardiac	O
injury	O
.	O

For	O
example	O
,	O
l	O
-cis	O
diltiazem	O
produces	O
a	O
high	O
recovery	O
of	O
cardiac	O
function	O
after	O
ischemia	O
/	O
reperfusion	O
and	O
inhibits	O
the	O
increase	O
of	O
non	O
-	O
esterified	O
fatty	O
acids	O
during	O
ischemia	O
in	O
isolated	O
,	O
perfused	O
working	O
rat	B
heart	O
(	O
Nasa	O
et	O
al.	O
,	O
1990	O
;	O
Xiao	O
et	O
al.	O
,	O
1997	O
)	O
.	O

Recently	O
,	O
our	O
laboratory	O
has	O
reported	O
that	O
treatment	O
with	O
l	O
-cis	O
diltiazem	O
reduced	O
infarct	O
size	O
without	O
affecting	O
any	O
hemodynamic	O
parameter	O
in	O
rabbit	B
heart	O
in	O
vivo	O
(	O
Nishida	O
et	O
al.	O
,	O
1999	O
)	O
.	O

Since	O
l	O
-cis	O
diltiazem	O
has	O
a	O
much	O
less	O
potent	O
Ca2	O
+	O
channel	O
blocking	O
action	O
than	O
diltiazem	O
,	O
it	O
has	O
been	O
suggested	O
that	O
l	O
-cis	O
diltiazem	O
protects	O
against	O
ischemia	O
/	O
reperfusion	O
injury	O
with	O
a	O
mechanism	O
other	O
than	O
Ca2	O
+	O
channel	O
blockade	O
.	O

We	O
have	O
also	O
demonstrated	O
that	O
treatment	O
with	O
l	O
-cis	O
diltiazem	O
before	O
reperfusion	O
also	O
reduced	O
infarct	O
size	O
in	O
ischemic	O
rabbit	B
heart	O
(	O
Nishida	O
et	O
al.	O
,	O
1999	O
)	O
.	O

Ca2	O
+	O
overload	O
at	O
reperfusion	O
after	O
ischemia	O
(	O
Allen	O
and	O
Orchard	O
,	O
1983	O
)	O
and	O
reoxygenation	O
after	O
hypoxia	O
(	O
Poole	O
-	O
Wilson	O
et	O
al.	O
,	O
1984	O
)	O
have	O
been	O
considered	O
to	O
be	O
involved	O
in	O
the	O
final	O
stage	O
of	O
ischemia	O
/	O
reperfusion	O
injury	O
of	O
cardiac	O
myocytes	O
(	O
Nayler	O
,	O
1981	O
;	O
Farber	O
,	O
1982	O
;	O
Steenbergen	O
et	O
al.	O
,	O
1990	O
)	O
.	O

Thus	O
,	O
it	O
is	O
postulated	O
that	O
l	O
-cis	O
diltiazem	O
elicits	O
a	O
cardioprotective	O
action	O
via	O
the	O
attenuation	O
of	O
Ca2	O
+	O
overload	O
after	O
reperfusion	O
.	O

In	O
terms	O
of	O
energy	O
metabolism	O
,	O
ischemic	O
insults	O
can	O
be	O
simulated	O
,	O
in	O
part	O
,	O
by	O
controlled	O
metabolic	O
inhibition	O
.	O

Li	O
et	O
al.	O
(	O
1989	O
)	O
has	O
reported	O
that	O
the	O
myocytes	O
were	O
reversibly	O
ATP	O
-	O
depleted	O
by	O
metabolic	O
inhibitors	O
.	O

Thus	O
,	O
myocardial	O
Ca2	O
+	O
overload	O
induced	O
by	O
ischemia	O
and	O
reperfusion	O
is	O
considered	O
to	O
be	O
simply	O
mimicked	O
,	O
in	O
part	O
,	O
by	O
treatment	O
with	O
carbonyl	O
cyanide	O
m	O
-chrolophenylhydrazone	O
(	O
CCCP	O
)	O
,	O
a	O
mitochondrial	O
uncoupler	O
,	O
followed	O
by	O
washout	O
of	O
CCCP	O
.	O

In	O
order	O
to	O
assess	O
the	O
effect	O
of	O
l	O
-cis	O
diltiazem	O
on	O
reperfusion	O
-	O
induced	O
Ca2	O
+	O
overload	O
,	O
we	O
used	O
a	O
model	O
for	O
Ca2	O
+	O
overload	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
in	O
isolated	O
guinea	B
pig	I
cardiomyocytes	O
.	O

We	O
also	O
assessed	O
the	O
effect	O
of	O
other	O
drugs	O
,	O
Ca2	O
+	O
channel	O
blockers	O
and	O
Na+	O
/Ca2	O
+	O
exchanger	O
blockers	O
,	O
to	O
clarify	O
the	O
mechanism	O
for	O
Ca2	O
+	O
overload	O
in	O
this	O
model	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Preparation	O
of	O
single	O
cells	O
Ventricular	O
myocytes	O
were	O
isolated	O
enzymatically	O
from	O
the	O
hearts	O
of	O
male	O
Hartley	B
guinea	I
pigs	I
(	O
weight	O
250–500	O
g	O
)	O
according	O
to	O
the	O
method	O
described	O
(	O
Kurokawa	O
et	O
al.	O
,	O
1997	O
)	O
.	O

The	O
animals	O
were	O
anaesthetized	O
with	O
sodium	O
pentobarbital	O
(	O
50	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
and	O
the	O
ascending	O
aorta	O
was	O
cannulated	O
in	O
situ	O
under	O
artificial	O
respiration	O
.	O

The	O
heart	O
was	O
perfused	O
with	O
Ca2	O
+	O
-free	O
Tyrode	O
solution	O
for	O
10	O
min	O
,	O
followed	O
by	O
the	O
same	O
solution	O
containing	O
collagenase	O
for	O
7–14	O
min	O
at	O
a	O
perfusion	O
rate	O
of	O
8–10	O
ml	O
/	O
min	O
via	O
a	O
Langendorff	O
apparatus	O
at	O
37	O
°	O
C	O
.	O

Subsequently	O
,	O
the	O
enzyme	O
solution	O
was	O
washed	O
out	O
with	O
a	O
high	O
K+	O
,	O
Ca2	O
+	O
-free	O
solution	O
(	O
Kraftbrühe	O
(	O
KB	O
)	O
solution	O
,	O
Isenberg	O
and	O
Klöckner	O
,	O
1982	O
)	O
.	O

The	O
ventricular	O
myocytes	O
were	O
dissociated	O
by	O
gentle	O
stirring	O
of	O
the	O
tissue	O
fragments	O
at	O
37	O
°	O
C	O
.	O

The	O
dissociated	O
cells	O
were	O
stored	O
in	O
KB	O
solution	O
at	O
4	O
°	O
C	O
,	O
and	O
were	O
used	O
up	O
to	O
10	O
h	O
after	O
isolation	O
.	O

Nominally	O
Ca2	O
+	O
-free	O
solution	O
had	O
the	O
following	O
composition	O
(	O
mM	O
)	O
:	O
NaCl	O
135	O
,	O
KCl	O
5.4	O
,	O
MgCl2	O
1	O
,	O
glucose	O
5.8	O
,	O
HEPES	O
5	O
(	O
pH	O
7.4	O
,	O
adjusted	O
with	O
tris	O
)	O
.	O

Normal	O
Tyrode	O
solution	O
was	O
made	O
by	O
adding	O
1.8	O
mM	O
CaCl2	O
to	O
nominally	O
Ca2	O
+	O
-free	O
solution	O
.	O

The	O
collagenase	O
solutions	O
were	O
prepared	O
by	O
adding	O
collagenase	O
(	O
110	O
units	O
/	O
ml	O
Collagenase	O
S-1	O
,	O
Nitta	O
Gelatin	O
,	O
Osaka	O
,	O
Japan	O
;	O
200–220	O
units	O
/	O
ml	O
collagenase	O
,	O
Yakult	O
,	O
Tokyo	O
.	O

Japan	O
)	O
and	O
10.8	O
nM	O
CaCl2	O
to	O
Ca2	O
+	O
-free	O
Tyrode	O
solution	O
,	O
or	O
by	O
combining	O
collagenase	O
(	O
0.145	O
U	O
/	O
ml	O
collagenase	O
A	O
,	O
Boehringer	O
Mannheim	O
,	O
Japan	O
)	O
and	O
protease	O
(	O
0.156	O
units	O
/	O
ml	O
protease	O
type	O
IX	O
,	O
Sigma	O
,	O
St.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
to	O
Ca2	O
+	O
-free	O
Tyrode	O
solution	O
.	O

The	O
KB	O
solution	O
contained	O
(	O
mM	O
)	O
:	O
potassium	O
glutamate	O
70	O
,	O
KCl	O
20	O
,	O
oxalic	O
acid	O
10	O
,	O
KH2	O
PO4	O
10	O
,	O
taurine	O
10	O
,	O
glucose	O
5.8	O
,	O
HEPES	O
5	O
,	O
EGTA	O
0.5	O
(	O
pH	O
7.4	O
,	O
adjusted	O
with	O
KOH	O
)	O
.	O

2.2	O
Measurement	O
of	O
fluorescence	O
ratio	O
of	O
fura-2	O
in	O
cardiac	O
myocytes	O
For	O
measurement	O
of	O
a	O
change	O
in	O
[	O
Ca2	O
+	O
]	O
i	O
of	O
cardiac	O
myocytes	O
,	O
a	O
Ca2	O
+	O
-sensitive	O
fluorescent	O
dye	O
,	O
fura-2	O
/	O
acetoxymethylester	O
(	O
fura-2	O
/	O
AM	O
)	O
,	O
was	O
used	O
.	O

Fura-2	O
/	O
AM	O
(	O
1	O
mM	O
,	O
dissolved	O
in	O
dimethylsulfoxide	O
,	O
DMSO	O
)	O
was	O
prepared	O
in	O
KB	O
solution	O
and	O
applied	O
to	O
isolated	O
myocytes	O
at	O
a	O
final	O
concentration	O
of	O
10	O
μM.	O
After	O
the	O
cell	O
suspension	O
had	O
been	O
incubated	O
for	O
10	O
min	O
at	O
37	O
°	O
C	O
,	O
the	O
cells	O
settled	O
out	O
and	O
became	O
loosely	O
attached	O
to	O
the	O
bottom	O
of	O
the	O
chamber	O
.	O

Then	O
the	O
fura-2-loaded	O
myocytes	O
were	O
washed	O
and	O
superfused	O
(	O
4–5	O
ml	O
/	O
min	O
,	O
37	O
°	O
C	O
)	O
with	O
normal	O
Tyrode	O
solution	O
containing	O
1.8	O
mM	O
Ca2	O
+	O
for	O
30	O
min	O
.	O

The	O
myocytes	O
were	O
illuminated	O
with	O
a	O
dual	O
wavelength	O
fluorometer	O
(	O
CAM-230	O
,	O
Japan	O
Spectroscopic	O
,	O
Tokyo	O
,	O
Japan	O
)	O
.	O

Video	O
images	O
were	O
digitized	O
,	O
using	O
an	O
Argus-50	O
/	O
Ca	O
system	O
(	O
Hamamatsu	O
Photonics	O
)	O
.	O

The	O
fluorescence	O
ratio	O
was	O
calculated	O
from	O
the	O
value	O
of	O
the	O
fluorescence	O
intensity	O
at	O
500	O
nm	O
with	O
340-	O
and	O
380-nm	O
excitation	O
.	O

The	O
digital	O
images	O
were	O
obtained	O
every	O
5	O
min	O
from	O
just	O
before	O
treatment	O
with	O
CCCP	O
till	O
the	O
end	O
of	O
the	O
experiment	O
.	O

2.3	O
Evaluation	O
of	O
morphological	O
changes	O
of	O
cardiac	O
myocytes	O
Cells	O
lightly	O
attached	O
to	O
the	O
perfusion	O
chamber	O
were	O
superfused	O
with	O
normal	O
Tyrode	O
solution	O
at	O
37	O
°	O
C	O
.	O

After	O
30	O
min	O
of	O
stabilization	O
,	O
a	O
rod	O
-	O
shaped	O
cell	O
was	O
selected	O
randomly	O
from	O
those	O
within	O
the	O
microscopic	O
field	O
of	O
the	O
chamber	O
.	O

Caffeine	O
(	O
5	O
mM	O
)	O
was	O
added	O
for	O
1	O
min	O
to	O
the	O
chamber	O
in	O
order	O
to	O
confirm	O
that	O
the	O
function	O
of	O
the	O
intracellular	O
Ca2	O
+	O
store	O
of	O
the	O
myocyte	O
was	O
maintained	O
.	O

After	O
washing	O
out	O
of	O
the	O
caffeine	O
for	O
5	O
min	O
,	O
the	O
morphology	O
of	O
the	O
myocyte	O
was	O
recorded	O
as	O
a	O
digital	O
image	O
using	O
the	O
Argus-50	O
/	O
Ca	O
system	O
.	O

To	O
examine	O
the	O
morphological	O
change	O
of	O
the	O
myocyte	O
,	O
the	O
morphology	O
of	O
the	O
same	O
cell	O
was	O
also	O
recorded	O
at	O
the	O
end	O
of	O
chemical	O
ischemia	O
and	O
also	O
at	O
the	O
end	O
of	O
30-min	O
reperfusion	O
.	O

After	O
Ca2	O
+	O
measurement	O
,	O
the	O
morphological	O
change	O
was	O
analyzed	O
by	O
measuring	O
the	O
area	O
of	O
the	O
myocyte	O
.	O

The	O
cell	O
surface	O
area	O
was	O
calculated	O
from	O
the	O
digitized	O
image	O
of	O
the	O
cell	O
and	O
the	O
post	O
-	O
ischemic	O
value	O
was	O
expressed	O
as	O
percentage	O
of	O
the	O
pre	O
-	O
ischemic	O
value	O
.	O

2.4	O
Experimental	O
protocols	O
In	O
order	O
to	O
determine	O
the	O
optimal	O
condition	O
of	O
the	O
Ca2	O
+	O
overload	O
model	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
,	O
we	O
performed	O
some	O
preliminary	O
experiments	O
.	O

We	O
first	O
followed	O
a	O
protocol	O
for	O
metabolic	O
inhibition	O
,	O
using	O
Tyrode	O
solution	O
containing	O
normal	O
Ca2	O
+	O
and	O
1	O
μM	O
of	O
CCCP	O
.	O

However	O
,	O
the	O
myocytes	O
exposed	O
to	O
CCCP	O
for	O
10–15	O
min	O
showed	O
a	O
rigor	O
contraction	O
with	O
an	O
increase	O
in	O
[	O
Ca2	O
+	O
]	O
i	O
,	O
but	O
failed	O
to	O
show	O
Ca2	O
+	O
overload	O
on	O
washout	O
of	O
CCCP	O
(	O
energy	O
repletion	O
)	O
after	O
the	O
transition	O
to	O
rigor	O
contraction	O
(	O
the	O
sign	O
of	O
ATP	O
depletion	O
)	O
.	O

These	O
cells	O
showed	O
neither	O
further	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
nor	O
morphological	O
changes	O
after	O
energy	O
repletion	O
.	O

To	O
improve	O
the	O
efficacy	O
of	O
the	O
assessment	O
of	O
reperfusion	O
injury	O
,	O
we	O
used	O
Ca2	O
+	O
-free	O
Tyrode	O
solution	O
for	O
metabolic	O
inhibition	O
,	O
since	O
it	O
was	O
reported	O
that	O
cells	O
in	O
the	O
low	O
Ca2	O
+	O
solution	O
remain	O
rod	O
-	O
shaped	O
for	O
a	O
longer	O
period	O
against	O
metabolic	O
inhibition	O
(	O
Li	O
et	O
al.	O
,	O
1988	O
)	O
.	O

We	O
also	O
examined	O
the	O
dose	O
-	O
dependent	O
effects	O
of	O
CCCP	O
(	O
100	O
nM	O
,	O
1	O
and	O
3	O
μM	O
)	O
,	O
and	O
confirmed	O
that	O
1	O
μM	O
of	O
CCCP	O
was	O
the	O
most	O
stable	O
to	O
induce	O
Ca2	O
+	O
overload	O
after	O
energy	O
repletion	O
.	O

Based	O
on	O
these	O
experiments	O
,	O
we	O
established	O
the	O
standard	O
procedure	O
as	O
follows	O
.	O

After	O
confirmation	O
of	O
the	O
integrity	O
of	O
the	O
myocardial	O
store	O
functions	O
described	O
in	O
the	O
previous	O
section	O
,	O
Ca2	O
+	O
-free	O
Tyrode	O
containing	O
CCCP	O
(	O
1	O
μM	O
)	O
was	O
perfused	O
for	O
40	O
min	O
at	O
a	O
perfusion	O
rate	O
of	O
2–3	O
ml	O
/	O
min	O
.	O

Ca2	O
+	O
overload	O
was	O
induced	O
by	O
washout	O
of	O
CCCP	O
with	O
normal	O
Tyrode	O
solution	O
for	O
30	O
min	O
at	O
a	O
perfusion	O
rate	O
of	O
4–5	O
ml	O
/	O
min	O
.	O

In	O
this	O
study	O
,	O
we	O
employed	O
the	O
following	O
two	O
protocols	O
:	O
(	O
A	O
)	O
before	O
metabolic	O
inhibition	O
,	O
in	O
which	O
drugs	O
were	O
included	O
throughout	O
the	O
experiment	O
,	O
and	O
(	O
B	O
)	O
before	O
energy	O
repletion	O
,	O
in	O
which	O
drugs	O
were	O
included	O
from	O
5	O
min	O
before	O
energy	O
repletion	O
to	O
the	O
end	O
of	O
the	O
experiment	O
.	O

2.5	O
Calibration	O
for	O
Ca2	O
+	O
concentration	O
The	O
maximum	O
ratio	O
(	O
R	O
max	O
)	O
unique	O
to	O
individual	O
cells	O
was	O
obtained	O
at	O
the	O
end	O
of	O
each	O
experiment	O
by	O
applying	O
ionomycin	O
(	O
2	O
μM	O
)	O
to	O
the	O
normal	O
Tyrode	O
solution	O
.	O

The	O
minimum	O
ratio	O
(	O
R	O
min	O
)	O
was	O
obtained	O
by	O
applying	O
EGTA	O
(	O
10	O
mM	O
)	O
to	O
the	O
ionomycin	O
containing	O
Tyrode	O
solution	O
.	O

Both	O
R	O
max	O
and	O
R	O
min	O
values	O
were	O
obtained	O
under	O
steady	O
state	O
conditions	O
.	O

[	O
Ca2	O
+	O
]	O
i	O
was	O
calculated	O
from	O
the	O
following	O
formula	O
:	O
[	O
Ca2	O
+	O
]	O
i	O
(	O
nM	O
)	O
=	O
(	O
R	O
−R	O
min	O
)	O
×K	O
d	O
×F	O
min	O
/	O
(	O
(	O
R	O
max	O
−R	O
)	O
×F	O
max	O
)	O
)	O
,	O
where	O
R	O
is	O
the	O
ratio	O
obtained	O
from	O
the	O
experiment	O
,	O
F	O
means	O
the	O
fluorescence	O
intensity	O
at	O
380-nm	O
excitation	O
,	O
and	O
K	O
d	O
is	O
the	O
dissociation	O
constant	O
defined	O
as	O
224	O
nM.	O
2.6	O
Chemicals	O
l	O
-cis	O
Diltiazem	O
and	O
diltiazem	O
were	O
kind	O
gifts	O
from	O
Tanabe	O
Seiyaku	O
(	O
Osaka	O
,	O
Japan	O
)	O
.	O

A	O
specific	O
inhibitor	O
of	O
Na+	O
/Ca2	O
+	O
exchanger	O
,	O
2-	O
[	O
2-	O
[	O
4-	O
(	O
4-nitrobenzyloxy	O
)	O
phenyl	O
]	O
ethyl	O
]	O
isothiourea	O
methanesulphonate	O
(	O
KB	O
-	O
R7943	O
)	O
,	O
was	O
a	O
kind	O
gift	O
from	O
Kanebo	O
(	O
Osaka	O
,	O
Japan	O
)	O
.	O

CCCP	O
was	O
purchased	O
from	O
Sigma	O
.	O

2.7	O
Statistical	O
analysis	O
All	O
data	O
were	O
expressed	O
as	O
means±S.E.M.	O
The	O
time	O
course	O
data	O
(	O
Ca2	O
+	O
measurement	O
)	O
were	O
divided	O
into	O
two	O
events	O
,	O
during	O
40	O
min	O
of	O
metabolic	O
inhibition	O
and	O
during	O
30-min	O
energy	O
repletion	O
,	O
and	O
repeated	O
measures	O
two	O
-	O
way	O
analysis	O
of	O
variance	O
was	O
used	O
.	O

If	O
there	O
was	O
no	O
interaction	O
between	O
the	O
drug	O
factor	O
and	O
the	O
time	O
factor	O
,	O
Bonferroni	O
/	O
Dunn	O
(	O
Dunn	O
's	O
Procedure	O
for	O
Comparing	O
a	O
Control	O
to	O
All	O
other	O
Means	O
)	O
post	O
-	O
hoc	O
test	O
was	O
done	O
thereafter	O
.	O

One	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
followed	O
by	O
the	O
Bonferroni	O
/	O
Dunn	O
post	O
-	O
hoc	O
test	O
was	O
used	O
for	O
the	O
cell	O
size	O
data	O
.	O

All	O
statistical	O
analyses	O
were	O
performed	O
using	O
Super	O
ANOVA	O
™	O
(	O
Abacus	O
Concepts	O
,	O
Berkeley	O
,	O
CA	O
)	O
.	O

Differences	O
were	O
considered	O
to	O
be	O
statistically	O
significant	O
when	O
the	O
P	O
value	O
was	O
less	O
than	O
0.05	O
.	O

3	O
Results	O
3.1	O
Cell	O
selection	O
In	O
all	O
the	O
experiments	O
,	O
rod	O
-	O
shaped	O
myocytes	O
as	O
shown	O
in	O
Fig.	O
1A	O
were	O
selected	O
.	O

A	O
single	O
myocyte	O
was	O
further	O
selected	O
for	O
the	O
ischemia	O
experiment	O
,	O
based	O
on	O
the	O
criterion	O
that	O
it	O
showed	O
a	O
transient	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
on	O
treatment	O
with	O
5	O
mM	O
caffeine	O
(	O
Fig.	O
1B	O
)	O
.	O

The	O
cells	O
,	O
which	O
did	O
not	O
satisfy	O
these	O
criteria	O
,	O
or	O
which	O
changed	O
morphologically	O
after	O
the	O
treatment	O
with	O
caffeine	O
,	O
were	O
excluded	O
.	O

3.2	O
Changes	O
in	O
[	O
Ca2	O
+	O
]	O
i	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
Fig.	O
2	O
represents	O
the	O
change	O
in	O
time	O
course	O
of	O
[	O
Ca2	O
+	O
]	O

i	O
in	O
the	O
absence	O
and	O
the	O
presence	O
of	O
drugs	O
.	O

Before	O
CCCP	O
treatment	O
,	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
of	O
all	O
cells	O
used	O
were	O
almost	O
identical	O
in	O
level	O
(	O
about	O
100	O
nM	O
)	O
.	O

In	O
the	O
control	O
myocytes	O
,	O
[	O
Ca2	O
+	O
]	O
i	O
did	O
not	O
change	O
during	O
40	O
min	O
of	O
CCCP	O
treatment	O
.	O

After	O
washout	O
of	O
CCCP	O
,	O
[	O
Ca2	O
+	O
]	O
i	O
increased	O
dramatically	O
within	O
5	O
min	O
and	O
continued	O
to	O
increase	O
until	O
the	O
end	O
of	O
energy	O
repletion	O
.	O

In	O
order	O
to	O
confirm	O
that	O
this	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
was	O
not	O
due	O
to	O
the	O
simple	O
entry	O
of	O
extracellular	O
Ca2	O
+	O
when	O
Ca2	O
+	O
-free	O
Tyrode	O
was	O
replaced	O
by	O
normal	O
Tyrode	O
,	O
we	O
performed	O
the	O
same	O
perfusion	O
protocol	O
without	O
CCCP	O
treatment	O
.	O

We	O
observed	O
that	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
showed	O
a	O
small	O
(	O
20–30	O
nM	O
)	O
,	O
but	O
not	O
significant	O
,	O
increase	O
at	O
5	O
min	O
after	O
energy	O
repletion	O
.	O

Therefore	O
,	O
the	O
Ca2	O
+	O
overload	O
observed	O
here	O
is	O
considered	O
to	O
be	O
induced	O
by	O
the	O
injury	O
due	O
to	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
.	O

Furthermore	O
,	O
Ni2	O
+	O
(	O
5	O
mM	O
)	O
and	O
KB	O
-	O
R7943	O
(	O
10	O
μM	O
)	O
,	O
known	O
as	O
inhibitors	O
of	O
the	O
Na+	O
/Ca2	O
+	O
exchanger	O
,	O
completely	O
blocked	O
the	O
initial	O
rise	O
of	O
[	O
Ca2	O
+	O
]	O
i	O
after	O
washout	O
of	O
CCCP	O
(	O
P	O
<	O
0.01	O
vs.	O
control	O
)	O
and	O
continued	O
to	O
attenuate	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
during	O
30	O
min	O
of	O
energy	O
repletion	O
.	O

However	O
,	O
nitrendipine	O
(	O
10	O
μM	O
)	O
,	O
a	O
dihydropyridine	O
Ca2	O
+	O
channel	O
blocker	O
,	O
failed	O
to	O
attenuate	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
after	O
washout	O
of	O
CCCP	O
.	O

Nicardipine	O
(	O
10	O
μM	O
)	O
,	O
another	O
dihydropyridine	O
Ca2	O
+	O
channel	O
blocker	O
,	O
also	O
failed	O
to	O
attenuate	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
(	O
see	O
Table	O
1	O
)	O
.	O

Thus	O
,	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
in	O
this	O
model	O
was	O
suggested	O
to	O
be	O
mediated	O
,	O
not	O
by	O
L	O
-	O
type	O
Ca2	O
+	O
channels	O
but	O
by	O
the	O
Na+	O
/Ca2	O
+	O
exchanger	O
.	O

As	O
for	O
the	O
treatment	O
with	O
drugs	O
before	O
metabolic	O
inhibition	O
(	O
protocol	O
(	O
A	O
)	O
)	O
,	O
diltiazem	O
(	O
3	O
μM	O
)	O
and	O
l	O
-cis	O
diltiazem	O
(	O
10	O
μM	O
)	O
,	O
but	O
not	O
l	O
-cis	O
diltiazem	O
(	O
3	O
μM	O
)	O
significantly	O
attenuated	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
during	O
energy	O
repletion	O
(	O
Fig.	O
3A	O
)	O
.	O

As	O
for	O
the	O
treatment	O
with	O
drugs	O
5	O
min	O
before	O
washout	O
of	O
CCCP	O
(	O
protocol	O
(	O
B	O
)	O
)	O
,	O
3	O
μM	O
of	O
diltiazem	O
,	O
which	O
was	O
effective	O
in	O
protocol	O
(	O
A	O
)	O
,	O
failed	O
to	O
attenuate	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
.	O

However	O
,	O
a	O
higher	O
concentration	O
of	O
diltiazem	O
(	O
10	O
μM	O
)	O
could	O
significantly	O
attenuate	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
after	O
energy	O
repletion	O
(	O
Fig.	O
3B	O
)	O
.	O

l	O
-cis	O
Diltiazem	O
(	O
10	O
μM	O
)	O
also	O
attenuated	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
(	O
P	O
<	O
0.01	O
vs.	O
control	O
)	O
.	O

3.3	O
Morphological	O
change	O
of	O
the	O
cell	O
after	O
energy	O
repletion	O
Cells	O
,	O
which	O
showed	O
a	O
rigor	O
contraction	O
during	O
CCCP	O
treatment	O
,	O
were	O
all	O
excluded	O
from	O
the	O
experiments	O
.	O

Table	O
1	O
represents	O
the	O
morphological	O
change	O
in	O
cell	O
size	O
caused	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
in	O
the	O
absence	O
and	O
the	O
presence	O
of	O
drugs	O
,	O
accompanied	O
by	O
[	O
Ca2	O
+	O
]	O
i	O
.	O

Compared	O
with	O
the	O
control	O
,	O
l	O
-cis	O
diltiazem	O
(	O
10	O
μM	O
)	O
,	O
diltiazem	O
(	O
10	O
μM	O
)	O
,	O
Ni2	O
+	O
(	O
5	O
mM	O
)	O
and	O
KB	O
-	O
R7943	O
(	O
10	O
μM	O
)	O
,	O
added	O
5	O
min	O
before	O
washout	O
of	O
CCCP	O
,	O
all	O
reduced	O
the	O
cell	O
shortening	O
(	O
P	O
<	O
0.05	O
)	O
,	O
and	O
these	O
effects	O
correlated	O
well	O
with	O
the	O
attenuation	O
in	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
.	O

Treatment	O
with	O
diltiazem	O
(	O
3	O
μM	O
)	O
failed	O
to	O
reduce	O
the	O
contraction	O
,	O
which	O
correlated	O
with	O
the	O
increase	O
in	O
[	O
Ca2	O
+	O
]	O
i	O
.	O

Neither	O
nitrendipine	O
(	O
10	O
μM	O
)	O
nor	O
nicardipine	O
(	O
10	O
μM	O
)	O
attenuated	O
the	O
contraction	O
or	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
after	O
energy	O
repletion	O
.	O

4	O
Discussion	O
4.1	O
Increase	O
in	O
[	O
Ca2	O
+	O
]	O
i	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
in	O
guinea	B
pig	I
isolated	O
myocytes	O
Isolated	O
cardiomyocytes	O
are	O
reversibly	O
made	O
ATP	O
-	O
depleted	O
by	O
CCCP	O
,	O
a	O
reversible	O
inhibitor	O
of	O
mitochondrial	O
oxidative	O
phosphorylation	O
(	O
Li	O
et	O
al.	O
,	O
1989	O
)	O
.	O

The	O
myocytes	O
,	O
which	O
show	O
a	O
rigor	O
contraction	O
on	O
metabolic	O
inhibition	O
are	O
reported	O
to	O
have	O
depressed	O
Ca2	O
+	O
overload	O
,	O
because	O
the	O
activity	O
of	O
the	O
Na+	O
/Ca2	O
+	O
exchanger	O
is	O
inhibited	O
by	O
energy	O
depletion	O
(	O
Li	O
et	O
al.	O
,	O
1988	O
;	O
Collins	O
et	O
al.	O
,	O
1992	O
)	O
.	O

Li	O
et	O
al.	O
(	O
1988	O
)	O
have	O
also	O
reported	O
that	O
cells	O
maintaining	O
a	O
low	O
[	O
Ca2	O
+	O
]	O
i	O
level	O
remain	O
rod	O
-	O
shaped	O
for	O
a	O
longer	O
period	O
against	O
metabolic	O
inhibition	O
.	O

Since	O
our	O
aim	O
was	O
to	O
assess	O
the	O
effect	O
of	O
l	O
-cis	O
diltiazem	O
on	O
reperfusion	O
-	O
induced	O
Ca2	O
+	O
overload	O
in	O
vitro	O
,	O
we	O
followed	O
a	O
protocol	O
with	O
Ca2	O
+	O
-free	O
Tyrode	O
solution	O
,	O
which	O
improves	O
the	O
efficacy	O
of	O
the	O
assessment	O
of	O
reperfusion	O
injury	O
.	O

Using	O
this	O
type	O
of	O
model	O
,	O
we	O
could	O
partially	O
simulate	O
the	O
ischemia	O
/	O
reperfusion	O
-	O
induced	O
Ca2	O
+	O
overload	O
in	O
vitro	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
.	O

A	O
marked	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
was	O
observed	O
after	O
washout	O
of	O
CCCP	O
with	O
Ca2	O
+	O
-containing	O
Tyrode	O
solution	O
.	O

This	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
was	O
suppressed	O
by	O
Ni2	O
+	O
or	O
KB	O
-	O
R7943	O
,	O
a	O
specific	O
inhibitor	O
of	O
the	O
Na+	O
/Ca2	O
+	O
exchanger	O
,	O
but	O
was	O
not	O
suppressed	O
by	O
nitrendipine	O
or	O
nicardipine	O
(	O
Fig.	O
2	O
)	O
.	O

These	O
results	O
indicate	O
that	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
by	O
energy	O
repletion	O
occurred	O
via	O
the	O
Na+	O
/Ca2	O
+	O
exchanger	O
,	O
but	O
not	O
through	O
the	O
dihydropyridine	O
-	O
sensitive	O
Ca2	O
+	O
channel	O
in	O
this	O
model	O
.	O

4.2	O
Cardioprotective	O
effect	O
of	O
l	O
-cis	O
diltiazem	O
on	O
Ca2	O
+	O
overload	O
in	O
guinea	B
pig	I
myocytes	O
In	O
the	O
present	O
study	O
,	O
l	O
-cis	O
diltiazem	O
and	O
diltiazem	O
attenuated	O
both	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
and	O
the	O
cell	O
shortening	O
induced	O
by	O
CCCP	O
.	O

Itogawa	O
et	O
al.	O
(	O
1996	O
)	O
demonstrated	O
that	O
both	O
l	O
-cis	O
diltiazem	O
and	O
diltiazem	O
attenuated	O
veratridine	O
-	O
induced	O
Ca2	O
+	O
overload	O
and	O
hypercontracture	O
in	O
isolated	O
rat	B
hearts	O
.	O

However	O
,	O
this	O
is	O
not	O
direct	O
evidence	O
that	O
l	O
-cis	O
diltiazem	O
actually	O
protects	O
against	O
ischemia	O
/	O
reperfusion	O
injury	O
by	O
inhibiting	O
Ca2	O
+	O
overload	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
mimicked	O
the	O
phenomenon	O
of	O
ischemia	O
/	O
reperfusion	O
injury	O
in	O
the	O
chamber	O
and	O
our	O
data	O
are	O
the	O
first	O
demonstration	O
that	O
both	O
l	O
-cis	O
diltiazem	O
and	O
diltiazem	O
protect	O
against	O
the	O
Ca2	O
+	O
overload	O
induced	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
in	O
the	O
same	O
concentration	O
range	O
.	O

This	O
observation	O
,	O
together	O
with	O
the	O
observation	O
that	O
nitrendipine	O
and	O
nicardipine	O
were	O
without	O
effect	O
,	O
suggests	O
that	O
their	O
effects	O
are	O
independent	O
of	O
L	O
-	O
type	O
Ca2	O
+	O
channel	O
blocking	O
.	O

This	O
possibility	O
is	O
also	O
supported	O
by	O
the	O
results	O
of	O
a	O
previous	O
study	O
in	O
our	O
laboratory	O
showing	O
that	O
l	O
-cis	O
diltiazem	O
(	O
10	O
μM	O
)	O
as	O
well	O
as	O
diltiazem	O
(	O
3	O
μM	O
)	O
worked	O
to	O
preserve	O
high	O
-	O
energy	O
phosphates	O
in	O
the	O
ischemia	O
–	O
reperfusion	O
model	O
of	O
isolated	O
guinea	B
pig	I
hearts	O
(	O
submitted	O
for	O
publication	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
inclusion	O
of	O
diltiazem	O
(	O
3	O
μM	O
)	O
throughout	O
the	O
experiment	O
attenuated	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
during	O
reperfusion	O
(	O
Fig.	O
3A	O
)	O
.	O

However	O
,	O
the	O
addition	O
of	O
diltiazem	O
(	O
3	O
μM	O
)	O
,	O
started	O
5	O
min	O
before	O
reperfusion	O
,	O
failed	O
to	O
attenuate	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
(	O
Fig.	O
3B	O
)	O
.	O

Thus	O
,	O
we	O
suggest	O
that	O
some	O
events	O
during	O
chemical	O
ischemia	O
,	O
which	O
could	O
be	O
affected	O
by	O
diltiazem	O
,	O
might	O
be	O
involved	O
in	O
the	O
Ca2	O
+	O
overload	O
during	O
reperfusion	O
(	O
Watts	O
et	O
al.	O
,	O
1990	O
;	O
Sakamoto	O
et	O
al.	O
,	O
1997	O
)	O
.	O

4.3	O
Cardioprotective	O
mechanism	O
by	O
l	O
-cis	O
diltiazem	O
on	O
Ca2	O
+	O
overload	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
In	O
the	O
present	O
model	O
,	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
after	O
energy	O
repletion	O
was	O
inhibited	O
by	O
both	O
Ni2	O
+	O
and	O
KB	O
-	O
R7943	O
(	O
Fig.	O
2	O
)	O
.	O

Concerning	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
in	O
this	O
model	O
,	O
the	O
L	O
-	O
type	O
Ca2	O
+	O
channel	O
does	O
not	O
seem	O
to	O
be	O
involved	O
.	O

This	O
is	O
because	O
the	O
dihydropyridine	O
Ca2	O
+	O
channel	O
blockers	O
,	O
nitrendipine	O
and	O
nicardipine	O
,	O
affected	O
neither	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
nor	O
cell	O
shortening	O
(	O
Table	O
1	O
)	O
.	O

The	O
inhibition	O
of	O
the	O
Na+	O
/Ca2	O
+	O
exchanger	O
may	O
afford	O
protection	O
from	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
.	O

A	O
previous	O
report	O
has	O
demonstrated	O
that	O
the	O
intracellular	O
Na+	O
concentration	O
(	O
[	O
Na+	O
]	O
i	O
)	O
is	O
increased	O
by	O
metabolic	O
inhibition	O
in	O
guinea	B
pig	I
myocytes	O
(	O
Satoh	O
et	O
al.	O
,	O
1995	O
)	O
.	O

This	O
indicates	O
that	O
Na+	O
overload	O
caused	O
during	O
metabolic	O
inhibition	O
is	O
important	O
in	O
this	O
model	O
.	O

Itogawa	O
et	O
al.	O
(	O
1996	O
)	O
previously	O
reported	O
that	O
l	O
-cis	O
diltiazem	O
inhibited	O
veratridine	O
-	O
induced	O
Na+	O
overload	O
in	O
rat	B
cardiac	O
myocytes	O
.	O

Haigney	O
et	O
al.	O
(	O
1992	O
)	O
reported	O
that	O
the	O
[	O
Na+	O
]	O
i	O
increase	O
seen	O
during	O
hypoxia	O
is	O
potentiated	O
after	O
rigor	O
contraction	O
in	O
isolated	O
rat	O
myocytes	O
.	O

They	O
also	O
suggested	O
that	O
inactivation	O
-	O
resistant	O
Na+	O
channels	O
were	O
involved	O
in	O
this	O
[	O
Na+	O
]	O
i	O
increase	O
.	O

We	O
demonstrated	O
in	O
the	O
present	O
study	O
that	O
both	O
l	O
-cis	O
diltiazem	O
and	O
diltiazem	O
at	O
10	O
μM	O
,	O
when	O
introduced	O
5	O
min	O
before	O
washout	O
of	O
CCCP	O
,	O
attenuated	O
cell	O
shortening	O
after	O
energy	O
repletion	O
(	O
Fig.	O
3B	O
)	O
.	O

Thus	O
,	O
it	O
is	O
speculated	O
that	O
both	O
l	O
-cis	O
diltiazem	O
and	O
diltiazem	O
attenuate	O
Ca2	O
+	O
overload	O
by	O
inhibiting	O
the	O
[	O
Na+	O
]	O
i	O
accumulation	O
early	O
after	O
energy	O
repletion	O
.	O

In	O
conclusion	O
,	O
we	O
first	O
demonstrated	O
that	O
l	O
-cis	O
diltiazem	O
attenuated	O
the	O
Ca2	O
+	O
overload	O
caused	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
in	O
guinea	B
pig	I
myocytes	O
.	O

The	O
cardioprotective	O
action	O
of	O
l	O
-cis	O
diltiazem	O
evidenced	O
in	O
the	O
present	O
work	O
merits	O
further	O
research	O
,	O
since	O
l	O
-cis	O
diltiazem	O
could	O
become	O
a	O
lead	O
compound	O
for	O
investigating	O
protection	O
against	O
ischemia	O
/	O
reperfusion	O
injury	O
.	O

Acknowledgements	O
The	O
authors	O
wish	O
to	O
thank	O
Dr.	O
Satomi	O
Adachi	O
-	O
Akahane	O
(	O
University	O
of	O
Tokyo	O
)	O
for	O
the	O
helpful	O
discussions	O
and	O
Mr.	O
Shoichi	O
Kanda	O
,	O
Ms.	O
Maki	O
Urata	O
,	O
and	O
Mr.	O
Taichiro	O
Tomida	O
(	O
University	O
of	O
Tokyo	O
)	O
for	O
the	O
kind	O
assistance	O
with	O
cell	O
preparation	O
.	O

We	O
thank	O
Tanabe	O
Seiyaku	O
for	O
the	O
kind	O
gift	O
of	O
l	O
-cis	O
diltiazem	O
and	O
diltiazem	O
.	O

We	O
thank	O
Kanebo	O
for	O
the	O
kind	O
gift	O
of	O
KB	O
-	O
R	O
7943	O
.	O

This	O
work	O
was	O
supported	O
by	O
a	O
Grant	O
-	O
in	O
-	O
Aid	O
for	O
Scientific	O
Research	O
from	O
the	O
Ministry	O
of	O
Education	O
,	O
Science	O
,	O
Sports	O
and	O
Culture	O
,	O
Japan	O
.	O

Dopamine	O
(	O
DA	O
)	O
is	O
a	O
neurotransmitter	O
that	O
plays	O
a	O
fundamental	O
role	O
in	O
the	O
control	O
of	O
a	O
variety	O
of	O
physiological	O
functions	O
including	O
locomotor	O
movement	O
,	O
learning	O
,	O
reward	O
behavior	O
,	O
and	O
hormone	O
synthesis	O
and	O
release	O
[	O
40	O
]	O
.	O

However	O
,	O
overflow	O
of	O
DA	O
in	O
the	O
brain	O
has	O
been	O
suggested	O
to	O
participate	O
in	O
certain	O
neurodegenerative	O
processes	O
.	O

These	O
include	O
ischemia	O
[	O
6	O
]	O
,	O
hypoxia	O
[	O
2	O
]	O
,	O
and	O
neurotoxicities	O
induced	O
by	O
excitatory	O
amino	O
acids	O
[	O
16	O
]	O
and	O
methamphetamine	O
[	O
38	O
]	O
.	O

In	O
all	O
of	O
the	O
above	O
cases	O
,	O
striatal	O
DA	O
availability	O
in	O
the	O
brain	O
is	O
significantly	O
increased	O
.	O

For	O
example	O
,	O
the	O
striatal	O
DA	O
concentration	O
rapidly	O
reaches	O
concentrations	O
as	O
high	O
as	O
0.2	O
mM	O
after	O
ligation	O
of	O
the	O
cervical	O
artery	O
in	O
the	O
gerbil	B
ischemic	O
model	O
[	O
45	O
]	O
.	O

Depletion	O
of	O
endogenous	O
DA	O
by	O
chemical	O
lesion	O
of	O
the	O
nigrostriatal	O
dopaminergic	O
pathway	O
reduces	O
ischemic	O
insult	O
to	O
the	O
striatum	O
[	O
17	O
]	O
.	O

Direct	O
intrastriatal	O
injections	O
of	O
DA	O
result	O
in	O
apoptosis	O
and	O
neurodegeneration	O
[	O
18	O
,	O
19	O
]	O
.	O

This	O
DA	O
neurotoxicity	O
is	O
believed	O
to	O
be	O
mediated	O
through	O
a	O
DA	O
-	O
oxidation	O
-	O
associated	O
pathway	O
.	O

DA	O
oxidative	O
stress	O
is	O
also	O
assumed	O
to	O
be	O
a	O
major	O
pathological	O
factor	O
that	O
contributes	O
to	O
dopaminergic	O
neuronal	O
degeneration	O
in	O
Parkinson	O
's	O
disease	O
[	O
14	O
]	O
.	O

We	O
have	O
recently	O
demonstrated	O
that	O
DA	O
induces	O
apoptosis	O
involving	O
the	O
oxidation	O
–	O
JNK	O
–	O
c	O
-	O
Jun	O
activation	O
pathway	O
in	O
in	O
vitro	O
cell	O
cultures	O
[	O
32	O
]	O
and	O
activation	O
of	O
transcription	O
factors	O
AP-1	O
and	O
NF	O
-	O
κB	O
in	O
an	O
in	O
vivo	O
rat	B
model	O
[	O
29	O
]	O
.	O

Direct	O
intrastriatal	O
injections	O
of	O
high	O
concentrations	O
of	O
DA	O
in	O
rats	B
also	O
result	O
in	O
activation	O
of	O
astrocytes	O
as	O
indicated	O
by	O
an	O
increase	O
of	O
glial	O
fibrillary	O
acidic	O
protein	O
(	O
GFAP	O
)	O
immunocytochemical	O
staining	O
and	O
astrocyte	O
proliferation	O
determined	O
by	O
[	O
3	O
H	O
]	O
R05	O
-	O
4864	O
binding	O
to	O
peripheral	O
benzodiazepine	O
receptors	O
on	O
astrocytes	O
[	O
15	O
]	O
.	O

Astrocytes	O
are	O
the	O
intimate	O
partners	O
of	O
neurons	O
and	O
play	O
important	O
physiological	O
roles	O
in	O
the	O
maintenance	O
of	O
the	O
microenvironment	O
of	O
neurons	O
,	O
including	O
sequestration	O
and	O
metabolism	O
of	O
various	O
neurotransmitters	O
,	O
and	O
production	O
of	O
proinflammatory	O
and	O
immunomodulatory	O
cytokines	O
and	O
neuropeptides	O
[	O
50	O
]	O
.	O

In	O
the	O
rat	B
ischemic	O
model	O
,	O
activated	O
striatal	O
astrocytes	O
appear	O
to	O
play	O
a	O
protective	O
role	O
for	O
DA	O
-	O
innervated	O
neurons	O
[	O
51	O
]	O
.	O

In	O
a	O
cell	O
culture	O
system	O
,	O
striatal	O
astrocytes	O
were	O
also	O
shown	O
to	O
have	O
a	O
protective	O
effect	O
against	O
hydrogen	O
peroxide	O
toxicity	O
in	O
dopaminergic	O
neurons	O
[	O
24	O
]	O
.	O

Nevertheless	O
,	O
the	O
mechanism	O
by	O
which	O
DA	O
activates	O
astrocytes	O
is	O
unknown	O
.	O

To	O
investigate	O
potential	O
signaling	O
of	O
activation	O
of	O
astrocytes	O
by	O
DA	O
,	O
we	O
have	O
chosen	O
a	O
rat	B
C6	O
glioma	O
cell	O
line	O
stably	O
expressing	O
DA	O
D2L	O
receptors	O
based	O
on	O
the	O
following	O
reasons	O
.	O

(	O
1	O
)	O
C6	O
glioma	O
cells	O
have	O
been	O
widely	O
used	O
as	O
a	O
model	O
of	O
glial	O
phenotype	O
[	O
5	O
,	O
39	O
]	O
.	O

(	O
2	O
)	O
Recent	O
evidence	O
suggests	O
that	O
D2	O
receptors	O
are	O
expressed	O
in	O
striatal	O
astrocytes	O
.	O

Physiologically	O
,	O
DA	O
can	O
induce	O
membrane	O
hyperpolarization	O
in	O
the	O
majority	O
of	O
astrocytes	O
from	O
the	O
striatum	O
,	O
which	O
can	O
be	O
inhibited	O
by	O
application	O
of	O
domperidone	O
,	O
a	O
D2	O
receptor	O
antagonist	O
[	O
21	O
]	O
.	O

D2	O
antagonists	O
,	O
[	O
3	O
H	O
]	O
domperidone	O
and	O
[	O
3	O
H	O
]	O
spiperone	O
,	O
can	O
specifically	O
label	O
striatal	O
astrocytes	O
[	O
20	O
]	O
.	O

D2	O
receptor	O
mRNA	O
can	O
be	O
detected	O
by	O
either	O
in	O
situ	O
hybridization	O
or	O
polymerase	O
chain	O
reaction	O
from	O
astrocytes	O
in	O
striatum	O
,	O
an	O
area	O
enriched	O
with	O
dopaminergic	O
termini	O
,	O
but	O
not	O
astrocytes	O
in	O
cerebellum	O
,	O
which	O
receives	O
little	O
dopaminergic	O
innervation	O
[	O
4	O
]	O
.	O

This	O
region	O
-	O
specific	O
expression	O
of	O
D2	O
receptors	O
suggests	O
that	O
dopaminergic	O
neurons	O
may	O
physiologically	O
influence	O
astrocyte	O
functions	O
.	O

(	O
3	O
)	O
C6-D2L	O
cells	O
stably	O
express	O
recombinant	O
D2L	O
DA	O
receptors	O
[	O
36	O
]	O
.	O

The	O
expression	O
level	O
of	O
D2	O
receptors	O
in	O
C6-D2L	O
cells	O
is	O
about	O
188	O
fmol	O
/	O
mg	O
protein	O
,	O
which	O
is	O
close	O
to	O
that	O
in	O
striatal	O
membranes	O
(	O
∼400	O
fmol	O
/	O
mg	O
protein	O
)	O
[	O
30	O
,	O
37	O
]	O
.	O

(	O
4	O
)	O
Like	O
native	O
neuronal	O
D2	O
receptors	O
,	O
the	O
binding	O
of	O
agonist	O
to	O
D2	O
receptors	O
in	O
the	O
C6-D2L	O
cells	O
is	O
functionally	O
coupled	O
to	O
pertussis	O
-	O
toxin	O
-	O
sensitive	O
G	O
proteins	O
,	O
resulting	O
in	O
inhibition	O
of	O
adenylate	O
cyclase	O
[	O
49	O
]	O
and	O
activation	O
of	O
both	O
extracellular	O
signal	O
-	O
regulated	O
kinases	O
(	O
ERKs	O
)	O
and	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
[	O
30	O
]	O
.	O

Given	O
the	O
fact	O
of	O
C6	O
glial	O
phenotype	O
and	O
D2	O
receptors	O
in	O
striatal	O
astrocytes	O
,	O
the	O
biological	O
functions	O
stimulated	O
by	O
D2	O
receptors	O
observed	O
in	O
C6-D2L	O
cells	O
may	O
mimic	O
those	O
produced	O
in	O
vivo	O
.	O

Thus	O
,	O
this	O
C6-D2L	O
cell	O
line	O
may	O
serve	O
as	O
a	O
good	O
in	O
vitro	O
cell	O
culture	O
model	O
for	O
studies	O
of	O
DA	O
regulation	O
of	O
glial	O
response	O
.	O

Using	O
this	O
C6-D2L	O
cell	O
line	O
,	O
we	O
have	O
previously	O
reported	O
that	O
nanomolar	O
levels	O
of	O
DA	O
stimulate	O
cell	O
proliferation	O
through	O
activation	O
of	O
both	O
ERKs	O
and	O
JNK	O
[	O
30	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
found	O
that	O
high	O
concentrations	O
(	O
micromolar	O
levels	O
)	O
of	O
DA	O
stimulate	O
a	O
delayed	O
mitogenesis	O
compared	O
to	O
that	O
induced	O
by	O
the	O
nanomolar	O
levels	O
of	O
DA	O
.	O

This	O
DA	O
-	O
stimulated	O
mitogenesis	O
requires	O
D2-receptor	O
-	O
mediated	O
intracellular	O
redox	O
–	O
tyrosine	O
kinase	O
cascade	O
,	O
but	O
does	O
not	O
need	O
ERK	O
activation	O
.	O

In	O
addition	O
,	O
micromolar	O
levels	O
of	O
DA	O
also	O
increase	O
GFAP	O
expression	O
,	O
which	O
is	O
linked	O
to	O
a	O
D2-receptor	O
-	O
independent	O
p38	O
MAPK	O
activation	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Materials	O
Antibodies	O
against	O
phosphorylated	O
tyrosine	O
(	O
PY99	O
)	O
and	O
ERK2	O
were	O
purchased	O
from	O
Santa	O
Cruz	O
Biotechnology	O
(	O
Santa	O
Cruz	O
,	O
CA	O
)	O
.	O

Antibodies	O
against	O
phospho	O
-	O
specific	O
ERK	O
and	O
phospho	O
-	O
specific	O
p38	O
MAPK	O
were	O
from	O
New	O
England	O
Biolabs	O
(	O
Beverly	O
,	O
MA	O
)	O
.	O

DA	O
,	O
(	O
+	O
)	O
-	O
and	O
(	O
−	O
)	O
-butaclamol	O
hydrochloride	O
,	O
and	O
(	O
−	O
)	O
-quinpirole	O
hydrochloride	O
were	O
from	O
Research	O
Biochemicals	O
International	O
(	O
Natick	O
,	O
MA	O
)	O
.	O

PD098059	O
,	O
p38	O
inhibitor	O
SB	O
203580	O
,	O
diphenyleneiodonium	O
chloride	O
(	O
DPI	O
)	O
,	O
Herbimycin	O
A	O
,	O
Wortmannin	O
,	O
H7	O
,	O
and	O
staurosporine	O
were	O
from	O
Calbiochem	O
(	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

Pertussis	O
toxin	O
(	O
PTX	O
)	O
and	O
N	O
-acetyl	O
-	O
l	O
-cysteine	O
(	O
NAC	O
)	O
were	O
from	O
Sigma	O
(	O
St.	O
Louis	O
,	O
MO	O
)	O
.	O

[	O
3	O
H	O
]	O
Thymidine	O
was	O
purchased	O
form	O
Amersham	O
(	O
Arlington	O
Heights	O
,	O
IL	O
)	O
.	O

Genistein	O
was	O
from	O
Gibco	O
BRL	O
(	O
Gaithersburg	O
,	O
MD	O
)	O
.	O

Hoechst	O
33342	O
was	O
from	O
Molecular	O
Probes	O
(	O
Eugene	O
,	O
OR	O
)	O
.	O

2.2	O
Cell	O
culture	O
and	O
treatments	O
Stably	O
transfected	O
C6-D2L	O
cells	O
were	O
prepared	O
as	O
described	O
[	O
46	O
]	O
and	O
maintained	O
in	O
Dulbecco	O
's	O
modified	O
Eagle	O
's	O
medium	O
(	O
DMEM	O
)	O
supplemented	O
with	O
5	O
%	O
fetal	O
bovine	B
serum	O
and	O
5	O
%	O
donor	O
calf	B
serum	O
with	O
penicillin	O
/	O
streptomycin	O
and	O
puromycin	O
(	O
2	O
μg	O
/	O
ml	O
)	O
.	O

The	O
wild	O
-	O
type	O
C6	O
cells	O
were	O
maintained	O
in	O
the	O
above	O
medium	O
without	O
puromycin	O
.	O

For	O
tyrosine	O
phosphorylation	O
and	O
GFAP	O
studies	O
,	O
the	O
cells	O
were	O
starved	O
with	O
serum	O
-	O
free	O
medium	O
containing	O
0.025	O
%	O
ascorbic	O
acid	O
for	O
6–8	O
h	O
and	O
then	O
stimulated	O
with	O
indicated	O
reagents	O
.	O

All	O
reagents	O
were	O
prepared	O
or	O
diluted	O
with	O
DMEM	O
plus	O
0.025	O
%	O
ascorbic	O
acid	O
.	O

For	O
inhibitory	O
experiments	O
,	O
all	O
inhibitory	O
reagents	O
except	O
PTX	O
were	O
added	O
0.5	O
h	O
(	O
PTX	O
for	O
6	O
h	O
)	O
prior	O
to	O
stimulation	O
with	O
DA	O
.	O

2.3	O
Lysate	O
preparation	O
After	O
stimulation	O
,	O
the	O
cells	O
were	O
immediately	O
washed	O
twice	O
using	O
cold	O
PBS	O
and	O
then	O
solubilized	O
with	O
ice	O
-	O
cold	O
buffer	O
consisting	O
of	O
25	O
mM	O
Hepes	O
,	O
pH	O
7.5	O
,	O
300	O
mM	O
NaCl	O
,	O
1.5	O
mM	O
MgCl2	O
,	O
0.2	O
mM	O
EDTA	O
,	O
0.1	O
%	O
Triton	O
X-100	O
,	O
20	O
mM	O
β	O
-	O
glycerophosphate	O
,	O
0.1	O
mM	O
sodium	O
orthovanadate	O
,	O
0.5	O
mM	O
DTT	O
,	O
100	O
μg	O
/	O
ml	O
PMSF	O
,	O
and	O
2	O
μg	O
/	O
ml	O
leupeptin	O
.	O

Cellular	O
extracts	O
were	O
cleared	O
by	O
centrifugation	O
for	O
30	O
min	O
at	O
14,000	O
rpm	O
at	O
4	O
°	O
C	O
.	O

The	O
supernatants	O
were	O
saved	O
and	O
the	O
protein	O
concentration	O
was	O
determined	O
using	O
Bio	O
-	O
Rad	O
protein	O
reagent	O
.	O

For	O
determination	O
of	O
GFAP	O
,	O
the	O
cell	O
lysates	O
were	O
prepared	O
as	O
follows	O
.	O

Stimulated	O
cells	O
were	O
scraped	O
and	O
collected	O
by	O
centrifugation	O
for	O
5	O
min	O
at	O
3000	O
rpm	O
.	O

The	O
cell	O
pellets	O
were	O
washed	O
once	O
with	O
cold	O
PBS	O
,	O
pH	O
7.4	O
,	O
solubilized	O
with	O
hot	O
lysis	O
buffer	O
(	O
80–90	O
°	O
C	O
)	O
containing	O
10	O
mM	O
Tris	O
–	O
HCl	O
,	O
pH	O
7.6	O
,	O
150	O
mM	O
NaCl	O
,	O
0.5	O
mm	O
EDTA	O
,	O
1	O
mM	O
EGTA	O
,	O
1	O
%	O
sodium	O
dodecyl	O
sulfate	O
(	O
SDS	O
)	O
,	O
1	O
mM	O
sodium	B
orthovanadate	I
,	O
1	O
mM	O
PMSF	O
,	O
1	O
μg	O
/	O
ml	O
pepstatin	O
A	O
,	O
and	O
2	O
μg	O
/	O
ml	O
aprotinin	O
,	O
and	O
heated	O
for	O
20	O
min	O
at	O
90	O
°	O
C	O
.	O

The	O
protein	O
concentration	O
of	O
the	O
lysates	O
was	O
determined	O
by	O
using	O
Micro	O
BCA	O
(	O
Pierce	O
,	O
Rockford	O
,	O
IL	O
)	O
.	O

All	O
lysates	O
were	O
used	O
immediately	O
or	O
aliquoted	O
and	O
stored	O
at	O
−70	O
°	O
C	O
for	O
further	O
use	O
.	O

2.4	O
Immunoblotting	O
Equal	O
amounts	O
of	O
lysate	O
protein	O
(	O
40	O
μg	O
/	O
lane	O
)	O
were	O
run	O
on	O
8–16	O
%	O
SDS	O
-	O
PAGE	O
and	O
electrophoretically	O
transferred	O
to	O
nitrocellulose	O
.	O

The	O
nitrocellulose	O
blot	O
was	O
blocked	O
with	O
10	O
%	O
non	O
-	O
fat	O
dry	O
milk	O
in	O
TBST	O
buffer	O
(	O
20	O
mM	O
Tris	O
–	O
HCl	O
,	O
pH	O
7.4	O
,	O
500	O
mM	O
NaCl	O
,	O
and	O
0.01	O
%	O
Tween-20	O
)	O
and	O
then	O
incubated	O
with	O
primary	O
antibodies	O
(	O
phospho	O
-	O
specific	O
ERK	O
,	O
ERK2	O
,	O
phospho	O
-	O
specific	O
p38	O
MAPK	O
,	O
or	O
PY99	O
,	O
1:1000	O
)	O
in	O
TBST	O
containing	O
5	O
%	O
BSA	O
overnight	O
at	O
4	O
°	O
C	O
.	O

The	O
immunoreactive	O
bands	O
were	O
detected	O
by	O
sequential	O
incubation	O
with	O
horseradish	O
-	O
peroxidase	O
-	O
conjugated	O
secondary	O
antibody	O
(	O
1:5000	O
,	O
Jackson	O
ImmunoResearch	O
Laboratories	O
,	O
West	O
Grove	O
,	O
PA	O
)	O
and	O
Renaissance	O
substrate	O
(	O
DuPont	O
;	O
Boston	O
,	O
MA	O
)	O
.	O

For	O
control	O
of	O
protein	O
loading	O
,	O
immunoblotting	O
with	O
ERK2	O
was	O
performed	O
using	O
either	O
a	O
sister	O
gel	O
or	O
a	O
stripped	O
blot	O
.	O

For	O
quantitative	O
studies	O
,	O
the	O
band	O
was	O
quantified	O
with	O
the	O
NIH	O
Image	O
1.55	O
Program	O
.	O

The	O
results	O
were	O
normalized	O
to	O
fold	O
of	O
control	O
and	O
presented	O
as	O
means±S.E.M.	O
2.5	O
Measurement	O
of	O
mitogenesis	O
The	O
procedures	O
were	O
described	O
elsewhere	O
[	O
31	O
]	O
.	O

C6-D2L	O
cells	O
(	O
1	O
×	O
105	O
/ml	O
,	O
0.2	O
ml	O
/	O
well	O
)	O
were	O
plated	O
in	O
a	O
96-well	O
plate	O
and	O
grown	O
for	O
24	O
h.	O
The	O
cells	O
were	O
rinsed	O
twice	O
with	O
serum	O
-	O
free	O
DMEM	O
and	O
starved	O
for	O
8	O
h	O
in	O
serum	O
-	O
free	O
medium	O
containing	O
0.025	O
%	O
ascorbic	O
acid	O
.	O

After	O
that	O
,	O
the	O
cells	O
were	O
incubated	O
with	O
DA	O
for	O
23	O
h	O
and	O
pulsed	O
with	O
2	O
μCi	O
[	O
3	O
H	O
]	O
thymidine	O
per	O
well	O
for	O
an	O
additional	O
6	O
h.	O
The	O
cells	O
in	O
each	O
well	O
were	O
fixed	O
with	O
ice	O
-	O
cold	O
5	O
%	O
trichloroacetic	O
acid	O
,	O
washed	O
three	O
times	O
with	O
cold	O
STE	O
buffer	O
(	O
150	O
mM	O
NaCl	O
,	O
50	O
mM	O
Tris	O
–	O
HCl	O
,	O
pH	O
7.2	O
,	O
1	O
mM	O
EDTA	O
)	O
,	O
and	O
solubilized	O
with	O
0.1	O
ml	O
of	O
a	O
mixture	O
of	O
0.1	O
%	O
SDS	O
and	O
0.01	O
N	O
NaOH	O
.	O

Incorporated	O
[	O
3	O
H	O
]	O
thymidine	O
was	O
counted	O
with	O
a	O
Beckman	O
liquid	O
scintillation	O
counter	O
and	O
expressed	O
as	O
counts	O
per	O
minute	O
per	O
well	O
(	O
cpm	O
/	O
well	O
)	O
.	O

2.6	O
Cell	O
cycle	O
analysis	O
by	O
flow	O
cytometry	O
Cell	O
cycle	O
analysis	O
was	O
performed	O
according	O
to	O
the	O
method	O
by	O
Chrest	O
et	O
al.	O
[	O
9	O
]	O
.	O

Briefly	O
,	O
C6-D2L	O
cells	O
were	O
plated	O
in	O
35	O
mm	O
dishes	O
,	O
and	O
seeded	O
overnight	O
.	O

The	O
cells	O
were	O
starved	O
for	O
8	O
h	O
by	O
replacing	O
the	O
mixture	O
of	O
DMEM	O
plus	O
0.025	O
%	O
ascorbic	O
acid	O
and	O
stimulated	O
for	O
29	O
h.	O
The	O
cells	O
were	O
then	O
collected	O
and	O
suspended	O
in	O
complete	O
cell	O
culture	O
medium	O
.	O

The	O
cells	O
(	O
1	O
×	O
106	O
cells	O
/	O
ml	O
)	O
were	O
treated	O
with	O
1	O
μM	O
Hoechst	O
33342	O
for	O
30	O
min	O
at	O
37	O
°	O
C	O
.	O

Cells	O
were	O
analyzed	O
for	O
DNA	O
content	O
using	O
a	O
FACStarplus	O
flow	O
cytometer	O
(	O
Becton	O
Dickinson	O
Immunocytometry	O
System	O
,	O
San	O
Jose	O
,	O
CA	O
)	O
equipped	O
with	O
argon	O
and	O
krypton	O
lasers	O
.	O

Hoechst	O
33342	O
stained	O
cells	O
were	O
excited	O
with	O
350–356	O
nm	O
wavelength	O
UV	O
light	O
from	O
the	O
krypton	O
laser	O
and	O
the	O
fluorescence	O
emission	O
was	O
collected	O
with	O
a	O
424-nm	O
filter	O
.	O

DNA	O
histograms	O
were	O
acquired	O
by	O
collecting	O
a	O
total	O
of	O
10,000	O
events	O
.	O

Cell	O
compartments	O
,	O
including	O
G1	O
,	O
S	O
,	O
and	O
G2	O
/M	O
phases	O
,	O
were	O
determined	O
using	O
the	O
Multicycle	O
software	O
(	O
Phoenix	O
Flow	O
Systems	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

3	O
Results	O
3.1	O
DA	O
stimulates	O
mitogenesis	O
We	O
have	O
previously	O
reported	O
that	O
nanomolar	O
levels	O
of	O
DA	O
stimulated	O
mitogenesis	O
in	O
C6-D2L	O
cells	O
[	O
30	O
]	O
.	O

The	O
maximal	O
[	O
3	O
H	O
]	O
thymidine	O
incorporation	O
into	O
DNA	O
occurs	O
at	O
17	O
h	O
after	O
exposure	O
to	O
100	O
nM	O
DA	O
concentration	O
.	O

We	O
extended	O
this	O
study	O
by	O
observing	O
the	O
cell	O
response	O
at	O
high	O
DA	O
concentrations	O
and	O
longer	O
exposure	O
.	O

Interestingly	O
,	O
micromolar	O
levels	O
of	O
DA	O
also	O
stimulate	O
DNA	O
synthesis	O
but	O
with	O
a	O
slower	O
time	O
course	O
(	O
about	O
29	O
h	O
after	O
DA	O
stimulation	O
,	O
data	O
not	O
shown	O
)	O
.	O

Under	O
these	O
conditions	O
,	O
DA	O
stimulated	O
[	O
3	O
H	O
]	O
thymidine	O
incorporation	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
Fig.	O
1	O
a	O
)	O
.	O

The	O
[	O
3	O
H	O
]	O
thymidine	O
incorporation	O
into	O
DNA	O
was	O
linearly	O
increased	O
from	O
0.1	O
to	O
500	O
μM	O
DA	O
.	O

The	O
mitogenic	O
activity	O
at	O
500	O
μM	O
DA	O
was	O
about	O
3.2±0.2	O
times	O
higher	O
than	O
that	O
of	O
control	O
group	O
.	O

This	O
DA	O
-	O
induced	O
mitogenesis	O
could	O
be	O
completely	O
inhibited	O
in	O
the	O
presence	O
of	O
aphidicoline	O
(	O
20	O
μg	O
/	O
ml	O
,	O
data	O
not	O
shown	O
)	O
,	O
a	O
potent	O
DNA	O
polymerase	O
a	O
inhibitor	O
.	O

To	O
confirm	O
the	O
DA	O
mitogenic	O
activation	O
,	O
we	O
also	O
determined	O
the	O
cell	O
cycle	O
distribution	O
.	O

As	O
shown	O
in	O
Table	O
1	O
,	O
200	O
μM	O
DA	O
increased	O
the	O
percentage	O
of	O
the	O
cells	O
in	O
S	O
phase	O
and	O
decreased	O
the	O
percentage	O
of	O
cells	O
in	O
G1	O
phase	O
,	O
suggesting	O
that	O
DA	O
promotes	O
progression	O
through	O
the	O
cell	O
cycle	O
.	O

Next	O
,	O
we	O
tested	O
whether	O
this	O
DA	O
-	O
stimulated	O
mitogenesis	O
requires	O
activation	O
of	O
D2	O
receptors	O
.	O

Pretreatment	O
of	O
the	O
C6-D2L	O
cells	O
with	O
10	O
μM	O
(	O
+	O
)	O
-butaclamol	O
,	O
a	O
potent	O
D2	O
receptor	O
antagonist	O
,	O
completely	O
inhibited	O
DA	O
-	O
induced	O
DNA	O
[	O
3	O
H	O
]	O
thymidine	O
incorporation	O
,	O
while	O
10	O
μM	O
(	O
−	O
)	O
-butaclamol	O
,	O
an	O
inactive	O
form	O
of	O
(	O
+	O
)	O
-butaclamol	O
,	O
had	O
no	O
effect	O
on	O
the	O
DA	O
-	O
stimulated	O
mitogenesis	O
(	O
Fig.	O
1	O
b	O
)	O
.	O

To	O
confirm	O
these	O
results	O
,	O
we	O
determined	O
the	O
effect	O
of	O
quinpirole	O
,	O
a	O
specific	O
D2	O
receptor	O
agonist	O
,	O
on	O
cell	O
cycling	O
.	O

Like	O
the	O
effect	O
of	O
micromolar	O
levels	O
of	O
DA	O
,	O
micromolar	O
levels	O
of	O
quinpirole	O
promoted	O
cell	O
proliferation	O
.	O

Quinpirole	O
increased	O
the	O
percentage	O
of	O
cells	O
in	O
S	O
phase	O
and	O
decreased	O
the	O
percentage	O
in	O
G1	O
phase	O
(	O
Table	O
1	O
)	O
.	O

Furthermore	O
,	O
we	O
did	O
not	O
observe	O
any	O
mitogenic	O
effect	O
within	O
a	O
DA	O
concentration	O
range	O
of	O
0–500	O
μM	O
in	O
wild	O
-	O
type	O
C6	O
cells	O
without	O
expression	O
of	O
D2L	O
receptors	O
(	O
Fig.	O
1	O
a	O
)	O
.	O

Instead	O
,	O
[	O
3	O
H	O
]	O
thymidine	O
incorporation	O
into	O
DNA	O
of	O
wild	O
-	O
type	O
C6	O
cells	O
was	O
decreased	O
about	O
20–26	O
%	O
at	O
DA	O
concentrations	O
from	O
10	O
to	O
500	O
μM	O
(	O
Fig.	O
1	O
a	O
)	O
.	O

Pretreatment	O
of	O
the	O
C6-D2L	O
cells	O
with	O
100	O
ng	O
/	O
ml	O
PTX	O
,	O
a	O
G	O
protein	O
-	O
receptor	O
uncoupler	O
,	O
partially	O
blocked	O
DA	O
-	O
stimulated	O
[	O
3	O
H	O
]	O
thymidine	O
incorporation	O
into	O
DNA	O
(	O
Fig.	O
1	O
b	O
)	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
this	O
DA	O
-	O
stimulated	O
mitogenesis	O
requires	O
DA	O
D2	O
receptor	O
activation	O
.	O

3.2	O
Effects	O
of	O
kinase	O
inhibitors	O
on	O
DA	O
-	O
induced	O
mitogenesis	O
In	O
order	O
to	O
examine	O
the	O
signaling	O
that	O
mediates	O
the	O
DA	O
-	O
stimulated	O
mitogenesis	O
,	O
we	O
first	O
tested	O
the	O
effect	O
of	O
DA	O
on	O
the	O
activity	O
of	O
ERK	O
,	O
a	O
protein	O
serine	O
kinase	O
that	O
is	O
linked	O
to	O
cell	O
proliferation	O
stimulated	O
by	O
growth	O
factors	O
,	O
cytokines	O
and	O
neurotransmitters	O
[	O
11	O
,	O
34	O
]	O
.	O

As	O
shown	O
in	O
the	O
phospho	O
-	O
specific	O
ERK	O
immunoblot	O
of	O
Fig.	O
2	O
a	O
,	O
DA	O
had	O
little	O
or	O
no	O
effect	O
on	O
ERK	O
phosphorylation	O
at	O
concentrations	O
corresponding	O
to	O
its	O
mitogenic	O
effect	O
(	O
10–500	O
μM	O
)	O
,	O
although	O
DA	O
at	O
lower	O
concentrations	O
did	O
stimulate	O
ERK	O
phosphorylation	O
and	O
activity	O
[	O
30	O
]	O
.	O

The	O
bottom	O
panel	O
in	O
Fig.	O
2	O
a	O
shows	O
ERK2	O
immunoblot	O
of	O
a	O
sister	O
gel	O
,	O
indicating	O
that	O
a	O
similar	O
amount	O
of	O
protein	O
was	O
loaded	O
.	O

To	O
confirm	O
that	O
ERK	O
was	O
not	O
involved	O
in	O
DA	O
-	O
induced	O
mitogenesis	O
,	O
we	O
also	O
examined	O
the	O
effect	O
of	O
PD098059	O
,	O
a	O
selective	O
MEK1	O
inhibitor	O
[	O
3	O
]	O
,	O
on	O
DA	O
-	O
induced	O
mitogenesis	O
.	O

As	O
shown	O
in	O
Fig.	O
2	O
b	O
,	O
the	O
DA	O
-	O
stimulated	O
DNA	O
synthesis	O
was	O
only	O
partially	O
inhibited	O
by	O
pretreatment	O
of	O
the	O
cells	O
with	O
PD	O
098059	O
(	O
10–50	O
μM	O
)	O
(	O
Fig.	O
2	O
b	O
)	O
.	O

With	O
application	O
of	O
either	O
10	O
or	O
50	O
μM	O
PD	O
098059	O
,	O
bFGF	O
-	O
stimulated	O
ERK	O
activity	O
,	O
as	O
indicated	O
by	O
ERK	O
phosphorylation	O
,	O
was	O
greatly	O
or	O
completely	O
inhibited	O
,	O
respectively	O
(	O
Fig.	O
2	O
c	O
)	O
,	O
which	O
serves	O
as	O
a	O
positive	O
control	O
of	O
the	O
inhibitory	O
effect	O
of	O
PD098059	O
on	O
MEK1–ERK	O
pathway	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
the	O
mitogenesis	O
induced	O
by	O
micromolar	O
levels	O
of	O
DA	O
is	O
not	O
mediated	O
by	O
a	O
MEK	O
–	O
ERK	O
activation	O
pathway	O
.	O

We	O
have	O
also	O
tested	O
other	O
kinase	O
inhibitors	O
on	O
DA	O
-	O
stimulated	O
mitogenesis	O
.	O

These	O
inhibitors	O
included	O
Wortmannin	O
for	O
PI3	O
kinase	O
,	O
rapamycin	O
for	O
S6	O
kinase	O
,	O
and	O
SB203580	O
for	O
p38	O
MAP	O
kinase	O
.	O

Staurosporine	O
and	O
H7	O
are	O
inhibitors	O
for	O
a	O
broad	O
spectrum	O
of	O
protein	O
kinases	O
,	O
which	O
include	O
protein	O
kinase	O
A	O
,	O
protein	O
kinase	O
C	O
,	O
protein	O
kinase	O
G	O
,	O
CaM	O
kinase	O
,	O
and	O
myosin	O
light	O
chain	O
kinase	O
.	O

The	O
effect	O
of	O
depletion	O
of	O
PKC	O
on	O
DA	O
-	O
stimulated	O
[	O
3	O
H	O
]	O
thymidine	O
incorporation	O
into	O
DNA	O
was	O
also	O
examined	O
by	O
prolonged	O
treatment	O
of	O
the	O
cells	O
with	O
PMA	O
.	O

The	O
data	O
are	O
summarized	O
on	O
Table	O
2	O
.	O

All	O
these	O
treatments	O
had	O
no	O
effect	O
on	O
DA	O
-	O
induced	O
DNA	O
synthesis	O
.	O

3.3	O
DA	O
stimulates	O
mitogenesis	O
-	O
associated	O
protein	O
tyrosine	O
phosphorylation	O
DA	O
stimulated	O
protein	O
tyrosine	O
phosphorylation	O
in	O
a	O
time-	O
and	O
concentration	O
-	O
dependent	O
manner	O
(	O
Fig.	O
3	O
a	O
and	O
b	O
)	O
.	O

The	O
phosphorylated	O
tyrosine	O
-	O
containing	O
proteins	O
were	O
easily	O
immunodetected	O
with	O
monoclonal	O
anti	O
-	O
phosphotyrosine	O
IgG	O
(	O
PY99	O
)	O
.	O

When	O
C6-D2L	O
cells	O
were	O
treated	O
with	O
200	O
μM	O
DA	O
,	O
protein	O
tyrosine	O
phosphorylation	O
rapidly	O
increased	O
within	O
5	O
min	O
,	O
reached	O
a	O
maximum	O
between	O
15	O
and	O
30	O
min	O
,	O
then	O
decreased	O
by	O
1	O
h	O
(	O
Fig.	O
3	O
a	O
)	O
.	O

A	O
majority	O
of	O
tyrosine	O
-	O
phosphorylated	O
proteins	O
were	O
located	O
within	O
the	O
molecular	O
size	O
range	O
of	O
50–200	O
kDa	O
,	O
some	O
of	O
which	O
are	O
indicated	O
by	O
arrows	O
in	O
Fig.	O
3	O
a.	O
DA	O
-	O
stimulated	O
tyrosine	O
phosphorylation	O
was	O
evident	O
within	O
DA	O
concentrations	O
ranging	O
from	O
10	O
to	O
500	O
μM	O
(	O
Fig.	O
3	O
b	O
)	O
,	O
which	O
paralleled	O
the	O
DA	O
concentrations	O
for	O
stimulation	O
of	O
mitogenesis	O
(	O
Fig.	O
1	O
a	O
)	O
.	O

To	O
monitor	O
the	O
amounts	O
of	O
protein	O
loaded	O
,	O
all	O
blots	O
were	O
stripped	O
and	O
then	O
immunoblotted	O
with	O
anti	O
-	O
ERK2	O
.	O

The	O
lower	O
anti	O
-	O
ERK2	O
immunoblottings	O
in	O
Fig.	O
3	O
a	O
and	O
b	O
show	O
that	O
a	O
similar	O
amount	O
of	O
protein	O
was	O
loaded	O
.	O

This	O
protein	O
tyrosine	O
phosphorylation	O
,	O
mostly	O
at	O
molecular	O
sizes	O
between	O
50	O
and	O
150	O
kDa	O
,	O
required	O
D2	O
receptor	O
activation	O
.	O

Preincubation	O
of	O
C6-D2L	O
cells	O
30	O
min	O
with	O
(	O
+	O
)	O
-butaclamol	O
,	O
a	O
specific	O
D2	O
receptor	O
antagonist	O
,	O
could	O
block	O
DA	O
-	O
induced	O
protein	O
tyrosine	O
phosphorylation	O
(	O
Fig.	O
3	O
c	O
)	O
.	O

This	O
antagonistic	O
effect	O
was	O
concentration	O
-	O
dependent	O
.	O

Increasing	O
(	O
+	O
)	O
-butaclamol	O
from	O
1	O
to	O
100	O
μM	O
resulted	O
in	O
significant	O
inhibition	O
of	O
protein	O
tyrosine	O
phosphorylation	O
.	O

Especially	O
in	O
the	O
presence	O
of	O
100	O
μM	O
(	O
+	O
)	O
-butaclamol	O
,	O
the	O
cells	O
failed	O
to	O
respond	O
to	O
200	O
μM	O
DA	O
stimulation	O
(	O
upper	O
left	O
panel	O
,	O
Fig.	O
3	O
c	O
)	O
.	O

This	O
blocking	O
effect	O
was	O
specific	O
to	O
D2	O
receptors	O
since	O
application	O
of	O
the	O
same	O
amount	O
of	O
(	O
−	O
)	O
-butaclamol	O
,	O
an	O
inactive	O
form	O
of	O
(	O
+	O
)	O
-butaclamol	O
,	O
did	O
not	O
show	O
any	O
effect	O
on	O
DA	O
-	O
stimulated	O
tyrosine	O
phosphorylation	O
.	O

We	O
have	O
also	O
directly	O
tested	O
the	O
effect	O
of	O
quinpirole	O
,	O
a	O
D2	O
receptor	O
agonist	O
,	O
on	O
protein	O
tyrosine	O
phosphorylation	O
.	O

As	O
shown	O
in	O
the	O
right	O
panel	O
of	O
Fig.	O
3	O
c	O
,	O
increasing	O
quinpirole	O
from	O
10	O
to	O
200	O
μM	O
resulted	O
in	O
a	O
great	O
increase	O
in	O
the	O
amount	O
of	O
tyrosine	O
-	O
phosphorylated	O
proteins	O
.	O

Furthermore	O
,	O
we	O
could	O
not	O
observe	O
significant	O
changes	O
in	O
tyrosine	O
-	O
phosphorylated	O
proteins	O
in	O
wild	O
-	O
type	O
C6	O
cells	O
treated	O
with	O
DA	O
concentrations	O
from	O
10	O
to	O
500	O
μM	O
(	O
data	O
not	O
shown	O
)	O
.	O

Inactivation	O
of	O
cellular	O
PTX	O
-	O
sensitive	O
G	O
proteins	O
by	O
PTX	O
partially	O
blocked	O
DA	O
-	O
induced	O
protein	O
tyrosine	O
phosphorylation	O
.	O

We	O
have	O
quantified	O
tyrosine	O
-	O
phosphorylated	O
proteins	O
between	O
50	O
and	O
150	O
kDa	O
by	O
using	O
the	O
NIH	O
Image	O
1.55	O
Program	O
.	O

Pretreatment	O
of	O
the	O
cells	O
with	O
500	O
ng	O
/	O
ml	O
PTX	O
inhibited	O
DA	O
(	O
200	O
μM	O
)	O
-stimulated	O
tyrosine	O
phosphorylation	O
by	O
57±15	O
%	O
(	O
n	O
=	O
3	O
)	O
.	O

PTX	O
at	O
a	O
concentration	O
of	O
100	O
ng	O
/	O
ml	O
also	O
reduced	O
the	O
tyrosine	O
-	O
phosphorylated	O
proteins	O
by	O
24±13	O
%	O
(	O
n	O
=	O
3	O
)	O
.	O

Coincidentally	O
,	O
this	O
percentage	O
of	O
reduction	O
of	O
tyrosine	O
phosphorylation	O
by	O
100	O
ng	O
/	O
ml	O
PTX	O
is	O
close	O
to	O
its	O
inhibitory	O
ability	O
(	O
32±10	O
%	O
,	O
n	O
=3	O
,	O
Fig.	O
1	O
b	O
)	O
to	O
DA	O
-	O
stimulated	O
mitogenesis	O
.	O

Thus	O
,	O
these	O
results	O
suggest	O
that	O
D2	O
receptor	O
activation	O
is	O
associated	O
with	O
protein	O
tyrosine	O
kinase	O
activity	O
.	O

In	O
order	O
to	O
test	O
the	O
idea	O
that	O
tyrosine	O
kinase	O
is	O
involved	O
in	O
DA	O
-	O
stimulated	O
mitogenesis	O
,	O
we	O
examined	O
the	O
effect	O
of	O
genistein	O
,	O
a	O
potent	O
tyrosine	O
kinase	O
inhibitor	O
,	O
on	O
DA	O
-	O
induced	O
tyrosine	O
phosphorylation	O
and	O
mitogenesis	O
.	O

As	O
shown	O
in	O
Fig.	O
4	O
a	O
,	O
preincubation	O
of	O
either	O
genistein	O
or	O
herbimycin	O
(	O
another	O
tyrosine	O
kinase	O
inhibitor	O
)	O
significantly	O
blocked	O
the	O
protein	O
tyrosine	O
phosphorylation	O
stimulated	O
by	O
200	O
μM	O
DA	O
.	O

Application	O
of	O
10	O
μM	O
genistein	O
completely	O
inhibited	O
the	O
DNA	O
synthesis	O
induced	O
by	O
DA	O
(	O
Fig.	O
4	O
b	O
)	O
.	O

These	O
observations	O
indicate	O
that	O
the	O
activation	O
of	O
protein	O
tyrosine	O
kinase	O
is	O
required	O
for	O
the	O
promotion	O
of	O
mitogenesis	O
induced	O
by	O
DA	O
.	O

3.4	O
DA	O
-	O
induced	O
mitogenesis	O
is	O
involved	O
in	O
an	O
intracellular	O
redox	O
–	O
tyrosine	O
phosphorylation	O
pathway	O
Although	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
are	O
implicated	O
in	O
pathological	O
cellular	O
processes	O
,	O
including	O
oxidative	O
stress	O
damage	O
[	O
47	O
]	O
and	O
ischemic	O
neuronal	O
injury	O
[	O
10	O
]	O
,	O
recent	O
evidence	O
suggests	O
that	O
ROS	O
are	O
involved	O
in	O
cell	O
signaling	O
that	O
regulates	O
proliferation	O
and	O
DNA	O
synthesis	O
[	O
22	O
]	O
.	O

To	O
test	O
the	O
idea	O
that	O
D2	O
receptors	O
stimulate	O
mitogenesis	O
through	O
regulation	O
of	O
an	O
intracellular	O
redox	O
–	O
tyrosine	O
kinase	O
cascade	O
,	O
we	O
examined	O
the	O
effect	O
of	O
diphenylene	O
iodonium	O
(	O
DPI	O
)	O
and	O
N	O
-acetyl	O
cysteine	O
(	O
NAC	O
)	O
on	O
DA	O
-	O
induced	O
tyrosine	O
phosphorylation	O
and	O
mitogenesis	O
.	O

DPI	O
is	O
an	O
inhibitor	O
of	O
flavonoid	O
-	O
containing	O
oxidases	O
that	O
can	O
catalyze	O
the	O
formation	O
of	O
superoxide	O
from	O
oxygen	O
with	O
NADH	O
/	O
NADPH	O
as	O
an	O
electron	O
donor	O
[	O
28	O
,	O
43	O
]	O
.	O

Some	O
flavonoid	O
-	O
containing	O
oxidases	O
,	O
such	O
as	O
NADPH	O
-	O
dependent	O
oxidase	O
,	O
have	O
been	O
shown	O
to	O
be	O
regulated	O
by	O
a	O
variety	O
of	O
membrane	O
receptors	O
,	O
such	O
as	O
intrinsic	O
tyrosine	O
-	O
kinase	O
-	O
containing	O
receptors	O
and	O
G	O
-	O
protein	O
-	O
coupled	O
receptors	O
[	O
22	O
,	O
23	O
]	O
.	O

NAC	O
is	O
an	O
antioxidant	O
that	O
can	O
scavenge	O
free	O
radicals	O
.	O

Pretreatment	O
of	O
C6-D2L	O
cells	O
with	O
either	O
1	O
μM	O
DPI	O
or	O
20	O
mM	O
NAC	O
greatly	O
reduced	O
tyrosine	O
phosphorylation	O
and	O
consequent	O
mitogenesis	O
induced	O
by	O
DA	O
(	O
Fig.	O
5	O
a	O
and	O
b	O
)	O
.	O

Either	O
DPI	O
or	O
NAC	O
itself	O
has	O
no	O
effect	O
on	O
tyrosine	O
phosphorylation	O
of	O
proteins	O
(	O
Fig.	O
5	O
)	O
.	O

The	O
anti	O
-	O
ERK2	O
immunoblotting	O
of	O
same	O
stripped	O
blot	O
shows	O
that	O
a	O
similar	O
amount	O
of	O
protein	O
was	O
loaded	O
in	O
each	O
lane	O
(	O
lower	O
panel	O
,	O
Fig.	O
5	O
a	O
)	O
.	O

Thus	O
,	O
these	O
results	O
suggest	O
that	O
the	O
protein	O
tyrosine	O
kinase	O
and	O
consequent	O
mitogenesis	O
may	O
be	O
regulated	O
by	O
intracellular	O
ROS	O
,	O
which	O
are	O
assumed	O
to	O
be	O
produced	O
by	O
flavonoid	O
-	O
containing	O
oxidases	O
.	O

Next	O
,	O
we	O
tested	O
the	O
roles	O
of	O
ROS	O
in	O
DA	O
-	O
induced	O
tyrosine	O
phosphorylation	O
and	O
mitogenesis	O
by	O
application	O
of	O
exogenous	O
H2	O
O2	O
.	O

We	O
assumed	O
that	O
the	O
protein	O
tyrosine	O
kinase	O
could	O
be	O
activated	O
by	O
DA	O
-	O
stimulated	O
increase	O
of	O
intracellular	O
ROS	O
.	O

If	O
this	O
is	O
the	O
case	O
,	O
exogenous	O
application	O
of	O
low	O
concentrations	O
of	O
H2	O
O2	O
may	O
enhance	O
protein	O
kinase	O
activity	O
and	O
subsequent	O
mitogenesis	O
induced	O
by	O
DA	O
.	O

As	O
shown	O
in	O
Fig.	O
6	O
a	O
,	O
increasing	O
extracellular	O
H2	O
O2	O
concentrations	O
did	O
result	O
in	O
increase	O
of	O
DA	O
-	O
induced	O
tyrosine	O
-	O
phosphorylated	O
proteins	O
.	O

The	O
upper	O
panel	O
shows	O
anti	O
-	O
phosphotyrosine	O
immunoblotting	O
,	O
while	O
the	O
lower	O
panel	O
is	O
a	O
quantified	O
data	O
(	O
from	O
50	O
to	O
150	O
kDa	O
)	O
of	O
at	O
least	O
three	O
experiments	O
using	O
the	O
NIH	O
Image	O
1.55	O
Program	O
.	O

The	O
sister	O
gel	O
was	O
run	O
and	O
immunostained	O
with	O
anti	O
-	O
ERK2	O
to	O
monitor	O
protein	O
loading	O
.	O

The	O
nanomolar	O
levels	O
of	O
H2	O
O2	O
enhanced	O
by	O
about	O
2.7-fold	O
amounts	O
of	O
tyrosine	O
-	O
phosphorylated	O
proteins	O
stimulated	O
by	O
10	O
μM	O
DA	O
,	O
although	O
H2	O
O2	O
levels	O
below	O
1	O
nM	O
show	O
only	O
a	O
small	O
effect	O
(	O
Fig.	O
6	O
a	O
)	O
.	O

Furthermore	O
,	O
an	O
enhancement	O
effect	O
of	O
H2	O
O2	O
on	O
DA	O
-	O
stimulated	O
mitogenesis	O
was	O
also	O
observed	O
(	O
Fig.	O
6	O
b	O
)	O
.	O

However	O
,	O
the	O
capability	O
of	O
increasing	O
DA	O
-	O
induced	O
mitogenesis	O
at	O
nanomolar	O
levels	O
of	O
H2	O
O2	O
was	O
reduced	O
when	O
compared	O
with	O
that	O
at	O
0.1	O
pM	O
H2	O
O2	O
(	O
Fig.	O
6	O
b	O
)	O
.	O

This	O
may	O
be	O
due	O
to	O
a	O
dual	O
effect	O
of	O
ROS	O
in	O
cell	O
proliferation	O
:	O
a	O
stimulatory	O
effect	O
at	O
low	O
concentrations	O
and	O
a	O
toxic	O
effect	O
at	O
high	O
concentrations	O
[	O
22	O
]	O
.	O

With	O
the	O
application	O
of	O
H2	O
O2	O
alone	O
without	O
DA	O
,	O
C6-D2L	O
cells	O
did	O
exhibit	O
such	O
a	O
dual	O
mitogenic	O
effect	O
(	O
data	O
not	O
shown	O
)	O
.	O

3.5	O
DA	O
increases	O
GFAP	O
expression	O
In	O
addition	O
to	O
stimulating	O
DNA	O
synthesis	O
,	O
DA	O
at	O
micromolar	O
levels	O
also	O
significantly	O
increased	O
the	O
expression	O
of	O
GFAP	O
,	O
a	O
sensitive	O
parameter	O
serving	O
as	O
another	O
criterion	O
of	O
reactive	O
astrocytes	O
[	O
33	O
]	O
.	O

As	O
shown	O
in	O
Fig.	O
7	O
a	O
,	O
C6-D2L	O
cells	O
responded	O
to	O
DA	O
(	O
200	O
μM	O
)	O
treatment	O
with	O
an	O
increase	O
in	O
GFAP	O
expression	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
.	O

Between	O
0	O
and	O
48	O
h	O
after	O
stimulation	O
,	O
the	O
amount	O
of	O
GFAP	O
was	O
increased	O
about	O
2.1±0.1-fold	O
(	O
Fig.	O
7	O
a	O
)	O
.	O

Concentration	O
dependence	O
studies	O
carried	O
out	O
at	O
24	O
h	O
showed	O
that	O
maximal	O
stimulation	O
of	O
GFAP	O
expression	O
occurred	O
at	O
200	O
μM	O
DA	O
(	O
Fig.	O
7	O
b	O
)	O
.	O

Interestingly	O
,	O
GFAP	O
production	O
was	O
decreased	O
when	O
the	O
cells	O
were	O
exposed	O
to	O
500	O
μM	O
DA	O
for	O
24	O
h	O
(	O
Fig.	O
7	O
b	O
)	O
,	O
which	O
differs	O
from	O
the	O
dose	O
–	O
response	O
data	O
of	O
DA	O
-	O
induced	O
mitogenesis	O
(	O
Fig.	O
1	O
)	O
.	O

This	O
observation	O
suggests	O
that	O
DA	O
stimulatory	O
GFAP	O
synthesis	O
may	O
be	O
regulated	O
by	O
a	O
different	O
pathway	O
from	O
mitogenesis	O
.	O

Alternatively	O
,	O
this	O
decrease	O
of	O
GFAP	O
expression	O
at	O
500	O
μM	O
DA	O
may	O
be	O
due	O
to	O
widespread	O
mitogenesis	O
since	O
immature	O
astrocytes	O
have	O
a	O
less	O
amount	O
of	O
GFAP	O
expression	O
.	O

3.6	O
DA	O
-	O
induced	O
GFAP	O
generation	O
involves	O
activation	O
of	O
p38	O
MAPK	O
It	O
became	O
important	O
to	O
determine	O
whether	O
DA	O
-	O
stimulated	O
GFAP	O
production	O
might	O
also	O
be	O
required	O
to	O
activate	O
the	O
D2	O
receptor	O
–	O
tyrosine	O
kinase	O
pathway	O
.	O

To	O
test	O
this	O
idea	O
,	O
we	O
used	O
a	O
paradigm	O
similar	O
to	O
that	O
for	O
DA	O
-	O
stimulated	O
mitogenesis	O
in	O
C6-D2L	O
cells	O
(	O
Fig.	O
1	O
)	O
.	O

Surprisingly	O
,	O
the	O
GFAP	O
stimulation	O
did	O
not	O
appear	O
to	O
be	O
regulated	O
by	O
D2	O
receptors	O
since	O
it	O
was	O
not	O
influenced	O
by	O
the	O
D2	O
receptor	O
antagonist	O
,	O
(	O
+	O
)	O
-butaclamol	O
(	O
Fig.	O
8	O
a	O
)	O
.	O

Application	O
of	O
DA	O
to	O
wild	O
-	O
type	O
C6	O
cells	O
also	O
resulted	O
in	O
a	O
similar	O
increase	O
in	O
GFAP	O
expression	O
as	O
that	O
in	O
C6-D2L	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

Moreover	O
,	O
direct	O
application	O
of	O
quinpirole	O
(	O
200	O
μM	O
)	O
,	O
a	O
D2	O
receptor	O
agonist	O
,	O
had	O
no	O
effect	O
on	O
GFAP	O
expression	O
(	O
Fig.	O
8	O
a	O
)	O
.	O

Pretreatment	O
of	O
the	O
C6-D2L	O
cells	O
with	O
PTX	O
for	O
6	O
h	O
had	O
no	O
effect	O
on	O
DA	O
-	O
stimulated	O
GFAP	O
generation	O
(	O
Fig.	O
8	O
a	O
)	O
,	O
suggesting	O
that	O
PTX	O
-	O
sensitive	O
G	O
proteins	O
might	O
also	O
not	O
be	O
involved	O
.	O

Pretreatment	O
of	O
the	O
cells	O
with	O
either	O
10	O
μM	O
genistein	O
or	O
20	O
mM	O
NAC	O
also	O
had	O
no	O
effect	O
on	O
GFAP	O
expression	O
due	O
to	O
DA	O
(	O
Fig.	O
8	O
a	O
)	O
,	O
while	O
the	O
identical	O
treatments	O
resulted	O
in	O
the	O
blocking	O
of	O
DA	O
-	O
induced	O
mitogenesis	O
(	O
Fig.	O
4	O
b	O
,	O
Fig.	O
5	O
b	O
)	O
.	O

PD098059	O
also	O
had	O
no	O
effect	O
on	O
DA	O
-	O
stimulated	O
GFAP	O
expression	O
(	O
Fig.	O
8	O
a	O
)	O
.	O

Thus	O
,	O
unlike	O
DA	O
-	O
induced	O
mitogenesis	O
,	O
GFAP	O
stimulation	O
does	O
not	O
seem	O
to	O
involve	O
the	O
D2	O
receptor	O
–	O
tyrosine	O
kinase	O
pathway	O
.	O

However	O
,	O
we	O
have	O
found	O
that	O
GFAP	O
expression	O
stimulated	O
by	O
DA	O
could	O
be	O
inhibited	O
by	O
pretreatment	O
of	O
the	O
cells	O
with	O
SB203580	O
,	O
a	O
selective	O
p38	O
MAPK	O
inhibitor	O
[	O
13	O
,	O
27	O
]	O
.	O

As	O
shown	O
in	O
Fig.	O
8	O
b	O
,	O
application	O
of	O
10	O
μM	O
SB	O
203580	O
completely	O
blocked	O
the	O
increases	O
in	O
GFAP	O
generation	O
stimulated	O
by	O
DA	O
at	O
concentrations	O
ranging	O
from	O
10	O
to	O
200	O
μM	O
,	O
suggesting	O
that	O
activation	O
of	O
p38	O
MAPK	O
might	O
be	O
required	O
for	O
the	O
regulation	O
of	O
GFAP	O
generation	O
.	O

By	O
using	O
anti	O
-	O
phospho	O
-	O
specific	O
p38	O
MAPK	O
immunoblotting	O
,	O
we	O
examined	O
the	O
effect	O
of	O
DA	O
on	O
p38	O
MAPK	O
phosphorylation	O
,	O
a	O
requirement	O
for	O
p38	O
MAPK	O
activity	O
[	O
42	O
]	O
.	O

With	O
the	O
application	O
of	O
100	O
μM	O
DA	O
to	O
C6-D2L	O
cells	O
,	O
p38	O
MAPK	O
was	O
rapidly	O
phosphorylated	O
within	O
5	O
min	O
,	O
reached	O
a	O
maximum	O
at	O
15	O
min	O
,	O
then	O
gradually	O
decreased	O
to	O
basal	O
level	O
by	O
about	O
1	O
h	O
(	O
Fig.	O
9	O
a	O
)	O
.	O

The	O
p38	O
MAPK	O
phosphorylation	O
was	O
greatly	O
increased	O
when	O
the	O
cells	O
were	O
exposed	O
to	O
DA	O
concentrations	O
ranging	O
from	O
10	O
to	O
200	O
μM	O
for	O
15	O
min	O
(	O
Fig.	O
9	O
b	O
)	O
.	O

Pretreatment	O
of	O
the	O
cells	O
with	O
(	O
+	O
)	O
-butaclamol	O
had	O
no	O
effect	O
on	O
DA	O
-	O
stimulated	O
phosphorylation	O
of	O
p38	O
MAPK	O
(	O
Fig.	O
9	O
c	O
)	O
.	O

These	O
data	O
suggest	O
that	O
DA	O
-	O
activated	O
p38	O
MAPK	O
may	O
not	O
be	O
mediated	O
by	O
D2	O
receptors	O
.	O

4	O
Discussion	O
In	O
this	O
paper	O
,	O
we	O
report	O
that	O
micromolar	O
levels	O
of	O
DA	O
stimulate	O
mitogenesis	O
in	O
C6-D2L	O
cells	O
.	O

In	O
contrast	O
with	O
our	O
previous	O
report	O
for	O
earlier	O
mitogenesis	O
(	O
peaking	O
at	O
17	O
h	O
)	O
induced	O
by	O
nanomolar	O
levels	O
of	O
DA	O
[	O
30	O
]	O
,	O
this	O
mitogenesis	O
stimulated	O
by	O
micromolar	O
levels	O
of	O
DA	O
occurs	O
at	O
about	O
29	O
h.	O
Biochemically	O
,	O
the	O
earlier	O
phase	O
of	O
mitogenesis	O
requires	O
D2	O
receptor	O
–	O
MAPK	O
signaling	O
,	O
while	O
the	O
later	O
phase	O
requires	O
the	O
D2-receptor	O
–	O
tyrosine	O
kinase	O
pathway	O
.	O

Although	O
relationship	O
of	O
the	O
two	O
phases	O
of	O
DA	O
-	O
induced	O
mitogenesis	O
is	O
not	O
clear	O
,	O
the	O
different	O
signaling	O
mechanisms	O
suggest	O
that	O
they	O
are	O
not	O
likely	O
to	O
be	O
dependent	O
on	O
each	O
other	O
.	O

For	O
example	O
,	O
nanomolar	O
levels	O
of	O
DA	O
strongly	O
stimulate	O
MAPK	O
without	O
significant	O
protein	O
tyrosine	O
phosphorylation	O
and	O
the	O
mitogenesis	O
can	O
be	O
inhibited	O
by	O
blockers	O
of	O
MAPK	O
pathway	O
.	O

Micromolar	O
levels	O
of	O
DA	O
strongly	O
stimulate	O
protein	O
tyrosine	O
kinase	O
without	O
effect	O
on	O
MAPK	O
,	O
and	O
the	O
consequent	O
mitogenesis	O
can	O
be	O
blocked	O
by	O
tyrosine	O
kinase	O
inhibitors	O
but	O
not	O
by	O
blockers	O
of	O
the	O
MAPK	O
pathway	O
.	O

Under	O
normal	O
physiological	O
conditions	O
,	O
striatal	O
astrocytes	O
surround	O
dopaminergic	O
neurons	O
.	O

Although	O
the	O
astrocytes	O
do	O
not	O
have	O
synaptic	O
contact	O
with	O
dopaminergic	O
neurons	O
,	O
D2	O
receptors	O
in	O
astrocytes	O
may	O
sense	O
DA	O
(	O
low	O
concentrations	O
)	O
that	O
might	O
escape	O
from	O
the	O
synapse	O
and	O
play	O
a	O
physiological	O
role	O
via	O
the	O
MAPK	O
pathway	O
.	O

In	O
pathologic	O
conditions	O
,	O
such	O
as	O
ischemia	O
,	O
hypoxia	O
and	O
excitatory	O
amino	O
acid	O
-	O
induced	O
neurotoxicity	O
,	O
the	O
extracellular	O
DA	O
concentration	O
in	O
striata	O
is	O
significantly	O
increased	O
to	O
micromolar	O
levels	O
[	O
2	O
,	O
6	O
,	O
45	O
]	O
.	O

Although	O
the	O
length	O
of	O
DA	O
exposure	O
in	O
our	O
cell	O
culture	O
was	O
relatively	O
long	O
,	O
the	O
signaling	O
responses	O
,	O
such	O
as	O
protein	O
tyrosine	O
phosphorylation	O
and	O
p38	O
MAPK	O
phosphorylation	O
,	O
were	O
rapid	O
,	O
within	O
a	O
few	O
minutes	O
(	O
Fig.	O
3	O
a	O
,	O
Fig.	O
9	O
a	O
)	O
.	O

Thus	O
,	O
the	O
micromolar	O
level	O
DA	O
-	O
induced	O
activation	O
of	O
astrocytes	O
may	O
be	O
implicated	O
in	O
these	O
pathologic	O
conditions	O
.	O

Our	O
results	O
suggest	O
that	O
micromolar	O
levels	O
of	O
DA	O
activate	O
C6-D2L	O
cells	O
through	O
an	O
interaction	O
with	O
receptors	O
.	O

This	O
is	O
evident	O
since	O
DA	O
-	O
stimulated	O
mitogenesis	O
can	O
be	O
blocked	O
by	O
(	O
+	O
)	O
-butaclamol	O
,	O
a	O
selective	O
D2	O
DA	O
receptor	O
antagonist	O
,	O
with	O
no	O
effect	O
of	O
(	O
−	O
)	O
-butaclamol	O
,	O
an	O
inactive	O
isoform	O
of	O
(	O
+	O
)	O
-butaclamol	O
.	O

Quinpirole	O
,	O
a	O
specific	O
D2	O
receptor	O
agonist	O
,	O
also	O
promotes	O
cell	O
cycle	O
progression	O
.	O

Furthermore	O
,	O
wild	O
-	O
type	O
C6	O
cells	O
,	O
lacking	O
the	O
expression	O
of	O
D2	O
receptors	O
,	O
exhibit	O
no	O
mitogenic	O
response	O
to	O
stimulation	O
by	O
DA	O
.	O

This	O
also	O
ruled	O
out	O
the	O
possibility	O
that	O
the	O
mitogenesis	O
might	O
be	O
mediated	O
by	O
ROS	O
produced	O
by	O
DA	O
autoxidation	O
.	O

However	O
,	O
considering	O
the	O
fact	O
that	O
C6	O
cells	O
contain	O
other	O
monoamine	O
receptors	O
,	O
such	O
as	O
β	O
adrenergic	O
receptors	O
[	O
35	O
]	O
,	O
we	O
can	O
not	O
exclude	O
the	O
possibility	O
that	O
micromolar	O
levels	O
of	O
DA	O
may	O
also	O
non	O
-	O
specifically	O
stimulate	O
these	O
receptors	O
and	O
may	O
cooperate	O
with	O
DA	O
receptors	O
.	O

A	O
receptor	O
-	O
mediated	O
mechanism	O
may	O
also	O
be	O
involved	O
in	O
GFAP	O
upregulation	O
stimulated	O
by	O
DA	O
since	O
GFAP	O
synthesis	O
could	O
not	O
be	O
prevented	O
by	O
preincubation	O
with	O
20	O
mM	O
NAC	O
,	O
which	O
can	O
scavenge	O
ROS	O
generated	O
either	O
by	O
DA	O
oxidation	O
or	O
through	O
a	O
D2-receptor	O
-	O
mediated	O
redox	O
system	O
.	O

Although	O
the	O
type	O
of	O
receptor	O
involved	O
in	O
DA	O
-	O
stimulated	O
GFAP	O
expression	O
is	O
currently	O
unknown	O
,	O
it	O
would	O
appear	O
not	O
to	O
be	O
D2	O
receptors	O
since	O
both	O
wild	O
-	O
type	O
C6	O
and	O
C6-D2L	O
cells	O
gave	O
a	O
similar	O
GFAP	O
regulatory	O
response	O
to	O
DA	O
stimulation	O
.	O

One	O
potential	O
candidate	O
would	O
be	O
β	O
adrenergic	O
receptors	O
,	O
shown	O
to	O
stimulate	O
GFAP	O
expression	O
through	O
cAMP	O
[	O
44	O
]	O
.	O

High	O
-	O
concentration	O
DA	O
-	O
stimulated	O
mitogenesis	O
appears	O
to	O
involve	O
the	O
intracellular	O
production	O
of	O
ROS	O
as	O
supported	O
by	O
the	O
following	O
evidence	O
.	O

First	O
,	O
DA	O
-	O
stimulated	O
mitogenesis	O
can	O
be	O
inhibited	O
by	O
DPI	O
.	O

DPI	O
has	O
been	O
demonstrated	O
to	O
be	O
a	O
potent	O
and	O
selective	O
inhibitor	O
for	O
membrane	O
-	O
bound	O
NADPH	O
-	O
dependent	O
oxidase	O
through	O
a	O
binding	O
to	O
the	O
flavoprotein	O
component	O
of	O
the	O
oxidase	O
[	O
12	O
,	O
28	O
,	O
43	O
]	O
.	O

This	O
intracellular	O
NADPH	O
-	O
dependent	O
oxidase	O
can	O
directly	O
catalyze	O
substrate	O
oxygen	O
conversion	O
to	O
the	O
superoxide	O
anion	O
,	O
which	O
can	O
in	O
turn	O
generate	O
other	O
reactive	O
oxygen	O
intermediates	O
.	O

Secondly	O
,	O
DA	O
-	O
induced	O
mitogenesis	O
is	O
prevented	O
by	O
the	O
membrane	O
-	O
permeable	O
antioxidant	O
,	O
NAC	O
.	O

Finally	O
,	O
application	O
of	O
very	O
low	O
concentrations	O
of	O
H2	O
O2	O
can	O
enhance	O
both	O
DA	O
-	O
induced	O
protein	O
tyrosine	O
phosphorylation	O
and	O
mitogenesis	O
.	O

These	O
observations	O
suggest	O
that	O
ROS	O
may	O
serve	O
as	O
a	O
second	O
messenger	O
in	O
the	O
signaling	O
of	O
DA	O
-	O
stimulated	O
mitogenesis	O
,	O
adding	O
evidence	O
in	O
support	O
of	O
the	O
recent	O
notion	O
that	O
ROS	O
act	O
as	O
intracellular	O
messengers	O
of	O
cell	O
proliferation	O
[	O
22	O
]	O
.	O

Like	O
other	O
astrocyte	O
mitogens	O
,	O
such	O
as	O
endothelin	O
[	O
7	O
,	O
26	O
]	O
,	O
micromolar	O
level	O
DA	O
-	O
induced	O
mitogenesis	O
requires	O
tyrosine	O
phosphorylation	O
.	O

Application	O
of	O
DA	O
to	O
C6-D2L	O
cells	O
rapidly	O
increases	O
protein	O
tyrosine	O
phosphorylation	O
.	O

Concentration	O
-	O
dependent	O
tyrosine	O
phosphorylation	O
studies	O
show	O
a	O
similar	O
profile	O
to	O
that	O
of	O
DA	O
-	O
induced	O
DNA	O
synthesis	O
.	O

Both	O
protein	O
tyrosine	O
phosphorylation	O
and	O
mitogenesis	O
can	O
be	O
effectively	O
blocked	O
by	O
preincubation	O
of	O
the	O
cells	O
with	O
genistein	O
,	O
a	O
potent	O
protein	O
tyrosine	O
kinase	O
inhibitor	O
[	O
1	O
]	O
.	O

However	O
,	O
unlike	O
for	O
the	O
mitogen	O
endothelin	O
,	O
DA	O
-	O
stimulated	O
mitogenesis	O
is	O
not	O
linked	O
to	O
the	O
tyrosine	O
kinase	O
–	O
ERK	O
pathway	O
since	O
DA	O
at	O
micromolar	O
levels	O
has	O
no	O
stimulatory	O
effect	O
on	O
ERK	O
activation	O
.	O

Furthermore	O
,	O
PD098095	O
,	O
the	O
MEK1	O
inhibitor	O
,	O
has	O
little	O
,	O
if	O
any	O
,	O
effect	O
on	O
high	O
concentration	O
of	O
DA	O
-	O
induced	O
mitogenesis	O
although	O
it	O
does	O
have	O
some	O
inhibitory	O
effects	O
on	O
basal	O
DNA	O
synthesis	O
.	O

DA	O
-	O
stimulated	O
mitogenesis	O
at	O
micromolar	O
levels	O
is	O
partially	O
mediated	O
by	O
PTX	O
-	O
sensitive	O
G	O
proteins	O
.	O

This	O
is	O
supported	O
by	O
the	O
following	O
evidence	O
.	O

(	O
1	O
)	O
Pretreatment	O
of	O
the	O
cells	O
with	O
100	O
ng	O
/	O
ml	O
PTX	O
only	O
inhibits	O
DA	O
-	O
stimulated	O
mitogenesis	O
by	O
about	O
24–50	O
%	O
,	O
depending	O
on	O
concentrations	O
of	O
DA	O
(	O
Fig.	O
1	O
b	O
)	O
.	O

(	O
2	O
)	O
Application	O
of	O
PTX	O
,	O
even	O
in	O
a	O
very	O
high	O
concentration	O
(	O
500	O
ng	O
/	O
ml	O
)	O
,	O
only	O
partially	O
blocks	O
DA	O
-	O
induced	O
tyrosine	O
phosphorylation	O
.	O

(	O
3	O
)	O
The	O
ability	O
of	O
PTX	O
to	O
inhibit	O
protein	O
tyrosine	O
phosphorylation	O
is	O
correlated	O
with	O
that	O
to	O
inhibit	O
DA	O
-	O
induced	O
mitogenesis	O
(	O
Fig.	O
1	O
b	O
)	O
.	O

These	O
observations	O
raise	O
the	O
possibility	O
that	O
PTX	O
-	O
resistant	O
G	O
proteins	O
may	O
participate	O
in	O
the	O
signaling	O
of	O
high	O
concentration	O
of	O
DA	O
-	O
induced	O
mitogenesis	O
,	O
although	O
further	O
studies	O
are	O
required	O
.	O

Some	O
literature	O
reports	O
suggest	O
that	O
receptors	O
coupled	O
to	O
PTX	O
-	O
insensitive	O
G	O
proteins	O
or	O
the	O
small	O
G	O
protein	O
Ras	O
can	O
regulate	O
cell	O
proliferation	O
.	O

For	O
example	O
,	O
thrombin	O
,	O
an	O
astrocytic	O
mitogen	O
,	O
has	O
been	O
shown	O
to	O
stimulate	O
DNA	O
synthesis	O
in	O
1321N1	O
astrocytoma	O
cells	O
through	O
coupling	O
with	O
G12	O
,	O
a	O
Gq	O
subtype	O
of	O
GTP	O
binding	O
proteins	O
[	O
41	O
]	O
.	O

Recently	O
,	O
D2	O
receptors	O
were	O
also	O
reported	O
to	O
stimulate	O
prolactin	O
release	O
via	O
coupling	O
of	O
a	O
PTX	O
-	O
insensitive	O
G	O
protein	O
pathway	O
[	O
8	O
]	O
.	O

Whether	O
or	O
not	O
D2	O
receptors	O
might	O
be	O
coupled	O
to	O
PTX	O
-	O
insensitive	O
G	O
proteins	O
or	O
Ras	O
small	O
G	O
proteins	O
in	O
response	O
to	O
high	O
concentrations	O
of	O
DA	O
needs	O
further	O
study	O
.	O

Our	O
data	O
suggest	O
that	O
activation	O
of	O
p38	O
MAPK	O
is	O
required	O
for	O
upregulation	O
of	O
GFAP	O
synthesis	O
following	O
high	O
concentrations	O
of	O
DA	O
stimulation	O
.	O

This	O
is	O
based	O
on	O
the	O
following	O
observations	O
.	O

(	O
1	O
)	O
Micromolar	O
level	O
DA	O
-	O
stimulated	O
GFAP	O
production	O
can	O
be	O
completely	O
inhibited	O
by	O
pretreatment	O
of	O
the	O
cells	O
with	O
SB203580	O
,	O
a	O
highly	O
selective	O
inhibitor	O
of	O
p38	O
MAPK	O
[	O
13	O
,	O
27	O
]	O
.	O

Inhibition	O
of	O
a	O
parallel	O
MAPK	O
pathway	O
by	O
PD098059	O
has	O
no	O
effect	O
on	O
DA	O
-	O
induced	O
GFAP	O
expression	O
,	O
suggesting	O
that	O
a	O
relative	O
specificity	O
of	O
p38	O
MAPK	O
may	O
play	O
a	O
role	O
in	O
GFAP	O
generation	O
.	O

(	O
2	O
)	O
DA	O
activates	O
p38	O
MAPK	O
activity	O
at	O
concentrations	O
similar	O
to	O
those	O
of	O
DA	O
-	O
induced	O
GFAP	O
expression	O
.	O

(	O
3	O
)	O
Both	O
activation	O
of	O
p38	O
MAPK	O
and	O
GFAP	O
synthesis	O
are	O
not	O
regulated	O
by	O
D2	O
receptors	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
regarding	O
the	O
regulation	O
of	O
GFAP	O
by	O
p38	O
MAPK	O
.	O

In	O
C6	O
cells	O
,	O
an	O
increase	O
in	O
intracellular	O
cAMP	O
,	O
either	O
by	O
stimulation	O
of	O
β	O
-	O
adrenergic	O
receptors	O
[	O
44	O
]	O
or	O
by	O
stimulation	O
of	O
adenylate	O
cyclase	O
by	O
forskolin	O
[	O
44	O
]	O
,	O
is	O
capable	O
of	O
stimulating	O
GFAP	O
.	O

The	O
relationship	O
of	O
cAMP	O
to	O
p38	O
MAPK	O
deserves	O
further	O
investigation	O
.	O

In	O
our	O
cell	O
culture	O
studies	O
,	O
at	O
least	O
two	O
pathways	O
have	O
been	O
demonstrated	O
to	O
activate	O
C6-D2L	O
glioma	O
cells	O
.	O

One	O
is	O
the	O
D2-receptor	O
-	O
required	O
intracellular	O
redox	O
–	O
protein	O
tyrosine	O
kinase	O
pathway	O
,	O
which	O
is	O
involved	O
in	O
stimulation	O
of	O
cell	O
mitogenesis	O
.	O

Another	O
is	O
the	O
D2	O
receptor	O
-	O
independent	O
p38	O
MAPK	O
cascade	O
,	O
which	O
is	O
involved	O
in	O
stimulation	O
of	O
GFAP	O
synthesis	O
.	O

Interestingly	O
,	O
in	O
an	O
in	O
vivo	O
rat	B
model	O
,	O
reactive	O
astrocytes	O
in	O
the	O
brain	O
respond	O
differently	O
to	O
brain	O
injury	O
.	O

Some	O
astrocytes	O
undergo	O
proliferation	O
as	O
indicated	O
only	O
by	O
[	O
3	O
H	O
]	O
thymidine	O
incorporation	O
;	O
some	O
exhibit	O
hypertrophy	O
labeled	O
only	O
by	O
GFAP	O
;	O
some	O
are	O
labeled	O
by	O
both	O
GFAP	O
and	O
[	O
3	O
H	O
]	O
thymidine	O
[	O
25	O
,	O
48	O
]	O
.	O

This	O
observation	O
suggests	O
that	O
these	O
two	O
separate	O
pathways	O
may	O
operate	O
in	O
the	O
in	O
vivo	O
situation	O
.	O

Taken	O
together	O
,	O
the	O
information	O
from	O
our	O
in	O
vitro	O
cell	O
culture	O
studies	O
may	O
provide	O
insight	O
into	O
the	O
mechanisms	O
of	O
in	O
vivo	O
striatal	O
astrocytic	O
response	O
and	O
help	O
to	O
elucidate	O
potential	O
roles	O
of	O
astrocytes	O
in	O
neurodegeneration	O
.	O

Acknowledgements	O

We	O
thank	O
Dr.	O
K.A.	O
Neve	O
for	O
providing	O
C6-D2L	O
cells	O
.	O

Malaria	O
is	O
still	O
the	O
most	O
important	O
parasitic	O
disease	O
in	O
the	O
world	O
,	O
causing	O
2–3	O
million	O
deaths	O
every	O
year	O
(	O
WHO	O
,	O
1997	O
)	O
.	O

The	O
rising	O
resistance	O
of	O
Plasmodium	B
spp	I
.	O
,	O
especially	O
Plasmodium	B
falciparum	I
,	O
to	O
known	O
antimalarials	O
such	O
as	O
chloroquine	O
makes	O
the	O
search	O
for	O
new	O
antimalarial	O
drugs	O
increasingly	O
important	O
.	O

Therefore	O
,	O
we	O
investigated	O
several	O
medicinal	O
plants	B
,	O
which	O
are	O
traditionally	O
used	O
as	O
antimalarial	O
or	O
antipyretic	O
remedies	O
by	O
the	O
indigenous	O
population	O
in	O
Latin	O
America	O
(	O
Duke	O
,	O
1975	O
;	O
Hirschhorn	O
,	O
1981	O
;	O
Joly	O
et	O
al.	O
,	O
1987	O
;	O
Gupta	O
et	O
al.	O
,	O
1993	O
)	O
.	O

During	O
a	O
screening	O
program	O
,	O
we	O
obtained	O
lipophilic	O
and	O
hydrophilic	O
extracts	O
of	O
these	O
plants	B
with	O
antiplasmodial	O
activity	O
and	O
we	O
selected	O
the	O
most	O
active	O
ones	O
for	O
further	O
investigation	O
(	O
Jenett	O
-	O
Siems	O
et	O
al.	O
,	O
1999	O
)	O
.	O

Andira	B
inermis	I
(	O
W.	O
Wright	O
)	O
H.B.K.	O
(	O
Fabaceae	O
)	O
is	O
a	O
tall	O
tree	O
characterised	O
by	O
a	O
thick	O
trunk	O
and	O
red	O
-	O
purple	O
flowers	O
,	O
native	O
from	O
southern	O
Mexico	O
to	O
northern	O
South	O
America	O
.	O

As	O
a	O
febrifuge	O
,	O
the	O
bark	O
is	O
boiled	O
in	O
milk	O
,	O
sweetened	O
water	O
or	O
performed	O
in	O
pills	O
.	O

It	O
is	O
also	O
used	O
as	O
a	O
purgative	O
,	O
vermifuge	O
,	O
or	O
for	O
dermal	O
irritations	O
.	O

The	O
seeds	O
have	O
similar	O
uses	O
.	O

Large	O
doses	O
of	O
the	O
stem	O
bark	O
or	O
seeds	O
caused	O
vomiting	O
and	O
violent	O
diarrhoea	O
;	O
in	O
some	O
cases	O
they	O
were	O
even	O
fatal	O
(	O
Hirschhorn	O
,	O
1981	O
;	O
Morton	O
,	O
1981	O
)	O
.	O

From	O
this	O
species	O
,	O
several	O
isoflavones	O
and	O
related	O
structures	O
have	O
been	O
reported	O
(	O
Cocker	O
et	O
al.	O
,	O
1962	O
;	O
Lock	O
de	O
Ugaz	O
et	O
al.	O
,	O
1991	O
)	O
.	O

The	O
lipophilic	O
extracts	O
of	O
stems	O
and	O
leaves	O
showed	O
moderate	O
in	O
vitro	O
activity	O
against	O
P.	B
falciparum	I
in	O
this	O
screening	O
program	O
and	O
were	O
further	O
analysed	O
by	O
bioassay	O
-	O
guided	O
fractionation	O
to	O
isolate	O
the	O
active	O
compounds	O
.	O

2	O
Material	O
and	O
methods	O
2.1	O
General	O
For	O
fractionation	O
,	O
silica	O
gel	O
60	O
(	O
70–230	O
mesh	O
)	O
was	O
utilised	O
.	O

Preparative	O
high	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
was	O
performed	O
on	O
a	O
Knauer	O
Eurochrom	O
2000	O
equipped	O
with	O
a	O
Nucleosil	O
P	O
300	O
C-18	O
(	O
10	O
μm	O
)	O
column	O
.	O

Mass	O
spectra	O
were	O
determined	O
with	O
a	O
Finnigan	O
MAT	O
CH7A	O
(	O
220	O
°	O
C	O
,	O
ionisation	O
70	O
eV	O
)	O
and	O
1	O
H	O
-	O
NMR	O
spectra	O
were	O
obtained	O
using	O
acetone	O
-	O
D6	O
as	O
a	O
solvent	O
with	O
a	O
Bruker	O
AVANCE	O
DPX	O
400	O
(	O
400	O
MHz	O
,	O
TMS	O
as	O
internal	O
standard	O
)	O
.	O

The	O
erythrocytes	O
were	O
harvested	O
with	O
an	O
Inotech	O
cell	O
harvester	O
and	O
the	O
β	O
-	O
radiation	O
of	O
the	O
incorporated	O
[	O
3	O
H	O
]	O
hypoxanthine	O
was	O
measured	O
with	O
a	O
Wallac	O
1450	O
MicroBeta	O
plus	O
liquid	O
scintillation	O
counter	O
.	O

2.2	O
Plant	O
material	O
Leaves	O
and	O
stems	O
of	O
A.	B
inermis	I
were	O
collected	O
in	O
the	O
area	O
of	O
Panama	O
City	O
(	O
at	O
the	O
road	O
El	O
Llano	O
-	O
Carti	O
)	O
,	O
Panama	O
,	O
during	O
March	O
1997	O
.	O

Voucher	O
specimens	O
(	O
FLORPAN	O
2758	O
)	O
were	O
identified	O
by	O
Professor	O
M.D.	O
Correa	O
A.	O
and	O
deposited	O
at	O
the	O
Herbarium	O
of	O
the	O
University	O
of	O
Panama	O
.	O

2.3	O
Extraction	O
and	O
isolation	O
In	O
the	O
screening	O
program	O
,	O
the	O
air	O
-	O
dried	O
stem	O
bark	O
and	O
leaves	O
(	O
20	O
g	O
)	O
were	O
extracted	O
three	O
times	O
for	O
2	O
h	O
with	O
150	O
ml	O
petroleum	O
ether	O
/	O
ethyl	O
acetate	O
(	O
1:1	O
)	O
at	O
room	O
temperature	O
.	O

Then	O
the	O
plant	O
material	O
was	O
air	O
dried	O
again	O
and	O
treated	O
three	O
times	O
with	O
150	O
ml	O
methanol	O
/	O
water	O
(	O
8:2	O
)	O
to	O
yield	O
the	O
hydrophilic	O
extracts	O
.	O

The	O
solvents	O
were	O
evaporated	O
under	O
reduced	O
pressure	O
at	O
40	O
°	O
C	O
.	O

For	O
further	O
investigations	O
,	O
the	O
crushed	O
stems	O
(	O
600	O
g	O
)	O
were	O
air	O
dried	O
and	O
extracted	O
three	O
times	O
with	O
2	O
l	O
of	O
petroleum	O
ether	O
/	O
ethyl	O
acetate	O
(	O
1:1	O
)	O
for	O
24	O
h	O
at	O
room	O
temperature	O
.	O

The	O
solvents	O
were	O
evaporated	O
under	O
reduced	O
pressure	O
at	O
40	O
°	O
C	O
.	O

The	O
oily	O
residue	O
(	O
3.3	O
g	O
)	O
was	O
subjected	O
to	O
column	O
chromatography	O
on	O
silica	O
gel	O
60	O
(	O
45	O
g	O
)	O
and	O
eluted	O
with	O
cyclohexane	O
,	O
cyclohexane	O
/	O
ethyl	O
acetate	O
mixtures	O
,	O
and	O
methanol	O
to	O
yield	O
seven	O
fractions	O
,	O
which	O
were	O
tested	O
against	O
P.	B
falciparum	I
.	O

Fraction	O
5	O
and	O
6	O
,	O
which	O
were	O
eluted	O
with	O
cyclohexane	O
/	O
ethyl	O
acetate	O
(	O
8:2	O
and	O
7:3	O
,	O
respectively	O
)	O
,	O
proved	O
to	O
be	O
most	O
active	O
.	O

Further	O
separation	O
of	O
fraction	O
5	O
(	O
150	O
mg	O
)	O
by	O
HPLC	O
at	O
a	O
5	O
ml	O
/	O
min	O
flow	O
rate	O
of	O
methanol	O
/	O
water	O
(	O
55:45	O
)	O
yielded	O
the	O
compounds	O
1	O
(	O
2.4	O
mg	O
)	O
,	O
2	O
(	O
6.1	O
mg	O
)	O
,	O
and	O
3	O
(	O
6.6	O
mg	O
)	O
.	O

Fraction	O
6	O
was	O
separated	O
with	O
methanol	O
/	O
water	O
(	O
45:55	O
)	O
to	O
give	O
the	O
compounds	O
4	O
(	O
8.3	O
mg	O
)	O
,	O
5	O
(	O
8.5	O
mg	O
)	O
,	O
and	O
6	O
(	O
1.6	O
mg	O
)	O
.	O

Compound	O
2	O
(	O
prunetin	O
)	O
:	O
EI	O
-	O
MS	O
:	O
m	O
/z	O
(	O
rel	O
.	O

int.	O
)	O
=284	O
(	O
M+	O
,	O
100	O
)	O
,	O
166	O
(	O
35	O
)	O
,	O
138	O
(	O
22	O
)	O
,	O
118	O
(	O
15	O
)	O
,	O
110	O
(	O
10	O
)	O
,	O
95	O
(	O
13	O
)	O
;	O
1	O
H	O
-	O
NMR	O
(	O
400	O
MHz	O
,	O
acetone	O
-	O
D6	O
):	O
δ	O
(	O
ppm	O
)	O
=3.93	O
(	O
3	O
H	O
,	O
s	O
,	O
CH3	O
O-7	O
)	O
,	O
6.36	O
(	O
1	O
H	O
,	O
d	O
,	O
J	O
=	O
2.3	O
Hz	O
,	O
H-6	O
)	O
,	O
6.55	O
(	O
1	O
H	O
,	O
d	O
,	O
J	O
=	O
2.4	O
Hz	O
,	O
H-8	O
)	O
,	O
6.91	O
(	O
2	O
H	O
,	O
d	O
,	O
J	O
=	O
8.5	O
Hz	O
,	O
H-3′,5′	O
)	O
,	O
7.47	O
(	O
2	O
H	O
,	O
d	O
,	O
J	O
=	O
8.5	O
Hz	O
,	O
H-2′,6′	O
)	O
,	O
8.22	O
(	O
1	O
H	O
,	O
s	O
,	O
H-2	O
)	O
,	O
13.4	O
(	O
1	O
H	O
,	O
s	O
,	O
OH-5	O
)	O
.	O

2.4	O
Antiplasmodial	O
bioassay	O
In	O
this	O
study	O
,	O
the	O
chloroquine	O
-	O
sensitive	O
strain	O
of	O
P.	B
falciparum	I
poW	I
(	O
IC50	O
=	O
0.015	O
μM	O
)	O
and	O
the	O
chloroquine	O
-	O
resistant	O
clone	O
Dd2	B
(	O
IC50	O
=	O
0.14	O
μM	O
)	O
were	O
used	O
.	O

They	O
were	O
maintained	O
in	O
continuous	O
culture	O
in	O
human	O
red	O
blood	O
cells	O
(	O
A+	O
)	O
diluted	O
to	O
5	O
%	O
haematocrit	O
in	O
RPMI	O
1640	O
medium	O
supplemented	O
with	O
25	O
mM	O
Hepes	O
,	O
30	O
mM	O
NaHCO3	O
,	O
and	O
10	O
%	O
human	O
A+	O
serum	O
.	O

Crude	O
extracts	O
and	O
isolated	O
compounds	O
were	O
dissolved	O
in	O
DMSO	O
(	O
1	O
mg	O
/	O
50	O
μl	O
)	O
and	O
diluted	O
in	O
RPMI	O
1640	O
medium	O
(	O
Trager	O
and	O
Jensen	O
,	O
1976	O
)	O
.	O

The	O
tests	O
were	O
performed	O
in	O
96-well	O
microtiter	O
plates	O
(	O
Desjardins	O
et	O
al.	O
,	O
1979	O
)	O
which	O
contained	O
150	O
μl	O
of	O
a	O
parasitized	O
red	O
blood	O
suspension	O
(	O
A+	O
,	O
2.5	O
%	O
haematocrit	O
,	O
0.5	O
%	O
parasitaemia	O
)	O
.	O

The	O
samples	O
were	O
added	O
to	O
give	O
final	O
concentrations	O
between	O
1.56	O
and	O
100	O
μg	O
/	O
ml	O
.	O

After	O
incubation	O
in	O
a	O
candle	O
jar	O
for	O
24	O
h	O
,	O
0.5	O
μCi	O
[	O
3	O
H	O
]	O
hypoxanthine	O
(	O
1	O
mCi	O
/	O
ml	O
,	O
ICN	O
)	O
was	O
added	O
to	O
each	O
well	O
and	O
the	O
plate	O
was	O
incubated	O
for	O
another	O
18	O
h.	O
Incorporation	O
of	O
[	O
3	O
H	O
]	O
hypoxanthine	O
was	O
measured	O
by	O
liquid	O
scintillation	O
after	O
harvesting	O
the	O
cells	O
on	O
glass	O
fibre	O
filters	O
with	O
the	O
cell	O
harvester	O
.	O

All	O
tests	O
were	O
performed	O
in	O
triplicate	O
.	O

The	O
percentage	O
of	O
growth	O
inhibition	O
was	O
calculated	O
as	O
follows	O
:	O
(	O
1−	O
[	O
cpm	O
in	O
drug	O
treated	O
cultures	O
/	O
cpm	O
in	O
untreated	O
cultures	O
]	O
)	O
×	O
100	O
.	O

The	O
concentration	O
at	O
which	O
growth	O
was	O
inhibited	O
by	O
50	O
%	O
(	O
IC50	O
)	O
was	O
estimated	O
by	O
interpolation	O
.	O

Extracts	O
with	O
IC50	O
values	O
above	O
50	O
μg	O
/	O
ml	O
were	O
considered	O
to	O
be	O
inactive	O
(	O
O'Neill	O
et	O
al.	O
,	O
1985	O
)	O
.	O

3	O
Results	O
The	O
isolated	O
compounds	O
1–6	O
(	O
Fig.	O
1	O
)	O
turned	O
out	O
to	O
be	O
isoflavones	O
.	O

Compound	O
1	O
,	O
isolated	O
from	O
both	O
stems	O
and	O
leaves	O
was	O
identified	O
as	O
formononetin	O
by	O
comparison	O
with	O
an	O
authentic	O
sample	O
.	O

According	O
to	O
the	O
spectral	O
data	O
(	O
1	O
H	O
-	O
NMR	O
,	O
EI	O
-	O
MS	O
)	O
,	O
compound	O
2	O
proved	O
to	O
be	O
prunetin	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
no	O
1	O
H	O
-	O
NMR	O
values	O
for	O
prunetin	O
have	O
been	O
published	O
so	O
far	O
,	O
therefore	O
they	O
are	O
given	O
in	O
Section	O
2.3	O
.	O

The	O
isoflavones	O
3	O
,	O
4	O
,	O
5	O
,	O
and	O
6	O
were	O
identified	O
as	O
biochanin	O
A	O
,	O
calycosin	O
,	O
genistein	O
,	O
and	O
pratensein	O
,	O
respectively	O
,	O
by	O
comparison	O
of	O
1	O
H	O
-	O
NMR	O
and	O
EI	O
-	O
MS	O
with	O
published	O
data	O
(	O
Asres	O
et	O
al.	O
,	O
1985	O
;	O
Kobayashi	O
et	O
al.	O
,	O
1985	O
)	O
.	O

Prunetin	O
(	O
2	O
)	O
,	O
calycosin	O
(	O
4	O
)	O
,	O
and	O
pratensein	O
(	O
6	O
)	O
were	O
detected	O
for	O
the	O
first	O
time	O
from	O
the	O
genus	O
Andira	B
.	O

The	O
lipophilic	O
extracts	O
of	O
A.	B
inermis	I
exhibited	O
IC50	O
values	O
from	O
56.0	O
μg	O
/	O
ml	O
(	O
leaves	O
)	O
to	O
108.7	O
μg	O
/	O
ml	O
(	O
stems	O
)	O
against	O
P.	B
falciparum	I
in	O
vitro	O
(	O
Table	O
1	O
)	O
.	O

The	O
hydrophilic	O
extracts	O
proved	O
to	O
be	O
inactive	O
.	O

For	O
all	O
tested	O
substances	O
the	O
antiparasitic	O
activity	O
against	O
the	O
chloroquine	O
-	O
sensitive	O
strain	B
poW	I
was	O
higher	O
(	O
factor	O
two	O
)	O
than	O
against	O
the	O
chloroquine	O
-	O
resistant	O
clone	B
Dd2	I
.	O

Calycosin	O
(	O
IC50	O
4.2	O
μg	O
/	O
ml	O
for	O
poW	O
;	O
9.8	O
μg	O
/	O
ml	O
for	O
Dd2	O
)	O
and	O
genistein	O
(	O
IC50	O
2.0	O
μg	O
/	O
ml	O
for	O
poW	O
;	O
4.1	O
μg	O
/	O
ml	O
for	O
Dd2	O
)	O
proved	O
to	O
be	O
most	O
active	O
.	O

The	O
other	O
four	O
compounds	O
were	O
considered	O
to	O
be	O
inactive	O
.	O

4	O
Discussion	O
Although	O
the	O
lipophilic	O
extracts	O
of	O
A.	B
inermis	I
showed	O
only	O
moderate	O
antiplasmodial	O
activity	O
compared	O
to	O
those	O
known	O
for	O
other	O
plant	O
remedies	O
(	O
O'Neill	O
et	O
al.	O
,	O
1985	O
;	O
Jenett	O
-	O
Siems	O
et	O
al.	O
,	O
1999	O
)	O
they	O
afforded	O
two	O
active	O
isoflavones	O
.	O

This	O
is	O
the	O
first	O
report	O
on	O
antiplasmodial	O
activity	O
of	O
isoflavones	O
against	O
P.	B
falciparum	I
.	O

The	O
low	O
concentration	O
of	O
calycosin	O
and	O
genistein	O
(	O
<	O
0.01	O
%	O
w	O
/	O
w	O
)	O
may	O
be	O
the	O
explanation	O
for	O
the	O
low	O
antiplasmodial	O
activity	O
of	O
the	O
crude	O
extract	O
.	O

It	O
is	O
known	O
that	O
calycosin	O
also	O
proved	O
to	O
be	O
active	O
against	O
Giardia	B
intestinalis	I
,	O
a	O
potent	O
protozoan	O
agent	O
for	O
enteric	O
diseases	O
(	O
ElSohly	O
et	O
al.	O
,	O
1999	O
)	O
.	O

During	O
the	O
preparation	O
of	O
this	O
paper	O
a	O
patent	O
application	O
was	O
published	O
(	O
Khan	O
et	O
al.	O
,	O
1999	O
)	O
,	O
which	O
claimed	O
a	O
method	O
of	O
treating	O
giardiasis	O
and/or	O
malaria	O
comprising	O
the	O
use	O
of	O
isoflavones	O
,	O
but	O
mentioning	O
no	O
data	O
,	O
proving	O
their	O
antiplasmodial	O
activity	O
against	O
P.	B
falciparum	I
.	O

In	O
our	O
study	O
,	O
we	O
have	O
focused	O
on	O
the	O
investigation	O
of	O
the	O
lipophilic	O
extract	O
.	O

The	O
indigenous	O
population	O
,	O
e.g.	O
in	O
Brazil	O
(	O
Morton	O
,	O
1981	O
)	O
,	O
prefer	O
to	O
boil	O
the	O
stem	O
bark	O
with	O
milk	O
.	O

This	O
procedure	O
covers	O
the	O
bitter	O
taste	O
and	O
probably	O
causes	O
the	O
extraction	O
of	O
lipophilic	O
constituents	O
.	O

Interestingly	O
,	O
hydrophilic	O
extracts	O
(	O
methanol	O
/	O
water	O
8:2	O
)	O
from	O
A.	B
inermis	I
did	O
not	O
show	O
antiplasmodial	O
activity	O
in	O
our	O
test	O
system	O
.	O

The	O
evaluation	O
of	O
extracts	O
obtained	O
with	O
water	O
or	O
milk	O
is	O
still	O
in	O
progress	O
and	O
might	O
be	O
interesting	O
with	O
regard	O
to	O
the	O
ethnobotanical	O
use	O
of	O
this	O
species	O
.	O

Acknowledgements	O
The	O
authors	O
are	O
indebted	O
to	O
C.	O
Guerra	O
,	O
for	O
his	O
support	O
in	O
collecting	O
the	O
plant	O
material	O
,	O
and	O
to	O
Professor	O
M.D.	O
Correa	O
A.	O
,	O
Herbarium	O
of	O
the	O
University	O
of	O
Panama	O
,	O
Republic	O
of	O
Panama	O
,	O
for	O
her	O
identification	O
of	O
the	O
species	O
.	O

We	O
thank	O
Drs	O
D.S.	O
Kim	O
and	O
B.	O
Kleuser	O
,	O
Institut	O
für	O
Pharmazie	O
,	O
Freie	O
Universität	O
Berlin	O
,	O
Germany	O
,	O
for	O
their	O
advice	O
concerning	O
determination	O
of	O
radioactivity	O
.	O

This	O
study	O
was	O
supported	O
by	O
a	O
grant	O
from	O
the	O
Deutsche	O
Pharmazeutische	O
Gesellschaft	O
to	O
K.	O
Jenett	O
-	O
Siems	O
and	O
by	O
Charité	O
Grant	O
Nr	O
.	O

98	O
-	O
700	O
.	O

CIFLORPAN	O
acknowledges	O
the	O
Fundation	O
Natura	O
and	O
the	O
Organization	O
of	O
American	O
States	O
(	O
OAS	O
)	O
for	O
financial	O
support	O
.	O

HP1	O
modulates	O
the	O
transcription	O
of	O
cell	O
-	O
cycle	O
regulators	O
in	O
Drosophila	B
melanogaster	I
Abstract	O
Heterochromatin	O
protein	O
1	O
(	O
HP1	O
)	O
was	O
originally	O
described	O
as	O
a	O
non	O
-	O
histone	O
chromosomal	O
protein	O
and	O
is	O
required	O
for	O
transcriptional	O
gene	O
silencing	O
and	O
the	O
formation	O
of	O
heterochromatin	O
.	O

Although	O
it	O
is	O
localized	O
primarily	O
at	O
pericentric	O
heterochromatin	O
,	O
a	O
scattered	O
distribution	O
over	O
a	O
large	O
number	O
of	O
euchromatic	O
loci	O
is	O
also	O
evident	O
.	O

Here	O
,	O
we	O
provide	O
evidence	O
that	O
Drosophila	B
HP1	O
is	O
essential	O
for	O
the	O
maintenance	O
of	O
active	O
transcription	O
of	O
euchromatic	O
genes	O
functionally	O
involved	O
in	O
cell	O
-	O
cycle	O
progression	O
,	O
including	O
those	O
required	O
for	O
DNA	O
replication	O
and	O
mitosis	O
.	O

Depletion	O
of	O
HP1	O
in	O
proliferating	O
embryonic	O
cells	O
caused	O
aberrant	O
progression	O
of	O
the	O
cell	O
cycle	O
at	O
S	O
phase	O
and	O
G2	O
/	O
M	O
phase	O
,	O
linked	O
to	O
aberrant	O
chromosome	O
segregation	O
,	O
cytokinesis	O
,	O
and	O
an	O
increase	O
in	O
apoptosis	O
.	O

The	O
chromosomal	O
distribution	O
of	O
Aurora	O
B	O
,	O
and	O
the	O
level	O
of	O
phosphorylation	O
of	O
histone	O
H3	O
serine	O
10	O
were	O
also	O
altered	O
in	O
the	O
absence	O
of	O
HP1	O
.	O

Using	O
chromatin	O
immunoprecipitation	O
analysis	O
,	O
we	O
further	O
demonstrate	O
that	O
the	O
promoters	O
of	O
a	O
number	O
of	O
cell	O
-	O
cycle	O
regulator	O
genes	O
are	O
bound	O
to	O
HP1	O
,	O
supporting	O
a	O
direct	O
role	O
for	O
HP1	O
in	O
their	O
active	O
transcription	O
.	O

Overall	O
,	O
our	O
data	O
suggest	O
that	O
HP1	O
is	O
essential	O
for	O
the	O
maintenance	O
of	O
cell	O
-	O
cycle	O
progression	O
and	O
the	O
transcription	O
of	O
cell	O
-	O
cycle	O
regulatory	O
genes	O
.	O

The	O
results	O
also	O
support	O
the	O
view	O
that	O
HP1	O
is	O
a	O
positive	O
regulator	O
of	O
transcription	O
in	O
euchromatin	O
.	O

INTRODUCTION	O
Chromatin	O
in	O
higher	O
eukaryotes	O
is	O
subdivided	O
into	O
different	O
functional	O
compartments	O
termed	O
heterochromatin	O
and	O
euchromatin	O
(	O
1	O
)	O
.	O

Heterochromatin	O
differs	O
from	O
euchromatin	O
in	O
its	O
DNA	O
composition	O
,	O
replication	O
timing	O
,	O
condensation	O
throughout	O
the	O
cell	O
cycle	O
,	O
and	O
its	O
ability	O
to	O
silence	O
euchromatic	O
genes	O
placed	O
adjacent	O
to	O
or	O
within	O
its	O
territory	O
,	O
often	O
described	O
as	O
position	O
-	O
effect	O
-	O
variegation	O
(	O
PEV	O
)	O
(	O
2	O
)	O
.	O

Heterochromatin	O
protein	O
1	O
(	O
HP1	O
)	O
was	O
the	O
first	O
protein	O
identified	O
in	O
Drosophila	B
melanogaster	I
as	O
a	O
heterochromatin	O
-	O
associated	O
protein	O
(	O
3	O
)	O
;	O
the	O
corresponding	O
gene	O
has	O
been	O
cloned	O
from	O
a	O
number	O
of	O
organisms	O
and	O
is	O
highly	O
conserved	O
from	O
yeast	B
to	O
human	B
(	O
4	O
)	O
.	O

Polytene	O
chromosome	O
staining	O
showed	O
that	O
,	O
in	O
Drosophila	B
,	O
HP1	O
is	O
distributed	O
mainly	O
in	O
pericentric	O
heterochromatin	O
,	O
telomeric	O
heterochromatin	O
,	O
the	O
banded	O
small	O
fourth	O
chromosome	O
(	O
5–8	O
)	O
,	O
as	O
well	O
as	O
∼200	O
individual	O
loci	O
scattered	O
throughout	O
the	O
euchromatic	O
chromosomal	O
arms	O
(	O
5	O
)	O
.	O

The	O
gene	O
encoding	O
HP1	O
in	O
D.melanogaster	B
,	O
Su	O
(	O
var	O
)	O
2	O
-	O
5	O
,	O
was	O
isolated	O
as	O
a	O
suppressor	O
of	O
PEV	O
(	O
9–11	O
)	O
.	O

The	O
protein	O
contains	O
a	O
highly	O
conserved	O
motif	O
,	O
the	O
chromo	O
(	O
chromatin	O
organization	O
modifier	O
)	O
domain	O
,	O
similar	O
to	O
Polycomb	O
(	O
Pc	O
)	O
,	O
a	O
repressor	O
of	O
homeotic	O
genes	O
(	O
12	O
)	O
.	O

The	O
association	O
between	O
HP1	O
and	O
pericentric	O
heterochromatin	O
is	O
believed	O
to	O
occur	O
via	O
the	O
chromo	O
domain	O
of	O
HP1	O
and	O
the	O
N	O
-	O
terminal	O
tail	O
of	O
histone	O
H3	O
methylated	O
at	O
lysine	O
9	O
(	O
13,14	O
)	O
,	O
generated	O
by	O
histone	O
methyltransferase	O
-	O
Su	O
(	O
var	O
)	O
3	O
-	O
9	O
,	O
a	O
partner	O
of	O
HP1	O
in	O
pericentric	O
heterochromatin	O
(	O
15	O
)	O
.	O

The	O
C	O
-	O
terminal	O
chromo	O
'	O
shadow	O
'	O
domain	O
of	O
HP1	O
interacts	O
with	O
other	O
silencing	O
complexes	O
to	O
suppress	O
local	O
transcriptional	O
activity	O
(	O
15–18	O
)	O
.	O

However	O
,	O
studies	O
of	O
HP1	O
chromosomal	O
distribution	O
also	O
showed	O
that	O
HP1	O
does	O
not	O
always	O
co	O
-	O
localize	O
with	O
lysine	O
9	O
methylated	O
histone	O
H3	O
or	O
Su	O
(	O
var	O
)	O
3	O
-	O
9	O
,	O
especially	O
in	O
euchromatic	O
regions	O
(	O
19–21	O
)	O
;	O
in	O
some	O
cases	O
,	O
HP1	O
is	O
found	O
directly	O
bound	O
to	O
DNA	O
(	O
22,23	O
)	O
.	O

All	O
these	O
features	O
argue	O
for	O
distinct	O
roles	O
for	O
HP1	O
in	O
chromatin	O
and	O
in	O
epigenetic	O
gene	O
regulation	O
.	O

HP1	O
is	O
believed	O
to	O
be	O
an	O
essential	O
structural	O
protein	O
protecting	O
the	O
integrity	O
of	O
chromosomes	O
during	O
cell	O
division	O
(	O
8,24	O
)	O
.	O

Swi6	O
,	O
the	O
homolog	O
of	O
HP1	O
in	O
fission	B
yeast	I
,	O
is	O
dispensable	O
for	O
survival	O
,	O
but	O
its	O
deletion	O
results	O
in	O
lagging	O
chromosomes	O
during	O
anaphase	O
,	O
and	O
a	O
high	O
rate	O
of	O
chromosome	O
loss	O
(	O
25,26	O
)	O
.	O

Mutations	O
of	O
HP1	O
in	O
D.melanogaster	B
result	O
in	O
late	O
larval	O
lethality	O
,	O
chromosome	O
breakages	O
/	O
loss	O
,	O
telomere	O
fusion	O
and	O
a	O
high	O
frequency	O
of	O
cells	O
with	O
abnormal	O
anaphase	O
(	O
8,27	O
)	O
.	O

Null	O
alleles	O
of	O
the	O
HP1	O
functional	O
partner	O
in	O
mice	B
(	O
SUVAR39	O
)	O
also	O
showed	O
various	O
chromosomal	O
defects	O
(	O
28	O
)	O
,	O
supporting	O
a	O
conserved	O
role	O
for	O
heterochromatin	O
proteins	O
in	O
the	O
regulation	O
of	O
chromosome	O
dynamics	O
during	O
cell	O
-	O
cycle	O
progression	O
.	O

However	O
,	O
the	O
mechanism	O
(	O
s	O
)	O
involved	O
remains	O
to	O
be	O
understood	O
.	O

In	O
this	O
study	O
,	O
we	O
utilized	O
Drosophila	B
embryonic	O
Kc	O
cells	O
and	O
an	O
RNA	O
interference	O
(	O
RNAi	O
)	O
-based	O
approach	O
to	O
demonstrate	O
that	O
HP1	O
plays	O
an	O
important	O
role	O
at	O
S	O
phase	O
and	O
G2	O
/	O
M	O
phases	O
during	O
the	O
cell	O
cycle	O
.	O

We	O
further	O
show	O
that	O
nearly	O
one	O
-	O
third	O
of	O
known	O
/	O
predicted	O
cell	O
-	O
cycle	O
regulators	O
require	O
HP1	O
to	O
maintain	O
their	O
active	O
transcription	O
.	O

These	O
genes	O
include	O
MCMs	O
,	O
Orc4	O
,	O
CDC45L	O
,	O
INCENP	O
,	O
Aurora	O
B	O
,	O
CAF1	O
,	O
Bub1	O
,	O
Bub3	O
and	O
a	O
few	O
other	O
cell	O
-	O
cycle	O
regulators	O
.	O

ChIP	O
analysis	O
suggests	O
that	O
HP1	O
plays	O
a	O
direct	O
role	O
in	O
their	O
transcription	O
.	O

Therefore	O
,	O
the	O
results	O
of	O
this	O
study	O
provide	O
an	O
alternative	O
explanation	O
for	O
the	O
specific	O
role	O
of	O
HP1	O
in	O
the	O
regulation	O
of	O
chromatin	O
dynamics	O
and	O
in	O
cell	O
-	O
cycle	O
progression	O
.	O

MATERIALS	O
AND	O
METHODS	O
RNAi	O
in	O
Kc	O
cells	O
Drosophila	B
Kc	O
cells	O
were	O
routinely	O
cultured	O
at	O
25	O
°	O
C	O
in	O
Schneider	O
Drosophila	B
medium	O
(	O
GIBCO	O
)	O
supplemented	O
with	O
10	O
%	O
fetal	O
calf	O
serum	O
,	O
160	O
μg	O
/	O
ml	O
penicillin	O
,	O
250	O
μg	O
/	O
ml	O
streptomycin	O
,	O
and	O
4	O
mM	O
l	O
-	O
glutamine	O
.	O

Double	O
-	O
stranded	O
RNA	O
(	O
dsRNA	O
)	O
of	O
HP1	O
was	O
generated	O
by	O
incubation	O
of	O
single	O
-	O
stranded	O
RNA	O
in	O
annealing	O
buffer	O
(	O
100	O
mM	O
potassium	O
acetate	O
,	O
30	O
mM	O
HEPES	O
-	O
KOH	O
,	O
pH	O
7.4	O
,	O
2	O
mM	O
magnesium	O
acetate	O
)	O
for	O
3	O
min	O
at	O
95	O
°	O
C	O
and	O
then	O
placed	O
in	O
a	O
beaker	O
with	O
water	O
at	O
75	O
°	O
C	O
and	O
allowed	O
to	O
cool	O
slowly	O
to	O
room	O
temperature	O
.	O

The	O
detailed	O
procedure	O
of	O
RNAi	O
was	O
carried	O
out	O
according	O
to	O
the	O
established	O
protocols	O
(	O
)	O
.	O

Briefly	O
,	O
Kc	O
cells	O
were	O
seeded	O
in	O
a	O
six	O
-	O
well	O
dish	O
using	O
serum	O
-	O
free	O
medium	O
at	O
1	O
×	O
106	O
cells	O
/	O
ml	O
.	O

HP1	O
dsRNA	O
(	O
5	O
μg	O
/	O
ml	O
)	O
was	O
added	O
to	O
the	O
cultured	O
Kc	O
cells	O
.	O

After	O
60	O
min	O
at	O
room	O
temperature	O
,	O
2	O
ml	O
of	O
medium	O
containing	O
10	O
%	O
serum	O
was	O
added	O
to	O
each	O
well	O
and	O
the	O
plates	O
transferred	O
to	O
25	O
°	O
C	O
for	O
up	O
to	O
8	O
days	O
.	O

Western	O
blotting	O
and	O
RT	O
–	O
PCR	O
were	O
carried	O
out	O
using	O
the	O
extract	O
/	O
total	O
RNA	O
isolated	O
from	O
control	O
and	O
dsRNA	O
-	O
treated	O
cells	O
on	O
days	O
2	O
,	O
6	O
and	O
8	O
.	O

Cell	O
-	O
cycle	O
and	O
apoptosis	O
analysis	O
The	O
procedure	O
for	O
flow	O
cytometric	O
analysis	O
of	O
Kc	O
cells	O
followed	O
that	O
in	O
the	O
manual	O
provided	O
with	O
the	O
BrdU	O
flow	O
kit	O
(	O
BD	O
PharMingen	O
)	O
.	O

The	O
cells	O
were	O
fed	O
with	O
BrdU	O
for	O
4	O
h	O
,	O
then	O
scraped	O
and	O
collected	O
.	O

Fluorescence	O
was	O
measured	O
using	O
a	O
FACSCalibur	O
(	O
Becton	O
Dickinson	O
)	O
.	O

Data	O
collection	O
and	O
analysis	O
were	O
performed	O
using	O
CellQuest	O
software	O
.	O

Electrophoresis	O
and	O
immunoblotting	O
Cell	O
extracts	O
(	O
15	O
μg	O
)	O
were	O
fractionated	O
by	O
10	O
%	O
SDS	O
–	O
PAGE	O
,	O
then	O
transferred	O
to	O
Hybond	O
-	O
P	O
PVDF	O
membranes	O
(	O
Amersham	O
)	O
and	O
probed	O
with	O
primary	O
antibodies	O
(	O
CIA9	O
)	O
,	O
and	O
secondary	O
antibodies	O
(	O
anti	O
-	O
rabbit	B
or	O
anti	O
-	O
mouse	B
horseradish	B
peroxidase	O
-	O
conjugated	O
IgG	O
)	O
,	O
obtained	O
from	O
Jackson	O
Immunoresearch	O
Laboratories	O
.	O

Enhanced	O
chemiluminescence	O
reagents	O
(	O
Amersham	O
Pharmacia	O
Biotech	O
)	O
were	O
used	O
for	O
signal	O
detection	O
.	O

For	O
the	O
analysis	O
of	O
H3	O
ser10	O
phosphorylation	O
,	O
we	O
used	O
whole	O
-	O
cell	O
extracts	O
from	O
700	O
000	O
Kc	O
cells	O
(	O
control	O
and	O
RNAi	O
at	O
day	O
8)	O
.	O

Western	O
blotting	O
was	O
performed	O
using	O
polyclonal	O
antibodies	O
against	O
ser10-phosphorylated	O
histone	O
H3	O
at	O
a	O
dilution	O
of	O
1:1000	O
(	O
Upstate	O
)	O
.	O

Kc	O
control	O
cells	O
arrested	O
in	O
mitosis	O
by	O
incubation	O
in	O
25	O
µM	O
colchicine	O
(	O
Sigma	O
)	O
for	O
24	O
h	O
were	O
also	O
analyzed	O
for	O
comparison	O
.	O

Immunofluorescence	O
Kc	O
cells	O
were	O
seeded	O
onto	O
polylysine	O
slides	O
,	O
fixed	O
with	O
4	O
%	O
formaldehyde	O
for	O
15	O
min	O
and	O
permeabilized	O
with	O
0.5	O
%	O
Triton	O
X-100	O
for	O
5	O
min	O
.	O

The	O
incubation	O
with	O
primary	O
antibodies	O
was	O
carried	O
out	O
in	O
blocking	O
solution	O
for	O
1	O
h.	O
For	O
staining	O
of	O
mitotic	O
cells	O
,	O
the	O
cells	O
were	O
permeabilized	O
using	O
PBST	O
(	O
PBS	O
containing	O
0.3	O
%	O
Triton	O
X-100	O
)	O
and	O
stained	O
with	O
polyclonal	O
antibody	O
against	O
Drosophila	B
Aurora	O
B	O
at	O
1:200	O
dilution	O
and	O
monoclonal	O
mouse	B
at	O
anti	O
-	O
β	O
-	O
tubulin	O
1:300	O
dilution	O
(	O
Chemicon	O
International	O
)	O
as	O
primary	O
antibodies	O
.	O

Secondary	O
antibodies	O
were	O
anti	O
-	O
rabbit	B
coupled	O
with	O
Alexa	O
488	O
(	O
1:500	O
)	O
and	O
anti	O
-	O
mouse	B
coupled	O
to	O
Alexa	O
546	O
(	O
1:500	O
)	O
(	O
Molecular	O
Probes	O
,	O
Eugene	O
,	O
Oregon	O
)	O
.	O

Images	O
were	O
acquired	O
using	O
a	O
confocal	O
LSM510	O
META	O
microscope	O
(	O
Zeiss	O
)	O
.	O

Stacks	O
of	O
images	O
were	O
analyzed	O
using	O
the	O
IMARIS	O
4.0	O
program	O
(	O
Media	O
cybernetics	O
,	O
Carlsbad	O
,	O
CA	O
)	O
.	O

Antibodies	O
Affinity	O
-	O
purified	O
polyclonal	O
antibodies	O
of	O
HP1	O
(	O
rabbit	B
#	O
192	O
and	O
#	O
187	O
,	O
5	O
μg	O
)	O
and	O
5	O
μg	O
of	O
polyclonal	O
anti	O
-	O
HA	O
antibodies	O
(	O
Sigma	O
)	O
were	O
used	O
in	O
each	O
ChIP	O
reaction	O
.	O

The	O
specificity	O
of	O
the	O
HP1	O
polyclonal	O
antibodies	O
was	O
determined	O
using	O
various	O
approaches	O
,	O
including	O
western	O
blotting	O
assay	O
,	O
immunofluorescence	O
staining	O
and	O
immunoprecipitation	O
to	O
pull	O
down	O
HP1	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
monoclonal	O
antibody	O
HP1–CIA9	O
(	O
5	O
)	O
was	O
used	O
at	O
a	O
dilution	O
of	O
1:20	O
in	O
immunoblotting	O
assays	O
.	O

Microarray	O
analysis	O
and	O
RT	O
–	O
PCR	O
Total	O
RNA	O
was	O
isolated	O
from	O
control	O
and	O
HP1-depleted	O
Kc	O
cells	O
at	O
day	O
8	O
using	O
an	O
RNeasy	O
kit	O
(	O
Qiagen	O
)	O
.	O

RNA	O
labeling	O
and	O
microarray	O
data	O
analysis	O
followed	O
the	O
standard	O
protocol	O
from	O
Affymetrix	O
.	O

We	O
used	O
ANOVA	O
(	O
P	O
<	O
0.001	O
)	O
to	O
assess	O
the	O
expression	O
confidence	O
for	O
each	O
gene	O
.	O

For	O
RT	O
–	O
PCR	O
analysis	O
,	O
poly	O
(	O
A	O
)	O
+	O
mRNA	O
was	O
purified	O
with	O
the	O
Oligotex	O
Direct	O
mRNA	O
kit	O
(	O
Qiagen	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

The	O
purified	O
poly	O
(	O
A	O
)	O
+	O
RNA	O
was	O
reverse	O
transcribed	O
using	O
the	O
Thermoscript	O
kit	O
(	O
Invitrogen	O
)	O
.	O

The	O
cDNA	O
was	O
then	O
used	O
for	O
PCR	O
amplification	O
for	O
35	O
cycles	O
with	O
gene	O
-	O
specific	O
primers	O
.	O

PCR	O
products	O
were	O
scanned	O
after	O
electrophoretic	O
separation	O
with	O
a	O
Typhoon	O
Scanner	O
,	O
quantified	O
using	O
ImageQuant	O
software	O
(	O
Amersham	O
Biosciences	O
)	O
and	O
normalized	O
for	O
amplification	O
of	O
the	O
Actin5c	O
transcript	O
.	O

The	O
sequence	O
of	O
primers	O
used	O
for	O
RT	O
–	O
PCR	O
and	O
ChIP	O
analysis	O
are	O
provided	O
in	O
the	O
Supplementary	O
Material	O
.	O

ChIP	O
ChIP	O
was	O
performed	O
according	O
to	O
Orlando	O
et	O
al.	O
(	O
29	O
)	O
and	O
the	O
protocol	O
provided	O
by	O
Upstate	O
(	O
)	O
with	O
some	O
modifications	O
.	O

In	O
brief	O
,	O
1–2	O
×	O
108	O
Kc	O
cells	O
were	O
prepared	O
and	O
fixed	O
in	O
1	O
%	O
formaldehyde	O
.	O

Nuclei	O
were	O
isolated	O
according	O
to	O
a	O
standard	O
procedure	O
in	O
Current	O
Protocols	O
(	O
)	O
,	O
then	O
resuspended	O
in	O
1.7	O
ml	O
of	O
lysis	O
buffer	O
(	O
50	O
mM	O
Tris	O
,	O
pH	O
8.0	O
,	O
10	O
mM	O
EDTA	O
,	O
1	O
%	O
SDS	O
and	O
protease	O
inhibitors	O
)	O
and	O
sonicated	O
using	O
a	O
Branson	O
sonifier	O
250	O
.	O

Chromatin	O
fractions	O
in	O
the	O
size	O
range	O
0.2–0.8	O
kb	O
were	O
used	O
to	O
perform	O
immunoprecipitation	O
experiments	O
.	O

We	O
used	O
5	O
μg	O
affinity	O
-	O
purified	O
polyclonal	O
antibodies	O
(	O
#	O
192	O
and	O
#	O
182	O
for	O
HP1	O
;	O
HA	O
antibody	O
for	O
control	O
)	O
and	O
1	O
ml	O
of	O
salmon	O
sperm	O
DNA	O
/	O
protein	O
-	O
A	O
-	O
agarose	O
(	O
Upstate	O
)	O
pre	O
-	O
cleared	O
chromatin	O
lysate	O
in	O
each	O
reaction	O
.	O

The	O
mixture	O
was	O
then	O
rotated	O
at	O
4	O
°	O
C	O
overnight	O
and	O
the	O
recovered	O
beads	O
were	O
washed	O
twice	O
with	O
1	O
ml	O
of	O
Low	O
salt	O
buffer	O
(	O
Upstate	O
)	O
,	O
once	O
with	O
High	O
salt	O
buffer	O
(	O
Upstate	O
)	O
,	O
once	O
with	O
LiCl	O
buffer	O
(	O
Upstate	O
)	O
and	O
twice	O
with	O
TE	O
at	O
4	O
°	O
C	O
for	O
8	O
min	O
.	O

ChIP	O
DNA	O
was	O
extracted	O
according	O
to	O
the	O
standard	O
procedures	O
(	O
29	O
)	O
.	O

RESULTS	O
Depletion	O
of	O
HP1	O
in	O
Drosophila	B
Kc	O
cells	O
Various	O
chromosomal	O
defects	O
in	O
the	O
cell	O
cycle	O
have	O
been	O
observed	O
in	O
embryos	O
or	O
larval	O
tissues	O
of	O
Drosophila	B
HP1	O
mutants	O
(	O
8,27	O
)	O
.	O

However	O
,	O
the	O
presence	O
of	O
maternally	O
loaded	O
HP1	O
in	O
embryos	O
and	O
the	O
lethality	O
of	O
HP1	O
mutants	O
at	O
late	O
larval	O
stages	O
have	O
so	O
far	O
precluded	O
a	O
systematic	O
study	O
of	O
the	O
role	O
of	O
HP1	O
in	O
cell	O
-	O
cycle	O
regulation	O
.	O

Therefore	O
,	O
we	O
used	O
Drosophila	B
Kc	O
cells	O
,	O
a	O
cell	O
line	O
derived	O
from	O
Drosophila	B
embryos	O
,	O
as	O
a	O
model	O
system	O
to	O
address	O
this	O
problem	O
.	O

HP1	O
transcripts	O
were	O
depleted	O
using	O
an	O
RNAi	O
-	O
based	O
approach	O
(	O
see	O
Materials	O
and	O
Methods	O
)	O
.	O

The	O
reduction	O
in	O
HP1	O
expression	O
was	O
measured	O
both	O
by	O
RT	O
–	O
PCR	O
and	O
by	O
western	O
blotting	O
analysis	O
(	O
Figure	O
1A	O
)	O
.	O

A	O
significant	O
reduction	O
in	O
the	O
HP1	O
expression	O
was	O
already	O
evident	O
after	O
2	O
days	O
treatment	O
with	O
HP1	O
dsRNA	O
.	O

Cells	O
at	O
day	O
8	O
showed	O
a	O
reduction	O
in	O
HP1	O
of	O
∼90	O
%	O
(	O
Figure	O
1A	O
)	O
and	O
were	O
therefore	O
used	O
in	O
all	O
subsequent	O
experiments	O
.	O

Cell	O
-	O
cycle	O
progression	O
at	O
S	O
and	O
G2	O
/	O
M	O
phase	O
is	O
altered	O
in	O
the	O
absence	O
of	O
HP1	O
The	O
impact	O
of	O
HP1	O
loss	O
on	O
the	O
cell	O
cycle	O
of	O
Kc	O
cells	O
was	O
determined	O
using	O
cell	O
-	O
cycle	O
profile	O
analysis	O
of	O
HP1-depleted	O
and	O
control	O
cells	O
.	O

The	O
percentage	O
of	O
cells	O
in	O
S	O
phase	O
was	O
determined	O
by	O
BrdU	O
incorporation	O
,	O
and	O
total	O
DNA	O
content	O
by	O
7-amino	O
-	O
actinomycin	O
(	O
7-AAD	O
)	O
.	O

The	O
results	O
showed	O
that	O
the	O
depletion	O
of	O
HP1	O
(	O
day	O
8)	O
caused	O
a	O
decrease	O
in	O
S	O
-	O
phase	O
cells	O
of	O
at	O
least	O
4-fold	O
,	O
and	O
a	O
2-fold	O
decrease	O
in	O
G2	O
/	O
M	O
-	O
phase	O
cells	O
(	O
Figure	O
1B	O
)	O
,	O
although	O
no	O
significant	O
effect	O
was	O
found	O
at	O
the	O
G1	O
phase	O
.	O

In	O
addition	O
,	O
depletion	O
of	O
HP1	O
caused	O
a	O
greater	O
than	O
7-fold	O
increase	O
in	O
the	O
number	O
of	O
apoptotic	O
cells	O
.	O

These	O
results	O
,	O
therefore	O
,	O
confirm	O
that	O
HP1	O
is	O
an	O
important	O
regulator	O
during	O
the	O
cell	O
cycle	O
,	O
especially	O
at	O
the	O
S	O
and	O
G2	O
/	O
M	O
phases	O
.	O

Cell	O
-	O
cycle	O
regulators	O
require	O
HP1	O
to	O
maintain	O
their	O
active	O
transcription	O
To	O
ask	O
whether	O
the	O
cell	O
-	O
cycle	O
defects	O
were	O
due	O
to	O
changes	O
in	O
the	O
transcription	O
of	O
genes	O
functionally	O
involved	O
in	O
S	O
phase	O
and	O
the	O
G2	O
/	O
M	O
phase	O
,	O
we	O
next	O
assessed	O
global	O
changes	O
in	O
gene	O
transcription	O
following	O
depletion	O
of	O
HP1	O
.	O

Expression	O
profile	O
analysis	O
was	O
performed	O
using	O
total	O
RNA	O
isolated	O
from	O
both	O
HP1-depleted	O
Kc	O
cells	O
and	O
control	O
Kc	O
cells	O
,	O
and	O
an	O
Affymetrix	O
Drosophila	B
chip	O
.	O

For	O
each	O
experiment	O
,	O
we	O
used	O
total	O
RNA	O
isolated	O
from	O
two	O
independent	O
HP1-depleted	O
and	O
control	O
samples	O
,	O
and	O
at	O
least	O
two	O
independent	O
experiments	O
were	O
performed	O
.	O

The	O
microarray	O
analysis	O
showed	O
that	O
loss	O
of	O
HP1	O
function	O
in	O
Kc	O
cells	O
resulted	O
in	O
alterations	O
in	O
transcription	O
of	O
>	O
500	O
genes	O
:	O
∼400	O
genes	O
were	O
down	O
-	O
regulated	O
and	O
∼120	O
genes	O
were	O
up	O
-	O
regulated	O
(	O
>	O
1.5-fold	O
,	O
ANOVA	O
)	O
.	O

The	O
function	O
of	O
these	O
genes	O
ranged	O
from	O
cellular	O
enzymes	O
,	O
signal	O
transduction	O
molecules	O
,	O
and	O
membrane	O
and	O
cell	O
structural	O
proteins	O
,	O
to	O
nucleic	O
acid	O
-	O
binding	O
proteins	O
and	O
cell	O
-	O
cycle	O
regulators	O
(	O
Figure	O
2A	O
)	O
.	O

At	O
the	O
chromosomal	O
level	O
,	O
the	O
genes	O
targeted	O
by	O
HP1	O
appeared	O
to	O
be	O
distributed	O
along	O
all	O
euchromatic	O
chromosomal	O
arms	O
(	O
data	O
not	O
shown	O
)	O
,	O
supporting	O
a	O
global	O
role	O
of	O
HP1	O
in	O
euchromatic	O
gene	O
regulation	O
(	O
20	O
)	O
.	O

Among	O
60	O
known	O
/	O
predicted	O
genes	O
associated	O
with	O
DNA	O
replication	O
function	O
,	O
15	O
were	O
down	O
-	O
regulated	O
in	O
the	O
absence	O
of	O
HP1	O
(	O
Figure	O
2B	O
)	O
.	O

These	O
included	O
McM2	O
,	O
McM5	O
,	O
McM6	O
and	O
CDC45L	O
,	O
which	O
are	O
required	O
for	O
processive	O
DNA	O
replication	O
and	O
correct	O
chromosome	O
condensation	O
(	O
30–32	O
)	O
.	O

Other	O
genes	O
involved	O
in	O
DNA	O
replication	O
,	O
such	O
as	O
components	O
of	O
the	O
origin	O
recognition	O
complex	O
(	O
Orc	O
)	O
—Orc4	O
,	O
Caf1	O
,	O
Gnf1	O
,	O
Dref1	O
,	O
DNA	O
polymerase	O
-	O
γ	O
and	O
Tam	O
—	O
were	O
also	O
down	O
-	O
regulated	O
(	O
Figure	O
2B	O
)	O
.	O

Aurora	O
B	O
and	O
inner	O
centromere	O
protein	O
(	O
INCENP	O
)	O
,	O
known	O
to	O
be	O
required	O
for	O
kinetochore	O
assembly	O
,	O
chromosome	O
condensation	O
and	O
bipolar	O
chromosome	O
attachment	O
during	O
mitosis	O
(	O
33	O
)	O
,	O
also	O
showed	O
a	O
reduction	O
in	O
transcription	O
.	O

A	O
similar	O
loss	O
of	O
transcription	O
was	O
observed	O
in	O
Bub1	O
and	O
Bub3	O
(	O
Figure	O
2B	O
)	O
,	O
encoding	O
mitotic	O
checkpoint	O
control	O
proteins	O
(	O
34,35	O
)	O
.	O

Loss	O
function	O
of	O
Bub1	O
has	O
been	O
shown	O
to	O
cause	O
chromatin	O
bridges	O
to	O
extend	O
between	O
the	O
two	O
separating	O
groups	O
of	O
chromosomes	O
,	O
and	O
extensive	O
chromosome	O
fragmentation	O
in	O
anaphase	O
cells	O
(	O
35	O
)	O
.	O

We	O
confirmed	O
the	O
changes	O
in	O
the	O
transcription	O
of	O
cell	O
-	O
cycle	O
regulators	O
using	O
semi	O
-	O
quantitative	O
RT	O
–	O
PCR	O
,	O
which	O
gave	O
results	O
consistent	O
with	O
the	O
microarray	O
analysis	O
.	O

In	O
addition	O
,	O
cell	O
-	O
cycle	O
regulator	O
genes	O
,	O
such	O
as	O
McM3	O
,	O
McM7	O
and	O
Asp	O
(	O
abnormal	O
spindle	O
)	O
,	O
were	O
also	O
confirmed	O
to	O
be	O
down	O
-	O
regulated	O
(	O
Figure	O
2C	O
)	O
.	O

Collectively	O
,	O
these	O
results	O
demonstrate	O
that	O
HP1	O
is	O
indeed	O
involved	O
in	O
the	O
regulation	O
of	O
transcription	O
of	O
cell	O
-	O
cycle	O
regulators	O
.	O

HP1	O
is	O
required	O
for	O
Aurora	O
B	O
distribution	O
and	O
histone	O
H3	O
phosphorylation	O
INCENP	O
is	O
localized	O
to	O
the	O
centromeric	O
region	O
of	O
chromosomes	O
at	O
metaphase	O
and	O
the	O
spindle	O
midzone	O
at	O
anaphase	O
,	O
which	O
then	O
targets	O
Aurora	O
B	O
,	O
a	O
kinase	O
essential	O
for	O
histone	O
H3	O
ser10	O
phosphorylation	O
,	O
to	O
these	O
sites	O
(	O
36	O
)	O
.	O

Loss	O
of	O
function	O
of	O
both	O
these	O
'	O
chromosomal	O
passenger	O
'	O
proteins	O
causes	O
abnormal	O
chromosomal	O
segregation	O
at	O
metaphase	O
,	O
as	O
well	O
as	O
certain	O
cytokinesis	O
defects	O
(	O
36,37	O
)	O
.	O

The	O
loss	O
of	O
transcription	O
of	O
both	O
INCENP	O
and	O
Aurora	O
B	O
after	O
depletion	O
of	O
HP1	O
,	O
therefore	O
,	O
raised	O
the	O
possibility	O
that	O
localization	O
of	O
Aurora	O
B	O
(	O
Figure	O
3	O
and	O
data	O
not	O
shown	O
)	O
may	O
be	O
altered	O
.	O

Staining	O
of	O
HP1-depleted	O
Kc	O
cells	O
with	O
anti	O
-	O
Aurora	O
B	O
antibodies	O
indeed	O
revealed	O
an	O
altered	O
localization	O
of	O
Aurora	O
B	O
and	O
,	O
in	O
a	O
number	O
of	O
cases	O
,	O
a	O
complete	O
loss	O
of	O
Aurora	O
B	O
(	O
Figure	O
3A	O
)	O
.	O

Consistent	O
with	O
the	O
loss	O
function	O
of	O
Aurora	O
B	O
,	O
the	O
spindles	O
in	O
the	O
metaphase	O
cells	O
were	O
also	O
disorganized	O
,	O
with	O
a	O
large	O
number	O
of	O
cells	O
showing	O
an	O
altered	O
prometaphase	O
chromosome	O
alignment	O
(	O
Figure	O
3A	O
)	O
.	O

Some	O
showed	O
extensive	O
chromosome	O
fragmentation	O
(	O
Figure	O
3B	O
)	O
,	O
or	O
the	O
presence	O
of	O
a	O
third	O
spindle	O
pole	O
-	O
like	O
structure	O
as	O
indicated	O
by	O
beta	O
-	O
tubulin	O
(	O
Figure	O
3A	O
)	O
.	O

At	O
telophase	O
,	O
we	O
observed	O
defective	O
separating	O
cells	O
with	O
an	O
extra	O
cell	O
envelope	O
-	O
like	O
structure	O
without	O
nuclei	O
(	O
Figure	O
3A	O
)	O
.	O

Chromatin	O
bridges	O
or	O
lagging	O
chromatids	O
at	O
telophase	O
were	O
also	O
evident	O
in	O
some	O
cells	O
(	O
Figure	O
3C	O
)	O
;	O
however	O
,	O
in	O
some	O
cases	O
,	O
localization	O
of	O
Aurora	O
B	O
appeared	O
not	O
to	O
be	O
affected	O
,	O
arguing	O
that	O
other	O
pathways	O
are	O
possibly	O
involved	O
.	O

We	O
next	O
analyzed	O
changes	O
in	O
histone	O
H3	O
serine	O
10	O
phosphorylation	O
,	O
since	O
the	O
loss	O
of	O
transcription	O
of	O
INCENP	O
is	O
known	O
to	O
affect	O
localization	O
of	O
Aurora	O
B	O
(	O
33	O
)	O
,	O
which	O
is	O
essential	O
in	O
the	O
regulation	O
of	O
histone	O
H3	O
phosphorylation	O
(	O
36	O
)	O
.	O

Total	O
cell	O
extracts	O
from	O
HP1-depleted	O
Kc	O
cells	O
were	O
analyzed	O
by	O
western	O
blotting	O
(	O
Figure	O
3D	O
)	O
.	O

The	O
results	O
indeed	O
showed	O
a	O
severalfold	O
reduction	O
in	O
H3	O
ser10	O
phosphorylation	O
after	O
depletion	O
of	O
HP1	O
,	O
consistent	O
with	O
the	O
functional	O
disruption	O
of	O
INCENP	O
and	O
Aurora	O
B	O
in	O
the	O
absence	O
of	O
HP1	O
.	O

HP1	O
directly	O
targets	O
genes	O
encoding	O
cell	O
-	O
cycle	O
regulators	O
in	O
euchromatin	O
To	O
test	O
whether	O
the	O
loss	O
of	O
transcription	O
of	O
genes	O
involved	O
in	O
DNA	O
replication	O
and	O
mitosis	O
was	O
a	O
direct	O
effect	O
of	O
the	O
loss	O
of	O
HP1	O
,	O
we	O
performed	O
a	O
ChIP	O
analysis	O
to	O
determine	O
whether	O
HP1	O
is	O
physically	O
associated	O
with	O
these	O
genes	O
.	O

Chromatin	O
lysates	O
from	O
formaldehyde	O
-	O
fixed	O
Kc	O
cells	O
were	O
sonicated	O
into	O
small	O
chromatin	O
fragments	O
(	O
0.2–0.8	O
kb	O
)	O
and	O
immunoprecipitated	O
with	O
polyclonal	O
antibodies	O
against	O
Drosophila	B
HP1	O
.	O

As	O
a	O
control	O
,	O
we	O
used	O
a	O
mock	O
precipitation	O
(	O
beads	O
only	O
)	O
and	O
polyclonal	O
antibodies	O
against	O
HA	O
.	O

Our	O
ChIP	O
results	O
showed	O
that	O
known	O
transposable	O
elements	O
distributed	O
in	O
heterochromatin	O
,	O
such	O
as	O
F	O
-	O
element	O
,	O
TART	O
and	O
1360	O
(	O
7,38	O
)	O
,	O
were	O
all	O
enriched	O
in	O
HP1	O
binding	O
(	O
Figure	O
4	O
)	O
,	O
which	O
is	O
also	O
consistent	O
with	O
a	O
previous	O
study	O
(	O
20	O
)	O
.	O

Using	O
the	O
same	O
ChIP	O
DNA	O
material	O
,	O
we	O
then	O
attempted	O
to	O
determine	O
whether	O
HP1	O
was	O
enriched	O
in	O
genes	O
involved	O
in	O
DNA	O
replication	O
.	O

Primers	O
were	O
designed	O
to	O
cover	O
the	O
promoter	O
regions	O
of	O
selected	O
genes	O
.	O

The	O
results	O
showed	O
that	O
McM3	O
,	O
McM5	O
and	O
Tam	O
were	O
all	O
enriched	O
in	O
HP1	O
binding	O
(	O
Figure	O
4	O
)	O
.	O

However	O
,	O
McM7	O
appeared	O
to	O
be	O
HP1-negative	O
,	O
although	O
its	O
transcription	O
was	O
also	O
affected	O
by	O
the	O
loss	O
of	O
HP1	O
function	O
.	O

Genes	O
essential	O
for	O
mitosis	O
,	O
such	O
as	O
Aurora	O
B	O
,	O
were	O
also	O
HP1-positive	O
(	O
Figure	O
4	O
)	O
.	O

These	O
results	O
demonstrate	O
that	O
these	O
cell	O
-	O
cycle	O
regulator	O
genes	O
are	O
directly	O
targeted	O
by	O
HP1	O
in	O
their	O
promoter	O
regions	O
.	O

DISCUSSION	O
In	O
this	O
study	O
,	O
we	O
used	O
microarray	O
and	O
RT	O
–	O
PCR	O
techniques	O
to	O
demonstrate	O
that	O
transcription	O
of	O
cell	O
-	O
cycle	O
regulators	O
is	O
misregulated	O
in	O
the	O
absence	O
of	O
HP1	O
.	O

Certain	O
defects	O
in	O
S	O
phase	O
may	O
be	O
a	O
direct	O
consequence	O
of	O
the	O
loss	O
of	O
transcription	O
of	O
DNA	O
replication	O
genes	O
such	O
as	O
McM2	O
,	O
McM5	O
,	O
McM6	O
,	O
CDC45L	O
,	O
Orc4	O
and	O
others	O
,	O
since	O
these	O
genes	O
have	O
been	O
functionally	O
implicated	O
in	O
the	O
initiation	O
of	O
DNA	O
replication	O
and/or	O
the	O
progression	O
of	O
replication	O
forks	O
(	O
39	O
)	O
.	O

Depletion	O
or	O
mutation	O
of	O
these	O
genes	O
has	O
been	O
shown	O
to	O
result	O
in	O
DNA	O
damage	O
(	O
32	O
)	O
,	O
the	O
blockage	O
of	O
replication	O
forks	O
(	O
39	O
)	O
,	O
increased	O
chromosome	O
loss	O
/	O
genome	O
instability	O
,	O
and	O
defective	O
condensation	O
(	O
30	O
)	O
.	O

The	O
reduction	O
in	O
the	O
number	O
of	O
cells	O
in	O
G2	O
/	O
M	O
phase	O
may	O
be	O
a	O
consequence	O
of	O
the	O
reduction	O
in	O
transcription	O
or	O
functional	O
disruption	O
of	O
INCENP	O
,	O
Aurora	O
B	O
,	O
Bub1	O
,	O
and	O
Bub3	O
(	O
34,36	O
)	O
.	O

Chromosome	O
segregation	O
defects	O
,	O
such	O
as	O
chromosome	O
fragmentation	O
and	O
chromatin	O
bridges	O
in	O
anaphase	O
/	O
telophase	O
cells	O
,	O
and	O
certain	O
cytokinesis	O
defects	O
in	O
HP1-depleted	O
cells	O
,	O
mimic	O
the	O
phenotype	O
of	O
cells	O
with	O
loss	O
function	O
of	O
INCENP	O
,	O
Aurora	O
B	O
or	O
Bub1	O
(	O
35–37	O
)	O
.	O

The	O
mislocalization	O
of	O
Aurora	O
B	O
in	O
the	O
absence	O
of	O
HP1	O
is	O
also	O
consistent	O
with	O
the	O
loss	O
of	O
transcription	O
and	O
functional	O
disruption	O
of	O
INCENP	O
(	O
37	O
)	O
,	O
and	O
the	O
reduction	O
in	O
Aurora	O
B	O
transcription	O
may	O
be	O
partially	O
responsible	O
for	O
the	O
observed	O
chromosomal	O
defects	O
,	O
including	O
loss	O
of	O
histone	O
H3	O
phosphorylation	O
at	O
serine	O
10	O
.	O

HP1	O
is	O
also	O
known	O
to	O
physically	O
interact	O
with	O
certain	O
components	O
of	O
replication	O
complexes	O
such	O
as	O
ORCs	O
and	O
MCMs	O
(	O
30,40,41	O
)	O
,	O
with	O
the	O
inner	O
centromere	O
protein	O
INCENP	O
(	O
42	O
)	O
and	O
the	O
chromatin	O
assembly	O
factor	O
CAF1	O
(	O
43	O
)	O
promoting	O
delivery	O
of	O
HP1	O
to	O
heterochromatin	O
sites	O
(	O
44	O
)	O
.	O

Loss	O
of	O
HP1	O
is	O
,	O
therefore	O
,	O
expected	O
to	O
cause	O
disruption	O
to	O
such	O
HP1-associated	O
complexes	O
,	O
and	O
will	O
partially	O
contribute	O
to	O
the	O
chromatin	O
/	O
chromosomal	O
defects	O
in	O
HP1	O
mutants	O
(	O
8,27	O
)	O
and	O
HP1-depleted	O
Kc	O
cells	O
.	O

It	O
is	O
therefore	O
well	O
possible	O
that	O
the	O
loss	O
of	O
transcription	O
of	O
these	O
cell	O
-	O
cycle	O
regulator	O
genes	O
,	O
and	O
consequent	O
disruption	O
of	O
HP1	O
functional	O
complexes	O
or	O
heterochromatin	O
structure	O
,	O
all	O
contributed	O
to	O
the	O
cell	O
-	O
cycle	O
defects	O
observed	O
.	O

The	O
ChIP	O
assay	O
supports	O
the	O
hypothesis	O
that	O
the	O
loss	O
of	O
transcription	O
of	O
cell	O
-	O
cycle	O
regulator	O
genes	O
is	O
a	O
direct	O
effect	O
of	O
the	O
lack	O
of	O
HP1	O
.	O

Aurora	O
B	O
,	O
McM3	O
,	O
and	O
McM5	O
were	O
all	O
bound	O
by	O
HP1	O
at	O
their	O
promoter	O
regions	O
,	O
although	O
other	O
cell	O
-	O
cycle	O
regulators	O
,	O
such	O
as	O
McM7	O
,	O
were	O
HP1-negative	O
,	O
implying	O
that	O
the	O
altered	O
transcription	O
in	O
these	O
genes	O
might	O
be	O
a	O
secondary	O
effect	O
of	O
the	O
loss	O
of	O
HP1	O
.	O

A	O
previous	O
study	O
in	O
Drosophila	B
Kc	O
cells	O
(	O
20	O
)	O
employed	O
an	O
approach	O
based	O
on	O
the	O
ectopic	O
expression	O
of	O
a	O
fusion	O
protein	O
of	O
HP1	O
with	O
a	O
prokaryotic	O
DNA	O
adenine	O
methyltransferase	O
and	O
identified	O
a	O
number	O
of	O
methylated	O
targets	O
in	O
the	O
genome	O
.	O

In	O
this	O
study	O
,	O
MCM3	O
and	O
MCM5	O
were	O
not	O
found	O
to	O
be	O
methylated	O
,	O
indicating	O
lack	O
of	O
association	O
with	O
HP1	O
.	O

On	O
the	O
other	O
hand	O
,	O
heterochromatin	O
repeats	O
,	O
such	O
F	O
-	O
element	O
and	O
1360	O
,	O
were	O
consistently	O
found	O
to	O
be	O
HP1-enriched	O
both	O
here	O
and	O
in	O
the	O
previous	O
study	O
.	O

It	O
remains	O
to	O
be	O
determined	O
whether	O
these	O
discrepancies	O
are	O
due	O
to	O
the	O
different	O
experimental	O
systems	O
used	O
.	O

However	O
,	O
we	O
note	O
that	O
the	O
previous	O
study	O
was	O
performed	O
using	O
a	O
cDNA	O
array	O
,	O
while	O
we	O
observe	O
binding	O
of	O
endogenous	O
HP1	O
at	O
the	O
promoter	O
of	O
these	O
genes	O
.	O

Similarly	O
,	O
another	O
study	O
using	O
chromatin	O
immunoprecipitation	O
in	O
larvae	O
also	O
showed	O
few	O
HP1-positive	O
genes	O
that	O
were	O
not	O
detected	O
in	O
Kc	O
cells	O
by	O
the	O
Dam	O
ID	O
approach	O
(	O
21	O
)	O
.	O

A	O
large	O
number	O
of	O
genes	O
affected	O
by	O
the	O
loss	O
of	O
D.melanogaster	B
HP1	O
in	O
larval	O
tissues	O
(	O
21	O
)	O
seem	O
to	O
be	O
different	O
from	O
that	O
in	O
embryonic	O
Kc	O
cells	O
.	O

The	O
change	O
in	O
the	O
transcription	O
of	O
Aurora	O
B	O
and	O
few	O
cell	O
-	O
cycle	O
regulators	O
reported	O
in	O
this	O
study	O
is	O
also	O
not	O
found	O
among	O
the	O
HP1-affected	O
genes	O
at	O
larval	O
stage	O
(	O
21	O
)	O
.	O

This	O
may	O
be	O
due	O
to	O
specific	O
role	O
(	O
s	O
)	O
of	O
HP1	O
in	O
different	O
stages	O
of	O
development	O
.	O

Alternatively	O
,	O
it	O
is	O
also	O
possible	O
that	O
the	O
impact	O
of	O
HP1	O
in	O
the	O
transcription	O
of	O
cell	O
-	O
cycle	O
regulators	O
in	O
proliferating	O
cells	O
is	O
underestimated	O
when	O
performing	O
the	O
analyses	O
on	O
larval	O
tissues	O
,	O
and	O
thus	O
on	O
mixed	O
populations	O
of	O
both	O
proliferating	O
and	O
differentiating	O
/	O
differentiated	O
cells	O
.	O

HP1	O
is	O
generally	O
known	O
as	O
a	O
transcriptional	O
repressor	O
,	O
as	O
supported	O
by	O
several	O
lines	O
of	O
evidence	O
:	O
silencing	O
of	O
a	O
euchromatic	O
reporter	O
gene	O
in	O
heterochromatin	O
requires	O
HP1	O
(	O
10,11	O
)	O
,	O
tethering	O
of	O
HP1	O
next	O
to	O
a	O
euchromatic	O
reporter	O
gene	O
causes	O
silencing	O
(	O
45	O
)	O
,	O
and	O
the	O
repression	O
of	O
genes	O
within	O
euchromatic	O
region	O
31	O
bound	O
by	O
HP1	O
is	O
relieved	O
in	O
the	O
absence	O
of	O
HP1	O
(	O
46	O
)	O
.	O

In	O
contrast	O
,	O
genes	O
in	O
heterochromatin	O
,	O
known	O
as	O
heterochromatic	O
genes	O
,	O
such	O
as	O
light	O
and	O
rolled	O
,	O
seem	O
to	O
require	O
HP1	O
to	O
maintain	O
their	O
active	O
transcription	O
(	O
47,48	O
)	O
.	O

The	O
level	O
of	O
transcription	O
of	O
heterochromatic	O
genes	O
was	O
dramatically	O
reduced	O
in	O
a	O
mutated	O
HP1	O
background	O
(	O
47–49	O
)	O
.	O

It	O
was	O
therefore	O
proposed	O
that	O
HP1	O
may	O
function	O
as	O
a	O
positive	O
regulator	O
of	O
transcription	O
of	O
these	O
genes	O
(	O
50,51	O
)	O
,	O
although	O
the	O
exact	O
regulation	O
mechanism	O
remains	O
unclear	O
.	O

A	O
study	O
of	O
heat	O
-	O
shock	O
genes	O
found	O
that	O
HP1	O
is	O
associated	O
with	O
RNA	O
transcripts	O
in	O
the	O
coding	O
region	O
,	O
and	O
is	O
also	O
a	O
positive	O
regulator	O
of	O
their	O
transcription	O
(	O
52,53	O
)	O
.	O

The	O
chromatin	O
association	O
of	O
HP1	O
at	O
the	O
promoter	O
region	O
of	O
active	O
euchromatic	O
genes	O
demonstrated	O
from	O
this	O
work	O
and	O
others	O
,	O
and	O
its	O
independence	O
from	O
histone	O
H3K9	O
methylation	O
(	O
21	O
)	O
,	O
all	O
suggest	O
that	O
mechanism	O
whereby	O
HP1	O
modulates	O
transcription	O
of	O
euchromatic	O
genes	O
is	O
potentially	O
distinct	O
from	O
its	O
role	O
in	O
heterochromatin	O
formation	O
.	O

Collectively	O
,	O
the	O
results	O
of	O
this	O
study	O
demonstrate	O
that	O
HP1	O
plays	O
an	O
essential	O
role	O
in	O
cell	O
-	O
cycle	O
progression	O
,	O
and	O
support	O
the	O
view	O
that	O
HP1	O
,	O
in	O
addition	O
to	O
its	O
role	O
in	O
heterochromatin	O
,	O
can	O
act	O
as	O
a	O
positive	O
transcriptional	O
regulator	O
of	O
euchromatic	O
genes	O
.	O

SUPPLEMENTARY	O
MATERIAL	O
Supplementary	O
Material	O
is	O
available	O
at	O
NAR	O
Online	O
.	O

Supplementary	O
Material	O

Physiological	O
and	O
chemical	O
characterization	O
of	O
cyanobacterial	B
metallothioneins	O
.	O

Abstract	O
Techniques	O
have	O
been	O
developed	O
for	O
detection	O
,	O
quantitation	O
,	O
and	O
isolation	O
of	O
bacterial	O
metallothioneins	O
(	O
MTs	O
)	O
from	O
cyanobacterial	O
species	O
.	O

These	O
methods	O
involve	O
differential	O
pulse	O
polarography	O
and	O
reverse	O
-	O
phase	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
and	O
have	O
allowed	O
detection	O
of	O
picomole	O
quantities	O
of	O
these	O
high	O
sulfhydryl	O
content	O
proteins	O
.	O

The	O
prokaryotic	O
molecule	O
was	O
found	O
to	O
be	O
induced	O
in	O
the	O
presence	O
of	O
Cd	O
or	O
Zn	O
salts	O
with	O
regulation	O
at	O
the	O
level	O
of	O
transcription	O
.	O

Cu	O
was	O
not	O
found	O
to	O
induce	O
synthesis	O
of	O
the	O
prokaryotic	O
MT	O
.	O

Exposure	O
to	O
the	O
former	O
metals	O
resulted	O
in	O
a	O
growth	O
lag	O
followed	O
by	O
simultaneous	O
induction	O
of	O
MT	O
synthesis	O
and	O
onset	O
of	O
growth	O
.	O

Amino	O
acid	O
analysis	O
and	O
N	O
-	O
terminal	O
sequence	O
analysis	O
indicated	O
that	O
the	O
bacterial	O
MTs	O
from	O
cyanobacteria	O
are	O
unique	O
,	O
having	O
many	O
aromatic	O
and	O
aliphatic	O
residues	O
and	O
no	O
apparent	O
association	O
of	O
hydroxylated	O
or	O
basic	O
amino	O
acids	O
with	O
cysteines	O
.	O

Although	O
the	O
characteristic	O
Cys	O
-	O
X	O
-	O
Cys	O
sequences	O
were	O
present	O
,	O
no	O
apparent	O
amino	O
acid	O
sequence	O
homology	O
with	O
the	O
eukaryotic	O
MTs	O
was	O
found	O
in	O
the	O
first	O
42	O
residues	O
.	O

Environmental	O
Health	O
Perspectives	O
Vol	O
.	O

65	O
,	O
pp	O
.	O

71	O
-	O
75	O
,	O
1986	O
Physiological	O
and	O
Chemical	O
Characterization	O
of	O
Cyanobacterial	O
Metallothioneins	O
by	O
Robert	O
W.	O
Olafson	O

*	O
Techniques	O
have	O
been	O
developed	O
for	O
detection	O
,	O
quantitation	O
,	O
and	O
isolation	O
of	O
bacterial	O
metallothioneins	O
(	O
MTs	O
)	O
from	O
cyanobacterial	O
species	O
.	O

These	O
methods	O
involve	O
differential	O
pulse	O
polarography	O
and	O
reverse	O
-	O
phase	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
and	O
have	O
allowed	O
detection	O
of	O
picomole	O
quantities	O
of	O
these	O
high	O
sulfhydryl	O
content	O
proteins	O
.	O

The	O
prokaryotic	O
molecule	O
was	O
found	O
to	O
be	O
induced	O
in	O
the	O
presence	O
of	O
Cd	O
or	O
Zn	O
salts	O
with	O
regulation	O
at	O
the	O
level	O
of	O
transcription	O
.	O

Cu	O
was	O
not	O
found	O
to	O
induce	O
synthesis	O
of	O
the	O
prokaryotic	O
MT	O
.	O

Exposure	O
to	O
the	O
former	O
metals	O
resulted	O
in	O
a	O
growth	O
lag	O
followed	O
by	O
simultaneous	O
induction	O
of	O
MT	O
synthesis	O
and	O
onset	O
of	O
growth	O
.	O

Amino	O
acid	O
analysis	O
and	O
N	O
-	O
terminal	O
sequence	O
analysis	O
indicated	O
that	O
the	O
bacterial	O
MTs	O
from	O
cyanobacteria	O
are	O
unique	O
,	O
having	O
many	O
aromatic	O
and	O
aliphatic	O
residues	O
and	O
no	O
apparent	O
association	O
of	O
hydroxylated	O
or	O
basic	O
amino	O
acids	O
with	O
cysteines	O
.	O

Although	O
the	O
characteristic	O
CysX	O
-	O
Cys	O
sequences	O
were	O
present	O
,	O
no	O
apparent	O
amino	O
acid	O
sequence	O
homology	O
with	O
the	O
eukaryotic	O
MTs	O
was	O
found	O
in	O
the	O
first	O
42	O
residues	O
.	O

Introduction	O
Metallothioneins	O
have	O
now	O
been	O
isolated	O
and	O
characterized	O
from	O
a	O
large	O
variety	O
of	O
eukaryotic	O
organisms	O
(	O
1	O
)	O
and	O
shown	O
to	O
be	O
involved	O
in	O
heavy	O
metal	O
detoxification	O
and/or	O
homeostasis	O
(	O
2	O
-	O
4	O
)	O
.	O

These	O
proteins	O
are	O
highly	O
homologous	O
with	O
respect	O
to	O
amino	O
acid	O
sequence	O
and	O
complex	O
metals	O
in	O
characteristic	O
metal	O
-	O
thiolate	O
cluster	O
arrangements	O
,	O
the	O
structures	O
of	O
which	O
have	O
been	O
recently	O
investigated	O
by	O
113Cd	O
-	O
NMR	O
(	O
6	O
)	O
.	O

Although	O
metallothionein	O
(	O
MT	O
)	O
is	O
found	O
throughout	O
the	O
eukaryotic	O
world	O
,	O
few	O
reports	O
of	O
the	O
presence	O
of	O
this	O
type	O
of	O
high	O
sulfhydryl	O
content	O
metal	O
-	O
binding	O
protein	O
exist	O
for	O
prokaryotes	O
.	O

We	O
earlier	O
reported	O
the	O
presence	O
of	O
a	O
prokaryotic	O
MT	O
in	O
cyanobacteria	O
(	O
7,8	O
)	O
and	O
have	O
recently	O
provided	O
primary	O
sequence	O
evidence	O
substantiating	O
these	O
data	O
.	O

This	O
manuscript	O
is	O
intended	O
to	O
summarize	O
the	O
present	O
state	O
of	O
knowledge	O
regarding	O
the	O
physiological	O
and	O
chemical	O
characterization	O
of	O
these	O
bacterial	O
MTs	O
,	O
with	O
an	O
emphasis	O
on	O
the	O
techniques	O
employed	O
in	O
such	O
studies	O
.	O

Analytical	O
Procedure	O
In	O
order	O
to	O
facilitate	O
rapid	O
detection	O
,	O
isolation	O
,	O
and	O
quantitation	O
of	O
MT	O
from	O
various	O
sources	O
,	O
we	O
have	O
routinely	O
employed	O
a	O
differential	O
pulse	O
polarographic	O
tech	O
*	O
Department	O
of	O
Biochemistry	O
and	O
Microbiology	O
,	O
University	O
of	O
Victoria	O
,	O
Victoria	O
,	O
British	O
Columbia	O
V8W	O
2Y2	O
,	O
Canada	O
.	O

nique	O
first	O
described	O
by	O
Brdicka	O
(	O
9	O
-	O
11	O
)	O
.	O

This	O
procedure	O
avoids	O
use	O
of	O
radioisotopes	O
and	O
circumvents	O
problems	O
such	O
as	O
species	O
specificity	O
and	O
metal	O
stoichiometric	O
assumptions	O
associated	O
with	O
radioimmunoassays	O
and	O
metal	O
binding	O
assays	O
.	O

Figure	O
1	O
shows	O
a	O
typical	O
polarographic	O
wave	O
for	O
MT	O
using	O
the	O
Brdicka	O
procedure	O
.	O

Measurement	O
of	O
the	O
wave	O
height	O
can	O
be	O
performed	O
from	O
either	O
the	O
0.20	O
glJ	O
MT-1	O
O	O
0.15	O
E	O
0	O
0.10	O
0	O
E	O
0.05	O
_	O
_	O
-1.35	O
-1.45	O
-1.55	O
-1.65	O
V	O
vs	O
Agt	O
/	O
AgC1	O
FIGURE	O
1	O
.	O

Differential	O
pulse	O
polarographic	O
wave	O
for	O
murine	O
MT-1	O
.	O

Wave	O
heights	O
were	O
calculated	O
from	O
the	O
broken	O
tangent	O
line	O
between	O
minima	O
rather	O
than	O
the	O
supporting	O
electrolyte	O
baseline	O
at	O
the	O
bottom	O
of	O
the	O
figure	O
.	O

R.	O
W	O
OLAFSON	O
supporting	O
electrolyte	O
baseline	O
or	O
a	O
tangent	O
to	O
the	O
minima	O
as	O
shown	O
in	O
the	O
preceding	O
figure	O
.	O

In	O
the	O
cobalt	O
hexaminechloride	O
supporting	O
electrolyte	O
,	O
the	O
half	O
-	O
wave	O
potential	O
for	O
all	O
MTs	O
studied	O
to	O
date	O
is	O
approximately	O
-1.45	O
V	O
versus	O
a	O
Ag	O
/	O
AgCl	O
reference	O
electrode	O
.	O

This	O
electrochemical	O
reaction	O
results	O
in	O
highly	O
reproducible	O
and	O
linear	O
current	O
responses	O
which	O
can	O
be	O
used	O
with	O
samples	O
containing	O
picomole	O
levels	O
of	O
MT	O
(	O
Fig.	O
2	O
)	O
.	O

Since	O
this	O
is	O
an	O
exceedingly	O
sensitive	O
instrument	O
,	O
attention	O
to	O
detail	O
is	O
particularly	O
important	O
for	O
successful	O
use	O
of	O
the	O
Brdicka	O
procedure	O
(	O
11	O
)	O
.	O

Routine	O
use	O
of	O
a	O
reference	O
standard	O
MT	O
is	O
highly	O
recommended	O
to	O
compensate	O
for	O
small	O
day	O
-	O
today	O
variations	O
in	O
response	O
.	O

For	O
absolute	O
values	O
,	O
standards	O
must	O
be	O
identical	O
to	O
the	O
species	O
of	O
protein	O
quantitated	O
;	O
otherwise	O
commercially	O
available	O
standard	O
is	O
adequate	O
.	O

Although	O
certain	O
tissues	O
and	O
cellular	O
types	O
can	O
be	O
shown	O
to	O
have	O
no	O
other	O
polarographically	O
active	O
material	O
other	O
than	O
MT	O
,	O
with	O
samples	O
from	O
new	O
species	O
,	O
it	O
is	O
necessary	O
to	O
evaluate	O
this	O
potential	O
problem	O
by	O
gelperneation	O
chromatography	O
and	O
,	O
if	O
necessary	O
,	O
take	O
steps	O
to	O
remove	O
contaminants	O
before	O
assaying	O
.	O

In	O
most	O
cases	O
,	O
0	O
E	O
i	O
m	O
0	O
0	O
E	O
0.31	O
0.11	O
O	O
0.1	O
0.3	O
0.5	O
MT	O
(	O
nanomoles	O
)	O
FIGURE	O
2	O
.	O

Standard	O
curve	O
for	O
polarographic	O
determination	O
of	O
me	O
tallothionein	O
.	O

FIGURE	O
3	O
.	O

Cyclic	O
voltamogram	O
obtained	O
by	O
equilibration	O
at	O
-1.0	O
V	O
for	O
4	O
min	O
followed	O
by	O
cyclic	O
scanning	O
to	O
OV	O
and	O
-1.4	O
V	O
at	O
a	O
scan	O
rate	O
of	O
200	O
mV	O
/	O
sec	O
with	O
a	O
PAR	O
Model	O
303	O
static	O
mercury	O
drop	O
electrode	O
in	O
the	O
hanging	O
drop	O
mode	O
.	O

The	O
mercury	O
drop	O
electrode	O
was	O
set	O
in	O
the	O
large	O
drop	O
position	O
producing	O
a	O
drop	O
of	O
0.0226	O
cm3	O
.	O

The	O
supporting	O
electrolyte	O
was	O
20	O
mM	O
HEPES	O
buffer	O
,	O
pH	O
7.3	O
.	O

The	O
dotted	O
line	O
is	O
the	O
equilibrium	O
trace	O
.	O

Adapted	O
Olafson	O
and	O
Sim	O
(	O
10	O
)	O
.	O

this	O
is	O
easily	O
managed	O
by	O
heat	O
denaturation	O
,	O
if	O
care	O
is	O
taken	O
to	O
assess	O
the	O
degree	O
of	O
MT	O
losses	O
due	O
to	O
coprecipitation	O
.	O

Such	O
losses	O
later	O
can	O
usually	O
be	O
minimized	O
to	O
less	O
than	O
10	O
%	O
by	O
adjustment	O
of	O
the	O
tissue	O
homogenate	O
density	O
prior	O
to	O
denaturation	O
.	O

It	O
should	O
be	O
indicated	O
that	O
additional	O
utility	O
can	O
be	O
found	O
with	O
a	O
polarographic	O
analyzer	O
beyond	O
application	O
of	O
the	O
Brdicka	O
procedure	O
.	O

For	O
example	O
,	O
metal	O
levels	O
can	O
be	O
readily	O
determined	O
by	O
using	O
differential	O
pulse	O
or	O
anodic	O
stripping	O
voltametry	O
procedures	O
(	O
10	O
)	O
,	O
while	O
Figure	O
3	O
shows	O
a	O
cyclic	O
voltamogram	O
of	O
bacterial	O
MT	O
.	O

The	O
latter	O
technique	O
is	O
potentially	O
useful	O
in	O
assessing	O
metal	O
speciation	O
and	O
integrity	O
of	O
the	O
protein	O
tertiary	O
structure	O
near	O
metal	O
clusters	O
,	O
particularly	O
after	O
metal	O
reconstitution	O
studies	O
.	O

E	O
'	O
C2A-	O
E	O
24	O
0	O
30	O
40	O
E0	O
*	O
~~~~~~~~~~~~	O
o	O
C~~~~~~~~~~~~~~~~~~~~C	O
Fraction	O
Number	O
(	O
18ml	O
)	O
FIGURE	O
4	O
.	O

Sephadex	O
G-75	O
chromatography	O
profile	O
of	O
bacterial	O
cell	O
lysate	O
applied	O
to	O
a	O
5	O
x	O
100	O
cm	O
column	O
and	O
eluted	O
with	O
10	O
mM	O
anunoium	O
bicarbonate	O
,	O
5	O
mM	O
mercaptoethanol	O
(	O
7	O
)	O
.	O

Elution	O
Time	O
(	O
min	O
)	O
FIGURE	O
5	O
.	O

Reverse	O
-	O
phase	O
high	O
-	O
performance	O
chromatography	O
profile	O
of	O
Sephadex	O
G-75	O
fractionated	O
bacterial	O
MT	O
.	O

The	O
300	O
A	O
pore	O
size	O
propyl	O
column	O
was	O
eluted	O
with	O
20	O
mM	O
triethylamine	O
phosphate	O
,	O
pH	O
7.0	O
,	O
by	O
using	O
an	O
acetonitrile	O
organic	O
modifier	O
(	O
phase	O
B	O
)	O
.	O

Column	O
effluent	O
was	O
monitored	O
at	O
250	O
nm	O
with	O
a	O
sensitivity	O
of	O
1.0	O
AUFS	O
(	O
12	O
)	O
.	O

72	O
CYANOBACTERIAL	B
METALLOTHIONEINS	O
Isolation	O
of	O
Cyanobacterial	O
MT	O
Synechococcus	B
strain	I
Tx-20	I
cyanobacteria	O
were	O
maintained	O
in	O
axenic	O
culture	O
on	O
BG-11	O
medium	O
(	O
7	O
)	O
and	O
harvested	O
from	O
aerated	O
20	O
L	O
cultures	O
grown	O
at	O
280C	O
under	O
fluorescent	O
light	O
.	O

Cells	O
were	O
broken	O
in	O
a	O
French	O
pressure	O
cell	O
at	O
0?C	O
in	O
0.5	O
M	O
Tris	O
-	O
HCI	O
,	O
pH	O
8.6	O
,	O
and	O
the	O
lysate	O
exposed	O
to	O
10	O
,	O
uCi	O
of	O
109CdCl	O
.	O

The	O
40,000	O
g	O
supernatant	O
was	O
applied	O
to	O
a	O
Sephadex	O
G-75	O
column	O
developed	O
with	O
10	O
mM	O
ammonium	O
bicarbonate	O
and	O
5	O
mM	O
mercaptoethanol	O
resulting	O
in	O
the	O
profile	O
shown	O
in	O
Figure	O
4	O
.	O

Polarographic	O
activity	O
and	O
radionuclide	O
binding	O
were	O
coincident	O
with	O
a	O
10,000	O
MW	O
ultraviolet	O
absorbing	O
fraction	O
.	O

Further	O
purification	O
of	O
this	O
material	O
could	O
be	O
undertaken	O
by	O
DEAE	O
-	O
cellulose	O
chromatography	O
or	O
isoelectric	O
focusing	O
but	O
maximum	O
resolution	O
of	O
isoproteins	O
was	O
best	O
attained	O
by	O
reverse	O
-	O
phase	O
high	O
-	O
performance	O
liquid	O
chromatogra	O
0	O
5	O
DAYS	O
I0	O
5	O
phy	O
.	O

Figure	O
5	O
shows	O
such	O
a	O
separation	O
performed	O
on	O
a	O
300	O
A	O
pore	O
size	O
C-3	O
column	O
(	O
Beckman	O
Instruments	O
)	O
.	O

Four	O
baseline	O
resolved	O
MT	O
peaks	O
appear	O
between	O
40	O
and	O
70	O
min	O
.	O

Peaks	O
eluting	O
at	O
80	O
min	O
contain	O
at	O
least	O
four	O
additional	O
MT	O
components	O
resolvable	O
by	O
adjustment	O
of	O
the	O
applied	O
organic	O
modifier	O
ramp	O
.	O

Preliminary	O
evidence	O
indicates	O
that	O
these	O
isoproteins	O
are	O
microheterogeneous	O
with	O
respect	O
to	O
both	O
amino	O
acid	O
composition	O
and	O
metal	O
speciation	O
resulting	O
in	O
the	O
observed	O
reverse	O
-	O
phase	O
separation	O
.	O

Physiological	O
Characteristics	O
of	O
Cyanobacterial	O
MT	O
Using	O
the	O
Brdicka	O
polarographic	O
procedure	O
,	O
it	O
is	O
possible	O
to	O
measure	O
basal	O
MT	O
levels	O
in	O
Synechococcus	O
strain	O
5	O
DAYS	O
10	O
15	O
FIGURE	O
6	O
.	O

Cell	O
numbers	O
and	O
MT	O
concentrations	O
as	O
a	O
function	O
of	O
time	O
after	O
inoculation	O
of	O
wild	O
-	O
type	O
cyanobacteria	O
in	O
the	O
presence	O
and	O
absence	O
of	O
(	O
A	O
)	O
22.5	O
,	O
uM	O
CdCl2	O
;	O
(	O
B	O
)	O
control	O
;	O
(	O
C	O
)	O
50	O
,	O
uM	O
ZnSO4	O
;	O
(	O
D	O
)	O
50	O
,	O
uM	O
CuCl2	O
(	O
8)	O
.	O

73	O
74	O
~~~~~~~~~~R.	O
W	O
OLAFSON	O
Table	O
1	O
.	O

Amino	O
acid	O
compositions	O
of	O
cyanobacterial	O
metallothioneins	O
compared	O
with	O
eukaryotic	O
metallothioneins	O
.	O

Nearest	O
integer	O
residues	O
per	O
molecule	O
Human	B
(	O
MT-2	O
)	O
Crab	O
(	O
MT-2	O
)	O
Tx-20	O
t	O
CysA	O
20	O
18	O
9.5	O
Asx	O
4	O
6	O
5.7	O
Thr	O
2	O
3	O
4.8	O
Ser	O
8	O
5	O
3.8	O
Glx	O
2	O
5	O
2.0	O
Gly	O
5	O
3	O
8.0	O
Ala	O
7	O
1	O
4.0	O
Val	O
1	O
-	O
2.3	O
Met	O
1	O
-	O
Ile	O
1	O
-1.1	O
Leu	O
Tyr	O
Phe	O

His	O
Lys	O

Arg	O
Pro	O
8	O
2	O
8	O
2	O
6	O
2.9	O
2.3	O
2.8	O
2.6	O
1.0	O
1.9	O
RRIMP	O
NI	O
cells	O
cultured	O
in	O
the	O
absence	O
of	O
added	O
metal	O
,	O
as	O
shown	O
in	O
Figure	O
6B	O
(	O
8)	O
.	O

Comparison	O
with	O
cultures	O
exposed	O
to	O
cadmium	O
chloride	O
(	O
Fig.	O
6A	O
)	O
or	O
zinc	O
sulfate	O
(	O
Fig.	O
6C	O
)	O
showed	O
that	O
introduction	O
of	O
metal	O
salts	O
resulted	O
in	O
a	O
growth	O
lag	O
and	O
that	O
resumption	O
of	O
growth	O
occurred	O
coincident	O
with	O
an	O
increase	O
in	O
cellular	O
levels	O
of	O
MT	O
.	O

In	O
addition	O
,	O
it	O
should	O
be	O
noted	O
that	O
,	O
like	O
mammalian	O
MT	O
,	O
cadmium	O
appears	O
to	O
be	O
a	O
more	O
potent	O
inducer	O
than	O
zinc	O
.	O

Twice	O
as	O
much	O
cadmium	O
-	O
thionein	O
was	O
synthesized	O
on	O
exposure	O
to	O
half	O
as	O
much	O
metal	O
as	O
was	O
used	O
in	O
the	O
zinc	O
induction	O
experiment	O
.	O

A	O
further	O
interesting	O
finding	O
was	O
that	O
copper	O
exposure	O
resulted	O
in	O
an	O
even	O
greater	O
growth	O
lag	O
than	O
observed	O
with	O
cadmium	O
,	O
but	O
on	O
resumption	O
of	O
growth	O
in	O
the	O
presence	O
copper	O
,	O
MT	O
synthesis	O
was	O
not	O
noted	O
(	O
Fig.	O
6D	O
)	O
.	O

Recent	O
results	O
suggest	O
that	O
this	O
copper	O
resistance	O
is	O
manifest	O
via	O
a	O
membrane	O
exclusion	O
mechanism	O
(	O
unpublished	O
results	O
)	O
.	O

HOURS	O
FIGURE	O
7	O
.	O

Inhibition	O
of	O
cadmium	O
induced	O
synthesis	O
by	O
actinomycin	O
D	O
(	O
hatched	O
bar	O
)	O
and	O
chloramphenicol	O
(	O
solid	O
bar	O
)	O
.	O

Control	O
cells	O
are	O
shown	O
by	O
unmarked	O
bars	O
.	O

In	O
order	O
that	O
the	O
level	O
of	O
regulation	O
of	O
metal	O
induction	O
be	O
determined	O
for	O
cyanobacteria	O
,	O
logarithmically	O
growing	O
cultures	O
were	O
exposed	O
to	O
cadmium	O
and	O
MT	O
concentrations	O
measured	O
at	O
several	O
time	O
intervals	O
thereafter	O
.	O

Two	O
cultures	O
were	O
exposed	O
to	O
either	O
chloramphenicol	O
or	O
actinomycin	O
D	O
30	O
min	O
prior	O
to	O
introduction	O
of	O
metal	O
,	O
while	O
a	O
third	O
culture	O
was	O
used	O
as	O
a	O
control	O
.	O

The	O
results	O
of	O
this	O
experiment	O
are	O
shown	O
in	O
Figure	O
7	O
and	O
indicate	O
induction	O
at	O
the	O
level	O
of	O
transcription	O
,	O
as	O
was	O
found	O
in	O
eukaryotic	O
organisms	O
.	O

The	O
assumption	O
at	O
this	O
stage	O
in	O
these	O
investigations	O
was	O
that	O
the	O
growth	O
lag	O
observed	O
in	O
cultures	O
exposed	O
to	O
Table	O
2	O
.	O

Amino	O
acid	O
sequence	O
analysis	O
.	O

Amino	O
acid	O
1	O
10	O
20	O
30	O
Cyanobacteria	O
T	O
S	O
T	O
T	O
L	O
V	O
K	O
C	O
A	O
C	O
E	O
P	O
C	O
L	O
C	O
N	O
V	O
D	O
P	O
S	O
K	O
A	O
I	O
D	O
R	O
N	O
G	O
L	O
Y	O
Y	O
Scylla	O
P	O
DP	O
C	O
C	O
NDK	O
C	O
DC	O
K	O
EG	O
EC	O
KT	O
GC	O
K	O
CT	O
S	O
C	O
Human	B
Ac	O
MD	O
P	O
NC	O
S	O
C	O
AA	O
G	O
DS	O
CT	O
C	O
AG	O
S	O
C	O
KC	O
KE	O
C	O
KC	O
T	O
S	O
C	O
Neurospora	O
G	O
D	O
C	O
G	O
C	O
S	O
G	O
A	O
S	O
S	O
C	O
N	O
C	O
G	O
S	O
G	O
C	O
S	O
C	O
S	O
N	O
C	O
G	O
S	O
K	O
Table	O
2	O
.	O

Continued	O
.	O

Amino	O
acid	O
40	O
50	O
60	O
C	O
C	O
EAC	O
A	O
H	O
GHT	O
G	O
G	O
R	O
CP	O
PC	O
EQ	O
C	O
S	O
SGC	O
K	O
CA	O
NK	O
E	O
DC	O
RK	O
TC	O
SK	O
PC	O
SCC	O
P	O
K	O
K	O
SCC	O
S	O
CCP	O
V	O
GC	O
A	O
KCA	O
Q	O
BC	O
I	O
C	O
K	O
GA	O
SDK	O
C	O
S	O
CC	O
A	O
74	O
I	O
II	O
I	O
I	O
CYANOBACTERIAL	B
METALLOTHIONEINS	O
75	O
cadmium	O
or	O
zinc	O
was	O
due	O
to	O
a	O
rather	O
protracted	O
time	O
of	O
MT	O
induction	O
,	O
perhaps	O
associated	O
with	O
toxic	O
burden	O
.	O

If	O
the	O
above	O
cadmium	O
-	O
resistant	O
cells	O
were	O
transferred	O
into	O
fresh	O
media	O
in	O
the	O
absence	O
of	O
cadmium	O
and	O
allowed	O
to	O
grow	O
up	O
between	O
three	O
successive	O
transfers	O
,	O
levels	O
of	O
MT	O
dropped	O
to	O
near	O
basal	O
values	O
as	O
synthesis	O
was	O
repressed	O
in	O
the	O
absence	O
of	O
metal	O
.	O

However	O
,	O
when	O
these	O
cells	O
were	O
now	O
transferred	O
into	O
cadmium	O
-	O
containing	O
media	O
,	O
instead	O
of	O
the	O
predicted	O
growth	O
lag	O
,	O
they	O
grew	O
immediately	O
.	O

Thus	O
,	O
these	O
cells	O
were	O
truly	O
cadmium	O
resistant	O
.	O

Since	O
50	O
tubes	O
of	O
wild	O
-	O
type	O
cells	O
at	O
a	O
dilution	O
of	O
104	O
grew	O
,	O
after	O
the	O
usual	O
lag	O
on	O
exposure	O
to	O
cadmium	O
-	O
containing	O
media	O
,	O
the	O
acquisition	O
of	O
cadmium	O
resistance	O
in	O
this	O
strain	O
of	O
Synechococcus	O
was	O
therefore	O
considered	O
unlikely	O
to	O
be	O
related	O
to	O
a	O
chromosomal	O
mutational	O
event	O
.	O

Such	O
a	O
mutation	O
frequency	O
would	O
be	O
unreasonably	O
high	O
.	O

Although	O
no	O
direct	O
evidence	O
exists	O
at	O
this	O
time	O
,	O
this	O
metal	O
resistance	O
phenomenon	O
is	O
best	O
explained	O
by	O
the	O
amplification	O
of	O
an	O
extrachromosomal	O
gene	O
,	O
especially	O
since	O
this	O
strain	O
is	O
known	O
to	O
have	O
plasmids	O
.	O

Structure	O
of	O
Cyanobacterial	O
MT	O
The	O
structural	O
determination	O
of	O
cyanobacterial	B
MT	O
is	O
not	O
yet	O
complete	O
,	O
although	O
a	O
substantial	O
amount	O
of	O
information	O
is	O
now	O
known	O
.	O

For	O
example	O
,	O
Table	O
1	O
compares	O
the	O
amino	O
acid	O
composition	O
of	O
a	O
Synechococcus	B
TX-20	I
isoprotein	O
with	O
two	O
eukaryotic	O
MTs	O
.	O

These	O
data	O
indicate	O
that	O
the	O
bacterial	O
form	O
is	O
unique	O
.	O

While	O
cysteine	O
was	O
still	O
the	O
predominant	O
amino	O
acid	O
in	O
this	O
protein	O
,	O
levels	O
of	O
the	O
amino	O
acid	O
were	O
half	O
that	O
seen	O
in	O
the	O
eukaryotes	O
.	O

In	O
addition	O
,	O
the	O
bacterial	O
protein	O
had	O
two	O
tyrosines	O
,	O
three	O
histidines	O
,	O
and	O
five	O
long	O
-	O
chain	O
aliphatics	O
-	O
all	O
residues	O
rarely	O
found	O
in	O
eukaryotic	O
MTs	O
.	O

Thus	O
,	O
the	O
amino	O
acid	O
composition	O
indicates	O
that	O
prokaryotic	O
MTs	O
are	O
not	O
as	O
structurally	O
homologous	O
with	O
eukaryotes	O
as	O
they	O
are	O
physiologically	O
homologous	O
.	O

This	O
was	O
further	O
exemplified	O
on	O
amino	O
terminal	O
amino	O
acid	O
sequence	O
analysis	O
(	O
12	O
)	O
.	O

With	O
the	O
exception	O
of	O
the	O
typical	O
Cys	O
-	O
X	O
-	O
Cys	O
sequences	O
,	O
the	O
first	O
42	O
residues	O
of	O
the	O
prokaryotic	O
MT	O
were	O
essentially	O
without	O
homology	O
on	O
comparison	O
with	O
the	O
crab	B
(	O
Scylla	B
)	O
,	O
human	B
,	O
or	O
Neurospora	B
crassa	I
MTs	O
(	O
Table	O
2	O
)	O
.	O

Of	O
the	O
above	O
-	O
mentioned	O
uncommon	O
MT	O
residues	O
,	O
two	O
tyrosines	O
were	O
found	O
together	O
in	O
positions	O
29	O
and	O
30	O
,	O
all	O
five	O
of	O
the	O
long	O
-	O
chain	O
aliphatic	O
amino	O
acids	O
were	O
located	O
in	O
the	O
first	O
28	O
residues	O
,	O
and	O
two	O
histidines	O
were	O
situated	O
at	O
positions	O
37	O
and	O
39	O
.	O

Perhaps	O
of	O
greater	O
interest	O
was	O
the	O
complete	O
lack	O
of	O
association	O
of	O
basic	O
residues	O
or	O
hydroxylated	O
residues	O
with	O
cysteines	O
,	O
as	O
is	O
found	O
in	O
eukaryotes	O
(	O
11	O
)	O
.	O

Instead	O
,	O
a	O
block	O
of	O
four	O
hydroxylated	O
amino	O
acids	O
was	O
found	O
at	O
the	O
amino	O
terminus	O
.	O

The	O
sequence	O
of	O
this	O
unique	O
MT	O
is	O
now	O
nearing	O
completion	O
,	O
opening	O
the	O
way	O
for	O
an	O
X	O
-	O
ray	O
crystallographic	O
investigation	O
.	O

However	O
,	O
the	O
degree	O
of	O
similarity	O
between	O
the	O
metal	O
cluster	O
arrangement	O
of	O
these	O
bacterial	O
molecules	O
with	O
the	O
eukaryotic	O
structures	O
will	O
initially	O
be	O
undertaken	O
spectroscopically	O
.	O

Reliable	O
interpretation	O
of	O
the	O
113Cd	O
-	O
NMR	O
data	O
for	O
this	O
molecule	O
will	O
be	O
dependent	O
upon	O
adequate	O
isolation	O
of	O
isoproteins	O
using	O
RP	O
-	O
HPLC	O
and	O
assessment	O
of	O
conformational	O
integrity	O
of	O
metal	O
reconstituted	O
molecules	O
,	O
using	O
procedures	O
such	O
as	O
cyclic	O
voltametry	O
.	O

Studies	O
along	O
these	O
lines	O
are	O
presently	O
underway	O
in	O
this	O
laboratory	O
The	O
author	O
gratefully	O
acknowledges	O
the	O
financial	O
support	O
of	O
the	O
Australian	O
Institute	O
of	O
Marine	O
Science	O
and	O
the	O
National	O
Science	O
and	O
Engineering	O
Research	O
Council	O
of	O
Canada	O
.	O

Excellent	O
technical	O
assistance	O
was	O
provided	O
by	O
R.	O
G.	O
Sim	O
and	O
S.	O
Kielland	O
in	O
carrying	O
out	O
the	O
polarographic	O
and	O
sequence	O
analyses	O
,	O
respectively	O
.	O

REFERENCES	O
1	O
.	O

Kagi	O
,	O
J.	O
H.	O
R.	O
,	O
and	O
Nordberg	O
,	O
M.	O
(	O
Eds	O
.	O
)	O
.	O

Metallothionein	O
.	O

Birk	O
hauser	O
Verlag	O
,	O
Basel	O
,	O
1979	O
,	O
pp	O
.	O

5	O
-	O
55	O
.	O

2	O
.	O

Olafson	O
,	O
R.	O
W	O
Differential	O
pulse	O
polarographic	O
determination	O
of	O
murine	O
metallothionein	O
induction	O
kinetics	O
.	O

J.	O
Biol	O
.	O

Chem	O
.	O

256:12631268	O
(	O
1981	O
)	O
.	O

3	O
.	O

Olafson	O
,	O
R.	O
W	O
Intestinal	O
metallothionein	O
:	O
effect	O
of	O
parenteral	O
and	O
enteral	O
zinc	O
exposure	O
on	O
tissue	O
levels	O
of	O
mice	B
on	O
controlled	O
zinc	O
diets	O
.	O

J.	O
Nutr	O
.	O

113	O
:	O
268	O
-	O
275	O
(	O
1983	O
)	O
.	O

4	O
.	O

McCarter	O
,	O
J.A.	O
,	O
and	O
Roch	O
,	O
M.	O
Chronic	O
exposure	O
of	O
Coho	B
salmon	I
to	O
sublethal	O
concentrations	O
of	O
copper	O
.	O

III	O
.	O

Kinetics	O
of	O
metabolism	O
of	O
metallothionein	O
.	O

Comp	O
.	O

Biochem	O
.	O

Physiol	O
.	O

77C	O
:	O
83	O
-	O
87	O
(	O
1984	O
)	O
.	O

5	O
.	O

Lerch	O
,	O
K.	O
,	O
Ammer	O
,	O
D.	O
,	O
and	O
Olafson	O
,	O
R.	O
W	O
Crab	O
metallothionein	O
primary	O
structures	O
of	O
metallothioneins	O
1	O
and	O
2	O
.	O

J.	O
Biol	O
.	O

Chem	O
.	O

257	O
:	O
2420	O
-	O
2426	O
(	O
1982	O
)	O
.	O

6	O
.	O

Otvos	O
,	O
J.	O
D.	O
,	O
Olafson	O
,	O
R.W	O
,	O
and	O
Armitage	O
,	O
I.	O
M.	O
Structure	O
of	O
an	O
invertebrate	O
metallothionein	O
from	O
Scylla	B
serrata	I
.	O

J.	O
Biol	O
.	O

Chem	O
.	O

257	O
:	O
2427	O
-	O
2431	O
(	O
1982	O
)	O
.	O

7	O
.	O

Olafson	O
,	O
R.	O
W	O
,	O
Abel	O
,	O
K.	O
,	O
and	O
Sim	O
,	O
R.	O
G.	O
Prokaryotic	O
metallothi	O
onein	O
:	O
preliminary	O
characteristics	O
of	O
a	O
blue	O
-	O
green	O
alga	O
heavy	O
metalbinding	O
protein	O
.	O

Biochem	O
.	O

Biophys	O
.	O

Res	O
.	O

Commun	O
.	O

89	O
:	O
36	O
-	O
40	O
(	O
1979	O
)	O
.	O

8	O
.	O

Olafson	O
,	O
R.	O
W	O
,	O
Loya	O
,	O
S.	O
,	O
and	O
Sim	O
,	O
R.	O
G.	O
Physiological	O
parameters	O
of	O
prokaryotic	O
metallothionein	O
induction	O
.	O

Biochem	O
.	O

Biophys	O
.	O

Res	O
.	O

Commun	O
.	O

95	O
:	O
1495	O
-	O
1503	O
(	O
1980	O
)	O
.	O

9	O
.	O

Brdicka	O
,	O
R.	O
Pblarographic	O
studies	O
with	O
the	O
dropping	O
mercury	O
ka	O
thode	O
.-	O
Part	O
XXXI	O
.-	O
A	O
new	O
test	O
for	O
proteins	O
in	O
the	O
presence	O
of	O
cobalt	O
salts	O
in	O
ammoniacal	O
solutions	O
of	O
ammonium	O
chloride	O
.	O

Collect	O
.	O

Czech	O
.	O

Chem	O
.	O

Commun	O
.	O

5	O
:	O
112	O
-	O
128	O
(	O
1933	O
)	O
.	O

10	O
.	O

Olafson	O
,	O
R.	O
W	O
,	O
and	O
Sim	O
,	O
R.	O
G.	O
An	O
electrochemical	O
approach	O
to	O
quantitation	O
and	O
characterization	O
of	O
metallothionein	O
.	O

Anal	O
.	O

Biochem	O
.	O

100	O
:	O
343	O
-	O
351	O
(	O
1979	O
)	O
.	O

11	O
.	O

Olafson	O
,	O
R.	O
W	O
Differential	O
pulse	O
polarographic	O
determination	O
of	O
murine	O
metallothionein	O
induction	O
kinetics	O
.	O

J.	O
Biol	O
.	O

Chem	O
.	O

256	O
:	O
12631268	O
(	O
1981	O
)	O
.	O

12	O
.	O

Olafson	O
,	O
R.	O
W	O
Prokaryotic	O
metallothionein	O
:	O
amino	O
terminal	O
se	O
quence	O
analysis	O
of	O
a	O
unique	O
metallothionein	O
.	O

Int	O
.	O

J.	O
Peptide	O
Protein	O
Res	O
.	O

24	O
:	O
303	O
-	O
308	O
(	O
1984	O
)	O
.	O

Drug	O
information	O
resources	O
used	O
by	O
nurse	O
practitioners	O
and	O
collaborating	O
physicians	O
at	O
the	O
point	O
of	O
care	O
in	O
Nova	O
Scotia	O
,	O
Canada	O
:	O
a	O
survey	O
and	O
review	O
of	O
the	O
literature	O
Abstract	O
Background	O
Keeping	O
current	O
with	O
drug	O
therapy	O
information	O
is	O
challenging	O
for	O
health	O
care	O
practitioners	O
.	O

Technologies	O
are	O
often	O
implemented	O
to	O
facilitate	O
access	O
to	O
current	O
and	O
credible	O
drug	O
information	O
sources	O
.	O

In	O
the	O
Canadian	O
province	O
of	O
Nova	O
Scotia	O
,	O
legislation	O
was	O
passed	O
in	O
2002	O
to	O
allow	O
nurse	O
practitioners	O
(	O
NPs	O
)	O
to	O
practice	O
collaboratively	O
with	O
physician	O
partners	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
current	O
utilization	O
patterns	O
of	O
information	O
technologies	O
by	O
these	O
groups	O
of	O
practitioners	O
.	O

Methods	O
Nurse	O
practitioners	O
and	O
their	O
collaborating	O
physician	O
partners	O
in	O
Nova	O
Scotia	O
were	O
sent	O
a	O
survey	O
in	O
February	O
2005	O
to	O
determine	O
the	O
frequency	O
of	O
use	O
,	O
usefulness	O
,	O
accessibility	O
,	O
credibility	O
,	O
and	O
current	O
/	O
timeliness	O
of	O
personal	O
digital	O
assistant	O
(	O
PDA	O
)	O
,	O
computer	O
,	O
and	O
print	O
drug	O
information	O
resources	O
.	O

Two	O
surveys	O
were	O
developed	O
(	O
one	O
for	O
PDA	O
users	O
and	O
one	O
for	O
computer	O
users	O
)	O
and	O
revised	O
based	O
on	O
a	O
literature	O
search	O
,	O
stakeholder	O
consultation	O
,	O
and	O
pilot	O
-	O
testing	O
results	O
.	O

A	O
second	O
distribution	O
to	O
nonresponders	O
occurred	O
two	O
weeks	O
following	O
the	O
first	O
.	O

Data	O
were	O
entered	O
and	O
analysed	O
with	O
SPSS	O
.	O

Results	O
Twenty	O
-	O
seven	O
(	O
14	O
NPs	O
and	O
13	O
physicians	O
)	O
of	O
36	O
(	O
75	O
%	O
)	O
recipients	O
responded	O
.	O

22	O
%	O
(	O
6	O
)	O
returned	O
personal	O
digital	O
assistant	O
(	O
PDA	O
)	O
surveys	O
.	O

Respondents	O
reported	O
print	O
,	O
health	O
professionals	O
,	O
and	O
online	O
/	O
electronic	O
resources	O
as	O
the	O
most	O
to	O
least	O
preferred	O
means	O
to	O
access	O
drug	O
information	O
,	O
respectively	O
.	O

37	O
%	O
and	O
35	O
%	O
of	O
respondents	O
reported	O
using	O
"	O
both	O
print	O
and	O
electronic	O
but	O
print	O
more	O
than	O
electronic	O
"	O
and	O
"	O
print	O
only	O
"	O
,	O
respectively	O
,	O
to	O
search	O
monograph	O
-	O
related	O
drug	O
information	O
queries	O
whereas	O
4	O
%	O
reported	O
using	O
"	O
PDA	O
only	O
"	O
.	O

Analysis	O
of	O
respondent	O
ratings	O
for	O
all	O
resources	O
in	O
the	O
categories	O
print	O
,	O
health	O
professionals	O
and	O
other	O
,	O
and	O
online	O
/	O
electronic	O
resources	O
,	O
indicated	O
that	O
the	O
Compendium	O
of	O
Pharmaceuticals	O
and	O
Specialties	O
and	O
pharmacists	O
ranked	O
highly	O
for	O
frequency	O
of	O
use	O
,	O
usefulness	O
,	O
accessibility	O
,	O
credibility	O
,	O
and	O
current	O
/	O
timeliness	O
by	O
both	O
groups	O
of	O
practitioners	O
.	O

Respondents	O
'	O
preferences	O
and	O
resource	O
ratings	O
were	O
consistent	O
with	O
self	O
-	O
reported	O
methods	O
for	O
conducting	O
drug	O
information	O
queries	O
.	O

Few	O
differences	O
existed	O
between	O
NP	O
and	O
physician	O
rankings	O
of	O
resources	O
.	O

Conclusion	O
The	O
use	O
of	O
computers	O
and	O
PDAs	O
remains	O
limited	O
,	O
which	O
is	O
also	O
consistent	O
with	O
preferred	O
and	O
frequent	O
use	O
of	O
print	O
resources	O
.	O

Education	O
for	O
these	O
practitioners	O
regarding	O
available	O
electronic	O
drug	O
information	O
resources	O
may	O
facilitate	O
future	O
computer	O
and	O
PDA	O
use	O
.	O

Further	O
research	O
is	O
needed	O
to	O
determine	O
methods	O
to	O
increase	O
computer	O
and	O
PDA	O
use	O
and	O
whether	O
these	O
technologies	O
affect	O
prescribing	O
and	O
patient	O
outcomes	O
.	O

Background	O
Challenges	O
with	O
knowledge	O
management	O
for	O
health	O
care	O
professionals	O
In	O
1986	O
,	O
Haynes	O
et	O
al.	O
published	O
a	O
series	O
of	O
6	O
articles	O
entitled	O
"	O
how	O
to	O
keep	O
up	O
with	O
the	O
medical	O
literature	O
"	O
in	O
an	O
effort	O
to	O
help	O
clinicians	O
with	O
information	O
management	O
,	O
but	O
this	O
challenge	O
has	O
not	O
decreased	O
in	O
last	O
two	O
decades	O
[	O
1	O
-	O
6	O
]	O
.	O

Alper	O
et	O
al.	O
suggest	O
that	O
maintaining	O
currency	O
with	O
relevant	O
literature	O
in	O
primary	O
care	O
would	O
"	O
require	O
627.5	O
hours	O
per	O
month	O
,	O
or	O
about	O
29	O
hours	O
per	O
weekday	O
,	O
or	O
3.6	O
full	O
-	O
time	O
equivalents	O
of	O
physician	O
effort	O
"	O
[	O
7	O
]	O
.	O

The	O
volume	O
of	O
information	O
associated	O
with	O
keeping	O
up	O
to	O
date	O
is	O
frequently	O
cited	O
as	O
a	O
barrier	O
[	O
8	O
]	O
.	O

It	O
is	O
estimated	O
that	O
annually	O
there	O
are	O
approximately	O
10,000	O
new	O
randomized	O
trials	O
in	O
MEDLINE	O
and	O
over	O
450,000	O
clinical	O
trials	O
identified	O
by	O
the	O
Cochrane	O
Collaboration	O
[	O
9,10	O
]	O
.	O

Keeping	O
up	O
to	O
date	O
has	O
been	O
described	O
with	O
several	O
analogies	O
including	O
clinicians	O
attempting	O
to	O
drink	O
water	O
from	O
a	O
fire	O
hose	O
and	O
swimming	O
in	O
rivers	O
of	O
clinical	O
research	O
with	O
unprecedented	O
depth	O
,	O
velocity	O
,	O
and	O
turbulence	O
[	O
11,12	O
]	O
.	O

Difficulties	O
with	O
dissemination	O
of	O
research	O
evidence	O
and	O
keeping	O
up	O
to	O
date	O
on	O
pharmacotherapeutic	O
interventions	O
are	O
reported	O
despite	O
the	O
development	O
of	O
tools	O
such	O
as	O
clinical	O
practice	O
guidelines	O
and	O
systematic	O
reviews	O
that	O
are	O
intended	O
to	O
reduce	O
the	O
need	O
for	O
practitioners	O
to	O
evaluate	O
original	O
research	O
[	O
13	O
]	O
.	O

To	O
complicate	O
matters	O
further	O
,	O
there	O
are	O
often	O
issues	O
of	O
credibility	O
,	O
timeliness	O
,	O
and	O
volume	O
of	O
clinical	O
practice	O
guidelines	O
and	O
reviews	O
.	O

Many	O
guidelines	O
are	O
criticized	O
for	O
their	O
methodological	O
development	O
.	O

Shaneyfelt	O
et	O
al.	O
reviewed	O
279	O
guidelines	O
for	O
methodological	O
standards	O
from	O
peer	O
reviewed	O
medical	O
literature	O
[	O
14	O
]	O
.	O

These	O
authors	O
found	O
that	O
only	O
51	O
%	O
,	O
33.6	O
%	O
,	O
and	O
46	O
%	O
adhered	O
to	O
standards	O
on	O
guideline	O
development	O
and	O
format	O
,	O
evidence	O
identification	O
and	O
summary	O
,	O
and	O
formulation	O
of	O
recommendations	O
,	O
respectively	O
[	O
14	O
]	O
.	O

A	O
Canadian	O
review	O
on	O
drug	O
therapy	O
guidelines	O
found	O
significant	O
variation	O
in	O
quality	O
depending	O
on	O
the	O
developer	O
[	O
13	O
]	O
.	O

Approximately	O
25	O
%	O
of	O
guidelines	O
were	O
not	O
recommended	O
for	O
use	O
in	O
practice	O
by	O
the	O
appraisers	O
'	O
criteria	O
[	O
13	O
]	O
.	O

As	O
an	O
example	O
of	O
the	O
volume	O
of	O
clinical	O
practice	O
guidelines	O
available	O
,	O
eleven	O
recent	O
guidelines	O
on	O
community	O
acquired	O
pneumonia	O
exist	O
[	O
15	O
]	O
.	O

To	O
add	O
to	O
the	O
complexities	O
involved	O
with	O
keeping	O
current	O
with	O
pharmacotherapeutic	O
management	O
strategies	O
,	O
as	O
of	O
2000	O
,	O
there	O
were	O
over	O
22,000	O
drug	O
products	O
approved	O
for	O
sale	O
in	O
Canada	O
for	O
human	B
use	O
[	O
16	O
]	O
.	O

There	O
is	O
also	O
considerable	O
debate	O
regarding	O
what	O
constitutes	O
"	O
evidence	O
"	O
in	O
practice	O
,	O
which	O
contributes	O
to	O
confusion	O
for	O
clinicians	O
[	O
17,18	O
]	O
.	O

Sim	O
et	O
al.	O
succinctly	O
describe	O
the	O
gap	O
between	O
evidence	O
and	O
action	O
as	O
difficulties	O
with	O
obtaining	O
,	O
systematically	O
reviewing	O
,	O
applying	O
in	O
context	O
,	O
and	O
measuring	O
the	O
outcome	O
following	O
application	O
of	O
evidence	O
[	O
19	O
]	O
.	O

Maintaining	O
competence	O
–	O
nurse	O
practitioners	O
as	O
a	O
new	O
group	O
of	O
prescribers	O
Competencies	O
for	O
nurse	O
practitioners	O
(	O
NPs	O
)	O
on	O
a	O
local	O
and	O
international	O
level	O
include	O
critically	O
appraising	O
and	O
applying	O
literature	O
and	O
research	O
findings	O
in	O
practice	O
[	O
20	O
-	O
23	O
]	O
.	O

The	O
Canadian	O
Nurses	O
Association	O
(	O
CNA	O
)	O
has	O
developed	O
the	O
Canadian	O
Nurse	O
Practitioner	O
Core	O
Competency	O
Framework	O
that	O
describes	O
the	O
knowledge	O
,	O
skills	O
,	O
judgment	O
,	O
and	O
attributes	O
required	O
for	O
practice	O
.	O

Evidence	O
based	O
practice	O
is	O
integral	O
to	O
pharmacotherapeutic	O
interventions	O
and	O
prescribing	O
competencies	O
[	O
23	O
]	O
.	O

The	O
National	O
Prescribing	O
Centre	O
,	O
an	O
organization	O
of	O
the	O
National	O
Health	O
Service	O
in	O
the	O
UK	O
,	O
describes	O
several	O
competencies	O
around	O
information	O
needs	O
relevant	O
to	O
prescribing	O
and	O
emphasis	O
is	O
placed	O
on	O
using	O
relevant	O
and	O
up	O
to	O
date	O
information	O
in	O
various	O
formats	O
(	O
e.g.	O
print	O
,	O
electronic	O
,	O
verbal	O
)	O
.	O

Several	O
related	O
competencies	O
include	O
understanding	O
advantages	O
and	O
disadvantages	O
of	O
information	O
sources	O
and	O
the	O
currency	O
of	O
resources	O
[	O
21	O
]	O
.	O

Researchers	O
in	O
the	O
US	O
developed	O
NP	O
informatics	O
competencies	O
for	O
integration	O
into	O
advanced	O
nursing	O
practice	O
curricula	O
[	O
24	O
]	O
.	O

Competencies	O
related	O
to	O
informatics	O
knowledge	O
include	O
critical	O
analysis	O
of	O
data	O
and	O
information	O
for	O
use	O
in	O
evidence	O
based	O
practice	O
,	O
evaluating	O
and	O
applying	O
relevant	O
information	O
,	O
synthesizing	O
best	O
evidence	O
,	O
and	O
using	O
optimal	O
search	O
strategies	O
to	O
locate	O
clinically	O
sound	O
and	O
useful	O
studies	O
from	O
information	O
resources	O
[	O
24	O
]	O
.	O

Achieving	O
and	O
maintaining	O
competence	O
in	O
these	O
domains	O
as	O
well	O
as	O
a	O
solid	O
foundation	O
in	O
pharmacology	O
is	O
necessary	O
to	O
support	O
NPs	O
in	O
their	O
relatively	O
new	O
role	O
as	O
a	O
prescriber	O
[	O
25	O
-	O
27	O
]	O
.	O

Knowledge	O
management	O
and	O
information	O
seeking	O
behaviours	O
among	O
nurse	O
practitioners	O
and	O
physicians	O
Information	O
seeking	O
behaviours	O
of	O
physicians	O
are	O
better	O
documented	O
than	O
NPs	O
[	O
11	O
]	O
.	O

Information	O
related	O
to	O
diagnosis	O
is	O
important	O
to	O
both	O
groups	O
but	O
drug	O
therapy	O
queries	O
may	O
occur	O
more	O
frequently	O
with	O
NPs	O
[	O
28	O
-	O
33	O
]	O
.	O

Research	O
on	O
nurses	O
'	O
behaviours	O
related	O
to	O
information	O
seeking	O
is	O
available	O
from	O
the	O
hospital	O
setting	O
[	O
33	O
-	O
35	O
]	O
but	O
the	O
generalizability	O
of	O
these	O
behaviours	O
to	O
NPs	O
with	O
a	O
prescribing	O
role	O
is	O
unclear	O
.	O

Differences	O
in	O
nursing	O
roles	O
,	O
responsibilities	O
,	O
and	O
legislation	O
,	O
including	O
prescriptive	O
authority	O
,	O
exist	O
depending	O
on	O
the	O
country	O
of	O
practice	O
.	O

Nurse	O
practitioners	O
and	O
their	O
collaborating	O
physician	O
partners	O
in	O
Nova	O
Scotia	O
Nova	O
Scotia	O
is	O
a	O
Canadian	O
province	O
with	O
a	O
population	O
of	O
approximately	O
942,000	O
[	O
36	O
]	O
.	O

The	O
province	O
is	O
divided	O
into	O
six	O
health	O
zones	O
that	O
include	O
nine	O
district	O
health	O
authorities	O
,	O
one	O
of	O
which	O
includes	O
the	O
provincial	O
capital	O
and	O
is	O
considered	O
to	O
be	O
urban	O
[	O
37,38	O
]	O
.	O

Health	O
care	O
service	O
delivery	O
is	O
challenging	O
due	O
to	O
many	O
factors	O
including	O
the	O
rural	O
nature	O
of	O
the	O
province	O
,	O
which	O
is	O
estimated	O
to	O
be	O
60	O
%	O
of	O
population	O
[	O
37,39	O
]	O
.	O

Starting	O
in	O
1998	O
,	O
the	O
Nova	O
Scotia	O
Department	O
of	O
Health	O
led	O
an	O
initiative	O
to	O
explore	O
different	O
methods	O
of	O
delivering	O
,	O
managing	O
,	O
and	O
funding	O
primary	O
care	O
services	O
.	O

The	O
Strengthening	O
Primary	O
Care	O
in	O
Nova	O
Scotia	O
Communities	O
Initiative	O
(	O
SPCI	O
)	O
was	O
established	O
with	O
the	O
selection	O
of	O
four	O
primary	O
care	O
demonstration	O
sites	O
where	O
a	O
primary	O
health	O
care	O
NP	O
was	O
hired	O
to	O
practice	O
collaboratively	O
with	O
one	O
or	O
more	O
family	O
/	O
general	O
physicians	O
and	O
other	O
members	O
of	O
an	O
interdisciplinary	O
team	O
.	O

Each	O
demonstration	O
site	O
adopted	O
alternative	O
(	O
non	O
fee	O
-	O
for	O
-	O
service	O
)	O
physician	O
payment	O
mechanisms	O
and	O
used	O
electronic	O
patient	O
records	O
(	O
EPRs	O
)	O
to	O
support	O
service	O
delivery	O
[	O
41	O
]	O
.	O

Demonstration	O
sites	O
participated	O
in	O
project	O
evaluation	O
components	O
that	O
included	O
,	O
but	O
were	O
not	O
limited	O
to	O
,	O
NP	O
roles	O
,	O
alternative	O
fee	O
structures	O
,	O
consumer	O
satisfaction	O
,	O
and	O
implementation	O
and	O
integration	O
of	O
EPRs	O
[	O
41,42	O
]	O
.	O

Legislation	O
to	O
allow	O
NPs	O
to	O
practice	O
collaboratively	O
with	O
physicians	O
in	O
Nova	O
Scotia	O
was	O
passed	O
in	O
2002	O
,	O
part	O
way	O
through	O
the	O
SPCI	O
project	O
[	O
39	O
]	O
.	O

Prescriptive	O
authority	O
granted	O
through	O
legislation	O
authorizes	O
NPs	O
to	O
prescribe	O
from	O
a	O
schedule	O
of	O
drugs	O
[	O
43,44	O
]	O
.	O

At	O
the	O
time	O
of	O
conducting	O
this	O
research	O
project	O
,	O
16	O
primary	O
health	O
care	O
NPs	O
were	O
in	O
active	O
practice	O
[	O
43	O
]	O
.	O

The	O
EPR	O
component	O
of	O
the	O
SPCI	O
project	O
evaluation	O
provided	O
information	O
on	O
the	O
use	O
of	O
technologies	O
in	O
the	O
community	O
context	O
.	O

Results	O
from	O
the	O
implementation	O
process	O
indicated	O
that	O
considerable	O
attention	O
is	O
required	O
for	O
technology	O
literacy	O
,	O
time	O
for	O
training	O
,	O
and	O
selection	O
of	O
software	O
for	O
EPRs	O
[	O
41	O
]	O
.	O

Although	O
the	O
majority	O
of	O
community	O
-	O
based	O
,	O
non	O
-	O
institutional	O
clinical	O
practice	O
settings	O
in	O
Nova	O
Scotia	O
primarily	O
operate	O
with	O
paper	O
-	O
based	O
charting	O
systems	O
,	O
there	O
is	O
a	O
movement	O
toward	O
integrating	O
electronic	O
technologies	O
,	O
including	O
the	O
EPR	O
,	O
in	O
practice	O
among	O
health	O
care	O
providers	O
,	O
administrators	O
,	O
and	O
the	O
provincial	O
government	O
.	O

In	O
addition	O
to	O
recording	O
patient	O
visit	O
information	O
,	O
a	O
component	O
of	O
the	O
EPR	O
package	O
serves	O
to	O
provide	O
drug	O
information	O
resources	O
.	O

Drug	O
therapy	O
information	O
resources	O
for	O
NPs	O
and	O
nurse	O
prescribers	O
have	O
frequently	O
been	O
described	O
as	O
essential	O
in	O
supporting	O
practice	O
[	O
25,28,29	O
]	O
.	O

The	O
role	O
of	O
NPs	O
is	O
relatively	O
new	O
in	O
Canada	O
[	O
39	O
]	O
and	O
there	O
is	O
limited	O
information	O
available	O
to	O
indicate	O
the	O
type	O
of	O
resources	O
(	O
e.g.	O
print	O
,	O
electronic	O
,	O
EPR	O
based	O
)	O
these	O
prescribers	O
use	O
for	O
drug	O
and	O
therapeutic	O
information	O
queries	O
at	O
the	O
point	O
of	O
care	O
.	O

It	O
is	O
unknown	O
as	O
to	O
whether	O
differences	O
exist	O
regarding	O
types	O
of	O
resources	O
used	O
,	O
drug	O
information	O
needs	O
,	O
and	O
utilization	O
patterns	O
among	O
NPs	O
and	O
collaborating	O
physician	O
partners	O
.	O

Some	O
research	O
has	O
suggested	O
that	O
the	O
degree	O
of	O
multidisciplinary	O
team	O
functioning	O
relates	O
to	O
the	O
adoption	O
of	O
technology	O
or	O
innovations	O
in	O
practice	O
but	O
more	O
research	O
is	O
required	O
to	O
determine	O
the	O
extent	O
of	O
these	O
relationships	O
[	O
45,46	O
]	O
.	O

The	O
use	O
of	O
EPR	O
technology	O
is	O
increasing	O
in	O
Nova	O
Scotia	O
but	O
little	O
information	O
is	O
available	O
regarding	O
the	O
readiness	O
of	O
practitioners	O
for	O
use	O
of	O
specific	O
features	O
such	O
as	O
drug	O
information	O
resources	O
.	O

Based	O
on	O
the	O
EPR	O
related	O
results	O
of	O
the	O
SPCI	O
evaluation	O
,	O
use	O
of	O
these	O
functions	O
could	O
be	O
challenging	O
without	O
proper	O
facilitation	O
.	O

The	O
purpose	O
of	O
the	O
survey	O
for	O
this	O
research	O
was	O
to	O
describe	O
drug	O
information	O
resources	O
used	O
by	O
NPs	O
and	O
their	O
collaborating	O
physician	O
partners	O
at	O
the	O
point	O
of	O
care	O
.	O

The	O
results	O
of	O
the	O
survey	O
will	O
be	O
used	O
to	O
guide	O
further	O
technology	O
implementation	O
strategies	O
and	O
stimulate	O
further	O
discussion	O
around	O
drug	O
information	O
resource	O
usage	O
at	O
the	O
point	O
of	O
care	O
.	O

Methods	O
Survey	O
development	O
Survey	O
development	O
involved	O
three	O
stages	O
including	O
identification	O
of	O
important	O
content	O
areas	O
,	O
development	O
of	O
draft	O
questions	O
,	O
and	O
survey	O
refinement	O
.	O

Identifying	O
important	O
content	O
areas	O
for	O
inclusion	O
in	O
the	O
survey	O
involved	O
conducting	O
a	O
comprehensive	O
English	O
language	O
literature	O
search	O
,	O
consultation	O
with	O
relevant	O
stakeholders	O
(	O
e.g.	O
members	O
of	O
the	O
Nova	O
Scotia	O
Department	O
of	O
Health	O
)	O
,	O
and	O
input	O
from	O
subject	O
matter	O
experts	O
at	O
Dalhousie	O
University	O
.	O

The	O
literature	O
review	O
was	O
conducted	O
using	O
the	O
following	O
bibliographic	O
databases	O
:	O
PubMed	O
,	O
Cumulative	O
Index	O
to	O
Nursing	O
and	O
Allied	O
Health	O
Literature	O
(	O
CINAHL	O
)	O
,	O
International	O
Pharmaceutical	O
Abstracts	O
(	O
IPA	O
)	O
,	O
and	O
Web	O
of	O
Science	O
Citation	O
Databases	O
.	O

Hand	O
and	O
electronic	O
searching	O
of	O
relevant	O
journals	O
was	O
also	O
conducted	O
.	O

Broad	O
search	O
terms	O
were	O
used	O
without	O
limits	O
on	O
publication	O
date	O
or	O
place	O
as	O
nurse	O
practitioner	O
titles	O
,	O
roles	O
and	O
scopes	O
of	O
practice	O
,	O
and	O
terminology	O
regarding	O
technology	O
vary	O
nationally	O
and	O
internationally	O
.	O

Some	O
examples	O
of	O
terms	O
used	O
included	O
nurse	O
practitioner	O
,	O
nurse	O
prescriber	O
,	O
nurse	O
clinicians	O
,	O
district	O
nurse	O
,	O
health	O
visitor	O
,	O
drug	O
information	O
resources	O
,	O
drug	O
information	O
services	O
,	O
information	O
needs	O
,	O
and	O
information	O
technology	O
.	O

The	O
draft	O
survey	O
was	O
reviewed	O
by	O
the	O
research	O
team	O
to	O
reduce	O
the	O
number	O
of	O
items	O
and	O
improve	O
clarity	O
.	O

The	O
layout	O
of	O
the	O
questionnaire	O
was	O
carefully	O
examined	O
to	O
ensure	O
that	O
it	O
was	O
easy	O
to	O
follow	O
and	O
complete	O
.	O

Research	O
results	O
from	O
a	O
previous	O
investigation	O
of	O
Nova	O
Scotian	O
physicians	O
'	O
behaviours	O
regarding	O
drug	O
information	O
were	O
also	O
used	O
to	O
further	O
revise	O
the	O
survey	O
[	O
47	O
]	O
.	O

This	O
draft	O
questionnaire	O
was	O
pilot	O
tested	O
by	O
two	O
out	O
of	O
province	O
NPs	O
and	O
one	O
physician	O
.	O

The	O
results	O
of	O
the	O
pilot	O
were	O
used	O
to	O
make	O
final	O
revisions	O
to	O
the	O
survey	O
.	O

Based	O
on	O
pilot	O
-	O
testing	O
feedback	O
and	O
investigator	O
consensus	O
,	O
the	O
final	O
survey	O
was	O
divided	O
into	O
2	O
versions	O
,	O
one	O
for	O
personal	O
digital	O
assistant	O
(	O
PDA	O
)	O
users	O
and	O
one	O
for	O
computer	O
users	O
.	O

The	O
10	O
page	O
surveys	O
for	O
PDA	O
and	O
computer	O
users	O
had	O
5	O
or	O
6	O
sections	O
,	O
respectively	O
,	O
and	O
37	O
questions	O
,	O
many	O
with	O
multiple	O
parts	O
.	O

The	O
survey	O
content	O
included	O
demographics	O
,	O
computer	O
or	O
PDA	O
use	O
and	O
experience	O
,	O
drug	O
and	O
therapeutic	O
resource	O
use	O
and	O
preferences	O
,	O
PDA	O
future	O
use	O
,	O
perceived	O
barriers	O
and	O
facilitators	O
to	O
PDA	O
use	O
,	O
and	O
technology	O
training	O
preferences	O
.	O

Section	O
one	O
contained	O
demographic	O
questions	O
such	O
as	O
gender	O
,	O
age	O
,	O
job	O
title	O
,	O
volume	O
of	O
patients	O
,	O
and	O
EPR	O
availability	O
in	O
the	O
practice	O
setting	O
.	O

Section	O
two	O
was	O
designed	O
to	O
determine	O
PDA	O
or	O
computer	O
use	O
and	O
experience	O
in	O
the	O
practice	O
setting	O
with	O
questions	O
regarding	O
length	O
of	O
use	O
,	O
costs	O
,	O
and	O
work	O
versus	O
home	O
usage	O
.	O

This	O
section	O
also	O
addressed	O
usage	O
and	O
rating	O
of	O
different	O
drug	O
information	O
resources	O
.	O

Resource	O
ratings	O
were	O
based	O
on	O
the	O
frequency	O
of	O
usage	O
,	O
usefulness	O
,	O
accessibility	O
,	O
credibility	O
,	O
and	O
current	O
/	O
timeliness	O
.	O

Resources	O
were	O
grouped	O
as	O
print	O
(	O
i.e.	O
books	O
,	O
journals	O
,	O
and	O
clinical	O
practice	O
guidelines	O
)	O
,	O
online	O
/	O
electronic	O
resources	O
,	O
and	O
health	O
professionals	O
and	O
other	O
.	O

Respondents	O
used	O
5-point	O
Likert	O
scales	O
(	O
strongly	O
agree	O
to	O
strongly	O
disagree	O
)	O
for	O
rating	O
opinions	O
related	O
to	O
resources	O
.	O

A	O
rating	O
of	O
6	O
(	O
not	O
applicable	O
,	O
I	O
do	O
not	O
use	O
this	O
resource	O
)	O
was	O
also	O
included	O
for	O
respondents	O
who	O
did	O
not	O
use	O
a	O
particular	O
resource	O
.	O

Frequency	O
of	O
searching	O
for	O
specific	O
information	O
was	O
rated	O
on	O
a	O
3-point	O
Likert	O
scale	O
(	O
frequently	O
to	O
never	O
)	O
.	O

The	O
final	O
sections	O
of	O
the	O
survey	O
included	O
categorical	O
,	O
open	O
-	O
ended	O
,	O
and	O
Likert	O
scale	O
questions	O
regarding	O
preferred	O
resources	O
,	O
technology	O
barriers	O
,	O
PDA	O
future	O
use	O
,	O
and	O
technology	O
training	O
preferences	O
.	O

Copies	O
of	O
the	O
surveys	O
are	O
attached	O
as	O
an	O
appendix	O
in	O
PDF	O
format	O
[	O
see	O
additional	O
file	O
1	O
and	O
2	O
]	O
or	O
can	O
also	O
be	O
accessed	O
from	O
the	O
Initiative	O
for	O
Medication	O
Management	O
,	O
Policy	O
Analysis	O
,	O
Research	O
&	O
Training	O
(	O
IMPART	O
)	O
website	O
[	O
48	O
]	O
.	O

Ethics	O
approval	O
for	O
the	O
survey	O
was	O
granted	O
through	O
Dalhousie	O
University	O
Research	O
Ethics	O
Board	O
on	O
February	O
3	O
,	O
2005	O
.	O

Survey	O
population	O
Licensed	O
,	O
actively	O
practicing	O
,	O
primary	O
health	O
care	O
NPs	O
(	O
n	O
=	O
16	O
)	O
and	O
their	O
collaborating	O
physician	O
partners	O
(	O
n	O
=	O
21	O
)	O
were	O
eligible	O
to	O
participate	O
.	O

Survey	O
procedures	O
The	O
survey	O
recruitment	O
procedures	O
were	O
based	O
on	O
the	O
methods	O
of	O
Dillman	O
[	O
49	O
]	O
and	O
Salant	O
and	O
Dillman	O
[	O
50	O
]	O
.	O

Survey	O
packages	O
contained	O
a	O
cover	O
letter	O
,	O
separate	O
surveys	O
for	O
PDA	O
and	O
computer	O
users	O
,	O
and	O
a	O
return	O
self	O
-	O
addressed	O
stamped	O
envelope	O
.	O

The	O
covering	O
letter	O
instructed	O
respondents	O
to	O
self	O
-	O
select	O
the	O
appropriate	O
survey	O
(	O
either	O
PDA	O
or	O
computer	O
)	O
based	O
on	O
their	O
drug	O
information	O
seeking	O
behaviours	O
.	O

Participants	O
who	O
had	O
used	O
a	O
PDA	O
at	O
any	O
time	O
were	O
instructed	O
to	O
complete	O
the	O
PDA	O
version	O
of	O
the	O
survey	O
.	O

Those	O
who	O
had	O
never	O
used	O
a	O
PDA	O
for	O
drug	O
information	O
were	O
instructed	O
to	O
complete	O
the	O
computer	O
version	O
of	O
the	O
survey	O
.	O

Several	O
strategies	O
were	O
used	O
to	O
optimize	O
response	O
rate	O
and	O
included	O
:	O
personalized	O
cover	O
letters	O
,	O
coloured	O
paper	O
for	O
surveys	O
,	O
stamped	O
return	O
envelopes	O
,	O
follow	O
-	O
up	O
mailing	O
,	O
and	O
a	O
priority	O
post	O
mailing	O
[	O
51	O
]	O
.	O

The	O
covering	O
letter	O
included	O
coloured	O
logos	O
of	O
Dalhousie	O
University	O
and	O
the	O
Nova	O
Scotia	O
Department	O
of	O
Health	O
representing	O
the	O
investigator	O
affiliations	O
and	O
endorsement	O
of	O
the	O
project	O
.	O

A	O
master	O
mailing	O
list	O
with	O
names	O
and	O
addresses	O
of	O
NPs	O
and	O
their	O
collaborating	O
physician	O
partners	O
was	O
created	O
.	O

To	O
maintain	O
confidentiality	O
of	O
respondents	O
,	O
a	O
number	O
placed	O
on	O
the	O
bottom	O
right	O
corner	O
of	O
each	O
survey	O
corresponded	O
to	O
a	O
name	O
on	O
the	O
confidential	O
master	O
mailing	O
sheet	O
.	O

The	O
postage	O
paid	O
return	O
envelopes	O
were	O
addressed	O
to	O
the	O
research	O
coordinator	O
at	O
the	O
School	O
of	O
Nursing	O
,	O
Dalhousie	O
University	O
,	O
who	O
matched	O
respondents	O
to	O
the	O
mailing	O
list	O
from	O
the	O
first	O
distribution	O
.	O

The	O
cross	O
-	O
referenced	O
mailing	O
list	O
was	O
not	O
accessible	O
to	O
those	O
entering	O
or	O
analysing	O
data	O
.	O

The	O
research	O
coordinator	O
sent	O
the	O
second	O
distribution	O
to	O
those	O
who	O
had	O
not	O
initially	O
responded	O
.	O

A	O
fluorescent	O
coloured	O
page	O
was	O
included	O
in	O
the	O
second	O
mailing	O
to	O
notify	O
recipients	O
of	O
the	O
second	O
and	O
final	O
mailing	O
status	O
.	O

The	O
second	O
mailing	O
followed	O
2	O
weeks	O
after	O
the	O
initial	O
mailing	O
(	O
February	O
2005	O
)	O
.	O

The	O
surveys	O
were	O
sent	O
via	O
Xpresspost	O
™	O
through	O
Canada	O
Post	O
.	O

Data	O
analyses	O
Quantitative	O
Data	O
were	O
entered	O
and	O
analysed	O
in	O
Statistical	O
Package	O
for	O
Social	O
Sciences	O
(	O
SPSS	O
)	O
(	O
version	O
11.5	O
for	O
Windows	O
)	O
.	O

Five	O
surveys	O
were	O
randomly	O
selected	O
as	O
a	O
check	O
for	O
accuracy	O
of	O
data	O
entry	O
.	O

Descriptive	O
statistics	O
were	O
used	O
to	O
describe	O
resource	O
usage	O
by	O
practitioners	O
.	O

Chi	O
Square	O
(	O
Fisher	O
's	O
Exact	O
when	O
cell	O
count	O
less	O
than	O
5	O
)	O
analyses	O
were	O
used	O
to	O
determine	O
differences	O
in	O
computer	O
or	O
PDA	O
use	O
based	O
on	O
predetermined	O
variables	O
(	O
e.g.	O
high	O
speed	O
Internet	O
connection	O
,	O
number	O
of	O
patients	O
per	O
day	O
)	O
.	O

Mann	O
Whitney	O
U	O
tests	O
were	O
used	O
to	O
compare	O
physician	O
and	O
NPs	O
Likert	O
scale	O
ratings	O
(	O
1	O
=	O
strongly	O
agree	O
to	O
5	O
=	O
strongly	O
disagree	O
)	O
of	O
resource	O
use	O
.	O

Physician	O
and	O
NP	O
rankings	O
of	O
all	O
resources	O
(	O
print	O
,	O
online	O
/	O
electronic	O
,	O
and	O
health	O
professionals	O
and	O
other	O
)	O
were	O
determined	O
from	O
means	O
of	O
Likert	O
scale	O
ratings	O
(	O
1	O
=	O
strongly	O
agree	O
,	O
5	O
=	O
strongly	O
disagree	O
)	O
for	O
each	O
of	O
the	O
pre	O
-	O
specified	O
characteristics	O
(	O
e.g.	O
frequency	O
of	O
use	O
,	O
accessibility	O
,	O
etc	O
.	O
)	O
and	O
the	O
frequency	O
of	O
use	O
of	O
the	O
resources	O
.	O

The	O
best	O
rankings	O
were	O
assigned	O
for	O
the	O
lowest	O
mean	O
scores	O
and	O
the	O
largest	O
number	O
of	O
the	O
sample	O
using	O
a	O
resource	O
.	O

These	O
rankings	O
(	O
ranks	O
based	O
on	O
mean	O
and	O
ranks	O
based	O
on	O
sample	O
)	O
were	O
then	O
entered	O
into	O
a	O
formula	O
to	O
calculate	O
an	O
overall	O
rank	O
.	O

The	O
formula	O
includes	O
:	O
rank	O
=	O
[	O
(	O
rank	O
according	O
to	O
%	O
of	O
sample	O
using	O
the	O
resource	O
+	O
rank	O
based	O
on	O
mean	O
score	O
)	O
÷	O
2	O
]	O
.	O

This	O
formula	O
was	O
used	O
to	O
account	O
for	O
mean	O
scores	O
based	O
on	O
small	O
samples	O
as	O
these	O
numbers	O
could	O
potentially	O
over	O
or	O
underestimate	O
the	O
value	O
of	O
a	O
resource	O
.	O

Ratings	O
of	O
6	O
(	O
i.e.	O
not	O
applicable	O
,	O
I	O
do	O
not	O
use	O
this	O
resource	O
)	O
were	O
excluded	O
from	O
the	O
analyses	O
.	O

Qualitative	O
Comments	O
were	O
entered	O
in	O
a	O
word	O
-	O
processing	O
program	O
and	O
organized	O
by	O
type	O
of	O
respondent	O
(	O
PDA	O
versus	O
computer	O
)	O
and	O
question	O
number	O
.	O

The	O
coded	O
survey	O
number	O
and	O
respondent	O
type	O
(	O
NP	O
or	O
physician	O
)	O
were	O
also	O
included	O
next	O
to	O
comments	O
.	O

Investigators	O
determined	O
themes	O
and	O
categorized	O
comments	O
based	O
on	O
previous	O
experience	O
,	O
knowledge	O
,	O
and	O
familiarity	O
with	O
the	O
topic	O
.	O

Results	O
Surveys	O
were	O
completed	O
and	O
returned	O
by	O
75	O
%	O
of	O
eligible	O
participants	O
(	O
27	O
of	O
36	O
)	O
.	O

One	O
physician	O
survey	O
was	O
undeliverable	O
.	O

The	O
response	O
rates	O
from	O
within	O
the	O
NP	O
and	O
physician	O
samples	O
were	O
88	O
%	O
and	O
65	O
%	O
,	O
respectively	O
.	O

Complete	O
demographic	O
information	O
is	O
available	O
in	O
Table	O
1	O
.	O

Methods	O
for	O
accessing	O
resources	O
and	O
self	O
-	O
reported	O
resource	O
use	O
Resource	O
use	O
was	O
similar	O
amongst	O
practitioners	O
.	O

Respondents	O
indicated	O
that	O
print	O
resources	O
(	O
mean	O
4.56	O
,	O
SD	O
0.80	O
)	O
,	O
health	O
professionals	O
(	O
mean	O
3.26	O
,	O
SD	O
0.90	O
)	O
,	O
and	O
online	O
/	O
electronic	O
resources	O
(	O
mean	O
2.70	O
,	O
SD	O
1.20	O
)	O
were	O
the	O
preferred	O
method	O
(	O
1	O
=	O
least	O
preferred	O
to	O
5	O
=	O
most	O
preferred	O
)	O
for	O
accessing	O
drug	O
information	O
.	O

Thirty	O
-	O
seven	O
percent	O
of	O
respondents	O
reported	O
that	O
searching	O
for	O
specific	O
questions	O
related	O
to	O
drug	O
information	O
(	O
e.g.	O
usual	O
dosage	O
,	O
duration	O
of	O
therapy	O
)	O
was	O
conducted	O
using	O
both	O
print	O
and	O
electronic	O
resources	O
(	O
but	O
print	O
use	O
greater	O
than	O
electronic	O
)	O
(	O
Table	O
2	O
)	O
.	O

The	O
preferred	O
means	O
(	O
i.e.	O
print	O
)	O
to	O
access	O
resources	O
was	O
consistent	O
with	O
the	O
most	O
common	O
means	O
of	O
conducting	O
searches	O
for	O
specific	O
drug	O
information	O
queries	O
.	O

Respondents	O
'	O
ratings	O
for	O
pre	O
-	O
specified	O
print	O
,	O
online	O
/	O
electronic	O
,	O
and	O
professional	O
resources	O
and	O
other	O
,	O
based	O
on	O
means	O
from	O
Likert	O
scales	O
and	O
number	O
of	O
respondents	O
using	O
the	O
resources	O
,	O
are	O
presented	O
in	O
Tables	O
3	O
,	O
4	O
,	O
and	O
5	O
.	O

Of	O
all	O
resources	O
within	O
the	O
print	O
,	O
online	O
/	O
electronic	O
,	O
and	O
health	O
professionals	O
or	O
other	O
categories	O
,	O
NPs	O
and	O
physicians	O
rated	O
the	O
Compendium	O
of	O
Pharmaceuticals	O
and	O
Specialties	O
(	O
CPS	O
)	O
[	O
52	O
]	O
and	O
pharmacists	O
as	O
the	O
top	O
two	O
most	O
frequently	O
used	O
resources	O
for	O
providing	O
drug	O
and	O
therapeutic	O
information	O
.	O

Physicians	O
rated	O
other	O
physicians	O
as	O
the	O
third	O
most	O
frequently	O
used	O
resource	O
.	O

The	O
book	O
Therapeutic	O
Choices	O
[	O
53	O
]	O
ranked	O
third	O
for	O
NPs	O
.	O

Based	O
on	O
written	O
feedback	O
,	O
physicians	O
and	O
NPs	O
consulted	O
pharmacists	O
and	O
other	O
physicians	O
most	O
frequently	O
.	O

The	O
CPS	O
and	O
pharmacists	O
were	O
also	O
ranked	O
as	O
the	O
top	O
two	O
resources	O
overall	O
in	O
terms	O
of	O
usefulness	O
,	O
accessibility	O
,	O
credibility	O
,	O
and	O
current	O
/	O
timeliness	O
for	O
physicians	O
.	O

Rankings	O
by	O
NPs	O
were	O
similar	O
for	O
usefulness	O
,	O
accessibility	O
,	O
and	O
credibility	O
.	O

NPs	O
ranked	O
pharmacists	O
,	O
Therapeutic	O
Choices	O
,	O
and	O
academic	O
detailing	O
first	O
and	O
the	O
CPS	O
as	O
second	O
for	O
current	O
/	O
timeliness	O
.	O

Within	O
the	O
online	O
/	O
electronic	O
category	O
,	O
electronic	O
clinical	O
practice	O
guidelines	O
(	O
eCPGs	O
)	O
were	O
rated	O
the	O
highest	O
for	O
all	O
characteristics	O
(	O
e.g.	O
usefulness	O
,	O
credibility	O
)	O
.	O

Although	O
eCPGs	O
were	O
highly	O
ranked	O
,	O
approximately	O
30	O
%	O
of	O
the	O
sample	O
reported	O
not	O
using	O
this	O
resource	O
.	O

Other	O
resources	O
in	O
this	O
category	O
were	O
infrequently	O
used	O
based	O
on	O
respondents	O
'	O
self	O
-	O
reports	O
.	O

Pharmaceutical	O
industry	O
representatives	O
were	O
used	O
as	O
a	O
source	O
of	O
drug	O
information	O
by	O
85	O
%	O
and	O
86	O
%	O
of	O
physicians	O
and	O
NPs	O
,	O
respectively	O
(	O
Table	O
5	O
)	O
.	O

This	O
was	O
higher	O
than	O
regional	O
drug	O
information	O
services	O
(	O
used	O
by	O
23	O
%	O
of	O
physicians	O
and	O
50	O
%	O
of	O
NPs	O
)	O
.	O

After	O
exclusion	O
of	O
traditional	O
health	O
professionals	O
(	O
i.e.	O
physicians	O
,	O
nurses	O
,	O
pharmacists	O
,	O
allied	O
health	O
)	O
in	O
the	O
health	O
professionals	O
and	O
other	O
category	O
,	O
pharmaceutical	O
industry	O
representatives	O
received	O
rankings	O
for	O
second	O
or	O
third	O
for	O
frequency	O
of	O
use	O
,	O
usefulness	O
,	O
accessibility	O
,	O
credibility	O
,	O
and	O
current	O
/	O
timeliness	O
,	O
based	O
on	O
means	O
and	O
number	O
of	O
respondents	O
using	O
this	O
resource	O
(	O
data	O
not	O
shown	O
)	O
.	O

Differences	O
between	O
nurse	O
practitioners	O
and	O
physicians	O
A	O
series	O
of	O
Mann	O
Whitney	O
U	O
tests	O
were	O
used	O
to	O
compare	O
the	O
responses	O
of	O
NPs	O
and	O
physicians	O
on	O
their	O
use	O
of	O
print	O
,	O
online	O
/	O
electronic	O
,	O
and	O
health	O
professional	O
resources	O
.	O

In	O
total	O
95	O
statistical	O
tests	O
were	O
conducted	O
.	O

The	O
large	O
number	O
of	O
tests	O
increases	O
the	O
likelihood	O
of	O
a	O
type	O
I	O
error	O
as	O
five	O
significant	O
differences	O
would	O
be	O
expected	O
by	O
chance	O
alone	O
at	O
an	O
alpha	O
threshold	O
of	O
0.05	O
.	O

It	O
is	O
therefore	O
important	O
to	O
treat	O
these	O
results	O
with	O
caution	O
.	O

A	O
limited	O
number	O
of	O
statistically	O
significant	O
(	O
p	O
<	O
0.05	O
)	O
differences	O
were	O
identified	O
between	O
physicians	O
and	O
NPs	O
and	O
are	O
reported	O
in	O
Table	O
6	O
.	O

Therapeutic	O
Choices	O
differed	O
significantly	O
for	O
frequency	O
of	O
use	O
with	O
more	O
NPs	O
making	O
use	O
of	O
this	O
resource	O
.	O

Allied	O
health	O
professionals	O
significantly	O
differed	O
between	O
NPs	O
and	O
physicians	O
for	O
accessibility	O
and	O
current	O
/	O
timeliness	O
while	O
NPs	O
were	O
more	O
in	O
agreement	O
with	O
these	O
characteristics	O
of	O
the	O
resource	O
.	O

Nurse	O
colleague	O
credibility	O
and	O
current	O
/	O
timeliness	O
was	O
rated	O
significantly	O
higher	O
by	O
NPs	O
versus	O
physicians	O
.	O

Factors	O
influencing	O
electronic	O
technology	O
use	O
at	O
the	O
point	O
of	O
care	O
Factors	O
such	O
as	O
gender	O
,	O
age	O
,	O
practitioner	O
type	O
(	O
NP	O
vs	O
physician	O
)	O
,	O
accessibility	O
,	O
technical	O
support	O
,	O
Internet	O
connection	O
speed	O
,	O
patient	O
volume	O
,	O
presence	O
of	O
an	O
EPR	O
,	O
and	O
home	O
computer	O
use	O
were	O
examined	O
to	O
determine	O
if	O
they	O
were	O
associated	O
with	O
the	O
use	O
of	O
a	O
work	O
computer	O
to	O
search	O
for	O
drug	O
information	O
at	O
the	O
point	O
of	O
care	O
.	O

No	O
statistically	O
significant	O
associations	O
were	O
found	O
(	O
Fisher	O
's	O
Exact	O
)	O
.	O

Additional	O
resources	O
from	O
respondent	O
comments	O
Respondents	O
indicated	O
other	O
resources	O
and	O
programs	O
,	O
such	O
as	O
clinical	O
calculators	O
,	O
that	O
they	O
would	O
like	O
to	O
access	O
from	O
their	O
computer	O
or	O
PDA	O
.	O

The	O
top	O
three	O
resources	O
that	O
were	O
desired	O
included	O
Canadian	O
clinical	O
practice	O
guidelines	O
,	O
patient	O
education	O
information	O
,	O
and	O
ability	O
to	O
track	O
clinical	O
activities	O
/	O
statistics	O
.	O

Further	O
comments	O
from	O
two	O
NP	O
computer	O
survey	O
respondents	O
revealed	O
that	O
a	O
resource	O
on	O
drug	O
interactions	O
and	O
dosages	O
would	O
be	O
desired	O
.	O

One	O
other	O
NP	O
also	O
indicated	O
"	O
up	O
to	O
date	O
info	O
[	O
sic	O
]	O
on	O
drugs	O
to	O
treat	O
various	O
illnesses	O
ie	O
doseage	O
[	O
sic	O
]	O
,	O
length	O
of	O
use	O
etc	O
.	O
"	O

Computer	O
or	O
personal	O
digital	O
assistant	O
use	O
in	O
practice	O
Approximately	O
50	O
%	O
of	O
computer	O
survey	O
respondents	O
reported	O
using	O
their	O
work	O
computers	O
for	O
searching	O
drug	O
or	O
therapeutic	O
information	O
related	O
to	O
patient	O
care	O
.	O

Of	O
those	O
respondents	O
,	O
just	O
over	O
half	O
(	O
54	O
%	O
)	O
also	O
reported	O
using	O
their	O
home	O
computer	O
for	O
this	O
purpose	O
.	O

Sixty	O
-	O
seven	O
and	O
17	O
%	O
of	O
PDA	O
survey	O
respondents	O
reported	O
using	O
their	O
PDA	O
for	O
searching	O
drug	O
or	O
therapeutic	O
information	O
related	O
to	O
patient	O
care	O
at	O
work	O
and	O
home	O
,	O
respectively	O
.	O

Searching	O
on	O
a	O
weekly	O
basis	O
for	O
specific	O
information	O
related	O
to	O
drugs	O
Of	O
the	O
24	O
specified	O
categories	O
of	O
drug	O
information	O
included	O
in	O
the	O
survey	O
,	O
the	O
majority	O
were	O
reported	O
as	O
infrequently	O
searched	O
and	O
a	O
smaller	O
percentage	O
as	O
never	O
searched	O
by	O
respondents	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
top	O
three	O
categories	O
rated	O
as	O
frequently	O
searched	O
were	O
side	O
effects	O
,	O
adult	O
or	O
usual	O
drug	O
dosage	O
,	O
and	O
most	O
appropriate	O
drug	O
for	O
an	O
indication	O
.	O

(	O
Table	O
7	O
)	O
Issues	O
related	O
to	O
personal	O
digital	O
assistants	O
Respondents	O
reported	O
their	O
level	O
of	O
agreement	O
with	O
statements	O
related	O
to	O
how	O
PDAs	O
may	O
influence	O
their	O
practice	O
.	O

The	O
statements	O
included	O
aspects	O
of	O
workload	O
(	O
organization	O
and	O
paper	O
work	O
)	O
,	O
convenience	O
,	O
and	O
improving	O
quality	O
of	O
care	O
and	O
patient	O
outcomes	O
.	O

(	O
Table	O
8)	O
Respondents	O
agreed	O
that	O
PDAs	O
are	O
a	O
convenient	O
resource	O
but	O
indicated	O
that	O
PDAs	O
would	O
not	O
decrease	O
paperwork	O
or	O
improve	O
patient	O
health	O
outcomes	O
.	O

Barriers	O
and	O
facilitators	O
to	O
personal	O
digital	O
assistants	O
:	O
themes	O
from	O
written	O
comments	O
Peer	O
support	O
from	O
colleagues	O
,	O
convenience	O
,	O
standardized	O
usage	O
,	O
and	O
financial	O
and	O
technical	O
support	O
were	O
the	O
main	O
perceived	O
facilitators	O
to	O
PDA	O
use	O
reported	O
by	O
respondents	O
.	O

The	O
main	O
perceived	O
barrier	O
to	O
PDA	O
use	O
reported	O
by	O
respondents	O
(	O
n	O
=	O
10	O
)	O
included	O
cost	O
.	O

Other	O
factors	O
such	O
as	O
technology	O
literacy	O
,	O
time	O
,	O
lack	O
of	O
peer	O
support	O
,	O
no	O
high	O
speed	O
internet	O
for	O
downloads	O
,	O
lack	O
of	O
needed	O
resources	O
,	O
keeping	O
up	O
to	O
date	O
on	O
resources	O
,	O
and	O
searching	O
speed	O
were	O
also	O
reported	O
.	O

Future	O
use	O
of	O
personal	O
digital	O
assistants	O
Fifty	O
-	O
two	O
percent	O
,	O
including	O
current	O
PDA	O
users	O
,	O
reported	O
that	O
they	O
would	O
use	O
a	O
PDA	O
in	O
the	O
future	O
.	O

Twenty	O
two	O
percent	O
were	O
uncertain	O
and	O
19	O
%	O
reported	O
that	O
they	O
would	O
not	O
use	O
a	O
PDA	O
in	O
the	O
future	O
.	O

Two	O
people	O
did	O
not	O
respond	O
.	O

Confidentiality	O
Fifty	O
two	O
percent	O
of	O
respondents	O
indicated	O
that	O
patient	O
confidentiality	O
with	O
PDAs	O
was	O
no	O
more	O
concerning	O
compared	O
to	O
use	O
of	O
other	O
technologies	O
.	O

Forty	O
-	O
four	O
percent	O
did	O
not	O
know	O
if	O
they	O
had	O
a	O
policy	O
on	O
patient	O
confidentiality	O
with	O
regard	O
to	O
technologies	O
.	O

Technology	O
training	O
and	O
reimbursement	O
Respondents	O
rated	O
(	O
1	O
=	O
least	O
preferred	O
to	O
5	O
=	O
most	O
preferred	O
)	O
one	O
on	O
one	O
instruction	O
and	O
group	O
learning	O
led	O
by	O
an	O
expert	O
facilitator	O
as	O
the	O
most	O
preferred	O
(	O
mean	O
4.32	O
,	O
SD	O
0.99	O
)	O
means	O
by	O
which	O
to	O
receive	O
instruction	O
on	O
a	O
new	O
technology	O
.	O

Least	O
preferred	O
methods	O
included	O
online	O
discussions	O
/	O
chatrooms	O
(	O
mean	O
1.52	O
,	O
SD	O
1.04	O
)	O
,	O
internet	O
videos	O
(	O
live	O
:	O
mean	O
1.70	O
,	O
SD	O
1.10	O
,	O
or	O
static	O
:	O
mean	O
1.87	O
,	O
SD	O
1.14	O
)	O
,	O
video	O
cassettes	O
(	O
mean	O
2.30	O
,	O
SD	O
1.55	O
)	O
,	O
trial	O
and	O
error	O
learning	O
(	O
mean	O
2.32	O
,	O
SD	O
1.28	O
)	O
,	O
and	O
written	O
manuals	O
(	O
mean	O
2.92	O
,	O
SD	O
1.44	O
)	O
.	O

Paid	O
leave	O
for	O
attendance	O
at	O
technology	O
training	O
sessions	O
was	O
the	O
preferred	O
means	O
(	O
mean	O
1.77	O
,	O
SD	O
0.86	O
;	O
1	O
=	O
strongly	O
agree	O
to	O
5	O
=	O
strongly	O
disagree	O
)	O
of	O
remuneration	O
for	O
respondents	O
.	O

Respondents	O
also	O
indicated	O
that	O
if	O
financial	O
remuneration	O
was	O
to	O
occur	O
,	O
it	O
should	O
correspond	O
to	O
the	O
amount	O
of	O
time	O
for	O
training	O
that	O
is	O
required	O
(	O
versus	O
a	O
flat	O
rate	O
)	O
(	O
mean	O
1.96	O
,	O
SD	O
1.08	O
)	O
.	O

Continuing	O
education	O
credits	O
were	O
not	O
viewed	O
as	O
an	O
incentive	O
(	O
mean	O
2.69	O
,	O
SD	O
1.44	O
)	O
.	O

Discussion	O
Preferred	O
resources	O
In	O
our	O
study	O
,	O
printed	O
materials	O
(	O
e.g.	O
compendia	O
,	O
journals	O
,	O
textbook	O
resources	O
)	O
and	O
professionals	O
(	O
e.g.	O
pharmacists	O
)	O
were	O
the	O
most	O
preferred	O
and	O
frequently	O
used	O
means	O
to	O
access	O
information	O
.	O

Physician	O
reliance	O
on	O
text	O
and	O
compendia	O
relative	O
to	O
online	O
/	O
electronic	O
resources	O
has	O
been	O
frequently	O
reported	O
[	O
11	O
]	O
.	O

In	O
a	O
study	O
examining	O
family	O
doctors	O
'	O
use	O
of	O
information	O
sources	O
to	O
answer	O
clinical	O
questions	O
,	O
human	B
resources	O
(	O
e.g.	O
doctor	O
,	O
pharmacist	O
)	O
,	O
non	O
-	O
prescribing	O
print	O
information	O
(	O
e.g.	O
textbooks	O
and	O
journal	O
articles	O
)	O
,	O
and	O
prescribing	O
texts	O
were	O
used	O
36	O
%	O
,	O
32	O
%	O
,	O
and	O
25	O
%	O
of	O
the	O
time	O
,	O
respectively	O
[	O
54	O
]	O
.	O

Books	O
from	O
the	O
workplace	O
were	O
reported	O
by	O
approximately	O
79	O
%	O
of	O
UK	O
primary	O
care	O
nurses	O
as	O
a	O
commonly	O
used	O
source	O
of	O
knowledge	O
and	O
information	O
used	O
to	O
support	O
practice	O
[	O
55	O
]	O
.	O

Fewer	O
than	O
one	O
-	O
third	O
(	O
31	O
%	O
)	O
reported	O
using	O
electronic	O
resources	O
(	O
e.g.	O
Internet	O
,	O
electronic	O
journals	O
)	O
for	O
this	O
purpose	O
[	O
55	O
]	O
.	O

Results	O
of	O
a	O
postal	O
questionnaire	O
to	O
NPs	O
demonstrated	O
that	O
61	O
%	O
and	O
51	O
%	O
of	O
respondents	O
reported	O
using	O
drug	O
reference	O
manuals	O
and	O
textbooks	O
,	O
respectively	O
,	O
a	O
few	O
times	O
a	O
week	O
or	O
more	O
[	O
29	O
]	O
.	O

These	O
frequencies	O
were	O
second	O
and	O
third	O
only	O
to	O
consulting	O
with	O
their	O
physician	O
supervisor	O
(	O
63	O
%	O
)	O
.	O

Data	O
from	O
structured	O
interviews	O
of	O
a	O
sample	O
of	O
22	O
community	O
nurse	O
prescribers	O
reported	O
by	O
Hall	O
et	O
al.	O
revealed	O
that	O
the	O
majority	O
relied	O
on	O
print	O
materials	O
to	O
access	O
information	O
,	O
namely	O
the	O
British	O
National	O
Formulary	O
[	O
32	O
]	O
.	O

A	O
survey	O
of	O
a	O
primary	O
care	O
practice	O
-	O
based	O
research	O
network	O
in	O
the	O
US	O
that	O
included	O
physicians	O
,	O
physician	O
assistants	O
,	O
and	O
nurse	O
practitioners	O
,	O
revealed	O
that	O
interpersonal	O
and	O
rapidly	O
accessed	O
print	O
resources	O
were	O
preferred	O
.	O

Sixty	O
-	O
one	O
and	O
58	O
%	O
of	O
respondents	O
reported	O
using	O
drug	O
reference	O
sources	O
such	O
as	O
the	O
Physician	O
's	O
Desk	O
Reference	O
(	O
PDR	O
)	O
and	O
medical	O
textbooks	O
,	O
respectively	O
,	O
a	O
few	O
times	O
a	O
day	O
or	O
daily	O
[	O
56	O
]	O
.	O

The	O
clinicians	O
in	O
our	O
sample	O
perceived	O
the	O
Canadian	O
compendium	O
,	O
the	O
CPS	O
,	O
to	O
be	O
useful	O
,	O
accessible	O
,	O
credible	O
,	O
and	O
current	O
/	O
timely	O
.	O

The	O
CPS	O
,	O
is	O
described	O
as	O
"	O
the	O
Canadian	O
drug	O
reference	O
for	O
health	O
professionals	O
"	O
and	O
is	O
intended	O
to	O
provide	O
a	O
central	O
source	O
of	O
drug	O
information	O
on	O
drug	O
products	O
available	O
in	O
Canada	O
[	O
52	O
]	O
.	O

It	O
is	O
available	O
in	O
print	O
(	O
English	O
and	O
French	O
)	O
and	O
became	O
available	O
online	O
in	O
June	O
2004	O
.	O

The	O
CPS	O
includes	O
drug	O
monographs	O
for	O
commonly	O
used	O
products	O
approved	O
for	O
use	O
in	O
Canada	O
,	O
but	O
it	O
does	O
not	O
include	O
all	O
drugs	O
available	O
on	O
the	O
Canadian	O
market	O
[	O
57	O
]	O
.	O

The	O
majority	O
of	O
these	O
product	O
monographs	O
are	O
based	O
on	O
monographs	O
submitted	O
by	O
pharmaceutical	O
manufacturers	O
and	O
approved	O
by	O
Health	O
Canada	O
.	O

Some	O
of	O
the	O
monographs	O
are	O
written	O
by	O
the	O
Canadian	O
Pharmacists	O
Association	O
and	O
are	O
described	O
as	O
being	O
evidence	O
-	O
based	O
[	O
52	O
]	O
.	O

The	O
CPS	O
also	O
includes	O
more	O
than	O
100	O
pages	O
of	O
clinical	O
tools	O
[	O
52	O
]	O
.	O

The	O
CPS	O
has	O
been	O
criticized	O
for	O
including	O
pharmaceutical	O
company	O
advertising	O
and	O
requiring	O
manufacturer	O
payment	O
for	O
inclusion	O
of	O
product	O
monographs	O
[	O
58	O
]	O
.	O

The	O
accuracy	O
of	O
particular	O
components	O
of	O
CPS	O
monographs	O
has	O
also	O
been	O
investigated	O
.	O

A	O
review	O
of	O
overdose	O
management	O
in	O
119	O
monographs	O
from	O
the	O
2001	O
CPS	O
revealed	O
considerable	O
variability	O
in	O
the	O
utility	O
of	O
information	O
with	O
50	O
%	O
of	O
the	O
monographs	O
containing	O
misleading	O
or	O
dangerous	O
advice	O
[	O
59	O
]	O
.	O

Since	O
2004	O
,	O
the	O
CPS	O
has	O
included	O
an	O
alert	O
box	O
in	O
the	O
overdose	O
section	O
of	O
monographs	O
notifying	O
users	O
to	O
contact	O
Poison	O
Control	O
Centres	O
for	O
overdose	O
management	O
information	O
.	O

Some	O
authors	O
have	O
criticized	O
references	O
that	O
are	O
similar	O
to	O
the	O
CPS	O
as	O
being	O
inadequate	O
with	O
regard	O
to	O
inclusion	O
of	O
evidence	O
based	O
information	O
[	O
60	O
]	O
.	O

The	O
NPs	O
in	O
our	O
sample	O
also	O
rated	O
Therapeutic	O
Choices	O
highly	O
for	O
all	O
characteristics	O
.	O

This	O
finding	O
is	O
most	O
likely	O
attributable	O
to	O
the	O
fact	O
that	O
it	O
is	O
a	O
recommended	O
resource	O
for	O
coursework	O
associated	O
with	O
the	O
Dalhousie	O
NP	O
university	O
program	O
curriculum	O
.	O

Therapeutic	O
Choices	O
is	O
a	O
concise	O
therapeutics	O
reference	O
text	O
published	O
by	O
the	O
Canadian	O
Pharmacists	O
Association	O
.	O

The	O
text	O
contains	O
approximately	O
120	O
extensively	O
referenced	O
chapters	O
with	O
a	O
disease	O
management	O
approach	O
including	O
easy	O
to	O
use	O
algorithms	O
and	O
tables	O
.	O

An	O
editorial	O
board	O
is	O
responsible	O
for	O
extensively	O
reviewing	O
the	O
content	O
to	O
ensure	O
unbiased	O
and	O
objective	O
information	O
is	O
presented	O
[	O
53	O
]	O
.	O

Health	O
professionals	O
Reliance	O
on	O
other	O
health	O
professionals	O
,	O
especially	O
pharmacists	O
and	O
physicians	O
,	O
as	O
a	O
resource	O
for	O
information	O
was	O
evident	O
from	O
our	O
study	O
and	O
concurs	O
with	O
the	O
findings	O
of	O
others	O
[	O
28,32,55,61	O
]	O
.	O

Nurse	O
practitioners	O
have	O
reported	O
that	O
collaborative	O
relationships	O
with	O
pharmacists	O
increase	O
NP	O
role	O
satisfaction	O
[	O
61	O
]	O
.	O

NPs	O
frequently	O
consult	O
with	O
allied	O
health	O
care	O
professionals	O
in	O
their	O
primary	O
health	O
care	O
provider	O
role	O
and	O
this	O
is	O
supported	O
by	O
written	O
feedback	O
from	O
our	O
sample	O
regarding	O
frequently	O
consulted	O
health	O
professionals	O
.	O

Nursing	O
colleagues	O
are	O
also	O
likely	O
to	O
be	O
rated	O
highly	O
by	O
NPs	O
due	O
to	O
their	O
affiliation	O
with	O
peers	O
from	O
the	O
same	O
profession	O
.	O

Some	O
investigators	O
have	O
shown	O
that	O
non	O
-	O
human	B
references	O
(	O
e.g.	O
textbook	O
)	O
are	O
sought	O
for	O
more	O
technical	O
aspects	O
of	O
prescribing	O
(	O
e.g.	O
dose	O
)	O
,	O
whereas	O
guidance	O
regarding	O
selection	O
of	O
agents	O
(	O
i.e.	O
right	O
drug	O
for	O
an	O
indication	O
)	O
is	O
sought	O
from	O
human	B
resources	O
(	O
e.g.	O
pharmacists	O
or	O
physicians	O
)	O
[	O
62	O
]	O
.	O

We	O
were	O
unable	O
to	O
determine	O
what	O
kinds	O
of	O
resources	O
were	O
used	O
for	O
specific	O
purposes	O
from	O
our	O
study	O
.	O

Online	O
and	O
electronic	O
resources	O
,	O
computers	O
,	O
and	O
personal	O
digital	O
assistants	O
From	O
our	O
study	O
,	O
computer	O
survey	O
respondents	O
ranked	O
online	O
/	O
electronic	O
resources	O
third	O
in	O
preference	O
following	O
print	O
and	O
health	O
professionals	O
.	O

Various	O
barriers	O
and	O
facilitators	O
to	O
accessing	O
information	O
online	O
/	O
electronically	O
or	O
via	O
the	O
Internet	O
have	O
been	O
described	O
in	O
the	O
literature	O
[	O
55,63	O
-	O
66	O
]	O
.	O

Variables	O
that	O
have	O
been	O
described	O
by	O
others	O
as	O
barriers	O
such	O
as	O
accessibility	O
,	O
high	O
speed	O
internet	O
access	O
,	O
patient	O
volume	O
,	O
age	O
,	O
practitioner	O
type	O
,	O
and	O
technology	O
support	O
did	O
not	O
appear	O
to	O
influence	O
computer	O
searching	O
for	O
information	O
on	O
drugs	O
or	O
therapeutics	O
related	O
to	O
patient	O
care	O
in	O
our	O
results	O
.	O

Some	O
qualitative	O
feedback	O
does	O
however	O
support	O
this	O
notion	O
.	O

As	O
an	O
example	O
,	O
in	O
response	O
to	O
a	O
request	O
for	O
a	O
rationale	O
for	O
not	O
using	O
computers	O
one	O
physician	O
commented	O
:	O
"	O
Retro	O
tech	O
[	O
sic	O
]	O
/	O
old	O
fashion	O
.	O

I	O
still	O
like	O
to	O
use	O
my	O
mind	O
and	O
have	O
always	O
been	O
a	O
fan	O
of	O
pen	O
and	O
paper	O
"	O
.	O

Barriers	O
that	O
were	O
identified	O
with	O
our	O
sample	O
regarding	O
the	O
use	O
of	O
handheld	O
technologies	O
such	O
as	O
PDAs	O
included	O
cost	O
,	O
time	O
,	O
and	O
issues	O
related	O
to	O
technology	O
literacy	O
.	O

Several	O
people	O
questioned	O
the	O
value	O
of	O
PDAs	O
.	O

One	O
GP	O
stated	O
when	O
referring	O
to	O
a	O
PDA	O
:	O
"	O
So	O
far	O
I	O
have	O
not	O
discovered	O
a	O
use	O
for	O
one	O
"	O
.	O

Other	O
respondents	O
reinforced	O
their	O
preferences	O
for	O
other	O
resources	O
(	O
e.g.	O
books	O
)	O
and	O
resistance	O
to	O
technology	O
.	O

When	O
responding	O
to	O
barriers	O
for	O
the	O
use	O
of	O
PDAs	O
,	O
one	O
NP	O
commented	O
,	O
"	O
My	O
huge	O
dislike	O
for	O
machinery	O
that	O
frequently	O
requires	O
updating	O
and	O
patience	O
"	O
.	O

A	O
physician	O
responded	O
,	O
"	O
as	O
stated	O
,	O
I	O
like	O
to	O
use	O
my	O
own	O
mind	O
,	O
and	O
can	O
get	O
all	O
the	O
info	O
I	O
need	O
from	O
books	O
relatively	O
quickly	O
"	O
.	O

Facilitators	O
to	O
the	O
use	O
of	O
PDAs	O
mainly	O
included	O
convenience	O
factors	O
such	O
as	O
having	O
resources	O
all	O
in	O
one	O
place	O
,	O
faster	O
means	O
to	O
get	O
information	O
,	O
and	O
portability	O
.	O

Our	O
sample	O
was	O
not	O
in	O
agreement	O
with	O
some	O
convenience	O
factors	O
in	O
that	O
they	O
did	O
not	O
feel	O
that	O
PDAs	O
would	O
decrease	O
paperwork	O
.	O

Practitioners	O
from	O
our	O
sample	O
felt	O
relatively	O
neutral	O
about	O
PDAs	O
improving	O
patient	O
's	O
health	O
outcomes	O
with	O
41	O
%	O
responding	O
in	O
this	O
manner	O
.	O

Results	O
from	O
a	O
sample	O
of	O
primary	O
care	O
practitioners	O
in	O
the	O
US	O
revealed	O
that	O
76	O
%	O
agreed	O
that	O
the	O
use	O
of	O
handheld	O
devices	O
for	O
electronic	O
prescribing	O
would	O
substantially	O
reduce	O
medical	O
errors	O
and	O
improve	O
the	O
quality	O
of	O
health	O
care	O
[	O
67	O
]	O
.	O

Our	O
study	O
also	O
suggests	O
that	O
resources	O
such	O
as	O
the	O
Cochrane	O
Library	O
and	O
its	O
Database	O
of	O
Systematic	O
Reviews	O
were	O
not	O
frequently	O
used	O
.	O

This	O
finding	O
is	O
similar	O
to	O
that	O
of	O
other	O
investigators	O
[	O
30,35,64	O
]	O
.	O

Despite	O
the	O
desire	O
of	O
some	O
clinicians	O
to	O
use	O
these	O
resources	O
,	O
lack	O
of	O
confidence	O
and	O
ability	O
to	O
use	O
them	O
appropriately	O
has	O
been	O
found	O
[	O
30,64,68,69	O
]	O
.	O

Our	O
study	O
suggests	O
that	O
although	O
this	O
resource	O
is	O
perceived	O
as	O
credible	O
,	O
current	O
/	O
timely	O
,	O
and	O
useful	O
,	O
it	O
is	O
also	O
perceived	O
to	O
be	O
somewhat	O
inaccessible	O
.	O

The	O
Cochrane	O
Library	O
is	O
available	O
to	O
the	O
health	O
professionals	O
(	O
e.g.	O
nurses	O
,	O
physicians	O
,	O
pharmacists	O
,	O
occupational	O
therapists	O
,	O
physiotherapists	O
,	O
etc	O
.	O
)	O
in	O
our	O
sample	O
through	O
professional	O
bodies	O
via	O
the	O
Atlantic	O
Health	O
Knowledge	O
Partnership	O
[	O
70	O
]	O
.	O

Technology	O
training	O
:	O
preferences	O
and	O
incentives	O
With	O
regard	O
to	O
receiving	O
training	O
for	O
a	O
new	O
technology	O
,	O
our	O
study	O
demonstrates	O
that	O
in	O
person	O
conferences	O
or	O
one	O
on	O
one	O
training	O
sessions	O
are	O
the	O
preferred	O
means	O
to	O
receive	O
continuing	O
education	O
.	O

Person	O
to	O
person	O
interaction	O
has	O
been	O
reported	O
as	O
the	O
preferred	O
and	O
most	O
frequently	O
used	O
means	O
to	O
access	O
continuing	O
education	O
or	O
training	O
by	O
other	O
investigators	O
[	O
55,71	O
]	O
.	O

Our	O
study	O
also	O
indicates	O
that	O
this	O
group	O
of	O
practitioners	O
may	O
benefit	O
from	O
accessing	O
resources	O
[	O
72	O
-	O
80	O
]	O
that	O
provide	O
guidance	O
on	O
useful	O
drug	O
information	O
resources	O
available	O
for	O
devices	O
such	O
as	O
PDAs	O
.	O

This	O
is	O
exemplified	O
by	O
one	O
respondent	O
's	O
statement	O
"	O
knowledge	O
regarding	O
good	O
software	O
programs	O
"	O
as	O
a	O
barrier	O
to	O
the	O
use	O
of	O
PDAs	O
.	O

Pharmaceutical	O
industry	O
The	O
influence	O
of	O
the	O
pharmaceutical	O
industry	O
on	O
physician	O
prescribing	O
and	O
research	O
outcomes	O
has	O
been	O
documented	O
[	O
81,82	O
]	O
.	O

Although	O
NP	O
use	O
of	O
industry	O
representatives	O
as	O
a	O
source	O
of	O
pharmacological	O
information	O
has	O
been	O
documented	O
,	O
the	O
influence	O
on	O
prescribing	O
is	O
largely	O
uninvestigated	O
[	O
32,61,83	O
-	O
85	O
]	O
.	O

The	O
CNA	O
competency	O
framework	O
includes	O
a	O
statement	O
regarding	O
prescribing	O
and	O
industry	O
relations	O
[	O
23	O
]	O
.	O

In	O
our	O
study	O
,	O
the	O
physician	O
and	O
NP	O
rankings	O
of	O
industry	O
representatives	O
were	O
similar	O
.	O

Within	O
the	O
health	O
professionals	O
and	O
other	O
category	O
,	O
pharmaceutical	O
representatives	O
were	O
used	O
as	O
a	O
resource	O
by	O
more	O
of	O
the	O
sample	O
than	O
regional	O
drug	O
information	O
services	O
and	O
comparably	O
to	O
academic	O
detailing	O
services	O
.	O

Academic	O
detailing	O
is	O
a	O
form	O
of	O
continuing	O
medical	O
education	O
where	O
a	O
trained	O
health	O
professional	O
visits	O
prescribers	O
for	O
a	O
fifteen	O
to	O
twenty	O
minute	O
session	O
to	O
provide	O
objective	O
information	O
regarding	O
a	O
therapeutic	O
topic	O
based	O
on	O
best	O
available	O
evidence	O
[	O
86,87	O
]	O
.	O

Following	O
academic	O
detailing	O
,	O
physician	O
and	O
NP	O
rankings	O
of	O
pharmaceutical	O
industry	O
representatives	O
were	O
second	O
or	O
third	O
for	O
frequency	O
of	O
use	O
,	O
usefulness	O
,	O
accessibility	O
,	O
credibility	O
,	O
and	O
current	O
/	O
timeliness	O
.	O

Limitations	O
We	O
do	O
not	O
have	O
demographics	O
or	O
information	O
regarding	O
the	O
reasons	O
why	O
survey	O
recipients	O
did	O
not	O
respond	O
.	O

As	O
per	O
ethical	O
requirements	O
to	O
maintain	O
confidentiality	O
of	O
respondents	O
,	O
we	O
were	O
not	O
able	O
to	O
match	O
respondents	O
from	O
their	O
respective	O
place	O
of	O
practice	O
and	O
therefore	O
can	O
not	O
conclude	O
whether	O
the	O
practitioners	O
within	O
a	O
practice	O
setting	O
influenced	O
the	O
others	O
'	O
responses	O
.	O

The	O
sample	O
size	O
of	O
the	O
survey	O
is	O
small	O
although	O
it	O
includes	O
88	O
%	O
response	O
from	O
community	O
based	O
NPs	O
in	O
Nova	O
Scotia	O
.	O

The	O
generalizability	O
of	O
the	O
results	O
is	O
limited	O
due	O
to	O
the	O
variations	O
in	O
NP	O
scopes	O
of	O
practice	O
nationally	O
and	O
internationally	O
.	O

It	O
is	O
unknown	O
whether	O
the	O
findings	O
are	O
generalizable	O
to	O
nonresponding	O
physicians	O
within	O
Nova	O
Scotia	O
collaborating	O
with	O
NPs	O
or	O
to	O
physicians	O
not	O
in	O
collaborative	O
practices	O
with	O
NPs	O
as	O
they	O
were	O
not	O
included	O
as	O
a	O
part	O
of	O
the	O
sample	O
.	O

Due	O
to	O
multiple	O
statistical	O
comparisons	O
(	O
Mann	O
Whitney	O
U	O
)	O
,	O
the	O
results	O
comparing	O
NP	O
and	O
physician	O
ratings	O
of	O
results	O
should	O
be	O
interpreted	O
with	O
caution	O
.	O

Conclusion	O
Respondent	O
ratings	O
of	O
resources	O
and	O
preferences	O
for	O
resource	O
use	O
were	O
consistent	O
with	O
self	O
-	O
reported	O
means	O
of	O
conducting	O
searches	O
for	O
specific	O
drug	O
information	O
queries	O
.	O

The	O
use	O
of	O
computers	O
and	O
PDAs	O
remains	O
limited	O
and	O
also	O
matches	O
preferences	O
and	O
resource	O
ratings	O
.	O

Education	O
to	O
this	O
group	O
of	O
practitioners	O
regarding	O
available	O
drug	O
information	O
resources	O
may	O
facilitate	O
use	O
of	O
computer	O
and	O
PDA	O
resources	O
.	O

Further	O
research	O
is	O
needed	O
to	O
determine	O
methods	O
to	O
increase	O
the	O
use	O
of	O
computers	O
and	O
PDAs	O
and	O
if	O
use	O
of	O
these	O
technologies	O
affects	O
prescribing	O
and	O
patient	O
outcomes	O
.	O

Competing	O
interests	O
Ingrid	O
Sketris	O
holds	O
a	O
Chair	O
from	O
Canadian	O
Institutes	O
of	O
Health	O
Research	O
(	O
CIHR	O
)	O
,	O
Canadian	O
Health	O
Services	O
Research	O
Foundation	O
(	O
CHSRF	O
)	O
co	O
-	O
sponsored	O
by	O
the	O
Nova	O
Scotia	O
Health	O
Research	O
Foundation	O
(	O
NSHRF	O
)	O
.	O

Andrea	O
Murphy	O
received	O
salary	O
support	O
through	O
this	O
Chair	O
as	O
a	O
research	O
fellow	O
at	O
the	O
time	O
of	O
conducting	O
this	O
research	O
.	O

The	O
survey	O
was	O
performed	O
in	O
fulfillment	O
of	O
the	O
requirements	O
for	O
the	O
Drug	O
Use	O
Management	O
and	O
Policy	O
Residency	O
that	O
Murphy	O
participated	O
in	O
as	O
a	O
part	O
of	O
her	O
fellowship	O
.	O

The	O
residency	O
was	O
conducted	O
with	O
a	O
decision	O
making	O
partner	O
from	O
the	O
Nova	O
Scotia	O
Department	O
of	O
Health	O
.	O

The	O
opinions	O
expressed	O
in	O
this	O
paper	O
are	O
those	O
of	O
the	O
authors	O
and	O
do	O
not	O
represent	O
the	O
opinions	O
of	O
the	O
Nova	O
Scotia	O
Department	O
of	O
Health	O
,	O
CIHR	O
/	O
CHSRF	O
or	O
NSHRF	O
.	O

MF	O
,	O
MM	O
,	O
RMM	O
,	O
and	O
DG	O
have	O
no	O
competing	O
interests	O
to	O
declare	O
.	O

Authors	O
'	O
contributions	O
AM	O
conceptualized	O
the	O
design	O
and	O
composed	O
the	O
survey	O
instruments	O
,	O
carried	O
out	O
the	O
study	O
,	O
entered	O
and	O
analyzed	O
the	O
data	O
,	O
drafted	O
the	O
original	O
manuscript	O
,	O
and	O
modified	O
subsequent	O
drafts	O
based	O
on	O
authors	O
'	O
and	O
reviewers	O
'	O
feedback	O
.	O

MF	O
,	O
RMM	O
,	O
IS	O
,	O
MM	O
,	O
and	O
DG	O
reviewed	O
and	O
suggested	O
revisions	O
to	O
the	O
survey	O
tools	O
,	O
covering	O
letters	O
,	O
overall	O
study	O
design	O
,	O
and	O
contributed	O
to	O
feedback	O
on	O
the	O
analysis	O
and	O
manuscript	O
revisions	O
.	O

Pre	O
-	O
publication	O
history	O
The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O
Supplementary	O
Material	O

Embryonic	O
sympathoblasts	O
transiently	O
express	O
TrkB	O
in	O
vivo	O
and	O
proliferate	O
in	O
response	O
to	O
brain	O
-	O
derived	O
neurotrophic	O
factor	O
in	O
vitro	O
Abstract	O
Background	O
Nerve	O
growth	O
factor	O
and	O
neurotrophin-3	O
are	O
involved	O
in	O
the	O
development	O
of	O
sympathetic	O
neurons	O
;	O
however	O
,	O
whether	O
brain	O
derived	O
neurotrophic	O
factor	O
also	O
plays	O
a	O
role	O
is	O
not	O
known	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
BDNF	O
and	O
its	O
receptor	O
,	O
TrkB	O
,	O
are	O
expressed	O
during	O
the	O
development	O
of	O
paravertebral	O
sympathetic	O
ganglia	O
in	O
vivo	O
and	O
to	O
determine	O
the	O
effect	O
of	O
BDNF	O
in	O
vitro	O
.	O

Results	O
As	O
neural	O
crest	O
cells	O
coalesce	O
to	O
form	O
sympathetic	O
ganglia	O
,	O
TrkB	O
-	O
positive	O
cells	O
are	O
seen	O
in	O
both	O
chicken	B
and	O
mouse	B
embryos	O
.	O

In	O
chicken	B
embryos	O
,	O
TrkB	O
-	O
expressing	O
cells	O
first	O
appear	O
at	O
Hamburger	O
-	O
Hamilton	O
Stage	O
(	O
St	O
)	O
27	O
and	O
they	O
co	O
-	O
express	O
HNK-1	O
,	O
confirming	O
that	O
they	O
are	O
migrating	O
neural	O
crest	O
cells	O
.	O

The	O
TrkB	O
-	O
positive	O
cells	O
lack	O
neural	O
markers	O
at	O
this	O
stage	O
;	O
however	O
,	O
they	O
migrate	O
with	O
other	O
neurally	O
differentiating	O
cells	O
that	O
are	O
TrkA	O
and	O
TrkC	O
-	O
positive	O
.	O

By	O
St.	O
29	O
/	O
30	O
,	O
TrkB	O
-	O
positive	O
cells	O
begin	O
to	O
express	O
the	O
neural	O
specific	O
markers	O
Hu	O
C	O
/	O
D	O
and	O
Islet-1	O
;	O
eventually	O
,	O
all	O
TrkB	O
positive	O
cells	O
commence	O
neural	O
differentiation	O
.	O

By	O
St.	O
34	O
,	O
TrkB	O
and	O
TrkC	O
staining	O
are	O
lost	O
.	O

BDNF	O
transcript	O
expression	O
parallels	O
that	O
of	O
TrkB.	O
In	O
the	O
mouse	B
,	O
TrkB	O
-	O
positive	O
cells	O
surround	O
newly	O
formed	O
sympathetic	O
ganglia	O
and	O
a	O
small	O
number	O
of	O
TrkB	O
positive	O
cells	O
that	O
co	O
-	O
express	O
tyrosine	O
hydroxylase	O
are	O
seen	O
within	O
ganglia	O
between	O
E13.5	O
-	O
15	O
.	O

In	O
cell	O
culture	O
,	O
many	O
cells	O
from	O
St.	O
29–30	O
chicken	B
lumbar	O
sympathetic	O
ganglia	O
express	O
neural	O
markers	O
and	O
are	O
dividing	O
,	O
indicating	O
that	O
they	O
are	O
sympathoblasts	O
.	O

Sympathoblasts	O
and	O
neurons	O
require	O
both	O
nerve	O
growth	O
factor	O
and	O
neurotrophin-3	O
for	O
survival	O
.	O

BDNF	O
increases	O
the	O
number	O
of	O
cells	O
expressing	O
neural	O
markers	O
in	O
culture	O
by	O
increasing	O
number	O
of	O
cells	O
that	O
incorporate	O
bromodeoxyuridine	O
.	O

In	O
contrast	O
,	O
most	O
TrkB	O
-	O
positive	O
sympathetic	O
cells	O
in	O
vivo	O
are	O
not	O
actively	O
proliferating	O
between	O
E6–E8	O
.	O

Conclusion	O
Developing	O
paravertebral	O
sympathetic	O
ganglia	O
in	O
avian	O
and	O
murine	O
embryos	O
contain	O
a	O
subpopulation	O
of	O
sympathoblasts	O
that	O
transiently	O
express	O
TrkB	O
and	O
ultimately	O
commence	O
neuronal	O
differentiation	O
.	O

These	O
TrkB	O
expressing	O
sympathoblasts	O
are	O
not	O
actively	O
dividing	O
in	O
vivo	O
;	O
yet	O
,	O
when	O
placed	O
in	O
vitro	O
,	O
will	O
divide	O
in	O
response	O
to	O
BDNF	O
.	O

This	O
suggests	O
that	O
the	O
availability	O
of	O
BDNF	O
in	O
vivo	O
fails	O
to	O
reach	O
a	O
threshold	O
necessary	O
to	O
induce	O
proliferation	O
.	O

We	O
suggest	O
that	O
excess	O
TrkB	O
stimulation	O
of	O
sympathoblasts	O
in	O
vivo	O
may	O
lead	O
to	O
the	O
genesis	O
of	O
neuroblastoma	O
.	O

Background	O
Neural	O
crest	O
cells	O
destined	O
to	O
become	O
paravertebral	O
sympathetic	O
neurons	O
proliferate	O
and	O
differentiate	O
during	O
migration	O
and	O
gangliogenesis	O
.	O

In	O
chicken	B
embryos	O
,	O
migrating	O
neural	O
crest	O
cells	O
express	O
catecholamines	O
at	O
Hamburger	O
/	O
Hamilton	O
Stage	O
(	O
St.	O
)	O
19	O
,	O
and	O
these	O
cells	O
form	O
the	O
primary	O
sympathetic	O
chain	O
dorsolateral	O
to	O
the	O
aorta	O
at	O
St.	O
22	O
(	O
E3.5	O
)	O
[	O
1	O
]	O
.	O

Between	O
St.	O
23	O
(	O
E4	O
)	O
and	O
St.	O
28	O
(	O
E6	O
)	O
,	O
these	O
cells	O
disperse	O
and	O
undergo	O
a	O
secondary	O
migration	O
to	O
form	O
the	O
paravertebral	O
sympathetic	O
chain	O
that	O
resides	O
ventral	O
to	O
the	O
spinal	O
cord	O
and	O
dorsal	O
root	O
ganglion	O
[	O
1	O
]	O
.	O

After	O
ganglia	O
coalesce	O
,	O
sympathoblasts	O
express	O
markers	O
of	O
neuronal	O
differentiation	O
,	O
such	O
as	O
Q211	O
and	O
tyrosine	O
hydroxylase	O
(	O
TH	O
)	O
,	O
at	O
a	O
time	O
when	O
they	O
also	O
incorporate	O
[	O
3H	O
]	O
-thymidine	O
[	O
2	O
]	O
.	O

Time	O
lapse	O
photography	O
has	O
shown	O
that	O
cultured	O
E15.5–E16.5	O
sympathetic	O
neurons	O
from	O
rat	B
embryos	O
extend	O
axons	O
while	O
they	O
divide	O
[	O
3	O
-	O
5	O
]	O
.	O

Although	O
proliferation	O
appears	O
to	O
be	O
an	O
important	O
process	O
to	O
expand	O
the	O
sympathetic	O
neuron	O
population	O
during	O
differentiation	O
,	O
the	O
mechanisms	O
that	O
guide	O
sympathoblast	O
proliferation	O
have	O
not	O
been	O
identified	O
.	O

The	O
development	O
of	O
sympathetic	O
neurons	O
is	O
guided	O
by	O
neurotrophins	O
.	O

Neurotrophin-3	O
(	O
NT-3	O
)	O
binds	O
to	O
its	O
receptor	O
,	O
TrkC	O
,	O
to	O
promote	O
the	O
survival	O
of	O
cultured	O
sympathoblasts	O
from	O
early	O
lumbar	O
paravertebral	O
ganglia	O
[	O
6	O
]	O
.	O

Nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
signals	O
through	O
its	O
receptor	O
,	O
TrkA	O
,	O
to	O
promote	O
the	O
survival	O
of	O
sympathetic	O
neurons	O
upon	O
target	O
innervation	O
[	O
7	O
]	O
.	O

There	O
are	O
severe	O
sympathetic	O
defects	O
in	O
the	O
superior	O
cervical	O
ganglion	O
of	O
individual	O
NT-3	O
and	O
NGF	O
knockout	O
mice	B
[	O
8	O
-	O
10	O
]	O
.	O

Furthermore	O
,	O
there	O
is	O
no	O
additional	O
cell	O
death	O
in	O
the	O
superior	O
cervical	O
ganglion	O
of	O
NT-3	O
and	O
NGF	O
double	O
knockout	O
mouse	B
embryos	O
,	O
suggesting	O
that	O
all	O
of	O
the	O
neurons	O
are	O
dependent	O
on	O
both	O
neurotrophins	O
for	O
survival	O
[	O
11	O
]	O
.	O

There	O
is	O
also	O
an	O
increase	O
in	O
sympathetic	O
neuron	O
cell	O
death	O
in	O
TrkA	O
knockout	O
mice	B
[	O
12	O
]	O
.	O

However	O
,	O
in	O
TrkB	O
and	O
BDNF	O
knockout	O
mice	B
,	O
there	O
is	O
no	O
apparent	O
phenotype	O
in	O
the	O
superior	O
cervical	O
ganglion	O
,	O
and	O
there	O
is	O
little	O
evidence	O
that	O
TrkB	O
or	O
BDNF	O
is	O
expressed	O
in	O
sympathetic	O
ganglia	O
.	O

Thus	O
,	O
it	O
is	O
generally	O
thought	O
that	O
TrkB	O
and	O
BDNF	O
have	O
little	O
or	O
no	O
roles	O
in	O
guiding	O
the	O
development	O
of	O
sympathetic	O
neurons	O
.	O

In	O
addition	O
to	O
their	O
developmental	O
functions	O
,	O
neurotrophin	O
receptors	O
regulate	O
cell	O
behavior	O
in	O
neuroblastoma	O
,	O
a	O
tumor	O
found	O
in	O
sympathetic	O
ganglia	O
and	O
adrenal	O
medulla	O
.	O

Tumors	O
that	O
express	O
TrkA	O
often	O
spontaneously	O
regress	O
,	O
while	O
those	O
that	O
express	O
TrkB	O
and	O
its	O
ligand	O
,	O
brain	O
-	O
derived	O
neurotrophic	O
factor	O
(	O
BDNF	O
)	O
,	O
grow	O
aggressively	O
,	O
are	O
invasive	O
,	O
and	O
fail	O
to	O
respond	O
to	O
chemotherapeutic	O
agents	O
[	O
13	O
]	O
.	O

The	O
presence	O
of	O
TrkA	O
in	O
neuroblastoma	O
tumors	O
is	O
consistent	O
with	O
its	O
expression	O
in	O
developing	O
sympathetic	O
neurons	O
,	O
and	O
suggests	O
that	O
regressive	O
neuroblastoma	O
tumors	O
arise	O
from	O
early	O
sympathetic	O
neurons	O
that	O
express	O
TrkA.	O
The	O
function	O
of	O
TrkB	O
in	O
early	O
sympathetic	O
development	O
is	O
unknown	O
,	O
which	O
makes	O
understanding	O
the	O
etiology	O
of	O
aggressive	O
neuroblastoma	O
tumors	O
difficult	O
.	O

Based	O
on	O
its	O
function	O
in	O
neuroblastoma	O
tumors	O
,	O
we	O
hypothesize	O
that	O
BDNF	O
and	O
TrkB	O
expression	O
in	O
differentiating	O
sympathoblasts	O
is	O
responsible	O
for	O
expanding	O
the	O
neuronal	O
population	O
through	O
proliferation	O
.	O

We	O
sought	O
to	O
determine	O
whether	O
BDNF	O
and	O
TrkB	O
are	O
involved	O
in	O
sympathetic	O
development	O
.	O

We	O
report	O
that	O
during	O
early	O
embryonic	O
development	O
,	O
TrkB	O
is	O
expressed	O
in	O
a	O
subset	O
of	O
differentiating	O
sympathoblasts	O
in	O
both	O
avian	O
and	O
murine	O
embryos	O
.	O

We	O
also	O
find	O
that	O
BDNF	O
promotes	O
the	O
proliferation	O
of	O
TrkB	O
-	O
positive	O
sympathoblasts	O
in	O
cell	O
culture	O
.	O

However	O
,	O
the	O
majority	O
of	O
TrkB	O
positive	O
cells	O
in	O
vivo	O
fail	O
to	O
take	O
up	O
bromodeoxyuridine	O
(	O
BrdU	O
)	O
over	O
a	O
24	O
hr	O
period	O
,	O
suggesting	O
that	O
endogenous	O
BDNF	O
concentrations	O
do	O
not	O
reach	O
a	O
threshold	O
necessary	O
to	O
stimulate	O
proliferation	O
of	O
sympathoblasts	O
.	O

Shortly	O
after	O
all	O
of	O
the	O
TrkB	O
positive	O
cells	O
commence	O
neuronal	O
differentiation	O
,	O
TrkB	O
immunoreactivity	O
is	O
lost	O
.	O

These	O
results	O
suggest	O
that	O
prolonged	O
expression	O
and/or	O
activation	O
of	O
TrkB	O
signaling	O
at	O
these	O
early	O
stages	O
may	O
be	O
an	O
early	O
event	O
triggering	O
the	O
formation	O
of	O
neuroblastoma	O
.	O

Results	O
TrkB	O
is	O
expressed	O
during	O
migration	O
of	O
neural	O
crest	O
cells	O
to	O
sympathetic	O
ganglia	O
We	O
first	O
determined	O
whether	O
TrkB	O
is	O
expressed	O
in	O
neural	O
crest	O
-	O
derived	O
cells	O
in	O
the	O
region	O
ventral	O
to	O
the	O
spinal	O
cord	O
and	O
dorsal	O
root	O
ganglia	O
where	O
sympathetic	O
ganglia	O
coalesce	O
between	O
Hamburger	O
/	O
Hamilton	O
Stages	O
(	O
St.	O
)	O
25–28	O
/	O
29	O
.	O

To	O
identify	O
cells	O
that	O
have	O
commenced	O
neuronal	O
differentiation	O
,	O
transverse	O
sections	O
of	O
the	O
lumbar	O
spinal	O
column	O
region	O
were	O
stained	O
with	O
antibodies	O
against	O
Hu	O
C	O
/	O
D	O
[	O
14	O
]	O
,	O
a	O
neuronal	O
-	O
specific	O
RNA	O
-	O
binding	O
protein	O
,	O
or	O
Islet-1	O
,	O
a	O
transcription	O
factor	O
found	O
in	O
sympathetic	O
neurons	O
[	O
15	O
]	O
.	O

We	O
found	O
that	O
Hu	O
C	O
/	O
D	O
and	O
Islet-1	O
are	O
expressed	O
in	O
the	O
same	O
cells	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
throughout	O
sympathetic	O
development	O
.	O

In	O
experiments	O
done	O
between	O
St.	O
25	O
and	O
28	O
,	O
Islet-1	O
staining	O
appeared	O
weaker	O
than	O
Hu	O
C	O
/	O
D	O
staining	O
,	O
and	O
thus	O
we	O
used	O
Hu	O
C	O
/	O
D	O
to	O
identify	O
differentiating	O
neurons	O
at	O
these	O
stages	O
.	O

At	O
later	O
stages	O
,	O
Islet-1	O
was	O
used	O
to	O
facilitate	O
the	O
identification	O
of	O
neurons	O
because	O
of	O
the	O
nuclear	O
location	O
of	O
its	O
immunoreactivity	O
.	O

Cells	O
expressing	O
Hu	O
C	O
/	O
D	O
are	O
first	O
detected	O
at	O
St.	O
25	O
ventral	O
to	O
the	O
spinal	O
cord	O
and	O
dorsal	O
root	O
ganglion	O
and	O
lateral	O
to	O
the	O
dorsal	O
aorta	O
(	O
Figure	O
1A	O
,	O
1B	O
)	O
.	O

By	O
St.	O
26	O
,	O
the	O
number	O
of	O
cells	O
that	O
express	O
Hu	O
C	O
/	O
D	O
in	O
this	O
region	O
increases	O
dramatically	O
(	O
Figure	O
1C	O
)	O
.	O

TrkB	O
-	O
expressing	O
cells	O
first	O
appear	O
at	O
St.	O
27	O
in	O
the	O
same	O
region	O
and	O
are	O
adjacent	O
to	O
Hu	O
C	O
/	O
D	O
-	O
positive	O
cells	O
(	O
Figure	O
1D	O
,	O
2A	O
,	O
2H	O
)	O
.	O

TrkB	O
-	O
positive	O
cells	O
co	O
-	O
localize	O
with	O
a	O
neural	O
crest	O
marker	O
,	O
HNK-1	O
(	O
Figures	O
2B	O
,	O
2C	O
,	O
2D	O
)	O
.	O

The	O
Hu	O
C	O
/	O
D	O
-	O
positive	O
cells	O
in	O
this	O
region	O
are	O
likely	O
to	O
be	O
sympathetic	O
neurons	O
,	O
since	O
they	O
appear	O
in	O
the	O
region	O
where	O
sympathetic	O
ganglia	O
form	O
and	O
express	O
tyrosine	O
hydroxylase	O
,	O
a	O
rate	O
-	O
limiting	O
enzyme	O
in	O
the	O
synthesis	O
of	O
catecholamines	O
(	O
Figures	O
2E	O
,	O
2F	O
,	O
2	O
G	O
)	O
.	O

At	O
St.	O
28	O
/	O
29	O
,	O
the	O
cells	O
begin	O
to	O
coalesce	O
ventral	O
to	O
the	O
dorsal	O
root	O
ganglion	O
and	O
the	O
Hu	O
C	O
/	O
D	O
-	O
positive	O
cells	O
and	O
TrkB	O
-	O
positive	O
cells	O
remain	O
as	O
two	O
separate	O
cell	O
populations	O
(	O
Figure	O
1E	O
)	O
;	O
however	O
,	O
shortly	O
afterwards	O
,	O
all	O
of	O
the	O
TrkB	O
-	O
positive	O
cells	O
begin	O
to	O
express	O
Islet-1	O
(	O
Figure	O
3B	O
)	O
and	O
Hu	O
C	O
/	O
D	O
(	O
data	O
not	O
shown	O
)	O
.	O

Developmental	O
regulation	O
of	O
TrkA	O
,	O
TrkB	O
,	O
TrkC	O
,	O
and	O
BDNF	O
expression	O
In	O
contrast	O
to	O
TrkB	O
,	O
the	O
other	O
neurotrophin	O
receptors	O
,	O
TrkA	O
and	O
TrkC	O
,	O
are	O
co	O
-	O
expressed	O
in	O
both	O
Hu	O
C	O
/	O
D	O
-	O
positive	O
and	O
Hu	O
C	O
/	O
D	O
-	O
negative	O
cells	O
at	O
St.	O
27	O
(	O
Figures	O
2I	O
,	O
2J	O
)	O
.	O

We	O
find	O
that	O
approximately	O
30	O
%	O
of	O
the	O
Islet-1-positive	O
cells	O
express	O
TrkA	O
(	O
Figure	O
3A	O
)	O
,	O
while	O
50	O
%	O
express	O
TrkB	O
(	O
Figure	O
3B	O
)	O
and	O
100	O
%	O
express	O
TrkC	O
(	O
Figure	O
3C	O
)	O
at	O
St.	O
29	O
/	O
30	O
(	O
E6.5	O
)	O
.	O

Thus	O
,	O
all	O
developing	O
neurons	O
express	O
TrkC	O
in	O
combination	O
with	O
either	O
TrkA	O
or	O
TrkB.	O
By	O
St.	O
31	O
(	O
E7	O
)	O
,	O
the	O
number	O
of	O
TrkA	O
-	O
positive	O
,	O
Islet-1-positive	O
cells	O
increases	O
to	O
100	O
%	O
(	O
Figure	O
3D	O
)	O
and	O
immunoreactivities	O
for	O
both	O
TrkB	O
and	O
TrkC	O
appear	O
dispersed	O
(	O
Figure	O
3E	O
,	O
3F	O
)	O
.	O

By	O
St.	O
34	O
(	O
E8	O
)	O
,	O
TrkA	O
expression	O
is	O
well	O
-	O
sustained	O
(	O
Figure	O
3	O
G	O
)	O
and	O
TrkB	O
and	O
TrkC	O
immunoreactivities	O
are	O
lost	O
(	O
Figure	O
3H	O
,	O
3I	O
)	O
.	O

We	O
also	O
examined	O
the	O
early	O
development	O
of	O
murine	O
sympathetic	O
ganglia	O
(	O
Figure	O
4	O
)	O
.	O

At	O
E13	O
,	O
the	O
newly	O
formed	O
lumbar	O
sympathetic	O
ganglia	O
can	O
be	O
observed	O
ventral	O
to	O
the	O
spinal	O
cord	O
and	O
notochord	O
by	O
their	O
staining	O
for	O
Hu	O
C	O
/	O
D	O
and	O
TH	O
(	O
Figure	O
4A	O
)	O
.	O

TrkB	O
-	O
positive	O
cells	O
can	O
be	O
seen	O
surrounding	O
developing	O
ganglia	O
,	O
as	O
well	O
as	O
in	O
occasional	O
cells	O
within	O
the	O
ganglia	O
(	O
Figure	O
4C	O
,	O
D	O
)	O
.	O

These	O
TrkB	O
-	O
positive	O
cells	O
within	O
the	O
ganglia	O
co	O
-	O
express	O
TH	O
and	O
are	O
seen	O
at	O
a	O
frequency	O
of	O
1–2	O
cells	O
per	O
section	O
starting	O
at	O
E13	O
(	O
Figure	O
4A	O
–	O
D	O
)	O
and	O
are	O
still	O
present	O
at	O
E15.5	O
(	O
data	O
not	O
shown	O
)	O
.	O

In	O
neuroblastoma	O
cells	O
,	O
BDNF	O
is	O
co	O
-	O
expressed	O
with	O
TrkB	O
,	O
suggesting	O
that	O
autocrine	O
stimulation	O
is	O
a	O
means	O
by	O
which	O
proliferation	O
is	O
sustained	O
in	O
the	O
transformed	O
cells	O
.	O

To	O
test	O
whether	O
BDNF	O
,	O
the	O
ligand	O
for	O
TrkB	O
,	O
was	O
present	O
in	O
embryonic	O
chick	O
sympathetic	O
ganglia	O
,	O
we	O
used	O
quantitative	O
real	O
-	O
time	O
PCR	O
with	O
TaqMan	O
probes	O
to	O
determine	O
the	O
relative	O
abundance	O
of	O
BDNF	O
transcripts	O
in	O
total	O
RNA	O
extracted	O
from	O
lumbar	O
sympathetic	O
ganglia	O
at	O
St.	O
29	O
/	O
30	O
(	O
E6.5	O
)	O
,	O
St.	O
31	O
(	O
E7	O
)	O
,	O
St.	O
34	O
(	O
E8	O
)	O
,	O
and	O
E9	O
.	O

BDNF	O
expression	O
within	O
the	O
ganglia	O
parallels	O
that	O
of	O
TrkB	O
:	O
BDNF	O
mRNA	O
expression	O
levels	O
are	O
highest	O
at	O
St	O
29	O
/	O
30	O
(	O
E6.5	O
)	O
,	O
and	O
these	O
levels	O
decrease	O
2-fold	O
at	O
St.	O
31	O
(	O
E7	O
)	O
and	O
St.	O
34	O
(	O
E8	O
;	O
Figure	O
5	O
)	O
.	O

By	O
E9	O
,	O
BDNF	O
levels	O
are	O
7	O
times	O
lower	O
than	O
at	O
St.	O
29	O
/	O
30	O
(	O
E6.5	O
;	O
Figure	O
5	O
)	O
.	O

NT3	O
and	O
NGF	O
promote	O
survival	O
of	O
differentiating	O
sympathetic	O
neurons	O
in	O
culture	O
To	O
determine	O
the	O
effect	O
of	O
neurotrophins	O
,	O
we	O
cultured	O
cells	O
dispersed	O
from	O
lumbar	O
sympathetic	O
ganglia	O
at	O
St.	O
29	O
/	O
30	O
(	O
E6.5	O
)	O
because	O
,	O
at	O
this	O
stage	O
,	O
ganglion	O
formation	O
is	O
complete	O
,	O
the	O
number	O
of	O
TrkA-	O
,	O
TrkB-	O
,	O
and	O
TrkC	O
-	O
positive	O
cells	O
have	O
peaked	O
,	O
and	O
all	O
Trk	O
-	O
expressing	O
cells	O
have	O
initiated	O
neural	O
differentiation	O
.	O

First	O
,	O
we	O
identified	O
markers	O
expressed	O
by	O
acutely	O
isolated	O
cells	O
.	O

As	O
shown	O
in	O
Table	O
1	O
,	O
80–91	O
%	O
of	O
the	O
cells	O
are	O
p75	O
neurotrophin	O
receptor	O
(	O
NTR	O
)	O
-positive	O
,	O
indicating	O
that	O
most	O
of	O
the	O
cells	O
are	O
neural	O
crest	O
-	O
derived	O
and	O
little	O
mesenchymal	O
contamination	O
is	O
introduced	O
by	O
the	O
isolation	O
procedure	O
.	O

In	O
addition	O
,	O
28–33	O
%	O
of	O
the	O
cultured	O
cells	O
express	O
the	O
neural	O
marker	O
Hu	O
C	O
/	O
D.	O
Approximately	O
half	O
of	O
these	O
Hu	O
C	O
/	O
D	O
-	O
positive	O
cells	O
express	O
TrkB.	O
Conversely	O
,	O
all	O
of	O
the	O
TrkB	O
positive	O
cells	O
express	O
Hu	O
C	O
/	O
D.	O
These	O
TrkB	O
-	O
positive	O
cells	O
comprise	O
approximately	O
14–17	O
%	O
of	O
the	O
total	O
cell	O
population	O
.	O

We	O
then	O
determined	O
how	O
many	O
of	O
the	O
acutely	O
isolated	O
cells	O
were	O
proliferating	O
by	O
incubating	O
them	O
for	O
12	O
hrs	O
in	O
BrdU	O
-	O
containing	O
medium	O
.	O

For	O
these	O
experiments	O
,	O
we	O
identified	O
differentiating	O
neurons	O
with	O
the	O
transcription	O
factor	O
Islet-1	O
because	O
this	O
marker	O
labels	O
nuclei	O
,	O
thus	O
it	O
co	O
localizes	O
with	O
any	O
BrdU	O
that	O
has	O
been	O
incorporated	O
into	O
the	O
DNA	O
,	O
allowing	O
us	O
to	O
determine	O
whether	O
the	O
cell	O
had	O
undergone	O
S	O
-	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

After	O
12	O
hrs	O
in	O
BrdU	O
,	O
59	O
%	O
of	O
Islet-1-positive	O
nuclei	O
stain	O
for	O
BrdU	O
immunoreactivity	O
.	O

Thus	O
,	O
cultures	O
of	O
St.	O
29	O
/	O
30	O
sympathetic	O
ganglia	O
contain	O
many	O
cells	O
that	O
proliferate	O
while	O
exhibiting	O
markers	O
of	O
neuronal	O
differentiation	O
,	O
confirming	O
previous	O
observations	O
[	O
2	O
]	O
.	O

We	O
call	O
these	O
dividing	O
neuronal	O
precursors	O
sympathoblasts	O
.	O

The	O
remaining	O
non	O
-	O
BrdU	O
incorporating	O
,	O
Islet-1	O
positive	O
cells	O
are	O
likely	O
to	O
be	O
post	O
mitotic	O
neurons	O
.	O

Finally	O
,	O
we	O
determined	O
the	O
trophic	O
requirements	O
of	O
St.	O
29	O
/	O
30	O
(	O
E6.5	O
)	O
sympathetic	O
neurons	O
and	O
sympathoblasts	O
.	O

We	O
monitored	O
cultures	O
over	O
a	O
three	O
day	O
period	O
after	O
plating	O
and	O
counted	O
the	O
number	O
of	O
phase	O
bright	O
cells	O
with	O
neurites	O
,	O
a	O
morphological	O
feature	O
of	O
both	O
neurons	O
and	O
sympathoblasts	O
.	O

In	O
the	O
absence	O
of	O
trophic	O
factors	O
,	O
more	O
than	O
2	O
/	O
3	O
of	O
the	O
cells	O
die	O
by	O
24	O
hours	O
in	O
culture	O
and	O
BDNF	O
,	O
NT-3	O
,	O
or	O
NGF	O
alone	O
is	O
not	O
sufficient	O
to	O
promote	O
survival	O
(	O
Figure	O
6	O
)	O
.	O

However	O
,	O
NGF	O
together	O
with	O
NT-3	O
supports	O
the	O
survival	O
of	O
a	O
significantly	O
larger	O
number	O
of	O
cells	O
(	O
Figure	O
6	O
)	O
.	O

For	O
the	O
subsequent	O
experiments	O
,	O
all	O
neurons	O
were	O
cultured	O
with	O
25	O
ng	O
/	O
ml	O
NT-3	O
and	O
1	O
μg	O
/	O
ml	O
7S	O
NGF	O
to	O
optimize	O
survival	O
.	O

BDNF	O
promotes	O
proliferation	O
of	O
TrkB	O
-	O
positive	O
sympathetic	O
neurons	O
in	O
culture	O
To	O
determine	O
the	O
effects	O
of	O
BDNF	O
,	O
cultures	O
of	O
cells	O
from	O
St.	O
29	O
/	O
30	O
(	O
E6.5	O
)	O
sympathetic	O
ganglia	O
were	O
supplemented	O
with	O
200	O
ng	O
/	O
ml	O
BDNF	O
and	O
the	O
number	O
of	O
neurons	O
and	O
sympathoblasts	O
were	O
counted	O
at	O
24	O
,	O
48	O
,	O
and	O
72	O
hours	O
using	O
phase	O
microscopy	O
(	O
Figure	O
7A	O
)	O
.	O

A	O
1.6-fold	O
increase	O
in	O
the	O
number	O
of	O
neurons	O
due	O
to	O
BDNF	O
is	O
observed	O
by	O
24	O
hours	O
and	O
this	O
number	O
does	O
not	O
increase	O
further	O
at	O
48	O
or	O
72	O
hours	O
.	O

This	O
effect	O
of	O
BDNF	O
is	O
concentration	O
-	O
dependent	O
with	O
an	O
EC50	O
of	O
75	O
ng	O
/	O
ml	O
(	O
Figure	O
7B	O
)	O
.	O

To	O
test	O
whether	O
the	O
increase	O
in	O
the	O
number	O
of	O
neurons	O
and	O
sympathoblasts	O
caused	O
by	O
BDNF	O
is	O
due	O
to	O
the	O
differentiation	O
of	O
pluripotent	O
neural	O
crest	O
cells	O
,	O
we	O
quantified	O
the	O
effects	O
of	O
BDNF	O
on	O
the	O
number	O
of	O
neurally	O
differentiating	O
cells	O
(	O
Hu	O
C	O
/	O
D	O
-	O
positive	O
)	O
versus	O
the	O
number	O
of	O
non	O
-	O
neuronal	O
cells	O
(	O
Hu	O
C	O
/	O
D	O
-	O
negative	O
)	O
after	O
identifying	O
all	O
neural	O
crest	O
-	O
derived	O
cells	O
by	O
staining	O
for	O
p75NTR	O
in	O
St.	O
29	O
/	O
30	O
(	O
E6.5	O
)	O
cultures	O
.	O

If	O
BDNF	O
increases	O
the	O
number	O
of	O
neurons	O
and	O
sympathoblasts	O
by	O
inducing	O
a	O
non	O
-	O
neuronal	O
cell	O
to	O
express	O
Hu	O
C	O
/	O
D	O
,	O
then	O
we	O
expected	O
that	O
the	O
total	O
cell	O
number	O
would	O
remain	O
the	O
same	O
and	O
that	O
there	O
would	O
be	O
a	O
decrease	O
in	O
the	O
number	O
of	O
non	O
-	O
neuronal	O
cells	O
as	O
well	O
as	O
a	O
corresponding	O
increase	O
in	O
the	O
number	O
of	O
neurons	O
.	O

After	O
24	O
hours	O
,	O
BDNF	O
significantly	O
increases	O
the	O
number	O
of	O
p75NTR	O
-	O
positive	O
cells	O
as	O
well	O
as	O
the	O
number	O
of	O
Hu	O
C	O
/	O
D	O
-	O
positive	O
cells	O
(	O
Figure	O
8A	O
)	O
.	O

However	O
,	O
there	O
was	O
no	O
statistically	O
significant	O
change	O
in	O
the	O
number	O
of	O
non	O
-	O
neuronal	O
cells	O
.	O

Thus	O
,	O
it	O
is	O
unlikely	O
that	O
BDNF	O
increases	O
the	O
number	O
of	O
neurons	O
and	O
sympathoblasts	O
by	O
inducing	O
differentiation	O
of	O
non	O
-	O
neuronal	O
cells	O
.	O

To	O
determine	O
whether	O
the	O
increase	O
in	O
the	O
total	O
number	O
of	O
neurons	O
and	O
sympathoblasts	O
is	O
caused	O
by	O
BDNF	O
-	O
induced	O
proliferation	O
,	O
control	O
and	O
BDNF	O
-	O
treated	O
sympathetic	O
cultures	O
were	O
exposed	O
to	O
BrdU	O
for	O
12	O
hours	O
after	O
plating	O
,	O
and	O
the	O
number	O
of	O
cells	O
that	O
incorporated	O
BrdU	O
into	O
their	O
DNA	O
was	O
determined	O
after	O
24	O
hours	O
in	O
culture	O
.	O

Even	O
in	O
the	O
control	O
condition	O
,	O
a	O
number	O
of	O
cells	O
in	O
the	O
culture	O
are	O
dividing	O
,	O
giving	O
a	O
high	O
baseline	O
of	O
BrdU	O
incorporation	O
(	O
Figure	O
8B	O
)	O
.	O

When	O
BDNF	O
is	O
added	O
,	O
the	O
total	O
number	O
of	O
BrdU	O
positive	O
cells	O
increases	O
approximately	O
1.6-fold	O
(	O
Figure	O
8B	O
)	O
.	O

This	O
BDNF	O
-	O
induced	O
increase	O
in	O
the	O
total	O
number	O
of	O
BrdU	O
positive	O
cells	O
occurs	O
in	O
sympathoblasts	O
because	O
the	O
number	O
of	O
Islet-1-positive	O
nuclei	O
from	O
control	O
cultures	O
that	O
label	O
with	O
BrdU	O
is	O
268	O
±	O
59	O
and	O
BDNF	O
treatment	O
raises	O
this	O
number	O
to	O
424	O
±	O
80	O
,	O
which	O
corresponds	O
to	O
an	O
increase	O
of	O
1.6-fold	O
.	O

This	O
accounts	O
for	O
the	O
1.6-fold	O
increase	O
in	O
total	O
neuron	O
number	O
and	O
total	O
BrdU	O
-	O
positive	O
cells	O
described	O
above	O
.	O

We	O
then	O
confirmed	O
that	O
BDNF	O
acts	O
on	O
TrkB	O
-	O
positive	O
cells	O
:	O
BDNF	O
increases	O
the	O
number	O
of	O
TrkB	O
-	O
expressing	O
cells	O
that	O
incorporate	O
BrdU	O
2.6	O
–	O
4-fold	O
over	O
control	O
(	O
Table	O
2	O
)	O
and	O
it	O
also	O
increases	O
the	O
overall	O
number	O
of	O
TrkB	O
-	O
positive	O
cells	O
2	O
–	O
2.5-fold	O
over	O
control	O
(	O
Table	O
2	O
)	O
.	O

BDNF	O
does	O
not	O
increase	O
the	O
number	O
of	O
BrdU	O
-	O
positive	O
,	O
TrkB	O
-	O
negative	O
cells	O
or	O
the	O
overall	O
number	O
of	O
TrkB	O
-	O
negative	O
cells	O
(	O
Table	O
2	O
)	O
.	O

In	O
further	O
support	O
that	O
BDNF	O
acts	O
directly	O
on	O
TrkB	O
-	O
expressing	O
cells	O
,	O
an	O
antibody	O
directed	O
against	O
the	O
extracellular	O
domain	O
of	O
TrkB	O
completely	O
prevents	O
the	O
effect	O
of	O
BDNF	O
in	O
promoting	O
proliferation	O
of	O
TrkB	O
-	O
positive	O
,	O
but	O
not	O
TrkB	O
-	O
negative	O
cells	O
(	O
compare	O
Figure	O
9A	O
to	O
9B	O
)	O
.	O

Thus	O
,	O
the	O
effect	O
of	O
BDNF	O
is	O
restricted	O
to	O
the	O
population	O
that	O
expresses	O
TrkB	O
,	O
which	O
are	O
developing	O
sympathoblasts	O
.	O

To	O
determine	O
whether	O
TrkB	O
-	O
positive	O
cells	O
are	O
actively	O
proliferating	O
in	O
vivo	O
,	O
embryos	O
were	O
injected	O
with	O
BrdU	O
at	O
St.	O
27	O
and	O
harvested	O
at	O
St.	O
29	O
,	O
approximately	O
24	O
hrs	O
later	O
.	O

The	O
majority	O
(	O
85–90	O
%	O
)	O
of	O
TrkB	O
-	O
positive	O
cells	O
do	O
not	O
incorporate	O
BrdU	O
into	O
their	O
nuclei	O
under	O
basal	O
conditions	O
in	O
vivo	O
(	O
Figure	O
10	O
)	O
,	O
although	O
a	O
few	O
TrkB	O
positive	O
cells	O
with	O
labeled	O
nuclei	O
could	O
be	O
observed	O
(	O
arrows	O
)	O
.	O

This	O
contrasts	O
with	O
our	O
observation	O
that	O
71–76	O
%	O
of	O
TrkB	O
-	O
positive	O
cells	O
incorporate	O
BrdU	O
in	O
culture	O
after	O
treatment	O
with	O
BDNF	O
(	O
Table	O
2	O
)	O
,	O
suggesting	O
that	O
endogenous	O
BDNF	O
does	O
not	O
achieve	O
a	O
threshold	O
sufficient	O
to	O
support	O
a	O
high	O
level	O
of	O
sympathoblast	O
proliferation	O
in	O
vivo	O
.	O

Discussion	O
We	O
report	O
that	O
the	O
neurotrophin	O
receptor	O
TrkB	O
is	O
expressed	O
in	O
a	O
subset	O
of	O
embryonic	O
sympathoblasts	O
during	O
the	O
early	O
development	O
of	O
lumbar	O
paravertebral	O
sympathetic	O
ganglia	O
in	O
chicken	B
and	O
mouse	B
embryos	O
.	O

In	O
the	O
chicken	B
,	O
TrkB	O
expression	O
is	O
transient	O
,	O
and	O
completely	O
lost	O
by	O
St	O
34	O
(	O
E8	O
)	O
.	O

Since	O
BDNF	O
induces	O
the	O
proliferation	O
of	O
sympathoblasts	O
in	O
cell	O
culture	O
,	O
yet	O
in	O
vivo	O
there	O
is	O
little	O
proliferation	O
observed	O
in	O
TrkB	O
-	O
positive	O
cells	O
in	O
nascent	O
ganglia	O
,	O
we	O
propose	O
that	O
if	O
TrkB	O
activation	O
becomes	O
unregulated	O
by	O
excess	O
BDNF	O
or	O
constitutive	O
phosphorylation	O
of	O
TrkB	O
[	O
16	O
]	O
,	O
this	O
transient	O
population	O
of	O
TrkB	O
-	O
positive	O
sympathoblasts	O
may	O
trigger	O
the	O
genesis	O
of	O
neuroblastoma	O
,	O
a	O
childhood	O
tumor	O
found	O
in	O
the	O
paravertebral	O
chain	O
and	O
adrenal	O
medulla	O
.	O

The	O
two	O
populations	O
of	O
sympathoblasts	O
that	O
we	O
observe	O
support	O
previous	O
findings	O
of	O
heterogeneity	O
among	O
developing	O
sympathetic	O
neurons	O
and	O
neural	O
crest	O
cells	O
.	O

Early	O
sympathetic	O
ganglia	O
contain	O
at	O
least	O
two	O
subpopulations	O
:	O
early	O
differentiating	O
neurons	O
that	O
lack	O
TrkB	O
expression	O
and	O
express	O
TrkA	O
and	O
TrkC	O
,	O
and	O
late	O
differentiating	O
sympathoblasts	O
that	O
express	O
TrkB.	O
Explant	O
cultures	O
of	O
sympathetic	O
ganglia	O
from	O
E16	O
chick	O
embryos	O
give	O
rise	O
to	O
two	O
neuronal	O
populations	O
:	O
one	O
that	O
remains	O
close	O
to	O
the	O
explant	O
,	O
and	O
one	O
that	O
migrates	O
away	O
from	O
the	O
explant	O
[	O
1	O
]	O
.	O

In	O
addition	O
,	O
early	O
neuronal	O
subpopulations	O
have	O
been	O
observed	O
in	O
cultures	O
of	O
neural	O
crest	O
cells	O
from	O
St.	O
13	O
/	O
14	O
quail	O
embryos	O
as	O
evidenced	O
by	O
the	O
expression	O
of	O
neuronal	O
cell	O
type	O
-	O
specific	O
gangliosides	O
[	O
17	O
]	O
.	O

Perhaps	O
these	O
different	O
subpopulations	O
will	O
ultimately	O
give	O
rise	O
to	O
the	O
two	O
neurochemically	O
distinct	O
populations	O
found	O
in	O
lumbar	O
sympathetic	O
ganglia	O
:	O
the	O
noradrenergic	O
,	O
NPY	O
-	O
containing	O
neurons	O
that	O
innervate	O
internal	O
organs	O
and	O
enteric	O
ganglia	O
and	O
the	O
cholinergic	O
,	O
VIP	O
-	O
containing	O
neurons	O
that	O
innervate	O
vasculature	O
in	O
the	O
hind	O
limbs	O
.	O

The	O
effects	O
of	O
BDNF	O
and	O
TrkB	O
deletion	O
and	O
over	O
expression	O
have	O
been	O
studied	O
on	O
superior	O
cervical	O
ganglion	O
and	O
preganglionic	O
neurons	O
in	O
thoracic	O
segments	O
of	O
the	O
spinal	O
column	O
,	O
but	O
not	O
on	O
paravertebral	O
sympathetic	O
neurons	O
.	O

In	O
the	O
superior	O
cervical	O
ganglion	O
,	O
an	O
increase	O
in	O
the	O
number	O
of	O
neurons	O
of	O
BDNF	O
null	O
mice	B
is	O
likely	O
due	O
to	O
apoptosis	O
induced	O
by	O
BDNF	O
via	O
p75NTR	O
[	O
18	O
]	O
.	O

In	O
contrast	O
,	O
the	O
responses	O
of	O
paravertebral	O
sympathetic	O
neurons	O
to	O
BDNF	O
are	O
complex	O
and	O
subtype	O
dependent	O
.	O

Over	O
expression	O
of	O
BDNF	O
leads	O
to	O
an	O
increase	O
in	O
the	O
number	O
of	O
noradrenergic	O
fibers	O
innervating	O
the	O
erector	O
pilli	O
muscles	O
of	O
hair	O
follicles	O
,	O
while	O
noradrenergic	O
fibers	O
innervating	O
blood	O
vessels	O
were	O
unaffected	O
[	O
19	O
]	O
.	O

If	O
our	O
results	O
indicating	O
that	O
BDNF	O
promotes	O
proliferation	O
of	O
TrkB	O
-	O
positive	O
sympathoblasts	O
in	O
the	O
chicken	B
embryo	O
can	O
be	O
extrapolated	O
to	O
the	O
subset	O
of	O
TrkB	O
-	O
positive	O
sympathoblasts	O
in	O
murine	O
ganglia	O
,	O
then	O
these	O
TrkB	O
-	O
positive	O
cells	O
may	O
be	O
neurons	O
destined	O
to	O
innervate	O
the	O
erector	O
pilli	O
.	O

In	O
other	O
studies	O
,	O
TrkB	O
null	O
mice	B
showed	O
no	O
changes	O
in	O
morphology	O
or	O
cell	O
number	O
in	O
superior	O
cervical	O
ganglia	O
[	O
12	O
]	O
or	O
in	O
the	O
intermediolateral	O
column	O
[	O
20	O
]	O
;	O
but	O
this	O
may	O
not	O
be	O
predictive	O
of	O
a	O
phenotype	O
in	O
the	O
lumbar	O
paravertebral	O
chain	O
.	O

It	O
is	O
thus	O
possible	O
that	O
BDNF	O
/	O
TrkB	O
signaling	O
could	O
play	O
a	O
specific	O
role	O
in	O
other	O
regions	O
of	O
the	O
paravertebral	O
sympathetic	O
chain	O
,	O
such	O
as	O
the	O
lumbar	O
region	O
.	O

However	O
,	O
if	O
TrkB	O
-	O
positive	O
cells	O
are	O
not	O
normally	O
actively	O
proliferating	O
in	O
vivo	O
,	O
then	O
it	O
would	O
not	O
be	O
surprising	O
that	O
the	O
development	O
of	O
the	O
paravertebral	O
sympathetic	O
chain	O
is	O
not	O
disrupted	O
in	O
TrkB	O
or	O
BDNF	O
null	O
mice	B
.	O

It	O
may	O
be	O
more	O
informative	O
to	O
examine	O
mice	B
that	O
over	O
express	O
BDNF	O
on	O
a	O
promoter	O
that	O
targets	O
expression	O
to	O
embryonic	O
lumbar	O
ganglia	O
.	O

Unfortunately	O
,	O
such	O
mice	B
do	O
not	O
exist	O
.	O

Our	O
findings	O
that	O
the	O
St.	O
29	O
/	O
30	O
(	O
E6.5	O
)	O
sympathoblasts	O
are	O
dependent	O
on	O
both	O
NT-3	O
and	O
NGF	O
for	O
survival	O
in	O
culture	O
are	O
consistent	O
with	O
previous	O
work	O
on	O
mouse	B
sympathoblasts	O
from	O
the	O
superior	O
cervical	O
ganglion	O
[	O
11	O
]	O
.	O

In	O
these	O
studies	O
,	O
NT-3	O
and	O
NGF	O
deletion	O
separately	O
led	O
to	O
a	O
decrease	O
in	O
the	O
number	O
of	O
sympathetic	O
neurons	O
at	O
E17.5	O
compared	O
to	O
control	O
.	O

Deletion	O
of	O
both	O
NT-3	O
and	O
NGF	O
together	O
did	O
not	O
enhance	O
cell	O
death	O
.	O

In	O
contrast	O
,	O
cultured	O
rat	B
superior	O
cervical	O
ganglion	O
sympathetic	O
neurons	O
respond	O
to	O
NT-3	O
at	O
E14.5	O
and	O
then	O
to	O
NGF	O
at	O
E19.5	O
,	O
although	O
time	O
points	O
in	O
between	O
were	O
not	O
analyzed	O
[	O
6	O
]	O
.	O

In	O
addition	O
to	O
promoting	O
survival	O
,	O
NT-3	O
,	O
NGF	O
,	O
and	O
BDNF	O
also	O
induce	O
proliferation	O
of	O
various	O
neuronal	O
precursors	O
at	O
different	O
stages	O
of	O
development	O
.	O

NT-3	O
can	O
promote	O
the	O
incorporation	O
of	O
[	O
3H	O
]	O
-thymidine	O
into	O
cultured	O
quail	O
neural	O
crest	O
cells	O
from	O
the	O
trunk	O
region	O
[	O
21,22	O
]	O
,	O
Later	O
in	O
rat	B
sympathetic	O
development	O
,	O
NT-3	O
supports	O
survival	O
of	O
neurons	O
,	O
but	O
does	O
not	O
promote	O
proliferation	O
[	O
6	O
]	O
,	O
which	O
is	O
consistent	O
with	O
our	O
results	O
.	O

NGF	O
promotes	O
an	O
increase	O
in	O
BrdU	O
incorporation	O
from	O
25	O
%	O
to	O
35	O
%	O
in	O
the	O
DRG	O
cervical	O
segment	O
2	O
in	O
the	O
chick	O
embryo	O
[	O
23	O
]	O
.	O

In	O
chicken	B
embryos	O
that	O
are	O
treated	O
with	O
NGF	O
in	O
ovo	O
at	O
St.	O
18	O
and	O
21	O
,	O
there	O
is	O
an	O
increase	O
in	O
BrdU	O
uptake	O
after	O
formation	O
of	O
the	O
primary	O
sympathetic	O
chain	O
at	O
St.	O
23	O
[	O
24	O
]	O
.	O

Since	O
NGF	O
does	O
not	O
appear	O
to	O
affect	O
proliferation	O
of	O
St.	O
29	O
/	O
30	O
(	O
E6.5	O
)	O
chick	O
sympathoblasts	O
,	O
NGF	O
may	O
only	O
promote	O
proliferation	O
in	O
primary	O
,	O
but	O
not	O
secondary	O
chain	O
sympathoblasts	O
.	O

Motor	O
neuron	O
progenitors	O
in	O
the	O
ventral	O
neural	O
tube	O
from	O
the	O
chick	O
embryo	O
express	O
TrkB	O
and	O
when	O
ventral	O
neural	O
tube	O
explants	O
are	O
treated	O
with	O
BDNF	O
,	O
there	O
is	O
an	O
increase	O
in	O
the	O
number	O
of	O
motor	O
neurons	O
produced	O
and	O
BrdU	O
incorporation	O
[	O
25	O
]	O
.	O

BDNF	O
also	O
promotes	O
the	O
proliferation	O
of	O
cultured	O
neuroblastoma	O
cells	O
[	O
13	O
]	O
.	O

Taken	O
together	O
,	O
these	O
results	O
are	O
consistent	O
with	O
our	O
findings	O
that	O
NT-3	O
and	O
NGF	O
do	O
not	O
promote	O
proliferation	O
of	O
St.	O
29	O
/	O
30	O
(	O
E6.5	O
)	O
sympathoblasts	O
,	O
and	O
support	O
the	O
assertion	O
that	O
BDNF	O
promotes	O
proliferation	O
of	O
TrkB	O
-	O
positive	O
sympathoblasts	O
in	O
culture	O
.	O

Our	O
observations	O
suggest	O
a	O
transient	O
function	O
of	O
TrkB	O
during	O
early	O
sympathetic	O
development	O
in	O
supporting	O
proliferation	O
of	O
this	O
early	O
subpopulation	O
of	O
sympathoblasts	O
.	O

However	O
,	O
the	O
in	O
vivo	O
labeling	O
suggests	O
that	O
only	O
a	O
minority	O
(	O
10–20	O
%	O
)	O
of	O
this	O
population	O
is	O
dividing	O
during	O
the	O
window	O
that	O
TrkB	O
is	O
expressed	O
.	O

In	O
light	O
of	O
the	O
very	O
strong	O
proliferative	O
effect	O
produced	O
in	O
cell	O
culture	O
,	O
these	O
TrkB	O
expressing	O
cells	O
could	O
respond	O
more	O
strongly	O
if	O
endogenous	O
BDNF	O
rises	O
to	O
higher	O
levels	O
,	O
or	O
if	O
the	O
mechanism	O
that	O
down	O
regulates	O
TrkB	O
expression	O
becomes	O
nonfunctional	O
.	O

Such	O
events	O
could	O
trigger	O
an	O
early	O
proliferative	O
event	O
that	O
leads	O
to	O
a	O
cascade	O
of	O
changes	O
that	O
initiates	O
transformation	O
of	O
cells	O
to	O
neuroblastoma	O
.	O

Thus	O
,	O
these	O
early	O
TrkB	O
expressing	O
cells	O
help	O
solve	O
the	O
puzzle	O
as	O
to	O
why	O
TrkB	O
is	O
expressed	O
in	O
aggressive	O
and	O
invasive	O
forms	O
of	O
neuroblastoma	O
,	O
particularly	O
because	O
BDNF	O
induces	O
cultured	O
neuroblastoma	O
cells	O
to	O
become	O
more	O
proliferative	O
,	O
invasive	O
,	O
angiogenic	O
,	O
and	O
resistant	O
to	O
chemotherapeutic	O
reagents	O
than	O
untreated	O
cultures	O
[	O
13	O
]	O
.	O

Future	O
studies	O
will	O
determine	O
whether	O
constitutive	O
expression	O
of	O
BDNF	O
and	O
TrkB	O
in	O
the	O
chick	O
embryo	O
sustains	O
proliferation	O
of	O
differentiating	O
sympathoblasts	O
.	O

Conclusion	O
We	O
have	O
identified	O
a	O
time	O
point	O
during	O
development	O
when	O
differentiating	O
lumbar	O
sympathetic	O
neurons	O
transiently	O
express	O
TrkB	O
and	O
proliferate	O
in	O
response	O
to	O
high	O
concentrations	O
of	O
BDNF	O
in	O
culture	O
.	O

These	O
studies	O
suggest	O
that	O
elevated	O
BDNF	O
expression	O
above	O
basal	O
levels	O
and	O
signaling	O
through	O
TrkB	O
may	O
be	O
a	O
mechanism	O
that	O
contributes	O
to	O
the	O
onset	O
of	O
neuroblastoma	O
.	O

A	O
further	O
understanding	O
of	O
the	O
two	O
populations	O
of	O
sympathetic	O
neurons	O
and	O
the	O
fate	O
of	O
the	O
TrkB	O
-	O
positive	O
cells	O
will	O
provide	O
additional	O
insight	O
into	O
the	O
development	O
of	O
paravertebral	O
sympathetic	O
ganglia	O
and	O
the	O
genesis	O
of	O
neuroblastoma	O
.	O

Methods	O
Preparation	O
of	O
tissue	O
for	O
immunohistochemistry	O
The	O
lumbar	O
spinal	O
column	O
and	O
surrounding	O
tissues	O
were	O
dissected	O
from	O
chicken	B
embryos	O
at	O
the	O
indicated	O
stages	O
and	O
placed	O
in	O
Zamboni	O
's	O
fixative	O
(	O
4	O
%	O
(	O
w	O
/	O
v	O
)	O
paraformaldehyde	O
,	O
15	O
%	O
(	O
v	O
/	O
v	O
)	O
picric	O
acid	O
in	O
0.1	O
M	O
sodium	O
phosphate	O
buffer	O
,	O
pH	O
7.4	O
)	O
for	O
two	O
hours	O
at	O
room	O
temperature	O
.	O

Mouse	B
embryos	O
at	O
13–15	O
days	O
post	O
-	O
coitus	O
were	O
collected	O
according	O
to	O
an	O
IACUC	O
-	O
approved	O
protocol	O
to	O
Dr.	O
L.	O
Sherman	O
at	O
the	O
Oregon	O
Health	O
and	O
Science	O
University	O
.	O

The	O
mouse	B
embryos	O
were	O
immersion	O
-	O
fixed	O
in	O
Zamboni	O
's	O
fixative	O
overnight	O
at	O
4	O
degrees	O
C	O
then	O
washed	O
with	O
phosphate	O
buffered	O
saline	O
(	O
PBS	O
;	O
130	O
mM	O
NaCl	O
,	O
20	O
mM	O
sodium	O
phosphate	O
buffer	O
,	O
pH	O
7.4	O
)	O
.	O

Fixed	O
tissues	O
were	O
equilibrated	O
in	O
30	O
%	O
sucrose	O
in	O
1	O
×	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
)	O
.	O

Fixed	O
mouse	B
embryos	O
were	O
shipped	O
to	O
Vermont	O
in	O
sucrose	O
.	O

Transverse	O
30	O
μM	O
sections	O
of	O
the	O
spinal	O
columns	O
were	O
cut	O
at	O
on	O
a	O
Microm	O
HM	O
cryostat	O
(	O
knife	O
temperature	O
:	O
16	O
°	O
C	O
;	O
object	O
temperature	O
:	O
23	O
°	O
C	O
)	O
and	O
collected	O
on	O
Superfrost	O
Plus	O
slides	O
(	O
Fisher	O
)	O
.	O

Sections	O
were	O
dried	O
at	O
room	O
temperature	O
,	O
washed	O
in	O
1	O
×	O
PBS	O
and	O
incubated	O
overnight	O
in	O
blocking	O
buffer	O
(	O
1	O
×	O
PBS	O
consisting	O
of	O
10	O
%	O
(	O
v	O
/	O
v	O
)	O
heat	O
-	O
inactivated	O
horse	B
serum	O
(	O
Invitrogen	O
/	O
Gibco	O
)	O
,	O
0.5	O
%	O
Triton	O
X-100	O
(	O
Sigma	O
)	O
,	O
and	O
0.1	O
%	O
sodium	O
azide	O
(	O
Fisher	O
)	O
)	O
.	O

Immunohistochemistry	O
Sections	O
were	O
incubated	O
with	O
primary	O
antibodies	O
overnight	O
at	O
4	O
°	O
C	O
,	O
followed	O
by	O
incubation	O
with	O
secondary	O
antibodies	O
for	O
2	O
hours	O
at	O
room	O
temperature	O
.	O

Primary	O
antibodies	O
used	O
were	O
:	O
rabbit	B
anti	O
-	O
p75	O
(	O
1:1500	O
,	O
generous	O
gift	O
from	O
Louis	O
Reichardt	O
,	O
UCSF	O
[	O
26	O
]	O
)	O
,	O
mouse	B
IgG2b	O
anti	O
-	O
Hu	O
C	O
/	O
D	O
,	O
(	O
1:250	O
,	O
Molecular	O
Probes	O
)	O
;	O
mouse	B
IgG1	O
anti	O
-	O
Islet-1	O
,	O
(	O
1:10	O
,	O
Developmental	O
Studies	O
Hybridoma	O
Bank	O
)	O
;	O
rabbit	B
anti	O
-	O
chicken	B
TrkA	O
(	O
1:500	O
)	O
;	O
rabbit	B
anti	O
-	O
chicken	B
TrkB	O
(	O
1:500	O
)	O
;	O
rabbit	B
anti	O
-	O
chicken	B
TrkC	O
(	O
1:500	O
)	O
(	O
all	O
Trk	O
antibodies	O
were	O
generous	O
gifts	O
of	O
Dr.	O
Louis	O
Reichardt	O
,	O
UCSF	O
[	O
26	O
-	O
28	O
]	O
)	O
;	O
mouse	B
anti	O
-	O
HNK-1	O
(	O
1:50	O
,	O
Developmental	O
Studies	O
Hybridoma	O
Bank	O
)	O
;	O
mouse	B
IgG2a	O
anti	O
-	O
tyrosine	O
hydroxylase	O
(	O
1:10	O
,	O
Developmental	O
Studies	O
Hybridoma	O
Bank	O
)	O
,	O
sheep	B
anti	O
-	O
BrdU	O
(	O
1:100	O
,	O
Biodesign	O
International	O
)	O
,	O
rabbit	B
anti	O
-	O
tyrosine	O
hydroxylase	O
(	O
1:100	O
,	O
Chemicon	O
)	O
,	O
and	O
goat	B
anti	O
-	O
TrkB	O
(	O
1:1000	O
,	O
R&D	O
Systems	O
)	O
.	O

Immunofluorescence	O
was	O
imaged	O
using	O
a	O
Nikon	O
C1	O
confocal	O
mounted	O
on	O
a	O
Nikon	O
Eclipse	O
E800	O
microscope	O
with	O
a	O
10	O
×	O
Plan	O
Apo	O
(	O
NA	O
0.785	O
)	O
air	O
objective	O
or	O
a	O
60	O
×	O
Plan	O
Apo	O
(	O
NA	O
1.4	O
)	O
oil	O
objective	O
lens	O
,	O
E7-C1	O
software	O
,	O
and	O
UV	O
,	O
Argon	O
,	O
and	O
He	O
/	O
Ne	O
lasers	O
exciting	O
at	O
408	O
,	O
488	O
,	O
and	O
543	O
nm	O
and	O
emitting	O
at	O
404	O
500–530	O
,	O
and	O
555–615	O
nm	O
,	O
respectively	O
.	O

A	O
Nikon	O
Eclipse	O
E800	O
microscope	O
in	O
the	O
nearby	O
COBRE	O
Molecular	O
/	O
Cellular	O
Core	O
Facility	O
was	O
used	O
for	O
counting	O
immunofluorescent	O
cells	O
at	O
200	O
×	O
using	O
epifluorescence	O
optics	O
.	O

RNA	O
Extraction	O
/	O
cDNA	O
synthesis	O
Sympathetic	O
ganglia	O
were	O
removed	O
from	O
chick	O
embryos	O
and	O
RNA	O
was	O
isolated	O
using	O
TriReagent	O
(	O
Molecular	O
Research	O
Center	O
)	O
,	O
an	O
acidified	O
guanidinium	O
with	O
phenol	O
extraction	O
method	O
[	O
29	O
]	O
.	O

RNA	O
was	O
transcribed	O
to	O
cDNA	O
using	O
oligo	O
-	O
dT	O
with	O
Superscript	O
II	O
Reverse	O
Transcriptase	O
(	O
Invitrogen	O
)	O
at	O
42	O
°	O
C	O
for	O
1	O
hour	O
.	O

Real	O
-	O
time	O
PCR	O
Relative	O
RNA	O
levels	O
were	O
determined	O
using	O
quantitative	O
real	O
-	O
time	O
PCR	O
with	O
an	O
ABI	O
7500	O
Fast	O
Real	O
Time	O
PCR	O
System	O
.	O

TaqMan	O
probes	O
were	O
used	O
to	O
quantify	O
the	O
progression	O
of	O
the	O
PCR	O
reaction	O
and	O
reactions	O
were	O
normalized	O
using	O
the	O
constitutively	O
expressed	O
gene	O
chick	O
ribosomal	O
binding	O
protein	O
s17	O
(	O
CHRPS	O
)	O
.	O

The	O
sequences	O
were	O
used	O
for	O
primer	O
/	O
probes	O
sets	O
:	O
for	O
BDNF	O
:	O
forward	O
:	O
5'-AGCCCAGTGAGGAAAACAAG-3	O
'	O
,	O
reverse	O
:	O
5'-ACTCCTCGAGCAGAAAGAGC-3	O
'	O
,	O
probe	O
:	O
5'-	O
[	O
6-FAM	O
]	O
-TACACATCCCGAGTCATGCTGAGCA-	O
[	O
BHQ	O
]	O
-3	O
'	O
;	O
for	O
CHRPS	O
(	O
chick	O
ribosomal	O
binding	O
protein	O
S-17	O
)	O
:	O
5'AACGACTTCCACACCAACAA3	O
'	O
,	O
reverse	O
:	O
5'CTTCATCAGGTGGGTGACAT3	O
'	O
,	O
probe	O
:	O
5'-	O
[	O
6-FAM	O
]	O
-CGCCATCATCCCCAGCAAGA	O
[	O
BHQ	O
]	O
-3	O
'	O
.	O

Primers	O
and	O
probes	O
were	O
synthesized	O
by	O
Operon	O
Technologies	O
,	O
Inc	O
(	O
Alameda	O
,	O
CA	O
)	O
.	O

The	O
primers	O
for	O
BDNF	O
were	O
validated	O
against	O
primers	O
for	O
CHRPS	O
according	O
to	O
an	O
Applied	O
BioSystems	O
protocol	O
by	O
serially	O
diluting	O
the	O
target	O
cDNA	O
1:10	O
,	O
determining	O
the	O
cycle	O
threshold	O
(	O
Ct	O
)	O
for	O
each	O
reaction	O
,	O
and	O
plotting	O
the	O
Ct	O
versus	O
log	O
concentration	O
.	O

Slopes	O
of	O
the	O
resulting	O
lines	O
were	O
calculated	O
and	O
primers	O
were	O
accepted	O
if	O
their	O
Ct	O
slopes	O
were	O
between	O
-3.2	O
and	O
-3.4	O
(	O
a	O
perfect	O
efficiency	O
of	O
1.0	O
yields	O
a	O
slope	O
of	O
-3.3	O
)	O
.	O

To	O
analyze	O
the	O
data	O
,	O
the	O
delta	O
Ct	O
method	O
of	O
relative	O
quantification	O
was	O
used	O
,	O
where	O
the	O
Ct	O
of	O
Chrps	O
was	O
subtracted	O
from	O
the	O
Ct	O
of	O
the	O
gene	O
of	O
interest	O
(	O
Delta	O
Ct	O
)	O
and	O
the	O
arbitrary	O
units	O
of	O
mRNA	O
were	O
expressed	O
as	O
10000	O
/	O
2^	O
(	O
Delta	O
Ct	O
)	O
.	O

Cell	O
culture	O
Sympathetic	O
neurons	O
were	O
cultured	O
as	O
previously	O
described	O
[	O
30	O
]	O
with	O
a	O
few	O
modifications	O
.	O

Sympathetic	O
ganglia	O
were	O
removed	O
from	O
the	O
lumbar	O
region	O
of	O
the	O
paravertebral	O
chain	O
of	O
St.	O
29	O
/	O
30	O
(	O
E6.5	O
)	O
chick	O
embryos	O
and	O
placed	O
in	O
Modified	O
Puck	O
's	O
solution	O
with	O
glucose	O
(	O
MPG	O
)	O
.	O

The	O
cells	O
were	O
dissociated	O
by	O
incubation	O
of	O
sympathetic	O
ganglia	O
with	O
0.1	O
%	O
trypsin	O
in	O
MPG	O
at	O
37	O
°	O
C	O
for	O
10	O
minutes	O
followed	O
by	O
triturating	O
with	O
a	O
fire	O
polished	O
9	O
"	O
Pasteur	O
pipette	O
.	O

Cells	O
were	O
then	O
resuspended	O
in	O
Dulbecco	O
's	O
Modified	O
Eagle	O
Medium	O
(	O
DMEM	O
)	O
consisting	O
of	O
10	O
%	O
horse	B
serum	O
,	O
2	O
%	O
fetal	O
calf	O
serum	O
,	O
and	O
10	O
mg	O
/	O
ml	O
penicillin	O
/	O
streptomycin	O
.	O

For	O
neurotrophin	O
studies	O
,	O
the	O
culture	O
medium	O
was	O
supplemented	O
with	O
25	O
ng	O
/	O
ml	O
NT-3	O
(	O
R	O
&	O
D	O
Systems	O
)	O
and	O
1	O
μg	O
/	O
ml	O
7S	O
NGF	O
(	O
Alomone	O
Labs	O
)	O
upon	O
plating	O
,	O
and	O
50	O
ng	O
/	O
ml	O
,	O
100	O
ng	O
/	O
ml	O
,	O
or	O
200	O
ng	O
/	O
ml	O
BDNF	O
(	O
R	O
&	O
D	O
Systems	O
)	O
once	O
the	O
cells	O
adhered	O
to	O
the	O
wells	O
.	O

Cells	O
were	O
plated	O
on	O
poly	O
-	O
D	O
-	O
lysine	O
/	O
laminin	O
coated	O
wells	O
or	O
cover	O
slips	O
(	O
Fisher	O
)	O
as	O
previously	O
described	O
[	O
30	O
]	O
.	O

Quantification	O
of	O
neurons	O
and	O
sympathoblasts	O
using	O
phase	O
microscopy	O
Embryonic	O
sympathoblasts	O
and	O
neurons	O
are	O
small	O
,	O
phase	O
bright	O
cells	O
with	O
neurites	O
.	O

The	O
total	O
number	O
of	O
cells	O
with	O
neurites	O
the	O
length	O
of	O
two	O
cell	O
bodies	O
were	O
counted	O
in	O
10	O
non	O
-	O
overlapping	O
fields	O
of	O
view	O
evenly	O
spaced	O
in	O
a	O
grid	O
-	O
like	O
pattern	O
across	O
the	O
bottom	O
of	O
a	O
well	O
from	O
a	O
24	O
well	O
plate	O
at	O
200	O
×	O
using	O
a	O
Nikon	O
Eclipse	O
TE200	O
microscope	O
.	O

BrdU	O
labeling	O
For	O
in	O
vitro	O
studies	O
,	O
approximately	O
2	O
hours	O
after	O
plating	O
cells	O
from	O
St.	O
29	O
/	O
30	O
(	O
E6.5	O
)	O
sympathetic	O
ganglia	O
,	O
cells	O
were	O
labeled	O
with	O
10	O
μM	O
bromodeoxyuridine	O
(	O
BrdU	O
,	O
Sigma	O
)	O
for	O
12	O
hours	O
at	O
37	O
°	O
C	O
.	O

Following	O
this	O
labeling	O
period	O
,	O
cells	O
were	O
incubated	O
in	O
complete	O
medium	O
without	O
BrdU	O
for	O
an	O
additional	O
10	O
hrs	O
.	O

Cells	O
were	O
then	O
fixed	O
in	O
Zamboni	O
's	O
fixative	O
for	O
30	O
min	O
at	O
room	O
temperature	O
and	O
rinsed	O
with	O
1	O
×	O
PBS	O
.	O

For	O
in	O
vivo	O
studies	O
,	O
25	O
μg	O
BrdU	O
was	O
injected	O
into	O
the	O
amnion	O
of	O
chick	O
embryos	O
at	O
St.	O
27	O
.	O

The	O
cells	O
and	O
sections	O
were	O
denatured	O
with	O
2	O
N	O
HCl	O
at	O
37	O
°	O
C	O
for	O
1	O
hr	O
,	O
and	O
were	O
then	O
neutralized	O
with	O
0.1	O
M	O
borate	O
buffer	O
,	O
pH	O
8.5	O
,	O
for	O
10	O
min	O
at	O
room	O
temperature	O
.	O

Immunochemistry	O
was	O
performed	O
as	O
described	O
above	O
.	O

Abbreviations	O
BDNF	O
,	O
brain	O
-	O
derived	O
neurotrophic	O
factor	O
;	O
BrdU	O
,	O
Bromodeoxyuridine	O
;	O
DA	O
,	O
dorsal	O
aorta	O
;	O
DMEM	O
,	O

Dulbecco	O
's	O
Modified	O
Eagle	O
's	O
Medium	O
;	O
DRG	O
,	O
dorsal	O
root	O
ganglion	O
;	O
E	O
,	O
embryonic	O
day	O
;	O
HS	O
,	O
horse	B
serum	O
;	O
MPG	O
,	O
Modified	O
Puck	O
's	O
solution	O
with	O
glucose	O
;	O
NGF	O
,	O
nerve	O
growth	O
factor	O
;	O
NC	O
,	O
notochord	O
;	O
NT	O
,	O
neural	O
tube	O
;	O
NT-3	O
,	O
neurotrophin-3	O
;	O
NTR	O
,	O
neurotrophin	O
receptor	O
;	O
PBS	O
,	O
phosphate	O
-	O
buffered	O
saline	O
;	O
SC	O
,	O
spinal	O
cord	O
;	O
SCG	O
,	O
superior	O
cervical	O
ganglion	O
;	O
SEM	O
,	O
standard	O
error	O
of	O
the	O
mean	O
;	O
SG	O
,	O
sympathetic	O
ganglion	O
;	O
St.	O
,	O
stage	O
;	O
w	O
/	O
v	O
,	O
weight	O
/	O
volume	O
;	O
v	O
/	O
v	O
,	O
volume	O
/	O
volume	O
.	O

Authors	O
'	O
contributions	O
JAS	O
designed	O
the	O
experiments	O
,	O
performed	O
the	O
experiments	O
,	O
analyzed	O
the	O
data	O
,	O
and	O
wrote	O
the	O
manuscript	O
.	O

GLSS	O
contributed	O
intellectually	O
to	O
the	O
conception	O
and	O
design	O
of	O
this	O
study	O
,	O
and	O
assisted	O
in	O
the	O
interpretation	O
of	O
the	O
results	O
.	O

RN	O
supervised	O
the	O
study	O
,	O
participated	O
in	O
the	O
design	O
of	O
experiments	O
,	O
edited	O
the	O
manuscript	O
,	O
and	O
obtained	O
funding	O
for	O
the	O
project	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

The	O
recombination	O
-	O
associated	O
protein	O
RdgC	O
adopts	O
a	O
novel	O
toroidal	O
architecture	O
for	O
DNA	O
binding	O
Abstract	O
RecA	O
plays	O
a	O
central	O
role	O
in	O
the	O
nonmutagenic	O
repair	O
of	O
stalled	O
replication	O
forks	O
in	O
bacteria	O
.	O

RdgC	O
,	O
a	O
recombination	O
-	O
associated	O
DNA	O
-	O
binding	O
protein	O
,	O
is	O
a	O
potential	O
negative	O
regulator	O
of	O
RecA	O
function	O
.	O

Here	O
,	O
we	O
have	O
determined	O
the	O
crystal	O
structure	O
of	O
RdgC	O
from	O
Pseudomonas	B
aeruginosa	I
.	O

The	O
J	O
-	O
shaped	O
monomer	O
has	O
a	O
unique	O
fold	O
and	O
can	O
be	O
divided	O
into	O
three	O
structural	O
domains	O
:	O
tip	O
domain	O
,	O
center	O
domain	O
and	O
base	O
domain	O
.	O

Two	O
such	O
monomers	O
dimerize	O
to	O
form	O
a	O
ring	O
-	O
shaped	O
molecule	O
of	O
approximate	O
2-fold	O
symmetry	O
.	O

Of	O
the	O
two	O
inter	O
-	O
subunit	O
interfaces	O
within	O
the	O
dimer	O
,	O
one	O
interface	O
(	O
'	O
interface	O
A	O
'	O
)	O
between	O
tip	O
/	O
center	O
domains	O
is	O
more	O
nonpolar	O
than	O
the	O
other	O
(	O
'	O
interface	O
B	O
'	O
)	O
between	O
base	O
domains	O
.	O

The	O
structure	O
allows	O
us	O
to	O
propose	O
that	O
the	O
RdgC	O
dimer	O
binds	O
dsDNA	O
through	O
the	O
central	O
hole	O
of	O
∼30	O
Å	O
diameter	O
.	O

The	O
proposed	O
model	O
is	O
supported	O
by	O
our	O
DNA	O
-	O
binding	O
assays	O
coupled	O
with	O
mutagenesis	O
,	O
which	O
indicate	O
that	O
the	O
conserved	O
positively	O
charged	O
residues	O
on	O
the	O
protein	O
surface	O
around	O
the	O
central	O
hole	O
play	O
important	O
roles	O
in	O
DNA	O
binding	O
.	O

The	O
novel	O
ring	O
-	O
shaped	O
architecture	O
of	O
the	O
RdgC	O
dimer	O
has	O
significant	O
implications	O
for	O
its	O
role	O
in	O
homologous	O
recombination	O
.	O

INTRODUCTION	O
Homologous	O
recombination	O
systems	O
contribute	O
to	O
the	O
maintenance	O
of	O
genome	O
integrity	O
and	O
are	O
essential	O
for	O
the	O
repair	O
of	O
stalled	O
replication	O
forks	O
(	O
1	O
)	O
.	O

Genetic	O
studies	O
of	O
the	O
recombination	O
-	O
dependent	O
growth	O
C	O
(	O
rdgC	O
)	O
gene	O
in	O
bacterial	O
systems	O
have	O
suggested	O
that	O
it	O
is	O
involved	O
in	O
DNA	O
replication	O
and	O
recombination	O
(	O
2,3	O
)	O
.	O

In	O
Neisseria	B
gonorrhoeae	I
(	O
the	O
gonococcus	O
)	O
,	O
RdgC	O
is	O
required	O
for	O
efficient	O
pilin	O
antigenic	O
variation	O
and	O
plays	O
some	O
role	O
in	O
cell	O
growth	O
(	O
4,5	O
)	O
.	O

The	O
Escherichia	B
coli	I
rdgC	O
gene	O
encodes	O
a	O
DNA	O
-	O
binding	O
protein	O
of	O
34	O
kDa	O
,	O
whose	O
expression	O
level	O
was	O
at	O
its	O
highest	O
during	O
exponential	O
phase	O
,	O
reaching	O
its	O
maximum	O
at	O
∼1000	O
dimers	O
per	O
cell	O
(	O
2	O
)	O
.	O

Its	O
level	O
decreased	O
sharply	O
to	O
∼50	O
dimers	O
per	O
cell	O
in	O
stationary	O
phase	O
.	O

This	O
profile	O
suggests	O
that	O
RdgC	O
might	O
function	O
during	O
the	O
period	O
of	O
DNA	O
replication	O
(	O
2	O
)	O
.	O

The	O
RecA	O
proteins	O
and	O
their	O
homologs	O
play	O
a	O
key	O
role	O
in	O
recombinational	O
DNA	O
repair	O
in	O
bacteria	O
and	O
eukaryotes	O
.	O

Their	O
aberrant	O
reactions	O
could	O
result	O
in	O
gross	O
chromosomal	O
rearrangements	O
that	O
lead	O
to	O
human	B
diseases	O
,	O
including	O
cancer	O
.	O

Therefore	O
,	O
their	O
functions	O
must	O
be	O
tightly	O
regulated	O
,	O
and	O
understanding	O
how	O
the	O
RecA	O
family	O
of	O
recombinases	O
is	O
regulated	O
is	O
of	O
utmost	O
importance	O
(	O
1	O
)	O
.	O

The	O
E.	B
coli	I
RdgC	O
protein	O
is	O
a	O
potential	O
negative	O
regulator	O
of	O
the	O
function	O
of	O
RecA	O
(	O
1	O
)	O
.	O

It	O
inhibits	O
RecA	O
-	O
promoted	O
DNA	O
strand	O
exchange	O
,	O
RecA	O
-	O
mediated	O
ATPase	O
activity	O
and	O
RecA	O
-	O
dependent	O
LexA	O
cleavage	O
(	O
1	O
)	O
.	O

Sedimentation	O
equilibrium	O
data	O
indicated	O
that	O
E.	B
coli	I
RdgC	O
exists	O
in	O
solution	O
as	O
a	O
mixture	O
of	O
oligomeric	O
states	O
in	O
equilibrium	O
,	O
most	O
likely	O
monomers	O
,	O
dimers	O
and	O
tetramers	O
(	O
1	O
)	O
.	O

This	O
concentration	O
-	O
dependent	O
change	O
in	O
the	O
oligomeric	O
state	O
appears	O
to	O
affect	O
its	O
mode	O
of	O
binding	O
to	O
DNA	O
and	O
its	O
capacity	O
to	O
inhibit	O
RecA	O
(	O
1	O
)	O
.	O

The	O
primary	O
mechanism	O
of	O
RdgC	O
inhibition	O
appears	O
to	O
involve	O
a	O
simple	O
competition	O
for	O
DNA	O
-	O
binding	O
sites	O
,	O
especially	O
on	O
double	O
-	O
stranded	O
DNA	O
(	O
dsDNA	O
)	O
(	O
1	O
)	O
.	O

Deletion	O
of	O
the	O
E.	B
coli	I
rdgC	O
gene	O
alone	O
causes	O
no	O
obvious	O
phenotype	O
but	O
is	O
highly	O
deleterious	O
in	O
strains	O
lacking	O
certain	O
enzymes	O
involved	O
in	O
recombination	O
and	O
replication	O
restart	O
(	O
2,3	O
)	O
.	O

RdgC	O
is	O
essential	O
for	O
the	O
growth	O
of	O
an	O
E.	B
coli	I
strain	O
lacking	O
PriA	O
,	O
indicating	O
that	O
it	O
might	O
affect	O
replication	O
fork	O
progression	O
or	O
fork	O
rescue	O
(	O
2	O
)	O
.	O

PriA	O
provides	O
a	O
means	O
to	O
load	O
the	O
DnaB	O
replicative	O
helicase	O
at	O
DNA	O
replication	O
fork	O
and	O
D	O
loop	O
structures	O
(	O
2	O
)	O
.	O

RdgC	O
is	O
,	O
therefore	O
,	O
a	O
key	O
factor	O
in	O
the	O
rescue	O
of	O
stalled	O
or	O
broken	O
forks	O
and	O
subsequent	O
replication	O
restart	O
.	O

dnaC	O
suppressors	O
of	O
PriA	O
can	O
overcome	O
this	O
inviability	O
,	O
especially	O
when	O
RecF	O
,	O
RecO	O
or	O
RecR	O
is	O
inactivated	O
,	O
which	O
indicates	O
that	O
RdgC	O
avoids	O
or	O
counters	O
the	O
toxic	O
effect	O
of	O
these	O
proteins	O
by	O
limiting	O
inappropriate	O
RecA	O
loading	O
on	O
SSB	O
-	O
coated	O
ssDNA	O
(	O
2	O
)	O
.	O

The	O
DNA	O
-	O
binding	O
ability	O
of	O
the	O
RdgC	O
protein	O
has	O
been	O
demonstrated	O
clearly	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
2	O
)	O
.	O

Escherichia	B
coli	I
RdgC	O
binds	O
non	O
-	O
specifically	O
to	O
dsDNA	O
and	O
with	O
higher	O
affinity	O
than	O
ssDNA	O
(	O
2	O
)	O
.	O

RdgC	O
from	O
N.	B
meningitidis	I
also	O
binds	O
DNA	O
with	O
little	O
specificity	O
for	O
sequence	O
or	O
structure	O
,	O
like	O
the	O
E.	B
coli	I
protein	O
(	O
4	O
)	O
.	O

RdgC	O
exhibits	O
no	O
preference	O
for	O
DNA	O
replication	O
or	O
recombination	O
intermediates	O
(	O
2	O
)	O
.	O

However	O
,	O
no	O
detectable	O
domains	O
or	O
nuclease	O
activity	O
could	O
be	O
identified	O
for	O
the	O
E.	B
coli	I
RdgC	O
protein	O
(	O
2,6	O
)	O
.	O

The	O
complexes	O
of	O
E.	B
coli	I
RdgC	O
with	O
both	O
linear	O
and	O
supercoiled	O
circular	O
plasmid	O
DNA	O
were	O
imaged	O
using	O
atomic	O
force	O
microscopy	O
(	O
7	O
)	O
.	O

RdgC	O
was	O
found	O
to	O
have	O
an	O
increased	O
affinity	O
to	O
DNA	O
ends	O
and	O
to	O
promote	O
bending	O
of	O
DNA	O
(	O
7	O
)	O
.	O

RdgC	O
has	O
the	O
effect	O
on	O
DNA	O
superstructure	O
;	O
the	O
promotion	O
of	O
DNA	O
condensation	O
was	O
observed	O
at	O
high	O
protein	O
concentrations	O
(	O
7	O
)	O
.	O

Recombination	O
is	O
largely	O
enhanced	O
by	O
close	O
contacts	O
of	O
distant	O
regions	O
along	O
the	O
DNA	O
strands	O
through	O
condensation	O
(	O
7	O
)	O
.	O

Pseudomonas	B
aeruginosa	I
is	O
a	O
ubiquitous	O
environmental	O
Gram	O
-	O
negative	O
bacterium	O
that	O
belongs	O
to	O
the	O
γ	O
subdivision	O
of	O
the	O
Proteobacteria	O
.	O

Orthologs	O
of	O
the	O
rdgC	O
gene	O
are	O
found	O
only	O
in	O
β	O
and	O
γ	O
subdivisions	O
of	O
the	O
Proteobacteria	O
(	O
2	O
)	O
.	O

The	O
amino	O
acid	O
sequence	O
of	O
P.	B
aeruginosa	I
RdgC	O
,	O
a	O
306-residue	O
protein	O
,	O
shows	O
46	O
and	O
36	O
%	O
identities	O
against	O
those	O
of	O
E.	B
coli	I
and	O
N.	B
meningitidis	I
,	O
respectively	O
.	O

Despite	O
the	O
importance	O
of	O
DNA	O
-	O
binding	O
ability	O
of	O
RdgC	O
in	O
its	O
biological	O
roles	O
,	O
the	O
structural	O
details	O
of	O
RdgC	O
and	O
the	O
mechanism	O
of	O
its	O
action	O
remain	O
unclear	O
.	O

Here	O
,	O
we	O
report	O
the	O
crystal	O
structure	O
of	O
P.	B
aeruginosa	I
RdgC	O
as	O
determined	O
by	O
the	O
multiwavelength	O
anomalous	O
diffraction	O
(	O
MAD	O
)	O
method	O
of	O
X	O
-	O
ray	O
crystallography	O
.	O

It	O
reveals	O
that	O
RdgC	O
dimer	O
is	O
ring	O
-	O
shaped	O
,	O
with	O
a	O
central	O
hole	O
of	O
∼30	O
Å	O
diameter	O
.	O

The	O
inside	O
surface	O
around	O
the	O
central	O
hole	O
is	O
rich	O
in	O
conserved	O
,	O
positively	O
charged	O
residues	O
,	O
which	O
are	O
implicated	O
in	O
DNA	O
-	O
binding	O
by	O
mutagenesis	O
.	O

We	O
propose	O
that	O
dsDNA	O
binds	O
to	O
RdgC	O
through	O
this	O
central	O
hole	O
.	O

Our	O
structure	O
provides	O
a	O
solid	O
structural	O
framework	O
for	O
a	O
better	O
understanding	O
of	O
the	O
role	O
of	O
RdgC	O
in	O
homologous	O
recombination	O
.	O

MATERIALS	O
AND	O
METHODS	O
Protein	O
expression	O
and	O
purification	O
The	O
rdgC	O
gene	O
(	O
PA3263	O
)	O
was	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
using	O
the	O
genomic	O
DNA	O
of	O
P.	B
aeruginosa	I
strain	O
PAO1	O
as	O
a	O
template	O
.	O

The	O
oligonucleotide	O
primers	O
designed	O
using	O
the	O
published	O
genome	O
sequence	O
(	O
8)	O
were	O
5′-G	O
GAA	O
TTC	O
CAT	O
ATG	O
TGG	O
TTC	O
CGC	O
AAT	O
CTG	O
CTC	O
G-3′	O
(	O
forward	O
)	O
and	O
5′-CCG	O
CCG	O
CTC	O
GAG	O
GAC	O
GCC	O
CTG	O
GGG	O
GAT	O
TTC	O
TTC-3′	O
(	O
reverse	O
)	O
.	O

The	O
bases	O
in	O
bold	O
denote	O
the	O
NdeI	O
and	O
XhoI	O
cleavage	O
sites	O
,	O
respectively	O
.	O

The	O
PCR	O
product	O
was	O
digested	O
with	O
NdeI	O
and	O
XhoI	O
,	O
and	O
was	O
then	O
inserted	O
into	O
the	O
NdeI	O
/	O
XhoI	O
-	O
digested	O
expression	O
vector	O
pET-21a	O
(	O
+	O
)	O
(	O
Novagen	O
)	O
.	O

This	O
vector	O
construction	O
adds	O
an	O
eight	O
-	O
residue	O
tag	O
(	O
LEHHHHHH	O
)	O
to	O
the	O
carboxyl	O
terminus	O
of	O
the	O
gene	O
product	O
to	O
facilitate	O
protein	O
purification	O
.	O

The	O
protein	O
was	O
expressed	O
in	O
E.	B
coli	I
C41	O
(	O
DE3	O
)	O
cells	O
(	O
9	O
)	O
.	O

The	O
cells	O
were	O
grown	O
at	O
37	O
°	O
C	O
up	O
to	O
OD600	O
of	O
0.6	O
in	O
Luria	O
–	O
Bertani	O
medium	O
that	O
contained	O
50	O
μg	O
ml−1	O
ampicillin	O
,	O
and	O
the	O
protein	O
expression	O
was	O
induced	O
by	O
0.5	O
mM	O
isopropyl	O
-	O
β	O
-	O
d	O
-	O
thiogalactopyranoside	O
(	O
IPTG	O
)	O
.	O

The	O
cells	O
were	O
allowed	O
to	O
grow	O
at	O
20	O
°	O
C	O
for	O
22	O
h	O
after	O
IPTG	O
induction	O
and	O
were	O
harvested	O
by	O
centrifugation	O
at	O
4200	O
g	O
(	O
6000	O
rev	O
min−1	O
;	O
Sorvall	O
GSA	O
rotor	O
)	O
for	O
10	O
min	O
at	O
4	O
°	O
C	O
.	O

The	O
cell	O
pellet	O
was	O
resuspended	O
in	O
an	O
ice	O
-	O
cold	O
lysis	O
buffer	O
[	O
20	O
mM	O
Tris	O
-	O
HCl	O
(	O
pH	O
7.9	O
)	O
,	O
500	O
mM	O
sodium	O
chloride	O
,	O
5	O
mM	O
imidazole	O
]	O
and	O
was	O
then	O
homogenized	O
with	O
an	O
ultrasonic	O
processor	O
.	O

The	O
crude	O
cell	O
extract	O
was	O
centrifuged	O
at	O
36	O
000	O
g	O
(	O
18	O
000	O
rev	O
min−1	O
;	O
Hanil	O
Supra	O
21	O
K	O
rotor	O
)	O
for	O
60	O
min	O
at	O
4	O
°	O
C	O
,	O
and	O
the	O
recombinant	O
protein	O
in	O
the	O
supernatant	O
fraction	O
was	O
purified	O
in	O
three	O
chromatographic	O
steps	O
.	O

The	O
first	O
purification	O
step	O
utilized	O
the	O
C	O
-	O
terminal	O
hexahistidine	O
-	O
tag	O
by	O
Ni2	O
+	O
-chelated	O
HiTrap	O
chelating	O
column	O
(	O
GE	O
Healthcare	O
)	O
.	O

The	O
eluent	O
was	O
diluted	O
3-fold	O
with	O
50	O
mM	O
Tris	O
-	O
HCl	O
at	O
pH	O
7.4	O
.	O

The	O
diluted	O
solution	O
was	O
applied	O
to	O
a	O
20-ml	O
heparin	O
-	O
Sepharose	O
column	O
(	O
GE	O
Healthcare	O
)	O
,	O
which	O
was	O
previously	O
equilibrated	O
with	O
a	O
buffer	O
of	O
50	O
mM	O
Tris	O
-	O
HCl	O
(	O
pH	O
7.4	O
)	O
,	O
1	O
mM	O
dithiothreitol	O
and	O
1	O
mM	O
EDTA	O
.	O

The	O
protein	O
was	O
eluted	O
with	O
a	O
linear	O
gradient	O
of	O
0–2.0	O
M	O
sodium	O
chloride	O
in	O
the	O
same	O
buffer	O
.	O

The	O
first	O
peak	O
corresponded	O
to	O
high	O
molecular	O
aggregates	O
of	O
RdgC	O
and	O
the	O
second	O
peak	O
to	O
RdgC	O
dimers	O
,	O
which	O
was	O
also	O
consistent	O
with	O
our	O
dynamic	O
light	O
scattering	O
measurements	O
.	O

When	O
the	O
aggregates	O
were	O
not	O
separated	O
from	O
the	O
dimers	O
,	O
the	O
protein	O
readily	O
aggregated	O
within	O
a	O
day	O
.	O

The	O
dimer	O
fractions	O
were	O
concentrated	O
to	O
∼6	O
mg	O
ml−1	O
concentration	O
using	O
an	O
YM10	O
ultrafiltration	O
membrane	O
(	O
Millipore	O
-	O
Amicon	O
)	O
and	O
further	O
purified	O
by	O
gel	O
filtration	O
on	O
a	O
HiLoad	O
XK	O
16	O
Superdex	O
200	O
prep	O
-	O
grade	O
column	O
(	O
GE	O
Healthcare	O
)	O
,	O
which	O
was	O
previously	O
equilibrated	O
with	O
a	O
buffer	O
of	O
50	O
mM	O
Tris	O
-	O
HCl	O
(	O
pH	O
7.4	O
)	O
,	O
200	O
mM	O
sodium	O
chloride	O
,	O
1	O
mM	O
dithiothreitol	O
and	O
1	O
mM	O
EDTA	O
.	O

The	O
first	O
peak	O
corresponding	O
to	O
the	O
high	O
molecular	O
aggregates	O
of	O
RdgC	O
was	O
only	O
a	O
minor	O
component	O
,	O
and	O
the	O
second	O
peak	O
corresponding	O
to	O
RdgC	O
dimers	O
was	O
stable	O
for	O
several	O
weeks	O
when	O
frozen	O
at	O
−70	O
°	O
C	O
.	O

The	O
procedure	O
for	O
purifying	O
the	O
SeMet	O
-	O
substituted	O
protein	O
was	O
the	O
same	O
,	O
except	O
for	O
the	O
presence	O
of	O
10	O
mM	O
dithiothreitol	O
in	O
all	O
buffers	O
used	O
during	O
purification	O
steps	O
.	O

Dynamic	O
light	O
scattering	O
experiments	O
were	O
performed	O
at	O
24	O
°	O
C	O
,	O
with	O
the	O
protein	O
(	O
at	O
2	O
mg	O
ml−1	O
concentration	O
)	O
dissolved	O
in	O
a	O
buffer	O
consisting	O
of	O
50	O
mM	O
Tris	O
-	O
HCl	O
(	O
pH	O
7.4	O
)	O
,	O
1	O
mM	O
dithiothreitol	O
,	O
1	O
mM	O
EDTA	O
and	O
200	O
mM	O
sodium	O
chloride	O
on	O
a	O
Model	O
DynaPro-801	O
instrument	O
(	O
Wyatt	O
,	O
Santa	O
Barbara	O
,	O
CA	O
,	O
USA	O
)	O
.	O

The	O
protein	O
concentration	O
was	O
estimated	O
by	O
measuring	O
the	O
absorbance	O
at	O
280	O
nm	O
,	O
employing	O
the	O
calculated	O
extinction	O
coefficient	O
of	O
20	O
910	O
M−1	O
cm−1	O
(	O
SWISS	O
-	O
PROT	O
;	O
http://www.expasy.ch/	O
)	O
.	O

Mutagenesis	O
and	O
electrophoretic	O
mobility	O
shift	O
assay	O
Point	O
mutants	O
were	O
prepared	O
using	O
the	O
QuikChange	O
Site	O
-	O
Directed	O
Mutagenesis	O
kit	O
(	O
Stratagene	O
)	O
,	O
and	O
the	O
mutations	O
were	O
confirmed	O
by	O
DNA	O
sequencing	O
.	O

The	O
seven	O
mutants	O
R4A	O
,	O
F120A	O
,	O
K146A	O
,	O
R198A	O
,	O
R208A	O
,	O
Q212A	O
and	O
R252A	O
were	O
well	O
expressed	O
and	O
soluble	O
.	O

The	O
three	O
mutants	O
K70A	O
,	O
R81A	O
and	O
R211A	O
were	O
not	O
expressed	O
,	O
while	O
R122A	O
mutant	O
was	O
expressed	O
but	O
was	O
not	O
soluble	O
.	O

Therefore	O
,	O
we	O
mutated	O
Lys70	O
,	O
Arg81	O
,	O
Arg122	O
and	O
Arg211	O
into	O
aspartate	O
.	O

The	O
K70D	O
,	O
R81D	O
,	O
R122D	O
and	O
R211D	O
mutants	O
were	O
well	O
expressed	O
and	O
soluble	O
.	O

The	O
soluble	O
mutants	O
were	O
expressed	O
and	O
purified	O
under	O
the	O
conditions	O
identical	O
to	O
those	O
for	O
the	O
wild	O
type	O
,	O
except	O
that	O
the	O
heparin	O
-	O
Sepharose	O
column	O
step	O
was	O
omitted	O
.	O

All	O
of	O
the	O
soluble	O
mutants	O
had	O
similar	O
elution	O
profiles	O
as	O
the	O
wild	O
type	O
upon	O
gel	O
filtration	O
,	O
and	O
the	O
dimer	O
fractions	O
were	O
used	O
for	O
DNA	O
-	O
binding	O
assays	O
.	O

We	O
mixed	O
5	O
μl	O
of	O
RdgC	O
(	O
1.1	O
μg	O
μl−1	O
)	O
and	O
5	O
μl	O
of	O
a	O
linear	O
dsDNA	O
with	O
414	O
bp	O
(	O
63	O
ng	O
μl−1	O
)	O
,	O
corresponding	O
to	O
the	O
molar	O
ratio	O
of	O
64:1	O
for	O
RdgC	O
dimer	O
to	O
dsDNA	O
.	O

The	O
reaction	O
mixtures	O
were	O
incubated	O
for	O
10	O
min	O
at	O
room	O
temperature	O
.	O

RdgC	O
–	O
DNA	O
complexes	O
were	O
analyzed	O
by	O
1.5	O
%	O
(	O
w	O
/	O
v	O
)	O
agarose	O
gel	O
electrophoresis	O
in	O
1	O
×	O
TAE	O
buffer	O
(	O
45	O
mM	O
Tris	O
-	O
acetate	O
at	O
pH	O
8.3	O
,	O
1	O
mM	O
EDTA	O
)	O
.	O

DNA	O
bands	O
were	O
visualized	O
by	O
ethidium	O
bromide	O
staining	O
.	O

For	O
DNA	O
-	O
binding	O
assays	O
,	O
the	O
protein	O
concentration	O
was	O
measured	O
with	O
a	O
Bio	O
-	O
Rad	O
protein	O
assay	O
kit	O
.	O

Crystallization	O
and	O
X	O
-	O
ray	O
data	O
collection	O
Crystals	O
were	O
grown	O
by	O
the	O
hanging	O
-	O
drop	O
vapor	O
diffusion	O
method	O
at	O
24	O
°	O
C	O
by	O
mixing	O
equal	O
volumes	O
(	O
2	O
μl	O
each	O
)	O
of	O
the	O
protein	O
solution	O
(	O
at	O
19	O
mg	O
ml−1	O
concentration	O
in	O
a	O
buffer	O
consisting	O
of	O
50	O
mM	O
Tris	O
-	O
HCl	O
(	O
pH	O
7.4	O
)	O
,	O
1	O
mM	O
dithiothreitol	O
,	O
1	O
mM	O
EDTA	O
and	O
200	O
mM	O
sodium	O
chloride	O
)	O
and	O
the	O
reservoir	O
solution	O
.	O

To	O
grow	O
the	O
native	O
crystals	O
,	O
we	O
used	O
a	O
reservoir	O
solution	O
consisting	O
of	O
0.1	O
M	O
sodium	O
HEPES	O
(	O
pH	O
7.5	O
)	O
,	O
1.0	O
M	O
tri	O
-	O
sodium	O
citrate	O
and	O
1	O
%	O
(	O
w	O
/	O
v	O
)	O
Anapoe	O
®	O
35	O
as	O
the	O
detergent	O
.	O

Native	O
crystals	O
grew	O
to	O
approximate	O
dimensions	O
of	O
0.2	O
mm	O
×	O
0.1	O
mm	O
×	O
0.1	O
mm	O
within	O
a	O
few	O
days	O
.	O

The	O
SeMet	O
-	O
substituted	O
protein	O
was	O
crystallized	O
under	O
conditions	O
identical	O
to	O
those	O
for	O
the	O
native	O
crystals	O
except	O
for	O
the	O
presence	O
of	O
10	O
mM	O
dithiothreitol	O
in	O
the	O
protein	O
solution	O
.	O

A	O
crystal	O
of	O
the	O
SeMet	O
-	O
substituted	O
protein	O
was	O
dipped	O
into	O
a	O
cryoprotectant	O
solution	O
for	O
a	O
few	O
seconds	O
and	O
was	O
flash	O
-	O
cooled	O
in	O
the	O
cold	O
nitrogen	O
gas	O
stream	O
at	O
100	O
K.	O
The	O
cryoprotectant	O
solution	O
consisted	O
of	O
0.1	O
M	O
sodium	O
HEPES	O
(	O
pH	O
7.5	O
)	O
,	O
1.0	O
M	O
tri	O
-	O
sodium	O
citrate	O
,	O
1	O
%	O
(	O
w	O
/	O
v	O
)	O
Anapoe	O
®	O
35	O
as	O
the	O
detergent	O
and	O
10	O
%	O
(	O
v	O
/	O
v	O
)	O
glycerol	O
.	O

A	O
set	O
of	O
Se	O
MAD	O
data	O
was	O
collected	O
at	O
100	O
K	O
at	O
three	O
different	O
wavelengths	O
using	O
an	O
Area	O
Detector	O
System	O
Corporation	O
Quantum	O
210	O
charge	O
-	O
coupled	O
device	O
detector	O
at	O
the	O
beamline	O
NW12A	O
of	O
Photon	O
Factory	O
,	O
Tsukuba	O
,	O
Japan	O
.	O

The	O
crystal	O
was	O
rotated	O
through	O
a	O
total	O
of	O
180	O
°	O
with	O
a	O
1	O
°	O
oscillation	O
range	O
per	O
frame	O
.	O

The	O
raw	O
data	O
were	O
processed	O
and	O
scaled	O
using	O
the	O
program	O
suit	O
HKL2000	O
(	O
10	O
)	O
.	O

The	O
SeMet	O
-	O
substituted	O
crystal	O
belongs	O
to	O
the	O
space	O
group	O
P21212	O
,	O
with	O
unit	O
cell	O
parameters	O
of	O
a	O
=	O
87.04	O
Å	O
,	O
b	O
=	O
115.60	O
Å	O
and	O
c	O
=	O
76.07	O
Å.	O
The	O
native	O
crystals	O
were	O
soaked	O
for	O
10	O
min	O
in	O
10	O
mM	O
ethyl	O
mercury	O
thiosalicylate	O
(	O
EMTS	O
)	O
to	O
collect	O
a	O
set	O
of	O
Hg	O
MAD	O
data	O
at	O
four	O
different	O
wavelengths	O
.	O

X	O
-	O
ray	O
diffraction	O
data	O
from	O
the	O
EMTS	O
-	O
derivatized	O
crystal	O
,	O
as	O
well	O
as	O
a	O
native	O
crystal	O
,	O
were	O
collected	O
on	O
a	O
Bruker	O
charge	O
-	O
coupled	O
device	O
detector	O
at	O
the	O
beamline	O
BL-6B	O
of	O
Pohang	O
Light	O
Source	O
,	O
Pohang	O
,	O
Korea	O
.	O

The	O
EMTS	O
-	O
soaked	O
crystal	O
belongs	O
to	O
the	O
space	O
group	O
P21212	O
,	O
with	O
unit	O
cell	O
parameters	O
of	O
a	O
=	O
87.16	O
Å	O
,	O
b	O
=	O
116.02	O
Å	O
and	O
c	O
=	O
74.97	O
Å.	O
The	O
native	O
crystal	O
belongs	O
to	O
the	O
space	O
group	O
P21212	O
,	O
with	O
unit	O
cell	O
parameters	O
of	O
a	O
=	O
87.49	O
Å	O
,	O
b	O
=	O
116.04	O
Å	O
and	O
c	O
=	O
76.03	O
Å.	O
If	O
the	O
presence	O
of	O
a	O
dimeric	O
molecule	O
in	O
the	O
asymmetric	O
unit	O
is	O
assumed	O
,	O
the	O
calculated	O
crystal	O
volume	O
per	O
protein	O
mass	O
(	O
VM	O
)	O
is	O
2.75	O
Å3	O
Da−1	O
and	O
the	O
solvent	O
content	O
is	O
55.3	O
%	O
.	O

Supplementary	O
Table	O
1	O
summarizes	O
the	O
statistics	O
of	O
X	O
-	O
ray	O
diffraction	O
data	O
collection	O
.	O

Structure	O
solution	O
and	O
refinement	O
Heavy	O
atom	O
sites	O
were	O
located	O
with	O
the	O
program	O
SOLVE	O
(	O
11	O
)	O
.	O

Four	O
Se	O
sites	O
from	O
the	O
SeMet	O
-	O
substituted	O
crystal	O
and	O
two	O
Hg	O
sites	O
from	O
the	O
EMTS	O
-	O
soaked	O
crystal	O
were	O
located	O
.	O

Two	O
sets	O
of	O
the	O
initial	O
Se	O
and	O
Hg	O
MAD	O
phases	O
were	O
separately	O
improved	O
using	O
the	O
program	O
RESOLVE	O
(	O
12	O
)	O
.	O

Two	O
electron	O
density	O
maps	O
were	O
independently	O
interpreted	O
,	O
and	O
the	O
fragments	O
of	O
the	O
two	O
models	O
were	O
combined	O
into	O
a	O
single	O
model	O
,	O
since	O
the	O
two	O
maps	O
were	O
complementary	O
to	O
each	O
other	O
.	O

Non	O
-	O
crystallographic	O
symmetry	O
(	O
NCS	O
)	O
matrices	O
were	O
found	O
from	O
a	O
partial	O
model	O
built	O
from	O
the	O
initial	O
electron	O
density	O
map	O
,	O
and	O
phases	O
were	O
further	O
improved	O
by	O
the	O
2-fold	O
NCS	O
averaging	O
,	O
solvent	O
flattening	O
and	O
histogram	O
matching	O
with	O
the	O
program	O
DM	O
(	O
13	O
)	O
.	O

The	O
model	O
was	O
built	O
with	O
O	O
(	O
14	O
)	O
.	O

The	O
model	O
was	O
refined	O
with	O
the	O
program	O
CNS	O
(	O
15	O
)	O
,	O
including	O
the	O
bulk	O
solvent	O
correction	O
.	O

10	O
%	O
of	O
the	O
data	O
were	O
randomly	O
set	O
aside	O
as	O
the	O
test	O
data	O
for	O
the	O
calculation	O
of	O
Rfree	O
(	O
16	O
)	O
.	O

Several	O
rounds	O
of	O
model	O
building	O
,	O
simulated	O
annealing	O
,	O
positional	O
refinement	O
and	O
individual	O
B	O
-	O
factor	O
refinement	O
were	O
performed	O
.	O

Subsequently	O
,	O
this	O
model	O
was	O
used	O
to	O
refine	O
the	O
structure	O
of	O
the	O
native	O
protein	O
.	O

The	O
model	O
has	O
excellent	O
stereochemistry	O
,	O
as	O
evaluated	O
by	O
the	O
program	O
PROCHECK	O
(	O
17	O
)	O
.	O

Refinement	O
statistics	O
are	O
summarized	O
in	O
Supplementary	O
Table	O
1	O
.	O

RESULTS	O
AND	O
DISCUSSION	O
Model	O
quality	O
and	O
monomer	O
structure	O
The	O
structure	O
of	O
P.	B
aeruginosa	I
RdgC	O
was	O
solved	O
using	O
two	O
sets	O
of	O
MAD	O
data	O
collected	O
from	O
a	O
crystal	O
of	O
the	O
selenomethionine	O
(	O
SeMet	O
)	O
-substituted	O
protein	O
and	O
from	O
a	O
mercury	O
derivative	O
crystal	O
of	O
the	O
native	O
protein	O
(	O
Supplementary	O
Table	O
1	O
)	O
.	O

The	O
model	O
has	O
subsequently	O
been	O
refined	O
using	O
the	O
20.0–2.50	O
Å	O
data	O
from	O
a	O
native	O
crystal	O
to	O
crystallographic	O
Rwork	O
and	O
Rfree	O
values	O
of	O
23.4	O
and	O
27.9	O
%	O
,	O
respectively	O
,	O
with	O
no	O
sigma	O
cut	O
-	O
off	O
.	O

The	O
refined	O
model	O
contains	O
612	O
residues	O
of	O
the	O
two	O
monomers	O
in	O
the	O
asymmetric	O
unit	O
of	O
the	O
crystal	O
(	O
residues	O
1–306	O
for	O
both	O
chains	O
A	O
and	O
B	O
)	O
and	O
87	O
water	O
molecules	O
.	O

The	O
C	O
-	O
terminal	O
eight	O
-	O
residue	O
fusion	O
tag	O
has	O
no	O
electron	O
density	O
in	O
both	O
subunits	O
and	O
has	O
not	O
been	O
modeled	O
.	O

Conformations	O
of	O
the	O
two	O
monomers	O
in	O
the	O
asymmetric	O
unit	O
are	O
similar	O
.	O

The	O
root	O
-	O
mean	O
-	O
square	O
(	O
r.m.s	O
.	O
)	O
difference	O
between	O
the	O
two	O
monomers	O
is	O
0.69	O
Å	O
for	O
306	O
Cα	O
atom	O
pairs	O
,	O
with	O
a	O
maximum	O
deviation	O
of	O
8.8	O
Å	O
for	O
the	O
Cα	O
atom	O
of	O
Gly305	O
.	O

The	O
residues	O
giving	O
r.m.s	O
.	O

differences	O
larger	O
than	O
2.0	O
Å	O
are	O
14–16	O
,	O
94–96	O
,	O
201–202	O
and	O
303–306	O
,	O
which	O
correspond	O
to	O
loops	O
connecting	O
secondary	O
structure	O
elements	O
or	O
the	O
C	O
-	O
terminus	O
.	O

They	O
are	O
located	O
on	O
the	O
surface	O
of	O
the	O
dimer	O
.	O

Subunit	O
A	O
has	O
a	O
better	O
map	O
quality	O
than	O
subunit	O
B	O
,	O
and	O
thus	O
has	O
a	O
lower	O
mean	O
B	O
-	O
factor	O
than	O
subunit	O
B	O
(	O
40.3	O
Å2	O
versus	O
.	O

56.1	O
Å2	O
for	O
all	O
4788	O
atoms	O
)	O
(	O
Supplementary	O
Figure	O
1	O
)	O
.	O

Therefore	O
,	O
subunit	O
A	O
is	O
chosen	O
for	O
discussions	O
,	O
unless	O
otherwise	O
stated	O
.	O

The	O
P.	B
aeruginosa	I
RdgC	O
monomer	O
is	O
J	O
-	O
shaped	O
and	O
has	O
approximate	O
dimensions	O
of	O
72	O
Å	O
×	O
60	O
Å	O
×	O
40	O
Å	O
(	O
Figure	O
1	O
)	O
.	O

It	O
can	O
be	O
divided	O
into	O
three	O
structural	O
domains	O
:	O
center	O
domain	O
,	O
tip	O
domain	O
and	O
base	O
domain	O
.	O

Center	O
domain	O
(	O
residues	O
1–73	O
and	O
121–167	O
)	O
includes	O
a	O
six	O
-	O
stranded	O
anti	O
-	O
parallel	O
β	O
-	O
sheet	O
with	O
two	O
flanking	O
α	O
helices	O
(	O
α1	O
and	O
α4	O
)	O
.	O

The	O
helix	O
α1	O
runs	O
nearly	O
parallel	O
to	O
the	O
two	O
outermost	O
strands	O
β2	O
and	O
β3	O
,	O
which	O
in	O
turn	O
lie	O
adjacent	O
to	O
β4	O
.	O

Strands	O
β2	O
and	O
β3	O
are	O
separated	O
by	O
a	O
loop	O
.	O

The	O
helix	O
α4	O
is	O
nearly	O
orthogonal	O
to	O
the	O
β	O
-	O
strands	O
.	O

Tip	O
domain	O
(	O
residues	O
74–120	O
)	O
contains	O
two	O
α	O
helices	O
(	O
α2	O
and	O
α3	O
)	O
and	O
is	O
inserted	O
between	O
strands	O
β4	O
and	O
β5	O
of	O
the	O
center	O
domain	O
.	O

It	O
sticks	O
out	O
from	O
the	O
center	O
domain	O
.	O

The	O
two	O
connections	O
between	O
the	O
center	O
domain	O
and	O
the	O
tip	O
domain	O
are	O
rich	O
in	O
conserved	O
residues	O
,	O
hinting	O
at	O
an	O
important	O
functional	O
role	O
of	O
these	O
joints	O
.	O

They	O
could	O
act	O
as	O
a	O
hinge	O
for	O
a	O
possible	O
conformational	O
change	O
.	O

The	O
C	O
-	O
terminal	O
region	O
of	O
the	O
polypeptide	O
chain	O
is	O
folded	O
into	O
the	O
base	O
domain	O
(	O
residues	O
168–306	O
)	O
,	O
which	O
consists	O
of	O
a	O
five	O
-	O
stranded	O
anti	O
-	O
parallel	O
β	O
-	O
sheet	O
with	O
four	O
α	O
-	O
helices	O
,	O
three	O
of	O
which	O
(	O
α5	O
,	O
α6	O
and	O
α8	O
)	O
cover	O
one	O
side	O
of	O
the	O
β	O
-	O
sheet	O
.	O

The	O
long	O
helix	O
α8	O
is	O
slightly	O
bent	O
.	O

Structural	O
similarity	O
searches	O
When	O
we	O
searched	O
for	O
structural	O
similarity	O
against	O
the	O
Protein	O
Data	O
Bank	O
database	O
using	O
the	O
program	O
DALI	O
(	O
18	O
)	O
,	O
the	O
P.	B
aeruginosa	I
RdgC	O
monomer	O
showed	O
no	O
significant	O
similarity	O
with	O
a	O
Z	O
score	O
above	O
5	O
.	O

Therefore	O
,	O
we	O
conclude	O
that	O
the	O
overall	O
fold	O
of	O
the	O
RdgC	O
polypeptide	O
chain	O
is	O
unique	O
.	O

When	O
we	O
elaborated	O
the	O
structural	O
comparisons	O
with	O
individual	O
domains	O
of	O
P.	B
aeruginosa	I
RdgC	O
,	O
only	O
the	O
center	O
domain	O
gave	O
a	O
Z	O
score	O
above	O
5	O
.	O

Using	O
the	O
center	O
domain	O
(	O
residues	O
1–73	O
and	O
121–167	O
)	O
alone	O
,	O
the	O
highest	O
structural	O
similarity	O
is	O
found	O
with	O
the	O
human	B
β2-adaptin	O
appendage	O
domain	O
(	O
PDB	O
code	O
1E42	O
,	O
Z	O
score	O
=	O
7.1	O
,	O
r.m.s	O
.	O

deviation	O
=	O
2.5	O
Å	O
for	O
85	O
structurally	O
aligned	O
residues	O
,	O
residues	O
1–12	O
,	O
14–30	O
,	O
44–47	O
,	O
58–72	O
,	O
122–133	O
and	O
135–160	O
of	O
P.	B
aeruginosa	I
RdgC	O
chain	O
A	O
and	O
residues	O
838–841	O
,	O
848–880	O
,	O
885–906	O
and	O
912–967	O
of	O
the	O
human	B
β2-adaptin	O
appendage	O
domain	O
chain	O
A	O
)	O
(	O
19	O
)	O
.	O

There	O
does	O
not	O
appear	O
to	O
be	O
any	O
functional	O
relatedness	O
between	O
these	O
two	O
proteins	O
.	O

The	O
next	O
highest	O
similarity	O
is	O
found	O
with	O
the	O
yeast	B
TATA	O
-	O
box	O
-	O
binding	O
protein	O
(	O
PDB	O
code	O
1YTB	O
,	O
Z	O
score	O
=	O
5.7	O
,	O
r.m.s	O
.	O

deviation	O
=	O
2.6	O
Å	O
for	O
79	O
structurally	O
aligned	O
residues	O
,	O
residues	O
4–12	O
,	O
14–19	O
,	O
21–27	O
,	O
56–70	O
,	O
124–132	O
and	O
134–166	O
of	O
P.	B
aeruginosa	I
RdgC	O
chain	O
A	O
and	O
residues	O
69–96	O
,	O
100–126	O
and	O
132–155	O
of	O
TATA	O
-	O
box	O
-	O
binding	O
protein	O
,	O
N	O
-	O
terminal	O
half	O
of	O
chain	O
A	O
)	O
(	O
20	O
)	O
.	O

The	O
TATA	O
-	O
box	O
-	O
binding	O
protein	O
is	O
composed	O
of	O
a	O
ten	O
-	O
stranded	O
antiparallel	O
β	O
-	O
sheet	O
with	O
four	O
flanking	O
α	O
-	O
helices	O
on	O
the	O
convex	O
side	O
of	O
the	O
β	O
-	O
sheet	O
(	O
20	O
)	O
.	O

It	O
has	O
an	O
internal	O
quasi	O
2-fold	O
symmetry	O
,	O
and	O
its	O
β	O
-	O
strands	O
are	O
involved	O
in	O
DNA	O
binding	O
.	O

There	O
is	O
,	O
however	O
,	O
no	O
structural	O
similarity	O
of	O
functional	O
significance	O
,	O
because	O
the	O
two	O
center	O
domains	O
of	O
the	O
RdgC	O
dimer	O
are	O
well	O
separated	O
and	O
do	O
not	O
associate	O
into	O
a	O
single	O
unit	O
(	O
Figure	O
1C	O
and	O
D	O
)	O
.	O

Using	O
the	O
tip	O
domain	O
(	O
residues	O
74–120	O
)	O
alone	O
,	O
the	O
ATPase	O
domain	O
of	O
bovine	B
Hsc70	O
chaperone	O
shows	O
highest	O
structural	O
similarity	O
(	O
PDB	O
code	O
1BA1	O
,	O
Z	O
score	O
=	O
4.8	O
,	O
r.m.s	O
.	O

deviation	O
=	O
1.7	O
Å	O
for	O
45	O
structurally	O
aligned	O
residues	O
,	O
residues	O
76–120	O
of	O
P.	B
aeruginosa	I
RdgC	O
chain	O
A	O
and	O
residues	O
230–253	O
and	O
256–276	O
of	O
the	O
Hsc70	O
ATPase	O
domain	O
)	O
(	O
21	O
)	O
.	O

There	O
does	O
not	O
seem	O
to	O
be	O
any	O
significant	O
functional	O
relationship	O
between	O
these	O
two	O
proteins	O
.	O

The	O
α	O
-	O
helix	O
-	O
loop	O
-	O
α	O
-	O
helix	O
structure	O
of	O
the	O
tip	O
domain	O
is	O
reminiscent	O
of	O
the	O
helix	O
–	O
hairpin	O
–	O
helix	O
(	O
HhH	O
)	O
DNA	O
-	O
binding	O
motif	O
that	O
is	O
present	O
in	O
a	O
number	O
of	O
DNA	O
repair	O
enzymes	O
(	O
22–25	O
)	O
.	O

The	O
HhH	O
motifs	O
are	O
characterized	O
by	O
the	O
conserved	O
sequence	O
motif	O
hxxhxGhGxxxAxxxhh	O
,	O
where	O
h	O
is	O
any	O
hydrophobic	O
residue	O
(	O
VILMWFYA	O
)	O
and	O
x	O
any	O
residue	O
(	O
23	O
)	O
.	O

Two	O
conserved	O
glycines	O
allow	O
a	O
tight	O
turn	O
between	O
two	O
α	O
-	O
helices	O
.	O

However	O
,	O
the	O
tip	O
domain	O
of	O
P.	B
aeruginosa	I
RdgC	O
protein	O
does	O
not	O
have	O
such	O
a	O
sequence	O
motif	O
,	O
and	O
the	O
loop	O
in	O
the	O
RdgC	O
tip	O
domain	O
is	O
much	O
more	O
extended	O
than	O
that	O
of	O
the	O
HhH	O
motifs	O
.	O

Therefore	O
,	O
the	O
RdgC	O
tip	O
domain	O
is	O
uniquely	O
folded	O
.	O

With	O
the	O
base	O
domain	O
(	O
residues	O
168–306	O
)	O
alone	O
,	O
the	O
highest	O
similarity	O
is	O
found	O
with	O
P.	B
aeruginosa	I
isochorismate	O
-	O
pyruvate	O
lyase	O
(	O
unpublished	O
deposition	O
;	O
PDB	O
code	O
2H9C	O
,	O
Z	O
score	O
=	O
4.0	O
,	O
r.m.s	O
.	O

deviation	O
=	O
4.8	O
Å	O
for	O
51	O
structurally	O
aligned	O
residues	O
,	O
residues	O
186–191	O
,	O
237–240	O
,	O
257–272	O
and	O
274–298	O
of	O
P.	B
aeruginosa	I
RdgC	O
chain	O
A	O
and	O
residues	O
36–41	O
,	O
50–53	O
,	O
55–66	O
and	O
68–96	O
of	O
P.	B
aeruginosa	I
isochorismate	O
-	O
pyruvate	O
lyase	O
chain	O
A	O
)	O
.	O

There	O
does	O
not	O
appear	O
to	O
be	O
any	O
functional	O
relationship	O
between	O
the	O
two	O
proteins	O
,	O
and	O
the	O
base	O
domain	O
of	O
RdgC	O
is	O
uniquely	O
folded	O
.	O

The	O
101-residue	O
chain	O
of	O
P.	B
aeruginosa	I
isochorismate	O
-	O
pyruvate	O
lyase	O
is	O
folded	O
into	O
three	O
α	O
-	O
helices	O
,	O
two	O
of	O
which	O
overlap	O
with	O
two	O
α	O
-	O
helices	O
(	O
α2	O
and	O
α3	O
)	O
of	O
the	O
base	O
domain	O
of	O
RdgC.	O
Ring	O
-	O
shaped	O
dimer	O
structure	O
and	O
inter	O
-	O
subunit	O
interface	O
Our	O
structure	O
reveals	O
that	O
P.	B
aeruginosa	I
RdgC	O
forms	O
a	O
ring	O
-	O
shaped	O
dimer	O
of	O
approximate	O
2-fold	O
symmetry	O
in	O
the	O
crystal	O
(	O
Figure	O
1	O
)	O
.	O

This	O
observation	O
is	O
consistent	O
with	O
the	O
results	O
of	O
previous	O
gel	O
filtration	O
and	O
sedimentation	O
equilibrium	O
experiments	O
,	O
which	O
suggested	O
the	O
presence	O
of	O
dimeric	O
species	O
of	O
E.	B
coli	I
RdgC	O
in	O
solution	O
(	O
1,2	O
)	O
.	O

Depending	O
on	O
the	O
concentration	O
,	O
RdgC	O
could	O
also	O
exist	O
in	O
solution	O
as	O
monomers	O
,	O
tetramers	O
and	O
higher	O
oligomers	O
(	O
1	O
)	O
.	O

In	O
the	O
crystal	O
lattice	O
,	O
no	O
monomeric	O
,	O
trimeric	O
or	O
tetrameric	O
species	O
exist	O
.	O

Our	O
structure	O
unequivocally	O
rules	O
out	O
the	O
monomer	O
–	O
trimer	O
model	O
,	O
which	O
fits	O
the	O
sedimentation	O
equilibrium	O
data	O
approximately	O
,	O
as	O
well	O
as	O
the	O
monomer	O
–	O
dimer	O
–	O
tetramer	O
model	O
(	O
1	O
)	O
.	O

The	O
RdgC	O
dimer	O
has	O
approximate	O
dimensions	O
of	O
80	O
Å	O
×	O
60	O
Å	O
×	O
40	O
Å	O
,	O
with	O
a	O
central	O
hole	O
of	O
∼30	O
Å	O
diameter	O
.	O

Only	O
a	O
moderate	O
amount	O
of	O
surface	O
area	O
is	O
buried	O
upon	O
the	O
formation	O
of	O
the	O
RdgC	O
dimer	O
.	O

The	O
monomer	O
–	O
monomer	O
interface	O
buries	O
a	O
solvent	O
-	O
accessible	O
surface	O
area	O
of	O
∼1360	O
Å2	O
per	O
monomer	O
,	O
corresponding	O
to	O
∼8	O
%	O
of	O
the	O
total	O
surface	O
area	O
of	O
the	O
monomer	O
(	O
Protein	O
–	O
Protein	O
Interaction	O
Server	O
at	O
http://www.biochem.ucl.ac.uk/bsm/PP/server/	O
)	O
.	O

Polar	O
and	O
nonpolar	O
atoms	O
in	O
interface	O
are	O
44	O
and	O
56	O
%	O
,	O
respectively	O
.	O

The	O
interface	O
can	O
be	O
divided	O
into	O
two	O
kinds	O
:	O
'	O
interface	O
A	O
'	O
involving	O
both	O
the	O
tip	O
domains	O
and	O
center	O
domains	O
,	O
and	O
'	O
interface	O
B	O
'	O
involving	O
the	O
base	O
domains	O
(	O
Figure	O
2A	O
)	O
.	O

These	O
two	O
interfaces	O
have	O
significantly	O
different	O
characters	O
.	O

The	O
interface	O
A	O
is	O
formed	O
largely	O
by	O
the	O
crossing	O
over	O
of	O
the	O
two	O
tip	O
domains	O
in	O
the	O
dimer	O
(	O
Figure	O
1	O
)	O
.	O

This	O
interface	O
covers	O
a	O
surface	O
area	O
of	O
∼565	O
Å2	O
and	O
is	O
largely	O
nonpolar	O
,	O
with	O
the	O
polar	O
and	O
nonpolar	O
atoms	O
in	O
the	O
interface	O
being	O
37.5	O
and	O
2.5	O
%	O
,	O
respectively	O
.	O

Phe120	O
contributes	O
considerably	O
to	O
the	O
nonpolar	O
character	O
of	O
the	O
interface	O
between	O
the	O
tip	O
domains	O
,	O
accounting	O
for	O
∼150	O
Å2	O
of	O
the	O
interface	O
area	O
.	O

Phe120	O
is	O
part	O
of	O
a	O
highly	O
conserved	O
sequence	O
segment	O
and	O
lies	O
at	O
the	O
boundary	O
between	O
the	O
tip	O
domain	O
and	O
the	O
center	O
domain	O
.	O

The	O
aromatic	O
ring	O
of	O
Phe120′	O
inserts	O
into	O
a	O
hydrophobic	O
pocket	O
,	O
which	O
is	O
formed	O
by	O
the	O
hydrophobic	O
residues	O
Ile74	O
,	O
Leu75	O
,	O
Pro76	O
,	O
Val79	O
,	O
Leu115	O
,	O
Ala119	O
and	O
Phe120	O
of	O
the	O
neighboring	O
monomer	O
(	O
Figure	O
2B	O
)	O
.	O

The	O
primed	O
residue	O
belongs	O
to	O
the	O
adjacent	O
subunit	O
.	O

These	O
residues	O
are	O
well	O
conserved	O
in	O
the	O
RdgC	O
family	O
(	O
indicated	O
by	O
green	O
triangles	O
below	O
the	O
aligned	O
sequences	O
in	O
Figure	O
3	O
)	O
.	O

As	O
these	O
hydrophobic	O
residues	O
are	O
located	O
near	O
the	O
molecular	O
2-fold	O
axis	O
,	O
the	O
two	O
clusters	O
of	O
hydrophobic	O
side	O
chains	O
are	O
merged	O
into	O
a	O
single	O
,	O
large	O
cluster	O
in	O
the	O
dimer	O
(	O
Figure	O
2B	O
)	O
.	O

Of	O
the	O
16	O
hydrogen	O
bonds	O
that	O
exist	O
between	O
the	O
two	O
subunits	O
,	O
only	O
one	O
is	O
made	O
in	O
this	O
interface	O
between	O
Arg118	O
and	O
Arg118′.	O
The	O
interface	O
B	O
is	O
contributed	O
to	O
exclusively	O
by	O
the	O
two	O
base	O
domains	O
.	O

This	O
interface	O
covers	O
a	O
surface	O
area	O
of	O
∼795	O
Å2	O
.	O

The	O
polar	O
and	O
nonpolar	O
atoms	O
in	O
this	O
interface	O
are	O
50	O
%	O
each	O
.	O

The	O
two	O
β	O
-	O
sheets	O
of	O
the	O
two	O
base	O
domains	O
merge	O
into	O
a	O
single	O
ten	O
-	O
stranded	O
antiparallel	O
β	O
-	O
sheet	O
in	O
this	O
interface	O
(	O
Figure	O
2A	O
)	O
.	O

Thus	O
,	O
15	O
of	O
16	O
inter	O
-	O
subunit	O
hydrogen	O
bonds	O
are	O
clustered	O
in	O
this	O
interface	O
.	O

The	O
hydrogen	O
bond	O
networks	O
can	O
be	O
divided	O
into	O
two	O
types	O
.	O

The	O
first	O
type	O
involves	O
the	O
main	O
chain	O
atoms	O
of	O
Val206	O
,	O
Arg208	O
and	O
Lys210	O
in	O
strand	O
β9	O
;	O
this	O
strand	O
associates	O
with	O
the	O
equivalent	O
strand	O
from	O
the	O
other	O
subunit	O
in	O
an	O
antiparallel	O
manner	O
(	O
Figure	O
2C	O
)	O
.	O

The	O
other	O
type	O
involves	O
both	O
the	O
side	O
chain	O
and	O
main	O
chain	O
atoms	O
.	O

The	O
side	O
chain	O
of	O
Arg211′	O
interacts	O
with	O
the	O
backbone	O
of	O
Gly204	O
,	O
while	O
the	O
side	O
chain	O
of	O
Lys227	O
hydrogen	O
bonds	O
to	O
those	O
of	O
both	O
Gln212′	O
and	O
Glu218	O
(	O
Figure	O
2D	O
)	O
.	O

In	O
addition	O
,	O
the	O
side	O
chain	O
of	O
Gln212′	O
interacts	O
with	O
that	O
of	O
Asp199	O
and	O
the	O
backbone	O
of	O
Arg211′	O
(	O
Figure	O
2D	O
)	O
.	O

Arg211	O
,	O
Gln212	O
,	O
Glu218	O
and	O
Lys227	O
are	O
highly	O
conserved	O
among	O
the	O
RdgC	O
family	O
members	O
.	O

The	O
residues	O
participating	O
in	O
the	O
hydrogen	O
bond	O
networks	O
are	O
indicated	O
by	O
red	O
circles	O
below	O
the	O
aligned	O
sequences	O
in	O
Figure	O
3	O
.	O

The	O
observation	O
that	O
conserved	O
residues	O
play	O
important	O
roles	O
in	O
forming	O
the	O
dimer	O
implies	O
that	O
dimerization	O
of	O
RdgC	O
is	O
critical	O
for	O
its	O
function	O
.	O

If	O
one	O
or	O
both	O
of	O
interfaces	O
A	O
and	O
B	O
are	O
to	O
be	O
broken	O
for	O
functional	O
reasons	O
such	O
as	O
for	O
allowing	O
dsDNA	O
to	O
enter	O
into	O
the	O
central	O
hole	O
of	O
the	O
RdgC	O
dimer	O
,	O
we	O
can	O
conceive	O
of	O
three	O
scenarios	O
.	O

The	O
first	O
possibility	O
would	O
be	O
a	O
simultaneous	O
breakage	O
of	O
the	O
two	O
interfaces	O
A	O
and	O
B.	O
The	O
second	O
would	O
be	O
the	O
sequential	O
disruption	O
of	O
the	O
interfaces	O
A	O
and	O
B.	O
The	O
third	O
would	O
be	O
the	O
disruption	O
of	O
only	O
one	O
of	O
the	O
two	O
interfaces	O
A	O
and	O
B.	O
Sedimentation	O
equilibrium	O
indicated	O
the	O
presence	O
of	O
monomers	O
in	O
solution	O
(	O
1	O
)	O
,	O
which	O
is	O
consistent	O
with	O
the	O
first	O
two	O
scenarios	O
.	O

If	O
the	O
third	O
scenario	O
holds	O
,	O
RdgC	O
dimers	O
could	O
possibly	O
exist	O
in	O
two	O
conformations	O
in	O
solution	O
,	O
i.e.	O
a	O
closed	O
form	O
as	O
observed	O
in	O
the	O
present	O
crystal	O
structure	O
,	O
and	O
an	O
open	O
form	O
,	O
in	O
which	O
one	O
of	O
the	O
two	O
interfaces	O
A	O
and	O
B	O
is	O
broken	O
.	O

A	O
model	O
for	O
DNA	O
binding	O
by	O
RdgC	O
and	O
DNA	O
-	O
binding	O
assay	O
The	O
net	O
charge	O
of	O
P.	B
aeruginosa	I
RdgC	O
is	O
highly	O
negative	O
,	O
since	O
each	O
monomer	O
contains	O
12	O
aspartate	O
,	O
13	O
glutamate	O
,	O
10	O
lysine	O
,	O
9	O
arginine	O
and	O
2	O
histidine	O
residues	O
.	O

The	O
net	O
charge	O
of	O
a	O
dimer	O
would	O
be	O
−12	O
(	O
or	O
−8	O
)	O
,	O
if	O
we	O
assume	O
none	O
(	O
or	O
all	O
)	O
of	O
histidines	O
to	O
be	O
positively	O
charged	O
.	O

The	O
electrostatic	O
potential	O
at	O
the	O
molecular	O
surface	O
of	O
RdgC	O
dimer	O
shows	O
that	O
the	O
charge	O
distribution	O
on	O
the	O
protein	O
surface	O
is	O
highly	O
nonuniform	O
(	O
Figure	O
4A	O
)	O
.	O

Since	O
the	O
inner	O
surface	O
of	O
the	O
RdgC	O
dimer	O
is	O
rich	O
in	O
conserved	O
,	O
positively	O
charged	O
residues	O
and	O
the	O
diameter	O
of	O
the	O
central	O
hole	O
(	O
∼30	O
Å	O
)	O
is	O
approximately	O
similar	O
to	O
that	O
of	O
other	O
toroidal	O
DNA	O
-	O
binding	O
proteins	O
(	O
26	O
)	O
,	O
it	O
appears	O
likely	O
that	O
RdgC	O
dimers	O
bind	O
dsDNA	O
through	O
the	O
central	O
hole	O
.	O

Despite	O
extensive	O
co	O
-	O
crystallization	O
and	O
soaking	O
trials	O
with	O
linear	O
dsDNAs	O
of	O
different	O
lengths	O
(	O
14-mer	O
,	O
16-mer	O
and	O
18-mer	O
)	O
,	O
we	O
could	O
not	O
locate	O
the	O
bound	O
DNA	O
experimentally	O
.	O

We	O
attribute	O
this	O
difficulty	O
to	O
the	O
nature	O
of	O
sequence	O
-	O
nonspecific	O
DNA	O
binding	O
by	O
RdgC.	O
Therefore	O
,	O
we	O
built	O
a	O
crude	O
model	O
of	O
a	O
DNA	O
complex	O
of	O
the	O
RdgC	O
dimer	O
by	O
fitting	O
dsDNA	O
into	O
the	O
central	O
hole	O
(	O
Figure	O
4B	O
)	O
.	O

This	O
model	O
is	O
supported	O
by	O
the	O
DNA	O
-	O
binding	O
assays	O
coupled	O
with	O
mutagenesis	O
,	O
as	O
described	O
below	O
.	O

It	O
is	O
also	O
consistent	O
with	O
the	O
suggested	O
binding	O
site	O
size	O
of	O
∼16	O
nt	O
for	O
the	O
E.	B
coli	I
RdgC	O
dimer	O
(	O
1	O
)	O
and	O
the	O
approximate	O
thickness	O
(	O
∼40	O
Å	O
)	O
of	O
the	O
P.	B
aeruginosa	I
RdgC	O
dimer	O
.	O

When	O
we	O
performed	O
electrophoretic	O
mobility	O
shift	O
assay	O
for	O
dsDNA	O
binding	O
,	O
P.	B
aeruginosa	I
RdgC	O
did	O
not	O
require	O
Mg2	O
+	O
ions	O
(	O
Supplementary	O
Figure	O
2	O
)	O
,	O
unlike	O
Deinococcus	B
radiodurans	I
RecR	O
,	O
which	O
required	O
high	O
concentrations	O
of	O
Mg2	O
+	O
ions	O
(	O
27	O
)	O
.	O

ATP	O
was	O
not	O
required	O
for	O
dsDNA	O
binding	O
by	O
P.	B
aeruginosa	I
RdgC	O
,	O
either	O
(	O
Supplementary	O
Figure	O
2	O
)	O
.	O

This	O
is	O
consistent	O
with	O
an	O
apparent	O
lack	O
of	O
an	O
ATP	O
-	O
binding	O
pocket	O
in	O
the	O
RdgC	O
dimer	O
structure	O
.	O

In	O
order	O
to	O
identify	O
the	O
residues	O
that	O
are	O
important	O
for	O
dsDNA	O
binding	O
,	O
we	O
carried	O
out	O
mutational	O
analyses	O
.	O

The	O
residues	O
for	O
mutagenesis	O
were	O
selected	O
on	O
the	O
basis	O
of	O
the	O
modeled	O
complex	O
between	O
RdgC	O
dimer	O
and	O
dsDNA	O
,	O
together	O
with	O
sequence	O
conservation	O
(	O
Figure	O
4C	O
)	O
.	O

We	O
prepared	O
eleven	O
point	O
mutants	O
(	O
R4A	O
,	O
K70D	O
,	O
R81D	O
,	O
F120A	O
,	O
R122D	O
,	O
K146A	O
,	O
R198A	O
,	O
R208A	O
,	O
R211D	O
,	O
Q212A	O
and	O
R252A	O
)	O
.	O

These	O
eleven	O
mutated	O
residues	O
are	O
well	O
conserved	O
among	O
RdgC	O
proteins	O
.	O

Eight	O
mutants	O
(	O
R4A	O
,	O
K70D	O
,	O
R81D	O
,	O
R122D	O
,	O
K146A	O
,	O
R198A	O
,	O
R208A	O
and	O
R252A	O
)	O
had	O
a	O
lower	O
affinity	O
for	O
dsDNA	O
than	O
the	O
wild	O
-	O
type	O
RdgC	O
(	O
Figure	O
4D	O
)	O
.	O

These	O
eight	O
mutated	O
residues	O
are	O
indicated	O
by	O
blue	O
squares	O
below	O
the	O
aligned	O
sequences	O
in	O
Figure	O
3	O
.	O

This	O
result	O
indicates	O
that	O
dsDNA	O
binds	O
to	O
the	O
inside	O
surface	O
around	O
the	O
central	O
hole	O
of	O
the	O
RdgC	O
dimer	O
,	O
since	O
the	O
mutated	O
residues	O
are	O
located	O
on	O
the	O
inner	O
surface	O
of	O
the	O
RdgC	O
dimer	O
.	O

It	O
is	O
worth	O
mentioning	O
that	O
a	O
single	O
mutation	O
introduces	O
two	O
alterations	O
per	O
RdgC	O
dimer	O
.	O

The	O
three	O
mutants	O
(	O
F120A	O
,	O
R211D	O
and	O
Q212A	O
)	O
were	O
prepared	O
to	O
investigate	O
whether	O
dimerization	O
of	O
RdgC	O
is	O
crucial	O
for	O
dsDNA	O
binding	O
.	O

Phe120	O
is	O
a	O
key	O
residue	O
located	O
in	O
the	O
inter	O
-	O
subunit	O
interface	O
A	O
(	O
Figure	O
2B	O
)	O
,	O
while	O
Arg211	O
makes	O
hydrogen	O
bonds	O
in	O
the	O
interface	O
B	O
(	O
Figure	O
2D	O
)	O
and	O
Gln212	O
is	O
involved	O
in	O
both	O
intra-	O
and	O
inter	O
-	O
subunit	O
interactions	O
(	O
Figure	O
2D	O
)	O
.	O

dsDNA	O
binding	O
by	O
the	O
F120A	O
mutant	O
is	O
considerably	O
weakened	O
,	O
compared	O
to	O
either	O
the	O
R211D	O
or	O
Q212A	O
mutant	O
(	O
Figure	O
4D	O
)	O
.	O

This	O
result	O
suggests	O
that	O
destabilization	O
of	O
the	O
ring	O
-	O
shaped	O
architecture	O
of	O
the	O
RdgC	O
dimer	O
is	O
deleterious	O
for	O
tight	O
dsDNA	O
binding	O
and	O
that	O
interface	O
A	O
is	O
probably	O
more	O
important	O
than	O
interface	O
B	O
for	O
dsDNA	O
binding	O
.	O

dsDNA	O
-	O
binding	O
affinity	O
of	O
the	O
Q212A	O
mutant	O
was	O
lower	O
than	O
the	O
wild	O
type	O
(	O
Figure	O
4D	O
)	O
,	O
whereas	O
that	O
of	O
the	O
R211D	O
mutant	O
was	O
comparable	O
to	O
the	O
wild	O
type	O
(	O
Figure	O
4D	O
)	O
.	O

This	O
result	O
suggests	O
that	O
disruption	O
of	O
the	O
inter	O
-	O
subunit	O
interface	O
B	O
is	O
also	O
detrimental	O
for	O
dsDNA	O
binding	O
but	O
to	O
a	O
smaller	O
extent	O
than	O
disruption	O
of	O
the	O
interface	O
A.	O
It	O
further	O
suggests	O
that	O
the	O
side	O
chain	O
of	O
Arg211	O
is	O
not	O
involved	O
in	O
recognizing	O
dsDNA	O
.	O

It	O
is	O
interesting	O
that	O
the	O
DNA	O
complex	O
for	O
wild	O
type	O
forms	O
a	O
distinct	O
band	O
(	O
lane	O
3	O
in	O
Figure	O
4D	O
)	O
,	O
as	O
opposed	O
to	O
a	O
more	O
diffuse	O
band	O
as	O
one	O
would	O
expect	O
if	O
the	O
complexes	O
contained	O
different	O
numbers	O
of	O
RdgC	O
dimers	O
.	O

Assuming	O
a	O
binding	O
site	O
size	O
of	O
∼16	O
nt	O
(	O
1	O
)	O
,	O
the	O
414-bp	O
duplex	O
DNA	O
would	O
bind	O
∼25	O
RdgC	O
dimers	O
if	O
it	O
is	O
fully	O
saturated	O
.	O

RdgC	O
is	O
unique	O
among	O
ring	O
-	O
shaped	O
DNA	O
-	O
binding	O
proteins	O
Pseudomonas	B
aeruginosa	I
RdgC	O
adds	O
a	O
unique	O
member	O
to	O
the	O
repertoire	O
of	O
toroidal	O
DNA	O
-	O
binding	O
proteins	O
(	O
26	O
)	O
such	O
as	O
D.	B
radiodurans	I
RecR	O
(	O
27	O
)	O
and	O
DNA	O
polymerase	O
processivity	O
factors	O
,	O
including	O
the	O
β	O
subunit	O
of	O
E.	B
coli	I
DNA	O
polymerase	O
III	O
(	O
28	O
)	O
,	O
gp45	O
of	O
T4	O
DNA	O
polymerase	O
(	O
29	O
)	O
and	O
PCNA	O
of	O
eukaryotic	O
DNA	O
polymerase	O
δ	O
(	O
30,31	O
)	O
(	O
Figure	O
5	O
)	O
.	O

These	O
proteins	O
do	O
not	O
have	O
an	O
overall	O
sequence	O
similarity	O
among	O
themselves	O
,	O
and	O
their	O
quaternary	O
structures	O
also	O
vary	O
.	O

P.	B
aeruginosa	I
RdgC	O
and	O
E.	B
coli	I
β	O
clamp	O
are	O
homodimers	O
,	O
T4	O
gp45	O
and	O
eukaryotic	O
PCNAs	O
are	O
homotrimers	O
and	O
D.	B
radiodurans	I
RecR	O
is	O
a	O
homotetramer	O
.	O

In	O
P.	B
aeruginosa	I
RdgC	O
,	O
the	O
inner	O
surface	O
of	O
the	O
ring	O
-	O
shaped	O
dimer	O
is	O
largely	O
formed	O
by	O
β	O
-	O
strands	O
,	O
while	O
the	O
outer	O
surface	O
of	O
the	O
ring	O
is	O
mostly	O
formed	O
by	O
α	O
-	O
helices	O
(	O
Figure	O
5	O
)	O
.	O

The	O
predicted	O
DNA	O
-	O
binding	O
site	O
of	O
P.	B
aeruginosa	I
RdgC	O
dimer	O
is	O
primarily	O
formed	O
by	O
β	O
-	O
strands	O
and	O
loops	O
.	O

In	O
contrast	O
,	O
in	O
other	O
ring	O
-	O
shaped	O
DNA	O
-	O
binding	O
proteins	O
such	O
as	O
the	O
β	O
subunit	O
of	O
E.	B
coli	I
DNA	O
polymerase	O
III	O
(	O
28	O
)	O
,	O
gp45	O
of	O
T4	O
DNA	O
polymerase	O
(	O
29	O
)	O
,	O
PCNA	O
of	O
eukaryotic	O
DNA	O
polymerases	O
δ	O
(	O
30,31	O
)	O
and	O
D.	B
radiodurans	I
RecR	O
(	O
27	O
)	O
,	O
α	O
-	O
helices	O
are	O
located	O
toward	O
the	O
center	O
of	O
the	O
ring	O
and	O
are	O
surrounded	O
by	O
β	O
-	O
strands	O
in	O
the	O
outermost	O
side	O
of	O
the	O
ring	O
(	O
Figure	O
5	O
)	O
.	O

Despite	O
a	O
superficial	O
resemblance	O
of	O
the	O
overall	O
ring	O
-	O
shaped	O
architecture	O
of	O
the	O
RdgC	O
dimer	O
with	O
those	O
of	O
other	O
toroidal	O
DNA	O
-	O
binding	O
proteins	O
,	O
the	O
internal	O
arrangement	O
of	O
the	O
secondary	O
structure	O
elements	O
in	O
the	O
RdgC	O
dimer	O
is	O
strikingly	O
different	O
from	O
those	O
of	O
other	O
toroidal	O
DNA	O
-	O
binding	O
proteins	O
.	O

Thus	O
,	O
RdgC	O
is	O
unique	O
among	O
ring	O
-	O
shaped	O
DNA	O
-	O
binding	O
proteins	O
.	O

A	O
number	O
of	O
other	O
proteins	O
involved	O
in	O
DNA	O
metabolism	O
also	O
adopt	O
a	O
ring	O
-	O
shaped	O
structure	O
despite	O
diversity	O
in	O
the	O
molecular	O
functions	O
(	O
26	O
)	O
.	O

They	O
include	O
NAD+-dependent	O
DNA	O
ligase	O
(	O
25	O
)	O
,	O
λ	O
exonuclease	O
(	O
32	O
)	O
,	O
hexameric	O
helicases	O
,	O
topoisomerases	O
,	O
the	O
trp	O
RNA	O
-	O
binding	O
attenuation	O
protein	O
,	O
the	O
bacteriophage	O
head	O
-	O
to	O
-	O
tail	O
connector	O
and	O
translin	O
(	O
26	O
)	O
.	O

There	O
are	O
also	O
many	O
examples	O
of	O
the	O
proteins	O
in	O
DNA	O
recombination	O
pathways	O
that	O
assemble	O
into	O
multi	O
-	O
subunit	O
toroids	O
containing	O
a	O
central	O
channel	O
(	O
26	O
)	O
.	O

Electron	O
microscopy	O
showed	O
that	O
the	O
E.	B
coli	I
RuvB	O
protein	O
,	O
in	O
the	O
presence	O
of	O
ATP	O
,	O
forms	O
a	O
dodecamer	O
on	O
double	O
-	O
stranded	O
DNA	O
in	O
which	O
two	O
stacked	O
hexameric	O
rings	O
encircle	O
the	O
DNA	O
and	O
are	O
oriented	O
in	O
opposite	O
directions	O
with	O
D6	O
symmetry	O
(	O
33	O
)	O
.	O

The	O
human	B
RAD52	O
protein	O
was	O
found	O
to	O
assemble	O
into	O
heptameric	O
rings	O
with	O
a	O
large	O
funnel	O
-	O
shaped	O
channel	O
,	O
40–60	O
Å	O
in	O
diameter	O
(	O
34	O
)	O
.	O

The	O
human	B
DMC1	O
protein	O
has	O
so	O
far	O
been	O
detected	O
only	O
as	O
an	O
octameric	O
ring	O
(	O
35	O
)	O
.	O

Inhibition	O
mechanism	O
of	O
RecA	O
function	O
by	O
RdgC	O
RdgC	O
inhibits	O
RecA	O
-	O
promoted	O
DNA	O
strand	O
exchange	O
,	O
RecA	O
-	O
mediated	O
ATPase	O
activity	O
and	O
RecA	O
-	O
dependent	O
LexA	O
cleavage	O
(	O
1	O
)	O
.	O

It	O
was	O
observed	O
that	O
the	O
effects	O
of	O
RdgC	O
on	O
RecA	O
-	O
promoted	O
DNA	O
strand	O
exchange	O
were	O
much	O
more	O
pronounced	O
than	O
the	O
effects	O
of	O
RdgC	O
on	O
other	O
RecA	O
functions	O
,	O
when	O
RdgC	O
was	O
added	O
to	O
the	O
reaction	O
late	O
(	O
1	O
)	O
.	O

By	O
examining	O
the	O
effects	O
of	O
the	O
DinI	O
protein	O
on	O
RdgC	O
-	O
mediated	O
inhibition	O
of	O
RecA	O
activities	O
,	O
it	O
was	O
concluded	O
that	O
the	O
potent	O
effect	O
of	O
RdgC	O
in	O
the	O
inhibition	O
of	O
strand	O
exchange	O
did	O
not	O
primarily	O
reflect	O
a	O
displacement	O
of	O
RecA	O
in	O
the	O
nucleoprotein	O
filament	O
by	O
RdgC	O
,	O
but	O
instead	O
a	O
binding	O
of	O
RdgC	O
to	O
the	O
dsDNA	O
substrate	O
so	O
as	O
to	O
make	O
it	O
unavailable	O
to	O
the	O
filaments	O
for	O
strand	O
exchange	O
(	O
1	O
)	O
.	O

Our	O
work	O
contributes	O
to	O
a	O
better	O
understanding	O
of	O
the	O
inhibition	O
mechanism	O
of	O
RecA	O
function	O
by	O
RdgC.	O
The	O
ring	O
-	O
shaped	O
architecture	O
with	O
a	O
central	O
hole	O
that	O
is	O
suitable	O
for	O
the	O
binding	O
of	O
dsDNA	O
lends	O
RdgC	O
with	O
a	O
capacity	O
to	O
hold	O
dsDNA	O
very	O
tightly	O
.	O

Therefore	O
,	O
we	O
suggest	O
that	O
RdgC	O
dimers	O
probably	O
function	O
as	O
a	O
tight	O
dsDNA	O
gripper	O
and	O
physically	O
block	O
access	O
to	O
the	O
target	O
dsDNA	O
by	O
RecA	O
filaments	O
,	O
because	O
tight	O
encircling	O
of	O
dsDNA	O
by	O
RdgC	O
dimers	O
,	O
possibly	O
as	O
a	O
linear	O
aggregate	O
,	O
would	O
prevent	O
the	O
two	O
strands	O
from	O
dissociating	O
.	O

However	O
,	O
it	O
remains	O
unclear	O
how	O
the	O
closed	O
-	O
ring	O
structure	O
of	O
the	O
RdgC	O
dimer	O
might	O
allow	O
binding	O
of	O
a	O
large	O
number	O
of	O
RdgC	O
dimers	O
on	O
the	O
duplex	O
DNA	O
.	O

It	O
may	O
be	O
conceivable	O
that	O
each	O
RdgC	O
dimer	O
can	O
open	O
temporarily	O
at	O
one	O
or	O
both	O
of	O
its	O
two	O
inter	O
-	O
subunit	O
interfaces	O
so	O
that	O
dsDNA	O
can	O
enter	O
the	O
central	O
hole	O
.	O

RdgC	O
was	O
at	O
its	O
highest	O
level	O
during	O
exponential	O
phase	O
,	O
reaching	O
its	O
maximum	O
of	O
∼1000	O
dimers	O
per	O
E.	B
coli	I
cell	O
.	O

Its	O
level	O
decreased	O
sharply	O
to	O
∼50	O
dimers	O
per	O
cell	O
in	O
stationary	O
phase	O
(	O
2	O
)	O
.	O

Under	O
normal	O
cellular	O
conditions	O
,	O
RecA	O
is	O
maintained	O
at	O
∼1000	O
molecules	O
per	O
cell	O
(	O
http://www.els.net/	O
)	O
.	O

Following	O
LexA	O
repressor	O
cleavage	O
,	O
the	O
level	O
of	O
RecA	O
protein	O
in	O
the	O
cell	O
increases	O
by	O
as	O
much	O
as	O
20-fold	O
.	O

RdgC	O
inhibition	O
of	O
the	O
RecA	O
function	O
by	O
a	O
simple	O
competition	O
mechanism	O
at	O
the	O
cellular	O
concentration	O
of	O
RdgC	O
clearly	O
requires	O
a	O
much	O
higher	O
affinity	O
for	O
DNA	O
by	O
RdgC	O
than	O
RecA.	O
Possible	O
protein	O
–	O
protein	O
interactions	O
between	O
RdgC	O
dimers	O
might	O
have	O
a	O
profound	O
effect	O
on	O
the	O
affinity	O
for	O
DNA	O
,	O
when	O
a	O
large	O
number	O
of	O
RdgC	O
dimers	O
are	O
bound	O
on	O
a	O
duplex	O
DNA	O
.	O

If	O
only	O
one	O
of	O
the	O
two	O
inter	O
-	O
subunit	O
interfaces	O
can	O
open	O
up	O
and	O
the	O
2-fold	O
symmetry	O
axes	O
of	O
the	O
RdgC	O
dimers	O
are	O
misaligned	O
sufficiently	O
,	O
the	O
escape	O
of	O
DNA	O
from	O
a	O
linear	O
array	O
of	O
interacting	O
RdgC	O
dimers	O
would	O
be	O
extremely	O
difficult	O
.	O

Alternatively	O
,	O
both	O
inter	O
-	O
subunit	O
interfaces	O
of	O
each	O
dimer	O
may	O
open	O
up	O
simultaneously	O
.	O

A	O
line	O
of	O
indirect	O
evidence	O
for	O
the	O
possible	O
protein	O
–	O
protein	O
interactions	O
between	O
RdgC	O
dimers	O
is	O
provided	O
by	O
the	O
cooperative	O
binding	O
of	O
RdgC	O
to	O
DNA	O
(	O
7	O
)	O
.	O

Cooperativity	O
of	O
RdgC	O
binding	O
may	O
be	O
caused	O
by	O
local	O
and	O
distant	O
protein	O
–	O
protein	O
interactions	O
(	O
7	O
)	O
.	O

A	O
kind	O
of	O
side	O
-	O
by	O
-	O
side	O
interaction	O
between	O
two	O
adjacent	O
molecules	O
of	O
RdgC	O
dimer	O
is	O
present	O
in	O
the	O
crystal	O
,	O
burying	O
an	O
accessible	O
surface	O
area	O
of	O
∼750	O
Å2	O
at	O
the	O
interface	O
.	O

The	O
interaction	O
involves	O
mostly	O
the	O
less	O
polar	O
side	O
surface	O
of	O
the	O
dimer	O
(	O
left	O
side	O
of	O
Figure	O
4A	O
)	O
,	O
with	O
2-fold	O
symmetry	O
axes	O
of	O
the	O
two	O
interacting	O
RdgC	O
molecules	O
making	O
an	O
angle	O
of	O
∼90	O
°	O
when	O
viewed	O
down	O
the	O
central	O
holes	O
and	O
∼15	O
°	O
when	O
viewed	O
perpendicular	O
to	O
the	O
holes	O
.	O

This	O
may	O
explain	O
the	O
observed	O
DNA	O
bending	O
by	O
RdgC	O
,	O
which	O
was	O
speculated	O
to	O
be	O
a	O
necessary	O
step	O
in	O
the	O
working	O
mechanism	O
of	O
RdgC	O
,	O
if	O
one	O
can	O
assume	O
that	O
the	O
strong	O
protein	O
–	O
protein	O
interactions	O
in	O
the	O
crystal	O
were	O
relevant	O
for	O
protein	O
–	O
protein	O
interactions	O
in	O
solution	O
(	O
7	O
)	O
.	O

RdgC	O
protein	O
was	O
shown	O
to	O
have	O
a	O
potent	O
effect	O
on	O
RecA	O
protein	O
-	O
promoted	O
DNA	O
strand	O
exchange	O
in	O
E.	B
coli	I
(	O
1	O
)	O
.	O

In	O
a	O
series	O
of	O
experiments	O
,	O
RdgC	O
was	O
added	O
after	O
RecA	O
filaments	O
had	O
formed	O
on	O
the	O
ssDNA	O
and	O
5	O
min	O
after	O
the	O
linear	O
dsDNA	O
was	O
added	O
.	O

With	O
3	O
μM	O
RecA	O
,	O
a	O
sharp	O
reduction	O
in	O
DNA	O
strand	O
exchange	O
products	O
was	O
seen	O
with	O
0.4	O
μM	O
RdgC	O
,	O
and	O
the	O
generation	O
of	O
products	O
was	O
abolished	O
at	O
0.8	O
μM	O
RdgC	O
(	O
1	O
)	O
.	O

This	O
suggests	O
that	O
the	O
binding	O
affinity	O
of	O
RdgC	O
to	O
dsDNA	O
is	O
considerably	O
higher	O
than	O
that	O
of	O
RecA.	O
The	O
high	O
affinity	O
of	O
RdgC	O
could	O
be	O
explained	O
by	O
its	O
ring	O
shape	O
and	O
the	O
suggested	O
mode	O
of	O
DNA	O
binding	O
.	O

Tetrameric	O
species	O
of	O
E.	B
coli	I
RdgC	O
,	O
which	O
started	O
to	O
form	O
at	O
around	O
2	O
µM	O
concentrations	O
,	O
were	O
speculated	O
to	O
be	O
the	O
species	O
with	O
the	O
most	O
potent	O
inhibitory	O
effect	O
,	O
possibly	O
by	O
having	O
a	O
higher	O
affinity	O
for	O
DNA	O
(	O
1	O
)	O
.	O

Higher	O
affinity	O
for	O
DNA	O
of	O
the	O
tetrameric	O
species	O
could	O
be	O
understood	O
,	O
if	O
the	O
formation	O
of	O
a	O
tetramer	O
in	O
solution	O
involves	O
a	O
protein	O
–	O
protein	O
interaction	O
similar	O
to	O
the	O
side	O
-	O
by	O
-	O
side	O
interaction	O
between	O
two	O
adjacent	O
RdgC	O
dimers	O
in	O
the	O
crystal	O
,	O
although	O
there	O
is	O
no	O
experimental	O
evidence	O
.	O

Obviously	O
,	O
there	O
are	O
still	O
many	O
open	O
questions	O
that	O
need	O
to	O
be	O
addressed	O
in	O
future	O
biochemical	O
experiments	O
.	O

SUMMARY	O
The	O
crystal	O
structure	O
of	O
RdgC	O
,	O
a	O
recombination	O
-	O
associated	O
DNA	O
-	O
binding	O
protein	O
,	O
determined	O
in	O
this	O
study	O
reveals	O
that	O
the	O
polypeptide	O
chain	O
is	O
uniquely	O
folded	O
and	O
two	O
monomers	O
associate	O
to	O
form	O
a	O
ring	O
-	O
shaped	O
dimer	O
with	O
a	O
central	O
hole	O
of	O
∼30	O
Å	O
diameter	O
.	O

The	O
inner	O
surface	O
around	O
the	O
central	O
hole	O
is	O
rich	O
in	O
positively	O
charged	O
residues	O
.	O

These	O
structural	O
features	O
suggest	O
that	O
dsDNA	O
runs	O
through	O
the	O
central	O
hole	O
when	O
it	O
binds	O
to	O
RdgC	O
dimers	O
.	O

This	O
idea	O
is	O
supported	O
by	O
our	O
mutational	O
studies	O
,	O
which	O
indicate	O
that	O
the	O
conserved	O
,	O
positively	O
charged	O
residues	O
around	O
the	O
central	O
hole	O
are	O
important	O
for	O
dsDNA	O
binding	O
.	O

The	O
toroidal	O
architecture	O
of	O
the	O
RdgC	O
dimer	O
provides	O
a	O
sound	O
framework	O
for	O
a	O
better	O
understanding	O
of	O
its	O
role	O
in	O
homologous	O
recombination	O
.	O

Coordinates	O
Atomic	O
coordinates	O
and	O
the	O
structure	O
factor	O
data	O
have	O
been	O
deposited	O
in	O
the	O
Protein	O
Data	O
Bank	O
(	O
accession	O
code	O
2OWY	O
)	O
.	O

SUPPLEMENTARY	O
DATA	O
Supplementary	O
Data	O
are	O
available	O
at	O
NAR	O
Online	O
.	O

Supplementary	O
Material	O

Elevated	O
Blood	O
Lead	O
Levels	O
of	O
Children	O
in	O
Guiyu	O
,	O
an	O
Electronic	O
Waste	O
Recycling	O
Town	O
in	O
China	O
Abstract	O
Background	O
Electronic	O
waste	O
(	O
e	O
-	O
waste	O
)	O
recycling	O
has	O
remained	O
primitive	O
in	O
Guiyu	O
,	O
China	O
,	O
and	O
thus	O
may	O
contribute	O
to	O
the	O
elevation	O
of	O
blood	O
lead	O
levels	O
(	O
BLLs	O
)	O
in	O
children	O
living	O
in	O
the	O
local	O
environment	O
.	O

Objectives	O
We	O
compared	O
the	O
BLLs	O
in	O
children	O
living	O
in	O
the	O
e	O
-	O
waste	O
recycling	O
town	O
of	O
Guiyu	O
with	O
those	O
living	O
in	O
the	O
neighboring	O
town	O
of	O
Chendian	O
.	O

Methods	O
We	O
observed	O
the	O
processing	O
of	O
e	O
-	O
waste	O
recycling	O
in	O
Guiyu	O
and	O
studied	O
BLLs	O
in	O
a	O
cluster	O
sample	O
of	O
226	O
children	O
<	O
6	O
years	O
of	O
age	O
who	O
lived	O
in	O
Guiyu	O
and	O
Chendian	O
.	O

BLLs	O
were	O
determined	O
with	O
atomic	O
absorption	O
spectrophotometry	O
.	O

Hemoglobin	O
(	O
Hgb	O
)	O
and	O
physical	O
indexes	O
(	O
height	O
and	O
weight	O
,	O
head	O
and	O
chest	O
circumferences	O
)	O
were	O
also	O
measured	O
.	O

Results	O
BLLs	O
in	O
165	O
children	O
of	O
Guiyu	O
ranged	O
from	O
4.40	O
to	O
32.67	O
μg	O
/	O
dL	O
with	O
a	O
mean	O
of	O
15.3	O
μg	O
/	O
dL	O
,	O
whereas	O
BLLs	O
in	O
61	O
children	O
of	O
Chendian	O
were	O
from	O
4.09	O
to	O
23.10	O
μg	O
/	O
dL	O
with	O
a	O
mean	O
of	O
9.94	O
μg	O
/	O
dL.	O
Statistical	O
analyses	O
showed	O
that	O
children	O
living	O
in	O
Guiyu	O
had	O
significantly	O
higher	O
BLLs	O
compared	O
with	O
those	O
living	O
in	O
Chendian	O
(	O
p	O
<	O
0.01	O
)	O
.	O

Of	O
children	O
in	O
Guiyu	O
,	O
81.8	O
%	O
(	O
135	O
of	O
165	O
)	O
had	O
BLLs	O
>	O
10	O
μg	O
/	O
dL	O
,	O
compared	O
with	O
37.7	O
%	O
of	O
children	O
(	O
23	O
of	O
61	O
)	O
in	O
Chendian	O
(	O
p	O
<	O
0.01	O
)	O
.	O

In	O
addition	O
,	O
we	O
observed	O
a	O
significant	O
increasing	O
trend	O
in	O
BLLs	O
with	O
increasing	O
age	O
in	O
Guiyu	O
(	O
p	O
<	O
0.01	O
)	O
.	O

It	O
appeared	O
that	O
there	O
was	O
correlation	O
between	O
the	O
BLLs	O
in	O
children	O
and	O
numbers	O
of	O
e	O
-	O
waste	O
workshops	O
.	O

However	O
,	O
no	O
significant	O
difference	O
in	O
Hgb	O
level	O
or	O
physical	O
indexes	O
was	O
found	O
between	O
the	O
two	O
towns	O
.	O

Conclusions	O
The	O
primitive	O
e	O
-	O
waste	O
recycling	O
activities	O
may	O
contribute	O
to	O
the	O
elevated	O
BLLs	O
in	O
children	O
living	O
in	O
Guiyu	O
.	O

Disposal	O
of	O
electronic	O
waste	O
,	O
or	O
e	O
-	O
waste	O
,	O
is	O
an	O
emerging	O
global	O
environmental	O
issue	O
,	O
as	O
these	O
wastes	O
have	O
become	O
the	O
most	O
rapidly	O
growing	O
segment	O
of	O
the	O
municipal	O
waste	O
stream	O
in	O
the	O
world	O
[	O
Dahl	O
2002	O
;	O
Halluite	O
et	O
al.	O
2005	O
;	O
Jang	O
and	O
Townsend	O
2003	O
;	O
Schmidt	O
2002	O
;	O
Silicon	O
Valley	O
Toxics	O
Coalition	O
(	O
SVTC	O
)	O
2001	O
]	O
.	O

It	O
is	O
reported	O
that	O
approximately	O
500	O
million	O
computers	O
became	O
obsolete	O
between	O
1997	O
and	O
2007	O
in	O
the	O
United	O
States	O
(	O
National	O
Safety	O
Council	O
1999	O
)	O
.	O

Up	O
to	O
80	O
%	O
of	O
e	O
-	O
waste	O
from	O
the	O
United	O
States	O
has	O
seeped	O
into	O
Asia	O
and	O
Africa	O
(	O
Johnson	O
2006	O
;	O
Puckett	O
et	O
al.	O
2002	O
;	O
Schmidt	O
2002	O
,	O
2006	O
;	O
SVTC	O
2001	O
)	O
.	O

It	O
is	O
noteworthy	O
that	O
the	O
United	O
States	O
is	O
the	O
only	O
developed	O
country	O
today	O
that	O
has	O
not	O
ratified	O
the	O
United	O
Nations	O
Basel	O
Convention	O
,	O
which	O
bans	O
the	O
export	O
of	O
hazardous	O
wastes	O
to	O
developing	O
countries	O
(	O
United	O
Nations	O
Environment	O
Programme	O
1992	O
,	O
2006	O
;	O
USA	O
Today	O
2002	O
)	O
.	O

Together	O
with	O
New	O
Delhi	O
in	O
India	O
,	O
Guiyu	O
in	O
Shantou	O
,	O
Guangdong	O
Province	O
,	O
China	O
(	O
Figure	O
1	O
)	O
,	O
is	O
one	O
of	O
the	O
popular	O
destinations	O
of	O
e	O
-	O
waste	O
(	O
Brigden	O
et	O
al.	O
2005	O
;	O
Puckett	O
et	O
al.	O
2002	O
)	O
.	O

Within	O
a	O
total	O
area	O
of	O
52	O
km2	O
and	O
local	O
population	O
of	O
132,000	O
(	O
in	O
2003	O
)	O
,	O
Guiyu	O
has	O
accommodated	O
millions	O
of	O
tons	O
of	O
e	O
-	O
waste	O
from	O
overseas	O
and	O
domestic	O
a	O
year	O
.	O

Nearly	O
60–80	O
%	O
of	O
families	O
in	O
the	O
town	O
have	O
engaged	O
in	O
e	O
-	O
waste	O
recycling	O
operations	O
conducted	O
by	O
small	O
scale	O
family	O
-	O
run	O
workshops	O
,	O
with	O
approximately	O
100,000	O
migrant	O
workers	O
employed	O
in	O
processing	O
e	O
-	O
waste	O
.	O

Because	O
the	O
implementation	O
of	O
a	O
clean	O
and	O
safe	O
high	O
-	O
tech	O
recovery	O
process	O
was	O
very	O
expensive	O
(	O
Allsopp	O
et	O
al.	O
2006	O
)	O
,	O
the	O
processes	O
and	O
techniques	O
used	O
during	O
the	O
recycling	O
activities	O
in	O
Guiyu	O
were	O
very	O
primitive	O
.	O

The	O
result	O
was	O
that	O
many	O
tons	O
of	O
e	O
-	O
waste	O
material	O
and	O
process	O
residues	O
were	O
dumped	O
in	O
workshops	O
,	O
yards	O
,	O
roadsides	O
,	O
open	O
fields	O
,	O
irrigation	O
canals	O
,	O
riverbanks	O
,	O
ponds	O
,	O
and	O
rivers	O
.	O

Hazardous	O
chemicals	O
can	O
be	O
released	O
from	O
e	O
-	O
wastes	O
through	O
disposal	O
or	O
recycling	O
processes	O
,	O
threatening	O
the	O
health	O
of	O
local	O
residents	O
.	O

Several	O
studies	O
have	O
reported	O
the	O
soaring	O
levels	O
of	O
toxic	O
heavy	O
metals	O
and	O
organic	O
contaminants	O
in	O
samples	O
of	O
dust	O
,	O
soil	O
,	O
river	O
sediment	O
,	O
surface	O
water	O
,	O
and	O
groundwater	O
of	O
Guiyu	O
(	O
Brigden	O
et	O
al.	O
2005	O
;	O
Puckett	O
et	O
al.	O
2002	O
;	O
Wang	O
and	O
Guo	O
2006	O
;	O
Wang	O
et	O
al.	O
2005	O
;	O
Wong	O
et	O
al.	O
2006	O
;	O
Yu	O
et	O
al.	O
2006	O
)	O
.	O

Previously	O
,	O
we	O
have	O
shown	O
that	O
the	O
residents	O
in	O
Guiyu	O
had	O
high	O
incidence	O
of	O
skin	O
damage	O
,	O
headaches	O
,	O
vertigo	O
,	O
nausea	O
,	O
chronic	O
gastritis	O
,	O
and	O
gastric	O
and	O
duodenal	O
ulcers	O
,	O
all	O
of	O
which	O
may	O
be	O
caused	O
by	O
the	O
primitive	O
recycling	O
processing	O
of	O
e	O
-	O
waste	O
(	O
Qiu	O
et	O
al.	O
2004	O
)	O
.	O

Of	O
many	O
toxic	O
heavy	O
metals	O
,	O
lead	O
is	O
the	O
most	O
widely	O
used	O
in	O
electronic	O
devices	O
for	O
various	O
purposes	O
,	O
resulting	O
in	O
a	O
variety	O
of	O
health	O
hazards	O
due	O
to	O
environmental	O
contamination	O
(	O
Jang	O
and	O
Townsend	O
2003	O
;	O
Musson	O
et	O
al.	O
2006	O
;	O
Vann	O
et	O
al.	O
2006	O
)	O
.	O

Lead	O
enters	O
biological	O
systems	O
via	O
food	O
,	O
water	O
,	O
air	O
,	O
and	O
soil	O
.	O

Children	O
are	O
particularly	O
vulnerable	O
to	O
lead	O
poisoning	O
—	O
more	O
so	O
than	O
adults	O
because	O
they	O
absorb	O
more	O
lead	O
from	O
their	O
environments	O
(	O
Baghurst	O
et	O
al.	O
1992	O
;	O
Grigg	O
2004	O
;	O
Guilarte	O
et	O
al.	O
2003	O
;	O
Jain	O
and	O
Hu	O
2006	O
;	O
Needleman	O
2004	O
;	O
Safi	O
et	O
al.	O
2006	O
;	O
Wasserman	O
et	O
al.	O
1998	O
)	O
.	O

The	O
U.S.	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
(	O
CDC	O
)	O
defined	O
elevated	O
blood	O
lead	O
levels	O
(	O
BLLs	O
)	O
as	O
those	O
≥	O
10	O
μg	O
/	O
dL	O
in	O
children	O
≤	O
6	O
years	O
of	O
age	O
(	O
CDC	O
1991	O
)	O
.	O

Nevertheless	O
,	O
studies	O
have	O
increasingly	O
shown	O
that	O
low	O
blood	O
lead	O
concentrations	O
,	O
even	O
<	O
10	O
μg	O
/	O
dL	O
,	O
were	O
inversely	O
associated	O
with	O
children	O
's	O
IQ	O
scores	O
and	O
academic	O
skills	O
(	O
Canfield	O
et	O
al.	O
2003	O
;	O
Lanphear	O
et	O
al.	O
2000	O
,	O
2005	O
;	O
Nevin	O
2000	O
;	O
Schnaas	O
et	O
al.	O
2006	O
)	O
.	O

Therefore	O
,	O
no	O
safety	O
margin	O
at	O
existing	O
exposures	O
has	O
been	O
identified	O
(	O
Chiodo	O
et	O
al.	O
2004	O
;	O
Koller	O
et	O
al.	O
2004	O
)	O
.	O

Considering	O
the	O
potential	O
heavy	O
metal	O
contamination	O
in	O
the	O
local	O
living	O
environment	O
of	O
Guiyu	O
,	O
we	O
hypothesized	O
that	O
children	O
living	O
in	O
Guiyu	O
may	O
have	O
elevated	O
BLLs	O
and	O
thus	O
their	O
physical	O
and	O
mental	O
development	O
may	O
have	O
been	O
affected	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
mean	O
BLLs	O
in	O
children	O
1–6	O
years	O
of	O
age	O
living	O
in	O
Guiyu	O
and	O
compared	O
them	O
with	O
those	O
living	O
in	O
the	O
neighboring	O
town	O
of	O
Chendian	O
,	O
where	O
no	O
e	O
-	O
waste	O
processing	O
was	O
taken	O
.	O

Materials	O
and	O
Methods	O
Geographic	O
location	O
and	O
site	O
description	O
There	O
are	O
28	O
villages	O
with	O
a	O
total	O
area	O
of	O
52	O
km2	O
and	O
a	O
resident	O
population	O
of	O
132,000	O
and	O
around	O
100,000	O
migrant	O
workers	O
in	O
Guiyu	O
(	O
Figure	O
1	O
)	O
.	O

We	O
chose	O
four	O
villages	O
for	O
their	O
differences	O
in	O
the	O
scale	O
and	O
type	O
of	O
e	O
-	O
waste	O
processing	O
.	O

Beilin	O
village	O
has	O
dense	O
e	O
-	O
waste	O
workshops	O
mainly	O
involved	O
in	O
equipment	O
dismantling	O
,	O
circuit	O
board	O
baking	O
,	O
and	O
acid	O
baths	O
;	O
Dutou	O
village	O
specializes	O
in	O
plastics	O
sorting	O
,	O
including	O
manually	O
stripping	O
plastic	O
materials	O
from	O
electronic	O
products	O
and	O
then	O
crudely	O
classifying	O
them	O
;	O
Huamei	O
village	O
had	O
workshops	O
similar	O
to	O
those	O
of	O
Beilin	O
,	O
but	O
they	O
are	O
fewer	O
and	O
scattered	O
;	O
and	O
Longgang	O
village	O
was	O
involved	O
in	O
plastic	O
reprocessing	O
in	O
which	O
plastics	O
collected	O
from	O
Dutou	O
and	O
other	O
villages	O
were	O
washed	O
and	O
smashed	O
into	O
tiny	O
pieces	O
of	O
recycled	O
plastic	O
.	O

We	O
used	O
the	O
neighboring	O
town	O
of	O
Chendian	O
as	O
a	O
control	O
because	O
the	O
local	O
residents	O
work	O
mainly	O
in	O
the	O
textiles	O
industry	O
,	O
not	O
in	O
e	O
-	O
waste	O
processing	O
.	O

The	O
population	O
,	O
traffic	O
density	O
,	O
lifestyle	O
,	O
and	O
socioeconomic	O
status	O
were	O
very	O
similar	O
to	O
those	O
of	O
Guiyu	O
.	O

Study	O
population	O
The	O
study	O
population	O
was	O
composed	O
of	O
children	O
≤	O
6	O
years	O
of	O
age	O
.	O

No	O
children	O
involved	O
in	O
the	O
study	O
had	O
any	O
occupational	O
exposure	O
to	O
e	O
-	O
waste	O
.	O

A	O
cluster	O
sample	O
of	O
165	O
children	O
with	O
a	O
median	O
age	O
of	O
5.0	O
years	O
lived	O
in	O
the	O
four	O
villages	O
of	O
Guiyu	O
(	O
Figure	O
1	O
)	O
.	O

Sixty	O
-	O
one	O
children	O
with	O
a	O
median	O
age	O
of	O
4.0	O
years	O
resided	O
in	O
Chendian	O
were	O
included	O
in	O
the	O
study	O
for	O
comparison	O
.	O

After	O
written	O
informed	O
consent	O
was	O
obtained	O
from	O
the	O
parents	O
or	O
guardians	O
,	O
blood	O
samples	O
were	O
collected	O
from	O
the	O
children	O
at	O
village	O
kindergartens	O
.	O

To	O
facilitate	O
the	O
counseling	O
process	O
,	O
advice	O
on	O
dietary	O
and	O
eating	O
habits	O
to	O
minimize	O
lead	O
exposure	O
were	O
provided	O
to	O
the	O
local	O
residents	O
.	O

All	O
children	O
found	O
to	O
have	O
high	O
BLLs	O
were	O
advised	O
to	O
get	O
further	O
hospital	O
treatment	O
.	O

The	O
study	O
was	O
approved	O
by	O
the	O
Human	O
Ethics	O
Committee	O
of	O
Shantou	O
University	O
Medical	O
College	O
.	O

Measurement	O
of	O
BLLs	O
and	O
hemoglobin	O
Venipuncture	O
blood	O
samples	O
were	O
obtained	O
from	O
each	O
volunteer	O
at	O
the	O
kindergarten	O
,	O
and	O
collected	O
in	O
lead	O
-	O
free	O
tubes	O
by	O
trained	O
nurses	O
.	O

Lead	O
in	O
total	O
blood	O
was	O
analyzed	O
by	O
graphite	O
furnace	O
atomic	O
absorption	O
spectrometry	O
(	O
GFAAS	O
)	O
,	O
which	O
consisted	O
of	O
a	O
Shimadzu	O
AA-660	O
AAS	O
and	O
GFA-4B	O
graphite	O
furnace	O
atomizer	O
and	O
an	O
ACS-60	O
G	O
autosampler	O
(	O
Shimadzu	O
Corporation	O
,	O
Kyoto	O
,	O
Japan	O
)	O
.	O

The	O
main	O
parameters	O
used	O
for	O
the	O
determination	O
were	O
a	O
wavelength	O
of	O
283.3	O
nm	O
,	O
current	O
of	O
8	O
mA	O
,	O
a	O
slit	O
width	O
of	O
1.00	O
nm	O
,	O
drying	O
at	O
150	O
°	O
C	O
,	O
ashing	O
at	O
325	O
°	O
C	O
,	O
and	O
atomization	O
at	O
1,400	O
°	O
C	O
.	O

The	O
accuracy	O
of	O
the	O
method	O
was	O
controlled	O
by	O
recoveries	O
between	O
95	O
%	O
and	O
107	O
%	O
from	O
the	O
spiked	O
blood	O
samples	O
.	O

Repeated	O
analyses	O
of	O
standard	O
solutions	O
confirmed	O
the	O
method	O
's	O
precision	O
.	O

The	O
BLLs	O
were	O
expressed	O
in	O
micrograms	O
per	O
deciliter	O
(	O
1	O
μg	O
/	O
dL	O
=	O
0.0484	O
μmol	O
/	O
L	O
)	O
.	O

Meanwhile	O
,	O
we	O
assessed	O
hemoglobin	O
(	O
Hgb	O
)	O
levels	O
by	O
hemoglobin	O
cyanide	O
method	O
with	O
hemoglobinometer	O
(	O
XK-2	O
,	O
JiangSu	O
,	O
China	O
)	O
.	O

Evaluation	O
of	O
physical	O
developmental	O
indexes	O
Children	O
's	O
physical	O
growth	O
and	O
development	O
,	O
such	O
as	O
body	O
height	O
,	O
weight	O
,	O
and	O
head	O
and	O
chest	O
circumferences	O
were	O
measured	O
when	O
blood	O
samples	O
were	O
collected	O
.	O

Weight	O
and	O
height	O
were	O
measured	O
using	O
a	O
weighing	O
and	O
height	O
scale	O
(	O
TZ120	O
;	O
Yuyao	O
Balance	O
Instrument	O
Factory	O
,	O
Yuyao	O
,	O
China	O
)	O
with	O
maximum	O
weight	O
of	O
120	O
kg	O
(	O
minimum	O
scale	O
,	O
50	O
g	O
)	O
and	O
minimum	O
height	O
of	O
70	O
cm	O
(	O
minimum	O
scale	O
,	O
0.5	O
cm	O
)	O
.	O

Head	O
and	O
chest	O
circumferences	O
were	O
measured	O
using	O
graduated	O
anthropometric	O
tapes	O
.	O

Statistical	O
analyses	O
We	O
performed	O
statistical	O
analyses	O
using	O
SPSS	O
version	O
10.0	O
software	O
(	O
SPSS	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
.	O

We	O
used	O
independent	O
sample	O
t	O
-	O
tests	O
or	O
covariance	O
analyses	O
for	O
comparisons	O
of	O
mean	O
,	O
chi	O
-	O
square	O
analyses	O
for	O
test	O
of	O
frequency	O
data	O
,	O
and	O
linear	O
regression	O
analysis	O
for	O
the	O
association	O
between	O
BLLs	O
and	O
age	O
.	O

Differences	O
were	O
considered	O
significant	O
with	O
a	O
p	O
-	O
value	O
<	O
0.05	O
.	O

Results	O
Observation	O
of	O
e	O
-	O
waste	O
processing	O
The	O
primitive	O
e	O
-	O
waste	O
recycling	O
procedures	O
in	O
Guiyu	O
were	O
mainly	O
as	O
follows	O
:	O
a	O
)	O
Old	O
electronic	O
equipment	O
was	O
dismantled	O
(	O
Figure	O
2	O
)	O
with	O
electric	O
drill	O
,	O
cutter	O
,	O
hammer	O
,	O
and	O
screwdriver	O
into	O
component	O
parts	O
such	O
as	O
monitor	O
,	O
hard	O
drive	O
,	O
CD	O
driver	O
,	O
wires	O
,	O
cables	O
,	O
circuit	O
boards	O
,	O
transformer	O
,	O
charger	O
,	O
battery	O
,	O
and	O
plastic	O
or	O
metal	O
frame	O
that	O
are	O
sold	O
for	O
reuse	O
or	O
to	O
other	O
workshops	O
for	O
further	O
recycling	O
.	O

b	O
)	O
Circuit	O
boards	O
(	O
Figure	O
3	O
)	O
of	O
computers	O
and	O
other	O
large	O
appliances	O
were	O
heated	O
over	O
coal	O
fires	O
to	O
melt	O
the	O
solder	O
to	O
release	O
valuable	O
electronic	O
components	O
,	O
such	O
as	O
diodes	O
,	O
resistors	O
,	O
and	O
microchips	O
.	O

c	O
)	O
Circuit	O
boards	O
of	O
cell	O
phones	O
and	O
other	O
hand	O
-	O
held	O
devices	O
were	O
taken	O
apart	O
by	O
a	O
electrothermal	O
machine	O
(	O
Figure	O
4	O
)	O
,	O
which	O
was	O
a	O
particular	O
environmental	O
and	O
human	B
health	O
concern	O
in	O
the	O
processing	O
of	O
e	O
-	O
waste	O
in	O
Guiyu	O
.	O

d	O
)	O
In	O
acid	O
baths	O
(	O
Figure	O
5	O
)	O
,	O
some	O
microchips	O
and	O
computer	O
parts	O
were	O
soaked	O
to	O
extract	O
precious	O
gold	O
and	O
palladium	O
,	O
from	O
which	O
the	O
waste	O
acids	O
were	O
discharged	O
into	O
nearby	O
fields	O
and	O
streams	O
.	O

e	O
)	O
Wires	O
and	O
cables	O
were	O
stripped	O
or	O
simply	O
burnt	O
in	O
open	O
air	O
to	O
recover	O
metals	O
.	O

f	O
)	O
Printer	O
cartridges	O
were	O
ripped	O
apart	O
for	O
their	O
toner	O
and	O
recyclable	O
aluminum	O
,	O
steel	O
,	O
and	O
plastic	O
parts	O
.	O

g	O
)	O
Plastic	O
[	O
e.g.	O
,	O
polyvinyl	O
chloride	O
(	O
PVC	O
)	O
,	O
acrylonitrile	O
butadiene	O
styrene	O
copolymer	O
(	O
ABS	O
)	O
,	O
high	O
-	O
density	O
polyethylene	O
(	O
HDPE	O
)	O
]	O
was	O
sorted	O
by	O
workers	O
according	O
to	O
rigidity	O
,	O
color	O
,	O
and	O
luster	O
.	O

Plastic	O
scraps	O
that	O
can	O
not	O
be	O
sorted	O
visually	O
must	O
be	O
burned	O
and	O
classified	O
by	O
burning	O
odor	O
.	O

Another	O
way	O
to	O
sort	O
different	O
plastics	O
was	O
gravitational	O
separation	O
into	O
ceramic	O
jugs	O
with	O
brine	O
(	O
Figure	O
6	O
)	O
,	O
after	O
which	O
the	O
pieces	O
were	O
spread	O
on	O
the	O
sidewalk	O
to	O
dry	O
;	O
h	O
)	O
For	O
reprocessing	O
,	O
after	O
sorting	O
plastic	O
scraps	O
were	O
fed	O
into	O
grinders	O
that	O
spit	O
out	O
tiny	O
pieces	O
of	O
plastic	O
.	O

i	O
)	O

For	O
metals	O
sorting	O
and	O
reprocessing	O
,	O
transformers	O
,	O
chargers	O
,	O
batteries	O
,	O
and	O
cathode	O
-	O
ray	O
tubes	O
were	O
separated	O
and	O
hammered	O
open	O
for	O
recycling	O
metals	O
such	O
as	O
copper	O
,	O
steel	O
,	O
silver	O
,	O
aluminum	O
,	O
which	O
were	O
then	O
reprocessed	O
to	O
raw	O
material	O
.	O

Although	O
the	O
methods	O
for	O
processing	O
e	O
-	O
waste	O
were	O
primitive	O
,	O
the	O
coordination	O
of	O
e	O
-	O
waste	O
recycling	O
in	O
Guiyu	O
was	O
very	O
well	O
organized	O
into	O
specific	O
tasks	O
.	O

Workshops	O
specializing	O
in	O
dismantled	O
equipment	O
would	O
not	O
conduct	O
circuit	O
board	O
baking	O
or	O
plastics	O
and	O
metals	O
reprocessing	O
.	O

The	O
chain	O
of	O
recycling	O
components	O
from	O
each	O
type	O
of	O
e	O
-	O
waste	O
was	O
well	O
established	O
in	O
the	O
town	O
.	O

BLLs	O
in	O
children	O
We	O
collected	O
blood	O
from	O
165	O
children	O
in	O
Guiyu	O
and	O
61	O
children	O
in	O
Chendian	O
and	O
measured	O
the	O
BLLs	O
in	O
these	O
children	O
.	O

Table	O
1	O
shows	O
that	O
the	O
BLLs	O
corresponded	O
to	O
the	O
children	O
's	O
age	O
,	O
sex	O
,	O
and	O
town	O
of	O
residence	O
.	O

As	O
expected	O
,	O
BLLs	O
among	O
Guiyu	O
children	O
were	O
much	O
higher	O
than	O
those	O
in	O
the	O
children	O
of	O
Chendian	O
(	O
p	O
<	O
0.01	O
)	O
.	O

Among	O
Guiyu	O
children	O
,	O
135	O
(	O
81.8	O
%	O
)	O
had	O
BLLs	O
>	O
10	O
μg	O
/	O
dL	O
,	O
whereas	O
23	O
(	O
37.7	O
%	O
)	O
in	O
Chendian	O
(	O
p	O
<	O
0.01	O
)	O
had	O
high	O
levels	O
.	O

Among	O
135	O
(	O
81.8	O
%	O
)	O
Guiyu	O
children	O
with	O
elevated	O
BLLs	O
,	O
61.8	O
%	O
and	O
20	O
%	O
had	O
BLLs	O
>	O
10	O
μg	O
/	O
dL	O
and	O
20	O
μg	O
/	O
dL	O
respectively	O
,	O
but	O
lead	O
levels	O
>	O
45	O
μg	O
/	O
dL	O
were	O
not	O
found	O
.	O

And	O
BLLs	O
of	O
Guiyu	O
increased	O
somewhat	O
with	O
age	O
(	O
p	O
<	O
0.01	O
)	O
;	O
older	O
children	O
tended	O
to	O
have	O
higher	O
BLLs	O
than	O
younger	O
ones	O
.	O

We	O
found	O
no	O
evidence	O
for	O
the	O
association	O
in	O
lead	O
concentrations	O
or	O
prevalence	O
of	O
elevated	O
BLLs	O
differentiated	O
by	O
sex	O
(	O
both	O
p	O
>	O
0.05	O
)	O
.	O

Table	O
2	O
presents	O
BLLs	O
for	O
165	O
exposed	O
children	O
in	O
the	O
four	O
villages	O
.	O

The	O
findings	O
showed	O
that	O
BLLs	O
from	O
different	O
villages	O
were	O
in	O
the	O
following	O
descending	O
order	O
:	O
Beilin	O
,	O
19.34	O
μg	O
/	O
dL	O
>	O
Dutou	O
,	O
17.86	O
μg	O
/	O
dL	O
>	O
Huamei	O
,	O
14.23	O
μg	O
/	O
dL	O
>	O
Longgang	O
,	O
13.13	O
μg	O
/	O
dL	O
(	O
Table	O
2	O
)	O
.	O

Children	O
living	O
in	O
Beilin	O
,	O
where	O
the	O
number	O
of	O
e	O
-	O
waste	O
workshops	O
specializing	O
in	O
equipment	O
dismantling	O
,	O
circuit	O
board	O
baking	O
,	O
and	O
acid	O
baths	O
,	O
had	O
the	O
highest	O
BLLs	O
.	O

Dutou	O
,	O
which	O
had	O
many	O
workshops	O
specializing	O
in	O
plastics	O
sorting	O
,	O
including	O
strip	O
plastic	O
materials	O
from	O
e	O
-	O
waste	O
,	O
had	O
the	O
second	O
highest	O
BLLs	O
in	O
children	O
.	O

Huamei	O
had	O
e	O
-	O
waste	O
workshops	O
similar	O
to	O
those	O
of	O
Beilin	O
,	O
but	O
fewer	O
and	O
less	O
centralized	O
;	O
the	O
BLLs	O
of	O
Huamei	O
children	O
were	O
much	O
lower	O
than	O
those	O
of	O
Beilin	O
and	O
Dutou	O
.	O

Longgang	O
,	O
a	O
village	O
specializing	O
in	O
reprocessing	O
plastics	O
collected	O
from	O
other	O
villages	O
that	O
had	O
no	O
workshops	O
directly	O
processing	O
e	O
-	O
waste	O
,	O
had	O
the	O
lowest	O
BLLs	O
.	O

There	O
was	O
a	O
significant	O
difference	O
in	O
BLLs	O
among	O
the	O
children	O
of	O
the	O
four	O
villages	O
(	O
p	O
<	O
0.01	O
)	O
.	O

In	O
Beilin	O
and	O
Dutou	O
,	O
88.8	O
%	O
and	O
100	O
%	O
children	O
had	O
elevated	O
BLLs	O
>	O
10	O
μg	O
/	O
dL	O
,	O
respectively	O
.	O

As	O
far	O
as	O
physical	O
indexes	O
and	O
Hgb	O
levels	O
were	O
concerned	O
,	O
there	O
was	O
no	O
significant	O
difference	O
between	O
Guiyu	O
and	O
Chendian	O
(	O
p	O
>	O
0.05	O
,	O
Table	O
3	O
)	O
.	O

Discussion	O
In	O
this	O
study	O
,	O
we	O
observed	O
that	O
the	O
processing	O
of	O
e	O
-	O
waste	O
in	O
Guiyu	O
was	O
very	O
primitive	O
and	O
the	O
recycling	O
industry	O
depended	O
mainly	O
on	O
manual	O
processing	O
methods	O
.	O

Despite	O
the	O
fact	O
that	O
the	O
coordination	O
of	O
the	O
e	O
-	O
waste	O
recycling	O
is	O
well	O
organized	O
in	O
family	O
-	O
based	O
small	O
business	O
units	O
,	O
the	O
manual	O
processing	O
methods	O
and	O
the	O
deposition	O
of	O
the	O
e	O
-	O
waste	O
have	O
contributed	O
to	O
the	O
contamination	O
by	O
heavy	O
metals	O
in	O
the	O
living	O
environment	O
.	O

Examination	O
of	O
the	O
possible	O
impact	O
of	O
the	O
e	O
-	O
waste	O
industry	O
on	O
the	O
BLLs	O
of	O
children	O
living	O
in	O
Guiyu	O
revealed	O
that	O
Guiyu	O
children	O
had	O
significantly	O
higher	O
BLLs	O
than	O
Chendian	O
children	O
.	O

Of	O
children	O
tested	O
in	O
Guiyu	O
,	O
81.8	O
%	O
had	O
BLLs	O
>	O
10	O
μg	O
/	O
dL	O
,	O
indicating	O
a	O
correlation	O
between	O
the	O
BLLs	O
in	O
children	O
and	O
the	O
numbers	O
of	O
e	O
-	O
waste	O
workshops	O
.	O

We	O
speculated	O
that	O
the	O
elevated	O
BLLs	O
in	O
Guiyu	O
children	O
may	O
be	O
directly	O
caused	O
by	O
the	O
contamination	O
of	O
the	O
lead	O
during	O
e	O
-	O
waste	O
recycling	O
.	O

However	O
,	O
further	O
study	O
should	O
be	O
conducted	O
to	O
determine	O
the	O
relationship	O
between	O
BLLs	O
in	O
Children	O
and	O
the	O
actual	O
lead	O
contamination	O
in	O
the	O
environment	O
.	O

Lead	O
is	O
considered	O
one	O
of	O
the	O
major	O
heavy	O
metal	O
contaminants	O
during	O
the	O
process	O
of	O
e	O
-	O
waste	O
recycling	O
.	O

A	O
cathode	O
ray	O
tube	O
inside	O
a	O
television	O
set	O
or	O
a	O
computer	O
monitor	O
contains	O
an	O
average	O
of	O
4–8	O
lb	O
lead	O
;	O
monitor	O
glass	O
contains	O
about	O
20	O
%	O
lead	O
by	O
weight	O
;	O
a	O
typical	O
battery	O
weighs	O
36	O
lb	O
and	O
contains	O
about	O
18	O
lb	O
of	O
lead	O
.	O

For	O
decades	O
,	O
lead	O
as	O
a	O
major	O
component	O
of	O
solders	O
has	O
been	O
used	O
to	O
attach	O
electronic	O
components	O
to	O
printed	O
circuit	O
boards	O
.	O

Lead	O
compounds	O
have	O
also	O
been	O
used	O
as	O
stabilizers	O
in	O
some	O
PVC	O
cables	O
and	O
other	O
products	O
.	O

Our	O
study	O
demonstrated	O
in	O
Guiyu	O
a	O
significant	O
increasing	O
trend	O
in	O
BLLs	O
with	O
increasing	O
age	O
;	O
older	O
children	O
tended	O
to	O
have	O
higher	O
BLLs	O
than	O
younger	O
ones	O
.	O

This	O
might	O
be	O
the	O
result	O
of	O
increasing	O
exposure	O
risk	O
because	O
older	O
children	O
might	O
have	O
more	O
outdoor	O
activities	O
.	O

In	O
addition	O
,	O
it	O
may	O
also	O
be	O
attributed	O
to	O
the	O
fact	O
that	O
the	O
heaviest	O
lead	O
-	O
contaminated	O
zone	O
in	O
air	O
after	O
the	O
burning	O
of	O
the	O
e	O
-	O
waste	O
was	O
75–100	O
cm	O
above	O
the	O
ground	O
(	O
Wang	O
and	O
Zhang	O
2006	O
)	O
,	O
which	O
was	O
the	O
height	O
range	O
for	O
normal	O
Chinese	O
children	O
5–6	O
years	O
of	O
age	O
.	O

In	O
China	O
,	O
the	O
mean	O
BLL	O
of	O
children	O
was	O
9.29	O
μg	O
/	O
dL	O
,	O
and	O
33.8	O
%	O
of	O
the	O
subjects	O
had	O
BLLs	O
>	O
10	O
μg	O
/	O
dL	O
;	O
boys	O
'	O
mean	O
BLL	O
was	O
9.64	O
μg	O
/	O
dL	O
,	O
significantly	O
higher	O
than	O
the	O
girls	O
'	O
mean	O
BLL	O
of	O
8.94	O
μg	O
/	O
dL	O
(	O
p	O
<	O
0.001	O
)	O
(	O
Wang	O
and	O
Zhang	O
2006	O
)	O
.	O

Generally	O
in	O
China	O
,	O
BLLs	O
of	O
children	O
living	O
in	O
industrial	O
and	O
urban	O
areas	O
were	O
significantly	O
higher	O
than	O
those	O
of	O
children	O
in	O
suburbs	O
and	O
rural	O
areas	O
(	O
Wang	O
and	O
Zhang	O
2006	O
)	O
.	O

In	O
Guiyu	O
,	O
the	O
BLLs	O
of	O
children	O
were	O
higher	O
than	O
the	O
mean	O
level	O
in	O
China	O
,	O
and	O
there	O
were	O
no	O
significant	O
different	O
between	O
boys	O
and	O
girls	O
.	O

Although	O
Guiyu	O
is	O
rural	O
,	O
the	O
children	O
's	O
BLLs	O
were	O
nearly	O
double	O
those	O
of	O
a	O
nearby	O
urban	O
area	O
,	O
Shantou	O
City	O
(	O
7.9	O
μg	O
/	O
dL	O
;	O
Luo	O
et	O
al.	O
2003	O
)	O
.	O

Compared	O
with	O
results	O
from	O
studies	O
conducted	O
in	O
some	O
other	O
part	O
of	O
Guangdong	O
province	O
,	O
such	O
as	O
Zhongshan	O
City	O
(	O
7.45	O
μg	O
/	O
dL	O
;	O
Huang	O
et	O
al.	O
2003	O
)	O
and	O
Shenzhen	O
City	O
(	O
9.06	O
μg	O
/	O
dL	O
;	O
Wang	O
et	O
al.	O
2003	O
)	O
,	O
we	O
observed	O
higher	O
BLLs	O
not	O
only	O
in	O
Guiyu	O
children	O
,	O
but	O
also	O
in	O
Chendian	O
children	O
(	O
9.94	O
μg	O
/	O
dL	O
)	O
.	O

The	O
lead	O
contamination	O
may	O
have	O
spread	O
from	O
Guiyu	O
to	O
nearby	O
Chendian	O
by	O
dust	O
,	O
river	O
,	O
and	O
air	O
and	O
contributed	O
to	O
the	O
elevation	O
of	O
Chendian	O
children	O
's	O
BLLs	O
.	O

In	O
conclusion	O
,	O
elevated	O
BLLs	O
in	O
Guiyu	O
children	O
are	O
common	O
as	O
a	O
result	O
of	O
exposure	O
to	O
lead	O
contamination	O
caused	O
by	O
primitive	O
e	O
-	O
waste	O
recycling	O
activities	O
.	O

Lead	O
contamination	O
from	O
e	O
-	O
waste	O
processing	O
appears	O
to	O
have	O
reached	O
the	O
level	O
considered	O
to	O
be	O
a	O
serious	O
threat	O
to	O
children	O
's	O
health	O
around	O
the	O
e	O
-	O
waste	O
recycling	O
area	O
.	O

Based	O
on	O
these	O
threats	O
,	O
it	O
is	O
necessary	O
to	O
increase	O
public	O
awareness	O
about	O
the	O
effects	O
of	O
exposure	O
to	O
lead	O
from	O
e	O
-	O
waste	O
and	O
arouse	O
local	O
governments	O
'	O
interest	O
in	O
public	O
health	O
and	O
safety	O
,	O
so	O
that	O
an	O
infrastructure	O
for	O
safe	O
management	O
of	O
e	O
-	O
waste	O
can	O
be	O
established	O
.	O

More	O
important	O
,	O
responsible	O
management	O
strategies	O
should	O
be	O
undertaken	O
to	O
minimize	O
e	O
-	O
waste	O
production	O
and	O
make	O
e	O
-	O
waste	O
components	O
more	O
easily	O
recycled	O
and	O
reused	O
.	O

Correction	O
In	O
the	O
Abstract	O
and	O
Discussion	O
,	O
the	O
percentage	O
of	O
Guiyu	O
children	O
with	O
BLLs	O
>	O
10	O
μg	O
/	O
dL	O
has	O
been	O
corrected	O
from	O
88	O
%	O
in	O
the	O
original	O
manuscript	O
published	O
online	O
to	O
81.8	O
%	O
.	O

Advanced	O
software	O
concepts	O
for	O
employing	O
microcomputers	O
in	O
the	O
laboratory	O
Abstract	O
IIII	O
II	O
,	O
Advanced	O
software	O
concepts	O
for	O
employing	O
microcomputers	O
in	O
the	O
laboratory	O
Scott	O
B.	O
Tilden	O
and	O
M.Bonner	O
Denton	O
,	O
Department	O
of	O
Chemistry	O
,	O
University	O
of	O
Arizona	O
,	O
Tucson	O
,	O
Arizona	O
85721	O
,	O
USA	O
.	O

Introduction	O
While	O
a	O
proliferation	O
of	O
commercial	O
chemical	O
instrumentation	O
is	O
appearing	O
today	O
employing	O
microprocessors	O
for	O
a	O
variety	O
of	O
control	O
and	O
data	O
reduction	O
applications	O
,	O
the	O
great	O
potential	O
of	O
microprocessors	O
has	O
not	O
been	O
exploited	O
extensively	O
for	O
individual	O
custom	O
applications	O
.	O

The	O
primary	O
reason	O
for	O
this	O
phenomenon	O
is	O
altogether	O
too	O
clear	O
microprocessor	O
software	O
is	O
either	O
difficult	O
to	O
develop	O
or	O
inefficient	O
in	O
memory	O
requirements	O
and	O
speed	O
.	O

This	O
problem	O
is	O
even	O
more	O
important	O
in	O
situations	O
requiring	O
constant	O
software	O
modification	O
.	O

Initially	O
,	O
most	O
instrument	O
manufacturers	O
utilized	O
cross	O
assemblers	O
supported	O
on	O
large	O
"	O
number	O
cruncher	O
"	O
computers	O
to	O
generate	O
the	O
required	O
machine	O
code	O
binary	O
program	O
.	O

More	O
recently	O
,	O
the	O
trend	O
has	O
been	O
toward	O
the	O
use	O
of	O
a	O
"	O
developmental	O
system	O
"	O
(	O
at	O
a	O
cost	O
comparable	O
to	O
a	O
moderate	O
minicomputer-	O
the	O
authors	O
use	O
the	O
term	O
"	O
mini	O
"	O
in	O
contrast	O
to	O
"	O
micro	O
"	O
reluctantly	O
because	O
of	O
the	O
ever	O
increasing	O
overlap	O
in	O
computing	O
capability	O
)	O
to	O
write	O
and	O
debug	O
assembly	O
level	O
porgrams	O
which	O
are	O
subsequently	O
converted	O
to	O
binary	O
and	O
incorporated	O
into	O
an	O
instrument	O
in	O
the	O
form	O
of	O
"	O
read	O
only	O
memory	O
"	O
(	O
ROM	O
)	O
.	O

While	O
this	O
approach	O
Interpretative	O
Machine	O
Code	O
Source	O
Code	O
File	O
to	O
Execute	O
Command	O
A	O
Hachine	O
Code	O
Various	O
to	O

Execute	O
Comma	O
nd	O
B	O
ne	O
Code	O
'	O
commands	O
making	O
up	O
,	O
lachi	O
to	O
Execute	O
Command	O
C	O
users	O
source	O
program	O
i	O

Machine	O
Code	O
to	O
Execute	O
Command	O
D	O
etc	O
.	O

Figure	O
1	O
.	O

The	O
interpretative	O
cycle	O
of	O
common	O
types	O
of	O
languages	O
such	O
as	O
BASIC	O
.	O

After	O
examining	O
each	O
command	O
in	O
the	O
source	O
file	O
,	O
the	O
interpreter	O
searches	O
for	O
and	O
branches	O
to	O
the	O
corresponding	O
block	O
of	O
machine	O
code	O
;	O
thus	O
,	O
program	O
execution	O
always	O
remains	O
within	O
the	O
interpreter	O
.	O

128	O
The	O
Journal	O
of	O
Automatic	O
Chemistry	O
Tilden	O
&	O
Denton	O
IIII	O
Advanced	O
software	O
concepts	O
III	O

Users	O
Source	O
File	O

The	O
Compiler	O
Command	O
A	O
Comma	O
nd	O
B	O
Command	O
C	O
Command	O
D	O
etc	O
.	O

/z	O
/	O
li	O
i	O
II	O
.	O

Machine	O
Code	O
etc	O
.	O

.lachi	O

ne	O
Code	O
to	O
Execute	O
Command	O
A	O
etc	O
.	O

to	O
Execute	O
Machine	O
Code	O
to	O
Execute	O
Command	O
C	O
Machine	O
Code	O
etc	O
.	O

Figure	O
2	O
.	O

Note	O
that	O
the	O
compiler	O
transforms	O
each	O
source	O
"	O
command	O
"	O
into	O
executable	O
machine	O
code	O
.	O

This	O
code	O
will	O
,	O
subsequently	O
,	O
be	O
loaded	O
and	O
executed	O
independently	O
of	O
the	O
compiler	O
.	O

has	O
proven	O
cost	O
effective	O
for	O
high	O
volume	O
mass	O
produced	O
applications	O
,	O
it	O
possesses	O
serious	O
limitations	O
for	O
system	O
updates	O
and	O
custom	O
applications	O
.	O

Additionally	O
,	O
the	O
ability	O
to	O
program	O
efficiently	O
at	O
the	O
assembly	O
level	O
is	O
a	O
talent	O
requiring	O
a	O
significant	O
expenditure	O
of	O
time	O
to	O
develop	O
.	O

During	O
the	O
past	O
several	O
years	O
,	O
a	O
virtual	O
deluge	O
of	O
sophisticated	O
,	O
flexible	O
,	O
high	O
performance	O
computer	O
hardware	O
has	O
been	O
introduced	O
primarily	O
aimed	O
at	O
a	O
rapidly	O
growing	O
"	O
hobbyist	O
"	O
market	O
.	O

Manufacturers	O
quickly	O
realilsed	O
that	O
to	O
sell	O
the	O
public	O
hardware	O
,	O
some	O
form	O
of	O
reasonably	O
high	O
level	O
software	O
must	O
be	O
made	O
available	O
.	O

A	O
variety	O
of	O
BASIC	O
interpreters	O
,	O
ranging	O
from	O
rather	O
"	O
dumb	O
"	O
to	O
"	O
quite	O
intelligent	O
"	O
have	O
since	O
evolved	O
.	O

The	O
more	O
intelligent	O
BASIC	O
interpreters	O
have	O
several	O
highly	O
attractive	O
attributes	O
for	O
"	O
hobbyist	O
"	O
applications	O
.	O

The	O
language	O
is	O
both	O
easy	O
to	O
master	O
and	O
conversational	O
.	O

Error	O
and	O
caution	O
messages	O
are	O
provided	O
as	O
aids	O
during	O
programming	O
.	O

Why	O
not	O
apply	O
the	O
"	O
hobbyist	O
"	O
technology	O
toward	O
the	O
implementation	O
of	O
custom	O
laboratory	O
systems	O
?	O

Many	O
investigators	O
have	O
and	O
,	O
no	O
doubt	O
,	O
many	O
more	O
will	O
take	O
this	O
approach	O
.	O

However	O
,	O
BASIC	O
interpreters	O
possess	O
serious	O
limitations	O
in	O
terms	O
of	O
system	O
speed	O
,	O
flexibility	O
and	O
input	O
/	O
output	O
(	O
I	O
/	O
O	O
)	O
capabilities	O
.	O

In	O
BASIC	O
,	O
each	O
command	O
must	O
first	O
be	O
interpreted	O
and	O
then	O
executed	O
(	O
see	O
Figure	O
1	O
)	O
.	O

In	O
many	O
cases	O
,	O
the	O
interpretation	O
process	O
takes	O
much	O
more	O
time	O
than	O
the	O
actual	O
execution	O
.	O

This	O
problem	O
is	O
compounded	O
by	O
the	O
fact	O
that	O
commands	O
interpreted	O
in	O
the	O
past	O
must	O
be	O
re	O
-	O
interpreted	O
each	O
time	O
they	O
are	O
used	O
causing	O
iterative	O
programs	O
to	O
be	O
very	O
slow	O
.	O

While	O
speed	O
is	O
often	O
not	O
a	O
serious	O
limitation	O
in	O
playing	O
computer	O
games	O
,	O
laboratory	O
application	O
requiring	O
high	O
speed	O
data	O
acquisition	O
and/or	O
data	O
manipulation	O
are	O
common	O
.	O

Additionally	O
,	O
the	O
more	O
intelligent	O
BASICs	O
make	O
very	O
inefficient	O
use	O
of	O
memory	O
often	O
requiring	O
minimum	O
of	O
12	O
or	O
16	O
K	O
bytes	O
(	O
twelve	O
or	O
sixteen	O
thousand	O
eight	O
bit	O
words	O
)	O
'	O
Volume	O
cS	O
H	O
A	O
D	O
H	O
Figure	O
3	O
.	O

The	O
'	O
threaded	O
'	O
code	O
approach	O
used	O
in	O
CONVERS	O
.	O

In	O
'	O
threaded	O
'	O
code	O
programming	O
modules	O
for	O
sub	O
-	O
routines	O
are	O
used	O
repetitively	O
in	O
a	O
variety	O
of	O
combinations	O
to	O
allow	O
implementation	O
of	O
an	O
infinite	O
number	O
of	O
functions	O
.	O

Note	O
that	O
the	O
flow	O
of	O
logic	O
threads	O
its	O
way	O
in	O
a	O
very	O
non.linear	O
fashion	O
through	O
these	O
modules	O
.	O

No.	O
3	O
April	O
1979	O
129	O
Tilden	O
&	O
Denton	O
Advanced	O
software	O
concepts	O
|I	O
Stack	O

Upper	O
Memory	O
Bound	O
User	O
's	O
Application	O
Dictionaries	O
4.5k	O
Octal	O
CONVERS	O
-	O
Di	O
sk	O
Operating	O
System	O
3.7k	O
Octal	O
Standard	O
High	O
Level	O
Dictionary	O
1.2k	O
Octal	O
Initial	O
Machine	O
Code	O
Dictionary	O
I@@	O
Octal	O
Figure	O
4	O
.	O

Memory	O
map	O
of	O
the	O
CON	O
VERS	O
dictionary	O
.	O

The	O
stack	O
which	O
is	O
composed	O
of	O
data	O
parameters	O
etc	O
.	O
acts	O
as	O
a	O
constantly	O
expanding	O
or	O
contracting	O
memory	O
buffer	O
which	O
allows	O
one	O
subroutine	O
to	O
communicate	O
with	O
another	O
without	O
either	O
needing	O
to	O
know	O
the	O
other	O
's	O
location	O
.	O

In	O
contrast	O
to	O
interpreters	O
,	O
high	O
level	O
compilers	O
,	O
such	O
as	O
FORTRAN	O
,	O
offer	O
a	O
much	O
faster	O
"	O
run	O
time	O
"	O
execution	O
speed	O
.	O

This	O
is	O
accomplished	O
through	O
generation	O
of	O
the	O
required	O
machine	O
code	O
during	O
a	O
series	O
of	O
programming	O
operations	O
.	O

Compilers	O
using	O
FORTRAN	O
,	O
which	O
are	O
designed	O
to	O
run	O
on	O
many	O
minicomputers	O
and	O
some	O
micros	O
,	O
often	O
first	O
transform	O
user	O
symbolic	O
source	O
code	O
into	O
assembly	O
code	O
.	O

An	O
assembler	O
program	O
,	O
subsequently	O
,	O
transforms	O
this	O
into	O
the	O
required	O
machine	O
code	O
.	O

This	O
ready	O
-	O
to	O
-	O
run	O
machine	O
code	O
is	O
often	O
loaded	O
along	O
with	O
a	O
run	O
time	O
package	O
which	O
executes	O
in	O
the	O
manner	O
shown	O
in	O
Figure	O
2	O
.	O

While	O
this	O
approach	O
greatly	O
improves	O
execution	O
speed	O
,	O
the	O
need	O
for	O
loading	O
several	O
different	O
soft	O
-	O
ware	O
routines	O
increases	O
the	O
"	O
hassle	O
"	O
associated	O
with	O
editing	O
and	O
debugging	O
.	O

Thus	O
,	O
this	O
makes	O
some	O
form	O
of	O
mass	O
memory	O
,	O
such	O
as	O
a	O
disk	O
or	O
magnetic	O
tape	O
,	O
almost	O
mandatory	O
.	O

Additionally	O
,	O
I	O
/	O
O	O
algorithms	O
generally	O
must	O
be	O
implemented	O
in	O
assembly	O
level	O
code	O
!	O

One	O
obvious	O
question	O
immediately	O
arises-	O
why	O
not	O
incorporate	O
the	O
most	O
desirable	O
characteristics	O
of	O
both	O
interpreters	O
and	O
compilers	O
into	O
a	O
single	O
language	O
?	O

Additionally	O
,	O
due	O
to	O
the	O
unique	O
requirements	O
found	O
in	O
many	O
applications	O
,	O
why	O
not	O
allow	O
the	O
programmer	O
additional	O
flexibility	O
by	O
providing	O
him	O
with	O
the	O
ability	O
to	O
actually	O
develop	O
his	O
own	O
individual	O
modifications	O
and	O
additions	O
to	O
the	O
language	O
itself	O
?	O

Other	O
desirable	O
features	O
would	O
include	O
high	O
memory	O
efficiency	O
,	O
high	O
level	O
I	O
]	O
O	O
programming	O
,	O
ease	O
of	O
understanding	O
the	O
language	O
's	O
"	O
inter	O
-	O
working	O
"	O
and	O
the	O
ability	O
to	O
be	O
transferred	O
from	O
one	O
CPU	O
to	O
another	O
with	O
minimum	O
effort	O
.	O

Type	O
"	O
ACQUIRE	O
"	O
ACQUIRE	O
#	O
of	O
characters	O
A	O
G	O
FORMAT	O
T	O
PLOT	O
START	O
SCAN	O
GALC%T	O
DISPLAY	O
RETURN	O
EXECUTIVE	O
Figure	O
5	O
.	O

If	O
a	O
previously	O
defined	O
program	O
name	O
(	O
A	O
CO	O
U	O
R	O
tQ	O
is	O
entered	O
when	O
in	O
EXECUTE	O
mode	O
,	O
a	O
dictionary	O
search	O
takes	O
place	O
locating	O
the	O
ACQUIRE	O
entry	O
.	O

Once	O
found	O
,	O
this	O
entry	O
contains	O
all	O
the	O
required	O
machine	O
code	O
and/or	O
calls	O
to	O
addresses	O
of	O
other	O
previously	O
compiled	O
machine	O
code	O
modules	O
to	O
completely	O
execute	O
the	O
desired	O
function	O
.	O

130	O
The	O
Journal	O
of	O
Automatic	O
Chemistry	O
Tilden	O
&	O
Denton	O
Advanced	O
software	O
concepts	O
2000	O
VARIABLE	O
VARIABLE	O
START	O
STOP	O
5000	O
20	O
VARIABLE	O
VARIABLE	O
7	O
INCREMENT	O
0	O
LOCATION	O
A	O
/	O
D7	O
INDEVICE	O
START	O
INITIALIZE	O
STEP	O
@	O
LOCATION	O
LOCATION	O
@	O
INCREMENT	O
5	O
INDEVICE	O
@	O
+	O
10	O
LOCATION	O
DELAY	O
MOVE	O
SCAN	O
BEGIN	O
-	O
HERE	O
LOCATION	O
AND	O
IF	O
DELAY	O
A	O
/	O
D7	O
ELSE	O
BEGIN	O
THEN	O
@	O
5	O
OUTDEVICE	O
STEP	O
INITIALIZE	O
BEGIN	O
-	O
HERE	O
MOVE	O
LOCATION	O
@	O
STOP	O
@	O
>	O
IF	O
END	O
ELSE	O
BEGIN	O
THEN	O
3000	O
6500	O
10	O
START	O
START	O
INCREMENT	O
SCAN	O
Figure	O
6	O
.	O

Ten	O
lines	O
of	O
typical	O
CONVERS	O
code	O
to	O
scan	O
wavelengths	O
between	O
two	O
easily	O
changed	O
limits	O
and	O
acquire	O
data	O
.	O

By	O
reference	O
to	O
notes	O
in	O
the	O
text	O
it	O
can	O
be	O
easily	O
understood	O
.	O

NOTE	O
:	O
a	O
number	O
or	O
name	O
pushes	O
the	O
number	O
of	O
address	O
occupied	O
by	O
the	O
name	O
on	O
the	O
stack	O
.	O

The	O
symbol	O
@	O
,	O
pips	O
the	O
top	O
number	O
from	O
the	O
stack	O
uses	O
it	O
as	O
the	O
address	O
from	O
which	O
to	O
obtain	O
a	O
number	O
and	O
pushes	O
that	O
number	O
on	O
the	O
stack	O
.	O

Development	O
of	O
CONVERS	O
During	O
the	O
past	O
two	O
years	O
,	O
a	O
different	O
approach	O
to	O
software	O
has	O
been	O
taking	O
place	O
at	O
the	O
University	O
of	O
Arizona	O
referred	O
to	O
as	O
an	O
"	O
Interpretive	O
Compiler	O
"	O
called	O
CONVERS	O
.	O

This	O
package	O
,	O
which	O
is	O
conceptually	O
similar	O
to	O
the	O
FORTH	O
language	O
currently	O
being	O
used	O
in	O
several	O
minicomputerastronomical	O
applications	O
]	O
,	O
is	O
able	O
to	O
provide	O
many	O
of	O
the	O
desirable	O
features	O
found	O
in	O
both	O
interpreters	O
and	O
compilers	O
by	O
separating	O
the	O
compile	O
and	O
execute	O
states	O
(	O
as	O
a	O
compiler	O
does	O
)	O
while	O
maintaining	O
a	O
resident	O
user	O
interactive	O
and	O
conversational	O
executive	O
which	O
oversees	O
system	O
operation	O
.	O

The	O
ability	O
to	O
realise	O
such	O
advanced	O
software	O
capabilities	O
in	O
a	O
very	O
modest	O
amount	O
of	O
memory	O
(	O
less	O
than	O
4	O
K	O
bytes	O
on	O
an	O
8080	O
based	O
micro	O
)	O
is	O
the	O
direct	O
result	O
of	O
exploiting	O
threaded	O
code	O
programming	O
techniques	O
(	O
see	O
Figure	O
3	O
)	O
.	O

The	O
approach	O
involves	O
highly	O
efficient	O
use	O
of	O
simple	O
macroinstructions	O
to	O
build	O
more	O
complex	O
subroutines	O
which	O
are	O
recombined	O
with	O
additional	O
macroinstructions	O
to	O
form	O
super	O
subroutines	O
.	O

This	O
process	O
of	O
combining	O
previously	O
defined	O
modules	O
to	O
form	O
ever	O
increasingly	O
sophisticated	O
routines	O
for	O
performing	O
the	O
task	O
at	O
hand	O
is	O
the	O
essence	O
of	O
threaded	O
code	O
programming	O
.	O

When	O
initially	O
loaded	O
and	O
running	O
,	O
CONVERS	O
acts	O
much	O
like	O
an	O
interpreter	O
,	O
i.e.	O
it	O
is	O
conversational	O
,	O
ready	O
to	O
either	O
execute	O
a	O
previously	O
programmed	O
algorithm	O
or	O
accept	O
a	O
new	O
one	O
.	O

However	O
,	O
in	O
contrast	O
to	O
BASIC	O
,	O
when	O
a	O
new	O
program	O
is	O
being	O
entered	O
under	O
CONVERS	O
,	O
it	O
is	O
immediately	O
transformed	O
into	O
binary	O
machine	O
code	O
or	O
to	O
the	O
binary	O
starting	O
addresses	O
of	O
other	O
previously	O
entered	O
and	O
compiled	O
machine	O
code	O
programs	O
.	O

During	O
this	O
process	O
,	O
the	O
operator	O
is	O
kept	O
informed	O
of	O
the	O
status	O
of	O
the	O
program	O
by	O
a	O
series	O
of	O
error	O
and	O
diagnostic	O
Volume	O
messages	O
.	O

When	O
the	O
new	O
program	O
has	O
been	O
completed	O
,	O
it	O
is	O
entered	O
in	O
a	O
program	O
library	O
or	O
dictionary	O
,	O
which	O
is	O
constantly	O
building	O
up	O
from	O
low	O
memory	O
(	O
see	O
Figure	O
4	O
)	O
.	O

If	O
the	O
operator	O
now	O
wants	O
to	O
execute	O
this	O
program	O
,	O
he	O
can	O
request	O
it	O
from	O
his	O
terminal	O
.	O

A	O
dictionary	O
search	O
will	O
begin	O
at	O
the	O
last	O
entry	O
and	O
progress	O
until	O
the	O
requested	O
program	O
is	O
located	O
.	O

Once	O
located	O
,	O
the	O
requested	O
program	O
will	O
run	O
in	O
its	O
entirety	O
without	O
need	O
for	O
any	O
additional	O
dictionary	O
searches	O
.	O

For	O
example	O
,	O
let	O
us	O
assume	O
an	O
algorithm	O
,	O
called	O
ACQUIRE	O
,	O
has	O
been	O
programmed	O
to	O
take	O
data	O
from	O
some	O
hypothetical	O
experimental	O
system	O
.	O

When	O
ACQUIRE	O
is	O
requested	O
from	O
the	O
terminal	O
,	O
a	O
dictionary	O
search	O
is	O
initiated	O
.	O

The	O
program	O
names	O
ACQUIRE	O
(	O
see	O
Figure	O
5	O
)	O
,	O
once	O
located	O
,	O
contains	O
the	O
starting	O
addresses	O
of	O
a	O
series	O
of	O
previously	O
defined	O
modules	O
which	O
implement	O
the	O
various	O
steps	O
necessary	O
to	O
perform	O
the	O
desired	O
experiment	O
.	O

For	O
example	O
,	O
the	O
module	O
SCAN	O
which	O
might	O
be	O
intended	O
to	O
scan	O
a	O
monochromator	O
's	O
wavelength	O
in	O
some	O
desired	O
manner	O
has	O
been	O
previously	O
defined	O
and	O
tested	O
.	O

This	O
ability	O
to	O
easily	O
test	O
each	O
module	O
separately	O
and	O
then	O
efficiently	O
combine	O
a	O
series	O
of	O
modules	O
to	O
perform	O
a	O
more	O
complex	O
function	O
,	O
test	O
this	O
function	O
,	O
and	O
then	O
employ	O
.it	O
in	O
a	O
vastly	O
more	O
complex	O
function	O
,	O
etc	O
.	O
,	O
i.e.	O
testing	O
each	O
step	O
as	O
the	O
threaded	O
code	O
is	O
made	O
increasingly	O
complex	O
,	O
is	O
a	O
major	O
factor	O
contributing	O
to	O
the	O
speed	O
with	O
which	O
software	O
can	O
be	O
developed	O
using	O
CONVERS	O
.	O

Use	O
of	O
a	O
software	O
stack	O
also	O
contributes	O
toward	O
improved	O
memory	O
efficiency	O
and	O
simplified	O
programming	O
.	O

The	O
stack	O
is	O
an	O
area	O
of	O
memory	O
set	O
aside	O
to	O
handle	O
parameters	O
,	O
data	O
numbers	O
,	O
etc	O
.	O

One	O
of	O
the	O
primary	O
advantages	O
of	O
the	O
stack	O
is	O
that	O
entries	O
can	O
leave	O
temporary	O
parameters	O
on	O
the	O
stack	O
without	O
having	O
to	O
assign	O
specific	O
131	O
No.	O
3	O
April	O
1979	O
Tilden	O
&	O
Denton	O
Advanced	O
software	O
concepts	O
DUAL	O
REGULATED	O
POWER	O
SUPPLY	O
I0	O
KV	O
I00	O
GRATING	O
PIEZOELECTRIC	O
TRANSLATOR	O
OP	O
TOACOUS	O
TIC	O
CELL	O
,	O
..	O
C02He	O
,	O
N2	O
MIRROR	O
TRANSLATOR	O
CHOPPER	O
POWER	O
DE	O
TECTOR	O
STEPPER	O
MOTOR	O
DRIVER	O
ADC	O
LOCK	O
-	O
IN	O
AMP	O
CONTROLLER	O
LOCK-	O
IN	O
AMP	O
MICROFLOPPY	O
DISK	O
24	O
K	O
RAM	O
1	O
Figure	O
7	O
.	O

The	O
optoacoustic	O
experiment	O
in	O
which	O
a	O
microcomputer	O
is	O
used	O
to	O
control	O
laser	O
wavelength	O
and	O
to	O
monitor	O
laser	O
power	O
and	O
optoacoustic	O
signal	O
.	O

memory	O
locations	O
to	O
store	O
them	O
.	O

This	O
not	O
only	O
can	O
save	O
considerable	O
memory	O
,	O
but	O
also	O
allows	O
programs	O
to	O
be	O
easily	O
relocatable	O
since	O
one	O
algorithm	O
need	O
only	O
know	O
that	O
a	O
previous	O
routine	O
left	O
so	O
many	O
words	O
of	O
data	O
,	O
etc	O
.	O
on	O
the	O
stack	O
.	O

It	O
need	O
not	O
know	O
where	O
the	O
previous	O
routine	O
is	O
nor	O
even	O
where	O
the	O
stack	O
is	O
located	O
.	O

A	O
series	O
of	O
stack	O
handling	O
routines	O
,	O
which	O
should	O
appear	O
quite	O
familiar	O
to	O
many	O
small	O
calculator	O
users	O
,	O
provide	O
an	O
array	O
of	O
capabilities	O
,	O
including	O
the	O
ability	O
to	O
PUSH	O
a	O
number	O
on	O
the	O
stack	O
,	O
POP	O
,	O
it	O
off	O
,	O
duplicate	O
it	O
,	O
SWAP	O
the	O
top	O
two	O
numbers	O
,	O
locate	O
a	O
number	O
some	O
distance	O
into	O
the	O
stack	O
,	O
and	O
copy	O
it	O
on	O
top	O
of	O
the	O
stack	O
,	O
etc	O
.	O

Additionally	O
,	O
a	O
variety	O
of	O
logic	O
functions	O
familiar	O
to	O
the	O
minicomputer	O
user	O
are	O
provided	O
including	O
OR	O
,	O
AND	O
,	O
shift	O
left	O
,	O
shift	O
right	O
,	O
greater	O
than	O
,	O
less	O
than	O
,	O
etc	O
.	O

Input	O
/	O
output	O
(	O
I	O
/	O
O	O
)	O
is	O
normally	O
accomplished	O
using	O
the	O
stack	O
in	O
conjunction	O
with	O
the	O
INDEVICE	O
or	O
OUTDEVICE	O
commands	O
.	O

For	O
example	O
,	O
to	O
take	O
data	O
from	O
a	O
device	O
located	O
at	O
I	O
/	O
O	O
,	O
port	O
7	O
,	O
the	O
number	O
seven	O
is	O
"	O
pushed	O
"	O
onto	O
the	O
stack	O
(	O
7	O
)	O
,	O
goes	O
to	O
this	O
I	O
/	O
O	O
port	O
,	O
takes	O
in	O
a	O
number	O
and	O
"	O
pushes	O
"	O
the	O
number	O
on	O
the	O
stack	O
.	O

OUTDEVICE	O
functions	O
in	O
a	O
similar	O
manner	O
,	O
requiring	O
the	O
number	O
to	O
be	O
sent	O
to	O
the	O
desired	O
device	O
to	O
be	O
"	O
pushed	O
"	O
onto	O
the	O
stack	O
followed	O
by	O
the	O
device	O
's	O
I	O
/	O
O	O
port	O
address	O
.	O

Hence	O
,	O
to	O
send	O
the	O
number	O
131	O
to	O
device	O
11	O
,	O
the	O
number	O
131	O
is	O
pushed	O
on	O
the	O
stack	O
followed	O
by	O
11	O
and	O
then	O
OUTDEVICE	O
.	O

This	O
"	O
pops	O
"	O
the	O
top	O
number	O
(	O
11	O
)	O
from	O
the	O
stack	O
,	O
uses	O
it	O
as	O
the	O
output	O
port	O
and	O
then	O
sends	O
the	O
number	O
131	O
to	O
that	O
location	O
.	O

SOUND	O
BELL	O
BELL	O
BELL	O
The	O
colon	O
denotes	O
changing	O
from	O
EXECUTE	O
to	O
COMPILE	O
mode	O
.	O

After	O
typing	O
the	O
name	O
of	O
the	O
new	O
routine	O
,	O
in	O
this	O
case	O
to	O
be	O
called	O
SOUND	O
,	O
typing	O
the	O
name	O
of	O
the	O
earlier	O
defined	O
routine	O
(	O
BELL	O
a	O
previously	O
defined	O
simple	O
program	O
to	O
rng	O
the	O
terminal	O
bell	O
)	O
initiates	O
a	O
dictionary	O
search	O
to	O
locate	O
this	O
routine	O
's	O
starting	O
address	O
which	O
subsequentially	O
is	O
entered	O
three	O
times	O
.	O

The	O
resulting	O
SOUND	O
routine	O
contains	O
machine	O
code	O
calls	O
to	O
the	O
BE	O
LL	O
routine	O
which	O
,	O
itself	O
,	O
is	O
composed	O
of	O
machine	O
code	O
.	O

Of	O
course	O
,	O
SOUND	O
could	O
also	O
have	O
been	O
defined	O
using	O
a	O
DO	O
-	O
LOOP	O
,	O
i.e.	O
SOUND	O
3	O
DO	O
BELL	O
LOOP	O
where	O
the	O
numbers	O
three	O
and	O
one	O
set	O
the	O
upper	O
and	O
lower	O
indices	O
.	O

If	O
it	O
were	O
desirable	O
to	O
change	O
the	O
actual	O
number	O
of	O
bell	O
rings	O
from	O
some	O
other	O
program	O
,	O
this	O
value	O
could	O
be	O
defined	O
as	O
a	O
VARIABLE	O
let	O
's	O
call	O
it	O
NOISE	O
.	O

3	O
VARIABLE	O
NOISE	O
In	O
this	O
case	O
,	O
the	O
number	O
three	O
is	O
first	O
pushed	O
on	O
the	O
stack	O
,	O
VARIABLE	O
transfers	O
the	O
top	O
number	O
on	O
the	O
stack	O
(	O
the	O
three	O
)	O
to	O
a	O
dictionary	O
location	O
named	O
NOISE	O
.	O

If	O
SOUND	O
were	O
now	O
defined	O
as	O
:	O
SOUND	O
NOISE	O
@	O
DO	O
BELL	O
LOOP	O
Applications	O
of	O
CONVERS	O
To	O
appreciate	O
the	O
ease	O
with	O
which	O
real	O
programs	O
can	O
be	O
written	O
,	O
a	O
few	O
examples	O
will	O
be	O
considered	O
.	O

A	O
trivial	O
program	O
,	O
called	O
SOUND	O
,	O
which	O
rings	O
the	O
terminal	O
bell	O
three	O
times	O
,	O
might	O
be	O
written	O
:	O
132	O
the	O
bell	O
would	O
again	O
ring	O
three	O
times	O
.	O

In	O
this	O
case	O
,	O
when	O
the	O
word	O
NOISE	O
iS	O
encountered	O
,	O
its	O
address	O
is	O
pushed	O
on	O
the	O
stack	O
,	O
the	O
@	O
is	O
a	O
simple	O
program	O
which	O
goes	O
to	O
the	O
address	O
indicated	O
on	O
the	O
top	O
of	O
the	O
stack	O
(	O
that	O
of	O
NOISE	O
)	O
and	O
replaces	O
it	O
with	O
the	O
actual	O
value	O
located	O
at	O
that	O
address	O
(	O
the	O
number	O
three	O
)	O
.	O

At	O
any	O
future	O
time	O
,	O
the	O
value	O
of	O
VARIABLE	O
can	O
be	O
changed	O
by	O
"	O
pushing	O
"	O
the	O
new	O
value	O
onto	O
the	O
stack	O
,	O
followed	O
by	O
the	O
address	O
of	O
the	O
variable	O
to	O
be	O
changed	O
,	O
generated	O
by	O
its	O
name	O
and	O
an	O
exclamation	O
mark	O
.	O

To	O
change	O
N	O
O	O
IS	O
E	O
to	O
5	O
,	O
The	O
Journal	O
of	O
Automatic	O
Chemistry	O
Tilden	O
&	O
Denton	O
Advanced	O
software	O
concepts	O
5	O
NOISE	O
a	O
number	O
five	O
is	O
pushed	O
onto	O
the	O
stack	O
,	O
NOISE	O
pushes	O
its	O
address	O
on	O
the	O
stack	O
,	O
and	O
goes	O
to	O
the	O
address	O
indicated	O
by	O
the	O
"	O
top	O
"	O
number	O
on	O
the	O
stack	O
and	O
deposits	O
the	O
next	O
number	O
.	O

Now	O
sound	O
would	O
ring	O
the	O
terminal	O
bell	O
five	O
times	O
.	O

A	O
much	O
less	O
trivial	O
program	O
which	O
could	O
be	O
written	O
to	O
scan	O
and	O
take	O
data	O
from	O
a	O
monochromator	O
equipped	O
with	O
a	O
DENCO	O
SM2A	O
stepper	O
motor	O
controller	O
[	O
2	O
]	O
(	O
the	O
SM2A	O
takes	O
a	O
parallel	O
number	O
as	O
an	O
address	O
,	O
sends	O
one	O
of	O
two	O
stepper	O
motors	O
to	O
this	O
location	O
and	O
outputs	O
an	O
arrival	O
flag	O
when	O
the	O
address	O
is	O
reached	O
)	O
is	O
given	O
in	O
Figure	O
6	O
.	O

Assume	O
that	O
the	O
experimental	O
system	O
is	O
configured	O
so	O
the	O
SM2A	O
is	O
at	O
I	O
/	O
O	O
,	O
port	O
5	O
and	O
an	O
analog	O
to	O
digital	O
converter	O
to	O
acquire	O
data	O
is	O
at	O
I	O
/	O
O	O
,	O
port	O
7	O
.	O

Let	O
us	O
assume	O
that	O
,	O
initially	O
,	O
a	O
scan	O
is	O
designed	O
from	O
a	O
starting	O
stepper	O
motor	O
location	O
of	O
2000	O
to	O
a	O
final	O
location	O
of	O
5000	O
,	O
taking	O
data	O
every	O
20	O
steps	O
.	O

The	O
program	O
illustrated	O
in	O
figure	O
6	O
acts	O
in	O
the	O
following	O
manner	O
.	O

Line	O
defines	O
a	O
variable	O
called	O
START	O
to	O
be	O
2000	O
,	O
which	O
is	O
the	O
starting	O
location	O
of	O
fhe	O
scan	O
.	O

The	O
end	O
of	O
the	O
scan	O
is	O
defined	O
as	O
5000	O
in	O
the	O
next	O
line	O
.	O

Line	O
3	O
defines	O
the	O
increment	O
between	O
data	O
points	O
.	O

A	O
variable	O
called	O
LOCATION	O
where	O
the	O
.	O

next	O
address	O
is	O
stored	O
is	O
defined	O
in	O
line	O
4	O
..	O

Colon	O
,	O
in	O
line	O
5	O
,	O
puts	O
the	O
system	O
in	O
the	O
compile	O
mode	O
,	O
A	O
/	O
D7	O
will	O
be	O
the	O
name	O
of	O
the	O
module	O
which	O
when	O
called	O
will	O
cause	O
a	O
7	O
to	O
be	O
pushed	O
onto	O
the	O
stack	O
.	O

INDEVICE	O
will	O
'	O
pop	O
'	O
it	O
back	O
off	O
and	O
use	O
it	O
as	O
a	O
device	O
address	O
to	O
go	O
and	O
take	O
a	O
data	O
point	O
and	O
push	O
the	O
data	O
onto	O
the	O
stack	O
.	O

Line	O
6	O
defines	O
a	O
module	O
INITIALIZE	O
,	O
START	O
puts	O
its	O
address	O
on	O
the	O
stack	O
,	O
@	O
replaces	O
the	O
address	O
with	O
the	O
value	O
at	O
that	O
address	O
,	O
LOCATION	O
puts	O
its	O
address	O
on	O
the	O
stack	O
,	O
'	O
!	O
'	O
goes	O
to	O
the	O
address	O
specified	O
by	O
the	O
number	O
on	O
the	O
stack	O
and	O
deposits	O
the	O
second	O
number	O
and	O
the	O
net	O
result	O
value	O
at	O
START	O
is	O
put	O
into	O
LOCATION	O
.	O

Line	O
7	O
defines	O
STEP	O
to	O
take	O
values	O
from	O
LOCATION	O
and	O
INCREMENT	O
adds	O
them	O
together	O
and	O
puts	O
the	O
result	O
into	O
LOCATION	O
,	O
i.e.	O
LOCATION	O
puts	O
its	O
address	O
on	O
the	O
stack	O
,	O
@	O
replaces	O
the	O
top	O
value	O
on	O
the	O
stack	O
with	O
the	O
number	O
stored	O
at	O
the	O
address	O
,	O
INCREMENT	O
@	O
gets	O
the	O
value	O
at	O
INCREMENT	O
and	O
puts	O
it	O
in	O
to	O
the	O
stack	O
,	O
and	O
adds	O
the	O
top	O
two	O
stack	O
numbers	O
and	O
pushes	O
the	O
result	O
on	O
the	O
stack	O
.	O

LOCATION	O
puts	O
its	O
address	O
on	O
the	O
stack	O
and	O
goes	O
to	O
the	O
address	O
specified	O
by	O
the	O
top	O
number	O
on	O
the	O
stack	O
and	O
deposits	O
the	O
second	O
number	O
.	O

Themodule	O
defined	O
in	O
line	O
8	O
takes	O
a	O
number	O
from	O
the	O
stepper	O
motor	O
controller	O
(	O
assume	O
device	O
numbered	O
5	O
)	O
pushes	O
on	O
the	O
stack	O
,	O
and	O
pushes	O
the	O
value	O
10	O
on	O
the	O
stack	O
and	O
does	O
a	O
logical	O
AND	O
to	O
see	O
if	O
the	O
controllers	O
flag	O
is	O
set	O
,	O
if	O
this	O
is	O
true	O
the	O
A	O
/	O
D7	O
module	O
will	O
be	O
called	O
to	O
input	O
data	O
,	O
if	O
the	O
flag	O
is	O
not	O
set	O
,	O
the	O
program	O
is	O
returned	O
to	O
BEGIN	O
-	O
HERE	O
.	O

Therefore	O
the	O
DELAY	O
module	O
is	O
a	O
loop	O
waiting	O
for	O
the	O
stepper	O
motor	O
to	O
arrive	O
at	O
its	O
new	O
location	O
followed	O
by	O
a	O
call	O
to	O
A	O
/	O
D7	O
data	O
acquisition	O
module	O
.	O

MOVE	O
defined	O
in	O
line	O
9	O
gets	O
the	O
value	O
stored	O
at	O
LOCATION	O
pushes	O
the	O
device	O
code	O
onto	O
the	O
stack	O
performs	O
an	O
outdevice	O
(	O
which	O
uses	O
the	O
top	O
stack	O
number	O
as	O
a	O
1	O
/	O
0	O
port	O
address	O
to	O
send	O
the	O
next	O
value	O
to	O
call	O
the	O
STEP	O
module	O
(	O
ie	O
the	O
value	O
at	O
LOCATION	O
)	O
,	O
this	O
increments	O
LOCATION	O
by	O
the	O
INCREM	O
E	O
N	O
T	O
value	O
and	O
finally	O
calls	O
D	O
E	O
L	O
A	O
Y	O
and	O
waits	O
for	O
a	O
flag	O
from	O
the	O
stepper	O
motor	O
controller	O
to	O
signal	O
its	O
arrival	O
at	O
the	O
desired	O
address	O
and	O
then	O
takes	O
a	O
data	O
point	O
.	O

The	O
final	O
line	O
shown	O
in	O
the	O
example	O
Called	O
SCAN	O
itself	O
calls	O
the	O
INITIALIZE	O
module	O
(	O
which	O
sets	O
LOCATION	O
to	O
the	O
START	O
location	O
for	O
the	O
Scan	O
)	O
it	O
also	O
calls	O
MOVE	O
(	O
which	O
sends	O
this	O
value	O
to	O
the	O
motor	O
LOCATION	O
controller	O
,	O
increments	O
the	O
value	O
stored	O
in	O
LOCATION	O
by	O
INCREMENT	O
and	O
calls	O
DELAY	O
which	O
waits	O
for	O
the	O
motor	O
to	O
arrive	O
and	O
then	O
takes	O
a	O
data	O
point	O
)	O
.	O

Next	O
the	O
incremented	O
value	O
from	O
LOCATION	O
is	O
placed	O
on	O
the	O
stack	O
(	O
LOCATION	O
)	O
followed	O
by	O
the	O
STOP	O
I0	O
KW	O
AMPLIFIER	O
MATCHING	O
,	O
NETWORKIS	O
PREAMP	O
MOTOR	O
CON	O
TROL	O
ER	O
MICRODISK	O
90	O
K	O
byte	O
INTEL	O
8080	O
based	O
MICROCOMPUTER	O
16	O
K	O
RAM	O
Figure	O
8	O
.	O

A	O
schematic	O
of	O
the	O
inductively	O
coupled	O
plasma	O
emission	O
spectrometer	O
in	O
which	O
the	O
microcomputer	O
is	O
used	O
to	O
control	O
radio	O
frequency	O
power	O
and	O
'	O
flame	O
'	O
positioning	O
as	O
well	O
as	O
to	O
monitor	O
light	O
intensity	O
.	O

Volume	O
No.	O
3	O
April	O
1979	O
133	O
Tilden	O
&	O
Denton	O
Advanced	O
software	O
concepts	O
value	O
(	O
STOP	O
@	O
)	O
,	O
the	O
two	O
are	O
compared	O
to	O
to	O
see	O
if	O
the	O
incremented	O
value	O
at	O
LOCATION	O
is	O
larger	O
then	O
the	O
STOP	O
value	O
,	O
if	O
it	O
is	O
the	O
program	O
ends	O
,	O
if	O
not	O
,	O
it	O
repeats	O
the	O
process	O
starting	O
at	O
BEGIN	O
--	O
HERE	O
.	O

It	O
should	O
be	O
noted	O
that	O
whilst	O
many	O
variables	O
have	O
been	O
pushed	O
on	O
the	O
stack	O
,	O
only	O
the	O
data	O
will	O
remain	O
,	O
since	O
each	O
time	O
a	O
value	O
is	O
used	O
it	O
is	O
'	O
popped	O
'	O
(	O
removed	O
)	O
from	O
the	O
stack	O
.	O

If	O
a	O
different	O
spectra	O
region	O
is	O
to	O
be	O
scanned	O
i.e.	O
from	O
3000	O
to	O
6500	O
with	O
10	O
increments	O
the	O
variables	O
need	O
only	O
be	O
>	O
data	O
acquisition	O
programs	O
have	O
been	O
easily	O
implemented	O
.	O

Memory	O
requirements	O
and	O
operating	O
speed	O
have	O
been	O
found	O
to	O
be	O
far	O
superior	O
to	O
conventional	O
approaches	O
.	O

Additionally	O
,	O
new	O
system	O
users	O
have	O
encountered	O
a	O
difficulty	O
in	O
utilising	O
previously	O
developed	O
custom	O
software	O
for	O
a	O
particular	O
experiment	O
even	O
when	O
documentation	O
was	O
vague	O
.	O

Discussion	O
The	O
authors	O
hope	O
that	O
this	O
short	O
introduction	O
to	O
only	O
a	O
few	O
of	O
the	O
concepts	O
employed	O
in	O
CONVERS	O
will	O
generate	O
interest	O
in	O
its	O
capabilities	O
.	O

A	O
much	O
more	O
complete	O
discussion	O
is	O
available	O
in	O
the	O
form	O
of	O
a	O
user	O
's	O
manual	O
[	O
3	O
]	O
available	O
from	O
the	O
authors	O
.	O

changed	O
thus	O
3000	O
START	O
!	O

6500	O
STOP	O
10	O
INCREMENT	O
and	O
type	O
SCAN	O
,	O
system	O
will	O
now	O
scan	O
from	O
3000	O
to	O
6500	O
taking	O
data	O
every	O
10	O
steps	O
.	O

While	O
the	O
code	O
might	O
look	O
a	O
little	O
strange	O
at	O
first	O
,	O
it	O
quickly	O
becomes	O
very	O
easy	O
to	O
work	O
with	O
.	O

The	O
SCAN	O
program	O
of	O
Figure	O
6	O
could	O
be	O
combined	O
with	O
other	O
modules	O
as	O
shown	O
in	O
Figure	O
5	O
to	O
perform	O
some	O
more	O
complex	O
experimental	O
function	O
.	O

Each	O
module	O
of	O
the	O
program	O
can	O
be	O
easily	O
tried	O
out	O
to	O
ensure	O
that	O
it	O
is	O
operational	O
before	O
proceeding	O
with	O
the	O
next	O
.	O

Presently	O
,	O
CONVERS	O
is	O
being	O
used	O
in	O
the	O
authors	O
'	O
laboratories	O
for	O
a	O
variety	O
of	O
spectrochemical	O
investigations	O
,	O
including	O
laser	O
excited	O
optoacoustic	O
spectroscopy	O
(	O
Figure	O
7	O
)	O
and	O
inductively	O
coupled	O
plasma	O
optical	O
emission	O
spectroscopy	O
(	O
Figure	O
8)	O
.	O

Rather	O
complex	O
interactive	O
control	O
and	O
ACKNOWLEDGEMENTS	O
The	O
development	O
of	O
the	O
CONVERS	O
system	O
was	O
partially	O
supported	O
by	O
the	O
Office	O
of	O
Naval	O
Research	O
and	O
a	O
Alfred	O
P.	O
Cloan	O
Foundation	O
Research	O
Fellowship	O
to	O
M.	O
Bonnet	O
Denton	O
.	O

REFERENCES	O
C.	O
Moore	O
,	O
Astronomical	O
Astrophysics	O
Supplemental	O
,	O
15,	O
(	O
1974	O
)	O
497	O
.	O

[	O
2	O
]	O
M.B.	O
Denton	O
,	O
J.D.	O
Mack	O
,	O
M.W.	O
Routh	O
and	O
D.B.	O
SwartzClmerican	O
[	O
3	O
]	O
Laboratory,8,69	O
(	O
1976	O
)	O
.	O

CONVERS	O
An	O
Interpretive	O
Compiler	O
,	O
developed	O
by	O
Scott	O
B.	O
Tilden	O
and	O
M.	O
Bonner	O
Denton	O
,	O
Department	O
of	O
Chemistry	O
,	O
University	O
of	O
Arizona	O
,	O
Tucson	O
,	O
Arizona	O
85721	O
,	O
USA	O
.	O

The	O
use	O
of	O
a	O
microcomputer	O
for	O
flexible	O
automation	O
of	O
a	O
liquid	O
chromatograph	O
A.D.	O
Mills	O
,	O
i.	O
Mackenzie	O
and	O
R.J.	O
Dolphin	O

*	O
Philips	O
Research	O
Laboratories	O
,	O
Redhill	O
,	O
Surrey	O
,	O
RH1	O
5HA	O
,	O
U.K.	O
Introduction	O
Microprocessors	O
are	O
being	O
used	O
to	O
add	O
inexpensive	O
automatic	O
control	O
and	O
data	O
handling	O
facilities	O
to	O
a	O
variety	O
of	O
chemical	O
instruments	O
.	O

With	O
a	O
microcomputer	O
it	O
is	O
now	O
possible	O
to	O
realise	O
the	O
flexibility	O
formerly	O
available	O
only	O
with	O
a	O
relatively	O
large	O
and	O
expensive	O
minicomputer	O
in	O
an	O
instrument	O
little	O
different	O
in	O
size	O
and	O
cost	O
from	O
one	O
controlled	O
by	O
inflexible	O
hardware	O
.	O

In	O
many	O
ways	O
chromatography	O
is	O
an	O
ideal	O
process	O
for	O
such	O
automation	O
.	O

Most	O
instruments	O
are	O
given	O
a	O
high	O
workload	O
and	O
,	O
although	O
many	O
applications	O
may	O
be	O
routine	O
and	O
repetitive	O
,	O
the	O
versatility	O
of	O
the	O
technique	O
requires	O
an	O
instrument	O
which	O
can	O
easily	O
be	O
used	O
in	O
a	O
variety	O
of	O
modes	O
.	O

In	O
addition	O
to	O
improving	O
the	O
convenience	O
to	O
the	O
user	O
,	O
automation	O
of	O
a	O
liquid	O
chromatrograph	O
should	O
enhance	O
the	O
performance	O
of	O
the	O
instrument	O
.	O

Some	O
aspects	O
of	O
high	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
which	O
can	O
benefit	O
in	O
this	O
way	O
are	O
as	O
follows	O
:	O
(	O
1	O
)	O
Accurate	O
control	O
of	O
solvent	O
flow	O
rate	O
will	O
compensate	O
for	O
changes	O
in	O
pressure	O
drop	O
and	O
lead	O
to	O
more	O
reliable	O
retention	O
times	O
.	O

(	O
2	O
)	O
The	O
composition	O
of	O
the	O
mobile	O
phase	O
can	O
be	O
accurately	O
controlled	O
in	O
either	O
isocratic	O
or	O
gradient	O
elution	O
chromatography	O
using	O
,	O
for	O
example	O
,	O
a	O
proportioning	O
valve	O
on	O
the	O
low	O
pressure	O
side	O
of	O
the	O
pump	O
.	O

(	O
3	O
)	O
Automatic	O
sampling	O
can	O
be	O
operated	O
in	O
a	O
variety	O
of	O
modes	O
to	O
process	O
a	O
number	O
of	O
samples	O
without	O
supervision	O
.	O

It	O
is	O
also	O
more	O
precise	O
than	O
manual	O
injection	O
.	O

(	O
4	O
)	O
A	O
built	O
-	O
in	O
data	O
handling	O
facility	O
can	O
present	O
the	O
analyst	O
with	O
an	O
easily	O
read	O
post	O
-	O
run	O
report	O
of	O
the	O
analytical	O
results	O
with	O
accurate	O
peak	O
area	O
measurements	O
even	O
for	O
peaks	O
which	O
are	O
poorly	O
resolved	O
.	O

Although	O
liquid	O
chromatographs	O
incorporating	O
microprocessors	O
for	O
control	O
and	O
data	O
handling	O
purposes	O
are	O
commercially	O
available	O
,	O
these	O
instruments	O
are	O
,	O
so	O
far	O
,	O
This	O
paper	O
describes	O
,	O
in	O
detail	O
,	O
the	O
relatively	O
inflexible	O
.	O

automation	O
of	O
a	O
liquid	O
chromatograph	O
using	O
an	O
inexpensive	O
general	O
purpose	O
microcomputer	O
,	O
which	O
has	O
previously	O
been	O
applied	O
in	O
atomic	O
absorption	O
spectrophotometry	O
[	O
1	O
]	O
and	O
for	O
column	O
switching	O
in	O
HPLC	O
2	O
]	O
.	O

Figure	O
illustrates	O
the	O
interconnection	O
of	O
the	O
chromatograph	O
and	O
the	O
microcomputer	O
which	O
controls	O
the	O
mobile	O
phase	O
flow	O
rate	O
,	O
operates	O
an	O
automatic	O
sampler	O
and	O
analyses	O
data	O
from	O
the	O
detector	O
.	O

The	O
control	O
and	O
data	O
handling	O
functions	O
are	O
integrated	O
in	O
a	O
program	O
which	O
enables	O
the	O
user	O
to	O
communicate	O
with	O
the	O
instrument	O
,	O
in	O
plain	O
English	O
,	O
via	O
a	O
visual	O
display	O
unit	O
(	O
VDU	O
)	O
or	O
teletypewriter	O
keyboard	O
.	O

A	O
variety	O
of	O
operational	O
modes	O
is	O
offered	O
,	O
giving	O
the	O
analyst	O
an	O
opportunity	O
to	O
establish	O
the	O
best	O
conditions	O
for	O
a	O
particular	O
separation	O
before	O
leaving	O
the	O
instrument	O
to	O
perform	O
its	O
given	O
tasks	O
without	O
further	O
interaction	O
.	O

The	O
microcomputer	O
Hardware	O

The	O
computer	O
is	O
a	O
general	O
purpose	O
instrument	O
constructed	O
using	O
a	O
set	O
of	O
ready	O
made	O
circuit	O
cards	O
(	O
Philips	O
,	O
Science	O
and	O
The	O
Journal	O
of	O
Automatic	O
Chemistry	O
*	O
Present	O
address	O
:	O
lye	O
Unicam	O
Ltd.	O
,	O
York	O
Street	O
,	O
Cambridge	O
,	O
CB1	O
2PX	O
,	O
U.K.	O
134	O

Efficacy	O
of	O
intra	O
-	O
articular	O
hyaluronan	O
(	O
Synvisc	O
®	O
)	O
for	O
the	O
treatment	O
of	O
osteoarthritis	O
affecting	O
the	O
first	O
metatarsophalangeal	O
joint	O
of	O
the	O
foot	O
(	O
hallux	O
limitus	O
)	O
:	O
study	O
protocol	O
for	O
a	O
randomised	O
placebo	O
controlled	O
trial	O
Abstract	O
Background	O
Osteoarthritis	O
of	O
the	O
first	O
metatarsophalangeal	O
joint	O
(	O
MPJ	O
)	O
of	O
the	O
foot	O
,	O
termed	O
hallux	O
limitus	O
,	O
is	O
common	O
and	O
painful	O
.	O

Numerous	O
non	O
-	O
surgical	O
interventions	O
have	O
been	O
proposed	O
for	O
this	O
disorder	O
,	O
however	O
there	O
is	O
limited	O
evidence	O
for	O
their	O
efficacy	O
.	O

Intra	O
-	O
articular	O
injections	O
of	O
hyaluronan	O
have	O
shown	O
beneficial	O
effects	O
in	O
case	O
-	O
series	O
and	O
clinical	O
trials	O
for	O
the	O
treatment	O
of	O
osteoarthritis	O
of	O
the	O
first	O
metatarsophalangeal	O
joint	O
.	O

However	O
,	O
no	O
study	O
has	O
evaluated	O
the	O
efficacy	O
of	O
this	O
form	O
of	O
treatment	O
using	O
a	O
randomised	O
placebo	O
controlled	O
trial	O
.	O

This	O
article	O
describes	O
the	O
design	O
of	O
a	O
randomised	O
placebo	O
controlled	O
trial	O
to	O
evaluate	O
the	O
efficacy	O
of	O
intra	O
-	O
articular	O
hyaluronan	O
(	O
Synvisc	O
®	O
)	O
to	O
reduce	O
pain	O
and	O
improve	O
function	O
in	O
people	O
with	O
hallux	O
limitus	O
.	O

Methods	O
One	O
hundred	O
and	O
fifty	O
community	O
-	O
dwelling	O
men	O
and	O
women	O
aged	O
18	O
years	O
and	O
over	O
with	O
hallux	O
limitus	O
(	O
who	O
satisfy	O
inclusion	O
and	O
exclusion	O
criteria	O
)	O
will	O
be	O
recruited	O
.	O

Participants	O
will	O
be	O
randomised	O
,	O
using	O
a	O
computer	O
-	O
generated	O
random	O
number	O
sequence	O
,	O
to	O
receive	O
a	O
single	O
intra	O
-	O
articular	O
injection	O
of	O
up	O
to	O
1	O
ml	O
hyaluronan	O
(	O
Synvisc	O
®	O
)	O
or	O
sterile	O
saline	O
(	O
placebo	O
)	O
into	O
the	O
first	O
MPJ	O
.	O

The	O
injections	O
will	O
be	O
performed	O
by	O
an	O
interventional	O
radiologist	O
using	O
fluoroscopy	O
to	O
ensure	O
accurate	O
deposition	O
of	O
the	O
hyaluronan	O
in	O
the	O
joint	O
.	O

Participants	O
will	O
be	O
given	O
the	O
option	O
of	O
a	O
second	O
and	O
final	O
intra	O
-	O
articular	O
injection	O
(	O
of	O
Synvisc	O
®	O
or	O
sterile	O
saline	O
according	O
to	O
the	O
treatment	O
group	O
they	O
are	O
in	O
)	O
either	O
1	O
or	O
3	O
months	O
post	O
-	O
treatment	O
if	O
there	O
is	O
no	O
improvement	O
in	O
pain	O
and	O
the	O
participant	O
has	O
not	O
experienced	O
severe	O
adverse	O
effects	O
after	O
the	O
first	O
injection	O
.	O

The	O
primary	O
outcome	O
measures	O
will	O
be	O
the	O
pain	O
and	O
function	O
subscales	O
of	O
the	O
Foot	O
Health	O
Status	O
Questionnaire	O
.	O

The	O
secondary	O
outcome	O
measures	O
will	O
be	O
pain	O
at	O
the	O
first	O
MPJ	O
(	O
during	O
walking	O
and	O
at	O
rest	O
)	O
,	O
stiffness	O
at	O
the	O
first	O
MPJ	O
,	O
passive	O
non	O
-	O
weightbearing	O
dorsiflexion	O
of	O
the	O
first	O
MPJ	O
,	O
plantar	O
flexion	O
strength	O
of	O
the	O
toe	O
-	O
flexors	O
of	O
the	O
hallux	O
,	O
global	O
satisfaction	O
with	O
the	O
treatment	O
,	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
assessed	O
using	O
the	O
Short	O
-	O
Form-36	O
version	O
two	O
questionnaire	O
)	O
,	O
magnitude	O
of	O
symptom	O
change	O
,	O
use	O
of	O
pain	O
-	O
relieving	O
medication	O
and	O
changes	O
in	O
dynamic	O
plantar	O
pressure	O
distribution	O
(	O
maximum	O
force	O
and	O
peak	O
pressure	O
)	O
during	O
walking	O
.	O

Data	O
will	O
be	O
collected	O
at	O
baseline	O
,	O
then	O
1	O
,	O
3	O
and	O
6	O
months	O
post	O
-	O
treatment	O
.	O

Data	O
will	O
be	O
analysed	O
using	O
the	O
intention	O
to	O
treat	O
principle	O
.	O

Discussion	O
This	O
study	O
is	O
the	O
first	O
randomised	O
placebo	O
controlled	O
trial	O
to	O
evaluate	O
the	O
efficacy	O
of	O
intra	O
-	O
articular	O
hyaluronan	O
(	O
Synvisc	O
®	O
)	O
for	O
the	O
treatment	O
of	O
osteoarthritis	O
of	O
the	O
first	O
MPJ	O
(	O
hallux	O
limitus	O
)	O
.	O

The	O
study	O
has	O
been	O
pragmatically	O
designed	O
to	O
ensure	O
that	O
the	O
study	O
findings	O
can	O
be	O
implemented	O
into	O
clinical	O
practice	O
if	O
this	O
form	O
of	O
treatment	O
is	O
found	O
to	O
be	O
an	O
effective	O
treatment	O
strategy	O
.	O

Trial	O
registration	O
Australian	O
New	O
Zealand	O
Clinical	O
Trials	O
Registry	O
:	O
ACTRN12607000654459	O
Background	O
Osteoarthritis	O
(	O
OA	O
)	O
is	O
a	O
degenerative	O
joint	O
disease	O
that	O
commonly	O
presents	O
within	O
the	O
first	O
metatarsophalangeal	O
joint	O
(	O
MPJ	O
)	O
of	O
the	O
foot	O
.	O

The	O
terms	O
hallux	O
limitus	O
and	O
hallux	O
rigidus	O
have	O
frequently	O
been	O
used	O
interchangeably	O
to	O
describe	O
differing	O
severities	O
of	O
pain	O
and	O
limitation	O
of	O
motion	O
associated	O
with	O
OA	O
at	O
the	O
first	O
MPJ	O
[	O
1	O
]	O
.	O

Hallux	O
limitus	O
is	O
a	O
progressive	O
osteoarthritic	O
condition	O
of	O
the	O
first	O
MPJ	O
that	O
may	O
advance	O
to	O
an	O
end	O
-	O
stage	O
presentation	O
of	O
hallux	O
rigidus	O
where	O
the	O
joint	O
fuses	O
and	O
there	O
is	O
a	O
complete	O
restriction	O
of	O
motion	O
[	O
1	O
]	O
.	O

First	O
MPJ	O
OA	O
is	O
the	O
second	O
most	O
common	O
disorder	O
affecting	O
the	O
foot	O
after	O
hallux	O
valgus	O
[	O
2	O
]	O
.	O

The	O
prevalence	O
of	O
the	O
condition	O
increases	O
with	O
age	O
,	O
and	O
it	O
has	O
been	O
reported	O
that	O
radiographic	O
changes	O
in	O
the	O
first	O
MPJ	O
affect	O
are	O
evident	O
in	O
approximately	O
46	O
%	O
of	O
women	O
and	O
32	O
%	O
of	O
men	O
at	O
60	O
years	O
of	O
age	O
[	O
3	O
]	O
.	O

Osteoarthritis	O
at	O
the	O
first	O
MPJ	O
is	O
characterised	O
by	O
the	O
symptoms	O
of	O
pain	O
and	O
stiffness	O
at	O
the	O
joint	O
[	O
1	O
]	O
.	O

Secondary	O
painful	O
symptoms	O
relate	O
to	O
compensations	O
during	O
gait	O
that	O
may	O
occur	O
due	O
to	O
the	O
reduced	O
motion	O
of	O
the	O
first	O
MPJ	O
[	O
1	O
]	O
.	O

The	O
presence	O
of	O
pain	O
associated	O
with	O
first	O
MPJ	O
OA	O
impacts	O
on	O
normal	O
walking	O
and	O
quality	O
of	O
life	O
[	O
4	O
]	O
.	O

Treatment	O
of	O
hallux	O
limitus	O
involves	O
conservative	O
measures	O
(	O
such	O
as	O
physical	O
therapy	O
,	O
foot	O
orthoses	O
,	O
footwear	O
modification	O
,	O
joint	O
manipulation	O
and	O
injection	O
with	O
corticosteroid	O
)	O
[	O
5	O
]	O
,	O
or	O
surgical	O
intervention	O
(	O
either	O
joint	O
-	O
salvage	O
or	O
joint	O
-	O
destructive	O
procedures	O
)	O
[	O
6	O
]	O
.	O

Pharmacological	O
treatment	O
is	O
also	O
often	O
undertaken	O
as	O
an	O
adjunct	O
for	O
pain	O
relief	O
in	O
the	O
management	O
of	O
hallux	O
limitus	O
[	O
6	O
]	O
.	O

However	O
,	O
although	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
and	O
cyclooxygenase-2	O
inhibitors	O
have	O
been	O
found	O
to	O
be	O
effective	O
in	O
the	O
management	O
of	O
various	O
forms	O
of	O
OA	O
,	O
gastrointestinal	O
complications	O
remain	O
a	O
concern	O
[	O
7	O
]	O
.	O

In	O
light	O
of	O
these	O
limitations	O
with	O
existing	O
treatments	O
,	O
an	O
alternative	O
treatment	O
termed	O
'	O
viscosupplementation	O
'	O
–	O
the	O
intra	O
-	O
articular	O
injection	O
of	O
hyaluronan	O
into	O
arthritic	O
joints	O
with	O
the	O
aim	O
of	O
restoring	O
the	O
viscoelasticity	O
of	O
the	O
synovial	O
fluid	O
[	O
8	O
]	O
–	O
has	O
been	O
proposed	O
and	O
has	O
attracted	O
considerable	O
attention	O
in	O
the	O
medical	O
literature	O
as	O
a	O
treatment	O
for	O
OA	O
[	O
9	O
]	O
.	O

In	O
particular	O
,	O
both	O
the	O
American	O
College	O
of	O
Rheumatology	O
(	O
ACR	O
)	O
and	O
European	O
League	O
Against	O
Rheumatism	O
(	O
EULAR	O
)	O
recommend	O
hyaluronan	O
in	O
the	O
management	O
of	O
OA	O
of	O
the	O
knee	O
[	O
10,11	O
]	O
.	O

Although	O
the	O
results	O
of	O
systematic	O
reviews	O
investigating	O
the	O
effectiveness	O
of	O
this	O
type	O
of	O
treatment	O
for	O
knee	O
OA	O
are	O
controversial	O
,	O
the	O
most	O
recent	O
update	O
of	O
the	O
Cochrane	O
systematic	O
review	O
evaluating	O
viscosupplementation	O
for	O
the	O
treatment	O
of	O
knee	O
OA	O
concluded	O
that	O
viscosupplementation	O
was	O
both	O
safe	O
and	O
effective	O
for	O
the	O
treatment	O
of	O
OA	O
and	O
was	O
superior	O
or	O
equivalent	O
to	O
any	O
form	O
of	O
systemic	O
intervention	O
or	O
intra	O
-	O
articular	O
corticosteroids	O
[	O
9,12	O
]	O
.	O

Despite	O
there	O
being	O
a	O
large	O
number	O
of	O
studies	O
investigating	O
the	O
effectiveness	O
of	O
hyaluronan	O
for	O
knee	O
OA	O
,	O
few	O
studies	O
have	O
investigated	O
the	O
effects	O
of	O
this	O
form	O
of	O
treatment	O
for	O
OA	O
at	O
the	O
first	O
MPJ	O
[	O
13	O
]	O
.	O

In	O
a	O
case	O
-	O
series	O
retrospective	O
study	O
,	O
14	O
patients	O
with	O
radiographically	O
confirmed	O
OA	O
at	O
the	O
first	O
MPJ	O
that	O
received	O
up	O
to	O
3	O
intra	O
-	O
articular	O
injections	O
of	O
1	O
ml	O
hyaluronan	O
(	O
Ostenil	O
®	O
Mini	O
)	O
(	O
sodium	O
hyaluronate	O
)	O
reported	O
a	O
statistically	O
significant	O
reduction	O
in	O
pain	O
(	O
reported	O
using	O
a	O
visual	O
analogue	O
scale	O
)	O
after	O
6	O
months	O
[	O
14	O
]	O
.	O

The	O
treatment	O
was	O
well	O
tolerated	O
,	O
with	O
3	O
/	O
14	O
(	O
21	O
%	O
)	O
participants	O
reporting	O
mild	O
adverse	O
reactions	O
at	O
the	O
injection	O
site	O
.	O

In	O
another	O
study	O
,	O
Pons	O
et	O
al	O
[	O
13	O
]	O
compared	O
a	O
single	O
intra	O
-	O
articular	O
injection	O
of	O
1	O
ml	O
Ostenil	O
®	O
Mini	O
(	O
sodium	O
hyaluronate	O
)	O
with	O
1	O
ml	O
Trigon	O
depot	O
®	O
(	O
triamcinolone	O
acetonide	O
,	O
a	O
corticosteroid	O
)	O
for	O
the	O
treatment	O
of	O
painful	O
,	O
grade	O
1	O
hallux	O
limitus	O
(	O
Karasick	O
and	O
Wapner	O
[	O
15	O
]	O
scale	O
)	O
in	O
37	O
participants	O
(	O
40	O
feet	O
)	O
[	O
13	O
]	O
.	O

Both	O
treatment	O
groups	O
showed	O
statistically	O
significant	O
reductions	O
in	O
pain	O
at	O
rest	O
or	O
on	O
palpation	O
for	O
up	O
to	O
12	O
weeks	O
post	O
-	O
injection	O
.	O

However	O
,	O
hyaluronan	O
treatment	O
resulted	O
in	O
a	O
statistically	O
significant	O
greater	O
reduction	O
in	O
pain	O
during	O
walking	O
and	O
greater	O
improvement	O
in	O
the	O
American	O
Orthopaedic	O
Foot	O
and	O
Ankle	O
Society	O
(	O
AOFAS	O
)	O
hallux	O
MPJ	O
score	O
compared	O
to	O
treatment	O
with	O
triamcinolone	O
acetonide	O
.	O

The	O
treatment	O
with	O
hyaluronan	O
was	O
well	O
tolerated	O
,	O
with	O
2	O
/	O
20	O
(	O
10	O
%	O
)	O
participants	O
reporting	O
mild	O
adverse	O
reactions	O
at	O
the	O
injection	O
site	O
.	O

Although	O
both	O
of	O
these	O
studies	O
suggest	O
that	O
intra	O
-	O
articular	O
hyaluronan	O
is	O
safe	O
and	O
effective	O
for	O
the	O
treatment	O
of	O
hallux	O
limitus	O
,	O
neither	O
used	O
a	O
placebo	O
control	O
group	O
[	O
13,14	O
]	O
.	O

This	O
limitation	O
is	O
significant	O
as	O
a	O
placebo	O
effect	O
can	O
account	O
for	O
79	O
%	O
of	O
the	O
efficacy	O
of	O
intra	O
-	O
articular	O
hyaluronan	O
treatment	O
[	O
16	O
]	O
.	O

Further	O
,	O
both	O
studies	O
are	O
limited	O
in	O
that	O
neither	O
of	O
the	O
studies	O
used	O
blinding	O
of	O
both	O
the	O
participants	O
and	O
assessors	O
in	O
their	O
protocols	O
.	O

It	O
is	O
therefore	O
possible	O
that	O
the	O
positive	O
effects	O
of	O
hyaluronan	O
may	O
have	O
been	O
overestimated	O
.	O

Accordingly	O
,	O
the	O
aims	O
of	O
this	O
project	O
are	O
to	O
conduct	O
a	O
double	O
blind	O
randomised	O
controlled	O
trial	O
to	O
determine	O
the	O
effectiveness	O
of	O
intra	O
-	O
articular	O
hyaluronan	O
(	O
Synvisc	O
®	O
)	O
on	O
(	O
i	O
)	O
foot	O
pain	O
and	O
function	O
;	O
(	O
ii	O
)	O
the	O
range	O
of	O
motion	O
of	O
the	O
first	O
MPJ	O
;	O
(	O
iii	O
)	O
the	O
strength	O
of	O
the	O
plantarflexor	O
muscles	O
of	O
the	O
first	O
MPJ	O
;	O
(	O
iv	O
)	O
the	O
health	O
related	O
quality	O
of	O
life	O
;	O
and	O
(	O
v	O
)	O
the	O
use	O
of	O
pain	O
-	O
relieving	O
medications	O
in	O
people	O
with	O
hallux	O
limitus	O
.	O

The	O
study	O
protocol	O
is	O
presented	O
in	O
this	O
paper	O
,	O
consistent	O
with	O
the	O
recommendations	O
of	O
Editorial	O
Board	O
of	O
BioMed	O
Central	O
[	O
17	O
]	O
.	O

Methods	O
Design	O
This	O
study	O
is	O
a	O
parallel	O
group	O
,	O
participant	O
and	O
assessor	O
blinded	O
,	O
randomised	O
controlled	O
trial	O
with	O
a	O
6	O
month	O
follow	O
-	O
up	O
(	O
Figure	O
1	O
)	O
.	O

It	O
has	O
been	O
developed	O
using	O
the	O
principles	O
described	O
by	O
Osteoarthritis	O
Research	O
Society	O
International	O
(	O
OARSI	O
)	O
Clinical	O
Trials	O
Task	O
Force	O
guidelines	O
[	O
18	O
]	O
.	O

Participants	O
will	O
be	O
randomised	O
to	O
receive	O
a	O
single	O
intra	O
-	O
articular	O
injection	O
of	O
up	O
to	O
1	O
ml	O
hyaluronan	O
(	O
Synvisc	O
®	O
)	O
or	O
sterile	O
saline	O
(	O
placebo	O
)	O
into	O
the	O
first	O
MPJ	O
.	O

Allocation	O
to	O
either	O
the	O
Synvisc	O
®	O
or	O
placebo	O
groups	O
will	O
be	O
achieved	O
using	O
a	O
computer	O
-	O
generated	O
random	O
number	O
sequence	O
.	O

The	O
allocation	O
sequence	O
will	O
be	O
generated	O
and	O
held	O
by	O
an	O
external	O
person	O
not	O
directly	O
involved	O
in	O
the	O
trial	O
.	O

Concealment	O
of	O
the	O
allocation	O
sequence	O
will	O
be	O
ensured	O
as	O
each	O
participant	O
's	O
allocation	O
will	O
be	O
contained	O
in	O
a	O
sealed	O
opaque	O
envelope	O
.	O

Envelopes	O
will	O
be	O
made	O
opaque	O
by	O
using	O
a	O
sheet	O
of	O
aluminium	O
foil	O
inside	O
the	O
envelope	O
.	O

In	O
addition	O
,	O
a	O
system	O
using	O
carbon	O
paper	O
will	O
be	O
employed	O
so	O
the	O
details	O
(	O
name	O
and	O
date	O
of	O
recruitment	O
)	O
are	O
transferred	O
from	O
the	O
outside	O
of	O
the	O
envelope	O
to	O
the	O
paper	O
inside	O
the	O
envelope	O
containing	O
the	O
allocation	O
prior	O
to	O
opening	O
the	O
seal	O
.	O

Assessors	O
and	O
participants	O
will	O
be	O
blinded	O
to	O
group	O
allocation	O
.	O

Participants	O
will	O
be	O
given	O
the	O
option	O
of	O
a	O
second	O
and	O
final	O
intra	O
-	O
articular	O
injection	O
(	O
of	O
Synvisc	O
®	O
or	O
sterile	O
saline	O
according	O
to	O
the	O
treatment	O
group	O
they	O
are	O
in	O
)	O
on	O
days	O
30	O
or	O
90	O
if	O
there	O
is	O
no	O
improvement	O
in	O
pain	O
and	O
the	O
participant	O
has	O
not	O
experienced	O
severe	O
adverse	O
effects	O
after	O
the	O
first	O
injection	O
)	O
.	O

Participants	O
The	O
Human	O
Studies	O
Ethics	O
Committee	O
at	O
La	O
Trobe	O
University	O
(	O
Human	O
Ethics	O
Committee	O
Application	O
No.	O
07	O
-	O
45	O
)	O
and	O
the	O
Radiation	O
Advisory	O
Committee	O
of	O
the	O
Victorian	O
Department	O
of	O
Human	O
Services	O
have	O
given	O
approval	O
for	O
the	O
study	O
.	O

Written	O
informed	O
consent	O
will	O
be	O
obtained	O
from	O
all	O
participants	O
prior	O
to	O
their	O
participation	O
.	O

People	O
with	O
hallux	O
limitus	O
will	O
be	O
recruited	O
from	O
a	O
number	O
of	O
sources	O
:	O
(	O
i	O
)	O
advertisements	O
in	O
relevant	O
Melbourne	O
(	O
Australia	O
)	O
newspapers	O
;	O
(	O
ii	O
)	O
mail	O
-	O
out	O
advertisements	O
to	O
health	O
-	O
care	O
practitioners	O
in	O
Melbourne	O
;	O
(	O
iii	O
)	O
advertisements	O
using	O
relevant	O
internet	O
web	O
-	O
sites	O
(	O
including	O
)	O
;	O
(	O
iv	O
)	O
posters	O
displayed	O
in	O
local	O
retirement	O
villages	O
,	O
community	O
centres	O
and	O
universities	O
located	O
in	O
Melbourne	O
.	O

Respondents	O
will	O
initially	O
be	O
screened	O
by	O
telephone	O
interview	O
to	O
ensure	O
they	O
are	O
suitable	O
for	O
the	O
study	O
.	O

Suitable	O
individuals	O
will	O
then	O
be	O
invited	O
to	O
participate	O
in	O
the	O
study	O
and	O
attend	O
an	O
initial	O
assessment	O
.	O

To	O
be	O
included	O
in	O
the	O
study	O
,	O
participants	O
must	O
meet	O
the	O
following	O
inclusion	O
criteria	O
:	O
(	O
i	O
)	O
be	O
aged	O
at	O
least	O
18	O
years	O
;	O
(	O
ii	O
)	O
report	O
having	O
symptoms	O
of	O
pain	O
,	O
during	O
walking	O
or	O
rest	O
,	O
in	O
the	O
first	O
MPJ	O
for	O
at	O
least	O
3	O
months	O
;	O
(	O
iii	O
)	O
report	O
having	O
pain	O
rated	O
at	O
least	O
20	O
mm	O
on	O
a	O
100	O
mm	O
visual	O
analogue	O
pain	O
scale	O
(	O
VAPS	O
)	O
;	O
(	O
iv	O
)	O
have	O
pain	O
upon	O
palpation	O
of	O
the	O
dorsal	O
aspect	O
of	O
the	O
first	O
MPJ	O
;	O
(	O
v	O
)	O
radiographic	O
evidence	O
of	O
OA	O
(	O
score	O
1	O
or	O
2	O
for	O
either	O
osteophytes	O
or	O
joint	O
space	O
narrowing	O
using	O
a	O
previously	O
published	O
radiographic	O
classification	O
)	O
[	O
19	O
]	O
at	O
the	O
first	O
MPJ	O
.	O

(	O
vi	O
)	O
able	O
to	O
walk	O
household	O
distances	O
(	O
>	O
50	O
meters	O
)	O
without	O
the	O
aid	O
of	O
a	O
walker	O
,	O
crutches	O
or	O
cane	O
;	O
(	O
vii	O
)	O
be	O
willing	O
to	O
attend	O
the	O
La	O
Trobe	O
University	O
Medical	O
Centre	O
(	O
Melbourne	O
,	O
Australia	O
)	O
for	O
treatment	O
with	O
either	O
Synvisc	O
®	O
or	O
placebo	O
(	O
single	O
intra	O
-	O
articular	O
injection	O
)	O
and	O
attend	O
the	O
Health	O
Sciences	O
Clinic	O
at	O
La	O
Trobe	O
University	O
(	O
Melbourne	O
,	O
Australia	O
)	O
for	O
the	O
initial	O
assessment	O
and	O
the	O
outcome	O
measurements	O
(	O
at	O
baseline	O
and	O
1	O
,	O
3	O
and	O
6	O
months	O
post	O
-	O
treatment	O
)	O
;	O
(	O
viii	O
)	O
not	O
receive	O
other	O
intra	O
-	O
articular	O
injections	O
into	O
the	O
first	O
MPJ	O
during	O
the	O
course	O
of	O
the	O
study	O
,	O
apart	O
from	O
those	O
dictated	O
by	O
the	O
study	O
;	O
(	O
ix	O
)	O
be	O
willing	O
to	O
discontinue	O
taking	O
all	O
pain	O
-	O
relieving	O
medications	O
(	O
analgesics	O
and	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
medications	O
(	O
NSAIDs	O
)	O
,	O
except	O
paracetamol	O
up	O
to	O
4	O
g	O
/	O
day	O
,	O
taken	O
by	O
mouth	O
or	O
applied	O
topically	O
)	O
:	O
-	O
for	O
at	O
least	O
14	O
days	O
prior	O
to	O
the	O
baseline	O
assessment	O
;	O
-	O
during	O
the	O
study	O
period	O
(	O
6	O
months	O
after	O
the	O
final	O
treatment	O
with	O
Synvisc	O
®	O
)	O
.	O

Participants	O
who	O
do	O
take	O
paracetamol	O
need	O
to	O
discontinue	O
its	O
use	O
at	O
least	O
24	O
hours	O
prior	O
to	O
the	O
baseline	O
assessment	O
and	O
follow	O
-	O
up	O
assessments	O
at	O
1	O
,	O
3	O
and	O
6	O
months	O
after	O
the	O
treatment	O
;	O
(	O
x	O
)	O
be	O
willing	O
to	O
not	O
receive	O
any	O
physical	O
therapy	O
on	O
the	O
involved	O
MPJ	O
or	O
trial	O
of	O
shoe	O
modifications	O
or	O
foot	O
orthoses	O
during	O
the	O
study	O
period	O
.	O

Exclusion	O
criteria	O
for	O
participants	O
in	O
this	O
study	O
will	O
be	O
:	O
(	O
i	O
)	O
Severe	O
radiographic	O
evidence	O
of	O
OA	O
(	O
score	O
3	O
for	O
either	O
osteophytes	O
or	O
joint	O
space	O
narrowing	O
)	O
at	O
the	O
first	O
MPJ	O
using	O
a	O
previously	O
published	O
radiographic	O
classification	O
[	O
19	O
]	O
;	O
(	O
ii	O
)	O
previous	O
surgery	O
on	O
the	O
first	O
MPJ	O
;	O
(	O
iii	O
)	O
intra	O
-	O
articular	O
steroid	O
,	O
or	O
any	O
other	O
intra	O
-	O
articular	O
injection	O
at	O
the	O
first	O
MPJ	O
in	O
the	O
previous	O
6	O
months	O
;	O
(	O
iv	O
)	O
treatment	O
with	O
systemic	O
steroid	O
(	O
excluding	O
inhalation	O
or	O
topical	O
steroids	O
)	O
,	O
immunosuppressives	O
or	O
anticoagulants	O
(	O
except	O
for	O
acetylsalicylic	O
acid	O
at	O
dosages	O
of	O
up	O
to	O
325	O
mg	O
/	O
day	O
)	O
;	O
(	O
v	O
)	O
presence	O
of	O
joint	O
infection	O
(	O
s	O
)	O
of	O
the	O
foot	O
;	O
(	O
vi	O
)	O
significant	O
deformity	O
of	O
the	O
first	O
MPJ	O
including	O
hallux	O
abducto	O
valgus	O
(	O
grade	O
of	O
3	O
or	O
4	O
scored	O
using	O
the	O
Manchester	O
Scale	O
[	O
20	O
]	O
;	O
(	O
vii	O
)	O
presence	O
of	O
peripheral	O
vascular	O
disease	O
.	O

Peripheral	O
vascular	O
disease	O
will	O
be	O
considered	O
to	O
be	O
present	O
if	O
any	O
of	O
the	O
following	O
are	O
present	O
[	O
21	O
]	O
;	O
▪	O
past	O
history	O
of	O
,	O
vascular	O
surgery	O
,	O
Raynaud	O
's	O
phenomenon	O
,	O
vasculitis	O
associated	O
with	O
connective	O
tissue	O
diseases	O
,	O
Buerger	O
's	O
disease	O
,	O
arterial	O
emboli	O
,	O
deep	O
vein	O
thrombosis	O
or	O
lower	O
limb	O
ulcers	O
;	O
▪	O
history	O
of	O
intermittent	O
claudication	O
or	O
rest	O
pain	O
;	O
▪	O
presence	O
of	O
atrophy	O
,	O
ulcers	O
or	O
significant	O
oedema	O
;	O
▪	O
inability	O
to	O
palpate	O
at	O
least	O
one	O
pedal	O
pulse	O
;	O
▪	O
Ankle	O
Brachial	O
Pressure	O
Index	O
<	O
0.9	O
;	O
(	O
viii	O
)	O
presence	O
of	O
one	O
or	O
more	O
conditions	O
that	O
can	O
confound	O
pain	O
and	O
functional	O
assessments	O
of	O
the	O
first	O
MPJ	O
,	O
such	O
as	O
metatarsalgia	O
,	O
plantar	O
fasciitis	O
,	O
pre	O
-	O
dislocation	O
syndrome	O
,	O
sprains	O
of	O
the	O
foot	O
,	O
Achilles	O
tendinopathy	O
,	O
degenerative	O
joint	O
disease	O
of	O
the	O
foot	O
(	O
other	O
than	O
the	O
first	O
MPJ	O
)	O
or	O
painful	O
corns	O
and	O
callus	O
;	O
(	O
ix	O
)	O
planning	O
to	O
undergo	O
any	O
surgical	O
procedure	O
or	O
receive	O
any	O
injections	O
,	O
apart	O
from	O
those	O
dictated	O
by	O
the	O
study	O
,	O
at	O
the	O
involved	O
first	O
MPJ	O
during	O
the	O
study	O
period	O
;	O
(	O
x	O
)	O
presence	O
of	O
systemic	O
inflammatory	O
condition	O
or	O
infection	O
,	O
such	O
as	O
inflammatory	O
arthritis	O
,	O
diagnosed	O
with	O
rheumatoid	O
arthritis	O
,	O
ankylosing	O
spondylitis	O
,	O
psoriatic	O
arthritis	O
,	O
reactive	O
arthritis	O
,	O
septic	O
arthritis	O
,	O
acute	O
pseudogout	O
,	O
or	O
any	O
other	O
connective	O
tissue	O
disease	O
;	O
(	O
xi	O
)	O
evidence	O
of	O
gout	O
or	O
other	O
musculoskeletal	O
disease	O
other	O
than	O
OA	O
within	O
the	O
feet	O
.	O

Gout	O
will	O
be	O
screened	O
for	O
using	O
clinical	O
history	O
and	O
physical	O
assessment	O
(	O
painful	O
joint	O
,	O
abrupt	O
onset	O
,	O
swelling	O
)	O
,	O
radiographic	O
assessment	O
(	O
asymmetrical	O
joint	O
swelling	O
,	O
subcortical	O
cysts	O
without	O
erosion	O
and	O
tophi	O
)	O
as	O
well	O
as	O
serum	O
uric	O
acid	O
levels	O
(	O
hyperuricaemia	O
=	O
serum	O
uric	O
acid	O
>	O
mean	O
+	O
2	O
SD	O
from	O
normal	O
population	O
)	O
[	O
22	O
]	O
;	O
(	O
xii	O
)	O
active	O
skin	O
disease	O
or	O
infection	O
in	O
the	O
area	O
of	O
the	O
injection	O
site	O
;	O
(	O
xiii	O
)	O
any	O
medical	O
condition	O
that	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigators	O
,	O
makes	O
the	O
participant	O
unsuitable	O
for	O
inclusion	O
(	O
e.g.	O
,	O
severe	O
progressive	O
chronic	O
disease	O
,	O
malignancy	O
,	O
bleeding	O
disorder	O
,	O
clinically	O
important	O
pain	O
in	O
a	O
part	O
of	O
the	O
musculoskeletal	O
system	O
other	O
than	O
the	O
first	O
MPJ	O
,	O
or	O
fibromyalgia	O
)	O
;	O
(	O
xiv	O
)	O
pregnant	O
or	O
lactating	O
women	O
,	O
or	O
women	O
who	O
are	O
of	O
child	O
bearing	O
age	O
or	O
have	O
not	O
undergone	O
menopause	O
(	O
Synvisc	O
®	O
has	O
not	O
been	O
tested	O
in	O
pregnant	O
women	O
or	O
women	O
who	O
are	O
nursing	O
)	O
;	O
(	O
xv	O
)	O
cognitive	O
impairment	O
(	O
defined	O
as	O
a	O
score	O
of	O
<	O
7	O
on	O
the	O
Short	O
Portable	O
Mental	O
Status	O
Questionnaire	O
)	O
[	O
23	O
]	O
;	O
(	O
xvi	O
)	O
known	O
hypersensitivity	O
(	O
allergy	O
)	O
to	O
hyaluronan	O
preparations	O
,	O
or	O
to	O
avian	O
proteins	O
,	O
feathers	O
or	O
egg	O
products	O
;	O
(	O
xvii	O
)	O
involvement	O
in	O
any	O
clinical	O
research	O
study	O
in	O
the	O
previous	O
3	O
months	O
that	O
could	O
be	O
considered	O
to	O
affect	O
the	O
results	O
of	O
this	O
study	O
.	O

Intra	O
-	O
articular	O
injections	O
for	O
the	O
treatment	O
groups	O
Participants	O
will	O
be	O
randomised	O
to	O
receive	O
a	O
single	O
intra	O
-	O
articular	O
injection	O
of	O
up	O
to	O
1	O
ml	O
of	O
hyaluronan	O
(	O
Synvisc	O
®	O
;	O
Genzyme	O
Biosurgery	O
,	O
Genzyme	O
Corporation	O
,	O
NJ	O
,	O
USA	O
)	O
or	O
sterile	O
saline	O
(	O
placebo	O
)	O
into	O
the	O
first	O
MPJ	O
.	O

Each	O
2	O
ml	O
ampoule	O
of	O
Synvisc	O
®	O
contains	O
16	O
mg	O
of	O
hylan	O
G	O
-	O
F	O
20	O
(	O
cross	O
-	O
linked	O
hylan	O
polymers	O
;	O
hylan	O
A	O
and	O
B	O
)	O
,	O
17	O
mg	O
sodium	O
chloride	O
,	O
0.32	O
mg	O
disodium	O
hydrogen	O
phosphate	O
,	O
0.08	O
mg	O
sodium	O
dihydrogen	O
phosphate	O
monohydrate	O
.	O

The	O
hyaluronan	O
is	O
extracted	O
from	O
chicken	B
combs	O
and	O
the	O
purified	O
material	O
has	O
an	O
average	O
molecular	O
weight	O
of	O
6,000	O
kDa	O
.	O

The	O
injections	O
will	O
be	O
performed	O
by	O
the	O
same	O
experienced	O
interventional	O
radiologist	O
(	O
AEZ	O
)	O
using	O
fluoroscopic	O
imaging	O
to	O
ensure	O
accurate	O
deposition	O
of	O
the	O
hyaluronan	O
within	O
the	O
joint	O
.	O

As	O
the	O
Synvisc	O
®	O
is	O
provided	O
in	O
ampoules	O
that	O
are	O
labelled	O
with	O
the	O
product	O
name	O
,	O
it	O
will	O
not	O
be	O
possible	O
to	O
blind	O
the	O
injector	O
,	O
however	O
this	O
person	O
is	O
not	O
involved	O
in	O
generation	O
of	O
the	O
allocation	O
order	O
,	O
recruitment	O
,	O
assessment	O
or	O
data	O
analysis	O
.	O

The	O
intra	O
-	O
articular	O
injection	O
will	O
be	O
performed	O
using	O
a	O
21	O
gauge	O
(	O
0.80	O
×	O
19	O
mm	O
)	O
Surflo	O
®	O
(	O
Terumo	O
®	O
Corp.	O
,	O
Tokyo	O
,	O
Japan	O
)	O
winged	O
infusion	O
set	O
under	O
aseptic	O
procedures	O
.	O

Either	O
a	O
dorso	O
-	O
lateral	O
or	O
dorso	O
-	O
medial	O
approach	O
for	O
injection	O
will	O
be	O
used	O
at	O
the	O
discretion	O
of	O
the	O
injector	O
(	O
depending	O
on	O
which	O
approach	O
provides	O
minimum	O
interference	O
from	O
the	O
osteophytes	O
at	O
the	O
first	O
MPJ	O
joint	O
margins	O
)	O
.	O

No	O
anaesthetic	O
will	O
be	O
used	O
.	O

If	O
the	O
participant	O
has	O
bilateral	O
painful	O
first	O
MPJs	O
,	O
only	O
one	O
side	O
(	O
the	O
most	O
painful	O
side	O
)	O
will	O
be	O
treated	O
and	O
used	O
for	O
data	O
collection	O
.	O

The	O
injector	O
will	O
record	O
the	O
volume	O
of	O
the	O
agent	O
that	O
is	O
injected	O
.	O

Participants	O
will	O
be	O
given	O
the	O
option	O
of	O
a	O
second	O
and	O
final	O
intra	O
-	O
articular	O
injection	O
(	O
of	O
Synvisc	O
®	O
or	O
sterile	O
saline	O
according	O
to	O
the	O
treatment	O
group	O
they	O
are	O
in	O
)	O
on	O
days	O
30	O
or	O
90	O
if	O
there	O
is	O
no	O
improvement	O
in	O
pain	O
(	O
assessed	O
using	O
the	O
VAPS	O
for	O
pain	O
during	O
walking	O
or	O
at	O
rest	O
)	O
and	O
the	O
participant	O
has	O
not	O
experienced	O
severe	O
adverse	O
effects	O
after	O
the	O
first	O
injection	O
)	O
.	O

Assessments	O
Initial	O
assessments	O
An	O
initial	O
assessment	O
will	O
be	O
performed	O
to	O
determine	O
the	O
eligibility	O
of	O
participants	O
for	O
this	O
study	O
.	O

Demographic	O
data	O
will	O
be	O
collected	O
including	O
the	O
age	O
,	O
gender	O
,	O
height	O
and	O
weight	O
of	O
participants	O
.	O

Data	O
will	O
also	O
be	O
obtained	O
concerning	O
the	O
presentation	O
of	O
symptoms	O
(	O
foot	O
affected	O
,	O
duration	O
of	O
symptoms	O
)	O
.	O

If	O
the	O
participant	O
has	O
bilateral	O
painful	O
first	O
MPJs	O
,	O
the	O
most	O
painful	O
side	O
will	O
be	O
used	O
for	O
data	O
collection	O
and	O
subsequent	O
treatment	O
.	O

To	O
establish	O
eligibility	O
for	O
the	O
study	O
,	O
participants	O
will	O
undergo	O
a	O
clinical	O
assessment	O
,	O
have	O
one	O
set	O
of	O
dorso	O
-	O
plantar	O
and	O
lateral	O
weight	O
-	O
bearing	O
x	O
-	O
rays	O
taken	O
of	O
their	O
feet	O
to	O
grade	O
the	O
severity	O
of	O
first	O
MPJ	O
OA	O
as	O
well	O
as	O
undergo	O
a	O
blood	O
test	O
to	O
assess	O
serum	O
uric	O
acid	O
levels	O
(	O
to	O
exclude	O
gout	O
)	O
.	O

Weightbearing	O
dorso	O
-	O
plantar	O
and	O
lateral	O
radiographic	O
views	O
will	O
be	O
obtained	O
from	O
both	O
feet	O
with	O
the	O
participant	O
standing	O
in	O
a	O
relaxed	O
bipedal	O
stance	O
position	O
.	O

All	O
x	O
-	O
rays	O
will	O
be	O
taken	O
by	O
the	O
same	O
medical	O
imaging	O
department	O
using	O
a	O
Shimadzu	O
UD150LRII	O
50	O
kw	O
/	O
30	O
kHz	O
Generator	O
and	O
0.6	O
/	O
1.2	O
P18DE-80S	O
high	O
speed	O
x	O
-	O
ray	O
tube	O
from	O
a	O
ceiling	O
suspended	O
tube	O
mount	O
.	O

AGFA	O
MD40	O
CR	O
digital	O
phosphor	O
plates	O
in	O
a	O
24	O
cm	O
×	O
30	O
cm	O
cassette	O
will	O
be	O
used	O
.	O

For	O
dorso	O
-	O
plantar	O
projections	O
,	O
the	O
x	O
-	O
ray	O
tube	O
will	O
be	O
angled	O
15	O
°	O
cephalad	O
and	O
centered	O
at	O
the	O
base	O
of	O
the	O
third	O
metatarsal	O
.	O

For	O
lateral	O
projections	O
,	O
the	O
tube	O
will	O
be	O
angled	O
90	O
°	O
and	O
centered	O
at	O
the	O
base	O
of	O
the	O
third	O
metatarsal	O
.	O

The	O
film	O
focus	O
distance	O
will	O
be	O
set	O
at	O
100	O
cm	O
[	O
19	O
]	O
.	O

Baseline	O
assessments	O
and	O
outcome	O
measures	O
Participants	O
who	O
are	O
eligible	O
for	O
the	O
study	O
will	O
be	O
invited	O
to	O
attend	O
a	O
baseline	O
assessment	O
.	O

During	O
the	O
baseline	O
assessment	O
,	O
participants	O
will	O
undergo	O
primary	O
and	O
secondary	O
outcome	O
measurements	O
prior	O
to	O
receiving	O
their	O
injection	O
.	O

The	O
outcome	O
measurements	O
have	O
been	O
developed	O
in	O
accordance	O
of	O
the	O
recommendations	O
of	O
the	O
OARSI	O
Clinical	O
Trials	O
Task	O
Force	O
guidelines	O
[	O
18	O
]	O
.	O

Primary	O
outcome	O
measures	O
Outcome	O
measurements	O
(	O
primary	O
and	O
secondary	O
)	O
will	O
occur	O
at	O
four	O
time	O
-	O
points	O
at	O
baseline	O
,	O
1	O
,	O
3	O
and	O
6	O
months	O
post	O
-	O
treatment	O
(	O
after	O
the	O
intra	O
-	O
articular	O
injection	O
of	O
Synvisc	O
®	O
or	O
placebo	O
)	O
.	O

The	O
assessor	O
performing	O
the	O
measurements	O
will	O
be	O
blinded	O
as	O
to	O
which	O
treatment	O
group	O
participants	O
have	O
been	O
allocated	O
to	O
.	O

Participants	O
who	O
receive	O
a	O
second	O
treatment	O
at	O
day	O
30	O
or	O
90	O
will	O
be	O
followed	O
for	O
a	O
further	O
30	O
days	O
or	O
90	O
days	O
respectively	O
and	O
undergo	O
outcome	O
measurements	O
at	O
7	O
or	O
9	O
months	O
respectively	O
.	O

The	O
primary	O
outcome	O
measures	O
will	O
be	O
the	O
Pain	O
and	O
Function	O
subscales	O
of	O
the	O
Foot	O
Health	O
Status	O
Questionnaire	O
(	O
FHSQ	O
)	O
[	O
24	O
]	O
.	O

The	O
FHSQ	O
includes	O
13	O
questions	O
that	O
assess	O
four	O
domains	O
of	O
foot	O
health	O
,	O
Foot	O
pain	O
,	O
Foot	O
function	O
,	O
Footwear	O
and	O
General	O
foot	O
health	O
.	O

The	O
FHSQ	O
has	O
been	O
subjected	O
to	O
an	O
extensive	O
validation	O
(	O
content	O
,	O
criterion	O
and	O
construct	O
validity	O
)	O
process	O
.	O

It	O
has	O
a	O
high	O
test	O
-	O
retest	O
reliability	O
(	O
intraclass	O
correlation	O
coefficients	O
ranging	O
from	O
0.74	O
to	O
0.92	O
)	O
and	O
a	O
high	O
degree	O
of	O
internal	O
consistency	O
(	O
Cronbach	O
's	O
α	O
ranging	O
from	O
0.85	O
to	O
0.88	O
)	O
[	O
24	O
]	O
.	O

Rigorous	O
reviews	O
have	O
rated	O
it	O
as	O
one	O
of	O
the	O
highest	O
quality	O
foot	O
health	O
status	O
measures	O
currently	O
available	O
[	O
25	O
-	O
27	O
]	O
.	O

Secondary	O
outcome	O
measures	O
The	O
secondary	O
outcome	O
measures	O
will	O
be	O
:	O
(	O
i	O
)	O
Severity	O
of	O
pain	O
Severity	O
of	O
pain	O
at	O
the	O
first	O
MPJ	O
during	O
walking	O
,	O
and	O
during	O
rest	O
,	O
over	O
the	O
past	O
week	O
will	O
be	O
assessed	O
using	O
a	O
100	O
mm	O
visual	O
analogue	O
pain	O
scale	O
.	O

The	O
left	O
side	O
of	O
the	O
scale	O
(	O
0	O
mm	O
)	O
will	O
be	O
labelled	O
"	O
no	O
pain	O
"	O
and	O
the	O
right	O
side	O
of	O
the	O
scale	O
(	O
100	O
mm	O
)	O
will	O
be	O
labelled	O
"	O
worst	O
pain	O
possible	O
"	O
for	O
each	O
question	O
[	O
25,28	O
]	O
.	O

(	O
ii	O
)	O
Severity	O
and	O
duration	O
of	O
stiffness	O
at	O
the	O
first	O
metatarsophalangeal	O
joint	O
The	O
severity	O
of	O
stiffness	O
at	O
the	O
first	O
MPJ	O
during	O
walking	O
over	O
the	O
past	O
week	O
will	O
be	O
assessed	O
using	O
a	O
100	O
mm	O
visual	O
analogue	O
scale	O
.	O

The	O
left	O
side	O
of	O
the	O
scale	O
(	O
0	O
mm	O
)	O
will	O
be	O
labelled	O
"	O
not	O
stiff	O
at	O
all	O
"	O
and	O
the	O
right	O
side	O
of	O
the	O
scale	O
(	O
100	O
mm	O
)	O
will	O
be	O
labelled	O
"	O
most	O
stiff	O
possible	O
"	O
.	O

The	O
average	O
duration	O
of	O
stiffness	O
at	O
the	O
first	O
MPJ	O
over	O
the	O
past	O
week	O
will	O
be	O
assessed	O
using	O
a	O
four	O
category	O
scale	O
response	O
.	O

The	O
responses	O
are	O
:	O
"	O
none	O
"	O
,	O
"	O
1–15	O
minutes	O
"	O
,	O
"	O
16–30	O
minutes	O
"	O
and	O
"	O
greater	O
than	O
30	O
minutes	O
"	O
[	O
29	O
]	O
.	O

(	O
iii	O
)	O
Passive	O
,	O
non	O
-	O
weightbearing	O
dorsiflexion	O
range	O
of	O
motion	O
of	O
the	O
first	O
metatarsophalangeal	O
joint	O
First	O
MPJ	O
dorsiflexion	O
range	O
of	O
motion	O
will	O
be	O
measured	O
using	O
a	O
goniometer	O
as	O
the	O
maximum	O
angle	O
at	O
which	O
the	O
hallux	O
can	O
not	O
be	O
passively	O
moved	O
into	O
further	O
extension	O
in	O
a	O
non	O
-	O
weightbearing	O
position	O
(	O
Figure	O
2	O
)	O
[	O
30	O
]	O
.	O

The	O
test	O
will	O
be	O
performed	O
two	O
times	O
and	O
the	O
average	O
will	O
be	O
used	O
for	O
analysis	O
.	O

This	O
measurement	O
technique	O
shows	O
high	O
intra	O
-	O
reliability	O
(	O
ICC	O
=	O
0.95	O
,	O
standard	O
error	O
of	O
mean	O
=	O
1.3	O
°	O
)	O
[	O
30	O
]	O
.	O

(	O
iv	O
)	O
Plantar	O
flexion	O
strength	O
of	O
the	O
toe	O
-	O
flexors	O
of	O
the	O
hallux	O
Plantar	O
flexion	O
strength	O
of	O
the	O
toe	O
-	O
flexors	O
of	O
the	O
hallux	O
will	O
be	O
measured	O
using	O
the	O
Mat	O
Scan	O
®	O
plantar	O
pressure	O
measurement	O
device	O
[	O
31	O
]	O
.	O

Participants	O
will	O
be	O
seated	O
with	O
the	O
hip	O
,	O
knee	O
,	O
and	O
ankle	O
at	O
90	O
degrees	O
and	O
their	O
foot	O
placed	O
over	O
the	O
Mat	O
Scan	O
®	O
plantar	O
pressure	O
measurement	O
device	O
(	O
Tekscan	O
,	O
Boston	O
,	O
MA	O
,	O
USA	O
)	O
(	O
Figure	O
3a	O
)	O
.	O

This	O
system	O
consists	O
of	O
a	O
5-mm	O
thick	O
floor	O
mat	O
(	O
432	O
×	O
368	O
mm	O
)	O
incorporating	O
2288	O
resistive	O
sensors	O
(	O
1.4	O
sensors	O
/	O
cm2	O
)	O
sampling	O
at	O
a	O
rate	O
of	O
40	O
Hz	O
.	O

The	O
mat	O
will	O
be	O
calibrated	O
for	O
each	O
participant	O
using	O
his	O
or	O
her	O
own	O
bodyweight	O
before	O
each	O
testing	O
session	O
.	O

Participants	O
will	O
be	O
instructed	O
to	O
use	O
their	O
toe	O
-	O
flexor	O
muscles	O
to	O
maximally	O
push	O
their	O
hallux	O
down	O
on	O
the	O
MatScan	O
®	O
device	O
and	O
forces	O
under	O
the	O
hallux	O
will	O
be	O
recorded	O
(	O
Figure	O
3b	O
)	O
.	O

The	O
test	O
will	O
be	O
performed	O
three	O
times	O
for	O
the	O
hallux	O
and	O
the	O
maximal	O
force	O
will	O
be	O
used	O
for	O
analysis	O
.	O

The	O
test	O
-	O
retest	O
reliability	O
of	O
this	O
measurement	O
technique	O
has	O
previously	O
been	O
shown	O
to	O
be	O
high	O
,	O
with	O
intraclass	O
correlation	O
coefficients	O
(	O
ICCs	O
)	O
=	O
0.88	O
(	O
95	O
%	O
CI	O
0.81	O
–	O
0.93	O
)	O
[	O
31	O
]	O
.	O

(	O
vi	O
)	O
Plantar	O
pressure	O
measurement	O
Plantar	O
pressures	O
will	O
be	O
recorded	O
during	O
level	O
barefoot	O
walking	O
using	O
the	O
MatScan	O
®	O
system	O
(	O
Tekscan	O
®	O
,	O
Boston	O
,	O
MA	O
,	O
USA	O
)	O
.	O

The	O
two	O
-	O
step	O
gait	O
initiation	O
protocol	O
will	O
be	O
used	O
to	O
obtain	O
foot	O
pressure	O
data	O
,	O
as	O
it	O
requires	O
fewer	O
trials	O
than	O
the	O
mid	O
-	O
gait	O
protocol	O
and	O
has	O
similar	O
re	O
-	O
test	O
reliability	O
[	O
32	O
]	O
.	O

Three	O
trials	O
will	O
be	O
recorded	O
,	O
which	O
has	O
been	O
found	O
to	O
be	O
sufficient	O
to	O
ensure	O
adequate	O
reliability	O
of	O
pressure	O
data	O
[	O
32,33	O
]	O
.	O

Following	O
data	O
collection	O
,	O
the	O
Research	O
Foot	O
®	O
software	O
(	O
version	O
5.24	O
)	O
will	O
be	O
used	O
to	O
construct	O
individual	O
"	O
masks	O
"	O
to	O
determine	O
maximum	O
force	O
(	O
kg	O
)	O
and	O
peak	O
pressure	O
(	O
kg	O
/	O
cm2	O
)	O
under	O
seven	O
regions	O
of	O
the	O
foot	O
:	O
hallux	O
,	O
lesser	O
toes	O
,	O
1st	O
MPJ	O
,	O
2nd	O
MPJ	O
,	O
3rd	O
to	O
5th	O
MPJs	O
,	O
midfoot	O
and	O
heel	O
(	O
Figure	O
4a	O
)	O
.	O

For	O
each	O
region	O
,	O
the	O
median	O
of	O
the	O
three	O
trials	O
will	O
be	O
used	O
for	O
analysis	O
.	O

Typical	O
plantar	O
pressure	O
recordings	O
from	O
a	O
participant	O
are	O
shown	O
in	O
Figure	O
4b	O
.	O

(	O
vi	O
)	O
Global	O
satisfaction	O
with	O
the	O
treatment	O
Global	O
satisfaction	O
with	O
the	O
treatment	O
will	O
be	O
assessed	O
using	O
a	O
5-point	O
Likert	O
scale	O
,	O
as	O
well	O
as	O
a	O
dichotomous	O
(	O
yes	O
/	O
no	O
)	O
scale	O
.	O

The	O
five	O
point	O
-	O
Likert	O
scale	O
will	O
ask	O
"	O
How	O
satisfied	O
are	O
you	O
with	O
the	O
treatment	O
you	O
received	O
for	O
your	O
big	O
-	O
toe	O
joint	O
pain	O
?	O
"	O
,	O
and	O
will	O
have	O
the	O
following	O
five	O
responses	O
:	O
"	O
Dissatisfied	O
"	O
,	O
"	O
Only	O
moderately	O
satisfied	O
"	O
,	O
"	O
Fairly	O
satisfied	O
"	O
,	O
"	O
Clearly	O
satisfied	O
"	O
and	O
"	O
Very	O
satisfied	O
"	O
.	O

The	O
dichotomous	O
scale	O
of	O
satisfaction	O
will	O
be	O
answered	O
as	O
"	O
Yes	O
"	O
'	O
or	O
"	O
No	O
"	O
in	O
response	O
to	O
the	O
question	O
:	O
"	O
Would	O
you	O
recommend	O
the	O
treatment	O
that	O
you	O
received	O
to	O
someone	O
else	O
with	O
big	O
-	O
toe	O
joint	O
pain	O
"	O
.	O

(	O
vii	O
)	O
Health	O
related	O
quality	O
of	O
life	O
The	O
Short	O
-	O
Form-36	O
(	O
version	O
two	O
)	O
(	O
SF-36	O
)	O
questionnaire	O
will	O
be	O
used	O
to	O
assess	O
health	O
related	O
quality	O
of	O
life	O
.	O

The	O
SF-36	O
is	O
a	O
36	O
question	O
survey	O
that	O
measures	O
eight	O
health	O
concepts	O
most	O
affected	O
by	O
disease	O
and	O
treatment	O
.	O

The	O
eight	O
health	O
concepts	O
can	O
then	O
be	O
used	O
to	O
form	O
two	O
summary	O
measures	O
:	O
Physical	O
health	O
and	O
Mental	O
health	O
.	O

The	O
Short	O
Form-36	O
(	O
SF-36	O
)	O
has	O
been	O
extensively	O
validated	O
and	O
is	O
one	O
of	O
the	O
most	O
widely	O
used	O
instruments	O
to	O
measure	O
health	O
status	O
.	O

The	O
SF-36	O
shows	O
content	O
,	O
concurrent	O
,	O
criterion	O
,	O
construct	O
,	O
and	O
predictive	O
evidence	O
of	O
validity	O
.	O

The	O
reliability	O
of	O
the	O
eight	O
concepts	O
and	O
two	O
summary	O
measures	O
has	O
been	O
assessed	O
using	O
both	O
internal	O
consistency	O
and	O
test	O
-	O
retest	O
methods	O
.	O

Reliability	O
statistics	O
have	O
exceeded	O
0.80	O
[	O
34	O
-	O
37	O
]	O
.	O

(	O
viii	O
)	O
Self	O
-	O
reported	O
magnitude	O
of	O
symptom	O
change	O
Self	O
-	O
reported	O
magnitude	O
of	O
symptom	O
change	O
will	O
be	O
measured	O
using	O
a	O
15-point	O
Likert	O
scale	O
.	O

The	O
scale	O
will	O
ask	O
participants	O
"	O
how	O
much	O
have	O
your	O
symptoms	O
in	O
your	O
big	O
-	O
toe	O
joint	O
have	O
changed	O
from	O
the	O
beginning	O
of	O
the	O
study	O
to	O
now	O
?	O
"	O
.	O

The	O
fifteen	O
responses	O
will	O
range	O
from	O
"	O
A	O
very	O
great	O
deal	O
better	O
"	O
to	O
"	O
A	O
very	O
great	O
deal	O
worse	O
"	O
.	O

(	O
ix	O
)	O
Use	O
of	O
rescue	O
medications	O
to	O
relieve	O
pain	O
at	O
the	O
first	O
metatarsophalangeal	O
joint	O
The	O
number	O
of	O
participants	O
who	O
consumed	O
rescue	O
medication	O
(	O
e.g.	O
,	O
paracetamol	O
)	O
and	O
mean	O
consumption	O
of	O
rescue	O
medication	O
to	O
relieve	O
pain	O
at	O
the	O
first	O
MPJ	O
(	O
mean	O
grams	O
of	O
paracetamol	O
/	O
participant	O
/	O
month	O
]	O
will	O
be	O
assessed	O
using	O
a	O
medications	O
diary	O
that	O
participants	O
will	O
self	O
-	O
complete	O
[	O
38,39	O
]	O
.	O

The	O
diary	O
will	O
be	O
returned	O
to	O
the	O
assessor	O
at	O
monthly	O
intervals	O
for	O
analysis	O
.	O

(	O
x	O
)	O
Frequency	O
and	O
severity	O
of	O
adverse	O
events	O
as	O
safety	O
variables	O
The	O
frequency	O
(	O
number	O
of	O
participants	O
affected	O
and	O
number	O
of	O
cases	O
)	O
and	O
types	O
of	O
adverse	O
events	O
(	O
including	O
adverse	O
drug	O
reactions	O
)	O
in	O
each	O
treatment	O
group	O
during	O
the	O
trial	O
will	O
be	O
recorded	O
using	O
a	O
questionnaire	O
that	O
participants	O
will	O
complete	O
during	O
the	O
follow	O
-	O
up	O
appointments	O
at	O
1	O
,	O
3	O
and	O
6	O
months	O
post	O
-	O
treatment	O
[	O
40	O
]	O
.	O

To	O
classify	O
the	O
'	O
type	O
'	O
of	O
adverse	O
event	O
,	O
a	O
blinded	O
assessor	O
will	O
classify	O
the	O
adverse	O
event	O
as	O
being	O
serious	O
or	O
non	O
-	O
serious	O
[	O
40	O
]	O
.	O

Any	O
serious	O
adverse	O
events	O
,	O
defined	O
as	O
adverse	O
events	O
leading	O
to	O
serious	O
disability	O
,	O
hospital	O
admission	O
,	O
or	O
prolongation	O
of	O
hospitalisation	O
,	O
life	O
-	O
threatening	O
events	O
;	O
or	O
death	O
)	O
will	O
be	O
further	O
classified	O
using	O
the	O
International	O
Classification	O
of	O
Diseases	O
(	O
ICD	O
)	O
codes	O
[	O
41	O
]	O
.	O

Non	O
-	O
serious	O
adverse	O
events	O
will	O
include	O
both	O
local	O
(	O
pain	O
,	O
effusion	O
and	O
heat	O
,	O
with	O
each	O
classified	O
as	O
mild	O
,	O
moderate	O
,	O
severe	O
)	O
and	O
systemic	O
adverse	O
events	O
.	O

An	O
open	O
-	O
response	O
type	O
format	O
will	O
also	O
be	O
available	O
for	O
participant	O
responses	O
.	O

Sample	O
size	O
The	O
sample	O
size	O
for	O
the	O
study	O
has	O
been	O
pre	O
-	O
specified	O
using	O
an	O
a	O
priori	O
power	O
analysis	O
using	O
the	O
primary	O
outcome	O
measure	O
of	O
the	O
pain	O
domain	O
of	O
the	O
FHSQ	O
[	O
42	O
]	O
.	O

One	O
hundred	O
and	O
forty	O
two	O
participants	O
(	O
i.e.	O
71	O
per	O
group	O
)	O
will	O
provide	O
power	O
of	O
90	O
%	O
to	O
detect	O
a	O
minimally	O
important	O
difference	O
in	O
the	O
pain	O
domain	O
of	O
the	O
FHSQ	O
(	O
i.e.	O
14	O
points	O
on	O
the	O
FHSQ	O
questionnaire	O
)	O
with	O
the	O
significance	O
level	O
set	O
at	O
p	O
<	O
0.05	O
.	O

A	O
difference	O
of	O
14	O
points	O
was	O
determined	O
to	O
be	O
a	O
clinically	O
significant	O
difference	O
worth	O
detecting	O
[	O
43	O
]	O
and	O
a	O
standard	O
deviation	O
of	O
25	O
was	O
derived	O
from	O
a	O
previous	O
report	O
[	O
44	O
]	O
.	O

This	O
calculation	O
included	O
a	O
5	O
%	O
drop	O
-	O
out	O
rate	O
[	O
13	O
]	O
.	O

However	O
,	O
we	O
will	O
aim	O
to	O
recruit	O
150	O
participants	O
(	O
~75	O
participants	O
per	O
intervention	O
group	O
)	O
.	O

Further	O
,	O
we	O
have	O
conservatively	O
ignored	O
the	O
extra	O
precision	O
provided	O
by	O
covariate	O
analysis	O
when	O
estimating	O
the	O
sample	O
size	O
.	O

Statistical	O
analysis	O
Statistical	O
analysis	O
will	O
be	O
undertaken	O
using	O
SPSS	O
version	O
14.0	O
(	O
SPSS	O
Corp	O
,	O
Chicago	O
,	O
Ill	O
,	O
USA	O
)	O
and	O
STATA	O
8	O
(	O
Stata	O
Corp	O
,	O
College	O
Station	O
,	O
Tex	O
.	O
,	O
USA	O
)	O
statistical	O
software	O
.	O

All	O
analyses	O
will	O
be	O
conducted	O
on	O
an	O
intention	O
-	O
to	O
-	O
treat	O
principle	O
using	O
all	O
randomised	O
participants	O
[	O
45	O
-	O
47	O
]	O
.	O

Missing	O
data	O
will	O
be	O
replaced	O
with	O
the	O
last	O
score	O
carried	O
forward	O
[	O
48	O
]	O
.	O

Standard	O
tests	O
for	O
normal	O
distribution	O
will	O
be	O
used	O
and	O
transformation	O
carried	O
out	O
if	O
required	O
.	O

Demographic	O
characteristics	O
(	O
gender	O
,	O
age	O
,	O
weight	O
,	O
height	O
,	O
body	O
mass	O
index	O
)	O
will	O
be	O
determined	O
for	O
the	O
baseline	O
visit	O
for	O
each	O
treatment	O
group	O
.	O

Summary	O
statistics	O
will	O
be	O
calculated	O
for	O
duration	O
of	O
symptoms	O
,	O
side	O
affected	O
(	O
left	O
,	O
right	O
,	O
bilateral	O
)	O
,	O
grade	O
of	O
OA	O
at	O
the	O
first	O
MPJ	O
[	O
19	O
]	O
as	O
well	O
as	O
all	O
primary	O
and	O
secondary	O
outcome	O
measurements	O
for	O
each	O
treatment	O
group	O
.	O

Analyses	O
will	O
be	O
conducted	O
on	O
1	O
,	O
3	O
and	O
6	O
month	O
outcome	O
measures	O
.	O

The	O
continuously	O
-	O
scored	O
outcome	O
measures	O
at	O
1	O
,	O
3	O
and	O
6	O
months	O
will	O
be	O
compared	O
using	O
analysis	O
of	O
covariance	O
with	O
baseline	O
scores	O
and	O
intervention	O
group	O
entered	O
as	O
independent	O
variables	O
[	O
49,50	O
]	O
.	O

The	O
exception	O
to	O
this	O
will	O
be	O
the	O
plantar	O
pressure	O
measurements	O
which	O
will	O
be	O
analysed	O
at	O
baseline	O
,	O
1	O
,	O
3	O
and	O
6	O
months	O
using	O
two	O
-	O
way	O
repeated	O
measures	O
analysis	O
of	O
variance	O
statistics	O
.	O

Post	O
-	O
hoc	O
comparisons	O
will	O
be	O
performed	O
using	O
Bonferroni	O
-	O
adjusted	O
t	O
-	O
tests	O
.	O

Nominal	O
and	O
ordinal	O
scaled	O
data	O
will	O
be	O
compared	O
at	O
1	O
,	O
3	O
and	O
6	O
months	O
using	O
Mann	O
-	O
Whitney	O
U	O
-	O
tests	O
and	O
chi	O
-	O
square	O
analyses	O
(	O
or	O
Fisher	O
's	O
exact	O
test	O
where	O
appropriate	O
)	O
respectively	O
.	O

Effect	O
sizes	O
will	O
be	O
determined	O
using	O
Cohen	O
's	O
d	O
(	O
continuous	O
scaled	O
data	O
)	O
or	O
odds	O
ratios	O
(	O
nominal	O
scaled	O
data	O
and	O
ordinal	O
scaled	O
data	O
)	O
as	O
appropriate	O
.	O

The	O
outcome	O
measurements	O
obtained	O
at	O
7	O
or	O
9	O
months	O
for	O
participants	O
that	O
receive	O
a	O
second	O
and	O
final	O
intra	O
-	O
articular	O
injection	O
(	O
of	O
Synvisc	O
®	O
or	O
sterile	O
saline	O
according	O
to	O
the	O
treatment	O
group	O
they	O
are	O
in	O
)	O
on	O
days	O
30	O
or	O
90	O
respectively	O
,	O
will	O
also	O
be	O
analysed	O
as	O
described	O
above	O
.	O

These	O
analyses	O
will	O
be	O
classified	O
as	O
secondary	O
outcomes	O
.	O

Discussion	O
This	O
study	O
is	O
a	O
randomised	O
placebo	O
controlled	O
trial	O
designed	O
to	O
investigate	O
the	O
efficacy	O
of	O
intra	O
-	O
articular	O
hyaluronan	O
(	O
Synvisc	O
®	O
)	O
to	O
reduce	O
pain	O
and	O
improve	O
function	O
in	O
people	O
with	O
OA	O
of	O
the	O
first	O
MPJ	O
(	O
hallux	O
limitus	O
)	O
.	O

Two	O
studies	O
have	O
previously	O
investigated	O
the	O
efficacy	O
of	O
intra	O
-	O
articular	O
hyaluronan	O
for	O
the	O
treatment	O
of	O
first	O
MPJ	O
OA	O
[	O
13,14	O
]	O
.	O

However	O
,	O
neither	O
of	O
these	O
studies	O
used	O
a	O
placebo	O
control	O
group	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
randomised	O
controlled	O
trial	O
using	O
intra	O
-	O
articular	O
hyaluronan	O
for	O
OA	O
of	O
the	O
first	O
MPJ	O
.	O

The	O
use	O
of	O
a	O
placebo	O
control	O
group	O
is	O
essential	O
for	O
studies	O
evaluating	O
the	O
effects	O
of	O
intra	O
-	O
articular	O
therapies	O
as	O
there	O
is	O
likely	O
to	O
be	O
a	O
large	O
placebo	O
response	O
related	O
to	O
the	O
injection	O
procedure	O
and	O
this	O
may	O
inflate	O
the	O
results	O
in	O
uncontrolled	O
evaluations	O
[	O
51	O
]	O
.	O

Indeed	O
,	O
a	O
recent	O
meta	O
-	O
analysis	O
of	O
hyaluronan	O
for	O
knee	O
OA	O
concluded	O
that	O
a	O
placebo	O
effect	O
accounted	O
for	O
79	O
%	O
of	O
the	O
efficacy	O
of	O
intra	O
-	O
articular	O
hyaluronan	O
[	O
16	O
]	O
.	O

The	O
study	O
protocol	O
and	O
outcome	O
measures	O
have	O
been	O
developed	O
in	O
accordance	O
of	O
the	O
recommendations	O
of	O
the	O
OARSI	O
Clinical	O
Trials	O
Task	O
Force	O
guidelines	O
[	O
18	O
]	O
.	O

The	O
outcome	O
measures	O
are	O
pain	O
and	O
function	O
subscales	O
of	O
the	O
FHSQ	O
,	O
pain	O
and	O
stiffness	O
at	O
the	O
first	O
MPJ	O
,	O
range	O
of	O
motion	O
(	O
dorsiflexion	O
)	O
of	O
the	O
first	O
MPJ	O
,	O
plantar	O
flexion	O
strength	O
of	O
muscles	O
of	O
the	O
first	O
MPJ	O
,	O
generic	O
health	O
related	O
quality	O
of	O
life	O
(	O
SF-36	O
)	O
,	O
patient	O
satisfaction	O
with	O
treatment	O
,	O
consumption	O
of	O
rescue	O
medication	O
as	O
well	O
as	O
frequency	O
and	O
nature	O
of	O
adverse	O
effects	O
.	O

These	O
outcomes	O
will	O
be	O
measured	O
at	O
baseline	O
then	O
at	O
1	O
,	O
3	O
and	O
6	O
months	O
after	O
treatment	O
.	O

Previous	O
research	O
suggests	O
that	O
the	O
effects	O
of	O
intra	O
-	O
articular	O
hyaluronan	O
persist	O
for	O
up	O
to	O
12	O
months	O
following	O
treatment	O
[	O
9,38	O
]	O
.	O

Thus	O
,	O
the	O
use	O
of	O
follow	O
-	O
up	O
assessments	O
at	O
6	O
month	O
post	O
-	O
treatment	O
will	O
allow	O
us	O
to	O
determine	O
if	O
the	O
effects	O
,	O
if	O
any	O
,	O
of	O
intra	O
-	O
articular	O
hyaluronan	O
persist	O
in	O
the	O
longer	O
term	O
.	O

Participants	O
will	O
be	O
given	O
the	O
option	O
of	O
a	O
second	O
and	O
final	O
intra	O
-	O
articular	O
injection	O
(	O
of	O
Synvisc	O
®	O
or	O
sterile	O
saline	O
according	O
to	O
the	O
treatment	O
group	O
they	O
are	O
in	O
)	O
on	O
days	O
30	O
or	O
90	O
if	O
there	O
is	O
no	O
improvement	O
in	O
their	O
symptoms	O
.	O

Although	O
this	O
has	O
the	O
potential	O
to	O
complicate	O
the	O
interpretation	O
of	O
the	O
results	O
of	O
the	O
study	O
,	O
this	O
protocol	O
was	O
included	O
as	O
it	O
is	O
likely	O
to	O
be	O
more	O
reflective	O
of	O
clinical	O
practice	O
[	O
14	O
]	O
,	O
and	O
this	O
is	O
in	O
keeping	O
with	O
the	O
pragmatic	O
nature	O
of	O
this	O
trial	O
.	O

In	O
summary	O
,	O
this	O
project	O
is	O
the	O
first	O
randomised	O
controlled	O
trial	O
to	O
be	O
conducted	O
to	O
evaluate	O
the	O
efficacy	O
of	O
intra	O
-	O
articular	O
hyaluronan	O
for	O
reducing	O
pain	O
and	O
improving	O
function	O
in	O
people	O
with	O
hallux	O
limitus	O
.	O

The	O
study	O
protocol	O
,	O
including	O
interventions	O
,	O
have	O
been	O
pragmatically	O
designed	O
to	O
ensure	O
that	O
the	O
study	O
findings	O
are	O
generaliseable	O
to	O
clinical	O
practice	O
.	O

Recruitment	O
for	O
the	O
study	O
will	O
commence	O
in	O
June	O
2008	O
,	O
and	O
we	O
expect	O
final	O
results	O
to	O
be	O
available	O
in	O
mid-2010	O
.	O

Competing	O
interests	O
HBM	O
and	O
KBL	O
are	O
Editor	O
-	O
in	O
-	O
Chief	O
and	O
Deputy	O
Editor	O
-	O
in	O
-	O
Chief	O
,	O
respectively	O
,	O
of	O
Journal	O
of	O
Foot	O
and	O
Ankle	O
Research	O
.	O

It	O
is	O
journal	O
policy	O
that	O
editors	O
are	O
removed	O
from	O
the	O
peer	O
review	O
and	O
editorial	O
decision	O
making	O
processes	O
for	O
papers	O
they	O
have	O
co	O
-	O
authored	O
.	O

Authors	O
'	O
contributions	O
SEM	O
,	O
HBM	O
,	O
KBL	O
and	O
CJH	O
conceived	O
the	O
idea	O
and	O
obtained	O
funding	O
for	O
the	O
study	O
.	O

SEM	O
,	O
HBM	O
,	O
KBL	O
,	O
AEZ	O
and	O
JDL	O
designed	O
the	O
trial	O
protocol	O
.	O

SEM	O
,	O
HBM	O
,	O
KBL	O
and	O
GVZ	O
drafted	O
the	O
manuscript	O
.	O

All	O
authors	O
have	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

A	O
novel	O
DNA	O
-	O
binding	O
protein	O
modulating	O
methicillin	O
resistance	O
in	O
Staphylococcus	B
aureus	I
Abstract	O
Background	O
Methicillin	O
resistance	O
in	O
Staphylococcus	B
aureus	I
is	O
conferred	O
by	O
the	O
mecA	O
-	O
encoded	O
penicillin	O
-	O
binding	O
protein	O
PBP2a	O
.	O

Additional	O
genomic	O
factors	O
are	O
also	O
known	O
to	O
influence	O
resistance	O
levels	O
in	O
strain	O
specific	O
ways	O
,	O
although	O
little	O
is	O
known	O
about	O
their	O
contribution	O
to	O
resistance	O
phenotypes	O
in	O
clinical	O
isolates	O
.	O

Here	O
we	O
searched	O
for	O
novel	O
proteins	O
binding	O
to	O
the	O
mec	O
operator	O
,	O
in	O
an	O
attempt	O
to	O
identify	O
new	O
factor	O
(	O
s	O
)	O
controlling	O
methicillin	O
resistance	O
phenotypes	O
.	O

Results	O
Analysis	O
of	O
proteins	O
binding	O
to	O
a	O
DNA	O
fragment	O
containing	O
the	O
mec	O
operator	O
region	O
identified	O
a	O
novel	O
,	O
putative	O
helix	O
-	O
turn	O
-	O
helix	O
DNA	O
-	O
binding	O
protein	O
,	O
SA1665	O
.	O

Nonpolar	O
deletion	O
of	O
SA1665	O
,	O
in	O
heterogeneously	O
methicillin	O
resistant	O
S.	B
aureus	I
(	O
MRSA	O
)	O
of	O
different	O
genetic	O
backgrounds	O
,	O
increased	O
methicillin	O
resistance	O
levels	O
in	O
a	O
strain	O
dependent	O
manner	O
.	O

This	O
phenotype	O
could	O
be	O
fully	O
complemented	O
by	O
reintroducing	O
SA1665	O
in	O
trans	O
.	O

Northern	O
and	O
Western	O
blot	O
analyses	O
,	O
however	O
,	O
revealed	O
that	O
SA1665	O
had	O
no	O
visible	O
influence	O
on	O
mecA	O
transcription	O
or	O
amounts	O
of	O
PBP2a	O
produced	O
.	O

Conclusion	O
SA1665	O
is	O
a	O
new	O
chromosomal	O
factor	O
which	O
influences	O
methicillin	O
resistance	O
in	O
MRSA	O
.	O

Although	O
SA1665	O
bound	O
to	O
the	O
mecA	O
promoter	O
region	O
,	O
it	O
had	O
no	O
apparent	O
influence	O
on	O
mecA	O
transcription	O
or	O
translation	O
,	O
suggesting	O
that	O
this	O
predicted	O
DNA	O
-	O
binding	O
protein	O
modulates	O
resistance	O
indirectly	O
,	O
most	O
likely	O
through	O
the	O
control	O
of	O
other	O
genomic	O
factors	O
which	O
contribute	O
to	O
resistance	O
.	O

Background	O
Methicillin	O
resistant	O
S.	B
aureus	I
(	O
MRSA	O
)	O
are	O
an	O
ever	O
increasing	O
threat	O
,	O
both	O
in	O
clinical	O
settings	O
and	O
more	O
recently	O
as	O
an	O
emerging	O
community	O
acquired	O
pathogen	O
.	O

Their	O
invasiveness	O
and	O
pathogenesis	O
relies	O
on	O
a	O
variable	O
arsenal	O
of	O
virulence	O
factors	O
,	O
paired	O
with	O
resistance	O
to	O
virtually	O
all	O
β	O
-	O
lactams	O
and	O
their	O
derivatives	O
.	O

Their	O
ability	O
to	O
rapidly	O
generate	O
resistance	O
to	O
other	O
unrelated	O
classes	O
of	O
antibiotics	O
,	O
or	O
to	O
take	O
up	O
additional	O
resistance	O
determinants	O
,	O
severely	O
hampers	O
therapy	O
and	O
eradication	O
.	O

In	O
S.	B
aureus	I
,	O
methicillin	O
resistance	O
is	O
conferred	O
by	O
an	O
acquired	O
,	O
β	O
-	O
lactam	O
-	O
insensitive	O
penicillin	O
-	O
binding	O
protein	O
(	O
PBP	O
)	O
,	O
PBP2a	O
[	O
1	O
-	O
4	O
]	O
.	O

PBP2a	O
is	O
encoded	O
by	O
mecA	O
,	O
which	O
is	O
divergently	O
transcribed	O
from	O
its	O
cognate	O
regulators	O
,	O
mecR1	O
(	O
sensor	O
/	O
signal	O
transducer	O
)	O
and	O
mecI	O
(	O
repressor	O
)	O
.	O

If	O
mecR1-mecI	O
are	O
absent	O
or	O
truncated	O
,	O
transcriptional	O
control	O
of	O
mecA	O
is	O
taken	O
over	O
by	O
the	O
structurally	O
similar	O
blaZ	O
(	O
penicillinase	O
)	O
regulatory	O
elements	O
blaR1	O
/	O
blaI	O
,	O
if	O
present	O
.	O

In	O
the	O
absence	O
of	O
both	O
regulatory	O
loci	O
,	O
mecA	O
is	O
constitutively	O
transcribed	O
[	O
5,6	O
]	O
.	O

In	O
the	O
presence	O
of	O
β	O
-	O
lactams	O
,	O
the	O
transmembrane	O
sensor	O
/	O
signal	O
transducers	O
BlaR1	O
/	O
MecR1	O
,	O
undergo	O
a	O
conformational	O
change	O
,	O
followed	O
by	O
autoproteolytic	O
cleavage	O
of	O
the	O
n	O
-	O
terminal	O
cytoplasmic	O
domain	O
,	O
leading	O
to	O
the	O
activation	O
of	O
the	O
cytoplasmic	O
peptidase	O
and	O
subsequent	O
dissociation	O
of	O
the	O
repressor	O
due	O
to	O
proteolytic	O
degradation	O
[	O
7	O
-	O
9	O
]	O
.	O

However	O
,	O
the	O
signal	O
transduction	O
cascade	O
of	O
this	O
regulatory	O
system	O
has	O
still	O
not	O
been	O
completely	O
elucidated	O
.	O

Oxacillin	O
resistance	O
levels	O
conferred	O
by	O
mecA	O
are	O
strain	O
specific	O
and	O
can	O
vary	O
greatly	O
,	O
with	O
oxacillin	O
minimal	O
inhibitory	O
concentrations	O
(	O
MICs	O
)	O
of	O
different	O
strains	O
ranging	O
from	O
phenotypically	O
susceptible	O
levels	O
,	O
as	O
low	O
as	O
1	O
μg	O
/	O
ml	O
up	O
to	O
extremely	O
high	O
values	O
of	O
>	O
500	O
μg	O
/	O
ml	O
.	O

Methicillin	O
resistance	O
is	O
also	O
generally	O
expressed	O
heterogeneously	O
.	O

Heterogeneously	O
resistant	O
MRSA	O
,	O
when	O
exposed	O
to	O
β	O
-	O
lactam	O
antibiotics	O
,	O
segregate	O
highly	O
resistant	O
subpopulations	O
,	O
which	O
are	O
much	O
more	O
resistant	O
than	O
the	O
majority	O
of	O
the	O
cells	O
[	O
10	O
]	O
.	O

The	O
frequency	O
of	O
highly	O
resistant	O
subclones	O
generated	O
is	O
often	O
well	O
above	O
the	O
spontaneous	O
mutation	O
frequency	O
,	O
and	O
once	O
selected	O
high	O
level	O
resistance	O
often	O
remains	O
stable	O
,	O
even	O
in	O
the	O
absence	O
of	O
selective	O
pressure	O
.	O

There	O
is	O
currently	O
no	O
satisfactory	O
genetic	O
model	O
which	O
explains	O
how	O
these	O
higher	O
resistance	O
levels	O
are	O
triggered	O
or	O
selected	O
and	O
exactly	O
what	O
factors	O
are	O
functionally	O
responsible	O
for	O
the	O
increased	O
resistance	O
in	O
clinical	O
isolates	O
.	O

Methicillin	O
resistance	O
levels	O
are	O
known	O
to	O
not	O
directly	O
correlate	O
with	O
mecA	O
transcription	O
or	O
levels	O
of	O
PBP2a	O
produced	O
[	O
11,12	O
]	O
.	O

However	O
,	O
resistance	O
levels	O
can	O
be	O
manipulated	O
by	O
environmental	O
conditions	O
,	O
such	O
as	O
temperature	O
,	O
pH	O
,	O
osmolarity	O
,	O
and	O
medium	O
composition	O
[	O
13,14	O
]	O
.	O

It	O
has	O
been	O
shown	O
experimentally	O
,	O
that	O
in	O
addition	O
to	O
mecA	O
,	O
methicillin	O
resistance	O
depends	O
on	O
the	O
correct	O
interplay	O
of	O
a	O
multitude	O
of	O
genomic	O
factors	O
,	O
termed	O
fem	O
/	O
aux	O
factors	O
,	O
including	O
genes	O
involved	O
in	O
peptidoglycan	O
precursor	O
formation	O
,	O
composition	O
and	O
turnover	O
;	O
teichoic	O
acid	O
synthesis	O
;	O
and	O
genes	O
of	O
unknown	O
or	O
poorly	O
characterised	O
functions	O
[	O
15	O
-	O
18	O
]	O
.	O

In	O
addition	O
to	O
structural	O
genes	O
,	O
many	O
regulatory	O
loci	O
have	O
also	O
been	O
shown	O
to	O
influence	O
resistance	O
levels	O
,	O
including	O
global	O
regulators	O
of	O
virulence	O
factor	O
production	O
such	O
as	O
the	O
quorum	O
sensing	O
agr	O
system	O
,	O
the	O
staphylococcal	O
accessory	O
regulator	O
SarA	O
and	O
the	O
alternate	O
sigma	O
factor	O
σB	O
[	O
19,20	O
]	O
;	O
regulators	O
of	O
metabolism	O
,	O
such	O
as	O
the	O
catabolite	O
control	O
protein	O
A	O
(	O
CcpA	O
)	O
[	O
21	O
]	O
;	O
and	O
the	O
VraSR	O
two	O
-	O
component	O
sensor	O
transducer	O
,	O
which	O
induces	O
the	O
cell	O
wall	O
stress	O
stimulon	O
in	O
response	O
to	O
cell	O
wall	O
active	O
antibiotic	O
challenge	O
[	O
22	O
]	O
.	O

The	O
vast	O
MIC	O
differences	O
between	O
MRSA	O
strains	O
,	O
the	O
population	O
heterogeneity	O
within	O
single	O
strains	O
and	O
the	O
dependence	O
of	O
resistance	O
levels	O
on	O
external	O
factors	O
are	O
reflected	O
in	O
these	O
many	O
structural	O
genes	O
and	O
global	O
regulators	O
,	O
which	O
can	O
influence	O
resistance	O
levels	O
.	O

While	O
typically	O
considered	O
nosocomial	O
pathogens	O
,	O
new	O
faster	O
growing	O
and	O
apparently	O
more	O
virulent	O
MRSA	O
have	O
begun	O
spreading	O
in	O
the	O
community	O
.	O

Interestingly	O
,	O
these	O
emerging	O
strains	O
often	O
express	O
very	O
low	O
methicillin	O
resistance	O
,	O
e.g.	O
the	O
MRSA	O
clone	O
spreading	O
amongst	O
intravenous	O
drug	O
users	O
in	O
the	O
Zurich	O
area	O
,	O
which	O
has	O
an	O
in	O
vitro	O
doubling	O
time	O
of	O
25	O
min	O
,	O
but	O
oxacillin	O
MICs	O
of	O
only	O
0.5	O
to	O
4	O
μg	O
/	O
ml	O
[	O
23	O
]	O
.	O

This	O
particular	O
clone	O
's	O
low	O
-	O
level	O
resistance	O
is	O
partially	O
due	O
to	O
a	O
promoter	O
mutation	O
,	O
leading	O
to	O
tight	O
repression	O
of	O
mecA	O
,	O
but	O
resistance	O
levels	O
appear	O
to	O
be	O
mainly	O
restricted	O
by	O
unknown	O
factors	O
within	O
its	O
genomic	O
background	O
[	O
12	O
]	O
.	O

To	O
identify	O
potential	O
factors	O
involved	O
in	O
mecA	O
regulation	O
or	O
methicillin	O
resistance	O
levels	O
in	O
such	O
an	O
extremely	O
low	O
level	O
resistant	O
MRSA	O
,	O
we	O
performed	O
DNA	O
-	O
binding	O
protein	O
purification	O
assays	O
,	O
using	O
the	O
mecA	O
operator	O
region	O
as	O
bait	O
.	O

A	O
novel	O
,	O
uncharacterized	O
protein	O
,	O
SA1665	O
,	O
was	O
found	O
to	O
bind	O
to	O
this	O
DNA	O
fragment	O
,	O
and	O
shown	O
to	O
increase	O
methicillin	O
resistance	O
levels	O
when	O
deleted	O
.	O

Results	O
Identification	O
of	O
SA1665	O
MRSA	O
strain	O
CHE482	O
is	O
the	O
type	O
strain	O
for	O
the	O
so	O
-	O
called	O
"	O
drug	O
clone	O
"	O
spreading	O
amongst	O
intravenous	O
drug	O
users	O
in	O
the	O
Zurich	O
area	O
[	O
12,23	O
]	O
.	O

This	O
strain	O
carries	O
mecA	O
and	O
expresses	O
PBP2a	O
,	O
but	O
appears	O
phenotypically	O
methicillin	O
susceptible	O
by	O
conventional	O
phenotypic	O
tests	O
.	O

However	O
,	O
like	O
most	O
other	O
low	O
-	O
level	O
resistant	O
MRSA	O
,	O
it	O
can	O
segregate	O
a	O
small	O
proportion	O
of	O
higher	O
resistant	O
subclones	O
in	O
the	O
presence	O
of	O
β	O
-	O
lactams	O
.	O

We	O
hypothesized	O
that	O
regulation	O
of	O
methicillin	O
resistance	O
in	O
such	O
low	O
-	O
level	O
resistant	O
clonal	O
lineages	O
may	O
differ	O
qualitatively	O
from	O
classical	O
heterogeneously-	O
or	O
highly	O
-	O
resistant	O
MRSA	O
.	O

A	O
DNA	O
-	O
binding	O
protein	O
purification	O
assay	O
was	O
performed	O
to	O
identify	O
new	O
potential	O
factors	O
involved	O
in	O
the	O
regulation	O
of	O
mecA	O
/	O
PBP2a	O
.	O

The	O
mecA	O
/	O
mecR1	O
intergenic	O
DNA	O
region	O
,	O
including	O
the	O
5	O
'	O
9	O
bp	O
of	O
mecR1	O
and	O
the	O
first	O
52	O
bp	O
of	O
mecA	O
,	O
was	O
used	O
as	O
bait	O
against	O
crude	O
protein	O
extract	O
from	O
strain	O
CHE482	O
.	O

Proteins	O
binding	O
to	O
this	O
DNA	O
fragment	O
were	O
analysed	O
by	O
SDS	O
-	O
PAGE	O
.	O

Even	O
though	O
CHE482	O
contained	O
BlaI	O
,	O
which	O
is	O
known	O
to	O
bind	O
to	O
the	O
mec	O
operator	O
,	O
this	O
band	O
could	O
not	O
be	O
identified	O
on	O
gels	O
due	O
to	O
co	O
-	O
migrating	O
,	O
non	O
-	O
specific	O
bands	O
the	O
same	O
size	O
as	O
BlaI	O
(	O
14.9	O
KDa	O
)	O
that	O
bound	O
to	O
both	O
the	O
DNA	O
-	O
coated	O
and	O
uncoated	O
control	O
beads	O
.	O

The	O
most	O
prominent	O
protein	O
band	O
of	O
~16–20	O
kDa	O
,	O
isolated	O
from	O
DNA	O
-	O
labelled	O
but	O
not	O
from	O
control	O
beads	O
,	O
was	O
identified	O
as	O
the	O
hypothetical	O
protein	O
SA1665	O
(	O
N315	O
genome	O
annotation	O
[	O
BA000018	O
]	O
)	O
(	O
Figure	O
1A	O
)	O
.	O

SA1665	O
encodes	O
a	O
predicted	O
17-kDa	O
protein	O
with	O
an	O
n	O
-	O
terminal	O
helix	O
-	O
turn	O
-	O
helix	O
(	O
HTH	O
)	O
motif	O
characteristic	O
of	O
DNA	O
-	O
binding	O
transcriptional	O
regulators	O
.	O

The	O
amino	O
acid	O
sequence	O
of	O
SA1665	O
showed	O
100	O
%	O
identity	O
amongst	O
S.	B
aureus	I
database	O
sequences	O
and	O
97–98	O
%	O
identity	O
amongst	O
other	O
staphylococci	O
,	O
including	O
S.	B
haemolyticus	I
,	O
S.	B
epidermidis	I
and	O
S.	B
saprophyticus	I
,	O
indicating	O
that	O
SA1665	O
is	O
highly	O
conserved	O
.	O

Conversely	O
,	O
there	O
were	O
no	O
orfs	O
highly	O
similar	O
to	O
SA1665	O
found	O
in	O
other	O
bacterial	O
species	O
,	O
with	O
the	O
most	O
similar	O
sequences	O
found	O
in	O
Bacillus	B
licheniformis	I
DSM13	O
and	O
Desulfitobacterium	B
hafniense	I
Y51	I
,	O
which	O
shared	O
only	O
64	O
%	O
and	O
59	O
%	O
similarity	O
,	O
respectively	O
.	O

Electro	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
EMSA	O
was	O
used	O
to	O
confirm	O
binding	O
of	O
SA1665	O
to	O
the	O
mec	O
operator	O
region	O
.	O

Crude	O
protein	O
extracts	O
of	O
E.	B
coli	I
strain	I
BL21	I
,	O
carrying	O
the	O
empty	O
plasmid	O
(	O
pET28nHis6	O
)	O
or	O
pME20	O
(	O
pET28nHis6-SA1665	O
)	O
which	O
expressed	O
nHis6-SA1665	O
upon	O
induction	O
with	O
IPTG	O
,	O
were	O
incubated	O
with	O
the	O
161-bp	O
biotinylated	O
-	O
DNA	O
fragment	O
previously	O
used	O
as	O
bait	O
in	O
the	O
DNA	O
-	O
binding	O
protein	O
assay	O
.	O

A	O
band	O
shift	O
was	O
observed	O
with	O
extracts	O
from	O
the	O
strain	O
expressing	O
recombinant	O
nHis6-SA1665	O
but	O
not	O
from	O
the	O
control	O
strain	O
carrying	O
the	O
empty	O
plasmid	O
.	O

Several	O
bands	O
resulted	O
from	O
the	O
shift	O
,	O
which	O
is	O
most	O
likely	O
due	O
to	O
protein	O
oligomerisation	O
(	O
Figure	O
2A	O
)	O
.	O

The	O
specificity	O
of	O
the	O
gel	O
shift	O
was	O
also	O
demonstrated	O
by	O
the	O
addition	O
of	O
increasing	O
concentrations	O
of	O
purified	O
nHis6-SA1665	O
protein	O
to	O
the	O
biotinylated	O
-	O
DNA	O
fragment	O
(	O
Figure	O
2B	O
)	O
.	O

Band	O
-	O
shift	O
of	O
the	O
biotinylated	O
DNA	O
was	O
inhibited	O
in	O
the	O
presence	O
of	O
specific	O
competitor	O
DNA	O
but	O
not	O
by	O
the	O
presence	O
of	O
the	O
non	O
-	O
specific	O
competitor	O
DNA	O
,	O
confirming	O
that	O
nHis6-SA1665	O
had	O
a	O
specific	O
binding	O
affinity	O
for	O
the	O
161-bp	O
DNA	O
fragment	O
.	O

Effect	O
of	O
SA1665	O
deletion	O
on	O
β	O
-	O
lactam	O
resistance	O
To	O
analyse	O
the	O
effect	O
of	O
SA1665	O
inactivation	O
on	O
methicillin	O
resistance	O
,	O
nonpolar	O
markerless	O
deletions	O
of	O
SA1665	O
(	O
Figure	O
1B	O
)	O
were	O
constructed	O
in	O
a	O
selection	O
of	O
clinical	O
MRSA	O
isolates	O
,	O
which	O
varied	O
in	O
their	O
genetic	O
background	O
,	O
SCCmec	O
type	O
,	O
and	O
mecA	O
regulation	O
[	O
24	O
]	O
.	O

Strain	O
CHE482	O
,	O
belongs	O
to	O
clonal	O
complex	O
CC45	O
and	O
sequence	O
type	O
ST45	O
,	O
and	O
contains	O
a	O
novel	O
SCCmec	O
(	O
SCCmecN1	O
[	O
23	O
]	O
)	O
;	O
while	O
strains	O
ZH37	O
(	O
CC45	O
/	O
ST45	O
)	O
and	O
ZH73	O
(	O
CC22	O
/	O
ST22	O
)	O
contain	O
type	O
IV	O
SCCmecs	O
.	O

All	O
three	O
of	O
these	O
strains	O
have	O
truncated	O
mecI	O
/	O
mecR1	O
regulatory	O
loci	O
but	O
intact	O
BlaI	O
/	O
BlaR1	O
loci	O
controlling	O
mecA	O
expression	O
.	O

Strain	O
ZH44	O
(	O
CCT8	O
/	O
ST8	O
)	O
contained	O
a	O
type	O
A	O
mec	O
complex	O
(	O
mecI	O
-	O
mecR1-mecA	O
)	O
within	O
a	O
type	O
II	O
SCCmec	O
,	O
and	O
had	O
no	O
β	O
-	O
lactamase	O
locus	O
;	O
so	O
mecA	O
was	O
only	O
under	O
the	O
control	O
of	O
its	O
cognate	O
regulators	O
MecI	O
/	O
MecR1	O
.	O

Deletion	O
of	O
SA1665	O
increased	O
oxacillin	O
resistance	O
in	O
all	O
mutants	O
compared	O
to	O
their	O
corresponding	O
parent	O
strains	O
,	O
as	O
demonstrated	O
on	O
oxacillin	O
gradient	O
plates	O
(	O
Figure	O
3A	O
)	O
;	O
with	O
mutants	O
ΔCHE482	O
and	O
ΔZH37	O
approximately	O
doubling	O
in	O
resistance	O
and	O
ΔZH44	O
and	O
ΔZH73	O
expressing	O
considerably	O
higher	O
resistance	O
.	O

Population	O
analysis	O
resistance	O
profiles	O
of	O
the	O
mutants	O
showed	O
a	O
distinct	O
shift	O
at	O
the	O
top	O
of	O
the	O
curve	O
,	O
indicating	O
that	O
the	O
higher	O
resistance	O
was	O
due	O
to	O
increased	O
basal	O
oxacillin	O
resistance	O
levels	O
(	O
Figure	O
3B	O
)	O
.	O

Strains	O
CHE482	O
/	O
ΔCHE482	O
and	O
ZH37	O
/	O
ΔZH37	O
had	O
very	O
similar	O
resistance	O
profiles	O
,	O
despite	O
having	O
different	O
SCCmec	O
elements	O
,	O
suggesting	O
that	O
it	O
was	O
their	O
common	O
clonal	O
background	O
(	O
CC45	O
)	O
that	O
determined	O
their	O
resistance	O
levels	O
and	O
the	O
extent	O
of	O
resistance	O
increase	O
upon	O
SA1665	O
deletion	O
.	O

Growth	O
curve	O
analyses	O
showed	O
that	O
deletion	O
of	O
SA1665	O
slightly	O
reduced	O
the	O
growth	O
rate	O
of	O
all	O
strains	O
tested	O
(	O
Figure	O
3C	O
)	O
.	O

Wild	O
type	O
growth	O
rates	O
were	O
restored	O
upon	O
complementation	O
(	O
data	O
not	O
shown	O
)	O
.	O

Resistance	O
complementation	O
Plasmids	O
pME26	O
and	O
pME27	O
were	O
constructed	O
for	O
complementation	O
of	O
the	O
deletion	O
mutants	O
.	O

Both	O
plasmids	O
contained	O
the	O
SA1665	O
orf	O
along	O
with	O
its	O
own	O
promoter	O
and	O
transcriptional	O
terminator	O
.	O

Strains	O
ΔCHE482	O
,	O
ΔZH37	O
,	O
and	O
ΔZH73	O
were	O
complemented	O
with	O
pME26	O
,	O
and	O
intrinsically	O
kanamycin	O
resistant	O
strain	O
ΔZH44	O
was	O
complemented	O
with	O
pME27	O
.	O

Wild	O
type	O
-	O
like	O
resistance	O
levels	O
were	O
restored	O
in	O
all	O
mutants	O
by	O
introduction	O
of	O
the	O
complementing	O
plasmids	O
,	O
as	O
shown	O
by	O
gradient	O
plates	O
(	O
Figure	O
3A	O
)	O
.	O

Transcriptional	O
analyses	O
Primer	O
extension	O
,	O
using	O
the	O
5'-biotinylated	O
primer	O
me97	O
,	O
identified	O
two	O
potential	O
SA1665	O
transcriptional	O
start	O
sites	O
(	O
TSS	O
)	O
,	O
76-nt	O
and	O
139-nt	O
upstream	O
of	O
the	O
SA1665	O
ATG	O
start	O
codon	O
(	O
Figure	O
4A	O
)	O
.	O

Predicted	O
σA	O
promoter	O
consensus	O
-10	O
/	O
-35	O
box	O
sequences	O
were	O
located	O
upstream	O
of	O
both	O
TSS	O
(	O
Figure	O
4B	O
)	O
.	O

Identical	O
TSS	O
were	O
also	O
identified	O
using	O
the	O
downstream	O
primer	O
me98	O
(	O
data	O
not	O
shown	O
)	O
.	O

Northern	O
blot	O
analysis	O
was	O
used	O
to	O
investigate	O
SA1665	O
expression	O
and	O
the	O
influence	O
of	O
SA1665	O
deletion	O
on	O
mecA	O
and	O
mecR1	O
transcription	O
.	O

RNA	O
samples	O
taken	O
from	O
different	O
time	O
points	O
over	O
the	O
growth	O
curve	O
of	O
CHE482	O
showed	O
that	O
SA1665	O
was	O
expressed	O
strongly	O
in	O
early	O
exponential	O
phase	O
at	O
OD600	O
nm	O
0.25	O
and	O
0.5	O
,	O
then	O
transcript	O
levels	O
decreased	O
and	O
were	O
almost	O
undetectable	O
in	O
early	O
stationary	O
phase	O
at	O
OD600	O
nm	O
4.0	O
(	O
Figure	O
5A	O
)	O
.	O

In	O
addition	O
to	O
the	O
main	O
transcript	O
of	O
~0.46	O
kb	O
,	O
a	O
weaker	O
,	O
larger	O
transcript	O
of	O
~0.6	O
kb	O
was	O
also	O
visible	O
,	O
especially	O
at	O
later	O
growth	O
stages	O
.	O

Figure	O
5B	O
shows	O
the	O
transcriptional	O
behaviour	O
of	O
SA1665	O
when	O
CHE482	O
cells	O
were	O
challenged	O
with	O
sub	O
-	O
inhibitory	O
(	O
4	O
μg	O
/	O
ml	O
)	O
and	O
inhibitory	O
(	O
120	O
μg	O
/	O
ml	O
)	O
concentrations	O
of	O
cefoxitin	O
.	O

These	O
results	O
showed	O
that	O
low	O
levels	O
of	O
cefoxitin	O
,	O
such	O
as	O
those	O
used	O
to	O
induce	O
mecA	O
/	O
mecR1	O
transcription	O
,	O
appeared	O
to	O
slightly	O
decrease	O
SA1665	O
transcription	O
after	O
30	O
min	O
exposure	O
,	O
while	O
larger	O
,	O
inhibitory	O
concentrations	O
caused	O
even	O
more	O
significant	O
alterations	O
in	O
the	O
SA1665	O
transcriptional	O
profile	O
,	O
making	O
it	O
similar	O
to	O
that	O
normally	O
seen	O
in	O
stationary	O
phase	O
growth	O
.	O

These	O
results	O
indicate	O
that	O
transcription	O
of	O
SA1665	O
may	O
respond	O
in	O
some	O
way	O
to	O
cell	O
wall	O
stress	O
,	O
rather	O
than	O
in	O
direct	O
response	O
to	O
the	O
presence	O
of	O
β	O
-	O
lactams	O
.	O

This	O
observation	O
is	O
based	O
on	O
relatively	O
subtle	O
changes	O
in	O
SA1665	O
transcription	O
,	O
especially	O
at	O
low	O
concentrations	O
of	O
cefoxitin	O
such	O
as	O
those	O
required	O
for	O
mecA	O
/	O
mecR1	O
induction	O
.	O

Since	O
deletion	O
of	O
SA1665	O
has	O
been	O
shown	O
to	O
increase	O
β	O
-	O
lactam	O
resistance	O
,	O
reduced	O
SA1665	O
transcription	O
in	O
the	O
presence	O
of	O
β	O
-	O
lactams	O
may	O
also	O
provide	O
some	O
protection	O
against	O
β	O
-	O
lactam	O
exposure	O
.	O

Northerns	O
also	O
showed	O
that	O
,	O
as	O
expected	O
,	O
the	O
SA1665	O
transcripts	O
were	O
absent	O
from	O
the	O
deletion	O
mutant	O
(	O
Figure	O
5C	O
)	O
,	O
and	O
additional	O
experiments	O
demonstrated	O
that	O
wild	O
type	O
SA1665	O
transcription	O
patterns	O
were	O
restored	O
by	O
complementation	O
of	O
ΔCHE482	O
with	O
pME26	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
effects	O
of	O
SA1665	O
deletion	O
on	O
directly	O
up-	O
and	O
down	O
-	O
stream	O
genes	O
were	O
also	O
investigated	O
.	O

Northern	O
blots	O
of	O
the	O
neighbouring	O
genes	O
SA1664	O
,	O
SA1666	O
and	O
SA1667	O
,	O
showed	O
that	O
expression	O
of	O
all	O
three	O
genes	O
was	O
very	O
weak	O
compared	O
to	O
that	O
of	O
SA1665	O
.	O

A	O
weak	O
transcript	O
of	O
about	O
3	O
kb	O
was	O
present	O
in	O
hybridizations	O
probed	O
with	O
orfs	O
SA1665-SA1667	O
.	O

This	O
band	O
decreased	O
in	O
size	O
in	O
the	O
SA1665	O
mutant	O
when	O
probed	O
with	O
SA1666	O
and	O
SA1667	O
.	O

One	O
of	O
the	O
transcripts	O
hybridising	O
to	O
the	O
SA1664	O
probe	O
also	O
decreased	O
in	O
size	O
by	O
~0.5	O
kb	O
in	O
the	O
SA1665	O
mutant	O
,	O
suggesting	O
that	O
SA1665	O
was	O
present	O
on	O
several	O
transcripts	O
of	O
different	O
lengths	O
,	O
including	O
a	O
high	O
abundance	O
monocistronic	O
transcript	O
and	O
low	O
abundance	O
polycistronic	O
transcripts	O
(	O
Figure	O
5C	O
)	O
.	O

Transcript	O
abundance	O
of	O
both	O
the	O
upstream	O
SA1666-SA1667	O
operon	O
and	O
the	O
downstream	O
SA1664-specific	O
transcript	O
all	O
appeared	O
to	O
increase	O
slightly	O
in	O
ΔCHE482	O
.	O

The	O
significance	O
of	O
these	O
subtle	O
increases	O
in	O
transcription	O
are	O
unknown	O
,	O
however	O
,	O
polar	O
effects	O
from	O
SA1665	O
deletion	O
seem	O
unlikely	O
,	O
based	O
on	O
the	O
facts	O
that	O
all	O
genes	O
were	O
still	O
transcribed	O
,	O
their	O
transcription	O
levels	O
all	O
remained	O
extremely	O
low	O
and	O
the	O
transcriptional	O
terminator	O
of	O
SA1665	O
remained	O
intact	O
in	O
the	O
deletion	O
mutant	O
(	O
Figure	O
1B	O
)	O
.	O

Expression	O
of	O
mecR1	O
and	O
mecA	O
were	O
analysed	O
from	O
RNA	O
of	O
uninduced	O
and	O
induced	O
cultures	O
of	O
CHE482	O
and	O
ΔCHE482	O
.	O

Cells	O
were	O
induced	O
at	O
OD600	O
nm	O
0.25	O
(	O
Figure	O
5D	O
)	O
and	O
1.0	O
(	O
data	O
not	O
shown	O
)	O
with	O
sub	O
-	O
inhibitory	O
concentrations	O
of	O
cefoxitin	O
,	O
to	O
relieve	O
BlaI	O
-	O
repression	O
of	O
mecA.	O
mecR1	O
,	O
although	O
truncated	O
in	O
CHE482	O
,	O
was	O
still	O
transcribed	O
and	O
had	O
the	O
same	O
expression	O
pattern	O
as	O
mecA	O
,	O
as	O
both	O
became	O
derepressed	O
over	O
time	O
and	O
had	O
the	O
highest	O
transcript	O
levels	O
after	O
30	O
min	O
of	O
induction	O
.	O

In	O
the	O
mutant	O
ΔCHE482	O
,	O
transcripts	O
of	O
both	O
mecA	O
and	O
mecR1	O
'	O
were	O
unaffected	O
by	O
SA1665	O
deletion	O
,	O
indicating	O
that	O
SA1665	O
had	O
no	O
influence	O
on	O
their	O
expression	O
at	O
either	O
OD	O
0.25	O
(	O
Figure	O
5D	O
)	O
or	O
OD	O
1.0	O
(	O
data	O
not	O
shown	O
)	O
.	O

SA1665	O
deletion	O
also	O
had	O
no	O
effect	O
on	O
mecA	O
transcription	O
or	O
induction	O
in	O
strains	O
ZH37	O
,	O
ZH44	O
and	O
ZH73	O
(	O
data	O
not	O
shown	O
)	O
.	O

Western	O
blot	O
analysis	O
Mutants	O
of	O
CHE482	O
and	O
of	O
ZH44	O
and	O
ZH73	O
,	O
which	O
had	O
the	O
largest	O
differences	O
in	O
oxacillin	O
resistance	O
levels	O
,	O
were	O
analysed	O
by	O
Western	O
blot	O
analysis	O
to	O
determine	O
if	O
SA1665	O
affected	O
production	O
of	O
PBP2a	O
from	O
mecA.	O
As	O
shown	O
in	O
Figure	O
5E	O
,	O
all	O
pairs	O
of	O
wild	O
type	O
and	O
mutant	O
strains	O
had	O
similar	O
amounts	O
of	O
PBP2a	O
present	O
both	O
before	O
and	O
after	O
induction	O
with	O
cefoxitin	O
,	O
indicating	O
that	O
SA1665	O
deletion	O
did	O
not	O
alter	O
amounts	O
of	O
PBP2a	O
produced	O
.	O

Therefore	O
it	O
seems	O
that	O
SA1665	O
exerts	O
no	O
direct	O
control	O
over	O
mecA	O
or	O
PBP2a	O
expression	O
.	O

Discussion	O
Methicillin	O
resistance	O
in	O
MRSA	O
is	O
primarily	O
dependent	O
on	O
the	O
presence	O
of	O
the	O
mecA	O
gene	O
,	O
however	O
,	O
resistance	O
levels	O
are	O
generally	O
governed	O
by	O
strain	O
-	O
specific	O
factors	O
including	O
mecA	O
regulatory	O
elements	O
and	O
other	O
chromosomal	O
fem	O
/	O
aux	O
factors	O
which	O
either	O
enhance	O
or	O
repress	O
the	O
expression	O
of	O
resistance	O
.	O

For	O
instance	O
,	O
the	O
very	O
low	O
-	O
level	O
methicillin	O
resistance	O
of	O
the	O
Zurich	O
drug	O
clone	O
CHE482	O
,	O
was	O
shown	O
to	O
be	O
controlled	O
by	O
its	O
genetic	O
background	O
[	O
12	O
]	O
suggesting	O
that	O
it	O
either	O
contained	O
or	O
lacked	O
certain	O
fem	O
/	O
aux	O
factors	O
involved	O
in	O
controlling	O
resistance	O
expression	O
.	O

Many	O
of	O
the	O
currently	O
known	O
fem	O
/	O
aux	O
factors	O
are	O
directly	O
or	O
indirectly	O
involved	O
in	O
cell	O
wall	O
synthesis	O
and	O
turnover	O
,	O
or	O
envelope	O
biogenesis	O
,	O
however	O
there	O
still	O
remain	O
factors	O
of	O
unknown	O
function	O
.	O

Most	O
of	O
the	O
currently	O
known	O
fem	O
/	O
aux	O
factors	O
reduce	O
methicillin	O
resistance	O
levels	O
when	O
inactivated	O
.	O

A	O
few	O
genes	O
,	O
such	O
as	O
lytH	O
,	O
dlt	O
,	O
norG	O
,	O
sarV	O
and	O
cidA	O
increase	O
resistance	O
levels	O
upon	O
inactivation	O
or	O
mutation	O
.	O

All	O
of	O
these	O
genes	O
,	O
except	O
norG	O
,	O
which	O
is	O
an	O
efflux	O
pump	O
regulator	O
,	O
play	O
a	O
role	O
in	O
either	O
autolysis	O
or	O
are	O
important	O
for	O
cell	O
physiology	O
and	O
growth	O
[	O
25	O
-	O
30	O
]	O
.	O

Other	O
genes	O
increase	O
β	O
-	O
lactam	O
resistance	O
upon	O
overexpression	O
,	O
such	O
as	O
hmrA	O
coding	O
for	O
a	O
putative	O
amidohydrolase	O
,	O
hmrB	O
coding	O
for	O
a	O
putative	O
acyl	O
carrier	O
protein	O
[	O
31	O
]	O
,	O
or	O
the	O
NorG	O
-	O
controlled	O
abcA	O
multidrug	O
efflux	O
pump	O
[	O
28	O
]	O
.	O

SA1665	O
,	O
a	O
predicted	O
DNA	O
-	O
binding	O
transcriptional	O
regulator	O
,	O
was	O
found	O
to	O
bind	O
to	O
a	O
DNA	O
fragment	O
containing	O
the	O
mecA	O
promoter	O
region	O
.	O

However	O
,	O
although	O
this	O
protein	O
shifted	O
the	O
mecA	O
operator	O
/	O
5	O
'	O
coding	O
sequence	O
,	O
it	O
did	O
not	O
appear	O
to	O
directly	O
control	O
mecA	O
or	O
mecR1	O
transcription	O
or	O
PBP2a	O
production	O
.	O

Therefore	O
its	O
binding	O
to	O
the	O
mecA	O
region	O
may	O
have	O
no	O
specific	O
regulatory	O
function	O
.	O

Such	O
interactions	O
have	O
been	O
noted	O
before	O
,	O
such	O
as	O
the	O
HTH	O
protein	O
NorG	O
,	O
which	O
was	O
shown	O
to	O
bind	O
specifically	O
to	O
norA	O
,	O
norB	O
and	O
norC	O
promoters	O
,	O
but	O
only	O
transcription	O
of	O
norB	O
was	O
increased	O
when	O
NorG	O
was	O
overexpressed	O
[	O
28	O
]	O
.	O

We	O
have	O
to	O
postulate	O
therefore	O
that	O
SA1665	O
may	O
modulate	O
β	O
-	O
lactam	O
resistance	O
in	O
a	O
mecA	O
-	O
independent	O
manner	O
,	O
by	O
controlling	O
cellular	O
functions	O
affecting	O
resistance	O
levels	O
.	O

Experiments	O
to	O
determine	O
the	O
SA1665	O
regulon	O
are	O
ongoing	O
.	O

The	O
impact	O
of	O
deleting	O
SA1665	O
in	O
MRSA	O
was	O
extremely	O
strain	O
specific	O
,	O
underlining	O
the	O
importance	O
of	O
the	O
genetic	O
background	O
in	O
governing	O
the	O
final	O
methicillin	O
resistance	O
levels	O
of	O
MRSA	O
,	O
and	O
demonstrating	O
the	O
large	O
genomic	O
variability	O
between	O
different	O
strain	O
lineages	O
.	O

Conclusion	O
SA1665	O
is	O
a	O
previously	O
uncharacterised	O
DNA	O
-	O
binding	O
protein	O
that	O
has	O
a	O
negative	O
effect	O
on	O
β	O
-	O
lactam	O
resistance	O
in	O
MRSA	O
.	O

The	O
SA1665	O
protein	O
was	O
identified	O
in	O
a	O
DNA	O
-	O
binding	O
protein	O
purification	O
assay	O
,	O
in	O
which	O
it	O
bound	O
to	O
a	O
DNA	O
fragment	O
covering	O
the	O
mec	O
operator	O
region	O
.	O

However	O
,	O
while	O
nonpolar	O
deletion	O
of	O
SA1665	O
was	O
shown	O
to	O
increase	O
oxacillin	O
resistance	O
levels	O
in	O
several	O
heterogeneously	O
resistant	O
MRSA	O
,	O
its	O
deletion	O
had	O
no	O
effect	O
on	O
mecA	O
transcription	O
or	O
PBP2a	O
production	O
.	O

Therefore	O
the	O
negative	O
impact	O
of	O
SA1665	O
on	O
methicillin	O
resistance	O
is	O
most	O
likely	O
to	O
be	O
through	O
the	O
regulation	O
of	O
other	O
chromosomal	O
factors	O
or	O
cellular	O
functions	O
required	O
for	O
methicllin	O
resistance	O
.	O

Methods	O
Strains	O
and	O
growth	O
conditions	O
Strains	O
and	O
plasmids	O
used	O
in	O
this	O
study	O
are	O
listed	O
in	O
Table	O
1	O
.	O

Clinical	O
isolates	O
are	O
from	O
the	O
IMM	O
collection	O
in	O
Zurich	O
,	O
Switzerland	O
.	O

Strains	O
were	O
grown	O
at	O
37	O
°	O
C	O
in	O
Luria	O
Bertani	O
(	O
LB	O
)	O
broth	O
,	O
shaking	O
at	O
180	O
rpm	O
,	O
or	O
on	O
LB	O
agar	O
.	O

Media	O
were	O
supplemented	O
with	O
the	O
following	O
antibiotics	O
when	O
appropriate	O
:	O
25	O
or	O
50	O
μg	O
/	O
ml	O
kanamycin	O
,	O
10	O
μg	O
/	O
ml	O
chloramphenicol	O
,	O
5	O
or	O
10	O
μg	O
/	O
ml	O
tetracycline	O
,	O
100	O
μg	O
/	O
ml	O
ampicillin	O
.	O

Concentrations	O
of	O
cefoxitin	O
used	O
for	O
transcriptional	O
induction	O
were	O
either	O
sub	O
-	O
inhibitory	O
(	O
4	O
μg	O
/	O
ml	O
)	O
or	O
inhibitory	O
(	O
120	O
μg	O
/	O
ml	O
)	O
.	O

Susceptibility	O
testing	O
Oxacillin	O
resistance	O
levels	O
were	O
compared	O
by	O
swabbing	O
0.5	O
McFarland	O
cell	O
suspensions	O
across	O
agar	O
plates	O
containing	O
appropriate	O
concentration	O
gradients	O
of	O
oxacillin	O
.	O

For	O
population	O
analysis	O
profiles	O
,	O
appropriate	O
dilutions	O
of	O
an	O
overnight	O
culture	O
,	O
ranging	O
from	O
100	O
to	O
108	O
,	O
were	O
plated	O
on	O
increasing	O
concentrations	O
of	O
oxacillin	O
.	O

Plates	O
were	O
incubated	O
at	O
35	O
°	O
C	O
and	O
colony	O
forming	O
units	O
per	O
ml	O
(	O
cfu	O
/	O
ml	O
)	O
were	O
determined	O
after	O
48	O
h.	O
Binding	O
-	O
protein	O
purification	O
Crude	O
protein	O
extracts	O
were	O
isolated	O
from	O
CHE482	O
,	O
grown	O
under	O
normal	O
culture	O
conditions	O
until	O
OD600	O
nm	O
1.5	O
.	O

Cells	O
were	O
harvested	O
,	O
resuspended	O
in	O
PBS	O
(	O
pH	O
7.4	O
)	O
and	O
mechanically	O
lysed	O
using	O
Lysing	O
Matrix	O
B	O
(	O
BIO	O
101	O
Systems	O
)	O
tubes	O
and	O
a	O
FastPrep	O
FP120	O
(	O
BIO	O
101	O
Systems	O
)	O
.	O

Suspensions	O
were	O
clarified	O
by	O
centrifugation	O
and	O
supernatants	O
,	O
containing	O
soluble	O
cytoplasmic	O
proteins	O
,	O
were	O
transferred	O
to	O
Amicon	O
Ultra	O
centrifugal	O
filter	O
devices	O
(	O
Millipore	O
)	O
with	O
a	O
pore	O
cut	O
-	O
off	O
size	O
of	O
10	O
kDa	O
.	O

Proteins	O
were	O
then	O
washed	O
and	O
concentrated	O
in	O
1	O
×	O
binding	O
buffer	O
(	O
10	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH	O
7.5	O
,	O
1	O
mM	O
EDTA	O
,	O
and	O
1	O
mM	O
DTT	O
,	O
0.5	O
M	O
NaCl	O
)	O
.	O

Protein	O
concentrations	O
were	O
measured	O
by	O
Bradford	O
assay	O
(	O
BioRad	O
Laboratories	O
GmbH	O
)	O
[	O
32	O
]	O
.	O

Primer	O
pair	O
me36F	O
/	O
me36Rbiot	O
(	O
Table	O
2	O
)	O
were	O
used	O
to	O
amplify	O
a	O
biotinylated	O
mecA	O
promoter	O
/	O
operator	O
fragment	O
,	O
which	O
was	O
bound	O
to	O
streptavidin	O
coated	O
magnetic	O
beads	O
(	O
Dynabeads	O
M-280	O
Streptavidin	O
,	O
DYNAL	O
BIOTECH	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

Binding	O
reactions	O
,	O
containing	O
DNA	O
-	O
coated	O
beads	O
mixed	O
with	O
100	O
μg	O
of	O
crude	O
protein	O
extract	O
in	O
1	O
×	O
protein	O
binding	O
buffer	O
(	O
20	O
mM	O
Hepes	O
,	O
pH	O
7.6	O
,	O
1	O
mM	O
EDTA	O
,	O
10	O
mM	O
(	O
NH4	O
)	O
2SO4	O
,	O
1	O
mM	O
DTT	O
,	O
0.2	O
%	O
Tween	O
20	O
(	O
w	O
/	O
v	O
)	O
,	O
30	O
mM	O
KCl	O
)	O
,	O
0.02	O
μg	O
/	O
μl	O
poly	O
d	O
(	O
I	O
-	O
C	O
)	O
and	O
2	O
ng	O
/	O
μl	O
poly	O
L	O
-	O
lysine	O
,	O
were	O
incubated	O
at	O
room	O
temperature	O
for	O
30	O
min	O
with	O
constant	O
rotation	O
.	O

Beads	O
were	O
then	O
washed	O
and	O
binding	O
-	O
proteins	O
eluted	O
in	O
elution	O
buffer	O
(	O
1	O
×	O
protein	O
binding	O
buffer	O
containing	O
2	O
M	O
KCl	O
)	O
.	O

Eluted	O
proteins	O
were	O
dialysed	O
against	O
water	O
,	O
concentrated	O
by	O
evaporation	O
,	O
and	O
run	O
on	O
15	O
%	O
SDS	O
polyacrylamide	O
gels	O
.	O

Gels	O
were	O
silver	O
stained	O
using	O
the	O
Protein	O
Silver	O
Staining	O
kit	O
(	O
Amersham	O
Biosciences	O
AB	O
)	O
without	O
the	O
addition	O
of	O
glutaraldehyde	O
.	O

Protein	O
bands	O
were	O
excised	O
from	O
gels	O
and	O
analysed	O
by	O
mass	O
spectrometry	O
(	O
LC	O
/	O
ESI	O
/	O
MS	O
/	O
MS	O
)	O
at	O
the	O
Functional	O
Genomics	O
Centre	O
,	O
Zurich	O
.	O

The	O
SA1665	O
protein	O
sequence	O
[	O
BAB42933	O
]	O
was	O
analysed	O
by	O
Blast	O
search	O
and	O
motif	O
scan	O
.	O

Expression	O
of	O
recombinant	O
SA1665	O
protein	O
SA1665	O
was	O
amplified	O
using	O
primer	O
pair	O
me65BamHI	O
/	O
me65XhoI	O
(	O
Table	O
2	O
)	O
and	O
cloned	O
in	O
-	O
frame	O
into	O
pET28nHis6	O
(	O
unpublished	O
,	O
D.	O
Frey	O
)	O
.	O

The	O
resulting	O
plasmid	O
,	O
pME20	O
,	O
was	O
transformed	O
into	O
E.	B
coli	I
BL21	I
for	O
expression	O
of	O
recombinant	O
nHis6-SA1665	O
protein	O
.	O

To	O
maximise	O
the	O
abundance	O
of	O
soluble	O
protein	O
produced	O
,	O
cultures	O
were	O
grown	O
in	O
osmotic	O
shock	O
medium	O
at	O
37	O
°	O
C	O
(	O
1	O
g	O
/	O
l	O
NaCl	O
,	O
16	O
g	O
/	O
l	O
tryptone	O
,	O
10	O
g	O
/	O
l	O
yeast	B
,	O
1	O
M	O
sorbitol	O
,	O
10	O
mM	O
betaine	O
,	O
modified	O
from	O
[	O
33	O
]	O
)	O
to	O
an	O
OD600	O
nm	O
of	O
0.5	O
,	O
cooled	O
briefly	O
on	O
ice	O
,	O
then	O
induced	O
by	O
adding	O
100	O
μM	O
IPTG	O
and	O
growing	O
overnight	O
at	O
22	O
°	O
C	O
.	O

Crude	O
soluble	O
proteins	O
were	O
extracted	O
using	O
CelLyticB	O
2	O
×	O
cell	O
lysis	O
reagent	O
(	O
SIGMA	O
)	O
.	O

HIS	O
-	O
Select	O
Cobalt	O
Affinity	O
Gel	O
(	O
SIGMA	O
)	O
was	O
used	O
to	O
purify	O
recombinant	O
nHis6-SA1665	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

Electro	O
mobility	O
shift	O
assay	O
For	O
gel	O
shift	O
assays	O
,	O
6	O
ng	O
aliquots	O
of	O
the	O
biotinylated	O
-	O
DNA	O
fragment	O
used	O
for	O
binding	O
-	O
protein	O
purification	O
were	O
incubated	O
with	O
0–250	O
ng	O
of	O
purified	O
nHis6-SA1665	O
protein	O
in	O
1	O
×	O
binding	O
buffer	O
(	O
20	O
mM	O
Hepes	O
pH	O
7.6	O
,	O
1	O
mM	O
EDTA	O
,	O
10	O
mM	O
(	O
NH4	O
)	O
2SO4	O
,	O
1	O
mM	O
DTT	O
,	O
0.2	O
%	O
Tween	O
20	O
(	O
w	O
/	O
v	O
)	O
,	O
30	O
mM	O
KCl	O
)	O
containing	O
0.05	O
μg	O
/	O
μl	O
poly	O
d	O
(	O
I	O
-	O
C	O
)	O
(	O
Roche	O
)	O
and	O
5	O
ng	O
/	O
μl	O
poly	O
L	O
-	O
lysine	O
(	O
Roche	O
)	O
.	O

For	O
control	O
binding	O
reactions	O
,	O
130	O
×	O
unlabelled	O
mec	O
operator	O
DNA	O
(	O
amplified	O
using	O
primers	O
me36F	O
/	O
me36R	O
,	O
Table	O
2	O
)	O
was	O
used	O
as	O
a	O
specific	O
binding	O
competitor	O
and	O
6	O
ng	O
of	O
herring	O
sperm	O
DNA	O
was	O
used	O
as	O
unspecific	O
competitor	O
DNA	O
.	O

Binding	O
was	O
carried	O
out	O
at	O
22	O
°	O
C	O
for	O
30	O
min	O
.	O

Samples	O
were	O
run	O
on	O
6	O
%	O
native	O
polyacrylamide	O
gels	O
,	O
contact	O
blotted	O
onto	O
positively	O
charged	O
nylon	O
membrane	O
and	O
detected	O
with	O
the	O
Biotin	O
Chromogenic	O
Detection	O
Kit	O
(	O
Fermentas	O
)	O
.	O

Primer	O
extension	O
RNA	O
was	O
extracted	O
from	O
CHE482	O
cultures	O
that	O
were	O
grown	O
to	O
OD600	O
nm	O
0.5	O
,	O
as	O
previously	O
described	O
[	O
12	O
]	O
.	O

Primer	O
extension	O
reactions	O
were	O
performed	O
using	O
20	O
μg	O
of	O
total	O
RNA	O
and	O
3	O
pmol	O
of	O
the	O
5'-biotin	O
-	O
labelled	O
primers	O
me97	O
and	O
me98	O
(	O
Table	O
2	O
)	O
using	O
Superscript	O
II	O
reverse	O
transcriptase	O
(	O
Invitrogen	O
)	O
,	O
according	O
to	O
the	O
manufacturers	O
instructions	O
.	O

Sequencing	O
reactions	O
were	O
performed	O
using	O
the	O
Thermo	O
Sequenase	O
cycle	O
sequencing	O
kit	O
(	O
U.S.	O
Biochemicals	O
)	O
.	O

The	O
Biotin	O
Chromogenic	O
Detection	O
Kit	O
(	O
Fermentas	O
)	O
was	O
used	O
for	O
biotin	O
detection	O
.	O

Markerless	O
deletion	O
of	O
SA1665	O
In	O
frame	O
markerless	O
deletions	O
of	O
SA1665	O
,	O
from	O
the	O
chromosomes	O
of	O
CHE482	O
,	O
ZH37	O
,	O
ZH44	O
,	O
and	O
ZH73	O
,	O
were	O
constructed	O
using	O
the	O
pKOR1	O
allelic	O
replacement	O
system	O
,	O
as	O
described	O
by	O
Bae	O
et	O
al.	O
[	O
34	O
]	O
.	O

Primer	O
pairs	O
used	O
to	O
amplify	O
the	O
DNA	O
fragments	O
flanking	O
SA1665	O
,	O
for	O
recombination	O
into	O
pKOR1	O
were	O
:	O
me62attB1	O
/	O
me51BamHI	O
and	O
me62BamHI	O
/	O
me62attB2	O
(	O
Table	O
2	O
)	O
.	O

All	O
deletion	O
mutants	O
were	O
confirmed	O
by	O
nucleotide	O
sequencing	O
over	O
the	O
deleted	O
region	O
,	O
as	O
well	O
as	O
by	O
Southern	O
blot	O
analysis	O
[	O
35	O
]	O
and	O
pulsed	O
field	O
gel	O
electrophoresis	O
(	O
PFGE	O
)	O
[	O
36	O
]	O
.	O

Cloning	O
of	O
SA1665	O
for	O
complementation	O
A	O
1533-bp	O
DNA	O
fragment	O
,	O
containing	O
SA1665	O
together	O
with	O
690-bp	O
of	O
upstream	O
and	O
379-bp	O
of	O
downstream	O
DNA	O
,	O
was	O
amplified	O
from	O
strain	O
CHE482	O
using	O
primers	O
me94BamHI	O
/	O
me94Asp718	O
(	O
Table	O
2	O
)	O
and	O
cloned	O
into	O
the	O
E.	B
coli	I
/	O
S.	B
aureus	I
shuttle	O
vectors	O
pAW17	O
and	O
pBUS1	O
[	O
37	O
]	O
,	O
creating	O
the	O
complementing	O
plasmids	O
pME26	O
and	O
pME27	O
,	O
respectively	O
.	O

Plasmids	O
were	O
electroporated	O
into	O
RN4220	O
[	O
38	O
]	O
and	O
then	O
transduced	O
into	O
different	O
strains	O
using	O
phage	O
80α	O
.	O

Northern	O
blot	O
analysis	O
Strains	O
were	O
grown	O
overnight	O
in	O
LB	O
(	O
Difco	O
)	O
,	O
diluted	O
1:200	O
and	O
grown	O
for	O
another	O
3	O
h.	O
This	O
preculture	O
was	O
used	O
to	O
inoculate	O
150	O
ml	O
(	O
1:1000	O
)	O
of	O
fresh	O
prewarmed	O
LB	O
.	O

Cells	O
were	O
then	O
grown	O
to	O
OD600	O
nm	O
0.25	O
or	O
1.0	O
and	O
either	O
left	O
uninduced	O
or	O
induced	O
with	O
cefoxitin	O
4	O
or	O
120	O
μg	O
/	O
ml	O
.	O

Cultures	O
were	O
sampled	O
from	O
both	O
uninduced	O
and	O
induced	O
cells	O
at	O
time	O
point	O
0	O
'	O
before	O
induction	O
and	O
at	O
10	O
'	O
and	O
30	O
'	O
(	O
min	O
)	O
after	O
induction	O
.	O

To	O
monitor	O
SA1665	O
expression	O
over	O
growth	O
,	O
separate	O
cultures	O
were	O
also	O
sampled	O
at	O
different	O
growth	O
stages	O
corresponding	O
to	O
OD600	O
nm	O
0.25	O
,	O
0.5	O
,	O
1	O
,	O
2	O
,	O
and	O
4	O
.	O

Total	O
RNA	O
was	O
extracted	O
as	O
described	O
by	O
Cheung	O
et	O
al.	O
[	O
39	O
]	O
.	O

RNA	O
samples	O
(	O
10	O
μg	O
)	O
were	O
separated	O
in	O
a	O
1.5	O
%	O
agarose-20	O
mM	O
guanidine	O
thiocyanate	O
gel	O
in	O
1	O
×	O
TBE	O
running	O
buffer	O
[	O
40	O
]	O
,	O
then	O
transferred	O
and	O
detected	O
as	O
described	O
previously	O
[	O
41	O
]	O
.	O

Digoxigenin	O
(	O
DIG	O
)	O
labelled	O
-	O
probes	O
were	O
amplified	O
using	O
the	O
PCR	O
DIG	O
Probe	O
synthesis	O
kit	O
(	O
Roche	O
)	O
.	O

Table	O
2	O
contains	O
the	O
list	O
of	O
primer	O
pairs	O
used	O
for	O
the	O
amplification	O
of	O
SA1664	O
,	O
SA1665	O
,	O
SA1666	O
,	O
SA1667	O
,	O
mecR1	O
and	O
mecA	O
[	O
42	O
]	O
probes	O
.	O

All	O
Northern	O
's	O
were	O
repeated	O
at	O
least	O
two	O
times	O
,	O
using	O
independently	O
isolated	O
RNA	O
samples	O
.	O

Western	O
blot	O
analysis	O
Cells	O
were	O
cultured	O
,	O
as	O
described	O
for	O
Northern	O
blot	O
analysis	O
,	O
to	O
OD600	O
nm	O
1.0	O
,	O
then	O
induced	O
with	O
cefoxitin	O
4	O
μg	O
/	O
ml	O
.	O

Samples	O
were	O
collected	O
at	O
time	O
0	O
(	O
before	O
induction	O
)	O
,	O
10	O
and	O
30	O
min	O
(	O
after	O
induction	O
)	O
.	O

Cells	O
were	O
harvested	O
by	O
centrifugation	O
,	O
resuspended	O
in	O
PBS	O
pH	O
7.4	O
containing	O
DNase	O
,	O
lysostaphin	O
and	O
lysozyme	O
(	O
150	O
μg	O
/	O
ml	O
of	O
each	O
)	O
and	O
incubated	O
for	O
1	O
h	O
at	O
37	O
°	O
C	O
.	O

Suspensions	O
were	O
then	O
sonicated	O
and	O
protein	O
aliquots	O
(	O
15	O
μg	O
)	O
were	O
separated	O
on	O
7.5	O
%	O
SDS	O
-	O
polyacrylamide	O
gels	O
,	O
blotted	O
onto	O
nitrocellulose	O
membranes	O
(	O
Hybond	O
)	O
and	O
stained	O
with	O
Ponceau	O
to	O
confirm	O
equal	O
protein	O
loading	O
.	O

PBP2a	O
detection	O
was	O
performed	O
using	O
monoclonal	O
PBP2a	O
antibody	O
(	O
1:20000	O
)	O
from	O
the	O
MRSA	O
-	O
screen	O
kit	O
(	O
Denka	O
Seiken	O
)	O
.	O

Authors	O
'	O
contributions	O
ME	O
carried	O
out	O
molecular	O
genetic	O
and	O
microbiological	O
studies	O
and	O
drafted	O
the	O
manuscript	O
.	O

BB	O
participated	O
in	O
the	O
design	O
of	O
the	O
study	O
and	O
helped	O
to	O
draft	O
the	O
manuscript	O
.	O

NM	O
participated	O
in	O
the	O
design	O
and	O
coordination	O
of	O
the	O
study	O
,	O
carried	O
out	O
molecular	O
biological	O
studies	O
and	O
helped	O
to	O
draft	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

p8	O
inhibits	O
the	O
growth	O
of	O
human	B
pancreatic	O
cancer	O
cells	O
and	O
its	O
expression	O
is	O
induced	O
through	O
pathways	O
involved	O
in	O
growth	O
inhibition	O
and	O
repressed	O
by	O
factors	O
promoting	O
cell	O
growth	O
Abstract	O
Background	O
p8	O
is	O
a	O
stress	O
-	O
induced	O
protein	O
with	O
multiple	O
functions	O
and	O
biochemically	O
related	O
to	O
the	O
architectural	O
factor	O
HMG	O
-	O
I	O
/	O
Y.	O
We	O
analyzed	O
the	O
expression	O
and	O
function	O
of	O
p8	O
in	O
pancreatic	O
cancer	O
-	O
derived	O
cells	O
.	O

Methods	O
Expression	O
of	O
p8	O
was	O
silenced	O
in	O
the	O
human	B
pancreatic	O
cancer	O
cell	O
lines	O
Panc-1	O
and	O
BxPc-3	O
by	O
infection	O
with	O
a	O
retrovirus	O
expressing	O
p8	O
RNA	O
in	O
the	O
antisense	O
orientation	O
.	O

Cell	O
growth	O
was	O
measured	O
in	O
control	O
and	O
p8-silenced	O
cells	O
.	O

Influence	O
on	O
p8	O
expression	O
of	O
the	O
induction	O
of	O
intracellular	O
pathways	O
promoting	O
cellular	O
growth	O
or	O
growth	O
arrest	O
was	O
monitored	O
.	O

Results	O
p8-silenced	O
cells	O
grew	O
more	O
rapidly	O
than	O
control	O
cells	O
transfected	O
with	O
the	O
empty	O
retrovirus	O
.	O

Activation	O
of	O
the	O
Ras→Raf→MEK→ERK	O
and	O
JNK	O
intracellular	O
pathways	O
down	O
-	O
regulated	O
p8	O
expression	O
.	O

In	O
addition	O
,	O
the	O
MEK1	O
/	O
2	O
inhibitor	O
U0126	O
and	O
the	O
JNK	O
inhibitor	O
SP600125	O
up	O
-	O
regulates	O
expression	O
of	O
p8	O
.	O

Conversely	O
,	O
p38	O
or	O
TGFβ-1	O
induced	O
p8	O
expression	O
whereas	O
the	O
specific	O
p38	O
inhibitor	O
SB203580	O
down	O
-	O
regulated	O
p8	O
expression	O
.	O

Finally	O
,	O
TGFβ-1	O
induction	O
was	O
in	O
part	O
mediated	O
through	O
p38	O
.	O

Conclusions	O
p8	O
inhibits	O
the	O
growth	O
of	O
human	B
pancreatic	O
cancer	O
cells	O
.	O

p8	O
expression	O
is	O
induced	O
through	O
pathways	O
involved	O
in	O
growth	O
inhibition	O
and	O
repressed	O
by	O
factors	O
that	O
promote	O
cell	O
growth	O
.	O

These	O
results	O
suggest	O
that	O
p8	O
belongs	O
to	O
a	O
pathway	O
regulating	O
the	O
growth	O
of	O
pancreatic	O
cancer	O
cells	O
.	O

Background	O
While	O
studying	O
the	O
molecular	O
response	O
of	O
the	O
injured	O
pancreas	O
,	O
we	O
identified	O
a	O
new	O
gene	O
,	O
called	O
p8	O
,	O
whose	O
expression	O
is	O
strongly	O
induced	O
during	O
the	O
acute	O
phase	O
of	O
pancreatitis	O
[	O
1	O
]	O
.	O

Further	O
experiments	O
have	O
shown	O
that	O
p8	O
mRNA	O
is	O
activated	O
in	O
almost	O
all	O
cells	O
in	O
response	O
to	O
several	O
stresses	O
[	O
2	O
]	O
,	O
including	O
minimal	O
stresses	O
such	O
as	O
after	O
routine	O
change	O
of	O
the	O
culture	O
medium	O
in	O
the	O
absence	O
of	O
any	O
added	O
substance	O
[	O
3	O
]	O
,	O
indicating	O
that	O
p8	O
is	O
a	O
ubiquitous	O
protein	O
induced	O
by	O
cellular	O
stress	O
.	O

The	O
p8	O
gene	O
was	O
cloned	O
in	O
human	B
,	O
rat	B
,	O
mouse	B
,	O
and	O
Xenopus	B
laevis	I
[	O
1,4	O
-	O
6	O
]	O
,	O
conceptually	O
translated	O
from	O
the	O
Drosophila	B
melanogaster	I
genome	O
or	O
deduced	O
from	O
EST	O
libraries	O
(	O
Bos	B
taurus	I
,	O
Xenopus	B
tropicalis	I
,	O
Zebrafish	B
,	O
Orzzias	B
latipes	I
,	O
Bombyx	B
mori	I
and	O
Paralichthys	B
olivaceous	I
)	O
.	O

The	O
overall	O
degree	O
of	O
homology	O
with	O
human	B
p8	O
ranged	O
from	O
81	O
to	O
40	O
%	O
.	O

Secondary	O
structure	O
prediction	O
methods	O
indicated	O
that	O
within	O
the	O
homologous	O
region	O
of	O
the	O
eleven	O
proteins	O
,	O
there	O
is	O
a	O
basic	O
Helix	O
-	O
Loop	O
-	O
Helix	O
secondary	O
structure	O
motif	O
,	O
characteristic	O
of	O
some	O
classes	O
of	O
transcription	O
factors	O
[	O
1	O
]	O
.	O

Even	O
though	O
a	O
small	O
protein	O
such	O
as	O
p8	O
would	O
not	O
need	O
a	O
nuclear	O
localization	O
signal	O
(	O
NLS	O
)	O
to	O
be	O
transported	O
to	O
the	O
nucleus	O
,	O
a	O
clear	O
NLS	O
can	O
be	O
predicted	O
for	O
the	O
eleven	O
proteins	O
comprising	O
a	O
bipartite	O
domain	O
of	O
positively	O
charged	O
aminoacids	O
.	O

In	O
addition	O
,	O
a	O
nuclear	O
/	O
cytoplasmic	O
location	O
has	O
been	O
demonstrated	O
for	O
human	B
p8	O
upon	O
overexpression	O
of	O
the	O
recombinant	O
protein	O
and	O
immunohistochemistry	O
[	O
4	O
]	O
,	O
and	O
for	O
recombinant	O
Xenopus	B
laevis	I
p8	O
fused	O
to	O
green	O
fluorescent	O
protein	O
[	O
6	O
]	O
.	O

Homology	O
searching	O
in	O
databases	O
did	O
not	O
reveal	O
significant	O
similarity	O
of	O
p8	O
with	O
other	O
proteins	O
of	O
known	O
function	O
.	O

However	O
,	O
biochemical	O
properties	O
of	O
the	O
mammalian	O
p8	O
proteins	O
are	O
shared	O
by	O
some	O
high	O
mobility	O
group	O
proteins	O
(	O
HMG	O
)	O
[	O
7	O
]	O
,	O
particularly	O
by	O
the	O
HMG	O
-	O
I	O
/	O
Y	O
family	O
.	O

The	O
overall	O
identity	O
of	O
human	B
p8	O
with	O
human	B
HMG	O
-	O
I	O
/	O
Y	O
is	O
only	O
about	O
35	O
%	O
,	O
but	O
the	O
molecular	O
mass	O
,	O
isoelectric	O
point	O
,	O
hydrophilicity	O
plot	O
,	O
the	O
resistance	O
to	O
denaturation	O
after	O
heating	O
at	O
100	O
°	O
C	O
and	O
the	O
charge	O
separation	O
are	O
very	O
similar	O
[	O
8	O
]	O
.	O

The	O
p8	O
protein	O
seems	O
to	O
bind	O
DNA	O
weakly	O
,	O
as	O
shown	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
without	O
preference	O
for	O
DNA	O
sequences	O
.	O

Finally	O
,	O
human	B
p8	O
has	O
also	O
been	O
shown	O
to	O
be	O
a	O
substrate	O
for	O
protein	O
kinase	O
A	O
in	O
vitro	O
and	O
phosphorylated	O
p8	O
has	O
a	O
higher	O
content	O
of	O
secondary	O
structure	O
and	O
binding	O
to	O
DNA	O
is	O
highly	O
increased	O
[	O
8	O
]	O
.	O

An	O
architectural	O
role	O
in	O
transcription	O
has	O
been	O
proposed	O
for	O
this	O
protein	O
,	O
in	O
analogy	O
with	O
the	O
HMG	O
-	O
I	O
/	O
Y	O
proteins	O
,	O
and	O
a	O
recent	O
work	O
seems	O
to	O
confirm	O
this	O
hypothesis	O
[	O
9	O
]	O
.	O

Functions	O
of	O
p8	O
appear	O
to	O
be	O
multiple	O
and	O
complex	O
.	O

For	O
example	O
,	O
p8	O
mRNA	O
expression	O
was	O
strongly	O
induced	O
in	O
3T3	O
cells	O
upon	O
TGFβ-1	O
treatment	O
which	O
in	O
turn	O
enhances	O
the	O
Smad	O
-	O
transactivating	O
function	O
responsible	O
for	O
TGFβ-1	O
activity	O
[	O
10	O
]	O
.	O

We	O
also	O
found	O
that	O
p8	O
is	O
involved	O
in	O
cell	O
cycle	O
regulation	O
since	O
p8-deficient	O
embryonic	O
fibroblasts	O
grew	O
more	O
rapidly	O
and	O
incorporated	O
more	O
[	O
3H	O
]	O
thymidine	O
and	O
BrdU	O
than	O
p8-expressing	O
cells	O
[	O
11	O
]	O
.	O

Moreover	O
,	O
expression	O
of	O
p8	O
in	O
breast	O
cancer	O
-	O
derived	O
cells	O
seems	O
to	O
mediate	O
the	O
inhibition	O
of	O
cell	O
growth	O
induced	O
by	O
1,25-Dihydroxyvitamin	O
D3	O
[	O
12	O
]	O
.	O

On	O
the	O
contrary	O
,	O
we	O
also	O
reported	O
that	O
p8	O
may	O
promote	O
cell	O
growth	O
when	O
overexpressed	O
in	O
Cos-7	O
,	O
AR42J	O
and	O
HeLa	O
cells	O
[	O
1,4	O
]	O
.	O

In	O
addition	O
,	O
p8	O
seems	O
to	O
be	O
involved	O
in	O
other	O
intracellular	O
functions	O
such	O
as	O
apoptosis	O
since	O
p8-expressing	O
fibroblasts	O
are	O
more	O
sensitive	O
than	O
p8-deficient	O
fibroblasts	O
to	O
the	O
apoptosis	O
induced	O
by	O
DNA	O
damage	O
.	O

Also	O
,	O
p8	O
is	O
required	O
for	O
endothelin	O
-	O
induced	O
mesangial	O
cell	O
hypertrophy	O
in	O
diabetic	O
kidney	O
,	O
in	O
a	O
mechanism	O
involving	O
ERK	O
,	O
JNK	O
and	O
PI3	O
kinase	O
[	O
13	O
]	O
.	O

p8	O
seems	O
to	O
play	O
a	O
functional	O
role	O
in	O
the	O
initiation	O
of	O
LHβ	O
gene	O
expression	O
during	O
embryonic	O
cell	O
differentiation	O
[	O
14	O
]	O
.	O

Moreover	O
,	O
the	O
Drosophila	B
melanogaster	I
p8	O
homologue	O
is	O
involved	O
in	O
response	O
to	O
starvation	O
and	O
might	O
be	O
activated	O
to	O
stop	O
cell	O
growth	O
in	O
case	O
of	O
nutrient	O
deprivation	O
[	O
15	O
]	O
.	O

Finally	O
,	O
a	O
particularly	O
attractive	O
role	O
in	O
tumour	O
progression	O
was	O
recently	O
proposed	O
for	O
p8	O
[	O
16	O
]	O
.	O

Fibroblasts	O
obtained	O
from	O
p8-expressing	O
or	O
p8-deficient	O
animals	O
were	O
transformed	O
with	O
a	O
retroviral	O
vector	O
expressing	O
both	O
the	O
rasV12	O
mutated	O
protein	O
and	O
the	O
E1A	O
adenoviral	O
oncogene	O
.	O

In	O
soft	O
-	O
agar	O
assays	O
,	O
transformed	O
p8-expressing	O
cells	O
formed	O
colonies	O
at	O
high	O
frequency	O
,	O
as	O
expected	O
,	O
but	O
p8-deficient	O
transformed	O
fibroblasts	O
were	O
unable	O
to	O
form	O
colonies	O
.	O

Similarly	O
,	O
transformed	O
p8-expressing	O
cells	O
produced	O
tumours	O
in	O
all	O
athymic	O
nude	B
mice	I
when	O
injected	O
subcutaneously	O
or	O
intraperitoneally	O
,	O
whereas	O
transformed	O
p8-deficient	O
fibroblasts	O
did	O
not	O
.	O

On	O
the	O
other	O
hand	O
,	O
studies	O
by	O
another	O
laboratory	O
revealed	O
that	O
expression	O
of	O
the	O
Com1	O
protein	O
[	O
17	O
]	O
,	O
which	O
is	O
identical	O
to	O
human	B
p8	O
,	O
mediates	O
the	O
growth	O
of	O
tumour	O
cells	O
after	O
metastatic	O
establishment	O
in	O
a	O
secondary	O
organ	O
,	O
indicating	O
that	O
activated	O
expression	O
of	O
Com1	O
/	O
p8	O
in	O
metastatic	O
cells	O
is	O
required	O
for	O
tumour	O
progression	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
p8	O
is	O
involved	O
in	O
the	O
cellular	O
pathway	O
(	O
s	O
)	O
required	O
for	O
tumour	O
progression	O
and	O
metastasis	O
.	O

Our	O
aim	O
is	O
to	O
check	O
the	O
relevance	O
of	O
p8	O
to	O
cancer	O
progression	O
in	O
human	B
.	O

As	O
a	O
first	O
step	O
,	O
we	O
investigated	O
in	O
the	O
present	O
study	O
the	O
function	O
of	O
p8	O
in	O
two	O
cell	O
lines	O
derived	O
from	O
human	B
pancreatic	O
cancer	O
.	O

We	O
observed	O
that	O
inhibition	O
of	O
p8	O
expression	O
increased	O
the	O
cells	O
growth	O
rate	O
.	O

In	O
addition	O
,	O
activations	O
of	O
the	O
Ras→Raf→MEK→ERK	O
and	O
JNK	O
intracellular	O
pathways	O
,	O
which	O
promote	O
the	O
growth	O
of	O
pancreatic	O
cells	O
,	O
down	O
-	O
regulated	O
p8	O
expression	O
,	O
whereas	O
activation	O
of	O
p38	O
or	O
TGFβ-1	O
,	O
which	O
inhibit	O
cell	O
growth	O
,	O
induced	O
its	O
expression	O
.	O

It	O
was	O
concluded	O
that	O
i	O
/	O
p8	O
inhibits	O
the	O
growth	O
of	O
human	B
pancreatic	O
cancer	O
cell	O
lines	O
,	O
ii	O
/	O
p8	O
expression	O
is	O
induced	O
through	O
pathways	O
involved	O
in	O
growth	O
inhibition	O
and	O
,	O
conversely	O
,	O
repressed	O
by	O
factors	O
that	O
promote	O
cell	O
growth	O
.	O

Results	O
p8	O
is	O
silenced	O
in	O
pancreatic	O
cancer	O
cells	O
by	O
infection	O
with	O
a	O
retrovirus	O
expressing	O
p8	O
RNA	O
in	O
the	O
antisense	O
orientation	O
Panc-1	O
and	O
BxPc-3	O
pancreatic	O
cells	O
were	O
chosen	O
for	O
this	O
study	O
because	O
,	O
on	O
the	O
one	O
hand	O
,	O
both	O
cells	O
express	O
higher	O
level	O
of	O
p8	O
(	O
Figure	O
1	O
)	O
and	O
,	O
on	O
the	O
other	O
hand	O
,	O
because	O
Panc-1	O
is	O
wild	O
-	O
type	O
for	O
Smad4	O
/	O
DPC4	O
and	O
mutated	O
for	O
K	O
-	O
ras	O
,	O
while	O
BxPc-3	O
is	O
Smad4	O
/	O
DPC4	O
mutated	O
and	O
K	O
-	O
ras	O
wild	O
-	O
type	O
[	O
18,19	O
]	O
,	O
therefore	O
representing	O
different	O
mechanisms	O
of	O
transformation	O
and	O
different	O
genetic	O
backgrounds	O
.	O

K	O
-	O
ras	O
and	O
Smad4	O
/	O
DPC4	O
mutations	O
are	O
the	O
major	O
mechanisms	O
involved	O
in	O
pancreatic	O
cancer	O
development	O
.	O

We	O
inhibited	O
p8	O
expression	O
in	O
both	O
Panc-1	O
and	O
BxPc-3	O
pancreatic	O
cells	O
by	O
infecting	O
cells	O
with	O
a	O
retrovirus	O
expressing	O
the	O
p8	O
asRNA	O
(	O
antisense	O
RNA	O
)	O
and	O
carrying	O
the	O
puromycin	O
resistance	O
.	O

The	O
antibiotic	O
-	O
selected	O
cells	O
were	O
analyzed	O
by	O
Western	O
blotting	O
to	O
evaluate	O
the	O
intracellular	O
amounts	O
of	O
p8	O
protein	O
.	O

As	O
shown	O
in	O
Figure	O
2	O
,	O
the	O
p8	O
protein	O
was	O
clearly	O
visible	O
in	O
both	O
Panc-1	O
and	O
BxPc-3	O
pancreatic	O
cells	O
infected	O
with	O
the	O
empty	O
retrovirus	O
but	O
almost	O
undetectable	O
in	O
cells	O
infected	O
with	O
the	O
retrovirus	O
encoding	O
the	O
p8	O
asRNA	O
showed	O
,	O
indicating	O
that	O
our	O
anti	O
-	O
sense	O
strategy	O
is	O
efficient	O
to	O
silence	O
p8	O
gene	O
expression	O
in	O
pancreatic	O
cancer	O
cells	O
.	O

Preliminary	O
studies	O
had	O
been	O
conducted	O
to	O
select	O
the	O
best	O
strategy	O
to	O
inhibit	O
p8	O
expression	O
.	O

We	O
compared	O
the	O
efficacy	O
of	O
the	O
stable	O
transfection	O
of	O
a	O
siRNA	O
,	O
using	O
a	O
retroviral	O
expression	O
vector	O
to	O
the	O
asRNA	O
strategy	O
described	O
above	O
.	O

In	O
our	O
hands	O
,	O
the	O
antisense	O
strategy	O
worked	O
best	O
,	O
as	O
judged	O
from	O
Western	O
blot	O
assessment	O
of	O
p8	O
protein	O
expression	O
(	O
data	O
not	O
shown	O
)	O
.	O

p8-silenced	O
pancreatic	O
cells	O
grow	O
more	O
rapidly	O
We	O
compared	O
in	O
the	O
two	O
cell	O
lines	O
the	O
influence	O
on	O
growth	O
parameters	O
of	O
blocking	O
p8	O
expression	O
with	O
the	O
p8	O
asRNA	O
.	O

Figure	O
3	O
shows	O
that	O
both	O
Panc-1	O
and	O
BxPc-3	O
cells	O
in	O
which	O
p8	O
has	O
been	O
silenced	O
grew	O
more	O
rapidly	O
than	O
cells	O
infected	O
with	O
the	O
empty	O
vector	O
suggesting	O
that	O
inhibition	O
by	O
p8	O
of	O
pancreatic	O
cancer	O
cell	O
growth	O
is	O
independent	O
from	O
the	O
mechanism	O
of	O
transformation	O
and	O
genetic	O
background	O
.	O

Serum	O
-	O
stimulated	O
cellular	O
growth	O
down	O
-	O
regulates	O
p8	O
expression	O
Fetal	O
calf	O
serum	O
,	O
which	O
contains	O
a	O
complex	O
mix	O
of	O
growth	O
factors	O
,	O
can	O
be	O
used	O
as	O
inductor	O
of	O
cell	O
growth	O
.	O

As	O
shown	O
in	O
Figure	O
4	O
expression	O
of	O
p8	O
mRNA	O
was	O
down	O
-	O
regulated	O
in	O
both	O
Panc-1	O
and	O
BxPc-3	O
when	O
the	O
cells	O
were	O
shifted	O
from	O
culture	O
media	O
containing	O
0.1	O
%	O
fetal	O
calf	O
serum	O
to	O
media	O
containing	O
10	O
%	O
FCS	O
.	O

p8	O
protein	O
showed	O
a	O
similar	O
behavior	O
.	O

These	O
results	O
show	O
that	O
p8	O
expression	O
is	O
down	O
-	O
regulated	O
in	O
growing	O
pancreatic	O
cells	O
.	O

The	O
Ras→Raf→MEK→ERK	O
pathway	O
down	O
-	O
regulates	O
p8	O
expression	O
in	O
pancreatic	O
cancer	O
cells	O
Most	O
human	B
pancreatic	O
cancers	O
harbor	O
mutations	O
in	O
the	O
K	O
-	O
ras	O
oncogene	O
,	O
which	O
happens	O
relatively	O
early	O
in	O
pancreatic	O
tumorigenesis	O
[	O
20	O
]	O
.	O

The	O
oncogenic	O
mutation	O
of	O
the	O
K	O
-	O
ras	O
gene	O
stabilizes	O
the	O
Ras	O
protein	O
in	O
a	O
GTP	O
-	O
bound	O
form	O
,	O
which	O
is	O
constitutively	O
active	O
and	O
make	O
the	O
cells	O
grow	O
more	O
rapidly	O
.	O

Contrary	O
to	O
the	O
activated	O
Ras	O
protein	O
,	O
p8	O
inhibits	O
cell	O
growth	O
(	O
Figure	O
3	O
)	O
.	O

We	O
looked	O
whether	O
the	O
Ras→Raf→MEK→ERK	O
pathway	O
was	O
also	O
involved	O
in	O
the	O
regulation	O
of	O
p8	O
expression	O
,	O
and	O
which	O
step	O
(	O
s	O
)	O
were	O
critical	O
.	O

Figure	O
5	O
shown	O
that	O
expression	O
of	O
a	O
mutated	O
form	O
of	O
the	O
Ras	O
protein	O
(	O
rasV12	O
)	O
in	O
BxPc-3	O
cells	O
,	O
which	O
are	O
wild	O
-	O
type	O
for	O
ras	O
,	O
resulted	O
in	O
decreased	O
p8	O
mRNA	O
concentration	O
and	O
protein	O
level	O
suggesting	O
that	O
the	O
activated	O
ras	O
inhibits	O
p8	O
expression	O
.	O

Figure	O
6	O
shows	O
that	O
overexpression	O
of	O
Raf	O
,	O
but	O
not	O
of	O
Raf301	O
(	O
a	O
negative	O
mutant	O
of	O
Raf	O
)	O
,	O
and	O
of	O
ERK	O
also	O
inhibited	O
the	O
expression	O
of	O
the	O
p8-CAT	O
construct	O
in	O
Panc-1	O
as	O
well	O
as	O
in	O
BxPc-3	O
.	O

Finally	O
,	O
the	O
MEK1	O
/	O
2	O
specific	O
inhibitor	O
U0126	O
[	O
21	O
]	O
activated	O
p8	O
mRNA	O
expression	O
in	O
pancreatic	O
cells	O
whether	O
they	O
carry	O
mutated	O
ras	O
(	O
Panc-1	O
)	O
or	O
wild	O
-	O
type	O
(	O
BxPc-3	O
)	O
.	O

Similar	O
results	O
were	O
observed	O
when	O
expression	O
of	O
the	O
p8	O
protein	O
was	O
monitored	O
by	O
Western	O
blotting	O
(	O
Figure	O
7	O
)	O
.	O

Activation	O
of	O
the	O
JNK	O
pathway	O
down	O
-	O
regulates	O
p8	O
expression	O
in	O
pancreatic	O
cancer	O
cells	O
c	O
-	O
Jun	O
NH2-terminal	O
kinase	O
(	O
JNK	O
)	O
is	O
another	O
major	O
MAPK	O
pathway	O
which	O
converts	O
extracellular	O
signals	O
into	O
expression	O
of	O
specific	O
target	O
genes	O
through	O
phosphorylation	O
and	O
activation	O
of	O
transcription	O
factors	O
.	O

JNK	O
activation	O
has	O
been	O
implicated	O
in	O
various	O
,	O
often	O
opposite	O
cellular	O
responses	O
,	O
such	O
as	O
cell	O
proliferation	O
,	O
transformation	O
and	O
apoptosis	O
.	O

As	O
shown	O
in	O
Figure	O
8	O
,	O
overexpression	O
of	O
JNK	O
down	O
-	O
regulates	O
the	O
gene	O
reporter	O
activity	O
of	O
the	O
p8-CAT	O
construct	O
in	O
Panc-1	O
cells	O
.	O

Similar	O
results	O
were	O
found	O
in	O
BxPc-3	O
cells	O
.	O

Treatment	O
of	O
these	O
cells	O
with	O
the	O
JNK	O
specific	O
inhibitor	O
SP600125	O
[	O
22	O
]	O
up	O
-	O
regulates	O
expression	O
of	O
the	O
p8	O
mRNA	O
and	O
p8	O
protein	O
(	O
Figure	O
9	O
)	O
.	O

These	O
results	O
show	O
that	O
the	O
JNK	O
pathway	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
p8	O
expression	O
.	O

The	O
p38	O
pathway	O
up	O
-	O
regulates	O
p8	O
expression	O
in	O
pancreatic	O
cancer	O
cells	O
The	O
p38	O
signal	O
transduction	O
pathway	O
also	O
plays	O
an	O
essential	O
role	O
in	O
regulating	O
several	O
cell	O
functions	O
including	O
growth	O
,	O
response	O
to	O
inflammation	O
,	O
differentiation	O
and	O
apoptosis	O
.	O

In	O
fact	O
,	O
in	O
pancreatic	O
cancer	O
cells	O
,	O
p38	O
is	O
a	O
strong	O
inhibitor	O
of	O
proliferation	O
[	O
23	O
]	O
contrary	O
to	O
the	O
Ras→Raf→MEK→ERK	O
and	O
JNK	O
pathways	O
.	O

We	O
therefore	O
analyzed	O
the	O
putative	O
role	O
of	O
the	O
p38	O
pathway	O
in	O
regulating	O
p8	O
expression	O
in	O
pancreatic	O
cancer	O
cells	O
.	O

Figure	O
10	O
shows	O
that	O
over	O
-	O
expression	O
of	O
the	O
plasmid	O
encoding	O
p38	O
significantly	O
increases	O
p8-CAT	O
activity	O
in	O
Panc-1	O
as	O
well	O
as	O
in	O
BxPc-3	O
cells	O
.	O

Then	O
,	O
cells	O
were	O
treated	O
with	O
SB203580	O
,	O
a	O
specific	O
inhibitor	O
of	O
p38	O
[	O
24	O
]	O
,	O
and	O
p8	O
expression	O
was	O
measured	O
.	O

p8	O
mRNA	O
as	O
well	O
as	O
the	O
encoded	O
protein	O
were	O
down	O
-	O
regulated	O
after	O
inhibition	O
of	O
the	O
p38	O
activity	O
(	O
Figure	O
11	O
)	O
.	O

These	O
results	O
indicate	O
that	O
the	O
p38	O
pathway	O
is	O
a	O
positive	O
regulator	O
of	O
p8	O
expression	O
in	O
pancreatic	O
cancer	O
cells	O
.	O

TGFβ-1	O
up	O
-	O
regulates	O
p8	O
expression	O
in	O
pancreatic	O
cancer	O
cells	O
The	O
most	O
prominent	O
biological	O
activity	O
of	O
TGFβ-1	O
is	O
its	O
potent	O
inhibition	O
of	O
cell	O
growth	O
in	O
a	O
wide	O
variety	O
of	O
cell	O
types	O
including	O
pancreatic	O
cells	O
.	O

TGFβ-1	O
signals	O
are	O
sent	O
through	O
two	O
types	O
of	O
transmembrane	O
serine	O
/	O
threonine	O
kinase	O
receptors	O
.	O

In	O
fact	O
,	O
TGFβ-1	O
binds	O
and	O
brings	O
together	O
the	O
type	O
I	O
and	O
type	O
II	O
receptors	O
.	O

In	O
the	O
resulting	O
complex	O
,	O
the	O
constitutively	O
active	O
TGFβ-1	O
type	O
II	O
receptor	O
phosphorylates	O
the	O
type	O
I	O
receptor	O
,	O
which	O
then	O
plays	O
a	O
major	O
role	O
in	O
transducing	O
the	O
signal	O
to	O
downstream	O
components	O
to	O
affect	O
gene	O
expression	O
through	O
phosphorylation	O
of	O
SMAD	O
proteins	O
.	O

Phosphorylated	O
receptor	O
-	O
regulated	O
SMADs	O
then	O
form	O
heteromeric	O
complexes	O
with	O
the	O
common	O
partner	O
SMAD4	O
.	O

These	O
heteromeric	O
complexes	O
then	O
move	O
to	O
the	O
nucleus	O
,	O
where	O
SMAD4	O
will	O
bind	O
DNA	O
and	O
contribute	O
to	O
transcriptional	O
activation	O
.	O

In	O
general	O
,	O
pancreatic	O
cancer	O
cells	O
present	O
with	O
defects	O
in	O
TGFβ-1	O
signaling	O
and	O
are	O
resistant	O
to	O
TGFβ-1-mediated	O
growth	O
suppression	O
.	O

Since	O
TGFβ-1	O
and	O
p8	O
are	O
inhibitors	O
of	O
pancreatic	O
cell	O
growth	O
we	O
analyzed	O
whether	O
p8	O
could	O
mediate	O
,	O
at	O
least	O
in	O
part	O
,	O
the	O
effect	O
of	O
TGFβ-1	O
.	O

First	O
,	O
we	O
found	O
that	O
treatment	O
of	O
Panc-1	O
cells	O
with	O
TGFβ-1	O
increased	O
p8	O
mRNA	O
levels	O
and	O
p8	O
protein	O
as	O
judged	O
by	O
Western	O
blot	O
(	O
Figure	O
12	O
)	O
.	O

Then	O
,	O
to	O
confirm	O
that	O
overexpression	O
is	O
regulated	O
at	O
the	O
transcriptional	O
level	O
,	O
we	O
analyzed	O
the	O
effect	O
of	O
some	O
constructs	O
expressing	O
constitutively	O
activated	O
type	O
I	O
TGFβ	O
receptor	O
,	O
dominant	O
negative	O
type	O
II	O
TGFβ	O
receptor	O
,	O
a	O
dominant	O
negative	O
of	O
Smad4	O
and	O
the	O
wild	O
-	O
type	O
Smad4	O
on	O
the	O
p8-CAT	O
activity	O
.	O

As	O
expected	O
,	O
the	O
constitutively	O
activated	O
type	O
I	O
TGFβ	O
receptor	O
but	O
not	O
the	O
dominant	O
negative	O
type	O
II	O
TGFβ	O
receptor	O
increased	O
CAT	O
activity	O
.	O

Also	O
,	O
expression	O
of	O
the	O
Smad4	O
,	O
contrary	O
to	O
that	O
of	O
the	O
negative	O
mutant	O
,	O
induced	O
p8	O
transcription	O
(	O
Figure	O
13	O
)	O
.	O

Together	O
,	O
these	O
results	O
indicate	O
that	O
p8	O
is	O
positively	O
regulated	O
by	O
TGFβ-1	O
.	O

Beside	O
the	O
Smad	O
proteins	O
,	O
TGFβ-1	O
also	O
activates	O
the	O
p38	O
MAPK	O
pathway	O
in	O
pancreas	O
-	O
derived	O
cells	O
,	O
which	O
may	O
play	O
an	O
important	O
role	O
in	O
TGFβ-1	O
induced	O
genes	O
[	O
25	O
]	O
.	O

Therefore	O
,	O
we	O
analyzed	O
the	O
p38-dependent	O
effect	O
of	O
TGFβ-1	O
on	O
p8	O
transcription	O
.	O

As	O
shown	O
in	O
Figure	O
13	O
,	O
inhibition	O
of	O
p38	O
activity	O
with	O
the	O
SB203580	O
specific	O
inhibitor	O
decreased	O
about	O
40	O
%	O
the	O
activity	O
of	O
TGFβ-1	O
on	O
the	O
p8	O
promoter	O
indicating	O
that	O
the	O
effect	O
of	O
TGFβ-1	O
on	O
p8	O
promoter	O
is	O
mediated	O
by	O
both	O
p38-dependent	O
and	O
p38-independent	O
pathways	O
.	O

Discussion	O
Pancreatic	O
adenocarcinoma	O
is	O
the	O
fourth	O
leading	O
cause	O
of	O
death	O
from	O
malignant	O
diseases	O
[	O
26	O
]	O
.	O

The	O
aggressive	O
nature	O
of	O
the	O
neoplasia	O
,	O
the	O
lack	O
of	O
early	O
detection	O
,	O
and	O
the	O
limited	O
response	O
to	O
treatments	O
such	O
as	O
chemotherapy	O
and	O
radiotherapy	O
contribute	O
to	O
the	O
high	O
mortality	O
rate	O
of	O
the	O
disease	O
.	O

Therefore	O
,	O
a	O
better	O
understanding	O
of	O
the	O
molecular	O
mechanism	O
leading	O
to	O
pancreatic	O
cancer	O
remains	O
a	O
major	O
goal	O
because	O
it	O
may	O
help	O
proposing	O
strategies	O
for	O
earlier	O
diagnosis	O
and	O
better	O
treatment	O
.	O

The	O
most	O
commonly	O
altered	O
genes	O
in	O
pancreatic	O
adenocarcinoma	O
are	O
K	O
-	O
ras	O
(	O
75	O
to	O
100	O
%	O
)	O
,	O
p16INK4a	O
(	O
95	O
%	O
)	O
,	O
p53	O
(	O
50	O
to	O
75	O
%	O
)	O
and	O
DPC4	O
(	O
50	O
%	O
)	O
[	O
27	O
-	O
31	O
]	O
.	O

Whereas	O
K	O
-	O
ras	O
is	O
a	O
proto	O
-	O
oncogene	O
all	O
the	O
others	O
are	O
tumour	O
suppressor	O
genes	O
.	O

Additional	O
genes	O
have	O
been	O
found	O
altered	O
at	O
lower	O
frequency	O
.	O

Panc-1	O
and	O
BxPc-3	O
pancreatic	O
cells	O
were	O
chosen	O
for	O
this	O
study	O
because	O
they	O
both	O
express	O
high	O
levels	O
of	O
p8	O
(	O
Figure	O
1	O
)	O
and	O
because	O
they	O
present	O
with	O
different	O
mechanisms	O
of	O
transformation	O
and	O
genetic	O
backgrounds	O
,	O
Panc-1	O
being	O
wild	O
-	O
type	O
for	O
Smad4	O
/	O
DPC4	O
but	O
mutated	O
for	O
K	O
-	O
ras	O
and	O
BxPc-3	O
mutated	O
for	O
Smad4	O
/	O
DPC4	O
and	O
wild	O
-	O
type	O
for	O
K	O
-	O
ras	O
[	O
18,19	O
]	O
.	O

This	O
work	O
presents	O
evidences	O
that	O
p8	O
inhibits	O
the	O
growth	O
rate	O
of	O
pancreatic	O
cancer	O
-	O
derived	O
cells	O
and	O
that	O
the	O
intracellular	O
pathways	O
promoting	O
cell	O
growth	O
down	O
-	O
regulate	O
p8	O
expression	O
whereas	O
those	O
promoting	O
growth	O
arrest	O
up	O
-	O
regulate	O
its	O
expression	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
p8	O
is	O
downstream	O
of	O
some	O
cell	O
growth	O
regulators	O
and	O
therefore	O
regulation	O
of	O
p8	O
expression	O
or	O
its	O
activity	O
could	O
be	O
used	O
as	O
a	O
target	O
for	O
treating	O
pancreatic	O
cancer	O
.	O

Silencing	O
p8	O
expression	O
was	O
able	O
to	O
strongly	O
promote	O
cell	O
growth	O
in	O
both	O
cell	O
types	O
,	O
Panc-1	O
and	O
BxPc-3	O
,	O
suggesting	O
that	O
p8	O
may	O
act	O
downstream	O
of	O
the	O
ras-	O
or	O
Smad4	O
/	O
DPC4-dependent	O
ways	O
.	O

Also	O
,	O
we	O
found	O
that	O
stimulating	O
cell	O
growth	O
by	O
the	O
complex	O
combination	O
of	O
growth	O
factors	O
contained	O
in	O
fetal	O
calf	O
serum	O
down	O
-	O
regulated	O
expression	O
of	O
p8	O
whereas	O
,	O
on	O
the	O
contrary	O
,	O
treating	O
the	O
cells	O
with	O
TGFβ-1	O
,	O
which	O
promotes	O
cell	O
cycle	O
arrest	O
,	O
stimulates	O
p8	O
expression	O
.	O

Therefore	O
,	O
p8	O
gene	O
expression	O
seems	O
to	O
be	O
regulated	O
in	O
opposite	O
directions	O
by	O
mechanisms	O
promoting	O
cell	O
growth	O
or	O
cell	O
cycle	O
arrest	O
.	O

It	O
is	O
interesting	O
to	O
note	O
that	O
while	O
p8	O
expression	O
is	O
under	O
the	O
control	O
of	O
cell	O
growth	O
regulatory	O
pathways	O
such	O
as	O
Ras→Raf→MEK→ERK	O
,	O
JNK	O
,	O
p38	O
and	O
TGFβ-1	O
,	O
p8	O
can	O
affect	O
cell	O
cycle	O
progression	O
,	O
suggesting	O
that	O
p8	O
is	O
a	O
target	O
for	O
factors	O
regulating	O
pancreatic	O
cell	O
growth	O
.	O

A	O
mechanism	O
by	O
which	O
p8	O
could	O
regulate	O
cell	O
cycle	O
progression	O
in	O
embryonic	O
fibroblasts	O
was	O
previously	O
proposed	O
[	O
11	O
]	O
.	O

In	O
fact	O
,	O
p8	O
seems	O
to	O
take	O
action	O
upstream	O
from	O
cyclin	O
-	O
dependent	O
kinases	O
because	O
the	O
intracellular	O
levels	O
and	O
activities	O
of	O
Cdk2	O
and	O
Cdk4	O
are	O
decreased	O
when	O
p8	O
is	O
expressed	O
.	O

Concomitantly	O
,	O
the	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
p27	O
is	O
expressed	O
at	O
a	O
low	O
level	O
in	O
p8-deficient	O
cells	O
which	O
may	O
explain	O
the	O
increased	O
activity	O
of	O
Cdk2	O
and	O
Cdk4	O
.	O

The	O
mechanism	O
by	O
which	O
p8	O
regulates	O
the	O
intracellular	O
level	O
of	O
those	O
proteins	O
remains	O
to	O
be	O
determined	O
.	O

However	O
,	O
because	O
p8	O
is	O
a	O
transcriptional	O
cofactor	O
,	O
it	O
is	O
possible	O
that	O
regulation	O
of	O
expression	O
of	O
these	O
molecules	O
takes	O
place	O
,	O
at	O
least	O
in	O
part	O
,	O
at	O
the	O
transcription	O
level	O
.	O

Interestingly	O
,	O
expression	O
of	O
p8	O
mRNA	O
seems	O
to	O
be	O
regulated	O
in	O
a	O
cell	O
type-	O
and	O
stimulus	O
-	O
specific	O
manner	O
since	O
,	O
for	O
example	O
,	O
p38	O
can	O
induce	O
p8	O
expression	O
in	O
response	O
to	O
stress	O
in	O
fibroblasts	O
[	O
3	O
]	O
but	O
not	O
in	O
renal	O
mesangial	O
cells	O
treated	O
with	O
endothelin	O
[	O
13	O
]	O
.	O

In	O
pancreatic	O
cancer	O
-	O
derived	O
cells	O
p38	O
seems	O
to	O
play	O
a	O
major	O
role	O
since	O
it	O
is	O
involved	O
in	O
p8	O
activation	O
as	O
judged	O
by	O
transient	O
transfection	O
assays	O
and	O
using	O
a	O
specific	O
p38	O
inhibitor	O
(	O
Figures	O
10	O
and	O
11	O
)	O
.	O

In	O
addition	O
,	O
p38	O
is	O
also	O
involved	O
in	O
TGFβ-1-induced	O
p8	O
expression	O
because	O
about	O
40	O
%	O
of	O
the	O
TGFβ-1	O
effect	O
was	O
abolished	O
when	O
p38	O
activity	O
was	O
specifically	O
blocked	O
(	O
Figure	O
13	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
ERK	O
and	O
JNK	O
are	O
inducers	O
of	O
p8	O
expression	O
in	O
mesangial	O
cells	O
treated	O
with	O
endothelin	O
,	O
but	O
not	O
involved	O
in	O
the	O
activation	O
of	O
p8	O
in	O
response	O
to	O
stress	O
in	O
fibroblasts	O
[	O
3	O
]	O
,	O
and	O
even	O
repressors	O
in	O
pancreatic	O
cells	O
(	O
Figures	O
5	O
,	O
6	O
,	O
7	O
,	O
8	O
and	O
9	O
)	O
.	O

Finally	O
,	O
PI3	O
kinase	O
is	O
an	O
inducer	O
of	O
p8	O
expression	O
in	O
both	O
endothelin	O
-	O
mediated	O
p8	O
activation	O
in	O
mesangial	O
cells	O
[	O
13	O
]	O
and	O
pancreatic	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

Based	O
on	O
these	O
observations	O
,	O
overexpression	O
of	O
p8	O
could	O
be	O
considered	O
a	O
possible	O
goal	O
for	O
treating	O
pancreatic	O
tumours	O
,	O
in	O
order	O
to	O
limit	O
their	O
growth	O
.	O

However	O
,	O
we	O
previously	O
reported	O
that	O
p8	O
repression	O
would	O
prevent	O
rasV12	O
/	O
E1A	O
transformed	O
fibroblasts	O
from	O
evolving	O
as	O
tumours	O
in	O
nude	B
mice	I
[	O
16	O
]	O
.	O

This	O
apparent	O
contradiction	O
needs	O
to	O
be	O
resolved	O
before	O
considering	O
p8	O
as	O
a	O
target	O
for	O
treating	O
cancer	O
progression	O
.	O

Conclusions	O
In	O
conclusion	O
(	O
see	O
Figure	O
14	O
)	O
,	O
we	O
report	O
in	O
this	O
paper	O
that	O
inhibition	O
of	O
p8	O
expression	O
by	O
an	O
anti	O
-	O
sense	O
strategy	O
increases	O
the	O
growth	O
rate	O
of	O
both	O
Panc-1	O
and	O
BxPc-3	O
pancreatic	O
cancer	O
-	O
derived	O
cells	O
.	O

Moreover	O
,	O
ERK-	O
and	O
JNK	O
-	O
mediated	O
pathways	O
down	O
-	O
regulate	O
p8	O
expression	O
,	O
whereas	O
p38	O
and	O
TGFβ-1	O
pathways	O
induce	O
p8	O
expression	O
.	O

Also	O
,	O
cell	O
growth	O
triggered	O
by	O
expression	O
of	O
a	O
RAS	O
mutated	O
protein	O
or	O
by	O
10	O
%	O
fetal	O
calf	O
serum	O
induces	O
down	O
-	O
regulation	O
of	O
p8	O
expression	O
.	O

Together	O
,	O
these	O
results	O
indicate	O
that	O
p8	O
is	O
an	O
intracellular	O
cell	O
growth	O
inhibitor	O
and	O
that	O
it	O
is	O
oppositely	O
regulated	O
by	O
growth	O
-	O
promoting	O
or	O
growth	O
-	O
inhibiting	O
factors	O
in	O
pancreatic	O
cancer	O
-	O
derived	O
cells	O
.	O

Material	O
and	O
Methods	O
Cell	O
lines	O
and	O
cell	O
culture	O
conditions	O
The	O
human	B
pancreatic	O
cancer	O
cell	O
lines	O
Panc-1	O
and	O
BxPc-3	O
were	O
a	O
kind	O
gift	O
of	O
Dr	O
C.	O
Susini	O
(	O
INSERM	O
U.531	O
,	O
Toulouse	O
)	O
and	O
A.	O
Hajri	O
(	O
IRCAD	O
,	O
Strasbourg	O
)	O
respectively	O
.	O

Panc-1	O
cells	O
were	O
grown	O
in	O
Dulbecco	O
's	O
modified	O
Eagle	O
's	O
medium	O
(	O
DMEM	O
)	O
supplemented	O
with	O
10	O
%	O
fetal	O
calf	O
serum	O
,	O
2	O
mM	O
L	O
-	O
glutamine	O
,	O
100	O
IU	O
/	O
ml	O
penicilin	O
G	O
and	O
100	O
μg	O
/	O
ml	O
streptomycin	O
.	O

BxPc-3	O
were	O
cultivated	O
in	O
RPMI	O
1640	O
medium	O
in	O
the	O
presence	O
of	O
2	O
mM	O
L	O
-	O
glutamine	O
,	O
4.5	O
g	O
/	O
L	O
glucose	O
,	O
10	O
mM	O
Hepes	O
,	O
1.0	O
mM	O
sodium	O
pyruvate	O
,	O
10	O
%	O
fetal	O
calf	O
serum	O
and	O
100	O
IU	O
/	O
ml	O
penicilin	O
G	O
and	O
100	O
μg	O
/	O
ml	O
streptomycin	O
.	O

Human	B
recombinant	O
TGFβ-1	O
was	O
obtained	O
from	O
Sigma	O
,	O
and	O
specific	O
SB203580	O
,	O
U0126	O
and	O
SP600125	O
inhibitors	O
were	O
from	O
Calbiochem	O
and	O
utilized	O
at	O
10	O
μM.	O
Expression	O
plasmids	O
Expression	O
plamids	O
encoding	O
p38	O
(	O
pCEFL	O
HA	O
p38	O
)	O
,	O
Erk2	O
(	O
pcDNAIII	O
HA	O
ERK2	O
)	O
,	O
JNK	O
(	O
pcDNAIIIB	O
HA	O
JNK	O
)	O
,	O
the	O
wild	O
-	O
type	O
Raf	O
(	O
pcDNA	O
RAF	O
BXB	O
)	O
and	O
the	O
Raf	O
dominant	O
negative	O
(	O
pcDNA	O
RAF	O
301	O
K375W	O
)	O
were	O
obtained	O
from	O
O	O
Coso	O
(	O
University	O
of	O
Buenos	O
Aires	O
)	O
.	O

Plamids	O
encoding	O
the	O
constitutively	O
activated	O
type	O
I	O
TGFβ	O
receptor	O
(	O
RI	O
ACT	O
)	O
,	O
the	O
dominant	O
negative	O
type	O
II	O
TGFβ	O
receptor	O
(	O
RII	O
DN	O
)	O
and	O
the	O
Smad4	O
dominant	O
negative	O
(	O
DPC4	O
1–514	O
a.a	O
.	O
)	O
were	O
obtained	O
from	O
R	O
Urrutia	O
(	O
Mayo	O
Clinic	O
,	O
Rochester	O
)	O
and	O
the	O
wild	O
type	O
Smad4	O
was	O
from	O
C	O
Heldin	O
(	O
Ludwig	O
Institute	O
,	O
Uppsala	O
)	O
.	O

Pancreatic	O
p8-deficient	O
cells	O
To	O
silence	O
p8	O
expression	O
in	O
pancreatic	O
cells	O
,	O
we	O
infected	O
these	O
cells	O
with	O
a	O
retrovirus	O
expressing	O
human	B
p8	O
in	O
the	O
antisense	O
orientation	O
.	O

The	O
retroviral	O
vector	O
was	O
constructed	O
as	O
follows	O
:	O
human	B
p8	O
cDNA	O
was	O
subcloned	O
in	O
HindIII	O
and	O
XhoI	O
restriction	O
sites	O
of	O
the	O
pLPC	O
plasmid	O
(	O
obtained	O
from	O
S.	O
Lowe	O
)	O
in	O
the	O
antisense	O
orientation	O
.	O

Amphotrope	O
human	B
p8	O
expressing	O
retrovirus	O
was	O
then	O
generated	O
by	O
transient	O
transfection	O
using	O
Phoenix	O
amphotrope	O
packaging	O
cells	O
.	O

Viral	O
supernatant	O
was	O
used	O
to	O
infect	O
Panc-1	O
and	O
BxPc-3	O
pancreatic	O
cells	O
and	O
the	O
population	O
of	O
p8-silenced	O
cells	O
was	O
isolated	O
by	O
selection	O
in	O
presence	O
of	O
puromycin	O
(	O
1	O
μg	O
/	O
ml	O
)	O
.	O

As	O
control	O
,	O
cells	O
were	O
infected	O
with	O
the	O
pLPC	O
empty	O
vector	O
.	O

p8	O
expression	O
in	O
arrested	O
and	O
growing	O
cells	O
One	O
million	O
of	O
Panc-1	O
or	O
BxPc-3	O
cells	O
were	O
cultivated	O
on	O
10-cm	O
Petri	O
plates	O
in	O
standard	O
conditions	O
(	O
with	O
10	O
%	O
FCS	O
)	O
.	O

After	O
48	O
h	O
,	O
culture	O
media	O
were	O
changed	O
for	O
fresh	O
media	O
with	O
FCS	O
restricted	O
to	O
0.1	O
%	O
,	O
in	O
order	O
to	O
stop	O
growth	O
.	O

After	O
24	O
hours	O
of	O
growth	O
arrest	O
,	O
culture	O
medium	O
was	O
replaced	O
either	O
by	O
medium	O
with	O
10	O
%	O
fetal	O
calf	O
serum	O
to	O
resume	O
cell	O
growth	O
or	O
,	O
as	O
control	O
,	O
by	O
medium	O
with	O
0.1	O
%	O
fetal	O
calf	O
serum	O
.	O

Twenty	O
four	O
hours	O
later	O
cells	O
were	O
recovered	O
and	O
RNA	O
and	O
protein	O
extracted	O
.	O

p8	O
expression	O
in	O
TGFβ-1-treated	O
Panc-1	O
cells	O
One	O
million	O
of	O
Panc-1	O
cells	O
were	O
cultivated	O
in	O
10-cm	O
culture	O
dishes	O
for	O
48	O
hours	O
under	O
standard	O
conditions	O
before	O
TGFβ-1	O
treatment	O
.	O

Human	B
recombinant	O
TGFβ-1	O
(	O
5	O
ng	O
/	O
ml	O
)	O
was	O
added	O
to	O
cells	O
,	O
without	O
changing	O
the	O
culture	O
medium	O
,	O
and	O
cells	O
were	O
collected	O
12	O
hours	O
later	O
for	O
RNA	O
and	O
protein	O
preparation	O
.	O

BxPc-3	O
rasV12-expressing	O
cells	O
pLPC	O
-	O
rasV12	O
and	O
pLPC	O
plasmids	O
were	O
obtained	O
from	O
S.	O
Lowe	O
.	O

Phoenix	O
amphotrope	O
packaging	O
cells	O
(	O
106	O
)	O
were	O
plated	O
in	O
a	O
6-well	O
plate	O
,	O
incubated	O
for	O
24	O
hours	O
,	O
then	O
transfected	O
with	O
PEI	O
with	O
5	O
μg	O
of	O
retroviral	O
plasmid	O
.	O

After	O
48	O
hours	O
,	O
the	O
medium	O
containing	O
virus	O
was	O
filtered	O
(	O
0.45	O
μm	O
filter	O
,	O
Millipore	O
)	O
to	O
obtain	O
the	O
viral	O
supernatant	O
.	O

Target	O
BxPc-3	O
were	O
plated	O
at	O
2	O
×	O
105	O
cells	O
per	O
35-mm	O
dish	O
and	O
incubated	O
overnight	O
.	O

For	O
infections	O
,	O
the	O
culture	O
medium	O
was	O
replaced	O
by	O
an	O
appropriate	O
mix	O
of	O
the	O
viral	O
supernatant	O
and	O
culture	O
medium	O
(	O
V	O
/	O
V	O
)	O
,	O
supplemented	O
with	O
4	O
μg	O
/	O
ml	O
polybrene	O
(	O
Sigma	O
)	O
,	O
and	O
cells	O
were	O
incubated	O
at	O
37	O
°	O
C	O
.	O

BxPc-3	O
rasV12-expressing	O
cells	O
were	O
selected	O
with	O
puromycin	O
(	O
1	O
μg	O
/	O
ml	O
)	O
.	O

Cells	O
infected	O
with	O
the	O
pLPC	O
empty	O
vector	O
were	O
used	O
as	O
control	O
.	O

Western	O
-	O
blot	O
analyses	O
One	O
hundred	O
μg	O
of	O
total	O
protein	O
extracted	O
from	O
cells	O
was	O
separated	O
with	O
standard	O
procedures	O
on	O
15.0	O
%	O
SDS	O
-	O
PAGE	O
using	O
the	O
Mini	O
Protean	O
System	O
(	O
Bio	O
-	O
Rad	O
)	O
and	O
transferred	O
to	O
a	O
nitrocellulose	O
membrane	O
(	O
Sigma	O
)	O
.	O

The	O
intracellular	O
level	O
of	O
p8	O
was	O
estimated	O
by	O
Western	O
blot	O
using	O
a	O
polyclonal	O
antibody	O
(	O
1:1000	O
)	O
raised	O
against	O
human	B
p8	O
[	O
4	O
]	O
.	O

Growth	O
curves	O
One	O
hundred	O
thousand	O
cells	O
per	O
well	O
were	O
plated	O
in	O
a	O
series	O
of	O
35-mm	O
culture	O
dishes	O
.	O

The	O
cell	O
number	O
was	O
estimated	O
daily	O
in	O
triplicate	O
,	O
during	O
1	O
to	O
5	O
days	O
,	O
in	O
a	O
haemocytometer	O
.	O

Within	O
experiments	O
,	O
each	O
point	O
was	O
determined	O
at	O
least	O
two	O
times	O
.	O

Cell	O
transfection	O
and	O
gene	O
reporter	O
assays	O
Panc-1	O
and	O
BxPc-3	O
(	O
105	O
)	O
were	O
cultivated	O
in	O
30	O
mm	O
diameter	O
culture	O
dishes	O
for	O
24	O
hours	O
then	O
transiently	O
transfected	O
with	O
0.5	O
μg	O
of	O
p8-CAT	O
reporter	O
plasmid	O
and	O
0.5	O
μg	O
of	O
pCMV	O
/	O
βgal	O
plasmid	O
(	O
to	O
control	O
transfection	O
efficiency	O
)	O
using	O
the	O
Fugene	O
reagent	O
in	O
accordance	O
with	O
the	O
manufacturer	O
's	O
protocol	O
(	O
Roche	O
Molecular	O
Biochemicals	O
)	O
.	O

The	O
p8-CAT	O
plasmid	O
is	O
the	O
previously	O
reported	O
p-1471	O
/	O
+37p8-CAT	O
promoter	O
construct	O
[	O
5	O
]	O
.	O

Reporter	O
activities	O
were	O
measured	O
as	O
previously	O
described	O
[	O
5	O
]	O
.	O

Briefly	O
,	O
cell	O
extracts	O
were	O
prepared	O
with	O
the	O
reporter	O
lysis	O
buffer	O
(	O
Promega	O
)	O
24	O
hours	O
after	O
transfection	O
and	O
CAT	O
activity	O
was	O
determined	O
by	O
the	O
phase	O
extraction	O
procedure	O
[	O
32	O
]	O
and	O
β	O
-	O
galactosidase	O
assay	O
was	O
performed	O
essentially	O
as	O
described	O
in	O
Sambrook	O
et	O
al.	O
[	O
33	O
]	O
.	O

CAT	O
activity	O
was	O
normalized	O
to	O
β	O
-	O
galactosidase	O
activity	O
.	O

Experiments	O
were	O
carried	O
out	O
in	O
triplicate	O
and	O
repeated	O
at	O
least	O
two	O
times	O
.	O

Expression	O
plasmids	O
(	O
0.5	O
μg	O
)	O
were	O
co	O
-	O
transfected	O
with	O
p8-CAT	O
and	O
pCMV	O
/	O
βgal	O
plasmids	O
as	O
indicated	O
.	O

RT	O
-	O
PCR	O
analysis	O
RNA	O
was	O
extracted	O
using	O
the	O
Trizol	O
(	O
Life	O
Technologies	O
)	O
procedure	O
.	O

Total	O
RNA	O
(	O
1	O
μg	O
)	O
was	O
analyzed	O
by	O
RT	O
-	O
PCR	O
with	O
the	O
SuperScript	O
™	O
One	O
-	O
step	O
RT	O
-	O
PCR	O
System	O
and	O
the	O
Platinum	O
Taq	O
kit	O
(	O
Life	O
Technologies	O
)	O
.	O

RT	O
-	O
PCR	O
was	O
performed	O
using	O
different	O
numbers	O
of	O
cycles	O
to	O
verify	O
that	O
the	O
conditions	O
chosen	O
were	O
within	O
the	O
linear	O
range	O
.	O

The	O
mRNA	O
coding	O
for	O
p8	O
was	O
specifically	O
amplified	O
with	O
sense	O
(	O
5	O
'	O
GAAGAGAGGCAGGGAAGACA	O
3	O
'	O
)	O
and	O
antisense	O
(	O
5	O
'	O
CTGCCGTGCGTGTCTATTTA	O
3	O
'	O
)	O
primers	O
,	O
in	O
positions	O
72	O
and	O
643	O
of	O
the	O
cDNA	O
(	O
accession	O
#	O
NM_012385	O
)	O
,	O
respectively	O
.	O

As	O
control	O
,	O
the	O
transcript	O
coding	O
for	O
the	O
ribosomal	O
protein	O
RL3	O
was	O
specifically	O
amplified	O
for	O
22	O
cycles	O
with	O
sense	O
(	O
5'GAAAGAAGTCGTGGAGGCTG3	O
'	O
)	O
and	O
antisense	O
(	O
5'ATCTCATCCTGCCCAAACAC3	O
'	O
)	O
primers	O
,	O
in	O
positions	O
216	O
and	O
637	O
of	O
the	O
cDNA	O
,	O
respectively	O
.	O

Author	O
's	O
contributions	O
CM	O
prepared	O
cells	O
and	O
retrovirus	O
,	O
carried	O
out	O
RNA	O
purification	O
,	O
RT	O
-	O
PCR	O
,	O
Western	O
blots	O
,	O
and	O
cell	O
growth	O
experiments	O
,	O
NL	O
carried	O
out	O
CAT	O
assays	O
,	O
SV	O
participated	O
in	O
the	O
design	O
of	O
the	O
study	O
and	O
analysis	O
of	O
data	O
,	O
JLI	O
participated	O
in	O
the	O
analysis	O
of	O
data	O
and	O
wrote	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Yeast	B
mitochondrial	O
dehydrogenases	O
are	O
associated	O
in	O
a	O
supramolecular	O
complex	O
.	O

Separation	O
of	O
yeast	B
mitochondrial	O
complexes	O
by	O
colorless	O
native	O
polyacrylamide	O
gel	O
electrophoresis	O
led	O
to	O
the	O
identification	O
of	O
a	O
supramolecular	O
structure	O
exhibiting	O
NADH	O
-	O
dehydrogenase	O
activity	O
.	O

Components	O
of	O
this	O
complex	O
were	O
identified	O
by	O
N	O
-	O
terminal	O
Edman	O
degradation	O
and	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
ionization	O
mass	O
spectrometry	O
.	O

The	O
complex	O
was	O
found	O
to	O
contain	O
the	O
five	O
known	O
intermembrane	O
space	O
-	O
facing	O
dehydrogenases	O
,	O
namely	O
two	O
external	O
NADH	O
-	O
dehydrogenases	O
Nde1p	O
and	O
Nde2p	O
,	O
glycerol-3-phosphate	O
dehydrogenase	O
Gut2p	O
,	O
D-	O
and	O
L	O
-	O
lactate	O
-	O
dehydrogenases	O
Dld1p	O
and	O
Cyb2p	O
,	O
the	O
matrix	O
-	O
facing	O
NADH	O
-	O
dehydrogenase	O
Ndi1p	O
,	O
two	O
probable	O
flavoproteins	O
YOR356Wp	O
and	O
YPR004Cp	O
,	O
four	O
tricarboxylic	O
acids	O
cycle	O
enzymes	O
(	O
malate	O
dehydrogenase	O
Mdh1p	O
,	O
citrate	O
synthase	O
Cit1p	O
,	O
succinate	O
dehydrogenase	O
Sdh1p	O
,	O
and	O
fumarate	O
hydratase	O
Fum1p	O
)	O
,	O
and	O
the	O
acetaldehyde	O
dehydrogenase	O
Ald4p	O
.	O

The	O
association	O
of	O
these	O
proteins	O
is	O
discussed	O
in	O
terms	O
of	O
NADH	O
-	O
channeling	O
.	O

Characterization	O
of	O
CAX4	O
,	O
an	O
Arabidopsis	B
H	O
(	O
+	O
)	O
/	O
cation	O
antiporter	O
.	O

Ion	O
compartmentalization	O
is	O
essential	O
for	O
plant	O
growth	O
and	O
development	O
.	O

The	O
Arabidopsis	B
open	O
reading	O
frames	O
for	O
CAX1	O
,	O
CAX2	O
,	O
and	O
CAX3	O
(	O
cation	O
exchangers	O
1	O
,	O
2	O
,	O
and	O
3	O
)	O
were	O
previously	O
identified	O
as	O
transporters	O
that	O
may	O
modulate	O
ion	O
fluxes	O
across	O
the	O
vacuolar	O
membrane	O
.	O

To	O
understand	O
the	O
diversity	O
and	O
role	O
of	O
H	O
(	O
+	O
)	O
/	O
cation	O
transporters	O
in	O
controlling	O
plant	O
ion	O
levels	O
,	O
another	O
homolog	O
of	O
the	O
CAX	O
genes	O
,	O
CAX4	O
,	O
was	O
cloned	O
from	O
an	O
Arabidopsis	B
cDNA	O
library	O
.	O

CAX4	O
is	O
53	O
%	O
identical	O
to	O
CAX1	O
at	O
the	O
amino	O
acid	O
level	O
,	O
42	O
%	O
identical	O
to	O
CAX2	O
,	O
and	O
54	O
%	O
identical	O
to	O
CAX3	O
.	O

CAX4	O
transcripts	O
appeared	O
to	O
be	O
expressed	O
at	O
low	O
levels	O
in	O
all	O
tissues	O
and	O
levels	O
of	O
CAX4	O
RNA	O
increased	O
after	O
Mn	O
(	O
2	O
+	O
)	O
,	O
Na	O
(	O
+	O
)	O
,	O
and	O
Ni	O
(	O
2	O
+	O
)	O
treatment	O
.	O

An	O
N	O
-	O
terminal	O
CAX4-hemagglutinin	O
fusion	O
appeared	O
to	O
localize	O
to	O
both	O
yeast	B
and	O
plant	O
vacuolar	O
membranes	O
.	O

When	O
expressed	O
in	O
yeast	B
,	O
CAX4	O
,	O
like	O
CAX3	O
,	O
failed	O
to	O
suppress	O
the	O
Ca	O
(	O
2	O
+	O
)	O
sensitivity	O
of	O
yeast	B
strains	O
deficient	O
in	O
vacuolar	O
Ca	O
(	O
2	O
+	O
)	O
transport	O
.	O

Several	O
modifications	O
to	O
CAX4	O
allowed	O
the	O
protein	O
to	O
transport	O
Ca	O
(	O
2	O
+	O
)	O
.	O

Addition	O
of	O
amino	O
acids	O
to	O
the	O
N	O
terminus	O
of	O
CAX4	O
and	O
CAX3	O
caused	O
both	O
transporters	O
to	O
suppress	O
the	O
sensitivity	O
of	O
yeast	B
strains	O
deficient	O
in	O
vacuolar	O
Ca	O
(	O
2	O
+	O
)	O
transport	O
.	O

These	O
findings	O
suggest	O
that	O
CAX	O
transporters	O
may	O
modulate	O
their	O
ion	O
transport	O
properties	O
through	O
alterations	O
at	O
the	O
N	O
terminus	O
.	O

A	O
new	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
-interacting	O
protein	O
,	O
Sab	O
(	O
SH3BP5	O
)	O
,	O
associates	O
with	O
mitochondria	O
.	O

We	O
have	O
identified	O
a	O
novel	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
-interacting	O
protein	O
,	O
Sab	O
,	O
by	O
yeast	B
two	O
-	O
hybrid	O
screening	O
.	O

Sab	O
binds	O
to	O
and	O
serves	O
as	O
a	O
substrate	O
for	O
JNK	O
in	O
vitro	O
,	O
and	O
was	O
previously	O
found	O
to	O
interact	O
with	O
the	O
Src	O
homology	O
3	O
(	O
SH3	O
)	O
domain	O
of	O
Bruton	O
's	O
tyrosine	O
kinase	O
(	O
Btk	O
)	O
.	O

Inspection	O
of	O
the	O
sequence	O
of	O
Sab	O
reveals	O
the	O
presence	O
of	O
two	O
putative	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
interaction	O
motifs	O
(	O
KIMs	O
)	O
similar	O
to	O
that	O
found	O
in	O
the	O
JNK	O
docking	O
domain	O
of	O
the	O
c	O
-	O
Jun	O
transcription	O
factor	O
,	O
and	O
four	O
potential	O
serine	O
-	O
proline	O
JNK	O
phosphorylation	O
sites	O
in	O
the	O
C	O
-	O
terminal	O
half	O
of	O
the	O
molecule	O
.	O

Using	O
deletion	O
and	O
site	O
-	O
directed	O
mutagenesis	O
,	O
we	O
demonstrate	O
that	O
the	O
most	O
N	O
-	O
terminal	O
KIM	O
in	O
Sab	O
is	O
essential	O
for	O
JNK	O
binding	O
,	O
and	O
that	O
,	O
as	O
with	O
c	O
-	O
Jun	O
,	O
physical	O
interaction	O
with	O
JNK	O
is	O
necessary	O
for	O
Sab	O
phosphorylation	O
.	O

Interestingly	O
,	O
confocal	O
immunocytochemistry	O
and	O
cell	O
fractionation	O
studies	O
indicate	O
that	O
Sab	O
is	O
associated	O
with	O
mitochondria	O
,	O
where	O
it	O
co	O
-	O
localizes	O
with	O
a	O
fraction	O
of	O
active	O
JNK	O
.	O

These	O
and	O
previously	O
reported	O
properties	O
of	O
Sab	O
suggest	O
a	O
possible	O
role	O
in	O
targeting	O
JNK	O
to	O
this	O
subcellular	O
compartment	O
and/or	O
mediating	O
cross	O
-	O
talk	O
between	O
the	O
Btk	O
and	O
JNK	O
signal	O
transduction	O
pathways	O
.	O

The	O
proteome	O
of	O
Saccharomyces	B
cerevisiae	I
mitochondria	O
.	O

We	O
performed	O
a	O
comprehensive	O
approach	O
to	O
determine	O
the	O
proteome	O
of	O
Saccharomyces	B
cerevisiae	I
mitochondria	O
.	O

The	O
proteins	O
of	O
highly	O
pure	O
yeast	B
mitochondria	O
were	O
separated	O
by	O
several	O
independent	O
methods	O
and	O
analyzed	O
by	O
tandem	O
MS	O
.	O

From	O
>	O
20	O
million	O
MS	O
spectra	O
,	O
750	O
different	O
proteins	O
were	O
identified	O
,	O
indicating	O
an	O
involvement	O
of	O
mitochondria	O
in	O
numerous	O
cellular	O
processes	O
.	O

All	O
known	O
components	O
of	O
the	O
oxidative	O
phosphorylation	O
machinery	O
,	O
the	O
tricarboxylic	O
acid	O
cycle	O
,	O
and	O
the	O
stable	O
mitochondria	O
-	O
encoded	O
proteins	O
were	O
found	O
.	O

Based	O
on	O
the	O
mitochondrial	O
proteins	O
described	O
in	O
the	O
literature	O
so	O
far	O
,	O
we	O
calculate	O
that	O
the	O
identified	O
proteins	O
represent	O
approximately	O
90	O
%	O
of	O
all	O
mitochondrial	O
proteins	O
.	O

The	O
function	O
of	O
a	O
quarter	O
of	O
the	O
identified	O
proteins	O
is	O
unknown	O
.	O

The	O
mitochondrial	O
proteome	O
will	O
provide	O
an	O
important	O
database	O
for	O
the	O
analysis	O
of	O
new	O
mitochondrial	O
and	O
mitochondria	O
-	O
associated	O
functions	O
and	O
the	O
characterization	O
of	O
mitochondrial	O
diseases	O
.	O

Expression	O
and	O
localization	O
of	O
ecto	O
-	O
nucleotide	O
pyrophosphatase	O
/	O
phosphodiesterase	O
I-1	O
(	O
E	O
-	O
NPP1	O
/	O
PC-1	O
)	O
and	O
-3	O
(	O
E	O
-	O
NPP3	O
/	O
CD203c	O
/	O
PD	O
-	O
Ibeta	O
/	O
B10	O
/	O
gp130	O
(	O
RB13	O
-	O
6	O
)	O
)	O
in	O
inflammatory	O
and	O
neoplastic	O
bile	O
duct	O
diseases	O
.	O

Ecto	O
-	O
nucleotide	O
pyrophosphatase	O
/	O
phosphodiesterase	O
-	O
I	O
enzyme	O
(	O
E	O
-	O
NPP	O
)	O
consists	O
of	O
three	O
closely	O
related	O
molecules	O
:	O
E	O
-	O
NPP1	O
,	O
E	O
-	O
NPP2	O
and	O
E	O
-	O
NPP3	O
.	O

We	O
investigated	O
the	O
expression	O
and	O
localization	O
of	O
E	O
-	O
NPP1	O
and	O
-3	O
in	O
human	B
inflammatory	O
and	O
neoplastic	O
bile	O
duct	O
diseases	O
.	O

Immunohistochemically	O
E	O
-	O
NPP1	O
was	O
located	O
on	O
the	O
apical	O
cytoplasmic	O
side	O
of	O
cancer	O
cells	O
,	O
whereas	O
E	O
-	O
NPP3	O
was	O
located	O
in	O
the	O
apical	O
plasma	O
membrane	O
.	O

Western	O
blot	O
analysis	O
revealed	O
that	O
the	O
expression	O
of	O
E	O
-	O
NPP3	O
,	O
but	O
not	O
E	O
-	O
NPP1	O
,	O
was	O
higher	O
in	O
tumor	O
tissues	O
than	O
in	O
surrounding	O
tissues	O
and	O
the	O
specific	O
form	O
of	O
the	O
E	O
-	O
NPP3	O
protein	O
was	O
readily	O
detected	O
in	O
the	O
sera	O
of	O
bile	O
duct	O
carcinoma	O
(	O
BDC	O
)	O
patients	O
.	O

Furthermore	O
,	O
it	O
was	O
confirmed	O
that	O
E	O
-	O
NPP3	O
was	O
associated	O
with	O
migration	O
ability	O
by	O
using	O
of	O
NIH3T3	O
cells	O
that	O
stably	O
transfected	O
with	O
E	O
-	O
NPP3	O
cDNA	O
.	O

These	O
results	O
suggest	O
that	O
E	O
-	O
NPP3	O
is	O
involved	O
in	O
the	O
infiltration	O
of	O
neoplastic	O
BDC	O
and	O
is	O
possible	O
to	O
be	O
a	O
tumor	O
marker	O
.	O

NFAM1	O
,	O
an	O
immunoreceptor	O
tyrosine	O
-	O
based	O
activation	O
motif	O
-	O
bearing	O
molecule	O
that	O
regulates	O
B	O
cell	O
development	O
and	O
signaling	O
.	O

A	O
functional	O
cDNA	O
cloning	O
system	O
was	O
developed	O
by	O
using	O
a	O
retrovirus	O
library	O
encoding	O
CD8-chimeric	O
proteins	O
and	O
a	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
-GFP	O
reporter	O
cell	O
line	O
to	O
identify	O
molecules	O
inducing	O
NFAT	O
activation	O
.	O

By	O
using	O
this	O
strategy	O
,	O
NFAT	O
activating	O
molecule	O
1	O
(	O
NFAM1	O
)	O
was	O
cloned	O
as	O
an	O
immunoreceptor	O
tyrosine	O
-	O
based	O
activation	O
motif	O
(	O
ITAM	O
)	O
-bearing	O
cell	O
surface	O
molecule	O
belonging	O
to	O
the	O
Ig	O
superfamily	O
and	O
is	O
predominantly	O
expressed	O
in	O
spleen	O
B	O
and	O
T	O
cells	O
.	O

NFAM1	O
crosslinking	O
induced	O
ITAM	O
phosphorylation	O
,	O
ZAP-70	O
/	O
Syk	O
recruitment	O
,	O
NFAT	O
activation	O
,	O
and	O
cytokine	O
production	O
.	O

In	O
vivo	O
overexpression	O
of	O
NFAM1	O
in	O
bone	O
marrow	O
chimeras	O
and	O
transgenic	O
mice	B
induced	O
severe	O
impairment	O
of	O
early	O
B	O
cell	O
development	O
in	O
an	O
ITAM	O
-	O
dependent	O
manner	O
.	O

In	O
NFAM1-expressing	O
B	O
cells	O
,	O
B	O
cell	O
antigen	O
receptor	O
stimulation	O
induced	O
NFAM1	O
translocation	O
to	O
lipid	O
raft	O
,	O
and	O
NFAM1	O
co	O
-	O
crosslinking	O
augmented	O
B	O
cell	O
antigen	O
receptor	O
signaling	O
.	O

The	O
results	O
suggest	O
that	O
NFAM1	O
modulates	O
B	O
cell	O
signaling	O
through	O
its	O
ITAM	O
,	O
which	O
regulates	O
B	O
cell	O
development	O
.	O

Vasohibin	O
as	O
an	O
endothelium	O
-	O
derived	O
negative	O
feedback	O
regulator	O
of	O
angiogenesis	O
.	O

Negative	O
feedback	O
is	O
a	O
crucial	O
physiological	O
regulatory	O
mechanism	O
,	O
but	O
no	O
such	O
regulator	O
of	O
angiogenesis	O
has	O
been	O
established	O
.	O

Here	O
we	O
report	O
a	O
novel	O
angiogenesis	O
inhibitor	O
that	O
is	O
induced	O
in	O
endothelial	O
cells	O
(	O
ECs	O
)	O
by	O
angiogenic	O
factors	O
and	O
inhibits	O
angiogenesis	O
in	O
an	O
autocrine	O
manner	O
.	O

We	O
have	O
performed	O
cDNA	O
microarray	O
analysis	O
to	O
survey	O
VEGF	O
-	O
inducible	O
genes	O
in	O
human	B
ECs	O
.	O

We	O
characterized	O
one	O
such	O
gene	O
,	O
KIAA1036	O
,	O
whose	O
function	O
had	O
been	O
uncharacterized	O
.	O

The	O
recombinant	O
protein	O
inhibited	O
migration	O
,	O
proliferation	O
,	O
and	O
network	O
formation	O
by	O
ECs	O
as	O
well	O
as	O
angiogenesis	O
in	O
vivo	O
.	O

This	O
inhibitory	O
effect	O
was	O
selective	O
to	O
ECs	O
,	O
as	O
the	O
protein	O
did	O
not	O
affect	O
the	O
migration	O
of	O
smooth	O
muscle	O
cells	O
or	O
fibroblasts	O
.	O

Specific	O
elimination	O
of	O
the	O
expression	O
of	O
KIAA1036	O
in	O
ECs	O
restored	O
their	O
responsiveness	O
to	O
a	O
higher	O
concentration	O
of	O
VEGF	O
.	O

The	O
expression	O
of	O
KIAA1036	O
was	O
selective	O
to	O
ECs	O
,	O
and	O
hypoxia	O
or	O
TNF	O
-	O
alpha	O
abrogated	O
its	O
inducible	O
expression	O
.	O

As	O
this	O
molecule	O
is	O
preferentially	O
expressed	O
in	O
ECs	O
,	O
we	O
designated	O
it	O
"	O
vasohibin	O
.	O
"	O

Transfection	O
of	O
Lewis	O
lung	O
carcinoma	O
cells	O
with	O
the	O
vasohibin	O
gene	O
did	O
not	O
affect	O
the	O
proliferation	O
of	O
cancer	O
cells	O
in	O
vitro	O
,	O
but	O
did	O
inhibit	O
tumor	O
growth	O
and	O
tumor	O
angiogenesis	O
in	O
vivo	O
.	O

We	O
propose	O
vasohibin	O
to	O
be	O
an	O
endothelium	O
-	O
derived	O
negative	O
feedback	O
regulator	O
of	O
angiogenesis	O
.	O

Yeast	B
homolog	O
of	O
a	O
cancer	O
-	O
testis	O
antigen	O
defines	O
a	O
new	O
transcription	O
complex	O
.	O

We	O
have	O
isolated	O
a	O
new	O
yeast	B
gene	O
(	O
PCC1	O
)	O
that	O
codes	O
for	O
a	O
factor	O
homologous	O
to	O
human	B
cancer	O
-	O
testis	O
antigens	O
.	O

We	O
provide	O
evidence	O
that	O
Pcc1p	O
is	O
a	O
new	O
transcription	O
factor	O
and	O
that	O
its	O
mutation	O
affects	O
expression	O
of	O
several	O
genes	O
,	O
some	O
of	O
which	O
are	O
involved	O
in	O
cell	O
cycle	O
progression	O
and	O
polarized	O
growth	O
.	O

Mutation	O
of	O
Pcc1p	O
also	O
affects	O
the	O
expression	O
of	O
GAL	O
genes	O
by	O
impairing	O
the	O
recruitment	O
of	O
the	O
SAGA	O
and	O
Mediator	O
co	O
-	O
activators	O
.	O

We	O
characterize	O
a	O
new	O
complex	O
that	O
contains	O
Pcc1p	O
,	O
a	O
kinase	O
,	O
Bud32p	O
,	O
a	O
putative	O
endopeptidase	O
,	O
Kae1p	O
and	O
two	O
additional	O
proteins	O
encoded	O
by	O
ORFs	O
YJL184w	O
and	O
YMLO36w	O
.	O

Genetic	O
and	O
physical	O
interactions	O
among	O
these	O
proteins	O
strongly	O
suggest	O
that	O
this	O
complex	O
is	O
a	O
functional	O
unit	O
.	O

Chromatin	O
immunoprecipitation	O
experiments	O
and	O
multiple	O
genetic	O
interactions	O
of	O
pcc1	O
mutants	O
with	O
mutants	O
of	O
the	O
transcription	O
apparatus	O
and	O
chromatin	O
modifying	O
enzymes	O
underscore	O
the	O
direct	O
role	O
of	O
the	O
complex	O
in	O
transcription	O
.	O

Functional	O
complementation	O
experiments	O
indicate	O
that	O
the	O
transcriptional	O
function	O
of	O
this	O
set	O
of	O
genes	O
is	O
conserved	O
throughout	O
evolution	O
.	O

Endoplasmic	O
reticulum	O
stress	O
-	O
activated	O
C	O
/	O
EBP	O
homologous	O
protein	O
enhances	O
nuclear	O
factor	O
-	O
kappaB	O
signals	O
via	O
repression	O
of	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
gamma	O
.	O

Endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
is	O
a	O
causative	O
factor	O
of	O
inflammatory	O
bowel	O
diseases	O
.	O

ER	O
stress	O
mediators	O
,	O
including	O
CCAAT	O
enhancer	O
-	O
binding	O
protein	O
(	O
C	O
/	O
EBP	O
)	O
homologous	O
protein	O
(	O
CHOP	O
)	O
,	O
are	O
elevated	O
in	O
intestinal	O
epithelia	O
from	O
patients	O
with	O
inflammatory	O
bowel	O
diseases	O
.	O

The	O
present	O
study	O
arose	O
from	O
the	O
question	O
of	O
how	O
chemical	O
ER	O
stress	O
and	O
CHOP	O
protein	O
were	O
associated	O
with	O
nuclear	O
factor	O
-	O
κB	O
(	O
NF	O
-	O
κB	O
)	O
-mediated	O
epithelial	O
inflammatory	O
response	O
.	O

In	O
a	O
human	B
intestinal	O
epithelial	O
cell	O
culture	O
model	O
,	O
chemical	O
ER	O
stresses	O
induced	O
proinflammatory	O
cytokine	O
interleukin-8	O
(	O
IL-8	O
)	O
expression	O
and	O
the	O
nuclear	O
translocation	O
of	O
CHOP	O
protein	O
.	O

CHOP	O
was	O
positively	O
involved	O
in	O
ER	O
-	O
activated	O
IL-8	O
production	O
and	O
was	O
negatively	O
associated	O
with	O
expression	O
of	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
γ	O
(	O
PPARγ	O
)	O
.	O

ER	O
stress	O
-	O
induced	O
IL-8	O
production	O
was	O
enhanced	O
by	O
NF	O
-	O
κB	O
activation	O
that	O
was	O
negatively	O
regulated	O
by	O
PPARγ	O
.	O

Mechanistically	O
,	O
ER	O
stress	O
-	O
induced	O
CHOP	O
suppressed	O
PPARγ	O
transcription	O
by	O
sequestering	O
C	O
/	O
EBPβ	O
and	O
limiting	O
availability	O
of	O
C	O
/	O
EBPβ	O
binding	O
to	O
the	O
PPARγ	O
promoter	O
.	O

Due	O
to	O
the	O
CHOP	O
-	O
mediated	O
regulation	O
of	O
PPARγ	O
action	O
,	O
ER	O
stress	O
can	O
enhance	O
proinflammatory	O
NF	O
-	O
κB	O
activation	O
and	O
maintain	O
an	O
increased	O
level	O
of	O
IL-8	O
production	O
in	O
human	B
intestinal	O
epithelial	O
cells	O
.	O

In	O
contrast	O
,	O
PPARγ	O
was	O
a	O
counteracting	O
regulator	O
of	O
gut	O
inflammatory	O
response	O
through	O
attenuation	O
of	O
NF	O
-	O
κB	O
activation	O
.	O

The	O
collective	O
results	O
support	O
the	O
view	O
that	O
balances	O
between	O
CHOP	O
and	O
PPARγ	O
are	O
crucial	O
for	O
epithelial	O
homeostasis	O
,	O
and	O
disruption	O
of	O
these	O
balances	O
in	O
mucosal	O
ER	O
stress	O
can	O
etiologically	O
affect	O
the	O
progress	O
of	O
human	B
inflammatory	O
bowel	O
diseases	O
.	O

Differential	O
extraction	O
and	O
protein	O
sequencing	O
reveals	O
major	O
differences	O
in	O
patterns	O
of	O
primary	O
cell	O
wall	O
proteins	O
from	O
plants	O
.	O

The	O
proteins	O
of	O
the	O
primary	O
cell	O
walls	O
of	O
suspension	O
cultured	O
cells	O
of	O
five	O
plant	O
species	O
,	O
Arabidopsis	B
,	O
carrot	B
,	O
French	B
bean	I
,	O
tomato	B
,	O
and	O
tobacco	B
,	O
have	O
been	O
compared	O
.	O

The	O
approach	O
that	O
has	O
been	O
adopted	O
is	O
differential	O
extraction	O
followed	O
by	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
PAGE	O
)	O
,	O
rather	O
than	O
two	O
-	O
dimensional	O
gel	O
analysis	O
,	O
to	O
facilitate	O
protein	O
sequencing	O
.	O

Whole	O
cells	O
were	O
washed	O
sequentially	O
with	O
the	O
following	O
aqueous	O
solutions	O
,	O
CaCl2	O
,	O
CDTA	O
(	O
cyclohexane	O
diaminotetraacetic	O
acid	O
,	O
DTT	O
(	O
dithiothreitol	O
)	O
,	O
NaCl	O
,	O
and	O
borate	O
.	O

SDS	O
-	O
PAGE	O
analysis	O
showed	O
consistent	O
differences	O
between	O
species	O
.	O

From	O
the	O
233	O
proteins	O
that	O
were	O
selected	O
for	O
sequencing	O
,	O
63	O
%	O
gave	O
N	O
-	O
terminal	O
data	O
.	O

This	O
analysis	O
shows	O
that	O
(	O
i	O
)	O
patterns	O
of	O
proteins	O
revealed	O
by	O
SDS	O
-	O
PAGE	O
are	O
strikingly	O
different	O
for	O
all	O
five	O
species	O
,	O
(	O
ii	O
)	O
a	O
large	O
number	O
of	O
these	O
proteins	O
can	O
not	O
be	O
identified	O
by	O
data	O
base	O
searches	O
indicating	O
that	O
a	O
significant	O
proportion	O
of	O
wall	O
proteins	O
have	O
not	O
been	O
previously	O
described	O
,	O
(	O
iii	O
)	O
the	O
major	O
proteins	O
that	O
can	O
be	O
identified	O
belong	O
to	O
very	O
different	O
classes	O
of	O
proteins	O
,	O
(	O
iv	O
)	O
the	O
majority	O
of	O
proteins	O
found	O
in	O
the	O
extracellular	O
growth	O
media	O
are	O
absent	O
from	O
their	O
respective	O
cell	O
wall	O
extracts	O
,	O
and	O
(	O
v	O
)	O
the	O
results	O
of	O
the	O
extraction	O
process	O
are	O
indicative	O
of	O
higher	O
order	O
structure	O
.	O

It	O
appears	O
that	O
aspects	O
of	O
speciation	O
reside	O
in	O
the	O
complement	O
of	O
extracellular	O
wall	O
proteins	O
.	O

The	O
data	O
represent	O
a	O
protein	O
resource	O
for	O
cell	O
wall	O
studies	O
complementary	O
to	O
EST	O
(	O
expressed	O
sequence	O
tag	O
)	O
and	O
DNA	O
sequencing	O
strategies	O
.	O

We	O
report	O
here	O
on	O
a	O
patient	B
who	O
was	O
treated	O
for	O
an	O
atypical	O
brain	O
meningioma	O
with	O
multiple	O
surgeries	O
and	O
multiple	O
sessions	O
of	O
stereotactic	O
radiosurgery	O
with	O
good	O
control	O
of	O
his	O
brain	O
disease	O
.	O

Thirteen	O
years	O
after	O
diagnosis	O
,	O
he	O
developed	O
bilateral	O
large	O
sacroiliac	O
and	O
abdominal	O
metastases	O
.	O

Extracranial	O
metastases	O
from	O
brain	O
meningiomas	O
is	O
a	O
rare	O
,	O
but	O
well	O
-	O
documented	O
entity	O
.	O

Metastases	O
occur	O
mostly	O
in	O
the	O
lungs	O
,	O
pleura	O
and	O
liver	O
,	O
but	O
may	O
also	O
affect	O
lymph	O
nodes	O
and	O
bones	O
.	O

Extraneural	O
metastases	O
from	O
cranial	O
meningioma	O
:	O
a	O
case	O
report	O
.	O

Here	O
we	O
expand	O
the	O
role	O
of	O
GRN	O
in	O
FTLD	O
-	O
U	O
and	O
demonstrate	O
that	O
a	O
common	O
genetic	O
variant	O
(	O
rs5848	O
)	O
,	O
located	O
in	O
the	O
3'-untranslated	O
region	O
(	O
UTR	O
)	O
of	O
GRN	O
in	O
a	O
binding	O
-	O
site	O
for	O
miR-659	O
,	O
is	O
a	O
major	O
susceptibility	O
factor	O
for	O
FTLD	O
-	O
U.	O

Loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
progranulin	O
(	O
GRN	O
)	O
cause	O
ubiquitin-	O
and	O
TAR	O
DNA	O
-	O
binding	O
protein	O
43	O
(	O
TDP-43	O
)	O
-positive	O
frontotemporal	O
dementia	O
(	O
FTLD	O
-	O
U	O
)	O
,	O
a	O
progressive	O
neurodegenerative	O
disease	O
affecting	O
approximately	O
10	O
%	O
of	O
early	O
-	O
onset	O
dementia	O
patients	B
.	O

Common	O
variation	O
in	O
the	O
miR-659	O
binding	O
-	O
site	O
of	O
GRN	O
is	O
a	O
major	O
risk	O
factor	O
for	O
TDP43-positive	O
frontotemporal	O
dementia	O
.	O

In	O
support	O
of	O
these	O
findings	O
,	O
the	O
neuropathology	O
of	O
homozygous	O
rs5848	O
T	O
-	O
allele	O
carriers	O
frequently	O
resembled	O
the	O
pathological	O
FTLD	O
-	O
U	O
subtype	O
of	O
GRN	O
mutation	O
carriers	O
.	O

A	O
significant	O
reduction	O
in	O
GRN	O
protein	O
was	O
observed	O
in	O
homozygous	O
T	O
-	O
allele	O
carriers	O
in	O
vivo	O
,	O
through	O
biochemical	O
and	O
immunohistochemical	O
methods	O
,	O
mimicking	O
the	O
effect	O
of	O
heterozygous	O
loss	O
-	O
of	O
-	O
function	O
GRN	O
mutations	O
.	O

We	O
further	O
demonstrate	O
that	O
miR-659	O
can	O
regulate	O
GRN	O
expression	O
in	O
vitro	O
,	O
with	O
miR-659	O
binding	O
more	O
efficiently	O
to	O
the	O
high	O
risk	O
T	O
-	O
allele	O
of	O
rs5848	O
resulting	O
in	O
augmented	O
translational	O
inhibition	O
of	O
GRN	O
.	O

In	O
a	O
series	O
of	O
pathologically	O
confirmed	O
FTLD	O
-	O
U	O
patients	B
without	O
GRN	O
mutations	O
,	O
we	O
show	O
that	O
carriers	O
homozygous	O
for	O
the	O
T	O
-	O
allele	O
of	O
rs5848	O
have	O
a	O
3.2-fold	O
increased	O
risk	O
to	O
develop	O
FTLD	O
-	O
U	O
compared	O
with	O
homozygous	O
C	O
-	O
allele	O
carriers	O
(	O
95	O
%	O
CI	O
:	O
1.50	O
-	O
6.73	O
)	O
.	O

Translational	O
regulation	O
by	O
miRNAs	O
may	O
represent	O
a	O
common	O
mechanism	O
underlying	O
complex	O
neurodegenerative	O
disorders	O
.	O

We	O
suggest	O
that	O
the	O
expression	O
of	O
GRN	O
is	O
regulated	O
by	O
miRNAs	O
and	O
that	O
common	O
genetic	O
variability	O
in	O
a	O
miRNA	O
binding	O
-	O
site	O
can	O
significantly	O
increase	O
the	O
risk	O
for	O
FTLD	O
-	O
U.	O

Here	O
,	O
we	O
discuss	O
recent	O
data	O
that	O
support	O
a	O
view	O
that	O
endolysosomal	O
positioning	O
of	O
RNA	O
might	O
facilitate	O
intercellular	O
transmission	O
of	O
RNA	O
and	O
host	O
defence	O
against	O
viruses	O
and	O
retrotransposons	O
.	O

Positioning	O
of	O
RNA	O
regulatory	O
mechanisms	O
on	O
endolysosomal	O
membranes	O
might	O
permit	O
rapid	O
and	O
localized	O
control	O
of	O
microRNA	O
(	O
miRNA	O
)	O
gene	O
regulatory	O
programs	O
and	O
mRNA	O
translation	O
in	O
response	O
to	O
environmental	O
signals	O
,	O
such	O
as	O
activated	O
plasma	O
membrane	O
receptors	O
transported	O
on	O
endosomes	O
.	O

Finally	O
,	O
we	O
suggest	O
that	O
the	O
pathology	O
of	O
several	O
conditions	O
,	O
including	O
Huntington	O
's	O
disease	O
,	O
might	O
be	O
a	O
consequence	O
of	O
the	O
disruption	O
of	O
the	O
control	O
of	O
RNA	O
via	O
endolysosomal	O
membranes	O
.	O

Control	O
of	O
RNA	O
silencing	O
and	O
localization	O
by	O
endolysosomes	O
.	O

Recent	O
advances	O
in	O
the	O
cell	O
biology	O
of	O
RNA	O
silencing	O
have	O
unraveled	O
an	O
intriguing	O
association	O
of	O
post	O
-	O
transcriptionally	O
regulated	O
RNA	O
with	O
endolysosomal	O
membranes	O
in	O
several	O
circumstances	O
of	O
mRNA	O
localization	O
,	O
microRNA	O
activity	O
and	O
viral	O
RNA	O
transport	O
and	O
packaging	O
.	O

Endolysosomal	O
membranes	O
are	O
a	O
nexus	O
of	O
communication	O
and	O
transport	O
between	O
cells	O
and	O
their	O
exterior	O
environment	O
for	O
signaling	O
receptors	O
,	O
pathogens	O
and	O
nutrients	O
.	O

The	O
method	O
by	O
which	O
MSCs	O
could	O
be	O
applied	O
for	O
future	O
therapies	O
might	O
require	O
trans	O
-	O
disciplinary	O
approaches	O
for	O
personalized	O
treatments	O
.	O

Implantation	O
of	O
adult	O
human	B
mesenchymal	O
stem	O
cells	O
(	O
MSCs	O
)	O
to	O
treat	O
neural	O
disorders	O
shows	O
promise	O
.	O

Depending	O
on	O
their	O
microenvironment	O
,	O
MSCs	O
could	O
potentially	O
be	O
used	O
for	O
the	O
repair	O
and/or	O
replacement	O
of	O
neurons	O
in	O
traumatic	O
brain	O
injury	O
or	O
the	O
treatment	O
of	O
Parkinson	O
's	O
disease	O
.	O

This	O
cross	O
-	O
disciplinary	O
review	O
incorporates	O
aspects	O
of	O
neuroscience	O
,	O
stem	O
cell	O
biology	O
,	O
cancer	O
biology	O
and	O
immunology	O
to	O
discuss	O
interactions	O
between	O
inflammatory	O
mediators	O
and	O
MSCs	O
.	O

We	O
first	O
discuss	O
the	O
role	O
of	O
microRNAs	O
(	O
miRNAs	O
)	O
in	O
neurological	O
development	O
.	O

Neurogenesis	O
:	O
role	O
for	O
microRNAs	O
and	O
mesenchymal	O
stem	O
cells	O
in	O
pathological	O
states	O
.	O

Exploring	O
the	O
predisposition	O
of	O
MSCs	O
to	O
oncogenesis	O
is	O
critical	O
for	O
translational	O
science	O
since	O
the	O
implementation	O
of	O
safeguarding	O
measures	O
prior	O
to	O
therapy	O
can	O
lead	O
to	O
the	O
successful	O
delivery	O
of	O
stem	O
cells	O
to	O
patients	B
.	O

The	O
administration	O
of	O
effective	O
and	O
safe	O
MSC	O
therapy	O
must	O
acknowledge	O
immune	O
mediators	O
that	O
may	O
predispose	O
the	O
early	O
differentiating	O
MSCs	O
to	O
oncogenic	O
insults	O
.	O

Secondly	O
,	O
we	O
discuss	O
the	O
ability	O
of	O
MSCs	O
to	O
transdifferentiate	O
into	O
functional	O
neurons	O
,	O
which	O
are	O
regulated	O
by	O
miRNAs	O
,	O
and	O
the	O
implications	O
of	O
these	O
cells	O
for	O
the	O
therapy	O
of	O
neuropathological	O
states	O
.	O

Immune	O
mediators	O
could	O
be	O
central	O
to	O
MSC	O
responses	O
within	O
a	O
region	O
of	O
tissue	O
injury	O
and	O
are	O
also	O
discussed	O
in	O
detail	O
.	O

Thus	O
,	O
we	O
discuss	O
a	O
key	O
gene	O
,	O
RE-1	O
silencing	O
transcription	O
factor	O
(	O
REST	O
)	O
,	O
based	O
on	O
its	O
dual	O
role	O
in	O
neurogenesis	O
and	O
cancer	O
development	O
.	O

Finally	O
,	O
a	O
phylogenetic	O
analysis	O
shows	O
that	O
ADCK3	O
belongs	O
to	O
the	O
family	O
of	O
atypical	O
kinases	O
,	O
which	O
includes	O
phosphoinositide	O
and	O
choline	O
kinases	O
,	O
suggesting	O
that	O
ADCK3	O
plays	O
an	O
indirect	O
regulatory	O
role	O
in	O
ubiquinone	O
biosynthesis	O
possibly	O
as	O
part	O
of	O
a	O
feedback	O
loop	O
that	O
regulates	O
ATP	O
production	O
.	O

ADCK3	O
,	O
an	O
ancestral	O
kinase	O
,	O
is	O
mutated	O
in	O
a	O
form	O
of	O
recessive	O
ataxia	O
associated	O
with	O
coenzyme	O
Q10	O
deficiency	O
.	O

Muscle	O
coenzyme	O
Q	O
(	O
10	O
)	O
(	O
CoQ	O
(	O
10	O
)	O
or	O
ubiquinone	O
)	O
deficiency	O
has	O
been	O
identified	O
in	O
more	O
than	O
20	O
patients	B
with	O
presumed	O
autosomal	O
-	O
recessive	O
ataxia	O
.	O

However	O
,	O
mutations	O
in	O
genes	O
required	O
for	O
CoQ	O
(	O
10	O
)	O
biosynthetic	O
pathway	O
have	O
been	O
identified	O
only	O
in	O
patients	B
with	O
infantile	O
-	O
onset	O
multisystemic	O
diseases	O
or	O
isolated	O
nephropathy	O
.	O

Our	O
SNP	O
-	O
based	O
genome	O
-	O
wide	O
scan	O
in	O
a	O
large	O
consanguineous	O
family	O
revealed	O
a	O
locus	O
for	O
autosomal	O
-	O
recessive	O
ataxia	O
at	O
chromosome	O
1q41	O
.	O

The	O
causative	O
mutation	O
is	O
a	O
homozygous	O
splice	O
-	O
site	O
mutation	O
in	O
the	O
aarF	O
-	O
domain	O
-	O
containing	O
kinase	O
3	O
gene	O
(	O
ADCK3	O
)	O
.	O

Five	O
additional	O
mutations	O
in	O
ADCK3	O
were	O
found	O
in	O
three	O
patients	B
with	O
sporadic	O
ataxia	O
,	O
including	O
one	O
known	O
to	O
have	O
CoQ	O
(	O
10	O
)	O
deficiency	O
in	O
muscle	O
.	O

All	O
of	O
the	O
patients	B
have	O
childhood	O
-	O
onset	O
cerebellar	O
ataxia	O
with	O
slow	O
progression	O
,	O
and	O
three	O
of	O
six	O
have	O
mildly	O
elevated	O
lactate	O
levels	O
.	O

ADCK3	O
is	O
a	O
mitochondrial	O
protein	O
homologous	O
to	O
the	O
yeast	O
COQ8	O
and	O
the	O
bacterial	O
UbiB	O
proteins	O
,	O
which	O
are	O
required	O
for	O
CoQ	O
biosynthesis	O
.	O

Three	O
out	O
of	O
four	O
patients	B
tested	O
showed	O
a	O
low	O
endogenous	O
pool	O
of	O
CoQ	O
(	O
10	O
)	O
in	O
their	O
fibroblasts	O
or	O
lymphoblasts	O
,	O
and	O
two	O
out	O
of	O
three	O
patients	B
showed	O
impaired	O
ubiquinone	O
synthesis	O
,	O
strongly	O
suggesting	O
that	O
ADCK3	O
is	O
also	O
involved	O
in	O
CoQ	O
(	O
10	O
)	O
biosynthesis	O
.	O

The	O
deleterious	O
nature	O
of	O
the	O
three	O
identified	O
missense	O
changes	O
was	O
confirmed	O
by	O
the	O
introduction	O
of	O
them	O
at	O
the	O
corresponding	O
positions	O
of	O
the	O
yeast	O
COQ8	O
gene	O
.	O

Interpretation	O
and	O
applicability	O
of	O
microRNA	O
data	O
to	O
the	O
context	O
of	O
Alzheimer	O
's	O
and	O
age	O
-	O
related	O
diseases	O
.	O

Generated	O
by	O
the	O
ribonuclease	O
III	O
Dicer	O
,	O
microRNAs	O
(	O
miRNAs	O
)	O
are	O
predicted	O
to	O
regulate	O
up	O
to	O
90	O
%	O
of	O
the	O
genes	O
in	O
humans	B
,	O
suggesting	O
that	O
they	O
may	O
control	O
every	O
cellular	O
processes	O
in	O
all	O
cells	O
and	O
tissues	O
of	O
the	O
human	B
body	O
!	O

Likely	O
to	O
play	O
a	O
central	O
role	O
in	O
health	O
and	O
disease	O
,	O
a	O
dysfunctional	O
miRNA	O
-	O
based	O
regulation	O
of	O
gene	O
expression	O
may	O
represent	O
the	O
main	O
etiologic	O
factor	O
underlying	O
age	O
-	O
related	O
diseases	O
affecting	O
major	O
organs	O
,	O
such	O
as	O
the	O
brain	O
.	O

Here	O
,	O
we	O
discuss	O
some	O
of	O
the	O
limitations	O
associated	O
to	O
the	O
interpretation	O
and	O
applicability	O
of	O
miRNA	O
data	O
,	O
based	O
on	O
our	O
recent	O
study	O
on	O
the	O
etiology	O
of	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

Using	O
transiently	O
transfected	O
murine	B
neuronal	O
N2a	O
cells	O
in	O
culture	O
,	O
in	O
parallel	O
to	O
a	O
mouse	B
model	O
of	O
AD	O
,	O
we	O
were	O
able	O
to	O
demonstrate	O
a	O
role	O
for	O
two	O
miRNAs	O
(	O
miR-298	O
and	O
miR-328	O
)	O
in	O
the	O
regulation	O
of	O
beta	O
-	O
amyloid	O
(	O
Abeta	O
)	O
precursor	O
protein	O
(	O
APP	O
)	O
-converting	O
enzyme	O
(	O
BACE	O
)	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
translation	O
,	O
thereby	O
providing	O
key	O
insights	O
into	O
the	O
molecular	O
basis	O
underlying	O
BACE	O
deregulation	O
in	O
AD	O
.	O

However	O
,	O
whether	O
miRNA	O
data	O
can	O
be	O
extrapolated	O
and	O
transposed	O
to	O
the	O
human	B
context	O
of	O
age	O
-	O
related	O
diseases	O
,	O
such	O
as	O
AD	O
,	O
not	O
only	O
requires	O
caution	O
,	O
but	O
also	O
warrants	O
several	O
considerations	O
.	O

Levels	O
of	O
protein	O
expression	O
of	O
endothelial	O
NO	O
synthase	O
(	O
eNOS	O
)	O
,	O
caveolin-1	O
,	O
and	O
calmodulin	O
were	O
assessed	O
in	O
carotid	O
arteries	O
using	O
Western	O
analysis	O
.	O

Plasma	O
NO	O
levels	O
were	O
doubled	O
by	O
daidzein	O
or	O
17beta	O
-	O
estradiol	O
.	O

NO	O
production	O
and	O
endothelium	O
-	O
dependent	O
contraction	O
in	O
response	O
to	O
the	O
NOS	O
inhibitor	O
NG	O
-	O
nitro	O
-	O
L	O
-	O
arginine	O
(	O
L	O
-	O
NNA	O
;	O
100	O
microM	O
)	O
was	O
enhanced	O
by	O
50	O
to	O
100	O
%	O
in	O
carotid	O
arteries	O
from	O
rats	B
treated	O
with	O
daidzein	O
or	O
17beta	O
-	O
estradiol	O
.	O

Acetylcholine	O
-	O
induced	O
relaxation	O
was	O
selectively	O
enhanced	O
in	O
carotid	O
arteries	O
from	O
rats	B
treated	O
with	O
daidzein	O
.	O

The	O
use	O
of	O
estrogen	O
for	O
protection	O
against	O
vascular	O
dysfunction	O
is	O
limited	O
due	O
to	O
its	O
effects	O
on	O
the	O
reproductive	O
system	O
,	O
particularly	O
in	O
males	O
.	O

We	O
postulated	O
that	O
daidzein	O
,	O
an	O
isoflavone	O
with	O
estrogen	O
-	O
like	O
effects	O
on	O
the	O
systemic	O
vasculature	O
but	O
not	O
the	O
reproductive	O
system	O
,	O
might	O
enhance	O
nitric	O
oxide	O
(	O
NO	O
)	O
-mediated	O
cerebral	O
vasodilatation	O
.	O

Male	O
rats	B
were	O
administered	O
vehicle	O
,	O
17beta	O
-	O
estradiol	O
(	O
0.1	O
mg	O
/	O
kg	O
s.c	O
.	O
)	O
,	O
or	O
daidzein	O
(	O
0.2	O
mg	O
/	O
kg	O
s.c	O
.	O
)	O
daily	O
for	O
7	O
days	O
.	O

Basal	O
and	O
acetylcholine	O
-	O
stimulated	O
NO	O
release	O
was	O
assessed	O
in	O
vitro	O
via	O
carotid	O
arterial	O
rings	O
or	O
in	O
vivo	O
by	O
measuring	O
changes	O
in	O
basilar	O
artery	O
diameter	O
.	O

Similarly	O
,	O
constrictor	O
responses	O
of	O
the	O
basilar	O
artery	O
to	O
L	O
-	O
NNA	O
in	O
vivo	O
were	O
selectively	O
augmented	O
by	O
approximately	O
100	O
%	O
by	O
17beta	O
-	O
estradiol	O
treatment	O
and	O
tended	O
to	O
be	O
approximately	O
50	O
%	O
greater	O
in	O
daidzein	O
-	O
treated	O
rats	B
.	O

Effect	O
of	O
short	O
-	O
term	O
phytoestrogen	O
treatment	O
in	O
male	O
rats	B
on	O
nitric	O
oxide	O
-	O
mediated	O
responses	O
of	O
carotid	O
and	O
cerebral	O
arteries	O
:	O
comparison	O
with	O
17beta	O
-	O
estradiol	O
.	O

These	O
data	O
suggest	O
that	O
short	O
-	O
term	O
administration	O
of	O
daidzein	O
or	O
17beta	O
-	O
estradiol	O
modulates	O
cerebral	O
artery	O
reactivity	O
in	O
males	O
by	O
enhancing	O
synthesis	O
and	O
release	O
of	O
endothelium	O
-	O
derived	O
NO	O
.	O
Isoflavone	O
therapy	O
may	O
therefore	O
be	O
a	O
feasible	O
approach	O
to	O
protect	O
against	O
cerebrovascular	O
disease	O
and	O
stroke	O
.	O

Expression	O
of	O
caveolin-1	O
was	O
decreased	O
,	O
and	O
calmodulin	O
was	O
increased	O
,	O
in	O
vessels	O
from	O
daidzein-	O
or	O
17beta	O
-	O
estradiol	O
-	O
treated	O
rats	B
.	O

eNOS	O
expression	O
was	O
unaffected	O
by	O
the	O
treatments	O
.	O

However	O
,	O
we	O
report	O
the	O
experience	O
of	O
a	O
patient	B
who	O
inadvertently	O
received	O
live	O
polio	O
vaccine	O
whilst	O
receiving	O
anti	O
-	O
TNF	O
therapy	O
.	O

International	O
guidelines	O
state	O
that	O
live	O
vaccines	O
are	O
contraindicated	O
in	O
patients	B
on	O
anti	O
-	O
TNF	O
therapy	O
.	O

Live	O
polio	O
vaccine	O
exposure	O
while	O
receiving	O
anti	O
-	O
TNF	O
therapy	O
for	O
reactive	O
arthritis	O
.	O

Patients	B
should	O
be	O
counseled	O
regarding	O
the	O
risks	O
of	O
live	O
vaccines	O
prior	O
to	O
treatment	O
with	O
anti	O
-	O
TNF	O
therapy	O
.	O

However	O
,	O
if	O
we	O
consider	O
adult	O
patients	B
with	O
rheumatic	O
diseases	O
to	O
have	O
altered	O
immunocompetence	O
,	O
it	O
is	O
recommended	O
that	O
they	O
receive	O
the	O
usual	O
inactivated	O
vaccines	O
according	O
to	O
standard	O
schedules	O
,	O
and	O
live	O
vaccines	O
should	O
be	O
avoided	O
in	O
those	O
who	O
are	O
treated	O
with	O
more	O
potent	O
forms	O
of	O
immune	O
suppression	O
.	O

No	O
clear	O
guidelines	O
are	O
available	O
for	O
all	O
vaccines	O
in	O
patients	B
with	O
specific	O
rheumatic	O
diseases	O
.	O

Patient	B
did	O
not	O
suffer	O
from	O
any	O
infectious	O
sequel	O
as	O
a	O
result	O
.	O

Autosomal	O
-	O
recessive	O
cerebellar	O
ataxias	O
comprise	O
a	O
clinically	O
and	O
genetically	O
heterogeneous	O
group	O
of	O
neurodegenerative	O
disorders	O
.	O

In	O
contrast	O
to	O
their	O
dominant	O
counterparts	O
,	O
unraveling	O
the	O
molecular	O
background	O
of	O
these	O
ataxias	O
has	O
proven	O
to	O
be	O
more	O
complicated	O
and	O
the	O
currently	O
known	O
mutations	O
provide	O
incomplete	O
coverage	O
for	O
genotyping	O
of	O
patients	B
.	O

By	O
combining	O
SNP	O
array	O
-	O
based	O
linkage	O
analysis	O
and	O
targeted	O
resequencing	O
of	O
relevant	O
sequences	O
in	O
the	O
linkage	O
interval	O
with	O
the	O
use	O
of	O
next	O
-	O
generation	O
sequencing	O
technology	O
,	O
we	O
identified	O
a	O
mutation	O
in	O
a	O
gene	O
and	O
have	O
shown	O
its	O
association	O
with	O
autosomal	O
-	O
recessive	O
cerebellar	O
ataxia	O
.	O

In	O
a	O
Dutch	O
consanguineous	O
family	O
with	O
three	O
affected	O
siblings	O
a	O
homozygous	O
12.5	O
Mb	O
region	O
on	O
chromosome	O
3	O
was	O
targeted	O
by	O
array	O
-	O
based	O
sequence	O
capture	O
.	O

Targeted	O
next	O
-	O
generation	O
sequencing	O
of	O
a	O
12.5	O
Mb	O
homozygous	O
region	O
reveals	O
ANO10	O
mutations	O
in	O
patients	B
with	O
autosomal	O
-	O
recessive	O
cerebellar	O
ataxia	O
.	O

The	O
analysis	O
of	O
ANO10	O
by	O
Sanger	O
sequencing	O
revealed	O
three	O
additional	O
mutations	O
:	O
a	O
homozygous	O
mutation	O
(	O
c.1150_1151del	O
[	O
p	O
.	O
Leu384fs	O
]	O
)	O
in	O
a	O
Serbian	O
family	O
and	O
a	O
compound	O
-	O
heterozygous	O
splice	O
-	O
site	O
mutation	O
(	O
c.1476	O
+	O
1G	O
>	O
T	O
)	O
and	O
a	O
frameshift	O
mutation	O
(	O
c.1604del	O
[	O
p	O
.	O
Leu535X	O
]	O
)	O
in	O
a	O
French	O
family	O
.	O

This	O
illustrates	O
the	O
power	O
of	O
using	O
initial	O
homozygosity	O
mapping	O
with	O
next	O
-	O
generation	O
sequencing	O
technology	O
to	O
identify	O
genes	O
involved	O
in	O
autosomal	O
-	O
recessive	O
diseases	O
.	O

Prioritization	O
of	O
all	O
detected	O
sequence	O
variants	O
led	O
to	O
four	O
candidate	O
genes	O
,	O
one	O
of	O
which	O
contained	O
a	O
variant	O
with	O
a	O
high	O
base	O
pair	O
conservation	O
score	O
(	O
phyloP	O
score	O
:	O
5.26	O
)	O
.	O

This	O
variant	O
was	O
a	O
leucine	O
-	O
to	O
-	O
arginine	O
substitution	O
in	O
the	O
DUF	O
590	O
domain	O
of	O
a	O
16	O
K	O
transmembrane	O
protein	O
,	O
a	O
putative	O
calcium	O
-	O
activated	O
chloride	O
channel	O
encoded	O
by	O
anoctamin	O
10	O
(	O
ANO10	O
)	O
.	O

Moreover	O
,	O
identifying	O
a	O
putative	O
calcium	O
-	O
dependent	O
chloride	O
channel	O
involved	O
in	O
cerebellar	O
ataxia	O
adds	O
another	O
pathway	O
to	O
the	O
list	O
of	O
pathophysiological	O
mechanisms	O
that	O
may	O
cause	O
cerebellar	O
ataxia	O
.	O

These	O
findings	O
further	O
support	O
the	O
idea	O
that	O
iron-	O
and	O
aluminum	O
-	O
sulfates	O
induce	O
genotoxicity	O
via	O
a	O
ROS	O
-	O
mediated	O
up	O
-	O
regulation	O
of	O
specific	O
regulatory	O
elements	O
and	O
pathogenic	O
genes	O
that	O
redirect	O
brain	O
cell	O
fate	O
towards	O
progressive	O
dysfunction	O
and	O
apoptotic	O
cell	O
death	O
.	O

Notably	O
,	O
these	O
same	O
miRNAs	O
are	O
up	O
-	O
regulated	O
in	O
AD	O
brain	O
.	O

The	O
main	O
finding	O
was	O
that	O
these	O
ROS	O
-	O
generating	O
neurotoxic	O
metal	O
sulfates	O
also	O
up	O
-	O
regulate	O
a	O
specific	O
set	O
of	O
miRNAs	O
that	O
includes	O
miR-9	O
,	O
miR-125b	O
and	O
miR-128	O
.	O

In	O
this	O
study	O
we	O
have	O
extended	O
our	O
investigations	O
to	O
analyze	O
the	O
expression	O
of	O
micro	O
RNA	O
(	O
miRNA	O
)	O
populations	O
in	O
iron-	O
and	O
aluminum	O
-	O
sulfate	O
treated	O
human	B
neural	O
cells	O
in	O
primary	O
culture	O
.	O

Notably	O
,	O
iron-	O
and	O
aluminum	O
-	O
sulfate	O
induce	O
genes	O
in	O
cultured	O
human	B
brain	O
cells	O
that	O
exhibit	O
expression	O
patterns	O
similar	O
to	O
those	O
observed	O
to	O
be	O
up	O
-	O
regulated	O
in	O
moderate-	O
to	O
late	O
-	O
stage	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
following	O
ROS	O
induction	O
,	O
a	O
family	O
of	O
pathogenic	O
brain	O
genes	O
that	O
promote	O
inflammatory	O
signalling	O
,	O
cellular	O
apoptosis	O
and	O
brain	O
cell	O
death	O
is	O
significantly	O
over	O
-	O
expressed	O
.	O

Iron-	O
and	O
aluminum	O
-	O
sulfate	O
together	O
,	O
at	O
nanomolar	O
concentrations	O
,	O
trigger	O
the	O
production	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
in	O
cultures	O
of	O
human	B
brain	O
cells	O
.	O

Induction	O
of	O
specific	O
micro	O
RNA	O
(	O
miRNA	O
)	O
species	O
by	O
ROS	O
-	O
generating	O
metal	O
sulfates	O
in	O
primary	O
human	B
brain	O
cells	O
.	O

The	O
rapid	O
and	O
exciting	O
pace	O
of	O
advances	O
in	O
glioblastoma	O
genetics	O
has	O
prompted	O
this	O
up	O
-	O
to	O
-	O
date	O
review	O
.	O

The	O
likely	O
impact	O
on	O
care	O
delivery	O
in	O
the	O
clinic	O
may	O
only	O
be	O
a	O
few	O
years	O
away	O
.	O

Within	O
the	O
last	O
few	O
years	O
,	O
high	O
-	O
throughput	O
efforts	O
such	O
as	O
The	O
Cancer	O
Genome	O
Atlas	O
and	O
a	O
massive	O
sequencing	O
project	O
have	O
yielded	O
novel	O
insights	O
and	O
classifications	O
of	O
this	O
dreaded	O
cancer	O
.	O

It	O
has	O
been	O
hoped	O
that	O
dissection	O
of	O
the	O
genetics	O
of	O
this	O
cancer	O
would	O
lead	O
to	O
more	O
targeted	O
and	O
effective	O
treatments	O
,	O
and	O
new	O
advances	O
may	O
finally	O
be	O
bringing	O
this	O
closer	O
to	O
fruition	O
.	O

Glioblastoma	O
genetics	O
:	O
in	O
rapid	O
flux	O
.	O

Glioblastoma	O
is	O
the	O
most	O
common	O
and	O
most	O
lethal	O
primary	O
brain	O
tumor	O
.	O

While	O
small	O
progress	O
has	O
been	O
made	O
in	O
treating	O
this	O
cancer	O
in	O
recent	O
years	O
,	O
glioblastoma	O
remains	O
largely	O
resistant	O
to	O
all	O
existing	O
therapies	O
.	O

Novel	O
animal	O
models	O
for	O
studying	O
complex	O
brain	O
disorders	O
:	O
BAC	O
-	O
driven	O
miRNA	O
-	O
mediated	O
in	O
vivo	O
silencing	O
of	O
gene	O
expression	O
.	O

In	O
schizophrenia	O
,	O
glutamic	O
acid	O
decarboxylase	O
1	O
(	O
GAD1	O
)	O
disturbances	O
are	O
robust	O
,	O
consistently	O
observed	O
,	O
cell	O
-	O
type	O
specific	O
and	O
represent	O
a	O
core	O
feature	O
of	O
the	O
disease	O
.	O

In	O
addition	O
,	O
neuropeptide	O
Y	O
(	O
NPY	O
)	O
,	O
which	O
is	O
a	O
phenotypic	O
marker	O
of	O
a	O
sub	O
-	O
population	O
of	O
GAD1-containing	O
interneurons	O
,	O
has	O
shown	O
reduced	O
expression	O
in	O
the	O
prefrontal	O
cortex	O
in	O
subjects	O
with	O
schizophrenia	O
,	O
suggesting	O
that	O
dysfunction	O
of	O
the	O
NPY+	O
cortical	O
interneuronal	O
sub	O
-	O
population	O
might	O
be	O
a	O
core	O
feature	O
of	O
this	O
devastating	O
disorder	O
.	O

However	O
,	O
modeling	O
gene	O
expression	O
disturbances	O
in	O
schizophrenia	O
in	O
a	O
cell	O
type	O
-	O
specific	O
manner	O
has	O
been	O
extremely	O
challenging	O
.	O

To	O
more	O
closely	O
mimic	O
these	O
molecular	O
and	O
cellular	O
human	B
post	O
-	O
mortem	O
findings	O
,	O
we	O
generated	O
a	O
transgenic	B
mouse	I
in	O
which	O
we	O
downregulated	O
GAD1	O
mRNA	O
expression	O
specifically	O
in	O
NPY+	O
neurons	O
.	O

This	O
novel	O
,	O
cell	O
type	O
-	O
specific	O
in	O
vivo	O
system	O
for	O
reducing	O
gene	O
expression	O
uses	O
a	O
bacterial	O
artificial	O
chromosome	O
(	O
BAC	O
)	O
containing	O
the	O
NPY	O
promoter	O
-	O
enhancer	O
elements	O
,	O
the	O
reporter	O
molecule	O
(	O
eGFP	O
)	O
and	O
a	O
modified	O
intron	O
containing	O
a	O
synthetic	O
microRNA	O
(	O
miRNA	O
)	O
targeted	O
to	O
GAD1	O
.	O

The	O
animals	O
of	O
isogenic	O
strains	O
are	O
generated	O
rapidly	O
,	O
providing	O
a	O
new	O
tool	O
for	O
better	O
understanding	O
the	O
molecular	O
disturbances	O
in	O
the	O
GABAergic	O
system	O
observed	O
in	O
complex	O
neuropsychiatric	O
disorders	O
such	O
as	O
schizophrenia	O
.	O

In	O
the	O
future	O
,	O
because	O
of	O
the	O
small	O
size	O
of	O
the	O
silencing	O
miRNAs	O
combined	O
with	O
our	O
BAC	O
strategy	O
,	O
this	O
method	O
may	O
be	O
modified	O
to	O
allow	O
generation	O
of	O
mice	B
with	O
simultaneous	O
silencing	O
of	O
multiple	O
genes	O
in	O
the	O
same	O
cells	O
with	O
a	O
single	O
construct	O
,	O
and	O
production	O
of	O
splice	O
-	O
variant	O
-	O
specific	O
knockdown	O
animals	O
.	O

Biomarkers	O
associated	O
with	O
metastasis	O
of	O
lung	O
cancer	O
to	O
brain	O
predict	O
patient	B
survival	O
.	O

This	O
research	O
involves	O
comprehensive	O
miRNA	O
expression	O
profiling	O
,	O
evaluation	O
of	O
normalisation	O
techniques	O
and	O
combination	O
of	O
miRNA	O
with	O
imaging	O
features	O
FDG	O
-	O
PET	O
/	O
CT	O
and	O
CT	O
Scan	O
.	O

We	O
combine	O
validated	O
miRNA	O
expression	O
values	O
with	O
imaging	O
features	O
to	O
classify	O
NSCLC	O
brain	O
mets	O
from	O
non	O
-	O
brain	O
mets	O
and	O
identify	O
possible	O
biomarkers	O
of	O
brain	O
mets	O
.	O

Generally	O
,	O
one	O
miRNA	O
is	O
predicted	O
to	O
regulate	O
several	O
hundred	O
genes	O
,	O
and	O
as	O
a	O
result	O
,	O
miRNAs	O
could	O
serve	O
as	O
a	O
better	O
classifier	O
than	O
gene	O
expression	O
.	O

MicroRNAs	O
influence	O
cell	O
physiology	O
;	O
alteration	O
in	O
miRNA	O
regulation	O
can	O
be	O
implicated	O
in	O
carcinogenesis	O
and	O
disease	O
progression	O
.	O

The	O
biomarkers	O
were	O
validated	O
on	O
an	O
independent	O
data	O
set	O
to	O
predict	O
potential	O
brain	O
mets	O
.	O

Through	O
various	O
experimental	O
approaches	O
,	O
we	O
validated	O
computational	O
predictions	O
and	O
demonstrated	O
that	O
miR-298	O
and	O
miR-328	O
recognize	O
specific	O
binding	O
sites	O
in	O
the	O
3'-UTR	O
of	O
BACE1	O
mRNA	O
and	O
exert	O
regulatory	O
effects	O
on	O
BACE1	O
protein	O
expression	O
in	O
cultured	O
neuronal	O
cells	O
.	O

Here	O
we	O
also	O
observed	O
a	O
loss	O
of	O
correlation	O
between	O
BACE1	O
mRNA	O
and	O
protein	O
levels	O
in	O
the	O
hippocampus	O
of	O
a	O
mouse	B
model	O
of	O
AD	O
.	O
Consistent	O
with	O
an	O
impairment	O
of	O
miRNA	O
-	O
mediated	O
regulation	O
of	O
BACE1	O
expression	O
,	O
these	O
findings	O
prompted	O
us	O
to	O
investigate	O
the	O
regulatory	O
role	O
of	O
the	O
BACE1	O
3'-UTR	O
element	O
and	O
the	O
possible	O
involvement	O
of	O
specific	O
miRNAs	O
in	O
cultured	O
neuronal	O
(	O
N2a	O
)	O
and	O
fibroblastic	O
(	O
NIH	O
3T3	O
)	O
cells	O
.	O

Our	O
results	O
may	O
provide	O
the	O
molecular	O
basis	O
underlying	O
BACE1	O
deregulation	O
in	O
AD	O
and	O
offer	O
new	O
perspectives	O
on	O
the	O
etiology	O
of	O
this	O
neurological	O
disorder	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
key	O
regulatory	O
RNAs	O
known	O
to	O
repress	O
mRNA	O
translation	O
through	O
recognition	O
of	O
specific	O
binding	O
sites	O
located	O
mainly	O
in	O
their	O
3'-untranslated	O
region	O
(	O
UTR	O
)	O
.	O

MicroRNA-298	O
and	O
microRNA-328	O
regulate	O
expression	O
of	O
mouse	B
beta	O
-	O
amyloid	O
precursor	O
protein	O
-	O
converting	O
enzyme	O
1	O
.	O

Intriguingly	O
,	O
previous	O
post	O
-	O
mortem	O
analyses	O
showed	O
higher	O
beta	O
-	O
amyloid	O
precursor	O
protein	O
-	O
converting	O
enzyme	O
(	O
BACE	O
)	O
protein	O
,	O
but	O
not	O
mRNA	O
,	O
levels	O
in	O
the	O
brain	O
of	O
patients	B
that	O
suffered	O
from	O
Alzheimer	O
disease	O
(	O
AD	O
)	O
.	O

Loss	O
of	O
specific	O
miRNA	O
control	O
of	O
gene	O
expression	O
is	O
thus	O
expected	O
to	O
underlie	O
serious	O
genetic	O
diseases	O
.	O

These	O
findings	O
reveal	O
a	O
significant	O
additional	O
mechanism	O
by	O
which	O
alpha	O
-	O
synuclein	O
is	O
regulated	O
and	O
point	O
toward	O
new	O
therapeutic	O
regimes	O
for	O
lowering	O
endogenous	O
alpha	O
-	O
synuclein	O
levels	O
in	O
patients	B
with	O
familial	O
or	O
sporadic	O
Parkinson	O
disease	O
.	O

Overexpression	O
of	O
mir-7	O
and	O
mir-153	O
significantly	O
reduces	O
endogenous	O
alpha	O
-	O
synuclein	O
levels	O
,	O
whereas	O
inhibition	O
of	O
mir-7	O
and	O
mir-153	O
enhances	O
translation	O
of	O
a	O
luciferase	O
construct	O
bearing	O
the	O
alpha	O
-	O
synuclein	O
3'-untranslated	O
region	O
in	O
primary	O
neurons	O
.	O

They	O
are	O
expressed	O
predominantly	O
in	O
the	O
brain	O
with	O
a	O
pattern	O
that	O
mirrors	O
synuclein	O
expression	O
in	O
different	O
tissues	O
as	O
well	O
as	O
during	O
neuronal	O
development	O
,	O
indicating	O
that	O
they	O
play	O
a	O
tuning	O
role	O
in	O
the	O
amount	O
of	O
alpha	O
-	O
synuclein	O
produced	O
.	O

These	O
microRNAs	O
bind	O
specifically	O
to	O
the	O
3'-untranslated	O
region	O
of	O
alpha	O
-	O
synuclein	O
and	O
down	O
-	O
regulate	O
its	O
mRNA	O
and	O
protein	O
levels	O
,	O
with	O
their	O
effect	O
being	O
additive	O
.	O

Here	O
,	O
two	O
microRNAs	O
,	O
namely	O
mir-7	O
and	O
mir-153	O
,	O
have	O
been	O
identified	O
to	O
regulate	O
alpha	O
-	O
synuclein	O
levels	O
post	O
-	O
transcriptionally	O
.	O

Genetic	O
and	O
biochemical	O
studies	O
have	O
established	O
a	O
central	O
role	O
for	O
alpha	O
-	O
synuclein	O
accumulation	O
in	O
the	O
pathogenesis	O
of	O
Parkinson	O
disease	O
.	O

Post	O
-	O
transcriptional	O
regulation	O
of	O
alpha	O
-	O
synuclein	O
expression	O
by	O
mir-7	O
and	O
mir-153	O
.	O

Learning	O
,	O
retention	O
and	O
generalization	O
of	O
a	O
mirror	O
tracing	O
skill	O
in	O
Alzheimer	O
's	O
disease	O
.	O

The	O
present	O
study	O
examined	O
the	O
ability	O
of	O
12	O
patients	B
with	O
probable	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
and	O
12	O
age-	O
and	O
education	O
-	O
matched	O
normal	O
control	O
(	O
NC	O
)	O
subjects	O
to	O
learn	O
and	O
retain	O
the	O
visuomotor	O
skills	O
necessary	O
to	O
efficiently	O
trace	O
a	O
pattern	O
(	O
e.g.	O
,	O
a	O
4-	O
or	O
6-pointed	O
star	O
)	O
seen	O
only	O
in	O
mirror	O
-	O
reversed	O
view	O
.	O

Those	O
AD	O
(	O
N=6	O
)	O
and	O
NC	O
(	O
N=7	O
)	O
subjects	O
who	O
were	O
able	O
to	O
initially	O
perform	O
the	O
basic	O
mirror	O
tracing	O
task	O
did	O
not	O
differ	O
significantly	O
in	O
initial	O
level	O
of	O
performance	O
,	O
learning	O
over	O
trials	O
,	O
retention	O
of	O
the	O
skill	O
over	O
a	O
30-min	O
delay	O
interval	O
,	O
and	O
generalization	O
of	O
the	O
skill	O
to	O
a	O
new	O
figure	O
or	O
to	O
the	O
opposite	O
direction	O
of	O
tracing	O
.	O

The	O
AD	O
patients	B
who	O
were	O
unable	O
to	O
initially	O
perform	O
the	O
mirror	O
tracing	O
task	O
were	O
significantly	O
worse	O
than	O
those	O
who	O
could	O
perform	O
the	O
task	O
on	O
several	O
neuropsychological	O
measures	O
sensitive	O
to	O
deficits	O
in	O
problem	O
solving	O
and	O
executive	O
functions	O
,	O
but	O
not	O
on	O
tests	O
of	O
global	O
cognitive	O
decline	O
,	O
memory	O
,	O
language	O
,	O
or	O
visuoperceptual	O
functioning	O
.	O

These	O
results	O
indicate	O
that	O
acquisition	O
and	O
retention	O
of	O
a	O
complex	O
visuomotor	O
skill	O
can	O
proceed	O
normally	O
in	O
the	O
early	O
stages	O
of	O
AD	O
in	O
those	O
individuals	O
who	O
can	O
initially	O
perform	O
the	O
basic	O
task	O
,	O
and	O
that	O
inability	O
to	O
perform	O
the	O
basic	O
task	O
may	O
be	O
related	O
to	O
the	O
frontal	O
lobe	O
dysfunction	O
that	O
is	O
often	O
prominent	O
in	O
the	O
disorder	O
.	O

Thus	O
,	O
miR-206	O
slows	O
ALS	O
progression	O
by	O
sensing	O
motor	O
neuron	O
injury	O
and	O
promoting	O
the	O
compensatory	O
regeneration	O
of	O
neuromuscular	O
synapses	O
.	O

Here	O
,	O
we	O
show	O
that	O
a	O
key	O
regulator	O
of	O
this	O
signaling	O
is	O
miR-206	O
,	O
a	O
skeletal	O
muscle	O
-	O
specific	O
microRNA	O
that	O
is	O
dramatically	O
induced	O
in	O
a	O
mouse	B
model	O
of	O
ALS	O
.	O

Mice	B
that	O
are	O
genetically	O
deficient	O
in	O
miR-206	O
form	O
normal	O
neuromuscular	O
synapses	O
during	O
development	O
,	O
but	O
deficiency	O
of	O
miR-206	O
in	O
the	O
ALS	O
mouse	B
model	O
accelerates	O
disease	O
progression	O
.	O

miR-206	O
is	O
required	O
for	O
efficient	O
regeneration	O
of	O
neuromuscular	O
synapses	O
after	O
acute	O
nerve	O
injury	O
,	O
which	O
probably	O
accounts	O
for	O
its	O
salutary	O
effects	O
in	O
ALS	O
.	O

miR-206	O
mediates	O
these	O
effects	O
at	O
least	O
in	O
part	O
through	O
histone	O
deacetylase	O
4	O
and	O
fibroblast	O
growth	O
factor	O
signaling	O
pathways	O
.	O

MicroRNA-206	O
delays	O
ALS	O
progression	O
and	O
promotes	O
regeneration	O
of	O
neuromuscular	O
synapses	O
in	O
mice	B
.	O

Amyotrophic	O
lateral	O
sclerosis	O
(	O
ALS	O
)	O
is	O
a	O
neurodegenerative	O
disease	O
characterized	O
by	O
loss	O
of	O
motor	O
neurons	O
,	O
denervation	O
of	O
target	O
muscles	O
,	O
muscle	O
atrophy	O
,	O
and	O
paralysis	O
.	O

Understanding	O
ALS	O
pathogenesis	O
may	O
require	O
a	O
fuller	O
understanding	O
of	O
the	O
bidirectional	O
signaling	O
between	O
motor	O
neurons	O
and	O
skeletal	O
muscle	O
fibers	O
at	O
neuromuscular	O
synapses	O
.	O

[	O
A	O
study	O
on	O
miRNA	O
alternation	O
after	O
H2O2-induced	O
PC12	O
cell	O
apoptosis	O
using	O
microarray	O
technique	O
]	O
.	O

METHODS	O
:	O
PC12	O
cells	O
were	O
treated	O
with	O
different	O
concentrations	O
of	O
H2O2	O
for	O
12	O
hours	O
,	O
and	O
then	O
the	O
cell	O
viabilities	O
were	O
evaluated	O
by	O
MTT	O
assay	O
and	O
cell	O
apoptosis	O
rates	O
were	O
assessed	O
by	O
flow	O
cytometry	O
(	O
FCM	O
)	O
.	O

OBJECTIVE	O
:	O
To	O
screen	O
the	O
differentially	O
expressed	O
microRNAs	O
(	O
miRNA	O
)	O
between	O
H2O2-induced	O
PC12	O
cell	O
apoptosis	O
and	O
normal	O
PC12	O
cells	O
with	O
microarray	O
chips	O
.	O

Of	O
the	O
46	O
miRNAs	O
in	O
the	O
H2O2	O
treated	O
groups	O
,	O
39	O
were	O
similar	O
to	O
that	O
of	O
the	O
control	O
group	O
and	O
6	O
were	O
significantly	O
down	O
-	O
regulated	O
.	O

CONCLUSION	O
:	O
Our	O
preliminary	O
data	O
may	O
provide	O
a	O
new	O
potential	O
foundation	O
for	O
further	O
study	O
of	O
pathogenesis	O
and	O
its	O
treatment	O
of	O
nerve	O
cell	O
apoptosis	O
caused	O
by	O
cerebral	O
ischemia	O
reperfusion	O
.	O

The	O
apoptosis	O
rates	O
for	O
them	O
were	O
2.6	O
%	O
,	O
5.2	O
%	O
,	O
7.2	O
%	O
,	O
10.4	O
%	O
,	O
16.6	O
%	O
,	O
and	O
72.2	O
%	O
accordingly	O
.	O

Expression	O
of	O
68	O
miRNAs	O
and	O
46	O
miRNAs	O
were	O
detected	O
in	O
both	O
control	O
group	O
and	O
the	O
H2O2	O
treated	O
groups	O
.	O

miRNAs	O
were	O
isolated	O
from	O
control	O
(	O
0	O
nmol	O
/	O
L	O
H2O2	O
)	O
and	O
H2O2	O
treated	O
(	O
at	O
concentrations	O
of	O
50	O
,	O
100	O
,	O
200	O
,	O
and	O
400	O
nmol	O
/	O
L	O
H2O2	O
,	O
respectively	O
)	O
groups	O
of	O
the	O
PC12	O
cells	O
,	O
respectively	O
,	O
and	O
were	O
then	O
detected	O
and	O
analyzed	O
by	O
microarray	O
chips	O
.	O

RESULTS	O
:	O
The	O
P12	O
cell	O
viabilities	O
in	O
control	O
and	O
H2O2	O
treated	O
group	O
were	O
(	O
92	O
+	O
/-	O
9.8	O
)	O
%	O
,	O
(	O
90	O
+	O
/-	O
14.70	O
)	O
%	O
,	O
(	O
80	O
+	O
/-	O
13.85	O
)	O
%	O
,	O
(	O
54	O
+	O
/-	O
12.23	O
)	O
%	O
,	O
and	O
(	O
22	O
+	O
/-	O
7.35	O
)	O
%	O
,	O
respectively	O
.	O

In	O
particular	O
,	O
SNP	O
rs12720208	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
(	O
3	O
'	O
UTR	O
)	O
was	O
linked	O
to	O
PD	O
-	O
risk	O
through	O
a	O
mechanism	O
that	O
would	O
implicate	O
a	O
differential	O
binding	O
to	O
microRNA-433	O
(	O
miR-433	O
)	O
.	O

The	O
reduction	O
of	O
the	O
affinity	O
of	O
miR-433	O
to	O
the	O
3	O
'	O
UTR	O
would	O
result	O
in	O
increased	O
FGF20	O
expression	O
and	O
upregulation	O
of	O
alpha	O
-	O
synuclein	O
,	O
which	O
could	O
in	O
turn	O
promote	O
dopaminergic	O
neurons	O
degeneration	O
.	O

FGF20	O
rs12720208	O
SNP	O
and	O
microRNA-433	O
variation	O
:	O
no	O
association	O
with	O
Parkinson	O
's	O
disease	O
in	O
Spanish	O
patients	B
.	O

DNA	O
variation	O
at	O
the	O
FGF20	O
gene	O
has	O
been	O
associated	O
with	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
.	O

In	O
conclusion	O
,	O
our	O
work	O
did	O
not	O
confirm	O
the	O
association	O
between	O
rs12720208	O
and	O
PD	O
,	O
or	O
an	O
effect	O
of	O
miR-433	O
variants	O
on	O
this	O
disease	O
.	O

None	O
of	O
the	O
patients	B
had	O
miR-433	O
variants	O
.	O

We	O
did	O
not	O
find	O
significant	O
differences	O
in	O
allele	O
and	O
genotype	O
frequencies	O
between	O
patients	B
and	O
controls	O
.	O

We	O
genotyped	O
the	O
rs12720208	O
SNP	O
in	O
a	O
total	O
of	O
512	O
PD	O
patients	B
and	O
258	O
healthy	O
controls	O
from	O
Spain	O
,	O
and	O
searched	O
for	O
miR-433	O
variants	O
in	O
the	O
patients	B
.	O

The	O
results	O
suggest	O
(	O
a	O
)	O
that	O
unless	O
specifically	O
stabilized	O
,	O
certain	O
brain	O
-	O
enriched	O
miRNAs	O
represent	O
a	O
rapidly	O
executed	O
signaling	O
system	O
employing	O
highly	O
transient	O
effectors	O
of	O
CNS	O
gene	O
expression	O
,	O
and	O
(	O
b	O
)	O
that	O
in	O
AD	O
temporal	O
lobe	O
neocortex	O
specific	O
brain	O
miRNAs	O
are	O
significantly	O
up	O
-	O
regulated	O
in	O
abundance	O
and	O
strongly	O
correlate	O
with	O
the	O
presence	O
of	O
AD	O
-	O
type	O
neuropatholgical	O
change	O
.	O

In	O
short	O
PMI	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
-affected	O
temporal	O
lobe	O
neocortex	O
,	O
miRNA-9	O
,	O
miRNA-125b	O
and	O
miRNA-146a	O
were	O
found	O
to	O
be	O
significantly	O
up	O
-	O
regulated	O
,	O
an	O
effect	O
that	O
was	O
not	O
seen	O
in	O
several	O
related	O
neurological	O
disorders	O
.	O

In	O
these	O
studies	O
,	O
miRNA	O
array	O
and	O
Northern	O
blot	O
based	O
tracking	O
of	O
specific	O
miRNA	O
abundances	O
and	O
decay	O
kinetics	O
in	O
human	B
neural	O
(	O
HN	O
)	O
cells	O
in	O
primary	O
culture	O
and	O
in	O
short	O
post	O
-	O
mortem	O
interval	O
(	O
PMI	O
,	O
approximately	O
1h	O
)	O
human	B
brain	O
tissues	O
showed	O
a	O
limited	O
stability	O
and	O
relatively	O
short	O
half	O
-	O
life	O
(	O
approximately	O
1	O
-	O
3.5h	O
)	O
for	O
specific	O
brain	O
-	O
enriched	O
miRNAs	O
.	O

Micro	O
-	O
RNA	O
(	O
miRNA	O
)	O
mediated	O
regulation	O
of	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
complexity	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
is	O
emerging	O
as	O
a	O
critical	O
factor	O
in	O
the	O
control	O
of	O
CNS	O
-	O
specific	O
gene	O
expression	O
during	O
development	O
,	O
plasticity	O
,	O
aging	O
and	O
disease	O
.	O

Micro	O
-	O
RNA	O
abundance	O
and	O
stability	O
in	O
human	B
brain	O
:	O
specific	O
alterations	O
in	O
Alzheimer	O
's	O
disease	O
temporal	O
lobe	O
neocortex	O
.	O

Keystone	O
symposium	O
,	O
Neurodegenerative	O
Diseases	O
:	O
New	O
Molecular	O
Mechanisms	O
17	O
-	O
22	O
February	O
2009	O
.	O

Glioma	O
angiogenesis	O
:	O
Towards	O
novel	O
RNA	O
therapeutics	O
.	O

Brain	O
tumors	O
exhibit	O
marked	O
and	O
aberrant	O
blood	O
vessel	O
formation	O
indicating	O
angiogenic	O
endothelial	O
cells	O
as	O
a	O
potential	O
target	O
for	O
brain	O
tumor	O
treatment	O
.	O

The	O
brain	O
tumor	O
blood	O
vessels	O
are	O
used	O
for	O
nutrient	O
delivery	O
,	O
and	O
possibly	O
for	O
cancer	O
cell	O
migration	O
.	O

The	O
process	O
of	O
angiogenesis	O
is	O
complex	O
and	O
involves	O
multiple	O
players	O
.	O

The	O
current	O
angiogenesis	O
inhibitors	O
used	O
in	O
clinical	O
trials	O
mostly	O
target	O
single	O
angiogenic	O
proteins	O
and	O
so	O
far	O
show	O
limited	O
effects	O
on	O
tumor	O
growth	O
.	O

Besides	O
the	O
conventional	O
angiogenesis	O
inhibitors	O
,	O
RNA	O
-	O
based	O
inhibitors	O
such	O
as	O
small	O
-	O
interfering	O
RNAs	O
(	O
siRNAs	O
)	O
are	O
being	O
analyzed	O
for	O
their	O
capacity	O
to	O
silence	O
the	O
message	O
of	O
proteins	O
involved	O
in	O
neovascularization	O
.	O

More	O
recently	O
,	O
a	O
new	O
family	O
of	O
non	O
-	O
coding	O
RNAs	O
,	O
named	O
angiomirs	O
[	O
microRNAs	O
(	O
miRNAs	O
)	O
involved	O
in	O
angiogenesis	O
]	O
has	O
emerged	O
.	O

These	O
small	O
RNAs	O
have	O
the	O
advantage	O
over	O
siRNAs	O
in	O
that	O
they	O
have	O
the	O
potential	O
of	O
silencing	O
multiple	O
messages	O
at	O
the	O
same	O
time	O
and	O
therefore	O
they	O
might	O
become	O
therapeutically	O
relevant	O
in	O
a	O
"	O
one	O
-	O
hit	O
multiple	O
-	O
target	O
"	O
context	O
against	O
brain	O
tumor	O
angiogenesis	O
.	O

In	O
this	O
review	O
we	O
will	O
discuss	O
the	O
emerging	O
technologies	O
in	O
anti	O
-	O
angiogenesis	O
emphasizing	O
on	O
RNA	O
-	O
based	O
therapeutics	O
.	O

Diseases	O
potentially	O
mediated	O
by	O
alterations	O
in	O
RNA	O
processes	O
include	O
tauopathies	O
,	O
myotonic	O
dystrophy	O
,	O
Alzheimer	O
disease	O
,	O
brain	O
cancer	O
,	O
and	O
many	O
others	O
.	O

Some	O
noncoding	O
RNAs	O
have	O
been	O
shown	O
to	O
be	O
involved	O
in	O
human	B
brain	O
diseases	O
.	O

Furthermore	O
,	O
there	O
is	O
poor	O
correlation	O
between	O
mRNA	O
levels	O
and	O
protein	O
levels	O
in	O
mammalian	O
cells	O
,	O
due	O
partly	O
to	O
complicated	O
post	O
-	O
transcriptional	O
regulation	O
by	O
hitherto	O
unknown	O
noncoding	O
RNAs	O
.	O

For	O
example	O
,	O
neurologic	O
illnesses	O
may	O
arise	O
because	O
of	O
perturbations	O
in	O
distinct	O
but	O
interrelated	O
tiers	O
of	O
RNA	O
-	O
based	O
genetic	O
regulation	O
:	O
pre	O
-	O
mRNA	O
splicing	O
;	O
nonsplicing	O
RNA	O
modifications	O
;	O
and	O
mRNA	O
translational	O
regulation	O
.	O

A	O
variety	O
of	O
unforeseen	O
complexities	O
have	O
been	O
identified	O
,	O
many	O
with	O
relevance	O
to	O
human	B
brain	O
disease	O
.	O

RNA	O
research	O
has	O
made	O
great	O
progress	O
in	O
recent	O
years	O
.	O

RNA	O
in	O
brain	O
disease	O
:	O
no	O
longer	O
just	O
"	O
the	O
messenger	O
in	O
the	O
middle	O
"	O
.	O

Here	O
we	O
present	O
an	O
overview	O
of	O
new	O
research	O
highlighting	O
functions	O
for	O
RNA	O
that	O
far	O
surpass	O
the	O
"	O
messenger	O
in	O
the	O
middle	O
"	O
role	O
and	O
that	O
identify	O
RNA	O
molecules	O
as	O
important	O
agents	O
in	O
the	O
human	B
brain	O
in	O
health	O
and	O
in	O
disease	O
states	O
.	O

RNA	O
editing	O
by	O
adenosine	O
deamination	O
is	O
a	O
posttranscriptional	O
mechanism	O
for	O
the	O
regulation	O
of	O
gene	O
expression	O
and	O
is	O
particularly	O
widespread	O
in	O
mammals	O
.	O

Gene	O
regulation	O
through	O
RNA	O
editing	O
.	O

Here	O
,	O
I	O
am	O
reviewing	O
main	O
features	O
of	O
this	O
epigenetic	O
phenomenon	O
,	O
its	O
relevance	O
for	O
health	O
and	O
disease	O
,	O
as	O
well	O
as	O
potential	O
prospects	O
for	O
using	O
RNA	O
editing	O
as	O
a	O
therapeutic	O
tool	O
.	O

Widespread	O
A	O
-	O
to	O
-	O
I	O
modification	O
of	O
repeat	O
sequences	O
in	O
the	O
human	B
transcriptome	O
suggests	O
additional	O
roles	O
for	O
RNA	O
editing	O
and	O
links	O
it	O
to	O
other	O
processes	O
of	O
gene	O
regulation	O
,	O
such	O
as	O
RNA	O
splicing	O
as	O
well	O
as	O
siRNA	O
mediated	O
gene	O
silencing	O
and	O
miRNA	O
function	O
.	O

The	O
deficiency	O
or	O
misregulation	O
of	O
editing	O
has	O
been	O
implicated	O
in	O
the	O
etiology	O
of	O
neurological	O
diseases	O
,	O
such	O
as	O
epilepsy	O
,	O
amyotrophic	O
lateral	O
sclerosis	O
(	O
ALS	O
)	O
,	O
depression	O
and	O
tumor	O
progression	O
.	O

Also	O
,	O
it	O
regulates	O
important	O
functional	O
properties	O
of	O
neurotransmitter	O
receptor	O
genes	O
in	O
the	O
central	O
nervous	O
system	O
by	O
changing	O
single	O
codons	O
in	O
pre	O
-	O
mRNA	O
.	O

A	O
-	O
to	O
-	O
I	O
RNA	O
editing	O
generates	O
transcriptome	O
and	O
proteome	O
diversity	O
allowing	O
organisms	O
to	O
produce	O
many	O
more	O
gene	O
products	O
and	O
functions	O
than	O
predicted	O
based	O
on	O
the	O
number	O
of	O
genes	O
within	O
their	O
genome	O
.	O

Gliomas	O
display	O
a	O
microRNA	O
expression	O
profile	O
reminiscent	O
of	O
neural	O
precursor	O
cells	O
.	O

Gliomas	O
express	O
many	O
genes	O
that	O
play	O
a	O
role	O
in	O
neural	O
precursor	O
cells	O
(	O
NPCs	O
)	O
,	O
but	O
no	O
direct	O
comparison	O
between	O
glioma	O
and	O
stem	O
cell	O
(	O
SC	O
)	O
gene	O
expression	O
profiles	O
has	O
been	O
performed	O
.	O

To	O
investigate	O
the	O
similarities	O
and	O
differences	O
between	O
gliomas	O
and	O
SCs	O
,	O
we	O
compared	O
the	O
microRNA	O
(	O
miRNA	O
)	O
expression	O
signatures	O
of	O
glial	O
tumors	O
,	O
embryonic	O
SCs	O
(	O
ESCs	O
)	O
,	O
NPCs	O
,	O
and	O
normal	O
adult	O
brains	O
from	O
both	O
human	B
and	O
mouse	B
tissues	O
.	O

We	O
demonstrated	O
that	O
both	O
human	B
gliomas	O
(	O
regardless	O
of	O
their	O
grade	O
)	O
and	O
methylcholanthrene	O
-	O
induced	O
mouse	B
glioma	O
shared	O
an	O
miRNA	O
expression	O
profile	O
that	O
is	O
reminiscent	O
of	O
NPCs	O
.	O

About	O
half	O
of	O
the	O
miRNAs	O
expressed	O
in	O
the	O
shared	O
profile	O
clustered	O
in	O
seven	O
genomic	O
regions	O
susceptible	O
to	O
genetic	O
/	O
epigenetic	O
alterations	O
in	O
various	O
cancers	O
.	O

These	O
clusters	O
comprised	O
the	O
miR17	O
family	O
,	O
mir183	O
-	O
182	O
,	O
and	O
the	O
SC	O
-	O
specific	O
clusters	O
mir367	O
-	O
302	O
and	O
mir371	O
-	O
373	O
,	O
which	O
are	O
upregulated	O
in	O
gliomas	O
,	O
ESCs	O
,	O
and	O
NPCs	O
.	O

The	O
bipartite	O
cluster	O
of	O
7	O
+	O
46	O
miRNAs	O
on	O
chromosome	O
14q32.31	O
,	O

which	O
might	O
represent	O
the	O
largest	O
tumor	O
suppressor	O
miRNA	O
cluster	O
,	O
was	O
downregulated	O
in	O
the	O
shared	O
expression	O
profile	O
.	O

This	O
study	O
provides	O
the	O
first	O
evidence	O
for	O
association	O
between	O
these	O
clusters	O
and	O
gliomas	O
.	O

Despite	O
the	O
broad	O
similarity	O
in	O
the	O
miRNA	O
expression	O
profiles	O
,	O
15	O
miRNAs	O
showed	O
disparate	O
expression	O
between	O
SC	O
and	O
gliomas	O
.	O

Ten	O
miRNAs	O
belong	O
to	O
the	O
2	O
SC	O
-	O
specific	O
clusters	O
and	O
the	O
remaining	O
(	O
mir135b	O
,	O
mir141	O
,	O
mir205	O
,	O
mir200C	O
,	O
and	O
mir301a	O
)	O
have	O
been	O
previously	O
shown	O
to	O
associate	O
with	O
malignancies	O
.	O

Our	O
finding	O
showed	O
that	O
all	O
gliomas	O
displayed	O
NPC	O
-	O
like	O
miRNA	O
signatures	O
,	O
which	O
may	O
have	O
implications	O
for	O
studies	O
of	O
glioma	O
origins	O
.	O

Furthermore	O
,	O
careful	O
study	O
of	O
the	O
15	O
miRNAs	O
that	O
differ	O
in	O
expression	O
between	O
SCs	O
and	O
gliomas	O
,	O
particularly	O
those	O
5	O
that	O
are	O
not	O
SC	O
-	O
specific	O
,	O
may	O
enhance	O
our	O
understanding	O
of	O
gliomagenesis	O
.	O

New	O
insights	O
into	O
the	O
roles	O
of	O
microRNAs	O
in	O
drug	O
addiction	O
and	O
neuroplasticity	O
.	O

In	O
this	O
review	O
,	O
the	O
aim	O
is	O
to	O
provide	O
an	O
overview	O
of	O
the	O
emerging	O
role	O
of	O
miRNAs	O
in	O
addiction	O
.	O

miRNAs	O
are	O
small	O
non	O
-	O
coding	O
RNAs	O
,	O
particularly	O
abundant	O
in	O
the	O
nervous	O
system	O
,	O
that	O
play	O
key	O
roles	O
as	O
regulatory	O
molecules	O
in	O
processes	O
such	O
as	O
neurogenesis	O
,	O
synapse	O
development	O
and	O
plasticity	O
in	O
the	O
brain	O
.	O

They	O
also	O
act	O
as	O
key	O
spatiotemporal	O
regulators	O
during	O
dendritic	O
morphogenesis	O
,	O
controlling	O
the	O
expression	O
of	O
hundreds	O
of	O
genes	O
involved	O
in	O
neuroplasticity	O
and	O
in	O
the	O
function	O
of	O
synapses	O
.	O

Recent	O
studies	O
have	O
identified	O
changes	O
of	O
several	O
specific	O
miRNA	O
expression	O
profiles	O
and	O
polymorphisms	O
affecting	O
the	O
interactions	O
between	O
miRNAs	O
and	O
their	O
targets	O
in	O
various	O
brain	O
disorders	O
,	O
including	O
addiction	O
:	O
miR-16	O
causes	O
adaptive	O
changes	O
in	O
production	O
of	O
the	O
serotonin	O
transporter	O
;	O
miR-133b	O
is	O
specifically	O
expressed	O
in	O
midbrain	O
dopaminergic	O
neurons	O
,	O
and	O
regulates	O
the	O
production	O
of	O
tyrosine	O
hydroxylase	O
and	O
the	O
dopamine	O
transporter	O
;	O
miR-212	O
affects	O
production	O
of	O
striatal	O
brain	O
-	O
derived	O
neurotrophic	O
factor	O
and	O
synaptic	O
plasticity	O
upon	O
cocaine	O
.	O

Clearly	O
,	O
specific	O
miRNAs	O
have	O
emerged	O
as	O
key	O
regulators	O
leading	O
to	O
addiction	O
,	O
and	O
could	O
serve	O
as	O
valuable	O
targets	O
for	O
more	O
efficient	O
therapies	O
.	O

ABSTRACT	O
:	O
Drug	O
addiction	O
is	O
a	O
major	O
public	O
health	O
issue	O
.	O

It	O
is	O
typically	O
a	O
multigenetic	O
brain	O
disorder	O
,	O
implying	O
combined	O
changes	O
of	O
expression	O
of	O
several	O
hundred	O
genes	O
.	O

Psychostimulants	O
(	O
such	O
as	O
cocaine	O
,	O
heroin	O
and	O
amphetamines	O
)	O
induce	O
strong	O
and	O
persistent	O
neuroadaptive	O
changes	O
through	O
a	O
surfeit	O
of	O
gene	O
regulatory	O
mechanisms	O
leading	O
to	O
addiction	O
.	O

Activity	O
-	O
dependent	O
synaptic	O
plasticity	O
of	O
the	O
mesolimbic	O
dopaminergic	O
system	O
,	O
known	O
as	O
the	O
'	O
reward	O
pathway	O
'	O
,	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
development	O
of	O
drug	O
dependence	O
.	O

Morphological	O
and	O
molecular	O
information	O
of	O
a	O
new	O
species	O
of	O
Geleia	O
(	O
Ciliophora	O
,	O
Karyorelictea	O
)	O
,	O
with	O
redescriptions	O
of	O
two	O
Kentrophoros	O
species	O
from	O
China	O
.	O

The	O
morphology	O
and	O
infraciliature	O
of	O
three	O
karyorelictean	O
ciliates	O
,	O
Geleia	B
sinica	I
spec	I
.	I

nov.	B
and	O
two	O
poorly	O
known	O
Kentrophoros	O
species	O
,	O
K.	B
flavus	I
and	O
K.	B
gracilis	I
,	O
isolated	O
from	O
the	O
intertidal	O
zone	O
of	O
a	O
beach	O
at	O
Qingdao	O
,	O
China	O
,	O
were	O
investigated	O
.	O

Geleia	B
sinica	I
spec	I
.	I

nov.	B
is	O
distinguished	O
from	O
its	O
congeners	O
by	O
the	O
following	O
combination	O
of	O
characters	O
:	O
body	O
medium	O
-	O
sized	O
and	O
slender	O
-	O
cylindrical	O
;	O
with	O
a	O
conspicuous	O
prebuccal	O
fossa	O
;	O
28	O
-	O
34	O
somatic	O
kineties	O
;	O
about	O
40	O
short	O
adoral	O
polykineties	O
;	O
intrabuccal	O
kinety	O
composed	O
of	O
25	O
-	O
34	O
dikinetids	O
;	O
paroral	O
kineties	O
composed	O
of	O
closely	O
spaced	O
dikinetids	O
.	O

The	O
comparison	O
with	O
similar	O
congeners	O
clearly	O
supports	O
the	O
validity	O
of	O
this	O
new	O
species	O
based	O
on	O
morphological	O
and	O
small	O
subunit	O
(	O
SSU	O
)	O
rRNA	O
gene	O
sequence	O
data	O
.	O

In	O
light	O
of	O
these	O
new	O
data	O
the	O
"	O
well	O
-	O
known	O
"	O
morphotype	O
,	O
Geleia	O
simplex	O
(	B
Faure	I
-	I
Fremiet	I
,	I
1951	I
)	I
,	I
is	I
redefined	I
.	O

Two	O
Kentrophoros	O
species	O
are	O
redescribed	O
and	O
improved	O
diagnoses	O
are	O
supplied	O
.	O

Kentrophoros	O
flavus	B
Raikov	I
and	I
Kovaleva	I
,	I
1968	I
is	I
mainly	I
characterized	O
by	O
having	O
about	O
33	O
macronuclei	O
and	O
12	O
micronuclei	O
forming	O
a	O
row	O
that	O
extends	O
along	O
the	O
cell	O
meridian	O
,	O
and	O
12	O
-	O
19	O
ciliary	O
rows	O
on	O
the	O
right	O
side	O
of	O
the	O
cell	O
.	O

Kentrophoros	O
gracilis	B
Raikov	I
,	I
1963	I
is	I
characterized	I
by	O
having	O
about	O
14	O
macronuclei	O
,	O
13	O
micronuclei	O
and	O
10	O
-	O
13	O
kineties	O
on	O
the	O
right	O
side	O
of	O
the	O
cell	O
.	O

Hydraulic	O
constraints	O
limit	O
height	O
growth	O
in	O
trees	O
at	O
high	O
altitude	O
.	O

*	O
Low	O
temperatures	O
limit	O
the	O
fixation	O
of	O
photosynthates	O
and	O
xylogenesis	O
.	O

Here	O
,	O
we	O
hypothesized	O
that	O
reduced	O
longitudinal	O
growth	O
in	O
trees	O
at	O
high	O
altitude	O
is	O
related	O
to	O
the	O
lower	O
hydraulic	O
efficiency	O
of	O
the	O
transport	O
system	O
.	O

*	O
Apical	O
buds	O
of	O
Norway	B
spruce	I
(	O
Picea	B
abies	I
)	O
trees	O
at	O
high	O
and	O
low	O
elevation	O
were	O
heated	O
during	O
2006	O
and	O
2007	O
.	O

At	O
the	O
end	O
of	O
the	O
experiment	O
,	O
trees	O
were	O
felled	O
.	O

Longitudinal	O
increments	O
and	O
tracheid	O
lumen	O
areas	O
were	O
measured	O
along	O
the	O
stem	O
.	O

Apical	O
hydraulic	O
conductivity	O
(	O
k	O
)	O
was	O
estimated	O
from	O
anatomical	O
data	O
.	O

*	O
Before	O
heating	O
,	O
high	O
-	O
altitude	O
trees	O
showed	O
fewer	O
(	O
P	O
=	O
0.002	O
)	O
and	O
smaller	O
(	O
P	O
=	O
0.008	O
)	O
apical	O
conduits	O
,	O
and	O
therefore	O
reduced	O
k	O
(	O
P	O
=	O
0.016	O
)	O
and	O
stem	O
elongation	O
(	O
P	O
<	O
0.0001	O
)	O
,	O
in	O
comparison	O
with	O
trees	O
at	O
low	O
elevation	O
.	O

After	O
2	O
yr	O
of	O
heating	O
,	O
k	O
increased	O
at	O
both	O
high	O
(	O
P	O
=	O
0.014	O
)	O
and	O
low	O
(	O
P	O
=	O
0.047	O
)	O
elevation	O
.	O

Only	O
high	O
-	O
altitude	O
trees	O
showed	O
increased	O
stem	O
elongation	O
,	O
which	O
reached	O
the	O
same	O
magnitude	O
as	O
that	O
of	O
controls	O
at	O
low	O
elevation	O
(	O
P	O
=	O
0.735	O
)	O
.	O

Heating	O
around	O
the	O
apical	O
shoots	O
did	O
not	O
appear	O
to	O
induce	O
significant	O
changes	O
in	O
conduit	O
dimension	O
along	O
the	O
rest	O
of	O
the	O
stem	O
.	O

*	O
The	O
total	O
number	O
and	O
size	O
of	O
xylem	O
elements	O
at	O
the	O
stem	O
apex	O
are	O
strongly	O
constrained	O
by	O
low	O
temperatures	O
.	O

Trees	O
at	O
high	O
altitude	O
are	O
therefore	O
prevented	O
from	O
building	O
up	O
an	O
efficient	O
transport	O
system	O
,	O
and	O
their	O
reduced	O
longitudinal	O
growth	O
reflects	O
strong	O
hydraulic	O
limitations	O
.	O

Fitness	O
effects	O
of	O
endemic	O
malaria	O
infections	O
in	O
a	O
wild	O
bird	O
population	O
:	O
the	O
importance	O
of	O
ecological	O
structure	O
.	O

1	O
.	O

Parasites	O
can	O
have	O
important	O
effects	O
on	O
host	O
populations	O
influencing	O
either	O
fecundity	O
or	O
mortality	O
,	O
but	O
understanding	O
the	O
magnitude	O
of	O
these	O
effects	O
in	O
endemic	O
host	O
-	O
parasite	O
systems	O
is	O
challenging	O
and	O
requires	O
an	O
understanding	O
of	O
ecological	O
processes	O
affecting	O
both	O
host	O
and	O
parasite	O
.	O

2	O
.	O

Avian	O
blood	O
parasites	O
(	O
Haemoproteus	O
and	O
Plasmodium	O
)	O
have	O
been	O
much	O
studied	O
,	O
but	O
the	O
effects	O
of	O
these	O
parasites	O
on	O
hosts	O
in	O
areas	O
where	O
they	O
are	O
endemic	O
remains	O
poorly	O
known	O
.	O

3	O
.	O

We	O
used	O
a	O
multistate	O
modelling	O
framework	O
to	O
explore	O
the	O
effects	O
of	O
chronic	O
infection	O
with	O
Plasmodium	O
on	O
survival	O
and	O
recapture	O
probability	O
in	O
a	O
large	O
data	O
set	O
of	O
breeding	O
blue	B
tits	I
,	O
involving	O
3424	O
individuals	O
and	O
3118	O
infection	O
diagnoses	O
over	O
nine	O
years	O
.	O

4	O
.	O

We	O
reveal	O
strong	O
associations	O
between	O
chronic	O
malaria	O
infection	O
and	O
both	O
recapture	O
and	O
survival	O
,	O
effects	O
that	O
are	O
dependent	O
on	O
the	O
clade	O
of	O
parasite	O
,	O
on	O
host	O
traits	O
and	O
on	O
the	O
local	O
risk	O
of	O
infection	O
.	O

5	O
.	O

Infection	O
with	O
Plasmodium	B
relictum	I
was	O
associated	O
with	O
reduced	O
recapture	O
probability	O
and	O
increased	O
survival	O
,	O
compared	O
to	O
P.	B
circumflexum	I
,	O
suggesting	O
that	O
these	O
parasites	O
have	O
differing	O
virulence	O
and	O
cause	O
different	O
types	O
of	O
selection	O
on	O
this	O
host	O
.	O

6	O
.	O

Our	O
results	O
suggest	O
a	O
large	O
potential	O
survival	O
cost	O
of	O
acute	O
infections	O
revealed	O
by	O
modelling	O
host	O
survival	O
as	O
a	O
function	O
of	O
the	O
local	O
risk	O
of	O
infection	O
.	O

7	O
.	O

Our	O
analyses	O
suggest	O
not	O
only	O
that	O
endemic	O
avian	O
malaria	O
may	O
have	O
multiple	O
fitness	O
effects	O
on	O
their	O
hosts	O
and	O
that	O
these	O
effects	O
are	O
species	O
dependent	O
,	O
but	O
also	O
that	O
adding	O
ecological	O
structure	O
(	O
in	O
this	O
case	O
parasite	O
species	O
and	O
spatial	O
variation	O
in	O
disease	O
occurrence	O
)	O
to	O
analyses	O
of	O
host	O
-	O
parasite	O
interactions	O
is	O
an	O
important	O
step	O
in	O
understanding	O
the	O
ecology	O
and	O
evolution	O
of	O
these	O
systems	O
.	O

Jiangella	B
muralis	I
sp.	I
nov.	I
,	O
from	O
an	O
indoor	O
environment	O
.	O

A	O
Gram	O
-	O
stain	O
-	O
positive	O
,	O
non	O
-	O
spore	O
-	O
forming	O
actinobacterium	O
,	O
designated	O
15-Je-017	B
(	I
T	I
)	O
,	O
was	O
isolated	O
from	O
wall	O
material	O
of	O
an	O
indoor	O
environment	O
.	O

The	O
isolate	O
formed	O
a	O
rudimentary	O
substrate	O
mycelium	O
that	O
fragmented	O
into	O
rod	O
-	O
shaped	O
cells	O
.	O

On	O
the	O
basis	O
of	O
16S	O
rRNA	O
gene	O
sequence	O
analysis	O
,	O
strain	O
15-Je-017	B
(	I
T	I
)	O
was	O
shown	O
to	O
belong	O
to	O
the	O
genus	O
Jiangella	O
and	O
was	O
most	O
closely	O
related	O
to	O
Jiangella	B
alba	I
YIM	I
61503	I
(	I
T	I
)	O
(	O
99.7	O
%	O
16S	O
rRNA	O
gene	O
sequence	O
similarity	O
)	O
,	O
Jiangella	B
alkaliphila	I
D8	I
-	I
87	I
(	I
T	I
)	O
(	O
99.0	O
%	O
)	O
and	O
Jiangella	B
gansuensis	I
YIM	I
002	I
(	I
T	I
)	O
(	O
99.0	O
%	O
)	O
.	O

The	O
predominant	O
menaquinone	O
was	O
MK-9	O
(	O
H	O
(	O
4	O
)	O
)	O
.	O

Whole	O
-	O
cell	O
hydrolysates	O
contained	O
ll	O
-	O
diaminopimelic	O
acid	O
as	O
the	O
diagnostic	O
diamino	O
acid	O
in	O
the	O
cell	O
wall	O
and	O
rhamnose	O
and	O
glucose	O
as	O
the	O
main	O
sugars	O
.	O

Mycolic	O
acids	O
were	O
absent	O
.	O

The	O
polar	O
lipid	O
profile	O
consisted	O
of	O
diphosphatidylglycerol	O
,	O
phosphatidylglycerol	O
,	O
phosphatidylinositol	O
,	O
phosphatidylinositol	O
mannoside	O
and	O
seven	O
unknown	O
phospholipids	O
.	O

The	O
fatty	O
acid	O
profile	O
contained	O
major	O
amounts	O
(	O
>	O
5	O
%	O
)	O
of	O
anteiso	O
-	O
C	O
(	O
15	O
:	O
0	O
)	O
,	O
iso	O
-	O
C	O
(	O
16	O
:	O
0	O
)	O
,	O
iso	O
-	O
C	O
(	O
15	O
:	O
0	O
)	O
,	O
iso	O
-	O
C	O
(	O
17	O
:	O
0	O
)	O
,	O
anteiso	O
-	O
C	O
(	O
17	O
:	O
0	O
)	O
and	O
C	O
(	O
17	O
:	O
1	O
)	O
omega8c	O
,	O
which	O
supported	O
the	O
affiliation	O
of	O
strain	O
15-Je-017	B
(	I
T	I
)	O
to	O
the	O
genus	O
Jiangella	O
.	O

DNA	O
-	O
DNA	O
relatedness	O
and	O
physiological	O
and	O
biochemical	O
tests	O
allowed	O
the	O
differentiation	O
of	O
strain	O
15-Je-017	B
(	I
T	I
)	O
from	O
the	O
type	O
strains	O
of	O
the	O
three	O
known	O
Jiangella	O
species	O
.	O

Strain	O
15-Je-017	B
(	I
T	I
)	O
represents	O
a	O
novel	O
Jiangella	O
species	O
,	O
for	O
which	O
we	O
propose	O
the	O
name	O
Jiangella	B
muralis	I
sp.	I
nov.	I
,	O
with	O
type	O
strain	O
15-Je-017	B
(	I
T	I
)	O
(	O
=	O
DSM	O
45357	O
(	O
T	O
)	O
=	O
CCM	O
7680	O
(	O
T	O
)	O
)	O
.	O

Soil	O
nutrient	O
status	O
determines	O
how	O
elephant	B
utilize	O
trees	O
and	O
shape	O
environments	O
.	O

1	O
.	O

Elucidation	O
of	O
the	O
mechanism	O
determining	O
the	O
spatial	O
scale	O
of	O
patch	O
selection	O
by	O
herbivores	O
has	O
been	O
complicated	O
by	O
the	O
way	O
in	O
which	O
resource	O
availability	O
at	O
a	O
specific	O
scale	O
is	O
measured	O
and	O
by	O
vigilance	O
behaviour	O
of	O
the	O
herbivores	O
themselves	O
.	O

To	O
reduce	O
these	O
complications	O
,	O
we	O
studied	O
patch	O
selection	O
by	O
an	O
animal	O
with	O
negligible	O
predation	O
risk	O
,	O
the	O
African	B
elephant	I
.	O

2	O
.	O

We	O
introduce	O
the	O
concept	O
of	O
nutrient	O
load	O
as	O
the	O
product	O
of	O
patch	O
size	O
,	O
number	O
of	O
patches	O
and	O
local	O
patch	O
nutrient	O
concentration	O
.	O

Nutrient	O
load	O
provides	O
a	O
novel	O
spatially	O
explicit	O
expression	O
of	O
the	O
total	O
available	O
nutrients	O
a	O
herbivore	O
can	O
select	O
from	O
.	O

3	O
.	O

We	O
hypothesized	O
that	O
elephant	B
would	O
select	O
nutrient	O
-	O
rich	O
patches	O
,	O
based	O
on	O
the	O
nutrient	O
load	O
per	O
2500	O
m	O
(	O
2	O
)	O
down	O
to	O
the	O
individual	O
plant	O
scale	O
,	O
and	O
that	O
this	O
selection	O
will	O
depend	O
on	O
the	O
nitrogen	O
and	O
phosphorous	O
contents	O
of	O
plants	O
.	O

4	O
.	O

We	O
predicted	O
that	O
elephant	B
would	O
cause	O
more	O
adverse	O
impact	O
to	O
trees	O
of	O
lower	O
value	O
to	O
them	O
in	O
order	O
to	O
reach	O
plant	O
parts	O
with	O
higher	O
nutrient	O
concentrations	O
such	O
as	O
bark	O
and	O
root	O
.	O

However	O
,	O
elephant	B
should	O
maintain	O
nutrient	O
-	O
rich	O
trees	O
by	O
inducing	O
coppicing	O
of	O
trees	O
through	O
re	O
-	O
utilization	O
of	O
leaves	O
.	O

5	O
.	O

Elephant	B
patch	O
selection	O
was	O
measured	O
in	O
a	O
homogenous	O
tree	O
species	O
stand	O
by	O
manipulating	O
the	O
spatial	O
distribution	O
of	O
soil	O
nutrients	O
in	O
a	O
large	O
field	O
experiment	O
using	O
NPK	O
fertilizer	O
.	O

6	O
.	O
Elephant	B
were	O
able	O
to	O
select	O
nutrient	O
-	O
rich	O
patches	O
and	O
utilized	O
Colophospermum	B
mopane	I
trees	O
inside	O
these	O
patches	O
more	O
than	O
outside	O
,	O
at	O
scales	O
ranging	O
from	O
2500	O
down	O
to	O
100	O
m	O
(	O
2	O
)	O
.	O

7	O
.	O

Although	O
both	O
nitrogen	O
and	O
phosphorus	O
contents	O
of	O
leaves	O
from	O
C.	B
mopane	I
trees	O
were	O
higher	O
in	O
fertilized	O
and	O
selected	O
patches	O
,	O
patch	O
choice	O
correlated	O
most	O
strongly	O
with	O
nitrogen	O
content	O
.	O

As	O
predicted	O
,	O
stripping	O
of	O
leaves	O
occurred	O
more	O
in	O
nutrient	O
-	O
rich	O
patches	O
,	O
while	O
adverse	O
impact	O
such	O
as	O
uprooting	O
of	O
trees	O
occurred	O
more	O
in	O
nutrient	O
-	O
poor	O
areas	O
.	O

8	O
.	O

Our	O
results	O
emphasize	O
the	O
necessity	O
of	O
including	O
scale	O
-	O
dependent	O
selectivity	O
in	O
foraging	O
studies	O
and	O
how	O
elephant	B
foraging	O
behaviour	O
can	O
be	O
used	O
as	O
indicators	O
of	O
change	O
in	O
the	O
availability	O
of	O
nutrients	O
.	O

Mating	O
differentiation	O
in	O
Cryptococcus	B
neoformans	I
is	O
negatively	O
regulated	O
by	O
the	O
Crk1	O
protein	O
kinase	O
.	O

Cryptococcus	B
neoformans	I
is	O
a	O
heterothallic	O
basidiomycete	O
that	O
grows	O
vegetatively	O
as	O
yeast	B
and	O
filamentous	O
hyphae	O
are	O
produced	O
in	O
the	O
sexual	O
state	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
C.	B
neoformans	I
Cwc1	O
and	O
Cwc2	O
are	O
two	O
central	O
photoregulators	O
which	O
form	O
a	O
complex	O
to	O
inhibit	O
the	O
production	O
of	O
sexual	O
filaments	O
upon	O
light	O
treatment	O
.	O

To	O
reveal	O
the	O
detailed	O
regulatory	O
mechanisms	O
,	O
a	O
genome	O
wide	O
mutagenesis	O
screen	O
was	O
conducted	O
and	O
components	O
in	O
the	O
Cwc1	O
/	O
Cwc2	O
complex	O
mediated	O
pathway	O
have	O
been	O
identified	O
.	O

In	O
this	O
study	O
,	O
one	O
suppressor	O
mutant	O
,	O
DJ22	O
,	O
is	O
characterized	O
and	O
T	O
-	O
DNA	O
is	O
found	O
to	O
disrupt	O
the	O
C.	B
neoformans	I
CRK1	O
gene	O
,	O
a	O
homologue	O
of	O
Saccharomyces	B
cerevisiae	I
IME2	O
and	O
Ustilago	B
maydis	I
crk1	O
.	O

Ime2	O
is	O
a	O
meiosis	O
-	O
specific	O
gene	O
with	O
the	O
conserved	O
Ser	O
/	O
Thr	O
kinase	O
domain	O
and	O
TXY	O
dual	O
phosphorylation	O
site	O
.	O

Consistent	O
with	O
the	O
findings	O
of	O
other	O
suppressors	O
in	O
our	O
screen	O
,	O
C.	B
neoformans	I
Crk1	O
plays	O
a	O
negative	O
role	O
in	O
the	O
mating	O
process	O
.	O

Dikaryotic	O
filaments	O
,	O
basidia	O
,	O
and	O
basidiospores	O
are	O
produced	O
earlier	O
in	O
the	O
crk1	O
mutant	O
crosses	O
and	O
mating	O
efficiency	O
is	O
also	O
increased	O
.	O

Artificial	O
elevation	O
of	O
the	O
CRK1	O
mRNA	O
level	O
inhibits	O
mating	O
.	O

Interestingly	O
,	O
monokaryotic	O
fruiting	O
is	O
defective	O
both	O
in	O
the	O
MATalpha	O
crk1	O
mutant	O
and	O
CRK1	O
overexpression	O
strains	O
.	O

Our	O
studies	O
demonstrate	O
that	O
C.	O
neoformans	O
CRK1	O
gene	O
functions	O
as	O
a	O
negative	O
regulator	O
in	O
the	O
mating	O
differentiation	O
.	O

The	O
Rcs	O
signal	O
transduction	O
pathway	O
is	O
triggered	O
by	O
enterobacterial	O
common	O
antigen	O
structure	O
alterations	O
in	O
Serratia	B
marcescens	I
.	O

The	O
enterobacterial	O
common	O
antigen	O
(	O
ECA	O
)	O
is	O
a	O
highly	O
conserved	O
exopolysaccharide	O
in	O
Gram	O
-	O
negative	O
bacteria	O
whose	O
role	O
remains	O
largely	O
uncharacterized	O
.	O

In	O
a	O
previous	O
work	O
,	O
we	O
have	O
demonstrated	O
that	O
disrupting	O
the	O
integrity	O
of	O
the	O
ECA	O
biosynthetic	O
pathway	O
imposed	O
severe	O
deficiencies	O
to	O
the	O
Serratia	B
marcescens	I
motile	O
(	O
swimming	O
and	O
swarming	O
)	O
capacity	O
.	O

In	O
this	O
work	O
,	O
we	O
show	O
that	O
alterations	O
in	O
the	O
ECA	O
structure	O
activate	O
the	O
Rcs	O
phosphorelay	O
,	O
which	O
results	O
in	O
the	O
repression	O
of	O
the	O
flagellar	O
biogenesis	O
regulatory	O
cascade	O
.	O

In	O
addition	O
,	O
a	O
detailed	O
analysis	O
of	O
wec	O
cluster	O
mutant	O
strains	O
,	O
which	O
provoke	O
the	O
disruption	O
of	O
the	O
ECA	O
biosynthesis	O
at	O
different	O
levels	O
of	O
the	O
pathway	O
,	O
suggests	O
that	O
the	O
absence	O
of	O
the	O
periplasmic	O
ECA	O
cyclic	O
structure	O
could	O
constitute	O
a	O
potential	O
signal	O
detected	O
by	O
the	O
RcsF	O
-	O
RcsCDB	O
phosphorelay	O
.	O

We	O
also	O
identify	O
SMA1167	O
as	O
a	O
member	O
of	O
the	O
S.	B
marcescens	I
Rcs	O
regulon	O
and	O
show	O
that	O
high	O
osmolarity	O
induces	O
Rcs	O
activity	O
in	O
this	O
bacterium	O
.	O

These	O
results	O
provide	O
a	O
new	O
perspective	O
from	O
which	O
to	O
understand	O
the	O
phylogenetic	O
conservation	O
of	O
ECA	O
among	O
enterobacteria	O
and	O
the	O
basis	O
for	O
the	O
virulence	O
attenuation	O
detected	O
in	O
wec	O
mutant	O
strains	O
in	O
other	O
pathogenic	O
bacteria	O
.	O

Pyrethroid	O
resistance	O
in	O
Sitophilus	B
zeamais	I
is	O
associated	O
with	O
a	O
mutation	O
(	O
T929I	O
)	O
in	O
the	O
voltage	O
-	O
gated	O
sodium	O
channel	O
.	O

The	O
maize	B
weevil	I
,	O
Sitophilus	B
zeamais	I
,	O
is	O
the	O
most	O
important	O
pest	O
affecting	O
stored	O
grain	O
in	O
Brazil	O
and	O
its	O
control	O
relies	O
heavily	O
on	O
the	O
use	O
of	O
insecticides	O
.	O

The	O
intensive	O
use	O
of	O
compounds	O
such	O
as	O
the	O
pyrethroids	O
has	O
led	O
to	O
the	O
emergence	O
of	O
resistance	O
,	O
and	O
previous	O
studies	O
have	O
suggested	O
that	O
resistance	O
to	O
both	O
pyrethroids	O
and	O
1,1,1-trichloro-2,2-bis	O
(	O
p	O
-	O
chlorophenyl	O
)	O
ethane	O
(	O
DDT	O
)	O
may	O
result	O
from	O
reduced	O
sensitivity	O
of	O
the	O
insecticide	O
target	O
,	O
the	O
voltage	O
-	O
gated	O
sodium	O
channel	O
.	O

To	O
identify	O
the	O
molecular	O
mechanisms	O
underlying	O
pyrethroid	O
resistance	O
in	O
S.	B
zeamais	I
,	O
the	O
domain	O
II	O
region	O
of	O
the	O
voltage	O
-	O
gated	O
sodium	O
channel	O
(	O
para	O
-	O
orthologue	O
)	O
gene	O
was	O
amplified	O
by	O
PCR	O
and	O
sequenced	O
from	O
susceptible	O
and	O
resistant	O
laboratory	O
S.	B
zeamais	I
strains	O
that	O
were	O
selected	O
with	O
a	O
discriminating	O
dose	O
of	O
DDT	O
.	O

A	O
single	O
point	O
mutation	O
,	O
T929I	O
,	O
was	O
found	O
in	O
the	O
para	O
gene	O
of	O
the	O
resistant	O
S.	B
zeamais	I
populations	O
and	O
its	O
presence	O
in	O
individual	O
weevils	O
was	O
strongly	O
associated	O
with	O
survival	O
after	O
DDT	O
exposure	O
.	O

This	O
is	O
the	O
first	O
identification	O
of	O
a	O
target	O
-	O
site	O
resistance	O
mutation	O
in	O
S.	B
zeamais	I
and	O
unusually	O
it	O
is	O
a	O
super	O
-	O
kdr	O
type	O
mutation	O
occurring	O
in	O
the	O
absence	O
of	O
the	O
more	O
common	O
kdr	O
(	O
L1014F	O
)	O
substitution	O
.	O

A	O
high	O
-	O
throughput	O
assay	O
based	O
on	O
TaqMan	O
single	O
nucleotide	O
polymorphism	O
genotyping	O
was	O
developed	O
for	O
sensitive	O
detection	O
of	O
the	O
mutation	O
and	O
used	O
to	O
screen	O
field	O
-	O
collected	O
strains	O
of	O
S.	B
zeamais	I
.	O

This	O
showed	O
that	O
the	O
mutation	O
is	O
present	O
at	O
low	O
frequency	O
in	O
field	O
populations	O
and	O
is	O
a	O
useful	O
tool	O
for	O
informing	O
control	O
strategies	O
.	O

Mapping	O
interactions	O
between	O
germinants	O
and	O
Clostridium	B
difficile	I
spores	O
.	O

Germination	O
of	O
Clostridium	B
difficile	I
spores	O
is	O
the	O
first	O
required	O
step	O
in	O
establishing	O
C.	B
difficile	I
-	O
associated	O
disease	O
(	O
CDAD	O
)	O
.	O

Taurocholate	O
(	O
a	O
bile	O
salt	O
)	O
and	O
glycine	O
(	O
an	O
amino	O
acid	O
)	O
have	O
been	O
shown	O
to	O
be	O
important	O
germinants	O
of	O
C.	B
difficile	I
spores	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
tested	O
a	O
series	O
of	O
glycine	O
and	O
taurocholate	O
analogs	O
for	O
the	O
ability	O
to	O
induce	O
or	O
inhibit	O
C.	B
difficile	I
spore	O
germination	O
.	O

Testing	O
of	O
glycine	O
analogs	O
revealed	O
that	O
both	O
the	O
carboxy	O
and	O
amino	O
groups	O
are	O
important	O
epitopes	O
for	O
recognition	O
and	O
that	O
the	O
glycine	O
binding	O
site	O
can	O
accommodate	O
compounds	O
with	O
more	O
widely	O
separated	O
termini	O
.	O

The	O
C.	B
difficile	I
germination	O
machinery	O
also	O
recognizes	O
other	O
hydrophobic	O
amino	O
acids	O
.	O

In	O
general	O
,	O
linear	O
alkyl	O
side	O
chains	O
are	O
better	O
activators	O
of	O
spore	O
germination	O
than	O
their	O
branched	O
analogs	O
.	O

However	O
,	O
L	O
-	O
phenylalanine	O
and	O
L	O
-	O
arginine	O
are	O
also	O
good	O
germinants	O
and	O
are	O
probably	O
recognized	O
by	O
distinct	O
binding	O
sites	O
.	O

Testing	O
of	O
taurocholate	O
analogs	O
revealed	O
that	O
the	O
12-hydroxyl	O
group	O
of	O
taurocholate	O
is	O
necessary	O
,	O
but	O
not	O
sufficient	O
,	O
to	O
activate	O
spore	O
germination	O
.	O

In	O
contrast	O
,	O
the	O
6-	O
and	O
7-hydroxyl	O
groups	O
are	O
required	O
for	O
inhibition	O
of	O
C.	B
difficile	I
spore	O
germination	O
.	O

Similarly	O
,	O
C.	B
difficile	I
spores	O
are	O
able	O
to	O
detect	O
taurocholate	O
analogs	O
with	O
shorter	O
,	O
but	O
not	O
longer	O
,	O
alkyl	O
amino	O
sulfonic	O
acid	O
side	O
chains	O
.	O

Furthermore	O
,	O
the	O
sulfonic	O
acid	O
group	O
can	O
be	O
partially	O
substituted	O
with	O
other	O
acidic	O
groups	O
.	O

Finally	O
,	O
a	O
taurocholate	O
analog	O
with	O
an	O
m	O
-	O
aminobenzenesulfonic	O
acid	O
side	O
chain	O
is	O
a	O
strong	O
inhibitor	O
of	O
C.	B
difficile	I
spore	O
germination	O
.	O

In	O
conclusion	O
,	O
C.	B
difficile	I
spores	O
recognize	O
both	O
amino	O
acids	O
and	O
taurocholate	O
through	O
multiple	O
interactions	O
that	O
are	O
required	O
to	O
bind	O
the	O
germinants	O
and/or	O
activate	O
the	O
germination	O
machinery	O
.	O

In	O
vitro	O
studies	O
of	O
peptidoglycan	O
binding	O
and	O
hydrolysis	O
by	O
the	O
Bacillus	B
anthracis	I
germination	O
-	O
specific	O
lytic	O
enzyme	O
SleB.	O
The	O
Bacillus	B
anthracis	I
endospore	O
loses	O
resistance	O
properties	O
during	O
germination	O
when	O
its	O
cortex	O
peptidoglycan	O
is	O
degraded	O
by	O
germination	O
-	O
specific	O
lytic	O
enzymes	O
(	O
GSLEs	O
)	O
.	O

Although	O
this	O
event	O
normally	O
employs	O
several	O
GSLEs	O
for	O
complete	O
cortex	O
removal	O
,	O
the	O
SleB	O
protein	O
alone	O
can	O
facilitate	O
enough	O
cortex	O
hydrolysis	O
to	O
produce	O
vulnerable	O
spores	O
.	O

As	O
a	O
means	O
to	O
better	O
understand	O
its	O
enzymatic	O
function	O
,	O
SleB	O
was	O
overexpressed	O
,	O
purified	O
,	O
and	O
tested	O
in	O
vitro	O
for	O
depolymerization	O
of	O
cortex	O
by	O
measurement	O
of	O
optical	O
density	O
loss	O
and	O
the	O
solubilization	O
of	O
substrate	O
.	O

Its	O
ability	O
to	O
bind	O
peptidoglycan	O
was	O
also	O
investigated	O
.	O

SleB	O
functions	O
independently	O
as	O
a	O
lytic	O
transglycosylase	O
on	O
both	O
intact	O
and	O
fragmented	O
cortex	O
.	O

Most	O
of	O
the	O
muropeptide	O
products	O
that	O
SleB	O
generates	O
are	O
large	O
and	O
are	O
potential	O
substrates	O
for	O
other	O
GSLEs	O
present	O
in	O
the	O
spore	O
.	O

Study	O
of	O
a	O
truncated	O
protein	O
revealed	O
that	O
SleB	O
has	O
two	O
domains	O
.	O

The	O
N	O
-	O
terminal	O
domain	O
is	O
required	O
for	O
stable	O
peptidoglycan	O
binding	O
,	O
while	O
the	O
C	O
-	O
terminal	O
domain	O
is	O
the	O
region	O
of	O
peptidoglycan	O
hydrolytic	O
activity	O
.	O

The	O
C	O
-	O
terminal	O
domain	O
also	O
exhibits	O
dependence	O
on	O
cortex	O
containing	O
muramic	O
-	O
delta	O
-	O
lactam	O
in	O
order	O
to	O
carry	O
out	O
hydrolysis	O
.	O

As	O
the	O
conditions	O
and	O
limitations	O
for	O
SleB	O
activity	O
are	O
further	O
elucidated	O
,	O
they	O
will	O
enable	O
the	O
development	O
of	O
treatments	O
that	O
stimulate	O
premature	O
germination	O
of	O
B.	B
anthracis	I
spores	O
,	O
greatly	O
simplifying	O
decontamination	O
measures	O
.	O

Endogenous	O
regulation	O
of	O
the	O
growth	O
-	O
rate	O
responses	O
of	O
a	O
spring	O
-	O
dwelling	O
strain	O
of	O
the	O
freshwater	O
alga	O
,	O
Chlorella	B
minutissima	I
,	O
to	O
light	O
and	O
temperature	O
.	O

The	O
paper	O
presents	O
a	O
laboratory	O
investigation	O
of	O
the	O
temperature-	O
and	O
light-	O
dependence	O
of	O
autotrophic	O
growth	O
of	O
the	O
alga	O
Chlorella	B
minutissima	I
.	O

It	O
was	O
isolated	O
from	O
the	O
storage	O
basin	O
of	O
a	O
spring	O
in	O
the	O
mountains	O
of	O
the	O
Massif	O
Central	O
,	O
France	O
.	O

The	O
alga	O
was	O
grown	O
at	O
temperatures	O
between	O
(	O
10	O
and	O
35	O
^0C	O
)	O
and	O
under	O
irradiances	O
from	O
30	O
to	O
550	O
mumol	O
m	O
(	O
-2	O
)	O
s	O
(	O
-1	O
)	O
,	O
under	O
a	O
light	O
/	O
dark	O
cycle	O
.	O

The	O
results	O
were	O
fitted	O
to	O
selected	O
descriptive	O
models	O
,	O
seeking	O
to	O
express	O
,	O
as	O
far	O
as	O
possible	O
,	O
the	O
observed	O
physiological	O
behaviour	O
of	O
the	O
strain	O
and	O
the	O
minimum	O
irradiance	O
required	O
to	O
sustain	O
net	O
growth	O
.	O

At	O
all	O
temperatures	O
,	O
the	O
maximum	O
rates	O
of	O
growth	O
observed	O
are	O
strikingly	O
slower	O
than	O
those	O
of	O
other	O
Chlorella	B
strains	I
and	O
of	O
other	O
small	O
algae	O
,	O
reported	O
in	O
the	O
literature	O
,	O
even	O
when	O
correction	O
is	O
made	O
for	O
continuous	O
light	O
.	O

The	O
Q10	O
statistic	O
for	O
growth	O
at	O
temperatures>20	O
^0C	O
rates	O
is	O
also	O
noticeably	O
lower	O
than	O
in	O
other	O
species	O
,	O
while	O
the	O
apparent	O
threshold	O
of	O
any	O
growth	O
is	O
about	O
8	O
^0C	O
.	O

Growth	O
rates	O
are	O
readily	O
light	O
-	O
saturated	O
at	O
all	O
temperatures	O
but	O
with	O
little	O
evidence	O
of	O
adaptation	O
of	O
photosynthesis	O
to	O
low	O
photon	O
-	O
flux	O
rates	O
.	O

No	O
short	O
-	O
term	O
flexibility	O
in	O
these	O
properties	O
(	O
over	O
a	O
time	O
-	O
scale	O
of	O
days	O
)	O
was	O
demonstrated	O
during	O
the	O
course	O
of	O
our	O
experiments	O
.	O

We	O
deduce	O
that	O
the	O
algal	O
strain	O
had	O
become	O
genetically	O
adapted	O
to	O
the	O
relatively	O
constant	O
,	O
even	O
-	O
temperature	O
and	O
low	O
-	O
light	O
conditions	O
of	O
the	O
spring	O
-	O
water	O
habitat	O
whence	O
it	O
was	O
originally	O
isolated	O
.	O

Systemic	O
virus	O
-	O
induced	O
gene	O
silencing	O
allows	O
functional	O
characterization	O
of	O
maize	B
genes	O
during	O
biotrophic	O
interaction	O
with	O
Ustilago	B
maydis	I
.	O

Infection	O
of	O
maize	B
(	O
Zea	B
mays	I
)	O
plants	O
with	O
the	O
corn	B
smut	O
fungus	O
Ustilago	B
maydis	I
leads	O
to	O
the	O
formation	O
of	O
large	O
tumors	O
on	O
the	O
stem	O
,	O
leaves	O
and	O
inflorescences	O
.	O

In	O
this	O
biotrophic	O
interaction	O
,	O
plant	O
defense	O
responses	O
are	O
actively	O
suppressed	O
by	O
the	O
pathogen	O
,	O
and	O
previous	O
transcriptome	O
analyses	O
of	O
infected	O
maize	B
plants	O
showed	O
massive	O
and	O
stage	O
-	O
specific	O
changes	O
in	O
host	O
gene	O
expression	O
during	O
disease	O
progression	O
.	O

To	O
identify	O
maize	B
genes	O
that	O
are	O
functionally	O
involved	O
in	O
the	O
interaction	O
with	O
U.	B
maydis	I
,	O
we	O
adapted	O
a	O
virus	O
-	O
induced	O
gene	O
silencing	O
(	O
VIGS	O
)	O
system	O
based	O
on	O
the	O
brome	O
mosaic	O
virus	O
(	O
BMV	O
)	O
for	O
maize	B
.	O

Conditions	O
were	O
established	O
that	O
allowed	O
successful	O
U.	B
maydis	I
infection	O
of	O
BMV	O
-	O
preinfected	O
maize	O
plants	O
.	O

This	O
set	O
-	O
up	O
enabled	O
quantification	O
of	O
VIGS	O
and	O
its	O
impact	O
on	O
U.	B
maydis	I
infection	O
using	O
a	O
quantitative	O
real	O
-	O
time	O
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O
-based	O
readout	O
.	O

In	O
proof	O
-	O
of	O
-	O
principle	O
experiments	O
,	O
an	O
U.	B
maydis	I
-	O
induced	O
terpene	O
synthase	O
was	O
shown	O
to	O
negatively	O
regulate	O
disease	O
development	O
while	O
a	O
protein	O
involved	O
in	O
cell	O
death	O
inhibition	O
was	O
required	O
for	O
full	O
virulence	O
of	O
U.	O
maydis	O
.	O

The	O
results	O
suggest	O
that	O
this	O
system	O
is	O
a	O
versatile	O
tool	O
for	O
the	O
rapid	O
identification	O
of	O
maize	B
genes	O
that	O
determine	O
compatibility	O
with	O
U.	B
maydis	I
.	O

Hyphal	O
and	O
cytoskeleton	O
polarization	O
in	O
Tuber	B
melanosporum	I
:	O
a	O
genomic	O
and	O
cellular	O
analysis	O
.	O

Filamentous	O
polarized	O
growth	O
involves	O
a	O
series	O
of	O
events	O
including	O
polarization	O
of	O
the	O
cytoskeleton	O
to	O
selected	O
growth	O
sites	O
,	O
and	O
the	O
transport	O
of	O
secretory	O
vesicles	O
containing	O
the	O
components	O
required	O
for	O
growth	O
.	O

The	O
availability	O
of	O
fungal	O
genome	O
sequences	O
has	O
recently	O
led	O
to	O
the	O
identification	O
of	O
a	O
large	O
number	O
of	O
proteins	O
involved	O
in	O
these	O
processes	O
.	O

We	O
have	O
explored	O
the	O
Tuber	B
melanosporum	I
genome	O
sequence	O
by	O
searching	O
for	O
homologs	O
of	O
genes	O
known	O
to	O
play	O
crucial	O
roles	O
in	O
the	O
morphogenesis	O
and	O
cell	O
polarity	O
of	O
yeasts	B
and	O
filamentous	O
fungi	O
.	O

One	O
hundred	O
and	O
forty	O
-	O
nine	O
genes	O
have	O
been	O
identified	O
and	O
functionally	O
grouped	O
according	O
to	O
the	O
deduced	O
amino	O
acid	O
sequences	O
(	O
44	O
genes	O
involved	O
in	O
cell	O
polarity	O
/	O
morphogenesis	O
,	O
39	O
belonging	O
to	O
the	O
actin	O
cytoskeleton	O
and	O
66	O
involved	O
in	O
membrane	O
dynamics	O
,	O
septation	O
and	O
exocytosis	O
)	O
.	O

A	O
detailed	O
gene	O
annotation	O
has	O
shown	O
that	O
most	O
components	O
of	O
the	O
cell	O
polarity	O
machinery	O
,	O
morphogenesis	O
and	O
cytoskeleton	O
found	O
in	O
yeasts	B
and	O
filamentous	O
fungi	O
are	O
conserved	O
,	O
although	O
the	O
degree	O
of	O
similarity	O
varies	O
from	O
strong	O
to	O
weak	O
.	O

Microscopic	O
analysis	O
of	O
quick	O
-	O
frozen	O
truffle	O
hyphae	O
detected	O
the	O
characteristic	O
subcellular	O
components	O
of	O
the	O
hyphal	O
tip	O
in	O
septate	O
filamentous	O
fungi	O
,	O
while	O
transcript	O
profiles	O
revealed	O
a	O
moderately	O
variable	O
pattern	O
during	O
the	O
biological	O
cycle	O
.	O

The	O
osmosensing	O
signal	O
transduction	O
pathway	O
from	O
Botrytis	B
cinerea	I
regulates	O
cell	O
wall	O
integrity	O
and	O
MAP	O
kinase	O
pathways	O
control	O
melanin	O
biosynthesis	O
with	O
influence	O
of	O
light	O
.	O

Mitogen	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
signal	O
transduction	O
pathways	O
are	O
ubiquitous	O
among	O
eukaryotic	O
organisms	O
with	O
evolutionary	O
conserved	O
modules	O
.	O

Although	O
generally	O
classified	O
as	O
osmotic	O
and	O
cell	O
wall	O
integrity	O
pathways	O
,	O
functional	O
divergences	O
have	O
been	O
observed	O
for	O
HOG1-	O
and	O
SLT2-related	O
MAPK	O
pathways	O
.	O

Here	O
we	O
show	O
that	O
the	O
osmotic	O
signal	O
transduction	O
cascade	O
is	O
involved	O
in	O
cell	O
wall	O
integrity	O
in	O
the	O
phytopathogenic	O
ascomycete	O
Botrytis	B
cinerea	I
.	O

The	O
deletion	O
mutants	O
of	O
the	O
upstream	O
histidine	O
kinase	O
Bos1	O
and	O
of	O
the	O
MAPK	O
Sak1	O
showed	O
modified	O
tolerance	O
to	O
cell	O
wall	O
degrading	O
enzymes	O
and	O
cell	O
wall	O
interfering	O
agents	O
,	O
as	O
well	O
as	O
increased	O
staining	O
of	O
Beta1	O
-	O
3	O
glucan	O
and	O
chitin	O
compared	O
to	O
the	O
wild	O
-	O
type	O
.	O

The	O
Sak1	O
MAPK	O
was	O
phosphorylated	O
upon	O
cell	O
wall	O
challenging	O
.	O

Sak1	O
interfered	O
with	O
the	O
phosphorylation	O
status	O
of	O
the	O
SLT2	O
type	O
MAPK	O
Bmp3	O
hinting	O
to	O
cross	O
talk	O
between	O
both	O
MAPK	O
pathways	O
.	O

All	O
signal	O
transduction	O
components	O
interfered	O
with	O
the	O
expression	O
of	O
melanin	O
biosynthesis	O
genes	O
in	O
dark	O
and	O
bright	O
,	O
suggesting	O
a	O
coordinated	O
control	O
of	O
melanin	O
biosynthesis	O
.	O

Ecosystem	O
engineering	O
and	O
predation	O
:	O
the	O
multi	O
-	O
trophic	O
impact	O
of	O
two	O
ant	O
species	O
.	O

1	O
.	O

Ants	O
are	O
ubiquitous	O
ecosystem	O
engineers	O
and	O
generalist	O
predators	O
and	O
are	O
able	O
to	O
affect	O
ecological	O
communities	O
via	O
both	O
pathways	O
.	O

They	O
are	O
likely	O
to	O
influence	O
any	O
other	O
terrestrial	O
arthropod	O
group	O
either	O
directly	O
or	O
indirectly	O
caused	O
by	O
their	O
high	O
abundance	O
and	O
territoriality	O
.	O

2	O
.	O

We	O
studied	O
the	O
impact	O
of	O
two	O
ant	O
species	O
common	O
in	O
Central	O
Europe	O
,	O
Myrmica	B
rubra	I
and	O
Lasius	B
niger	I
,	O
on	O
an	O
arthropod	O
community	O
.	O

Colony	O
presence	O
and	O
density	O
of	O
these	O
two	O
ant	O
species	O
were	O
manipulated	O
in	O
a	O
field	O
experiment	O
from	O
the	O
start	O
of	O
ant	O
activity	O
in	O
spring	O
to	O
late	O
summer	O
.	O

3	O
.	O

The	O
experiment	O
revealed	O
a	O
positive	O
influence	O
of	O
the	O
presence	O
of	O
one	O
ant	O
colony	O
on	O
densities	O
of	O
decomposers	O
,	O
herbivores	O
and	O
parasitoids	O
.	O

However	O
,	O
in	O
the	O
case	O
of	O
herbivores	O
and	O
parasitoids	O
,	O
this	O
effect	O
was	O
reversed	O
in	O
the	O
presence	O
of	O
two	O
colonies	O
.	O

4	O
.	O
Generally	O
,	O
effects	O
of	O
the	O
two	O
ant	O
species	O
were	O
similar	O
with	O
the	O
exception	O
of	O
their	O
effect	O
on	O
Braconidae	O
parasitoid	O
densities	O
that	O
responded	O
positively	O
to	O
one	O
colony	O
of	O
M.	B
rubra	I
but	O
not	O
of	O
L.	B
niger	I
.	O

5	O
.	O

Spider	O
density	O
was	O
not	O
affected	O
by	O
ant	O
colony	O
manipulation	O
,	O
but	O
species	O
richness	O
of	O
spiders	O
responded	O
positively	O
to	O
ant	O
presence	O
.	O

This	O
effect	O
was	O
independent	O
of	O
ant	O
colony	O
density	O
,	O
but	O
where	O
two	O
colonies	O
were	O
present	O
,	O
spider	O
richness	O
was	O
significantly	O
greater	O
in	O
plots	O
with	O
two	O
M.	B
rubra	I
colonies	O
than	O
in	O
plots	O
with	O
one	O
colony	O
of	O
each	O
ant	O
species	O
.	O

6	O
.	O

To	O
test	O
whether	O
the	O
positive	O
ecosystem	O
engineering	O
effects	O
were	O
purely	O
caused	O
by	O
modified	O
properties	O
of	O
the	O
soil	O
,	O
we	O
added	O
in	O
an	O
additional	O
experiment	O
(	O
i	O
)	O
the	O
soil	O
from	O
ant	O
nests	O
(	O
without	O
ants	O
)	O
or	O
(	O
ii	O
)	O
unmodified	O
soil	O
or	O
(	O
iii	O
)	O
ant	O
nests	O
(	O
including	O
ants	O
)	O
to	O
experimental	O
plots	O
.	O

Ant	O
nest	O
soil	O
on	O
its	O
own	O
did	O
not	O
have	O
a	O
significant	O
impact	O
on	O
densities	O
of	O
decomposers	O
,	O
herbivores	O
or	O
predators	O
,	O
which	O
were	O
significantly	O
,	O
and	O
positively	O
,	O
affected	O
by	O
the	O
addition	O
of	O
an	O
intact	O
nest	O
.	O

7	O
.	O

The	O
results	O
suggest	O
an	O
important	O
role	O
of	O
both	O
ant	O
species	O
in	O
the	O
grassland	O
food	O
web	O
,	O
strongly	O
affecting	O
the	O
densities	O
of	O
decomposers	O
,	O
herbivores	O
and	O
higher	O
trophic	O
levels	O
.	O

We	O
discuss	O
how	O
the	O
relative	O
impact	O
via	O
bottom	O
-	O
up	O
and	O
top	O
-	O
down	O
effects	O
of	O
ants	O
depends	O
on	O
nest	O
density	O
,	O
with	O
a	O
relatively	O
greater	O
top	O
-	O
down	O
predatory	O
impact	O
at	O
higher	O
densities	O
.	O

The	O
effects	O
of	O
dsRNA	O
mycoviruses	O
on	O
growth	O
and	O
murine	O
virulence	O
of	O
Aspergillus	B
fumigatus	I
.	O

Some	O
isolates	O
of	O
the	O
opportunistic	O
human	B
pathogenic	O
fungus	O
Aspergillus	B
fumigatus	I
are	O
known	O
to	O
be	O
infected	O
with	O
mycoviruses	O
.	O

The	O
dsRNA	O
genomes	O
of	O
two	O
of	O
these	O
mycoviruses	O
,	O
which	O
include	O
a	O
chrysovirus	O
and	O
a	O
partitivirus	O
,	O
have	O
been	O
completely	O
sequenced	O
and	O
an	O
RT	O
-	O
PCR	O
assay	O
for	O
the	O
viruses	O
has	O
been	O
developed	O
.	O

Through	O
curing	O
virus	O
-	O
infected	O
A.	B
fumigatus	I
isolates	O
by	O
cycloheximide	O
treatment	O
and	O
transfecting	O
virus	O
-	O
free	O
isolates	O
with	O
purified	O
virus	O
,	O
as	O
checked	O
by	O
RT	O
-	O
PCR	O
,	O
isogenic	O
virus	O
-	O
free	O
and	O
virus	O
-	O
infected	O
lines	O
of	O
the	O
fungus	O
were	O
generated	O
whose	O
phenotypes	O
and	O
growth	O
have	O
been	O
directly	O
compared	O
.	O

Mycovirus	O
infection	O
of	O
A.	B
fumigatus	I
with	O
either	O
the	O
chrysovirus	O
or	O
the	O
partitivirus	O
resulted	O
in	O
significant	O
aberrant	O
phenotypic	O
alterations	O
and	O
attenuation	O
of	O
growth	O
of	O
the	O
fungus	O
but	O
had	O
no	O
effect	O
on	O
susceptibility	O
to	O
common	O
antifungals	O
.	O

Chrysovirus	O
infection	O
of	O
A.	B
fumigatus	I
caused	O
no	O
significant	O
alterations	O
to	O
murine	O
pathogenicity	O
.	O

Suitability	O
of	O
different	O
media	O
for	O
in	O
vitro	O
cultivation	O
of	O
the	O
ruminal	O
protozoa	O
species	O
Entodinium	B
caudatum	I
,	O
Eudiplodinium	B
maggii	I
,	O
and	O
Epidinium	B
ecaudatum	I
.	O

Three	O
protozoal	O
cultivation	O
media	O
were	O
tested	O
to	O
determine	O
the	O
medium	O
which	O
best	O
facilitated	O
growth	O
and	O
viability	O
of	O
key	O
B	O
-	O
type	O
ciliates	O
isolated	O
from	O
the	O
sheep	O
rumen	O
.	O

Entodinium	B
caudatum	I
and	O
Eudiplodinium	B
maggii	I
were	O
grown	O
anaerobically	O
in	O
50-ml	O
flasks	O
for	O
32	O
days	O
in	O
Caudatum	O
-	O
type	O
(	O
C	O
)	O
,	O
Kisidayova	O
(	O
K	O
)	O
or	O
Dehority	O
(	O
M	O
)	O
medium	O
.	O

On	O
day	O
32	O
,	O
in	O
media	O
K	O
and	O
M	O
,	O
E.	B
caudatum	I
cell	O
counts	O
were	O
high	O
with	O
5.6x10	O
(	O
3	O
)	O
and	O
7.8x10	O
(	O
3	O
)	O
mL	O
(	O
-1	O
)	O
,	O
respectively	O
,	O
and	O
the	O
proportion	O
of	O
dead	O
cells	O
was	O
low	O
with	O
0.6	O
and	O
1.4	O
%	O
,	O
respectively	O
.	O

E.	B
maggii	I
concentrations	O
when	O
grown	O
in	O
medium	O
M	O
and	O
C	O
were	O
2.7x10	O
(	O
3	O
)	O
and	O
2.4x10	O
(	O
3	O
)	O
mL	O
(	O
-1	O
)	O
,	O
respectively	O
,	O
with	O
3.9	O
and	O
14.1	O
%	O
dead	O
cells	O
.	O

Medium	O
M	O
,	O
which	O
favoured	O
growth	O
of	O
both	O
protozoa	O
species	O
,	O
was	O
tested	O
again	O
and	O
Epidinium	B
ecaudatum	I
was	O
included	O
.	O

Protozoa	O
were	O
grown	O
for	O
a	O
4-month	O
period	O
and	O
samples	O
were	O
taken	O
in	O
the	O
last	O
two	O
months	O
on	O
days	O
1	O
,	O
7	O
,	O
35	O
and	O
57	O
.	O

Average	O
cell	O
concentrations	O
were	O
10.0	O
,	O
0.8	O
and	O
0.5x10	O
(	O
3	O
)	O
mL	O
(	O
-1	O
)	O
for	O
E.	B
caudatum	I
,	O
E.	B
maggii	I
,	O
and	O
E.	B
ecaudatum	I
,	O
respectively	O
.	O

In	O
conclusion	O
,	O
medium	O
M	O
would	O
appear	O
to	O
be	O
the	O
best	O
choice	O
for	O
cultivating	O
these	O
three	O
species	O
in	O
one	O
medium	O
.	O

Non	O
-	O
structural	O
protein	O
1	O
(	O
NS1	O
)	O
antibody	O
-	O
based	O
assays	O
to	O
differentiate	O
West	B
Nile	I
(	O
WN	O
)	O
virus	O
from	O
Japanese	O
encephalitis	O
virus	O
infections	O
in	O
horses	O
:	O
effects	O
of	O
WN	B
virus	I
NS1	O
antibodies	O
induced	O
by	O
inactivated	O
WN	O
vaccine	O
.	O

Antibodies	O
to	O
non	O
-	O
structural	O
protein	O
1	O
(	O
NS1	O
)	O
of	O
West	O
Nile	O
virus	O
(	O
WNV	O
)	O
have	O
been	O
used	O
to	O
differentiate	O
WNV	O
infection	O
from	O
infection	O
by	O
serologically	O
cross	O
-	O
reactive	O
flaviviruses	O
,	O
including	O
Japanese	B
encephalitis	I
virus	I
(	O
JEV	O
)	O
,	O
in	O
horses	O
.	O

However	O
,	O
since	O
the	O
inactivated	O
West	O
Nile	O
(	O
WN	B
)	O
vaccine	O
has	O
been	O
reported	O
to	O
induce	O
NS1	O
antibodies	O
,	O
there	O
is	O
concern	O
about	O
the	O
reliability	O
of	O
using	O
NS1-based	O
assays	O
for	O
testing	O
vaccinated	O
horses	O
.	O

Therefore	O
,	O
the	O
effect	O
of	O
inactivated	O
WN	B
vaccine	O
-	O
induced	O
antibodies	O
on	O
an	O
epitope	O
-	O
blocking	O
ELISA	O
and	O
complement	O
-	O
dependent	O
cytotoxicity	O
(	O
CDC	O
)	O
assay	O
were	O
investigated	O
.	O

Both	O
assays	O
are	O
based	O
on	O
NS1	O
antibodies	O
and	O
were	O
established	O
previously	O
to	O
differentiate	O
WNV	B
from	O
JEV	O
infections	O
in	O
horses	O
.	O

Groups	O
of	O
three	O
horses	O
were	O
vaccinated	O
with	O
two	O
or	O
three	O
doses	O
of	O
a	O
commercial	O
inactivated	O
WN	O
vaccine	O
and	O
NS1	O
antibodies	O
were	O
detected	O
by	O
a	O
conventional	O
ELISA	O
after	O
the	O
second	O
vaccination	O
.	O

Vaccine	O
-	O
induced	O
NS1	O
antibodies	O
were	O
also	O
detected	O
by	O
blocking	O
ELISA	O
and	O
a	O
CDC	O
assay	O
and	O
affected	O
the	O
ability	O
of	O
these	O
assays	O
to	O
differentiate	O
WNV	B
from	O
JEV	B
infections	O
.	O

However	O
,	O
the	O
effect	O
was	O
less	O
significant	O
in	O
the	O
CDC	O
assay	O
,	O
where	O
use	O
of	O
a	O
low	O
serum	O
concentration	O
ensured	O
effective	O
differentiation	O
.	O

The	O
more	O
efficient	O
detection	O
of	O
infection	O
-	O
induced	O
antibodies	O
over	O
vaccine	O
-	O
induced	O
antibodies	O
by	O
the	O
CDC	O
assay	O
was	O
potentially	O
attributable	O
to	O
the	O
different	O
IgG	O
isotype	O
profiles	O
of	O
these	O
antibodies	O
.	O

Involvement	O
of	O
extracellular	O
oxidative	O
burst	O
in	O
salicylic	O
acid	O
-	O
induced	O
stomatal	O
closure	O
in	O
Arabidopsis	B
.	O

Salicylic	O
acid	O
(	O
SA	O
)	O
,	O
a	O
ubiquitous	O
phenolic	O
phytohormone	O
,	O
is	O
involved	O
in	O
many	O
plant	O
physiological	O
processes	O
including	O
stomatal	O
movement	O
.	O

We	O
analysed	O
SA	O
-	O
induced	O
stomatal	O
closure	O
,	O
production	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
and	O
nitric	O
oxide	O
(	O
NO	O
)	O
,	O
cytosolic	O
calcium	O
ion	O
(	O
[	O
Ca^2+	O
]	O
(	O
cyt	O
)	O
)	O
oscillations	O
and	O
inward	O
-	O
rectifying	O
potassium	O
(	O
K+	O
(	O
in	O
)	O
)	O
channel	O
activity	O
in	O
Arabidopsis	B
.	O

SA	O
-	O
induced	O
stomatal	O
closure	O
was	O
inhibited	O
by	O
pre	O
-	O
treatment	O
with	O
catalase	O
(	O
CAT	O
)	O
and	O
superoxide	O
dismutase	O
(	O
SOD	O
)	O
,	O
suggesting	O
the	O
involvement	O
of	O
extracellular	O
ROS	O
.	O

A	O
peroxidase	O
inhibitor	O
,	O
SHAM	O
(	O
salicylhydroxamic	O
acid	O
)	O
completely	O
abolished	O
SA	O
-	O
induced	O
stomatal	O
closure	O
whereas	O
neither	O
an	O
inhibitor	O
of	O
NADPH	O
oxidase	O
(	O
DPI	O
)	O
nor	O
atrbohD	O
atrbohF	O
mutation	O
impairs	O
SA	O
-	O
induced	O
stomatal	O
closures	O
.	O

3,3'-Diaminobenzidine	O
(	O
DAB	O
)	O
and	O
nitroblue	O
tetrazolium	O
(	O
NBT	O
)	O
stainings	O
demonstrated	O
that	O
SA	O
induced	O
H2O2	O
and	O
O2-	O
production	O
.	O

Guard	O
cell	O
ROS	O
accumulation	O
was	O
significantly	O
increased	O
by	O
SA	O
,	O
but	O
that	O
ROS	O
was	O
suppressed	O
by	O
exogenous	O
CAT	O
,	O
SOD	O
and	O
SHAM	O
.	O

NO	O
scavenger	O
2-	O
(	O
4-carboxyphenyl	O
)	O
-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide	O
(	O
cPTIO	O
)	O
suppressed	O
the	O
SA	O
-	O
induced	O
stomatal	O
closure	O
but	O
did	O
not	O
suppress	O
guard	O
cell	O
ROS	O
accumulation	O
whereas	O
SHAM	O
suppressed	O
SA	O
-	O
induced	O
NO	O
production	O
.	O

SA	O
failed	O
to	O
induce	O
[	O
Ca^2+	O
]	O
(	O
cyt	O
)	O
oscillations	O
in	O
guard	O
cells	O
whereas	O
K+	O
(	O
in	O
)	O
channel	O
activity	O
was	O
suppressed	O
by	O
SA	O
.	O

These	O
results	O
indicate	O
that	O
SA	O
induces	O
stomatal	O
closure	O
accompanied	O
with	O
extracellular	O
ROS	O
production	O
mediated	O
by	O
SHAM	O
-	O
sensitive	O
peroxidase	O
,	O
intracellular	O
ROS	O
accumulation	O
and	O
K+	O
(	O
in	O
)	O
channel	O
inactivation	O
.	O

Influence	O
of	O
Sticky	O
Trap	O
Color	O
and	O
Height	O
Above	O
Ground	O
on	O
Capture	O
of	O
Alate	O
Elatobium	B
abietinum	I
(	O
Hemiptera	O
:	O
Aphididae	O
)	O
in	O
Sitka	O
Spruce	O
Plantations	O
.	O

A	O
series	O
of	O
field	O
trials	O
were	O
used	O
to	O
assess	O
the	O
practicality	O
of	O
using	O
sticky	O
traps	O
to	O
monitor	O
populations	O
of	O
green	O
spruce	O
aphid	O
,	O
Elatobium	O
abietinum	O
(	O
Walker	O
)	O
,	O
in	O
plantations	O
of	O
Sitka	B
spruce	I
.	O

The	O
highest	O
numbers	O
of	O
alate	O
E.	B
abietinum	I
were	O
caught	O
on	O
sticky	O
traps	O
placed	O
in	O
the	O
upper	O
third	O
of	O
the	O
live	O
canopy	O
at	O
9	O
-	O
17	O
m	O
above	O
the	O
ground	O
,	O
whereas	O
low	O
numbers	O
of	O
aphids	O
were	O
caught	O
just	O
below	O
the	O
live	O
canopy	O
or	O
at	O
2	O
m	O
above	O
the	O
ground	O
.	O

Trials	O
in	O
2005	O
with	O
sticky	O
traps	O
of	O
different	O
colors	O
showed	O
that	O
significantly	O
more	O
alate	O
E.	B
abietinum	I
were	O
caught	O
on	O
yellow	O
,	O
red	O
,	O
and	O
green	O
sticky	O
traps	O
than	O
on	O
white	O
,	O
blue	O
,	O
and	O
black	O
traps	O
.	O

A	O
repeat	O
trial	O
in	O
2007	O
resulted	O
in	O
significantly	O
more	O
alate	O
aphids	O
being	O
caught	O
on	O
red	O
sticky	O
traps	O
than	O
on	O
traps	O
of	O
any	O
other	O
color	O
except	O
for	O
green	O
.	O

Attraction	O
to	O
red	O
is	O
unusual	O
among	O
aphids	O
,	O
as	O
aphids	O
are	O
thought	O
not	O
to	O
possess	O
a	O
red	O
-	O
sensitive	O
photoreceptor	O
.	O

The	O
attraction	O
of	O
E.	B
abietinum	I
to	O
red	O
-	O
colored	O
sticky	O
traps	O
suggests	O
that	O
conifer	O
-	O
feeding	O
aphids	O
might	O
have	O
a	O
fundamentally	O
different	O
color	O
response	O
compared	O
with	O
aphids	O
that	O
live	O
on	O
cereals	O
,	O
grasses	O
,	O
or	O
herbaceous	O
plants	O
.	O

Alternatively	O
,	O
the	O
attraction	O
to	O
red	O
might	O
be	O
a	O
physiological	O
artifact	O
related	O
to	O
the	O
presence	O
of	O
red	O
-	O
screening	O
pigments	O
in	O
the	O
aphid	O
's	O
compound	O
eye	O
.	O

Host	O
plant	O
effects	O
on	O
alkaline	O
phosphatase	O
activity	O
in	O
the	O
whiteflies	O
,	O
Bemisia	B
tabaci	I
Biotype	O
B	O
and	O
Trialeurodes	B
vaporariorum	I
.	O

Bemisia	B
tabaci	I
(	O
Gennadius	O
)	O
B	O
-	O
biotype	O
and	O
Trialeurodes	B
vaporariorum	I
(	O
Westwood	O
)	O
(	O
Hemiptera	O
:	O
Aleyrodidae	O
)	O
often	O
coexist	O
on	O
greenhouse	O
-	O
grown	O
vegetable	O
crops	O
in	O
northern	O
China	O
.	O

The	O
recent	O
spread	O
of	O
B.	B
tabaci	I
B	O
-	O
biotype	O
has	O
largely	O
replaced	O
T.	B
vaporariorum	I
,	O
and	O
B	O
-	O
biotype	O
now	O
overlaps	O
with	O
T.	B
vaporariorum	I
where	O
common	O
hosts	O
occur	O
in	O
most	O
invaded	O
areas	O
.	O

The	O
impact	O
of	O
the	O
B	O
-	O
biotype	O
on	O
the	O
agro	O
eco	O
system	O
appears	O
to	O
be	O
widespread	O
,	O
and	O
involves	O
the	O
ability	O
to	O
compete	O
with	O
and	O
perhaps	O
replace	O
other	O
phytophages	O
like	O
T.	B
vaporariorum	I
.	O

An	O
emerging	O
hypothesis	O
is	O
that	O
the	O
B	O
-	O
biotype	O
is	O
physiologically	O
superior	O
due	O
at	O
least	O
in	O
part	O
to	O
an	O
improved	O
ability	O
to	O
metabolically	O
utilize	O
the	O
alkaline	O
phosphatase	O
pathway	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
alkaline	O
phosphatase	O
activity	O
was	O
studied	O
in	O
the	O
B	O
-	O
biotype	O
and	O
T.	B
vaporariorum	I
after	O
feeding	O
on	O
a	O
number	O
of	O
different	O
hosts	O
for	O
a	O
range	O
of	O
durations	O
,	O
with	O
and	O
without	O
host	O
switching	O
.	O

Alkaline	O
phosphatase	O
activity	O
in	O
T.	B
vaporariorum	I
was	O
1.45	O
to	O
2.53-fold	O
higher	O
than	O
that	O
of	O
the	O
B	O
-	O
biotype	O
when	O
fed	O
on	O
tomato	B
for	O
4	O
and	O
24	O
h	O
,	O
or	O
switched	O
from	O
tomato	B
to	O
cotton	B
and	O
cabbage	B
for	O
the	O
same	O
durations	O
.	O

However	O
,	O
alkaline	O
phosphatase	O
activity	O
in	O
the	O
B	O
-	O
biotype	O
was	O
1.40	O
to	O
3.35-fold	O
higher	O
than	O
that	O
of	O
T.	B
vaporariorum	I
when	O
the	O
host	O
switching	O
time	O
was	O
-72	O
and	O
-120	O
h	O
on	O
the	O
same	O
plant	O
.	O

Both	O
short	O
-	O
term	O
(	O
4	O
h	O
)	O
and	O
long	O
-	O
term	O
(	O
72	O
h	O
)	O
switching	O
of	O
plant	O
hosts	O
can	O
significantly	O
affect	O
the	O
alkaline	O
phosphatase	O
activity	O
in	O
the	O
two	O
species	O
.	O

After	O
-120	O
h	O
,	O
feeding	O
on	O
tomato	B
and	O
cotton	B
alkaline	O
phosphatase	O
activity	O
in	O
the	O
B	O
-	O
biotype	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
T.	B
vaporariorum	I
.	O

It	O
was	O
shown	O
that	O
alkaline	O
phosphatase	O
aids	O
the	O
species	O
feeding	O
on	O
different	O
plant	O
species	O
,	O
and	O
that	O
the	O
B	O
-	O
biotype	O
is	O
physiologically	O
superior	O
to	O
T.	B
vaporariorum	I
in	O
utilizing	O
the	O
enzyme	O
compared	O
to	O
T.	B
vaporariorum	I
over	O
longer	O
periods	O
of	O
feeding	O
.	O

T	O
cell	O
-	O
mediated	O
protection	O
against	O
lethal	B
2009	I
pandemic	I
H1N1	I
influenza	I
virus	I
infection	O
in	O
a	O
mouse	O
model	O
.	O

Genetic	O
mutation	O
and	O
reassortment	O
of	O
influenza	B
virus	I
gene	O
segments	O
,	O
in	O
particular	O
those	O
of	O
hemagglutinin	O
(	O
HA	O
)	O
and	O
neuraminidase	O
(	O
NA	O
)	O
,	O
that	O
lead	O
to	O
antigenic	O
drift	O
and	O
shift	O
are	O
the	O
major	O
strategies	O
for	O
influenza	B
virus	I
to	O
escape	O
preexisting	O
immunity	O
.	O

The	O
most	O
recent	O
example	O
of	O
such	O
phenomena	O
is	O
the	O
first	O
pandemic	O
of	O
H1N1	B
influenza	I
of	O
the	O
21st	O
century	O
,	O
which	O
started	O
in	O
2009	O
.	O

Cross	O
-	O
reactive	O
antibodies	O
raised	O
against	O
H1N1	B
viruses	I
circulating	O
before	O
1930	O
show	O
protective	O
activity	O
against	O
the	O
2009	B
pandemic	I
virus	I
.	O

Cross	O
-	O
reactive	O
T	O
-	O
cell	O
responses	O
can	O
also	O
contribute	O
to	O
protection	O
,	O
but	O
in	O
vivo	O
support	O
of	O
this	O
view	O
is	O
lacking	O
.	O

To	O
explore	O
the	O
protection	O
mechanisms	O
in	O
vivo	O
,	O
we	O
primed	O
mice	O
with	O
H1	B
and	O
H3	B
influenza	I
virus	I
isolates	O
and	O
rechallenged	O
them	O
with	O
a	O
virus	O
derived	O
from	O
the	O
2009	B
H1N1	I
A	I
/	I
CA	I
/	I
04	I
/	I
09	I
virus	I
,	O
named	O
CA	O
/	O
E3	O
/	O
09	O
.	O

We	O
found	O
that	O
priming	O
with	O
influenza	O
viruses	O
of	O
both	O
H1	B
and	O
H3	O
homo-	O
and	O
heterosubtypes	O
protected	O
against	O
lethal	O
CA	O
/	O
E3	O
/	O
09	O
virus	O
challenge	O
.	O

Convalescent	O
-	O
phase	O
sera	O
from	O
these	O
primed	O
mice	O
conferred	O
no	O
neutralization	O
activity	O
in	O
vitro	O
and	O
no	O
protection	O
in	O
vivo	O
.	O

However	O
,	O
T	O
-	O
cell	O
depletion	O
studies	O
suggested	O
that	O
both	O
CD4	O
and	O
CD8	O
T	O
cells	O
contributed	O
to	O
the	O
protection	O
.	O

Taken	O
together	O
,	O
these	O
results	O
indicate	O
that	O
cross	O
-	O
reactive	O
T	O
cells	O
established	O
after	O
initial	O
priming	O
with	O
distally	O
related	O
viruses	O
can	O
be	O
a	O
vital	O
component	O
for	O
prevention	O
of	O
disease	O
and	O
control	O
of	O
pandemic	B
H1N1	I
influenza	I
virus	I
infection	O
.	O

Our	O
results	O
highlight	O
the	O
importance	O
of	O
establishing	O
cross	O
-	O
reactive	O
T	O
-	O
cell	O
responses	O
for	O
protecting	O
against	O
existing	O
or	O
newly	O
emerging	O
pandemic	O
influenza	O
viruses	O
.	O

Association	O
of	O
TRIM22	O
with	O
the	O
type	O
1	O
interferon	O
response	O
and	O
viral	O
control	O
during	O
primary	O
HIV-1	B
infection	O
.	O

Type	O
1	O
interferons	O
(	O
IFNs	O
)	O
induce	O
the	O
expression	O
of	O
the	O
tripartite	O
interaction	O
motif	O
(	O
TRIM	O
)	O
family	O
of	O
E3	O
ligases	O
,	O
but	O
the	O
contribution	O
of	O
these	O
antiviral	O
factors	O
to	O
HIV	B
pathogenesis	O
is	O
not	O
completely	O
understood	O
.	O

We	O
hypothesized	O
that	O
the	O
increased	O
expression	O
of	O
select	O
type	O
1	O
IFN	O
and	O
TRIM	O
isoforms	O
is	O
associated	O
with	O
a	O
significantly	O
lower	O
likelihood	O
of	O
HIV-1	B
acquisition	O
and	O
viral	O
control	O
during	O
primary	O
HIV-1	B
infection	O
.	O

We	O
measured	O
IFN	O
-	O
alpha	O
,	O
IFN	O
-	O
Beta	O
,	O
myxovirus	O
resistance	O
protein	O
A	O
(	O
MxA	O
)	O
,	O
human	B
TRIM5alpha	O
(	O
huTRIM5alpha	O
)	O
,	O
and	O
TRIM22	O
mRNA	O
levels	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
of	O
high	O
-	O
risk	O
,	O
HIV-1-uninfected	B
participants	O
and	O
HIV-1-positive	B
study	O
participants	O
.	O

Samples	O
were	O
available	O
for	O
32	O
uninfected	O
subjects	O
and	O
28	O
infected	O
persons	O
,	O
all	O
within	O
1	O
year	O
of	O
infection	O
.	O

HIV-1-positive	B
participants	O
had	O
higher	O
levels	O
of	O
IFN	O
-	O
Beta	O
(	O
P	O
=	O
0.0005	O
)	O
,	O
MxA	O
(	O
P	O
=	O
0.007	O
)	O
,	O
and	O
TRIM22	O
(	O
P	O
=	O
0.01	O
)	O
and	O
lower	O
levels	O
of	O
huTRIM5alpha	O
(	O
P	O
<	O
0.001	O
)	O
than	O
did	O
HIV-1-negative	O
participants	O
.	O

TRIM22	O
but	O
not	O
huTRIM5alpha	O
correlated	O
positively	O
with	O
type	O
1	O
IFN	O
(	O
IFN	O
-	O
alpha	O
,	O
IFN	O
-	O
Beta	O
,	O
and	O
MxA	O
)	O
(	O
all	O
P	O
<	O
0.0001	O
)	O
.	O

In	O
a	O
multivariate	O
model	O
,	O
increased	O
MxA	O
expression	O
showed	O
a	O
significant	O
positive	O
association	O
with	O
viral	O
load	O
(	O
P	O
=	O
0.0418	O
)	O
.	O

Furthermore	O
,	O
TRIM22	O
but	O
not	O
huTRIM5alpha	O
,	O
IFN	O
-	O
alpha	O
,	O
IFN	O
-	O
Beta	O
,	O
or	O
MxA	O
showed	O
a	O
negative	O
correlation	O
with	O
plasma	O
viral	O
load	O
(	O
P	O
=	O
0.0307	O
)	O
and	O
a	O
positive	O
correlation	O
with	O
CD4	O
(	O
+	O
)	O
T	O
-	O
cell	O
counts	O
(	O
P	O
=	O
0.0281	O
)	O
.	O

In	O
vitro	O
studies	O
revealed	O
that	O
HIV	O
infection	O
induced	O
TRIM22	O
expression	O
in	O
PBMCs	O
obtained	O
from	O
HIV	O
-	O
negative	O
donors	O
.	O

Stable	O
TRIM22	O
knockdown	O
resulted	O
in	O
increased	O
HIV-1	O
particle	B
release	O
and	O
replication	O
in	O
Jurkat	O
reporter	O
cells	O
.	O

Collectively	O
,	O
these	O
data	O
suggest	O
concordance	O
between	O
type	O
1	O
IFN	O
and	O
TRIM22	O
but	O
not	O
huTRIM5alpha	O
expression	O
in	O
PBMCs	O
and	O
that	O
TRIM22	O
likely	O
acts	O
as	O
an	O
antiviral	O
effector	O
in	O
vivo	O
.	O

The	O
B	O
cell	O
response	O
is	O
redundant	O
and	O
highly	O
focused	O
on	O
V1V2	O
during	O
early	O
subtype	O
C	O
infection	O
in	O
a	O
Zambian	O
seroconverter	O
.	O

High	O
-	O
titer	O
autologous	O
neutralizing	O
antibody	O
responses	O
have	O
been	O
demonstrated	O
during	O
early	O
subtype	O
C	O
human	B
immunodeficiency	I
virus	I
type	I
1	O
(	O
HIV-1	B
)	O
infection	O
.	O

However	O
,	O
characterization	O
of	O
this	O
response	O
against	O
autologous	O
virus	O
at	O
the	O
monoclonal	O
antibody	O
(	O
MAb	O
)	O
level	O
has	O
only	O
recently	O
begun	O
to	O
be	O
elucidated	O
.	O

Here	O
we	O
describe	O
five	O
monoclonal	O
antibodies	O
derived	O
from	O
a	O
subtype	O
C	O
-	O
infected	O
seroconverter	O
and	O
their	O
neutralizing	O
activities	O
against	O
pseudoviruses	O
that	O
carry	O
envelope	O
glycoproteins	O
from	O
48	O
days	O
(	O
0	O
month	O
)	O
,	O
2	O
months	O
,	O
and	O
8	O
months	O
after	O
the	O
estimated	O
time	O
of	O
infection	O
.	O

Sequence	O
analysis	O
indicated	O
that	O
the	O
MAbs	O
arose	O
from	O
three	O
distinct	O
B	O
cell	O
clones	O
,	O
and	O
their	O
pattern	O
of	O
neutralization	O
compared	O
to	O
that	O
in	O
patient	O
plasma	O
suggested	O
that	O
they	O
circulated	O
between	O
2	O
and	O
8	O
months	O
after	O
infection	O
.	O

Neutralization	O
by	O
MAbs	O
representative	O
of	O
each	O
B	O
cell	O
clone	O
was	O
mapped	O
to	O
two	O
residues	O
:	O
position	O
134	O
in	O
V1	O
and	O
position	O
189	O
in	O
V2	O
.	O

Mutational	O
analysis	O
revealed	O
cooperative	O
effects	O
between	O
glycans	O
and	O
residues	O
at	O
these	O
two	O
positions	O
,	O
arguing	O
that	O
they	O
contribute	O
to	O
a	O
single	O
epitope	O
.	O

Analysis	O
of	O
the	O
cognate	O
gp120	O
sequence	O
through	O
homology	O
modeling	O
places	O
this	O
potential	O
epitope	O
near	O
the	O
interface	O
between	O
the	O
V1	O
and	O
V2	O
loops	O
.	O

Additionally	O
,	O
the	O
escape	O
mutation	O
R189S	O
in	O
V2	O
,	O
which	O
conferred	O
resistance	O
against	O
all	O
three	O
MAbs	O
,	O
had	O
no	O
detrimental	O
effect	O
on	O
virus	O
replication	O
in	O
vitro	O
.	O

Taken	O
together	O
,	O
our	O
data	O
demonstrate	O
that	O
independent	O
B	O
cells	O
repeatedly	O
targeted	O
a	O
single	O
structure	O
in	O
V1V2	O
during	O
early	O
infection	O
.	O

Despite	O
this	O
assault	O
,	O
a	O
single	O
amino	O
acid	O
change	O
was	O
sufficient	O
to	O
confer	O
complete	O
escape	O
with	O
minimal	O
impact	O
on	O
replication	O
fitness	O
.	O

Translational	O
control	O
of	O
the	O
abundance	O
of	O
cytoplasmic	O
poly	O
(	O
A	O
)	O
binding	O
protein	O
in	O
human	B
cytomegalovirus	I
-	O
infected	O
cells	O
.	O

Irrespective	O
of	O
their	O
effects	O
on	O
ongoing	O
host	O
protein	O
synthesis	O
,	O
productive	O
replication	O
of	O
the	O
representative	O
alphaherpesvirus	O
herpes	B
simplex	I
virus	I
type	I
1	O
,	O
the	O
representative	O
gammaherpesvirus	O
Kaposi	B
's	I
sarcoma	I
herpesvirus	I
,	O
and	O
the	O
representative	O
betaherpesvirus	O
human	B
cytomegalovirus	I
[	O
HCMV	B
]	O
stimulates	O
the	O
assembly	O
of	O
the	O
multisubunit	O
,	O
cap	O
-	O
binding	O
translation	O
factor	O
eIF4F	O
.	O

However	O
,	O
only	O
HCMV	B
replication	O
is	O
associated	O
with	O
an	O
increased	O
abundance	O
of	O
eIF4F	O
core	O
components	O
(	O
eIF4E	O
,	O
eIF4	O
G	O
,	O
eIF4A	O
)	O
and	O
the	O
eIF4F	O
-	O
associated	O
factor	O
poly	O
(	O
A	O
)	O
binding	O
protein	O
(	O
PABP	O
)	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
the	O
increase	O
in	O
translation	O
factor	O
concentration	O
was	O
readily	O
detected	O
in	O
an	O
asynchronous	O
population	O
of	O
HCMV	B
-	O
infected	O
primary	O
human	B
fibroblasts	O
,	O
abolished	O
by	O
prior	O
UV	O
inactivation	O
of	O
virus	O
,	O
and	O
genetically	O
dependent	O
upon	O
viral	O
immediate	O
-	O
early	O
genes	O
.	O

Strikingly	O
,	O
while	O
increased	O
mRNA	O
steady	O
-	O
state	O
levels	O
accompanied	O
the	O
rise	O
in	O
eIF4E	O
and	O
eIF4	O
G	O
protein	O
levels	O
,	O
the	O
overall	O
abundance	O
of	O
PABP	O
mRNA	O
,	O
together	O
with	O
the	O
half	O
-	O
life	O
of	O
the	O
polypeptide	O
it	O
encodes	O
,	O
remained	O
relatively	O
unchanged	O
by	O
HCMV	B
infection	O
.	O

Instead	O
,	O
HCMV	B
-	O
induced	O
PABP	O
accumulation	O
resulted	O
from	O
new	O
protein	O
synthesis	O
and	O
was	O
sensitive	O
to	O
the	O
mTORC1-selective	O
inhibitor	O
rapamycin	O
,	O
which	O
interferes	O
with	O
phosphorylation	O
of	O
the	O
mTORC1	O
substrate	O
p70	O
S6	O
K	O
and	O
the	O
translational	O
repressor	O
4E	O
-	O
BP1	O
.	O

While	O
virus	O
-	O
induced	O
PABP	O
accumulation	O
did	O
not	O
require	O
p70	O
S6	O
K	O
,	O
it	O
was	O
inhibited	O
by	O
the	O
expression	O
of	O
a	O
dominant	O
-	O
acting	O
4E	O
-	O
BP1	O
variant	O
unable	O
to	O
be	O
inactivated	O
by	O
mTORC1	O
.	O

Finally	O
,	O
unlike	O
the	O
situation	O
in	O
alpha-	O
or	O
gammaherpesvirus	O
-	O
infected	O
cells	O
,	O
where	O
PABP	O
is	O
redistributed	O
to	O
nuclei	O
,	O
PABP	O
accumulated	O
in	O
the	O
cytoplasm	O
of	O
HCMV	B
-	O
infected	O
cells	O
.	O

Thus	O
,	O
cytoplasmic	O
PABP	O
accumulation	O
is	O
translationally	O
controlled	O
in	O
HCMV	B
-	O
infected	O
cells	O
via	O
a	O
mechanism	O
requiring	O
mTORC1-mediated	O
inhibition	O
of	O
the	O
cellular	O
4E	O
-	O
BP1	O
translational	O
repressor	O
.	O

Chikungunya	B
virus	I
induces	O
IPS-1-dependent	O
innate	O
immune	O
activation	O
and	O
protein	O
kinase	O
R	O
-	O
independent	O
translational	O
shutoff	O
.	O

Chikungunya	B
virus	I
(	O
CHIKV	B
)	O
is	O
an	O
arthritogenic	O
mosquito	O
-	O
transmitted	O
alphavirus	O
that	O
is	O
undergoing	O
reemergence	O
in	O
areas	O
around	O
the	O
Indian	O
Ocean	O
.	O

Despite	O
the	O
current	O
and	O
potential	O
danger	O
posed	O
by	O
this	O
virus	O
,	O
we	O
know	O
surprisingly	O
little	O
about	O
the	O
induction	O
and	O
evasion	O
of	O
CHIKV	B
-	O
associated	O
antiviral	O
immune	O
responses	O
.	O

With	O
this	O
in	O
mind	O
we	O
investigated	O
innate	O
immune	O
reactions	O
to	O
CHIKV	B
in	O
human	B
fibroblasts	O
,	O
a	O
demonstrable	O
in	O
vivo	O
target	O
of	O
virus	O
replication	O
and	O
spread	O
.	O

We	O
show	O
that	O
CHIKV	B
infection	O
leads	O
to	O
activation	O
of	O
the	O
transcription	O
factor	O
interferon	O
regulatory	O
factor	O
3	O
(	O
IRF3	O
)	O
and	O
subsequent	O
transcription	O
of	O
IRF3-dependent	O
antiviral	O
genes	O
,	O
including	O
beta	O
interferon	O
(	O
IFN	O
-	O
Beta	O
)	O
.	O

IRF3	O
activation	O
occurs	O
by	O
way	O
of	O
a	O
virus	O
-	O
induced	O
innate	O
immune	O
signaling	O
pathway	O
that	O
includes	O
the	O
adaptor	O
molecule	O
interferon	O
promoter	O
stimulator	O
1	O
(	O
IPS-1	O
)	O
.	O

Despite	O
strong	O
transcriptional	O
upregulation	O
of	O
these	O
genes	O
,	O
however	O
,	O
translation	O
of	O
the	O
corresponding	O
proteins	O
is	O
not	O
observed	O
.	O

We	O
further	O
demonstrate	O
that	O
translation	O
of	O
cellular	O
(	O
but	O
not	O
viral	O
)	O
genes	O
is	O
blocked	O
during	O
infection	O
and	O
that	O
although	O
CHIKV	B
is	O
found	O
to	O
trigger	O
inactivation	O
of	O
the	O
translational	O
molecule	O
eukaryotic	O
initiation	O
factor	O
subunit	O
2alpha	O
by	O
way	O
of	O
the	O
double	O
-	O
stranded	O
RNA	O
sensor	O
protein	O
kinase	O
R	O
,	O
this	O
response	O
is	O
not	O
required	O
for	O
the	O
block	O
to	O
protein	O
synthesis	O
.	O

Furthermore	O
,	O
overall	O
diminution	O
of	O
cellular	O
RNA	O
synthesis	O
is	O
also	O
observed	O
in	O
the	O
presence	O
of	O
CHIKV	B
and	O
transcription	O
of	O
IRF3-dependent	O
antiviral	O
genes	O
appears	O
specifically	O
blocked	O
late	O
in	O
infection	O
.	O

We	O
hypothesize	O
that	O
the	O
observed	O
absence	O
of	O
IFN	O
-	O
Beta	O
and	O
antiviral	O
proteins	O
during	O
infection	O
results	O
from	O
an	O
evasion	O
mechanism	O
exhibited	O
by	O
CHIKV	B
that	O
is	O
dependent	O
on	O
widespread	O
shutoff	O
of	O
cellular	O
protein	O
synthesis	O
and	O
a	O
targeted	O
block	O
to	O
late	O
synthesis	O
of	O
antiviral	O
mRNA	O
transcripts	O
.	O

Domain	O
structure	O
of	O
Lassa	B
virus	I
L	O
protein	O
.	O

The	O
200-kDa	O
L	O
protein	O
of	O
arenaviruses	O
plays	O
a	O
central	O
role	O
in	O
viral	O
genome	O
replication	O
and	O
transcription	O
.	O

This	O
study	O
aimed	O
at	O
providing	O
evidence	O
for	O
the	O
domain	O
structure	O
of	O
L	O
protein	O
by	O
combining	O
bioinformatics	O
with	O
a	O
stepwise	O
mutagenesis	O
approach	O
using	O
the	O
Lassa	B
virus	I
minireplicon	O
system	O
.	O

Potential	O
interdomain	O
linkers	O
were	O
predicted	O
using	O
various	O
algorithms	O
.	O

The	O
prediction	O
was	O
challenged	O
by	O
insertion	O
of	O
flexible	O
sequences	O
into	O
the	O
predicted	O
linkers	O
.	O

Insertion	O
of	O
5	O
or	O
10	O
amino	O
acid	O
residues	O
was	O
tolerated	O
at	O
seven	O
sites	O
(	O
S407	O
,	O
G446	O
,	O
G467	O
,	O
G774	O
,	O
G939	O
,	O
S1952	O
,	O
and	O
V2074	O
in	O
Lassa	B
virus	I
AV	I
)	O
.	O

At	O
two	O
of	O
these	O
sites	O
,	O
G467	O
and	O
G939	O
,	O
L	O
protein	O
could	O
be	O
split	O
into	O
an	O
N	O
-	O
terminal	O
and	O
a	O
C	O
-	O
terminal	O
part	O
,	O
which	O
were	O
able	O
to	O
trans	O
-	O
complement	O
each	O
other	O
and	O
reconstitute	O
a	O
functional	O
complex	O
upon	O
coexpression	O
.	O

Coimmunoprecipitation	O
studies	O
revealed	O
physical	O
interaction	O
between	O
the	O
N-	O
and	O
C	O
-	O
terminal	O
domains	O
,	O
irrespective	O
of	O
whether	O
L	O
protein	O
was	O
split	O
at	O
G467	O
or	O
G939	O
.	O

In	O
confocal	O
immunofluorescence	O
microscopy	O
,	O
the	O
N	O
-	O
terminal	O
domains	O
showed	O
a	O
dot	O
-	O
like	O
,	O
sometimes	O
perinuclear	O
,	O
cytoplasmic	O
distribution	O
similar	O
to	O
that	O
of	O
full	O
-	O
length	O
L	O
protein	O
,	O
while	O
the	O
C	O
-	O
terminal	O
domains	O
were	O
homogenously	O
distributed	O
in	O
cytoplasm	O
.	O

The	O
latter	O
were	O
redistributed	O
into	O
the	O
dot	O
-	O
like	O
structures	O
upon	O
coexpression	O
with	O
the	O
corresponding	O
N	O
-	O
terminal	O
domain	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
demonstrates	O
two	O
interdomain	O
linkers	O
in	O
Lassa	B
virus	I
L	O
protein	O
,	O
at	O
G467	O
and	O
G939	O
,	O
suggesting	O
that	O
L	O
protein	O
is	O
composed	O
of	O
at	O
least	O
three	O
structural	O
domains	O
spanning	O
residues	O
1	O
to	O
467	O
,	O
467	O
to	O
939	O
,	O
and	O
939	O
to	O
2220	O
.	O

The	O
first	O
domain	O
seems	O
to	O
mediate	O
accumulation	O
of	O
L	O
protein	O
into	O
cytoplasmic	O
dot	O
-	O
like	O
structures	O
.	O

Antiviral	O
effects	O
of	O
a	O
transgenic	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
.	O

Transgenic	O
expression	O
of	O
the	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
3D	O
(	O
pol	O
)	O
inhibited	O
infection	O
of	O
Theiler	B
's	I
murine	I
encephalitis	I
virus	I
(	O
TMEV	B
)	O
,	O
a	O
picornavirus	O
from	O
which	O
it	O
was	O
derived	O
.	O

Here	O
,	O
we	O
infected	O
3D	O
(	O
pol	O
)	O
transgenic	O
mice	B
with	O
another	O
picornavirus	O
,	O
as	O
well	O
as	O
an	O
alphaherpesvirus	O
and	O
a	O
rhabdovirus	O
.	O

3D	O
(	O
pol	O
)	O
transgenic	O
FVB	O
mice	B
had	O
significantly	O
lower	O
viral	O
loads	O
and	O
survived	O
longer	O
after	O
infection	O
with	O
all	O
three	O
types	O
of	O
viruses	O
than	O
nontransgenic	O
FVB	O
mice	B
.	O

Viral	O
inhibition	O
among	O
three	O
different	O
types	O
of	O
virus	O
by	O
transgenic	O
3D	O
(	O
pol	O
)	O
suggests	O
that	O
the	O
mechanism	O
of	O
action	O
is	O
not	O
the	O
direct	O
interference	O
with	O
picornaviral	O
3D	O
(	O
pol	O
)	O
but	O
instead	O
may	O
be	O
the	O
changing	O
of	O
host	O
cells	O
to	O
an	O
antiviral	O
state	O
before	O
or	O
after	O
viral	O
infection	O
occurs	O
,	O
as	O
basal	O
interferon	O
levels	O
were	O
higher	O
in	O
3D	O
(	O
pol	O
)	O
transgenic	O
mice	B
before	O
infection	O
.	O

Further	O
study	O
of	O
this	O
mechanism	O
may	O
open	O
new	O
possibilities	O
for	O
future	O
antiviral	O
therapy	O
.	O

The	O
absence	O
of	O
sex	O
-	O
biased	O
dispersal	O
in	O
the	O
cooperatively	O
breeding	O
grey	B
-	I
crowned	I
babbler	I
.	O

1	O
.	O

Cooperatively	O
breeding	O
birds	O
are	O
thought	O
to	O
be	O
especially	O
vulnerable	O
to	O
habitat	O
fragmentation	O
,	O
in	O
part	O
because	O
dispersal	O
is	O
typically	O
restricted	O
for	O
one	O
sex	O
,	O
increasing	O
the	O
likelihood	O
of	O
inbreeding	O
.	O

Knowledge	O
of	O
dispersal	O
is	O
essential	O
to	O
conservation	O
efforts	O
,	O
but	O
is	O
often	O
hampered	O
by	O
our	O
inability	O
to	O
measure	O
its	O
frequency	O
and	O
distance	O
when	O
dispersal	O
is	O
infrequent	O
and	O
difficult	O
to	O
observe	O
.	O

2	O
.	O

Disrupted	O
dispersal	O
is	O
a	O
purported	O
cause	O
of	O
decline	O
in	O
the	O
Australian	O
grey	B
-	I
crowned	I
babbler	I
(	O
Pomatostomus	B
temporalis	I
)	O
.	O

Both	O
sexes	O
of	O
offspring	O
delay	O
dispersal	O
for	O
up	O
to	O
several	O
years	O
to	O
help	O
parents	O
raise	O
subsequent	O
broods	O
,	O
yet	O
little	O
else	O
is	O
known	O
about	O
the	O
dispersal	O
of	O
this	O
cooperatively	O
breeding	O
woodland	O
bird	O
.	O

3	O
.	O

As	O
both	O
sexes	O
appear	O
to	O
help	O
,	O
but	O
only	O
male	O
helpers	O
boost	O
fledgling	O
production	O
,	O
we	O
hypothesized	O
that	O
males	O
would	O
be	O
the	O
more	O
philopatric	O
sex	O
in	O
this	O
species	O
,	O
and	O
that	O
female	O
grey	B
-	I
crowned	I
babblers	I
would	O
disperse	O
over	O
greater	O
distances	O
.	O

4	O
.	O
To	O
ensure	O
reliable	O
determination	O
of	O
sex	O
and	O
minimize	O
bias	O
towards	O
detecting	O
short	O
-	O
distance	O
dispersal	O
events	O
,	O
we	O
combined	O
molecular	O
-	O
based	O
sexing	O
and	O
analyses	O
of	O
population	O
genetic	O
structure	O
using	O
polymorphic	O
microsatellite	O
loci	O
with	O
observational	O
data	O
obtained	O
over	O
multiple	O
field	O
seasons	O
.	O

5	O
.	O
Observations	O
of	O
banded	O
birds	O
showed	O
only	O
infrequent	O
fission	O
of	O
groups	O
or	O
short	O
-	O
distance	O
dispersal	O
(	O
mean=854	O
m	O
)	O
,	O
but	O
no	O
apparent	O
sex	O
-	O
bias	O
in	O
these	O
patterns	O
.	O

6	O
.	O

There	O
was	O
significant	O
genetic	O
differentiation	O
between	O
social	O
groups	O
,	O
but	O
not	O
between	O
the	O
sexes	O
.	O

Spatial	O
genetic	O
autocorrelation	O
analysis	O
of	O
breeders	O
revealed	O
a	O
random	O
distribution	O
of	O
genotypes	O
across	O
the	O
study	O
area	O
for	O
both	O
sexes	O
.	O

Thus	O
,	O
contrary	O
to	O
expectations	O
,	O
we	O
found	O
no	O
genetic	O
evidence	O
for	O
restricted	O
dispersal	O
or	O
for	O
sex	O
-	O
biased	O
dispersal	O
over	O
the	O
85-km	O
scale	O
of	O
this	O
study	O
,	O
indicating	O
that	O
effective	O
dispersal	O
occurs	O
over	O
greater	O
distances	O
and	O
more	O
frequently	O
than	O
recoveries	O
of	O
banded	O
birds	O
indicated	O
.	O

7	O
.	O

We	O
conclude	O
that	O
while	O
constraints	O
on	O
independent	O
breeding	O
encourage	O
high	O
rates	O
of	O
philopatry	O
,	O
incest	O
avoidance	O
nonetheless	O
drives	O
high	O
rates	O
of	O
dispersal	O
by	O
both	O
sexes	O
.	O

In	O
fragmented	O
habitat	O
,	O
the	O
dispersal	O
dynamics	O
of	O
this	O
cooperatively	O
breeding	O
species	O
are	O
unlikely	O
to	O
render	O
them	O
particularly	O
vulnerable	O
to	O
genetic	O
consequences	O
such	O
as	O
inbreeding	O
,	O
but	O
may	O
lead	O
to	O
increased	O
group	O
dissolution	O
.	O

Acclimation	O
to	O
high	O
CO2	O
in	O
maize	B
is	O
related	O
to	O
water	O
status	O
and	O
dependent	O
on	O
leaf	O
rank	O
.	O

The	O
responses	O
of	O
C	O
(	O
3	O
)	O
plants	O
to	O
rising	O
atmospheric	O
CO	O
(	O
2	O
)	O
levels	O
are	O
considered	O
to	O
be	O
largely	O
dependent	O
on	O
effects	O
exerted	O
through	O
altered	O
photosynthesis	O
.	O

In	O
contrast	O
,	O
the	O
nature	O
of	O
the	O
responses	O
of	O
C	O
(	O
4	O
)	O
plants	O
to	O
high	O
CO	O
(	O
2	O
)	O
remains	O
controversial	O
because	O
of	O
the	O
absence	O
of	O
CO	O
(	O
2	O
)	O
-dependent	O
effects	O
on	O
photosynthesis	O
.	O

In	O
this	O
study	O
,	O
the	O
effects	O
of	O
atmospheric	O
CO	O
(	O
2	O
)	O
availability	O
on	O
the	O
transcriptome	O
,	O
proteome	O
and	O
metabolome	O
profiles	O
of	O
two	O
ranks	O
of	O
source	O
leaves	O
in	O
maize	B
(	O
Zea	B
mays	I
L.	O
)	O
were	O
studied	O
in	O
plants	O
grown	O
under	O
ambient	O
CO	O
(	O
2	O
)	O
conditions	O
(	O
350	O
+	O
/-	O

20	O
muL	O
L	O
(	O
-1	O
)	O
CO	O
(	O
2	O
)	O
)	O
or	O
with	O
CO	O
(	O
2	O
)	O
enrichment	O
(	O
700	O
+	O
/-	O

20	O
muL	O
L	O
(	O
-1	O
)	O
CO	O
(	O
2	O
)	O
)	O
.	O

Growth	O
at	O
high	O
CO	O
(	O
2	O
)	O
had	O
no	O
effect	O
on	O
photosynthesis	O
,	O
photorespiration	O
,	O
leaf	O
C	O
/	O
N	O
ratios	O
or	O
anthocyanin	O
contents	O
.	O

However	O
,	O
leaf	O
transpiration	O
rates	O
,	O
carbohydrate	O
metabolism	O
and	O
protein	O
carbonyl	O
accumulation	O
were	O
altered	O
at	O
high	O
CO	O
(	O
2	O
)	O
in	O
a	O
leaf	O
-	O
rank	O
specific	O
manner	O
.	O

Although	O
no	O
significant	O
CO	O
(	O
2	O
)	O
-dependent	O
changes	O
in	O
the	O
leaf	O
transcriptome	O
were	O
observed	O
,	O
qPCR	O
analysis	O
revealed	O
that	O
the	O
abundance	O
of	O
transcripts	O
encoding	O
a	O
Bowman	O
-	O
Birk	O
protease	O
inhibitor	O
and	O
a	O
serpin	O
were	O
changed	O
by	O
the	O
growth	O
CO	O
(	O
2	O
)	O
level	O
in	O
a	O
leaf	O
rank	O
specific	O
manner	O
.	O

Moreover	O
,	O
CO	O
(	O
2	O
)	O
-dependent	O
changes	O
in	O
the	O
leaf	O
proteome	O
were	O
most	O
evident	O
in	O
the	O
oldest	O
source	O
leaves	O
.	O

Small	O
changes	O
in	O
water	O
status	O
may	O
be	O
responsible	O
for	O
the	O
observed	O
responses	O
to	O
high	O
CO	O
(	O
2	O
,	O
)	O
particularly	O
in	O
the	O
older	O
leaf	O
ranks	O
.	O

Agrobacterium	B
tumefasciens	I
-	O
mediated	O
transformation	O
of	O
the	O
aquatic	O
fungus	O
Blastocladiella	B
emersonii	I
.	O

Agrobacterium	B
tumefaciens	I
is	O
widely	O
used	O
for	O
plant	O
DNA	O
transformation	O
and	O
more	O
recently	O
,	O
has	O
also	O
been	O
used	O
to	O
transform	O
yeast	B
,	O
filamentous	O
fungi	O
and	O
even	O
human	B
cells	O
.	O

Using	O
this	O
technique	O
,	O
we	O
developed	O
the	O
first	O
transformation	O
protocol	O
for	O
the	O
saprobic	O
aquatic	O
fungus	O
Blastocladiella	B
emersonii	I
,	O
a	O
Blastocladiomycete	O
localized	O
at	O
the	O
base	O
of	O
fungal	O
phylogenetic	O
tree	O
,	O
which	O
has	O
been	O
shown	O
as	O
a	O
promising	O
and	O
interesting	O
model	O
of	O
study	O
of	O
cellular	O
function	O
and	O
differentiation	O
.	O

We	O
constructed	O
binary	O
T	O
-	O
DNA	O
vectors	O
containing	O
hygromycin	O
phosphotransferase	O
(	O
hph	O
)	O
or	O
enhanced	O
green	O
fluorescent	O
protein	O
(	O
egfp	O
)	O
genes	O
,	O
under	O
the	O
control	O
of	O
Aspergillus	B
nidulans	I
trpC	O
promoter	O
and	O
terminator	O
sequences	O
.	O

24	O
h	O
of	O
co	O
-	O
cultivation	O
in	O
induction	O
medium	O
(	O
IM	O
)	O
agar	O
plates	O
,	O
followed	O
by	O
transfer	O
to	O
PYG	O
-	O
agar	O
plates	O
containing	O
cefotaxim	O
to	O
kill	O
Agrobacterium	B
tumefsciens	I
and	O
hygromycin	O
to	O
select	O
transformants	O
,	O
resulted	O
in	O
growth	O
and	O
sporulation	O
of	O
resistant	O
transformants	O
.	O

Genomic	O
DNA	O
from	O
the	O
pool	O
o	O
resistant	O
zoospores	O
were	O
shown	O
to	O
contain	O
T	O
-	O
DNA	O
insertion	O
as	O
evidenced	O
by	O
PCR	O
amplification	O
of	O
hph	O
gene	O
.	O

Using	O
a	O
similar	O
protocol	O
we	O
could	O
also	O
evidence	O
the	O
expression	O
of	O
enhanced	O
green	O
fluorescent	O
protein	O
(	O
EGFP	O
)	O
in	O
zoospores	O
derived	O
from	O
transformed	O
cells	O
.	O

This	O
protocol	O
can	O
also	O
open	O
new	O
perspectives	O
for	O
other	O
non	O
-	O
transformable	O
closely	O
related	O
fungi	O
,	O
like	O
the	O
Chytridiomycete	O
class	O
.	O

Characterization	O
of	O
the	O
oxysterol	O
-	O
binding	O
protein	O
gene	O
family	O
in	O
the	O
yellow	B
fever	I
mosquito	I
,	O
Aedes	B
aegypti	I
.	O

The	O
oxysterol	O
-	O
binding	O
protein	O
(	O
OSBP	O
)	O
and	O
OSBP	O
-	O
related	O
proteins	O
(	O
ORPs	O
)	O
are	O
sterol	O
-	O
binding	O
proteins	O
that	O
may	O
be	O
involved	O
in	O
cellular	O
sterol	O
transportation	O
,	O
sterol	O
metabolism	O
and	O
signal	O
transduction	O
pathways	O
.	O

Four	O
ORP	O
genes	O
were	O
cloned	O
from	O
Aedes	B
aegypti	I
.	O

Based	O
on	O
amino	O
acid	O
sequence	O
homology	O
to	O
human	B
proteins	O
,	O
they	O
are	O
AeOSBP	O
,	O
AeORP1	O
,	O
AeORP8	O
and	O
AeORP9	O
.	O

Splicing	O
variants	O
of	O
AeOSBP	O
and	O
AeORP8	O
were	O
identified	O
.	O

The	O
temporal	O
and	O
spatial	O
transcription	O
patterns	O
of	O
members	O
of	O
the	O
AeOSBP	O
gene	O
family	O
through	O
developmental	O
stages	O
and	O
the	O
gonotrophic	O
cycle	O
were	O
profiled	O
.	O

AeORP1	O
transcription	O
seemed	O
to	O
be	O
head	O
tissue	O
-	O
specific	O
,	O
whereas	O
AeOSBP	O
and	O
AeORP9	O
expression	O
was	O
induced	O
by	O
a	O
bloodmeal	O
.	O

Furthermore	O
,	O
over	O
-	O
expression	O
of	O
AeORPs	O
facilitated	O
[	O
(	O
3	O
)	O
H	O
]	O
-cholesterol	O
uptake	O
in	O
Ae	B
.	I

aegypti	B
cultured	O
Aag	O
-2	O
cells	O
.	O

The	O
minor	O
pilin	O
subunit	O
Sgp2	O
is	O
necessary	O
for	O
assembly	O
of	O
the	O
pilus	O
encoded	O
by	O
the	O
srtG	O
cluster	O
of	O
Streptococcus	B
suis	I
.	O

Gram	O
-	O
positive	O
pili	O
are	O
composed	O
of	O
covalently	O
bound	O
pilin	O
subunits	O
whose	O
assembly	O
is	O
mediated	O
via	O
a	O
pilus	O
-	O
specific	O
sortase	O
(	O
s	O
)	O
.	O

Major	O
subunits	O
constitute	O
the	O
pilus	O
backbone	O
and	O
are	O
therefore	O
essential	O
for	O
pilus	O
formation	O
.	O

Minor	O
subunits	O
are	O
also	O
incorporated	O
into	O
the	O
pilus	O
,	O
but	O
they	O
are	O
considered	O
to	O
be	O
dispensable	O
for	O
backbone	O
formation	O
.	O

The	O
srtG	O
cluster	O
is	O
one	O
of	O
the	O
putative	O
pilus	O
gene	O
clusters	O
identified	O
in	O
the	O
major	O
swine	B
pathogen	O
Streptococcus	B
suis	I
.	O

It	O
consists	O
of	O
one	O
sortase	O
gene	O
(	O
srtG	O
)	O
and	O
two	O
putative	O
pilin	O
subunit	O
genes	O
(	O
sgp1	O
and	O
sgp2	O
)	O
.	O

In	O
this	O
study	O
,	O
by	O
constructing	O
mutants	O
for	O
each	O
of	O
the	O
genes	O
in	O
the	O
cluster	O
and	O
by	O
both	O
immunoblotting	O
and	O
immunogold	O
electron	O
microscopic	O
analysis	O
with	O
antibodies	O
against	O
Sgp1	O
and	O
Sgp2	O
,	O
we	O
found	O
that	O
the	O
srtG	O
cluster	O
mediates	O
the	O
expression	O
of	O
pilus	O
-	O
like	O
structures	O
in	O
S.	B
suis	I
strain	I
89	I
/	I
1591	I
.	O

In	O
this	O
pilus	O
,	O
Sgp1	O
forms	O
the	O
backbone	O
,	O
whereas	O
Sgp2	O
is	O
incorporated	O
as	O
the	O
minor	O
subunit	O
.	O

In	O
accordance	O
with	O
the	O
current	O
model	O
of	O
pilus	O
assembly	O
by	O
Gram	O
-	O
positive	O
organisms	O
,	O
the	O
major	O
subunit	O
Sgp1	O
was	O
indispensable	O
for	O
backbone	O
formation	O
and	O
the	O
cognate	O
sortase	O
SrtG	O
mediated	O
the	O
polymerization	O
of	O
both	O
subunits	O
.	O

However	O
,	O
unlike	O
other	O
well	O
-	O
characterized	O
Gram	O
-	O
positive	O
bacterial	O
pili	O
,	O
the	O
minor	O
subunit	O
Sgp2	O
was	O
required	O
for	O
polymerization	O
of	O
the	O
major	O
subunit	O
Sgp1	O
.	O

Because	O
Sgp2	O
homologues	O
are	O
encoded	O
in	O
several	O
other	O
Gram	O
-	O
positive	O
bacterial	O
pilus	O
gene	O
clusters	O
,	O
in	O
some	O
types	O
of	O
pili	O
,	O
minor	O
pilin	O
subunits	O
may	O
contribute	O
to	O
backbone	O
formation	O
by	O
a	O
novel	O
mechanism	O
.	O

Spatial	O
regulation	O
of	O
histidine	O
kinases	O
governing	O
biofilm	O
formation	O
in	O
Bacillus	B
subtilis	I
.	O

Bacillus	B
subtilis	I
is	O
able	O
to	O
form	O
architecturally	O
complex	O
biofilms	O
on	O
solid	O
medium	O
due	O
to	O
the	O
production	O
of	O
an	O
extracellular	O
matrix	O
.	O

A	O
master	O
regulator	O
that	O
controls	O
the	O
expression	O
of	O
the	O
genes	O
involved	O
in	O
matrix	O
synthesis	O
is	O
Spo0A	O
,	O
which	O
is	O
activated	O
by	O
phosphorylation	O
via	O
a	O
phosphorelay	O
involving	O
multiple	O
histidine	O
kinases	O
.	O

Here	O
we	O
report	O
that	O
four	O
kinases	O
,	O
KinA	O
,	O
KinB	O
,	O
KinC	O
,	O
and	O
KinD	O
,	O
help	O
govern	O
biofilm	O
formation	O
but	O
that	O
their	O
contributions	O
are	O
partially	O
masked	O
by	O
redundancy	O
.	O

We	O
show	O
that	O
the	O
kinases	O
fall	O
into	O
two	O
categories	O
and	O
that	O
the	O
members	O
of	O
each	O
pair	O
(	O
one	O
pair	O
comprising	O
KinA	O
and	O
KinB	O
and	O
the	O
other	O
comprising	O
KinC	O
and	O
KinD	O
)	O
are	O
partially	O
redundant	O
with	O
each	O
other	O
.	O

We	O
also	O
show	O
that	O
the	O
kinases	O
are	O
spatially	O
regulated	O
:	O
KinA	O
and	O
KinB	O
are	O
active	O
principally	O
in	O
the	O
older	O
,	O
inner	O
regions	O
of	O
the	O
colony	O
,	O
and	O
KinC	O
and	O
KinD	O
function	O
chiefly	O
in	O
the	O
younger	O
,	O
outer	O
regions	O
.	O

These	O
conclusions	O
are	O
based	O
on	O
the	O
morphology	O
of	O
kinase	O
mutants	O
,	O
real	O
-	O
time	O
measurements	O
of	O
gene	O
expression	O
using	O
luciferase	O
as	O
a	O
reporter	O
,	O
and	O
confocal	O
microscopy	O
using	O
a	O
fluorescent	O
protein	O
as	O
a	O
reporter	O
.	O

Our	O
findings	O
suggest	O
that	O
multiple	O
signals	O
from	O
the	O
older	O
and	O
younger	O
regions	O
of	O
the	O
colony	O
are	O
integrated	O
by	O
the	O
kinases	O
to	O
determine	O
the	O
overall	O
architecture	O
of	O
the	O
biofilm	O
community	O
.	O

Genome	O
copy	O
numbers	O
and	O
gene	O
conversion	O
in	O
methanogenic	B
archaea	I
.	O

Previous	O
studies	O
revealed	O
that	O
one	O
species	O
of	O
methanogenic	B
archaea	I
,	O
Methanocaldococcus	B
jannaschii	I
,	O
is	O
polyploid	O
,	O
while	O
a	O
second	O
species	O
,	O
Methanothermobacter	B
thermoautotrophicus	I
,	O
is	O
diploid	O
.	O

To	O
further	O
investigate	O
the	O
distribution	O
of	O
ploidy	O
in	O
methanogenic	B
archaea	I
,	O
species	O
of	O
two	O
additional	O
genera	O
-	O
Methanosarcina	B
acetivorans	I
and	O
Methanococcus	B
maripaludis	I
-	O
were	O
investigated	O
.	O

M.	B
acetivorans	I
was	O
found	O
to	O
be	O
polyploid	O
during	O
fast	O
growth	O
(	O
t	O
(	O
D	O
)	O
=	O
6	O
h	O
;	O
17	O
genome	O
copies	O
)	O
and	O
oligoploid	O
during	O
slow	O
growth	O
(	O
doubling	O
time	O
=	O
49	O
h	O
;	O
3	O
genome	O
copies	O
)	O
.	O

M.	B
maripaludis	I
has	O
the	O
highest	O
ploidy	O
level	O
found	O
for	O
any	O
archaeal	O
species	O
,	O
with	O
up	O
to	O
55	O
genome	O
copies	O
in	O
exponential	O
phase	O
and	O
ca	O
.	O

30	O
in	O
stationary	O
phase	O
.	O

A	O
compilation	O
of	O
archaeal	O
species	O
with	O
quantified	O
ploidy	O
levels	O
reveals	O
a	O
clear	O
dichotomy	O
between	O
Euryarchaeota	O
and	O
Crenarchaeota	O
:	O
none	O
of	O
seven	O
euryarchaeal	O
species	O
of	O
six	O
genera	O
is	O
monoploid	O
(	O
haploid	O
)	O
,	O
while	O
,	O
in	O
contrast	O
,	O
all	O
six	O
crenarchaeal	O
species	O
of	O
four	O
genera	O
are	O
monoploid	O
,	O
indicating	O
significant	O
genetic	O
differences	O
between	O
these	O
two	O
kingdoms	O
.	O

Polyploidy	O
in	O
asexual	O
species	O
should	O
lead	O
to	O
accumulation	O
of	O
inactivating	O
mutations	O
until	O
the	O
number	O
of	O
intact	O
chromosomes	O
per	O
cell	O
drops	O
to	O
zero	O
(	O
called	O
"	O
Muller	O
's	O
ratchet	O
"	O
)	O
.	O

A	O
mechanism	O
to	O
equalize	O
the	O
genome	O
copies	O
,	O
such	O
as	O
gene	O
conversion	O
,	O
would	O
counteract	O
this	O
phenomenon	O
.	O

Making	O
use	O
of	O
a	O
previously	O
constructed	O
heterozygous	O
mutant	O
strain	O
of	O
the	O
polyploid	O
M.	O
maripaludis	O
we	B
could	I
show	O
that	O
in	O
the	O
absence	O
of	O
selection	O
very	O
fast	O
equalization	O
of	O
genomes	O
in	O
M.	O
maripaludis	O
took	B
place	I
probably	O
via	O
a	O
gene	O
conversion	O
mechanism	O
.	O

In	O
addition	O
,	O
it	O
was	O
shown	O
that	O
the	O
velocity	O
of	O
this	O
phenomenon	O
is	O
inversely	O
correlated	O
to	O
the	O
strength	O
of	O
selection	O
.	O

The	O
peptidoglycan	O
-	O
binding	O
protein	O
FimV	O
promotes	O
assembly	O
of	O
the	O
Pseudomonas	B
aeruginosa	I
type	O
IV	O
pilus	O
secretin	O
.	O

The	O
Pseudomonas	B
aeruginosa	I
inner	O
membrane	O
protein	O
FimV	O
is	O
among	O
several	O
proteins	O
of	O
unknown	O
function	O
required	O
for	O
type	O
IV	O
pilus	O
-	O
mediated	O
twitching	O
motility	O
,	O
arising	O
from	O
extension	O
and	O
retraction	O
of	O
pili	O
from	O
their	O
site	O
of	O
assembly	O
in	O
the	O
inner	O
membrane	O
.	O

The	O
pili	O
transit	O
the	O
periplasm	O
and	O
peptidoglycan	O
(	O
PG	O
)	O
layer	O
,	O
ultimately	O
exiting	O
the	O
cell	O
through	O
the	O
PilQ	O
secretin	O
.	O

Although	O
fimV	O
mutants	O
are	O
nonmotile	O
,	O
they	O
are	O
susceptible	O
to	O
killing	O
by	O
pilus	O
-	O
specific	O
bacteriophage	B
,	O
a	O
hallmark	O
of	O
retractable	O
surface	O
pili	O
.	O

Here	O
we	O
show	O
that	O
levels	O
of	O
recoverable	O
surface	O
pili	O
were	O
markedly	O
decreased	O
in	O
fimV	O
pilT	O
retraction	O
-	O
deficient	O
mutants	O
compared	O
with	O
levels	O
in	O
the	O
pilT	O
control	O
,	O
demonstrating	O
that	O
FimV	O
acts	O
at	O
the	O
level	O
of	O
pilus	O
assembly	O
.	O

Levels	O
of	O
inner	O
membrane	O
assembly	O
subcomplex	O
proteins	O
PilM	O
/	O
N	O
/	O
O	O
/	O
P	O
were	O
decreased	O
in	O
fimV	O
mutants	O
,	O
but	O
supplementation	O
of	O
these	O
components	O
in	O
trans	O
did	O
not	O
restore	O
pilus	O
assembly	O
or	O
motility	O
.	O

Loss	O
of	O
FimV	O
dramatically	O
reduced	O
the	O
levels	O
of	O
the	O
PilQ	O
secretin	O
multimer	O
through	O
which	O
pili	O
exit	O
the	O
cell	O
,	O
in	O
part	O
due	O
to	O
decreased	O
levels	O
of	O
PilQ	O
monomers	O
,	O
while	O
PilF	O
pilotin	O
levels	O
were	O
unchanged	O
.	O

Expression	O
of	O
pilQ	O
in	O
trans	O
in	O
the	O
wild	O
type	O
or	O
fimV	O
mutants	O
increased	O
total	O
PilQ	O
monomer	O
levels	O
but	O
did	O
not	O
alter	O
secretin	O
multimer	O
levels	O
or	O
motility	O
.	O

PG	O
pulldown	O
assays	O
showed	O
that	O
the	O
N	O
terminus	O
of	O
FimV	O
bound	O
PG	O
in	O
a	O
LysM	O
motif	O
-	O
dependent	O
manner	O
,	O
and	O
a	O
mutant	O
with	O
an	O
in	O
-	O
frame	O
chromosomal	O
deletion	O
of	O
the	O
LysM	O
motif	O
had	O
reduced	O
motility	O
,	O
secretin	O
levels	O
,	O
and	O
surface	O
piliation	O
.	O

Together	O
,	O
our	O
data	O
show	O
that	O
FimV	O
's	O
role	O
in	O
pilus	O
assembly	O
is	O
to	O
promote	O
secretin	O
formation	O
and	O
that	O
this	O
function	O
depends	O
upon	O
its	O
PG	O
-	O
binding	O
domain	O
.	O

Activation	O
of	O
the	O
heat	O
shock	O
transcription	O
factor	O
Hsf1	O
is	O
essential	O
for	O
the	O
full	O
virulence	O
of	O
the	O
fungal	O
pathogen	O
Candida	B
albicans	I
.	O

The	O
evolutionarily	O
conserved	O
heat	O
shock	O
transcription	O
factor	O
Hsf1	O
plays	O
a	O
central	O
role	O
in	O
thermal	O
adaptation	O
in	O
the	O
major	O
fungal	O
pathogen	O
of	O
humans	B
,	O
Candida	B
albicans	I
.	O

Hsf1	O
becomes	O
hyperphosphorylated	O
in	O
response	O
to	O
heat	O
shock	O
and	O
activates	O
the	O
transcription	O
of	O
genes	O
with	O
heat	O
shock	O
elements	O
(	O
HSEs	O
)	O
in	O
their	O
promoters	O
,	O
these	O
genes	O
contributing	O
to	O
thermal	O
adaptation	O
.	O

However	O
,	O
the	O
relevance	O
of	O
Hsf1	O
activation	O
to	O
C.	B
albicans	I
virulence	O
is	O
not	O
clear	O
as	O
this	O
pathogen	O
is	O
thought	O
to	O
be	O
obligately	O
associated	O
with	O
warm	O
blooded	O
animals	O
,	O
and	O
this	O
issue	O
has	O
not	O
been	O
tested	O
because	O
HSF1	O
is	O
essential	O
for	O
viability	O
in	O
C.	B
albicans	I
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
the	O
HSE	O
regulon	O
is	O
active	O
in	O
C.	B
albicans	I
cells	O
infecting	O
the	O
kidney	O
.	O

We	O
also	O
show	O
the	O
CE2	O
region	O
of	O
Hsf1	O
is	O
required	O
for	O
activation	O
and	O
that	O
the	O
phosphorylation	O
of	O
specific	O
residues	O
in	O
this	O
domain	O
contributes	O
to	O
Hsf1	O
activation	O
.	O

C.	B
albicans	I
HSF1	O
mutants	O
that	O
lack	O
this	O
CE2	O
region	O
are	O
viable	O
.	O

However	O
,	O
they	O
are	O
unable	O
to	O
activate	O
HSE	O
-	O
containing	O
genes	O
in	O
response	O
to	O
heat	O
shock	O
,	O
and	O
they	O
are	O
thermosensitive	O
.	O

Using	O
this	O
HSF1	O
CE2	O
deletion	O
mutant	O
we	O
demonstrate	O
that	O
Hsf1	O
activation	O
,	O
and	O
hence	O
thermal	O
adaptation	O
,	O
contributes	O
significantly	O
to	O
the	O
virulence	O
of	O
C.	B
albicans	I
.	O

Characterization	O
of	O
the	O
developmental	O
regulator	O
FlbE	O
in	O
Aspergillus	B
fumigatus	I
and	O
Aspergillus	B
nidulans	I
.	O

Several	O
upstream	O
developmental	O
activators	O
control	O
asexual	O
development	O
(	O
conidiation	O
)	O
in	O
Aspergillus	O
.	O

In	O
this	O
study	O
,	O
we	O
characterize	O
one	O
of	O
such	O
activators	O
called	O
flbE	O
in	O
Aspergillus	B
fumigatus	I
and	O
Aspergillus	B
nidulans	I
.	O

The	O
predicted	O
FlbE	O
protein	O
is	O
composed	O
of	O
222	O
and	O
201	O
aa	O
in	O
A.	B
fumigatus	I
and	O
A.	B
nidulans	I
,	O
respectively	O
.	O

While	O
flbE	O
is	O
transiently	O
expressed	O
during	O
early	O
phase	O
of	O
growth	O
in	O
A.	B
nidulans	I
,	O
it	O
is	O
somewhat	O
constitutively	O
expressed	O
during	O
the	O
lifecycle	O
of	O
A.	B
fumigatus	I
.	O

The	O
deletion	O
of	O
flbE	O
causes	O
reduced	O
conidiation	O
and	O
delayed	O
expression	O
of	O
brlA	O
and	O
vosA	O
in	O
both	O
species	O
.	O

Moreover	O
,	O
FlbE	O
is	O
necessary	O
for	O
salt	O
-	O
induced	O
development	O
in	O
liquid	O
submerged	O
culture	O
in	O
A.	B
fumigatus	I
.	O

The	O
A.	B
nidulans	I
flbE	O
null	O
mutation	O
is	O
fully	O
complemented	O
by	O
A.	B
fumigatus	I
flbE	O
,	O
indicating	O
a	O
functional	O
conservancy	O
of	O
FlbE	O
in	O
Aspergillus	O
.	O

Both	O
the	O
deletion	O
and	O
overexpression	O
of	O
flbE	O
in	O
A.	B
nidulans	I
result	O
in	O
developmental	O
defects	O
,	O
enhanced	O
autolysis	O
,	O
precocious	O
cell	O
death	O
,	O
and	O
delayed	O
expression	O
of	O
brlA	O
/	O
vosA	O
,	O
suggesting	O
that	O
balanced	O
activity	O
of	O
FlbE	O
is	O
crucial	O
for	O
proper	O
growth	O
and	O
development	O
.	O

Importantly	O
,	O
the	O
N	O
-	O
terminal	O
portion	O
of	O
FlbE	O
exhibits	O
the	O
trans	O
-	O
activation	O
ability	O
in	O
yeast	B
,	O
whereas	O
the	O
C	O
-	O
terminal	O
half	O
negatively	O
affects	O
its	O
activity	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
of	O
certain	O
conserved	O
N	O
-	O
terminal	O
amino	O
acids	O
abolishes	O
the	O
ability	O
of	O
trans	O
-	O
activation	O
,	O
overexpression	O
-	O
induced	O
autolysis	O
,	O
and	O
complementing	O
the	O
null	O
mutation	O
.	O

Finally	O
,	O
overexpression	O
of	O
flbD	O
,	O
but	O
not	O
flbB	O
or	O
flbC	O
,	O
restores	O
conidiation	O
in	O
A.	B
nidulans	I
DeltaflbE	O
,	O
generally	O
supporting	O
the	O
current	O
genetic	O
model	O
for	O
developmental	O
regulation	O
.	O

Universal	O
primers	O
for	O
rapid	O
detection	O
of	O
hytrosaviruses	O
.	O

Hytrosaviridae	O
is	O
a	O
proposed	O
virus	O
family	O
encompassing	O
viruses	O
that	O
cause	O
salivary	O
gland	O
hypertrophy	O
(	O
SGH	O
)	O
syndrome	O
in	O
infected	O
insects	O
and	O
reduce	O
the	O
fertility	O
in	O
their	O
dipteran	O
insect	O
hosts	O
.	O

They	O
contain	O
a	O
large	O
,	O
double	O
stranded	O
DNA	O
genome	O
of	O
120	O
-	O
190	O
kbp	O
.	O

To	O
date	O
,	O
these	O
viruses	O
have	O
been	O
detected	O
only	O
in	O
adult	O
Diptera	O
.	O

These	O
include	O
hytrosaviruses	O
detected	O
in	O
various	O
tsetse	O
fly	O
species	O
(	O
Glossina	O
spp	O
.	O
)	O
,	O
the	O
narcissus	B
bulb	I
fly	I
Merodon	B
equestris	I
and	O
the	O
house	B
fly	I
Musca	B
domestica	I
.	O

The	O
limited	O
number	O
of	O
hytrosaviruses	O
reported	O
to	O
date	O
may	O
be	O
a	O
reflection	O
of	O
the	O
frequent	O
absence	O
of	O
external	O
symptoms	O
in	O
infected	O
adult	O
flies	O
and	O
the	O
fact	O
that	O
the	O
virus	O
does	O
not	O
cause	O
rapid	O
mortality	O
.	O

Based	O
on	O
the	O
complete	O
genome	O
sequence	O
of	O
Glossinia	B
pallidipes	I
(	O
GpSGHV	O
)	O
and	O
Musca	B
domestica	I
(	O
MdSGHV	O
)	O
salivary	O
gland	O
hypertrophy	O
viruses	O
,	O
a	O
PCR	O
based	O
methodology	O
was	O
developed	O
to	O
detect	O
the	O
viruses	O
in	O
these	O
species	O
.	O

To	O
be	O
able	O
to	O
detect	O
hytrosaviruses	O
in	O
other	O
Diptera	O
,	O
five	O
degenerate	O
primer	O
pairs	O
were	O
designed	O
and	O
tested	O
on	O
GpSGHV	O
and	O
MdSGHV	O
DNA	O
using	O
gradient	O
PCR	O
with	O
annealing	O
temperatures	O
from	O
37	O
to	O
61	O
^	O
0C	O
.	O

Two	O
pairs	O
of	O
primers	O
were	O
selected	O
from	O
p74	O
,	O
two	O
pairs	O
from	O
PIF-1	O
and	O
one	O
pair	O
from	O
ODV	O
-	O
e66	O
homologous	O
proteins	O
.	O

Four	O
primer	O
pairs	O
generated	O
a	O
virus	O
specific	O
PCR	O
product	O
on	O
both	O
MdSGHV	O
and	O
GpSGHV	O
at	O
all	O
tested	O
annealing	O
temperatures	O
,	O
while	O
the	O
ODV	O
-	O
e66	O
based	O
primers	O
did	O
not	O
generate	O
a	O
virus	O
specific	O
product	O
with	O
annealing	O
temperatures	O
higher	O
that	O
47	O
^	O
0C	O
.	O

No	O
non	O
-	O
specific	O
PCR	O
product	O
was	O
found	O
when	O
using	O
genomic	O
DNA	O
of	O
infected	O
flies	O
as	O
template	O
DNA	O
.	O

These	O
results	O
offer	O
new	O
sets	O
of	O
primers	O
that	O
could	O
be	O
used	O
to	O
detect	O
hytrosaviruses	O
in	O
other	O
insects	O
.	O

Candidate	O
chemosensory	O
ionotropic	O
receptors	O
in	O
a	O
Lepidoptera	O
.	O

A	O
new	O
family	O
of	O
candidate	O
chemosensory	O
ionotropic	O
receptors	O
(	O
IRs	O
)	O
related	O
to	O
ionotropic	O
glutamate	O
receptors	O
(	O
iGluRs	O
)	O
was	O
recently	O
discovered	O
in	O
Drosophila	B
melanogaster	I
.	O

Through	O
Blast	O
analyses	O
of	O
an	O
expressed	O
sequenced	O
tag	O
library	O
prepared	O
from	O
male	O
antennae	O
of	O
the	O
noctuid	O
moth	O
Spodoptera	B
littoralis	I
,	O
we	O
identified	O
12	O
unigenes	O
encoding	O
proteins	O
related	O
to	O
D.	B
melanogaster	I
and	O
Bombyx	B
mori	I
IRs	O
.	O

Their	O
full	O
length	O
sequences	O
were	O
obtained	O
and	O
the	O
analyses	O
of	O
their	O
expression	O
patterns	O
suggest	O
that	O
they	O
were	O
exclusively	O
expressed	O
or	O
clearly	O
enriched	O
in	O
chemosensory	O
organs	O
.	O

The	O
deduced	O
protein	O
sequences	O
were	O
more	O
similar	O
to	O
B.	B
mori	I
and	O
D.	B
melanogaster	I
IRs	O
than	O
to	O
iGluRs	O
and	O
showed	O
considerable	O
variations	O
in	O
the	O
predicted	O
ligand	O
-	O
binding	O
domains	O
;	O
none	O
have	O
the	O
three	O
glutamate	O
-	O
interacting	O
residues	O
found	O
in	O
iGluRs	O
,	O
suggesting	O
different	O
binding	O
specificities	O
.	O

Our	O
data	O
suggest	O
that	O
we	O
identified	O
members	O
of	O
the	O
insect	O
IR	O
chemosensory	O
receptor	O
family	O
in	O
S.	B
littoralis	I
and	O
we	O
report	O
here	O
the	O
first	O
demonstration	O
of	O
IR	O
expression	O
in	O
Lepidoptera	O
.	O

The	O
RNA	O
-	O
Seq	O
approach	O
to	O
studying	O
the	O
expression	O
of	O
mosquito	O
mitochondrial	O
genes	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
extensive	O
expressed	O
sequence	O
tag	O
evidence	O
obtained	O
through	O
454	O
and	O
Solexa	O
next	O
-	O
generation	O
sequencing	O
to	O
explore	O
mtDNA	O
transcription	O
in	O
male	O
and	O
female	O
first	O
instar	O
larvae	O
of	O
Aedes	B
aegypti	I
and	O
adults	O
of	O
Aedes	B
aegypti	I
,	O
Anopheles	B
gambiae	I
,	O
and	O
Anopheles	B
quadrimaculatus	I
.	O

Relative	O
abundances	O
of	O
individual	O
transcripts	O
differed	O
considerably	O
within	O
each	O
sample	O
,	O
consistent	O
with	O
the	O
differential	O
stability	O
of	O
messenger	O
RNA	O
species	O
.	O

Large	O
differences	O
were	O
also	O
observed	O
between	O
species	O
and	O
between	O
larval	O
and	O
adult	O
stages	O
;	O
however	O
,	O
the	O
male	O
and	O
female	O
larval	O
samples	O
were	O
remarkably	O
similar	O
.	O

Quantitative	O
PCR	O
analysis	O
of	O
selected	O
genes	O
,	O
cox1	O
,	O
l	O
-	O
rRNA	O
and	O
nd5	O
,	O
in	O
larvae	O
and	O
adults	O
of	O
Ae	B
.	I

aegypti	B
and	O
in	O
An	B
.	I

gambiae	B
adults	O
was	O
consistent	O
with	O
the	O
RNA	O
-	O
Seq	O
-	O
based	O
quantification	O
of	O
expression	O
.	O

Finally	O
,	O
the	O
absence	O
of	O
a	O
conserved	O
mtDNA	O
region	O
involved	O
in	O
transcriptional	O
control	O
in	O
other	O
dipterans	O
suggests	O
that	O
mosquitoes	O
have	O
evolved	O
a	O
distinct	O
mechanism	O
of	O
regulation	O
of	O
gene	O
expression	O
in	O
the	O
mitochondrion	O
.	O

Differential	O
PbP27	O
expression	O
in	O
the	O
yeast	O
and	O
mycelial	O
forms	O
of	O
the	O
Paracoccidioides	B
brasiliensis	I
species	O
complex	O
.	O

p27	O
is	O
an	O
antigenic	O
protein	O
produced	O
by	O
Paracoccidioides	B
brasiliensis	I
,	O
the	O
etiologic	O
agent	O
of	O
paracoccidioidomycosis	O
(	O
PCM	O
)	O
.	O

Despite	O
its	O
unknown	O
function	O
,	O
it	O
has	O
been	O
suggested	O
as	O
a	O
putative	O
virulence	O
factor	O
,	O
proposed	O
as	O
a	O
suitable	O
target	O
for	O
the	O
design	O
of	O
diagnostic	O
tools	O
and	O
vaccines	O
,	O
and	O
considered	O
as	O
an	O
enhancer	O
in	O
antifungal	O
treatment	O
of	O
PCM	O
.	O

We	O
evaluated	O
sequence	O
polymorphisms	O
of	O
PbP27	O
gene	O
sequence	O
among	O
isolates	O
,	O
finding	O
some	O
polymorphisms	O
associated	O
with	O
the	O
isolates	O
'	O
phylogenetic	O
origin	O
.	O

In	O
order	O
to	O
determine	O
if	O
there	O
was	O
a	O
differential	O
expression	O
pattern	O
between	O
morphological	O
states	O
and	O
among	O
isolates	O
,	O
we	O
also	O
evaluated	O
PbP27	O
expression	O
,	O
at	O
transcriptional	O
and	O
translational	O
levels	O
,	O
in	O
mycelia	O
and	O
yeast	O
cultures	O
in	O
14	O
isolates	O
belonging	O
to	O
the	O
P.	B
brasiliensis	I
species	I
complex	I
(	O
S1	O
,	O
PS2	O
,	O
PS3	O
,	O
and	O
"	O
Pb01-like	O
"	O
,	O
proposed	O
to	O
be	O
named	O
Paracoccidioides	B
lutzii	I
)	O
by	O
two	O
techniques	O
,	O
real	O
time	O
RT	O
-	O
PCR	O
(	O
RT	O
-	O
qPCR	O
)	O
and	O
protein	O
dot	O
blot	O
.	O

For	O
the	O
latter	O
,	O
four	O
protein	O
extracts	O
from	O
different	O
cell	O
localizations	O
(	O
SDS	O
or	O
Beta	O
-	O
mercaptoethanol	O
,	O
cytoplasmic	O
and	O
extracellular	O
proteins	O
)	O
were	O
analyzed	O
for	O
each	O
isolate	O
.	O

p27	O
was	O
present	O
in	O
the	O
four	O
extracts	O
evaluated	O
,	O
mainly	O
in	O
the	O
SDS	O
extract	O
,	O
corresponding	O
to	O
an	O
extract	O
containing	O
proteins	O
loosely	O
attached	O
to	O
the	O
cell	O
wall	O
.	O

This	O
information	O
correlates	O
with	O
immunohistochemical	O
analysis	O
,	O
where	O
positive	O
staining	O
of	O
the	O
yeasts	O
'	O
cell	O
wall	O
was	O
observed	O
.	O

We	O
found	O
that	O
p27	O
was	O
present	O
in	O
all	O
isolates	O
,	O
mainly	O
in	O
the	O
yeast	O
form	O
.	O

This	O
pattern	O
was	O
corroborated	O
by	O
RT	O
-	O
qPCR	O
results	O
,	O
with	O
higher	O
expression	O
levels	O
found	O
in	O
the	O
yeast	O
form	O
for	O
most	O
of	O
the	O
isolates	O
.	O

The	O
results	O
provide	O
new	O
insights	O
into	O
the	O
expression	O
patterns	O
of	O
this	O
protein	O
,	O
and	O
further	O
characterize	O
it	O
in	O
view	O
of	O
potential	O
uses	O
as	O
a	O
diagnostic	O
and/or	O
therapeutic	O
tool	O
.	O

Role	O
of	O
lupeol	O
synthase	O
in	O
Lotus	B
japonicus	I
nodule	O
formation	O
.	O

*	O
Triterpenes	O
are	O
plant	O
secondary	O
metabolites	O
,	O
derived	O
from	O
the	O
cyclization	O
of	O
2,3-oxidosqualene	O
by	O
oxidosqualene	O
cyclases	O
(	O
OSCs	O
)	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
role	O
of	O
lupeol	O
synthase	O
,	O
encoded	O
by	O
OSC3	O
,	O
and	O
its	O
product	O
,	O
lupeol	O
,	O
in	O
developing	O
roots	O
and	O
nodules	O
of	O
the	O
model	O
legume	O
Lotus	B
japonicus	I
.	O

*	O
The	O
expression	O
patterns	O
of	O
OSC3	O
in	O
different	O
developmental	O
stages	O
of	O
uninfected	O
roots	O
and	O
in	O
roots	O
infected	O
with	O
Mesorhizobium	B
loti	I
were	O
determined	O
.	O

The	O
tissue	O
specificity	O
of	O
OSC3	O
expression	O
was	O
analysed	O
by	O
in	O
situ	O
hybridization	O
.	O

Functional	O
analysis	O
,	O
in	O
which	O
transgenic	O
L.	B
japonicus	I
roots	O
silenced	O
for	O
OSC3	O
were	O
generated	O
,	O
was	O
performed	O
.	O

The	O
absence	O
of	O
lupeol	O
in	O
the	O
silenced	O
plant	O
lines	O
was	O
determined	O
by	O
GC	O
-	O
MS	O
.	O

*	O
The	O
expression	O
of	O
ENOD40	O
,	O
a	O
marker	O
gene	O
for	O
nodule	O
primordia	O
initiation	O
,	O
was	O
increased	O
significantly	O
in	O
the	O
OSC3-silenced	O
plant	O
lines	O
,	O
suggesting	O
that	O
lupeol	O
influences	O
nodule	O
formation	O
.	O

Silenced	O
plants	O
also	O
showed	O
a	O
more	O
rapid	O
nodulation	O
phenotype	O
,	O
consistent	O
with	O
this	O
.	O

Exogenous	O
application	O
of	O
lupeol	O
to	O
M.	B
loti	I
-	O
infected	O
wild	O
-	O
type	O
plants	O
provided	O
further	O
evidence	O
for	O
a	O
negative	O
regulatory	O
effect	O
of	O
lupeol	O
on	O
the	O
expression	O
of	O
ENOD40	O
.	O

*	O
The	O
synthesis	O
of	O
lupeol	O
in	O
L.	B
japonicus	I
roots	O
and	O
nodules	O
can	O
be	O
solely	O
attributed	O
to	O
OSC3	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
a	O
role	O
for	O
lupeol	O
biosynthesis	O
in	O
nodule	O
formation	O
through	O
the	O
regulation	O
of	O
ENOD40	O
gene	O
expression	O
.	O

Overexpression	O
of	O
the	O
trichodiene	O
synthase	O
gene	O
tri5	O
increases	O
trichodermin	O
production	O
and	O
antimicrobial	O
activity	O
in	O
Trichoderma	B
brevicompactum	I
.	O

Trichoderma	B
brevicompactum	I
produces	O
trichodermin	O
,	O
a	O
simple	O
trichothecene	O
-	O
type	O
toxin	O
that	O
shares	O
the	O
first	O
steps	O
of	O
the	O
sesquiterpene	O
biosynthetic	O
pathway	O
with	O
other	O
phytotoxic	O
trichothecenes	O
from	O
Fusarium	B
spp	I
.	O

Trichodiene	O
synthase	O
catalyses	O
the	O
conversion	O
of	O
farnesyl	O
pyrophosphate	O
to	O
trichodiene	O
and	O
it	O
is	O
encoded	O
by	O
the	O
tri5	O
gene	O
that	O
was	O
cloned	O
and	O
analysed	O
functionally	O
by	O
homologous	O
overexpression	O
in	O
T.	B
brevicompactum	I
.	O

tri5	O
expression	O
was	O
up	O
-	O
regulated	O
in	O
media	O
with	O
glucose	O
,	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
or	O
glycerol	O
.	O

tri5	O
repression	O
was	O
observed	O
in	O
cultures	O
supplemented	O
with	O
the	O
antioxidants	O
ferulic	O
acid	O
and	O
tyrosol	O
.	O

Acetone	O
extracts	O
of	O
tri5-overexpressing	O
transformants	O
displayed	O
higher	O
antifungal	O
activity	O
than	O
those	O
from	O
the	O
wild	O
-	O
type	O
.	O

Chromatographic	O
and	O
spectroscopic	O
analyses	O
revealed	O
that	O
tri5	O
overexpression	O
led	O
to	O
an	O
increased	O
production	O
of	O
trichodermin	O
and	O
tyrosol	O
.	O

Agar	O
diffusion	O
assays	O
with	O
these	O
two	O
purified	O
metabolites	O
from	O
the	O
tri5-overexpressing	O
transformant	O
T.	B
brevicompactum	I
Tb41tri5	O
showed	O
that	O
only	O
trichodermin	O
had	O
antifungal	O
activity	O
against	O
Saccharomyces	B
cerevisiae	I
,	O
Kluyveromyces	B
marxianus	I
,	O
Candida	B
albicans	I
,	O
Candida	B
glabrata	I
,	O
Candida	B
tropicalis	I
and	O
Aspergillus	B
fumigatus	I
,	O
in	O
most	O
cases	O
such	O
activity	O
being	O
higher	O
than	O
that	O
observed	O
for	O
amphotericin	O
B	O
and	O
hygromycin	O
.	O

Our	O
results	O
point	O
to	O
the	O
significant	O
role	O
of	O
tri5	O
in	O
the	O
production	O
of	O
trichodermin	O
and	O
in	O
the	O
antifungal	O
activity	O
of	O
T.	B
brevicompactum	I
.	O

Limitation	O
of	O
Sludge	O
Biotic	O
Index	O
application	O
for	O
control	O
of	O
a	O
wastewater	O
treatment	O
plant	O
working	O
with	O
shock	O
organic	O
and	O
ammonium	O
loadings	O
.	O

This	O
study	O
aimed	O
to	O
determine	O
the	O
relationship	O
between	O
activated	O
sludge	O
microfauna	O
,	O
the	O
sludge	O
biotic	O
index	O
(	O
SBI	O
)	O
and	O
the	O
effluent	O
quality	O
of	O
a	O
full	O
-	O
scale	O
municipal	O
wastewater	O
treatment	O
plant	O
(	O
WWTP	O
)	O
working	O
with	O
shock	O
organic	O
and	O
ammonium	O
loadings	O
caused	O
by	O
periodic	O
wastewater	O
delivery	O
from	O
septic	O
tanks	O
.	O

Irrespective	O
of	O
high	O
/	O
low	O
effluent	O
quality	O
in	O
terms	O
of	O
COD	O
,	O
BOD	O
(	O
5	O
)	O
,	O
ammonium	O
and	O
suspended	O
solids	O
,	O
high	O
SBI	O
values	O
(	O
8	O
-	O
10	O
)	O
,	O
which	O
correspond	O
to	O
the	O
first	O
quality	O
class	O
of	O
sludge	O
,	O
were	O
observed	O
.	O

High	O
SBI	O
values	O
were	O
connected	O
with	O
abundant	O
taxonomic	O
composition	O
and	O
the	O
domination	O
of	O
crawling	O
ciliates	O
with	O
shelled	O
amoebae	O
and	O
attached	O
ciliates	O
.	O

High	O
SBI	O
values	O
,	O
even	O
at	O
a	O
low	O
effluent	O
quality	O
,	O
limit	O
the	O
usefulness	O
of	O
the	O
index	O
for	O
monitoring	O
the	O
status	O
of	O
an	O
activated	O
sludge	O
system	O
and	O
the	O
effluent	O
quality	O
in	O
municipal	O
WWTP	O
-	O
treated	O
wastewater	O
from	O
septic	O
tanks	O
.	O

It	O
was	O
shown	O
that	O
a	O
more	O
sensitive	O
indicator	O
of	O
effluent	O
quality	O
was	O
a	O
change	O
in	O
the	O
abundance	O
of	O
attached	O
ciliates	O
with	O
a	O
narrow	O
peristome	O
(	O
Vorticella	B
infusionum	I
and	O
Opercularia	O
coarctata	O
)	O
,	O
small	O
flagellates	O
and	O
crawling	O
ciliates	O
(	O
Acineria	O
uncinata	O
)	O
feeding	O
on	O
flagellates	O
.	O

A	O
small	O
protein	O
required	O
for	O
the	O
switch	O
from	O
{	O
sigma	O
}	O
F	O
to	O
{	O
sigma	O
}	O
G	O
during	O
sporulation	O
in	O
Bacillus	B
subtilis	I
.	O

A	O
cascade	O
of	O
alternative	O
sigma	O
factors	O
governs	O
the	O
program	O
of	O
developmental	O
gene	O
expression	O
during	O
sporulation	O
in	O
Bacillus	B
subtilis	I
.	O

Little	O
is	O
known	O
,	O
however	O
,	O
about	O
how	O
the	O
early	O
-	O
acting	O
sigma	O
factors	O
are	O
inactivated	O
and	O
replaced	O
by	O
the	O
later	O
-	O
acting	O
factors	O
.	O

Here	O
we	O
identify	O
a	O
small	O
protein	O
,	O
Fin	O
(	O
formerly	O
known	O
as	O
YabK	O
)	O
,	O
that	O
is	O
required	O
for	O
efficient	O
switching	O
from	O
sigma	O
(	O
F	O
)	O
-	O
to	O
sigma	O
(	O
G	O
)	O
-directed	O
gene	O
expression	O
in	O
the	O
forespore	O
compartment	O
of	O
the	O
developing	O
sporangium	O
.	O

The	O
fin	O
gene	O
,	O
which	O
is	O
conserved	O
among	O
Bacillus	O
species	O
and	O
species	O
of	O
related	O
genera	O
,	O
is	O
transcribed	O
in	O
the	O
forespore	O
under	O
the	O
control	O
of	O
both	O
sigma	O
(	O
F	O
)	O
and	O
sigma	O
(	O
G	O
)	O
.	O

Cells	O
mutant	O
for	O
fin	O
are	O
unable	O
to	O
fully	O
deactivate	O
sigma	O
(	O
F	O
)	O
and	O
,	O
conversely	O
,	O
are	O
unable	O
to	O
fully	O
activate	O
sigma	O
(	O
G	O
)	O
.	O

Consistent	O
with	O
their	O
deficiency	O
in	O
sigma	O
(	O
G	O
)	O
-directed	O
gene	O
expression	O
,	O
fin	O
cells	O
are	O
arrested	O
in	O
large	O
numbers	O
following	O
the	O
engulfment	O
stage	O
of	O
sporulation	O
,	O
ultimately	O
forming	O
50-fold	O
fewer	O
heat	O
-	O
resistant	O
spores	O
than	O
the	O
wild	O
type	O
.	O

Based	O
in	O
part	O
on	O
the	O
similarity	O
of	O
Fin	O
to	O
the	O
anti	O
-	O
sigma	O
(	O
G	O
)	O
factor	O
CsfB	O
(	O
also	O
called	O
Gin	O
)	O
,	O
we	O
speculate	O
that	O
Fin	O
is	O
an	O
anti	O
-	O
sigma	O
(	O
F	O
)	O
factor	O
which	O
,	O
by	O
disabling	O
sigma	O
(	O
F	O
)	O
,	O
promotes	O
the	O
switch	O
to	O
late	O
developmental	O
gene	O
expression	O
in	O
the	O
forespore	O
.	O

X	O
-	O
ray	O
structure	O
and	O
site	O
-	O
directed	O
mutagenesis	O
analysis	O
of	O
the	O
Escherichia	B
coli	I
colicin	O
M	O
immunity	O
protein	O
.	O

Colicin	O
M	O
(	O
ColM	O
)	O
,	O
which	O
is	O
produced	O
by	O
some	O
Escherichia	B
coli	I
strains	O
to	O
kill	O
competitor	O
strains	O
from	O
the	O
same	O
or	O
related	O
species	O
,	O
was	O
recently	O
shown	O
to	O
inhibit	O
cell	O
wall	O
peptidoglycan	O
biosynthesis	O
through	O
enzymatic	O
degradation	O
of	O
its	O
lipid	O
II	O
precursor	O
.	O

ColM	O
-	O
producing	O
strains	O
are	O
protected	O
from	O
the	O
toxin	O
that	O
they	O
produce	O
by	O
coexpression	O
of	O
a	O
specific	O
immunity	O
protein	O
,	O
named	O
Cmi	O
,	O
whose	O
mode	O
of	O
action	O
still	O
remains	O
to	O
be	O
identified	O
.	O

We	O
report	O
here	O
the	O
resolution	O
of	O
the	O
crystal	O
structure	O
of	O
Cmi	O
,	O
which	O
is	O
composed	O
of	O
four	O
Beta	O
strands	O
and	O
four	O
alpha	O
helices	O
.	O

This	O
rather	O
compact	O
structure	O
revealed	O
a	O
disulfide	O
bond	O
between	O
residues	O
Cys31	O
and	O
Cys107	O
.	O

Interestingly	O
,	O
these	O
two	O
cysteines	O
and	O
several	O
other	O
residues	O
appeared	O
to	O
be	O
conserved	O
in	O
the	O
sequences	O
of	O
several	O
proteins	O
of	O
unknown	O
function	O
belonging	O
to	O
the	O
YebF	O
family	O
which	O
exhibit	O
25	O
to	O
35	O
%	O
overall	O
sequence	O
similarity	O
with	O
Cmi	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
was	O
performed	O
to	O
assess	O
the	O
role	O
of	O
these	O
residues	O
in	O
the	O
ColM	O
immunity	O
-	O
conferring	O
activity	O
of	O
Cmi	O
,	O
which	O
showed	O
that	O
the	O
disulfide	O
bond	O
and	O
residues	O
from	O
the	O
C	O
-	O
terminal	O
extremity	O
of	O
the	O
protein	O
were	O
functionally	O
essential	O
.	O

The	O
involvement	O
of	O
DsbA	O
oxidase	O
in	O
the	O
formation	O
of	O
the	O
Cmi	O
disulfide	O
bond	O
is	O
also	O
demonstrated	O
.	O

Cannibalism	O
and	O
intraguild	O
predation	O
of	O
eggs	O
within	O
a	O
diverse	O
predator	O
assemblage	O
.	O

Greater	O
biodiversity	O
among	O
aphid	O
predators	O
sometimes	O
leads	O
to	O
greater	O
predator	O
reproductive	O
success	O
.	O

This	O
could	O
occur	O
if	O
cannibalism	O
of	O
predator	O
eggs	O
is	O
consistently	O
stronger	O
than	O
intraguild	O
predation	O
,	O
such	O
that	O
diversity	O
dilutes	O
cannibalism	O
risk	O
when	O
total	O
predator	O
densities	O
remain	O
constant	O
across	O
diversity	O
levels	O
.	O

We	O
compared	O
the	O
frequency	O
of	O
cannibalism	O
versus	O
intraguild	O
predation	O
by	O
adult	O
predators	O
of	O
four	O
species	O
[	O
the	O
lady	O
beetles	O
Coccinella	B
septempunctata	I
L.	I
and	O
Hippodamia	B
convergens	I
Guerin	I
-	I
Meneville	I
,	O
and	O
the	O
predatory	O
bugs	O
Geocoris	B
bullatus	I
(	I
Say	I
)	O
and	O
Nabis	O
alternatus	O
Parshley	O
]	O
on	O
the	O
eggs	O
of	O
three	O
predator	O
species	O
(	O
all	O
of	O
these	O
predators	O
but	O
Nabis	O
)	O
.	O

For	O
both	O
coccinellid	O
species	O
,	O
egg	O
predation	O
averaged	O
across	O
all	O
intraguild	O
predators	O
was	O
less	O
frequent	O
than	O
cannibalism	O
.	O

In	O
contrast	O
,	O
Geocoris	B
eggs	O
were	O
generally	O
more	O
likely	O
to	O
be	O
consumed	O
by	O
intraguild	O
predators	O
than	O
by	O
conspecifics	O
.	O

Closer	O
inspection	O
of	O
the	O
data	O
revealed	O
that	O
Geocoris	B
consistently	O
consumed	O
fewer	O
eggs	O
than	O
the	O
other	O
species	O
,	O
regardless	O
of	O
egg	O
species	O
.	O

Indeed	O
,	O
for	O
lady	O
beetle	O
eggs	O
it	O
was	O
relatively	O
infrequent	O
egg	O
predation	O
by	O
Geocoris	B
that	O
brought	O
down	O
the	O
average	O
across	O
all	O
heterospecific	O
predators	O
,	O
masking	O
the	O
fact	O
that	O
adults	O
of	O
the	O
two	O
lady	O
beetles	O
were	O
no	O
more	O
likely	O
to	O
act	O
as	O
egg	O
cannibals	O
than	O
as	O
intraguild	O
predators	O
.	O

Nabis	O
ate	O
eggs	O
of	O
the	O
two	O
beetles	O
at	O
approximately	O
equal	O
rates	O
,	O
but	O
rarely	O
ate	O
Geocoris	B
eggs	O
.	O

Female	O
predators	O
generally	O
consumed	O
more	O
eggs	O
than	O
did	O
males	O
,	O
but	O
this	O
did	O
not	O
alter	O
any	O
of	O
the	O
patterns	O
described	O
above	O
.	O

Altogether	O
,	O
our	O
results	O
suggest	O
that	O
species	O
-	O
specific	O
differences	O
in	O
egg	O
predation	O
rates	O
determined	O
the	O
relative	O
intensity	O
of	O
egg	O
intraguild	O
-	O
predation	O
versus	O
cannibalism	O
,	O
rather	O
than	O
any	O
more	O
general	O
trend	O
for	O
egg	O
cannibalism	O
to	O
always	O
exceed	O
intraguild	O
predation	O
.	O

Reproductive	O
health	O
,	O
and	O
child	O
health	O
and	O
nutrition	O
in	O
India	O
:	O
meeting	O
the	O
challenge	O
.	O

India	O
,	O
with	O
a	O
population	O
of	O
more	O
than	O
1	O
billion	O
people	O
,	O
has	O
many	O
challenges	O
in	O
improving	O
the	O
health	O
and	O
nutrition	O
of	O
its	O
citizens	O
.	O

Steady	O
declines	O
have	O
been	O
noted	O
in	O
fertility	O
,	O
maternal	O
,	O
infant	O
and	O
child	O
mortalities	O
,	O
and	O
the	O
prevalence	O
of	O
severe	O
manifestations	O
of	O
nutritional	O
deficiencies	O
,	O
but	O
the	O
pace	O
has	O
been	O
slow	O
and	O
falls	O
short	O
of	O
national	O
and	O
Millennium	O
Development	O
Goal	O
targets	O
.	O

The	O
likely	O
explanations	O
include	O
social	O
inequities	O
,	O
disparities	O
in	O
health	O
systems	O
between	O
and	O
within	O
states	O
,	O
and	O
consequences	O
of	O
urbanisation	O
and	O
demographic	O
transition	O
.	O

In	O
2005	O
,	O
India	O
embarked	O
on	O
the	O
National	O
Rural	O
Health	O
Mission	O
,	O
an	O
extraordinary	O
effort	O
to	O
strengthen	O
the	O
health	O
systems	O
.	O

However	O
,	O
coverage	O
of	O
priority	O
interventions	O
remains	O
insufficient	O
,	O
and	O
the	O
content	O
and	O
quality	O
of	O
existing	O
interventions	O
are	O
suboptimum	O
.	O

Substantial	O
unmet	O
need	O
for	O
contraception	O
remains	O
,	O
adolescent	O
pregnancies	O
are	O
common	O
,	O
and	O
access	O
to	O
safe	O
abortion	O
is	O
inadequate	O
.	O

Increases	O
in	O
the	O
numbers	O
of	O
deliveries	O
in	O
institutions	O
have	O
not	O
been	O
matched	O
by	O
improvements	O
in	O
the	O
quality	O
of	O
intrapartum	O
and	O
neonatal	O
care	O
.	O

Infants	O
and	O
young	O
children	O
do	O
not	O
get	O
the	O
health	O
care	O
they	O
need	O
;	O
access	O
to	O
effective	O
treatment	O
for	O
neonatal	O
illness	O
,	O
diarrhoea	O
,	O
and	O
pneumonia	O
shows	O
little	O
improvement	O
;	O
and	O
the	O
coverage	O
of	O
nutrition	O
programmes	O
is	O
inadequate	O
.	O

Absence	O
of	O
well	O
functioning	O
health	O
systems	O
is	O
indicated	O
by	O
the	O
inadequacies	O
related	O
to	O
planning	O
,	O
financing	O
,	O
human	B
resources	O
,	O
infrastructure	O
,	O
supply	O
systems	O
,	O
governance	O
,	O
information	O
,	O
and	O
monitoring	O
.	O

We	O
provide	O
a	O
case	O
for	O
transformation	O
of	O
health	O
systems	O
through	O
effective	O
stewardship	O
,	O
decentralised	O
planning	O
in	O
districts	O
,	O
a	O
reasoned	O
approach	O
to	O
financing	O
that	O
affects	O
demand	O
for	O
health	O
care	O
,	O
a	O
campaign	O
to	O
create	O
awareness	O
and	O
change	O
health	O
and	O
nutrition	O
behaviour	O
,	O
and	O
revision	O
of	O
programmes	O
for	O
child	O
nutrition	O
on	O
the	O
basis	O
of	O
evidence	O
.	O

This	O
agenda	O
needs	O
political	O
commitment	O
of	O
the	O
highest	O
order	O
and	O
the	O
development	O
of	O
a	O
people	O
's	O
movement	O
.	O

FAD	O
binding	O
by	O
ApbE	O
protein	O
from	O
Salmonella	B
enterica	I
:	O
a	O
new	O
class	O
of	O
FAD	O
-	O
binding	O
proteins	O
.	O

The	O
periplasmic	O
protein	O
ApbE	O
was	O
identified	O
through	O
the	O
analysis	O
of	O
several	O
mutants	O
defective	O
in	O
thiamine	O
biosynthesis	O
and	O
was	O
implicated	O
as	O
having	O
a	O
role	O
in	O
iron	O
-	O
sulfur	O
cluster	O
biosynthesis	O
or	O
repair	O
.	O

While	O
mutations	O
in	O
apbE	O
cause	O
decreased	O
activity	O
of	O
several	O
iron	O
-	O
sulfur	O
enzymes	O
in	O
vivo	O
,	O
the	O
specific	O
role	O
of	O
ApbE	O
remains	O
unknown	O
.	O

Members	O
of	O
the	O
AbpE	O
family	O
include	O
NosX	O
and	O
RnfF	O
,	O
which	O
have	O
been	O
implicated	O
in	O
oxidation	O
-	O
reduction	O
associated	O
with	O
nitrous	O
oxide	O
and	O
nitrogen	O
metabolism	O
,	O
respectively	O
.	O

In	O
this	O
work	O
,	O
we	O
show	O
that	O
ApbE	O
binds	O
one	O
FAD	O
molecule	O
per	O
monomeric	O
unit	O
.	O

The	O
structure	O
of	O
ApbE	O
in	O
the	O
presence	O
of	O
bound	O
FAD	O
reveals	O
a	O
new	O
FAD	O
-	O
binding	O
motif	O
.	O

Protein	O
variants	O
that	O
are	O
nonfunctional	O
in	O
vivo	O
were	O
generated	O
by	O
random	O
and	O
targeted	O
mutagenesis	O
.	O

Each	O
variant	O
was	O
substituted	O
in	O
the	O
environment	O
of	O
the	O
FAD	O
and	O
analyzed	O
for	O
FAD	O
binding	O
after	O
reconstitution	O
.	O

The	O
variant	O
that	O
altered	O
a	O
key	O
tyrosine	O
residue	O
involved	O
in	O
FAD	O
binding	O
prevented	O
reconstitution	O
of	O
the	O
protein	O
.	O

Expanding	O
character	O
sampling	O
for	O
ciliate	O
phylogenetic	O
inference	O
using	O
mitochondrial	O
SSU	O
-	O
rDNA	O
as	O
a	O
molecular	O
marker	O
.	O

Molecular	O
systematics	O
of	O
ciliates	O
,	O
particularly	O
at	O
deep	O
nodes	O
,	O
has	O
largely	O
focused	O
on	O
increasing	O
taxon	O
sampling	O
using	O
the	O
nuclear	O
small	O
subunit	O
rDNA	O
(	O
nSSU	O
-	O
rDNA	O
)	O
locus	O
.	O

These	O
previous	O
analyses	O
have	O
generally	O
been	O
congruent	O
with	O
morphologically	O
-	O
based	O
classifications	O
,	O
although	O
there	O
is	O
extensive	O
non	O
-	O
monophyly	O
at	O
many	O
levels	O
.	O

However	O
,	O
caution	O
is	O
needed	O
in	O
interpreting	O
these	O
results	O
as	O
nSSU	O
-	O
rDNA	O
is	O
just	O
a	O
single	O
molecular	O
marker	O
.	O

Here	O
the	O
mitochondrial	O
small	O
subunit	O
rDNA	O
(	O
mtSSU	O
-	O
rDNA	O
)	O
is	O
evaluated	O
for	O
deep	O
ciliate	O
nodes	O
using	O
the	O
Colpodea	O
as	O
an	O
example	O
.	O

Overall	O
,	O
well	O
-	O
supported	O
nodes	O
in	O
the	O
mtSSU	O
-	O
rDNA	O
and	O
concatenated	O
topologies	O
are	O
well	O
supported	O
in	O
the	O
nSSU	O
-	O
rDNA	O
topology	O
;	O
e.g.	O
,	O
the	O
non	O
-	O
monophyly	O
of	O
the	O
Cyrtolophosidida	O
.	O

The	O
two	O
moderately-	O
to	O
well	O
-	O
supported	O
incongruences	O
between	O
the	O
loci	O
are	O
the	O
placement	O
of	O
the	O
Sorogenida	O
and	O
Colpoda	B
aspera	I
.	O

Our	O
analyses	O
of	O
mtSSU	O
-	O
rDNA	O
support	O
the	O
conclusion	O
,	O
originally	O
derived	O
from	O
nSSU	O
-	O
rDNA	O
,	O
that	O
the	O
morphological	O
characters	O
used	O
in	O
taxonomic	O
circumscriptions	O
of	O
the	O
Colpodea	O
represent	O
a	O
mixture	O
of	O
ancestral	O
and	O
derived	O
states	O
.	O

This	O
demonstration	O
of	O
the	O
efficacy	O
of	O
the	O
mtSSU	O
-	O
rDNA	O
will	O
enable	O
phylogenetic	O
reconstructions	O
of	O
deep	O
nodes	O
in	O
the	O
ciliate	O
tree	O
of	O
life	O
to	O
move	O
from	O
a	O
single	O
-	O
locus	O
to	O
a	O
multi	O
-	O
locus	O
approach	O
.	O

Isolation	O
and	O
characterization	O
of	O
P1	O
adhesin	O
,	O
a	O
leg	O
protein	O
of	O
the	O
gliding	O
bacterium	O
Mycoplasma	B
pneumoniae	I
.	O

Mycoplasma	B
pneumoniae	I
,	O
a	O
pathogen	O
causing	O
human	B
pneumonia	O
,	O
binds	O
to	O
solid	O
surfaces	O
at	O
its	O
membrane	O
protrusion	O
and	O
glides	O
by	O
a	O
unique	O
mechanism	O
.	O

In	O
this	O
study	O
,	O
P1	O
adhesin	O
,	O
which	O
functions	O
as	O
a	O
"	O
leg	O
"	O
in	O
gliding	O
,	O
was	O
isolated	O
from	O
mycoplasma	O
culture	B
and	O
characterized	O
.	O

Using	O
gel	O
filtration	O
,	O
blue	O
-	O
native	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
BN	O
-	O
PAGE	O
)	O
,	O
and	O
chemical	O
cross	O
-	O
linking	O
,	O
the	O
isolated	O
P1	O
adhesin	O
was	O
shown	O
to	O
form	O
a	O
complex	O
with	O
an	O
accessory	O
protein	O
named	O
P90	O
.	O

The	O
complex	O
included	O
two	O
molecules	O
each	O
of	O
P1	O
adhesin	O
and	O
P90	O
(	O
protein	O
B	O
)	O
,	O
had	O
a	O
molecular	O
mass	O
of	O
about	O
480	O
kDa	O
,	O
and	O
was	O
observed	O
by	O
electron	O
microscopy	O
to	O
form	O
20-nm	O
-	O
diameter	O
spheres	O
.	O

Partial	O
digestion	O
of	O
isolated	O
P1	O
adhesin	O
by	O
trypsin	O
showed	O
that	O
the	O
P1	O
adhesin	O
molecule	O
can	O
be	O
divided	O
into	O
three	O
domains	O
,	O
consistent	O
with	O
the	O
results	O
from	O
trypsin	O
treatment	O
of	O
the	O
cell	O
surface	O
.	O

Sequence	O
analysis	O
of	O
P1	O
adhesin	O
and	O
its	O
orthologs	O
showed	O
that	O
domain	O
I	O
is	O
well	O
conserved	O
and	O
that	O
a	O
transmembrane	O
segment	O
exists	O
near	O
the	O
link	O
between	O
domains	O
II	O
and	O
III	O
.	O

Anoxybacillus	B
tengchongensis	I
sp.	O
nov.	O
and	O
Anoxybacillus	B
eryuanensis	I
sp.	O
nov.	O
,	O
facultatively	O
anaerobic	O
,	O
alkalitolerant	O
bacteria	O
from	O
hot	O
springs	O
.	O

Two	O
novel	O
thermophilic	O
,	O
spore	O
-	O
forming	O
bacterial	O
strains	O
,	O
T-11	B
(	O
T	O
)	O
and	O
E-112	B
(	O
T	O
)	O
,	O
were	O
isolated	O
from	O
hot	O
springs	O
in	O
Tengchong	O
and	O
Eryuan	O
counties	O
of	O
Yunnan	O
province	O
in	O
south	O
-	O
west	O
China	O
.	O

The	O
strains	O
were	O
Gram	O
-	O
stain	O
-	O
positive	O
rods	O
,	O
occurring	O
singly	O
or	O
in	O
chains	O
.	O

Growth	O
of	O
strain	O
T-11	B
(	O
T	O
)	O
was	O
observed	O
between	O
30	O
and	O
75	O
^0C	O
(	O
optimum	O
50	O
^0C	O
)	O
and	O
at	O
pH	O
7	O
-	O
11	O
(	O
optimum	O
pH	O
8.5	O
)	O
,	O
while	O
the	O
temperature	O
range	O
for	O
strain	O
E-112	B
(	O
T	O
)	O
was	O
35	O
-	O
70	O
^0C	O
(	O
optimum	O
55	O
^0C	O
)	O
and	O
the	O
pH	O
range	O
was	O
7.0	O
-	O
11.0	O
(	O
optimum	O
pH	O
8.0	O
)	O
.	O

The	O
DNA	O
G+C	O
contents	O
of	O
strains	O
T-11	B
(	O
T	O
)	O
and	O
E-112	B
(	O
T	O
)	O
were	O
41.1	O
and	O
42.6	O
mol%	O
,	O
respectively	O
.	O

On	O
the	O
basis	O
of	O
16S	O
rRNA	O
gene	O
sequence	O
similarity	O
,	O
the	O
two	O
strains	O
were	O
shown	O
to	O
be	O
related	O
most	O
closely	O
to	O
Anoxybacillus	O
species	O
.	O

The	O
chemotaxonomic	O
characteristics	O
[	O
predominant	O
isoprenoid	O
quinone	O
menaquinone	O
7	O
(	O
MK-7	O
)	O
;	O
major	O
fatty	O
acids	O
iso	O
-	O
C	O
(	O
15	O
:	O
0	O
)	O
and	O
iso	O
-	O
C	O
(	O
17	O
:	O
0	O
)	O
]	O
also	O
supported	O
the	O
affiliation	O
of	O
strains	O
T-11	B
(	O
T	O
)	O
and	O
E-112	B
(	O
T	O
)	O
to	O
the	O
genus	O
Anoxybacillus	O
.	O

The	O
results	O
of	O
DNA	O
-	O
DNA	O
hybridization	O
and	O
physiological	O
and	O
biochemical	O
tests	O
allowed	O
genotypic	O
and	O
phenotypic	O
differentiation	O
of	O
strains	O
T-11	B
(	O
T	O
)	O
and	O
E-112	B
(	O
T	O
)	O
from	O
Anoxybacillus	O
species	O
with	O
validly	O
published	O
names	O
.	O

Strains	O
T-11	B
(	O
T	O
)	O
and	O
E-112	B
(	O
T	O
)	O
therefore	O
represent	O
two	O
novel	O
species	O
,	O
for	O
which	O
the	O
names	O
Anoxybacillus	B
tengchongensis	I
sp.	O
nov.	O
(	O
type	O
strain	O
T-11	B
(	O
T	O
)	O
=	O
CCTCC	O
AB209237	O
(	O
T	O
)	O
=	O
KCTC	O
13721	O
(	O
T	O
)	O
)	O
and	O
Anoxybacillus	B
eryuanensis	I
sp.	O
nov.	O
(	O
type	O
strain	O
E-112	B
(	O
T	O
)	O
=	O
CCTCC	O
AB209236	O
(	O
T	O
)	O
=	O
KCTC	O
13720	O
(	O
T	O
)	O
)	O
are	O
proposed	O
.	O

Complete	O
genome	O
sequence	O
of	O
Burkholderia	B
rhizoxinica	I
,	O
an	O
Endosymbiont	O
of	O
Rhizopus	B
microsporus	I
.	O

Burkholderia	B
rhizoxinica	I
is	O
an	O
intracellular	O
symbiont	O
of	O
the	O
phytopathogenic	O
fungus	O
Rhizopus	B
microsporus	I
.	O

The	O
vertically	O
transmitted	O
endosymbiont	O
not	O
only	O
delivers	O
the	O
antimitotic	O
macrolide	O
rhizoxin	O
to	O
its	O
host	O
but	O
is	O
also	O
essential	O
for	O
vegetative	O
spore	O
formation	O
of	O
the	O
fungus	O
.	O

To	O
shed	O
light	O
on	O
the	O
genetic	O
equipment	O
of	O
this	O
model	O
organism	O
,	O
we	O
sequenced	O
the	O
whole	O
genome	O
of	O
B.	B
rhizoxinica	I
HKI	I
0454	I
,	O
thus	O
providing	O
the	O
first	O
genomic	O
insight	O
into	O
an	O
intracellular	O
mutualist	O
of	O
a	O
fungal	O
species	O
.	O

The	O
3.75-Mb	O
genome	O
consists	O
of	O
a	O
chromosome	O
and	O
two	O
strain	O
-	O
specific	O
plasmids	O
.	O

The	O
primary	O
metabolism	O
appears	O
to	O
be	O
specialized	O
for	O
the	O
uptake	O
of	O
fungal	O
metabolites	O
.	O

Besides	O
the	O
rhizoxin	O
biosynthesis	O
gene	O
cluster	O
,	O
there	O
are	O
14	O
loci	O
coding	O
for	O
nonribosomal	O
peptide	O
synthetase	O
(	O
NRPS	O
)	O
assembly	O
lines	O
,	O
which	O
represent	O
novel	O
targets	O
for	O
genomic	O
mining	O
of	O
cryptic	O
natural	O
products	O
.	O

Furthermore	O
,	O
the	O
endosymbionts	O
are	O
equipped	O
with	O
a	O
repertoire	O
of	O
virulence	O
-	O
related	O
factors	O
,	O
which	O
can	O
now	O
be	O
studied	O
to	O
elucidate	O
molecular	O
mechanisms	O
underlying	O
bacterial	O
-	O
fungal	O
interaction	O
.	O

R5	O
HIV	B
env	O
and	O
vesicular	B
stomatitis	I
virus	I
G	O
protein	O
cooperate	O
to	O
mediate	O
fusion	O
to	O
naive	O
CD4	O
+	O
T	O
Cells	O
.	O

Naive	O
CD4	O
(	O
4	O
)	O
T	O
cells	O
are	O
resistant	O
to	O
both	O
HIV	B
R5	O
env	O
and	O
vesicular	B
stomatitis	I
virus	I
G	O
protein	O
(	O
VSV	B
-	O
G	O
)	O
-mediated	O
fusion	O
.	O

However	O
,	O
viral	B
particles	O
carrying	O
both	O
HIV	B
R5	O
env	O
and	O
VSV	B
-	O
G	O
infect	O
naive	O
cells	O
by	O
an	O
unexplained	O
mechanism	O
.	O

We	O
show	O
that	O
VSV	B
-	O
G	O
-	O
pseudotyped	O
virus	B
can	O
not	O
fuse	O
to	O
unstimulated	O
cells	O
because	O
the	O
viral	B
particles	O
can	O
not	O
be	O
endocytosed	O
.	O

However	O
,	O
virions	O
carrying	O
both	O
HIV	B
R5	O
env	O
and	O
VSV	B
-	O
G	O
can	O
fuse	O
because	O
CD4	O
binding	O
allows	O
viral	B
uptake	O
.	O

Our	O
findings	O
reveal	O
a	O
unique	O
mechanism	O
by	O
which	O
R5	O
HIV	B
env	O
and	O
VSV	B
-	O
G	O
cooperate	O
to	O
allow	O
entry	O
to	O
naive	O
CD4	O
(	O
+	O
)	O
T	O
cells	O
,	O
providing	O
a	O
tool	O
to	O
target	O
naive	O
CD4	O
(	O
+	O
)	O
T	O
cells	O
with	O
R5	O
HIV	B
to	O
study	O
HIV	B
coreceptor	O
signaling	O
and	O
latency	O
.	O

The	O
alphaherpesvirus	O
US3	O
/	O
ORF66	O
protein	O
kinases	O
direct	O
phosphorylation	O
of	O
the	O
nuclear	O
matrix	O
protein	O
matrin	O
3	O
.	O

The	O
protein	O
kinase	O
found	O
in	O
the	O
short	O
region	O
of	O
alphaherpesviruses	O
,	O
termed	O
US3	O
in	O
herpes	B
simplex	I
virus	I
type	I
1	O
(	O
HSV-1	B
)	O
and	O
pseudorabies	B
virus	I
(	O
PRV	B
)	O
and	O
ORF66	O
in	O
varicella	B
-	I
zoster	I
virus	I
(	O
VZV	B
)	O
,	O
affects	O
several	O
viral	O
and	O
host	O
cell	O
processes	O
,	O
and	O
its	O
specific	O
targets	O
remain	O
an	O
area	O
of	O
active	O
investigation	O
.	O

Reports	O
suggesting	O
that	O
HSV-1	B
US3	O
substrates	O
overlap	O
with	O
those	O
of	O
cellular	O
protein	O
kinase	O
A	O
(	O
PKA	O
)	O
prompted	O
the	O
use	O
of	O
an	O
antibody	O
specific	O
for	O
phosphorylated	O
PKA	O
substrates	O
to	O
identify	O
US3	O
/	O
ORF66	O
targets	O
.	O

HSV-1	B
,	O
VZV	B
,	O
and	O
PRV	B
induced	O
very	O
different	O
substrate	O
profiles	O
that	O
were	O
US3	O
/	O
ORF66	O
kinase	O
dependent	O
.	O

The	O
predominant	O
VZV	B
-	O
phosphorylated	O
125-kDa	O
species	O
was	O
identified	O
as	O
matrin	O
3	O
,	O
one	O
of	O
the	O
major	O
nuclear	O
matrix	O
proteins	O
.	O

Matrin	O
3	O
was	O
also	O
phosphorylated	O
by	O
HSV-1	B
and	O
PRV	B
in	O
a	O
US3	O
kinase	O
-	O
dependent	O
manner	O
and	O
by	O
VZV	B
ORF66	O
kinase	O
at	O
a	O
novel	O
residue	O
(	O
KRRRT150EE	O
)	O
.	O

Since	O
VZV	B
-	O
directed	O
T150	O
phosphorylation	O
was	O
not	O
blocked	O
by	O
PKA	O
inhibitors	O
and	O
was	O
not	O
induced	O
by	O
PKA	O
activation	O
,	O
and	O
since	O
PKA	O
predominantly	O
targeted	O
matrin	O
3	O
S188	O
,	O
it	O
was	O
concluded	O
that	O
phosphorylation	O
by	O
VZV	B
was	O
PKA	O
independent	O
.	O

However	O
,	O
purified	O
VZV	B
ORF66	O
kinase	O
did	O
not	O
phosphorylate	O
matrin	O
3	O
in	O
vitro	O
,	O
suggesting	O
that	O
additional	O
cellular	O
factors	O
were	O
required	O
.	O

In	O
VZV	B
-	O
infected	O
cells	O
in	O
the	O
absence	O
of	O
the	O
ORF66	O
kinase	O
,	O
matrin	O
3	O
displayed	O
intranuclear	O
changes	O
,	O
while	O
matrin	O
3	O
showed	O
a	O
pronounced	O
cytoplasmic	O
distribution	O
in	O
late	O
-	O
stage	O
cells	O
infected	O
with	O
US3-negative	O
HSV-1	B
or	O
PRV	B
.	O

This	O
work	O
identifies	O
phosphorylation	O
of	O
the	O
nuclear	O
matrix	O
protein	O
matrin	O
3	O
as	O
a	O
new	O
conserved	O
target	O
of	O
this	O
kinase	O
group	O
.	O

Persistent	O
Friend	B
virus	I
replication	O
and	O
disease	O
in	O
Apobec3-deficient	O
mice	B
expressing	O
functional	O
B	O
-	O
cell	O
-	O
activating	O
factor	O
receptor	O
.	O

Rfv3	O
is	O
an	O
autosomal	O
dominant	O
gene	O
that	O
influences	O
the	O
recovery	O
of	O
resistant	O
mice	B
from	O
Friend	B
retrovirus	I
(	O
FV	B
)	O
infection	O
by	O
limiting	O
viremia	O
and	O
promoting	O
a	O
more	O
potent	O
neutralizing	O
antibody	O
response	O
.	O

We	O
previously	O
reported	O
that	O
Rfv3	O
is	O
encoded	O
by	O
Apobec3	O
,	O
an	O
innate	O
retrovirus	O
restriction	O
factor	O
.	O

However	O
,	O
it	O
was	O
recently	O
suggested	O
that	O
the	O
Rfv3	O
susceptible	O
phenotype	O
of	O
high	O
viremia	O
at	O
28	O
days	O
postinfection	O
(	O
dpi	O
)	O
was	O
more	O
dominantly	O
controlled	O
by	O
the	O
B	O
-	O
cell	O
-	O
activating	O
factor	O
receptor	O
(	O
BAFF	O
-	O
R	O
)	O
,	O
a	O
gene	O
that	O
is	O
linked	O
to	O
but	O
located	O
outside	O
the	O
genetically	O
mapped	O
region	O
containing	O
Rfv3	O
.	O

Although	O
one	O
prototypical	O
Rfv3	O
susceptible	O
mouse	B
strain	O
,	O
A	O
/	O
WySn	O
,	O
indeed	O
contains	O
a	O
dysfunctional	O
BAFF	O
-	O
R	O
,	O
two	O
other	O
Rfv3	O
susceptible	O
strains	O
,	O
BALB	O
/	O
c	O
and	O
A.BY	O
,	O
express	O
functional	O
BAFF	O
-	O
R	O
genes	O
,	O
determined	O
on	O
the	O
basis	O
of	O
genotyping	O
and	O
B	O
-	O
cell	O
immunophenotyping	O
.	O

Furthermore	O
,	O
transcomplementation	O
studies	O
in	O
(	O
C57BL	O
/	O
6	O
[	O
B6	O
]	O
x	O
BALB	O
/	O
c	O
)	O
F	O
(	O
1	O
)	O
and	O
(	O
B6	O
x	O
A.BY	O
)	O
F	O
(	O
1	O
)	O
mice	B
revealed	O
that	O
the	O
B6	O
Apobec3	O
gene	O
significantly	O
influences	O
recovery	O
from	O
FV	B
viremia	O
,	O
cellular	O
infection	O
,	O
and	O
disease	O
at	O
28	O
dpi	O
.	O

Finally	O
,	O
the	O
Rfv3	O
phenotypes	O
of	O
prototypic	O
B6	O
,	O
A.BY	O
,	O
A	O
/	O
WySn	O
,	O
and	O
BALB	O
/	O
c	O
mouse	B
strains	O
correlate	O
with	O
reported	O
Apobec3	O
mRNA	O
expression	O
levels	O
.	O

Overall	O
,	O
these	O
findings	O
argue	O
against	O
the	O
generality	O
of	O
BAFF	O
-	O
R	O
polymorphisms	O
as	O
a	O
dominant	O
mechanism	O
to	O
explain	O
the	O
Rfv3	O
recovery	O
phenotype	O
and	O
further	O
strengthen	O
the	O
evidence	O
that	O
Apobec3	O
encodes	O
Rfv3	O
.	O

Pterin	O
-	O
based	O
ornamental	O
coloration	O
predicts	O
yolk	O
antioxidant	O
levels	O
in	O
female	O
striped	B
plateau	I
lizards	I
(	O
Sceloporus	B
virgatus	I
)	O
.	O

1	O
.	O

Maternal	O
investment	O
in	O
egg	O
quality	O
can	O
have	O
important	O
consequences	O
for	O
offspring	O
fitness	O
.	O

For	O
example	O
,	O
yolk	O
antioxidants	O
can	O
affect	O
embryonic	O
development	O
as	O
well	O
as	O
juvenile	O
and	O
adult	O
phenotype	O
.	O

Thus	O
,	O
females	O
may	O
be	O
selected	O
to	O
advertise	O
their	O
yolk	O
antioxidant	O
deposition	O
to	O
discriminatory	O
males	O
via	O
ornamental	O
signals	O
,	O
perhaps	O
depending	O
on	O
the	O
reproductive	O
costs	O
associated	O
with	O
signal	O
production	O
.	O

2	O
.	O

Female	O
striped	B
plateau	I
lizards	I
(	O
Sceloporus	B
virgatus	I
)	O
develop	O
pterin	O
-	O
based	O
orange	O
colour	O
patches	O
during	O
the	O
reproductive	O
season	O
that	O
influence	O
male	O
behaviour	O
and	O
that	O
are	O
positively	O
associated	O
with	O
the	O
phenotypic	O
quality	O
of	O
the	O
female	O
and	O
her	O
offspring	O
.	O

Here	O
,	O
we	O
assessed	O
one	O
potential	O
developmental	O
mechanism	O
underlying	O
the	O
relationship	O
between	O
offspring	O
quality	O
and	O
female	O
ornamentation	O
in	O
S.	B
virgatus	I
,	O
by	O
examining	O
the	O
relationship	O
between	O
ornament	O
expression	O
and	O
yolk	O
antioxidant	O
levels	O
.	O

3	O
.	O

As	O
expected	O
,	O
concentrations	O
of	O
the	O
yolk	O
antioxidants	O
vitamin	O
A	O
,	O
vitamin	O
E	O
and	O
carotenoids	O
(	O
lutein	O
and	O
zeaxanthin	O
)	O
were	O
strongly	O
positively	O
intercorrelated	O
.	O

Eggs	O
from	O
larger	O
clutches	O
had	O
fewer	O
antioxidants	O
than	O
eggs	O
from	O
smaller	O
clutches	O
,	O
suggesting	O
that	O
females	O
may	O
be	O
limited	O
in	O
antioxidant	O
availability	O
or	O
use	O
.	O

Fertilized	O
and	O
unfertilized	O
eggs	O
did	O
not	O
differ	O
in	O
yolk	O
antioxidant	O
levels	O
.	O

4	O
.	O

The	O
size	O
of	O
a	O
female	O
's	O
ornament	O
was	O
positively	O
related	O
to	O
both	O
the	O
concentration	O
and	O
total	O
amount	O
of	O
yolk	O
antioxidants	O
,	O
and	O
ornament	O
colour	O
was	O
positively	O
related	O
to	O
yolk	O
antioxidant	O
concentration	O
.	O

Thus	O
,	O
in	O
S.	B
virgatus	I
,	O
female	O
ornaments	O
may	O
advertise	O
egg	O
quality	O
.	O

In	O
addition	O
,	O
these	O
data	O
suggest	O
that	O
more	O
ornamented	O
females	O
may	O
produce	O
higher	O
-	O
quality	O
offspring	O
,	O
in	O
part	O
because	O
their	O
eggs	O
contain	O
more	O
antioxidants	O
.	O

As	O
the	O
colour	O
ornament	O
of	O
interest	O
is	O
derived	O
from	O
pterins	O
,	O
not	O
carotenoids	O
,	O
direct	O
resource	O
trade	O
-	O
offs	O
between	O
ornaments	O
and	O
eggs	O
may	O
be	O
eliminated	O
,	O
reducing	O
reproductive	O
costs	O
associated	O
with	O
signalling	O
.	O

5	O
.	O

This	O
is	O
the	O
first	O
example	O
of	O
a	O
positive	O
relationship	O
between	O
female	O
ornamentation	O
and	O
yolk	O
antioxidants	O
in	O
reptiles	O
and	O
may	O
indicate	O
the	O
general	O
importance	O
of	O
these	O
patterns	O
in	O
oviparous	O
vertebrates	O
.	O

The	O
contribution	O
of	O
the	O
S	O
-	O
phase	O
checkpoint	O
genes	O
MEC1	O
and	O
SGS1	O
to	O
genome	O
stability	O
maintenance	O
in	O
Candida	B
albicans	I
.	O

Genome	O
rearrangements	O
,	O
a	O
common	O
feature	O
of	O
Candida	B
albicans	I
isolates	O
,	O
are	O
often	O
associated	O
with	O
the	O
acquisition	O
of	O
antifungal	O
drug	O
resistance	O
.	O

In	O
Saccharomyces	B
cerevisiae	I
,	O
perturbations	O
in	O
the	O
S	O
-	O
phase	O
checkpoints	O
result	O
in	O
the	O
same	O
sort	O
of	O
Gross	O
Chromosomal	O
Rearrangements	O
(	O
GCRs	O
)	O
observed	O
in	O
C.	B
albicans	I
.	O

Several	O
proteins	O
are	O
involved	O
in	O
the	O
S.	B
cerevisiae	I
cell	O
cycle	O
checkpoints	O
,	O
including	O
Mec1p	O
,	O
a	O
protein	O
kinase	O
of	O
the	O
PIKK	O
(	O
phosphatidyl	O
inositol	O
3-kinase	O
-	O
like	O
kinase	O
)	O
family	O
and	O
the	O
central	O
player	O
in	O
the	O
DNA	O
damage	O
checkpoint	O
.	O

Sgs1p	O
,	O
the	O
ortholog	O
of	O
BLM	O
,	O
the	O
Bloom	O
's	O
syndrome	O
gene	O
,	O
is	O
a	O
RecQ	O
-	O
related	O
DNA	O
helicase	O
;	O
cells	O
from	O
BLM	O
patients	O
are	O
characterized	O
by	O
an	O
increase	O
in	O
genome	O
instability	O
.	O

Yeast	B
strains	O
bearing	O
deletions	O
in	O
MEC1	O
or	O
SGS1	O
are	O
viable	O
(	O
in	O
contrast	O
to	O
the	O
inviability	O
seen	O
with	O
loss	O
of	O
MEC1	O
in	O
S.	B
cerevisiae	I
)	O
but	O
the	O
different	O
deletion	O
mutants	O
have	O
significantly	O
different	O
phenotypes	O
.	O

The	O
mec1Delta	O
/	O
Delta	O
colonies	O
have	O
a	O
wild	O
-	O
type	O
colony	O
morphology	O
,	O
while	O
the	O
sgs1Delta	O
/	O
Delta	O
mutants	O
are	O
slow	O
-	O
growing	O
,	O
producing	O
wrinkled	O
colonies	O
with	O
pseudohyphal	O
-	O
like	O
cells	O
.	O

The	O
mec1Delta	O
/	O
Delta	O
mutants	O
are	O
only	O
sensitive	O
to	O
ethylmethane	O
sulfonate	O
(	O
EMS	O
)	O
,	O
methylmethane	O
sulfonate	O
(	O
MMS	O
)	O
,	O
and	O
hydroxyurea	O
(	O
HU	O
)	O
but	O
the	O
sgs1Delta	O
/	O
Delta	O
mutants	O
exhibit	O
a	O
high	O
sensitivity	O
to	O
all	O
DNA	O
-	O
damaging	O
agents	O
tested	O
.	O

In	O
an	O
assay	O
for	O
chromosome	O
1	O
integrity	O
,	O
the	O
mec1Delta	O
/	O
Delta	O
mutants	O
exhibit	O
an	O
increase	O
in	O
genome	O
instability	O
;	O
no	O
change	O
was	O
observed	O
in	O
the	O
sgs1Delta	O
/	O
Delta	O
mutants	O
.	O

Finally	O
,	O
loss	O
of	O
MEC1	O
does	O
not	O
affect	O
sensitivity	O
to	O
the	O
antifungal	O
drug	O
fluconazole	O
,	O
while	O
loss	O
of	O
SGS1	O
leads	O
to	O
an	O
increased	O
susceptibility	O
to	O
fluconazole	O
.	O

Neither	O
deletion	O
elevated	O
the	O
level	O
of	O
antifungal	O
drug	O
resistance	O
acquisition	O
.	O

Statistical	O
methods	O
We	O
analyzed	O
correlations	O
between	O
categorical	O
variables	O
using	O
the	O
χ2	O
or	O
Fisher	O
's	O
exact	O
test	O
.	O

We	O
used	O
analysis	O
of	O
variance	O
to	O
study	O
correlations	O
between	O
continuous	O
and	O
categorical	O
variables	O
,	O
and	O
simple	O
regression	O
to	O
analyze	O
correlations	O
between	O
continuous	O
variables	O
.	O

p53	O
mutation	O
is	O
strongly	O
associated	O
with	O
Type	O
A	O
MSI	O
in	O
human	O
colorectal	O
cancer	O
One	O
view	O
of	O
the	O
involvement	O
of	O
MMR	O
defects	O
in	O
cancer	O
development	O
is	O
that	O
the	O
'	O
microsatellite	O
mutator	O
phenotype	O
(	O
MMP	O
)	O
'	O
(	O
29,30	O
)	O
in	O
mismatch	O
repair	O
-	O
defective	O
cells	O
offers	O
an	O
alternative	O
to	O
chromosomal	O
instability	O
as	O
a	O
mechanism	O
for	O
genetic	O
instability	O
in	O
cancer	O
(	O
31	O
)	O
.	O

On	O
this	O
model	O
,	O
MSI	O
and	O
chromosomal	O
instability	O
represent	O
mutually	O
exclusive	O
pathways	O
of	O
tumour	O
development	O
.	O

This	O
reasoning	O
is	O
based	O
partly	O
in	O
the	O
observation	O
that	O
p53	O
mutations	O
,	O
commonly	O
associated	O
with	O
chromosomal	O
instability	O
,	O
are	O
infrequent	O
among	O
MSI+	O
tumours	O
(	O
2,32–34	O
)	O
.	O

To	O
examine	O
the	O
relationship	O
between	O
Type	O
A	O
/	O
B	O
instability	O
and	O
p53	O
mutation	O
,	O
we	O
sequenced	O
the	O
p53	O
gene	O
in	O
our	O
panel	O
of	O
79	O
colorectal	O
tumours	O
.	O

p53	O
mutations	O
resulting	O
in	O
an	O
amino	O
acid	O
substitution	O
were	O
detected	O
in	O
23	O
tumours	O
(	O
29.1	O
%	O
)	O
.	O

The	O
mutations	O
were	O
predominantly	O
transitions	O
in	O
acknowledged	O
hot	O
spots	O
;	O
codons	O
175	O
,	O
248	O
and	O
273	O
(	O
Table	O
2	O
)	O
.	O

Of	O
the	O
p53	O
mutations	O
that	O
were	O
found	O
in	O
MSI+	O
tumours	O
,	O
all	O
were	O
associated	O
with	O
Type	O
A	O
MSI	O
(	O
Tables	O
2	O
and	O
3	O
)	O
.	O

No	O
p53	O
mutations	O
were	O
detected	O
among	O
the	O
14	O
Type	O
B	O
tumours	O
.	O

Among	O
Type	O
A	O
tumours	O
,	O
the	O
frequency	O
of	O
p53	O
mutation	O
approached	O
50	O
%	O
(	O
12	O
/	O
25	O
)	O
.	O

These	O
findings	O
confirm	O
that	O
p53	O
mutations	O
are	O
rare	O
in	O
tumours	O
with	O
Type	O
B	O
MSI	O
.	O

More	O
importantly	O
,	O
they	O
suggest	O
that	O
,	O
in	O
contrast	O
to	O
prevailing	O
opinion	O
,	O
defective	O
MMR	O
is	O
significantly	O
associated	O
with	O
p53	O
mutation	O
,	O
at	O
least	O
in	O
human	O
colorectal	O
cancer	O
.	O

Discussion	O
The	O
exact	O
identities	O
and	O
numbers	O
of	O
mutations	O
required	O
for	O
transformation	O
are	O
uncertain	O
.	O

With	O
simple	O
multistage	O
models	O
[	O
3	O
-	O
6,11	O
]	O
,	O
all	O
cancers	O
of	O
a	O
given	O
type	O
require	O
the	O
same	O
number	O
of	O
oncogenic	O
mutations	O
,	O
but	O
stochastic	O
differences	O
in	O
the	O
times	O
to	O
accumulate	O
these	O
mutations	O
allow	O
individual	O
cancers	O
to	O
appear	O
at	O
different	O
ages	O
.	O

Precisely	O
when	O
and	O
how	O
quickly	O
mutations	O
accumulate	O
are	O
unknown	O
,	O
but	O
a	O
basic	O
premise	O
is	O
that	O
cancer	O
types	O
requiring	O
more	O
mutations	O
will	O
tend	O
to	O
appear	O
later	O
in	O
life	O
.	O

Therefore	O
,	O
numbers	O
of	O
mutations	O
may	O
be	O
estimated	O
from	O
cancer	O
epidemiology	O
.	O

Colorectal	O
cancer	O
frequencies	O
increase	O
with	O
age	O
,	O
and	O
the	O
pattern	O
of	O
this	O
increase	O
is	O
consistent	O
with	O
approximately	O
five	O
to	O
seven	O
oncogenic	O
mutations	O
[	O
3	O
-	O
6	O
]	O
.	O

In	O
this	O
study	O
numbers	O
of	O
mutations	O
were	O
estimated	O
for	O
well	O
-	O
defined	O
subgroups	O
of	O
colorectal	O
cancers	O
because	O
biological	O
heterogeneity	O
may	O
confound	O
this	O
type	O
of	O
quantitative	O
analysis	O
.	O

Such	O
estimates	O
should	O
be	O
considered	O
rough	O
guides	O
rather	O
than	O
absolute	O
values	O
because	O
our	O
model	O
does	O
not	O
account	O
for	O
all	O
factors	O
.	O

Cancers	O
were	O
classified	O
as	O
MSI+	O
or	O
MSI-	O
,	O
and	O
MSI+	O
cancers	O
were	O
further	O
sub	O
-	O
classified	O
as	O
either	O
hereditary	O
(	O
HNPCC	O
)	O
or	O
sporadic	O
.	O

As	O
expected	O
because	O
one	O
MMR	O
mutation	O
is	O
inherited	O
,	O
estimated	O
numbers	O
of	O
critical	O
mutations	O
were	O
less	O
for	O
MSI+	O
HNPCC	O
cancers	O
compared	O
to	O
sporadic	O
MSI+	O
cancers	O
.	O

However	O
,	O
sporadic	O
MSI+	O
cancers	O
required	O
more	O
than	O
one	O
additional	O
somatic	O
mutation	O
compared	O
to	O
HNPCC	O
cancers	O
.	O

Of	O
interest	O
,	O
a	O
difference	O
of	O
more	O
than	O
a	O
single	O
mutation	O
has	O
also	O
been	O
inferred	O
between	O
sporadic	O
and	O
FAP	O
cancers	O
,	O
with	O
estimates	O
of	O
three	O
to	O
four	O
mutations	O
for	O
FAP	O
cancers	O
versus	O
six	O
for	O
sporadic	O
cancers	O
[	O
6,13	O
]	O
,	O
although	O
another	O
analysis	O
was	O
consistent	O
with	O
a	O
difference	O
of	O
only	O
a	O
single	O
mutation	O
[	O
14	O
]	O
.	O

Therefore	O
,	O
germline	O
mutations	O
(	O
APC	O
and	O
MMR	O
loci	O
)	O
in	O
both	O
common	O
colorectal	O
familial	O
cancer	O
syndromes	O
(	O
FAP	O
and	O
HNPCC	O
)	O
appear	O
to	O
advance	O
progression	O
by	O
more	O
than	O
a	O
single	O
mutation	O
relative	O
to	O
their	O
sporadic	O
counterparts	O
.	O

An	O
epigenetic	O
mechanism	O
may	O
help	O
explain	O
why	O
sporadic	O
MSI+	O
cancers	O
require	O
more	O
than	O
one	O
additional	O
somatic	O
alteration	O
relative	O
to	O
HNPCC	O
cancers	O
.	O

Inactivation	O
of	O
the	O
normal	O
MMR	O
allele	O
occurs	O
through	O
mutation	O
(	O
usually	O
LOH	O
[	O
15	O
]	O
)	O
in	O
HNPCC	O
whereas	O
MMR	O
loss	O
in	O
sporadic	O
MSI+	O
cancers	O
is	O
associated	O
with	O
MLH1	O
promoter	O
methylation	O
[	O
16,17	O
]	O
.	O

CpG	O
islands	O
may	O
be	O
"	O
protected	O
"	O
from	O
methylation	O
because	O
most	O
are	O
unmethylated	O
at	O
birth	O
and	O
usually	O
remain	O
unmethylated	O
throughout	O
life	O
[	O
18	O
]	O
.	O

Epigenetic	O
MLH1	O
inactivation	O
may	O
require	O
at	O
least	O
two	O
cis	O
acting	O
somatic	O
alterations	O
---	O
loss	O
of	O
a	O
mechanism	O
that	O
normally	O
prevents	O
methylation	O
,	O
followed	O
by	O
the	O
accumulation	O
of	O
methylation	O
at	O
sufficient	O
numbers	O
of	O
CpG	O
sites	O
to	O
silence	O
expression	O
.	O

In	O
agreement	O
with	O
prior	O
studies	O
,	O
there	O
were	O
seven	O
mutations	O
estimated	O
for	O
sporadic	O
MSI-	O
Finnish	O
cancers	O
[	O
4	O
]	O
,	O
and	O
seven	O
or	O
eight	O
mutations	O
for	O
MSI+	O
cancers	O
.	O

A	O
requirement	O
for	O
more	O
alterations	O
before	O
tranformation	O
for	O
sporadic	O
MSI+	O
compared	O
to	O
sporadic	O
MSI-	O
cancers	O
may	O
help	O
explain	O
why	O
sporadic	O
MSI+	O
cancers	O
are	O
a	O
minority	O
of	O
all	O
colorectal	O
cancers	O
and	O
occur	O
in	O
slightly	O
older	O
patients	O
[	O
19,20	O
]	O
.	O

Although	O
numbers	O
of	O
oncogenic	O
mutations	O
before	O
transformation	O
are	O
similar	O
between	O
sporadic	O
MSI+	O
and	O
MSI-	O
cancers	O
,	O
their	O
identities	O
likely	O
differ	O
[	O
7,8	O
]	O
.	O

Discussion	O
In	O
this	O
study	O
,	O
the	O
occurrence	O
of	O
mutations	O
in	O
the	O
APC	O
,	O
CTNNB1	O
and	O
K	O
-	O
ras	O
genes	O
as	O
well	O
as	O
expression	O
of	O
the	O
hMLH1	O
protein	O
in	O
tumour	O
tissue	O
of	O
656	O
sporadic	O
colorectal	O
cancer	O
cases	O
were	O
investigated	O
.	O

The	O
occurrence	O
of	O
mutations	O
in	O
the	O
CTNNB1	O
gene	O
,	O
which	O
codes	O
for	O
β	O
-	O
catenin	O
,	O
was	O
rare	O
:	O
only	O
five	O
of	O
464	O
tumours	O
analysed	O
were	O
found	O
to	O
have	O
a	O
mutation	O
at	O
one	O
of	O
the	O
phosphorylation	O
sites	O
in	O
exon	O
3	O
.	O

Truncating	O
mutations	O
in	O
APC	O
and	O
activating	O
mutations	O
in	O
K	O
-	O
ras	O
appeared	O
to	O
occur	O
at	O
similar	O
frequencies	O
.	O

Although	O
tumours	O
harbouring	O
both	O
mutations	O
were	O
relatively	O
rare	O
,	O
mutations	O
in	O
APC	O
and	O
K	O
-	O
ras	O
seemed	O
to	O
occur	O
co	O
-	O
dependently	O
.	O

Nine	O
percent	O
of	O
all	O
tumours	O
(	O
58	O
/	O
656	O
)	O
lacked	O
hMLH1	O
expression	O
,	O
and	O
in	O
these	O
tumours	O
almost	O
no	O
APC	O
or	O
K	O
-	O
ras	O
mutations	O
was	O
detected	O
.	O

Patients	O
harbouring	O
a	O
tumour	O
with	O
absent	O
hMLH1	O
expression	O
were	O
older	O
,	O
more	O
often	O
women	O
,	O
more	O
often	O
had	O
proximal	O
colon	O
tumours	O
that	O
showed	O
poorer	O
differentiation	O
when	O
compared	O
to	O
patients	O
who	O
harboured	O
a	O
tumour	O
with	O
an	O
APC	O
and/or	O
K	O
-	O
ras	O
mutation	O
.	O

The	O
selection	O
of	O
patients	O
included	O
in	O
this	O
study	O
was	O
based	O
on	O
the	O
completeness	O
of	O
analyses	O
of	O
both	O
APC	O
and	O
K	O
-	O
ras	O
genes	O
as	O
well	O
as	O
hMLH1	O
expression	O
and	O
this	O
led	O
to	O
a	O
considerable	O
reduction	O
in	O
the	O
number	O
of	O
cases	O
that	O
could	O
be	O
included	O
in	O
the	O
analyses	O
presented	O
in	O
this	O
study	O
.	O

The	O
largest	O
reduction	O
(	O
72	O
cases	O
)	O
was	O
due	O
to	O
incompleteness	O
of	O
the	O
analysis	O
of	O
all	O
fragments	O
comprising	O
the	O
APC	O
mutation	O
cluster	O
region	O
.	O

Tumour	O
DNA	O
was	O
derived	O
from	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tumour	O
tissue	O
blocks	O
.	O

Depending	O
on	O
the	O
conditions	O
of	O
fixation	O
and	O
storage	O
,	O
the	O
extracted	O
DNA	O
is	O
more	O
or	O
less	O
fragmented	O
,	O
which	O
may	O
have	O
impaired	O
the	O
analysis	O
of	O
mutations	O
in	O
the	O
APC	O
gene	O
more	O
than	O
in	O
the	O
K	O
-	O
ras	O
gene	O
,	O
since	O
the	O
analysis	O
of	O
the	O
latter	O
is	O
based	O
on	O
the	O
amplification	O
of	O
a	O
smaller	O
gene	O
fragment	O
.	O

It	O
should	O
be	O
emphasized	O
that	O
characteristics	O
of	O
patients	O
(	O
age	O
,	O
sex	O
,	O
family	O
history	O
of	O
colorectal	O
cancer	O
)	O
and	O
tumours	O
(	O
sub	O
-	O
localisation	O
,	O
Dukes	O
'	O
stage	O
and	O
differentiation	O
)	O
of	O
the	O
group	O
under	O
study	O
are	O
similar	O
to	O
the	O
737	O
patients	O
for	O
whom	O
tumour	O
material	O
was	O
available	O
and	O
to	O
all	O
819	O
patients	O
initially	O
recognized	O
within	O
the	O
cohort	O
(	O
data	O
not	O
shown	O
)	O
.	O

Moreover	O
,	O
the	O
K	O
-	O
ras	O
and	O
hMLH1data	O
presented	O
here	O
are	O
similar	O
to	O
the	O
data	O
for	O
K	O
-	O
ras	O
and	O
hMLH1	O
based	O
on	O
the	O
complete	O
groups	O
(	O
737	O
and	O
724	O
cases	O
,	O
respectively	O
)	O
(	O
data	O
not	O
shown	O
)	O
.	O

Mutations	O
in	O
exon	O
3	O
of	O
the	O
CTNNB1	O
gene	O
leading	O
to	O
loss	O
of	O
one	O
of	O
the	O
phosphorylation	O
sites	O
were	O
rare	O
.	O

Strikingly	O
,	O
all	O
five	O
of	O
these	O
mutations	O
occurred	O
in	O
the	O
proximal	O
colon	O
and	O
three	O
of	O
these	O
also	O
had	O
absent	O
hMLH1	O
expression	O
.	O

This	O
may	O
indicate	O
that	O
these	O
proximal	O
colon	O
tumours	O
,	O
which	O
often	O
also	O
show	O
mismatch	O
repair	O
deficiency	O
,	O
are	O
more	O
likely	O
to	O
harbour	O
CTNNB1	O
mutations	O
.	O

This	O
was	O
also	O
found	O
in	O
a	O
study	O
of	O
microsatellite	O
instable	O
colorectal	O
tumours	O
[	O
26	O
]	O
.	O

The	O
WAVE	O
screening	O
technique	O
has	O
not	O
been	O
used	O
previously	O
for	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tissue	O
,	O
and	O
therefore	O
it	O
seems	O
plausible	O
that	O
samples	O
harbouring	O
a	O
CTNNB1	O
mutation	O
have	O
escaped	O
detection	O
.	O

However	O
,	O
all	O
58	O
hMLH1	O
deficient	O
samples	O
were	O
analysed	O
by	O
direct	O
sequencing	O
without	O
a	O
prior	O
screening	O
step	O
,	O
and	O
only	O
three	O
of	O
these	O
samples	O
harboured	O
a	O
CTNNB1	O
mutation	O
,	O
indicating	O
the	O
low	O
frequency	O
of	O
such	O
mutations	O
.	O

Background	O
Hereditary	O
non	O
-	O
polyposis	O
colorectal	O
cancer	O
(	O
HNPCC	O
)	O
is	O
an	O
inherited	O
syndrome	O
predisposing	O
to	O
the	O
early	O
development	O
of	O
cancers	O
of	O
colon	O
,	O
rectum	O
,	O
endometrium	O
,	O
ovarium	O
,	O
small	O
bowel	O
,	O
stomach	O
and	O
urinary	O
tract	O
[	O
1,2	O
]	O
.	O

Since	O
there	O
are	O
no	O
premonitory	O
signs	O
of	O
susceptibility	O
to	O
HNPCC	O
,	O
family	O
history	O
has	O
been	O
the	O
primary	O
method	O
for	O
identifying	O
patients	O
at	O
risk	O
.	O

Defined	O
by	O
the	O
International	O
Collaborative	O
group	O
on	O
HNPCC	O
,	O
the	O
typical	O
HNPCC	O
family	O
fulfill	O
the	O
following	O
criteria	O
(	O
referred	O
to	O
as	O
the	O
Amsterdam	O
-	O
I	O
criteria	O
[	O
3	O
]	O
)	O
:	O
1	O
.	O

Three	O
or	O
more	O
relatives	O
with	O
histologically	O
verified	O
colorectal	O
cancer	O
,	O
one	O
of	O
whom	O
is	O
a	O
first	O
-	O
degree	O
relative	O
of	O
the	O
other	O
two	O
;	O
2	O
.	O

Colorectal	O
cancer	O
affecting	O
at	O
least	O
2	O
successive	O
generations	O
;	O
and	O
3	O
.	O

At	O
least	O
one	O
relative	O
diagnosed	O
with	O
colorectal	O
cancer	O
under	O
the	O
age	O
of	O
50	O
.	O

The	O
fulfillment	O
of	O
these	O
criteria	O
prompted	O
further	O
genetics	O
investigations	O
.	O

More	O
recently	O
it	O
has	O
been	O
revised	O
to	O
take	O
into	O
account	O
the	O
prevalence	O
of	O
extracolonic	O
cancer	O
in	O
certain	O
HNPCC	O
families	O
[	O
4	O
]	O
.	O

This	O
autosomal	O
dominantly	O
inherited	O
disorder	O
is	O
caused	O
by	O
germline	O
mutations	O
in	O
genes	O
coding	O
proteins	O
responsible	O
for	O
the	O
repair	O
of	O
DNA	O
replication	O
errors	O
,	O
which	O
are	O
referred	O
to	O
as	O
DNA	O
mismatch	O
repair	O
(	O
MMR	O
)	O
genes	O
[	O
5	O
]	O
.	O

DNA	O
mismatch	O
repair	O
machinery	O
plays	O
a	O
critical	O
role	O
in	O
genomic	O
stability	O
,	O
including	O
correction	O
of	O
mispaired	O
bases	O
associated	O
with	O
DNA	O
replication	O
and	O
recombination	O
.	O

Germline	O
mutations	O
in	O
one	O
allele	O
of	O
any	O
of	O
these	O
genes	O
followed	O
by	O
the	O
somatic	O
loss	O
or	O
inactivation	O
of	O
the	O
wild	O
-	O
type	O
allele	O
leads	O
to	O
a	O
defective	O
mismatch	O
repair	O
mechanism	O
.	O

The	O
current	O
"	O
gold	O
standard	O
"	O
for	O
assessing	O
tumor	O
DNA	O
MMR	O
activity	O
is	O
molecular	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
testing	O
.	O

In	O
most	O
cases	O
,	O
it	O
involves	O
extracting	O
DNA	O
from	O
both	O
tumor	O
and	O
normal	O
tissue	O
.	O

The	O
DNA	O
is	O
subjected	O
to	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
of	O
five	O
or	O
more	O
different	O
chromosomal	O
loci	O
that	O
compare	O
"	O
microsatellites	O
"	O
,	O
running	O
the	O
PCR	O
products	O
through	O
a	O
gel	O
to	O
separate	O
DNA	O
fragments	O
by	O
size	O
,	O
comparing	O
the	O
tumor	O
-	O
normal	O
pairs	O
,	O
and	O
scoring	O
for	O
differences	O
between	O
the	O
two	O
.	O

Instability	O
at	O
two	O
or	O
more	O
out	O
of	O
five	O
markers	O
defines	O
a	O
tumor	O
as	O
MSI	O
-	O
H	O
and	O
prompts	O
further	O
analysis	O
,	O
as	O
sequencing	O
of	O
DNA	O
MMR	O
genes	O
.	O

A	O
number	O
of	O
them	O
have	O
been	O
associated	O
with	O
HNPCC	O
,	O
including	O
hMSH2	O
,	O
hMLH1	O
,	O
hPMS1	O
,	O
hPMS2	O
,	O
hMSH3	O
,	O
and	O
hMSH6	O
.	O

Most	O
of	O
the	O
HNPCC	O
families	O
in	O
which	O
mutations	O
have	O
been	O
identified	O
involved	O
hMSH2	O
and	O
hMLH1	O
genes	O
[	O
6	O
]	O
.	O

A	O
much	O
less	O
labor	O
-	O
intensive	O
alternative	O
method	O
used	O
to	O
prescreen	O
high	O
-	O
risk	O
individuals	O
for	O
further	O
germline	O
mutation	O
analysis	O
is	O
immunohistochemistry	O
(	O
IHC	O
)	O
testing	O
for	O
MLH1	O
and	O
MSH2	O
expression	O
.	O

IHC	O
testing	O
may	O
identify	O
which	O
gene	O
to	O
target	O
for	O
analysis	O
.	O

We	O
describe	O
MSI	O
testing	O
in	O
the	O
absence	O
of	O
proband	O
non	O
-	O
tumor	O
tissue	O
using	O
the	O
Bethesda	O
consensus	O
panel	O
(	O
mononucleotide	O
repeats	O
BAT25	O
and	O
BAT26	O
,	O
and	O
dinucleotide	O
repeats	O
D2S123	O
,	O
D5S346	O
,	O
and	O
D17S250	O
)	O
and	O
we	O
report	O
a	O
novel	O
hMSH2	O
germline	O
mutation	O
found	O
in	O
the	O
family	O
.	O

Microsatellite	O
instability	O
.	O

Three	O
of	O
five	O
microsatellite	O
markers	O
(	O
BAT-25	O
,	O
BAT-26	O
and	O
D5S346	O
)	O
presented	O
different	O
alleles	O
(	O
*	O
)	O
in	O
the	O
proband	O
's	O
primary	O
tumor	O
(	O
T	O
'	O
)	O
and	O
its	O
metastasis	O
(	O
T	O
"	O
)	O
of	O
those	O
inherited	O
from	O
his	O
biological	O
mother	O
(	O
BM	O
)	O
and	O
father	O
(	O
BF	O
)	O
.	O

DNA	O
sequencing	O
of	O
hMSH2	O
and	O
hMLH1	O
genes	O
A	O
second	O
blood	O
sample	O
was	O
obtained	O
from	O
the	O
proband	O
's	O
mother	O
and	O
forwarded	O
to	O
the	O
Department	O
of	O
Clinical	O
Cancer	O
Genetics	O
(	O
City	O
of	O
Hope	O
Cancer	O
Center	O
,	O
Duarte	O
,	O
California	O
,	O
USA	O
)	O
to	O
full	O
mutation	O
analysis	O
of	O
the	O
hMSH2	O
and	O
hMLH1	O
genes	O
.	O

The	O
sample	O
was	O
amplified	O
followed	O
by	O
direct	O
sequencing	O
to	O
screen	O
the	O
coding	O
regions	O
of	O
both	O
the	O
hMSH2	O
and	O
the	O
hMLH1	O
genes	O
for	O
germline	O
mutation	O
in	O
the	O
DNA	O
.	O

After	O
establishing	O
the	O
familial	O
mutation	O
in	O
the	O
proband	O
's	O
mother	O
,	O
located	O
in	O
the	O
exon	O
12	O
of	O
hMSH2	O
gene	O
,	O
it	O
was	O
searched	O
in	O
the	O
proband	O
's	O
sisters	O
by	O
direct	O
sequencing	O
using	O
a	O
manual	O
Sequenase	O
PCR	O
products	O
kit	O
(	O
Amersham	O
Biosciences	O
)	O
.	O

Mutation	O
screening	O
was	O
done	O
in	O
both	O
sisters	O
to	O
assign	O
their	O
risk	O
to	O
develop	O
HNPCC	O
and	O
other	O
related	O
cancers	O
.	O

We	O
found	O
the	O
mutation	O
in	O
one	O
of	O
them	O
and	O
opportune	O
recommendations	O
for	O
surveillance	O
and	O
prophylaxis	O
were	O
given	O
.	O

Two	O
years	O
after	O
that	O
,	O
the	O
proband	O
's	O
mother	O
,	O
unaffected	O
during	O
this	O
study	O
,	O
developed	O
an	O
endometrial	O
adenocarcinoma	O
.	O

Methods	O
Patients	O
25	O
colorectal	O
cancer	O
patients	O
undergoing	O
elective	O
standard	O
oncological	O
resection	O
at	O
the	O
department	O
of	O
surgery	O
,	O
Charité	O
,	O
Campus	O
Benjamin	O
Franklin	O
,	O
Berlin	O
,	O
Germany	O
were	O
prospectively	O
recruited	O
for	O
this	O
study	O
.	O

The	O
study	O
was	O
approved	O
by	O
the	O
local	O
ethical	O
committee	O
and	O
informed	O
consent	O
was	O
obtained	O
from	O
all	O
patients	O
.	O

Rectal	O
cancer	O
patients	O
receiving	O
neo	O
-	O
adjuvant	O
radiochemotherapy	O
were	O
excluded	O
from	O
this	O
study	O
.	O

Tissue	O
samples	O
and	O
UV	O
-	O
laser	O
microdissection	O
Transmural	O
cancer	O
specimens	O
were	O
snap	O
frozen	O
(	O
liquid	O
nitrogen	O
)	O
within	O
20	O
minutes	O
following	O
excision	O
and	O
stored	O
at	O
-80	O
°	O
C	O
.	O

All	O
tissue	O
samples	O
were	O
evaluated	O
by	O
a	O
pathologist	O
before	O
and	O
during	O
laser	O
micro	O
-	O
dissection	O
to	O
ensure	O
an	O
enrichment	O
of	O
vital	O
tumor	O
cells	O
.	O

Six	O
-	O
micron	O
serial	O
frozen	O
sections	O
were	O
cut	O
on	O
a	O
standard	O
cryostat	O
and	O
mounted	O
on	O
RNase	O
-	O
free	O
foil	O
(	O
2,5	O
μm	O
)	O
coated	O
on	O
glass	O
slides	O
followed	O
by	O
immediate	O
fixation	O
(	O
70	O
%	O
ethanol	O
for	O
30s	O
)	O
,	O
H&E	O
staining	O
,	O
and	O
ethanol	O
dehydration	O
(	O
70	O
%	O
,	O
95	O
%	O
and	O
finally	O
100	O
%	O
ethanol	O
)	O
.	O

After	O
vacuum	O
drying	O
the	O
membranes	O
carrying	O
the	O
sections	O
were	O
manually	O
turned	O
and	O
coated	O
on	O
new	O
RNase	O
free	O
glass	O
slides	O
.	O

Optically	O
transparent	O
CapSure	O
LCM	O
caps	O
(	O
ARCTURUS	O
,	O
CA	O
)	O
were	O
placed	O
on	O
the	O
foil	O
over	O
a	O
selected	O
field	O
of	O
cells	O
.	O

Vital	O
colorectal	O
epithelial	O
carcinoma	O
cells	O
(	O
>	O
90	O
%	O
proportion	O
)	O
from	O
the	O
invasion	O
front	O
were	O
isolated	O
using	O
UV	O
-	O
LCM	O
Systems	O
from	O
PALM	O
(	O
Microlaser	O
Technologie	O
,	O
Germany	O
)	O
and	O
SL	O
(	O
Microtest	O
GmbH	O
,	O
Germany	O
)	O
.	O

After	O
visual	O
control	O
of	O
completeness	O
of	O
dissection	O
the	O
captured	O
cells	O
were	O
immersed	O
in	O
denaturation	O
buffer	O
(	O
GTC	O
Extraction	O
Buffer	O
,	O
2	O
%	O
beta	O
-	O
mercaptoethanol	O
,	O
Promega	O
,	O
WI	O
)	O
and	O
stored	O
at	O
-80	O
°	O
C	O
.	O

mRNA	O
-	O
extraction	O
,	O
cRNA	O
-	O
preparation	O
and	O
-amplification	O
Poly	O
(	O
A	O
)	O
+	O
RNAs	O
were	O
isolated	O
using	O
PolyATtract	O
1000	O
kit	O
(	O
Promega	O
,	O
Heidelberg	O
,	O
Germany	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
recommendations	O
.	O

For	O
each	O
sample	O
the	O
cDNA	O
synthesis	O
and	O
repetitive	O
in	O
vitro	O
transcription	O
were	O
performed	O
three	O
times	O
,	O
as	O
described	O
previously	O
[	O
38	O
-	O
40	O
]	O
.	O

In	O
brief	O
,	O
the	O
total	O
amount	O
of	O
prepared	O
mRNA	O
from	O
one	O
sample	O
was	O
used	O
.	O

First	O
strand	O
cDNA	O
synthesis	O
was	O
initiated	O
using	O
the	O
Affymetrix	O
T7-oligo	O
-	O
dT	O
promoter	O
-	O
primer	O
combination	O
.	O

The	O
second	O
strand	O
cDNA	O
was	O
synthesized	O
by	O
internal	O
priming	O
.	O

In	O
vitro	O
transcription	O
was	O
performed	O
using	O
Ambion	O
's	O
Megascript	O
kit	O
(	O
Ambion	O
,	O
Huntington	O
,	O
UK	O
)	O
as	O
recommended	O
by	O
the	O
manufacturer	O
.	O

From	O
the	O
generated	O
cRNA	O
a	O
new	O
first	O
strand	O
synthesis	O
was	O
initiated	O
using	O
0.025	O
mM	O
of	O
a	O
random	O
hexamer	O
as	O
primer	O
.	O

After	O
completion	O
,	O
the	O
second	O
strand	O
synthesis	O
was	O
primed	O
using	O
the	O
Affymetrix	O
T7-oligo	O
-	O
dT	O
promoter	O
-	O
primer	O
combination	O
at	O
a	O
concentration	O
of	O
0.1	O
mM.	O
A	O
second	O
in	O
vitro	O
transcription	O
was	O
performed	O
and	O
then	O
the	O
procedure	O
was	O
repeated	O
one	O
additional	O
time	O
.	O

During	O
the	O
third	O
in	O
vitro	O
transcription	O
biotin	O
-	O
labeled	O
nucleotides	O
were	O
incorporated	O
into	O
the	O
cRNA	O
as	O
recommended	O
by	O
the	O
Affymetrix	O
protocol	O
.	O

Microarray	O
hybridization	O
BIO+cRNAs	O
were	O
hybridized	O
on	O
Affymetrix	O
Human	O
Genome	O
U133A	O
and	O
U133B	O
GeneChips	O
,	O
that	O
consist	O
of	O
44.928	O
probe	O
sets	O
(	O
Affymetrix	O
,	O
Santa	O
Clara	O
,	O
CA	O
)	O
.	O

Fragmentation	O
,	O
preparation	O
of	O
hybridization	O
cocktails	O
,	O
hybridization	O
,	O
washing	O
,	O
staining	O
and	O
scanning	O
of	O
Affymetrix	O
GeneChip	O
were	O
performed	O
according	O
to	O
the	O
manufacturer	O
's	O
protocols	O
.	O

Introduction	O

The	O
traditional	O
view	O
of	O
epithelial	O
polyps	O
of	O
the	O
colorectum	O
envisages	O
a	O
larger	O
non	O
-	O
neoplastic	O
category	O
of	O
hyperplastic	O
polyps	O
(	O
HPs	O
)	O
that	O
can	O
be	O
safely	O
ignored	O
and	O
a	O
smaller	O
category	O
of	O
neoplastic	O
polyps	O
or	O
adenomas	O
that	O
are	O
precancerous.1	O
With	O
respect	O
to	O
adenomas	O
,	O
it	O
is	O
clear	O
that	O
the	O
majority	O
will	O
not	O
progress	O
to	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
.2	O
The	O
risk	O
of	O
cancer	O
developing	O
within	O
an	O
adenoma	O
increases	O
with	O
size	O
,	O
grade	O
of	O
dysplasia	O
(	O
synonymous	O
with	O
intraepithelial	O
neoplasia	O
)	O
and	O
villosity.3	O
These	O
features	O
,	O
together	O
with	O
polyp	O
numbers	O
,	O
are	O
also	O
predictive	O
of	O
metachronous	O
neoplasia	O
and	O
may	O
therefore	O
influence	O
the	O
decision	O
to	O
offer	O
follow	O
-	O
up	O
endoscopic	O
surveillance.4	O
However	O
,	O
the	O
grading	O
of	O
dysplasia	O
and	O
estimation	O
of	O
the	O
extent	O
of	O
villous	O
change	O
may	O
not	O
be	O
fully	O
reproducible	O
and	O
it	O
may	O
be	O
difficult	O
to	O
distinguish	O
new	O
from	O
recurrent	O
adenomas	O
.	O

Establishing	O
a	O
risk	O
profile	O
on	O
the	O
basis	O
of	O
the	O
traditional	O
features	O
of	O
adenoma	O
is	O
therefore	O
not	O
always	O
straightforward	O
.	O

The	O
addition	O
of	O
molecular	O
profiling	O
to	O
polyp	O
description	O
offers	O
hope	O
of	O
a	O
more	O
objective	O
and	O
therefore	O
reproducible	O
approach	O
to	O
the	O
classification	O
of	O
colorectal	O
adenomas	O
.	O

The	O
genetic	O
evolutionary	O
paradigm	O
envisages	O
a	O
linear	O
sequence	O
of	O
changes	O
beginning	O
with	O
bi	O
-	O
allelic	O
inactivation	O
of	O
APC	O
,	O
followed	O
by	O
oncogenic	O
KRAS	O
mutation	O
and	O
culminating	O
in	O
inactivation	O
of	O
TP53	O
at	O
the	O
transition	O
from	O
adenoma	O
to	O
carcinoma.5	O
While	O
there	O
is	O
good	O
evidence	O
that	O
KRAS	O
mutation	O
is	O
associated	O
with	O
advanced	O
adenoma	O
features6	O
and	O
could	O
therefore	O
be	O
used	O
as	O
objective	O
evidence	O
of	O
aggression	O
,	O
this	O
approach	O
has	O
a	O
number	O
of	O
limitations	O
.	O

First	O
,	O
KRAS	O
mutation	O
also	O
occurs	O
frequently	O
in	O
dysplastic	O
aberrant	O
crypt	O
foci	O
(	O
microadenomas	O
)	O
and	O
in	O
some	O
small	O
tubular	O
adenomas	O
,	O
suggesting	O
that	O
KRAS	O
mutation	O
may	O
initiate	O
a	O
subset	O
of	O
small	O
adenomas	O
with	O
limited	O
potential	O
for	O
progression.6,7	O
Second	O
,	O
around	O
70	O
%	O
of	O
CRCs	O
lack	O
mutation	O
of	O
KRAS.8	O
From	O
this	O
it	O
follows	O
that	O
most	O
of	O
the	O
precancerous	O
lesions	O
that	O
eventually	O
become	O
cancers	O
do	O
not	O
in	O
fact	O
have	O
KRAS	O
mutation	O
.	O

There	O
is	O
increasing	O
evidence	O
that	O
CRC	O
evolves	O
through	O
a	O
number	O
of	O
pathways	O
and	O
the	O
traditional	O
adenoma	O
–	O
carcinoma	O
sequence	O
,	O
with	O
its	O
accompanying	O
genetic	O
steps	O
,	O
provides	O
a	O
surprisingly	O
narrow	O
window	O
of	O
understanding	O
of	O
this	O
multipathway	O
reality.9	O
In	O
recent	O
years	O
,	O
the	O
fundamental	O
division	O
of	O
colorectal	O
polyps	O
into	O
precancerous	O
adenomas	O
and	O
innocent	O
HPs	O
has	O
begun	O
to	O
erode	O
and	O
the	O
concept	O
of	O
an	O
alternative	O
serrated	O
pathway	O
has	O
gained	O
support	O
.	O

This	O
revision	O
began	O
with	O
the	O
description	O
of	O
an	O
intermediate	O
lesion	O
described	O
as	O
serrated	O
adenoma	O
(	O
SA	O
)	O
.10	O
Initially	O
,	O
however	O
,	O
SA	O
was	O
not	O
conceived	O
as	O
an	O
intermediate	O
category	O
of	O
polyp	O
but	O
essentially	O
as	O
an	O
adenoma	O
with	O
a	O
superimposed	O
serrated	O
architecture	O
that	O
conferred	O
only	O
a	O
superficial	O
likeness	O
to	O
a	O
HP.10	O
Additionally	O
,	O
the	O
mixed	O
polyp	O
(	O
MP	O
)	O
was	O
perceived	O
as	O
a	O
chance	O
collision	O
between	O
a	O
HP	O
and	O
an	O
adenoma	O
,	O
giving	O
a	O
combined	O
polyp	O
.	O

These	O
preliminary	O
interpretations	O
did	O
not	O
represent	O
a	O
major	O
departure	O
from	O
the	O
traditional	O
classification	O
of	O
colorectal	O
polyps	O
but	O
preserved	O
the	O
fundamental	O
distinction	O
of	O
neoplastic	O
adenomas	O
versus	O
non	O
-	O
neoplastic	O
HPs	O
.	O

Statistics	O
Data	O
were	O
analysed	O
by	O
χ2	O
test	O
,	O
Fisher	O
's	O
exact	O
test	O
or	O
T	O
-	O
test	O
,	O
as	O
appropriate	O
,	O
using	O
SAS	O
software	O
,	O
version	O
8.2	O
(	O
Cary	O
,	O
NC	O
,	O
USA	O
)	O
.	O

P	O
-	O
values	O
<	O
0.05	O
were	O
interpreted	O
as	O
significant	O
.	O

Results	O
KRAS	O
and	O
BRAF	O
mutation	O
DNA	O
failed	O
to	O
amplify	O
in	O
the	O
KRAS	O
assay	O
for	O
one	O
SSA	O
and	O
one	O
TA	O
<	O
10	O
mm	O
.	O

Overall	O
,	O
34	O
of	O
188	O
polyps	O
(	O
18	O
%	O
)	O
had	O
mutation	O
of	O
KRAS	O
.	O

Twenty	O
-	O
eight	O
mutations	O
were	O
in	O
codon	O
12	O
(	O
20	O
G→A	O
,	O
seven	O
G→T	O
and	O
one	O
G→C	O
)	O
and	O
six	O
mutations	O
were	O
in	O
codon	O
13	O
(	O
all	O
G→A	O
)	O
.	O

One	O
serrated	O
adenoma	O
had	O
two	O
KRAS	O
mutations	O
in	O
codon	O
12	O
(	O
G→T	O
at	O
position	O
35	O
and	O
T→G	O
at	O
position	O
36	O
)	O
.	O

BRAF	O
mutation	O
at	O
V600E	O
could	O
be	O
assessed	O
in	O
all	O
polyps	O
except	O
for	O
a	O
single	O
TA	O
<	O
10	O
mm	O
.	O

BRAF	O
mutation	O
was	O
found	O
in	O
82	O
of	O
189	O
polyps	O
(	O
43	O
%	O
)	O
.	O

BRAF	O
and	O
KRAS	O
mutations	O
were	O
negatively	O
correlated	O
,	O
with	O
only	O
four	O
polyps	O
having	O
both	O
mutations	O
(	O
two	O
TAs	O
,	O
one	O
TVA	O
and	O
one	O
SSA	O
)	O
.	O

The	O
three	O
conventional	O
adenomas	O
with	O
mutations	O
of	O
both	O
BRAF	O
and	O
KRAS	O
were	O
among	O
only	O
four	O
adenomas	O
that	O
had	O
any	O
BRAF	O
mutations	O
at	O
all	O
.	O

Mutation	O
frequencies	O
for	O
both	O
KRAS	O
and	O
BRAF	O
were	O
distributed	O
differently	O
across	O
the	O
seven	O
polyp	O
groups	O
(	O
Table	O
1	O
)	O
.	O

Frequency	O
of	O
KRAS	O
and	O
BRAF	O
mutation	O
and	O
loss	O
of	O
expression	O
of	O
O-6-methylguanine	O
DNA	O
methyltransferase	O
(	O
MGMT	O
)	O
by	O
polyp	O
type	O
Mutation	O
frequencies	O
for	O
both	O
KRAS	O
(	O
P	O
<	O
0.0001	O
)	O
and	O
BRAF	O
(	O
P	O
<	O
0.0001	O
)	O
are	O
distributed	O
differently	O
across	O
the	O
seven	O
classes	O
of	O
polyp	O
(	O
see	O
Results	O
for	O
individual	O
comparisons	O
)	O
.	O

Distribution	O
of	O
MGMT	O
loss	O
differs	O
across	O
the	O
seven	O
classes	O
of	O
polyp	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Note	O
:	O
no	O
result	O
for	O
KRAS	O
in	O
one	O
sessile	O
serrated	O
adenoma	O
(	O
SSA	O
)	O
and	O
one	O
tubular	O
adenoma	O
(	O
TA	O
)	O
or	O
for	O
BRAF	O
in	O
one	O
TA	O
.	O

MGMT	O
immunstaining	O
not	O
performed	O
in	O
15	O
polyps	O
(	O
seven	O
HPs	O
,	O
one	O
SSA	O
,	O
one	O
MP	O
and	O
six	O
TAs	O
)	O
.	O

KRAS	O
mutation	O
occurred	O
in	O
26.5	O
%	O
and	O
BRAF	O
mutation	O
in	O
4.8	O
%	O
of	O
adenomas	O
(	O
all	O
types	O
)	O
(	O
Table	O
1	O
)	O
(	O
P	O
<	O
0.0001	O
)	O
.	O

TVAs	O
/	O
VAs	O
were	O
more	O
likely	O
to	O
have	O
KRAS	O
mutation	O
(	O
50	O
%	O
)	O
than	O
TAs	O
<	O
10	O
mm	O
(	O
18	O
%	O
)	O
(	O
P	O
<	O
0.004	O
)	O
or	O
TAS	O
>	O
10	O
mm	O
in	O
diameter	O
(	O
17	O
%	O
)	O
(	O
P	O
<	O
0.02	O
)	O
.	O

In	O
the	O
case	O
of	O
TAs	O
there	O
was	O
a	O
trend	O
for	O
KRAS	O
mutation	O
to	O
occur	O
more	O
frequently	O
in	O
polyps	O
from	O
the	O
proximal	O
colon	O
(	O
P	O
=	O
0.08	O
)	O
and	O
in	O
females	O
(	O
P	O
=	O
0.07	O
)	O
.	O

SSAs	O
were	O
more	O
likely	O
to	O
have	O
BRAF	O
mutation	O
(	O
81	O
%	O
)	O
than	O
either	O
SAs	O
(	O
33	O
%	O
)	O
(	O
P	O
<	O
0.001	O
)	O
or	O
MPs	O
(	O
40	O
%	O
)	O
(	O
P	O
<	O
0.02	O
)	O
.	O

KRAS	O
mutation	O
was	O
infrequent	O
among	O
both	O
SSAs	O
(	O
3	O
%	O
)	O
and	O
HPs	O
(	O
4	O
%	O
)	O
(	O
Table	O
1	O
)	O
.	O

Patient	O
age	O
,	O
gender	O
and	O
anatomical	O
location	O
were	O
not	O
predictors	O
of	O
BRAF	O
mutation	O
in	O
either	O
SSAs	O
or	O
HPs	O
.	O

The	O
mean	O
age	O
of	O
subjects	O
with	O
SSAs	O
(	O
64	O
years	O
)	O
differed	O
from	O
that	O
of	O
subjects	O
with	O
HPs	O
(	O
55	O
years	O
)	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Background	O
Colorectal	O
cancer	O
(	O
CRC	O
)	O
is	O
the	O
one	O
of	O
the	O
most	O
common	O
malignancies	O
in	O
the	O
Western	O
world	O
.	O

Already	O
in	O
1913	O
,	O
familial	O
aggregation	O
of	O
CRC	O
was	O
described	O
by	O
Warthin	O
[	O
1	O
]	O
and	O
later	O
Lynch	O
et	O
al.	O
described	O
an	O
additional	O
family	O
with	O
clustering	O
of	O
colorectal	O
and	O
endometrial	O
cancer	O
[	O
2	O
]	O
.	O

Clinical	O
definition	O
of	O
Lynch	O
syndrome	O
,	O
or	O
HNPCC	O
,	O
in	O
1991	O
[	O
3,4	O
]	O
was	O
instrumental	O
for	O
linkage	O
analysis	O
,	O
and	O
ultimately	O
for	O
the	O
identification	O
of	O
the	O
underlying	O
gene	O
defects	O
in	O
HNPCC	O
families	O
.	O

The	O
first	O
HNPCC	O
loci	O
were	O
mapped	O
to	O
chromosomes	O
2	O
and	O
3	O
using	O
microsatellite	O
markers	O
[	O
5,6	O
]	O
.	O

This	O
eventually	O
led	O
to	O
the	O
identification	O
of	O
germ	O
line	O
mutations	O
in	O
MSH2	O
[	O
7	O
]	O
and	O
MLH1	O
[	O
8	O
]	O
,	O
respectively	O
.	O

Later	O
,	O
PMS2	O
[	O
9	O
]	O
,	O
MSH6	O
[	O
10,11	O
]	O
and	O
recently	O
MutYH	O
[	O
12	O
]	O
were	O
identified	O
as	O
CRC	O
susceptibility	O
genes	O
.	O

However	O
,	O
the	O
so	O
far	O
identified	O
CRC	O
susceptibility	O
genes	O
can	O
only	O
explain	O
up	O
to	O
5	O
%	O
of	O
all	O
cases	O
[	O
13	O
]	O
,	O
while	O
in	O
~35	O
%	O
of	O
all	O
colorectal	O
cancer	O
cases	O
familial	O
clustering	O
is	O
seen	O
[	O
14	O
]	O
.	O

Furthermore	O
,	O
it	O
is	O
shown	O
that	O
first	O
degree	O
relatives	O
of	O
patients	O
with	O
colorectal	O
cancer	O
have	O
a	O
relative	O
risk	O
of	O
2.3	O
to	O
develop	O
the	O
disease	O
[	O
15	O
]	O
.	O

This	O
indicates	O
that	O
still	O
some	O
genes	O
with	O
strong	O
or	O
moderate	O
effect	O
on	O
CRC	O
development	O
remain	O
to	O
be	O
identified	O
.	O

In	O
order	O
to	O
identify	O
these	O
genes	O
,	O
linkage	O
analysis	O
in	O
families	O
could	O
point	O
to	O
the	O
loci	O
where	O
unknown	O
susceptibility	O
genes	O
may	O
reside	O
.	O

Indeed	O
,	O
different	O
linkage	O
analysis	O
studies	O
revealed	O
potentially	O
interesting	O
regions	O
on	O
chromosomes	O
3q	O
,	O
9q	O
,	O
11q	O
,	O
14q	O
,	O
15q	O
and	O
22q	O
[	O
16	O
-	O
20	O
]	O
.	O

Families	O
with	O
a	O
clustering	O
of	O
colorectal	O
cancer	O
but	O
without	O
germ	O
line	O
mutations	O
in	O
CRC	O
genes	O
have	O
been	O
under	O
surveillance	O
in	O
Leiden	O
since	O
the	O
1980s	O
.	O

Due	O
to	O
the	O
long	O
period	O
of	O
follow	O
-	O
up	O
,	O
with	O
three	O
to	O
four	O
affected	O
generations	O
,	O
these	O
Dutch	O
HNPCC	O
-	O
like	O
families	O
have	O
become	O
informative	O
for	O
linkage	O
analysis	O
.	O

Traditionally	O
,	O
linkage	O
analysis	O
is	O
performed	O
with	O
multi	O
-	O
allelic	O
microsatellite	O
markers	O
.	O

Recently	O
,	O
however	O
,	O
the	O
more	O
advanced	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
arrays	O
were	O
brought	O
into	O
use	O
for	O
linkage	O
analysis	O
.	O

It	O
was	O
shown	O
that	O
the	O
information	O
content	O
of	O
a	O
dense	O
SNP	O
map	O
is	O
significantly	O
and	O
uniformly	O
higher	O
than	O
that	O
of	O
a	O
genome	O
wide	O
microsatellite	O
marker	O
map	O
[	O
21	O
]	O
.	O

Several	O
studies	O
conducting	O
linkage	O
analysis	O
on	O
genotype	O
data	O
from	O
SNP	O
arrays	O
appeared	O
in	O
recent	O
years	O
[	O
22	O
-	O
24	O
]	O
.	O

In	O
these	O
studies	O
non	O
-	O
parametric	O
as	O
well	O
as	O
parametric	O
linkage	O
analysis	O
was	O
performed	O
in	O
sib	O
pairs	O
or	O
in	O
small	O
to	O
moderate	O
size	O
pedigrees	O
.	O

However	O
,	O
to	O
date	O
,	O
no	O
studies	O
have	O
been	O
published	O
on	O
linkage	O
analysis	O
using	O
SNPs	O
in	O
large	O
pedigrees	O
(	O
e.g.	O
>	O
35–40	O
bits	O
)	O
.	O

Studying	O
large	O
families	O
with	O
thousands	O
of	O
SNPs	O
results	O
in	O
a	O
computational	O
complex	O
analysis	O
that	O
is	O
challenging	O
for	O
existing	O
statistical	O
packages	O
and	O
that	O
may	O
even	O
exceed	O
their	O
capacity	O
.	O

Current	O
linkage	O
analysis	O
programs	O
can	O
handle	O
either	O
large	O
pedigrees	O
or	O
large	O
numbers	O
of	O
markers	O
,	O
depending	O
on	O
the	O
underlying	O
algorithm	O
.	O

In	O
order	O
to	O
perform	O
linkage	O
analysis	O
in	O
large	O
pedigrees	O
using	O
SNP	O
arrays	O
,	O
we	O
explored	O
the	O
possibilities	O
of	O
currently	O
available	O
linkage	O
analysis	O
software	O
.	O

Most	O
currently	O
available	O
programs	O
are	O
based	O
on	O
the	O
Lander	O
-	O
Green	O
or	O
the	O
Elston	O
-	O
Stewart	O
algorithm	O
or	O
both	O
.	O

The	O
computation	O
time	O
of	O
the	O
former	O
algorithm	O
increases	O
exponentially	O
with	O
the	O
number	O
of	O
bits	O
(	O
2n	O
-	O
f	O
,	O
where	O
'	O
n	O
'	O
is	O
the	O
number	O
of	O
non	O
-	O
founders	O
and	O
'	O
f	O
'	O
the	O
number	O
of	O
founders	O
)	O
in	O
a	O
pedigree	O
,	O
whereas	O
the	O
latter	O
scales	O
exponentially	O
with	O
the	O
number	O
of	O
markers	O
.	O

To	O
perform	O
multipoint	O
linkage	O
analysis	O
in	O
a	O
large	O
family	O
with	O
SNP	O
arrays	O
in	O
one	O
run	O
would	O
probably	O
take	O
several	O
months	O
computation	O
time	O
,	O
if	O
at	O
all	O
possible	O
.	O

Statistics	O
Significance	O
values	O
were	O
calculated	O
using	O
the	O
software	O
package	O
SPSS	O
10.0.7	O
(	O
SPSS	O
Inc.	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
.	O

Methods	O
Colorectal	O
cancer	O
samples	O
Samples	O
of	O
colorectal	O
cancer	O
tissue	O
and	O
matched	O
normal	O
colonic	O
mucosa	O
were	O
obtained	O
from	O
fresh	O
surgical	O
specimens	O
,	O
frozen	O
in	O
liquid	O
nitrogen	O
,	O
and	O
stored	O
at	O
-80	O
°	O
C	O
.	O

Thirty	O
nine	O
carcinomas	O
,	O
23	O
microsatellite	O
stable	O
(	O
MSS	O
)	O
and	O
16	O
with	O
high	O
-	O
frequency	O
MSI	O
(	O
MSI	O
-	O
H	O
)	O
were	O
analyzed	O
in	O
the	O
course	O
of	O
the	O
study	O
.	O

The	O
clinico	O
-	O
pathological	O
features	O
of	O
the	O
tumors	O
are	O
detailed	O
in	O
Table	O
1	O
.	O

MSI	O
status	O
was	O
determined	O
with	O
a	O
fluorescence	O
-	O
based	O
PCR	O
method	O
,	O
using	O
the	O
five	O
markers	O
of	O
the	O
panel	O
of	O
Bethesda	O
(	O
BAT25	O
,	O
BAT26	O
,	O
D2S123	O
,	O
D5S346	O
,	O
and	O
D17S250	O
)	O
[	O
42	O
]	O
.	O

PCR	O
products	O
were	O
run	O
in	O
an	O
ABI	O
PRISM	O
377	O
DNA	O
sequencer	O
(	O
Perkin	O
-	O
Elmer	O
Applied	O
Biosystems	O
Division	O
,	O
Foster	O
City	O
,	O
CA	O
)	O
and	O
analyzed	O
by	O
the	O
GeneScan	O
3.1	O
version	O
software	O
(	O
Perkin	O
-	O
Elmer	O
)	O
[	O
43	O
]	O
.	O

According	O
to	O
the	O
guidelines	O
of	O
the	O
Workshop	O
of	O
Bethesda	O
[	O
42	O
]	O
,	O
tumors	O
showing	O
instability	O
at	O
two	O
or	O
more	O
loci	O
were	O
classified	O
as	O
MSI	O
-	O
H	O
and	O
tumors	O
without	O
instability	O
at	O
any	O
locus	O
as	O
MSS	O
.	O

None	O
of	O
the	O
tumors	O
included	O
in	O
this	O
study	O
exhibited	O
instability	O
at	O
a	O
single	O
locus	O
(	O
low	O
-	O
frequency	O
MSI	O
or	O
MSI	O
-	O
L	O
)	O
.	O

All	O
MSI	O
-	O
H	O
carcinomas	O
displayed	O
instability	O
at	O
mononucleotide	O
DNA	O
sequences	O
(	O
BAT25	O
and	O
BAT26	O
markers	O
)	O
.	O

Tumors	O
were	O
also	O
examined	O
for	O
expression	O
of	O
the	O
DNA	O
mismatch	O
repair	O
proteins	O
MLH1	O
and	O
MSH2	O
,	O
using	O
the	O
immunohistochemical	O
analytic	O
procedure	O
previously	O
described	O
[	O
43	O
]	O
.	O

Carcinomas	O
showing	O
complete	O
loss	O
of	O
nuclear	O
MLH1	O
or	O
MSH2	O
expression	O
were	O
classified	O
as	O
MLH1	O
or	O
MSH2	O
negative	O
,	O
whereas	O
cancers	O
with	O
normal	O
expression	O
of	O
MLH1	O
and	O
MSH2	O
gene	O
products	O
were	O
classified	O
as	O
MLH1	O
and	O
MSH2	O
positive	O
.	O

As	O
reported	O
in	O
Table	O
1	O
,	O
all	O
MSS	O
carcinomas	O
demonstrated	O
normal	O
nuclear	O
expression	O
of	O
both	O
MLH1	O
and	O
MSH2	O
proteins	O
(	O
MLH1	O
/	O
MSH2	O
positive	O
)	O
.	O

By	O
contrast	O
,	O
of	O
the	O
16	O
MSI	O
-	O
H	O
tumors	O
15	O
were	O
MLH1	O
negative	O
and	O
one	O
was	O
MSH2	O
negative	O
.	O

As	O
expected	O
,	O
MSI	O
-	O
H	O
carcinomas	O
were	O
more	O
frequently	O
located	O
in	O
the	O
proximal	O
colon	O
(	O
P	O
<	O
0.001	O
)	O
and	O
poorly	O
differentiated	O
(	O
P	O
<	O
0.001	O
)	O
and	O
more	O
often	O
contained	O
a	O
mucinous	O
component	O
(	O
P	O
<	O
0.001	O
)	O
with	O
respect	O
to	O
MSS	O
tumors	O
(	O
Table	O
1	O
)	O
.	O

Total	O
RNA	O
was	O
isolated	O
using	O
Trizol	O
(	O
Invitrogen	O
)	O
following	O
manufacturer	O
's	O
indications	O
.	O

RNA	O
integrity	O
was	O
assessed	O
on	O
a	O
2100	O
Agilent	O
Bioanalyzer	O
.	O

Only	O
samples	O
with	O
intact	O
RNA	O
were	O
used	O
for	O
the	O
gene	O
expression	O
analysis	O
.	O

RNA	O
labeling	O
and	O
microarray	O
hybridization	O
RNA	O
labeling	O
and	O
hybridization	O
on	O
microRNA	O
microarray	O
chips	O
was	O
performed	O
as	O
previously	O
described	O
.	O

[	O
21,22	O
]	O
Briefly	O
,	O
5	O
μg	O
of	O
total	O
RNA	O
from	O
each	O
sample	O
was	O
biotin	O
-	O
labeled	O
by	O
reverse	O
transcription	O
using	O
5	O
'	O
biotin	O
end	O
labeled	O
random	O
examers	O
oligo	O
primer	O
.	O

Hybridization	O
of	O
biotin	O
-	O
labeled	O
cDNA	O
was	O
carried	O
out	O
on	O
our	O
miRNA	O
microarray	O
chip	O
(	O
ArrayExpress	O
accession	O
number	O
:	O
A	O
-	O
MEXP-86	O
)	O
,	O
which	O
contains	O
230	O
human	O
microRNA	O
probes	O
,	O
in	O
triplicate	O
.	O

Hybridization	O
signals	O
were	O
detected	O
by	O
biotin	O
binding	O
of	O
a	O
Streptavidin	O
–	O
Alexa	O
647	O
conjugate	O
using	O
Axon	O
Scanner	O
4000B	O
(	O
Axon	O
Instrument	O
Inc.	O
CA	O
)	O
.	O

Introduction	O
The	O
immune	O
system	O
is	O
thought	O
to	O
have	O
an	O
important	O
function	O
in	O
controlling	O
tumor	O
growth	O
and	O
eliminating	O
metastasizing	O
tumor	O
cells	O
.	O

The	O
expression	O
of	O
human	O
leukocyte	O
antigen	O
(	O
HLA	O
)	O
class	O
I	O
,	O
presenting	O
tumor	O
-	O
associated	O
antigens	O
on	O
the	O
tumor	O
cell	O
surface	O
,	O
is	O
considered	O
as	O
a	O
prerequisite	O
for	O
an	O
effective	O
T	O
cell	O
immune	O
response	O
[	O
34	O
]	O
.	O

As	O
a	O
consequence	O
,	O
tumor	O
cells	O
with	O
down	O
-	O
regulated	O
HLA	O
class	O
I	O
expression	O
might	O
escape	O
this	O
immune	O
response	O
,	O
resulting	O
in	O
a	O
selective	O
outgrowth	O
of	O
these	O
tumor	O
cells	O
.	O

Many	O
studies	O
described	O
HLA	O
class	O
I	O
expression	O
in	O
cancer	O
[	O
10	O
,	O
17	O
,	O
22	O
,	O
33	O
]	O
.	O

Only	O
limited	O
studies	O
have	O
reported	O
on	O
the	O
clinical	O
impact	O
of	O
HLA	O
class	O
I	O
expression	O
in	O
colorectal	O
cancer	O
with	O
contrasting	O
results	O
.	O

Some	O
studies	O
found	O
no	O
significant	O
correlation	O
between	O
staining	O
intensity	O
and	O
survival	O
[	O
1	O
,	O
19	O
,	O
20	O
]	O
,	O
while	O
others	O
found	O
a	O
prognostic	O
correlation	O
between	O
HLA	O
expression	O
and	O
survival	O
[	O
18	O
,	O
35	O
]	O
.	O

The	O
latter	O
two	O
studies	O
had	O
in	O
common	O
that	O
total	O
absence	O
of	O
HLA	O
class	O
I	O
resulted	O
in	O
a	O
favorable	O
prognosis	O
as	O
compared	O
to	O
patients	O
with	O
down	O
-	O
regulated	O
expression	O
of	O
HLA	O
class	O
I	O
of	O
tumor	O
cells	O
.	O

The	O
discrepancy	O
between	O
these	O
two	O
studies	O
is	O
,	O
whereas	O
the	O
one	O
described	O
high	O
expression	O
of	O
HLA	O
class	O
I	O
in	O
tumor	O
cells	O
that	O
resulted	O
in	O
a	O
better	O
prognosis	O
as	O
compared	O
to	O
the	O
partial	O
down	O
-	O
regulation	O
of	O
HLA	O
class	O
I	O
[	O
35	O
]	O
,	O
the	O
other	O
found	O
the	O
opposite	O
[	O
18	O
]	O
.	O

These	O
studies	O
both	O
analyzed	O
a	O
mixed	O
population	O
of	O
colon	O
and	O
rectal	O
cancer	O
patients	O
.	O

For	O
rectal	O
cancer	O
patients	O
,	O
the	O
clinical	O
impact	O
of	O
HLA	O
class	O
I	O
expression	O
is	O
still	O
unknown	O
.	O

Since	O
HLA	O
class	O
I	O
expression	O
is	O
often	O
absent	O
in	O
microsatellite	O
instable	O
(	O
MSI	O
)	O
tumors	O
[	O
9	O
,	O
16	O
]	O
and	O
MSI	O
is	O
more	O
frequently	O
observed	O
in	O
right	O
-	O
sided	O
colon	O
tumors	O
than	O
in	O
rectal	O
tumors	O
[	O
30	O
]	O
,	O
therefore	O
the	O
results	O
obtained	O
from	O
a	O
mixed	O
population	O
of	O
colon	O
and	O
rectal	O
cancer	O
patients	O
might	O
not	O
hold	O
true	O
for	O
rectal	O
cancer	O
patients	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
clinical	O
relevance	O
of	O
HLA	O
class	O
I	O
expression	O
for	O
rectal	O
cancer	O
patients	O
.	O

In	O
addition	O
to	O
determining	O
the	O
impact	O
of	O
MSI	O
on	O
HLA	O
class	O
I	O
expression	O
,	O
the	O
tumors	O
most	O
at	O
risk	O
for	O
MSI	O
i.e.	O
HLA	O
-	O
negative	O
tumors	O
were	O
examined	O
for	O
MSI	O
by	O
determining	O
the	O
expression	O
of	O
the	O
mismatch	O
repair	O
proteins	O
,	O
mismatch	O
mutL	O
homolog	O
1	O
(	O
MLH1	O
)	O
and	O
postmeiotic	O
segregation	O
increased	O
2	O
(	O
PMS2	O
)	O
,	O
that	O
are	O
most	O
absent	O
in	O
sporadic	O
MSI	O
tumors	O
[	O
7	O
,	O
36	O
]	O
.	O

Radiotherapy	O
has	O
been	O
described	O
recently	O
to	O
increase	O
cell	O
surface	O
expression	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
I	O
molecules	O
in	O
a	O
murine	B
colon	O
adenocarcinoma	O
cell	O
line	O
[	O
26	O
]	O
.	O

Therefore	O
,	O
our	O
study	O
also	O
evaluated	O
the	O
effect	O
of	O
radiotherapy	O
on	O
HLA	O
class	O
I	O
expression	O
in	O
rectal	O
cancer	O
patients	O
.	O

For	O
these	O
purposes	O
,	O
HLA	O
class	O
I	O
expression	O
was	O
evaluated	O
in	O
a	O
set	O
of	O
1,135	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
rectal	O
cancer	O
specimens	O
.	O

The	O
tumors	O
studied	O
were	O
obtained	O
at	O
the	O
time	O
of	O
surgery	O
from	O
patients	O
of	O
a	O
prospective	O
multicenter	O
trial	O
,	O
who	O
were	O
randomized	O
between	O
standardized	O
preoperative	O
radiotherapy	O
treatment	O
followed	O
by	O
surgery	O
or	O
surgery	O
alone	O
[	O
15	O
]	O
.	O

Expression	O
of	O
HLA	O
class	O
I	O
in	O
rectal	O
cancer	O
using	O
HCA2	O
and	O
HC10	O
antibodies	O
Expression	O
of	O
results	O
of	O
HCA2	O
and	O
HC10	O
staining	O
in	O
a	O
cross	O
table	O
for	O
numbers	O
(	O
N	O
)	O
of	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
;	O
expression	O
of	O
HCA2	O
and	O
HC10	O
in	O
more	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
(	O
high	O
)	O
versus	O
expression	O
in	O
less	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
(	O
low	O
)	O
is	O
shown	O
.	O

A	O
significant	O
correlation	O
was	O
noted	O
between	O
HCA2	O
and	O
HC10	O
staining	O
for	O
both	O
irradiated	O
(	O
χ2	O
=	O
53.947	O
,	O
P	O
<	O
0.001	O
)	O
and	O
non	O
-	O
irradiated	O
patients	O
(	O
χ2	O
=	O
61.257	O
,	O
P	O
<	O
0.001	O
)	O
.	O

The	O
right	O
side	O
of	O
the	O
table	O
displays	O
HLA	O
class	O
I	O
expression	O
estimated	O
on	O
HCA2	O
and	O
HC10	O
expression	O
.	O

A	O
total	O
of	O
406	O
(	O
85	O
%	O
)	O
irradiated	O
and	O
445	O
(	O
84	O
%	O
)	O
non	O
-	O
irradiated	O
tumors	O
exhibited	O
expression	O
of	O
at	O
least	O
one	O
of	O
the	O
two	O
markers	O
showing	O
>	O
50	O
%	O
positive	O
staining	O
of	O
all	O
tumor	O
cells	O
.	O

A	O
total	O
of	O
70	O
(	O
15	O
%	O
)	O
irradiated	O
and	O
88	O
(	O
16	O
%	O
)	O
non	O
-	O
irradiated	O
tumors	O
showed	O
reduced	O
numbers	O
(	O
≤50	O
%	O
)	O
of	O
HLA	O
class	O
I	O
positive	O
tumor	O
cells	O
.	O

The	O
number	O
of	O
patients	O
in	O
the	O
group	O
of	O
the	O
HLA	O
class	O
I	O
high	O
expression	O
group	O
and	O
the	O
HLA	O
class	O
I	O
low	O
expression	O
group	O
was	O
equally	O
distributed	O
between	O
irradiated	O
and	O
non	O
-	O
irradiated	O
tumors	O
(	O
χ2	O
=	O
0.519	O
,	O
P	O
=	O
0.471	O
)	O
HLA	O
class	O
I	O
negative	O
cells	O
and	O
microsatellite	O
instability	O
It	O
has	O
been	O
described	O
that	O
a	O
majority	O
of	O
MSI	O
colorectal	O
tumors	O
do	O
not	O
express	O
HLA	O
class	O
I	O
,	O
while	O
only	O
a	O
minority	O
of	O
MSS	O
tumors	O
do	O
not	O
express	O
HLA	O
class	O
I	O
[	O
8	O
,	O
16	O
]	O
.	O

Therefore	O
,	O
HLA	O
class	O
I	O
negative	O
rectal	O
tumors	O
are	O
the	O
most	O
at	O
risk	O
to	O
be	O
MSI	O
tumors	O
.	O

To	O
evaluate	O
the	O
numbers	O
of	O
sporadic	O
MSI	O
tumors	O
in	O
our	O
study	O
,	O
HCA2	O
or	O
HC10	O
negative	O
tumors	O
were	O
analyzed	O
for	O
the	O
expression	O
of	O
PMS2	O
and	O
MLH1	O
.	O

PMS2	O
and	O
MLH1	O
are	O
mismatch	O
repairs	O
proteins	O
that	O
are	O
most	O
frequently	O
absent	O
in	O
MSI	O
sporadic	O
tumors	O
[	O
6	O
]	O
.	O

Of	O
the	O
HLA	O
class	O
I	O
negative	O
tumors	O
only	O
1	O
out	O
of	O
11	O
tumors	O
did	O
not	O
express	O
PMS2	O
and	O
MLH1	O
.	O

In	O
the	O
tumor	O
group	O
negative	O
for	O
only	O
1	O
of	O
the	O
2	O
HLA	O
class	O
I	O
markers	O
,	O
2	O
of	O
81	O
tumors	O
displayed	O
no	O
PMS2	O
and	O
MLH1	O
staining	O
.	O

These	O
results	O
indicate	O
that	O
HLA	O
class	O
I	O
down	O
-	O
regulation	O
is	O
not	O
associated	O
with	O
MSI	O
in	O
rectal	O
cancer	O
and	O
are	O
in	O
accordance	O
with	O
the	O
previous	O
findings	O
that	O
only	O
a	O
very	O
small	O
minority	O
of	O
rectal	O
tumors	O
are	O
MSI	O
[	O
4	O
,	O
25	O
]	O
.	O

HLA	O
class	O
I	O
expression	O
and	O
clinicopathological	O
parameters	O
The	O
relationship	O
between	O
HLA	O
class	O
I	O
expression	O
and	O
patient	O
/	O
tumor	O
characteristics	O
was	O
assessed	O
(	O
Table	O
3	O
)	O
.	O

The	O
HLA	O
class	O
I	O
expression	O
levels	O
were	O
distributed	O
equally	O
in	O
non	O
-	O
irradiated	O
and	O
irradiated	O
patients	O
with	O
regard	O
to	O
most	O
clinical	O
and	O
pathological	O
parameters	O
.	O

Three	O
significant	O
differences	O
were	O
observed	O
.	O

For	O
the	O
non	O
-	O
irradiated	O
patients	O
,	O
significantly	O
more	O
men	O
appeared	O
in	O
the	O
HLA	O
class	O
I	O
low	O
-	O
expression	O
group	O
(	O
P	O
=	O
0.03	O
)	O
.	O

The	O
group	O
of	O
irradiated	O
tumors	O
with	O
HLA	O
class	O
I	O
low	O
expression	O
contained	O
significantly	O
more	O
stage	O
III	O
and	O
IV	O
tumors	O
(	O
P	O
=	O
0.01	O
)	O
and	O
also	O
more	O
patients	O
with	O
a	O
tumor	O
-	O
positive	O
circumferential	O
resection	O
margin	O
(	O
P	O
=	O
0.02	O
)	O
when	O
compared	O
with	O
tumors	O
with	O
high	O
HLA	O
class	O
I	O
expression	O
.	O

Table	O
3Clinicopathological	O
characteristics	O
of	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
with	O
high	O
or	O
low	O
numbers	O
of	O
HLA	O
class	O
I	O
positive	O
tumor	O
cells	O
Non	O
-	O
irradiated	O
patientsIrradiated	O
patientsHigh	O
N	O
=	O
445Low	O
N	O
=	O
87P	O
valueHigh	O
N	O
=	O
406Low	O
N	O
=	O
70P	O
valueGender	O
Male	O
(	O
%	O
)	O
63750.0365660.90Age	O
Median	O
years65680.3265650.99TNM	O
stage	O
(	O
%	O
)	O
I31240.5233240.01	O
II27303021	O
III36383240	O
IV58514Circumferential	O
margin	O
Negative	O
(	O
%	O
)	O
83770.2886740.02Distant	O
from	O
anal	O
verge	O
(	O
%	O
)	O
≥10	O
cm28330.1727320.30	O
5–10	O
cm41314636	O
<	O
5	O
cm31362732Operation	O
type	O
(	O
%	O
)	O
Low	O
anterior	O
resection66610.7765660.89	O
Abdomino	O
-	O
perineal	O
resection29332930	O
Hartmann5664Number	O
(	O
N	O
)	O
of	O
patients	O
with	O
expression	O
of	O
total	O
HLA	O
class	O
I	O
expression	O
in	O
more	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
(	O
high	O
)	O
and	O
expression	O
in	O
less	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
(	O
low	O
)	O

*	O
Statistical	O
significant	O
P	O
values	O
are	O
in	O
bold	O

Clinicopathological	O
characteristics	O
of	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
with	O
high	O
or	O
low	O
numbers	O
of	O
HLA	O
class	O
I	O
positive	O
tumor	O
cells	O
Number	O
(	O
N	O
)	O
of	O
patients	O
with	O
expression	O
of	O
total	O
HLA	O
class	O
I	O
expression	O
in	O
more	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
(	O
high	O
)	O
and	O
expression	O
in	O
less	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
(	O
low	O
)	O
*	O
Statistical	O
significant	O
P	O
values	O
are	O
in	O
bold	O
Expression	O
of	O
HLA	O
class	O
I	O
and	O
clinical	O
prognosis	O
Because	O
radiotherapy	O
might	O
influence	O
local	O
tumor	O
recurrences	O
[	O
15	O
]	O
,	O
irradiated	O
and	O
non	O
-	O
irradiated	O
tumors	O
were	O
analyzed	O
separately	O
in	O
order	O
to	O
evaluate	O
the	O
impact	O
of	O
HLA	O
class	O
I	O
expression	O
on	O
tumor	O
recurrence	O
and	O
patient	O
survival	O
.	O

The	O
HLA	O
class	O
I	O
expression	O
was	O
not	O
related	O
with	O
distant	O
or	O
local	O
recurrence	O
rates	O
.	O

The	O
patients	O
with	O
low	O
expression	O
of	O
HLA	O
class	O
I	O
had	O
a	O
worse	O
overall	O
survival	O
and	O
disease	O
-	O
free	O
survival	O
when	O
compared	O
to	O
patients	O
with	O
HLA	O
class	O
I	O
high	O
expression	O
,	O
irrespective	O
of	O
treatment	O
(	O
Fig.	O
2	O
;	O
overall	O
survival	O
:	O
P	O
=	O
0.008	O
and	O
P	O
=	O
0.01	O
;	O
disease	O
free	O
survival	O
:	O
P	O
=	O
0.01	O
,	O
P	O
=	O
0.006	O
in	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
,	O
respectively	O
)	O
.	O

Irradiated	O
patients	O
with	O
low	O
HLA	O
class	O
I	O
expression	O
also	O
had	O
a	O
worse	O
cancer	O
-	O
specific	O
survival	O
(	O
P	O
=	O
0.003	O
)	O
.	O

For	O
non	O
-	O
irradiated	O
patients	O
,	O
HLA	O
class	O
I	O
expression	O
had	O
no	O
significant	O
effect	O
on	O
cancer	O
-	O
specific	O
survival	O
(	O
Fig.	O
2	O
)	O
.	O

All	O
results	O
of	O
univariate	O
analysis	O
are	O
shown	O
in	O
Table	O
4	O
.	O

Univariate	O
analysis	O
showed	O
a	O
better	O
outcome	O
for	O
overall	O
survival	O
and	O
disease	O
-	O
free	O
survival	O
in	O
patients	O
with	O
high	O
HLA	O
class	O
I	O
expression	O
.	O

Fig.	O
2Examples	O
of	O
Kaplan	O
–	O
Meier	O
curves	O
showing	O
overall	O
survival	O
and	O
cancer	O
specific	O
survival	O
for	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
(	O
a	O
–	O
d	O
)	O
.	O

Kaplan	O
–	O
Meier	O
curves	O
for	O
overall	O
survival	O
(	O
a	O
,	O
b	O
)	O
and	O
cancer	O
specific	O
survival	O
(	O
c	O
,	O
d	O
)	O
;	O
curves	O
show	O
prognosis	O
for	O
non	O
-	O
irradiated	O
(	O
a	O
,	O
c	O
)	O
and	O
irradiated	O
patients	O
(	O
b	O
,	O
d	O
)	O
for	O
HLA	O
class	O
I	O
expression	O
in	O
more	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
(	O
high	O
)	O
versus	O
expression	O
in	O
less	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
(	O
low	O
)	O
.	O

P	O
value	O
is	O
based	O
on	O
univariate	O
log	O
rank	O
analysesTable	O
4Both	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
with	O
high	O
expression	O
of	O
HLA	O
class	O
I	O
have	O
a	O
better	O
overall	O
,	O
and	O
disease	O
free	O
survivalNon	O
-	O
irradiated	O
patientsIrradiated	O
patientsHigh	O
(	O
%	O
)	O
Low	O
(	O
%	O
)	O
P	O
valueHigh	O
(	O
%	O
)	O
Low	O
(	O
%	O
)	O
P	O
valueOverall	O
survival65.558.50.01267.551.30.008Disease	O
free	O
survival62.253.50.01562.248.30.006Cancer	O
specific	O
survival74.371.40.4180.161.80.003Local	O
recurrence8.913.70.224.73.20.72Distant	O
recurrence26.728.70.8824.729.30.34Survival	O
and	O
recurrence	O
rates	O
indicated	O
in	O
percentages	O
after	O
5-years	O
of	O
follow	O
-	O
up	O
for	O
non	O
-	O
irradiated	O
and	O
irradiated	O
patients	O
for	O
HLA	O
class	O
I	O
expression	O
in	O
more	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
(	O
high	O
)	O
versus	O
expression	O
in	O
less	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
(	O
low	O
)	O
.	O

P	O
value	O
is	O
based	O
on	O
univariate	O
log	O
rank	O
analyses	O
for	O
overall	O
survival	O
,	O
disease	O
free	O
survival	O
,	O
cancer	O
specific	O
survival	O
,	O
local	O
recurrence	O
and	O
distant	O
recurrence	O
*	O
Statistical	O
significant	O
P	O
values	O
are	O
in	O
bold	O

Discussion	O
We	O
showed	O
that	O
rectal	O
cancer	O
patients	O
from	O
the	O
HLA	O
class	O
I	O
low	O
expression	O
group	O
had	O
an	O
independent	O
worse	O
overall	O
and	O
disease	O
-	O
free	O
survival	O
when	O
compared	O
to	O
patients	O
from	O
the	O
HLA	O
class	O
I	O
high	O
-	O
expression	O
group	O
.	O

These	O
data	O
imply	O
that	O
the	O
expression	O
of	O
HLA	O
class	O
I	O
in	O
tumor	O
cells	O
predicts	O
survival	O
for	O
rectal	O
cancer	O
patients	O
.	O

Although	O
significant	O
better	O
cancer	O
-	O
specific	O
survival	O
for	O
irradiated	O
patients	O
with	O
high	O
HLA	O
class	O
I	O
was	O
found	O
in	O
univariate	O
analysis	O
,	O
the	O
predictive	O
value	O
was	O
lost	O
in	O
multivariate	O
analysis	O
.	O

This	O
observation	O
can	O
be	O
explained	O
by	O
the	O
fact	O
that	O
the	O
group	O
with	O
low	O
HLA	O
class	O
I	O
significantly	O
included	O
more	O
stage	O
III	O
/	O
IV	O
and	O
more	O
patients	O
with	O
a	O
positive	O
circumferential	O
margin	O
as	O
compared	O
to	O
the	O
group	O
of	O
patients	O
with	O
high	O
expression	O
of	O
HLA	O
class	O
I.	O
Also	O
no	O
predictive	O
value	O
of	O
HLA	O
class	O
I	O
expression	O
was	O
found	O
with	O
regard	O
to	O
recurrence	O
-	O
free	O
survival	O
of	O
these	O
patients	O
.	O

Therefore	O
,	O
we	O
have	O
no	O
indications	O
that	O
support	O
the	O
notion	O
that	O
better	O
survival	O
of	O
high	O
HLA	O
class	O
I	O
expression	O
is	O
due	O
to	O
the	O
better	O
antigen	O
presenting	O
function	O
of	O
these	O
tumor	O
cells	O
,	O
as	O
has	O
been	O
suggested	O
[	O
18	O
,	O
35	O
]	O
.	O

In	O
our	O
study	O
,	O
no	O
difference	O
was	O
found	O
between	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
for	O
HLA	O
class	O
I	O
expression	O
in	O
tumor	O
cells	O
.	O

It	O
has	O
been	O
described	O
that	O
γ	O
-	O
irradiation	O
induces	O
enhanced	O
peptide	O
production	O
and	O
surface	O
expression	O
of	O
MHC	O
class	O
I	O
in	O
a	O
colorectal	O
mouse	B
tumor	O
cell	O
line	O
[	O
26	O
]	O
.	O

The	O
fact	O
that	O
we	O
could	O
not	O
find	O
more	O
HLA	O
class	O
I	O
expression	O
in	O
irradiated	O
tumors	O
than	O
in	O
non	O
-	O
irradiated	O
tumors	O
indicates	O
that	O
radiotherapy	O
does	O
not	O
induce	O
HLA	O
class	O
I	O
expression	O
in	O
vivo	O
.	O

Immunohistochemistry	O
,	O
however	O
,	O
is	O
less	O
suitable	O
to	O
measure	O
subtle	O
expression	O
changes	O
.	O

Therefore	O
,	O
additional	O
research	O
is	O
required	O
to	O
determine	O
the	O
impact	O
of	O
radiotherapy	O
on	O
expression	O
levels	O
of	O
HLA	O
class	O
I	O
in	O
human	B
tumors	O
.	O

In	O
our	O
study	O
,	O
more	O
tumors	O
showed	O
HLA	O
class	O
I	O
down	O
-	O
regulation	O
after	O
immunohistochemical	O
staining	O
using	O
HCA2	O
than	O
using	O
HC10	O
.	O

This	O
difference	O
might	O
be	O
due	O
to	O
differences	O
in	O
reactivity	O
spectrum	O
of	O
both	O
antibodies	O
(	O
see	O
Materials	O
and	O
methods	O
)	O
or	O
to	O
the	O
fact	O
that	O
HLA	O
alleles	O
are	O
differently	O
affected	O
in	O
colorectal	O
cancer	O
.	O

If	O
the	O
latter	O
is	O
the	O
case	O
,	O
our	O
results	O
suggest	O
that	O
HLA	O
A	O
alleles	O
preferentially	O
show	O
down	O
-	O
regulation	O
in	O
rectal	O
cancer	O
.	O

Previous	O
reports	O
evaluated	O
HLA	O
class	O
I	O
expression	O
in	O
mixed	O
patient	O
populations	O
of	O
colon	O
and	O
rectal	O
cancer	O
patients	O
[	O
18	O
,	O
35	O
]	O
.	O

Watson	O
et	O
al.	O
also	O
found	O
in	O
a	O
large	O
group	O
of	O
colorectal	O
cancer	O
patients	O
that	O
patients	O
with	O
low	O
expression	O
of	O
HLA	O
class	O
I	O
had	O
a	O
poor	O
prognosis	O
[	O
35	O
]	O
.	O

However	O
,	O
in	O
contrast	O
to	O
our	O
results	O
,	O
both	O
studies	O
described	O
a	O
substantial	O
population	O
of	O
patients	O
with	O
tumors	O
showing	O
absence	O
of	O
HLA	O
class	O
I.	O
In	O
addition	O
,	O
they	O
described	O
that	O
absence	O
of	O
HLA	O
class	O
I	O
was	O
associated	O
with	O
better	O
prognosis	O
as	O
compared	O
to	O
tumors	O
expressing	O
reduced	O
numbers	O
of	O
HLA	O
class	O
I	O
positive	O
tumor	O
cells	O
.	O

A	O
relatively	O
low	O
number	O
(	O
1.1	O
%	O
)	O
of	O
HLA	O
class	O
I	O
negative	O
tumors	O
was	O
observed	O
in	O
our	O
cohort	O
of	O
rectal	O
cancer	O
patients	O
only	O
.	O

These	O
patients	O
showed	O
no	O
survival	O
advantage	O
when	O
compared	O
to	O
patients	O
with	O
reduced	O
numbers	O
of	O
HLA	O
class	O
I	O
positive	O
tumor	O
cells	O
.	O

There	O
are	O
several	O
explanations	O
for	O
the	O
discrepancy	O
in	O
the	O
number	O
of	O
HLA	O
class	O
I	O
negative	O
tumors	O
between	O
the	O
study	O
of	O
Watson	O
et	O
al.	O
and	O
ours	O
,	O
like	O
different	O
definition	O
of	O
HLA	O
class	O
I	O
expression	O
,	O
differences	O
in	O
staining	O
techniques	O
,	O
different	O
patient	O
cohort	O
and	O
number	O
of	O
MSI	O
tumors	O
.	O

Both	O
human	B
CRCs	O
and	O
mouse	B
colon	O
tumors	O
reactivate	O
an	O
embryonic	O
gene	O
signature	O
.	O

When	O
human	B
and	O
murine	B
tumors	O
are	O
compared	O
,	O
they	O
both	O
broadly	O
re	O
-	O
express	O
an	O
embryonic	O
gene	O
expression	O
pattern	O
.	O

Gene	O
expression	O
profiles	O
from	O
the	O
mouse	B
tumor	O
models	O
and	O
human	B
CRC	O
samples	O
were	O
combined	O
into	O
a	O
single	O
non	O
-	O
redundant	O
gene	O
ortholog	O
genome	O
table	O
structure	O
and	O
subjected	O
to	O
comparative	O
profile	O
analysis	O
.	O

Informative	O
probe	O
-	O
sets	O
from	O
human	O
and	O
mouse	O
platforms	O
were	O
selected	O
,	O
mapped	O
to	O
corresponding	O
ortholog	O
genes	O
,	O
and	O
used	O
to	O
populate	O
a	O
table	O
in	O
which	O
normalized	O
expression	O
for	O
each	O
gene	O
is	O
relative	O
to	O
normal	O
adult	O
colon	O
.	O

(	O
a	O
)	O
Heatmap	O
plot	O
for	O
all	O
cross	O
-	O
species	O
gene	O
orthologs	O
both	O
present	O
and	O
successfully	O
measured	O
on	O
both	O
the	O
Affymetrix	O
Hg	O
-	O
U133	O
and	O
Vanderbilt	O
Mouse	O
NIA	O
20	O
K	O
microarrays	O
(	O
n	O
=	O
8,621	O
features	O
)	O
.	O

This	O
representation	O
suggests	O
that	O
a	O
large	O
number	O
of	O
human	B
CRC	O
signatures	O
exhibit	O
similar	O
behaviors	O
in	O
the	O
mouse	B
tumors	O
and	O
during	O
embryonic	O
mouse	O
colon	O
development	O
(	O
sidebar	O
:	O
1,080	O
(	O
red	O
)	O
and	O
431	O
(	O
green	O
)	O
gene	O
lists	O
from	O
(	O
b	O
)	O
)	O
.	O

(	O
b	O
)	O
Based	O
on	O
results	O
in	O
(	O
a	O
)	O
,	O
four	O
separate	O
gene	O
lists	O
were	O
generated	O
with	O
criteria	O
of	O
over-	O
or	O
under	O
-	O
expression	O
in	O
development	O
or	O
over	O
-	O
expression	O
or	O
under	O
-	O
expression	O
in	O
human	B
CRCs	O
(	O
2,718	O
,	O
2,365	O
,	O
2,212	O
,	O
and	O
737	O
,	O
respectively	O
,	O
with	O
the	O
overlaps	O
shown	O
as	O
a	O
sidebar	O
in	O
(	O
a	O
)	O
;	O
red	O
,	O
1,080	O
transcripts	O
,	O
and	O
green	O
,	O
431	O
transcripts	O
)	O
.	O

Genes	O
over	O
-	O
expressed	O
and	O
under	O
-	O
expressed	O
in	O
embryonic	O
mouse	O
colon	O
and	O
human	B
CRCs	O
were	O
found	O
to	O
be	O
over	O
-	O
represented	O
as	O
determined	O
by	O
Fisher	O
's	O
exact	O
test	O
analysis	O
(	O
*	O
p	O
<	O
7	O
×	O
10	O
-	O
88	O
,	O
*	O

*	O
p	O
<	O
1	O
×	O
10	O
-	O
76	O
,	O

*	O

*	O
*	O
p	O
<	O
5	O
×	O
10	O
-	O
4	O
,	O

*	O

*	O

*	O

*	O
p	O
<	O
1	O
×	O
10	O
-	O
76	O
)	O
.	O

(	O
c	O
)	O
Heatmap	O
plot	O
of	O
all	O
genes	O
co	O
-	O
regulated	O
in	O
human	B
CRCs	O
and	O
during	O
early	O
(	O
ED	O
)	O
and	O
late	O
(	O
LD	O
)	O
mouse	O
embryonic	O
colon	O
development	O
(	O
n	O
=	O
2,216	O
features	O
)	O
.	O

Six	O
predominant	O
clusters	O
(	O
C18-C23	O
)	O
characterize	O
the	O
transcriptional	O
relationship	O
between	O
human	B
CRC	O
and	O
mouse	B
colon	O
tumor	O
models	O
and	O
embryonic	O
development	O
.	O

Two	O
clusters	O
(	O
C20	O
and	O
21	O
)	O
primarily	O
distinguish	O
human	B
CRCs	O
from	O
murine	B
tumors	O
(	O
A	O
,	O
M	O
,	O
S	O
and	O
T	O
)	O
.	O

For	O
example	O
,	O
CRC	O
up	O
-	O
regulated	O
transcripts	O
that	O
are	O
either	O
developmentally	O
up-	O
or	O
down	O
-	O
regulated	O
are	O
represented	O
by	O
cluster	O
C22	O
(	O
n	O
=	O
860	O
features	O
)	O
and	O
clusters	O
C21	O
/	O
C23	O
(	O
n	O
=	O
142	O
features	O
)	O
,	O
respectively	O
.	O

Conversely	O
,	O
CRC	O
down	O
-	O
regulated	O
transcripts	O
that	O
are	O
either	O
down-	O
or	O
up	O
-	O
regulated	O
during	O
development	O
are	O
shown	O
in	O
clusters	O
C18	O
/	O
C19	O
(	O
n	O
=	O
258	O
features	O
)	O
and	O
cluster	O
C20	O
(	O
n	O
=	O
42	O
features	O
)	O
,	O
respectively	O
.	O

Interestingly	O
,	O
while	O
approximately	O
80	O
%	O
and	O
approximately	O
60	O
%	O
of	O
genes	O
up-	O
and	O
down	O
-	O
regulated	O
in	O
both	O
human	B
CRCs	O
and	O
mouse	O
development	O
were	O
also	O
up-	O
and	O
down	O
-	O
regulated	O
in	O
tumors	O
from	O
the	O
various	O
mouse	B
models	O
,	O
several	O
clusters	O
provide	O
very	O
interesting	O
exceptions	O
:	O
cluster	O
C20	O
comprises	O
genes	O
down	O
-	O
regulated	O
in	O
human	B
CRCs	O
that	O
are	O
routinely	O
over	O
-	O
expressed	O
in	O
mouse	B
tumors	O
and	O
development	O
;	O
cluster	O
C21	O
comprises	O
genes	O
robustly	O
expressed	O
in	O
human	B
CRC	O
that	O
are	O
rarely	O
expressed	O
in	O
embryonic	O
colon	O
or	O
murine	B
tumors	O
.	O

Sample	O
groups	O
:	O
ED	O
,	O
early	O
development	O
(	O
E13.5-E15.5	O
)	O
;	O
LD	O
,	O
late	O
development	O
(	O
E16.5-E18.5	O
)	O
;	O
A	O
,	O
AOM	O
-	O
induced	O
;	O
M	O
,	O
ApcMin	O
/	O
+	O
;	O
T	O
,	O
Tgfb1-	O
/	O
-	O
;	O
Rag2-	O
/	O
-	O
;	O
S	O
,	O
Smad3-	O
/	O
-	O
.	O

Tissue	O
groups	O
:	O
AC	O
,	O
adult	O
colon	O
;	O
CRC	O
,	O
human	B
CRC	O
.	O

Staging	O
:	O
nAC	O
,	O
normal	O
colon	O
.	O

Detailed	O
cluster	O
analysis	O
:	O
differential	O
and	O
statistically	O
significant	O
biological	O
functions	O
in	O
clusters	O
C18-C23	O
A	O
,	O
AOM	O
-	O
induced	O
;	O
M	O
,	O
ApcMin	O
/	O
+	O
;	O
PS	O
,	O
ProbeSets	O
;	O
S	O
,	O
Smad3-	O
/	O
-	O
;	O
T	O
,	O
Tgfb1-	O
/	O
-	O
;	O
Rag2-	O
/	O
-	O
.	O

The	O
up	O
-	O
regulated	O
signature	O
in	O
tumors	O
from	O
ApcMin	O
/	O
+	O
(	O
M	O
)	O
and	O
AOM	O
(	O
A	O
)	O
models	O
(	O
cluster	O
C6	O
,	O
Figure	O
2	O
)	O
is	O
enriched	O
with	O
genes	O
associated	O
with	O
the	O
activation	O
of	O
the	O
canonical	O
WNT	O
signaling	O
pathway	O
,	O
as	O
determined	O
by	O
nuclear	O
β	O
-	O
catenin	O
positivity	O
.	O

(	O
a	O
)	O
Schematic	O
diagram	O
of	O
the	O
canonical	O
WNT	O
signaling	O
pathway	O
showing	O
elements	O
present	O
in	O
cluster	O
C6	O
(	O
gene	O
symbols	O
with	O
gray	O
background	O
)	O
.	O

Key	O
elements	O
of	O
this	O
pathway	O
(	O
Ctnnb1	O
,	O
Lef1	O
,	O
Tcf	O
and	O
Myc	O
)	O
are	O
outlined	O
in	O
blue	O
.	O

(	O
b	O
)	O
Relative	O
gene	O
expression	O
for	O
MYC	O
and	O
SOX4	O
is	O
plotted	O
for	O
individual	O
murine	B
and	O
human	B
tumors	O
.	O

The	O
relative	O
expression	O
level	O
of	O
MYC	O
and	O
SOX4	O
is	O
normalized	O
to	O
adult	O
colon	O
.	O

Note	O
that	O
whereas	O
Sox4	O
,	O
a	O
canonical	O
WNT	O
target	O
gene	O
,	O
is	O
expressed	O
at	O
high	O
levels	O
in	O
all	O
human	B
CRCs	O
,	O
A	O
/	O
M	O
tumors	O
and	O
during	O
embryonic	O
mouse	O
colon	O
development	O
,	O
it	O
is	O
not	O
expressed	O
in	O
Smad3-	O
/	O
-	O
(	O
S	O
)	O
and	O
Tgfb1-	O
/	O
-	O
;	O
Rag2-	O
/	O
-	O
(	O
T	O
)	O
tumors	O
(	O
black	O
)	O
.	O

In	O
contrast	O
,	O
MYC	O
is	O
over	O
-	O
expressed	O
in	O
all	O
human	B
and	O
murine	B
tumors	O
and	O
during	O
colonic	O
embryonic	O
development	O
(	O
red	O
)	O
,	O
irrespective	O
of	O
the	O
activation	O
of	O
canonical	O
WNT	O
signaling	O
,	O
as	O
determined	O
by	O
nuclear	O
β	O
-	O
catenin	O
positivity	O
(	O
Figure	O
2	O
)	O
.	O

Tissue	O
groups	O
:	O
as	O
above	O
and	O
:	O
nAC	O
-	O
m	O
,	O
normal	O
adult	O
mouse	B
colon	O
;	O
nAC	O
-	O
h	O
,	O
normal	O
adult	O
human	B
colon	O
;	O
Dev	O
,	O
developing	O
mouse	O
colon	O
.	O

Materials	O
and	O
methods	O
Individuals	O
and	O
study	O
samples	O
The	O
research	O
was	O
completed	O
in	O
compliance	O
with	O
the	O
Helsinki	O
Declaration	O
.	O

The	O
Ethics	O
of	O
Human	O
Research	O
Committee	O
of	O
Peter	O
MacCallum	O
Cancer	O
Centre	O
approved	O
the	O
study	O
(	O
approval	O
number	O
02	O
/	O
70	O
)	O
.	O

Individuals	O
used	O
in	O
the	O
study	O
were	O
enrolled	O
in	O
the	O
Kathleen	O
Cuningham	O
Consortium	O
for	O
Research	O
in	O
Familial	O
Breast	O
Cancer	O
(	O
kConFab	O
)	O
.	O

kConFab	O
identified	O
seven	O
breast	O
cancer	O
cases	O
(	O
KCF1	O
-	O
7	O
)	O
with	O
BRCA1-like	O
features	O
for	O
analysis	O
.	O

kConFab	O
provided	O
DNA	O
extracted	O
from	O
peripheral	O
blood	O
leukocytes	O
from	O
each	O
case	O
and	O
DNA	O
from	O
buccal	O
mucosa	O
of	O
patient	O
KCF3	O
.	O

Tumour	O
material	O
from	O
the	O
KCF1	O
,	O
KCF2	O
,	O
KCF3	O
,	O
KCF4	O
and	O
KCF6	O
cases	O
was	O
available	O
.	O

Four	O
unstained	O
,	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
sections	O
from	O
each	O
tumour	O
were	O
provided	O
for	O
analysis	O
.	O

DNA	O
was	O
extracted	O
from	O
the	O
paraffin	O
sections	O
using	O
the	O
DNeasy	O
tissue	O
kit	O
(	O
Qiagen	O
,	O
Hilden	O
,	O
Germany	O
)	O
.	O

Normal	O
control	O
DNAs	O
were	O
provided	O
by	O
the	O
Peter	O
MacCallum	O
Cancer	O
Centre	O
tissue	O
bank	O
.	O

Methylation	O
analysis	O
CpGenome	O
Universal	O
Methylated	O
DNA	O
(	O
Chemicon	O
,	O
Millipore	O
,	O
Billerica	O
,	O
MA	O
,	O
USA	O
)	O
was	O
used	O
as	O
the	O
100	O
%	O
methylated	O
control	O
and	O
DNA	O
extracted	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
of	O
normal	O
individuals	O
was	O
used	O
as	O
unmethylated	O
control	O
DNA	O
.	O

Bisulfite	O
modification	O
of	O
DNA	O
was	O
performed	O
with	O
the	O
MethylEasy	O
kit	O
(	O
Human	O
Genetic	O
Signatures	O
,	O
Sydney	O
,	O
Australia	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

Methylation	O
standards	O
were	O
constructed	O
by	O
diluting	O
100	O
%	O
methylated	O
control	O
DNA	O
(	O
bisulfite	O
modified	O
)	O
in	O
a	O
pool	O
of	O
normal	O
DNA	O
(	O
bisulfite	O
modified	O
)	O
at	O
50	O
%	O
,	O
25	O
%	O
,	O
10	O
%	O
,	O
5	O
%	O
and	O
1	O
%	O
ratios	O
.	O

Methylation	O
of	O
the	O
BRCA1	O
promoter	O
was	O
assessed	O
using	O
real	O
-	O
time	O
methylation	O
specific	O
PCR	O
(	O
MethyLight	O
)	O
[	O
19	O
]	O
and	O
methylation	O
-	O
sensitive	O
high	O
resolution	O
melting	O
(	O
MS	O
-	O
HRM	O
)	O
[	O
20	O
]	O
.	O

All	O
samples	O
were	O
run	O
in	O
triplicate	O
for	O
each	O
assay	O
.	O

The	O
locations	O
of	O
the	O
MethyLight	O
and	O
MS	O
-	O
HRM	O
primers	O
and	O
probes	O
on	O
the	O
BRCA1	O
promoter	O
are	O
illustrated	O
in	O
Figure	O
1	O
.	O

The	O
MethyLight	O
assay	O
assessed	O
five	O
CpG	O
sites	O
and	O
the	O
MS	O
-	O
HRM	O
assay	O
assessed	O
four	O
sites	O
.	O

Careful	O
design	O
of	O
each	O
assay	O
was	O
required	O
to	O
avoid	O
amplification	O
from	O
the	O
BRCA1	O
pseudogene	O
.	O

The	O
HMBS	O
gene	O
was	O
used	O
as	O
a	O
control	O
for	O
the	O
BRCA1	O
MethyLight	O
assay	O
.	O

Primer	O
sequences	O
are	O
available	O
on	O
request	O
.	O

Map	O
of	O
the	O
BRCA1	O
promoter	O
region	O
studied	O
by	O
the	O
MethyLight	O
and	O
MS	O
-	O
HRM	O
assays	O
.	O

The	O
numbering	O
of	O
the	O
promoter	O
is	O
according	O
to	O
that	O
used	O
by	O
Rice	O
et	O
al.	O
[	O
24	O
]	O
.	O

TSS	O
denotes	O
the	O
transcription	O
start	O
site	O
.	O

The	O
positions	O
of	O
the	O
primers	O
flanking	O
the	O
MethyLight	O
and	O
MS	O
-	O
HRM	O
amplicons	O
are	O
indicated	O
as	O
well	O
as	O
the	O
position	O
of	O
the	O
MethyLight	O
probe	O
.	O

Experiments	O
were	O
performed	O
on	O
the	O
RotorGene	O
™	O
3000	O
(	O
MethyLight	O
assays	O
)	O
and	O
RotorGene	O
™	O
6000	O
(	O
MS	O
-	O
HRM	O
assays	O
)	O
instruments	O
(	O
Corbett	O
Research	O
,	O
Sydney	O
,	O
Australia	O
)	O
.	O

The	O
MethyLight	O
data	O
was	O
analysed	O
by	O
obtaining	O
the	O
take	O
-	O
off	O
(	O
Ct	O
)	O
and	O
amplification	O
efficiency	O
values	O
for	O
each	O
sample	O
for	O
BRCA1	O
and	O
HMBS	O
from	O
the	O
comparative	O
quantitation	O
tab	O
of	O
the	O
RotorGene	O
™	O
analysis	O
software	O
and	O
comparing	O
them	O
to	O
the	O
values	O
for	O
the	O
100	O
%	O
methylated	O
DNA	O
according	O
to	O
the	O
Pfaffl	O
method	O
of	O
relative	O
quantification	O
[	O
21	O
]	O
.	O

Ingenuity	O
Pathway	O
Analysis	O
(	O
Ingenuity	O
Systems	O
,	O
www.ingenuity.com	O
)	O
was	O
used	O
for	O
biological	O
interpretation	O
of	O
gene	O
lists	O
.	O

Analysis	O
of	O
the	O
transcripts	O
found	O
to	O
be	O
up-	O
and	O
down	O
-	O
regulated	O
in	O
irradiated	O
LCLs	O
as	O
identified	O
for	O
the	O
different	O
mutation	O
categories	O
identified	O
those	O
biochemical	O
networks	O
most	O
likely	O
to	O
be	O
affected	O
by	O
a	O
BRCA1	O
and	O
BRCA2	O
truncating	O
and	O
missense	O
mutation	O
,	O
relative	O
to	O
BRCAX	O
.	O

Those	O
pathways	O
with	O
multiple	O
hits	O
or	O
a	O
significance	O
score	O
≥20	O
were	O
then	O
compared	O
.	O

Methods	O
Patients	O
Between	O
1957	O
and	O
31	O
December	O
2004	O
the	O
Swedish	O
Polyposis	O
Registry	O
included	O
data	O
on	O
196	O
families	O
with	O
verified	O
FAP	O
(	O
defined	O
as	O
more	O
than	O
100	O
colorectal	O
adenomas	O
or	O
if	O
less	O
with	O
a	O
family	O
history	O
of	O
FAP	O
)	O
.	O

Sixty	O
-	O
one	O
of	O
these	O
families	O
are	O
now	O
extinct	O
but	O
135	O
families	O
with	O
at	O
least	O
one	O
living	O
disease	O
-	O
affected	O
member	O
remain	O
.	O

Presently	O
,	O
315	O
disease	O
-	O
affected	O
living	O
patients	O
are	O
included	O
in	O
the	O
registry	O
.	O

The	O
geographical	O
catchment	O
area	O
comprises	O
the	O
whole	O
of	O
Sweden	O
.	O

Details	O
of	O
how	O
patients	O
have	O
been	O
eligible	O
for	O
accession	O
into	O
the	O
registry	O
are	O
given	O
in	O
[	O
30	O
]	O
.	O

In	O
this	O
study	O
we	O
have	O
analyzed	O
96	O
families	O
included	O
in	O
the	O
registry	O
for	O
mutations	O
in	O
the	O
APC	O
gene	O
.	O

Twenty	O
-	O
four	O
of	O
the	O
remaining	O
39	O
families	O
have	O
been	O
analyzed	O
for	O
APC	O
gene	O
mutations	O
at	O
other	O
genetic	O
laboratories	O
and	O
15	O
families	O
remain	O
to	O
be	O
tested	O
.	O

We	O
have	O
previously	O
reported	O
six	O
of	O
these	O
patients	O
who	O
carried	O
bi	O
-	O
allelic	O
MUTYH	O
mutations	O
[	O
31	O
]	O
.	O

Probands	O
were	O
defined	O
as	O
those	O
diagnosed	O
on	O
the	O
basis	O
of	O
the	O
occurrence	O
of	O
symptoms	O
and	O
irrespective	O
of	O
other	O
cases	O
in	O
the	O
family	O
and	O
call	O
-	O
up	O
patients	O
,	O
as	O
those	O
identified	O
as	O
subjects	O
at	O
risk	O
on	O
the	O
basis	O
of	O
studies	O
of	O
pedigrees	O
and	O
found	O
to	O
have	O
FAP	O
.	O

De	O
novo	O
mutations	O
were	O
defined	O
in	O
those	O
individuals	O
where	O
none	O
of	O
the	O
parents	O
carried	O
the	O
mutation	O
or	O
where	O
the	O
parents	O
had	O
a	O
negative	O
colonoscopy	O
after	O
the	O
age	O
of	O
50	O
or	O
died	O
of	O
a	O
non	O
-	O
FAP	O
related	O
cause	O
after	O
the	O
age	O
of	O
75	O
.	O

All	O
patients	O
have	O
given	O
their	O
consent	O
and	O
the	O
local	O
ethics	O
committees	O
have	O
approved	O
the	O
study	O
.	O

The	O
clinical	O
features	O
of	O
index	O
patients	O
of	O
each	O
of	O
the	O
families	O
analyzed	O
are	O
listed	O
in	O
Additional	O
file	O
1	O
and	O
Table	O
1	O
.	O

Patients	O
without	O
any	O
detected	O
mutation	O
in	O
APC	O
or	O
MUTYH	O
Age	O
,	O
age	O
at	O
diagnosis	O
;	O
DL	O
,	O
duodenal	O
lesion	O
;	O
dom	O
,	O
dominant	O
;	O
FGP	O
,	O
fundic	O
gland	O
polyps	O
;	O
NA	O
,	O
no	O
available	O
data	O
;	O
NI	O
,	O
no	O
inheritance	O
;	O
Number	O
of	O
polyps	O
,	O
number	O
of	O
polyps	O
at	O
diagnosis	O
;	O
rec	O
,	O
recessive	O
Patient	O
C896	O
,	O
with	O
only	O
five	O
adenomas	O
,	O
was	O
included	O
because	O
of	O
a	O
family	O
history	O
of	O
FAP	O
.	O

Patient	O
C107	O
underwent	O
her	O
first	O
colonoscopy	O
due	O
to	O
intestinal	O
bleeding	O
at	O
age	O
47	O
.	O

At	O
diagnosis	O
,	O
10–20	O
small	O
(	O
less	O
than	O
10	O
mm	O
)	O
polyps	O
were	O
found	O
in	O
most	O
colorectal	O
parts	O
.	O

Tubular	O
and	O
tubulovillous	O
adenomas	O
were	O
removed	O
yearly	O
.	O

At	O
age	O
50	O
,	O
carcinoma	O
(	O
Dukes	O
A	O
)	O
was	O
diagnosed	O
4	O
cm	O
from	O
valvula	O
Bauhini	O
in	O
conjunction	O
with	O
several	O
new	O
adenomas	O
.	O

At	O
that	O
time	O
the	O
patient	O
underwent	O
total	O
colectomy	O
with	O
ileorectal	O
anastomosis	O
(	O
IRA	O
)	O
.	O

DNA	O
,	O
RNA	O
and	O
cDNA	O
preparation	O
Genomic	O
DNA	O
was	O
isolated	O
from	O
samples	O
of	O
venous	O
blood	O
,	O
anti	O
-	O
coagulated	O
in	O
ethylenediaminetetraacetic	O
acid	O
(	O
EDTA	O
)	O
.	O

DNA	O
purification	O
was	O
performed	O
using	O
the	O
PuregeneR	O
DNA	O
Isolation	O
Kit	O
(	O
Gentra	O
Systems	O
,	O
Minneapolis	O
,	O
MN	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
recommendations	O
.	O

DNA	O
was	O
extracted	O
from	O
paraffin	O
-	O
embedded	O
tissue	O
as	O
described	O
previously	O
[	O
32	O
]	O
.	O

Histopaque	O
(	O
Sigma	O
,	O
St	O
Louis	O
,	O
MO	O
)	O
or	O
Lymphoprep	O
(	O
Axis	O
-	O
Shield	O
PoC	O
AS	O
,	O
Oslo	O
,	O
Norway	O
)	O
was	O
used	O
for	O
purification	O
of	O
the	O
lymphocytes	O
,	O
and	O
total	O
RNA	O
was	O
extracted	O
using	O
RNA	O
-	O
Stat	O
60	O
(	O
Tel	O
-	O
Test	O
,	O
Friendswood	O
,	O
TX	O
)	O
.	O

cDNA	O
was	O
synthesized	O
as	O
described	O
previously	O
[	O
33	O
]	O
.	O

The	O
phenotype	O
of	O
the	O
patient	O
(	O
C157	O
)	O
,	O
carrying	O
the	O
c.70C	O
>	O
T	O
mutation	O
,	O
is	O
in	O
agreement	O
with	O
the	O
suggested	O
genotype	O
-	O
phenotype	O
correlation	O
where	O
a	O
milder	O
form	O
of	O
polyposis	O
is	O
proposed	O
to	O
be	O
caused	O
by	O
mutations	O
in	O
the	O
5	O
'	O
end	O
of	O
the	O
gene	O
.	O

A	O
model	O
for	O
the	O
attenuated	O
phenotype	O
in	O
patients	O
carrying	O
mutations	O
in	O
the	O
first	O
four	O
exons	O
of	O
APC	O
have	O
been	O
suggested	O
by	O
Heppner	O
Goss	O
et	O
al	O
[	O
42	O
]	O
,	O
in	O
which	O
the	O
internal	O
ATG	O
at	O
codon	O
184	O
could	O
be	O
used	O
as	O
an	O
alternative	O
translation	O
initiation	O
codon	O
in	O
the	O
allele	O
carrying	O
a	O
truncating	O
mutation	O
upstream	O
of	O
this	O
site	O
(	O
Figure	O
1	O
)	O
.	O

Such	O
an	O
alternative	O
start	O
of	O
translation	O
would	O
supply	O
the	O
cell	O
with	O
an	O
APC	O
protein	O
of	O
almost	O
full	O
length	O
,	O
thus	O
explaining	O
the	O
attenuated	O
phenotype	O
.	O

Patient	O
C159	O
,	O
with	O
the	O
most	O
3	O
'	O
localized	O
mutation	O
was	O
a	O
case	O
of	O
attenuated	O
FAP	O
(	O
100–1000	O
polyps	O
,	O
46	O
years	O
of	O
age	O
at	O
diagnosis	O
)	O
.	O

In	O
family	O
1	O
(	O
reduced	O
expression	O
of	O
APC	O
)	O
,	O
patient	O
C152	O
displayed	O
a	O
classical	O
FAP	O
phenotype	O
including	O
a	O
large	O
number	O
of	O
polyps	O
,	O
duodenal	O
adenomas	O
,	O
and	O
fundic	O
gland	O
polyps	O
(	O
Additional	O
file	O
1	O
)	O
.	O

The	O
APC-	O
and	O
MUTYH	O
-	O
mutation	O
negative	O
patients	O
all	O
display	O
an	O
attenuated	O
form	O
of	O
disease	O
with	O
a	O
low	O
number	O
of	O
polyps	O
,	O
comparably	O
high	O
age	O
at	O
diagnosis	O
,	O
and	O
a	O
low	O
frequency	O
of	O
extracolonic	O
manifestations	O
.	O

Whether	O
these	O
patients	O
really	O
are	O
affected	O
by	O
APC	O
-	O
associated	O
FAP	O
can	O
(	O
of	O
course	O
)	O
be	O
called	O
into	O
question	O
.	O

However	O
,	O
among	O
attenuated	O
cases	O
of	O
FAP	O
in	O
these	O
study	O
we	O
have	O
found	O
very	O
subtle	O
mutations	O
such	O
as	O
the	O
mosaic	O
case	O
as	O
well	O
as	O
the	O
c.70C	O
>	O
T	O
mutation	O
and	O
splice	O
-	O
site	O
mutations	O
.	O

Considering	O
these	O
facts	O
,	O
at	O
least	O
some	O
of	O
the	O
cases	O
could	O
be	O
caused	O
by	O
mutations	O
in	O
APC	O
resulting	O
in	O
only	O
partially	O
inactivation	O
of	O
the	O
gene	O
function	O
.	O

Since	O
the	O
main	O
purpose	O
of	O
this	O
study	O
was	O
to	O
achieve	O
as	O
high	O
mutation	O
-	O
detection	O
rate	O
as	O
possible	O
in	O
families	O
with	O
colorectal	O
polyposis	O
syndromes	O
,	O
using	O
a	O
range	O
of	O
different	O
molecular	O
genetic	O
techniques	O
,	O
we	O
have	O
not	O
yet	O
performed	O
any	O
further	O
analyses	O
of	O
the	O
relatively	O
few	O
mutation	O
negative	O
cases	O
to	O
determine	O
if	O
they	O
belong	O
to	O
non	O
-	O
polyposis	O
CRC	O
syndromes	O
.	O

Large	O
deletions	O
of	O
the	O
APC	O
gene	O
The	O
fraction	O
of	O
large	O
deletions	O
of	O
all	O
APC	O
mutations	O
identified	O
in	O
the	O
Swedish	O
patients	O
was	O
9	O
%	O
,	O
which	O
is	O
higher	O
than	O
the	O
5	O
%	O
of	O
large	O
deletions	O
reported	O
in	O
[	O
38	O
]	O
.	O

The	O
relatively	O
large	O
number	O
of	O
gross	O
deletions	O
identified	O
could	O
be	O
a	O
result	O
of	O
the	O
thorough	O
analysis	O
applied	O
for	O
every	O
patient	O
,	O
including	O
the	O
use	O
of	O
the	O
MLPA	O
technique	O
.	O

It	O
is	O
noteworthy	O
that	O
no	O
deletion	O
of	O
APC	O
exon	O
4	O
in	O
patient	O
3765	O
was	O
detected	O
using	O
MLPA	O
although	O
it	O
had	O
been	O
identified	O
and	O
confirmed	O
by	O
other	O
methods	O
.	O

A	O
still	O
untested	O
possibility	O
is	O
that	O
exon	O
4	O
has	O
been	O
translocated	O
to	O
another	O
chromosomal	O
locus	O
and	O
thus	O
generates	O
the	O
positive	O
MLPA	O
result	O
.	O

RESULTS	O
MSH6	O
Good	O
quality	O
sequence	O
was	O
obtained	O
for	O
all	O
10	O
exons	O
of	O
MSH6	O
in	O
220	O
participants	O
,	O
115	O
from	O
HNPCC	O
cohort	O
,	O
and	O
105	O
from	O
endometrial	O
cohort	O
.	O

Results	O
with	O
exact	O
binomial	O
confidence	O
limits	O
for	O
a	O
proportion	O
are	O
shown	O
in	O
table	O
I.	O
Given	O
that	O
the	O
pathogenicity	O
of	O
the	O
missense	O
mutations	O
identified	O
has	O
yet	O
to	O
be	O
determined	O
,	O
arguably	O
the	O
proportion	O
of	O
the	O
truncating	O
mutations	O
is	O
more	O
relevant	O
.	O

All	O
sequences	O
were	O
viewed	O
with	O
reference	O
to	O
a	O
control	O
sample	O
(	O
with	O
a	O
known	O
mutation	O
in	O
MLH1	O
or	O
MSH2	O
)	O
,	O
and	O
reference	O
sequences	O
(	O
,	O
)	O
.	O

All	O
variants	O
are	O
described	O
with	O
reference	O
to	O
den	O
Dunnen	O
et	O
al26	O
.	O

All	O
truncating	O
and	O
missense	O
variants	O
identified	O
are	O
shown	O
in	O
tables	O
II	O
and	O
III	O
(	O
example	O
figure	O
1	O
)	O
with	O
their	O
corresponding	O
cohort	O
and	O
family	O
classification	O
.	O

Participants	O
from	O
the	O
endometrial	O
cohort	O
with	O
a	O
variant	O
identified	O
were	O
also	O
classified	O
according	O
to	O
Amsterdam	O
I	O
,	O
II	O
,	O
'	O
HNPCC	O
like	O
'	O
,	O
or	O
,	O
a	O
family	O
history	O
that	O
was	O
not	O
in	O
keeping	O
with	O
HNPCC	O
.	O

All	O
missense	O
variants	O
were	O
subject	O
to	O
analysis	O
by	O
PolyPhen	O
(	O
)	O
,	O
a	O
tool	O
that	O
predicts	O
the	O
potential	O
impact	O
of	O
an	O
amino	O
acid	O
substitution	O
on	O
the	O
structure	O
and	O
function	O
of	O
a	O
human	O
protein	O
(	O
see	O
table	O
III	O
for	O
predictions	O
)	O
.	O

Further	O
population	O
,	O
family	O
and	O
functional	O
studies	O
were	O
not	O
carried	O
out	O
to	O
evaluate	O
the	O
missense	O
variants	O
but	O
further	O
work	O
is	O
planned	O
.	O

Sequencing	O
analysis	O
showing	O
a	O
truncating	O
mutation	O
c.755	O
C	O
>	O
G	O
(	O
p.	O

Ser252X	O
)	O
in	O
exon	O
4	O
of	O
MSH6	O
Truncating	O
mutations	O
identified	O
Missense	O
variants	O
identified	O
MLPA	O
All	O
samples	O
underwent	O
MLPA	O
analysis	O
.	O

Out	O
of	O
268	O
successful	O
MLPA	O
results	O
,	O
no	O
aberration	O
in	O
copy	O
number	O
was	O
identified	O
.	O

Methods	O
Cell	O
Culture	O
MCF7	O
,	O
MDA	O
-	O
MB-231	O
,	O
MDA	O
-	O
MB-468	O
,	O
T-47D	O
,	O
HT-29	O
,	O
Caco-2	O
,	O
Colo320	O
,	O
SW480	O
,	O
RKO	O
,	O
and	O
HCT116	O
cells	O
and	O
isogenic	O
DNA	O
methyltransferase	O
(	O
DNMT	O
)	O
1	O
/	O
3b	O
genetic	O
knockout	O
derivatives	O
were	O
maintained	O
in	O
culture	O
as	O
recommended	O
by	O
American	O
Type	O
Tissue	O
Culture	O
(	O
ATCC	O
)	O
.	O

All	O
HCC	O
series	O
lines	O
used	O
were	O
obtained	O
from	O
ATCC	O
.	O

For	O
drug	O
treatments	O
,	O
log	O
phase	O
cells	O
were	O
cultured	O
in	O
the	O
appropriate	O
media	O
(	O
Invitrogen	O
)	O
containing	O
10	O
%	O
FBS	O
and	O
1	O
×	O
penicillin	O
/	O
streptomycin	O
with	O
5	O
μM	O
5aza	O
-	O
deoxycytidine	O
(	O
DAC	O
)	O
(	O
Sigma	O
;	O
stock	O
solution	O
:	O
1	O
mM	O
in	O
PBS	O
)	O
for	O
96	O
h	O
,	O
replacing	O
media	O
and	O
DAC	O
every	O
24	O
h.	O
Cell	O
treatment	O
with	O
300	O
nM	O
Trichostatin	O
A	O
(	O
Sigma	O
;	O
stock	O
solution	O
:	O
1.5	O
mM	O
dissolved	O
in	O
ethanol	O
)	O
was	O
performed	O
for	O
18	O
h.	O
Control	O
cells	O
underwent	O
mock	O
treatment	O
in	O
parallel	O
with	O
addition	O
of	O
equal	O
volume	O
of	O
PBS	O
or	O
ethanol	O
without	O
drugs	O
.	O

Microarray	O
Analysis	O
Total	O
RNA	O
was	O
harvested	O
from	O
log	O
phase	O
cells	O
using	O
the	O
Qiagen	O
RNEasy	O
kit	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

Sample	O
amplification	O
and	O
labeling	O
procedures	O
were	O
carried	O
out	O
using	O
the	O
Low	O
RNA	O
Input	O
Fluorescent	O
Linear	O
Amplification	O
kit	O
(	O
Agilent	O
Technologies	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

Hybridization	O
was	O
carried	O
out	O
according	O
to	O
the	O
Agilent	O
microarray	O
protocol	O
.	O

Scanning	O
was	O
performed	O
with	O
the	O
Agilent	O
G2565BA	O
microarray	O
scanner	O
.	O

Data	O
Analysis	O
All	O
arrays	O
were	O
subject	O
to	O
quality	O
checks	O
recommended	O
by	O
the	O
manufacturer	O
.	O

All	O
calculations	O
were	O
performed	O
using	O
the	O
R	O
statistical	O
computing	O
platform	O
[	O
16	O
]	O
and	O
packages	O
from	O
Bioconductor	O
bioinformatics	O
software	O
project	O
[	O
17	O
]	O
.	O

The	O
log	O
ratio	O
of	O
red	O
signal	O
to	O
green	O
signal	O
was	O
calculated	O
after	O
background	O
-	O
subtraction	O
and	O
LoEss	O
normalization	O
as	O
implemented	O
in	O
the	O
limma	O
package	O
from	O
Bioconductor	O
[	O
18	O
]	O
.	O

Individual	O
arrays	O
were	O
scaled	O
to	O
have	O
the	O
same	O
interquartile	O
range	O
(	O
75th	O
percentile	O
to	O
25th	O
percentile	O
)	O
.	O

Patient	O
information	O
,	O
including	O
clinical	O
data	O
and	O
gene	O
expression	O
data	O
,	O
was	O
obtained	O
from	O
and	O
analyzed	O
using	O
Oncomine	O
(	O
http://www.oncomine.org	O
)	O
.	O

Our	O
analysis	O
included	O
microarray	O
databases	O
such	O
as	O
the	O
Netherlands	O
Cancer	O
Institute	O
breast	O
cancer	O
database	O
[	O
19	O
]	O
.	O

The	O
microarray	O
meta	O
-	O
analysis	O
algorithms	O
and	O
statistical	O
analysis	O
used	O
were	O
as	O
previously	O
described	O
[	O
20,21	O
]	O
.	O

p	O
-	O
Values	O
were	O
calculated	O
using	O
adjustment	O
for	O
multiple	O
testing	O
and	O
false	O
discovery	O
as	O
described	O
at	O
http://www.oncomine.org	O
[	O
21	O
]	O
.	O

Methylation	O
and	O
Gene	O
Expression	O
Analysis	O
RNA	O
was	O
isolated	O
with	O
TRIzol	O
Reagent	O
(	O
Invitrogen	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

For	O
reverse	O
transcription	O
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
,	O
1	O
μg	O
of	O
total	O
RNA	O
was	O
reverse	O
transcribed	O
by	O
using	O
Ready	O
-	O
To	O
-	O
Go	O
You	O
-	O
Prime	O
First	O
-	O
Strand	O
Beads	O
(	O
Amersham	O
Biosciences	O
)	O
with	O
addition	O
of	O
random	O
hexamers	O
(	O
0.2	O
μg	O
per	O
reaction	O
)	O
.	O

Bisulfite	O
modification	O
of	O
genomic	O
DNA	O
was	O
carried	O
out	O
using	O
the	O
EZ	O
DNA	O
methylation	O
kit	O
(	O
Zymo	O
Research	O
)	O
.	O

Selection	O
of	O
primers	O
used	O
for	O
methylation	O
-	O
specific	O
PCR	O
(	O
MSP	O
)	O
and	O
determinants	O
for	O
CpG	O
island	O
localization	O
and	O
designation	O
was	O
accomplished	O
using	O
MSPPrimer	O
(	O
http://www.mspprimer.org	O
)	O
[	O
22	O
]	O
.	O

MSP	O
was	O
performed	O
as	O
previously	O
described	O
[	O
23	O
]	O
.	O

Primer	O
sequences	O
are	O
listed	O
in	O
Table	O
S3	O
.	O

Bisulfite	O
sequencing	O
and	O
RT	O
-	O
PCR	O
was	O
preformed	O
as	O
previously	O
described	O
[	O
24	O
]	O
.	O

Gene	O
expression	O
quantitation	O
was	O
performed	O
using	O
RT	O
-	O
PCR	O
and	O
the	O
1D	O
software	O
package	O
(	O
Kodak	O
)	O
.	O

For	O
Table	O
S1	O
,	O
decreased	O
expression	O
was	O
defined	O
as	O
expression	O
that	O
was	O
not	O
detectable	O
with	O
RT	O
-	O
PCR	O
or	O
decreased	O
by	O
two	O
-	O
thirds	O
compared	O
to	O
expression	O
levels	O
in	O
normal	O
tissue	O
measured	O
using	O
the	O
1D	O
software	O
to	O
quantitate	O
bands	O
.	O

Quantitative	O
PCR	O
was	O
performed	O
using	O
the	O
Invitrogen	O
SYBR	O
Green	O
qPCR	O
kit	O
according	O
the	O
manufacturer	O
's	O
instructions	O
.	O

Real	O
-	O
time	O
PCR	O
reactions	O
were	O
performed	O
using	O
the	O
Mastercycler	O
Realplex	O
machine	O
(	O
Eppendorf	O
)	O
.	O

Readings	O
were	O
normalized	O
using	O
GAPDH	O
.	O

Discussion	O
Overall	O
our	O
study	O
presents	O
an	O
extensive	O
search	O
for	O
the	O
presence	O
of	O
and	O
interactions	O
between	O
both	O
genetic	O
and	O
epigenetic	O
alterations	O
in	O
cancer	O
.	O

As	O
it	O
currently	O
stands	O
,	O
these	O
studies	O
do	O
have	O
several	O
limitations	O
.	O

First	O
,	O
our	O
data	O
do	O
not	O
address	O
the	O
biological	O
effects	O
of	O
the	O
individual	O
mutations	O
observed	O
in	O
the	O
CAN	O
genes	O
.	O

Second	O
,	O
the	O
data	O
draw	O
on	O
only	O
the	O
13,023	O
subset	O
of	O
CCDS	O
genes	O
that	O
were	O
previously	O
sequenced	O
,	O
and	O
additional	O
genes	O
have	O
now	O
been	O
sequenced	O
and	O
more	O
mutations	O
have	O
been	O
discovered	O
[	O
42	O
]	O
.	O

Despite	O
these	O
limitations	O
,	O
our	O
study	O
describes	O
a	O
valuable	O
approach	O
to	O
begin	O
to	O
understand	O
the	O
biological	O
significance	O
of	O
the	O
vast	O
amount	O
of	O
mutational	O
data	O
generated	O
by	O
cancer	O
resequencing	O
efforts	O
.	O

In	O
these	O
regards	O
,	O
our	O
findings	O
allow	O
several	O
important	O
conclusions	O
to	O
be	O
drawn	O
.	O

First	O
,	O
our	O
study	O
shows	O
that	O
large	O
-	O
scale	O
,	O
combined	O
genetic	O
and	O
epigenetic	O
analysis	O
is	O
feasible	O
and	O
useful	O
for	O
cancer	O
gene	O
discovery	O
.	O

Such	O
combined	O
analyses	O
can	O
markedly	O
enhance	O
links	O
made	O
between	O
gene	O
alterations	O
and	O
key	O
clinical	O
parameters	O
for	O
cancer	O
.	O

It	O
is	O
becoming	O
increasingly	O
clear	O
that	O
examination	O
and	O
interpretation	O
of	O
mutations	O
to	O
identify	O
cancer	O
genes	O
on	O
a	O
genome	O
-	O
wide	O
scale	O
can	O
be	O
significantly	O
complicated	O
by	O
passenger	O
mutations	O
[	O
43,44	O
]	O
.	O

Furthermore	O
,	O
as	O
we	O
mentioned	O
above	O
in	O
the	O
Results	O
,	O
it	O
is	O
very	O
unlikely	O
that	O
a	O
given	O
gene	O
that	O
in	O
breast	O
and/or	O
colon	O
cancer	O
has	O
evidence	O
for	O
mutations	O
,	O
promoter	O
hypermethylation	O
,	O
reduced	O
expression	O
,	O
and	O
is	O
localized	O
to	O
chromosome	O
regions	O
harboring	O
frequent	O
deletions	O
in	O
tumors	O
is	O
not	O
important	O
for	O
tumor	O
development	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
by	O
beginning	O
with	O
a	O
large	O
pool	O
of	O
genes	O
harboring	O
mostly	O
low	O
incidence	O
heterozygous	O
missense	O
mutations	O
and	O
then	O
characterizing	O
the	O
methylation	O
and	O
expression	O
status	O
of	O
these	O
genes	O
,	O
our	O
approach	O
allowed	O
us	O
to	O
identify	O
genes	O
that	O
possess	O
potentially	O
prognostic	O
value	O
.	O

Our	O
results	O
also	O
confirm	O
that	O
our	O
microarray	O
strategy	O
is	O
an	O
effective	O
approach	O
to	O
identify	O
genes	O
that	O
are	O
silenced	O
by	O
hypermethylation	O
in	O
colon	O
and	O
breast	O
cancer	O
.	O

Other	O
methods	O
have	O
been	O
developed	O
to	O
identify	O
hypermethylated	O
genes	O
in	O
cancer	O
,	O
including	O
restriction	O
landmark	O
genomic	O
scanning	O
,	O
promoter	O
CpG	O
island	O
microarrays	O
,	O
and	O
methylation	O
-	O
specific	O
digital	O
karyotyping	O
[	O
28,45	O
]	O
.	O

However	O
,	O
the	O
sensitivity	O
of	O
these	O
techniques	O
is	O
restricted	O
by	O
the	O
locations	O
of	O
methylation	O
-	O
sensitive	O
restriction	O
sites	O
in	O
the	O
genome	O
.	O

Several	O
of	O
the	O
common	O
target	O
genes	O
have	O
been	O
noted	O
to	O
undergo	O
methylation	O
-	O
associated	O
silencing	O
in	O
cancers	O
by	O
other	O
investigators	O
.	O

Lund	O
et	O
al.	O
noted	O
that	O
oncogenic	O
RAS	O
can	O
lead	O
to	O
the	O
hypermethylation	O
of	O
the	O
MMP2	O
gene	O
[	O
46	O
]	O
.	O

EVL	O
has	O
been	O
found	O
to	O
be	O
hypermethylated	O
in	O
colon	O
carcinoma	O
[	O
47	O
]	O
.	O

N	O
-	O
CAM	O
has	O
been	O
found	O
to	O
be	O
hypermethylated	O
in	O
lung	O
cancer	O
in	O
a	O
survey	O
of	O
methylated	O
genes	O
described	O
by	O
Shames	O
et	O
al.	O
[	O
48	O
]	O
.	O

The	O
presence	O
of	O
methylation	O
of	O
the	O
common	O
target	O
genes	O
in	O
other	O
tumor	O
types	O
suggests	O
that	O
these	O
genes	O
may	O
be	O
targets	O
of	O
inactivation	O
in	O
a	O
broader	O
range	O
of	O
cancers	O
,	O
a	O
hypothesis	O
that	O
warrants	O
future	O
investigation	O
.	O

In	O
particular	O
,	O
it	O
would	O
be	O
of	O
value	O
to	O
directly	O
compare	O
our	O
results	O
with	O
those	O
derived	O
by	O
other	O
strategies	O
for	O
analyzing	O
the	O
hypermethylome	O
from	O
the	O
same	O
as	O
well	O
as	O
from	O
other	O
types	O
of	O
malignancies	O
[	O
48–51	O
]	O
.	O

Together	O
with	O
these	O
studies	O
,	O
our	O
data	O
strongly	O
suggest	O
that	O
a	O
compendium	O
of	O
epigenetic	O
changes	O
underlie	O
the	O
progression	O
of	O
human	O
cancers	O
.	O

Stabilizing	O
mutation	O
of	O
/beta	O
-	O
catenin	O
and	O
protein	O
accumulation	O
analyzed	O
in	O
a	O
large	O
series	O
of	O
parathyroid	O
tumors	O
of	O
Swedish	O
patients	O
Abstract	O
Background	O
Aberrant	O
accumulation	O
of	O
β	O
-	O
catenin	O
plays	O
an	O
important	O
role	O
in	O
a	O
variety	O
of	O
human	B
neoplasms	O
.	O

We	O
recently	O
reported	O
accumulation	O
of	O
β	O
-	O
catenin	O
in	O
parathyroid	O
adenomas	O
from	O
patients	O
with	O
primary	O
hyperparathyroidism	O
(	O
pHPT	O
)	O
.	O

In	O
CTNNB1	O
exon	O
3	O
,	O
we	O
detected	O
a	O
stabilizing	O
mutation	O
(	O
S37A	O
)	O
in	O
3	O
out	O
of	O
20	O
analyzed	O
adenomas	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
frequency	O
and	O
zygosity	O
of	O
mutations	O
in	O
CTNNB1	O
exon	O
3	O
,	O
and	O
β	O
-	O
catenin	O
accumulation	O
in	O
a	O
large	O
series	O
of	O
parathyroid	O
adenomas	O
of	O
Swedish	O
patients	O
.	O

Results	O
The	O
mutation	O
S37A	O
(	O
TCT	O
>	O
GCT	O
)	O
was	O
detected	O
by	O
direct	O
DNA	O
sequencing	O
of	O
PCR	O
fragments	O
in	O
6	O
out	O
of	O
104	O
sporadic	O
parathyroid	O
adenomas	O
(	O
5.8	O
%	O
)	O
.	O

Taking	O
our	O
previous	O
study	O
into	O
account	O
,	O
a	O
total	O
of	O
9	O
out	O
of	O
124	O
(	O
7.3	O
%	O
)	O
adenomas	O
displayed	O
the	O
same	O
mutation	O
.	O

The	O
mutations	O
were	O
homozygous	O
by	O
DNA	O
sequencing	O
,	O
restriction	O
enzyme	O
cleavage	O
,	O
and	O
gene	O
copy	O
number	O
determination	O
using	O
the	O
GeneChip	O
500	O
K	O
Mapping	O
Array	O
Set	O
.	O

All	O
tumors	O
analyzed	O
by	O
immunohistochemistry	O
,	O
including	O
those	O
with	O
mutation	O
,	O
displayed	O
aberrant	O
β	O
-	O
catenin	O
accumulation	O
.	O

Western	O
blotting	O
revealed	O
a	O
slightly	O
higher	O
expression	O
level	O
of	O
β	O
-	O
catenin	O
and	O
nonphosphorylated	O
active	O
β	O
-	O
catenin	O
in	O
tumors	O
with	O
mutation	O
compared	O
to	O
those	O
without	O
.	O

Presence	O
of	O
the	O
mutation	O
was	O
not	O
related	O
to	O
distinct	O
clinical	O
characteristics	O
.	O

Conclusion	O
Aberrant	O
accumulation	O
of	O
β	O
-	O
catenin	O
is	O
very	O
common	O
in	O
parathyroid	O
tumors	O
,	O
and	O
is	O
caused	O
by	O
stabilizing	O
homozygous	O
mutation	O
in	O
7.3	O
%	O
of	O
Swedish	O
pHPT	O
patients	O
.	O

Hybridization	O
of	O
the	O
SBE	O
reaction	O
products	O
The	O
slides	O
printed	O
with	O
'	O
anti	O
-	O
tags	O
'	O
were	O
pre	O
-	O
heated	O
to	O
42	O
°	O
C	O
in	O
a	O
custom	O
-	O
made	O
aluminium	O
reaction	O
rack	O
with	O
a	O
re	O
-	O
usable	O
silicon	O
rubber	O
grid	O
placed	O
on	O
the	O
slides	O
to	O
form	O
75	O
separate	O
reaction	O
chambers	O
on	O
each	O
slide	O
[	O
24	O
]	O
.	O

The	O
hybridization	O
mixtures	O
,	O
containing	O
the	O
SBE	O
reaction	O
products	O
in	O
6.5	O
×	O
SSC	O
were	O
added	O
to	O
each	O
reaction	O
chamber	O
on	O
the	O
pre	O
-	O
heated	O
slide	O
.	O

The	O
hybridization	O
time	O
was	O
2.5	O
hours	O
at	O
42	O
°	O
C	O
followed	O
by	O
a	O
brief	O
rinse	O
with	O
4	O
×	O
SSC	O
at	O
room	O
temperature	O
.	O

Subsequently	O
,	O
the	O
slides	O
were	O
washed	O
twice	O
for	O
5	O
min	O
.	O

in	O
2	O
×	O
SSC	O
,	O
0.1	O
%	O
SDS	O
(	O
42	O
°	O
C	O
)	O
and	O
twice	O
for	O
1	O
min	O
.	O

in	O
0.2	O
×	O
SSC	O
(	O
room	O
temperature	O
)	O
.	O

Finally	O
,	O
the	O
slides	O
were	O
spin	O
dried	O
for	O
3	O
min	O
.	O

at	O
800	O
rpm	O
.	O

Signal	O
detection	O
The	O
signal	O
detection	O
was	O
performed	O
mainly	O
as	O
described	O
by	O
Lindroos	O
et	O
al.	O
[	O
23	O
]	O
.	O

The	O
fluorescence	O
signals	O
were	O
detected	O
with	O
a	O
ScanArray	O
4000XL	O
instrument	O
and	O
the	O
ScanArray	O
Express	O
software	O
(	O
PerkinElmer	O
Life	O
and	O
Analytical	O
Sciences	O
,	O
Inc	O
,	O
Wellesley	O
,	O
Ma	O
)	O
.	O

The	O
four	O
excitation	O
lasers	O
were	O
:	O
blue	O
Argon	O
,	O
488	O
nm	O
;	O
Green	O
HeNe	O
,	O
543.8	O
nm	O
;	O
Yellow	O
HeNe	O
,	O
594	O
nm	O
and	O
Red	O
HeNe	O
632.8	O
nm	O
.	O

The	O
laser	O
power	O
was	O
kept	O
constant	O
at	O
90	O
%	O
,	O
whereas	O
the	O
photo	O
-	O
multiplier	O
tube	O
(	O
PMT	O
)	O
varied	O
between	O
fluorophores	O
.	O

A	O
typical	O
setting	O
for	O
the	O
PMT	O
gain	O
was	O
65	O
,	O
75	O
,	O
65	O
and	O
70	O
%	O
for	O
the	O
fluorophores	O
Cy5-ddCTP	O
,	O
TAMRA	O
-	O
ddUTP	O
,	O
Texas	O
Red	O
®	O
-5-ddATP	O
and	O
R110-ddGTP	O
,	O
respectively	O
.	O

Statistics	O
Association	O
tests	O
A	O
Bonferroni	O
corrected	O
Fisher	O
exact	O
test	O
was	O
used	O
to	O
test	O
for	O
association	O
between	O
the	O
genotypes	O
of	O
each	O
SNP	O
and	O
the	O
familiar	O
CRC	O
cohort	O
and	O
the	O
cohort	O
of	O
sporadic	O
CRC	O
,	O
respectively	O
.	O

Fifteen	O
tests	O
were	O
made	O
for	O
single	O
marker	O
associations	O
,	O
in	O
the	O
cohort	O
of	O
familiar	O
CRC	O
,	O
yielding	O
a	O
Bonferroni	O
corrected	O
significance	O
level	O
of	O
0.05	O
/	O
15	O
=	O
0.0033	O
.	O

Likewise	O
the	O
Bonferroni	O
corrected	O
p	O
-	O
value	O
of	O
the	O
cohort	O
of	O
sporadic	O
cases	O
was	O
0.05	O
/	O
13	O
=	O
0.0038	O
.	O

A	O
Bonferroni	O
corrected	O
Monte	O
Carlo	O
(	O
MC	O
)	O
Fisher	O
exact	O
test	O
was	O
used	O
to	O
test	O
for	O
association	O
between	O
each	O
pair	O
of	O
SNPs	O
,	O
and	O
sporadic	O
or	O
familiar	O
CRC	O
.	O

One	O
hundred	O
thousand	O
permutations	O
were	O
used	O
for	O
each	O
test	O
.	O

Missing	O
data	O
were	O
handled	O
by	O
omitting	O
persons	O
with	O
missing	O
data	O
in	O
the	O
genotype	O
counts	O
;	O
e.g.	O
all	O
individuals	O
with	O
missing	O
data	O
in	O
either	O
variant	O
i	O
d	O
26	O
or	O
variant	O
i	O
d	O
27	O
were	O
omitted	O
when	O
calculating	O
the	O
genotype	O
frequencies	O
of	O
that	O
specific	O
SNP	O
-	O
pair	O
.	O

Power	O
calculations	O

The	O
power	O
was	O
calculated	O
by	O
applying	O
the	O
Fisher	O
exact	O
test	O
to	O
10000	O
independent	O
simulated	O
cases	O
with	O
the	O
given	O
odds	O
ratio	O
and	O
frequency	O
of	O
the	O
disease	O
causing	O
genotype	O
.	O

In	O
that	O
case	O
the	O
power	O
is	O
the	O
proportion	O
of	O
the	O
simulations	O
that	O
reach	O
a	O
p	O
-	O
value	O
lower	O
than	O
0.05	O
/	O
15	O
=	O
0.0033	O
.	O

Test	O
for	O
Hardy	O
-	O
Weinberg	O
proportions	O
Each	O
variant	O
was	O
tested	O
for	O
deviation	O
from	O
Hardy	O
-	O
Weinberg	O
proportions	O
in	O
the	O
sub	O
-	O
cohort	O
,	O
using	O
the	O
exact	O
test	O
described	O
by	O
Wigginton	O
et	O
al.	O
[	O
25	O
]	O
.	O

The	O
used	O
significance	O
level	O
was	O
0.01	O
.	O

Linkage	O
disequilibrium	O
Linkage	O
disequilibrium	O
(	O
LD	O
)	O
was	O
investigated	O
using	O
HaploView	O
(	O
v.	O
3.31	O
)	O
,	O
[	O
26	O
]	O
and	O
genome	O
build	O
NCBI35	O
for	O
information	O
track	O
.	O

In	O
silico	O
analysis	O
In	O
silico	O
prediction	O
of	O
the	O
functional	O
consequence	O
of	O
the	O
missense	O
variants	O
was	O
performed	O
using	O
SIFT	O
(	O
Sorting	O
Intolerant	O
From	O
Tolerant	O
)	O
[	O
27	O
]	O
,	O
Polyphen	O
[	O
28	O
]	O
and	O
PMUT	O
[	O
29	O
]	O
.	O

Mis	O
-	O
splicing	O
was	O
analysed	O
using	O
SNAP	O
(	O
SNP	O
Annotation	O
Platform	O
)	O
[	O
30	O
]	O
.	O

The	O
alignments	O
of	O
MSH2	O
or	O
MLH1	O
polypeptides	O
used	O
in	O
the	O
phylogenetic	O
analysis	O
of	O
the	O
missense	O
variants	O
was	O
performed	O
using	O
ClustalW	O
[	O
31	O
]	O
.	O

Thirteen	O
variants	O
were	O
polymorphic	O
in	O
the	O
present	O
study	O
.	O

The	O
majority	O
of	O
the	O
polymorphic	O
variants	O
(	O
i.e.	O
9	O
/	O
13	O
)	O
were	O
silent	O
or	O
present	O
in	O
non	O
-	O
coding	O
regions	O
.	O

This	O
corresponds	O
with	O
common	O
variants	O
being	O
more	O
abundant	O
in	O
introns	O
and	O
other	O
regions	O
than	O
in	O
coding	O
regions	O
[	O
38	O
]	O
.	O

Three	O
of	O
polymorphic	O
variants	O
i.e.	O
MLH1	O
p.	O

Val219Ile	O
,	O
p.	O

Ser406Asn	O
and	O
p.	O

Lys618Ala	O
changed	O
non	O
-	O
conserved	O
amino	O
acids	O
and	O
one	O
i.e.	O
MSH2	O
pGly322Asp	O
changed	O
a	O
conserved	O
amino	O
acid	O
.	O

Furthermore	O
,	O
two	O
polymorphic	O
variants	O
i.e.hMSH2	O
c.-118	O
T	O
>	O
C	O
and	O
hMLH1	O
c.1668	O
-	O
19	O
A	O
>	O
G	O
demonstrated	O
borderline	O
significant	O
p	O
-	O
values	O
i.e.	O
0.0037	O
(	O
significance	O
level	O
:	O
0.05	O
/	O
13	O
=	O
0.0038	O
)	O
and	O
0.0044	O
(	O
significance	O
level	O
:	O
0.05	O
/	O
15	O
=	O
0.0033	O
)	O
,	O
respectively	O
.	O

It	O
has	O
been	O
stated	O
that	O
the	O
conventional	O
threshold	O
for	O
declaration	O
of	O
statistical	O
evidence	O
of	O
association	O
(	O
i.e.	O
a	O
p	O
-	O
value	O
of	O
5	O
×	O
10	O
-	O
2	O
)	O
is	O
not	O
sufficient	O
to	O
detect	O
gene	O
-	O
disease	O
interactions	O
.	O

Consequently	O
,	O
it	O
has	O
been	O
suggested	O
to	O
lower	O
the	O
threshold	O
to	O
5	O
×	O
10	O
-	O
5	O
[	O
39	O
]	O
.	O

The	O
borderline	O
significant	O
p	O
-	O
values	O
and	O
the	O
previously	O
published	O
functional	O
analysis	O
of	O
one	O
of	O
the	O
variants	O
suggest	O
that	O
hMSH2	O
c.-118	O
T	O
>	O
C	O
and	O
hMLH1	O
c.1668	O
-	O
19	O
A	O
>	O
G	O
are	O
not	O
associated	O
with	O
increased	O
susceptibility	O
to	O
neither	O
sporadic	O
nor	O
familiar	O
CRC	O
in	O
the	O
Danish	O
population	O
.	O

The	O
remaining	O
polymorphic	O
variants	O
were	O
not	O
associated	O
with	O
CRC	O
in	O
the	O
analyzed	O
cohorts	O
,	O
neither	O
individually	O
nor	O
as	O
pairs	O
,	O
and	O
they	O
are	O
hence	O
neutral	O
variants	O
in	O
the	O
Danish	O
population	O
.	O

Some	O
of	O
these	O
variants	O
i.e.	O
hMLH1	O
c.655	O
A	O
>	O
G	O
(	O
p	O
.	O
Val219Ile	O
)	O
,	O
c.1217G	O
>	O
A	O
(	O
p.	O

Ser406Asn	O
)	O
,	O
c.1558	O
+	O
14	O
G	O
>	O
A	O
and	O
hMSH2	O
c.1959G	O
>	O
T	O
(	O
p.	O

Leu653Leu	O
)	O
have	O
been	O
characterized	O
as	O
neutral	O
variants	O
in	O
other	O
studies	O
as	O
well	O
[	O
40	O
-	O
42	O
]	O
.	O

In	O
vitro	O
functional	O
analysis	O
have	O
also	O
demonstrated	O
that	O
the	O
variants	O
MLH1	O
p.	O

Val219Ile	O
and	O
p.	O

Ser406Asn	O
exhibit	O
wild	O
-	O
type	O
activity	O
[	O
8,11,12	O
]	O
.	O

The	O
hMSH2	O
variant	O
c.965G	O
>	O
A	O
(	O
p.	O

Gly322Asp	O
)	O
has	O
previously	O
been	O
classified	O
as	O
a	O
neutral	O
variant	O
[	O
43	O
]	O
.	O

This	O
variant	O
changes	O
a	O
conserved	O
amino	O
acid	O
and	O
functional	O
analysis	O
in	O
yeast	O
has	O
shown	O
that	O
it	O
has	O
a	O
slightly	O
reduced	O
MMR	O
activity	O
[	O
8,44	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
frequency	O
of	O
the	O
c.965	O
G	O
>	O
A	O
variant	O
was	O
higher	O
in	O
the	O
cohort	O
of	O
individuals	O
with	O
familiar	O
CRC	O
compared	O
to	O
the	O
sub	O
-	O
cohort	O
although	O
this	O
was	O
not	O
statistically	O
significant	O
(	O
Tables	O
3	O
and	O
4	O
)	O
.	O

Results	O
regarding	O
the	O
MLH1	O
p.	O

Lys618Ala	O
variants	O
have	O
so	O
far	O
been	O
contradictory	O
.	O

Functional	O
analyses	O
have	O
identified	O
this	O
variant	O
both	O
as	O
a	O
pathogenic	O
mutation	O
and	O
as	O
a	O
neutral	O
variant	O
[	O
9,11,45	O
-	O
47	O
]	O
.	O

Raevaara	O
et	O
al.	O
used	O
four	O
different	O
assays	O
to	O
evaluate	O
the	O
pathogenic	O
status	O
[	O
9	O
]	O
.	O

In	O
all	O
four	O
assays	O
the	O
p.	O

Lys618Val	O
variant	O
functioned	O
like	O
wt	O
MLH1	O
.	O

In	O
addition	O
,	O
p.	O

Lys618Ala	O
has	O
been	O
identified	O
in	O
one	O
healthy	O
control	O
in	O
a	O
previous	O
study	O
[	O
48	O
]	O
.	O

The	O
identification	O
of	O
the	O
p.	O

Lys618Ala	O
variant	O
in	O
controls	O
in	O
the	O
present	O
study	O
further	O
support	O
,	O
that	O
this	O
variant	O
is	O
not	O
a	O
disease	O
causing	O
mutation	O
involved	O
in	O
HNPCC	O
or	O
HNPCC	O
-	O
related	O
cancers	O
.	O

In	O
addition	O
,	O
the	O
frequencies	O
of	O
the	O
variant	O
in	O
the	O
cohorts	O
analyzed	O
in	O
the	O
present	O
study	O
did	O
not	O
differ	O
significantly	O
and	O
therefore	O
p.	O

Lys618Ala	O
does	O
not	O
increase	O
susceptibility	O
to	O
sporadic	O
CRC	O
in	O
the	O
Danish	O
population	O
.	O

In	O
conclusion	O
none	O
of	O
the	O
polymorphic	O
variants	O
in	O
the	O
present	O
study	O
are	O
highly	O
associated	O
with	O
CRC	O
in	O
the	O
Danish	O
population	O
.	O

When	O
we	O
ran	O
null	O
simulations	O
in	O
the	O
presence	O
of	O
heterogeneity	O
of	O
marker	O
alleles	O
,	O
disease	O
alleles	O
,	O
or	O
both	O
,	O
we	O
observed	O
that	O
Zc	O
and	O
Zp	O
behaved	O
differently	O
depending	O
on	O
the	O
heterogeneity	O
model	O
we	O
simulated	O
.	O

Although	O
Zp	O
was	O
conservatively	O
biased	O
when	O
disease	O
allele	O
frequencies	O
differed	O
between	O
populations	O
,	O
regardless	O
of	O
whether	O
marker	O
allele	O
frequencies	O
differed	O
,	O
its	O
small	O
conservative	O
bias	O
was	O
not	O
significantly	O
different	O
from	O
that	O
observed	O
in	O
the	O
homogeneous	O
population	O
of	O
Table	O
2	O
.	O

In	O
contrast	O
,	O
Zc	O
exhibited	O
an	O
anticonservative	O
bias	O
when	O
marker	O
allele	O
frequencies	O
differed	O
between	O
populations	O
,	O
regardless	O
of	O
whether	O
disease	O
allele	O
frequencies	O
differed	O
.	O

Alternative	O
Model	O
Simulation	O
Results	O
A	O
subset	O
of	O
results	O
from	O
alternative	O
model	O
simulations	O
in	O
which	O
there	O
were	O
linkages	O
are	O
given	O
in	O
Table	O
4	O
,	O
based	O
on	O
20	O
replicate	O
simulations	O
for	O
each	O
combination	O
of	O
parameters	O
.	O

The	O
numbers	O
given	O
represent	O
mean	O
Z	O
statistics	O
,	O
their	O
ARE	O
values	O
,	O
and	O
sample	O
sizes	O
required	O
to	O
attain	O
80	O
%	O
power	O
.	O

The	O
results	O
displayed	O
were	O
chosen	O
to	O
highlight	O
the	O
effect	O
of	O
sampling	O
(	O
and	O
genotyping	O
)	O
varying	O
the	O
numbers	O
of	O
unaffected	O
sibs	O
and/or	O
parents	O
from	O
families	O
with	O
two	O
or	O
three	O
affected	O
sibs	O
and	O
two	O
unaffected	O
sibs	O
.	O

Full	O
results	O
are	O
available	O
online	O
[	O
64	O
]	O
.	O

On	O
average	O
,	O
the	O
concordant	O
test	O
was	O
always	O
more	O
efficient	O
on	O
a	O
per	O
-	O
genotype	O
basis	O
than	O
the	O
paired	O
test	O
,	O
although	O
the	O
power	O
of	O
the	O
paired	O
test	O
was	O
usually	O
greater	O
when	O
the	O
number	O
of	O
unaffected	O
sibs	O
tested	O
was	O
>	O
2	O
.	O

Alternative	O
Model	O
Simulation	O
Mean	O
Z	O
score	O
,	O
asymptotic	O
relative	O
efficiency	O
per	O
genotype	O
(	O
ARE	O
–	O
see	O
text	O
)	O
,	O
and	O
sample	O
size	O
required	O
to	O
attain	O
80	O
%	O
power	O
for	O
two	O
-	O
point	O
linkage	O
(	O
θ	O
=	O
0.05	O
)	O
for	O
predisposition	O
to	O
colorectal	O
cancer	O
with	O
a	O
baseline	O
risk	O
of	O
0.018	O
,	O
a	O
relative	O
risk	O
to	O
carriers	O
of	O
20	O
,	O
allele	O
frequency	O
of	O
0.003	O
,	O
with	O
a	O
lifetime	O
penetrance	O
of	O
0.27	O
,	O
under	O
3	O
different	O
heterogeneity	O
models	O
:	O
A	O
)	O
no	O
heterogeneity	O
;	O
B	O
)	O
an	O
equally	O
penetrant	O
,	O
less	O
common	O
(	O
allele	O
frequency	O
0.001	O
)	O
unlinked	O
predisposing	O
locus	O
;	O
C	O
)	O
an	O
equally	O
penetrant	O
,	O
equally	O
common	O
unlinked	O
predisposing	O
locus	O
.	O

All	O
results	O
based	O
on	O
500	O
simulated	O
families	O
and	O
20	O
replicate	O
simulations	O
per	O
parameter	O
set	O
.	O

Zc	O
mean	O
concordant	O
test	O
;	O

Zp	O
mean	O
paired	O
test	O
;	O
ARE	O
(	O
Zc	O
)	O
asymptotic	O
relative	O
efficiency	O
concordant	O
test	O
;	O
ARE	O
(	O
Zp	O
)	O
asymptotic	O
relative	O
efficiency	O
paired	O
test	O
;	O
Nc	O
(	O
80	O
%	O
)	O
number	O
of	O
families	O
required	O
for	O
80	O
%	O
power	O
using	O
concordant	O
test	O
;	O
Np	O
(	O
80	O
%	O
)	O
number	O
of	O
families	O
required	O
for	O
80	O
%	O
power	O
using	O
paired	O
test	O
.	O

Regression	O
Models	O
Table	O
5	O
shows	O
the	O
effect	O
of	O
various	O
design	O
and	O
population	O
parameters	O
on	O
the	O
noncentrality	O
parameter	O
for	O
both	O
the	O
concordant	O
-	O
only	O
test	O
(	O
Zc	O
/	O
F	O
)	O
and	O
the	O
paired	O
test	O
(	O
Zp	O
/	O
F	O
)	O
.	O

The	O
only	O
change	O
in	O
parameterization	O
of	O
the	O
model	O
for	O
the	O
paired	O
test	O
vis	O
-	O
a	O
-	O
vis	O
the	O
concordant	O
test	O
involved	O
substituting	O
the	O
number	O
of	O
typed	O
unaffected	O
sibs	O
for	O
the	O
total	O
number	O
of	O
unaffected	O
sibs	O
.	O

The	O
AR	O
for	O
the	O
linked	O
locus	O
had	O
the	O
largest	O
positive	O
effect	O
on	O
power	O
of	O
the	O
concordant	O
test	O
,	O
followed	O
closely	O
by	O
the	O
negative	O
effect	O
on	O
power	O
of	O
increasing	O
AR	O
at	O
the	O
unlinked	O
locus	O
and	O
increasing	O
recombination	O
fraction	O
between	O
the	O
marker	O
and	O
trait	O
loci	O
.	O

Increasing	O
the	O
number	O
of	O
affected	O
sibs	O
per	O
family	O
and	O
increasing	O
the	O
number	O
of	O
affected	O
sibs	O
genotyped	O
per	O
family	O
both	O
substantially	O
improved	O
power	O
.	O

The	O
number	O
of	O
unaffected	O
sibs	O
present	O
in	O
sampled	O
families	O
had	O
little	O
or	O
no	O
effect	O
on	O
power	O
.	O

Increased	O
power	O
was	O
also	O
observed	O
for	O
increasing	O
numbers	O
of	O
available	O
parents	O
,	O
the	O
size	O
of	O
the	O
effect	O
on	O
Zc	O
/	O
F	O
being	O
about	O
15	O
%	O
of	O
the	O
effect	O
of	O
increasing	O
numbers	O
of	O
affected	O
sibs	O
.	O

Substituting	O
spouse	O
and	O
offspring	O
for	O
an	O
unavailable	O
affected	O
sib	O
reduced	O
power	O
substantially	O
,	O
but	O
genotyping	O
a	O
second	O
child	O
recovered	O
much	O
of	O
that	O
lost	O
power	O
.	O

Comparison	O
of	O
two	O
-	O
point	O
vs.	O
multipoint	O
linkage	O
scores	O
under	O
various	O
non	O
-	O
null	O
simulation	O
conditions	O
.	O

All	O
simulations	O
employed	O
20	O
replicates	O
of	O
500	O
families	O
with	O
2	O
affected	O
and	O
2	O
unaffected	O
sibs	O
,	O
all	O
sibs	O
typed	O
,	O
no	O
parents	O
or	O
children	O
typed	O
.	O

a	O
Baseline	O
risk	O
of	O
0.018	O
,	O
a	O
relative	O
risk	O
to	O
carriers	O
of	O
20	O
,	O
allele	O
frequency	O
of	O
0.003	O
,	O
with	O
a	O
lifetime	O
penetrance	O
of	O
0.27	O
,	O
no	O
genetic	O
heterogeneity	O
.	O

b	O
Baseline	O
risk	O
of	O
0.018	O
,	O
a	O
relative	O
risk	O
to	O
carriers	O
of	O
20	O
,	O
allele	O
frequency	O
of	O
0.003	O
,	O
with	O
a	O
lifetime	O
penetrance	O
of	O
0.27	O
,	O
and	O
a	O
less	O
common	O
(	O
allele	O
frequency	O
0.001	O
)	O
,	O
equally	O
penetrant	O
unlinked	O
predisposition	O
syndrome	O
.	O

c	O
Two	O
populations	O
modeled	O
in	O
an	O
80%	O
/	O
20	O
%	O
mixture	O
:	O
1	O
)	O
marker	O
allele	O
frequencies	O
for	O
all	O
markers	O
[	O
0.25,0.25,0.25,0.25	O
]	O
,	O
disease	O
allele	O
0.00325	O
;	O
2	O
)	O
marker	O
alleles	O
[	O
0.4,0.3,0.2,0.1	O
]	O
,	O
disease	O
allele	O
0.002	O
.	O

d	O
Two	O
populations	O
modeled	O
in	O
an	O
80%	O
/	O
20	O
%	O
mixture	O
:	O
1	O
)	O
marker	O
allele	O
frequencies	O
for	O
all	O
markers	O
[	O
0.25,0.25,0.25,0.25	O
]	O
,	O
disease	O
allele	O
0.0035	O
;	O
2	O
)	O
marker	O
alleles	O
[	O
0.4,0.3,0.2,0.1	O
]	O
,	O
disease	O
allele	O
0.001	O
.	O

Replacement	O
of	O
a	O
missing	O
affected	O
individual	O
by	O
a	O
spouse	O
and	O
offspring	O
is	O
not	O
generally	O
as	O
efficient	O
per	O
genotype	O
as	O
if	O
that	O
individual	O
had	O
been	O
available	O
,	O
although	O
the	O
efficiency	O
improves	O
with	O
each	O
additional	O
offspring	O
included	O
.	O

Figure	O
5	O
shows	O
the	O
effect	O
of	O
replacing	O
one	O
member	O
of	O
an	O
ASP	O
with	O
one	O
or	O
two	O
offspring	O
and	O
the	O
spouse	O
.	O

Figure	O
6	O
shows	O
the	O
effect	O
of	O
replacing	O
one	O
member	O
of	O
an	O
affected	O
sib	O
trio	O
with	O
one	O
or	O
two	O
offspring	O
and	O
the	O
spouse	O
.	O

Because	O
families	O
with	O
three	O
affected	O
sibs	O
are	O
more	O
likely	O
to	O
be	O
segregating	O
a	O
disease	O
-	O
predisposing	O
allele	O
than	O
families	O
with	O
two	O
affected	O
sibs	O
,	O
each	O
family	O
is	O
more	O
informative	O
for	O
linkage	O
,	O
even	O
if	O
DNA	O
is	O
available	O
for	O
only	O
two	O
sibs	O
.	O

Substituting	O
the	O
spouse	O
and	O
one	O
or	O
more	O
offspring	O
for	O
the	O
missing	O
sib	O
adds	O
additional	O
power	O
,	O
although	O
at	O
the	O
cost	O
of	O
additional	O
genotyping	O
.	O

Conclusion	O
We	O
have	O
shown	O
that	O
for	O
a	O
wide	O
variety	O
of	O
situations	O
relevant	O
to	O
sib	O
-	O
pair	O
studies	O
of	O
colon	O
cancer	O
and	O
similar	O
late	O
-	O
onset	O
complex	O
diseases	O
,	O
standard	O
concordant	O
-	O
pair	O
allele	O
-	O
sharing	O
statistics	O
based	O
on	O
identity	O
by	O
descent	O
probabilities	O
are	O
more	O
efficient	O
than	O
similarly	O
constructed	O
discordant	O
statistics	O
in	O
homogeneous	O
populations	O
,	O
but	O
may	O
be	O
biased	O
away	O
from	O
the	O
null	O
in	O
situations	O
where	O
subjects	O
are	O
chosen	O
from	O
multiple	O
populations	O
having	O
differing	O
marker	O
allele	O
frequencies	O
or	O
other	O
sources	O
of	O
bias	O
.	O

Where	O
heterogeneity	O
in	O
marker	O
allele	O
frequencies	O
is	O
anticipated	O
because	O
of	O
underlying	O
population	O
admixture	O
,	O
linkage	O
tests	O
based	O
on	O
comparison	O
of	O
concordant	O
vs.	O
discordant	O
allele	O
sharing	O
should	O
be	O
considered	O
.	O

Either	O
of	O
these	O
approaches	O
should	O
allow	O
studies	O
of	O
500–1000	O
families	O
containing	O
an	O
ASP	O
to	O
achieve	O
reasonable	O
power	O
to	O
detect	O
linkage	O
under	O
conditions	O
including	O
genetic	O
and	O
population	O
heterogeneity	O
,	O
unavailable	O
parents	O
,	O
misspecified	O
allele	O
frequencies	O
,	O
and	O
other	O
afflictions	O
of	O
the	O
sib	O
-	O
pair	O
design	O
.	O

While	O
collecting	O
DNA	O
samples	O
from	O
unaffected	O
sibs	O
can	O
be	O
useful	O
for	O
a	O
wide	O
variety	O
of	O
purposes	O
–	O
especially	O
if	O
multipoint	O
methods	O
are	O
used	O
–	O
in	O
many	O
circumstances	O
it	O
should	O
be	O
unnecessary	O
to	O
genotype	O
these	O
samples	O
for	O
purposes	O
of	O
performing	O
a	O
genome	O
scan	O
.	O

If	O
adequate	O
allele	O
frequency	O
data	O
are	O
available	O
and	O
microsatellites	O
are	O
being	O
used	O
,	O
we	O
suggest	O
a	O
single	O
-	O
point	O
affecteds	O
-	O
only	O
analysis	O
for	O
a	O
initial	O
scan	O
,	O
followed	O
by	O
a	O
multipoint	O
analysis	O
of	O
affected	O
and	O
unaffected	O
members	O
of	O
all	O
available	O
sibships	O
with	O
additional	O
markers	O
around	O
initial	O
hits	O
.	O

For	O
dense	O
SNP	O
mapping	O
studies	O
,	O
analysis	O
using	O
individual	O
SNPs	O
will	O
not	O
be	O
sufficiently	O
informative	O
and	O
so	O
multipoint	O
analyses	O
will	O
be	O
required	O
,	O
but	O
unless	O
the	O
parents	O
are	O
all	O
available	O
,	O
analyses	O
should	O
be	O
restricted	O
to	O
markers	O
that	O
show	O
low	O
levels	O
of	O
linkage	O
disequilibrium	O
(	O
the	O
reference	O
here	O
would	O
be	O
to	O
a	O
paper	O
by	O
Bacanu	O
SA	O
.	O

Multipoint	O
linkage	O
analysis	O
for	O
a	O
very	O
dense	O
set	O
of	O
markers	O
Genet	O
Epidemiol	O
.	O

2005	O
Nov;29	O
(	O
3	O
)	O
:195–203	O
.	O
)	O
or	O
estimate	O
haplotype	O
frequencies	O
(	O
Abecasis	O
and	O
Wigginton	O
,	O
Handling	O
marker	O
-	O
marker	O
linkage	O
disequilibrium	O
:	O
pedigree	O
analysis	O
with	O
clustered	O
markers	O
.	O

Am	O
J	O
Hum	O
Genet	O
.	O

2005	O
Nov;77	O
(	O
5	O
)	O
:754–67	O
.	O

Epub	O
2005	O
Sep	O
20	O
.	O
)	O

If	O
the	O
parents	O
are	O
available	O
,	O
even	O
though	O
we	O
have	O
shown	O
that	O
genotyping	O
them	O
is	O
inefficient	O
,	O
an	O
argument	O
can	O
be	O
made	O
for	O
genotyping	O
them	O
because	O
their	O
inclusion	O
ameliorates	O
any	O
potential	O
effect	O
of	O
population	O
admixture	O
,	O
greatly	O
facilitates	O
the	O
identification	O
of	O
any	O
genotyping	O
errors	O
and	O
reduces	O
the	O
dependence	O
upon	O
correct	O
specification	O
of	O
haplotype	O
frequencies	O
when	O
multipoint	O
analyses	O
are	O
conducted	O
(	O
can	O
refer	O
to	O
Huang	O
et	O
al	O
,	O
2004	O
Ignoring	O
linkage	O
disequilibrium	O
among	O
tightly	O
linked	O
markers	O
induces	O
false	O
-	O
positive	O
evidence	O
of	O
linkage	O
for	O
affected	O
sib	O
pair	O
analysis	O
.	O

Am	O
J	O
Hum	O
Genet	O
.	O

2004	O
Dec;75	O
(	O
6	O
)	O
:1106	O
-	O
12	O
.	O

Epub	O
2004	O
Oct	O
18	O
.	O
)	O
.	O

The	O
choice	O
of	O
whether	O
or	O
not	O
to	O
genotype	O
unaffected	O
individuals	O
also	O
would	O
depend	O
upon	O
the	O
feasibility	O
and	O
cost	O
of	O
cherry	O
-	O
picking	O
for	O
regional	O
genotyping	O
of	O
regions	O
showing	O
evidence	O
for	O
linkage	O
,	O
but	O
we	O
have	O
not	O
studied	O
either	O
of	O
these	O
issues	O
in	O
this	O
paper	O
.	O

Admixture	O
is	O
more	O
likely	O
to	O
be	O
of	O
concern	O
when	O
studying	O
populations	O
that	O
are	O
known	O
to	O
have	O
been	O
founded	O
by	O
different	O
ethnic	O
groups	O
or	O
races	O
such	O
as	O
Hispanics	O
and	O
African	O
-	O
Americans	O
.	O

INTRODUCTION	O
Colorectal	O
cancer	O
arises	O
from	O
a	O
series	O
of	O
somatically	O
inherited	O
changes	O
,	O
including	O
mutations	O
and	O
transmissible	O
epigenetic	O
events	O
such	O
as	O
methylation	O
of	O
CpG	O
islands	O
(	O
1	O
)	O
,	O
some	O
or	O
all	O
of	O
which	O
produce	O
a	O
growth	O
advantage	O
relative	O
to	O
surrounding	O
cells	O
(	O
2	O
,	O
3	O
)	O
.	O

Among	O
the	O
epigenetic	O
events	O
involved	O
in	O
tumorigenesis	O
are	O
DNA	O
methylation	O
,	O
genomic	O
imprinting	O
,	O
and	O
histone	O
modification	O
(	O
4	O
)	O
.	O

Global	O
decreases	O
in	O
5-methylcytosine	O
content	O
have	O
been	O
associated	O
with	O
tumor	O
formation	O
,	O
including	O
that	O
of	O
colorectal	O
cancers	O
.	O

Another	O
molecular	O
defect	O
commonly	O
occurring	O
during	O
neoplasia	O
is	O
de	O
novo	O
CpG	O
island	O
methylation	O
(	O
4	O
-	O
6	O
)	O
.	O

Recently	O
,	O
a	O
distinct	O
pathway	O
of	O
colorectal	O
carcinogenesis	O
was	O
described	O
,	O
termed	O
the	O
CpG	O
island	O
methylation	O
phenotype	O
(	O
CIMP	O
)	O
(	O
7	O
)	O
.	O

This	O
pathway	O
was	O
uncovered	O
through	O
a	O
series	O
of	O
observations	O
that	O
included	O
association	O
between	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
and	O
hypermethylation	O
of	O
multiple	O
genes	O
,	O
from	O
the	O
concordance	O
between	O
the	O
methylation	O
status	O
of	O
different	O
genes	O
unrelated	O
to	O
the	O
gene	O
function	O
or	O
chromosomal	O
location	O
,	O
and	O
from	O
the	O
bimodal	O
distribution	O
of	O
methylation	O
in	O
a	O
selected	O
subset	O
of	O
genes	O
.	O

Colorectal	O
cancer	O
is	O
the	O
third	O
leading	O
cause	O
of	O
cancer	O
-	O
related	O
deaths	O
worldwide	O
(	O
8)	O
.	O

Almost	O
70	O
%	O
of	O
all	O
colorectal	O
cancers	O
are	O
sporadic	O
.	O

Of	O
the	O
remaining	O
30	O
%	O
,	O
a	O
small	O
number	O
belong	O
to	O
the	O
familial	O
syndromes	O
of	O
hereditary	O
nonpolyposis	O
colorectal	O
cancer	O
(	O
HNPCC	O
)	O
and	O
familial	O
adenomatous	O
polyposis	O
(	O
FAP	O
)	O
,	O
whereas	O
the	O
vast	O
majority	O
show	O
non	O
-	O
syndromatic	O
familial	O
susceptibility	O
(	O
9	O
)	O
.	O

The	O
proportion	O
of	O
all	O
cases	O
considered	O
familial	O
depends	O
in	O
the	O
definition	O
.	O

Of	O
all	O
patients	O
with	O
colorectal	O
cancer	O
,	O
11	O
-	O
16	O
%	O
have	O
at	O
least	O
one	O
first	O
-	O
degree	O
relative	O
with	O
colorectal	O
cancer	O
(	O
10	O
,	O
11	O
)	O
,	O
but	O
the	O
proportion	O
is	O
much	O
higher	O
if	O
second-	O
or	O
third	O
-	O
degree	O
relatives	O
are	O
considered	O
.	O

In	O
one	O
study	O
,	O
53	O
%	O
of	O
colorectal	O
cancer	O
probands	O
had	O
a	O
first	O
-	O
degree	O
relative	O
with	O
cancer	O
(	O
11	O
)	O
.	O

In	O
fact	O
,	O
first	O
-	O
degree	O
relatives	O
of	O
patients	O
affected	O
by	O
colorectal	O
cancer	O
,	O
but	O
who	O
do	O
not	O
fulfill	O
the	O
criteria	O
for	O
FAP	O
and	O
HNPCC	O
,	O
have	O
a	O
more	O
than	O
2-fold	O
increased	O
risk	O
of	O
developing	O
tumors	O
of	O
the	O
large	O
intestine	O
(	O
12	O
)	O
.	O

HNPCC	O
is	O
caused	O
by	O
germline	O
mutations	O
in	O
the	O
mismatch	O
repair	O
(	O
MMR	O
)	O
genes	O
hMLH1	O
,	O
hMSH2	O
,	O
hMSH6	O
,	O
and	O
hPMS2	O
,	O
with	O
a	O
penetrance	O
of	O
approximately	O
80	O
%	O
for	O
colorectal	O
cancer	O
,	O
60	O
%	O
for	O
endometrial	O
cancer	O
,	O
and	O
below	O
20	O
%	O
for	O
other	O
cancers	O
(	O
13	O
)	O
.	O

HNPCC	O
is	O
characterized	O
by	O
early	O
onset	O
,	O
the	O
development	O
of	O
neoplastic	O
lesions	O
in	O
a	O
variety	O
of	O
tissues	O
,	O
and	O
MSI	O
.	O

The	O
Amsterdam	O
criteria	O
for	O
HNPCC	O
are	O
strictly	O
defined	O
and	O
exclude	O
most	O
tumors	O
suspected	O
of	O
being	O
hereditary	O
.	O

In	O
contrast	O
,	O
the	O
Bethesda	O
guidelines	O
broaden	O
the	O
disease	O
spectrum	O
by	O
including	O
colorectal	O
cancer	O
families	O
with	O
specific	O
accompanying	O
cancers	O
and	O
clinicopathologic	O
characteristics	O
(	O
13	O
,	O
14	O
)	O
.	O

These	O
latter	O
criteria	O
provide	O
important	O
clues	O
for	O
identifying	O
genetic	O
pathways	O
associated	O
with	O
atypical	O
phenotypes	O
of	O
hereditary	O
colorectal	O
cancer	O
.	O

Although	O
the	O
strict	O
Amsterdam	O
criteria	O
could	O
be	O
used	O
to	O
detect	O
underlying	O
molecular	O
events	O
in	O
hereditary	O
colorectal	O
cancers	O
,	O
only	O
50	O
%	O
(	O
range	O
,	O
30	O
-	O
80	O
%	O
)	O
of	O
cases	O
involve	O
a	O
detectable	O
germline	O
mutation	O
in	O
an	O
MMR	O
gene	O
(	O
15	O
)	O
.	O

Therefore	O
,	O
by	O
restricting	O
the	O
definition	O
of	O
HNPCC	O
to	O
tumors	O
containing	O
an	O
MMR	O
germline	O
mutation	O
,	O
only	O
about	O
2.5	O
%	O
of	O
colorectal	O
cancers	O
are	O
thought	O
to	O
be	O
caused	O
by	O
HNPCC	O
.	O

Thus	O
,	O
the	O
carcinogenesis	O
pathways	O
and	O
molecular	O
events	O
in	O
familial	O
cancers	O
with	O
no	O
detectable	O
germline	O
mutations	O
and/or	O
not	O
fulfilling	O
HNPCC	O
criteria	O
,	O
remain	O
to	O
be	O
determined	O
.	O

Grouping	O
of	O
adenomas	O
and	O
carcinomas	O
by	O
promoter	O
methylation	O
status	O
Tumors	O
were	O
classified	O
as	O
methylation	O
-	O
resistant	O
(	O
MR	O
)	O
if	O
fewer	O
than	O
two	O
loci	O
were	O
methylated	O
or	O
methylation	O
-	O
prone	O
(	O
MP	O
)	O
if	O
two	O
or	O
more	O
loci	O
were	O
methylated	O
.	O

Each	O
tumor	O
and	O
group	O
were	O
represented	O
by	O
a	O
methylation	O
index	O
(	O
number	O
of	O
loci	O
methylated	O
/	O
number	O
of	O
loci	O
evaluated	O
)	O
.	O

MSI	O
MSI	O
status	O
was	O
determined	O
by	O
PCR	O
using	O
primers	O
to	O
amplify	O
the	O
five	O
microsatellite	O
markers	O
recommended	O
by	O
the	O
National	O
Cancer	O
Institute	O
(	O
Bethesda	O
,	O
MD	O
.	O
,	O
U.S.A.	O
)	O
,	O
i.e.	O
,	O
BAT25	O
,	O
BAT26	O
,	O
D17S250	O
,	O
D5S346	O
,	O
and	O
D2S123	O
(	O
13	O
)	O
.	O

Denaturation	O
of	O
the	O
PCR	O
products	O
,	O
gel	O
electrophoresis	O
,	O
and	O
silver	O
staining	O
were	O
performed	O
as	O
described	O
.	O

MSI	O
was	O
scored	O
as	O
positive	O
when	O
there	O
was	O
a	O
definite	O
shift	O
of	O
PCR	O
product	O
in	O
tumor	O
DNA	O
compared	O
with	O
normal	O
mucosal	O
DNA	O
.	O

All	O
MSI	O
-	O
positive	O
loci	O
were	O
confirmed	O
on	O
duplicate	O
examinations	O
.	O

Tumors	O
with	O
MSI	O
in	O
at	O
least	O
two	O
loci	O
were	O
classified	O
as	O
high	O
-	O
frequency	O
MSI	O
(	O
MSI	O
-	O
H	O
)	O
,	O
tumors	O
with	O
MSI	O
at	O
one	O
locus	O
were	O
classified	O
as	O
low	O
frequency	O
MSI	O
(	O
MSI	O
-	O
L	O
)	O
,	O
and	O
tumors	O
with	O
MSI	O
at	O
no	O
locus	O
were	O
classified	O
as	O
microsatellite	O
stable	O
(	O
MSS	O
)	O
.	O

Statistical	O
analysis	O
The	O
interactions	O
between	O
methylation	O
and	O
clinicopathologic	O
parameters	O
in	O
two	O
groups	O
were	O
evaluated	O
with	O
chi	O
-	O
square	O
tests	O
and	O
Fisher	O
's	O
exact	O
tests	O
.	O

All	O
p	O
values	O
were	O
two	O
-	O
sided	O
,	O
and	O
a	O
p	O
value	O
less	O
than	O
0.05	O
was	O
considered	O
statistically	O
significant	O
.	O

Calculations	O
were	O
performed	O
using	O
the	O
SPSS	O
program	O
(	O
Version	O
12.0	O
,	O
Chicago	O
,	O
IL	O
,	O
U.S.A.	O
)	O
.	O

The	O
majority	O
of	O
tumors	O
were	O
found	O
to	O
be	O
moderately	O
differentiated	O
in	O
African	O
Americans	O
(	O
79	O
%	O
)	O
and	O
Omanis	O
(	O
82	O
%	O
;	O
Table	O
1	O
,	O
2	O
)	O
.	O

Iranian	O
tumors	O
were	O
mostly	O
well	O
differentiated	O
(	O
54	O
%	O
)	O
.	O

The	O
percentage	O
of	O
moderately	O
differentiated	O
tumors	O
was	O
86	O
%	O
in	O
the	O
MSI	O
-	O
H	O
Omani	O
group	O
compared	O
with	O
72	O
%	O
in	O
African	O
Americans	O
and	O
64	O
%	O
in	O
Iranians	O
(	O
Table	O
1	O
,	O
3	O
)	O
.	O

In	O
addition	O
,	O
seven	O
and	O
one	O
MSI	O
-	O
H	O
tumors	O
showed	O
poor	O
differentiation	O
in	O
African	O
Americans	O
and	O
Omanis	O
,	O
respectively	O
.	O

While	O
in	O
African	O
Americans	O
,	O
one	O
MSI	O
-	O
H	O
was	O
well	O
differentiated	O
,	O
no	O
patient	O
in	O
Iranian	O
non	O
-	O
MSI	O
-	O
H	O
cases	O
was	O
poorly	O
differentiated	O
(	O
Table	O
1	O
,	O
3	O
)	O
.	O

The	O
difference	O
was	O
insignificant	O
trend	O
in	O
African	O
Americans	O
and	O
Omanis	O
but	O
in	O
Iranian	O
patients	O
differentiation	O
was	O
significantly	O
correlated	O
with	O
MSI	O
-	O
H	O
occurrence	O
.	O

This	O
finding	O
was	O
not	O
sustained	O
in	O
multivariate	O
analysis	O
.	O

Most	O
of	O
the	O
patients	O
in	O
the	O
series	O
were	O
stage	O
II	O
or	O
higher	O
(	O
Table	O
1	O
,	O
2	O
,	O
3	O
)	O
,	O
with	O
45	O
%	O
[	O
13	O
]	O
of	O
African	O
American	O
,	O
62	O
%	O
[	O
5	O
]	O
of	O
Omani	O
,	O
and	O
14	O
%	O
[	O
2	O
]	O
of	O
Iranian	O
MSI	O
-	O
H	O
lesions	O
at	O
stage	O
II	O
.	O

Thirty	O
-	O
eight	O
percent	O
[	O
24	O
]	O
of	O
African	O
American	O
,	O
28	O
%	O
[	O
15	O
]	O
of	O
Omani	O
,	O
and	O
23	O
%	O
[	O
12	O
]	O
of	O
Iranian	O
of	O
the	O
non	O
-	O
MSI	O
-	O
H	O
lesions	O
were	O
at	O
stage	O
II	O
(	O
Table	O
3	O
)	O
.	O

Forty	O
-	O
one	O
percent	O
[	O
12	O
]	O
of	O
African	O
American	O
,	O
25	O
%	O
[	O
2	O
]	O
of	O
Omani	O
,	O
and	O
79	O
%	O
[	O
11	O
]	O
of	O
Iranian	O
of	O
the	O
MSI	O
-	O
H	O
lesions	O
were	O
at	O
stage	O
III	O
(	O
Table	O
1	O
,	O
2	O
,	O
3	O
)	O
.	O

Thirty	O
-	O
seven	O
percent	O
[	O
23	O
]	O
of	O
African	O
American	O
,	O
55	O
%	O
[	O
29	O
]	O
of	O
Omani	O
,	O
and	O
67	O
%	O
[	O
26	O
]	O
of	O
Iranian	O
of	O
the	O
non	O
-	O
MSI	O
-	O
H	O
lesions	O
were	O
at	O
stage	O
III	O
.	O

Fourteen	O
percent	O
[	O
9	O
]	O
of	O
African	O
American	O
,	O
15	O
%	O
[	O
8	O
]	O
of	O
Omani	O
,	O
and	O
7	O
%	O
[	O
3	O
]	O
of	O
Iranian	O
of	O
the	O
non	O
-	O
MSI	O
-	O
H	O
lesions	O
were	O
at	O
stage	O
IV	O
(	O
Table	O
1	O
,	O
2	O
,	O
3	O
)	O
.	O

There	O
was	O
insignificant	O
trend	O
in	O
the	O
stage	O
of	O
the	O
lesions	O
between	O
the	O
MSI	O
and	O
non	O
-	O
MSI	O
-	O
H	O
groups	O
.	O

Correlation	O
between	O
methylation	O
pattern	O
of	O
the	O
hMLH1	O
promoter	O
and	O
MSI	O
status	O
Among	O
MSI	O
-	O
H	O
samples	O
,	O
hMLH1	O
promoter	O
methylation	O
was	O
found	O
in	O
90	O
%	O
[	O
18	O
]	O
of	O
African	O
American	O
,	O
75	O
%	O
[	O
6	O
]	O
of	O
Omani	O
and	O
71	O
%	O
[	O
10	O
]	O
of	O
Iranian	O
tumors	O
,	O
confirming	O
a	O
previous	O
finding	O
of	O
predominant	O
methylation	O
of	O
these	O
genes	O
of	O
the	O
promoter	O
in	O
Africans	O
(	O
Table	O
1	O
,	O
2	O
,	O
3	O
)	O
[	O
3,4	O
]	O
.	O

Non	O
-	O
MSI	O
-	O
H	O
tumors	O
in	O
both	O
African	O
Americans	O
and	O
Omani	O
tumors	O
showed	O
methylation	O
of	O
the	O
hMLH1	O
promoter	O
as	O
well	O
(	O
>	O
80	O
%	O
)	O
.	O

In	O
Iranian	O
non	O
-	O
MSI	O
-	O
H	O
patients	O
,	O
the	O
frequency	O
of	O
hMLH1	O
methylation	O
was	O
3	O
%	O
[	O
1	O
]	O
.	O

The	O
methylation	O
status	O
of	O
hMLH1	O
does	O
not	O
seem	O
to	O
be	O
gender-	O
or	O
stage	O
-	O
specific	O
.	O

In	O
multivariate	O
analysis	O
,	O
including	O
the	O
interaction	O
terms	O
,	O
the	O
hMLH1	O
methylation	O
has	O
a	O
significant	O
effect	O
on	O
MSI	O
-	O
H	O
occurrence	O
(	O
OR	O
=	O
13.84	O
(	O
1.05–182.72	O
)	O
;	O
p	O
=	O
0.046	O
)	O
(	O
Table	O
4	O
)	O
.	O

In	O
MSI	O
-	O
H	O
tumors	O
,	O
p16	O
methylation	O
occurred	O
in	O
33	O
%	O
[	O
7	O
]	O
of	O
African	O
American	O
,	O
12	O
%	O
[	O
1	O
]	O
of	O
Omani	O
and	O
50	O
%	O
[	O
7	O
]	O
of	O
Iranian	O
tumors	O
.	O

While	O
it	O
was	O
more	O
than	O
40	O
%	O
in	O
non	O
-	O
MSI	O
-	O
H	O
tumors	O
in	O
African	O
Americans	O
and	O
Omani	O
patient	O
populations	O
,	O
this	O
figure	O
was	O
3	O
%	O
[	O
1	O
]	O
in	O
Iranian	O
non	O
-	O
MSI	O
-	O
H	O
CRC	O
patients	O
.	O

Methods	O
We	O
analyzed	O
40	O
HNPCC	O
patients	O
(	O
25	O
males	O
and	O
15	O
females	O
)	O
with	O
histological	O
verified	O
colorectal	O
carcinoma	O
and	O
a	O
consecutive	O
series	O
of	O
573	O
(	O
312	O
males	O
and	O
261	O
females	O
)	O
sporadic	O
CRC	O
patients	O
with	O
no	O
familial	O
predisposition	O
,	O
observed	O
and	O
treated	O
at	O
the	O
Regina	O
Elena	O
Cancer	O
Institute	O
of	O
Rome	O
during	O
the	O
period	O
1970–1993	O
[	O
23	O
]	O
.	O

HNPCC	O
patients	O
were	O
selected	O
by	O
both	O
personal	O
and	O
familial	O
history	O
(	O
performing	O
complete	O
pedigree	O
including	O
first	O
and	O
second	O
-	O
degree	O
relatives	O
)	O
according	O
to	O
Amsterdam	O
I	O
criteria	O
.	O

In	O
15	O
patients	O
of	O
the	O
HNPCC	O
group	O
,	O
we	O
performed	O
mutational	O
analysis	O
for	O
microsatellite	O
instability	O
,	O
investigating	O
mutations	O
in	O
mismatch	O
repair	O
genes	O
as	O
hMLH1	O
and	O
hMSH2	O
correlated	O
with	O
disease	O
.	O

We	O
analyzed	O
seven	O
microsatellite	O
loci	O
:	O
D2S123	O
,	O
D3S1611	O
,	O
and	O
BAT-26	O
,	O
D9S145	O
,	O
D1S158	O
,	O
SCZD1	O
,	O
and	O
D11S905	O
[	O
5,14,24,25	O
]	O
.	O

All	O
cases	O
were	O
pathologically	O
staged	O
taking	O
into	O
account	O
a	O
total	O
number	O
of	O
lymphonodes	O
exceeding	O
7	O
(	O
range	O
7	O
to	O
31	O
,	O
mean	O
13.0	O
,	O
mode	O
11.9	O
,	O
standard	O
deviation	O
6.2	O
)	O
,	O
as	O
recommended	O
by	O
the	O
American	O
Joint	O
Committee	O
on	O
Cancer	O
/	O
International	O
Union	O
Against	O
Cancer	O
[	O
26	O
]	O
.	O

Histological	O
examination	O
was	O
performed	O
according	O
to	O
WHO	O
criteria	O
and	O
carcinomas	O
were	O
classified	O
according	O
to	O
the	O
Dukes	O
'	O
stage	O
.	O

Furthermore	O
,	O
we	O
defined	O
the	O
right	O
colon	O
as	O
the	O
tract	O
from	O
the	O
cecum	O
to	O
the	O
splenic	O
flexure	O
.	O

The	O
left	O
colon	O
included	O
the	O
descending	O
and	O
sigmoid	O
colon	O
.	O

The	O
rectum	O
was	O
defined	O
as	O
the	O
rectosigmoid	O
junction	O
and	O
rectum	O
.	O

From	O
1990	O
,	O
the	O
rectal	O
cancer	O
patients	O
clinically	O
staged	O
Dukes	O
'	O
B	O
and	O
C	O
were	O
addressed	O
to	O
high	O
-	O
dose	O
pelvic	O
radiotherapy	O
,	O
all	O
the	O
rectal	O
cancer	O
patients	O
underwent	O
a	O
total	O
mesorectal	O
excision	O
(	O
TME	O
)	O
surgery	O
.	O

Adjuvant	O
i.v	O
.	O

chemotherapy	O
was	O
administered	O
in	O
all	O
the	O
eligible	O
Dukes	O
'	O
C	O
colorectal	O
cancer	O
patients	O
,	O
those	O
staged	O
Dukes	O
'	O
D	O
underwent	O
chemotherapy	O
.	O

Patients	O
with	O
sporadic	O
CRC	O
were	O
submitted	O
to	O
a	O
yearly	O
colonoscopy	O
for	O
the	O
first	O
5	O
years	O
and	O
every	O
2	O
years	O
thereafter	O
[	O
23	O
]	O
,	O
HNPCC	O
patients	O
with	O
CRC	O
were	O
submitted	O
to	O
a	O
yearly	O
colonoscopy	O
.	O

Considering	O
the	O
increased	O
risk	O
of	O
extracolonic	O
manifestations	O
,	O
hereditary	O
colorectal	O
cancer	O
patients	O
were	O
also	O
submitted	O
to	O
periodical	O
instrumental	O
examinations	O
tailored	O
to	O
the	O
different	O
spectrum	O
of	O
the	O
disease	O
[	O
4,27	O
]	O
.	O

The	O
index	O
date	O
for	O
survival	O
calculation	O
was	O
defined	O
as	O
the	O
date	O
of	O
treatment	O
for	O
the	O
first	O
colorectal	O
cancer	O
.	O

Clinical	O
follow	O
-	O
up	O
procedures	O
provided	O
information	O
on	O
the	O
subject	O
's	O
status	O
.	O

Statistical	O
analysis	O
Survival	O
curves	O
were	O
estimated	O
using	O
the	O
Kaplan	O
-	O
Meier	O
method	O
and	O
stratified	O
according	O
to	O
various	O
clinical	O
and	O
pathological	O
variables	O
.	O

Differences	O
were	O
tested	O
using	O
the	O
log	O
-	O
rank	O
test	O
.	O

Multivariate	O
analysis	O
was	O
performed	O
using	O
the	O
Cox	O
regression	O
analysis	O
.	O

The	O
multivariate	O
analysis	O
of	O
the	O
HNPCC	O
versus	O
CRC	O
groups	O
,	O
Dukes	O
'	O
stage	O
,	O
tumor	O
site	O
showed	O
that	O
all	O
these	O
parameters	O
independently	O
affected	O
disease	O
-	O
specific	O
survival	O
(	O
p	O
<	O
0.0001	O
,	O
p	O
<	O
0.0001	O
and	O
p	O
=	O
0.03	O
respectively	O
)	O
.	O

Out	O
of	O
40	O
HNPCC	O
patients	O
,	O
15	O
were	O
investigated	O
for	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
;	O
all	O
resulting	O
positive	O
.	O

Furthermore	O
,	O
the	O
HNPCC	O
patients	O
with	O
MSI	O
(	O
15	O
/	O
40	O
)	O
had	O
a	O
survival	O
of	O
100	O
%	O
.	O

Statistical	O
analysis	O
Mutation	O
rates	O
of	O
cell	O
lines	O
were	O
compared	O
by	O
T	O
-	O
test	O
or	O
one	O
-	O
way	O
ANOVA	O
.	O

